Accession,Title,Organism,Samples,SRA,Release_Date,All_protocols,seq_types,GSE,GSE_Supplementary,BioProject,PMID,authors,abstract,title,doi,date_published,PMC,journal
GSE180669,Ribosome profiling in DDX3X degron cell lines and complementation with sex-linked paralogs,Homo sapiens,16,SRP329509,2021-11-24,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE180669,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE180nnn/GSE180669/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA749053,34535544," Srivats Venkataramanan,  Margaret Gadek,  Lorenzo Calviello,  Kevin Wilkins,  Stephen N Floor",DDX3 is a DEAD-box RNA helicase that regulates translation and is encoded by the,DDX3X and DDX3Y are redundant in protein synthesis.,10.1261/rna.078926.121,2021 Dec,PMC8594478,"RNA (New York, N.Y.)"
GSE156796,Determine the effects of METTL16 on global translation efficiency via ribosome profiling (Ribo-seq),Homo sapiens,8,SRP278667,2021-10-28,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156796,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE156nnn/GSE156796/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA659038,,,,,,,,
GSE185286,RNA Sequencing and Ribosome profiling of GIR2 and PUB1 knockout yeast strains.,Saccharomyces cerevisiae,26,SRP339974,2021-10-11,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE185286,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE185nnn/GSE185286/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA768456,34900236," Artyom A Egorov,  Desislava S Makeeva,  Nadezhda E Makarova,  Dmitri A Bykov,  Yanislav S Hrytseniuk,  Olga V Mitkevich,  Valery N Urakov,  Alexander I Alexandrov,  Ivan V Kulakovskiy,  Sergey E Dmitriev","In eukaryotes, stalled and collided ribosomes are recognized by several conserved multicomponent systems, which either block protein synthesis in situ and resolve the collision locally, or trigger a general stress response. Yeast ribosome-binding GTPases RBG1 (DRG1 in mammals) and RBG2 (DRG2) form two distinct heterodimers with TMA46 (DFRP1) and GIR2 (DFRP2), respectively, both involved in mRNA translation. Accumulated evidence suggests that the dimers play partially redundant roles in elongation processivity and resolution of ribosome stalling and collision events, as well as in the regulation of GCN1-mediated signaling involved in ribosome-associated quality control (RQC). They also genetically interact with SLH1 (ASCC3) helicase, a key component of RQC trigger (RQT) complex disassembling collided ribosomes. Here, we present RNA-Seq and ribosome profiling (Ribo-Seq) data from S. cerevisiae strains with individual deletions of the TMA46 and GIR2 genes. Raw RNA-Seq and Ribo-Seq data as well as gene-level read counts are available in NCBI Gene Expression Omnibus (GEO) repository under GEO accession GSE185458 and GSE185286.",Ribo-Seq and RNA-Seq of TMA46 ( DFRP1) and GIR2 ( DFRP2) knockout yeast strains.,10.12688/f1000research.74727.1,2021,PMC8637242,F1000Research
GSE185458,"RNA Sequencing and Ribosome profiling of TMA46, STM1 and YGR054W knockout yeast strains",Saccharomyces cerevisiae,32,SRP340281,2021-10-08,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE185458,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE185nnn/GSE185458/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA769126,34900236," Artyom A Egorov,  Desislava S Makeeva,  Nadezhda E Makarova,  Dmitri A Bykov,  Yanislav S Hrytseniuk,  Olga V Mitkevich,  Valery N Urakov,  Alexander I Alexandrov,  Ivan V Kulakovskiy,  Sergey E Dmitriev","In eukaryotes, stalled and collided ribosomes are recognized by several conserved multicomponent systems, which either block protein synthesis in situ and resolve the collision locally, or trigger a general stress response. Yeast ribosome-binding GTPases RBG1 (DRG1 in mammals) and RBG2 (DRG2) form two distinct heterodimers with TMA46 (DFRP1) and GIR2 (DFRP2), respectively, both involved in mRNA translation. Accumulated evidence suggests that the dimers play partially redundant roles in elongation processivity and resolution of ribosome stalling and collision events, as well as in the regulation of GCN1-mediated signaling involved in ribosome-associated quality control (RQC). They also genetically interact with SLH1 (ASCC3) helicase, a key component of RQC trigger (RQT) complex disassembling collided ribosomes. Here, we present RNA-Seq and ribosome profiling (Ribo-Seq) data from S. cerevisiae strains with individual deletions of the TMA46 and GIR2 genes. Raw RNA-Seq and Ribo-Seq data as well as gene-level read counts are available in NCBI Gene Expression Omnibus (GEO) repository under GEO accession GSE185458 and GSE185286.",Ribo-Seq and RNA-Seq of TMA46 ( DFRP1) and GIR2 ( DFRP2) knockout yeast strains.,10.12688/f1000research.74727.1,2021,PMC8637242,F1000Research
GSE158141,Ribosome Profiling with CNOT1 depletion,Homo sapiens,12,SRP282906,2021-8-23,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158141,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE158nnn/GSE158141/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA664116,34615539," Sarah L Gillen,  Chiara Giacomelli,  Kelly Hodge,  Sara Zanivan,  Martin Bushell,  Ania Wilczynska","BACKGROUND: Regulation of protein output at the level of translation allows for a rapid adaptation to dynamic changes to the cell's requirements. This precise control of gene expression is achieved by complex and interlinked biochemical processes that modulate both the protein synthesis rate and stability of each individual mRNA. A major factor coordinating this regulation is the Ccr4-Not complex. Despite playing a role in most stages of the mRNA life cycle, no attempt has been made to take a global integrated view of how the Ccr4-Not complex affects gene expression. RESULTS: This study has taken a comprehensive approach to investigate post-transcriptional regulation mediated by the Ccr4-Not complex assessing steady-state mRNA levels, ribosome position, mRNA stability, and protein production transcriptome-wide. Depletion of the scaffold protein CNOT1 results in a global upregulation of mRNA stability and the preferential stabilization of mRNAs enriched for G/C-ending codons. We also uncover that mRNAs targeted to the ER for their translation have reduced translational efficiency when CNOT1 is depleted, specifically downstream of the signal sequence cleavage site. In contrast, translationally upregulated mRNAs are normally localized in p-bodies, contain disorder-promoting amino acids, and encode nuclear localized proteins. Finally, we identify ribosome pause sites that are resolved or induced by the depletion of CNOT1. CONCLUSIONS: We define the key mRNA features that determine how the human Ccr4-Not complex differentially regulates mRNA fate and protein synthesis through a mechanism linked to codon composition, amino acid usage, and mRNA localization.",Differential regulation of mRNA fate by the human Ccr4-Not complex is driven by coding sequence composition and mRNA localization.,10.1186/s13059-021-02494-w,2021 Oct 6,PMC8496106,Genome biology
GSE173856,RiboDoc: a Docker-based package for ribosome profiling analysis,Saccharomyces cerevisiae,4,SRP318454,2021-8-04,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173856,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE173nnn/GSE173856/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA727314,34093996," Pauline Francois,  Hugo Arbes,  Stephane Demais,  Agnes Baudin-Baillieu,  Olivier Namy","Ribosome profiling (RiboSeq) has emerged as a powerful technique for studying the genome-wide regulation of translation in various cells. Several steps in the biological protocol have been improved, but the bioinformatics part of RiboSeq suffers from a lack of standardization, preventing the straightforward and complete reproduction of published results. Too many published studies provide insufficient detail about the bioinformatics pipeline used. The broad range of questions that can be asked with RiboSeq makes it difficult to use a single bioinformatics tool. Indeed, many scripts have been published for addressing diverse questions. Here (https://github.com/equipeGST/RiboDoc), we propose a unique tool (for use with multiple operating systems, OS) to standardize the general steps that must be performed systematically in RiboSeq analysis, together with the statistical analysis and quality control of the sample. The data generated can then be exploited with more specific tools. We hope that this tool will help to standardize bioinformatics analyses pipelines in the field of translation.",RiboDoc: A Docker-based package for ribosome profiling analysis.,10.1016/j.csbj.2021.05.014,2021,PMC8141510,Computational and structural biotechnology journal
GSE136940,Humans and other commonly used model organisms are resistant to cycloheximide-mediated biases in ribosome profiling experiments,Candida albicans;Homo sapiens;Saccharomyces cerevisiae;Schizosaccharomyces pombe,33,SRP220473,2021-7-28,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136940,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE136nnn/GSE136940/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA564089,34429433," Puneet Sharma,  Jie Wu,  Benedikt S Nilges,  Sebastian A Leidel","Ribosome profiling measures genome-wide translation dynamics at sub-codon resolution. Cycloheximide (CHX), a widely used translation inhibitor to arrest ribosomes in these experiments, has been shown to induce biases in yeast, questioning its use. However, whether such biases are present in datasets of other organisms including humans is unknown. Here we compare different CHX-treatment conditions in human cells and yeast in parallel experiments using an optimized protocol. We find that human ribosomes are not susceptible to conformational restrictions by CHX, nor does it distort gene-level measurements of ribosome occupancy, measured decoding speed or the translational ramp. Furthermore, CHX-induced codon-specific biases on ribosome occupancy are not detectable in human cells or other model organisms. This shows that reported biases of CHX are species-specific and that CHX does not affect the outcome of ribosome profiling experiments in most settings. Our findings provide a solid framework to conduct and analyze ribosome profiling experiments.",Humans and other commonly used model organisms are resistant to cycloheximide-mediated biases in ribosome profiling experiments.,10.1038/s41467-021-25411-y,2021 Aug 24,PMC8384890,Nature communications
GSE130465,Multiplexed functional genomic analysis of somatic 5' untranslated region mutations across the spectrum of human prostate cancer (Ribosome Profiling),Homo sapiens,30,SRP194188,2021-5-17,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130465,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE130nnn/GSE130465/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA540298,34244513," Yiting Lim,  Sonali Arora,  Samantha L Schuster,  Lukas Corey,  Matthew Fitzgibbon,  Cynthia L Wladyka,  Xiaoying Wu,  Ilsa M Coleman,  Jeffrey J Delrow,  Eva Corey,  Lawrence D True,  Peter S Nelson,  Gavin Ha,  Andrew C Hsieh",The functional consequences of genetic variants within 5' untranslated regions (UTRs) on a genome-wide scale are poorly understood in disease. Here we develop a high-throughput multi-layer functional genomics method called PLUMAGE (Pooled full-length UTR Multiplex Assay on Gene Expression) to quantify the molecular consequences of somatic 5' UTR mutations in human prostate cancer. We show that 5' UTR mutations can control transcript levels and mRNA translation rates through the creation of DNA binding elements or RNA-based cis-regulatory motifs. We discover that point mutations can simultaneously impact transcript and translation levels of the same gene. We provide evidence that functional 5' UTR mutations in the MAP kinase signaling pathway can upregulate pathway-specific gene expression and are associated with clinical outcomes. Our study reveals the diverse mechanisms by which the mutational landscape of 5' UTRs can co-opt gene expression and demonstrates that single nucleotide alterations within 5' UTRs are functional in cancer.,Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.,10.1038/s41467-021-24445-6,2021 Jul 9,PMC8270899,Nature communications
GSE157361,Ebp1-selective ribosome profiling analysis of Neuro2a cells with Ebp1-immuno-precipitation,Mus musculus,4,SRP279771,2021-3-23,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157361,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE157nnn/GSE157361/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA661060,33357414," Matthew L Kraushar,  Ferdinand Krupp,  Dermot Harnett,  Paul Turko,  Mateusz C Ambrozkiewicz,  Thiemo Sprink,  Koshi Imami,  Manuel Gunnigmann,  Ulrike Zinnall,  Carlos H Vieira-Vieira,  Theres Schaub,  Agnieszka Munster-Wandowski,  Jorg Burger,  Ekaterina Borisova,  Hiroshi Yamamoto,  Mladen-Roko Rasin,  Uwe Ohler,  Dieter Beule,  Thorsten Mielke,  Victor Tarabykin,  Markus Landthaler,  Gunter Kramer,  Imre Vida,  Matthias Selbach,  Christian M T Spahn","Protein synthesis must be finely tuned in the developing nervous system as the final essential step of gene expression. This study investigates the architecture of ribosomes from the neocortex during neurogenesis, revealing Ebp1 as a high-occupancy 60S peptide tunnel exit (TE) factor during protein synthesis at near-atomic resolution by cryoelectron microscopy (cryo-EM). Ribosome profiling demonstrated Ebp1-60S binding is highest during start codon initiation and N-terminal peptide elongation, regulating ribosome occupancy of these codons. Membrane-targeting domains emerging from the 60S tunnel, which recruit SRP/Sec61 to the shared binding site, displace Ebp1. Ebp1 is particularly abundant in the early-born neural stem cell (NSC) lineage and regulates neuronal morphology. Ebp1 especially impacts the synthesis of membrane-targeted cell adhesion molecules (CAMs), measured by pulsed stable isotope labeling by amino acids in cell culture (pSILAC)/bioorthogonal noncanonical amino acid tagging (BONCAT) mass spectrometry (MS). Therefore, Ebp1 is a central component of protein synthesis, and the ribosome TE is a focal point of gene expression control in the molecular specification of neuronal morphology during development.",Protein Synthesis in the Developing Neocortex at Near-Atomic Resolution Reveals Ebp1-Mediated Neuronal Proteostasis at the 60S Tunnel Exit.,10.1016/j.molcel.2020.11.037,2021 Jan 21,PMC8163098,Molecular cell
GSE157423,Ribosome profiling analysis of Neuro2a cells with Ebp1 knockdown,Mus musculus,12,SRP279969,2021-3-23,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157423,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE157nnn/GSE157423/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA661275,33357414," Matthew L Kraushar,  Ferdinand Krupp,  Dermot Harnett,  Paul Turko,  Mateusz C Ambrozkiewicz,  Thiemo Sprink,  Koshi Imami,  Manuel Gunnigmann,  Ulrike Zinnall,  Carlos H Vieira-Vieira,  Theres Schaub,  Agnieszka Munster-Wandowski,  Jorg Burger,  Ekaterina Borisova,  Hiroshi Yamamoto,  Mladen-Roko Rasin,  Uwe Ohler,  Dieter Beule,  Thorsten Mielke,  Victor Tarabykin,  Markus Landthaler,  Gunter Kramer,  Imre Vida,  Matthias Selbach,  Christian M T Spahn","Protein synthesis must be finely tuned in the developing nervous system as the final essential step of gene expression. This study investigates the architecture of ribosomes from the neocortex during neurogenesis, revealing Ebp1 as a high-occupancy 60S peptide tunnel exit (TE) factor during protein synthesis at near-atomic resolution by cryoelectron microscopy (cryo-EM). Ribosome profiling demonstrated Ebp1-60S binding is highest during start codon initiation and N-terminal peptide elongation, regulating ribosome occupancy of these codons. Membrane-targeting domains emerging from the 60S tunnel, which recruit SRP/Sec61 to the shared binding site, displace Ebp1. Ebp1 is particularly abundant in the early-born neural stem cell (NSC) lineage and regulates neuronal morphology. Ebp1 especially impacts the synthesis of membrane-targeted cell adhesion molecules (CAMs), measured by pulsed stable isotope labeling by amino acids in cell culture (pSILAC)/bioorthogonal noncanonical amino acid tagging (BONCAT) mass spectrometry (MS). Therefore, Ebp1 is a central component of protein synthesis, and the ribosome TE is a focal point of gene expression control in the molecular specification of neuronal morphology during development.",Protein Synthesis in the Developing Neocortex at Near-Atomic Resolution Reveals Ebp1-Mediated Neuronal Proteostasis at the 60S Tunnel Exit.,10.1016/j.molcel.2020.11.037,2021 Jan 21,PMC8163098,Molecular cell
GSE152554,Ribosome profiling analysis of aging human skeletal muscle (RNA-Seq),Homo sapiens,5,SRP267469,2021-3-08,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152554,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE152nnn/GSE152554/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA639715,33472542," Ravi Tharakan,  Ceereena Ubaida-Mohien,  Yulan Piao,  Myriam Gorospe,  Luigi Ferrucci","With advancing age, human muscle loses strength and function, but the molecular causes of these losses are unknown. Skeletal muscle shows an age-dependent decline in the levels of different proteins, but whether such decline is associated with reduced translation has not been studied. To address this gap of knowledge, we used the technique of ribosome profiling to study translation in muscle from middle-aged and old individuals. Using ribosome occupancy as a measure of translation status, several mRNAs showed differential translation with age. Older age was associated with lower translation of myosin and titin isoforms and more broadly with the translation of proteins involved in oxidative phosphorylation encoded by the mitochondrial genome. Based on our findings, we propose that mitochondrial proteins are less translated in old skeletal muscle.",Ribosome profiling analysis of human skeletal muscle identifies reduced translation of mitochondrial proteins with age.,10.1080/15476286.2021.1875647,2021 Nov,PMC8583053,RNA biology
GSE152556,Ribosome profiling analysis of aging human skeletal muscle (Ribo-Seq),Homo sapiens,5,SRP267470,2021-3-08,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152556,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE152nnn/GSE152556/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA639716,33472542," Ravi Tharakan,  Ceereena Ubaida-Mohien,  Yulan Piao,  Myriam Gorospe,  Luigi Ferrucci","With advancing age, human muscle loses strength and function, but the molecular causes of these losses are unknown. Skeletal muscle shows an age-dependent decline in the levels of different proteins, but whether such decline is associated with reduced translation has not been studied. To address this gap of knowledge, we used the technique of ribosome profiling to study translation in muscle from middle-aged and old individuals. Using ribosome occupancy as a measure of translation status, several mRNAs showed differential translation with age. Older age was associated with lower translation of myosin and titin isoforms and more broadly with the translation of proteins involved in oxidative phosphorylation encoded by the mitochondrial genome. Based on our findings, we propose that mitochondrial proteins are less translated in old skeletal muscle.",Ribosome profiling analysis of human skeletal muscle identifies reduced translation of mitochondrial proteins with age.,10.1080/15476286.2021.1875647,2021 Nov,PMC8583053,RNA biology
GSE152558,Ribosome profiling analysis of aging human skeletal muscle,Homo sapiens,10,,2021-3-08,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152558,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE152nnn/GSE152558/suppl,,33472542," Ravi Tharakan,  Ceereena Ubaida-Mohien,  Yulan Piao,  Myriam Gorospe,  Luigi Ferrucci","With advancing age, human muscle loses strength and function, but the molecular causes of these losses are unknown. Skeletal muscle shows an age-dependent decline in the levels of different proteins, but whether such decline is associated with reduced translation has not been studied. To address this gap of knowledge, we used the technique of ribosome profiling to study translation in muscle from middle-aged and old individuals. Using ribosome occupancy as a measure of translation status, several mRNAs showed differential translation with age. Older age was associated with lower translation of myosin and titin isoforms and more broadly with the translation of proteins involved in oxidative phosphorylation encoded by the mitochondrial genome. Based on our findings, we propose that mitochondrial proteins are less translated in old skeletal muscle.",Ribosome profiling analysis of human skeletal muscle identifies reduced translation of mitochondrial proteins with age.,10.1080/15476286.2021.1875647,2021 Nov,PMC8583053,RNA biology
GSE167704,Ribosome profiling experiments of LRRK2 mouse models,Mus musculus,26,SRP308389,2021-2-27,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167704,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE167nnn/GSE167704/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA705181,34759048," Jungwoo Wren Kim,  Xiling Yin,  Ian Martin,  Yulan Xiong,  Stephen M Eacker,  Nicholas T Ingolia,  Ted M Dawson,  Valina L Dawson","The G2019S mutation in leucine-rich repeat kinase 2 (LRRK2) causes familial Parkinson's disease (PD) and is also found in a subset of idiopathic cases. Prior studies in Drosophila and human induced pluripotent stem cell (iPSC)-derived dopamine neurons uncovered a pronounced effect of G2019S LRRK2 on mRNA translation. It was previously reported that G2019S LRRK2 promotes translation of mRNAs with complex 5' untranslated region (UTR) secondary structure, resulting in increased expression of calcium channels and dysregulated calcium homeostasis in human dopamine neurons. Here, we show that dysregulated translation occurs in the brains of mammalian LRRK2 models in vivo Through ribosome profiling studies of global translation, we observe that mRNAs with complex 5'UTR structure are also preferentially translated in the G2019S LRRK2-expressing mouse brain. Reporter assays suggest that this 5'UTR preference is independent of translation initiation factors. Conversely, translation of mRNAs with complex 5'UTR secondary structure is downregulated in LRRK2 knock-out (KO) mouse brain, indicating a robust link between LRRK2 kinase activity and translation of mRNA with complex 5'UTR structure. Further, substantia nigra pars compacta (SNpc) dopamine neurons in the G2019S LRRK2-expressing brain exhibit increased calcium influx, which is consistent with the previous report from human dopamine neurons. These results collectively suggest that LRRK2 plays a mechanistic role in translational regulation, and the G2019S mutation in LRRK2 causes translational defects leading to calcium dysregulation in the mammalian brain.",Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains.,10.1523/ENEURO.0310-21.2021,2021 Nov-Dec,PMC8638676,eNeuro
GSE167223,Long-RNA sequencing and ribosome profiling of inflamed beta-cells reveal an extensive translatome landscape,Homo sapiens,12,SRP307513,2021-2-23,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167223,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE167nnn/GSE167223/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA703954,34554924," Sofia Thomaidou,  Roderick C Slieker,  Arno R van der Slik,  Jasper Boom,  Flip Mulder,  Amadeo Munoz-Garcia,  Leen M 't Hart,  Bobby Koeleman,  Francoise Carlotti,  Rob C Hoeben,  Bart O Roep,  Hailiang Mei,  Arnaud Zaldumbide","Type 1 diabetes (T1D) is an autoimmune disease characterized by autoreactive T cell-mediated destruction of the insulin-producing pancreatic beta-cells. Increasing evidence suggest that the beta-cells themselves contribute to their own destruction by generating neoantigens through the production of aberrant or modified proteins that escape central tolerance. We recently demonstrated that ribosomal infidelity amplified by stress could lead to the generation of neoantigens in human beta-cells, emphasizing the participation of nonconventional translation events in autoimmunity, as occurring in cancer or virus-infected tissues. Using a transcriptome-wide profiling approach to map translation initiation start sites in human beta-cells under standard and inflammatory conditions, we identify a completely new set of polypeptides derived from noncanonical start sites and translation initiation within long noncoding RNA. Our data underline the extreme diversity of the beta-cell translatome and may reveal new functional biomarkers for beta-cell distress, disease prediction and progression, and therapeutic intervention in T1D.",Long RNA Sequencing and Ribosome Profiling of Inflamed beta-Cells Reveal an Extensive Translatome Landscape.,10.2337/db20-1122,2021 Oct,,Diabetes
GSE166874,Ribosome profiling reveals sequence-independent post-initiation pausing as a signature of translation,Homo sapiens,4,SRP306724,2021-2-17,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166874,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE166nnn/GSE166874/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA702160,24903108," Yan Han,  Xiangwei Gao,  Botao Liu,  Ji Wan,  Xingqian Zhang,  Shu-Bing Qian","The journey of a newly synthesized polypeptide starts in the peptidyltransferase center of the ribosome, from where it traverses the exit tunnel. The interior of the ribosome exit tunnel is neither straight nor smooth. How the ribosome dynamics in vivo is influenced by the exit tunnel is poorly understood. Genome-wide ribosome profiling in mammalian cells reveals elevated ribosome density at the start codon and surprisingly the downstream 5th codon position as well. We found that the highly focused ribosomal pausing shortly after initiation is attributed to the geometry of the exit tunnel, as deletion of the loop region from ribosome protein L4 diminishes translational pausing at the 5th codon position. Unexpectedly, the ribosome variant undergoes translational abandonment shortly after initiation, suggesting that there exists an obligatory step between initiation and elongation commitment. We propose that the post-initiation pausing of ribosomes represents an inherent signature of the translation machinery to ensure productive translation.",Ribosome profiling reveals sequence-independent post-initiation pausing as a signature of translation.,10.1038/cr.2014.74,2014 Jul,PMC4085768,Cell research
GSE160917,Ribosome profiling and mRNA-seq of muscle skeletal muscle and DROSHA KO 293T cells,Homo sapiens;Mus musculus,14,SRP291315,2020-12-31,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160917,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE160nnn/GSE160917/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA674837,,,,,,,,
GSE144539,Ribosome profiling and RNA-seq of Tsc2+/- hippocampal slices,Mus musculus,24,SRP246149,2020-10-05,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144539,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE144nnn/GSE144539/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA603987,33054857," Annie Hien,  Gemma Molinaro,  Botao Liu,  Kimberly M Huber,  Joel D Richter","BACKGROUND: Mutations in TSC2 are the most common cause of tuberous sclerosis (TSC), a disorder with a high incidence of autism and intellectual disability. TSC2 regulates mRNA translation required for group 1 metabotropic glutamate receptor-dependent synaptic long-term depression (mGluR-LTD) and behavior, but the identity of mRNAs responsive to mGluR-LTD signaling is largely unknown. METHODS: We utilized Tsc2(+/-) mice as a mouse model of TSC and prepared hippocampal slices from these animals. We induced mGluR-LTD synaptic plasticity in slices and processed the samples for RNA-seq and ribosome profiling to identify differentially expressed genes in Tsc2(+/-) and following mGluR-LTD synaptic plasticity. RESULTS: Ribosome profiling reveals that in Tsc2(+/-) mouse hippocampal slices, the expression of several mRNAs was dysregulated: terminal oligopyrimidine (TOP)-containing mRNAs decreased, while FMRP-binding targets increased. Remarkably, we observed the opposite changes of FMRP binding targets in Fmr1(-/y) hippocampi. In wild-type hippocampus, induction of mGluR-LTD caused rapid changes in the steady-state levels of hundreds of mRNAs, many of which are FMRP targets. Moreover, mGluR-LTD failed to promote phosphorylation of eukaryotic elongation factor 2 (eEF2) in TSC mice, and chemically mimicking phospho-eEF2 with low cycloheximide enhances mGluR-LTD in TSC mice. CONCLUSION: These results suggest a molecular basis for bidirectional regulation of synaptic plasticity and behavior by TSC2 and FMRP. Our study also suggests that altered mGluR-regulated translation elongation contributes to impaired synaptic plasticity in Tsc2(+/-) mice.",Ribosome profiling in mouse hippocampus: plasticity-induced regulation and bidirectional control by TSC2 and FMRP.,10.1186/s13229-020-00384-9,2020 Oct 14,PMC7556950,Molecular autism
GSE158881,Ribosome profiling and RNA-seq of wild-type hippocampal slices,Mus musculus,19,SRP286016,2020-10-02,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158881,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE158nnn/GSE158881/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA666888,33054857," Annie Hien,  Gemma Molinaro,  Botao Liu,  Kimberly M Huber,  Joel D Richter","BACKGROUND: Mutations in TSC2 are the most common cause of tuberous sclerosis (TSC), a disorder with a high incidence of autism and intellectual disability. TSC2 regulates mRNA translation required for group 1 metabotropic glutamate receptor-dependent synaptic long-term depression (mGluR-LTD) and behavior, but the identity of mRNAs responsive to mGluR-LTD signaling is largely unknown. METHODS: We utilized Tsc2(+/-) mice as a mouse model of TSC and prepared hippocampal slices from these animals. We induced mGluR-LTD synaptic plasticity in slices and processed the samples for RNA-seq and ribosome profiling to identify differentially expressed genes in Tsc2(+/-) and following mGluR-LTD synaptic plasticity. RESULTS: Ribosome profiling reveals that in Tsc2(+/-) mouse hippocampal slices, the expression of several mRNAs was dysregulated: terminal oligopyrimidine (TOP)-containing mRNAs decreased, while FMRP-binding targets increased. Remarkably, we observed the opposite changes of FMRP binding targets in Fmr1(-/y) hippocampi. In wild-type hippocampus, induction of mGluR-LTD caused rapid changes in the steady-state levels of hundreds of mRNAs, many of which are FMRP targets. Moreover, mGluR-LTD failed to promote phosphorylation of eukaryotic elongation factor 2 (eEF2) in TSC mice, and chemically mimicking phospho-eEF2 with low cycloheximide enhances mGluR-LTD in TSC mice. CONCLUSION: These results suggest a molecular basis for bidirectional regulation of synaptic plasticity and behavior by TSC2 and FMRP. Our study also suggests that altered mGluR-regulated translation elongation contributes to impaired synaptic plasticity in Tsc2(+/-) mice.",Ribosome profiling in mouse hippocampus: plasticity-induced regulation and bidirectional control by TSC2 and FMRP.,10.1186/s13229-020-00384-9,2020 Oct 14,PMC7556950,Molecular autism
GSE157063,Ribosome profiling in DDX3X degron cell lines and covering variants,Homo sapiens,16,SRP279211,2020-9-30,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157063,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE157nnn/GSE157063/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA660002,33905506," Lorenzo Calviello,  Srivats Venkataramanan,  Karol J Rogowski,  Emanuel Wyler,  Kevin Wilkins,  Malvika Tejura,  Bao Thai,  Jacek Krol,  Witold Filipowicz,  Markus Landthaler,  Stephen N Floor","DDX3 is an RNA chaperone of the DEAD-box family that regulates translation. Ded1, the yeast ortholog of DDX3, is a global regulator of translation, whereas DDX3 is thought to preferentially affect a subset of mRNAs. However, the set of mRNAs that are regulated by DDX3 are unknown, along with the relationship between DDX3 binding and activity. Here, we use ribosome profiling, RNA-seq, and PAR-CLIP to define the set of mRNAs that are regulated by DDX3 in human cells. We find that while DDX3 binds highly expressed mRNAs, depletion of DDX3 particularly affects the translation of a small subset of the transcriptome. We further find that DDX3 binds a site on helix 16 of the human ribosomal rRNA, placing it immediately adjacent to the mRNA entry channel. Translation changes caused by depleting DDX3 levels or expressing an inactive point mutation are different, consistent with different association of these genetic variant types with disease. Taken together, this work defines the subset of the transcriptome that is responsive to DDX3 inhibition, with relevance for basic biology and disease states where DDX3 is altered.",DDX3 depletion represses translation of mRNAs with complex 5' UTRs.,10.1093/nar/gkab287,2021 May 21,PMC8136831,Nucleic acids research
GSE134152,RNAseq and ribosome profiling of yeast cells grown under glucose restriction condition.,Saccharomyces cerevisiae,10,SRP214259,2020-7-10,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134152,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE134nnn/GSE134152/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA554100,32821821," Ke Zou,  Silvia Rouskin,  Kevin Dervishi,  Mark A McCormick,  Arjun Sasikumar,  Changhui Deng,  Zhibing Chen,  Matt Kaeberlein,  Rachel B Brem,  Michael Polymenis,  Brian K Kennedy,  Jonathan S Weissman,  Jiashun Zheng,  Qi Ouyang,  Hao Li","Caloric restriction (CR) is known to extend life span across species; however, the molecular mechanisms are not well understood. We investigate the mechanism by which glucose restriction (GR) extends yeast replicative life span, by combining ribosome profiling and RNA-seq with microfluidic-based single-cell analysis. We discovered a cross-talk between glucose sensing and the regulation of intracellular methionine: GR down-regulated the transcription and translation of methionine biosynthetic enzymes and transporters, leading to a decreased intracellular methionine concentration; external supplementation of methionine cancels the life span extension by GR. Furthermore, genetic perturbations that decrease methionine synthesis/uptake extend life span. These observations suggest that intracellular methionine mediates the life span effects of various nutrient and genetic perturbations, and that the glucose-methionine cross-talk is a general mechanism for coordinating the nutrient status and the translation/growth of a cell. Our work also implicates proteasome as a downstream effector of the life span extension by GR.",Life span extension by glucose restriction is abrogated by methionine supplementation: Cross-talk between glucose and methionine and implication of methionine as a key regulator of life span.,10.1126/sciadv.aba1306,2020 Aug,PMC7406366,Science advances
GSE143301,Ribosome profiling under ABCE1 depletion to study aberrant translation termination,Homo sapiens,21,SRP240357,2020-6-30,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143301,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143301/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA599943,32807779," Evangelos D Karousis,  Lukas-Adrian Gurzeler,  Giuditta Annibaldis,  Rene Dreos,  Oliver Muhlemann","Nonsense-mediated mRNA decay (NMD) is a translation-dependent RNA degradation pathway that is important for the elimination of faulty, and the regulation of normal, mRNAs. The molecular details of the early steps in NMD are not fully understood but previous work suggests that NMD activation occurs as a consequence of ribosome stalling at the termination codon (TC). To test this hypothesis, we established an in vitro translation-coupled toeprinting assay based on lysates from human cells that allows monitoring of ribosome occupancy at the TC of reporter mRNAs. In contrast to the prevailing NMD model, our in vitro system reveals similar ribosomal occupancy at the stop codons of NMD-sensitive and NMD-insensitive reporter mRNAs. Moreover, ribosome profiling reveals a similar density of ribosomes at the TC of endogenous NMD-sensitive and NMD-insensitive mRNAs in vivo. Together, these data show that NMD activation is not accompanied by stable stalling of ribosomes at TCs.",Human NMD ensues independently of stable ribosome stalling.,10.1038/s41467-020-17974-z,2020 Aug 17,PMC7431590,Nature communications
GSE126660,Epidermal basal cell-specific in vivo ribosome profiling to describe the translation landscape of HrasG12V and Eif2b5,Mus musculus,18,SRP186092,2020-6-10,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126660,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126660/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA522866,32516567," Elise Y Cai,  Megan N Kufeld,  Samantha Schuster,  Sonali Arora,  Madeline Larkin,  Alexandre A Germanos,  Andrew C Hsieh,  Slobodan Beronja","Human skin tolerates a surprisingly high burden of oncogenic lesions. Although adult epidermis can suppress the expansion of individual mutant clones, the mechanisms behind tolerance to oncogene activation across broader regions of tissue are unclear. Here, we uncover a dynamic translational mechanism that coordinates oncogenic HRAS-induced hyperproliferation with loss of progenitor self-renewal to restrain aberrant growth and tumorigenesis. We identify translation initiator eIF2B5 as a central co-regulator of HRAS proliferation and cell fate choice. By coupling in vivo ribosome profiling with genetic screening, we provide direct evidence that oncogene-induced loss of progenitor self-renewal is driven by eIF2B5-mediated translation of ubiquitination genes. Ubiquitin ligase FBXO32 specifically inhibits epidermal renewal without affecting overall proliferation, thus restraining HRAS-driven tumorigenesis while maintaining normal tissue growth. Thus, oncogene-driven translation is not necessarily inherently tumor promoting but instead can manage widespread oncogenic stress by steering progenitor fate to prolong normal tissue growth.",Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress.,10.1016/j.stem.2020.05.007,2020 Aug 6,PMC7993921,Cell stem cell
GSE123981,Age-resolved ribosome profiling and RNA-Seq data of mice liver and kidney samples,Mus musculus,56,SRP173659,2020-6-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123981,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123981/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA510416,32576685," Aleksandra S Anisimova,  Mark B Meerson,  Maxim V Gerashchenko,  Ivan V Kulakovskiy,  Sergey E Dmitriev,  Vadim N Gladyshev","Protein synthesis represents a major metabolic activity of the cell. However, how it is affected by aging and how this in turn impacts cell function remains largely unexplored. To address this question, herein we characterized age-related changes in both the transcriptome and translatome of mouse tissues over the entire life span. We showed that the transcriptome changes govern those in the translatome and are associated with altered expression of genes involved in inflammation, extracellular matrix, and lipid metabolism. We also identified genes that may serve as candidate biomarkers of aging. At the translational level, we uncovered sustained down-regulation of a set of 5'-terminal oligopyrimidine (5'-TOP) transcripts encoding protein synthesis and ribosome biogenesis machinery and regulated by the mTOR pathway. For many of them, ribosome occupancy dropped twofold or even more. Moreover, with age, ribosome coverage gradually decreased in the vicinity of start codons and increased near stop codons, revealing complex age-related changes in the translation process. Taken together, our results reveal systematic and multidimensional deregulation of protein synthesis, showing how this major cellular process declines with age.",Multifaceted deregulation of gene expression and protein synthesis with age.,10.1073/pnas.2001788117,2020 Jul 7,PMC7354943,Proceedings of the National Academy of Sciences of the United States of America
GSE131074,Ribosome profiling of eIF3e-KD MCF-10a cells,Homo sapiens,15,SRP198221,2020-6-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131074,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE131nnn/GSE131074/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA542601,32589965," Yingying Lin,  Fajin Li,  Linlu Huang,  Christine Polte,  Haoran Duan,  Jianhuo Fang,  Li Sun,  Xudong Xing,  Guiyou Tian,  Yabin Cheng,  Zoya Ignatova,  Xuerui Yang,  Dieter A Wolf","eIF3, a multi-subunit complex with numerous functions in canonical translation initiation, is known to interact with 40S and 60S ribosomal proteins and translation elongation factors, but a direct involvement in translation elongation has never been demonstrated. We found that eIF3 deficiency reduced early ribosomal elongation speed between codons 25 and 75 on a set of approximately 2,700 mRNAs encoding proteins associated with mitochondrial and membrane functions, resulting in defective synthesis of their encoded proteins. To promote elongation, eIF3 interacts with 80S ribosomes translating the first approximately 60 codons and serves to recruit protein quality-control factors, functions required for normal mitochondrial physiology. Accordingly, eIF3e(+/-) mice accumulate defective mitochondria in skeletal muscle and show a progressive decline in muscle strength. Hence, eIF3 interacts with 80S ribosomes to enhance, at the level of early elongation, the synthesis of proteins with membrane-associated functions, an activity that is critical for mitochondrial physiology and muscle health.","eIF3 Associates with 80S Ribosomes to Promote Translation Elongation, Mitochondrial Homeostasis, and Muscle Health.",10.1016/j.molcel.2020.06.003,2020 Aug 20,,Molecular cell
GSE140565,Ribosome profiling and RNA-seq of Fragile X mouse brain cortex,Mus musculus,16,SRP230417,2020-6-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140565,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140565/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA590189,,,,,,,,
GSE129757,Whole transcriptome profiles and ribosome profiling of thapsigargin- and tunicamycin-treated LN308 cells,Homo sapiens,22,SRP192442,2020-4-30,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129757,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129757/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA532643,,,,,,,,
GSE137626,BacTRAP-based ribosome profiling of murine hypothalamic PNOC neurons,Mus musculus,16,SRP222256,2020-4-16,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137626,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE137nnn/GSE137626/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA566097,32302532," Alexander Jais,  Lars Paeger,  Tamara Sotelo-Hitschfeld,  Stephan Bremser,  Melanie Prinzensteiner,  Paul Klemm,  Vasyl Mykytiuk,  Pia J M Widdershooven,  Anna Juliane Vesting,  Katarzyna Grzelka,  Marielle Minere,  Anna Lena Cremer,  Jie Xu,  Tatiana Korotkova,  Bradford B Lowell,  Hanns Ulrich Zeilhofer,  Heiko Backes,  Henning Fenselau,  F Thomas Wunderlich,  Peter Kloppenburg,  Jens C Bruning","Calorie-rich diets induce hyperphagia and promote obesity, although the underlying mechanisms remain poorly defined. We find that short-term high-fat-diet (HFD) feeding of mice activates prepronociceptin (PNOC)-expressing neurons in the arcuate nucleus of the hypothalamus (ARC). PNOC(ARC) neurons represent a previously unrecognized GABAergic population of ARC neurons distinct from well-defined feeding regulatory AgRP or POMC neurons. PNOC(ARC) neurons arborize densely in the ARC and provide inhibitory synaptic input to nearby anorexigenic POMC neurons. Optogenetic activation of PNOC(ARC) neurons in the ARC and their projections to the bed nucleus of the stria terminalis promotes feeding. Selective ablation of these cells promotes the activation of POMC neurons upon HFD exposure, reduces feeding, and protects from obesity, but it does not affect food intake or body weight under normal chow consumption. We characterize PNOC(ARC) neurons as a novel ARC neuron population activated upon palatable food consumption to promote hyperphagia.",PNOC(ARC) Neurons Promote Hyperphagia and Obesity upon High-Fat-Diet Feeding.,10.1016/j.neuron.2020.03.022,2020 Jun 17,PMC7303947,Neuron
GSE138278,Ribosome profiling of Streptomyces griseus NBRC13350 and Streptomyces venezuelae ATCC15439,Streptomyces griseus;Streptomyces venezuelae,16,SRP223903,2020-3-03,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138278,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138278/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA575265,32385251," Woori Kim,  Soonkyu Hwang,  Namil Lee,  Yongjae Lee,  Suhyung Cho,  Bernhard Palsson,  Byung-Kwan Cho","Streptomyces are efficient producers of various bioactive compounds, which are mostly synthesized by their secondary metabolite biosynthetic gene clusters (smBGCs). The smBGCs are tightly controlled by complex regulatory systems at transcriptional and translational levels to effectively utilize precursors that are supplied by primary metabolism. Thus, dynamic changes in gene expression in response to cellular status at both the transcriptional and translational levels should be elucidated to directly reflect protein levels, rapid downstream responses, and cellular energy costs. In this study, RNA-Seq and ribosome profiling were performed for five industrially important Streptomyces species at different growth phases, for the deep sequencing of total mRNA, and only those mRNA fragments that are protected by translating ribosomes, respectively. Herein, 12.0 to 763.8 million raw reads were sufficiently obtained with high quality of more than 80% for the Phred score Q30 and high reproducibility. These data provide a comprehensive understanding of the transcriptional and translational landscape across the Streptomyces species and contribute to facilitating the rational engineering of secondary metabolite production.",Transcriptome and translatome profiles of Streptomyces species in different growth phases.,10.1038/s41597-020-0476-9,2020 May 8,PMC7210306,Scientific data
GSE128538,Ribosome profiling in RPEI cells upon CDK1-inhibition,Homo sapiens,12,SRP188848,2020-2-06,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128538,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128538/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA528026,32040547," Katharina Haneke,  Johanna Schott,  Doris Lindner,  Anne Kruse Hollensen,  Christian Kroun Damgaard,  Cyril Mongis,  Michael Knop,  Wilhelm Palm,  Alessia Ruggieri,  Georg Stoecklin","Cell proliferation exerts a high demand on protein synthesis, yet the mechanisms coupling the two processes are not fully understood. A kinase and phosphatase screen for activators of translation, based on the formation of stress granules in human cells, revealed cell cycle-associated kinases as major candidates. CDK1 was identified as a positive regulator of global translation, and cell synchronization experiments showed that this is an extramitotic function of CDK1. Different pathways including eIF2alpha, 4EBP, and S6K1 signaling contribute to controlling global translation downstream of CDK1. Moreover, Ribo-Seq analysis uncovered that CDK1 exerts a particularly strong effect on the translation of 5'TOP mRNAs, which includes mRNAs encoding ribosomal proteins and several translation factors. This effect requires the 5'TOP mRNA-binding protein LARP1, concurrent to our finding that LARP1 phosphorylation is strongly dependent on CDK1. Thus, CDK1 provides a direct means to couple cell proliferation with biosynthesis of the translation machinery and the rate of protein synthesis.",CDK1 couples proliferation with protein synthesis.,10.1083/jcb.201906147,2020 Mar 2,PMC7054999,The Journal of cell biology
GSE139399,Ribosome profiling study of Miwi-null testes,Mus musculus,8,SRP227006,2019-12-15,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139399,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139399/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA579549,31835033," Peng Dai,  Xin Wang,  Lan-Tao Gou,  Zhi-Tong Li,  Ze Wen,  Zong-Gui Chen,  Min-Min Hua,  Ai Zhong,  Lingbo Wang,  Haiyang Su,  Huida Wan,  Kun Qian,  Lujian Liao,  Jinsong Li,  Bin Tian,  Dangsheng Li,  Xiang-Dong Fu,  Hui-Juan Shi,  Yu Zhou,  Mo-Fang Liu","Spermiogenesis is a highly orchestrated developmental process during which chromatin condensation decouples transcription from translation. Spermiogenic mRNAs are transcribed earlier and stored in a translationally inert state until needed for translation; however, it remains largely unclear how such repressed mRNAs become activated during spermiogenesis. We previously reported that the MIWI/piRNA machinery is responsible for mRNA elimination during late spermiogenesis in preparation for spermatozoa production. Here we unexpectedly discover that the same machinery is also responsible for activating translation of a subset of spermiogenic mRNAs to coordinate with morphological transformation into spermatozoa. Such action requires specific base-pairing interactions of piRNAs with target mRNAs in their 3' UTRs, which activates translation through coupling with cis-acting AU-rich elements to nucleate the formation of a MIWI/piRNA/eIF3f/HuR super-complex in a developmental stage-specific manner. These findings reveal a critical role of the piRNA system in translation activation, which we show is functionally required for spermatid development.",A Translation-Activating Function of MIWI/piRNA during Mouse Spermiogenesis.,10.1016/j.cell.2019.11.022,2019 Dec 12,PMC8139323,Cell
GSE126736,ribosome profiling of cell line models of human breast cancer,Homo sapiens,30,SRP186252,2019-12-05,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126736,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126736/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA523167,31911279," Christos Vaklavas,  Scott W Blume,  William E Grizzle","Gene expression is extensively and dynamically modulated at the level of translation. How cancer cells prioritize the translation of certain mRNAs over others from a pool of competing mRNAs remains an open question. Here, we analyze translation in cell line models of breast cancer and normal mammary tissue by ribosome profiling. We identify key recurrent themes of oncogenic translation: higher ribosome occupancy, greater variance of translational efficiencies, and preferential translation of transcriptional regulators and signaling proteins in malignant cells as compared with their nonmalignant counterpart. We survey for candidate RNA interacting proteins that could associate with the 5'untranslated regions of the transcripts preferentially translated in breast tumour cells. We identify SRSF1, a prototypic splicing factor, to have a pervasive direct and indirect impact on translation. In a representative estrogen receptor-positive and estrogen receptor-negative cell line, we find that protein synthesis relies heavily on SRSF1. SRSF1 is predominantly intranuclear. Under certain conditions, SRSF1 translocates from the nucleus to the cytoplasm where it associates with MYC and CDK1 mRNAs and upregulates their internal ribosome entry site-mediated translation. Our results point to a synergy between splicing and translation and unveil how certain RNA-binding proteins modulate the translational landscape in breast cancer.",Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer.,10.1016/j.tranon.2019.12.002,2020 Feb,PMC6948383,Translational oncology
GSE139880,Recruitment of mRNAs to P granules by gelation with intrinsically-disordered proteins (RNAseq and ribosome profiling),Caenorhabditis elegans,12,SRP228538,2019-12-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139880,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139880/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA587444,31975687," Chih-Yung S Lee,  Andrea Putnam,  Tu Lu,  ShuaiXin He,  John Paul T Ouyang,  Geraldine Seydoux","RNA granules are protein/RNA condensates. How specific mRNAs are recruited to cytoplasmic RNA granules is not known. Here, we characterize the transcriptome and assembly of P granules, RNA granules in the C. elegans germ plasm. We find that P granules recruit mRNAs by condensation with the disordered protein MEG-3. MEG-3 traps mRNAs into non-dynamic condensates in vitro and binds to ~500 mRNAs in vivo in a sequence-independent manner that favors embryonic mRNAs with low ribosome coverage. Translational stress causes additional mRNAs to localize to P granules and translational activation correlates with P granule exit for two mRNAs coding for germ cell fate regulators. Localization to P granules is not required for translational repression but is required to enrich mRNAs in the germ lineage for robust germline development. Our observations reveal similarities between P granules and stress granules and identify intrinsically-disordered proteins as drivers of RNA condensation during P granule assembly.",Recruitment of mRNAs to P granules by condensation with intrinsically-disordered proteins.,10.7554/eLife.52896,2020 Jan 24,PMC7007223,eLife
GSE104503,Ribosome-profiling experiments for Chronic repression by MAF1 supports futile RNA cycling as a mechanism for obesity resistance,Mus musculus,12,SRP119310,2019-11-04,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104503,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE104nnn/GSE104503/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA412979,32686713," Nicolas Bonhoure,  Viviane Praz,  Robyn D Moir,  Gilles Willemin,  Francois Mange,  Catherine Moret,  Ian M Willis,  Nouria Hernandez","Maf1(-/-) mice are lean, obesity-resistant and metabolically inefficient. Their increased energy expenditure is thought to be driven by a futile RNA cycle that reprograms metabolism to meet an increased demand for nucleotides stemming from the deregulation of RNA polymerase (pol) III transcription. Metabolic changes consistent with this model have been reported in both fasted and refed mice, however the impact of the fasting-refeeding-cycle on pol III function has not been examined. Here we show that changes in pol III occupancy in the liver of fasted versus refed wild-type mice are largely confined to low and intermediate occupancy genes; high occupancy genes are unchanged. However, in Maf1(-/-) mice, pol III occupancy of the vast majority of active loci in liver and the levels of specific precursor tRNAs in this tissue and other organs are higher than wild-type in both fasted and refed conditions. Thus, MAF1 functions as a chronic repressor of active pol III loci and can modulate transcription under different conditions. Our findings support the futile RNA cycle hypothesis, elaborate the mechanism of pol III repression by MAF1 and demonstrate a modest effect of MAF1 on global translation via reduced mRNA levels and translation efficiencies for several ribosomal proteins.",MAF1 is a chronic repressor of RNA polymerase III transcription in the mouse.,10.1038/s41598-020-68665-0,2020 Jul 20,PMC7371695,Scientific reports
GSE105782,N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis[Ribosome Profiling],Homo sapiens,12,SRP120964,2019-8-12,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE105782,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE105nnn/GSE105782/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA415390,31601799," Daniel A Kuppers,  Sonali Arora,  Yiting Lim,  Andrea R Lim,  Lucas M Carter,  Philip D Corrin,  Christopher L Plaisier,  Ryan Basom,  Jeffrey J Delrow,  Shiyan Wang,  Housheng Hansen He,  Beverly Torok-Storb,  Andrew C Hsieh,  Patrick J Paddison","Many of the regulatory features governing erythrocyte specification, maturation, and associated disorders remain enigmatic. To identify new regulators of erythropoiesis, we utilize a functional genomic screen for genes affecting expression of the erythroid marker CD235a/GYPA. Among validating hits are genes coding for the N(6)-methyladenosine (m(6)A) mRNA methyltransferase (MTase) complex, including, METTL14, METTL3, and WTAP. We demonstrate that m(6)A MTase activity promotes erythroid gene expression programs through selective translation of ~300 m(6)A marked mRNAs, including those coding for SETD histone methyltransferases, ribosomal components, and polyA RNA binding proteins. Remarkably, loss of m(6)A marks results in dramatic loss of H3K4me3 marks across key erythroid-specific KLF1 transcriptional targets (e.g., Heme biosynthesis genes). Further, each m(6)A MTase subunit and a subset of their mRNAs targets are required for human erythroid specification in primary bone-marrow derived progenitors. Thus, m(6)A mRNA marks promote the translation of a network of genes required for human erythropoiesis.",N(6)-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis.,10.1038/s41467-019-12518-6,2019 Oct 10,PMC6787028,Nature communications
GSE128344,"A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP b-CTFs, not Ab [ribosome profiling]",Homo sapiens,12,SRP188505,2019-8-08,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128344,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128344/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA527204,31416668," Dylan Kwart,  Andrew Gregg,  Claudia Scheckel,  Elisabeth A Murphy,  Dominik Paquet,  Michael Duffield,  John Fak,  Olav Olsen,  Robert B Darnell,  Marc Tessier-Lavigne","Familial Alzheimer's disease (fAD) results from mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes. Here we leveraged recent advances in induced pluripotent stem cell (iPSC) and CRISPR/Cas9 genome editing technologies to generate a panel of isogenic knockin human iPSC lines carrying APP and/or PSEN1 mutations. Global transcriptomic and translatomic profiling revealed that fAD mutations have overlapping effects on the expression of AD-related and endocytosis-associated genes. Mutant neurons also increased Rab5+ early endosome size. APP and PSEN1 mutations had discordant effects on Abeta production but similar effects on APP beta C-terminal fragments (beta-CTFs), which accumulate in all mutant neurons. Importantly, endosomal dysfunction correlated with accumulation of beta-CTFs, not Abeta, and could be rescued by pharmacological modulation of beta-secretase (BACE). These data display the utility of our mutant iPSCs in studying AD-related phenotypes in a non-overexpression human-based system and support mounting evidence that beta-CTF may be critical in AD pathogenesis.","A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta.",10.1016/j.neuron.2019.07.010,2019 Oct 23,,Neuron
GSE119681,Ribosome profiling of selenoproteins in vivo reveals consequences of pathogenic Secisbp2 missense mutations,Mus musculus,8,SRP160398,2019-7-26,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119681,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE119nnn/GSE119681/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA489895,31350336," Wenchao Zhao,  Simon Bohleber,  Henrik Schmidt,  Sandra Seeher,  Michael T Howard,  Doreen Braun,  Simone Arndt,  Uschi Reuter,  Hagen Wende,  Carmen Birchmeier,  Noelia Fradejas-Villar,  Ulrich Schweizer","Recoding of UGA codons as selenocysteine (Sec) codons in selenoproteins depends on a selenocysteine insertion sequence (SECIS) in the 3'-UTR of mRNAs of eukaryotic selenoproteins. SECIS-binding protein 2 (SECISBP2) increases the efficiency of this process. Pathogenic mutations in SECISBP2 reduce selenoprotein expression and lead to phenotypes associated with the reduction of deiodinase activities and selenoprotein N expression in humans. Two functions have been ascribed to SECISBP2: binding of SECIS elements in selenoprotein mRNAs and facilitation of co-translational Sec insertion. To separately probe both functions, we established here two mouse models carrying two pathogenic missense mutations in Secisbp2 previously identified in patients. We found that the C696R substitution in the RNA-binding domain abrogates SECIS binding and does not support selenoprotein translation above the level of a complete Secisbp2 null mutation. The R543Q missense substitution located in the selenocysteine insertion domain resulted in residual activity and caused reduced selenoprotein translation, as demonstrated by ribosomal profiling to determine the impact on UGA recoding in individual selenoproteins. We found, however, that the R543Q variant is thermally unstable in vitro and completely degraded in the mouse liver in vivo, while being partially functional in the brain. The moderate impairment of selenoprotein expression in neurons led to astrogliosis and transcriptional induction of genes associated with immune responses. We conclude that differential SECISBP2 protein stability in individual cell types may dictate clinical phenotypes to a much greater extent than molecular interactions involving a mutated amino acid in SECISBP2.",Ribosome profiling of selenoproteins in vivo reveals consequences of pathogenic Secisbp2 missense mutations.,10.1074/jbc.RA119.009369,2019 Sep 27,PMC6768643,The Journal of biological chemistry
GSE132725,Transcriptome and ribosome profiling of XRN1-null HEK293T human cell line generated by CRISPR/Cas9 gene editing,Homo sapiens,8,SRP201395,2019-7-25,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132725,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132725/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA548813,31340047," Chung-Te Chang,  Sowndarya Muthukumar,  Ramona Weber,  Yevgen Levdansky,  Ying Chen,  Dipankar Bhandari,  Catia Igreja,  Lara Wohlbold,  Eugene Valkov,  Elisa Izaurralde","XRN1 is the major cytoplasmic exoribonuclease in eukaryotes, which degrades deadenylated and decapped mRNAs in the last step of the 5'-3' mRNA decay pathway. Metazoan XRN1 interacts with decapping factors coupling the final stages of decay. Here, we reveal a direct interaction between XRN1 and the CCR4-NOT deadenylase complex mediated by a low-complexity region in XRN1, which we term the 'C-terminal interacting region' or CIR. The CIR represses reporter mRNA deadenylation in human cells when overexpressed and inhibits CCR4-NOT and isolated CAF1 deadenylase activity in vitro. Through complementation studies in an XRN1-null cell line, we dissect the specific contributions of XRN1 domains and regions toward decay of an mRNA reporter. We observe that XRN1 binding to the decapping activator EDC4 counteracts the dominant negative effect of CIR overexpression on decay. Another decapping activator PatL1 directly interacts with CIR and alleviates the CIR-mediated inhibition of CCR4-NOT activity in vitro. Ribosome profiling revealed that XRN1 loss impacts not only on mRNA levels but also on the translational efficiency of many cellular transcripts likely as a consequence of incomplete decay. Our findings reveal an additional layer of direct interactions in a tightly integrated network of factors mediating deadenylation, decapping and 5'-3' exonucleolytic decay.",A low-complexity region in human XRN1 directly recruits deadenylation and decapping factors in 5'-3' messenger RNA decay.,10.1093/nar/gkz633,2019 Sep 26,PMC6753473,Nucleic acids research
GSE125725,RNA-seq and ribosome profiling of heat shocked wild type and Mettl14 -/- mouse embryonic stem cells,Mus musculus,48,SRP182641,2019-7-15,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125725,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE125nnn/GSE125725/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA517401,31292544," Ryan J Ries,  Sara Zaccara,  Pierre Klein,  Anthony Olarerin-George,  Sim Namkoong,  Brian F Pickering,  Deepak P Patil,  Hojoong Kwak,  Jun Hee Lee,  Samie R Jaffrey","N(6)-methyladenosine (m(6)A) is the most prevalent modified nucleotide in mRNA(1,2), with around 25% of mRNAs containing at least one m(6)A. Methylation of mRNA to form m(6)A is required for diverse cellular and physiological processes(3). Although the presence of m(6)A in an mRNA can affect its fate in different ways, it is unclear how m(6)A directs this process and why the effects of m(6)A can vary in different cellular contexts. Here we show that the cytosolic m(6)A-binding proteins-YTHDF1, YTHDF2 and YTHDF3-undergo liquid-liquid phase separation in vitro and in cells. This phase separation is markedly enhanced by mRNAs that contain multiple, but not single, m(6)A residues. Polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their low-complexity domains and thereby leading to phase separation. The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated compartments, such as P-bodies, stress granules or neuronal RNA granules. m(6)A-mRNA is subject to compartment-specific regulation, including a reduction in the stability and translation of mRNA. These studies reveal that the number and distribution of m(6)A sites in cellular mRNAs can regulate and influence the composition of the phase-separated transcriptome, and suggest that the cellular properties of m(6)A-modified mRNAs are governed by liquid-liquid phase separation principles.",m(6)A enhances the phase separation potential of mRNA.,10.1038/s41586-019-1374-1,2019 Jul,PMC6662915,Nature
GSE133125,Ribosome profiling of Cryptococcus neoformans H99,Cryptococcus neoformans;Cryptococcus neoformans var. neoformans,12,SRP202195,2019-6-22,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133125,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE133nnn/GSE133125/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA550038,32020195," Edward W J Wallace,  Corinne Maufrais,  Jade Sales-Lee,  Laura R Tuck,  Luciana de Oliveira,  Frank Feuerbach,  Frederique Moyrand,  Prashanthi Natarajan,  Hiten D Madhani,  Guilhem Janbon","Eukaryotic protein synthesis generally initiates at a start codon defined by an AUG and its surrounding Kozak sequence context, but the quantitative importance of this context in different species is unclear. We tested this concept in two pathogenic Cryptococcus yeast species by genome-wide mapping of translation and of mRNA 5' and 3' ends. We observed thousands of AUG-initiated upstream open reading frames (uORFs) that are a major contributor to translation repression. uORF use depends on the Kozak sequence context of its start codon, and uORFs with strong contexts promote nonsense-mediated mRNA decay. Transcript leaders in Cryptococcus and other fungi are substantially longer and more AUG-dense than in Saccharomyces. Numerous Cryptococcus mRNAs encode predicted dual-localized proteins, including many aminoacyl-tRNA synthetases, in which a leaky AUG start codon is followed by a strong Kozak context in-frame AUG, separated by mitochondrial-targeting sequence. Analysis of other fungal species shows that such dual-localization is also predicted to be common in the ascomycete mould, Neurospora crassa. Kozak-controlled regulation is correlated with insertions in translational initiation factors in fidelity-determining regions that contact the initiator tRNA. Thus, start codon context is a signal that quantitatively programs both the expression and the structures of proteins in diverse fungi.",Quantitative global studies reveal differential translational control by start codon context across the fungal kingdom.,10.1093/nar/gkaa060,2020 Mar 18,PMC7049704,Nucleic acids research
GSE133111,Ribosome profiling of A549 cells depleted of RPLP1 and RPLP2 and infected with DENV.,Homo sapiens,12,SRP202033,2019-6-21,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133111,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE133nnn/GSE133111/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA549955,,,,,,,,
GSE112705,Landscapes of gene translation in hepatocellular carcinoma tumors revealed by ribosome profiling,Homo sapiens,40,SRP137150,2019-6-14,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112705,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112705/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA448763,31281537," Qin Zou,  Zhengtao Xiao,  Rongyao Huang,  Xin Wang,  Xun Wang,  Haitao Zhao,  Xuerui Yang","Despite the critical position of translation in the multilevel gene expression regulation program, high-resolution and genome-wide view of the landscape of RNA translation in solid tumors is still limited. Methods: With a ribosome profiling procedure optimized for solid tissue samples, we profiled the translatomes of liver tumors and their adjacent noncancerous normal liver tissues from 10 patients with hepatocellular carcinoma (HCC). A set of bioinformatics tools was then applied to these data for the mining of novel insights into the translation shifts in HCC. Results: This is the first translatome data resource for dissecting dysregulated translation in HCC at the sub-codon resolution. Based on our data, quantitative comparisons of mRNA translation rates yielded the genes and processes that were subjected to patient specific or universal dysregulations of translation efficiencies in tumors. For example, multiple proteins involved in extracellular matrix organization exhibited significant translational upregulation in tumors. We then experimentally validated the tumor-promoting functions of two such genes as examples: AGRN and VWA1. In addition, the data was also used for de novo annotation of the translatomes in tumors and normal tissues, including multiple types of novel non-canonical small ORFs, which would be a resource for further functional studies. Conclusions: The present study generates the first survey of the HCC translatome with ribosome profiling, which is an insightful data resource for dissecting the translatome shift in liver cancer, at sub-codon resolution.",Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling.,10.7150/thno.35033,2019,PMC6592166,Theranostics
GSE116233,Optimization of Ribosome Profiling Using Brain Tissue from Fragile X Mice,Homo sapiens;Mus musculus,56,SRP151279,2019-3-15,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116233,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE116nnn/GSE116233/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA477831,30590705," Botao Liu,  Gemma Molinaro,  Huan Shu,  Emily E Stackpole,  Kimberly M Huber,  Joel D Richter","Dysregulated protein synthesis is a major underlying cause of many neurodevelopmental diseases including fragile X syndrome. In order to capture subtle but biologically significant differences in translation in these disorders, a robust technique is required. One powerful tool to study translational control is ribosome profiling, which is based on deep sequencing of mRNA fragments protected from ribonuclease (RNase) digestion by ribosomes. However, this approach has been mainly applied to rapidly dividing cells where translation is active and large amounts of starting material are readily available. The application of ribosome profiling to low-input brain tissue where translation is modest and gene expression changes between genotypes are expected to be small has not been carefully evaluated. Using hippocampal tissue from wide type and fragile X mental retardation 1 (Fmr1) knockout mice, we show that variable RNase digestion can lead to significant sample batch effects. We also establish GC content and ribosome footprint length as quality control metrics for RNase digestion. We performed RNase titration experiments for low-input samples to identify optimal conditions for this critical step that is often improperly conducted. Our data reveal that optimal RNase digestion is essential to ensure high quality and reproducibility of ribosome profiling for low-input brain tissue.",Optimization of ribosome profiling using low-input brain tissue from fragile X syndrome model mice.,10.1093/nar/gky1292,2019 Mar 18,PMC6411937,Nucleic acids research
GSE127713,Cellular gene expression during Hepatitis C Virus replication revealed by Ribosome profiling,Homo sapiens,12,SRP187206,2019-3-02,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE127713,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE127nnn/GSE127713/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA525090,30875926," Gesche K Gerresheim,  Jochen Bathke,  Audrey M Michel,  Dmitri E Andreev,  Lyudmila A Shalamova,  Oliver Rossbach,  Pan Hu,  Dieter Glebe,  Markus Fricke,  Manja Marz,  Alexander Goesmann,  Stephen J Kiniry,  Pavel V Baranov,  Ivan N Shatsky,  Michael Niepmann","BACKGROUND: Hepatitis C virus (HCV) infects human liver hepatocytes, often leading to liver cirrhosis and hepatocellular carcinoma (HCC). It is believed that chronic infection alters host gene expression and favors HCC development. In particular, HCV replication in Endoplasmic Reticulum (ER) derived membranes induces chronic ER stress. How HCV replication affects host mRNA translation and transcription at a genome wide level is not yet known. METHODS: We used Riboseq (Ribosome Profiling) to analyze transcriptome and translatome changes in the Huh-7.5 hepatocarcinoma cell line replicating HCV for 6 days. RESULTS: Established viral replication does not cause global changes in host gene expression-only around 30 genes are significantly differentially expressed. Upregulated genes are related to ER stress and HCV replication, and several regulated genes are known to be involved in HCC development. Some mRNAs (PPP1R15A/GADD34, DDIT3/CHOP, and TRIB3) may be subject to upstream open reading frame (uORF) mediated translation control. Transcriptional downregulation mainly affects mitochondrial respiratory chain complex core subunit genes. CONCLUSION: After establishing HCV replication, the lack of global changes in cellular gene expression indicates an adaptation to chronic infection, while the downregulation of mitochondrial respiratory chain genes indicates how a virus may further contribute to cancer cell-like metabolic reprogramming (""Warburg effect"") even in the hepatocellular carcinoma cells used here.",Cellular Gene Expression during Hepatitis C Virus Replication as Revealed by Ribosome Profiling.,10.3390/ijms20061321,2019 Mar 15,PMC6470931,International journal of molecular sciences
GSE121952,Active ribosome profiling in SETD2 or METTL14 knockdown HepG2 cells,Homo sapiens,12,SRP167238,2019-2-21,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121952,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE121nnn/GSE121952/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA501872,30867593," Huilin Huang,  Hengyou Weng,  Keren Zhou,  Tong Wu,  Boxuan Simen Zhao,  Mingli Sun,  Zhenhua Chen,  Xiaolan Deng,  Gang Xiao,  Franziska Auer,  Lars Klemm,  Huizhe Wu,  Zhixiang Zuo,  Xi Qin,  Yunzhu Dong,  Yile Zhou,  Hanjun Qin,  Shu Tao,  Juan Du,  Jun Liu,  Zhike Lu,  Hang Yin,  Ana Mesquita,  Celvie L Yuan,  Yueh-Chiang Hu,  Wenju Sun,  Rui Su,  Lei Dong,  Chao Shen,  Chenying Li,  Ying Qing,  Xi Jiang,  Xiwei Wu,  Miao Sun,  Jun-Lin Guan,  Lianghu Qu,  Minjie Wei,  Markus Muschen,  Gang Huang,  Chuan He,  Jianhua Yang,  Jianjun Chen","DNA and histone modifications have notable effects on gene expression(1). Being the most prevalent internal modification in mRNA, the N(6)-methyladenosine (m(6)A) mRNA modification is as an important post-transcriptional mechanism of gene regulation(2-4) and has crucial roles in various normal and pathological processes(5-12). However, it is unclear how m(6)A is specifically and dynamically deposited in the transcriptome. Here we report that histone H3 trimethylation at Lys36 (H3K36me3), a marker for transcription elongation, guides m(6)A deposition globally. We show that m(6)A modifications are enriched in the vicinity of H3K36me3 peaks, and are reduced globally when cellular H3K36me3 is depleted. Mechanistically, H3K36me3 is recognized and bound directly by METTL14, a crucial component of the m(6)A methyltransferase complex (MTC), which in turn facilitates the binding of the m(6)A MTC to adjacent RNA polymerase II, thereby delivering the m(6)A MTC to actively transcribed nascent RNAs to deposit m(6)A co-transcriptionally. In mouse embryonic stem cells, phenocopying METTL14 knockdown, H3K36me3 depletion also markedly reduces m(6)A abundance transcriptome-wide and in pluripotency transcripts, resulting in increased cell stemness. Collectively, our studies reveal the important roles of H3K36me3 and METTL14 in determining specific and dynamic deposition of m(6)A in mRNA, and uncover another layer of gene expression regulation that involves crosstalk between histone modification and RNA methylation.",Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally.,10.1038/s41586-019-1016-7,2019 Mar,PMC6438714,Nature
GSE110618,Ribosome profiling uncovers selective mRNA translation associated with eIF2 phosphorylation in erythroid progenitors,Mus musculus,18,SRP132874,2019-2-01,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110618,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110618/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA434112,,,,,,,,
GSE123675,Identifying small proteins by ribosome profiling with stalled initiation complexes,Escherichia coli str. K-12 substr. MG1655,2,SRP173310,2019-2-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123675,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123675/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA509509,30837344," Jeremy Weaver,  Fuad Mohammad,  Allen R Buskirk,  Gisela Storz","Small proteins consisting of 50 or fewer amino acids have been identified as regulators of larger proteins in bacteria and eukaryotes. Despite the importance of these molecules, the total number of small proteins remains unknown because conventional annotation pipelines usually exclude small open reading frames (smORFs). We previously identified several dozen small proteins in the model organism Escherichia coli using theoretical bioinformatic approaches based on sequence conservation and matches to canonical ribosome binding sites. Here, we present an empirical approach for discovering new proteins, taking advantage of recent advances in ribosome profiling in which antibiotics are used to trap newly initiated 70S ribosomes at start codons. This approach led to the identification of many novel initiation sites in intergenic regions in E. coli We tagged 41 smORFs on the chromosome and detected protein synthesis for all but three. Not only are the corresponding genes intergenic but they are also found antisense to other genes, in operons, and overlapping other open reading frames (ORFs), some impacting the translation of larger downstream genes. These results demonstrate the utility of this method for identifying new genes, regardless of their genomic context.IMPORTANCE Proteins comprised of 50 or fewer amino acids have been shown to interact with and modulate the functions of larger proteins in a range of organisms. Despite the possible importance of small proteins, the true prevalence and capabilities of these regulators remain unknown as the small size of the proteins places serious limitations on their identification, purification, and characterization. Here, we present a ribosome profiling approach with stalled initiation complexes that led to the identification of 38 new small proteins.",Identifying Small Proteins by Ribosome Profiling with Stalled Initiation Complexes.,10.1128/mBio.02819-18,2019 Mar 5,PMC6401488,mBio
GSE97286,Ribosome profiling in wild-type and APOBEC1-deficient BMDMs,Mus musculus,24,SRP102816,2018-12-31,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97286,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE97nnn/GSE97286/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA381205,,,,,,,,
GSE102216,Ribosome profiling analysis of heat effect on rice,Oryza sativa,4,SRP114761,2018-11-12,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102216,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102216/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA397035,30413617," Zhao Su,  Yin Tang,  Laura E Ritchey,  David C Tack,  Mengmeng Zhu,  Philip C Bevilacqua,  Sarah M Assmann","The heat shock response is crucial for organism survival in natural environments. RNA structure is known to influence numerous processes related to gene expression, but there have been few studies on the global RNA structurome as it prevails in vivo. Moreover, how heat shock rapidly affects RNA structure genome-wide in living systems remains unknown. We report here in vivo heat-regulated RNA structuromes. We applied Structure-seq chemical [dimethyl sulfate (DMS)] structure probing to rice (Oryza sativa L.) seedlings with and without 10 min of 42 degrees C heat shock and obtained structural data on >14,000 mRNAs. We show that RNA secondary structure broadly regulates gene expression in response to heat shock in this essential crop species. Our results indicate significant heat-induced elevation of DMS reactivity in the global transcriptome, revealing RNA unfolding over this biological temperature range. Our parallel Ribo-seq analysis provides no evidence for a correlation between RNA unfolding and heat-induced changes in translation, in contrast to the paradigm established in prokaryotes, wherein melting of RNA thermometers promotes translation. Instead, we find that heat-induced DMS reactivity increases correlate with significant decreases in transcript abundance, as quantified from an RNA-seq time course, indicating that mRNA unfolding promotes transcript degradation. The mechanistic basis for this outcome appears to be mRNA unfolding at both 5' and 3'-UTRs that facilitates access to the RNA degradation machinery. Our results thus reveal unexpected paradigms governing RNA structural changes and the eukaryotic RNA life cycle.",Genome-wide RNA structurome reprogramming by acute heat shock globally regulates mRNA abundance.,10.1073/pnas.1807988115,2018 Nov 27,PMC6275526,Proceedings of the National Academy of Sciences of the United States of America
GSE102354,Active ribosome profiling  from mouse brains with RiboLace,Mus musculus,2,SRP115013,2018-10-09,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102354,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102354/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA397543,30355487," Massimiliano Clamer,  Toma Tebaldi,  Fabio Lauria,  Paola Bernabo,  Rodolfo F Gomez-Biagi,  Marta Marchioretto,  Divya T Kandala,  Luca Minati,  Elena Perenthaler,  Daniele Gubert,  Laura Pasquardini,  Graziano Guella,  Ewout J N Groen,  Thomas H Gillingwater,  Alessandro Quattrone,  Gabriella Viero","Ribosome profiling, or Ribo-seq, is based on large-scale sequencing of RNA fragments protected from nuclease digestion by ribosomes. Thanks to its unique ability to provide positional information about ribosomes flowing along transcripts, this method can be used to shed light on mechanistic aspects of translation. However, current Ribo-seq approaches lack the ability to distinguish between fragments protected by either ribosomes in active translation or inactive ribosomes. To overcome this possible limitation, we developed RiboLace, a method based on an original puromycin-containing molecule capable of isolating active ribosomes by means of an antibody-free and tag-free pull-down approach. RiboLace is fast, works reliably with low amounts of input material, and can be easily and rapidly applied both in vitro and in vivo, thereby generating a global snapshot of active ribosome footprints at single nucleotide resolution.",Active Ribosome Profiling with RiboLace.,10.1016/j.celrep.2018.09.084,2018 Oct 23,,Cell reports
GSE120097,Dazl regulates germ cell survival through a network of polA-proximal mRNA interactions [GC1-spg cells (parental line) Ribosome Profiling and RNA-seq],Mus musculus,12,SRP161995,2018-9-18,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120097,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE120nnn/GSE120097/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA491649,30380414," Leah L Zagore,  Thomas J Sweet,  Molly M Hannigan,  Sebastien M Weyn-Vanhentenryck,  Raul Jobava,  Maria Hatzoglou,  Chaolin Zhang,  Donny D Licatalosi","The RNA binding protein DAZL is essential for gametogenesis, but its direct in vivo functions, RNA targets, and the molecular basis for germ cell loss in Dazl-null mice are unknown. Here, we mapped transcriptome-wide DAZL-RNA interactions in vivo, revealing DAZL binding to thousands of mRNAs via polyA-proximal 3' UTR interactions. In parallel, fluorescence-activated cell sorting and RNA-seq identified mRNAs sensitive to DAZL deletion in male germ cells. Despite binding a broad set of mRNAs, integrative analyses indicate that DAZL post-transcriptionally controls only a subset of its mRNA targets, namely those corresponding to a network of genes that are critical for germ cell proliferation and survival. In addition, we provide evidence that polyA sequences have key roles in specifying DAZL-RNA interactions across the transcriptome. Our results reveal a mechanism for DAZL-RNA binding and illustrate that DAZL functions as a master regulator of a post-transcriptional mRNA program essential for germ cell survival.",DAZL Regulates Germ Cell Survival through a Network of PolyA-Proximal mRNA Interactions.,10.1016/j.celrep.2018.10.012,2018 Oct 30,PMC6878787,Cell reports
GSE102837,Prediction of ribosomal elongation rate from ribosome profiling data,Saccharomyces cerevisiae,2,SRP115846,2018-8-18,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102837,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102837/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA399079,29997263," Gavin Hanson,  Najwa Alhusaini,  Nathan Morris,  Thomas Sweet,  Jeff Coller","Messenger RNA (mRNA) degradation plays a critical role in regulating transcript levels in eukaryotic cells. Previous work by us and others has shown that codon identity exerts a powerful influence on mRNA stability. In Saccharomyces cerevisiae, studies using a handful of reporter mRNAs show that optimal codons increase translation elongation rate, which in turn increases mRNA stability. However, a direct relationship between elongation rate and mRNA stability has not been established across the entire yeast transcriptome. In addition, there is evidence from work in higher eukaryotes that amino acid identity influences mRNA stability, raising the question as to whether the impact of translation elongation on mRNA decay is at the level of tRNA decoding, amino acid incorporation, or some combination of each. To address these questions, we performed ribosome profiling of wild-type yeast. In good agreement with other studies, our data showed faster codon-specific elongation over optimal codons and faster transcript-level elongation correlating with transcript optimality. At both the codon-level and transcript-level, faster elongation correlated with increased mRNA stability. These findings were reinforced by showing increased translation efficiency and kinetics for a panel of 11 HIS3 reporter mRNAs of increasing codon optimality. While we did observe that elongation measured by ribosome profiling is composed of both amino acid identity and synonymous codon effects, further analyses of these data establish that A-site tRNA decoding rather than other steps of translation elongation is driving mRNA decay in yeast.",Translation elongation and mRNA stability are coupled through the ribosomal A-site.,10.1261/rna.066787.118,2018 Oct,PMC6140462,"RNA (New York, N.Y.)"
GSE116523,A Chemical Kinetic Basis for Measuring Translation Initiation and Elongation Rates from Ribosome Profiling data,Saccharomyces cerevisiae,2,SRP151781,2018-8-07,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116523,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE116nnn/GSE116523/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA478925,31120880," Ajeet K Sharma,  Pietro Sormanni,  Nabeel Ahmed,  Prajwal Ciryam,  Ulrike A Friedrich,  Gunter Kramer,  Edward P O'Brien","Analysis methods based on simulations and optimization have been previously developed to estimate relative translation rates from next-generation sequencing data. Translation involves molecules and chemical reactions, hence bioinformatics methods consistent with the laws of chemistry and physics are more likely to produce accurate results. Here, we derive simple equations based on chemical kinetic principles to measure the translation-initiation rate, transcriptome-wide elongation rate, and individual codon translation rates from ribosome profiling experiments. Our methods reproduce the known rates from ribosome profiles generated from detailed simulations of translation. By applying our methods to data from S. cerevisiae and mouse embryonic stem cells, we find that the extracted rates reproduce expected correlations with various molecular properties, and we also find that mouse embryonic stem cells have a global translation speed of 5.2 AA/s, in agreement with previous reports that used other approaches. Our analysis further reveals that a codon can exhibit up to 26-fold variability in its translation rate depending upon its context within a transcript. This broad distribution means that the average translation rate of a codon is not representative of the rate at which most instances of that codon are translated, and it suggests that translational regulation might be used by cells to a greater degree than previously thought.",A chemical kinetic basis for measuring translation initiation and elongation rates from ribosome profiling data.,10.1371/journal.pcbi.1007070,2019 May,PMC6559674,PLoS computational biology
GSE112766,DDX6 decouples translational repression from RNA degradation of miRNA targets [Ribosome Profiling],Mus musculus,12,SRP137758,2018-7-25,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112766,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112766/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA448921,30044225," Jacob W Freimer,  T J Hu,  Robert Blelloch","Translation and mRNA degradation are intimately connected, yet the mechanisms that link them are not fully understood. Here, we studied these mechanisms in embryonic stem cells (ESCs). Transcripts showed a wide range of stabilities, which correlated with their relative translation levels and that did not change during early ESC differentiation. The protein DHH1 links translation to mRNA stability in yeast; however, loss of the mammalian homolog, DDX6, in ESCs did not disrupt the correlation across transcripts. Instead, the loss of DDX6 led to upregulated translation of microRNA targets, without concurrent changes in mRNA stability. The Ddx6 knockout cells were phenotypically and molecularly similar to cells lacking all microRNAs (Dgcr8 knockout ESCs). These data show that the loss of DDX6 can separate the two canonical functions of microRNAs: translational repression and transcript destabilization. Furthermore, these data uncover a central role for translational repression independent of transcript destabilization in defining the downstream consequences of microRNA loss.",Decoupling the impact of microRNAs on translational repression versus RNA degradation in embryonic stem cells.,10.7554/eLife.38014,2018 Jul 25,PMC6086665,eLife
GSE111866,Ribosome profiling and transcriptome profiling of MCF-7 cells,Homo sapiens,2,SRP135757,2018-7-13,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111866,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111866/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA438445,30102689," Fabio Lauria,  Toma Tebaldi,  Paola Bernabo,  Ewout J N Groen,  Thomas H Gillingwater,  Gabriella Viero","Ribosome profiling is a powerful technique used to study translation at the genome-wide level, generating unique information concerning ribosome positions along RNAs. Optimal localization of ribosomes requires the proper identification of the ribosome P-site in each ribosome protected fragment, a crucial step to determine the trinucleotide periodicity of translating ribosomes, and draw correct conclusions concerning where ribosomes are located. To determine the P-site within ribosome footprints at nucleotide resolution, the precise estimation of its offset with respect to the protected fragment is necessary. Here we present riboWaltz, an R package for calculation of optimal P-site offsets, diagnostic analysis and visual inspection of ribosome profiling data. Compared to existing tools, riboWaltz shows improved accuracies for P-site estimation and neat ribosome positioning in multiple case studies. riboWaltz was implemented in R and is available as an R package at https://github.com/LabTranslationalArchitectomics/RiboWaltz.",riboWaltz: Optimization of ribosome P-site positioning in ribosome profiling data.,10.1371/journal.pcbi.1006169,2018 Aug,PMC6112680,PLoS computational biology
GSE113789,Ribosome profiling Seq of mouse adult cortex after acute stress,Mus musculus,24,SRP143492,2018-7-10,,Expression profiling by high throughput sequencing;Other,,,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA453992,30048615," Mareen Engel,  Carola Eggert,  Paul M Kaplick,  Matthias Eder,  Simone Roh,  Lisa Tietze,  Christian Namendorf,  Janine Arloth,  Peter Weber,  Monika Rex-Haffner,  Shay Geula,  Mira Jakovcevski,  Jacob H Hanna,  Dena Leshkowitz,  Manfred Uhr,  Carsten T Wotjak,  Mathias V Schmidt,  Jan M Deussing,  Elisabeth B Binder,  Alon Chen","N(6)-methyladenosine (m(6)A) and N(6),2'-O-dimethyladenosine (m(6)Am) are abundant mRNA modifications that regulate transcript processing and translation. The role of both, here termed m(6)A/m, in the stress response in the adult brain in vivo is currently unknown. Here, we provide a detailed analysis of the stress epitranscriptome using m(6)A/m-seq, global and gene-specific m(6)A/m measurements. We show that stress exposure and glucocorticoids region and time specifically alter m(6)A/m and its regulatory network. We demonstrate that deletion of the methyltransferase Mettl3 or the demethylase Fto in adult neurons alters the m(6)A/m epitranscriptome, increases fear memory, and changes the transcriptome response to fear and synaptic plasticity. Moreover, we report that regulation of m(6)A/m is impaired in major depressive disorder patients following glucocorticoid stimulation. Our findings indicate that brain m(6)A/m represents a novel layer of complexity in gene expression regulation after stress and that dysregulation of the m(6)A/m response may contribute to the pathophysiology of stress-related psychiatric disorders.",The Role of m(6)A/m-RNA Methylation in Stress Response Regulation.,10.1016/j.neuron.2018.07.009,2018 Jul 25,PMC6069762,Neuron
GSE116570,Cotranslational assembly of protein complexes in eukaryotes revealed by ribosome profiling,Saccharomyces cerevisiae BY4741,68,SRP152018,2018-7-05,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116570,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE116nnn/GSE116570/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA479682,30158700," Ayala Shiber,  Kristina Doring,  Ulrike Friedrich,  Kevin Klann,  Dorina Merker,  Mostafa Zedan,  Frank Tippmann,  Gunter Kramer,  Bernd Bukau","The folding of newly synthesized proteins to the native state is a major challenge within the crowded cellular environment, as non-productive interactions can lead to misfolding, aggregation and degradation(1). Cells cope with this challenge by coupling synthesis with polypeptide folding and by using molecular chaperones to safeguard folding cotranslationally(2). However, although most of the cellular proteome forms oligomeric assemblies(3), little is known about the final step of folding: the assembly of polypeptides into complexes. In prokaryotes, a proof-of-concept study showed that the assembly of heterodimeric luciferase is an organized cotranslational process that is facilitated by spatially confined translation of the subunits encoded on a polycistronic mRNA(4). In eukaryotes, however, fundamental differences-such as the rarity of polycistronic mRNAs and different chaperone constellations-raise the question of whether assembly is also coordinated with translation. Here we provide a systematic and mechanistic analysis of the assembly of protein complexes in eukaryotes using ribosome profiling. We determined the in vivo interactions of the nascent subunits from twelve hetero-oligomeric protein complexes of Saccharomyces cerevisiae at near-residue resolution. We find nine complexes assemble cotranslationally; the three complexes that do not show cotranslational interactions are regulated by dedicated assembly chaperones(5-7). Cotranslational assembly often occurs uni-directionally, with one fully synthesized subunit engaging its nascent partner subunit, thereby counteracting its propensity for aggregation. The onset of cotranslational subunit association coincides directly with the full exposure of the nascent interaction domain at the ribosomal tunnel exit. The action of the ribosome-associated Hsp70 chaperone Ssb(8) is coordinated with assembly. Ssb transiently engages partially synthesized interaction domains and then dissociates before the onset of partner subunit association, presumably to prevent premature assembly interactions. Our study shows that cotranslational subunit association is a prevalent mechanism for the assembly of hetero-oligomers in yeast and indicates that translation, folding and the assembly of protein complexes are integrated processes in eukaryotes.",Cotranslational assembly of protein complexes in eukaryotes revealed by ribosome profiling.,10.1038/s41586-018-0462-y,2018 Sep,PMC6372068,Nature
GSE70549,RNA-Seq matched to ribosome profiling over a zebrafish developmental timecourse,Danio rerio,8,SRP060373,2018-7-02,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70549,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE70nnn/GSE70549/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA288987,,,,,,,,
GSE90469,Ribosome profiling of G2019S LRRK2 human dopamine neurons,Homo sapiens,20,SRP093833,2018-7-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90469,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE90nnn/GSE90469/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA354729,,,,,,,,
GSE111891,Ribosome profiling experiment in control or Elp3 depleted B16 melanoma cells,Mus musculus,12,SRP135781,2018-6-26,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111891,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111891/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA438489,29925953," Francesca Rapino,  Sylvain Delaunay,  Florian Rambow,  Zhaoli Zhou,  Lars Tharun,  Pascal De Tullio,  Olga Sin,  Kateryna Shostak,  Sebastian Schmitz,  Jolanda Piepers,  Bart Ghesquiere,  Latifa Karim,  Benoit Charloteaux,  Diane Jamart,  Alexandra Florin,  Charles Lambert,  Andree Rorive,  Guy Jerusalem,  Eleonora Leucci,  Michael Dewaele,  Marc Vooijs,  Sebastian A Leidel,  Michel Georges,  Marianne Voz,  Bernard Peers,  Reinhard Buttner,  Jean-Christophe Marine,  Alain Chariot,  Pierre Close","Reprogramming of mRNA translation has a key role in cancer development and drug resistance (1) . However, the molecular mechanisms that are involved in this process remain poorly understood. Wobble tRNA modifications are required for specific codon decoding during translation(2,3). Here we show, in humans, that the enzymes that catalyse modifications of wobble uridine 34 (U34) tRNA (U34 enzymes) are key players of the protein synthesis rewiring that is induced by the transformation driven by the BRAF (V600E) oncogene and by resistance to targeted therapy in melanoma. We show that BRAF (V600E) -expressing melanoma cells are dependent on U34 enzymes for survival, and that concurrent inhibition of MAPK signalling and ELP3 or CTU1 and/or CTU2 synergizes to kill melanoma cells. Activation of the PI3K signalling pathway, one of the most common mechanisms of acquired resistance to MAPK therapeutic agents, markedly increases the expression of U34 enzymes. Mechanistically, U34 enzymes promote glycolysis in melanoma cells through the direct, codon-dependent, regulation of the translation of HIF1A mRNA and the maintenance of high levels of HIF1alpha protein. Therefore, the acquired resistance to anti-BRAF therapy is associated with high levels of U34 enzymes and HIF1alpha. Together, these results demonstrate that U34 enzymes promote the survival and resistance to therapy of melanoma cells by regulating specific mRNA translation.",Codon-specific translation reprogramming promotes resistance to targeted therapy.,10.1038/s41586-018-0243-7,2018 Jun,,Nature
GSE66580,Ribosome profiling reveals changes in translational status of soybean transcripts during immature cotyledon development,Glycine max,20,SRP055880,2018-3-23,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66580,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE66nnn/GSE66580/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA277363,29570733," Md Shamimuzzaman,  Lila Vodkin","To understand translational capacity on a genome-wide scale across three developmental stages of immature soybean seed cotyledons, ribosome profiling was performed in combination with RNA sequencing and cluster analysis. Transcripts representing 216 unique genes demonstrated a higher level of translational activity in at least one stage by exhibiting higher translational efficiencies (TEs) in which there were relatively more ribosome footprint sequence reads mapping to the transcript than were present in the control total RNA sample. The majority of these transcripts were more translationally active at the early stage of seed development and included 12 unique serine or cysteine proteases and 16 2S albumin and low molecular weight cysteine-rich proteins that may serve as substrates for turnover and mobilization early in seed development. It would appear that the serine proteases and 2S albumins play a vital role in the early stages. In contrast, our investigation of profiles of 19 genes encoding high abundance seed storage proteins, such as glycinins, beta-conglycinins, lectin, and Kunitz trypsin inhibitors, showed that they all had similar patterns in which the TE values started at low levels and increased approximately 2 to 6-fold during development. The highest levels of these seed protein transcripts were found at the mid-developmental stage, whereas the highest ribosome footprint levels of only up to 1.6 TE were found at the late developmental stage. These experimental findings suggest that the major seed storage protein coding genes are primarily regulated at the transcriptional level during normal soybean cotyledon development. Finally, our analyses also identified a total of 370 unique gene models that showed very low TE values including over 48 genes encoding ribosomal family proteins and 95 gene models that are related to energy and photosynthetic functions, many of which have homology to the chloroplast genome. Additionally, we showed that genes of the chloroplast were relatively translationally inactive during seed development.",Ribosome profiling reveals changes in translational status of soybean transcripts during immature cotyledon development.,10.1371/journal.pone.0194596,2018,PMC5865733,PloS one
GSE99395,Comparative ribosome profiling uncovers a dominant role for translational control in Toxoplasma gondii,Toxoplasma gondii,8,SRP108243,2017-11-23,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99395,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE99nnn/GSE99395/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA388385,29228904," Musa A Hassan,  Juan J Vasquez,  Chew Guo-Liang,  Markus Meissner,  T Nicolai Siegel","BACKGROUND: The lytic cycle of the protozoan parasite Toxoplasma gondii, which involves a brief sojourn in the extracellular space, is characterized by defined transcriptional profiles. For an obligate intracellular parasite that is shielded from the cytosolic host immune factors by a parasitophorous vacuole, the brief entry into the extracellular space is likely to exert enormous stress. Due to its role in cellular stress response, we hypothesize that translational control plays an important role in regulating gene expression in Toxoplasma during the lytic cycle. Unlike transcriptional profiles, insights into genome-wide translational profiles of Toxoplasma gondii are lacking. METHODS: We have performed genome-wide ribosome profiling, coupled with high throughput RNA sequencing, in intracellular and extracellular Toxoplasma gondii parasites to investigate translational control during the lytic cycle. RESULTS: Although differences in transcript abundance were mostly mirrored at the translational level, we observed significant differences in the abundance of ribosome footprints between the two parasite stages. Furthermore, our data suggest that mRNA translation in the parasite is potentially regulated by mRNA secondary structure and upstream open reading frames. CONCLUSION: We show that most of the Toxoplasma genes that are dysregulated during the lytic cycle are translationally regulated.",Comparative ribosome profiling uncovers a dominant role for translational control in Toxoplasma gondii.,10.1186/s12864-017-4362-6,2017 Dec 11,PMC5725899,BMC genomics
GSE99920,Transcriptional and ribosome profiling of Drosophila 3rd instar larvae muscle,Drosophila melanogaster,21,SRP108999,2017-11-06,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99920,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE99nnn/GSE99920/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA390134,,,,,,,,
GSE97461,TRAP sequencing of D1 and D2 spiny projection neurons from young and old mice and ribosome profiling in NIH-3T3 cells,Mus musculus,19,SRP103213,2017-8-30,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97461,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE97nnn/GSE97461/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA381914,30485811," Peter H Sudmant,  Hyeseung Lee,  Daniel Dominguez,  Myriam Heiman,  Christopher B Burge","Particular brain regions and cell populations exhibit increased susceptibility to aging-related stresses. Here, we describe the age-specific and brain-region-specific accumulation of ribosome-associated 3' UTR RNAs that lack the 5' UTR and open reading frame. Our study reveals that this phenomenon impacts hundreds of genes in aged D1 spiny projection neurons of the mouse striatum and also occurs in the aging human brain. Isolated 3' UTR accumulation is tightly correlated with mitochondrial gene expression and oxidative stress, with full-length mRNA expression that is reduced but not eliminated, and with production of short 3' UTR-encoded peptides. Depletion of the oxidation-sensitive Fe-S cluster ribosome recycling factor ABCE1 induces the accumulation of 3' UTRs, consistent with a model in which ribosome stalling and mRNA cleavage by No-Go decay yields isolated 3' UTR RNAs protected by ribosomes. Isolated 3' UTR accumulation is a hallmark of brain aging, likely reflecting regional differences in metabolism and oxidative stress.",Widespread Accumulation of Ribosome-Associated Isolated 3' UTRs in Neuronal Cell Populations of the Aging Brain.,10.1016/j.celrep.2018.10.094,2018 Nov 27,PMC6354779,Cell reports
GSE59819,Ribosome profiling and RNA sequencing of U2OS cells overexpressing myc,Homo sapiens,8,SRP044936,2017-7-27,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59819,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59819/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA256317,,,,,,,,
GSE69047,Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics,Homo sapiens,12,SRP058501,2017-5-18,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69047,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69047/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA284399,28578850," Tzu-Yu Liu,  Hector H Huang,  Diamond Wheeler,  Yichen Xu,  James A Wells,  Yun S Song,  Arun P Wiita","Ribosome profiling is a widespread tool for studying translational dynamics in human cells. Its central assumption is that ribosome footprint density on a transcript quantitatively reflects protein synthesis. Here, we test this assumption using pulsed-SILAC (pSILAC) high-accuracy targeted proteomics. We focus on multiple myeloma cells exposed to bortezomib, a first-line chemotherapy and proteasome inhibitor. In the absence of drug effects, we found that direct measurement of protein synthesis by pSILAC correlated well with indirect measurement of synthesis from ribosome footprint density. This correlation, however, broke down under bortezomib-induced stress. By developing a statistical model integrating longitudinal proteomic and mRNA-sequencing measurements, we found that proteomics could directly detect global alterations in translational rate caused by bortezomib; these changes are not detectable by ribosomal profiling alone. Further, by incorporating pSILAC data into a gene expression model, we predict cell-stress specific proteome remodeling events. These results demonstrate that pSILAC provides an important complement to ribosome profiling in measuring proteome dynamics.",Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics.,10.1016/j.cels.2017.05.001,2017 Jun 28,PMC5546878,Cell systems
GSE83684,"Ribosome Profiling analysis of Follicular B (FoB) cells purified from WT, miR-17~92 transgenic and  miR-17-92 tKO mice",Mus musculus,9,SRP077043,2017-3-08,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83684,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE83nnn/GSE83684/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA326723,28241004," Hyun Yong Jin,  Hiroyo Oda,  Pengda Chen,  Chao Yang,  Xiaojuan Zhou,  Seung Goo Kang,  Elizabeth Valentine,  Jennifer M Kefauver,  Lujian Liao,  Yaoyang Zhang,  Alicia Gonzalez-Martin,  Jovan Shepherd,  Gareth J Morgan,  Tony S Mondala,  Steven R Head,  Pyeung-Hyeun Kim,  Nengming Xiao,  Guo Fu,  Wen-Hsien Liu,  Jiahuai Han,  James R Williamson,  Changchun Xiao","MicroRNAs (miRNAs) are thought to exert their functions by modulating the expression of hundreds of target genes and each to a small degree, but it remains unclear how small changes in hundreds of target genes are translated into the specific function of a miRNA. Here, we conducted an integrated analysis of transcriptome and translatome of primary B cells from mutant mice expressing miR-17~92 at three different levels to address this issue. We found that target genes exhibit differential sensitivity to miRNA suppression and that only a small fraction of target genes are actually suppressed by a given concentration of miRNA under physiological conditions. Transgenic expression and deletion of the same miRNA gene regulate largely distinct sets of target genes. miR-17~92 controls target gene expression mainly through translational repression and 5'UTR plays an important role in regulating target gene sensitivity to miRNA suppression. These findings provide molecular insights into a model in which miRNAs exert their specific functions through a small number of key target genes.",Differential Sensitivity of Target Genes to Translational Repression by miR-17~92.,10.1371/journal.pgen.1006623,2017 Feb,PMC5348049,PLoS genetics
GSE91068,RNAseq and ribosome profiling of yeast cells grown under methionine restriction condition.,Saccharomyces cerevisiae,4,SRP094800,2017-2-24,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE91068,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE91nnn/GSE91068/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA356775,28212626," Ke Zou,  Qi Ouyang,  Hao Li,  Jiashun Zheng","BACKGROUND: Among twenty amino acids, methionine has a special role as it is coded by the translation initiation codon and methionyl-tRNAi (Met-tRNAi) is required for the assembly of the translation initiation complex. Thus methionine may play a special role in global gene regulation. Methionine has also been known to play important roles in cell growth, development, cancer, and aging. In this work, we characterize the translational and transcriptional programs induced by methionine restriction (MetR) and investigate the potential mechanisms through which methionine regulates gene expression, using the budding yeast S. cerevisiae as the model organism. RESULTS: Using ribosomal profiling and RNA-seq, we observed a broad spectrum of gene expression changes in response to MetR and identified hundreds of genes whose transcript level and/or translational efficiency changed significantly. These genes show clear functional themes, suggesting that cell slows down its growth and cell cycle progression and increases its stress resistance and maintenance in response to MetR. Interestingly, under MetR cell also decreases glycolysis and increases respiration, and increased respiration was linked to lifespan extension caused by caloric restriction. Analysis of genes whose translational efficiency changed significantly under MetR revealed different modes of translational regulation: 1) Ribosome loading patterns in the 5'UTR and coding regions of genes with increased translational efficiency suggested mechanisms both similar and different from that for the translational regulation of Gcn4 under general amino acid starvation condition; 2) Genes with decreased translational efficiency showed strong enrichment of lysine, glutamine, and glutamate codons, supporting the model that methionine can regulate translation by controlling tRNA thiolation. CONCLUSIONS: MetR induced a broad spectrum of gene expression changes at both the transcriptional and translational levels, with clear functional themes indicative of the physiological state of the cell under MetR. Different modes of translational regulation were induced by MetR, including the regulation of the ribosome loading at 5'UTR and regulation by tRNA thiolation. Since MetR extends the lifespan of many species, the list of genes we identified in this study can be good candidates for studying the mechanisms of lifespan extension.",A global characterization of the translational and transcriptional programs induced by methionine restriction through ribosome profiling and RNA-seq.,10.1186/s12864-017-3483-2,2017 Feb 17,PMC5316152,BMC genomics
GSE94385,Ribosome profiling and RNA-Sequencing of wild type and Pelota knockout mouse epidermis,Mus musculus,7,SRP098700,2017-2-02,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94385,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE94nnn/GSE94385/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA369542,29643507," Kifayathullah Liakath-Ali,  Eric W Mills,  Ines Sequeira,  Beate M Lichtenberger,  Angela Oliveira Pisco,  Kalle H Sipila,  Ajay Mishra,  Harunori Yoshikawa,  Colin Chih-Chien Wu,  Tony Ly,  Angus I Lamond,  Ibrahim M Adham,  Rachel Green,  Fiona M Watt","Ribosome-associated mRNA quality control mechanisms ensure the fidelity of protein translation(1,2). Although these mechanisms have been extensively studied in yeast, little is known about their role in mammalian tissues, despite emerging evidence that stem cell fate is controlled by translational mechanisms(3,4). One evolutionarily conserved component of the quality control machinery, Dom34 (in higher eukaryotes known as Pelota (Pelo)), rescues stalled ribosomes (5) . Here we show that Pelo is required for mammalian epidermal homeostasis. Conditional deletion of Pelo in mouse epidermal stem cells that express Lrig1 results in hyperproliferation and abnormal differentiation of these cells. By contrast, deletion of Pelo in Lgr5-expressing stem cells has no effect and deletion in Lgr6-expressing stem cells induces only a mild phenotype. Loss of Pelo results in accumulation of short ribosome footprints and global upregulation of translation, rather than affecting the expression of specific genes. Translational inhibition by rapamycin-mediated downregulation of mTOR (mechanistic target of rapamycin kinase) rescues the epidermal phenotype. Our study reveals that the ribosome-rescue machinery is important for mammalian tissue homeostasis and that it has specific effects on different stem cell populations.",An evolutionarily conserved ribosome-rescue pathway maintains epidermal homeostasis.,10.1038/s41586-018-0032-3,2018 Apr,,Nature
GSE91066,REPARATION:  Ribosome Profiling Assisted (Re-) Annotation of Bacterial genomes,Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344,4,SRP094797,2017-1-30,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE91066,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE91nnn/GSE91066/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA356772,28854918," Adam Giess,  Veronique Jonckheere,  Elvis Ndah,  Katarzyna Chyzynska,  Petra Van Damme,  Eivind Valen","BACKGROUND: While methods for annotation of genes are increasingly reliable, the exact identification of translation initiation sites remains a challenging problem. Since the N-termini of proteins often contain regulatory and targeting information, developing a robust method for start site identification is crucial. Ribosome profiling reads show distinct patterns of read length distributions around translation initiation sites. These patterns are typically lost in standard ribosome profiling analysis pipelines, when reads from footprints are adjusted to determine the specific codon being translated. RESULTS: Utilising these signatures in combination with nucleotide sequence information, we build a model capable of predicting translation initiation sites and demonstrate its high accuracy using N-terminal proteomics. Applying this to prokaryotic translatomes, we re-annotate translation initiation sites and provide evidence of N-terminal truncations and extensions of previously annotated coding sequences. These re-annotations are supported by the presence of structural and sequence-based features next to N-terminal peptide evidence. Finally, our model identifies 61 novel genes previously undiscovered in the Salmonella enterica genome. CONCLUSIONS: Signatures within ribosome profiling read length distributions can be used in combination with nucleotide sequence information to provide accurate genome-wide identification of translation initiation sites.",Ribosome signatures aid bacterial translation initiation site identification.,10.1186/s12915-017-0416-0,2017 Aug 30,PMC5576327,BMC biology
GSE83332,Epidermis-specific ribosome profiling to describe the translational landscape of SOX2,Mus musculus,30,SRP076538,2017-1-12,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83332,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE83nnn/GSE83332/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA325618,28077873," Ataman Sendoel,  Joshua G Dunn,  Edwin H Rodriguez,  Shruti Naik,  Nicholas C Gomez,  Brian Hurwitz,  John Levorse,  Brian D Dill,  Daniel Schramek,  Henrik Molina,  Jonathan S Weissman,  Elaine Fuchs","We are just beginning to understand how translational control affects tumour initiation and malignancy. Here we use an epidermis-specific, in vivo ribosome profiling strategy to investigate the translational landscape during the transition from normal homeostasis to malignancy. Using a mouse model of inducible SOX2, which is broadly expressed in oncogenic RAS-associated cancers, we show that despite widespread reductions in translation and protein synthesis, certain oncogenic mRNAs are spared. During tumour initiation, the translational apparatus is redirected towards unconventional upstream initiation sites, enhancing the translational efficiency of oncogenic mRNAs. An in vivo RNA interference screen of translational regulators revealed that depletion of conventional eIF2 complexes has adverse effects on normal but not oncogenic growth. Conversely, the alternative initiation factor eIF2A is essential for cancer progression, during which it mediates initiation at these upstream sites, differentially skewing translation and protein expression. Our findings unveil a role for the translation of 5' untranslated regions in cancer, and expose new targets for therapeutic intervention.",Translation from unconventional 5' start sites drives tumour initiation.,10.1038/nature21036,2017 Jan 26,PMC5287289,Nature
GSE81932,"Ribosome profiling of synchronous, non-arrested yeast cells identifies translational control of lipid biosynthesis enzymes in the cell cycle",Saccharomyces cerevisiae,48,SRP075766,2017-1-09,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81932,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE81nnn/GSE81932/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA323467,28057705," Heidi M Blank,  Ricardo Perez,  Chong He,  Nairita Maitra,  Richard Metz,  Joshua Hill,  Yuhong Lin,  Charles D Johnson,  Vytas A Bankaitis,  Brian K Kennedy,  Rodolfo Aramayo,  Michael Polymenis","Translational control during cell division determines when cells start a new cell cycle, how fast they complete it, the number of successive divisions, and how cells coordinate proliferation with available nutrients. The translational efficiencies of mRNAs in cells progressing synchronously through the mitotic cell cycle, while preserving the coupling of cell division with cell growth, remain uninvestigated. We now report comprehensive ribosome profiling of a yeast cell size series from the time of cell birth, to identify mRNAs under periodic translational control. The data reveal coordinate translational activation of mRNAs encoding lipogenic enzymes late in the cell cycle including Acc1p, the rate-limiting enzyme acetyl-CoA carboxylase. An upstream open reading frame (uORF) confers the translational control of ACC1 and adjusts Acc1p protein levels in different nutrients. The ACC1 uORF is relevant for cell division because its ablation delays cell cycle progression, reduces cell size, and suppresses the replicative longevity of cells lacking the Sch9p protein kinase regulator of ribosome biogenesis. These findings establish an unexpected relationship between lipogenesis and protein synthesis in mitotic cell divisions.","Translational control of lipogenic enzymes in the cell cycle of synchronous, growing yeast cells.",10.15252/embj.201695050,2017 Feb 15,PMC5694946,The EMBO journal
GSE89011,Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells [ribosome profiling],Mus musculus,16,SRP091889,2017-1-06,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89011,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE89nnn/GSE89011/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA349752,28003464," Hayami Sugiyama,  Kazutoshi Takahashi,  Takuya Yamamoto,  Mio Iwasaki,  Megumi Narita,  Masahiro Nakamura,  Tim A Rand,  Masato Nakagawa,  Akira Watanabe,  Shinya Yamanaka","Novel APOBEC1 target 1 (Nat1) (also known as ""p97,"" ""Dap5,"" and ""Eif4g2"") is a ubiquitously expressed cytoplasmic protein that is homologous to the C-terminal two thirds of eukaryotic translation initiation factor 4G (Eif4g1). We previously showed that Nat1-null mouse embryonic stem cells (mES cells) are resistant to differentiation. In the current study, we found that NAT1 and eIF4G1 share many binding proteins, such as the eukaryotic translation initiation factors eIF3 and eIF4A and ribosomal proteins. However, NAT1 did not bind to eIF4E or poly(A)-binding proteins, which are critical for cap-dependent translation initiation. In contrast, compared with eIF4G1, NAT1 preferentially interacted with eIF2, fragile X mental retardation proteins (FMR), and related proteins and especially with members of the proline-rich and coiled-coil-containing protein 2 (PRRC2) family. We also found that Nat1-null mES cells possess a transcriptional profile similar, although not identical, to the ground state, which is established in wild-type mES cells when treated with inhibitors of the ERK and glycogen synthase kinase 3 (GSK3) signaling pathways. In Nat1-null mES cells, the ERK pathway is suppressed even without inhibitors. Ribosome profiling revealed that translation of mitogen-activated protein kinase kinase kinase 3 (Map3k3) and son of sevenless homolog 1 (Sos1) is suppressed in the absence of Nat1 Forced expression of Map3k3 induced differentiation of Nat1-null mES cells. These data collectively show that Nat1 is involved in the translation of proteins that are required for cell differentiation.",Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells.,10.1073/pnas.1617234114,2017 Jan 10,PMC5240712,Proceedings of the National Academy of Sciences of the United States of America
GSE79512,Ribosome profiling-guided depletion of an mRNA improves CHO cell growth and recombinant product titers,Cricetulus griseus,12,SRP072205,2016-12-21,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79512,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE79nnn/GSE79512/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA316065,28091612," Thomas Beuchert Kallehauge,  Shangzhong Li,  Lasse Ebdrup Pedersen,  Tae Kwang Ha,  Daniel Ley,  Mikael Rordam Andersen,  Helene Faustrup Kildegaard,  Gyun Min Lee,  Nathan E Lewis","Recombinant protein production coopts the host cell machinery to provide high protein yields of industrial enzymes or biotherapeutics. However, since protein translation is energetically expensive and tightly controlled, it is unclear if highly expressed recombinant genes are translated as efficiently as host genes. Furthermore, it is unclear how the high expression impacts global translation. Here, we present the first genome-wide view of protein translation in an IgG-producing CHO cell line, measured with ribosome profiling. Through this we found that our recombinant mRNAs were translated as efficiently as the host cell transcriptome, and sequestered up to 15% of the total ribosome occupancy. During cell culture, changes in recombinant mRNA translation were consistent with changes in transcription, demonstrating that transcript levels influence specific productivity. Using this information, we identified the unnecessary resistance marker NeoR to be a highly transcribed and translated gene. Through siRNA",Ribosome profiling-guided depletion of an mRNA increases cell growth rate and protein secretion.,10.1038/srep40388,2017 Jan 16,PMC5238448,Scientific reports
GSE81332,Ribosome profiling in Arabidopsis root and shoot,Arabidopsis thaliana,12,SRP074840,2016-11-04,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81332,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE81nnn/GSE81332/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA321304,27791167," Polly Yingshan Hsu,  Lorenzo Calviello,  Hsin-Yen Larry Wu,  Fay-Wei Li,  Carl J Rothfels,  Uwe Ohler,  Philip N Benfey","Deep sequencing of ribosome footprints (ribosome profiling) maps and quantifies mRNA translation. Because ribosomes decode mRNA every 3 nt, the periodic property of ribosome footprints could be used to identify novel translated ORFs. However, due to the limited resolution of existing methods, the 3-nt periodicity is observed mostly in a global analysis, but not in individual transcripts. Here, we report a protocol applied to Arabidopsis that maps over 90% of the footprints to the main reading frame and thus offers super-resolution profiles for individual transcripts to precisely define translated regions. The resulting data not only support many annotated and predicted noncanonical translation events but also uncover small ORFs in annotated noncoding RNAs and pseudogenes. A substantial number of these unannotated ORFs are evolutionarily conserved, and some produce stable proteins. Thus, our study provides a valuable resource for plant genomics and an efficient optimization strategy for ribosome profiling in other organisms.",Super-resolution ribosome profiling reveals unannotated translation events in Arabidopsis.,10.1073/pnas.1614788113,2016 Nov 8,PMC5111709,Proceedings of the National Academy of Sciences of the United States of America
GSE87892,Ribosome profiling of dhh1? yeast,Saccharomyces cerevisiae,6,SRP091454,2016-11-04,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87892,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE87nnn/GSE87892/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA348115,27821408," Jennifer Jungfleisch,  Danny D Nedialkova,  Ivan Dotu,  Katherine E Sloan,  Neus Martinez-Bosch,  Lukas Bruning,  Emanuele Raineri,  Pilar Navarro,  Markus T Bohnsack,  Sebastian A Leidel,  Juana Diez","The impact of RNA structures in coding sequences (CDS) within mRNAs is poorly understood. Here, we identify a novel and highly conserved mechanism of translational control involving RNA structures within coding sequences and the DEAD-box helicase Dhh1. Using yeast genetics and genome-wide ribosome profiling analyses, we show that this mechanism, initially derived from studies of the Brome Mosaic virus RNA genome, extends to yeast and human mRNAs highly enriched in membrane and secreted proteins. All Dhh1-dependent mRNAs, viral and cellular, share key common features. First, they contain long and highly structured CDSs, including a region located around nucleotide 70 after the translation initiation site; second, they are directly bound by Dhh1 with a specific binding distribution; and third, complementary experimental approaches suggest that they are activated by Dhh1 at the translation initiation step. Our results show that ribosome translocation is not the only unwinding force of CDS and uncover a novel layer of translational control that involves RNA helicases and RNA folding within CDS providing novel opportunities for regulation of membrane and secretome proteins.",A novel translational control mechanism involving RNA structures within coding sequences.,10.1101/gr.209015.116,2017 Jan,PMC5204348,Genome research
GSE85540,A ribosome profiling study of mRNA cleavage by the endonuclease RelE,Escherichia coli,9,SRP081474,2016-10-19,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85540,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE85nnn/GSE85540/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA338762,27924019," Jae-Yeon Hwang,  Allen R Buskirk","Implicated in persistence and stress response pathways in bacteria, RelE shuts down protein synthesis by cleaving mRNA within the ribosomal A site. Structural and biochemical studies have shown that RelE cuts with some sequence specificity, which we further characterize here, and that it shows no activity outside the context of the ribosome. We obtained a global view of the effect of RelE on translation by ribosome profiling, observing that ribosomes accumulate on the 5'-end of genes through dynamic cycles of mRNA cleavage, ribosome rescue and initiation. Moreover, the addition of purified RelE to cell lysates shows promise as a method for generating ribosome footprints. In bacteria, profiling studies have suffered from relatively low resolution and have yielded no information on reading frame due to problems inherent to MNase digestion, the method used to degrade unprotected regions of mRNA. In contrast, we find that RelE yields precise 3'-ends that for the first time reveal reading frame in bacteria. Given that RelE has been shown to function in all three domains of life, RelE has potential to improve reading frame and shed light on A-site occupancy in ribosome profiling experiments more broadly.",A ribosome profiling study of mRNA cleavage by the endonuclease RelE.,10.1093/nar/gkw944,2017 Jan 9,PMC5224514,Nucleic acids research
GSE85864,"Ribosome profiling of human platelets, reticulocytes, and in vitro cell lines",Homo sapiens,32,SRP082436,2016-9-29,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85864,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE85nnn/GSE85864/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA339577,27681415," Eric W Mills,  Jamie Wangen,  Rachel Green,  Nicholas T Ingolia","Protein synthesis continues in platelets and maturing reticulocytes, although these blood cells lack nuclei and do not make new mRNA or ribosomes. Here, we analyze translation in primary human cells from anucleate lineages by ribosome profiling and uncover a dramatic accumulation of post-termination unrecycled ribosomes in the 3\' UTRs of mRNAs. We demonstrate that these ribosomes accumulate as a result of the natural loss of the ribosome recycling factor ABCE1 during terminal differentiation. Induction of the ribosome rescue factors PELO and HBS1L is required to support protein synthesis when ABCE1 levels fall and for hemoglobin production during blood cell development. Our observations suggest that this distinctive loss of ABCE1 in anucleate blood lineages could sensitize them to defects in ribosome homeostasis, perhaps explaining in part why genetic defects in the fundamental process of ribosome production (""ribosomopathies"") often affect hematopoiesis specifically.",Dynamic Regulation of a Ribosome Rescue Pathway in Erythroid Cells and Platelets.,10.1016/j.celrep.2016.08.088,2016 Sep 27,PMC5111367,Cell reports
GSE73565,Complementary Post Transcriptional Regulatory Information is Detected by PUNCH-P and Ribosome Profiling,Homo sapiens,16,SRP064313,2016-9-28,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73565,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE73nnn/GSE73565/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA297338,,,,,,,,
GSE69602,Ribosome profiling analysis of Dengue Virus,Homo sapiens,116,SRP059187,2016-9-01,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69602,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69602/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA285961,29321322," David W Reid,  Rafael K Campos,  Jessica R Child,  Tianli Zheng,  Kitti Wing Ki Chan,  Shelton S Bradrick,  Subhash G Vasudevan,  Mariano A Garcia-Blanco,  Christopher V Nicchitta","A primary question in dengue virus (DENV) biology is the molecular strategy for recruitment of host cell protein synthesis machinery. Here, we combined cell fractionation, ribosome profiling, and transcriptome sequencing (RNA-seq) to investigate the subcellular organization of viral genome translation and replication as well as host cell translation and its response to DENV infection.",Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis.,10.1128/JVI.01766-17,2018 Apr 1,PMC5972907,Journal of virology
GSE60930,Genome-wide translational analysis of RAW264 macrophages by ribosome profiling,Mus musculus,12,SRP045893,2016-8-31,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60930,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60930/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA259844,,,,,,,,
GSE84746,Dual randomization of oligonucleotides to reduce the bias in ribosome-profiling libraries,Saccharomyces cerevisiae,19,SRP079402,2016-8-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84746,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE84nnn/GSE84746/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA330982,27450428," Aaron Lecanda,  Benedikt S Nilges,  Puneet Sharma,  Danny D Nedialkova,  Juliane Schwarz,  Juan M Vaquerizas,  Sebastian A Leidel","Protein translation is at the heart of cellular metabolism and its in-depth characterization is key for many lines of research. Recently, ribosome profiling became the state-of-the-art method to quantitatively characterize translation dynamics at a transcriptome-wide level. However, the strategy of library generation affects its outcomes. Here, we present a modified ribosome-profiling protocol starting from yeast, human cells and vertebrate brain tissue. We use a DNA linker carrying four randomized positions at its 5' end and a reverse-transcription (RT) primer with three randomized positions to reduce artifacts during library preparation. The use of seven randomized nucleotides allows to efficiently detect library-generation artifacts. We find that the effect of polymerase chain reaction (PCR) artifacts is relatively small for global analyses when sufficient input material is used. However, when input material is limiting, our strategy improves the sensitivity of gene-specific analyses. Furthermore, randomized nucleotides alleviate the skewed frequency of specific sequences at the 3' end of ribosome-protected fragments (RPFs) likely resulting from ligase specificity. Finally, strategies that rely on dual ligation show a high degree of gene-coverage variation. Taken together, our approach helps to remedy two of the main problems associated with ribosome-profiling data. This will facilitate the analysis of translational dynamics and increase our understanding of the influence of RNA modifications on translation.",Dual randomization of oligonucleotides to reduce the bias in ribosome-profiling libraries.,10.1016/j.ymeth.2016.07.011,2016 Sep 1,PMC5024760,"Methods (San Diego, Calif.)"
GSE75947,SPECtre: a spectral coherence-based classifier of actively translated transcripts from ribosome profiling sequence data,Homo sapiens,1,SRP067300,2016-7-01,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75947,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE75nnn/GSE75947/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA305807,,,,,,,,
GSE72066,Ribosome Profiling of mouse skin squamous tumours,Mus musculus,12,SRP062409,2016-6-16,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72066,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE72nnn/GSE72066/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA292862,27306184," Sandra Blanco,  Roberto Bandiera,  Martyna Popis,  Shobbir Hussain,  Patrick Lombard,  Jelena Aleksic,  Abdulrahim Sajini,  Hinal Tanna,  Rosana Cortes-Garrido,  Nikoletta Gkatza,  Sabine Dietmann,  Michaela Frye","Whether protein synthesis and cellular stress response pathways interact to control stem cell function is currently unknown. Here we show that mouse skin stem cells synthesize less protein than their immediate progenitors in vivo, even when forced to proliferate. Our analyses reveal that activation of stress response pathways drives both a global reduction of protein synthesis and altered translational programmes that together promote stem cell functions and tumorigenesis. Mechanistically, we show that inhibition of post-transcriptional cytosine-5 methylation locks tumour-initiating cells in this distinct translational inhibition programme. Paradoxically, this inhibition renders stem cells hypersensitive to cytotoxic stress, as tumour regeneration after treatment with 5-fluorouracil is blocked. Thus, stem cells must revoke translation inhibition pathways to regenerate a tissue or tumour.",Stem cell function and stress response are controlled by protein synthesis.,10.1038/nature18282,2016 Jun 16,PMC5040503,Nature
GSE78163,Ligation-Free Ribosome Profiling Reveals Cell Type-Specific Regulation of Protein Synthesis in the Brain,Mus musculus,12,SRP070655,2016-6-07,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78163,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE78nnn/GSE78163/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA312799,27380875," Nicholas Hornstein,  Daniela Torres,  Sohani Das Sharma,  Guomei Tang,  Peter Canoll,  Peter A Sims","Ribosome profiling has emerged as a powerful tool for genome-wide measurements of translation, but library construction requires multiple ligation steps and remains cumbersome relative to more conventional deep-sequencing experiments. We report a new, ligation-free approach to ribosome profiling that does not require ligation. Library construction for ligation-free ribosome profiling can be completed in one day with as little as 1 ng of purified RNA footprints. We apply ligation-free ribosome profiling to mouse brain tissue to identify new patterns of cell type-specific translation and test its ability to identify translational targets of mTOR signaling in the brain.",Ligation-free ribosome profiling of cell type-specific translation in the brain.,10.1186/s13059-016-1005-1,2016 Jul 5,PMC4934013,Genome biology
GSE81269,Ribosome profiling study of Dhh1p overexpression and the dhh1 knockout strain using monosome-protected footprints,Saccharomyces cerevisiae,18,SRP074750,2016-5-11,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81269,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE81nnn/GSE81269/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA321151,27641505," Aditya Radhakrishnan,  Ying-Hsin Chen,  Sophie Martin,  Najwa Alhusaini,  Rachel Green,  Jeff Coller","A major determinant of mRNA half-life is the codon-dependent rate of translational elongation. How the processes of translational elongation and mRNA decay communicate is unclear. Here, we establish that the DEAD-box protein Dhh1p is a sensor of codon optimality that targets an mRNA for decay. First, we find mRNAs whose translation elongation rate is slowed by inclusion of non-optimal codons are specifically degraded in a Dhh1p-dependent manner. Biochemical experiments show Dhh1p is preferentially associated with mRNAs with suboptimal codon choice. We find these effects on mRNA decay are sensitive to the number of slow-moving ribosomes on an mRNA. Moreover, we find Dhh1p overexpression leads to the accumulation of ribosomes specifically on mRNAs (and even codons) of low codon optimality. Lastly, Dhh1p physically interacts with ribosomes in vivo. Together, these data argue that Dhh1p is a sensor for ribosome speed, targeting an mRNA for repression and subsequent decay.",The DEAD-Box Protein Dhh1p Couples mRNA Decay and Translation by Monitoring Codon Optimality.,10.1016/j.cell.2016.08.053,2016 Sep 22,PMC5635654,Cell
GSE68200,Ribosome Profiling Reveals Translational Control During the Caulobacter crescentus cell cycle,Caulobacter vibrioides NA1000,12,SRP057599,2016-4-20,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68200,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68200/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA282016,27791168," Jared M Schrader,  Gene-Wei Li,  W Seth Childers,  Adam M Perez,  Jonathan S Weissman,  Lucy Shapiro,  Harley H McAdams","Progression of the Caulobacter cell cycle requires temporal and spatial control of gene expression, culminating in an asymmetric cell division yielding distinct daughter cells. To explore the contribution of translational control, RNA-seq and ribosome profiling were used to assay global transcription and translation levels of individual genes at six times over the cell cycle. Translational efficiency (TE) was used as a metric for the relative rate of protein production from each mRNA. TE profiles with similar cell cycle patterns were found across multiple clusters of genes, including those in operons or in subsets of operons. Collections of genes associated with central cell cycle functional modules (e.g., biosynthesis of stalk, flagellum, or chemotaxis machinery) have consistent but different TE temporal patterns, independent of their operon organization. Differential translation of operon-encoded genes facilitates precise cell cycle-timing for the dynamic assembly of multiprotein complexes, such as the flagellum and the stalk and the correct positioning of regulatory proteins to specific cell poles. The cell cycle-regulatory pathways that produce specific temporal TE patterns are separate from-but highly coordinated with-the transcriptional cell cycle circuitry, suggesting that the scheduling of translational regulation is organized by the same cyclical regulatory circuit that directs the transcriptional control of the Caulobacter cell cycle.",Dynamic translation regulation in Caulobacter cell cycle control.,10.1073/pnas.1614795113,2016 Nov 1,PMC5098616,Proceedings of the National Academy of Sciences of the United States of America
GSE72899,Clarifying the translational pausing landscape in bacteria by ribosome profiling,Escherichia coli str. K-12 substr. MG1655,5,SRP063562,2016-1-13,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72899,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE72nnn/GSE72899/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA295296,26776510," Fuad Mohammad,  Christopher J Woolstenhulme,  Rachel Green,  Allen R Buskirk","The rate of protein synthesis varies according to the mRNA sequence in ways that affect gene expression. Global analysis of translational pausing is now possible with ribosome profiling. Here, we revisit an earlier report that Shine-Dalgarno sequences are the major determinant of translational pausing in bacteria. Using refinements in the profiling method as well as biochemical assays, we find that SD motifs have little (if any) effect on elongation rates. We argue that earlier evidence of pausing arose from two factors. First, in previous analyses, pauses at Gly codons were difficult to distinguish from pauses at SD motifs. Second, and more importantly, the initial study preferentially isolated long ribosome-protected mRNA fragments that are enriched in SD motifs. These findings clarify the landscape of translational pausing in bacteria as observed by ribosome profiling.",Clarifying the Translational Pausing Landscape in Bacteria by Ribosome Profiling.,10.1016/j.celrep.2015.12.073,2016 Feb 2,PMC4835026,Cell reports
GSE67741,Ribosome profiling with translation inhibitors reveals pervasive translation in murine ES cells,Mus musculus,10,SRP057051,2016-1-12,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67741,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE67nnn/GSE67741/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA280809,26764022," Alexandra Popa,  Kevin Lebrigand,  Pascal Barbry,  Rainer Waldmann","BACKGROUND: Open reading frames are common in long noncoding RNAs (lncRNAs) and 5'UTRs of protein coding transcripts (uORFs). The question of whether those ORFs are translated was recently addressed by several groups using ribosome profiling. Most of those studies concluded that certain lncRNAs and uORFs are translated, essentially based on computational analysis of ribosome footprints. However, major discrepancies remain on the scope of translation and the translational status of individual ORFs. In consequence, further criteria are required to reliably identify translated ORFs from ribosome profiling data. RESULTS: We examined the effect of the translation inhibitors pateamine A, harringtonine and puromycin on murine ES cell ribosome footprints. We found that pateamine A, a drug that targets eIF4A, allows a far more accurate identification of translated sequences than previously used drugs and computational scoring schemes. Our data show that at least one third but less than two thirds of ES cell lncRNAs are translated. We also identified translated uORFs in hundreds of annotated coding transcripts including key pluripotency transcripts, such as dicer, lin28, trim71, and ctcf. CONCLUSION: Pateamine A inhibition data clearly increase the precision of the detection of translated ORFs in ribosome profiling experiments. Our data show that translation of lncRNAs and uORFs in murine ES cells is rather common although less pervasive than previously suggested. The observation of translated uORFs in several key pluripotency transcripts suggests that translational regulation by uORFs might be part of the network that defines mammalian stem cell identity.",Pateamine A-sensitive ribosome profiling reveals the scope of translation in mouse embryonic stem cells.,10.1186/s12864-016-2384-0,2016 Jan 14,PMC4712605,BMC genomics
GSE72463,Advancing Trypanosoma brucei genome annotation through ribosome profiling and spliced leader mapping,Trypanosoma brucei,22,SRP062914,2015-12-22,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72463,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE72nnn/GSE72463/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA294100,26393539," Marilyn Parsons,  Gowthaman Ramasamy,  Elton J R Vasconcelos,  Bryan C Jensen,  Peter J Myler","Since the initial publication of the trypanosomatid genomes, curation has been ongoing. Here we make use of existing Trypanosoma brucei ribosome profiling data to provide evidence of ribosome occupancy (and likely translation) of mRNAs from 225 currently unannotated coding sequences (CDSs). A small number of these putative genes correspond to extra copies of previously annotated genes, but 85% are novel. The median size of these novels CDSs is small (81 aa), indicating that past annotation work has excelled at detecting large CDSs. Of the unique CDSs confirmed here, over half have candidate orthologues in other trypanosomatid genomes, most of which were not yet annotated as protein-coding genes. Nonetheless, approximately one-third of the new CDSs were found only in T. brucei subspecies. Using ribosome footprints, RNA-Seq and spliced leader mapping data, we updated previous work to definitively revise the start sites for 414 CDSs as compared to the current gene models. The data pointed to several regions of the genome that had sequence errors that altered coding region boundaries. Finally, we consolidated this data with our previous work to propose elimination of 683 putative genes as protein-coding and arrive at a view of the translatome of slender bloodstream and procyclic culture form T. brucei.",Advancing Trypanosoma brucei genome annotation through ribosome profiling and spliced leader mapping.,10.1016/j.molbiopara.2015.09.002,2015 Aug,PMC4644489,Molecular and biochemical parasitology
GSE65885,Ribosome profiling and RNA sequencing of MCF10A-ER-Src and fibroblast cell transformation,Homo sapiens,36,SRP054971,2015-11-13,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65885,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE65nnn/GSE65885/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA275305,26900662," Zhe Ji,  Ruisheng Song,  Hailiang Huang,  Aviv Regev,  Kevin Struhl","Ribosome profiling is widely used to study translation in vivo, but not all sequence reads correspond to ribosome-protected RNA. Here we describe Rfoot, a computational pipeline that analyzes ribosomal profiling data and identifies native, nonribosomal RNA-protein complexes. We use Rfoot to precisely map RNase-protected regions within small nucleolar RNAs, spliceosomal RNAs, microRNAs, tRNAs, long noncoding (lnc)RNAs and 3' untranslated regions of mRNAs in human cells. We show that RNAs of the same class can show differential complex association. Although only a subset of lncRNAs show RNase footprints, many of these have multiple footprints, and the protected regions are evolutionarily conserved, suggestive of biological functions.",Transcriptome-scale RNase-footprinting of RNA-protein complexes.,10.1038/nbt.3441,2016 Apr,PMC4824641,Nature biotechnology
GSE66927,Ribo_seq (aka ribosome profiling) analysis of control and Myc-induced U2OS cells,Homo sapiens,10,SRP056200,2015-11-04,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66927,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE66nnn/GSE66927/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA278390,26538417," Ran Elkon,  Fabricio Loayza-Puch,  Gozde Korkmaz,  Rui Lopes,  Pieter C van Breugel,  Onno B Bleijerveld,  A F Maarten Altelaar,  Elmar Wolf,  Francesca Lorenzin,  Martin Eilers,  Reuven Agami","c-Myc is one of the major human proto-oncogenes and is often associated with tumor aggression and poor clinical outcome. Paradoxically, Myc was also reported as a suppressor of cell motility, invasiveness, and metastasis. Among the direct targets of Myc are many components of the protein synthesis machinery whose induction results in an overall increase in protein synthesis that empowers tumor cell growth. At present, it is largely unknown whether beyond the global enhancement of protein synthesis, Myc activation results in translation modulation of specific genes. Here, we measured Myc-induced global changes in gene expression at the transcription, translation, and protein levels and uncovered extensive transcript-specific regulation of protein translation. Particularly, we detected a broad coordination between regulation of transcription and translation upon modulation of Myc activity and showed the connection of these responses to mTOR signaling to enhance oncogenic transformation and to the TGFbeta pathway to modulate cell migration and invasiveness. Our results elucidate novel facets of Myc-induced cellular responses and provide a more comprehensive view of the consequences of its activation in cancer cells.",Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.,10.15252/embr.201540717,2015 Dec,PMC4687422,EMBO reports
GSE67305,Ribosome profiling reveals the rhythmic liver translatome and circadian clock regulation by upstream open reading frames,Mus musculus,48,SRP056576,2015-10-14,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67305,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE67nnn/GSE67305/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA279465,26486724," Peggy Janich,  Alaaddin Bulak Arpat,  Violeta Castelo-Szekely,  Maykel Lopes,  David Gatfield","Mammalian gene expression displays widespread circadian oscillations. Rhythmic transcription underlies the core clock mechanism, but it cannot explain numerous observations made at the level of protein rhythmicity. We have used ribosome profiling in mouse liver to measure the translation of mRNAs into protein around the clock and at high temporal and nucleotide resolution. We discovered, transcriptome-wide, extensive rhythms in ribosome occupancy and identified a core set of approximately 150 mRNAs subject to particularly robust daily changes in translation efficiency. Cycling proteins produced from nonoscillating transcripts revealed thus-far-unknown rhythmic regulation associated with specific pathways (notably in iron metabolism, through the rhythmic translation of transcripts containing iron responsive elements), and indicated feedback to the rhythmic transcriptome through novel rhythmic transcription factors. Moreover, estimates of relative levels of core clock protein biosynthesis that we deduced from the data explained known features of the circadian clock better than did mRNA expression alone. Finally, we identified uORF translation as a novel regulatory mechanism within the clock circuitry. Consistent with the occurrence of translated uORFs in several core clock transcripts, loss-of-function of Denr, a known regulator of reinitiation after uORF usage and of ribosome recycling, led to circadian period shortening in cells. In summary, our data offer a framework for understanding the dynamics of translational regulation, circadian gene expression, and metabolic control in a solid mammalian organ.",Ribosome profiling reveals the rhythmic liver translatome and circadian clock regulation by upstream open reading frames.,10.1101/gr.195404.115,2015 Dec,PMC4665006,Genome research
GSE69800,Ribosome profiling analysis of GADD34 null cells,Mus musculus,40,SRP059390,2015-10-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69800,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69800/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA286792,27161320," David W Reid,  Angeline S L Tay,  Jeyapriya R Sundaram,  Irene C J Lee,  Qiang Chen,  Simi E George,  Christopher V Nicchitta,  Shirish Shenolikar","Phosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha) controls transcriptome-wide changes in mRNA translation in stressed cells. While phosphorylated eIF2alpha (P-eIF2alpha) attenuates global protein synthesis, mRNAs encoding stress proteins are more efficiently translated. Two eIF2alpha phosphatases, containing GADD34 and CReP, catalyze P-eIF2alpha dephosphorylation. The current view of GADD34, whose transcription is stress induced, is that it functions in a feedback loop to resolve cell stress. In contrast, CReP, which is constitutively expressed, controls basal P-eIF2alpha levels in unstressed cells. Our studies show that GADD34 drives substantial changes in mRNA translation in unstressed cells, particularly targeting the secretome. Following activation of the unfolded protein response (UPR), rapid translation of GADD34 mRNA occurs and GADD34 is essential for UPR progression. In the absence of GADD34, eIF2alpha phosphorylation is persistently enhanced and the UPR translational program is significantly attenuated. This ""stalled"" UPR is relieved by the subsequent activation of compensatory mechanisms that include AKT-mediated suppression of PKR-like kinase (PERK) and increased expression of CReP mRNA, partially restoring protein synthesis. Our studies highlight the coordinate regulation of UPR by the",,10.1128/MCB.00190-16,2016 Jul 1TI - Complementary Roles of GADD34- and CReP-Containing Eukaryotic Initiation Factor 2alpha Phosphatases during the Unfolded Protein Response.,PMC4911741,Molecular and cellular biology
GSE41246,Ribosome profiling in muscle reveals the translation landscape of the giant protein titin,Mus musculus,4,SRP015946,2015-9-01,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41246,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE41nnn/GSE41246/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA176310,,,,,,,,
GSE56924,Ribosome profiling reveals an important role for translational control in circadian gene expression,Homo sapiens,96,SRP041298,2015-8-19,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56924,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE56nnn/GSE56924/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA244941,26338483," Christopher Jang,  Nicholas F Lahens,  John B Hogenesch,  Amita Sehgal","Physiological and behavioral circadian rhythms are driven by a conserved transcriptional/translational negative feedback loop in mammals. Although most core clock factors are transcription factors, post-transcriptional control introduces delays that are critical for circadian oscillations. Little work has been done on circadian regulation of translation, so to address this deficit we conducted ribosome profiling experiments in a human cell model for an autonomous clock. We found that most rhythmic gene expression occurs with little delay between transcription and translation, suggesting that the lag in the accumulation of some clock proteins relative to their mRNAs does not arise from regulated translation. Nevertheless, we found that translation occurs in a circadian fashion for many genes, sometimes imposing an additional level of control on rhythmically expressed mRNAs and, in other cases, conferring rhythms on noncycling mRNAs. Most cyclically transcribed RNAs are translated at one of two major times in a 24-h day, while rhythmic translation of most noncyclic RNAs is phased to a single time of day. Unexpectedly, we found that the clock also regulates the formation of cytoplasmic processing (P) bodies, which control the fate of mRNAs, suggesting circadian coordination of mRNA metabolism and translation.",Ribosome profiling reveals an important role for translational control in circadian gene expression.,10.1101/gr.191296.115,2015 Dec,PMC4665005,Genome research
GSE70159,Dietary selenium levels affect selenoprotein expression and support the interferon-? and IL-6 immune response pathways in mice [Ribosome Profiling],Mus musculus,8,SRP059780,2015-8-06,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70159,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE70nnn/GSE70159/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA287766,26258789," Petra A Tsuji,  Bradley A Carlson,  Christine B Anderson,  Harold E Seifried,  Dolph L Hatfield,  Michael T Howard","Selenium is an essential element that is required to support a number of cellular functions and biochemical pathways. The objective of this study was to examine the effects of reduced dietary selenium levels on gene expression to assess changes in expression of non-selenoprotein genes that may contribute to the physiological consequences of selenium deficiency. Mice were fed diets that were either deficient in selenium or supplemented with selenium in the form of sodium selenite for six weeks. Differences in liver mRNA expression and translation were measured using a combination of ribosome profiling, RNA-Seq, microarrays, and qPCR. Expression levels and translation of mRNAs encoding stress-related selenoproteins were shown to be up-regulated by increased selenium status, as were genes involved in inflammation and response to interferon-gamma. Changes in serum cytokine levels were measured which confirmed that interferon-gamma, as well as IL-6, were increased in selenium adequate mice. Finally, microarray and qPCR analysis of lung tissue demonstrated that the selenium effects on immune function are not limited to liver. These data are consistent with previous reports indicating that adequate selenium levels can support beneficial immune responses, and further identify the IL-6 and interferon-gamma pathways as being responsive to dietary selenium intake.",Dietary Selenium Levels Affect Selenoprotein Expression and Support the Interferon-gamma and IL-6 Immune Response Pathways in Mice.,10.3390/nu7085297,2015 Aug 6,PMC4555136,Nutrients
GSE68705,Genome-wide reprogramming of transcript architecture by temperature specifies the developmental states of the human pathogen Histoplasma [ribosome profiling],Histoplasma capsulatum,8,SRP058148,2015-7-16,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68705,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68705/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA283425,26177267," Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil","Eukaryotic cells integrate layers of gene regulation to coordinate complex cellular processes; however, mechanisms of post-transcriptional gene regulation remain poorly studied. The human fungal pathogen Histoplasma capsulatum (Hc) responds to environmental or host temperature by initiating unique transcriptional programs to specify multicellular (hyphae) or unicellular (yeast) developmental states that function in infectivity or pathogenesis, respectively. Here we used recent advances in next-generation sequencing to uncover a novel re-programming of transcript length between Hc developmental cell types. We found that ~2% percent of Hc transcripts exhibit 5' leader sequences that differ markedly in length between morphogenetic states. Ribosome density and mRNA abundance measurements of differential leader transcripts revealed nuanced transcriptional and translational regulation. One such class of regulated longer leader transcripts exhibited tight transcriptional and translational repression. Further examination of these dually repressed genes revealed that some control Hc morphology and that their strict regulation is necessary for the pathogen to make appropriate developmental decisions in response to temperature.",Genome-Wide Reprogramming of Transcript Architecture by Temperature Specifies the Developmental States of the Human Pathogen Histoplasma.,10.1371/journal.pgen.1005395,2015 Jul,PMC4503680,PLoS genetics
GSE68008,Methods comparison for ribosome profiling,Homo sapiens,2,SRP057384,2015-7-01,,Expression profiling by high throughput sequencing;Other,,,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA281481,26164698," David W Reid,  Shirish Shenolikar,  Christopher V Nicchitta","The development and application of ribosome profiling has markedly advanced our understanding of ribosomes and mRNA translation. The experimental approach, which relies on deep sequencing of ribosome-protected mRNA fragments generated by treatment of polyribosomes with exogenous nucleases, provides a transcriptome-wide assessment of translation. The broad application of ribosome profiling has been slowed by the complexity and expense of the protocol. Here, we provide a simplified ribosome profiling method that uses micrococcal nuclease to generate ribosome footprints in crude cellular extracts, which are then purified simply by size selection via polyacrylamide gel electrophoresis. This simplification removes the laborious or expensive purification of ribosomes that has typically been used. This direct extraction method generates gene-level ribosome profiling data that are similar to a method that includes ribosome purification. This protocol should significantly ease the barrier to entry for research groups interested in employing ribosome profiling.",Simple and inexpensive ribosome profiling analysis of mRNA translation.,10.1016/j.ymeth.2015.07.003,2015 Dec,PMC4684803,"Methods (San Diego, Calif.)"
GSE63858,Ribosome profiling of E. coli K-12 MG1655 MOPS rich media with 0.2% glucose,Escherichia coli str. K-12 substr. MG1655,2,SRP050548,2015-6-09,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63858,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE63nnn/GSE63858/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA269272,26054770," Haythem Latif,  Richard Szubin,  Justin Tan,  Elizabeth Brunk,  Anna Lechner,  Karsten Zengler,  Bernhard O Palsson","Ribosome profiling is a powerful tool for characterizing in vivo protein translation at the genome scale, with multiple applications ranging from detailed molecular mechanisms to systems-level predictive modeling. Though highly effective, this intricate technique has yet to become widely used in the microbial research community. Here we present a streamlined ribosome profiling protocol with reduced barriers to entry for microbial characterization studies. Our approach provides simplified alternatives during harvest, lysis, and recovery of monosomes and also eliminates several time-consuming steps, in particular size-selection steps during library construction. Furthermore, the abundance of rRNAs and tRNAs in the final library is drastically reduced. Our streamlined workflow enables greater throughput, cuts the time from harvest to the final library in half (down to 3-4 days), and generates a high fraction of informative reads, all while retaining the high quality standards of the existing protocol.",A streamlined ribosome profiling protocol for the characterization of microorganisms.,10.2144/000114302,2015 Jun,,BioTechniques
GSE69414,Ribosome profiling study of rli1 depeletion strain,Saccharomyces cerevisiae,10,SRP058910,2015-6-02,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69414,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69414/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA285458,26276635," David J Young,  Nicholas R Guydosh,  Fan Zhang,  Alan G Hinnebusch,  Rachel Green","To study the function of Rli1/ABCE1 in vivo, we used ribosome profiling and biochemistry to characterize its contribution to ribosome recycling. When Rli1 levels were diminished, 80S ribosomes accumulated both at stop codons and in the adjoining 3'UTRs of most mRNAs. Frequently, these ribosomes reinitiated translation without the need for a canonical start codon, as small peptide products predicted by 3'UTR ribosome occupancy in all three reading frames were confirmed by western analysis and mass spectrometry. Eliminating the ribosome-rescue factor Dom34 dramatically increased 3'UTR ribosome occupancy in Rli1 depleted cells, indicating that Dom34 clears the bulk of unrecycled ribosomes. Thus, Rli1 is crucial for ribosome recycling in vivo and controls ribosome homeostasis. 3'UTR translation occurs in wild-type cells as well, and observations of elevated 3'UTR ribosomes during stress suggest that modulating recycling and reinitiation is involved in responding to environmental changes.",Rli1/ABCE1 Recycles Terminating Ribosomes and Controls Translation Reinitiation in 3'UTRs In Vivo.,10.1016/j.cell.2015.07.041,2015 Aug 13,PMC4556345,Cell
GSE60040,Wide-spread disruption of transcription termination in HSV-1 infection: Next-generation sequencing of translational activityd by ribosome profiling,Homo sapiens,12,SRP045214,2015-5-26,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60040,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60040/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA257365,25989971," Andrzej J Rutkowski,  Florian Erhard,  Anne L'Hernault,  Thomas Bonfert,  Markus Schilhabel,  Colin Crump,  Philip Rosenstiel,  Stacey Efstathiou,  Ralf Zimmer,  Caroline C Friedel,  Lars Dolken","Herpes simplex virus 1 (HSV-1) is an important human pathogen and a paradigm for virus-induced host shut-off. Here we show that global changes in transcription and RNA processing and their impact on translation can be analysed in a single experimental setting by applying 4sU-tagging of newly transcribed RNA and ribosome profiling to lytic HSV-1 infection. Unexpectedly, we find that HSV-1 triggers the disruption of transcription termination of cellular, but not viral, genes. This results in extensive transcription for tens of thousands of nucleotides beyond poly(A) sites and into downstream genes, leading to novel intergenic splicing between exons of neighbouring cellular genes. As a consequence, hundreds of cellular genes seem to be transcriptionally induced but are not translated. In contrast to previous reports, we show that HSV-1 does not inhibit co-transcriptional splicing. Our approach thus substantially advances our understanding of HSV-1 biology and establishes HSV-1 as a model system for studying transcription termination.",Widespread disruption of host transcription termination in HSV-1 infection.,10.1038/ncomms8126,2015 May 20,PMC4441252,Nature communications
GSE60752,Time resolved ribosome profiling study of oxygen and glucose deprivation of rat pheochromocytoma cells,Rattus norvegicus,16,SRP045777,2015-4-10,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60752,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60752/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA259424,25943107," Dmitry E Andreev,  Patrick B F O'Connor,  Alexander V Zhdanov,  Ruslan I Dmitriev,  Ivan N Shatsky,  Dmitri B Papkovsky,  Pavel V Baranov","BACKGROUND: Oxygen and glucose metabolism play pivotal roles in many (patho)physiological conditions. In particular, oxygen and glucose deprivation (OGD) during ischemia and stroke results in extensive tissue injury and cell death. RESULTS: Using time-resolved ribosome profiling, we assess gene expression levels in a neural cell line, PC12, during the first hour of OGD. The most substantial alterations are seen to occur within the first 20 minutes of OGD. While transcription of only 100 genes is significantly altered during one hour of OGD, the translation response affects approximately 3,000 genes. This response involves reprogramming of initiation and elongation rates, as well as the stringency of start codon recognition. Genes involved in oxidative phosphorylation are most affected. Detailed analysis of ribosome profiles reveals salient alterations of ribosome densities on individual mRNAs. The mRNA-specific alterations include increased translation of upstream open reading frames, site-specific ribosome pauses, and production of alternative protein isoforms with amino-terminal extensions. Detailed analysis of ribosomal profiles also reveals six mRNAs with translated ORFs occurring downstream of annotated coding regions and two examples of dual coding mRNAs, where two protein products are translated from the same long segment of mRNA, but in two different frames. CONCLUSIONS: These findings uncover novel regulatory mechanisms of translational response to OGD in mammalian cells that are different from the classical pathways such as hypoxia inducible factor (HIF) signaling, while also revealing sophisticated organization of protein coding information in certain genes.",Oxygen and glucose deprivation induces widespread alterations in mRNA translation within 20 minutes.,10.1186/s13059-015-0651-z,2015 May 6,PMC4419486,Genome biology
GSE55195,Ribosome profiling data obtained from HEK293T cells 30 minutes after treatment with arsenite to a final concentration of 40 M,Homo sapiens,8,SRP038695,2015-1-27,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55195,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE55nnn/GSE55195/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA238879,25621764," Dmitry E Andreev,  Patrick B F O'Connor,  Ciara Fahey,  Elaine M Kenny,  Ilya M Terenin,  Sergey E Dmitriev,  Paul Cormican,  Derek W Morris,  Ivan N Shatsky,  Pavel V Baranov","Eukaryotic cells rapidly reduce protein synthesis in response to various stress conditions. This can be achieved by the phosphorylation-mediated inactivation of a key translation initiation factor, eukaryotic initiation factor 2 (eIF2). However, the persistent translation of certain mRNAs is required for deployment of an adequate stress response. We carried out ribosome profiling of cultured human cells under conditions of severe stress induced with sodium arsenite. Although this led to a 5.4-fold general translational repression, the protein coding open reading frames (ORFs) of certain individual mRNAs exhibited resistance to the inhibition. Nearly all resistant transcripts possess at least one efficiently translated upstream open reading frame (uORF) that represses translation of the main coding ORF under normal conditions. Site-specific mutagenesis of two identified stress resistant mRNAs (PPP1R15B and IFRD1) demonstrated that a single uORF is sufficient for eIF2-mediated translation control in both cases. Phylogenetic analysis suggests that at least two regulatory uORFs (namely, in SLC35A4 and MIEF1) encode functional protein products.",Translation of 5' leaders is pervasive in genes resistant to eIF2 repression.,10.7554/eLife.03971,2015 Jan 26,PMC4383229,eLife
GSE58207,PROTEOFORMER: deep proteome coverage through ribosome profiling and MS integration,Homo sapiens,2,SRP042937,2014-12-01,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58207,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE58nnn/GSE58207/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA251587,25510491," Jeroen Crappe,  Elvis Ndah,  Alexander Koch,  Sandra Steyaert,  Daria Gawron,  Sarah De Keulenaer,  Ellen De Meester,  Tim De Meyer,  Wim Van Criekinge,  Petra Van Damme,  Gerben Menschaert","An increasing amount of studies integrate mRNA sequencing data into MS-based proteomics to complement the translation product search space. However, several factors, including extensive regulation of mRNA translation and the need for",PROTEOFORMER: deep proteome coverage through ribosome profiling and MS integration.,10.1093/nar/gku1283,2015 Mar 11,PMC4357689,Nucleic acids research
GSE58402,Ribosome Profiling in P. falciparum asexual blood stages,Plasmodium falciparum,10,SRP043116,2014-12-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58402,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE58nnn/GSE58402/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA252511,25493618," Florence Caro,  Vida Ahyong,  Miguel Betegon,  Joseph L DeRisi","The characterization of the transcriptome and proteome of Plasmodium falciparum has been a tremendous resource for the understanding of the molecular physiology of this parasite. However, the translational dynamics that link steady-state mRNA with protein levels are not well understood. In this study, we bridge this disconnect by measuring genome-wide translation using ribosome profiling, through five stages of the P. falciparum blood phase developmental cycle. Our findings show that transcription and translation are tightly coupled, with overt translational control occurring for less than 10% of the transcriptome. Translationally regulated genes are predominantly associated with merozoite egress functions. We systematically define mRNA 5' leader sequences, and 3' UTRs, as well as antisense transcripts, along with ribosome occupancy for each, and establish that accumulation of ribosomes on 5' leaders is a common transcript feature. This work represents the highest resolution and broadest portrait of gene expression and translation to date for this medically important parasite.",Genome-wide regulatory dynamics of translation in the Plasmodium falciparum asexual blood stages.,10.7554/eLife.04106,2014 Dec 10,PMC4371882,eLife
GSE61375,Ribosome profiling upon inhibition of eIF4A,Homo sapiens,13,SRP047065,2014-9-13,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61375,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE61nnn/GSE61375/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA260909,25273840," Claudia A Rubio,  Benjamin Weisburd,  Matthew Holderfield,  Carolina Arias,  Eric Fang,  Joseph L DeRisi,  Abdallah Fanidi","BACKGROUND: Protein synthesis is tightly regulated and alterations to translation are characteristic of many cancers.Translation regulation is largely exerted at initiation through the eukaryotic translation initiation factor 4 F (eIF4F). eIF4F is pivotal for oncogenic signaling as it integrates mitogenic signals to amplify production of pro-growth and pro-survival factors. Convergence of these signals on eIF4F positions this factor as a gatekeeper of malignant fate. While the oncogenic properties of eIF4F have been characterized, genome-wide evaluation of eIF4F translational output is incomplete yet critical for developing novel translation-targeted therapies. RESULTS: To understand the impact of eIF4F on malignancy, we utilized a genome-wide ribosome profiling approach to identify eIF4F-driven mRNAs in MDA-MB-231 breast cancer cells. Using Silvestrol, a selective eIF4A inhibitor, we identify 284 genes that rely on eIF4A for efficient translation. Our screen confirmed several known eIF4F-dependent genes and identified many unrecognized targets of translation regulation. We show that 5'UTR complexity determines Silvestrol-sensitivity and altering 5'UTR structure modifies translational output. We highlight physiological implications of eIF4A inhibition, providing mechanistic insight into eIF4F pro-oncogenic activity. CONCLUSIONS: Here we describe the transcriptome-wide consequence of eIF4A inhibition in malignant cells, define mRNA features that confer eIF4A dependence, and provide genetic support for Silvestrol's anti-oncogenic properties. Importantly, our results show that eIF4A inhibition alters translation of an mRNA subset distinct from those affected by mTOR-mediated eIF4E inhibition. These results have significant implications for therapeutically targeting translation and underscore a dynamic role for eIF4F in remodeling the proteome toward malignancy.",Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.,10.1186/s13059-014-0476-1,2014,PMC4203936,Genome biology
GSE51424,Cell type-specific ribosome profiling in vivo.,Homo sapiens;Mus musculus,25,SRP031501,2014-8-25,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51424,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE51nnn/GSE51424/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA223060,25122893," Christian Gonzalez,  Jennifer S Sims,  Nicholas Hornstein,  Angeliki Mela,  Franklin Garcia,  Liang Lei,  David A Gass,  Benjamin Amendolara,  Jeffrey N Bruce,  Peter Canoll,  Peter A Sims","Glioma growth is driven by signaling that ultimately regulates protein synthesis. Gliomas are also complex at the cellular level and involve multiple cell types, including transformed and reactive cells in the brain tumor microenvironment. The distinct functions of the various cell types likely lead to different requirements and regulatory paradigms for protein synthesis. Proneural gliomas can arise from transformation of glial progenitors that are driven to proliferate via mitogenic signaling that affects translation. To investigate translational regulation in this system, we developed a RiboTag glioma mouse model that enables cell-type-specific, genome-wide ribosome profiling of tumor tissue. Infecting glial progenitors with Cre-recombinant retrovirus simultaneously activates expression of tagged ribosomes and delivers a tumor-initiating mutation. Remarkably, we find that although genes specific to transformed cells are highly translated, their translation efficiencies are low compared with normal brain. Ribosome positioning reveals sequence-dependent regulation of ribosomal activity in 5'-leaders upstream of annotated start codons, leading to differential translation in glioma compared with normal brain. Additionally, although transformed cells express a proneural signature, untransformed tumor-associated cells, including reactive astrocytes and microglia, express a mesenchymal signature. Finally, we observe the same phenomena in human disease by combining ribosome profiling of human proneural tumor and non-neoplastic brain tissue with computational deconvolution to assess cell-type-specific translational regulation.",Ribosome profiling reveals a cell-type-specific translational landscape in brain tumors.,10.1523/JNEUROSCI.0084-14.2014,2014 Aug 13,PMC4131009,The Journal of neuroscience : the official journal of the Society for Neuroscience
GSE60095,Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes,Homo sapiens;Mus musculus,4,SRP045257,2014-8-21,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60095,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60095/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA257463,25159147," Nicholas T Ingolia,  Gloria A Brar,  Noam Stern-Ginossar,  Michael S Harris,  Gaelle J S Talhouarne,  Sarah E Jackson,  Mark R Wills,  Jonathan S Weissman","Ribosome profiling suggests that ribosomes occupy many regions of the transcriptome thought to be noncoding, including 5' UTRs and long noncoding RNAs (lncRNAs). Apparent ribosome footprints outside of protein-coding regions raise the possibility of artifacts unrelated to translation, particularly when they occupy multiple, overlapping open reading frames (ORFs). Here, we show hallmarks of translation in these footprints: copurification with the large ribosomal subunit, response to drugs targeting elongation, trinucleotide periodicity, and initiation at early AUGs. We develop a metric for distinguishing between 80S footprints and nonribosomal sources using footprint size distributions, which validates the vast majority of footprints outside of coding regions. We present evidence for polypeptide production beyond annotated genes, including the induction of immune responses following human cytomegalovirus (HCMV) infection. Translation is pervasive on cytosolic transcripts outside of conserved reading frames, and direct detection of this expanded universe of translated products enables efforts at understanding how cells manage and exploit its consequences.",Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes.,10.1016/j.celrep.2014.07.045,2014 Sep 11,PMC4216110,Cell reports
GSE56622,Ribosome profiling upon glucose starvation in S. cerevisiae,Saccharomyces cerevisiae,22,SRP041039,2014-7-28,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56622,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE56nnn/GSE56622/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA244101,25119046," Brian M Zid,  Erin K O'Shea","A universal feature of the response to stress and nutrient limitation is transcriptional upregulation of genes that encode proteins important for survival. Under many such conditions, the overall protein synthesis level is reduced, thereby dampening the stress response at the level of protein expression. For example, during glucose starvation in Saccharomyces cerevisiae",Promoter sequences direct cytoplasmic localization and translation of mRNAs during starvation in yeast.,10.1038/nature13578,2014 Oct 2,PMC4184922,Nature
GSE57336,Stage-specific regulation of translation revealed by ribosome profiling of Trypanosoma brucei,Trypanosoma brucei,22,SRP041705,2014-5-24,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57336,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE57nnn/GSE57336/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA246300,25331479," Bryan C Jensen,  Gowthaman Ramasamy,  Elton J R Vasconcelos,  Nicholas T Ingolia,  Peter J Myler,  Marilyn Parsons","BACKGROUND: Trypanosoma brucei subspecies infect humans and animals in sub-Saharan Africa. This early diverging eukaryote shows many novel features in basic biological processes, including the use of polycistronic transcription to generate all protein-coding mRNAs. Therefore we hypothesized that translational control provides a means to tune gene expression during parasite development in mammalian and fly hosts. RESULTS: We used ribosome profiling to examine genome-wide protein synthesis in animal-derived slender bloodstream forms and cultured procyclic (insect midgut) forms. About one-third of all CDSs showed statistically significant regulation of protein production between the two stages. Of these, more than two-thirds showed a change in translation efficiency, but few appeared to be controlled by this alone. Ribosomal proteins were translated poorly, especially in animal-derived parasites. A disproportionate number of metabolic enzymes were up-regulated at the mRNA level in procyclic forms, as were variant surface glycoproteins in bloodstream forms. Comparison with cultured bloodstream forms from another strain revealed stage-specific changes in gene expression that transcend strain and growth conditions. Genes with upstream ORFs had lower mean translation efficiency, but no evidence was found for involvement of uORFs in stage-regulation. CONCLUSIONS: Ribosome profiling revealed that differences in the production of specific proteins in T. brucei bloodstream and procyclic forms are more extensive than predicted by analysis of mRNA abundance. While in vivo and in vitro derived bloodstream forms from different strains are more similar to one another than to procyclic forms, they showed many differences at both the mRNA and protein production level.",Extensive stage-regulation of translation revealed by ribosome profiling of Trypanosoma brucei.,10.1186/1471-2164-15-911,2014 Oct 20,PMC4210626,BMC genomics
GSE34438,Ribosome profiling of wild-type and loc1- cells in S. cerevisiae,Saccharomyces cerevisiae,4,SRP009836,2014-1-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34438,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE34nnn/GSE34438/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA156379,,,,,,,,
GSE52968,Ribosome profiling study of dom34 and hbs1 knockout strains using short (16-nt) and long (28-nt) monosome-protected footprints and disome-protected footprints,Saccharomyces cerevisiae,25,SRP033499,2013-12-19,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52968,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE52nnn/GSE52968/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA230577,24581494," Nicholas R Guydosh,  Rachel Green","Ribosomes that stall before completing peptide synthesis must be recycled and returned to the cytoplasmic pool. The protein Dom34 and cofactors Hbs1 and Rli1 can dissociate stalled ribosomes in vitro, but the identity of targets in the cell is unknown. Here, we extend ribosome profiling methodology to reveal a high-resolution molecular characterization of Dom34 function in vivo. Dom34 removes stalled ribosomes from truncated mRNAs, but, in contrast, does not generally dissociate ribosomes on coding sequences known to trigger stalling, such as polyproline. We also show that Dom34 targets arrested ribosomes near the ends of 3' UTRs. These ribosomes appear to gain access to the 3' UTR via a mechanism that does not require decoding of the mRNA. These results suggest that ribosomes frequently enter downstream noncoding regions and that Dom34 carries out the important task of rescuing them.",Dom34 rescues ribosomes in 3' untranslated regions.,10.1016/j.cell.2014.02.006,2014 Feb 27,PMC4022138,Cell
GSE49197,Ribosome profiling reveals pervasive and regulated stop codon readthrough  in Drosophila melanogaster,Drosophila melanogaster,12,SRP028243,2013-12-05,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49197,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE49nnn/GSE49197/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA213294,24302569," Joshua G Dunn,  Catherine K Foo,  Nicolette G Belletier,  Elizabeth R Gavis,  Jonathan S Weissman","Ribosomes can read through stop codons in a regulated manner, elongating rather than terminating the nascent peptide. Stop codon readthrough is essential to diverse viruses, and phylogenetically predicted to occur in a few hundred genes in Drosophila melanogaster, but the importance of regulated readthrough in eukaryotes remains largely unexplored. Here, we present a ribosome profiling assay (deep sequencing of ribosome-protected mRNA fragments) for Drosophila melanogaster, and provide the first genome-wide experimental analysis of readthrough. Readthrough is far more pervasive than expected: the vast majority of readthrough events evolved within D. melanogaster and were not predicted phylogenetically. The resulting C-terminal protein extensions show evidence of selection, contain functional subcellular localization signals, and their readthrough is regulated, arguing for their importance. We further demonstrate that readthrough occurs in yeast and humans. Readthrough thus provides general mechanisms both to regulate gene expression and function, and to add plasticity to the proteome during evolution. DOI: http://dx.doi.org/10.7554/eLife.01179.001.",Ribosome profiling reveals pervasive and regulated stop codon readthrough in Drosophila melanogaster.,10.7554/eLife.01179,2013 Dec 3,PMC3840789,eLife
GSE48933,Ribosome profiling reveals features of normal and disease-associated mitochondrial translation,Homo sapiens,10,SRP027514,2013-10-17,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48933,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE48nnn/GSE48933/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA212323,24301020," Koos Rooijers,  Fabricio Loayza-Puch,  Leo G Nijtmans,  Reuven Agami","Mitochondria are essential cellular organelles for generation of energy and their dysfunction may cause diabetes, Parkinson's disease and multi-systemic failure marked by failure to thrive, gastrointestinal problems, lactic acidosis and early lethality. Disease-associated mitochondrial mutations often affect components of the mitochondrial translation machinery. Here we perform ribosome profiling to measure mitochondrial translation at nucleotide resolution. Using a protocol optimized for the retrieval of mitochondrial ribosome protected fragments (RPFs) we show that the size distribution of wild-type mitochondrial RPFs follows a bimodal distribution peaking at 27 and 33 nucleotides, which is distinct from the 30-nucleotide peak of nuclear RPFs. Their cross-correlation suggests generation of mitochondrial RPFs during ribosome progression. In contrast, RPFs from patient-derived mitochondria mutated in tRNA-Tryptophan are centered on tryptophan codons and reduced downstream, indicating ribosome stalling. Intriguingly, long RPFs are enriched in mutated mitochondria, suggesting they characterize stalled ribosomes. Our findings provide the first model for translation in wild-type and disease-triggering mitochondria.",Ribosome profiling reveals features of normal and disease-associated mitochondrial translation.,10.1038/ncomms3886,2013,PMC3863897,Nature communications
GSE51164,Ribosome profiling of whi3 mutant yeast,Saccharomyces cerevisiae,4,SRP030453,2013-9-26,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51164,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE51nnn/GSE51164/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA221377,24386402," Ying Cai,  Bruce Futcher","Whi3 is an RNA binding protein known to bind the mRNA of the yeast G1 cyclin gene CLN3. It inhibits CLN3 function, but the mechanism of this inhibition is unclear; in previous studies, Whi3 made no observable difference to CLN3 mRNA levels, translation, or protein abundance. Here, we re-approach this issue using microarrays, RNA-Seq, ribosome profiling, and other methods. By multiple methods, we find that the whi3 mutation causes a small but consistent increase in the abundance of hundreds of mRNAs, including the CLN3 mRNA. The effect on various mRNAs is roughly in proportion to the density of GCAU or UGCAU motifs carried by these mRNAs, which may be a binding site for Whi3. mRNA instability of Whi3 targets may in part depend on a 3' AU rich element (ARE), AUUUUA. In addition, the whi3 mutation causes a small increase in the translational efficiency of CLN3 mRNA. The increase in CLN3 mRNA half-life and abundance together with the increase in translational efficiency is fully sufficient to explain the small-cell phenotype of whi3 mutants. Under stress conditions, Whi3 becomes a component of P-bodies or stress granules, but Whi3 also acts under non-stress condition, when no P-bodies are visible. We suggest that Whi3 may be a very broadly-acting, but mild, modulator of mRNA stability. In CLN3, Whi3 may bind to the 3' GCAU motifs to attract the Ccr4-Not complex to promote RNA deadenylation and turnover, and Whi3 may bind to the 5' GCAU motifs to inhibit translation.",Effects of the yeast RNA-binding protein Whi3 on the half-life and abundance of CLN3 mRNA and other targets.,10.1371/journal.pone.0084630,2013,PMC3875557,PloS one
GSE47509,High resolution view of bacteriophage lambda gene expression by ribosome profiling,Escherichia coli str. K-12 substr. MG1655,20,SRP023499,2013-7-01,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47509,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE47nnn/GSE47509/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA205933,23812753," Xiaoqiu Liu,  Huifeng Jiang,  Zhenglong Gu,  Jeffrey W Roberts","Bacteriophage lambda is one of the most extensively studied organisms and has been a primary model for understanding basic modes of genetic regulation. Here, we examine the progress of lambda gene expression during phage development by ribosome profiling and, thereby, provide a very-high-resolution view of lambda gene expression. The known genes are expressed in a predictable fashion, authenticating the analysis. However, many previously unappreciated potential open reading frames become apparent in the expression analysis, revealing an unexpected complexity in the pattern of lambda gene function.",High-resolution view of bacteriophage lambda gene expression by ribosome profiling.,10.1073/pnas.1309739110,2013 Jul 16,PMC3718152,Proceedings of the National Academy of Sciences of the United States of America
GSE48140,mRNA and Ribosome Profiling in Four Nematode Species Traversing a Shared Developmental Transition,Caenorhabditis brenneri;Caenorhabditis briggsae;Caenorhabditis elegans;Caenorhabditis remanei,48,SRP026198,2013-6-21,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48140,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE48nnn/GSE48140/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA208993,24098135," Michael Stadler,  Andrew Fire","Nematodes of the genus Caenorhabditis enter a developmental diapause state after hatching in the absence of food. To better understand the relative contributions of distinct regulatory modalities to gene expression changes associated with this developmental transition, we characterized genome-wide changes in mRNA abundance and translational efficiency associated with L1 diapause exit in four species using ribosome profiling and mRNA-seq. We found a strong tendency for translational regulation and mRNA abundance processes to act synergistically, together effecting a dramatic remodeling of the gene expression program. While gene-specific differences were observed between species, overall translational dynamics were broadly and functionally conserved. A striking, conserved feature of the response was strong translational suppression of ribosomal protein production during L1 diapause, followed by activation upon resumed development. On a global scale, ribosome footprint abundance changes showed greater similarity between species than changes in mRNA abundance, illustrating a substantial and genome-wide contribution of translational regulation to evolutionary maintenance of stable gene expression.",Conserved translatome remodeling in nematode species executing a shared developmental transition.,10.1371/journal.pgen.1003739,2013,PMC3789828,PLoS genetics
GSE45785,"Transcriptome-profiling (RNA-seq) and Ribosome-profiling (Ribo-seq) of BJ cells treated with Nutlin-3a, an MDM2 inhibitor, which induces p53.",Homo sapiens,10,SRP020544,2013-6-01,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45785,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE45nnn/GSE45785/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA196335,23594524," Fabricio Loayza-Puch,  Jarno Drost,  Koos Rooijers,  Rui Lopes,  Ran Elkon,  Reuven Agami","BACKGROUND: Cell growth and proliferation are tightly connected to ensure that appropriately sized daughter cells are generated following mitosis. Energy stress blocks cell growth and proliferation, a critical response for survival under extreme conditions. Excessive oncogenic stress leads to p53 activation and the induction of senescence, an irreversible state of cell-cycle arrest and a critical component in the suppression of tumorigenesis. Nutrient-sensing and mitogenic cues converge on a major signaling node, which regulates the activity of the mTOR kinase. Although transcriptional responses to energy and oncogenic stresses have been examined by many gene-expression experiments, a global exploration of the modulation of mRNA translation in response to these conditions is lacking. RESULTS: We combine RNA sequencing and ribosomal profiling analyses to systematically delineate modes of transcriptional and translational regulation induced in response to conditions of limited energy, oncogenic stress and cellular transformation. We detect a key role for mTOR and p53 in these distinct physiological states, and provide the first genome-wide demonstration that p53 activation results in mTOR inhibition and a consequent global repression of protein translation. We confirm the role of the direct p53 target genes Sestrin1 and Sestrin2 in this response, as part of the broad modulation of gene expression induced by p53 activation. CONCLUSIONS: We delineate a bimodal tumor-suppressive regulatory program activated by p53, in which cell-cycle arrest is imposed mainly at the transcriptional level, whereas cell growth inhibition is enforced by global repression of the translation machinery.",p53 induces transcriptional and translational programs to suppress cell proliferation and growth.,10.1186/gb-2013-14-4-r32,2013 Apr 17,PMC4053767,Genome biology
GSE42509,"Transcriptome-profiling (RNA-seq) and Ribosome-profiling (Ribo-seq) in proliferation, quiescence, senescence and transformed states.",Homo sapiens,17,SRP017378,2013-3-24,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42509,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE42nnn/GSE42509/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA182756,23594524," Fabricio Loayza-Puch,  Jarno Drost,  Koos Rooijers,  Rui Lopes,  Ran Elkon,  Reuven Agami","BACKGROUND: Cell growth and proliferation are tightly connected to ensure that appropriately sized daughter cells are generated following mitosis. Energy stress blocks cell growth and proliferation, a critical response for survival under extreme conditions. Excessive oncogenic stress leads to p53 activation and the induction of senescence, an irreversible state of cell-cycle arrest and a critical component in the suppression of tumorigenesis. Nutrient-sensing and mitogenic cues converge on a major signaling node, which regulates the activity of the mTOR kinase. Although transcriptional responses to energy and oncogenic stresses have been examined by many gene-expression experiments, a global exploration of the modulation of mRNA translation in response to these conditions is lacking. RESULTS: We combine RNA sequencing and ribosomal profiling analyses to systematically delineate modes of transcriptional and translational regulation induced in response to conditions of limited energy, oncogenic stress and cellular transformation. We detect a key role for mTOR and p53 in these distinct physiological states, and provide the first genome-wide demonstration that p53 activation results in mTOR inhibition and a consequent global repression of protein translation. We confirm the role of the direct p53 target genes Sestrin1 and Sestrin2 in this response, as part of the broad modulation of gene expression induced by p53 activation. CONCLUSIONS: We delineate a bimodal tumor-suppressive regulatory program activated by p53, in which cell-cycle arrest is imposed mainly at the transcriptional level, whereas cell growth inhibition is enforced by global repression of the translation machinery.",p53 induces transcriptional and translational programs to suppress cell proliferation and growth.,10.1186/gb-2013-14-4-r32,2013 Apr 17,PMC4053767,Genome biology
GSE41605,Decoding human cytomegalovirus using ribosome profiling,Human betaherpesvirus 5,16,SRP016143,2012-10-17,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41605,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE41nnn/GSE41605/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA177721,23180859," Noam Stern-Ginossar,  Ben Weisburd,  Annette Michalski,  Vu Thuy Khanh Le,  Marco Y Hein,  Sheng-Xiong Huang,  Ming Ma,  Ben Shen,  Shu-Bing Qian,  Hartmut Hengel,  Matthias Mann,  Nicholas T Ingolia,  Jonathan S Weissman","The human cytomegalovirus (HCMV) genome was sequenced 20 years ago. However, like those of other complex viruses, our understanding of its protein coding potential is far from complete. We used ribosome profiling and transcript analysis to experimentally define the HCMV translation products and follow their temporal expression. We identified hundreds of previously unidentified open reading frames and confirmed a fraction by means of mass spectrometry. We found that regulated use of alternative transcript start sites plays a broad role in enabling tight temporal control of HCMV protein expression and allowing multiple distinct polypeptides to be generated from a single genomic locus. Our results reveal an unanticipated complexity to the HCMV coding capacity and illustrate the role of regulated changes in transcript start sites in generating this complexity.",Decoding human cytomegalovirus.,10.1126/science.1227919,2012 Nov 23,PMC3817102,"Science (New York, N.Y.)"
GSE34743,Ribosome profiling of early zebrafish embryos -- miRNA-mediated regulation during embryogenesis causes translational repression before mRNA decay,Danio rerio,22,SRP010040,2012-3-15,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34743,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE34nnn/GSE34743/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA150397,22422859," Ariel A Bazzini,  Miler T Lee,  Antonio J Giraldez","MicroRNAs regulate gene expression through deadenylation, repression, and messenger RNA (mRNA) decay. However, the contribution of each mechanism in non-steady-state situations remains unclear. We monitored the impact of miR-430 on ribosome occupancy of endogenous mRNAs in wild-type and dicer mutant zebrafish embryos and found that miR-430 reduces the number of ribosomes on target mRNAs before causing mRNA decay. Translational repression occurs before complete deadenylation, and disrupting deadenylation with use of an internal polyadenylate tail did not block target repression. Lastly, we observed that ribosome density along the length of the message remains constant, suggesting that translational repression occurs by reducing the rate of initiation rather than affecting elongation or causing ribosomal drop-off. These results show that miR-430 regulates translation initiation before inducing mRNA decay during zebrafish development.",Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish.,10.1126/science.1215704,2012 Apr 13,PMC3547538,"Science (New York, N.Y.)"
GSE34082,High-resolution view of the yeast meiotic program revealed by ribosome profiling,Saccharomyces cerevisiae,70,SRP009639,2012-1-06,,Expression profiling by high throughput sequencing,,,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA149975,22194413," Gloria A Brar,  Moran Yassour,  Nir Friedman,  Aviv Regev,  Nicholas T Ingolia,  Jonathan S Weissman","Meiosis is a complex developmental process that generates haploid cells from diploid progenitors. We measured messenger RNA (mRNA) abundance and protein production through the yeast meiotic sporulation program and found strong, stage-specific expression for most genes, achieved through control of both mRNA levels and translational efficiency. Monitoring of protein production timing revealed uncharacterized recombination factors and extensive organellar remodeling. Meiotic translation is also shifted toward noncanonical sites, including short open reading frames (ORFs) on unannnotated transcripts and upstream regions of known transcripts (uORFs). Ribosome occupancy at near-cognate uORFs was associated with more efficient ORF translation; by contrast, some AUG uORFs, often exposed by regulated 5' leader extensions, acted competitively. This work reveals pervasive translational control in meiosis and helps to illuminate the molecular basis of the broad restructuring of meiotic cells.",High-resolution view of the yeast meiotic program revealed by ribosome profiling.,10.1126/science.1215110,2012 Feb 3,PMC3414261,"Science (New York, N.Y.)"
GSE33671,Selective ribosome profiling reveals the co-translational chaperone action of trigger factor in vivo,Escherichia coli,8,SRP009321,2011-12-09,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33671,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE33nnn/GSE33671/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA148631,22153074," Eugene Oh,  Annemarie H Becker,  Arzu Sandikci,  Damon Huber,  Rachna Chaba,  Felix Gloge,  Robert J Nichols,  Athanasios Typas,  Carol A Gross,  Gunter Kramer,  Jonathan S Weissman,  Bernd Bukau","As nascent polypeptides exit ribosomes, they are engaged by a series of processing, targeting, and folding factors. Here, we present a selective ribosome profiling strategy that enables global monitoring of when these factors engage polypeptides in the complex cellular environment. Studies of the Escherichia coli chaperone trigger factor (TF) reveal that, though TF can interact with many polypeptides, beta-barrel outer-membrane proteins are the most prominent substrates. Loss of TF leads to broad outer-membrane defects and premature, cotranslational protein translocation. Whereas in vitro studies suggested that TF is prebound to ribosomes waiting for polypeptides to emerge from the exit channel, we find that in vivo TF engages ribosomes only after ~100 amino acids are translated. Moreover, excess TF interferes with cotranslational removal of the N-terminal formyl methionine. Our studies support a triaging model in which proper protein biogenesis relies on the fine-tuned, sequential engagement of processing, targeting, and folding factors.",Selective ribosome profiling reveals the cotranslational chaperone action of trigger factor in vivo.,10.1016/j.cell.2011.10.044,2011 Dec 9,PMC3277850,Cell
GSE30839,RibosomeProfilingof Mouse Embryonic Stem Cells Reveals the Complexity of Mammalian Proteomes,Mus musculus,18,SRP007567,2011-11-03,,Expression profiling by high throughput sequencing;Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30839,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE30839/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA144149,22056041," Nicholas T Ingolia,  Liana F Lareau,  Jonathan S Weissman","The ability to sequence genomes has far outstripped approaches for deciphering the information they encode. Here we present a suite of techniques, based on ribosome profiling (the deep sequencing of ribosome-protected mRNA fragments), to provide genome-wide maps of protein synthesis as well as a pulse-chase strategy for determining rates of translation elongation. We exploit the propensity of harringtonine to cause ribosomes to accumulate at sites of translation initiation together with a machine learning algorithm to define protein products systematically. Analysis of translation in mouse embryonic stem cells reveals thousands of strong pause sites and unannotated translation products. These include amino-terminal extensions and truncations and upstream open reading frames with regulatory potential, initiated at both AUG and non-AUG codons, whose translation changes after differentiation. We also define a class of short, polycistronic ribosome-associated coding RNAs (sprcRNAs) that encode small proteins. Our studies reveal an unanticipated complexity to mammalian proteomes.",Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes.,10.1016/j.cell.2011.10.002,2011 Nov 11,PMC3225288,Cell
GSE21992,"Analysis of HeLa cells after transfection with miR-1 or miR-155, by ribosome profiling and mRNA-Seq",Homo sapiens,12,SRP002605,2010-8-03,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21992,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE21nnn/GSE21992/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA129385,20703300," Huili Guo,  Nicholas T Ingolia,  Jonathan S Weissman,  David P Bartel","MicroRNAs (miRNAs) are endogenous approximately 22-nucleotide RNAs that mediate important gene-regulatory events by pairing to the mRNAs of protein-coding genes to direct their repression. Repression of these regulatory targets leads to decreased translational efficiency and/or decreased mRNA levels, but the relative contributions of these two outcomes have been largely unknown, particularly for endogenous targets expressed at low-to-moderate levels. Here, we use ribosome profiling to measure the overall effects on protein production and compare these to simultaneously measured effects on mRNA levels. For both ectopic and endogenous miRNA regulatory interactions, lowered mRNA levels account for most (>/=84%) of the decreased protein production. These results show that changes in mRNA levels closely reflect the impact of miRNAs on gene expression and indicate that destabilization of target mRNAs is the predominant reason for reduced protein output.",Mammalian microRNAs predominantly act to decrease target mRNA levels.,10.1038/nature09267,2010 Aug 12,PMC2990499,Nature
GSE22001,"Analysis of mir-223 knockout cultured neutrophils versus wild-type cultured neutrophils, by ribosome profiling and mRNA-Seq",Mus musculus,4,SRP003554,2010-8-03,,Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22001,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE22nnn/GSE22001/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA129411,20703300," Huili Guo,  Nicholas T Ingolia,  Jonathan S Weissman,  David P Bartel","MicroRNAs (miRNAs) are endogenous approximately 22-nucleotide RNAs that mediate important gene-regulatory events by pairing to the mRNAs of protein-coding genes to direct their repression. Repression of these regulatory targets leads to decreased translational efficiency and/or decreased mRNA levels, but the relative contributions of these two outcomes have been largely unknown, particularly for endogenous targets expressed at low-to-moderate levels. Here, we use ribosome profiling to measure the overall effects on protein production and compare these to simultaneously measured effects on mRNA levels. For both ectopic and endogenous miRNA regulatory interactions, lowered mRNA levels account for most (>/=84%) of the decreased protein production. These results show that changes in mRNA levels closely reflect the impact of miRNAs on gene expression and indicate that destabilization of target mRNAs is the predominant reason for reduced protein output.",Mammalian microRNAs predominantly act to decrease target mRNA levels.,10.1038/nature09267,2010 Aug 12,PMC2990499,Nature
GSE13750,Genome-Wide Analysis In Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling,Saccharomyces cerevisiae,8,SRP000637,2009-2-12,,Other;Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13750,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE13nnn/GSE13750/suppl,https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA109405,19213877," Nicholas T Ingolia,  Sina Ghaemmaghami,  John R S Newman,  Jonathan S Weissman","Techniques for systematically monitoring protein translation have lagged far behind methods for measuring messenger RNA (mRNA) levels. Here, we present a ribosome-profiling strategy that is based on the deep sequencing of ribosome-protected mRNA fragments and enables genome-wide investigation of translation with subcodon resolution. We used this technique to monitor translation in budding yeast under both rich and starvation conditions. These studies defined the protein sequences being translated and found extensive translational control in both determining absolute protein abundance and responding to environmental stress. We also observed distinct phases during translation that involve a large decrease in ribosome density going from early to late peptide elongation as well as widespread regulated initiation at non-adenine-uracil-guanine (AUG) codons. Ribosome profiling is readily adaptable to other organisms, making high-precision investigation of protein translation experimentally accessible.",Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling.,10.1126/science.1168978,2009 Apr 10,PMC2746483,"Science (New York, N.Y.)"
GSE140995,Multiple links between 5-methylcytosine content of mRNA and translation,Homo sapiens,12,SRP233220,2019-11-25,"[Overal design]Bisulfite RNA sequencing of HeLa cell polysome profiling-derived samples representing different translational states; in biological triplicates.; [Treatment]'Cells were incubated with 0.1mg/ml cycloheximide for 3 minutes prior to lysate preparation'; [Growth]'6x106 HeLa cells were cultured in DMEM supplemented with 5% FBS and 2mM L-glutamine until 70% confluent'; [Extraction]'Cell lysates were cleared and polysome gradients obtained by sucrose density centrfugation. Samples were fractionated and RNA isolated by ethanol precipitation and subsequent trizol extraction of pellets\nLibraries were prepared using 10ug of total RNA per sample according to the Illumina TruSeq Stranded Total RNA Library Kit including a bisulfite conversion step following rRNA depletion.'; [Cell type]'cervical cancer cells''cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate B-Polysome Fraction 1; translation state: small ribosomal subunit; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate B-Polysome Fraction 2; translation state: large ribosomal subunit and monosome; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate B-Polysome Fraction 3; translation state: light polysomal region; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate B-Polysome Fraction 4; translation state: heavy polysomal region; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate C-Polysome Fraction 1; translation state: small ribosomal subunit; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate C-Polysome Fraction 2; translation state: large ribosomal subunit and monosome; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate C-Polysome Fraction 3; translation state: light polysomal region; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate C-Polysome Fraction 4; translation state: heavy polysomal region; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate E-Polysome Fraction 1; translation state: small ribosomal subunit; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate E-Polysome Fraction 2; translation state: large ribosomal subunit and monosome; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate E-Polysome Fraction 3; translation state: light polysomal region; ', 'cell line: HeLa; cell type: cervical cancer cells; polysomal fraction: Replicate E-Polysome Fraction 4; translation state: heavy polysomal region; '",Methylation profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140995,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140995/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA591627,32293435," Ulrike Schumann,  He-Na Zhang,  Tennille Sibbritt,  Anyu Pan,  Attila Horvath,  Simon Gross,  Susan J Clark,  Li Yang,  Thomas Preiss","BACKGROUND: 5-Methylcytosine (m(5)C) is a prevalent base modification in tRNA and rRNA but it also occurs more broadly in the transcriptome, including in mRNA, where it serves incompletely understood molecular functions. In pursuit of potential links of m(5)C with mRNA translation, we performed polysome profiling of human HeLa cell lysates and subjected RNA from resultant fractions to efficient bisulfite conversion followed by RNA sequencing (bsRNA-seq). Bioinformatic filters for rigorous site calling were devised to reduce technical noise. RESULTS: We obtained ~ 1000 candidate m(5)C sites in the wider transcriptome, most of which were found in mRNA. Multiple novel sites were validated by amplicon-specific bsRNA-seq in independent samples of either human HeLa, LNCaP and PrEC cells. Furthermore, RNAi-mediated depletion of either the NSUN2 or TRDMT1 m(5)C:RNA methyltransferases showed a clear dependence on NSUN2 for the majority of tested sites in both mRNAs and noncoding RNAs. Candidate m(5)C sites in mRNAs are enriched in 5'UTRs and near start codons and are embedded in a local context reminiscent of the NSUN2-dependent m(5)C sites found in the variable loop of tRNA. Analysing mRNA sites across the polysome profile revealed that modification levels, at bulk and for many individual sites, were inversely correlated with ribosome association. CONCLUSIONS: Our findings emphasise the major role of NSUN2 in placing the m(5)C mark transcriptome-wide. We further present evidence that substantiates a functional interdependence of cytosine methylation level with mRNA translation. Additionally, we identify several compelling candidate sites for future mechanistic analysis.",Multiple links between 5-methylcytosine content of mRNA and translation.,10.1186/s12915-020-00769-5,2020 Apr 15,PMC7158060,BMC biology
GSE128345,"A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP b-CTFs, not Ab",Homo sapiens,24,None,2019-03-15,"[Overal design]Refer to individual Series; [Treatment]'None'; [Growth]'induction and maturation of cortical neurons from iPS cells (total of 80 days in vitro; detailed protocol in accompanying paper)'; [Extraction]'Trizol extraction, rRNA removal via Ribo-Zero treatment, DNAse-digestion\nIllumina High-Throughput TruSeq', ""cell lysis and partial RNAse digestion followed by ribosome immunoprecipitation to extract ribosome associated fragments (detailed protocol in accompanying paper)\npartial RNAse digestion, ribosome associated fragment purification, linker ligation, reverse transcription, cDNA purification, PCR amplification (detailed protocol in accompanying paper)\nligation of 3' linker, addition of 5'linker with barcode and UMI via RT (detailed protocol in accompanying paper)""; [Cell type]'co-isogenic iPS cells''cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: none; ', 'cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: APP Swe/Swe; ', 'cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: PSEN1 M146V/M146V; ', 'cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: APP Swe/Swe; PSEN1 M146V/M146V; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128345,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128345/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA527199,31416668," Dylan Kwart,  Andrew Gregg,  Claudia Scheckel,  Elisabeth A Murphy,  Dominik Paquet,  Michael Duffield,  John Fak,  Olav Olsen,  Robert B Darnell,  Marc Tessier-Lavigne","Familial Alzheimer's disease (fAD) results from mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes. Here we leveraged recent advances in induced pluripotent stem cell (iPSC) and CRISPR/Cas9 genome editing technologies to generate a panel of isogenic knockin human iPSC lines carrying APP and/or PSEN1 mutations. Global transcriptomic and translatomic profiling revealed that fAD mutations have overlapping effects on the expression of AD-related and endocytosis-associated genes. Mutant neurons also increased Rab5+ early endosome size. APP and PSEN1 mutations had discordant effects on Abeta production but similar effects on APP beta C-terminal fragments (beta-CTFs), which accumulate in all mutant neurons. Importantly, endosomal dysfunction correlated with accumulation of beta-CTFs, not Abeta, and could be rescued by pharmacological modulation of beta-secretase (BACE). These data display the utility of our mutant iPSCs in studying AD-related phenotypes in a non-overexpression human-based system and support mounting evidence that beta-CTF may be critical in AD pathogenesis.","A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta.",10.1016/j.neuron.2019.07.010,2019 Oct 23,,Neuron
GSE102204,Transcriptome and translatome profiling from brains of  a mouse model of severe SMA,Mus musculus,20,SRP114759,2017-08-03,"[Overal design]We extracted both total cytoplasmic and polysomal RNAs from pooled sucrose fractions from early-symptomatic and late-symptomatic brains of SMA mice, as well as from littermate controls. Experiments were performed in biological triplicate for late-symptomatic mice, and in biological duplicate for early-symptomatic mice, for a total of 20 samples.; [Treatment]'Early symptomatic brains were P5 and late symptomatic brains were P7. Neonatal mice were euthanized by overdose of anaesthetic, before decapitation to allow the brain to be removed. Following isolation, all tissues were immediately snap-frozen on dry ice and then transferred to -80 C for storage.'; [Growth]'The Taiwanese mouse model of severe SMA was used in this study (Hsieh-Li et al., 2000; Riessland et al., 2010; Somers et al., 2015). All mice were on a congenic FVB background, with colonies at the University of Edinburgh established from breeding pairs purchased from Jackson Labs. Taiwanese SMA mice (Smn-/-; SMN2tg/0) carry two copies of SMN2 on one allele and are on a null murine Smn background. Litters were retrospectively genotyped using standard PCR protocols. All mice were housed within the animal care facilities in Edinburgh under standard SPF conditions. All animal procedures and breeding were performed in accordance with University of Edinburgh institutional guidelines and under appropriate project and personal licenses granted by the UK Home Office.'; [Extraction]'Cytoplasmic lysates from frozen mouse tissues and polysomal profiling were performed as described previously (Lunelli et al., 2016).RNA was extracted from control and SMA brains (at early and late symptomatic stage). Sucrose fractions from all fractions (total RNA) or polysomal fractions only (polysomal RNA) were pooled. The fractions were first digested with proteinase K (100 mg/mL, Euroclone) for 90 minutes at 37C and then RNA was extracted with acid-phenol:chloroform:isoamylalcohol, pH 4.5 (Sigma Aldrich) and isopropanol precipitation.\nRNA libraries were prepared for sequencing using standard Illumina protocols, using the TruSeq Stranded Total RNA (Illumina) kit'; [Cell type]'Source: ''strain background: congenic FVB background; genotype/variation: control; Stage: early-symptomatic; tissue: brain; rna fraction: total RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: early-symptomatic; tissue: brain; rna fraction: total RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: early-symptomatic; tissue: brain; rna fraction: total RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: early-symptomatic; tissue: brain; rna fraction: total RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: early-symptomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: early-symptomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: early-symptomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: early-symptomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: late-symtomatic; tissue: brain; rna fraction: total RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: late-symtomatic; tissue: brain; rna fraction: total RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: late-symtomatic; tissue: brain; rna fraction: total RNA; replicate: #3; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: late-symtomatic; tissue: brain; rna fraction: total RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: late-symtomatic; tissue: brain; rna fraction: total RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: late-symtomatic; tissue: brain; rna fraction: total RNA; replicate: #3; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: late-symtomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: late-symtomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: control; Stage: late-symtomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #3; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: late-symtomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #1; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: late-symtomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #2; ', 'strain background: congenic FVB background; genotype/variation: Taiwanese mouse model of severe Spinal muscular atrophy (SMA); Stage: late-symtomatic; tissue: brain; rna fraction: polysomal RNA; replicate: #3; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102204,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102204/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA397005,29069603," Paola Bernabo,  Toma Tebaldi,  Ewout J N Groen,  Fiona M Lane,  Elena Perenthaler,  Francesca Mattedi,  Helen J Newbery,  Haiyan Zhou,  Paola Zuccotti,  Valentina Potrich,  Hannah K Shorrock,  Francesco Muntoni,  Alessandro Quattrone,  Thomas H Gillingwater,  Gabriella Viero","Genetic alterations impacting ubiquitously expressed proteins involved in RNA metabolism often result in neurodegenerative conditions, with increasing evidence suggesting that translation defects can contribute to disease. Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein, whose role in pathogenesis remains unclear. Here, we identified in vivo and in vitro translation defects that are cell autonomous and SMN dependent. By determining in parallel the in vivo transcriptome and translatome in SMA mice, we observed a robust decrease in translation efficiency arising during early stages of disease. We provide a catalogue of RNAs with altered translation efficiency, identifying ribosome biology and translation as central processes affected by SMN depletion. This was further supported by a decrease in the number of ribosomes in SMA motor neurons in vivo. Overall, our findings suggest ribosome biology as an important, yet largely overlooked, factor in motor neuron degeneration.",In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology.,10.1016/j.celrep.2017.10.010,2017 Oct 24,PMC5668566,Cell reports
GSE129818,Next Generation Sequencing Facilitates Quantitative Analysis of Wild Type and FMCD mice Translatomics,Mus musculus,18,SRP192590,2019-04-15,"[Overal design]Examination of transcriptome and translatome in 3 mouse types.; [Treatment]'None'; [Growth]'In utero electroporation at mouse cortex with MTOR mutation in E14. Electroporated tissues were surgically resected from E18. Electroporated cortical neurons were FACS sorted E18.'; [Extraction]""RNA was extract using Trizol\nLibraries were prepared according to reference (Cho et al., Science 2015, Oct 2;350(6256):82-7. doi: 10.1126/science.aac7368). Libraries were prepared according to Illumina's instructions accompanying the TruSeq small RNA Kit (Cat#RS-200-0012). Briefly, Ribosome protected fragment (RPF) were purifed using a RNase I and Sephacryl S-400 column. mRNAs were heat fragmented. RPF and mRNAs were labeled with 32P using a T4 polynucleotide kinase. RPF and mRNAs were size selected usign Urea-PAGE. RPFs and mRNAs were end-repaired using antarctic phosphatase and T4 polynucleotide kinase. After purification, 3' adaptor and 5' adaptor ligated and purifed by UREA PAGE. After RT-PCR, libraries were sequenced using Hiseq 2000.""; [Cell type]'Cortical neuron sorted from brain''cell type: Cortical neuron sorted from brain; strain: C57BL/6; developmental stage: E18; genotype: WT; ', 'cell type: Cortical neuron sorted from brain; strain: C57BL/6; developmental stage: E18; genotype: C1483Y; ', 'cell type: Cortical neuron sorted from brain; strain: C57BL/6; developmental stage: E18; genotype: L2427P; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129818,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129818/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532897,31483294," Jang Keun Kim,  Jun Cho,  Se Hoon Kim,  Hoon-Chul Kang,  Dong-Seok Kim,  V Narry Kim,  Jeong Ho Lee","Brain somatic mutations confer genomic diversity in the human brain and cause neurodevelopmental disorders. Recently, brain somatic activating mutations in MTOR have been identified as a major etiology of intractable epilepsy in patients with cortical malformations. However, the molecular genetic mechanism of how brain somatic mutations in MTOR cause intractable epilepsy has remained elusive. In this study, translational profiling of intractable epilepsy mouse models with brain somatic mutations and genome-edited cells revealed a novel translational dysregulation mechanism and mTOR activation-sensitive targets mediated by human MTOR mutations that lead to intractable epilepsy with cortical malformation. These mTOR targets were found to be regulated by novel mTOR-responsive 5'-UTR motifs, distinct from known mTOR inhibition-sensitive targets regulated by 5' terminal oligopyrimidine motifs. Novel mTOR target genes were validated in patient brain tissues, and the mTOR downstream effector eIF4E was identified as a new therapeutic target in intractable epilepsy via pharmacological or genetic inhibition. We show that metformin, an FDA-approved eIF4E inhibitor, suppresses intractable epilepsy. Altogether, the present study describes translational dysregulation resulting from brain somatic mutations in MTOR, as well as the pathogenesis and potential therapeutic targets of intractable epilepsy.",Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy.,10.1172/JCI127032,2019 Oct 1,PMC6763223,The Journal of clinical investigation
GSE61375,Ribosome profiling upon inhibition of eIF4A,Homo sapiens,13,SRP047065,2014-09-12,"[Overal design]Translation efficiency (TE) of mRNAs dervied from ribosome footprints was monitored in the presence or absence of 25 nM Silvestrol, an inhibitor of eukaryotic translation initiation factor 4A (eIF4A). Transcripts with reduced TE in the presence of Silvestrol were compare to transcripts with reduced TE in the presence of INK128, a catalytic mTOR inhbitor.; [Treatment]'Cells were treated in culture with fresh media containing vehicle (DMSO) or drug for 1-2 hours before harvesting'; [Growth]'MDA-MB-231 cells were grown in culture at a density of 1-7 x 106 cells/ml in RPMI supplemented with 10% Fetal Calf Serum'; [Extraction]'Extraction protocol was carried out as described by Ingolia et al. Nat Protoc 2012, 7:153450.\nLibrary construction was performed as described by Ingolia et al. Nat Protoc 2012, 7:153450.'; [Cell type]'Ductal breast carcinoma''cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 3; treatment: DMSO for 1 hour; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 3; treatment: DMSO for 2 hours; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 3; treatment: 25 nM Silvestrol for 1 hour; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 3; treatment: untreated; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 3; treatment: 25 nM Silvestrol for 2 hours; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 4; treatment: DMSO for 2 hours; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 4; treatment: 25 nM Silvestrol for 2 hours; ', 'cell line: MDA-MB-231; cell type: Ductal breast carcinoma; passage #: 3; treatment: 200 nM INK128 for 2 hours; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61375,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE61nnn/GSE61375/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA260909,25273840," Claudia A Rubio,  Benjamin Weisburd,  Matthew Holderfield,  Carolina Arias,  Eric Fang,  Joseph L DeRisi,  Abdallah Fanidi","BACKGROUND: Protein synthesis is tightly regulated and alterations to translation are characteristic of many cancers.Translation regulation is largely exerted at initiation through the eukaryotic translation initiation factor 4 F (eIF4F). eIF4F is pivotal for oncogenic signaling as it integrates mitogenic signals to amplify production of pro-growth and pro-survival factors. Convergence of these signals on eIF4F positions this factor as a gatekeeper of malignant fate. While the oncogenic properties of eIF4F have been characterized, genome-wide evaluation of eIF4F translational output is incomplete yet critical for developing novel translation-targeted therapies. RESULTS: To understand the impact of eIF4F on malignancy, we utilized a genome-wide ribosome profiling approach to identify eIF4F-driven mRNAs in MDA-MB-231 breast cancer cells. Using Silvestrol, a selective eIF4A inhibitor, we identify 284 genes that rely on eIF4A for efficient translation. Our screen confirmed several known eIF4F-dependent genes and identified many unrecognized targets of translation regulation. We show that 5'UTR complexity determines Silvestrol-sensitivity and altering 5'UTR structure modifies translational output. We highlight physiological implications of eIF4A inhibition, providing mechanistic insight into eIF4F pro-oncogenic activity. CONCLUSIONS: Here we describe the transcriptome-wide consequence of eIF4A inhibition in malignant cells, define mRNA features that confer eIF4A dependence, and provide genetic support for Silvestrol's anti-oncogenic properties. Importantly, our results show that eIF4A inhibition alters translation of an mRNA subset distinct from those affected by mTOR-mediated eIF4E inhibition. These results have significant implications for therapeutically targeting translation and underscore a dynamic role for eIF4F in remodeling the proteome toward malignancy.",Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.,10.1186/s13059-014-0476-1,2014,PMC4203936,Genome biology
GSE138643,Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides,Homo sapiens,41,None,2019-10-09,"[Overal design]Refer to individual Series; [Treatment]'Aminoglycosides were added to cells, and treated for either 10 minutes or 24 hours', 'Aminoglycosides were added to cells, and treated for 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation. For RNAseq, total RNA was extracted using Trizol, and sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Library Prep Gold (20020598) kit.\nFor ribosome profiling, fragments ranging from 15-34 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing. RNA-seq samples were prepared from 1 ug of total RNA following the Truseq protocol.', 'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 15-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.', 'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 26-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.', 'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation. For RNAseq, total RNA was extracted using Trizol, and sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Library Prep Gold (20020598) kit.\nFor ribosome profiling, fragments ranging from 26-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Gentamicin; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Paromomycin; concentration: 3000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Neomycin; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Tobramycin; concentration: 1000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Amikacin; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Amikcain; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 10 minutes; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: G418; concentration: 2000 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 10 minutes; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: Calu-6 cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: Calu-6 cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: Calu-6 cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: Calu-6 cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138643,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138643/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576648,31971508," Jamie R Wangen,  Rachel Green",eng,Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.,10.7554/eLife.52611,2020 Jan 23,PMC7089771,eLife
GSE68707,Genome-wide reprogramming of transcript architecture by temperature specifies the developmental states of the human pathogen Histoplasma,Histoplasma capsulatum,24,None,2015-05-08,"[Overal design]Refer to individual Series; [Treatment]'None'; [Growth]'Biological duplicates of G217B yeast cells were grown at 37C in HMM liquid medium to mid-log phase. Biological duplicates of G217B hyphal cells were grown for 4  6 weeks with passaging three times (1:5 dilution) into fresh HMM medium at RT before reaching a sufficient density of cells for harvesting.', 'G217B, G186AR, H88, and H143 yeast cells were inoculated from HMM agarose plates into HMM liquid medium for yeast-phase growth. Yeast cells were passaged at a 1:25 dilution three times and 2-day cultures of each strain were harvested for RNA collection after the third passage. For hyphal cells, G217B, G186AR, H88, and H143 hyphae were inoculated from Sabouraud dextrose agar plates grown at RT into HMM liquid medium. Hyphal cells were grown for 4  6 weeks with passaging 3 times (1:5 dilution) into fresh HMM medium at RT before reaching a sufficient density of cells for harvesting.'; [Extraction]'Hyphal and yeast cells were treated with 100 ?g/mL cycloheximide for 2 minutes (MP Biomedicals, Santa Ana, CA) before harvesting of cells by filtration. Total RNA for mRNA library preparation was isolated from a small fraction of the total yeast or hyphal cells collected for ribosome profiling using a guanidine thiocyanate lysis protocol as previously described (Hwang et al, Molecular Biology of the Cell 14:2314).\nRibosome profiling and matched mRNA-seq sample preparation and library building were performed as described (Ingolia et al Science 324:218), except that the 3' linker ligation strategy was used instead of poly(A) tailing for marking and capturing the 3 RNA end (Dunn et al eLife 2:e01179). Libraries were multiplexed and subjected to 50 bp single-end sequencing with an Illumina HiSeq2000 sequencer (Illumina).', 'Hyphal and yeast cells were collected by centrifugation or filtration and total RNA was isolated using a guanidine thiocyanate lysis protocol as previously described (Hwang et al, Molecular Biology of the Cell 14:2314).\nPaired-end RNA-seq libraries were made from biological duplicate cultures of G217B, G186AR, H88, and H143 for both yeast and hyphae. DNA was depleted from 10  20 ?g of total RNA by 1 hour of DNaseI digestion at 37C (Ambion by Life Technologies, Carlsbad, CA). Poly(A)+ RNA was selected from DNA-depleted RNA on oligo- dT25 DynaBeads (Invitrogen by Life Technologies) using 2 rounds of selection per the manufacturers instructions. Approximately 50 ng of poly(A)+ RNA was used as input for generating sequencing libraries with the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre, Madison, WI) per the manufacturers instructions with the following modifications.  After 11 cycles of the ScriptSeq v2 PCR cDNA amplification step, cDNA libraries were resolved on an 8% TBE gel (Invitrogen by Life Technologies) and a 350  500 bp range of cDNA library was excised, eluted, and precipitated from the gel. Seven additional PCR cycles were resumed following the ScriptSeq v2 Kit protocol. cDNA libraries were purified with AMPure XP beads (Beckman Coulter, Brea, CA) to deplete primers. Libraries were multiplexed and subjected to 100 bp paired-end sequencing using the Illumina HiSeq2000 sequencer (Illumina, San Diego, CA).'; [Cell type]'Source: ''strain: G217B; growth phase: hyphae; ', 'strain: G217B; growth phase: yeast; ', 'strain: G186AR; growth phase: hyphae; ', 'strain: G186AR; growth phase: yeast; ', 'strain: H88; growth phase: hyphae; ', 'strain: H88; growth phase: yeast; ', 'strain: H143; growth phase: hyphae; ', 'strain: H143; growth phase: yeast; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68707,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68707/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA283424,26177267," Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil,  Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil","Eukaryotic cells integrate layers of gene regulation to coordinate complex cellular processes; however, mechanisms of post-transcriptional gene regulation remain poorly studied. The human fungal pathogen Histoplasma capsulatum (Hc) responds to environmental or host temperature by initiating unique transcriptional programs to specify multicellular (hyphae) or unicellular (yeast) developmental states that function in infectivity or pathogenesis, respectively. Here we used recent advances in next-generation sequencing to uncover a novel re-programming of transcript length between Hc developmental cell types. We found that ~2% percent of Hc transcripts exhibit 5' leader sequences that differ markedly in length between morphogenetic states. Ribosome density and mRNA abundance measurements of differential leader transcripts revealed nuanced transcriptional and translational regulation. One such class of regulated longer leader transcripts exhibited tight transcriptional and translational repression. Further examination of these dually repressed genes revealed that some control Hc morphology and that their strict regulation is necessary for the pathogen to make appropriate developmental decisions in response to temperature.",Genome-Wide Reprogramming of Transcript Architecture by Temperature Specifies the Developmental States of the Human Pathogen Histoplasma.,10.1371/journal.pgen.1005395,2015 Jul,PMC4503680,PLoS genetics
GSE131074,Ribosome profiling of eIF3e-KD MCF-10a cells,Homo sapiens,15,SRP198221,2019-05-13,"[Overal design]Using si-RNA to do eIF3e-KD then do the ribosome profiling samples with total RNA, 3 replicates.; [Treatment]'The cells were treated with 20nM si-control or si-eIF3e for 72h.'; [Growth]'MCF-10a cells were cultured in DMEM/F12 medium with 0.5mg/mL hydrocortisone, 10g/mL insulin, 20ng/mL EGF, 5% serum, 1X Pen/Strep, and incubate in 37? with 5% CO2.'; [Extraction]'The RNA were extracted with TRIzol reagent(thermo ambion, REF,15596018) and its standard protocol.\nAfter clarification, 5 OD260 units of lysates were treated with 450 units of RNaseI (Ambion) for 45 min at RT. RPFs were isolated with Sephacryl S400 (GE, MicroSpin S-400 HR, 27514001). mRNAs and RPFs were isolated with TRIzol reagent(thermo ambion, REF,15596018). The rRNA removal for total mRNAs and RPFs was accomplished using Ribo-zero Gold (rRNA removal reagent(Human/Mouse/Rat)(illumina, REF, RZG1224) & Core kit(illumina, REF, MRZ11124C). For RPF, the extracted RNA was size-selected from 15% denaturing PAGE gels, cutting between 26-34 nt. An oligonucleotide adaptor was ligated to the 3 end of footprints. Followed by reverse transcription, circularization and PCR amplification.'; [Cell type]'epithelial''cell line: MCF10-A; cell type: epithelial; treatment: eIF3e siRNA; ', 'cell line: MCF10-A; cell type: epithelial; treatment: Control siRNA; ', 'cell line: MCF10-A; cell type: epithelial; treatment: Total RPF (all the ribosome protected footprints from the 80S ribosomes isolated from total cell lysate); ', 'cell line: MCF10-A; cell type: epithelial; treatment: Selective RPF (eIF3B-bound ribosomes protected footprints); ', 'cell line: MCF10-A; cell type: epithelial; treatment: Selective RPF; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131074,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE131nnn/GSE131074/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA542601,32589965," Yingying Lin,  Fajin Li,  Linlu Huang,  Christine Polte,  Haoran Duan,  Jianhuo Fang,  Li Sun,  Xudong Xing,  Guiyou Tian,  Yabin Cheng,  Zoya Ignatova,  Xuerui Yang,  Dieter A Wolf","eIF3, a multi-subunit complex with numerous functions in canonical translation initiation, is known to interact with 40S and 60S ribosomal proteins and translation elongation factors, but a direct involvement in translation elongation has never been demonstrated. We found that eIF3 deficiency reduced early ribosomal elongation speed between codons 25 and 75 on a set of approximately 2,700 mRNAs encoding proteins associated with mitochondrial and membrane functions, resulting in defective synthesis of their encoded proteins. To promote elongation, eIF3 interacts with 80S ribosomes translating the first approximately 60 codons and serves to recruit protein quality-control factors, functions required for normal mitochondrial physiology. Accordingly, eIF3e(+/-) mice accumulate defective mitochondria in skeletal muscle and show a progressive decline in muscle strength. Hence, eIF3 interacts with 80S ribosomes to enhance, at the level of early elongation, the synthesis of proteins with membrane-associated functions, an activity that is critical for mitochondrial physiology and muscle health.","eIF3 Associates with 80S Ribosomes to Promote Translation Elongation, Mitochondrial Homeostasis, and Muscle Health.",10.1016/j.molcel.2020.06.003,2020 Aug 20,,Molecular cell
GSE142822,Anti-tumor immunity induces the presentation of aberrant peptides in melanoma,Homo sapiens,57,SRP239266,2020-01-02,"[Overal design]RNA sequencing, ribosome profiling, and mass spectrometry to measure mRNA levels, mRNA translation, and protein levels.; [Treatment]'cell where cultured with Tryptophan-free RPMI 1640 media (custom purchased from Biological Industries)/ Tyrosine-free medium (custom purchased from Cell Culture Technologies) for 48h, IFN? (PeproTech) was used at 250 U/mL for the indicated durations of time. IDO inhibitor, 1-Methyl-L-Tryptophan (SIGMA) was dissolved in 0.1N NaOH at a 20mM concentration, adjusted to PH=7.5, filter sterilized and used at a final concentration of 300M for 48h.'; [Growth]'12T, 108T, MD55A3 Cell lines were derived from pathology-confirmed metastatic melanoma tumor resections. Cells were authenticated by Finger printing with STR profiling. 12T, 108T, MD55A3, 888-Mel and D10 cells were cultured in RPMI 1640 medium supplemented with heat-inactivated 10% fetal bovine serum 25 mM HEPES and 100 U/mL penicillin/streptomycin.'; [Extraction]'For the generation of total RNA libraries, total RNA was extracted using TRI Reagent (SIGMA), and mRNA was purified using Dynabeads mRNA DIRECT Purification Kit (Invitrogen), according to the manufactures protocol. For ribosome profiling in melanoma cell lines, cells were treated with Cycloheximide for 1 min (100ug/ml), lysed in lysis buffer (20mM Tris 7.5, 150mM NaCl, 15mM MgCl2, 1mM dithiothreitol) supplemented with 0.5% triton, 30 U/ml Turbo DNase (Ambion) and 100?g/ml cycloheximide. Cell lysates were loaded on sucrose cushion, followed by ultracentrifugation, and RNA was extracted from pelletsd using TRI reagent following manufacture protocol.\nThe construction of ribosome protected fragments (RPF) libraries were done as previously described in Ingolia NT et al, doi:10.1038/nprot.2012.086 (2012). Total RNA libraries were constructed using SENSE Total RNA-Seq Library Prep Kit for Illunima (LEXOGEN).'; [Cell type]'Melanoma  cancer cells''cell type: Melanoma  cancer cells; treatment: Control; ', 'cell type: Melanoma  cancer cells; treatment: IFNg; ', 'cell type: Melanoma  cancer cells; treatment: IDO; ', 'cell type: Melanoma  cancer cells; treatment: IDO + IFNg; ', 'cell type: Melanoma  cancer cells; treatment: starvation media, Tryptophan depletion for 24h; ', 'cell type: Melanoma  cancer cells; treatment: starvation media + Tryptophan addition for 24h; ', 'cell type: Melanoma  cancer cells; treatment: starvation media, Tryptophan depletion for 48h; ', 'cell type: Melanoma  cancer cells; treatment: starvation media + Tryptophan addition for 48h; ', 'cell type: Melanoma  cancer cells; treatment: starvation media + Tyrosine addition; ', 'cell type: Melanoma  cancer cells; treatment: starvation media, Tyrosine depletion; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142822,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE142nnn/GSE142822/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA598557,33328638," Osnat Bartok,  Abhijeet Pataskar,  Remco Nagel,  Maarja Laos,  Eden Goldfarb,  Deborah Hayoun,  Ronen Levy,  Pierre-Rene Korner,  Inger Z M Kreuger,  Julien Champagne,  Esther A Zaal,  Onno B Bleijerveld,  Xinyao Huang,  Juliana Kenski,  Jennifer Wargo,  Alexander Brandis,  Yishai Levin,  Orel Mizrahi,  Michal Alon,  Sacha Lebon,  Weiwen Yang,  Morten M Nielsen,  Noam Stern-Ginossar,  Maarten Altelaar,  Celia R Berkers,  Tamar Geiger,  Daniel S Peeper,  Johanna Olweus,  Yardena Samuels,  Reuven Agami","Extensive tumour inflammation, which is reflected by high levels of infiltrating T cells and interferon-gamma (IFNgamma) signalling, improves the response of patients with melanoma to checkpoint immunotherapy(1,2). Many tumours, however, escape by activating cellular pathways that lead to immunosuppression. One such mechanism is the production of tryptophan metabolites along the kynurenine pathway by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which is induced by IFNgamma(3-5). However, clinical trials using inhibition of IDO1 in combination with blockade of the PD1 pathway in patients with melanoma did not improve the efficacy of treatment compared to PD1 pathway blockade alone(6,7), pointing to an incomplete understanding of the role of IDO1 and the consequent degradation of tryptophan in mRNA translation and cancer progression. Here we used ribosome profiling in melanoma cells to investigate the effects of prolonged IFNgamma treatment on mRNA translation. Notably, we observed accumulations of ribosomes downstream of tryptophan codons, along with their expected stalling at the tryptophan codon. This suggested that ribosomes bypass tryptophan codons in the absence of tryptophan. A detailed examination of these tryptophan-associated accumulations of ribosomes-which we term 'W-bumps'-showed that they were characterized by ribosomal frameshifting events. Consistently, reporter assays combined with proteomic and immunopeptidomic analyses demonstrated the induction of ribosomal frameshifting, and the generation and presentation of aberrant trans-frame peptides at the cell surface after treatment with IFNgamma. Priming of naive T cells from healthy donors with aberrant peptides induced peptide-specific T cells. Together, our results suggest that IDO1-mediated depletion of tryptophan, which is induced by IFNgamma, has a role in the immune recognition of melanoma cells by contributing to diversification of the peptidome landscape.",Anti-tumour immunity induces aberrant peptide presentation in melanoma.,10.1038/s41586-020-03054-1,2021 Feb,,Nature
GSE128324,Translation and transcription start site profiling of HSV-1 infected cells,Homo sapiens,28,None,2019-03-14,"[Overal design]Refer to individual Series; [Treatment]'Cells were infected for 10 min with HSV-1 strain 17 at an MOI of 10 followed by PBS wash and media replacement. 500M 4-thiouridine was added to the cell culture at the indicated time points.', 'Cells were infected for 15 min using an MOI of 10. 15min after infection (time point 0h), cell culture media was replaced with fresh media. Cells were harvested prior to or at 8h p.i. cRNA-seq and dRNA-seq libraries were prepared.'; [Growth]'Human foreskin fibroblasts were cultured in DMEM supplements with 10% FBS and P/S. Cells at passage 13 were infected at 60% confluency 24h after the last split.', 'Primary human foreskin fibroblasts were cultured in DMEM supplements with 10% FBS and P/S. Cells at passage 15 were infected with HSV-1 strain 17 at an MOI of 10'; [Extraction]'Cells were snap frozen followed by cell lysis in presence of cycloheximide. Following removal of cell nuclei by centrifugation and stringent RNAse digest, ribosomes were pelleted through a sucrose cushion. Translated RNA fragments were recovered by size selection.\nTranslated RNA fragments were cloned following the protocol described by Stern-Ginossar N et al. Science 2012. rRNA depletion involved additional biotinylated oligos to improve depletion. To efficiently remove all biotinylated oligos complementary to specific rRNA sequences, two rounds of streptavidin depletion were performed. cDNA libraries were amplified by PCR and sequenced (HiSeq 50nt reads).', 'Cells were lyzed using Trizol and total cellular RNA was isolated.\nSequencing libraries were prepared using the cRNA-seq and dRNA-seq inhouse protocols.'; [Cell type]'human foreskin fibroblasts', 'primary fibroblasts''cell type: human foreskin fibroblasts; time post infection: 2 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNAATANN; ', 'cell type: human foreskin fibroblasts; time post infection: 8 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNTTAANN; ', 'cell type: human foreskin fibroblasts; time post infection: mock; infection with: mock; barcode: NNNTTGTNN; ', 'cell type: human foreskin fibroblasts; time post infection: 4 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCAATNN; ', 'cell type: human foreskin fibroblasts; time post infection: 8 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCCGGNN; ', 'cell type: human foreskin fibroblasts; time post infection: mock; infection with: mock; barcode: NNNCGGANN; ', 'cell type: human foreskin fibroblasts; time post infection: 4 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNAATAANN; ', ""cell type: primary fibroblasts; time post infection: Mock; replicate: Replicate 1; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: Mock; replicate: Replicate 2; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 1 h p.i.; replicate: Replicate 1; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 1 h p.i.; replicate: Replicate 2; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 2 h p.i.; replicate: Replicate 1; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 2 h p.i.; replicate: Replicate 2; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 4 h p.i.; replicate: Replicate 1; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 4 h p.i.; replicate: Replicate 2; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 8 h p.i.; replicate: Replicate 1; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 8 h p.i.; replicate: Replicate 2; enrichment: 5' RNA ends enriched; "", ""cell type: primary fibroblasts; time post infection: Mock; replicate: Replicate 1; enrichment: 5' RNA ends (selective); treatment: XRN1; "", ""cell type: primary fibroblasts; time post infection: Mock; replicate: Replicate 1; enrichment: 5' RNA ends (selective); "", ""cell type: primary fibroblasts; time post infection: Mock; replicate: Replicate 2; enrichment: 5' RNA ends (selective); treatment: XRN1; "", ""cell type: primary fibroblasts; time post infection: Mock; replicate: Replicate 2; enrichment: 5' RNA ends (selective); "", ""cell type: primary fibroblasts; time post infection: HSV-1, 8 h p.i.; replicate: Replicate 1; enrichment: 5' RNA ends (selective); treatment: XRN1; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 8 h p.i.; replicate: Replicate 1; enrichment: 5' RNA ends (selective); "", ""cell type: primary fibroblasts; time post infection: HSV-1, 8 h p.i.; replicate: Replicate 2; enrichment: 5' RNA ends (selective); treatment: XRN1; "", ""cell type: primary fibroblasts; time post infection: HSV-1, 8 h p.i.; replicate: Replicate 2; enrichment: 5' RNA ends (selective); """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128324,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128324/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA527125,32341360," Adam W Whisnant,  Christopher S Jurges,  Thomas Hennig,  Emanuel Wyler,  Bhupesh Prusty,  Andrzej J Rutkowski,  Anne L'hernault,  Lara Djakovic,  Margarete Gobel,  Kristina Doring,  Jennifer Menegatti,  Robin Antrobus,  Nicholas J Matheson,  Florian W H Kunzig,  Guido Mastrobuoni,  Chris Bielow,  Stefan Kempa,  Chunguang Liang,  Thomas Dandekar,  Ralf Zimmer,  Markus Landthaler,  Friedrich Grasser,  Paul J Lehner,  Caroline C Friedel,  Florian Erhard,  Lars Dolken","The predicted 80 open reading frames (ORFs) of herpes simplex virus 1 (HSV-1) have been intensively studied for decades. Here, we unravel the complete viral transcriptome and translatome during lytic infection with base-pair resolution by computational integration of multi-omics data. We identify a total of 201 transcripts and 284 ORFs including all known and 46 novel large ORFs. This includes a so far unknown ORF in the locus deleted in the FDA-approved oncolytic virus Imlygic. Multiple transcript isoforms expressed from individual gene loci explain translation of the vast majority of ORFs as well as N-terminal extensions (NTEs) and truncations. We show that NTEs with non-canonical start codons govern the subcellular protein localization and packaging of key viral regulators and structural proteins. We extend the current nomenclature to include all viral gene products and provide a genome browser that visualizes all the obtained data from whole genome to single-nucleotide resolution.",Integrative functional genomics decodes herpes simplex virus 1.,10.1038/s41467-020-15992-5,2020 Apr 27,PMC7184758,Nature communications
GSE69906,The transcription and translation landscapes during human cytomegalovirus infection reveal novel host-pathogen interactions,Homo sapiens,14,SRP059531,2015-06-16,"[Overal design]Ribosome profiling and mRNA-seq along HCMV infection; [Treatment]'None'; [Growth]'None'; [Extraction]'Cells were lysed with 0.5% Triton, and the lysate was cleared by centrifugation, treated with RNase I for 45min and then loaded on a sucrose cushion. RNA was then isolated from cells using the acid:phenol extraction method.\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circularized and PCR amplified.'; [Cell type]'Primary fibroblasts''cell type: Primary fibroblasts; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69906,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69906/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA287112,26599541," Osnat Tirosh,  Yifat Cohen,  Alina Shitrit,  Odem Shani,  Vu Thuy Khanh Le-Trilling,  Mirko Trilling,  Gilgi Friedlander,  Marvin Tanenbaum,  Noam Stern-Ginossar","Viruses are by definition fully dependent on the cellular translation machinery, and develop diverse mechanisms to co-opt this machinery for their own benefit. Unlike many viruses, human cytomegalovirus (HCMV) does suppress the host translation machinery, and the extent to which translation machinery contributes to the overall pattern of viral replication and pathogenesis remains elusive. Here, we combine RNA sequencing and ribosomal profiling analyses to systematically address this question. By simultaneously examining the changes in transcription and translation along HCMV infection, we uncover extensive transcriptional control that dominates the response to infection, but also diverse and dynamic translational regulation for subsets of host genes. We were also able to show that, at late time points in infection, translation of viral mRNAs is higher than that of cellular mRNAs. Lastly, integration of our translation measurements with recent measurements of protein abundance enabled comprehensive identification of dozens of host proteins that are targeted for degradation during HCMV infection. Since targeted degradation indicates a strong biological importance, this approach should be applicable for discovering central host functions during viral infection. Our work provides a framework for studying the contribution of transcription, translation and degradation during infection with any virus.",The Transcription and Translation Landscapes during Human Cytomegalovirus Infection Reveal Novel Host-Pathogen Interactions.,10.1371/journal.ppat.1005288,2015,PMC4658056,PLoS pathogens
GSE115162,Regulation of Translation Elongation Revealed by Ribosome Profiling,Homo sapiens; Saccharomyces cerevisiae; Caenorhabditis elegans,56,None,2018-05-31,"[Overal design]Refer to individual Series; [Treatment]'Cells were treated with antibiotics and modified by DMS.', 'After lysis, lysates were diluted to 15 mL with footprint lysis buffer with or without TIG and modified by DMS.', 'Cells were harvested by vacuum filtration and flash frozen. Samples were homogenized and lysed with lysis buffer using a freezer mill.', 'Yeast cells were harvested by vacuum filtration and flash frozen. Samples were homogenized and lysed with lysis buffer using a freezer mill.'; [Growth]'Cells were grown to an OD of 0.7 in YPD media', 'Cells were grown to an OD of 0.6 in YPD media and harvested by fast filtration and flash frozen in liquid nitrogen.', 'Cells were grown to an OD of 0.5', 'Yeast cells were grown to OD ~0.5; mammalian cells were grown to ~75% confluence; Synchronized L1 worms were plated on HT115 bacteria transformed with pL4440 vector and cultured at 25?C for ~48 hours.', 'Yeast cells were grown to OD ~0.5.'; [Extraction]'RNA was extracted using SDS/hot phenol/chloroform.\nFragments ranging from 60-80 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product was once again gel purified. This was followed by reverse transcription as well as circularization of cDNAs. PCR amplification of this library was then sent for sequencing.', 'Lysates were clarified and monosomes were isolated by sucrose gradient centrifugation after RNaseI treatment. RNA was extracted using SDS/hot phenol/chloroform.\nFragments ranging from 15-34 nt were gel purified and rRNA was depleted from this pool through Ribo-Zero Gold (Yeast) treatment. Upon dephosphorylation of sample RNA, IDT miRNA Cloning Linker 1 was ligated and this product was once again gel purified. This was followed by reverse transcription as well as circularization of cDNAs. PCR amplification of this library was then sent for sequencing.', 'Lysates were clarified and monosomes were isolated by sucrose gradient centrifugation after RNaseI treatment. RNA was extracted using SDS/hot phenol/chloroform.\nFragments ranging from 15-34 nt were gel purified and rRNA was depleted from this pool through Ribo-Zero Gold treatment. Upon dephosphorylation of sample RNA, linker was ligated and this product was once again gel purified. This was followed by reverse transcription as well as circularization of cDNAs. PCR amplification of this library was then sent for sequencing.'; [Cell type]'Source: ''genotype/variation: Wild-Type; plasmid(s): None; molecule subtype: Fragmented total RNA; ', 'strain: yCW30; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yCW19; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: Wild-Type; plasmid(s): pRS416; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yKW13; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'cell line: MDA-MB-231; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'tissue: embryos; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'cell line: HeLa; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yCW66; plasmid: None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'genotype/variation: Wild-Type; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'genotype/variation: rck2{delta}; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yCW66; plasmid(s): pRS416-GalL-gamma toxin; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: Wild-Type; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115162,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE115nnn/GSE115162/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA473984,31858614," Petr Tesina,  Laura N Lessen,  Robert Buschauer,  Jingdong Cheng,  Colin Chih-Chien Wu,  Otto Berninghausen,  Allen R Buskirk,  Thomas Becker,  Roland Beckmann,  Rachel Green","Inhibitory codon pairs and poly(A) tracts within the translated mRNA cause ribosome stalling and reduce protein output. The molecular mechanisms that drive these stalling events, however, are still unknown. Here, we use a combination of in vitro biochemistry, ribosome profiling, and cryo-EM to define molecular mechanisms that lead to these ribosome stalls. First, we use an in vitro reconstituted yeast translation system to demonstrate that inhibitory codon pairs slow elongation rates which are partially rescued by increased tRNA concentration or by an artificial tRNA not dependent on wobble base-pairing. Ribosome profiling data extend these observations by revealing that paused ribosomes with empty A sites are enriched on these sequences. Cryo-EM structures of stalled ribosomes provide a structural explanation for the observed effects by showing",Molecular mechanism of translational stalling by inhibitory codon combinations and poly(A) tracts.,10.15252/embj.2019103365,2020 Feb 3,PMC6996574,The EMBO journal
GSE157723,Astroglial FMRP deficiency cell-autonomously up-regulates miR-128 and disrupts developmental astroglial mGluR5 signaling (RNA-Seq),Mus musculus,12,SRP281862,2020-09-09,"[Overal design]examine the genome-wide mRNA expression profiles in cortical astroglia in Fmr1+/y and Fmr1?/y mice; [Treatment]'N/A'; [Growth]'N/A'; [Extraction]""Ribosome-bound RNAs were isolated as described previously (\u200b47\u200b). Briefly, somatosensory cortical sections (1 mm) from Fmr1+/yAldh1l1-TRAP and Fmr1?/yAldh1l1-TRAP mice were prepared on a mouse brain matrix. The anti-eGFP antibody (mouse clone HtzGFP-19C8, Memorial Sloan Kettering Cancer Center) was coupled to magnetic beads (Dynabeads, Invitrogen) as described in the kit instructions. Tissue homogenates were prepared and mixed with eGFP antibody-coupled beads for immunoprecipitation. Following immunoprecipitation, RNA was isolated using the TRIzol reagent and precipitated with isopropanol.\nLibraries were prepared according to Illumina's instructions with TrUSeq Stranded Total RNA with RiboZero Gold kit\nPair-end (100bp) RNA-seq""; [Cell type]'Source: ''genotype: Fmr1 KO; mouse strain: FVB/C57; age: P40; ', 'genotype: WT; mouse strain: FVB/C57; age: P40; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157723,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE157nnn/GSE157723/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA662567,,,,,,,,
GSE118215,Widespread EJC footprints in the RNA degradome mark mRNA degradation before steady-state translation,Arabidopsis thaliana,14,SRP156540,2018-08-07,"[Overal design]Profiling 5' ends of RNA degradation intermediates in Arabidopsis thaliana by parallel analysis of RNA ends (PARE); [Treatment]'None'; [Growth]'Arabidopsis seedlings was grown on 0.8% Bacto-agar plates containing half-strength Murashige and Skoog (MS) medium (pH 5.7) and 1% sucrose under a 16/8-h light/dark cycle at 22C.  For smg7-1 and the WT control, the soil-grown plants were first grown at 22C then transferred to 28C.'; [Extraction]'Total RNA was extracted from the powder of frozen plant tissues by PureLink Plant RNA Reagent (Thermo Fisher).\nPARE libraries were constructed from 80 ?g total RNA following the protocol described previously ( Zhai J, Arikit S, Simon SA, Kingham BF, Meyers BC: Rapid construction of parallel analysis of RNA end (PARE) libraries for Illumina sequencing. Methods 2014, 67:84-90).'; [Cell type]'Source: ''tissue: seedlings; ecotype: Col-0; growth medium: 1/2 MS + 1% sucrose + 0.8% agar; age: 10-day; genotype: wild-type; treatment: NA; ', 'tissue: seedlings; ecotype: Col-0; growth medium: 1/2 MS + 1% sucrose + 0.8% agar; age: 10-day; genotype: xrn4-6 mutant; treatment: NA; ', 'tissue: seedlings; ecotype: Col-0; growth medium: 1/2 MS + 1% sucrose + 0.8% agar; age: 10-day; genotype: fry1-6 mutant; treatment: NA; ', 'tissue: seedlings; ecotype: Col-0; growth medium: 1/2 MS + 1% sucrose + 0.8% agar; age: 12-day; genotype: wild-type; treatment: Mock for cyclohexmine treatment; ', 'tissue: seedlings; ecotype: Col-0; growth medium: 1/2 MS + 1% sucrose + 0.8% agar; age: 12-day; genotype: wild-type; treatment: Treatment of 10 g/ml cyclohexmine for 6 hours; ', 'tissue: flower; ecotype: Col-0; growth medium: soil; age: 4-5wk-flowers; genotype: wild-type; treatment: NA; ', 'tissue: flower; ecotype: Col-0; growth medium: soil; age: 4-5wk-flowers; genotype: smg7-1 mutant; treatment: NA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118215,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE118nnn/GSE118215/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA484887,31988264," Wen-Chi Lee,  Bo-Han Hou,  Cheng-Yu Hou,  Shu-Ming Tsao,  Ping Kao,  Ho-Ming Chen","Exon junction complexes (EJCs) are deposited on mRNAs during splicing and displaced by ribosomes during the pioneer round of translation. Nonsense-mediated mRNA decay (NMD) degrades EJC-bound mRNA, but the lack of suitable methodology has prevented the identification of other degradation pathways. Here, we show that the RNA degradomes of Arabidopsis (Arabidopsis thaliana), rice (Oryza sativa), worm (Caenorhabditis elegans), and human (Homo sapiens) cells exhibit an enrichment of 5' monophosphate (5'P) ends of degradation intermediates that map to the canonical EJC region. Inhibition of 5' to 3' exoribonuclease activity and overexpression of an EJC disassembly factor in Arabidopsis reduced the accumulation of these 5'P ends, supporting the notion that they are in vivo EJC footprints. Hundreds of Arabidopsis NMD targets possess evident EJC footprints, validating their degradation during the pioneer round of translation. In addition to premature termination codons, plant microRNAs can also direct the degradation of EJC-bound mRNAs. However, the production of EJC footprints from NMD but not microRNA targets requires the NMD factor SUPPRESSOR WITH MORPHOLOGICAL EFFECT ON GENITALIA PROTEIN7. Together, our results demonstrating in vivo EJC footprinting in Arabidopsis unravel the composition of the RNA degradome and provide a new avenue for studying NMD and other mechanisms targeting EJC-bound mRNAs for degradation before steady state translation.",Widespread Exon Junction Complex Footprints in the RNA Degradome Mark mRNA Degradation before Steady State Translation.,10.1105/tpc.19.00666,2020 Apr,PMC7145476,The Plant cell
GSE113695,EIF1AX-A113 splice and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC,Homo sapiens,18,SRP142722,2018-04-26,"[Overal design]Comparison of Ribosome footprints in the context of EIF1AX-splice mutated (C643) and splice reverted isogenic cell line (C643-spl- rev), three replicates of ribosome-protected RNA sequencing and three replicates of RNA-seq were used. Additionally, 3 replicates of RNA-seq comparing KRAS G12R mutant CAL62 vs. CAL62-splice, an isogenic cell line generated with CRISPR-Cas9 mediated knock in of EIF1AX-splice mutation.; [Treatment]'None'; [Growth]'Cell lines were maintained at 37C and 5% CO 2 \xa0in humidified atmosphere and were grown in RPMI-1640.'; [Extraction]'Ribosome-protected RNA extraction was performed following the published protocol by Ingolia NT et al., Nature Protocols, 2012. and for RNA-seq, total RNA was extracted using Trizol.\nRibosome Footprint library construction was performed following the protocol by Ingolia NT et al., Nature Protocols, 2012; with a modification of including unique molecular identifiers (UMI) in the Reverse transcription primer in order to remove PCR duplicates. 5'-(Phos)-GGNNNNTCANNNN- AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGC-(SpC18)-CACTCA- (SpC18)-\xa0TTCAGACGTGTGCTCTTCCGATCTATTGATGGTGCCTACAG-3''; [Cell type]'Source: ''mrna type: mRNA; splice status: WT-splice; cell line: C643; ', 'mrna type: mRNA; splice status: Splice Reversed; cell line: C643; ', 'mrna type: mRNA; splice status: WT no splice; cell line: CAL62; ', 'mrna type: mRNA; splice status: Splice Induced; cell line: CAL62; ', 'mrna type: ribosome protected mRNA; splice status: WT-splice; cell line: C643; ', 'mrna type: ribosome protected mRNA; splice status: Splice Reversed; cell line: C643; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113695,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE113nnn/GSE113695/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA453686,30305285," Gnana P Krishnamoorthy,  Natalie R Davidson,  Steven D Leach,  Zhen Zhao,  Scott W Lowe,  Gina Lee,  Inigo Landa,  James Nagarajah,  Mahesh Saqcena,  Kamini Singh,  Hans-Guido Wendel,  Snjezana Dogan,  Prasanna P Tamarapu,  John Blenis,  Ronald A Ghossein,  Jeffrey A Knauf,  Gunnar Ratsch,  James A Fagin","Translation initiation is orchestrated by the cap binding and 43S preinitiation complexes (PIC). Eukaryotic initiation factor 1A (EIF1A) is essential for recruitment of the ternary complex and for assembling the 43S PIC. Recurrent EIF1AX mutations in papillary thyroid cancers are mutually exclusive with other drivers, including RAS. EIF1AX mutations are enriched in advanced thyroid cancers, where they display a striking co-occurrence with RAS, which cooperates to induce tumorigenesis in mice and isogenic cell lines. The C-terminal EIF1AX-A113splice mutation is the most prevalent in advanced thyroid cancer. EIF1AX-A113splice variants stabilize the PIC and induce ATF4, a sensor of cellular stress, which is co-opted to suppress EIF2alpha phosphorylation, enabling a general increase in protein synthesis. RAS stabilizes c-MYC, an effect augmented by EIF1AX-A113splice. ATF4 and c-MYC induce expression of amino acid transporters and enhance sensitivity of mTOR to amino acid supply. These mutually reinforcing events generate therapeutic vulnerabilities to MEK, BRD4, and mTOR kinase inhibitors. SIGNIFICANCE: Mutations of EIF1AX, a component of the translation PIC, co-occur with RAS in advanced thyroid cancers and promote tumorigenesis. EIF1AX-A113splice drives an ATF4-induced dephosphorylation of EIF2alpha, resulting in increased protein synthesis. ATF4 also cooperates with c-MYC to sensitize mTOR to amino acid supply, thus generating vulnerability to mTOR kinase inhibitors. This article is highlighted in the In This Issue feature, p. 151.",EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC.,10.1158/2159-8290.CD-18-0606,2019 Feb,PMC6373451,Cancer discovery
GSE142895,Robust partitioning of microRNA targets from downstream regulatory changes [RNA-seq],Homo sapiens,24,SRP239336,2020-01-02,"[Overal design]Gene expression profiling of HEK293 cells with and without specific miRNAs by high-throughput sequencing, in duplicate or triplicate, using Illumina NextSeq500.; [Treatment]'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven days.'; [Growth]'Flp-In T-REx 293 (HEK293) cells were cultured in DMEM containing 10% FBS, 1% Pen/Strap and 0.1% Zeocin.'; [Extraction]'Total RNA from HEK293 cells was isolated with Trizol, with an extra chloroform extraction to remove residual phenol and addition of glyco-blue as a carrier to promote RNA precipitation.\nDirectional RNA-seq libraries were prepared from 1000ng total RNA per sample using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs), with initial polyA+ isolation, by the RNA Sequencing Core and the Transcriptional Regulation and Expression Facility at Cornell University.'; [Cell type]'Source: ''cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-1; batch: 1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-122; batch: 1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-133a; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-155; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-302a; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-372; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-373; batch: 2; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142895,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE142nnn/GSE142895/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA598734,32821933," Ravi K Patel,  Jessica D West,  Ya Jiang,  Elizabeth A Fogarty,  Andrew Grimson","The biological impact of microRNAs (miRNAs) is determined by their targets, and robustly identifying direct miRNA targets remains challenging. Existing methods suffer from high false-positive rates and are unable to effectively differentiate direct miRNA targets from downstream regulatory changes. Here, we present an experimental and computational framework to deconvolute post-transcriptional and transcriptional changes using a combination of RNA-seq and PRO-seq. This novel approach allows us to systematically profile the regulatory impact of a miRNA. We refer to this approach as CARP: Combined Analysis of RNA-seq and PRO-seq. We apply CARP to multiple miRNAs and show that it robustly distinguishes direct targets from downstream changes, while greatly reducing false positives. We validate our approach using Argonaute eCLIP-seq and ribosome profiling, demonstrating that CARP defines a comprehensive repertoire of targets. Using this approach, we identify miRNA-specific activity of target sites within the open reading frame. Additionally, we show that CARP facilitates the dissection of complex changes in gene regulatory networks triggered by miRNAs and identification of transcription factors that mediate downstream regulatory changes. Given the robustness of the approach, CARP would be particularly suitable for dissecting miRNA regulatory networks in vivo.",Robust partitioning of microRNA targets from downstream regulatory changes.,10.1093/nar/gkaa687,2020 Sep 25,PMC7515711,Nucleic acids research
GSE119615,Translation of upstream open reading frames in a model of neuronal differentiation,Homo sapiens,10,SRP159962,2018-09-06,"[Overal design]Examination of upstream open reading frame dependent translation regulation across non-differentiated and RA-differentiated SH-SY5Y cells; [Treatment]'SH-SY5Y cells were differentiated for 6 days in 10?M retinoic acid (all-trans, Sigma), with media changed every 24 hours.'; [Growth]'SH-SY5Y cells were grown in DMEM:F12 media (Invitrogen) supplemented with 10% FBS, .01mg mL-1Gentamicin and .25ug mL-1 Amphoreticin B. Cells were plated on 150mm plates that were either coated with .1mg/mL poly-D lysine (Millipore) for differentiation or uncoated. Cells were allowed to propagate to 80% confluency for 1-2 days prior to lysing for ribosome profiling or induction of differentiation.'; [Extraction]'Cells were washed with ice cold PBS with CHX at 100ug mL-1. Plates were immediately flash frozen in liquid nitrogen, moved to dry ice, and lysed (in the presence of CHX) to prevent ribosome loading and runoff. Additional lysates were processed in parallel for poly(A) mRNA purification  and  mRNA-sequencing  library  preparation.  Polysomes  were  isolated  from  the ribosome footprinting lysates on a 1M sucrose cushionwith high speed centrifugation using a 70.1Ti rotor (Beckman) at 55,000 r.p.m. for 4 hrs at 4C. rRNA was eliminated prior to linker ligation using Ribo-Zero Gold rRNA Removal Kit (Illumina).\nRibosome profiling libraries were prepared as in Ingolia et al., 2010 and Ingolia et al., 2012.\nRibosome Profiling libraries were barcoded and multiplexed with2-4 libraries per lane, and sequenced on a HiSeq 2000 (Illumina) using 50 cycles of single end reads. mRNA libraries were multiplexed on a single lane. All sequencing was conducted at the University of Michigan DNA Sequencing Core.'; [Cell type]'Non-differentiated SH-SY5Y cells', 'RA-differentiated SH-SY5Y cells''cell type: Non-differentiated SH-SY5Y cells; days treatment: 0; ', 'cell type: RA-differentiated SH-SY5Y cells; days treatment: 6; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119615,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE119nnn/GSE119615/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA489713,31109297," Caitlin M Rodriguez,  Sang Y Chun,  Ryan E Mills,  Peter K Todd","BACKGROUND: Upstream open reading frames (uORFs) initiate translation within mRNA 5' leaders, and have the potential to alter main coding sequence (CDS) translation on transcripts in which they reside. Ribosome profiling (RP) studies suggest that translating ribosomes are pervasive within 5' leaders across model systems. However, the significance of this observation remains unclear. To explore a role for uORF usage in a model of neuronal differentiation, we performed RP on undifferentiated and differentiated human neuroblastoma cells. RESULTS: Using a spectral coherence algorithm (SPECtre), we identify 4954 consistently translated uORFs across 31% of all neuroblastoma transcripts. These uORFs predominantly utilize non-AUG initiation codons and exhibit translational efficiencies (TE) comparable to annotated coding regions. On a population basis, the global impact of both AUG and non-AUG initiated uORFs on basal CDS translation were small, even when analysis is limited to conserved and consistently translated uORFs. However, uORFs did alter the translation of a subset of genes, including the Diamond-Blackfan Anemia associated ribosomal gene RPS24. With retinoic acid induced differentiation, we observed an overall positive correlation in translational shifts between uORF/CDS pairs. However, CDSs downstream of uORFs show smaller shifts in TE with differentiation relative to CDSs without a predicted uORF, suggesting that uORF translation buffers cell state dependent fluctuations in CDS translation. CONCLUSION: This work provides insights into the dynamic relationships and potential regulatory functions of uORF/CDS pairs in a model of neuronal differentiation.",Translation of upstream open reading frames in a model of neuronal differentiation.,10.1186/s12864-019-5775-1,2019 May 20,PMC6528255,BMC genomics
GSE102315,Nutritional control of protein translation,Homo sapiens,20,SRP114965,2017-08-07,"[Overal design]Cytoplasmic RNA and Cytoplasmic RNA protected by ribosome from RNase I (Ribonuclease I) cleavage, were sequenced. Small RNA libraries were performed according to the protocol using NEB NEXT Small RNA library Prep Set for Illumina (Multiplex Compatible) E7330, and size-selected (120-170 base pairs) before sequencing.; [Treatment]'None'; [Growth]'We compared HeLa cells that were cultured 45 days under serum free (SF) conditions with cells that were first cultured under serum free conditions for 30 days and then received 20 nM queuine for 15 days (SF+qR) to rescue any q-dependent defects . Furthermore, a parallel control culture (45 days) was established using SF conditions supplemented with 20 nM queuine (SF+q). HeLa cells grown in standard medium (S) and in standard medium supplemented with 20 nM queuine were included as additional controls.'; [Extraction]""Ribosome footprint was performed according to (Ingolia et al, 2011). 2x107 HeLa cells from each culture condition were treated with cycloheximide (100 g/ml) for 5 minutes prior to lysis in 800 l of 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 100 g/ml cycloheximide, 1Complete Protease Inhibitors (Roche). 200 l aliquot was used to extract cytoplasmic RNA to perform RNAseq.  200 l aliquot was used to produce ribosome profiling. The left over 400 l aliquot of lysate was treated with 4 U DNase I (ThermoScientific) and 800 U of RNase I (Ambion), for 45 minutes at room temperature with gentle shaking.   800 U of RNasin ribonuclease inhibitor (Promega) was added to quench the reaction.    The  samples were run on a 17.5-50% sucrose gradient to isolate monosome.  Footprint monosome RNA was end using RNA were end-repaired with T4 polynucleotide kinase (TaKaRa), and size selected 28-31 nucleotide on a 15% polyacrylamide TBE-urea gel.\nSmall RNA libraries were performed according to the protocol using NEB NEXT Small RNA library Prep Set for Illumina (Multiplex Compatible) E7330, and size-selected (120-170 base pairs) before sequencing. RNA Sequencing libraries were prepared using the TruSeq RNA Sample Preparation Kit v2 (Illumina) according to the manufacturer's protocol. Briefly, poly(A)+ RNA was purified from 1g of total RNA using oligo(dT) beads, fragmented and converted to cDNA. The double stranded cDNA fragments were then end-repaired, adenylated on the 3' end, adapter ligated and amplified with 12 cycles of PCR. The final libraries were validated using Qubit Fluorometer (Life Technologies-Invitrogen) and Agilent TapeStation 4200 (Agilent Technologies). After sizing analysis, multiplexed sequencing libraries were normalized, pooled and clustered on the cBot (Illumina, Inc.) with a final concentration of 10 pM (spiked with 1% PhiX control v3, Cat No. FC-110-3001) using the TruSeq SR Cluster Kit v3 (Cat no. GD-401-3001). Sequencing on HiSeq 2000 (Illumina) was performed using the 50 cycles TruSeq SBS Kit v3 according to the manufacturer's protocol.""; [Cell type]'Source: ''cell line: cervix adenocarcinoma cell line HeLa; treatment: Serum; ', 'cell line: cervix adenocarcinoma cell line HeLa; treatment: Serum +20nM queuine; ', 'cell line: cervix adenocarcinoma cell line HeLa; treatment: Serum free; ', 'cell line: cervix adenocarcinoma cell line HeLa; treatment: Serum free 30 days+20nm queuine 15 days; ', 'cell line: cervix adenocarcinoma cell line HeLa; treatment: Serum free+20nm queuine 45 days; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102315,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102315/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA397422,30093495," Francesca Tuorto,  Carine Legrand,  Cansu Cirzi,  Giuseppina Federico,  Reinhard Liebers,  Martin Muller,  Ann E Ehrenhofer-Murray,  Gunnar Dittmar,  Hermann-Josef Grone,  Frank Lyko","Global protein translation as well as translation at the codon level can be regulated by tRNA modifications. In eukaryotes, levels of tRNA queuosinylation reflect the bioavailability of the precursor queuine, which is salvaged from the diet and gut microbiota. We show here that nutritionally determined Q-tRNA levels promote Dnmt2-mediated methylation of tRNA Asp and control translational speed of Q-decoded codons as well as at near-cognate codons. Deregulation of translation upon queuine depletion results in unfolded proteins that trigger endoplasmic reticulum stress and activation of the unfolded protein response, both in cultured human cell lines and in germ-free mice fed with a queuosine-deficient diet. Taken together, our findings comprehensively resolve the role of this anticodon tRNA modification in the context of native protein translation and describe a novel mechanism that links nutritionally determined modification levels to effective polypeptide synthesis and cellular homeostasis.",Queuosine-modified tRNAs confer nutritional control of protein translation.,10.15252/embj.201899777,2018 Sep 14,PMC6138434,The EMBO journal
GSE123608,Codon usage optimization in pluripotent embryonic stem cells [tRNA sequencing],Homo sapiens,8,SRP173268,2018-12-11,"[Overal design]tRNA sequencing of self-renewing and differentiating human H9 cells, 4 biological replicates per condition; [Treatment]'Differentiating hESC were cultured in MEF-conditioned KSR media plus 1uM retinoic acid in DMSO, while the control hESC population was maintained in MEF-conditioned KSR media completed with 4 ng/mL FGF2. Self-renewing cells were collected at Day 0, while differentiating cells at day 5 of treatment.'; [Growth]'hESC were maintained in Essential 8 media (Thermo Fisher Scientific) on hESC-Qualified Matrigel (Corning) coated plates at 37C, 5 % CO2. Cultures were dissociated in clumps using 0.5mM EDTA every 4 days and media was renewed daily.'; [Extraction]'Total RNA was extracted using Trizol.\xa0After DNAse treatment and de-aminoacylation, tRNAs were size excised from a TBE-UREA polyacrylamide gel. Fragments ends were repaired used T4 PNK.\xa0\nLibraries from the tRNAs were prepared using the TruSeq Small RNA library preparation Kit from Illumina.'; [Cell type]'human embryonic stem cells''cell type: human embryonic stem cells; cell line: H9; condition: self-renewing; ', 'cell type: human embryonic stem cells; cell line: H9; condition: differentiating; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123608,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123608/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA509375,31174582," Susanne Bornelov,  Tommaso Selmi,  Sophia Flad,  Sabine Dietmann,  Michaela Frye","BACKGROUND: The uneven use of synonymous codons in the transcriptome regulates the efficiency and fidelity of protein translation rates. Yet, the importance of this codon bias in regulating cell state-specific expression programmes is currently debated. Here, we ask whether different codon usage controls gene expression programmes in self-renewing and differentiating embryonic stem cells. RESULTS: Using ribosome and transcriptome profiling, we identify distinct codon signatures during human embryonic stem cell differentiation. We find that cell state-specific codon bias is determined by the guanine-cytosine (GC) content of differentially expressed genes. By measuring the codon frequencies at the ribosome active sites interacting with transfer RNAs (tRNA), we further discover that self-renewing cells optimize translation of codons that depend on the inosine tRNA modification in the anticodon wobble position. Accordingly, inosine levels are highest in human pluripotent embryonic stem cells. This effect is conserved in mice and is independent of the differentiation stimulus. CONCLUSIONS: We show that GC content influences cell state-specific mRNA levels, and we reveal how translational mechanisms based on tRNA modifications change codon usage in embryonic stem cells.",Codon usage optimization in pluripotent embryonic stem cells.,10.1186/s13059-019-1726-z,2019 Jun 7,PMC6555954,Genome biology
GSE77033,nanoCAGE reveals 5 UTR features that define specific modes of translation of functionally related mTOR-sensitive mRNAs,Homo sapiens,1,SRP068675,2016-01-20,"[Overal design]Determination of 5'UTR lengths using nanoCAGE in MCF7 cells; [Treatment]'None'; [Growth]'MCF7 cells (ATCC) were maintained in Dulbecco modified Eagle medium (DMEM; Wisent, St-Bruno, Quebec, Canada), supplemented with 10% fetal bovine serum (Wisent), 1% penicillin/streptomycin (Wisent) and 1% L-Glutamine (Wisent).'; [Extraction]'Total RNA was extracted using Trizol'; [Cell type]'Source: ''cell line: MCF7; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77033,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE77nnn/GSE77033/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA309302,26984228," Valentina Gandin,  Laia Masvidal,  Laura Hulea,  Simon-Pierre Gravel,  Marie Cargnello,  Shannon McLaughlan,  Yutian Cai,  Preetika Balanathan,  Masahiro Morita,  Arjuna Rajakumar,  Luc Furic,  Michael Pollak,  John A Jr Porco,  Julie St-Pierre,  Jerry Pelletier,  Ola Larsson,  Ivan Topisirovic","The diversity of MTOR-regulated mRNA translation remains unresolved. Whereas ribosome-profiling suggested that MTOR almost exclusively stimulates translation of the TOP (terminal oligopyrimidine motif) and TOP-like mRNAs, polysome-profiling indicated that MTOR also modulates translation of mRNAs without the 5' TOP motif (non-TOP mRNAs). We demonstrate that in ribosome-profiling studies, detection of MTOR-dependent changes in non-TOP mRNA translation was obscured by low sensitivity and methodology biases. Transcription start site profiling using nano-cap analysis of gene expression (nanoCAGE) revealed that not only do many MTOR-sensitive mRNAs lack the 5' TOP motif but that 5' UTR features distinguish two functionally and translationally distinct subsets of MTOR-sensitive mRNAs: (1) mRNAs with short 5' UTRs enriched for mitochondrial functions, which require EIF4E but are less EIF4A1-sensitive; and",nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.,10.1101/gr.197566.115,2016 May,PMC4864462,Genome research
GSE143623,Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis [ribo-Seq BRx142],Homo sapiens,4,SRP241899,2020-01-14,"[Overal design]We performed ribosomal profiling in control and RPL15 overexpressing circulating tumor cell-derived cell lines to determine the global ribosome occupancy of mRNA transcripts, identify changes in translational preference, and calculate the translational efficiency for any given transcript (i.e., the ratio of ribosome-bound mRNA to all polyA-mRNA). One control specimen and one RPL15 overexpressing specimen was profiled in each of two batches.; [Treatment]'Control or a CMV promoter-driven, lentiviral encoded vector to ectopically express RPL15. Lentiviral expression constructs for RPL15 (Accession: BC071672) were obtained from the CCSB-Broad Lentiviral Expression Library.'; [Growth]'CTCs were grown in suspension in ultra-low attachment plates (Corning) in tumor sphere media, consisting of RPMI-1640 with GlutaMAX supplemented with EGF (20ng/mL), FGF (20ng/mL), 1X B27, and 1X antibiotic/antimycotic (Life Technologies), in 4% O2, as previously described (PUBMED IDs  27556950 and 25013076). CTC lines were routinely checked for mycoplasma (MycoAlert, Lonza), and were authenticated by RNA-seq and DNA-seq.'; [Extraction]'Ribosome profiling was performed as previously described (PUBMED ID 22836135). Briefly, 10 million RPL15- or control-expressing Brx-142 cells were treated with 0.1 mg/ml cyclohexamide for 1 minute, washed with cold PBS containing cycloheximide and lysed. A range of RNase I (Thermofisher) concentrations was tested, and an optimal concentration was chosen that did not lead to degradation of the ribosome protected fragments. RNase I (Thermofisher) treatment was performed and the monosomes were isolated by gel filtration MicroSpin S-400 HR Columns (GE Healthcare). After RNA extraction using RNA Clean & Concentrator-25 kit (Zymo Research), rRNA was depleted (Ribo-Zero Gold rRNA Removal Kit, Illumina), and ribosome-protected fragments were purified by PAGE. The fragments were end- repaired with PNK (NEB).\nLibraries were prepared using a TruSeq small RNA Library Prep Kit (Illumina) and sequenced on a NextSeq 500 Illumina (76 bp single-end reads).'; [Cell type]'Source: ''tissue: circulating tumor cell - derived cell line; rpl15 overexpressing: control; batch: batch1; molecule subtype: ribosome-bound mRNA; ', 'tissue: circulating tumor cell - derived cell line; rpl15 overexpressing: RPL15 overexpressing; batch: batch1; molecule subtype: ribosome-bound mRNA; ', 'tissue: circulating tumor cell - derived cell line; rpl15 overexpressing: control; batch: batch2; molecule subtype: ribosome-bound mRNA; ', 'tissue: circulating tumor cell - derived cell line; rpl15 overexpressing: RPL15 overexpressing; batch: batch2; molecule subtype: ribosome-bound mRNA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143623,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143623/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA601135,32029688," Richard Y Ebright,  Sooncheol Lee,  Ben S Wittner,  Kira L Niederhoffer,  Benjamin T Nicholson,  Aditya Bardia,  Samuel Truesdell,  Devon F Wiley,  Benjamin Wesley,  Selena Li,  Andy Mai,  Nicola Aceto,  Nicole Vincent-Jordan,  Annamaria Szabolcs,  Brian Chirn,  Johannes Kreuzer,  Valentine Comaills,  Mark Kalinich,  Wilhelm Haas,  David T Ting,  Mehmet Toner,  Shobha Vasudevan,  Daniel A Haber,  Shyamala Maheswaran,  Douglas S Micalizzi","Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors, but only a small subset of these cells generates metastases. We conducted an in vivo genome-wide CRISPR activation screen in CTCs from breast cancer patients to identify genes that promote distant metastasis in mice. Genes coding for ribosomal proteins and regulators of translation were enriched in this screen. Overexpression of RPL15, which encodes a component of the large ribosomal subunit, increased metastatic growth in multiple organs and selectively enhanced translation of other ribosomal proteins and cell cycle regulators. RNA sequencing of freshly isolated CTCs from breast cancer patients revealed a subset with strong ribosome and protein synthesis signatures; these CTCs expressed proliferation and epithelial markers and correlated with poor clinical outcome. Therapies targeting this aggressive subset of CTCs may merit exploration as potential suppressors of metastatic progression.",Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis.,10.1126/science.aay0939,2020 Mar 27,PMC7307008,"Science (New York, N.Y.)"
GSE79539,Finding new proteins encoded by long non-coding RNAs in human cells,Homo sapiens,3,SRP072231,2016-03-23,"[Overal design]HBE, A549 and H1299 cells were cultured in the complete DMEM medium. We detected and analyzed the new proteins with ribosome profiling.; [Treatment]'None'; [Growth]'HBE, A549 and H1299 cells were cultured in the complete DMEM medium. We detected and analyzed the new proteins with ribosome profiling.'; [Extraction]'We performed ribosome profiling. Ribosome footprints was extracted using Trizol method.\nWe used Ribo-Zero Magnetic Kit (Human/Mouse/Rat) to remove the rRNA. We used NEBNext Multiplex Small RNA Library Prep Set for Illumina (1-12) to construct sequencing libraries.'; [Cell type]'Source: ''condition: Grown under normal condition; cell line: HBE; ', 'condition: Grown under normal condition; cell line: A549; ', 'condition: Grown under normal condition; cell line: H1299; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79539,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE79nnn/GSE79539/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA316125,31340039," Shaohua Lu,  Jing Zhang,  Xinlei Lian,  Li Sun,  Kun Meng,  Yang Chen,  Zhenghua Sun,  Xingfeng Yin,  Yaxing Li,  Jing Zhao,  Tong Wang,  Gong Zhang,  Qing-Yu He","It has been a long debate whether the 98% 'non-coding' fraction of human genome can encode functional proteins besides short peptides. With full-length translating mRNA sequencing and ribosome profiling, we found that up to 3330 long non-coding RNAs (lncRNAs) were bound to ribosomes with active translation elongation. With shotgun proteomics, 308 lncRNA-encoded new proteins were detected. A total of 207 unique peptides of these new proteins were verified by multiple reaction monitoring (MRM) and/or parallel reaction monitoring (PRM); and 10 new proteins were verified by immunoblotting. We found that these new proteins deviated from the canonical proteins with various physical and chemical properties, and emerged mostly in primates during evolution. We further deduced the protein functions by the assays of translation efficiency, RNA folding and intracellular localizations. As the new protein UBAP1-AST6 is localized in the nucleoli and is preferentially expressed by lung cancer cell lines, we biologically verified that it has a function associated with cell proliferation. In sum, we experimentally evidenced a hidden human functional proteome encoded by purported lncRNAs, suggesting a resource for annotating new human proteins.",A hidden human proteome encoded by 'non-coding' genes.,10.1093/nar/gkz646,2019 Sep 5,PMC6735797,Nucleic acids research
GSE74365,Ribosomal profiling in Cystic Fibrosis Bronchial Epithelial cells,Homo sapiens,3,SRP065282,2015-10-26,"[Overal design]Ribosome profiling of cells at steady state. 3 biological replicates.; [Treatment]'None'; [Growth]""Cystic Fibrosis Bronchial Epithelial cells were grown at 37C to 80% confluency in Eagle's MEM.""; [Extraction]'Total RNA was extracted using TRIzol reagent (Invitrogen) and the sample was enriched in mRNA using the Ribo-Zero Gold rRNA Removal Kit (Illumina) and spiked with ERCC RNA Spike-In Mix(Thermo Fisher).\nRNA-size selection and generation of the cDNA libraries was performed as described {Ingolia, 2009}'; [Cell type]'CFBE''cell type: CFBE; molecule type: Ribosome protected fragments; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74365,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE74nnn/GSE74365/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA299827,28510592," Sebastian Kirchner,  Zhiwei Cai,  Robert Rauscher,  Nicolai Kastelic,  Melanie Anding,  Andreas Czech,  Bertrand Kleizen,  Lynda S Ostedgaard,  Ineke Braakman,  David N Sheppard,  Zoya Ignatova","Synonymous single nucleotide polymorphisms (sSNPs) are considered neutral for protein function, as by definition they exchange only codons, not amino acids. We identified an sSNP that modifies the local translation speed of the cystic fibrosis transmembrane conductance regulator (CFTR), leading to detrimental changes to protein stability and function. This sSNP introduces a codon pairing to a low-abundance tRNA that is particularly rare in human bronchial epithelia, but not in other human tissues, suggesting tissue-specific effects of this sSNP. Up-regulation of the tRNA cognate to the mutated codon counteracts the effects of the sSNP and rescues protein conformation and function. Our results highlight the wide-ranging impact of sSNPs, which invert the programmed local speed of mRNA translation and provide direct evidence for the central role of cellular tRNA levels in mediating the actions of sSNPs in a tissue-specific manner.",Alteration of protein function by a silent polymorphism linked to tRNA abundance.,10.1371/journal.pbio.2000779,2017 May,PMC5433685,PLoS biology
GSE61073,mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues,Mus musculus; Homo sapiens,95,None,2014-09-03,"[Overal design]Refer to individual Series; [Treatment]'RNA-seq: For most samples, cytoplasmically-enriched RNA was extracted, poly(A)-selected, randomly fragmented by partial alkaline hydrolysis and then size-selected RNA fragments were used for library preparation In the case of B cells total RNA was extracted and then poly(A)-selected. In the case of U2OS cells, three different isolation methods were performed, two of them are the aforementioned isolation methods, the third total RNA was depleted of tRNA and rRNA. Ribosome profiling: In most cases, cell extracts were processed as described in Subtelny et al., 2014 (GSE52809). For U2OS and B cell samples, cell extracts were processed as described in Guo et al., 2010 (GSE22004). SmallRNA-seq: Total RNA was extracted as described in Chiang et al., 2010 (GSE20384)'; [Growth]'Each sample was grown or maintained according to standard protocols', 'Samples were isolated from a mouse and cultured according to standard protocols'; [Extraction]'RNA-seq and RPF libraries were constructed exactly as described in Subtelny et al., 2014 (GSE52809) except for B cell and U2OS samples, which were constructed as described in Guo et al., 2010 (GSE22004). SmallRNA-seq libraries were constructed as described in Chiang et al., 2010 (GSE20384).\nRNA-seq or SmallRNA-seq', 'Tri Reagent (Ambion) followed by RNeasy Plus (Qiagen)'; [Cell type]'primary B cell', 'Source: ', 'primary Macrophage', 'primary Neutrophil', 'primary neutrophil', 'primary b cell', 'primary macrophage''time: 2 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 4 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 8 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 48 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 2h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 4h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 8h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 48h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'cell line: U2OS cell line; treatment: mock transfection; ', 'cell line: U2OS cell line; treatment: miR-1 transfection; ', 'cell line: U2OS cell line; treatment: miR-155 transfection; ', 'cell line: HEK293T cell line; treatment: mock transfection; ', 'cell line: HEK293T cell line; treatment: miR-1 transfection; ', 'tissue: primary liver tissue; strain: C57BL/6; age: 6 weeks; Sex: male; ', 'time: 0 h; cell line: 3T3 cell line; growth condition: contact inhibited; ', 'time: 4 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 8 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 12 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 48 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 6 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 10 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 0 h; cell line: 3T3 cell line; growth condition: actively dividing; ', 'time: 12 h; cell line: 3T3 cell line; growth condition: actively dividing; treatment: doxycycline; ', 'time: 0 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: Torin1; ', 'time: 12 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline, Torin1; ', 'cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary Macrophage; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary Neutrophil; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary neutrophil; genotype/variation: wild type; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary neutrophil; genotype/variation: knock out; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary b cell; genotype/variation: wild type; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary b cell; genotype/variation: knock out; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary macrophage; genotype/variation: wild type; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary macrophage; genotype/variation: knock out; strain: C57BL/6; age: 3 months; Sex: male; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing; Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61073,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE61nnn/GSE61073/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA260185,25263593," Stephen W Eichhorn,  Huili Guo,  Sean E McGeary,  Ricard A Rodriguez-Mias,  Chanseok Shin,  Daehyun Baek,  Shu-Hao Hsu,  Kalpana Ghoshal,  Judit Villen,  David P Bartel","MicroRNAs (miRNAs) regulate target mRNAs through a combination of translational repression and mRNA destabilization, with mRNA destabilization dominating at steady state in the few contexts examined globally. Here, we extend the global steady-state measurements to additional mammalian contexts and find that regardless of the miRNA, cell type, growth condition, or translational state, mRNA destabilization explains most (66%->90%) miRNA-mediated repression. We also determine the relative dynamics of translational repression and mRNA destabilization for endogenous mRNAs as a miRNA is induced. Although translational repression occurs rapidly, its effect is relatively weak, such that by the time consequential repression ensues, the effect of mRNA destabilization dominates. These results imply that consequential miRNA-mediated repression is largely irreversible and provide other insights into the nature of miRNA-mediated regulation. They also simplify future studies, dramatically extending the known contexts and time points for which monitoring mRNA changes captures most of the direct miRNA effects.",mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues.,10.1016/j.molcel.2014.08.028,2014 Oct 2,PMC4292926,Molecular cell
GSE143691,Super-enhancer redistribution as a mechanism of broad gene dysregulation in repeatedly drug-treated cancer cells [dataset 3],Homo sapiens,4,SRP242004,2020-01-15,"[Overal design]All ChIP-Seq, GRO-seq, RNA-seq, and ribosome-profiling experiments were designed to understand the effects of cisplatin on 6 different layers of gene-expression regulation in cancer cells.; [Treatment]'The treatment administrated to A2780cis cells was described in the Sigma-Aldrich website as chronic exposure of the parent A27890 line to increasing concentrations of cisplatin Sigma-Aldrich (#93112517-19). Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.', 'Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.'; [Growth]'Cells  were cultured in RPMI-1640-Glutamax I (#61870-036, Life Technologies) and 10% fetal bovine serum (FBS, #FB-11, Omega Scientific) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.', 'The human lung adenocarcinoma A549 cell line (RRID:CVCL_0023) were cultured in Dulbeccos modified Eagles-Glutamax I medium (DMEM-Glutamax I, Gibco, Cat#10566-016) supplemented with 10% FBS (FBS, Omega Scientific, Cat#FB-11) and antibiotics penicillin and streptomycin (100 ug/mL, Gemini Bio, Cat#400-109) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.'; [Extraction]'Cells were fixed with 1% formaldehyde for 10mins, and followed by glycine for 5 mins. Chromatin DNA was sheared to 200500 bp average in size by sonication and chromatin was immunoprecipitated with antibodies. Protein G magnetic beads  were added and incubated overnight at 4C. After washing and elution, the proteinDNA complex was reverse-crosslinked by heating at 65C, and immunoprecipitated DNA was purified by using QIAquick Spin column.\nChIP-seq libraries were prepared using the KAPA Library Preparation Kit (KK8201)', 'GRO-seq analysis was perfromed as previously reported (PMID: 21572438, Wang et al., 2011).\nRNA quality was calculated on TapeStation (Agilent Technologies). PolyA+ RNA-seq libraries were generated using the Illumina TruSeq Stranded RNA LT kit and following manufacturers detailed instructions.'; [Cell type]'Source: ''cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): Anti-CCTCF antibody Active Motif (Cat#61932; RRID:AB_2614975); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): Anti-CCTCF antibody Active Motif (Cat#61932; RRID:AB_2614975); ', 'cell line: A549; treatment: vehicle; ', 'cell line: A549; treatment: cisplatin; '",Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143691,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143691/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA601312,32320655," Qi Ma,  Feng Yang,  Carlos Mackintosh,  Ranveer Singh Jayani,  Soohwan Oh,  Chunyu Jin,  Sreejith Janardhanan Nair,  Daria Merkurjev,  Wubin Ma,  Stephanie Allen,  Dong Wang,  Angels Almenar-Queralt,  Ivan Garcia-Bassets","Cisplatin is an antineoplastic drug administered at suboptimal and intermittent doses to avoid life-threatening effects. Although this regimen shortly improves symptoms in the short term, it also leads to more malignant disease in the long term. We describe a multilayered analysis ranging from chromatin to translation-integrating chromatin immunoprecipitation sequencing (ChIP-seq), global run-on sequencing (GRO-seq), RNA sequencing (RNA-seq), and ribosome profiling-to understand how cisplatin confers (pre)malignant features by using a well-established ovarian cancer model of cisplatin exposure. This approach allows us to segregate the human transcriptome into gene modules representing distinct regulatory principles and to characterize that the most cisplatin-disrupted modules are associated with underlying events of super-enhancer plasticity. These events arise when cancer cells initiate without ultimately ending the program of drug-stimulated death. Using a PageRank-based algorithm, we predict super-enhancer regulator ISL1 as a driver of this plasticity and validate this prediction by using CRISPR/dCas9-KRAB inhibition (CRISPRi) and CRISPR/dCas9-VP64 activation (CRISPRa) tools. Together, we propose that cisplatin reprograms cancer cells when inducing them to undergo near-to-death experiences.",Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells.,10.1016/j.celrep.2020.107532,2020 Apr 21,,Cell reports
GSE58402,Ribosome Profiling in P. falciparum asexual blood stages,Plasmodium falciparum,10,SRP043116,2014-06-11,"[Overal design]Cultures corresponding to ring, early trophozoite, late trophozoite, schizont stage, merozoite were harvested for both mRNA and polysome isolation using cycloheximide to freeze ribosomes in place.; [Treatment]'Cells were synchronized by two consecutive sorbitol treatments for three generations, for a total of six treatments. Maximum invasion, point at which half of the culture is either rings or schizonts, was defined as hour zero and independent timepoints were harvested 2, 10, 19, 31 and 46 hours later.'; [Growth]'W2 strain cultures were maintained in Hyperflasks (Corning) in 500 ml RPMIc (RPMI 1640 media supplemented with 0.25% Albumax II (GIBCO), 2 g/l sodium bicarbonate, 0.1 mM hypoxanthine, 25 mM HEPES (pH 7.4), and 50 ?g/l gentamycin), at 37C, 5% O2, and 6% CO2, to maximum 10-15% parasitemia at 5% HC and frequent media changes (at least every 6-8 hours).'; [Extraction]'Cultures were incubated for 5 min in 500 ml 37C RPMIc, 100g/ml cycloheximide (Acros Organics) and harvested by centrifugation for 8 min at 3.65 xg at room temperature. An aliquot was removed and flash frozen in lN2 for total total RNA purification and mRNA-Seq library preparation. RBCs were lysed with ice-cold 0.1% saponin in 1X PBS, 100ug/ml cicloheximide. Parasites were resuspended in ice-cold parasite lysis buffer (15 mM KOAc, 15 mM MgOAc, 10 mM Tris HCl pH 7.4, 0.5 mM DTT, 0.5% Triton X-100, 100 ug/ml cyclohexamide) and dripped into a conical tube filled with, and immersed in, lN2. Frozen cells transferred placed in lN2 pre-chilled chambers and pulverized for 3 min at 15 Hz, on a Retsch MM301 mixer mill. Pulverized cells were thawed on ice and cell debris was removed by centrifugation at 4C, 16000 xg for 10 min. The polysome-containing supernatant was treated with 2.88 U/ug Micrococcal nuclease for 30 min at room temperature and immediately loaded onto sucrose gradients. Ribosome footprints were extracted from sucrose gradient monosome peak fractions.\nLibraries were prepared as in Ingolia et al. Science 2009'; [Cell type]'Source: ''Stage: Rings; strain: W2; ', 'Stage: Early Trophozoites; strain: W2; ', 'Stage: Late Trophozoites; strain: W2; ', 'Stage: Schizonts; strain: W2; ', 'Stage: Merozoites; strain: W2; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58402,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE58nnn/GSE58402/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA252511,25493618," Florence Caro,  Vida Ahyong,  Miguel Betegon,  Joseph L DeRisi","The characterization of the transcriptome and proteome of Plasmodium falciparum has been a tremendous resource for the understanding of the molecular physiology of this parasite. However, the translational dynamics that link steady-state mRNA with protein levels are not well understood. In this study, we bridge this disconnect by measuring genome-wide translation using ribosome profiling, through five stages of the P. falciparum blood phase developmental cycle. Our findings show that transcription and translation are tightly coupled, with overt translational control occurring for less than 10% of the transcriptome. Translationally regulated genes are predominantly associated with merozoite egress functions. We systematically define mRNA 5' leader sequences, and 3' UTRs, as well as antisense transcripts, along with ribosome occupancy for each, and establish that accumulation of ribosomes on 5' leaders is a common transcript feature. This work represents the highest resolution and broadest portrait of gene expression and translation to date for this medically important parasite.",Genome-wide regulatory dynamics of translation in the Plasmodium falciparum asexual blood stages.,10.7554/eLife.04106,2014 Dec 10,PMC4371882,eLife
GSE156749,Upregulation of 5-terminal oligopyrimidine mRNA translation upon loss of the tumor suppressor ARF,Mus musculus,12,SRP278615,2020-08-24,"[Overal design]RNAseq and Ribosome profiling for three conditions with two replicates for each.; [Treatment]'Transduced with lentiviral shRNA (shARF or shSCR)'; [Growth]'MEFs were cultured in Dulbeccos modified Eagles medium (DMEM) (Hyclone) with 10% fetal bovine serum (Invitrogen), 2 mM glutamine (Hyclone), 0.1 mM nonessential amino acids (Hyclone), 1 mM sodium pyruvate (Hyclone), and 2 ?g/ml gentamicin (Invitrogen)'; [Extraction]'RNA was extracted by Trizol and purified using the Zymo Research Direct-Zol RNA Cleanup kit. Ribosome profiling samples were processed as described in https://doi.org/10.1016/j.ymeth.2017.05.028.\nFor RNAseq, total RNA was fragmented by partial alkaline hydrolysis. Fragments between 17 and 34 nt were purified by PAGE. Library construction was performed as described in https://doi.org/10.1016/j.ymeth.2017.05.028.'; [Cell type]'embryonic fibroblast''mouse strain: C57BL/6J; passage: 4; cell type: embryonic fibroblast; genotype: WT; transduction: shSCR; ', 'mouse strain: C57BL/6J; passage: 4; cell type: embryonic fibroblast; genotype: WT; transduction: shARF; ', 'mouse strain: B6.129X1-Cdkn2atm1Cjs/KaiJ; passage: 4; cell type: embryonic fibroblast; genotype: ArfKO; transduction: shSCR; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156749,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE156nnn/GSE156749/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA658965,33335292," Kyle A Cottrell,  Ryan C Chiou,  Jason D Weber","Tumor cells require nominal increases in protein synthesis in order to maintain high proliferation rates. As such, tumor cells must acquire enhanced ribosome production. How the numerous mutations in tumor cells ultimately achieve this aberrant production is largely unknown. The gene encoding ARF is the most commonly deleted gene in human cancer. ARF plays a significant role in regulating ribosomal RNA synthesis and processing, ribosome export into the cytoplasm, and global protein synthesis. Utilizing ribosome profiling, we show that ARF is a major suppressor of 5'-terminal oligopyrimidine mRNA translation. Genes with increased translational efficiency following loss of ARF include many ribosomal proteins and translation factors. Knockout of p53 largely phenocopies ARF loss, with increased protein synthesis and expression of 5'-TOP encoded proteins. The",Upregulation of 5'-terminal oligopyrimidine mRNA translation upon loss of the ARF tumor suppressor.,10.1038/s41598-020-79379-8,2020 Dec 17,PMC7747592,Scientific reports
GSE57336,Stage-specific regulation of translation revealed by ribosome profiling of Trypanosoma brucei,Trypanosoma brucei,22,SRP041705,2014-05-06,"[Overal design]Ribosome profiling and mRNA libraries were constructed in triplicate from in vitro PCF and in vivo BF lifestages of theT. brucei Treu927 and in vitro T. brucei Lister427, to evaluate role of translational gene regulation; [Treatment]'Cells were treated with 100 g/ml cycloheximide for 2 min at either room temperature (procylic cells) or 37 (bloodform cells) to arrest elongating ribosomes.'; [Growth]'In vivo T brucei TREU927 were grown in irradiated Wistar rats infected with 107-108 parasites.  The parasites were harvested on day 3 at a parasitemia of 4107-1.2108 cells/ml.  In vitro procyclic TREU927 cell were grown in SDM-79 to a cell density of 5106-1.2107 cells/ml.  In vitro bloodform Lister427 was grown in HMI-9 to a density of 8105 to 1.5106 cells/ml.'; [Extraction]'For in vivo blood form parasites, the blood from 2-3 infects rats was pooled and centrifuged and the buffy coat extracted and placed into 20 ml HMI-9 without serum pre-warmed to 37C.  To arrest translation, cycloheximide was added to 100 ?g/ml and incubated for 2 minutes at 37.  To rapidly chill the cells, 300 ml of ice-cold phosphate buffered saline with glucose (PSG) was added and the cells were pelleted at 4.  Only parasite populations with greater than 99% slender cells were used.  In vitro grown parasites were pelleted at 5000g and resuspended in 50 mls of media lacking serum.  Cycloheximide was added to 100 mg/ml at the cell incubated for 2min at room temperature (procyclic cells) or 37 (bloodform cells). Following cycloheximide treatment the cells were rapidly chilled with PSG and pelleted at 5000g.  Lysates from both type of parasite pellets were then prepared as following. Cell pellets were resuspended in Buffer A (10 mM Tris pH 7.4, 300 mM KCl, 10 mM MgCl2 plus protease inhibitors to approximately 1.3x109/ml.  Approximately one-third of the sample was placed into TRIzol (Life Technologies) for RNA extraction following manufacturers suggested protocol.  To the remainder, one-sixth volume of buffer A containing 0.2M sucrose and 1.2% Triton N-101 was added and the samples were dounced (30 strokes in a chilled homogenizer). After transfer to a prechilled microfuge tube, the samples were clarified by centrifugation in a microfuge at 15000 rpm for one minute.  The supernatant was withdrawn, pooled if needed, and then aliquots flash frozen in liquid nitrogen for storage at -70C.\nAfter thawing on ice, RNase I (Ambion) was added at 30 units/OD260 of lysate.  Samples were then incubated for 1 hour at room temperature.  RNase digestion was stopped by adding 400 units RNasin (Promega).  Samples were them layered over a 1 ml 1M sucrose cushion prepared in buffer A and ribosomes were pelleted by centrifuging for 4 hours at 70,000g in an SW55 rotor.  After removing the supernatant, the ribosomal pellet was resuspended in 500 ?l buffer A with the MgCl2 replaced with 10 mM EDTA to dissociate the ribosomes and deplete larger rRNA fragments.  The protected fragments were then separated from contaminating ribosomal RNA by passage through an Amicon Ultra-4 or YM-100 column with 100,000 MW cutoff. After more than 400 ?l had flowed through the membrane the RNA in the flow-through was extracted with phenol:CHCl3:iAA and the RNA precipitated.  Poly(A)+ RNA was isolated using Dynabeads mRNA Direct (Life Technologies).  RNA was fragmented as described Ingolia et all 2011.  Ribosomal protected fragments between 28 and 31 nucleotides and fragmented Poly(A)+ RNA between 30 and 70 nucleotides was isolated from 15% accrylimide gels and libraries prepared for sequencing.  For detailed protocol on generating sequencing libraries for both the ribosome protected and fragmented mRNA library see Ingolia et a 2011.  Briefly, following dephosphorylation the adapter Linker-1 (IDT) was ligated to the 3 end of the fragment and the ligated product gel purified.  The adapter was used for priming reverse.  Following gel purification the cDNA was circularized with Circ Ligase (Epicenter Biotechnologies).  Circles containing ribosomal RNA were subtracted using biotinylated primers .  The final library was generated by PCR..To map the 5 end of the transcripts, libraries enriched for the 5 ends of mRNAs were constructed from three biological samples of strain 927 (2 PCF and 1 slBF selected from the biological samples above).  SL libraries were constructed as described Mittra B et al 2013.  In brief, RNA was prepared and cDNA synthesized using primer ending in a random 6 bases.  Second strand synthesis was primed using a primer that matches the T. brucei SL sequence.  The sequencing library was generated by PCR. Duplexed libraries were sequenced using Illumina GA II machines at the High Throughput Genomics Unit at the University of Washington to generate ~36 nt reads.'; [Cell type]'Source: ''strain: 927; developmental stage: Procyclic Form; ', 'strain: 927; developmental stage: Slender bloodstream Form; ', 'strain: 427; developmental stage: cultrured bloodstream Form; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57336,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE57nnn/GSE57336/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA246300,25331479," Bryan C Jensen,  Gowthaman Ramasamy,  Elton J R Vasconcelos,  Nicholas T Ingolia,  Peter J Myler,  Marilyn Parsons","BACKGROUND: Trypanosoma brucei subspecies infect humans and animals in sub-Saharan Africa. This early diverging eukaryote shows many novel features in basic biological processes, including the use of polycistronic transcription to generate all protein-coding mRNAs. Therefore we hypothesized that translational control provides a means to tune gene expression during parasite development in mammalian and fly hosts. RESULTS: We used ribosome profiling to examine genome-wide protein synthesis in animal-derived slender bloodstream forms and cultured procyclic (insect midgut) forms. About one-third of all CDSs showed statistically significant regulation of protein production between the two stages. Of these, more than two-thirds showed a change in translation efficiency, but few appeared to be controlled by this alone. Ribosomal proteins were translated poorly, especially in animal-derived parasites. A disproportionate number of metabolic enzymes were up-regulated at the mRNA level in procyclic forms, as were variant surface glycoproteins in bloodstream forms. Comparison with cultured bloodstream forms from another strain revealed stage-specific changes in gene expression that transcend strain and growth conditions. Genes with upstream ORFs had lower mean translation efficiency, but no evidence was found for involvement of uORFs in stage-regulation. CONCLUSIONS: Ribosome profiling revealed that differences in the production of specific proteins in T. brucei bloodstream and procyclic forms are more extensive than predicted by analysis of mRNA abundance. While in vivo and in vitro derived bloodstream forms from different strains are more similar to one another than to procyclic forms, they showed many differences at both the mRNA and protein production level.",Extensive stage-regulation of translation revealed by ribosome profiling of Trypanosoma brucei.,10.1186/1471-2164-15-911,2014 Oct 20,PMC4210626,BMC genomics
GSE157608,Cytoplasmic mRNA and Heavy polysome-associated mRNAs from U251 Cells treated with Control or eIF3e siRNAs,Homo sapiens,14,None,2020-09-08,"[Overal design]Four-condition experiment, cytoplasmic mRNA and polysome associated-mRNA in U251 cells siScr VS sieIF3e . Biological replicates: 4 replicates; [Treatment]""Human U251  glioblastoma cells were transfected with 20 nmol/L of siScramble (siScr, Qiagen, Venlo, Limburg, The Netherlands) or 20 nmol/L of siRNA against human INT6/eIF3e (si3e: SI02662499, FlexiTube EIF3E siRNA, 20 nmol, 5'-CCCAAAGGUCGCGAUAAUAUU-3', Qiagen; or si3e#2: Dharmacon ON-TARGET plus SMART pool EIF3E siRNA 3646, 10 nmol) for 72h""; [Growth]'Human glioblastoma cell lines  U251 (obtained from C. Simons laboratory, UPENN, Philadelphia, PA, USA) were used and routinely maintained in Dulbeccos Modified Eagle Medium (Lonza, Portsmouth, NH, USA) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 ?g/ml streptomycin at 37C in 5% CO2-humidified incubators as previously described.'; [Extraction]""Total RNA extracted using Trizol following manufacturer's instructions""; [Cell type]'Source: ''cell line: U251; tissue/cell type: Human glioblastoma cell line; genotype/variation: siRNA\xa0Scramble/control\xa0(siSCR); molecule subtype: Cytoplasmic RNA; ', 'cell line: U251; tissue/cell type: Human glioblastoma cell line; genotype/variation: siRNA Scramble/control\xa0(siSCR); molecule subtype: heavy\xa0polysome-associated RNA; ', 'cell line: U251; tissue/cell type: Human glioblastoma cell line; genotype/variation: siRNA\xa0eif3e\xa0(siEIF3E); molecule subtype: Cytoplasmic RNA; ', 'cell line: U251; tissue/cell type: Human glioblastoma cell line; genotype/variation: siRNA eif3e\xa0(siEIF3E); molecule subtype: heavy\xa0polysome-associated RNA; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157608,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE157nnn/GSE157608/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA662223,,,,,,,,
GSE35106,Polysome-bound mRNA during oocyte maturation,Mus musculus,9,None,2012-01-13,"[Overal design]Forty-eight hours (h) after PMSG injection, mice were stimulated with hCG for 0, 4, or 14 h, and GV-, MI- and MII-stage oocytes were collected. Polysome-bound mRNAs were purified, reverse-transcribed and linearly amplified with the WT-Ovation FFPE RNA Amplification System V2 (NuGEN). 5g cDNA were fragmented and hybridized with Affymetrix Mouse Genome 430.2 array chips. Experiments were done using 3 independent sample sets.; [Treatment]""Forty-eight hours (h) after pregnant mare's serum gonadotropin (PMSG) injection, mice were stimulated with human chorionic gonadotrophin (hCG) for 0, 4, or 14 h, and GV-, MI- and MII-stage oocytes were collected.""; [Growth]'None'; [Extraction]'Polysome-bound mRNAs were purified using the RNeasy Plus Micro kit (Qiagen), and then reverse-transcribed and linearly amplified with the WT-Ovation FFPE RNA Amplification System V2 (NuGEN).'; [Cell type]'Source: ''tissue: oocyte; oocyte stage: germinal vesicle (GV); ', 'tissue: oocyte; oocyte stage: metaphase I (MI); ', 'tissue: oocyte; oocyte stage: metaphase II (MII); '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35106,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE35nnn/GSE35106/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA150899,21460039," Jing Chen,  Collin Melton,  Nayoung Suh,  Jeong Su Oh,  Kathleen Horner,  Fang Xie,  Claudio Sette,  Robert Blelloch,  Marco Conti","Oocyte maturation, fertilization, and early embryonic development occur in the absence of gene transcription. Therefore, it is critical to understand at a global level the post-transcriptional events that are driving these transitions. Here we used a systems approach by combining polysome mRNA profiling and bioinformatics to identify RNA-binding motifs in mRNAs that either enter or exit the polysome pool during mouse oocyte maturation. Association of mRNA with the polysomes correlates with active translation. Using this strategy, we identified highly specific patterns of mRNA recruitment to the polysomes that are synchronized with the cell cycle. A large number of the mRNAs recovered with translating ribosomes contain motifs for the RNA-binding proteins DAZL (deleted in azoospermia-like) and CPEB (cytoplasmic polyadenylation element-binding protein). Although a Dazl role in early germ cell development is well established, no function has been described during oocyte-to-embryo transition. We demonstrate that CPEB1 regulates Dazl post-transcriptionally, and that DAZL is essential for meiotic maturation and embryonic cleavage. In the absence of DAZL synthesis, the meiotic spindle fails to form due to disorganization of meiotic microtubules. Therefore, Cpeb1 and Dazl function in a progressive, self-reinforcing pathway to promote oocyte maturation and early embryonic development.",Genome-wide analysis of translation reveals a critical role for deleted in azoospermia-like (Dazl) at the oocyte-to-zygote transition.,10.1101/gad.2028911,2011 Apr 1,PMC3070937,Genes & development
GSE77180,Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism,Homo sapiens,8,None,2016-01-25,"[Overal design]8 total samples were analyzed. We generated the following pairwise comparisons: -5FU polysome vs -5FU non-polysome +5FU polysome vs +5FU non-polysome +5FU polysome vs -5FU polysome. Genes and exons with an fold change >= 1.5 and a p-value <= 0.05 were selected.; [Treatment]'HCT116 cells were treated or not by 10M 5-FU for 24h'; [Growth]'HCT116 cells were cultured in DMEM medium with 10 % SVF and 1% antibiotict'; [Extraction]""Total RNA was isolated using Trizol LS total RNA isolation reagent (Invitrogen) according to the manufacturer's protocol.""; [Cell type]'Source: ''treatment: 5FU; fraction: non-polysome; ', 'treatment: 5FU; fraction: polysome; ', 'treatment: No treatment; fraction: non-polysome; ', 'treatment: No treatment; fraction: polysome; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77180,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE77nnn/GSE77180/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA309671,28515355," Zeina Bash-Imam,  Gabriel Therizols,  Anne Vincent,  Florian Laforets,  Micaela Polay Espinoza,  Nathalie Pion,  Francoise Macari,  Julie Pannequin,  Alexandre David,  Jean-Christophe Saurin,  Hichem C Mertani,  Julien Textoris,  Didier Auboeuf,  Frederic Catez,  Nicole Dalla Venezia,  Martin Dutertre,  Virginie Marcel,  Jean-Jacques Diaz","5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer. Previous studies showed that 5-FU modulates RNA metabolism and mRNA expression. In addition, it has been reported that 5-FU incorporates into the RNAs constituting the translational machinery and that 5-FU affects the amount of some mRNAs associated with ribosomes. However, the impact of 5-FU on translational regulation remains unclear. Using translatome profiling, we report that a clinically relevant dose of 5-FU induces a translational reprogramming in colorectal cancer cell lines. Comparison of mRNA distribution between polysomal and non-polysomal fractions in response to 5-FU treatment using microarray quantification identified 313 genes whose translation was selectively regulated. These regulations were mostly stimulatory (91%). Among these genes, we showed that 5-FU increases the mRNA translation of HIVEP2, which encodes a transcription factor whose translation in normal condition is known to be inhibited by mir-155. In response to 5-FU, the expression of mir-155 decreases thus stimulating the translation of HIVEP2 mRNA. Interestingly, the 5-FU-induced increase in specific mRNA translation was associated with reduction of global protein synthesis. Altogether, these findings indicate that 5-FU promotes a translational reprogramming leading to the increased translation of a subset of mRNAs that involves at least for some of them, miRNA-dependent mechanisms. This study supports a still poorly evaluated role of translational control in drug response.",Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism.,10.18632/oncotarget.17597,2017 Jul 11,PMC5542262,Oncotarget
GSE69922,Ribosome profiling of MCF10A cells treated with TGFb and esterified leucine,Homo sapiens,3,SRP059547,2015-06-16,"[Overal design]1 replicate per condition; [Treatment]'Cells were treated with TGF-beta (10ng/ml) for 48 hrs. For rescue experiments, cells were treated with esterified Leucine (2.5 mM) for 18 hrs'; [Growth]'MCF10A-inducible RASV12 cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: ''cell line: MCF10A; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69922,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69922/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA287138,28274951," Fabricio Loayza-Puch,  Koos Rooijers,  Jelle Zijlstra,  Behzad Moumbeini,  Esther A Zaal,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro P Ugalde,  Celia R Berkers,  Reuven Agami","Cancer cells modulate their metabolic networks to support cell proliferation and a higher demand of building blocks. These changes may restrict the availability of certain amino acids for protein synthesis, which can be utilized for cancer therapy. However, little is known about the amino acid demand changes occurring during aggressive and invasive stages of cancer. Recently, we developed diricore, an approach based on ribosome profiling that can uncover amino acid limitations. Here, we applied diricore to a cellular model in which epithelial breast cells respond rapidly to TGFbeta1, a cytokine essential for cancer progression and metastasis, and uncovered shortage of leucine. Further analyses indicated that TGFbeta1 treatment of human breast epithelial cells reduces the expression of SLC3A2, a subunit of the leucine transporter, which diminishes leucine uptake and inhibits cell proliferation. Thus, we identified a specific amino acid limitation associated with the TGFbeta1 response, a vulnerability that might be associated with aggressiveness in cancer.",TGFbeta1-induced leucine limitation uncovered by differential ribosome codon reading.,10.15252/embr.201744000,2017 Apr,PMC5376977,EMBO reports
GSE132007,Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection (Ribosome profiling),Homo sapiens,6,SRP199985,2019-05-31,"[Overal design]Ribosome profiling (and complementary RNA-sequencing) was performed in HCT116 cells that received, via lentivirus, Cas9 and sgRNAs targeting either EIF5A, DOHH or non-targeting control sgRNAs. Two sgRNAs were used for each condition, and thus 6 biological samples were used for these experiments.; [Treatment]'N/A.'; [Growth]'HCT116 cells were infected with lentivirus to deliver Cas9 and sgRNAs targeting either EIF5A or DOHH, or non-target sgRNAs. Successfully transduced cells were selected in puromycin for 6 days, before harvesting for both ribosome profiling and RNA-sequencing as described in McGlincy and Ingolia, Methods, 2017.'; [Extraction]'Ribosome protected fragments were isolated as described in McGlincy and Ingolia, Methods, 2017.\nRibosome profiling libraries were prepared as described in Ingolia et al., Nature Protocols, 2012, and McGlincy and Ingolia, Methods, 2017, and sequenced on a NextSeq500 platform.'; [Cell type]'Source: ''genotype: EIF5A-/-; sgrna received: EIF5A sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: EIF5A-/-; sgrna received: EIF5A sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'genotype: DOHH-/-; sgrna received: DOHH sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: DOHH-/-; sgrna received: DOHH sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'genotype: +/+; sgrna received: NT sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: +/+; sgrna received: NT sgRNA #2; tissue: HCT116 colon cancer cell line; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132007,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132007/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA545625,31801078," Hema Manjunath,  He Zhang,  Frederick Rehfeld,  Jaeil Han,  Tsung-Cheng Chang,  Joshua T Mendell","Sequences within 5' UTRs dictate the site and efficiency of translation initiation. In this study, an unbiased screen designed to interrogate the 5' UTR-mediated regulation of the growth-promoting gene MYC unexpectedly revealed the ribosomal pause relief factor eIF5A as a regulator of translation initiation codon selection. Depletion of eIF5A enhances upstream translation within 5' UTRs across yeast and human transcriptomes, including on the MYC transcript, where this results in increased production of an N-terminally extended protein. Furthermore, ribosome profiling experiments established that the function of eIF5A as a suppressor of ribosomal pausing at sites of suboptimal peptide bond formation is conserved in human cells. We present evidence that proximal ribosomal pausing on a transcript triggers enhanced use of upstream suboptimal or non-canonical initiation codons. Thus, we propose that eIF5A functions not only to maintain efficient translation elongation in eukaryotic cells but also to maintain the fidelity of translation initiation.",Suppression of Ribosomal Pausing by eIF5A Is Necessary to Maintain the Fidelity of Start Codon Selection.,10.1016/j.celrep.2019.10.129,2019 Dec 3,PMC6917043,Cell reports
GSE166874,Ribosome profiling reveals sequence-independent post-initiation pausing as a signature of translation,Homo sapiens,4,SRP306724,2021-02-16,"[Overal design]We performed Ribo-seq in wildtype HEK293 cells and the cells expressed with mutated RPL4.; [Treatment]'HEK293 stable cell lines expressing GFP control, L4 wild type, or ?loop mutant were infected with lentiviruses encoding shRNA targeting RPL4 or scramble control.'; [Growth]""HEK293 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS).""; [Extraction]""Sucrose solutions were prepared in polysome gradient buffer (10 mM Hepes, pH 7.4, 100 mM KCl, 5 mM MgCl2, 100 ?g/ml CHX, 5 mM DTT, and 20 U/ml SUPERase_In (Ambion)). Sucrose density gradients (15% - 45% (wt/vol)) were freshly made in SW41 ultracentrifuge tubes (Fisher) using a BioComp Gradient Master (BioComp) according to the manufacturer's instructions. Cells were plated to four 10-cm dishes before ribosome profiling. HEK293 cells were first treated with CHX (100 ?M) or LTM (50 ?M) for 30 min at 37 C to freeze the translating ribosomes or initiating ribosomes, respectively. After ice-cold PBS solution wash, cells were then harvested by ice-cold polysome lysis buffer (10 mM Hepes, pH 7.4, 100 mM KCl, 5 mM MgCl2, 100 ?g/ml CHX, 5 mM DTT, 20 U/ml SUPERase_In, and 2% (vol/vol) Triton X-100). After centrifugation at 4 C and 10 000 g for 10 min, approximately 650 ?l supernatant was loaded onto sucrose gradients, followed by centrifugation for 100 min at 38 000 rpm, 4 C, in an SW41 rotor. Separated samples were fractionated at 0.375 ml/min by using a fractionation system (Isco) that continually monitored OD254 values. Fractions were collected into tubes at 1-min intervals. To convert the polysome into monosome, E. coli RNase I (Ambion) was added into the pooled polysome samples (750 U per 100 A260 units) and incubated at 4 C for 1 h. SUPERase_In (50 U per 100 U RNase I) was then added to stop digestion. Total RNA extraction was performed using TRIzol reagent.\nPurified RNA samples were dephosphorylated in a 15 ?l reaction containing 1 T4 polynucleotide kinase buffer, 10 U SUPERase_In, and 20 U T4 polynucleotide kinase (NEB). Dephosphorylation was carried out for 1 h at 37 C, and the enzyme was then heat inactivated for 20 min at 65 C. Dephosphorylated samples were then mixed with 2 Novex TBE-Urea sample buffer (Invitrogen) and loaded on a Novex denaturing 15% polyacrylamide TBE-urea gel (Invitrogen). The gel was stained with SYBR Gold (Invitrogen) to visualize the RNA fragments. Gel bands containing RNA species corresponding to 28 nt were excised and physically disrupted by centrifugation through the holes of the tube. RNA fragments were dissolved by soaking overnight in gel elution buffer (300 mM NaOAc, pH 5.5, 1 mM EDTA, 0.1 U/ml SUPERase_In). The gel debris was removed using a Spin-X column (Corning) and RNA was purified by using ethanol precipitation. Purified RNA fragments were resuspended in 10 mM Tris (pH 8) and denatured briefly at 65 C for 30 s. Poly-(A) tailing reaction was performed in a 8 ?l buffer with 1 poly-(A) polymerase, 1 mM ATP, 0.75 U/?l SUPERase_In, and 3 U E. coli poly-(A) polymerase (NEB). Tailing was carried out for 45 min at 37 C. For reverse transcription, the following oligos containing barcodes were synthesized:    MCA02, 5'-pCAGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3'; LGT03, 5'-pGTGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3'; YAG04, 5'-pTCGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3'; HTC05, 5'-pAGGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3'.    In brief, the tailed RNA product was mixed with 0.5 mM dNTP and 2.5 mM synthesized primer and incubated at 65 C for 5 min, followed by incubation on ice for 5 min. The reaction mix was then added with 20 mM Tris (pH 8.4), 50 mM KCl, 5 mM MgCl2, 10 mM DTT, 40 U RNaseOUT, and 200 U SuperScript III (Invitrogen). Reverse transcription reaction was performed according to the manufacturer's instructions. RNA was eliminated from cDNA by adding 1.8 ?l of 1 M NaOH and incubating at 98 C for 20 min. The reaction was then neutralized with 1.8 ?l of 1 M HCl. Reverse transcription products were separated on a 10% polyacrylamide TBE-urea gel as described earlier. The extended first-strand product band was expected to be approximately 100 nt, and the corresponding region was excised. The cDNA was recovered by using DNA gel elution buffer (300 mM NaCl, 1 mM EDTA). First-strand cDNA was circularized in 20 ?l of reaction containing 1 CircLigase buffer, 2.5 mM MnCl2, 1M Betaine, and 100 U CircLigase II (Epicentre). Circularization was performed at 60 C for 1 h, and the reaction was heat inactivated at 80 C for 10 min. Circular single-strand DNA was relinearized with 20 mM Tris-acetate, 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM DTT, and 7.5 U APE 1 (NEB). The reaction was carried out at 37 C for 1 h. The linearized single-strand DNA was separated on a Novex 10% polyacrylamide TBE-urea gel (Invitrogen) as described earlier. The expected 100-nt product bands were excised and recovered as described earlier.""; [Cell type]'Source: ''cell line: HEK293; genotype: Wild type; treatment: no erythromycin; ', 'cell line: HEK293; genotype: Wild type; treatment: erythromycin; ', 'cell line: HEK293; genotype: RPL4 mutant; treatment: no erythromycin; ', 'cell line: HEK293; genotype: RPL4 mutant; treatment: erythromycin; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE166874,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE166nnn/GSE166874/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA702160,24903108," Yan Han,  Xiangwei Gao,  Botao Liu,  Ji Wan,  Xingqian Zhang,  Shu-Bing Qian","The journey of a newly synthesized polypeptide starts in the peptidyltransferase center of the ribosome, from where it traverses the exit tunnel. The interior of the ribosome exit tunnel is neither straight nor smooth. How the ribosome dynamics in vivo is influenced by the exit tunnel is poorly understood. Genome-wide ribosome profiling in mammalian cells reveals elevated ribosome density at the start codon and surprisingly the downstream 5th codon position as well. We found that the highly focused ribosomal pausing shortly after initiation is attributed to the geometry of the exit tunnel, as deletion of the loop region from ribosome protein L4 diminishes translational pausing at the 5th codon position. Unexpectedly, the ribosome variant undergoes translational abandonment shortly after initiation, suggesting that there exists an obligatory step between initiation and elongation commitment. We propose that the post-initiation pausing of ribosomes represents an inherent signature of the translation machinery to ensure productive translation.",Ribosome profiling reveals sequence-independent post-initiation pausing as a signature of translation.,10.1038/cr.2014.74,2014 Jul,PMC4085768,Cell research
GSE108820,mRNA length and 3UTR structure govern the translation selectivity in RPS14-haploinsufficient erythroblasts [transcriptome],Homo sapiens,9,None,2018-01-05,"[Overal design]The purpose of the dataset is to profile analyze the effect of silencing RPS14; [Treatment]'A scramble (SCR) control shRNA and RPS14 shRNA (640 and 641) were cloned in pLKO.1 Tet-On vector. Cells were selected with puromycine (1 mg/mL). shRNA expression was induced by doxycycline (0.2 ?g/mL) for 3 days'; [Growth]'The UT-7/EPO erythro-megakaryocytic cell line was cultured in ?Minimum Essential Medium (?MEM) containing 10% fetal calf serum (FCS), 1mM glutamine, 100UI/mL penicillin-streptomycin and 1 UI/mL EPO'; [Extraction]'RNA was extracted using the Kit QIAamp RNA Blood MiniKit. RNA from ribosomal fractions was purified using Trizol (Invitrogen).'; [Cell type]'Source: ''cell line: UT7/EPO cells; shRNA: lentivirus expressing SCR shRNA; time post induction: 72h; ', 'cell line: UT7/EPO cells; shRNA: lentivirus expressing shRPS14 640; time post induction: 72h; ', 'cell line: UT7/EPO cells; shRNA: lentivirus expressing shRPS14 641; time post induction: 72h; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108820,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE108nnn/GSE108820/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA428741,32327500," Ismael Boussaid,  Salome Le Goff,  Celia Floquet,  Emilie-Fleur Gautier,  Anna Raimbault,  Pierre-Julien Viailly,  Dina Al Dulaimi,  Barbara Burroni,  Isabelle Dusanter-Fourt,  Isabelle Hatin,  Patrick Mayeux,  Bertrand Cosson,  Michaela Fontenay",,Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells.,10.3324/haematol.2019.239970,2021 Mar 1,PMC7927886,Haematologica
GSE114002,Human 5' UTR design and variant effect prediction from a massively parallel translation assay,Homo sapiens,10,SRP144485,2018-05-03,"[Overal design]Polysom profiling and sequencing was performed using a library of 300,000 randomized 5' UTR 50-mers with eGFP used as the CDS. Three RNA chemistries were tested: unmodified, pseudouridine, and 1-methylpseudouridine. These were performed in duplicate (6 samples total). A designed library that includes human 5' UTRs, SNVs, and sequences engineered with a genetic algorithm was used with the eGFP CDS (no duplicate). A second randomized library used mCherry as the CDS, also performed in duplicate.; [Treatment]'HEK293T cells were plated on 10cm cell culture dishes 24 hours before transfection (1 - 2 million per plate). At 60% to 80% confluency, cells were transfected with 14.5 g of library mRNA using Lipofectamine MessengerMAX (Thermo Fisher Scientific) following the manufacturers protocol. Washed plates with 10 ml 1x DBPS and 10 ml media (DMEM with 10% FBS and 1% Penicillin-Streptomycin) after one hour of incubation. Cells were lysed 12 hours after transfection.'; [Growth]""HEK293T cells were cultured on ECM-coated plates in Dubelco's DMEM media supplemented with FBS (5%), penicillin (.05%), and streptomycin (.05%)""; [Extraction]""Salt solution (10x): 100 mM NaCl, 100 mM MgCl2,100 mM Tris-HCl pH 7.5, and RNase-free water (Zuccotti P, Modelska A 2016). Wash buffer: 100 g/ml cycloheximide in RNase-free DPBS (10 ml per plate). Lysis buffer: 1x salt solution, 1% of 20% Triton X-100, 1 mM DTT, 0.2 U/l SUPERase-In (Thermo Fisher Scientific), 100 g/ml cycloheximide. Wash buffer and lysis buffer were chilled throughout the protocol. After 12 hours of growth at 37 C, cells were placed on ice and media was aspirated. Translating ribosomes were halted by adding 5 ml of wash buffer and were then placed at 37 C for 5 minutes followed by aspiration on ice. Washed by adding 5 ml wash buffer and aspirating thoroughly. Added 300 l of ice-cold lysis buffer, scraped cells, broke up cell clumps by pipetting ~5 times, and then placed suspended cells into a pre-chilled microcentrifuge tube. Let sit for 10 minutes on ice and then triturated by passing through a 25-G needle 10 times [1]. Spun at 16,000 x g for 5 minutes to pellet cell debris and nuclei. Saved supernatant and added 1.5 l of 1 U/l DNase I (final concentration of 0.005 U/l) and placed on ice for 30 minutes. Either stored at -80 C or proceeded directly to polysome profiling.\nFor both the eGFP and mCherry library, randomized 50-mer oligos were Gibson assembled to serve as 5' UTRs for each CDS. To create the designed library, oligos were made via oligo synthesis array (CustomArray Inc.) and cloned into the eGFP vector.For all libraries, 25 nucleotides of defined sequence preceed the inserted 5' UTRs.""; [Cell type]'HEK293T''cell type: HEK293T; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114002,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE114nnn/GSE114002/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA454863,31267113," Paul J Sample,  Ban Wang,  David W Reid,  Vlad Presnyak,  Iain J McFadyen,  David R Morris,  Georg Seelig","The ability to predict the impact of cis-regulatory sequences on gene expression would facilitate discovery in fundamental and applied biology. Here we combine polysome profiling of a library of 280,000 randomized 5' untranslated regions (UTRs) with deep learning to build a predictive model that relates human 5' UTR sequence to translation. Together with a genetic algorithm, we use the model to engineer new 5' UTRs that accurately direct specified levels of ribosome loading, providing the ability to tune sequences for optimal protein expression. We show that the same approach can be extended to chemically modified RNA, an important feature for applications in mRNA therapeutics and synthetic biology. We test 35,212 truncated human 5' UTRs and 3,577 naturally occurring variants and show that the model predicts ribosome loading of these sequences. Finally, we provide evidence of 45 single-nucleotide variants (SNVs) associated with human diseases that substantially change ribosome loading and thus may represent a molecular basis for disease.",Human 5' UTR design and variant effect prediction from a massively parallel translation assay.,10.1038/s41587-019-0164-5,2019 Jul,PMC7100133,Nature biotechnology
GSE134517,A global overview of translation efficiency and ribosome occupancy at nucleotide resolution in HEK293 cells,Homo sapiens,6,SRP216422,2019-07-19,"[Overal design]Ribosome Profiling conducted in HEK293 cells treated with control siRNA. Ribo-zero treated total RNA for the same samples is also included.; [Treatment]'None'; [Growth]'HEK293 cells grown in DMEM with 10% FBS and 2mM L-glutamine'; [Extraction]'Cells were lysed with 400ul lysis buffer (20mM Tris-Cl pH 7.4, 150mM NaCl, 5mM MgCl2, 1mM DTT and 100ug/ml CHX, 25U/ml Turbo DNase, 1% Triton X100), 50ul lysate taken for total RNA and the rest digested with RNase I and ran on a sucrose cushion to produce the RPF sample\nAll samples were rRNA depleted using Illumina RiboZero Gold; libraries for Ribo-Seq were prepared with Nextflex small RNA-seq; libraries for RNA-Seq were prepared with Nextflex rapid directional qRNA-seq'; [Cell type]'Source: ''sirna treatment: Control siRNA; cell line: HEK293; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134517,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE134nnn/GSE134517/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA556704,31791371," Ania Wilczynska,  Sarah L Gillen,  Tobias Schmidt,  Hedda A Meijer,  Rebekah Jukes-Jones,  Claudia Langlais,  Kari Kopra,  Wei-Ting Lu,  Jack D Godfrey,  Benjamin R Hawley,  Kelly Hodge,  Sara Zanivan,  Kelvin Cain,  John Le Quesne,  Martin Bushell","BACKGROUND: Regulation of the mRNA life cycle is central to gene expression control and determination of cell fate. miRNAs represent a critical mRNA regulatory mechanism, but despite decades of research, their mode of action is still not fully understood. RESULTS: Here, we show that eIF4A2 is a major effector of the repressive miRNA pathway functioning via the Ccr4-Not complex. We demonstrate that while DDX6 interacts with Ccr4-Not, its effects in the mechanism are not as pronounced. Through its interaction with the Ccr4-Not complex, eIF4A2 represses mRNAs at translation initiation. We show evidence that native eIF4A2 has similar RNA selectivity to chemically inhibited eIF4A1. eIF4A2 exerts its repressive effect by binding purine-rich motifs which are enriched in the 5'UTR of target mRNAs directly upstream of the AUG start codon. CONCLUSIONS: Our data support a model whereby purine motifs towards the 3' end of the 5'UTR are associated with increased ribosome occupancy and possible uORF activation upon eIF4A2 binding.",eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5'UTR.,10.1186/s13059-019-1857-2,2019 Dec 2,PMC6886185,Genome biology
GSE51584,Expanded identification and characterization of mammalian circular RNAs,Homo sapiens,9,SRP031849,2013-10-23,"[Overal design]Examination of 9 samples in 1 cell type Note: The ENCODE data we used are under GEO SuperSeries GSE26284 (all samples labeled ""_cell_total""). But they were not used in the processing of the U2OS data.; [Treatment]'All samples were treated with cycloheximide (100ug/mL) for 8 minutes immediately prior to harvesting.'; [Growth]'None'; [Extraction]'mRNA-seq: Total mRNA was either depleted of tRNAs/rRNAs or used for poly(A)-selection. In both cases, the RNA was randomly fragmented by partial alkaline hydrolysis and then size-selected RNA fragments (25-45 nt) were used for library preparation. Ribosome profiling: Cell extracts were processed exactly as described in Guo et al., 2010 (GSE22004)\nLibraries were constructed exactly as described in Guo et al., 2010 (GSE22004)'; [Cell type]'Source: ''transfection: miR-1 duplex; time: 32 hours; ', 'transfection: miR-155 duplex; time: 32 hours; ', 'transfection: mock; time: 32 hours; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51584,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE51nnn/GSE51584/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA223608,25070500," Junjie U Guo,  Vikram Agarwal,  Huili Guo,  David P Bartel","BACKGROUND: The recent reports of two circular RNAs (circRNAs) with strong potential to act as microRNA (miRNA) sponges suggest that circRNAs might play important roles in regulating gene expression. However, the global properties of circRNAs are not well understood. RESULTS: We developed a computational pipeline to identify circRNAs and quantify their relative abundance from RNA-seq data. Applying this pipeline to a large set of non-poly(A)-selected RNA-seq data from the ENCODE project, we annotated 7,112 human circRNAs that were estimated to comprise at least 10% of the transcripts accumulating from their loci. Most circRNAs are expressed in only a few cell types and at low abundance, but they are no more cell-type-specific than are mRNAs with similar overall expression levels. Although most circRNAs overlap protein-coding sequences, ribosome profiling provides no evidence for their translation. We also annotated 635 mouse circRNAs, and although 20% of them are orthologous to human circRNAs, the sequence conservation of these circRNA orthologs is no higher than that of their neighboring linear exons. The previously proposed miR-7 sponge, CDR1as, is one of only two circRNAs with more miRNA sites than expected by chance, with the next best miRNA-sponge candidate deriving from a gene encoding a primate-specific zinc-finger protein, ZNF91. CONCLUSIONS: Our results provide a new framework for future investigation of this intriguing topological isoform while raising doubts regarding a biological function of most circRNAs.",Expanded identification and characterization of mammalian circular RNAs.,10.1186/s13059-014-0409-z,2014 Jul 29,PMC4165365,Genome biology
GSE144165,Ribosome recycling by ABCE1 links lysosomal function and iron homeostasis to 3? UTR- directed regulation and nonsense-mediated decay,Homo sapiens,16,None,2020-01-23,"[Overal design]Refer to individual Series; [Treatment]'N/A.'; [Growth]'Fluorescent-reporter coupled CRISPR/Cas9-mediated loss of function screening was carried out as described in Golden et al., Nature, 2017, except for the Brunello library (Addgene #73179) but not the GeCKO V2 libarary was used, in both NMD EGFP reporter and control EGFP reporter cell lines. Reporter cell line generation and more information about the screen are described in the manuscript.', 'HCT116 cells were infected with lentivirus to deliver Cas9 and sgRNAs targeting ABCE1, or non-target sgRNAs. Successfully transduced cells were selected in puromycin for 4 days, before harvesting for ribosome profiling as described in the manuscript.', 'HCT116 cells were infected with lentivirus to deliver Cas9 and sgRNAs targeting ABCE1, or non-target sgRNAs. Successfully transduced cells were selected in puromycin for 4 days, before harvesting for RNA-sequencing.'; [Extraction]'Genomic DNA was extracted from cell pellets using either a gDNA isolation method that has been previously described Golden et al., Nature, 2017 for the sorted cells or the MasterPureTM Complete DNA Purification Kit (Lucigen) for the unsorted cells.\nPCR amplicon libraries were generated as described in the manuscript.\nCRISPR/Cas9-mediated loss of function screening.', 'Ribosome protected fragments were isolated as described in McGlincy and Ingolia, Methods, 2017.\nRibosome profiling libraries were prepared as described in Ingolia et al., Nature Protocols, 2012, and McGlincy and Ingolia, Methods, 2017, and sequenced on a NextSeq500 platform.', 'RNA was isolated using the RNeasy Mini kit (Qiagen) and gDNA contamination was removed using the TURBO DNA-Free kit (ThermoFisher Scientific)\nRNA-seq libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina) and sequenced using the 75 bp single-read protocol on a NextSeq 500 platform (Illumina).'; [Cell type]'Source: ''experiment: NMD screen; lentiviral library received: Brunello library; reporter cell line: NMD reporter; ', 'experiment: NMD screen; lentiviral library received: Brunello library; reporter cell line: Control reporter; ', 'genotype: ABCE1-/-; sgrna received: sgABCE1-1; cell line: NMD reporter; ', 'genotype: ABCE1-/-; sgrna received: sgABCE1-2; cell line: NMD reporter; ', 'genotype: +/+; sgrna received: sgNT1; cell line: NMD reporter; ', 'genotype: +/+; sgrna received: sgNT2; cell line: NMD reporter; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144165,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE144nnn/GSE144165/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA602913,32668236," Xiaoqiang Zhu,  He Zhang,  Joshua T Mendell","Nonsense-mediated decay (NMD) is a pathway that degrades mRNAs containing premature termination codons. Here we describe a genome-wide screen for NMD factors that uncovers an unexpected mechanism that broadly governs 3' untranslated region (UTR)-directed regulation. The screen reveals that NMD requires lysosomal acidification, which allows transferrin-mediated iron uptake, which, in turn, is necessary for iron-sulfur (Fe-S) cluster biogenesis. This pathway maintains the activity of the Fe-S cluster-containing ribosome recycling factor ABCE1, whose impaired function results in movement of ribosomes into 3' UTRs, where they displace exon junction complexes, abrogating NMD. Importantly, these effects extend beyond NMD substrates, with ABCE1 activity required to maintain the accessibility of 3' UTRs to diverse regulators, including microRNAs and RNA binding proteins. Because of the sensitivity of the Fe-S cluster of ABCE1 to iron availability and reactive oxygen species, these findings reveal an unanticipated vulnerability of 3' UTR-directed regulation to lysosomal dysfunction, iron deficiency, and oxidative stress.",Ribosome Recycling by ABCE1 Links Lysosomal Function and Iron Homeostasis to 3' UTR-Directed Regulation and Nonsense-Mediated Decay.,10.1016/j.celrep.2020.107895,2020 Jul 14,PMC7433747,Cell reports
GSE62247,Cell fate determination by ubiquitin-dependent regulation of translation,Homo sapiens,46,SRP048825,2014-10-10,"[Overal design]Ribosome profiling and mRNA-Seq; [Treatment]'None'; [Growth]'feeder-free in mTESR1', 'neural conversion with NIM for 1d', 'neural conversion with NIM for 3d', 'neural conversion with NIM for 6d'; [Extraction]'RNA extraction, preadenylated linker ligation, reverse transcription, cDNA circularization, PCR amplification'; [Cell type]'Source: ''treatment: lentiviral infection with sh control; cell line: H1; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; ', 'treatment: lentiviral infection with sh KBTBD8; cell line: H1; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; ', 'treatment: lentiviral infection with sh control; cell line: H1; extract_protocol: Standard mRNA-seq; ', 'treatment: lentiviral infection with sh KBTBD8; cell line: H1; extract_protocol: Standard mRNA-seq; ', 'treatment: lentiviral infection with sh TCOF1; cell line: H1; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; ', 'treatment: lentiviral infection with sh TCOF1; cell line: H1; extract_protocol: Standard mRNA-seq; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62247,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE62nnn/GSE62247/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA263582,26399832," Achim Werner,  Shintaro Iwasaki,  Colleen A McGourty,  Sofia Medina-Ruiz,  Nia Teerikorpi,  Indro Fedrigo,  Nicholas T Ingolia,  Michael Rape","Metazoan development depends on the accurate execution of differentiation programs that allow pluripotent stem cells to adopt specific fates. Differentiation requires changes to chromatin architecture and transcriptional networks, yet whether other regulatory events support cell-fate determination is less well understood. Here we identify the ubiquitin ligase CUL3 in complex with its vertebrate-specific substrate adaptor KBTBD8 (CUL3(KBTBD8)) as an essential regulator of human and Xenopus tropicalis neural crest specification. CUL3(KBTBD8) monoubiquitylates NOLC1 and its paralogue TCOF1, the mutation of which underlies the neurocristopathy Treacher Collins syndrome. Ubiquitylation drives formation of a TCOF1-NOLC1 platform that connects RNA polymerase I with ribosome modification enzymes and remodels the translational program of differentiating cells in favour of neural crest specification. We conclude that ubiquitin-dependent regulation of translation is an important feature of cell-fate determination.",Cell-fate determination by ubiquitin-dependent regulation of translation.,10.1038/nature14978,2015 Sep 24,PMC4602398,Nature
GSE140366,Robust partitioning of microRNA targets from downstream regulatory changes [Ribo-seq],Homo sapiens,12,SRP229759,2019-11-13,"[Overal design]Ribosome profiling of HEK293 cells with and without specific miRNAs by high-throughput sequencing, in duplicate, using Illumina NextSeq500; [Treatment]'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven days. To stall ribosomes, cells were treated with 100 ug/ml cycloheximide for two minutes at 37C.'; [Growth]'Flp-In T-REx 293 (HEK293) cells were cultured in DMEM containing 10% FBS, 1% Pen/Strap and 0.1% Zeocin.'; [Extraction]'Cycloheximide-treated cells were lysed and digested with nuclease to generate ribosome footprints (RBFs). Ribosomes and ribosome footprints were isolated by size exclusion with a MicroSpin S-400 column. The cycloheximide-treated cells from the same pool were also used to extract total RNA for RNA-seq libraries.\nRibosome profiling libraries and RNA-seq libraries (used for normalizing ribosome footprint (RBF) data) were generated using the TruSeq Ribo Profile (Mammalian) Kit (illumina). The rRNA was depleted from the ribosome footprints and the total RNA using Ribo-Zero rRNA Removal Kit (illumina). The ribosome footprints were size selected using Urea-PAGE before library preparation. The total RNA was fragmented with heat. The size selected RBFs and fragmented total RNA were ligated to a 3' adaptor, and reverse transcribed. cDNA was purified by Urea-PAGE and circularized. The cDNA library was amplified and barcoded with Illumina-compatible primers.'; [Cell type]'Source: ''cell line: Flp-In T-REx 293 Cell; induced mirna: None; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-122; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140366,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140366/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA589466,32821933," Ravi K Patel,  Jessica D West,  Ya Jiang,  Elizabeth A Fogarty,  Andrew Grimson","The biological impact of microRNAs (miRNAs) is determined by their targets, and robustly identifying direct miRNA targets remains challenging. Existing methods suffer from high false-positive rates and are unable to effectively differentiate direct miRNA targets from downstream regulatory changes. Here, we present an experimental and computational framework to deconvolute post-transcriptional and transcriptional changes using a combination of RNA-seq and PRO-seq. This novel approach allows us to systematically profile the regulatory impact of a miRNA. We refer to this approach as CARP: Combined Analysis of RNA-seq and PRO-seq. We apply CARP to multiple miRNAs and show that it robustly distinguishes direct targets from downstream changes, while greatly reducing false positives. We validate our approach using Argonaute eCLIP-seq and ribosome profiling, demonstrating that CARP defines a comprehensive repertoire of targets. Using this approach, we identify miRNA-specific activity of target sites within the open reading frame. Additionally, we show that CARP facilitates the dissection of complex changes in gene regulatory networks triggered by miRNAs and identification of transcription factors that mediate downstream regulatory changes. Given the robustness of the approach, CARP would be particularly suitable for dissecting miRNA regulatory networks in vivo.",Robust partitioning of microRNA targets from downstream regulatory changes.,10.1093/nar/gkaa687,2020 Sep 25,PMC7515711,Nucleic acids research
GSE143301,Ribosome profiling under ABCE1 depletion to study aberrant translation termination,Homo sapiens,21,SRP240357,2020-01-08,"[Overal design]Control and ABCE1 KD conditions, three replicates for condition. totalRNA samples in parallel for input control.; [Treatment]'siRNA transfection with Lullaby (Ozscience) for 72 hours, two siRNA transfections (20 nM)'; [Growth]'None'; [Extraction]'ribosome-protected fragments were isolated after snap-freezing of HeLa cells and Rnase I digestion using gel filtration columns. Gel purified fragments between 26 nt and 34 nt were isolated, rRNAs were removed using the RiboZero kit (Illumina). RNA-seq libraries were prepared from cells lysed similar as the ribosome profiling samples. totalRNAs was isolated from cleared lysates by addition of TriReagent as for the ribosome-protected fragments.\nSequencing libraries from ribosome footprints were generated as previously described (Aeschimann et al., 2015).  Total RNA was used for library generation with the TruSeq Stranded mRNA Library Prep Kit (Illumina).\nLibraries were sequenced on an Illumina HiSeq2500 generating 100 nt single-end reads.'; [Cell type]'Source: ''cell line: HeLa cells; genotype: control; strategy: Ribo-Seq; ', 'cell line: HeLa cells; genotype: siRNA-mediated ABCE1 KD; strategy: Ribo-Seq; ', 'cell line: HeLa cells; genotype: control; strategy: RNA-Seq; ', 'cell line: HeLa cells; genotype: siRNA-mediated ABCE1 KD; strategy: RNA-Seq; ', 'cell line: HeLa cells; sirna: UPF1 knockdowns; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143301,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143301/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA599943,32807779," Evangelos D Karousis,  Lukas-Adrian Gurzeler,  Giuditta Annibaldis,  Rene Dreos,  Oliver Muhlemann","Nonsense-mediated mRNA decay (NMD) is a translation-dependent RNA degradation pathway that is important for the elimination of faulty, and the regulation of normal, mRNAs. The molecular details of the early steps in NMD are not fully understood but previous work suggests that NMD activation occurs as a consequence of ribosome stalling at the termination codon (TC). To test this hypothesis, we established an in vitro translation-coupled toeprinting assay based on lysates from human cells that allows monitoring of ribosome occupancy at the TC of reporter mRNAs. In contrast to the prevailing NMD model, our in vitro system reveals similar ribosomal occupancy at the stop codons of NMD-sensitive and NMD-insensitive reporter mRNAs. Moreover, ribosome profiling reveals a similar density of ribosomes at the TC of endogenous NMD-sensitive and NMD-insensitive mRNAs in vivo. Together, these data show that NMD activation is not accompanied by stable stalling of ribosomes at TCs.",Human NMD ensues independently of stable ribosome stalling.,10.1038/s41467-020-17974-z,2020 Aug 17,PMC7431590,Nature communications
GSE59818,Knockdown and overexpression of SLC3A2 in MCF10A cells,Homo sapiens,12,SRP044935,2014-07-28,"[Overal design]1 biological replicate of each condition.; [Treatment]""MCF10A cells were transfected using Dharmafect I reagent (Dharmacon) following the manufacturer's instructions. For TGF?1 treatment, MCF10a cells were treated with human recombinant TGF?1 (10ng/ml) for 48 hours (R&D Systems)."", 'SLC3A2 expression vector were kindly provided by Roy Zent. Stable expression clones were selected with blasticidin. For TGF?1 treatment, MCF10a cells were treated with human recombinant TGF?1 (10ng/ml) for 48 hours (R&D Systems).'; [Growth]'MCF10A cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', ""RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nPoly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the manufacturer's instructions.""; [Cell type]'Source: ''cell line: MCF10A; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59818,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59818/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256318,28274951," Fabricio Loayza-Puch,  Koos Rooijers,  Jelle Zijlstra,  Behzad Moumbeini,  Esther A Zaal,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro P Ugalde,  Celia R Berkers,  Reuven Agami","Cancer cells modulate their metabolic networks to support cell proliferation and a higher demand of building blocks. These changes may restrict the availability of certain amino acids for protein synthesis, which can be utilized for cancer therapy. However, little is known about the amino acid demand changes occurring during aggressive and invasive stages of cancer. Recently, we developed diricore, an approach based on ribosome profiling that can uncover amino acid limitations. Here, we applied diricore to a cellular model in which epithelial breast cells respond rapidly to TGFbeta1, a cytokine essential for cancer progression and metastasis, and uncovered shortage of leucine. Further analyses indicated that TGFbeta1 treatment of human breast epithelial cells reduces the expression of SLC3A2, a subunit of the leucine transporter, which diminishes leucine uptake and inhibits cell proliferation. Thus, we identified a specific amino acid limitation associated with the TGFbeta1 response, a vulnerability that might be associated with aggressiveness in cancer.",TGFbeta1-induced leucine limitation uncovered by differential ribosome codon reading.,10.15252/embr.201744000,2017 Apr,PMC5376977,EMBO reports
GSE34740,K562 polyA RNA-Seq,Homo sapiens,9,SRP010061,2011-12-27,"[Overal design]K562 polyA+ RNA (Batch 1) and total RNA (batch 2) was purchased from Ambion. We used oligo (dT)-selected polyA+ RNA to construct libraries for RNA-Seq.We then profiled the transcriptome of polyadenylated mRNA-Seq using Illumina sequencing platforms. We then used the sequenced reads to reconstruct the transcriptome using the Cufflinks de-novo assembler (Trapnell et al. Nat.Bio.Tech. 2010). Recent computational and ribosome profiling analyses suggest that many short open reading frames (sORFs) in eukaryotic genomes are translated. However, evidence that these sORFs produce stable polypeptides is lacking. Here we develop a strategy to discover and validate novel sORF-encoded polypeptides (SEPs) in human cells. In total, we detect 117 SEPs, 114 of which are novel, varying in length from 15 to 149 amino acids. Of these, 10 SEPs (0.5%) are derived from long intergenic non-coding RNAs (lincRNAs). We also observe the presence of polycistronic genes and the widespread use of non-AUG start codons, which is a phenomenon historically thought to be rare in the mammalian genome. Quantitative measurements reveal that SEPs can be found at concentrations between ~10-2000 copies per cell, which is within the range of typical cellular proteins. We confirm the translation of a number of these SEPs through heterologous expression of their encoding cDNAs. We also discover that several SEPs possess properties characteristic of functional proteins. These results demonstrate that human sORFs produce numerous stable polypeptides, revealing that the human proteome is larger and more diverse than previously appreciated.; [Treatment]'None'; [Growth]'None'; [Extraction]'Standard Illumina cDNA library preparation as per Levin et al. (2010) Nature Methods , v. 7, pp.709-715\nRNA purchased from Ambion/ABI', 'Illumina TruSeq RNA sample prep kit used with these changes:  SuperScript III instead of SuperScript II & optimization of PCR cycle number\nRNA purchased from Ambion/ABI'; [Cell type]'immortalised chronic myelogenous leukemia (CML)''cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 std gel sized; average insert size: 336; std. dev. insert size: 223.877392; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 10000ng; average insert size: 229; std. dev. insert size: 172.945267; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 3000ng; average insert size: 239; std. dev. insert size: 185.42764; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 1000ng; average insert size: 229; std. dev. insert size: 173.245305; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 500ng; average insert size: 268; std. dev. insert size: 227.16942; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 250ng; average insert size: 249; std. dev. insert size: 203.395985; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 100ng; average insert size: 237; std. dev. insert size: 179.351572; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 50ng; average insert size: 230; std. dev. insert size: 170.945188; ', 'cell type: immortalised chronic myelogenous leukemia (CML); cell line: K562; sample type: K-562 truseq 30ng; average insert size: 235; std. dev. insert size: 173.524507; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34740,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE34nnn/GSE34740/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA150405,23160002," Sarah A Slavoff,  Andrew J Mitchell,  Adam G Schwaid,  Moran N Cabili,  Jiao Ma,  Joshua Z Levin,  Amir D Karger,  Bogdan A Budnik,  John L Rinn,  Alan Saghatelian","The complete extent to which the human genome is translated into polypeptides is of fundamental importance. We report a peptidomic strategy to detect short open reading frame (sORF)-encoded polypeptides (SEPs) in human cells. We identify 90 SEPs, 86 of which are previously uncharacterized, which is the largest number of human SEPs ever reported. SEP abundances range from 10-1,000 molecules per cell, identical to abundances of known proteins. SEPs arise from sORFs in noncoding RNAs as well as multicistronic mRNAs, and many SEPs initiate with non-AUG start codons, indicating that noncanonical translation may be more widespread in mammals than previously thought. In addition, coding sORFs are present in a small fraction (8 out of 1,866) of long intergenic noncoding RNAs. Together, these results provide strong evidence that the human proteome is more complex than previously appreciated.",Peptidomic discovery of short open reading frame-encoded peptides in human cells.,10.1038/nchembio.1120,2013 Jan,PMC3625679,Nature chemical biology
GSE158669,BCDIN3D RNA methyltransferase stimulates Aldolase C expression and glycolysis through let-7 microRNA in breast cancer cells,Homo sapiens,24,SRP285644,2020-09-28,"[Overal design]We performed combined RNA-Seq, miRNA-seq, and ribosome profiling in shBCDIN3D MDA-MB-231 breast cancer cells; [Treatment]'No treatment - collected 48h after seeding at 10^5 cells/mL', '24h with 10nM Rapamycin - collected 48h after seeding at 10^5 cells/mL'; [Growth]'DMEM+10%FBS+PSQ+1g/mL puromycin'; [Extraction]'As in Ingolia at al, 2012\nAs in Ingolia at al, 2012', 'Norgen RNA/protein purification kit\nTruSeq Stranded Total RNA', 'Norgen RNA/protein purification kit followed by gel extraction of small RNAs < 35 nt\nAs in Ingolia at al, 2012'; [Cell type]'Source: ''cell line: MDA-MB-231; shRNA status: shNC; molecule type: ribosome-protected RNA; ', 'cell line: MDA-MB-231; shRNA status: shBCDIN3D; molecule type: ribosome-protected RNA; ', 'cell line: MDA-MB-231; shRNA status: shNC; molecule type: total RNA; ', 'cell line: MDA-MB-231; shRNA status: shBCDIN3D; molecule type: total RNA; ', 'cell line: MDA-MB-231; shRNA status: shNC; molecule type: Gel-fractionated small RNA; ', 'cell line: MDA-MB-231; shRNA status: shBCDIN3D; molecule type: Gel-fractionated small RNA; '",Expression profiling by high throughput sequencing; Other; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158669,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE158nnn/GSE158669/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA666167,33664453," Calder W Reinsborough,  Helene Ipas,  Nathan S Abell,  Ellen B Gouws,  J Paige Williams,  Marvin Mercado,  Carla Van Den Berg,  Blerta Xhemalce","Type II diabetes (T2D) and specific cancers share many risk factors, however, the molecular mechanisms underlying these connections are often not well-understood. BCDIN3D is an RNA modifying enzyme that methylates specific precursor microRNAs and tRNA(His). In addition to breast cancer, BCDIN3D may also be linked to metabolism, as its gene locus is associated with obesity and T2D. In order to uncover metabolic pathways regulated by BCDIN3D in cancer, we performed an unbiased analysis of the metabolome, transcriptome, and proteome of breast cancer cells depleted for BCDIN3D. Intersection of these analyses showed that BCDIN3D-depleted cells have increased levels of Fructose 1,6 Bisphosphate (F1,6-BP), the last six-carbon glycolytic intermediate accompanied by reduced glycolytic capacity. We further show that elevated F1,6-BP is due to downregulation of Aldolase C (ALDOC), an enzyme that cleaves F1,6-BP mainly in the brain, but whose high expression/amplification is associated with poor prognosis in breast cancer. BCDIN3D regulates ALDOC through a non-canonical mechanism involving the crucial let-7 microRNA family and its target site on the 3'UTR of ALDOC. Overall, our results reveal an important connection between BCDIN3D, let-7 and glycolysis that may be relevant to breast cancer, obesity, and T2D.",BCDIN3D RNA methyltransferase stimulates Aldolase C expression and glycolysis through let-7 microRNA in breast cancer cells.,10.1038/s41388-021-01702-y,2021 Apr,PMC8026734,Oncogene
GSE113171,Mapping multi-layered regulation in response to environmental stress,Homo sapiens,72,SRP140470,2018-04-16,"[Overal design]Hela cells were subjected to ER stress or oxidative stress. Transcript, ribosome footprint and protein occupency profiles were generated for different time points (0, 1 , 4 , and 8 hours) by deep sequencing, in triplicate, using Illumina Illumina HiSeq 2500.; [Treatment]'At ~60% confluency, we treated the cells with 60 ?M H2O2or 0.5 ?g/ml tunicamycin \xa0to induce oxidative and ER stress, respectively. We treated samples 8, 4, 1, and 0 hours prior to collection and therefore collected all samples at the same time with similar confluency. For protein occupancy profiling, we added 200 ?M of 4-thiouridine (4-SU) at ten hours before the treatment to incorporate photoreactive ribonucleoside analog required for protein occupancy profiling. For ribosome footprinting, we added 0.1 mg/ml cycloheximide for 5 min at 37? before the harvesting the cells.'; [Growth]'All samples for the total RNA, ribosome footprinting and protein occupancy / footprint profiling were derived from cells grown in parallel. We grew Hela cells under standard conditions, i.e  in DMEM (Sigma) with 10% fetal bovine serum (Atlanta biologicals) and 1X penicillin streptomycin solution (Corning cellgro) at 37? and 5% CO2.'; [Extraction]'For RNA seq and ribosome foot print experiment, confluent plates of HeLa cells were first aspirated of their growth media and washed with fresh media supplemented with 0.1 mg/ml cycloheximide. The media was then removed and the cells were washed with 10 ml chilled PBS containing 0.1 mg/ml cycloheximide. Following removal of the PBS, 800 ul of Lysis Buffer was added and the cells were extensively scraped off plate and transferred to a pre-chilled eppendorf tube, recovering ~1 ml of lysate per sample. To insure complete lysis, we passed the lysate through a 25 gauge needle and further incubated on ice for ~10 min. The lysate was then clarified by centrifugation for 10 min at 20,000, 4C and ?1 ml supernatant was recovered. For each treatment (tunicamycin and hydrogen peroxide), we aliquoted 100 ul of the cell lysate for total RNA extraction and 200ul for ribosome footprinting. For protein foot print, we scraped crosslinked cells off the plates with a rubber policeman, collected by centrifugation, washed with ice-cold PBS . We resuspended cell pellets in lysis/binding buffer (100 mM Tris-HCl pH 7.5 at 25 C, 500 mM LiCl, 10 mM EDTA pH 8.0 at 25 C, 1% LiDS, 5 mM DTT, Complete Mini EDTA-free protease inhibitor (Roche)), incubated them at room temperature for 15 minutes for lysis and passed cells through a 21 gauge needle 10 times for shearing of genomic DNA. Lysates were processed to recover RNA-protein complex as described previously (Munschauer, 2015).\nRNA libraries for RNA seq, Ribosome foot print and protein foot print were prepared according to the TruSeq Ribo Profile (Mammalian) kit protocol.'; [Cell type]'Source: ''treatment: No Tunicamycin(Tm); cell line: HeLa; ', 'treatment: Tunicamycin(Tm) 1Hr; cell line: HeLa; ', 'treatment: Tunicamycin(Tm) 4Hr; cell line: HeLa; ', 'treatment: Tunicamycin(Tm) 8Hr; cell line: HeLa; ', 'treatment: No Hydrogen peroxide; cell line: HeLa; ', 'treatment: Hydrogen peroxide 1Hr; cell line: HeLa; ', 'treatment: Hydrogen peroxide 4Hr; cell line: HeLa; ', 'treatment: Hydrogen peroxide 8Hr; cell line: HeLa; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113171,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE113nnn/GSE113171/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA450369,30272558," Justin Rendleman,  Zhe Cheng,  Shuvadeep Maity,  Nicolai Kastelic,  Mathias Munschauer,  Kristina Allgoewer,  Guoshou Teo,  Yun Bin Matteo Zhang,  Amy Lei,  Brian Parker,  Markus Landthaler,  Lindsay Freeberg,  Scott Kuersten,  Hyungwon Choi,  Christine Vogel","Maintaining a healthy proteome involves all layers of gene expression regulation. By quantifying temporal changes of the transcriptome, translatome, proteome, and RNA-protein interactome in cervical cancer cells, we systematically characterize the molecular landscape in response to proteostatic challenges. We identify shared and specific responses to misfolded proteins and to oxidative stress, two conditions that are tightly linked. We reveal new aspects of the unfolded protein response, including many genes that escape global translation shutdown. A subset of these genes supports rerouting of energy production in the mitochondria. We also find that many genes change at multiple levels, in either the same or opposing directions, and at different time points. We highlight a variety of putative regulatory pathways, including the stress-dependent alternative splicing of aminoacyl-tRNA synthetases, and protein-RNA binding within the 3' untranslated region of molecular chaperones. These results illustrate the potential of this information-rich resource.",New insights into the cellular temporal response to proteostatic stress.,10.7554/eLife.39054,2018 Oct 12,PMC6185107,eLife
GSE40745,Transcriptomic analyses of Myc-induced zebrafish liver cancer,Danio rerio,8,SRP015680,2012-09-10,"[Overal design]Transcriptome profiling of tumor samples (M+D+) and control samples (M-D-, M+D-, M-D+) were generated by deep sequencing, each in duplicates, using 3' RNA-SAGE on the SOLiD system.; [Treatment]'Transgenic zebrafish and their wildtype siblings were treated starting from 21 dpf. Doxycycline treatment was conducted in 6-L tanks with around 25 adults and water was changed every other day.'; [Growth]'None'; [Extraction]'Total RNA was extracted using TRIzol (Invitrogen). Library construction was conducted by Mission Biotech (Taiwan) following the standard ABI SOLiD protocol.'; [Cell type]'Source: ''genotype: wildtype; tissue: liver; treatment: none; ', 'genotype: Tg(fabp10:TA; TRE:Myc; krt4:GFP); tissue: liver; treatment: none; ', 'genotype: wildtype; tissue: liver; treatment: doxycycline; ', 'genotype: Tg(fabp10:TA; TRE:Myc; krt4:GFP); tissue: liver; treatment: doxycycline; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40745,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE40nnn/GSE40745/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA174800,23038063," Zhen Li,  Weiling Zheng,  Zhengyuan Wang,  Zhiqiang Zeng,  Huiqing Zhan,  Caixia Li,  Li Zhou,  Chuan Yan,  Jan M Spitsbergen,  Zhiyuan Gong","Myc is a pleiotropic transcription factor that is involved in many cellular activities relevant to carcinogenesis, including hepatocarcinogenesis. The zebrafish has been increasingly used to model human diseases and it is particularly valuable in helping to identify common and conserved molecular mechanisms in vertebrates. Here we generated a liver tumor model in transgenic zebrafish by liver-specific expression of mouse Myc using a Tet-On system. Dosage-dependent induction of Myc expression specifically in the liver was observed in our Myc transgenic zebrafish, TO(Myc), and the elevated Myc expression caused liver hyperplasia, which progressed to hepatocellular adenoma and carcinoma with prolonged induction. Next generation sequencing-based transcriptomic analyses indicated that ribosome proteins were overwhelmingly upregulated in the Myc-induced liver tumors. Cross-species analyses showed that the zebrafish Myc model correlated well with Myc transgenic mouse models for liver cancers. The Myc-induced zebrafish liver tumors also possessed molecular signatures highly similar to human those of hepatocellular carcinoma. Finally, we found that a small Myc target gene set of 16 genes could be used to identify liver tumors due to Myc upregulation. Thus, our zebrafish model demonstrated the conserved role of Myc in promoting hepatocarcinogenesis in all vertebrate species.",A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors.,10.1242/dmm.010462,2013 Mar,PMC3597023,Disease models & mechanisms
GSE128947,Developmental changes of rRNA ribose methylations in the mouse,Mus musculus,33,SRP189642,2019-03-27,"[Overal design]11 samples analyzed in biological triplicates, in total 33 samples; [Treatment]'None'; [Growth]'None'; [Extraction]""Tissues were homogenized and whole cell RNA was extracted using Tri-Reagent (Euromedex) according to the manufacturers instructions.\nRiboMeth-seq: 5-10 ug of RNA was partially degraded by alkaline at denaturing temperatures. The size fraction 20-40 nt was purified on gels and linkers added using a system relying on a modified Arabidopsis tRNA ligase joining 2',3' cyclic phosphate and 5' phosphate ends. The library fragments were then sequenced on the Ion Proton platform. See Birkedal U, Christensen-Dalsgaard M, Krogh N, Sabarinathan R, Gorodkin J, Nielsen H. Profiling of ribose methylations in RNA by high-throughput sequencing. Angewandte Chemie. 2015;54(2):451-5 for detailed description""; [Cell type]'Source: ''tissue: Brain; developmental stage: adult; ', 'tissue: Brain; developmental stage: E16.5; ', 'tissue: Whole head; developmental stage: E9.5; ', 'tissue: Heart; developmental stage: adult; ', 'tissue: Heart; developmental stage: E16.5; ', 'tissue: Kidney; developmental stage: adult; ', 'tissue: Kidney; developmental stage: E16.5; ', 'tissue: Liver; developmental stage: adult; ', 'tissue: Liver; developmental stage: E16.5; ', 'tissue: Lung; developmental stage: adult; ', 'tissue: Lung; developmental stage: E16.5; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128947,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128947/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA529461,31566069," Jade Hebras,  Nicolai Krogh,  Virginie Marty,  Henrik Nielsen,  Jerome Cavaille","A sequencing-based profiling method (RiboMeth-seq) for ribose methylations was used to study methylation patterns in mouse adult tissues and during development. In contrast to previous reports based on studies of human cancer cell lines, almost all methylation sites were close to fully methylated in adult tissues. A subset of sites was differentially modified in developing tissues compared to their adult counterparts and showed clear developmental dynamics. This provides the first evidence for ribosome heterogeneity at the level of rRNA modifications during mouse development. In a prominent example, the expression levels of SNORD78 during development appeared to be regulated by alternative splicing of the Gas5 host-gene and to correlate with the methylation level of its target site at LSU-G4593. The results are discussed in the context of the specialized ribosome hypothesis.",Developmental changes of rRNA ribose methylations in the mouse.,10.1080/15476286.2019.1670598,2020 Jan,PMC6948968,RNA biology
GSE115647,The LIN28B-IMP1 post-transcriptional regulon has opposing effects on oncogenic  signaling in the intestine,Homo sapiens,4,SRP150308,2018-06-12,"[Overal design]Ribosome-footprinting and RNA-seq samples from LIN28B OE SW480 cells and LIN28B OE+IMP1-/- knockout cells; [Treatment]'None'; [Growth]'None'; [Extraction]'Ribosome profiling libraries from 3 pooled cell culture plates were prepared using a standard protocol (McGlincy and Ingolia, Methods 2017), with minor modifications.\nSeparate 5 and 3 linkers were ligated to the RNA-fragment instead of 3 linker followed by circularization (Subtelny et al, Nature 2014). 5 linkers contained 4 random nt unique molecular identifier (UMI) similar to a 5 nt UMI in 3 linkers. During size-selection, we restricted the footprint lengths to 18-34 nts. Matched RNA-seq libraries were prepared using RNA that was randomly fragmentation by incubating for 15 min at 95C with in 1 mM EDTA, 6 mM Na2CO3, 44 mM NaHCO3, pH 9.3. RNA-seq fragments were restricted to 18-50 nts. Ribosomal rRNA were removed from pooled RNA-seq and footprinting samples using RiboZero (Epicenter MRZH116). cDNA for the pooled library were PCR amplified for 15 cycles.'; [Cell type]'Source: ''cell line: SW480; genotype/variation: LIN28B OE; ', 'cell line: SW840; genotype/variation: LIN28B OE; ', 'cell line: SW480; genotype/variation: LIN28B OE+IMP1-/- knockout; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115647,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE115nnn/GSE115647/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA475675,30068703," Priya Chatterji,  Kathryn E Hamilton,  Shun Liang,  Sarah F Andres,  H R Sagara Wijeratne,  Rei Mizuno,  Lauren A Simon,  Philip D Hicks,  Shawn W Foley,  Jason R Pitarresi,  Andres J Klein-Szanto,  Amanda T Mah,  Laurianne Van Landeghem,  Brian D Gregory,  Christopher J Lengner,  Blair B Madison,  Premal Shah,  Anil K Rustgi","RNA-binding proteins (RBPs) are expressed broadly during both development and malignant transformation, yet their mechanistic roles in epithelial homeostasis or as drivers of tumor initiation and progression are incompletely understood. Here we describe a novel interplay between RBPs LIN28B and IMP1 in intestinal epithelial cells. Ribosome profiling and RNA sequencing identified IMP1 as a principle node for gene expression regulation downstream from LIN28B In vitro and in vivo data demonstrate that epithelial IMP1 loss increases expression of WNT target genes and enhances LIN28B-mediated intestinal tumorigenesis, which was reversed when we overexpressed IMP1 independently in vivo. Furthermore, IMP1 loss in wild-type or LIN28B-overexpressing mice enhances the regenerative response to irradiation. Together, our data provide new evidence for the opposing effects of the LIN28B-IMP1 axis on post-transcriptional regulation of canonical WNT signaling, with implications in intestinal homeostasis, regeneration and tumorigenesis.",The LIN28B-IMP1 post-transcriptional regulon has opposing effects on oncogenic signaling in the intestine.,10.1101/gad.314369.118,2018 Aug 1,PMC6075153,Genes & development
GSE81802,Translational profiling of B cells infected with the Epstein-Barr virus reveals 5 leader ribosome recruitment through upstream open reading frames,Homo sapiens,13,SRP075585,2016-05-23,"[Overal design]Sample 1 experimental set-up: B cells were infected with either the B95-8 or M81 Epstein-Barr virus (EBV) strain. These cells were then treated with cycloheximide for 10 min and ribosome profiles were generated that were then converted into a cDNA library for sequencing. In parallel, these cells were also treated for 2 minutes with harringtonine and again ribosome profiles were generated that were subsequently sequenced. Additionally, the total RNA was sequenced from cells infected with the B95-8 or M81 strain. Sample 2 experimental set-up: B cells were infected with either the B95-8 or M81 EBV strain. These cells were treated for 2 or 5 minutes with harringtonine and ribosome profiles were generated that were subsequently sequenced. Additionally, the total RNA from cells infected with the B95-8 or M81 strain was sequenced. HEK293 cells carrying a stably transfected B95-8 BACMID were induced into lytic replication by transfecting a lytic cycle transactivator and these cells were then treated for 2 minutes with harringtonine. Ribosome profiling was also performed with this sample and it was subsequently sequenced.; [Treatment]'Cycloheximide treatment was performed at 37C for 10 minutes at a concentration of 100g/ml. Harringtonine treatments were performed at 37C for 2 or 5 minutes at a concentration of 2g/ml.', 'Cycloheximide treatment was performed at 37C for 10 minutes at a concentration of 100g/ml. Harringtonine treatments were performed at 37C for 2 or 5 minutes at a concentration of 2g/ml. For total RNA sequencing, the samples were left untreated.'; [Growth]'EBV-transformed B cells and HEK293 cells were maintained in RPMI-1640 medium (Invitrogen). B cells were subpassaged every 3-4 days, depending on cell density. HEK293 cells were routinely split at a 1:7 ratio by resuspension and transfer onto a new culture dish.'; [Extraction]'Lysates were clarified by centrifugation and ribosome covered RNA was isolated by sucrose gradient ultracentrifugation and subsequent fractionation. Isolated fractions were RNAse I treated for 15 minutes at room temperature. Following nuclease treatment ribosome protected fragments were gel purified.\nLibraries for highthroughput sequencing were generated according to the published protocol from Ingolia et al. 2012 published in Nature Protocols.', ""Lysates were clarified by centrifugation and ribosome covered RNA was isolated by sucrose gradient ultracentrifugation and subsequent fractionation. Isolated fractions were RNase I treated for 15 minutes at room temperature. Following nuclease treatment, ribosome protected fragments were gel purified. For total RNA sequencing, cells were lysed with Trizol (Ambion) reagent and RNA was purified according to manufacturer's instructions.\nRibosome profiling libraries for high-throughput sequencing were generated according to the published protocol from Ingolia et al. 2012 published in Nature Protocols. The total RNA sequencing libaries were prepared by the DKFZ core facility using the strand-specific RNA preparation kit from Agilent.""; [Cell type]'CD19+ B cells', 'HEK293 cells''cell type: CD19+ B cells; in vitro transformed by: EBV strain B95-8; treatment: pretreated for 2 minutes with harringtonine; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain B95-8; treatment: pretreated for 5 minutes with harringtonine; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain B95-8; treatment: pretreated with cycloheximide; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain M81; treatment: pretreated for 2 minutes with harringtonine; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain M81; treatment: pretreated for 5 minutes with harringtonine; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain M81; treatment: pretreated with cycloheximide; ', 'cell type: HEK293 cells; in vitro transformed by: EBV strain B95-8; treatment: pretreated for 2 minutes with harringtonine; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain B95-8; treatment: None; ', 'cell type: CD19+ B cells; in vitro transformed by: EBV strain M81; treatment: None; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81802,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE81nnn/GSE81802/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA322561,,,,,,,,
GSE69921,Ribosome profiling of control and leucine-starved SUM159 cells,Homo sapiens,3,SRP059546,2015-06-16,"[Overal design]1 replicate per condition; [Treatment]'For Leucine starvation, cells were cultured in the same medium lacking Leucine for 12 and 24hrs.'; [Growth]'SUM159PT cells were cultured in DMEM/F12 1:1 medium supplemented with 5% FCS, insulin (5 ?g/ml), and hydrocortisone (1ug/ml) in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: ''cell line: SUM159; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69921,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69921/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA287136,,,,,,,,
GSE59820,Ribosome profiling on sections taken from a kidney tumor,Homo sapiens,22,SRP044937,2014-07-28,"[Overal design]For two tumors: 2 sections of normal tissue and 4 samples of tumor tissue, for another two tumors 1 section of normal tissue and 1 section of tumor tissue; [Treatment]'None'; [Growth]'None'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', ""RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nPoly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the manufacturer's instructions.""; [Cell type]'Source: ''tissue: Kidney; ', 'tissue: kidney; ', ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; tissue: normal; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; tissue: tumor; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59820,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59820/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256316,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE125686,"Transcriptomic profiling of peripheral blood NK cells of chronic HBV, HCV and HIV patients",Homo sapiens,62,SRP182096,2019-01-25,"[Overal design]We analyzed NK cell transcripts collected from the blood of well-characterized chronic HBV patients (n=32), chronic HCV patients (n=8), and HIV patients (n=6). Differential gene expression analysis, global module analysis, and unsupervised clustering analysis were performed by employing RNA-sequencing on blood NK cell transcriptomes.; [Treatment]'Not applicable.'; [Growth]'Not applicable.'; [Extraction]""Total RNA was isolated from purified NK cells using the PicoPure RNA Isolation Kit (Arcturus). To assess the quantity of the samples, the concentration of the RNA was determined using the Nanodrop ND1000 spectrophotometer. The quality and integrity of the RNA samples were analyzed on a RNA 6000 Lab-on-a-Chip using the Bioanalyzer 2100 (Agilent Technologies). mRNA was isolated from total RNA using the poly-T-oligo-attached magnetic beads. After fragmentation of the mRNA, a cDNA synthesis was performed.\nThe sequence libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) according to the manufacturer's protocol. The quality and yield after sample preparation were measured with a DNA 1000 Lab-on-a-Chip. The size of the resulting products had a peak around 300 basepairs on a DNA 1000 chip.""; [Cell type]'CD3-CD56+ NK cells''cell type: CD3-CD56+ NK cells; gender: Female; diagnosis: Chronic HBV; hbv clinical phase: HBeAg- Hepatitis; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: Chronic HBV; hbv clinical phase: HBeAg- Hepatitis; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: HCV; hbv clinical phase: HCV; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: Healthy; hbv clinical phase: Healthy; ', 'cell type: CD3-CD56+ NK cells; gender: Female; diagnosis: Healthy; hbv clinical phase: Healthy; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: HIV; hbv clinical phase: HIV-1; ', 'cell type: CD3-CD56+ NK cells; gender: Female; diagnosis: Chronic HBV; hbv clinical phase: Immune Active; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: Chronic HBV; hbv clinical phase: Immune Active; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: Chronic HBV; hbv clinical phase: Immune Control; ', 'cell type: CD3-CD56+ NK cells; gender: Female; diagnosis: Chronic HBV; hbv clinical phase: Immune Control; ', 'cell type: CD3-CD56+ NK cells; gender: Female; diagnosis: Chronic HBV; hbv clinical phase: Immune Tolerant; ', 'cell type: CD3-CD56+ NK cells; gender: Male; diagnosis: Chronic HBV; hbv clinical phase: Immune Tolerant; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125686,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE125nnn/GSE125686/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA517165,30185599," Lauke L Boeijen,  Jun Hou,  Rik A de Groen,  Annelies Verbon,  Andre Boonstra","Natural killer (NK) cells during chronic viral infection have been well studied in the past. We performed an unbiased next-generation RNA-sequencing approach to identify commonalities or differences of the effect of HIV, HCV, and HBV viremia on NK cell transcriptomes. Using cell sorting, we obtained CD3(-) CD56(+) NK cells from blood of 6 HIV-, 8 HCV-, and 32 HBV-infected patients without treatment. After library preparation and sequencing, we used an in-house analytic pipeline to compare expression levels with matched healthy controls. In NK cells from HIV-, HCV-, and HBV-infected patients, transcriptome analysis identified 272, 53, and 56 differentially expressed genes, respectively (fold change, >1.5; q-value, 0.2). Interferon-stimulated genes were induced in NK cells from HIV/HCV patients, but not during HBV infection. HIV viremia downregulated ribosome assembly genes in NK cells. In HBV-infected patients, viral load and alanine aminotransferase (ALT) variation had little effect on genes related to NK effector function. In conclusion, we compare, for the first time, NK cell transcripts of viremic HIV, HCV, and HBV patients. We clearly demonstrate distinctive NK cell gene signatures in three different populations, suggestive for a different degree of functional alterations of the NK cell compartment compared to healthy individuals.IMPORTANCE Three viruses exist that can result in persistently high viral loads in immunocompetent humans: human immunodeficiency virus (HIV), hepatitis C virus, and hepatitis B virus. In the last decades, by using flow cytometry and in vitro assays on NK cells from patients with these types of infections, several impairments have been established, particularly during and possibly contributing to HIV viremia. However, the background of NK cell impairments in viremic patients is not well understood. In this study, we describe the NK cell transcriptomes of patients with high viral loads of different etiologies. We clearly demonstrate distinctive NK cell gene signatures with regard to interferon-stimulated gene induction and the expression of genes coding for activation markers or proteins involved in cytotoxic action, as well immunological genes. This study provides important details necessary to uncover the origin of functional and phenotypical differences between viremic patients and healthy subjects and provides many leads that can be confirmed using future in vitro manipulation experiments.","Persistent Replication of HIV, Hepatitis C Virus (HCV), and HBV Results in Distinct Gene Expression Profiles by Human NK Cells.",10.1128/JVI.00575-18,2019 May 1,PMC6475777,Journal of virology
GSE64304,Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on alpha-synuclein,Saccharomyces cerevisiae,4,SRP051314,2014-12-18,"[Overal design]Ribosome profiling (RiboSeq) of wild type and VPS35 deletion yeast strains, with or without overexpression of the TIF4631 initiation factor; [Treatment]'None'; [Growth]'Yeast were grown in synthetic defined media to early-log phase. Expression of plasmid-encoded open reading frames is induced for two hours. Yeast are harvested by fast filtration and plunged in liquid nitrogen.'; [Extraction]""Cells were lysed using a cryogenic mixer mill. Lysates were clarified by centrifugation, and digested using Rnase I. Ribosomes were isolated by ultracentrifugation through a sucrose cushion, and RNA was extracted from the pellet.\nRNA fragments of approximately 30 nucleotides were extracted from a polyacrylamide gel. A DNA adapter was ligated to the 3' of fragments and used to prime reverse transcription. cDNA were circularized and rRNA-originating fragments were removed using biotinylated subtraction oligonucleotides. The library was barcoded during PCR amplification.""; [Cell type]'Source: ''tissue: whole cell lysate; strain: Y7092; vps35 genotype: wild type; plasmid: pAG416GAL-ccdB; assayed molecue: Ribosome protected mRNA; ', 'tissue: whole cell lysate; strain: Y7092; vps35 genotype: wild type; plasmid: pAG416GAL-TIF4631; assayed molecue: Ribosome protected mRNA; ', 'tissue: whole cell lysate; strain: Y7092; vps35 genotype: vps35::natMX; plasmid: pAG416GAL-ccdB; assayed molecue: Ribosome protected mRNA; ', 'tissue: whole cell lysate; strain: Y7092; vps35 genotype: vps35::natMX; plasmid: pAG416GAL-TIF4631; assayed molecue: Ribosome protected mRNA; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64304,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE64nnn/GSE64304/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA270712,25533483," Nripesh Dhungel,  Simona Eleuteri,  Ling-Bo Li,  Nicholas J Kramer,  Justin W Chartron,  Brian Spencer,  Kori Kosberg,  Jerel Adam Fields,  Klodjan Stafa,  Anthony Adame,  Hilal Lashuel,  Judith Frydman,  Kang Shen,  Eliezer Masliah,  Aaron D Gitler","UNLABELLED: Parkinson's disease (PD) is a common neurodegenerative disorder. Functional interactions between some PD genes, like PINK1 and parkin, have been identified, but whether other ones interact remains elusive. Here we report an unexpected genetic interaction between two PD genes, VPS35 and EIF4G1. We provide evidence that EIF4G1 upregulation causes defects associated with protein misfolding. Expression of a sortilin protein rescues these defects, downstream of VPS35, suggesting a potential role for sortilins in PD. We also show interactions between VPS35, EIF4G1, and alpha-synuclein, a protein with a key role in PD. We extend our findings from yeast to an animal model and show that these interactions are conserved in neurons and in transgenic mice. Our studies reveal unexpected genetic and functional interactions between two seemingly unrelated PD genes and functionally connect them to alpha-synuclein pathobiology in yeast, worms, and mouse. Finally, we provide a resource of candidate PD genes for future interrogation. VIDEO ABSTRACT:",Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on alpha-synuclein.,10.1016/j.neuron.2014.11.027,2015 Jan 7,PMC4289081,Neuron
GSE129700,Super-enhancer redistribution as a mechanism of broad gene dysregulation in repeatedly drug-treated cancer cells [dataset 1],Homo sapiens,22,SRP192313,2019-04-12,"[Overal design]All ChIP-Seq, GRO-seq, RNA-seq, and ribosome-profiling experiments were designed to understand the effects of cisplatin on 6 different layers of gene-expression regulation in cancer cells.; [Treatment]'The treatment administrated to A2780cis cells was described in the Sigma-Aldrich website as chronic exposure of the parent A27890 line to increasing concentrations of cisplatin Sigma-Aldrich (_93112517-19). Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.'; [Growth]'Cells  were cultured in RPMI-1640-Glutamax I (#61870-036, Life Technologies) and 10% fetal bovine serum (FBS, _FB-11, Omega Scientific) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.'; [Extraction]'Cells were fixed with 1% formaldehyde for 10mins, and followed by glycine for 5 mins. Chromatin DNA was sheared to 200500 bp average in size by sonication and chromatin was immunoprecipitated with antibodies. Protein G magnetic beads  were added and incubated overnight at 4C. After washing and elution, the proteinDNA complex was reverse-crosslinked by heating at 65C, and immunoprecipitated DNA was purified by using QIAquick Spin column.\nChIP-seq libraries were prepared using the KAPA Library Preparation Kit (KK8201)'; [Cell type]'Source: ''cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me3 (Millipore, 07-473); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me3 (Millipore, 07-473); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me2 (Active Motif, 39141); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me2 (Active Motif, 39141); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): p53 (Active Motif, _39334); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): ISL1 (DHSB, _39.4D5-s); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): EGR1 (Santa Cruz Biotechnology, 588, sc-110); ', 'cell line: A2780-CRISPR/dCas9-KRAB-modified; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780cis-CRISPR/dCas9-VP64-modified; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); '",Genome binding/occupancy profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129700,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129700/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532531,32320655," Qi Ma,  Feng Yang,  Carlos Mackintosh,  Ranveer Singh Jayani,  Soohwan Oh,  Chunyu Jin,  Sreejith Janardhanan Nair,  Daria Merkurjev,  Wubin Ma,  Stephanie Allen,  Dong Wang,  Angels Almenar-Queralt,  Ivan Garcia-Bassets","Cisplatin is an antineoplastic drug administered at suboptimal and intermittent doses to avoid life-threatening effects. Although this regimen shortly improves symptoms in the short term, it also leads to more malignant disease in the long term. We describe a multilayered analysis ranging from chromatin to translation-integrating chromatin immunoprecipitation sequencing (ChIP-seq), global run-on sequencing (GRO-seq), RNA sequencing (RNA-seq), and ribosome profiling-to understand how cisplatin confers (pre)malignant features by using a well-established ovarian cancer model of cisplatin exposure. This approach allows us to segregate the human transcriptome into gene modules representing distinct regulatory principles and to characterize that the most cisplatin-disrupted modules are associated with underlying events of super-enhancer plasticity. These events arise when cancer cells initiate without ultimately ending the program of drug-stimulated death. Using a PageRank-based algorithm, we predict super-enhancer regulator ISL1 as a driver of this plasticity and validate this prediction by using CRISPR/dCas9-KRAB inhibition (CRISPRi) and CRISPR/dCas9-VP64 activation (CRISPRa) tools. Together, we propose that cisplatin reprograms cancer cells when inducing them to undergo near-to-death experiences.",Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells.,10.1016/j.celrep.2020.107532,2020 Apr 21,,Cell reports
GSE63570,High-throughput sequencing of pluripotent cells,Homo sapiens,11,SRP050147,2014-11-21,"[Overal design]HERV-K Rec iCLIP-seq: 2 replicates in NCCIT. Ribosome profiling: 4 replicates each of Rec-overexpressing NCCIT vs. control NCCIT; RNAseq: 3 replicates each of HERV-K Rec siRNA vs. control siRNA in NCCIT; RNA-seq: 3 replicates each of ELF1 nave hESC vs. primed hESC.; [Treatment]'UV-crosslinking in a Stratalinker 0.3J/cm2.', 'Cells were treated with cyclohexamide at 37C for 3 minutes, as per ART-seq kit instructions.', 'Cells were transfected with 25nM siRNA for three consecutive days with lipo2000.'; [Growth]'NCCIT cells were maintained in 10% FBS/RPMI with 1x glutamax, 1x non-essential amino acids, 1x antibiotics/antimycotic.', 'Nave and primed ELF1 hESC were maintained as described in Ware, et al. PNAS 2014 111(12):4484-9 (PMID 24623855). On MEFs.', 'NCCIT cells were maintained in 10%FBS/RPMI with 1x glutamax, 1x non-essential amino acids, 1x antibiotics/antimycotic'; [Extraction]'Crosslinked RNAs were purified with tandem FLAG/eGFP immunoprecipitation.\nHuppertz, I. et al. iCLIP: protein-RNA interactions at nucleotide resolution. Methods 2014 65(3):274-87 (PMID 24184352).', 'Ribosome-protected fragments were purified using the ART-seq kit.\nHuppertz, I. et al. iCLIP: protein-RNA interactions at nucleotide resolution. Methods 2014 65(3):274-87 (PMID 24184352).', 'Trizol, Ambion polyA purification kit.\nLibraries were constructed using NEBnext kit.', 'Trizol, total RNA, rRNA depletion\nLibraries were constructed using NEBnext kit'; [Cell type]'NCCIT cells, hECC', 'naive hESC', 'primed hESC''cell type: NCCIT cells, hECC; Sex: male; ', 'cell type: naive hESC; Sex: female; ', 'cell type: primed hESC; Sex: female; ', 'gender: male; cell type: NCCIT cells, hECC; molecule subtype: total RNA (rRNA depleted); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63570,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE63nnn/GSE63570/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA268222,25896322," Edward J Grow,  Ryan A Flynn,  Shawn L Chavez,  Nicholas L Bayless,  Mark Wossidlo,  Daniel J Wesche,  Lance Martin,  Carol B Ware,  Catherine A Blish,  Howard Y Chang,  Renee A Reijo Pera,  Joanna Wysocka","Endogenous retroviruses (ERVs) are remnants of ancient retroviral infections, and comprise nearly 8% of the human genome. The most recently acquired human ERV is HERVK(HML-2), which repeatedly infected the primate lineage both before and after the divergence of the human and chimpanzee common ancestor. Unlike most other human ERVs, HERVK retained multiple copies of intact open reading frames encoding retroviral proteins. However, HERVK is transcriptionally silenced by the host, with the exception of in certain pathological contexts such as germ-cell tumours, melanoma or human immunodeficiency virus (HIV) infection. Here we demonstrate that DNA hypomethylation at long terminal repeat elements representing the most recent genomic integrations, together with transactivation by OCT4 (also known as POU5F1), synergistically facilitate HERVK expression. Consequently, HERVK is transcribed during normal human embryogenesis, beginning with embryonic genome activation at the eight-cell stage, continuing through the emergence of epiblast cells in preimplantation blastocysts, and ceasing during human embryonic stem cell derivation from blastocyst outgrowths. Remarkably, we detected HERVK viral-like particles and Gag proteins in human blastocysts, indicating that early human development proceeds in the presence of retroviral products. We further show that overexpression of one such product, the HERVK accessory protein Rec, in a pluripotent cell line is sufficient to increase IFITM1 levels on the cell surface and inhibit viral infection, suggesting at least one mechanism through which HERVK can induce viral restriction pathways in early embryonic cells. Moreover, Rec directly binds a subset of cellular RNAs and modulates their ribosome occupancy, indicating that complex interactions between retroviral proteins and host factors can fine-tune pathways of early human development.",Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells.,10.1038/nature14308,2015 Jun 11,PMC4503379,Nature
GSE70802,Profiles of ribosome-associated mRNAs regulated by expression of wild-type (WT) or R534H variant of DDX3 with or without Sodium Arsenite treatment [Ribo-Seq],Homo sapiens,12,SRP060676,2015-07-11,"[Overal design]Cells expressing either DDX3 WT or R534H variant were treated with or without sodium arsenite and lysed in the presence of cyclohexime. Ribosome-protected mRNA fragments after RNase I treatment were recovered and sequenced.; [Treatment]'Cells were treated with or without 0.5 mM sodium arsenite for 45 minutes.'; [Growth]'HEK293 cells were grown under standard serum conditions and FLAG-tagged Renilla luciferease (Rluc) control, DDX3 WT, or DDX3 R534H expression was induced by doxycycline addition.'; [Extraction]'Lysates were treated with RNase I, ribosomes were collected, ribosomal RNAs were depleted with Ribo-Zero kit (EpiCentre), and ribosome-protected mRNA fragments were enriched.\nLibraries were prepared according to the ribosome profiling protocol (PMID: 19213877) and ARTseqTM Ribosome Profiling Kit protocol (EpiCentre).'; [Cell type]'Embryonic kidney''cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; expressed protein: Rluc control; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; expressed protein: DDX3 WT; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; expressed protein: DDX3 R534H; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; expressed protein: Rluc control; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; expressed protein: DDX3 WT; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; expressed protein: DDX3 R534H; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70802,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE70nnn/GSE70802/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA289569,27058758," Sekyung Oh,  Ryan A Flynn,  Stephen N Floor,  James Purzner,  Lance Martin,  Brian T Do,  Simone Schubert,  Dedeepya Vaka,  Sorana Morrissy,  Yisu Li,  Marcel Kool,  Volker Hovestadt,  David T W Jones,  Paul A Northcott,  Thomas Risch,  Hans-Jorg Warnatz,  Marie-Laure Yaspo,  Christopher M Adams,  Ryan D Leib,  Marcus Breese,  Marco A Marra,  David Malkin,  Peter Lichter,  Jennifer A Doudna,  Stefan M Pfister,  Michael D Taylor,  Howard Y Chang,  Yoon-Jae Cho","DDX3X encodes a DEAD-box family RNA helicase (DDX3) commonly mutated in medulloblastoma, a highly aggressive cerebellar tumor affecting both children and adults. Despite being implicated in several facets of RNA metabolism, the nature and scope of DDX3's interactions with RNA remain unclear. Here, we show DDX3 collaborates extensively with the translation initiation machinery through direct binding to 5'UTRs of nearly all coding RNAs, specific sites on the 18S rRNA, and multiple components of the translation initiation complex. Impairment of translation initiation is also evident in primary medulloblastomas harboring mutations in DDX3X, further highlighting DDX3's role in this process. Arsenite-induced stress shifts DDX3 binding from the 5'UTR into the coding region of mRNAs concomitant with a general reduction of translation, and both the shift of DDX3 on mRNA and decreased translation are blunted by expression of a catalytically-impaired, medulloblastoma-associated DDX3R534H variant. Furthermore, despite the global repression of translation induced by arsenite, translation is preserved on select genes involved in chromatin organization in DDX3R534H-expressing cells. Thus, DDX3 interacts extensively with RNA and ribosomal machinery to help remodel the translation landscape in response to stress, while cancer-related DDX3 variants adapt this response to selectively preserve translation.",Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress.,10.18632/oncotarget.8612,2016 May 10,PMC5053718,Oncotarget
GSE71898,AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [GRO-Seq],Homo sapiens,8,SRP062229,2015-08-10,"[Overal design]Profiles of MCF7 and HCT116 Akti-1/2 treated cells and MCF7 and HCT116 vehicle (i.e. DMSO) treated cells were generated, each in duplicate, using GRO-Seq.; [Treatment]'Cells were treated for 72h with vehicle (DMSO), Akti-1/2 inhibitor (HCT116: 20M; MCF7: 2M) (Sigma)'; [Growth]'MCF7 was maintained in DMEM, 10% FCS, 40mM glutamine, 100 U/mL penicillin, and 100g/mL streptomycin; HCT116 was maintained in McCoys 5? medium supplemented with 10% FCS, 100U/mL penicillin, and 100g/mL streptomycin. All cells were grown at 37C and 5% CO2.'; [Extraction]'Isolation of nuclei and nuclear run-on was carried out as described in Core et al, Science (2008) . Nascent RNAs were on average approximately 100nt long.\nThe immuno-purified RNA was resuspended in 8.5l water and 5- or 3- adapters ligated using Tru-Seq Small RNA Kit, Illumina. RNAs were reverse transcribed and amplified. The NRO-cDNA libraries were then run on a non-denaturing 1XTBE, 8% acrylamide gel, and cDNAs greater than 90 nucleotides were excised from the gel and eluted, precipitated and sequenced on the HiSeq 2000.'; [Cell type]'breast adenocarcinoma', 'colon carcinoma''cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 Low; ', 'cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 WT; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 Low; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 WT; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71898,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71898/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292421,26637368," Salony,  Xavier Sole,  Cleidson P Alves,  Ipsita Dey-Guha,  Laila Ritsma,  Myriam Boukhali,  Ju H Lee,  Joeeta Chowdhury,  Kenneth N Ross,  Wilhelm Haas,  Shobha Vasudevan,  Sridhar Ramaswamy","Small molecule inhibitors of AKT (v-akt murine thymoma viral oncogene homolog) signaling are being evaluated in patients with various cancer types, but have so far proven therapeutically disappointing for reasons that remain unclear. Here, we treat cancer cells with subtherapeutic doses of Akti-1/2, an allosteric small molecule AKT inhibitor, in order to experimentally model pharmacologic inhibition of AKT signaling in vitro. We then apply a combined RNA, protein, and metabolite profiling approach to develop an integrated, multiscale, molecular snapshot of this ""AKT(low)"" cancer cell state. We find that AKT-inhibited cancer cells suppress thousands of mRNA transcripts, and proteins related to the cell cycle, ribosome, and protein translation. Surprisingly, however, these AKT-inhibited cells simultaneously upregulate a host of other proteins and metabolites posttranscriptionally, reflecting activation of their endo-vesiculo-membrane system, secretion of inflammatory proteins, and elaboration of extracellular microvesicles. Importantly, these microvesicles enable rapidly proliferating cancer cells of various types to better withstand different stress conditions, including serum deprivation, hypoxia, or cytotoxic chemotherapy in vitro and xenografting in vivo. These findings suggest a model whereby cancer cells experiencing a partial inhibition of AKT signaling may actually promote the survival of neighbors through non-cell autonomous communication.",AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.,10.1158/1535-7163.MCT-15-0414,2016 Jan,PMC4707053,Molecular cancer therapeutics
GSE68008,Methods comparison for ribosome profiling,Homo sapiens,2,SRP057384,2015-04-17,"[Overal design]Immortalized human lymphocytes were analyzed by ribosome profiling protocols with or without ribosome purification; [Treatment]'-'; [Growth]'RPMI + 15% FBS, 37C, 5% CO2'; [Extraction]'Cells lysed in 200 mM KOAC, 15 mM MgCl, 15 mM K-HEPES pH 7.2, 180 uM cycloheximide. Treated with 10 ug/ml Mnase for 30 min\nNEB Directional Small RNA kit. Libraries purified by gel electrophoresis'; [Cell type]'Lymphocytes''sample type: No ribosome purification; cell type: Lymphocytes; ', 'sample type: With ribosome purification; cell type: Lymphocytes; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68008,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68008/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA281481,26164698," David W Reid,  Shirish Shenolikar,  Christopher V Nicchitta","The development and application of ribosome profiling has markedly advanced our understanding of ribosomes and mRNA translation. The experimental approach, which relies on deep sequencing of ribosome-protected mRNA fragments generated by treatment of polyribosomes with exogenous nucleases, provides a transcriptome-wide assessment of translation. The broad application of ribosome profiling has been slowed by the complexity and expense of the protocol. Here, we provide a simplified ribosome profiling method that uses micrococcal nuclease to generate ribosome footprints in crude cellular extracts, which are then purified simply by size selection via polyacrylamide gel electrophoresis. This simplification removes the laborious or expensive purification of ribosomes that has typically been used. This direct extraction method generates gene-level ribosome profiling data that are similar to a method that includes ribosome purification. This protocol should significantly ease the barrier to entry for research groups interested in employing ribosome profiling.",Simple and inexpensive ribosome profiling analysis of mRNA translation.,10.1016/j.ymeth.2015.07.003,2015 Dec,PMC4684803,"Methods (San Diego, Calif.)"
GSE6043,Translation initiation factor 4E confers primary human cells with neoplastic properties,Homo sapiens,9,None,2006-10-16,"[Overal design]A comparison of HMEC/hTERT and HMEC/hTERT/eIF4E cells using both total and polyribosoaml associated RNA.; [Treatment]'None'; [Growth]'Serum starvation for 24h, see manuscript'; [Extraction]'Polysomal preparation, see manuscript', 'Trizol'; [Cell type]'Source: '''",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6043,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE6nnn/GSE6043/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA97777,17638893," Ola Larsson,  Shunan Li,  Olga A Issaenko,  Svetlana Avdulov,  Mark Peterson,  Karen Smith,  Peter B Bitterman,  Vitaly A Polunovsky","Pathologic redirection of translational control by constitutive activation of eukaryotic translation initiation factor 4F (eIF4F), the cap-dependent translation initiation apparatus, is an obligatory step in oncogenesis; however, its mechanism remains undefined. Here, we simulate this pro-oncogenic state by overexpressing eIF4E, the rate-limiting component of eIF4F, in primary human mammary epithelial cells (HMECs) and examine the resultant changes in cell biology and gene expression profiles of total and polyribosome-bound mRNA genome wide. Overexpressed eIF4E rescues primary HMECs from telomere-independent growth arrest and disables checkpoints governing S-phase entry as well as apoptosis in HMECs immortalized by telomerase, imparting cells with proliferative and survival autonomy. Although the transcriptional response to increased eIF4E was modest, the translational response was large, selective, and bidirectional. In addition to translational activation of known and novel eIF4E-responsive oncogenic drivers regulating cell growth and survival, our data unveil previously unrecognized cellular defenses including translational activation of tumor suppressors, translational repression of transcripts enriched with miRNA target sites, and translational modulation of genes governing translation itself. These findings provide insight into the proneoplastic and compensatory mechanisms embedded in the oncogenic translational program. They support a model whereby deregulated eIF4E moves human epithelial cells along the cancer pathway by profoundly altering ribosomal recruitment to cancer-related transcripts, and eIF4E-modified cells counter these potentially oncogenic alterations with a compensatory translational mechanism that mitigates acquisition of malignancy.",Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors.,10.1158/0008-5472.CAN-07-0752,2007 Jul 15,,Cancer research
GSE110323,Histone H3 Trimethylation at Lysine 36 (H3K36me3) Guides m6A RNA Modification,Homo sapiens; Mus musculus,119,None,2018-02-08,"[Overal design]Refer to individual Series; [Treatment]'Lentivirus were produced in HEK293T cells by co-transfecting individual shRNA construct with packing vectors (pMD2.G, pMDLg/pRRE and pRSV-Rev) into HEK293T cells in 60 mm cell culture dish using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Grenzach-Wyhlen, Germany). The lentivirus particles were harvested at 48 and 72 hours after transfection and directly added into HepG2 cells with 4 ?g/mL polybrene. After two rounds of infection, cells were selected for at least three passages by adding 1 ?g/mL puromycin into growth medium.', 'Cells were treated with 1 g/ml doxycycline for 4 consecutive days to induce Setd2 knockdown.', 'Lentivirus were produced in HEK293T cells by co-transfecting individual shRNA construct with packaging vectors (pMD2.G, pMDLg/pRRE and pRSV-Rev) into HEK293T cells in 60 mm cell culture dish using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Grenzach-Wyhlen, Germany). The lentivirus particles were harvested at 48 and 72 hours after transfection and directly added into HepG2 cells with 4 ?g/mL polybrene. After two rounds of infection, cells were selected for at least three passages by adding 1 ?g/mL puromycin into growth medium.', 'For overexpression, PLJM1 vectors with METTL14 cDNA fused with HA-tag at N-terminal and EGFP at C-terminal, along with 2nd generation packaging vectors (pMD2.G and psPAX2), were co-transfected into HEK293T cells using X-tremeGENE HP DNA Transfection Reagent. The lentivirus particles were harvested at 48 and 72 hours after transfection and were used for infection of target cells with the supplement polybrene. After two rounds of infection, cells were selected with 1 ?g/ml puromycin. GFP-high cells were then sorted by flow cytometry to make sure that the stable cells have relatively high expression of METTL14. HepG2 cells were treated with or withour 100M DRB for 3 hours.', 'For overexpression, PLJM1 vectors with METTL14 cDNA fused with HA-tag at N-terminal and EGFP at C-terminal, along with 2nd generation packaging vectors (pMD2.G and psPAX2), were co-transfected into HEK293T cells using X-tremeGENE HP DNA Transfection Reagent. The lentivirus particles were harvested at 48 and 72 hours after transfection and were used for infection of target cells with the supplement polybrene. After two rounds of infection, cells were selected with 1 ?g/ml puromycin. GFP-high cells were then sorted by flow cytometry to make sure that the stable cells have relatively high expression of METTL14. HepG2 cells with HA-tagged METTL14 were treated with 200 M of 4-thiouridine for 16 h before subjected to UV crosslinking (365 nm, 0.15 J/cm2) at 4 ?C for 3 times.', 'HepG2 cells with stably expressed shRNAs against SETD2 or METTL14 were seeded into 6-well plates to get 50% confluency after 24 hours. Cells were then treated with 5 ?g/mL actinomycin D and collected at indicated time points.', 'Lentivirus were produced in HEK293T cells by co-transfecting individual shRNA construct with packing vectors (pMD2.G, pMDLg/pRRE and pRSV-Rev) into HEK293T cells in 60 mm cell culture dish using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Grenzach-Wyhlen, Germany). The lentivirus particles were harvested at 48 and 72 hours after transfection and directly added into HepG2 cells with 4 ?g/mL polybrene. After two rounds of infection, cells were selected for at least two passages by adding 1 ?g/mL puromycin into growth medium. Cells were grown at around 70% confluence and treated with 100 ug/mL cycloheximide (Sigma) at 37 ?C for 7 min before collection.'; [Growth]'The human hepatocellular carcinoma cell line HepG2 (ATCC HB-8065) was maintained in EMEM medium (ATCC) supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 2 mM L-Glutamine and 1% penicillin-streptomycin.', 'Feeder-free mESCs with doxycycline (Dox)-inducible knockdown of Setd2 were cultured as spheres in 2i medium (a serum-free N2B27 medium supplemented with MEK inhibitor PD0325901 (1 ?M, Selleckchem), GSK3 inhibitor CHIR99021 (3 ?M, Selleckchem), and 1,000 U/ml leukemia inhibitory factor (LIF, Millipore)) on gelatin-coated plates.', 'The human hepatocellular carcinoma cell line HepG2 (ATCC HB-8065) was maintained in EMEM medium (ATCC) supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 2 mM L-Glutamine and 1% penicillin-streptomycin. Lentivirus were produced in HEK293T cells by co-transfecting individual shRNA construct with packaging vectors (pMD2.G, pMDLg/pRRE and pRSV-Rev) into HEK293T cells in 60 mm cell culture dish using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Grenzach-Wyhlen, Germany). The lentivirus particles were harvested at 48 and 72 hours after transfection and directly added into HepG2 cells with 4 ?g/mL polybrene. After two rounds of infection, cells were selected for at least two passages by adding 1 ?g/mL puromycin into growth medium.'; [Extraction]""Cell lysate was sonicated and clarified by using 0.22 m filter. Histone-DNA complexes were isolated with H3K36me3 antibody.\nLibraries were constructed by using Auto iDeal ChIP-seq kit for Histones (Diagenode, C01010057) following manufacturer's prorocol."", 'Total RNA was extracted using Direct-zol RNA MiniPrep Kit (Zymo). mRNA was further purified using Dynabeads mRNA DIRECT Kit (Thermo Fisher). mRNA was then sonicated. For IP samples, RNA was subjected to IP using m6A antibody (Synaptic Systems, 202003).\xa0\nLibraries were constructed using TruSeq Stranded mRNA Library Prep Kit (Illumina).', 'METTL14 ChIP experiment was performed using iDeal ChIP-seq Kit for Transcription Factors (Diagenode) following the manufacturers protocol. Briefly, HepG2 cells transduced with HA-tagged METTL14 were crosslinked with formaldehyde, lysed, and subjected to chromatin shearing by sonication in a Bioruptor Pico (Diagenode) with 30s on/30s off for 20 cycles. Immunoprecipitation was performed using 2 g anti-HA antibody (11867423001, Roche).\nProduct DNA (including IP product and the Input control) was decrosslinked and subjected to library construction using KAPA Hyper Prep Kit (Roche). Libraries were purified using AxyPrep Mag PCR Clean-up kit (Thermo Fisher Scientific). Each library was quantified using a Qubit fluorometer (Thermo Fisher Scientific) and the size distribution assessed using the 2100 Bioanalyzer (Agilent Technologies). The amplified libraries were hybridized to the Illumina single end flow cell and amplified using the cBot (Illumina). Single end reads of 50 nt were generated on Illumina HiSeq2500.', 'Cells were then harvested and lysed in lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.5% NP-40, 0.5 mM DTT) supplemented with proteinase inhibitors. The lysate was cleared by centrifuge and filter, and was then digested by using 0.2 U/L RNase T1 at 22 ?C for 15 min. The reaction was quenched by incubating on ice for 5 min followed by incubating with 30 L pre-washed HA-beads (88836, Thermo Fisher Scientific) at 4 ?C for 4 h. Beads were then collected and washed 3 times with wash buffer (50 mM HEPS, pH 7.5, 300 mM NaCl, 0.05% NP-40) supplemented with proteinase inhibitor. 50 L wash buffer was used to resuspend the beads and the RNA was further digested by using 10 U/L RNase T1 at 22 ?C for 6 min. Beads were washed with high salt wash buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 0.05% NP-40) 3 times and end repair was performed by using T4 PNK (M0201S, NEB) according to manufacturers protocol. RNA was then released by incubating beads in 100 L proteinase K buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.5% SDS) supplemented with 2 mg/mL proteinase K (Invitrogen, 25530049) and SUPERNase inhibitor at 55 ?C for 20 min. RNA was extracted by phenol:chloroform, recovered by EtOH precipitation.\nLibraries were constructed using NEBNext small RNA library prep kit (E7330S) and sequenced on illumina Hiseq4000.', 'The total RNA was extracted by miRNeasy Kit (Qiagen).\nFor RNA sequencing, equal amount of ERCC RNA spike-in control (Thermo Fisher Scientific) was added to the total RNA samples as internal controls before library construction. Sequencing libraries were prepared using TruSeq SR Cluster Kit V4-cBot-HS (illumina).', 'For each replicate, 1x107 cells were used and 1 mL lysis buffer (20\u2009mM HEPES pH 7.6, 100\u2009mM KCl, 5\u2009mM MgCl2, 100\u2009?g/ml cycloheximide, 1% Triton X-100) was added supplemented with 1:100 protease inhibitor (Roche), 40\u2009U/mL SUPERNase inhibitor (Ambion). Cells were resuspended and the mixture was rotated at 4 ?C for 15 min. After centrifuge at 14,000 rpm for 15 min, the supernatant was collected and 8 ?L Turbo DNase (Invitrogen) was added. 20% of the lysate was saved as input, from which total RNA and mRNA were isolated. 40 L 10 MNase buffer and 3 L MNase (NEB) were added to the rest 80% of the lysate and the mixture was incubated at room temperature for 15 min before 8 L SUPERNase inhibitor was added. The mixture was then loaded onto a 10/50% (w/v) sucrose gradient prepared in a lysis buffer without Triton X-100 and centrifuged at 4 ?C for 3 h at 27,500 rpm. The sample was then fractioned and analyzed by Gradient Station (BioCamp) equipped with ECONO UV monitor (BioRad) and fraction collector (Gilson, FC203B). The fractions corresponding to 80S monosome were collected. RNA were isolated from the collected fractions and rRNAs were removed by using RiboMinus Eukaryote kit (Invitrogen). rRNA-depleted RNA was separated on a 15% TBE-Urea gel and the gel band between 20-30 nt was cut. RNA was recovered from the gel by elution buffer (300 mM NaOAc pH 5.5, 1 mM EDTA, 0.1 U/mL SUPERNase inhibitor) by rotating at 4 ?C overnight and the RNA was purified from the eluent by EtOH precipitation. For input, mRNA was fragmented by using 1 PNK buffer (NEB) by heating at 94 ?C for 25 min. RNA were then subjected to end repair using T4 PNK (NEB) according to manufacturers protocol and then purified by the RNA Clean and Concentrator kit (Zymo).\nLibraries were constructed using the NEBNext small RNA library prep kit (E7330S) and sequenced on illumina Hiseq4000.'; [Cell type]'Source: ', 'mESC''cell line: HepG2; shRNA: Non-specific control; genotype: control; chip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: SETD2 shRNA; genotype: SETD2 knockdown; chip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 1; ', 'cell line: HepG2; shRNA: SETD2 shRNA; genotype: SETD2 knockdown; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 1; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; chip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: SETD2 shRNA; genotype: SETD2 knockdown; chip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 2; ', 'cell line: HepG2; shRNA: SETD2 shRNA; genotype: SETD2 knockdown; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 2; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; rip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; rip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; rip antibody: none; replicate: 3; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 1; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 2; ', 'cell line: HepG2; shRNA: Non-specific control; genotype: control; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 3; ', 'cell line: HepG2; shRNA: shMETTL3; genotype: METTL3 knockdown; rip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: shMETTL3; genotype: METTL3 knockdown; rip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: shMETTL3; genotype: METTL3 knockdown; rip antibody: none; replicate: 3; ', 'cell line: HepG2; shRNA: shMETTL3; genotype: METTL3 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 1; ', 'cell line: HepG2; shRNA: shMETTL3; genotype: METTL3 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 2; ', 'cell line: HepG2; shRNA: shMETTL3; genotype: METTL3 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 3; ', 'cell line: HepG2; shRNA: shMETLT14; genotype: METLT14 knockdown; rip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: shMETLT14; genotype: METLT14 knockdown; rip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: shMETLT14; genotype: METLT14 knockdown; rip antibody: none; replicate: 3; ', 'cell line: HepG2; shRNA: shMETLT14; genotype: METLT14 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 1; ', 'cell line: HepG2; shRNA: shMETLT14; genotype: METLT14 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 2; ', 'cell line: HepG2; shRNA: shMETLT14; genotype: METLT14 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 3; ', 'cell line: HepG2; shRNA: shSETD2#1; genotype: SETD2 knockdown; rip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: shSETD2#1; genotype: SETD2 knockdown; rip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: shSETD2#1; genotype: SETD2 knockdown; rip antibody: none; replicate: 3; ', 'cell line: HepG2; shRNA: shSETD2#1; genotype: SETD2 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 1; ', 'cell line: HepG2; shRNA: shSETD2#1; genotype: SETD2 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 2; ', 'cell line: HepG2; shRNA: shSETD2#1; genotype: SETD2 knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 3; ', 'cell line: HepG2; shRNA: shWTAP; genotype: WTAP knockdown; rip antibody: none; replicate: 1; ', 'cell line: HepG2; shRNA: shWTAP; genotype: WTAP knockdown; rip antibody: none; replicate: 2; ', 'cell line: HepG2; shRNA: shWTAP; genotype: WTAP knockdown; rip antibody: none; replicate: 3; ', 'cell line: HepG2; shRNA: shWTAP; genotype: WTAP knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 1; ', 'cell line: HepG2; shRNA: shWTAP; genotype: WTAP knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 2; ', 'cell line: HepG2; shRNA: shWTAP; genotype: WTAP knockdown; rip antibody: m6A antibody (Synaptic Systems, catalog# 202003, lot# 202003/2-75); replicate: 3; ', 'cell type: mESC; treatment: Dox -; genotype: control; chip antibody: none; replicate: 1; ', 'cell type: mESC; treatment: Dox -; genotype: control; chip antibody: none; replicate: 2; ', 'cell type: mESC; treatment: Dox +; genotype: Setd2 knockdown; chip antibody: none; replicate: 1; ', 'cell type: mESC; treatment: Dox +; genotype: Setd2 knockdown; chip antibody: none; replicate: 2; ', 'cell type: mESC; treatment: Dox -; genotype: control; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 1; ', 'cell type: mESC; treatment: Dox -; genotype: control; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 2; ', 'cell type: mESC; treatment: Dox +; genotype: Setd2 knockdown; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 1; ', 'cell type: mESC; treatment: Dox +; genotype: Setd2 knockdown; chip antibody: H3K36me3 (Abcam, catalog# ab9050, lot# GR166781-1); replicate: 2; ', 'cell line: HepG2; shRNA: Non-specific control; replication: replication 1; ', 'cell line: HepG2; shRNA: Non-specific control; replication: replication 2; ', 'cell line: HepG2; shRNA: Non-specific control; replication: replication 3; ', 'cell line: HepG2; shRNA: shSETD2#1; replication: replication 1; ', 'cell line: HepG2; shRNA: shSETD2#1; replication: replication 2; ', 'cell line: HepG2; shRNA: shSETD2#1; replication: replication 3; ', 'cell line: HepG2; shRNA: shSETD2#2; replication: replication 1; ', 'cell line: HepG2; shRNA: shSETD2#2; replication: replication 2; ', 'cell line: HepG2; shRNA: shSETD2#2; replication: replication 3; ', 'cell line: HepG2; ip antibody: none; replication: 1; ', 'cell line: HepG2; ip antibody: none; replication: 2; ', 'cell line: HepG2; ip antibody: HA antibody (11867423001, Roche); replication: 1; ', 'cell line: HepG2; ip antibody: HA antibody (11867423001, Roche); replication: 2; ', 'cell line: HepG2; ip antibody: none; treatment: DRB; replication: 1; ', 'cell line: HepG2; ip antibody: HA antibody (11867423001, Roche); treatment: DRB; replication: 1; ', 'cell line: HepG2; replication: 1; ', 'cell line: HepG2; replication: 2; ', 'cell line: HepG2; shRNA: non-specific control; treatment: untreated; time point: 0h; ', 'cell line: HepG2; shRNA: non-specific control; treatment: 5 ug/mL actinomycin D; time point: 1h; ', 'cell line: HepG2; shRNA: non-specific control; treatment: 5 ug/mL actinomycin D; time point: 3h; ', 'cell line: HepG2; shRNA: non-specific control; treatment: 5 ug/mL actinomycin D; time point: 6h; ', 'cell line: HepG2; shRNA: shSETD2; treatment: untreated; time point: 0h; ', 'cell line: HepG2; shRNA: shSETD2; treatment: 5 ug/mL actinomycin D; time point: 1h; ', 'cell line: HepG2; shRNA: shSETD2; treatment: 5 ug/mL actinomycin D; time point: 3h; ', 'cell line: HepG2; shRNA: shSETD2; treatment: 5 ug/mL actinomycin D; time point: 6h; ', 'cell line: HepG2; shRNA: shMETTl14; treatment: untreated; time point: 0h; ', 'cell line: HepG2; shRNA: shMETTl14; treatment: 5 ug/mL actinomycin D; time point: 1h; ', 'cell line: HepG2; shRNA: shMETTl14; treatment: 5 ug/mL actinomycin D; time point: 3h; ', 'cell line: HepG2; shRNA: shMETTl14; treatment: 5 ug/mL actinomycin D; time point: 6h; ', 'cell line: HepG2; shRNA: Non specific control; fraction: input; ', 'cell line: HepG2; shRNA: shMETTL14; fraction: input; ', 'cell line: HepG2; shRNA: shSETD2; fraction: input; ', 'cell line: HepG2; shRNA: Non specific control; fraction: 80S monosome; ', 'cell line: HepG2; shRNA: shMETTL14; fraction: 80S monosome; ', 'cell line: HepG2; shRNA: shSETD2; fraction: 80S monosome; ', 'cell line: HepG2; shRNA: Non-specific control; replication: 1; ', 'cell line: HepG2; shRNA: Non-specific control; replication: 2; ', 'cell line: HepG2; shRNA: Non-specific control; replication: 3; ', 'cell line: HepG2; shRNA: Non-specific control; ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 1; ', 'cell line: HepG2; shRNA: Non-specific control; ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 2; ', 'cell line: HepG2; shRNA: Non-specific control; ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 3; ', 'cell line: HepG2; shRNA: shSETD2#2; replication: 1; ', 'cell line: HepG2; shRNA: shSETD2#2; replication: 2; ', 'cell line: HepG2; shRNA: shSETD2#2; replication: 3; ', 'cell line: HepG2; shRNA: shSETD2#2; ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 1; ', 'cell line: HepG2; shRNA: shSETD2#2; ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 2; ', 'cell line: HepG2; shRNA: shSETD2#2; ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 3; ', 'dox treatment: Dox - (control); ip antibody: none; replication: 1; ', 'dox treatment: Dox - (control); ip antibody: none; replication: 2; ', 'dox treatment: Dox + (Setd2 knockdown); ip antibody: none; replication: 1; ', 'dox treatment: Dox + (Setd2 knockdown); ip antibody: none; replication: 2; ', 'dox treatment: Dox - (control); ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 1; ', 'dox treatment: Dox - (control); ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 2; ', 'dox treatment: Dox + (Setd2 knockdown); ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 1; ', 'dox treatment: Dox + (Setd2 knockdown); ip antibody: m6A antibody (Synaptic Systems, 202003); replication: 2; '",Genome binding/occupancy profiling by high throughput sequencing; Methylation profiling by high throughput sequencing; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110323,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110323/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA433476,30867593," Huilin Huang,  Hengyou Weng,  Keren Zhou,  Tong Wu,  Boxuan Simen Zhao,  Mingli Sun,  Zhenhua Chen,  Xiaolan Deng,  Gang Xiao,  Franziska Auer,  Lars Klemm,  Huizhe Wu,  Zhixiang Zuo,  Xi Qin,  Yunzhu Dong,  Yile Zhou,  Hanjun Qin,  Shu Tao,  Juan Du,  Jun Liu,  Zhike Lu,  Hang Yin,  Ana Mesquita,  Celvie L Yuan,  Yueh-Chiang Hu,  Wenju Sun,  Rui Su,  Lei Dong,  Chao Shen,  Chenying Li,  Ying Qing,  Xi Jiang,  Xiwei Wu,  Miao Sun,  Jun-Lin Guan,  Lianghu Qu,  Minjie Wei,  Markus Muschen,  Gang Huang,  Chuan He,  Jianhua Yang,  Jianjun Chen","DNA and histone modifications have notable effects on gene expression(1). Being the most prevalent internal modification in mRNA, the N(6)-methyladenosine (m(6)A) mRNA modification is as an important post-transcriptional mechanism of gene regulation(2-4) and has crucial roles in various normal and pathological processes(5-12). However, it is unclear how m(6)A is specifically and dynamically deposited in the transcriptome. Here we report that histone H3 trimethylation at Lys36 (H3K36me3), a marker for transcription elongation, guides m(6)A deposition globally. We show that m(6)A modifications are enriched in the vicinity of H3K36me3 peaks, and are reduced globally when cellular H3K36me3 is depleted. Mechanistically, H3K36me3 is recognized and bound directly by METTL14, a crucial component of the m(6)A methyltransferase complex (MTC), which in turn facilitates the binding of the m(6)A MTC to adjacent RNA polymerase II, thereby delivering the m(6)A MTC to actively transcribed nascent RNAs to deposit m(6)A co-transcriptionally. In mouse embryonic stem cells, phenocopying METTL14 knockdown, H3K36me3 depletion also markedly reduces m(6)A abundance transcriptome-wide and in pluripotency transcripts, resulting in increased cell stemness. Collectively, our studies reveal the important roles of H3K36me3 and METTL14 in determining specific and dynamic deposition of m(6)A in mRNA, and uncover another layer of gene expression regulation that involves crosstalk between histone modification and RNA methylation.",Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally.,10.1038/s41586-019-1016-7,2019 Mar,PMC6438714,Nature
GSE134865,Transcriptome-wide analysis of RNA structure in MCF7 cells with and without inhibition of eIF4A by hippuristanol treatment,Homo sapiens,12,SRP216397,2019-07-25,"[Overal design]MCF7 cells were treated with and without dimethyl sulphate (DMS) following treatment with and without hippuristanol in triplicate. Poly(A) RNA was extracted and underwent Structure-seq 2 library preparation; [Treatment]'Cells were treated for 1h with 150nM hippuristanol or an equal volume of DMSO (0.07%) by replenishment of the growth media. Following 1h incubation, media was replaced with PBS with or without  50mM dimethyl sulphate (DMS) for 10min. PBS was then replaced with PBS containing 250mM DTT to quench the DMS, followed by extraction of the RNA with TRIzol'; [Growth]'MCF7 cells grown in DMEM, high glucose, GlutaMAX Supplement, pyruvate (ThermoFisher 31966-021), supplemented with 10% FCS'; [Extraction]""RNA was extracted with TRIzol (ThermoFisher 15596026) as per manufacturer's instructions followed by isopropanol precipitation\n120 g total RNA per sample was subjected to two rounds of poly(A) selection with the Poly(A)Purist MAG Kit (AM1922), as per manufacturer's instructions. Poly(A) RNA was dissolved in 17 l TE (10mM Tris-HCl pH7.5, 1mM EDTA). 1 l was used to run on Bioanalyzer with the mRNA Nano assay to confirm removal of rRNA and 1 l was used to determine RNA concentration with a nanodrop. The remaining 15 l (typically slightly more than 1g) was used in the following reverse transcription step. For each sample, 1 g of poly(A) RNA was diluted to 15 l and mixed with 2 l of the N6 linker oligo: 5CAGACGTGTGCTCTTCCGATCNNNNNN3 (100 M) and 3 l KCl (1M) and split between 2 x 10 l. RNA was denatured in a thermal cycler at 90C for 1 min before rapidly cooling to 4C and held for 1 min. Temperature was increased to 25C and 4 l 5X buffer (100mM Tris-HCl pH 8.4, 25mM MgCl2, 25mM DTT, 2.5mM dNTPs), 5 l nuclease free water and 1 l SuperScript III (200U/l) (Thermo Fisher 18080085) was added to each 10 l sample. Samples were incubated for 5 min at 25C to promote annealing and to allow slight extension of RT primers, followed by 5 min at 42C for further extension and finally 55C for 50 min for full extension. Samples were then heated at 85C for 5 min to denature the enzyme, followed by addition of 2 l NaOH (1M) and incubation at 95C for 10 min to hydrolyse the RNA. Samples were purified by gel extraction with an 8% polyacrylamide, 1mm thick denaturing gel. To ensure maximal removal of the N6 linker, which can form an unwanted byproduct if not removed, cDNA running above an N78 ssDNA oligo was purified, which should run 50nt higher than the N6 linker. cDNA was dissolved in 5.5 l Tris-HCl (pH 8.0). To the 5.5 l cDNA was added 0.5 l hairpin donor oligo /5Phos/TGAAGAGCCTAGTCGCTGTTCANNNNNNCTGCCCATAGAG/3SpC3/ (400 M), 2 l betaine (5M) and 8 l 50% PEG 8000 (added last and at room temperature to avoid precipitating DNA). Samples were heated at 95C for 90sec and allowed to cool slowly to room temperature. 2 l 10X T4 DNA ligase buffer and 2 l T4 DNA ligase (400U/l) (NEB M0202S) were added and the samples were incubated at 16C for 6h followed by 30C for 6h and then 65C for 10 min to denature the enzyme. Samples were purified by gel extraction with a 6% polyacrylamide, 1mm thick denaturing gel and cDNA running above an N118 ssDNA oligo was purified; this oligo should run 50nt above any ligated N6 linker. Ligated cDNA was dissolved in 18 l Tris-HCl (pH 8.0). To determine the number of PCR cycles required, 25 l reactions were set up with 5 l taken from the samples at cycles 11, 14, 17, 20 and 23 and the amplified DNA was run on a 5% polyacrylamide denaturing gel. Reactions were set up with 5 l 1X Q5 buffer, 5 l GC rich enhancer buffer, 0.5 l dNTPs (10mM each), 0.25 l Q5 Hot Start High-Fidelity DNA Polymerase (2000U/ml) (NEB M0493L), 1 l Truseq forward primer: 5AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGAACAGCGACTAGGCTCTTCA3 (10 M), 1 l relevant Truseq reverse primer: 5CAAGCAGAAGACGGCATACGAGATBARCODEGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC3 (10 M), 4.5 l ligated cDNA and 7.75 water. Reactions were activated at 98C for 30sec followed by cycling between 98C for 10sec and 72C for 45sec. It was determined that 17 cycles was optimal, as this was the first cycle where the product was visible on the gel. The remaining samples were amplified in 3 x 25 l reactions as above, for 17 cycles plus a final extension time of 5 mins at 72C and then combined and gel purified on a 5% polyacrylamide, 1.5mm thick denaturing gel. Resultant PCR products running between ~200-600nt, as determined with ss50 ladder (Simplex Sciences) were purified and dissolved in 20 l Tris-HCl (pH 8.0). Samples were run on the Bioanalyzer with the high sensitivity DNA assay to ensure the size of the libraries was as expected with minimal byproduct contamination.""; [Cell type]'Source: ''strain: MCF7; dms: no; hippuristanol treatment: no; ', 'strain: MCF7; dms: yes; hippuristanol treatment: no; ', 'strain: MCF7; dms: no; hippuristanol treatment: yes; ', 'strain: MCF7; dms: yes; hippuristanol treatment: yes; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134865,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE134nnn/GSE134865/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA556678,31888698," Joseph A Waldron,  David C Tack,  Laura E Ritchey,  Sarah L Gillen,  Ania Wilczynska,  Ernest Turro,  Philip C Bevilacqua,  Sarah M Assmann,  Martin Bushell,  John Le Quesne","BACKGROUND: The RNA helicase eIF4A1 is a key component of the translation initiation machinery and is required for the translation of many pro-oncogenic mRNAs. There is increasing interest in targeting eIF4A1 therapeutically in cancer, thus understanding how this protein leads to the selective re-programming of the translational landscape is critical. While it is known that eIF4A1-dependent mRNAs frequently have long GC-rich 5'UTRs, the details of how 5'UTR structure is resculptured by eIF4A1 to enhance the translation of specific mRNAs are unknown. RESULTS: Using Structure-seq2 and polysome profiling, we assess global mRNA structure and translational efficiency in MCF7 cells, with and without eIF4A inhibition with hippuristanol. We find that eIF4A inhibition does not lead to global increases in 5'UTR structure, but rather it leads to 5'UTR remodeling, with localized gains and losses of structure. The degree of these localized structural changes is associated with 5'UTR length, meaning that eIF4A-dependent mRNAs have greater localized gains of structure due to their increased 5'UTR length. However, it is not solely increased localized structure that causes eIF4A-dependency but the position of the structured regions, as these structured elements are located predominantly at the 3' end of the 5'UTR. CONCLUSIONS: By measuring changes in RNA structure following eIF4A inhibition, we show that eIF4A remodels local 5'UTR structures. The location of these structural elements ultimately determines the dependency on eIF4A, with increased structure just upstream of the CDS being the major limiting factor in translation, which is overcome by eIF4A activity.",mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity.,10.1186/s13059-019-1901-2,2019 Dec 30,PMC6936103,Genome biology
GSE87888,A novel translational control mechanism involving RNA structures within coding sequences,Saccharomyces cerevisiae,4,SRP091450,2016-10-12,"[Overal design]Wild-type BY4741 yeast cells or cells expressing genomically His-Tev-ProtA-tagged Dhh1 were crosslinked using UV and analysed by CRAC.; [Treatment]'Cells were crosslinked using UV (254 nm) in culturo as previously described (Bohnsack et al., 2012)'; [Growth]'Wild-type BY4741 yeast cells or yeast cells expressing Dhh1-His-Tev-ProtA from the genomic Dhh1 locus were grown in exponential phase in YPD.'; [Extraction]""Crosslinked RNA-protein complexes were purified under denaturing conditions and RNAs associated with His-ProtA-tagged proteins were trimmed (Bohnsack et al., 2012).\n3' and 5' adapters were ligated and a cDNA library was prepared by reverse transcription and amplified by PCR (Bohnsack et al., 2012).""; [Cell type]'Source: ''tag: no tag; ', 'tag: Dhh1-His-Tev-ProtA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87888,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE87nnn/GSE87888/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA348109,27821408," Jennifer Jungfleisch,  Danny D Nedialkova,  Ivan Dotu,  Katherine E Sloan,  Neus Martinez-Bosch,  Lukas Bruning,  Emanuele Raineri,  Pilar Navarro,  Markus T Bohnsack,  Sebastian A Leidel,  Juana Diez","The impact of RNA structures in coding sequences (CDS) within mRNAs is poorly understood. Here, we identify a novel and highly conserved mechanism of translational control involving RNA structures within coding sequences and the DEAD-box helicase Dhh1. Using yeast genetics and genome-wide ribosome profiling analyses, we show that this mechanism, initially derived from studies of the Brome Mosaic virus RNA genome, extends to yeast and human mRNAs highly enriched in membrane and secreted proteins. All Dhh1-dependent mRNAs, viral and cellular, share key common features. First, they contain long and highly structured CDSs, including a region located around nucleotide 70 after the translation initiation site; second, they are directly bound by Dhh1 with a specific binding distribution; and third, complementary experimental approaches suggest that they are activated by Dhh1 at the translation initiation step. Our results show that ribosome translocation is not the only unwinding force of CDS and uncover a novel layer of translational control that involves RNA helicases and RNA folding within CDS providing novel opportunities for regulation of membrane and secretome proteins.",A novel translational control mechanism involving RNA structures within coding sequences.,10.1101/gr.209015.116,2017 Jan,PMC5204348,Genome research
GSE138640,Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides [Dataset 3],Homo sapiens,3,SRP224954,2019-10-09,"[Overal design]3 ribosome profiling samples are included from HEK293T cells; [Treatment]'Aminoglycosides were added to cells, and treated for 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 26-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138640,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138640/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576651,31971508," Jamie R Wangen,  Rachel Green",eng,Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.,10.7554/eLife.52611,2020 Jan 23,PMC7089771,eLife
GSE128320,The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments in HuH-7 cells,Homo sapiens,2,SRP188452,2019-03-14,"[Overal design]Ribo-seq profiles of HuH-7 cells were generated by deep sequencing, in two independent experiments, using Xten Illumina sequencing platform. The ribo-seq data of the two biological replicates were integrated.Then,for the analysis of Ribo-seq data, sequenced reads that were trimmed for the adaptor sequence were aligned to the UCSC hg19 reference genome by STAR (version 2.4.2a) with parameters provided by the RiboCode (version 1.2.10) manual.; [Treatment]'None'; [Growth]'HuH-7 cells were cultured in DMEM medium (GIBCO) supplemented with  10% foetal bovine serum plus antibiotics.Cells were maintained in a 5% CO2 atmosphere at 37?.'; [Extraction]'The cell medium was discarded and HuH-7 cells were washed twice with ice-cold PBS containing 100 g/mL cycloheximide,which was added to inhibit the translational elongation of ribosomes. The 26-30-nt RPFs were isolated to generate ribosome profiling sequencing libraries.\nThe ribosome profiling assay was performed as described in the Nature Methods protocol and the Ribo-seq libraries were prepared according to Illuminas instructions'; [Cell type]'Source: ''genotype: wild type; cell line: HuH-7; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128320,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128320/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA527113,31240521," Wenli Xu,  Bing Deng,  Penghui Lin,  Chang Liu,  Bin Li,  Qiaojuan Huang,  Hui Zhou,  Jianhua Yang,  Lianghu Qu","The roles of concealed microproteins encoded by long noncoding RNAs (lncRNAs) are gradually being exposed, but their functions in tumorigenesis are still largely unclear. Here, we identify and characterize a conserved 99-amino acid microprotein named KRASIM that is encoded by the putative lncRNA NCBP2-AS2. KRASIM is differentially expressed in normal hepatocytes and hepatocellular carcinoma (HCC) cells and can suppress HCC cell growth and proliferation. Mechanistically, KRASIM interacts and colocalizes with the KRAS protein in the cytoplasm of human HuH-7 hepatoma cells. More importantly, the overexpression of KRASIM decreases the KRAS protein level, leading to the inhibition of ERK signaling activity in HCC cells. These results demonstrate a novel microprotein repressor of the KRAS pathway for the first time and provide new insights into the regulatory mechanisms of oncogenic signaling and HCC therapy.",Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells.,10.1007/s11427-019-9580-5,2020 Apr,,Science China. Life sciences
GSE126382,Modeling ribosome dwell times and relationship with tRNA loading and codon usage in mammals (tRNA Profiling),Mus musculus,24,SRP185476,2019-02-11,"[Overal design]Profiling of total and (aminoacyl)-tRNAs in liver of mice fed Ad libitum or fasted; [Treatment]'None'; [Growth]'None'; [Extraction]'RNAs were extracted from mouse liver using phenol/chloroform and miRNeasy Kit (Qiagen) under cold and acidic conditions (pH4.9). Samples were either treated with NaCl (control) or NaI04 (periodate) for 3-oxidation. Purified tRNAs were deacylated and 3-end biotinylated. DNA probes designed to target annotated mouse tRNAs (GtRNAdb), mixed at an equimolar ratio, were hybridized. Dynabeads MyOne Streptavidin C1 (Thermo Fisher) beads were incubated with the resulting RNA-DNA hybridization reaction and magnetized. Bead purified DNA-RNA hybrids were ligated at the anticodon nick by a combination of SplintR and T4 DNA ligases (NEB). RNase H and A (NEB) were added and digestion was performed. DNA probes were purified.\nDNA ligated-probes was assessed by quantitative PCR and amplified by PCR (13-17 cycles). The PCR was designed following Illuminas recommendation taking advantage of the indexed oligos from the TruSeq small RNA kit.  Amplified libraries were quantified with Picogreen. An equimolar library pool was prepared from the individual libraries based on the concentrations calculated from Picogreen data. Pools were denaturated with NaOH and neutralized with HT1 buffer (Illumina) to reach a final concentration of 20pM. Pools were spiked with 10% PhiX and clustered (loading equivalent to 12 samples per lane) onto a rapid single-end flow cell v2 at a final concentration of 7pM. Sequencing was performed on a HiSeq 2500 (Illumina) in rapid mode for 130 cycles.'; [Cell type]'Source: ''strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Ad Libitum; rna treatment: NaCl; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Ad Libitum; rna treatment: NaCl; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Ad Libitum; rna treatment: NaCl; ', 'strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Fasted; rna treatment: NaCl; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Fasted; rna treatment: NaCl; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Fasted; rna treatment: NaCl; ', 'strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Ad Libitum; rna treatment: NaIO4; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Ad Libitum; rna treatment: NaIO4; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Ad Libitum; rna treatment: NaIO4; ', 'strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Fasted; rna treatment: NaIO4; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Fasted; rna treatment: NaIO4; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Fasted; rna treatment: NaIO4; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126382,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126382/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA521743,32295881," Cedric Gobet,  Benjamin Dieter Weger,  Julien Marquis,  Eva Martin,  Nagammal Neelagandan,  Frederic Gachon,  Felix Naef","Translation depends on messenger RNA (mRNA)-specific initiation, elongation, and termination rates. While translation elongation is well studied in bacteria and yeast, less is known in higher eukaryotes. Here we combined ribosome and transfer RNA (tRNA) profiling to investigate the relations between translation elongation rates, (aminoacyl-) tRNA levels, and codon usage in mammals. We modeled codon-specific ribosome dwell times from ribosome profiling, considering codon pair interactions between ribosome sites. In mouse liver, the model revealed",Robust landscapes of ribosome dwell times and aminoacyl-tRNAs in response to nutrient stress in liver.,10.1073/pnas.1918145117,2020 Apr 28,PMC7196831,Proceedings of the National Academy of Sciences of the United States of America
GSE112305,Post-transcriptional regulation of the epithelial cell response to colitis,Homo sapiens,4,SRP136411,2018-03-25,"[Overal design]Ribosome-footprinting and RNA-seq samples from WT SW480 cells and IMP1-/- knockout cells; [Treatment]'None'; [Growth]'None'; [Extraction]'Ribosome profiling libraries from 3 pooled cell culture plates were prepared using a standard protocol (McGlincy and Ingolia, Methods 2017), with minor modifications.\nSeparate 5 and 3 linkers were ligated to the RNA-fragment instead of 3 linker followed by circularization (Subtelny et al, Nature 2014). 5 linkers contained 4 random nt unique molecular identifier (UMI) similar to a 5 nt UMI in 3 linkers. During size-selection, we restricted the footprint lengths to 18-34 nts. Matched RNA-seq libraries were prepared using RNA that was randomly fragmentation by incubating for 15 min at 95C with in 1 mM EDTA, 6 mM Na2CO3, 44 mM NaHCO3, pH 9.3. RNA-seq fragments were restricted to 18-50 nts. Ribosomal rRNA were removed from pooled RNA-seq and footprinting samples using RiboZero (Epicenter MRZH116). cDNA for the pooled library were PCR amplified for 15 cycles.'; [Cell type]'intestinal epithelial''cell line: SW480; cell type: intestinal epithelial; genotype: wild type; library type: Ribosome-protected fragments; ', 'cell line: SW840; cell type: intestinal epithelial; genotype: wild type; library type: Total RNA; ', 'cell line: SW480; cell type: intestinal epithelial; genotype: IMP1-/-; library type: Ribosome-protected fragments; ', 'cell line: SW480; cell type: intestinal epithelial; genotype: IMP1-/-; library type: Total RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112305,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112305/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445600,31061170," Priya Chatterji,  Patrick A Williams,  Kelly A Whelan,  Fernando C Samper,  Sarah F Andres,  Lauren A Simon,  Louis R Parham,  Rei Mizuno,  Emma T Lundsmith,  David Sm Lee,  Shun Liang,  Hr Sagara Wijeratne,  Stefanie Marti,  Lillian Chau,  Veronique Giroux,  Benjamin J Wilkins,  Gary D Wu,  Premal Shah,  Gian G Tartaglia,  Kathryn E Hamilton","RNA binding proteins, including IMP1/IGF2BP1, are essential regulators of intestinal development and cancer. Imp1 hypomorphic mice exhibit gastrointestinal growth defects, yet the specific role for IMP1 in colon epithelial repair is unclear. Our prior work revealed that intestinal epithelial cell-specific Imp1 deletion (Imp1 (Delta) (IEC) ) was associated with better regeneration in mice after irradiation. Here, we report increased IMP1 expression in patients with Crohn's disease and ulcerative colitis. We demonstrate that Imp1 (Delta) (IEC) mice exhibit enhanced recovery following dextran sodium sulfate (DSS)-mediated colonic injury. Imp1 (Delta) (IEC) mice exhibit Paneth cell granule changes, increased autophagy flux, and upregulation of Atg5. In silico and biochemical analyses revealed direct binding of IMP1 to MAP1LC3B, ATG3, and ATG5 transcripts. Genetic deletion of essential autophagy gene Atg7 in Imp1 (Delta) (IEC) mice revealed increased sensitivity of double-mutant mice to colonic injury compared to control or Atg7 single mutant mice, suggesting a compensatory relationship between Imp1 and the autophagy pathway. The present study defines a novel interplay between IMP1 and autophagy, where IMP1 may be transiently induced during damage to modulate colonic epithelial cell responses to damage.",Posttranscriptional regulation of colonic epithelial repair by RNA binding protein IMP1/IGF2BP1.,10.15252/embr.201847074,2019 Jun,PMC6549032,EMBO reports
GSE119886,The tumor suppressor BRCA1 is a translational regulator,Homo sapiens,6,None,2018-09-12,"[Overal design]The experiment is realised on breast carcinoma MCF-7 cell line and is based on the combination of RNA-binding protein immunoprecipitation and transcriptome analysis with microarray technology, as well as polysome profiling; [Treatment]'For RIP experiment, Cells (MCF-7) were washed with ice-cold PBS and lysed in RIP buffer (25 mM Tris-HCl at pH 7.4, 150 mM KCl, 2 mM EDTA, 0.5 % NP40, 0.5 mM DTT, 200 U/ml RNaseOut, protease inhibitors). Where indicated, a small fraction of the lysate (5 %) was used to prepare total RNA extracts and this was considered the input. The remaining lysates were then split into equal parts: half was incubated with anti-BRCA1 antibody (BRCA1) coupled to Dynabeads (Life Technologies) and half was incubated with non-relevant isotype-matched IgG (NR) used as control and coupled to Dynabeads. Immunoprecipitates were washed seven times with RIPA buffer (50 mM Tris-HCl at pH 7.4, 150 mM KCl, 0.5 % NP40).'; [Growth]'None'; [Extraction]'The RNA associated with each type of beads, and the total RNA (input) were then eluted with elution buffer (50 mM Tris-HCl at pH 7.4, 5 mM EDTA, 10 mM DTT, 1 % SDS, 200 U/ml RNase Out) and digested with proteinase K. RNA was finally extracted using the RNeasy micro kit (Qiagen).'; [Cell type]'Source: ''cell line: MCF-7; tissue: breast carcinoma; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119886,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE119nnn/GSE119886/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA490557,32290274," Elise Berthel,  Anne Vincent,  Lauriane Eberst,  Adrian Gabriel Torres,  Estelle Dacheux,  Catherine Rey,  Virginie Marcel,  Hermes Paraqindes,  Joel Lachuer,  Frederic Catez,  Lluis Ribas de Pouplana,  Isabelle Treilleux,  Jean-Jacques Diaz,  Nicole Dalla Venezia","BRCA1 inactivation is a hallmark of familial breast cancer, often associated with aggressive triple negative breast cancers. BRCA1 is a tumor suppressor with known functions in DNA repair, transcription regulation, cell cycle control, and apoptosis. In the present study, we demonstrate that BRCA1 is also a translational regulator. We previously showed that BRCA1 was implicated in translation regulation. Here, we asked whether translational control could be a novel function of BRCA1 that contributes to its tumor suppressive activity. A combination of RNA-binding protein immunoprecipitation, microarray analysis, and polysome profiling, was used to identify the mRNAs that were specifically deregulated under BRCA1 deficiency. Western blot analysis allowed us to confirm at the protein level the deregulated translation of a subset of mRNAs. A unique and dedicated cohort of patients with documented germ-line BRCA1 pathogenic variant statues was set up, and tissue microarrays with the biopsies of these patients were constructed and analyzed by immunohistochemistry for their content in each candidate protein. Here, we show that BRCA1 translationally regulates a subset of mRNAs with which it associates. These mRNAs code for proteins involved in major programs in cancer. Accordingly, the level of these key proteins is correlated with BRCA1 status in breast cancer cell lines and in patient breast tumors. ADAT2, one of these key proteins, is proposed as a predictive biomarker of efficacy of treatments recently recommended to patients with BRCA1 deficiency. This study proposes that translational control may represent a novel molecular mechanism with potential clinical impact through which BRCA1 is a tumor suppressor.",Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.,10.3390/cells9040941,2020 Apr 10,PMC7226996,Cells
GSE153716,TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation,Homo sapiens,4,None,2020-07-02,"[Overal design]Transcriptome profiling of TMBIM6 wild type and knock out HT1080 cells using Affymetrix GeneChip Human Gene 2.0 ST oligonucleotide Array. Two replicates of cells for each cell type were performed.; [Treatment]'No treatment'; [Growth]'HT1080 cell was maintained in Dulbeccos modified Eagles medium (DMEM high glucose) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Grand Island, NY, USA) and 100 U/ml penicillin-streptomycin at 37C in a humidified 5% CO2 incubator.'; [Extraction]""Trizol extraction of total RNA was performed according to the manufacturer's instructions.""; [Cell type]'fibrosarcoma cell''cell line: HT1080; cell type: fibrosarcoma cell; genotype: wild type; ', 'cell line: HT1080; cell type: fibrosarcoma cell; genotype: TMBIM6 KO; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153716,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE153nnn/GSE153716/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA643795,32782388," Hyun-Kyoung Kim,  Kashi Raj Bhattarai,  Raghu Patil Junjappa,  Jin Hee Ahn,  Suvarna H Pagire,  Hyun Ju Yoo,  Jaeseok Han,  Duckgue Lee,  Kyung-Woon Kim,  Hyung-Ryong Kim,  Han-Jung Chae","Transmembrane B cell lymphoma 2-associated X protein inhibitor motif-containing (TMBIM) 6, a Ca(2+) channel-like protein, is highly up-regulated in several cancer types. Here, we show that TMBIM6 is closely associated with survival in patients with cervical, breast, lung, and prostate cancer. TMBIM6 deletion or knockdown suppresses primary tumor growth. Further, mTORC2 activation is up-regulated by TMBIM6 and stimulates glycolysis, protein synthesis, and the expression of lipid synthesis genes and glycosylated proteins. Moreover, ER-leaky Ca(2+) from TMBIM6, a unique characteristic, is shown to affect mTORC2 assembly and its association with ribosomes. In addition, we identify that the BIA compound, a potentialTMBIM6 antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca(2+), further suppressing tumor formation and progression in cancer xenograft models. This previously unknown signaling cascade in which mTORC2 activity is enhanced via the interaction with TMBIM6 provides potential therapeutic targets for various malignancies.",TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation.,10.1038/s41467-020-17802-4,2020 Aug 11,PMC7419509,Nature communications
GSE162197,OXPHOS deficiency activates global adaptation pathways to maintain mitochondrial membrane potential,Saccharomyces cerevisiae W303,86,SRP294317,2020-11-26,"[Overal design]1. Differential expression analysis between OXPHOS mutants and WT cells. 2. Examination of gene expression upon PUF3 deletion in WT, atp7D and r0 cells. 3. Examination of gene expression upon blocking Puf3 hyperphosphorylation in WT and r0 cells. 4. Examination of gene expression upon SNF1 deletion in WT and r0 cells. 5. Examination of gene expression upon INH1 overexpression in r0 cells. 6. Examination of gene expression upon MIG1 deletion in snf1 r0 cells. 7. Analysis of ribosome footprints in WT, puf3D, r0, puf3D r0 cells. Three biological replicates were prepared for mRNA profiles, and two biological replicates were prepared for ribosome profiling.; [Treatment]'None'; [Growth]'Yeast cells were grown in SCD (0.67% yeast nitrogen base without amino acids, 0.079% complete supplement mixture, and 2% glucose) to mid-log phase (OD 0.5-0.8).'; [Extraction]'Total RNA was isolated using hot phenol method (Lyne et al., 2003), then polyA RNA was purified from total RNA by Oligo d(T)25 Magnetic beads (NEB). Ribosome protected mRNA was isolated as described previously (Ingolia et al., 2012; Ingolia et al., 2009). Briefly, cells were treated with 100 ?g/ml cycloheximide for 2 min, and flash-frozen in polysome lysis buffer. Cell lysates were treated with 7.5 ?l RNase I (Ambion) at room temperature for 1 hour, and separated by sucrose density gradient centrifugation. Monosome fractions were collected, and RNA was extracted by Trizol reagent.\nLibraries for mRNA abundance examination was prepared by using NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB). Libraries for ribosome footprints examination was prepared by linker ligation, reverse transcription, circularization as described previously (Ingolia et al., 2012).'; [Cell type]'Source: ''strain: W303-1A; genotype: WT; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: cor1; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: cox9; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: atp7; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: rho0; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: puf3; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: puf3 rho0; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: atp7 puf3; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: puf3-15A; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: puf3-15A rho0; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: snf1; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: WT; growth phase: mid-log phase; treatment: 25 g/ml Ethidium Bromide, 48 hour; ', 'strain: W303-1A; genotype: snf1; growth phase: mid-log phase; treatment: 25 g/ml Ethidium Bromide, 48 hour; ', 'strain: W303-1A; genotype: snf1 mig1; growth phase: mid-log phase; treatment: 25 g/ml Ethidium Bromide, 48 hour; ', 'strain: W303-1A; genotype: rho0 CUP1p-INH1; growth phase: mid-log phase; treatment: None; ', 'strain: W303-1A; genotype: rho0 CUP1p-INH1; growth phase: mid-log phase; treatment: 10mM CuSO4 12 hour; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162197,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE162nnn/GSE162197/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA680923,33655635," Siqi Liu,  Shanshan Liu,  Baiyu He,  Lanlan Li,  Lin Li,  Jiawen Wang,  Tao Cai,  She Chen,  Hui Jiang","Reduction of mitochondrial membrane potential (Deltapsim ) is a hallmark of mitochondrial dysfunction. It activates adaptive responses in organisms from yeast to human to rewire metabolism, remove depolarized mitochondria, and degrade unimported precursor proteins. It remains unclear how cells maintain Deltapsim , which is critical for maintaining iron-sulfur cluster (ISC) synthesis, an indispensable function of mitochondria. Here, we show that yeast oxidative phosphorylation mutants deficient in complex III, IV, V, and mtDNA, respectively, exhibit activated stress responses and progressive reduction of Deltapsim . Extensive omics analyses of these mutants show that these mutants progressively activate adaptive responses, including transcriptional downregulation of ATP synthase inhibitor Inh1 and OXPHOS subunits, Puf3-mediated upregulation of import receptor Mia40 and global mitochondrial biogenesis, Snf1/AMPK-mediated upregulation of glycolysis and repression of ribosome biogenesis, and transcriptional upregulation of cytoplasmic chaperones. These adaptations disinhibit mitochondrial ATP hydrolysis, remodel mitochondrial proteome, and optimize ATP supply to mitochondria to convergently maintain Deltapsim , ISC biosynthesis, and cell proliferation.",OXPHOS deficiency activates global adaptation pathways to maintain mitochondrial membrane potential.,10.15252/embr.202051606,2021 Apr 7,2022/04/07 00:00,EMBO reports
GSE130742,Effect of ILF3 on translation during homeostasis and the antiviral response,Homo sapiens,12,SRP195527,2019-05-06,"[Overal design]To study the effect of ILF3 on translation, HeLa cells were first depleted of ILF3 by transfection with either a pool of siRNAs that target all splice isoforms of ILF3 (siILF3) or a pool of non-targeting control (Mock) siRNAs for 72h. Following the depletion, the antiviral response was activated by transfection with poly(I:C) for 4 hours. 30min prior to harvest, the cells were treated with 50ng/mL Cycloheximide to inhibit protein synthesis. Cytoplasmic lysates of identical numbers of cells were then subject to separation by velocity sedimentation through 10-60% sucrose gradients. This separated the subpolysomal fractions (which include free mRNA complexed to RNPs and the 40S, 60S and 80S ribosomal subunits) with the polysomal fractions (>2 polysomes) which were collected in a fraction collector. RNA was extracted from the subpolysomal and polysomal pools by precipitation with ethanol followed by Trizol LS RNA purification. The purified RNA was then enriched for poly(A) tailed mRNAs and subject to Illumina based RNA sequencing.; [Treatment]'HeLa cells were transfected with siRNAs targetting ILF3 (siILF3) or with non-targetting siRNAs(Mock) for 72h. The cells were then transfected with or without poly(I:C) for 4 hours'; [Growth]'HeLa cells were grown in DMEM supplemented with 10% FBS'; [Extraction]'Cytoplasmic lysates of HeLa cells treated with siRNAs and transfected with or without poly(I:C) were fractionated on a sucrose gradient into 10 fractions. Fractions 1-5 were pooled and fractions 6-to 10 were pooled to form subpolysomal and polysomal pools. RNA was extracted by first precipitating the RNA overnight in ethanol and finally exctacted using Trizol LS.\nThe libraries were enriched for polyA tailed RNA libraries were prepared using the Illumina Truseq protocol (Illumina)'; [Cell type]'cervix adenocarcinoma cells''cell line: HeLa; cell type: cervix adenocarcinoma cells; treatment: Mock transfected, poly(IC) -; polysome pools: Polysomal; molecule subtype: Polysome profile associated  RNA; ', 'cell line: HeLa; cell type: cervix adenocarcinoma cells; treatment: Mock transfected, poly(IC) +; polysome pools: Polysomal; molecule subtype: Polysome profile associated  RNA; ', 'cell line: HeLa; cell type: cervix adenocarcinoma cells; treatment: siILF3 transfected, poly(IC) -; polysome pools: Polysomal; molecule subtype: Polysome profile associated  RNA; ', 'cell line: HeLa; cell type: cervix adenocarcinoma cells; treatment: siILF3 transfected, poly(IC) +; polysome pools: Polysomal; molecule subtype: Polysome profile associated  RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130742,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE130nnn/GSE130742/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA541267,31701124," Samir F Watson,  Nicolas Bellora,  Sara Macias","Upon detection of viral infections, cells activate the expression of type I interferons (IFNs) and pro-inflammatory cytokines to control viral dissemination. As part of their antiviral response, cells also trigger the translational shutoff response which prevents translation of viral mRNAs and cellular mRNAs in a non-selective manner. Intriguingly, mRNAs encoding for antiviral factors bypass this translational shutoff, suggesting the presence of additional regulatory mechanisms enabling expression of the self-defence genes. Here, we identified the dsRNA binding protein ILF3 as an essential host factor required for efficient translation of the central antiviral cytokine, IFNB1, and a subset of interferon-stimulated genes. By combining polysome profiling and next-generation sequencing, ILF3 was also found to be necessary to establish the dsRNA-induced transcriptional and translational programs. We propose a central role for the host factor ILF3 in enhancing expression of the antiviral defence mRNAs in cellular conditions where cap-dependent translation is compromised.",ILF3 contributes to the establishment of the antiviral type I interferon program.,10.1093/nar/gkz1060,2020 Jan 10,PMC7145544,Nucleic acids research
GSE102040,Base-resolution mapping reveals distinct classes of N1-methyladenosine methylome in nuclear- and mitochondrial-encoded transcripts,Homo sapiens,24,SRP114321,2017-07-30,"[Overal design]We developed a method named ""m1A-MAP"" to detect m1A in both the nuclear-encoded and mitochondrial encoded transcriptome in a single-base resolution. We first tested several available RTases (including AMV, SuperScript II, SuperScript III and TGIRT) under different conditions for their performance on capturing m1A-induced reverse transcription signature (RT1-RT10). Then we applied our methods to detect m1A sites in the human transcriptome (m1A_input_TGIRT,m1A_IP_TGIRT, m1A_IP_demethylase_TGIRT, two replicates for each sample) . We also perform m1A seq for RNA fractions below 200nt in TRMT6/61 KD cells to evaluate the substrat specifity of m1A sites in tRNA (Mock and TRMT6_61A). Lastly, we investigated the correlation between m1A-mRNAs and their translation efficiency by performing ribosome profiling (HEK293T_RNA-seq and HEK293_Ribo-seq). Please note that these data were produced from the X-ten sequencing platform, and the output raw data were pair-end. However, due to the particularity of our library construction (a random barcode of 10 nt were included in our 3' end cDNA adapter, which cannot be precisely located in Read 1), data of Read 1 were discarded and only the data of Read 2 were used in our analysis and, therefore, submitted as single-end files.; [Treatment]'None'; [Growth]'cells was maintained in DMEM with 10% FBS and penicillin/streptomycin.'; [Extraction]'Total RNA was isolated from cell lines by Trizol(invitrogen).mRNA was enriched from total RNA with size selection using Megaclear kit (invitrogen) followed by two rounds of polyA selection using Dynabeads Oligo(dT)25 (invitrogen); RNA fraction under 200nt was collected from the flow through of Megaclear kit.\nRNA samples were dephosphorylated with PNK (NEB) and ligated to 3 RNA linker using T4 RNA ligase2, truncated KQ (NEB). Reverse transcription was carried using different reverse transcriptase for different samples.  5 adaptor was ligated to cDNA and then amplified by PCR. PCR products were purified by 8% TBE gel'; [Cell type]'human embryonic kindey cells', 'human embryonic kidney cells''cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: AMV; pH 7.0; 10mM MgCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: AMV; pH 8.3; 10mM MgCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 7.0; 6mM MgCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 8.3; 6mM MgCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 7.0; 3mM MgCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 8.3; 3mM MgCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 7.0; 6mM MnCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 8.0; 6mM MnCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS II; pH 7.0; 6mM MnCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS II; pH 8.0; 6mM MnCl2; molecule subtype: Total RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: TGIRT; pH 8.3; 3mM MgCl2; molecule subtype: poly-A RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: Immunoprecipation with anti-m1A antibody  (MBL; D345-3 lot 002); further treatment: None; reverse transcription condition: TGIRT; pH 8.3; 3mM MgCl2; molecule subtype: poly-A RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: Immunoprecipation with anti-m1A antibody  (MBL; D345-3 lot 002) followed by demethylase treatment; further treatment: Demethylation using purified AlkB; reverse transcription condition: TGIRT; pH 8.3; 3mM MgCl2; molecule subtype: poly-A RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 8.3; 3mM MgCl2; molecule subtype: rRNA depleted fraction; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: SS III; pH 8.3; 3mM MgCl2; molecule subtype: Ribosome protected RNA; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; enrichment: None; further treatment: None; reverse transcription condition: TGIRT; pH 8.3; 3mM MgCl2; molecule subtype: RNA fraction under 200 nt; ', 'cell line: HEK293T; cell type: human embryonic kindey cells; genotype/variation: TRMT6/61A KD; enrichment: None; further treatment: None; reverse transcription condition: TGIRT; pH 8.3; 3mM MgCl2; molecule subtype: RNA fraction under 200 nt; ', 'cell line: HEK293T; cell type: human embryonic kidney cells; enrichment: No antibody enriched; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102040,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102040/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA396456,29107537," Xiaoyu Li,  Xushen Xiong,  Meiling Zhang,  Kun Wang,  Ying Chen,  Jun Zhou,  Yuanhui Mao,  Jia Lv,  Danyang Yi,  Xiao-Wei Chen,  Chu Wang,  Shu-Bing Qian,  Chengqi Yi","Gene expression can be post-transcriptionally regulated via dynamic and reversible RNA modifications. N(1)-methyladenosine (m(1)A) is a recently identified mRNA modification; however, little is known about its precise location and biogenesis. Here, we develop a base-resolution m(1)A profiling method, based on m(1)A-induced misincorporation during reverse transcription, and report distinct classes of m(1)A methylome in the human transcriptome. m(1)A in 5' UTR, particularly those at the mRNA cap, associate with increased translation efficiency. A different, small subset of m(1)A exhibit a GUUCRA tRNA-like motif, are evenly distributed in the transcriptome, and are dependent on the methyltransferase TRMT6/61A. Additionally, we show that m(1)A is prevalent in the mitochondrial-encoded transcripts. Manipulation of m(1)A level via TRMT61B, a mitochondria-localizing m(1)A methyltransferase, demonstrates that m(1)A in mitochondrial mRNA interferes with translation. Collectively, our approaches reveal distinct classes of m(1)A methylome and provide a resource for functional studies of m(1)A-mediated epitranscriptomic regulation.",,10.1016/j.molcel.2017.10.019,2017 Dec 7TI - Base-Resolution Mapping Reveals Distinct m(1)A Methylome in Nuclear- and Mitochondrial-Encoded Transcripts.,PMC5722686,Molecular cell
GSE87892,Ribosome profiling of dhh1? yeast,Saccharomyces cerevisiae,6,SRP091454,2016-10-12,"[Overal design]Cells were grown in rich medium and sequencing was performed on ribosome-protected footprints and matched samples of randomly fragmented polyA-enriched RNA. Dataset contains three biological replicates.; [Treatment]'YPD medium; cycloheximide (1 min)'; [Growth]'Cells were grown from OD600 of 0.02 to OD600=0.4, collected by rapid vacuum filtration, and immediately frozen in liquid nitrogen.'; [Extraction]""Frozen cells were pulverized under cryogenic conditions in 20 mM Tris-HCl (pH=7.5), 100 mM NaCl, 10 mM MgCl2, 1% Triton X100, 0.5 mM DTT, 100 g/ml CHX. Extracts were treated with RNAse I and resolved on sucrose gradients. RNA from monosome fractions was extracted by hot phenol and ribosome footprints of 28-32 nt were purified by size selection and gel extraction.\nFootprints were dephosphorylated and ligated to a preadenylated 3' linker. Following reverse transcription, cDNA was cirularized and amplified by PCR."", ""Frozen cells were pulverized under cryogenic conditions in 20 mM Tris-HCl (pH=7.5), 100 mM NaCl, 10 mM MgCl2, 1% Triton X100, 0.5 mM DTT, 100 g/ml CHX. Extracts were treated with RNAse I and resolved on sucrose gradients. RNA from monosome fractions was extracted by hot phenol and ribosome footprints of 28-32 nt were purified by size selection and gel extraction. Footprints were dephosphorylated and ligated to a preadenylated 3' linker. Following reverse transcription, cDNA was cirularized and amplified by PCR.\nFootprints were dephosphorylated and ligated to a preadenylated 3' linker. Following reverse transcription, cDNA was cirularized and amplified by PCR."", ""Frozen cells were were resuspended in 50 mM NaOAc (pH=5.5), 10 mM EDTA, 1% SDS to 1% and homogenized in a Precellys 24 bead beater. Clarified ysates were treated with Proteinase Kand total RNA was extracted with acid phenol. Following DNase treatment,d poly(A) RNA was purified by two rounds of selection with Poly(A)Purist MAG Kit. Purified RNA was fragmented by alkaline hydrolysis and fragments of 50-80 nt were used for library preparation.\nFragmented poly(A) RNA was dephosphorylated and ligated to a preadenylated 3' linker. Following reverse transcription, cDNA was cirularized and amplified by PCR.""; [Cell type]'Source: ''strain: wild-type (BY4741); replicate: 1; molecule: ribosome-protected footprint; ', 'strain: wild-type (BY4741); replicate: 2; molecule: ribosome-protected footprint; ', 'strain: wild-type (BY4741); replicate: 3; molecule: ribosome-protected footprint; ', 'strain: wild-type (BY4741); replicate: 1; molecule: total RNA; ', 'strain: wild-type (BY4741); replicate: 2; molecule: total RNA; ', 'strain: wild-type (BY4741); replicate: 3; molecule: total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87892,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE87nnn/GSE87892/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA348115,27821408," Jennifer Jungfleisch,  Danny D Nedialkova,  Ivan Dotu,  Katherine E Sloan,  Neus Martinez-Bosch,  Lukas Bruning,  Emanuele Raineri,  Pilar Navarro,  Markus T Bohnsack,  Sebastian A Leidel,  Juana Diez","The impact of RNA structures in coding sequences (CDS) within mRNAs is poorly understood. Here, we identify a novel and highly conserved mechanism of translational control involving RNA structures within coding sequences and the DEAD-box helicase Dhh1. Using yeast genetics and genome-wide ribosome profiling analyses, we show that this mechanism, initially derived from studies of the Brome Mosaic virus RNA genome, extends to yeast and human mRNAs highly enriched in membrane and secreted proteins. All Dhh1-dependent mRNAs, viral and cellular, share key common features. First, they contain long and highly structured CDSs, including a region located around nucleotide 70 after the translation initiation site; second, they are directly bound by Dhh1 with a specific binding distribution; and third, complementary experimental approaches suggest that they are activated by Dhh1 at the translation initiation step. Our results show that ribosome translocation is not the only unwinding force of CDS and uncover a novel layer of translational control that involves RNA helicases and RNA folding within CDS providing novel opportunities for regulation of membrane and secretome proteins.",A novel translational control mechanism involving RNA structures within coding sequences.,10.1101/gr.209015.116,2017 Jan,PMC5204348,Genome research
GSE123564,Mammalian Hbs1L deficiency causes Pelota depletion and is associated with a unique phenotype,Homo sapiens,22,SRP173240,2018-12-10,"[Overal design]12 physical samples of cell cultures (patient and 2 healthy individuals as controls, 2-6 replicates per individual). Ribo-seq and mRNA-seq libraries prepared from the same samples (matched within sample); [Treatment]'None'; [Growth]'DMEM medium with 15% FBS serum'; [Extraction]'mRNA extracted with trizol and Direct-Zol kit from Zymo; ribosomal footprints isolated by fractionation of ribosomes using ultracentrifuge and then extracting footprints according to the protocol in the manuscript\nmRNA-seq samples were prepared with TruSeq kit, Ribo-seq samples were prepared with custom protocol described in the manuscript'; [Cell type]'Source: ''passage: 6; rna type: polyA enriched mRNA-seq; ', 'passage: 7; rna type: polyA enriched mRNA-seq; ', 'passage: 9; rna type: polyA enriched mRNA-seq; ', 'passage: 5; rna type: polyA enriched mRNA-seq; ', 'passage: 9; rna type: Ribosomal profiling; ', 'passage: 6; rna type: Ribosomal profiling; ', 'passage: 5; rna type: Ribosomal profiling; ', 'passage: 7; rna type: Ribosomal profiling; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123564,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123564/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA509230,30707697," Amy E O'Connell,  Maxim V Gerashchenko,  Marie-Francoise O'Donohue,  Samantha M Rosen,  Eric Huntzinger,  Diane Gleeson,  Antonella Galli,  Edward Ryder,  Siqi Cao,  Quinn Murphy,  Shideh Kazerounian,  Sarah U Morton,  Klaus Schmitz-Abe,  Vadim N Gladyshev,  Pierre-Emmanuel Gleizes,  Bertrand Seraphin,  Pankaj B Agrawal","Hbs1 has been established as a central component of the cell's translational quality control pathways in both yeast and prokaryotic models; however, the functional characteristics of its human ortholog (Hbs1L) have not been well-defined. We recently reported a novel human phenotype resulting from a mutation in the critical coding region of the HBS1L gene characterized by facial dysmorphism, severe growth restriction, axial hypotonia, global developmental delay and retinal pigmentary deposits. Here we further characterize downstream effects of the human HBS1L mutation. HBS1L has three transcripts in humans, and RT-PCR demonstrated reduced mRNA levels corresponding with transcripts V1 and V2 whereas V3 expression was unchanged. Western blot analyses revealed Hbs1L protein was absent in the patient cells. Additionally, polysome profiling revealed an abnormal aggregation of 80S monosomes in patient cells under baseline conditions. RNA and ribosomal sequencing demonstrated an increased translation efficiency of ribosomal RNA in Hbs1L-deficient fibroblasts, suggesting that there may be a compensatory increase in ribosome translation to accommodate the increased 80S monosome levels. This enhanced translation was accompanied by upregulation of mTOR and 4-EBP protein expression, suggesting an mTOR-dependent phenomenon. Furthermore, lack of Hbs1L caused depletion of Pelota protein in both patient cells and mouse tissues, while PELO mRNA levels were unaffected. Inhibition of proteasomal function partially restored Pelota expression in human Hbs1L-deficient cells. We also describe a mouse model harboring a knockdown mutation in the murine Hbs1l gene that shared several of the phenotypic elements observed in the Hbs1L-deficient human including facial dysmorphism, growth restriction and retinal deposits. The Hbs1lKO mice similarly demonstrate diminished Pelota levels that were rescued by proteasome inhibition.",Mammalian Hbs1L deficiency causes congenital anomalies and developmental delay associated with Pelota depletion and 80S monosome accumulation.,10.1371/journal.pgen.1007917,2019 Feb,PMC6373978,PLoS genetics
GSE99909,Polysome-profiling in small tissue samples - proof of concept experiment for the use of an optimized non linear gradient,Homo sapiens,24,SRP108979,2017-06-12,"[Overal design]We used two cell lines that differ in their p53 status (HCT-116 p53+/+ and HCT-116 p53-/-) and serum-starved them (16 h). We prepared cytosolic lysates from 6 plates (15 cm) from each cell type and divided the lysates equally between the optimized non-linear gradient and the linear gradient groups. We then collected fractions corresponding to mRNA associated with >3 ribosomes from the linear gradient, peak 0 and +1 from the optimized non-linear gradient as well as the cytosolic input. We repeated the experiment four times.; [Treatment]'Cells were serum-starved for 16 hours.'; [Growth]'HCT-116 p53+/+ and HCT-116 p53-/- and MCF7 ATCC HTB-22 cell lines were cultured in Dulbeccos Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum 1% penicillin/streptomycin and 1% L-glutamine (Gibco, Life Technologies).'; [Extraction]'RNA was extracted using Tri-reagent and further purified with RNAeasy MinElute Cleanup Kit (Qiagen) according to manufacturers recommendations.\nSmart-seq2 was performed as described in Picelli S et al. Nature protocols, 9, 171-181 (2014) using 10 ng (when possible, otherwise less) of RNA as starting material. Prior to sequencing, all RNAseq libraries were adjusted to a concentration of 10 nM and then pooled.'; [Cell type]'Source: ''cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 1; sample identifier: P4902_1001; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 1; sample identifier: P4902_1002; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 1; sample identifier: P4902_1003; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 1; sample identifier: P4902_1004; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 1; sample identifier: P4902_1005; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 1; sample identifier: P4902_1006; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 2; sample identifier: P4902_1007; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 2; sample identifier: P4902_1008; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 2; sample identifier: P4902_1009; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 2; sample identifier: P4902_1010; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 2; sample identifier: P4902_1011; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 2; sample identifier: P4902_1012; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 3; sample identifier: P4902_1013; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 3; sample identifier: P4902_1014; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 3; sample identifier: P4902_1015; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 3; sample identifier: P4902_1016; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 3; sample identifier: P4902_1017; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 3; sample identifier: P4902_1018; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 4; sample identifier: P4902_1019; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Linear gradient; replicate identifier: 4; sample identifier: P4902_1020; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 4; sample identifier: P4902_1021; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: polysome-associated RNA; gradient preparation method: Optimized non-linear gradient; replicate identifier: 4; sample identifier: P4902_1022; ', 'cell line background: HCT116; p53 status: p53+/+; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 4; sample identifier: P4902_1023; ', 'cell line background: HCT116; p53 status: p53-/-; rna type: cytosolic RNA; gradient preparation method: NA; replicate identifier: 4; sample identifier: P4902_1024; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99909,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE99nnn/GSE99909/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA390060,29069469," Shuo Liang,  Hermano Martins Bellato,  Julie Lorent,  Fernanda C S Lupinacci,  Christian Oertlin,  Vincent van Hoef,  Victor P Andrade,  Martin Roffe,  Laia Masvidal,  Glaucia N M Hajj,  Ola Larsson","Polysome-profiling is commonly used to study translatomes and applies laborious extraction of efficiently translated mRNA (associated with >3 ribosomes) from a large volume across many fractions. This property makes polysome-profiling inconvenient for larger experimental designs or samples with low RNA amounts. To address this, we optimized a non-linear sucrose gradient which reproducibly enriches for efficiently translated mRNA in only one or two fractions, thereby reducing sample handling 5-10-fold. The technique generates polysome-associated RNA with a quality reflecting the starting material and, when coupled with smart-seq2 single-cell RNA sequencing, translatomes in small tissues from biobanks can be obtained. Translatomes acquired using optimized non-linear gradients resemble those obtained with the standard approach employing linear gradients. Polysome-profiling using optimized non-linear gradients in serum starved HCT-116 cells with or without p53 showed that p53 status associates with changes in mRNA abundance and translational efficiency leading to changes in protein levels. Moreover, p53 status also induced translational buffering whereby changes in mRNA levels are buffered at the level of mRNA translation. Thus, here we present a polysome-profiling technique applicable to large study designs, primary cells and frozen tissue samples such as those collected in biobanks.",Polysome-profiling in small tissue samples.,10.1093/nar/gkx940,2018 Jan 9,PMC5758873,Nucleic acids research
GSE93133,The novel lysine specific methyltransferase METTL21B affects mRNA translation through inducible and dynamic methylation of Lys-165 in human eukaryotic elongation factor 1 alpha (eEF1A),Homo sapiens,4,SRP096025,2017-01-04,"[Overal design]Ribosome profiling libraries from haploid human cells from both wt and METTL21B knockouts.; [Treatment]'Cells were treated with cycloheximide for 1min, lyzed by scraping in a buffer containing 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5 mM DTT, 100  g/ml CHX and flash-frozen in liquid nitrogen.'; [Growth]'Cells were routinely cultured in Dulbeccos modified Eagles medium, supplemented with 10% (v/v)  fetal bovine serum (FBS), 1 GlutaMAX and 100 units/ml of penicillin and streptomycin (P/S).'; [Extraction]""Cell lysates were incubated with RNAseI and subjected to sucrose gradient centrifugation. Monosomes were isolated and used for library preparation.\nLibraries were prepared by isolating ribosome prorotected fragments, 3' linker ligation, reverse transcription with an RT primer complementary to the linker, cicularization of the resulting ssDNA and a final PCR to attach illumina index primers and amplify the library.""; [Cell type]'Source: ''genotype: wild type; tissue: Kidney; cell line: Flp-In T-REx-293; ', 'genotype: METTL21B knockout; tissue: Kidney; cell line: Flp-In T-REx-293; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93133,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE93nnn/GSE93133/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA360112,28108655," Jedrzej Malecki,  Vinay Kumar Aileni,  Angela Y Y Ho,  Juliane Schwarz,  Anders Moen,  Vigdis Sorensen,  Benedikt S Nilges,  Magnus E Jakobsson,  Sebastian A Leidel,  Pal O Falnes","Lysine methylation is abundant on histone proteins, representing a dynamic regulator of chromatin state and gene activity, but is also frequent on many non-histone proteins, including eukaryotic elongation factor 1 alpha (eEF1A). However, the functional significance of eEF1A methylation remains obscure and it has remained unclear whether eEF1A methylation is dynamic and subject to active regulation. We here demonstrate, using a wide range of in vitro and in vivo approaches, that the previously uncharacterized human methyltransferase METTL21B",The novel lysine specific methyltransferase METTL21B affects mRNA translation through inducible and dynamic methylation of Lys-165 in human eukaryotic elongation factor 1 alpha (eEF1A).,10.1093/nar/gkx002,2017 May 5,PMC5416902,Nucleic acids research
GSE148962,N6-methyladenosine (m6A) profiling and translatome of human trophoblast,Homo sapiens,14,SRP257540,2020-04-20,"[Overal design]m6A-seq and Ribosome-nascent chain complex-RNA sequencing of the METTL3 knockdown and control HTR8/SVneo cells with treatment of 30 mM glucose for 24 hours; [Treatment]'Cells were treated with 30 mM glucose for 24 hour'; [Growth]'HTR8/SVneo cells were grown in RPMI-1640 media supplemented with 10% fetal bovine serum and 50 units/mL penicillin and 50 g/mL streptomycin'; [Extraction]'For m6A-seq, total RNA was extracted using TRIZOL Reagent (Life technologies), and was fragmented and mixed with anti-m6A antibody (Millipore, cat# ABE572 ) in 1 IP buffer and incubated with head-to-tail mixing at 4 C for 2 h. The mixture was supplemented with 25 m L Protein A/G magnetic beads pre-washed two times with 1 IP buffer and incubated with head-to-tail mixing at 4 C for another 2 h. The beads were then separated and washed with 1x IP buffer three times before eluted with m6A elution buffer for two times. The eluates were combined and puri?ed with RNA Clean and Concentrator\nm6A-seq libraries were constructed using SMARTer Stranded Total RNA-Seq Kit version 2', 'For RNC-seq, RNC isolation was performed in accordance with a previously reported procedure. Briefly, cells were cultured in 10 cm dishes and incubated with 100 mg/ml cycloheximide (APExBIO) for 15 min, washed with pre-chilled PBS and add 2 ml cell lysis buffer (1% Triton X-100 in ribosome buffer (RB buffer) (20 mM HEPES-KOH (pH 7.4), 15 mM MgCl2, 200 mM KCl, 100 mg/ml cycloheximide and 2 mM dithiothreitol). After 30-min ice-bath, cell lysates were scraped and transferred to pre-chilled 2 ml tubes. Cell debris was removed by centrifuging at 16200 g for 10 min at 4 C. Supernatants were transferred on the surface of 12 ml of sucrose buffer (30% sucrose in RB buffer). RNCs were pelleted after ultra-centrifugation at 185,000 g for 5 h at 4 C. The RNC-RNA was isolated by using TRIzol.\nRNC-seq libraries were constructed usinig NEBNext UltraTM RNA Library Prep Kit'; [Cell type]'immortalized first-trimester invasive trophoblast cell line''cell line: HTR8/SVneo cells; cell type: immortalized first-trimester invasive trophoblast cell line; genotype: control; ', 'cell line: HTR8/SVneo cells; cell type: immortalized first-trimester invasive trophoblast cell line; genotype: METTL3 knockdown; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148962,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148962/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA626630,,,,,,,,
GSE65999,The contribution of Alu exons to the human proteome,Homo sapiens,9,SRP055105,2015-02-17,"[Overal design]Comparing the A-I RNA editing levels of HEK293 cells transfected with empty vector (CV) control, Alu exon inclusion (long) isoform of ADARB1, and Alu exon skipping (short) isoform of ADARB1. Each group has 3 replicates.; [Treatment]'Cells were transiently transfected with Lipofectamine 2000 reagent according to the manufacturers protocol.'; [Growth]'HEK293 cell line was grown in DMEM with 10% FBS.'; [Extraction]'48 hours after transfection, cells were collected for RNA extraction using TRIzol reagent (Life technologies) and protein lysates with RIPA buffer. Total RNA samples were treated with DNaseI (Fermentas) and reverse transcribed using the High-Capacity cDNA RT kit (Applied Biosystem).\nRNA-Seq libraries were prepared using TruSeq Stranded mRNA Sample Prep Kit (Illumina).'; [Cell type]'Source: ''cell line: HEK293; transfection: Control (empty vector); ', 'cell line: HEK293; transfection: ADARB1 long isoform; ', 'cell line: HEK293; transfection: ADARB1 short isoform; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65999,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE65nnn/GSE65999/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA275667,26821878," Lan Lin,  Peng Jiang,  Juw Won Park,  Jinkai Wang,  Zhi-Xiang Lu,  Maggie P Y Lam,  Peipei Ping,  Yi Xing","BACKGROUND: Alu elements are major contributors to lineage-specific new exons in primate and human genomes. Recent studies indicate that some Alu exons have high transcript inclusion levels or tissue-specific splicing profiles, and may play important regulatory roles in modulating mRNA degradation or translational efficiency. However, the contribution of Alu exons to the human proteome remains unclear and controversial. The prevailing view is that exons derived from young repetitive elements, such as Alu elements, are restricted to regulatory functions and have not had adequate evolutionary time to be incorporated into stable, functional proteins. RESULTS: We adopt a proteotranscriptomics approach to systematically assess the contribution of Alu exons to the human proteome. Using RNA sequencing, ribosome profiling, and proteomics data from human tissues and cell lines, we provide evidence for the translational activities of Alu exons and the presence of Alu exon derived peptides in human proteins. These Alu exon peptides represent species-specific protein differences between primates and other mammals, and in certain instances between humans and closely related primates. In the case of the RNA editing enzyme ADARB1, which contains an Alu exon peptide in its catalytic domain, RNA sequencing analyses of A-to-I editing demonstrate that both the Alu exon skipping and inclusion isoforms encode active enzymes. The Alu exon derived peptide may fine tune the overall editing activity and, in limited cases, the site selectivity of ADARB1 protein products. CONCLUSIONS: Our data indicate that Alu elements have contributed to the acquisition of novel protein sequences during primate and human evolution.",The contribution of Alu exons to the human proteome.,10.1186/s13059-016-0876-5,2016 Jan 28,PMC4731929,Genome biology
GSE148827,Characterising the Transcriptional and Translational Impact of the Schizophrenia-associated miR-1271-5p in Neuronal Cells,Homo sapiens,28,SRP256886,2020-04-17,"[Overal design]Examination of changes in mRNA expression and translation in neuronally differentiated SH-SY5Y cells after overexpression or knockdown of miR-1271-5p; [Treatment]'Transfections were conducted 24 hours after removal of ATRA-medium. Each culture was transfected with 5L Lipofectamine 2000 (L2K, ThermoFisher) and 100pmol of either miR-1271-5p mimic, mimic control (scrambled siRNA), inhibitor or inhibitor control (mirVana, ThermoFisher). Briefly, L2K and RNA were mixed separately in 500L OptiMEM (ThermoFisher) at room temperature for 5 min, after which both were combined to a final volume of 1mL and incubated for an additional 25 min. Standard culture medium was then replaced with L2K/RNA/OptiMEM and cells were incubated at 37C for 6 hours, following which cells were returned to normal culture medium. At 72 hours post-transfection, cells were harvested as per the ribosome profiling methodology (see below), with both total RNA and ribosome protected RNA collected. In parallel to this experiment, transfection efficiency was quantified by co-transfecting additional cells with 100pmol RNA and 2g pEZ-Lv205CT empty vector control lentiviral expression plasmid, which contains the eGFP gene under the CMV promoter. The proportion of GFP+ cells was analysed via Countess II FL automated fluorescent cell counter 72 hours post-transfection, which revealed transfection efficiencies of: 52.5% (mimic), 75% (nonsense siRNA/mimic control), 72% (inhibitor) and 79% (inhibitor scramble control).'; [Growth]'SH-SY5Y cultures were neuronally differentiated using all-trans retinoic acid (ATRA, Sigma-Aldrich). One day prior to differentiation (day -1), cells were seeded into new 6 well plates at a density of 25,000 cells/cm2 in complete culture medium. The next day (day 0), standard culture medium was replaced with ATRA-supplemented medium (10M final) and cells were wrapped in foil to protect from light exposure. ATRA-medium was subsequently replaced on day 2. On day 5, cells were washed with sterile PBS and returned to normal culture medium. Successful differentiation was confirmed by visual assessment of neurite outgrowth and quantification of neuronal marker genes (Fig 1AC).'; [Extraction]'Cells were exposed to cycloheximide (0.1mg/mL) prior to detergent lysis and scraping as per the Illumina TruSeq Ribo Profile kit manual.\nTotal RNA was extracted from 300L of clarified generated from the ribosome profiling methodology. For each sample, 1g of high quality (RIN ? 8.5) total RNA was subjected to library preparation for mRNA sequencing using the TruSeq Stranded mRNA Kit (Illumina), as per the manufacturers instructions. Briefly, mRNA was denatured (65C, 5 min) and ligated to oligo-dT magnetic beads (room temperature, 5 min), after which unbound RNA and non-specifically bound rRNA was discarded. mRNA was then heat fragmented (94C, 8 min), following which reverse transcription and adapter ligation were performed as per the manufacturers instructions. Enrichment of cDNA fragments was subsequently conducted via 15 cycles of PCR, after which libraries were normalised, pooled and subjected to 151 cycles of sequencing using the NextSeq 500 system.', 'Cells were exposed to cycloheximide (0.1mg/mL) prior to detergent lysis and scraping as per the Illumina TruSeq Ribo Profile kit manual.\nRibosome profiling was conducted using the Illumina TruSeq Ribo Profile Kit (H/M/R) according to the manufacturers instructions, with minor amendments. To inhibit translational activity, transfected cells were treated with culture medium supplemented with 0.1mg/mL cycloheximide (CHX) for 1 min. Cells were subsequently washed with ice-cold CHX-supplemented PBS, then harvested on ice via the addition of 1mL mammalian lysis buffer (containing 200L 5x mammalian polysome buffer, 2L CHX and 10 units (U) DNase I) and extensive scraping. Ribosome foot-printing was performed by adding 90U RNase I to 300L clarified lysate and incubating samples at room temperature for 45 min, after which reactions were stopped with 15L SUPERase inhibitor (Invitrogen). Ribosome-protected RNA fragments (RPFs) were then enriched using MicroSpin S-400 columns (GE Life Sciences), prior to ribosomal RNA depletion, RPF size selection, end repair, adapter ligation, reverse transcription and PAGE purification, conducted according to the manufacturers instructions. RPF cDNA libraries were subsequently produced with 12 PCR cycles, following which adapter dimers were removed via 8% native polyacrylamide gel prior to library normalization and pooling. RPF libraries were then sequenced using the Illumina NextSeq 500 system, with a total of 76 single-end cycles performed.'; [Cell type]'Neuronally differentiated SH-SY5Y''cell type: Neuronally differentiated SH-SY5Y; passages: 11; molecule subtype: poly(A) mRNA; ', 'cell type: Neuronally differentiated SH-SY5Y; passages: 11; molecule subtype: Ribosome protected mRNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148827,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148827/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA625926,32325711," Dylan J Kiltschewskij,  Michael P Geaghan,  Murray J Cairns","MicroRNA (miRNA) coordinate complex gene expression networks in cells that are vital to support highly specialised morphology and cytoarchitecture. Neurons express a rich array of miRNA, including many that are specific or enriched, which have important functions in this context and implications for neurological conditions. While the neurological function of a number of brain-derived miRNAs have been examined thoroughly, the mechanistic basis of many remain obscure. In this case, we investigated the transcriptome-wide impact of schizophrenia-associated miR-1271-5p in response to bidirectional modulation. Alteration of miR-1271-5p induced considerable changes to mRNA abundance and translation, which spanned a diverse range of cellular functions, including directly targeted genes strongly associated with cytoskeletal dynamics and cellular junctions. Mechanistic analyses additionally revealed that upregulation of miR-1271-5p predominantly repressed mRNAs through destabilisation, wherein 3'UTR and coding sequence binding sites exhibited similar efficacy. Knockdown, however, produced no discernible trend in target gene expression and strikingly resulted in increased expression of the highly conserved miR-96-5p, which shares an identical seed region with miR-1271-5p, suggesting the presence of feedback mechanisms that sense disruptions to miRNA levels. These findings indicate that, while bidirectional regulation of miR-1271-5p results in substantial remodeling of the neuronal transcriptome, these effects are not inverse in nature. In addition, we provide further support for the idea that destabilisation of mRNA is the predominant mechanism by which miRNAs regulate complementary mRNAs.",Characterising the Transcriptional and Translational Impact of the Schizophrenia-Associated miR-1271-5p in Neuronal Cells.,10.3390/cells9041014,2020 Apr 18,PMC7226585,Cells
GSE127713,Cellular gene expression during Hepatitis C Virus replication revealed by Ribosome profiling,Homo sapiens,12,SRP187206,2019-03-01,"[Overal design]Transcriptome and translatome changes in Huh-7.5 hepatoma cells replicating HCV for 6 days in comparison to non-infected cells were analyzed, in triplicates, by NGS.; [Treatment]'None'; [Growth]'None'; [Extraction]'Six days post transfection cells were washed with ice-cold PBS with cycloheximide and harvested by adding 500 l polysome lysis buffer (20 mM TrisHCl (pH 7.5), 250 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 0.5 % Triton X-100, 100 ?g/ml, 20 U/ml TURBO DNase) per 15 cm2 dish\nLibraries were prepared using the ribosome profiling method.'; [Cell type]'Source: ''cell line: Huh-7.5; time: 6 days post HCV transfection; molecule: Ribo protected RNA; ', 'cell line: Huh-7.5; time: 6 days post HCV transfection; molecule: Total RNA; ', 'cell line: Huh-7.5; time: 6 days post mock transfection; molecule: Ribo protected RNA; ', 'cell line: Huh-7.5; time: 6 days post mock transfection; molecule: Total RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE127713,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE127nnn/GSE127713/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA525090,30875926," Gesche K Gerresheim,  Jochen Bathke,  Audrey M Michel,  Dmitri E Andreev,  Lyudmila A Shalamova,  Oliver Rossbach,  Pan Hu,  Dieter Glebe,  Markus Fricke,  Manja Marz,  Alexander Goesmann,  Stephen J Kiniry,  Pavel V Baranov,  Ivan N Shatsky,  Michael Niepmann","BACKGROUND: Hepatitis C virus (HCV) infects human liver hepatocytes, often leading to liver cirrhosis and hepatocellular carcinoma (HCC). It is believed that chronic infection alters host gene expression and favors HCC development. In particular, HCV replication in Endoplasmic Reticulum (ER) derived membranes induces chronic ER stress. How HCV replication affects host mRNA translation and transcription at a genome wide level is not yet known. METHODS: We used Riboseq (Ribosome Profiling) to analyze transcriptome and translatome changes in the Huh-7.5 hepatocarcinoma cell line replicating HCV for 6 days. RESULTS: Established viral replication does not cause global changes in host gene expression-only around 30 genes are significantly differentially expressed. Upregulated genes are related to ER stress and HCV replication, and several regulated genes are known to be involved in HCC development. Some mRNAs (PPP1R15A/GADD34, DDIT3/CHOP, and TRIB3) may be subject to upstream open reading frame (uORF) mediated translation control. Transcriptional downregulation mainly affects mitochondrial respiratory chain complex core subunit genes. CONCLUSION: After establishing HCV replication, the lack of global changes in cellular gene expression indicates an adaptation to chronic infection, while the downregulation of mitochondrial respiratory chain genes indicates how a virus may further contribute to cancer cell-like metabolic reprogramming (""Warburg effect"") even in the hepatocellular carcinoma cells used here.",Cellular Gene Expression during Hepatitis C Virus Replication as Revealed by Ribosome Profiling.,10.3390/ijms20061321,2019 Mar 15,PMC6470931,International journal of molecular sciences
GSE126912,The splicing factor U2AF1 contributes to cancer progression through a non-canonical role in translation regulation,Homo sapiens,39,SRP186535,2019-02-21,"[Overal design]PAR-CLIP on Chromatin and Cytoplasmic fractions of Flp-In-293 cells expressing FLAG-HA tagged WT or S34F mutant U2AF1. RIP-Seq was performed from U2AF1 WT,S34F and FS HBECs. To estimate translation efficiency, Ribosomal profiling followed by RNA sequencing of monosome and polysome- associated mRNA was performed from the same cells. Please note that the PAR-CLIP processed data was generated from both replicates (i.e. A and B) and is linked to the corresponding A sample.; [Treatment]'None'; [Growth]""HEK 293 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Catalog No. 11995065), respectively, supplemented with 10% fetal bovine serum (FBS, GE Healthcare, Catalog No. SH30071.03) and 100 units of penicillin and 0,1 mg/ ml of streptomycin (Sigma-Aldrich Co., Catalog No. P4333). Cells were cultivated at 37C and 5% CO2, HBEC lines were cultured in Keratinocyte Serum Free Media supplemented with bovine pituitary extract and EGF as prescribed by the manufacturer (Invitrogen, Carlsbad, CA) at 37 oC and 5% CO2""; [Extraction]'Total RNA was extracted monosome and polysomes using TRIzol Reagent (Invitrogen, Catalog No. 15596026). PAR-CLIP was performed as previously  described (Benhalevy et al., 2016; Hafner et al., 2010)\nRNA-seq  of the monosome and polysomes  was performed using the NEBNext Ultra II RNA Library Prep Kit for Illuminal.PAR-CLIP libraries were constructed as previously  described (Benhalevy et al., 2016; Hafner et al., 2010)'; [Cell type]'Source: ''cell line: HBEC; ', 'cell line: Flp-In-293; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126912,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126912/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA523666,30842218," Murali Palangat,  Dimitrios G Anastasakis,  Dennis Liang Fei,  Katherine E Lindblad,  Robert Bradley,  Christopher S Hourigan,  Markus Hafner,  Daniel R Larson","Somatic mutations in the genes encoding components of the spliceosome occur frequently in human neoplasms, including myeloid dysplasias and leukemias, and less often in solid tumors. One of the affected factors, U2AF1, is involved in splice site selection, and the most common change, S34F, alters a conserved nucleic acid-binding domain, recognition of the 3' splice site, and alternative splicing of many mRNAs. However, the role that this mutation plays in oncogenesis is still unknown. Here, we uncovered a noncanonical function of U2AF1, showing that it directly binds mature mRNA in the cytoplasm and negatively regulates mRNA translation. This splicing-independent role of U2AF1 is altered by the S34F mutation, and polysome profiling indicates that the mutation affects translation of hundreds of mRNA. One functional consequence is increased synthesis of the secreted chemokine interleukin 8, which contributes to metastasis, inflammation, and cancer progression in mice and humans.",The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.,10.1101/gad.319590.118,2019 May 1,PMC6499322,Genes & development
GSE156671,Genome-wide structure changes during neuronal differentiation drive gene regulatory networks,Homo sapiens,95,SRP278460,2020-08-22,"[Overal design]High throughput RNA structure probing experiments in vivo using icSHAPE, as well as RNA sequencing, ribosome profiling and RNA decay experiments in hESCs (Day 0, D0), neuronal precursor cells (Day 7, D7), early neurons (Day 8, D8) and neurons (Day 14, D14).; [Treatment]'To determine the half-life of cellular RNAs, we stopped transcription by treating cells with 5mM Actinomycin D (A1410, Sigma) for 0, 1, 2, 4 and 8 hours.'; [Growth]'HEK293T cells were obtained from neighbouring labs, and cultured in DMEM with 10% FBS and 1% Pen-Strep.  Human ESCs, neural stem cell induction and neuronal differentiation were performed as previously described. Briefly, human embryonic stem cells (H9) were cultured in mTeSRTM1 (#05851, stem cell technologies) medium, in the presence of 1X Supplement (#05852, stem cell technologies). hESC H9 cells were used as Day 0 sample in this manuscript. Yeast cells (S288C) were grown to log phase in YPD media at 30C.'; [Extraction]'RNA was extracted by trizol, and mRNA was purifiied by Poly(A)Purist MAG Kit\nRNA secondary structure libraries were performed by published icSHAPE method. Ribosome profiling was performed by following illumina TruSeq Ribo Profile (mammalian) Library Prep kit (RPHMR12126). RNA sequence library was performed by following NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (NEB #E7760L).\nRNA structure, RNA expression, RNA decay and translation efficiency libraries were performed for the same 4 time point. Then all the different data can be used to do correlation analysis with high confidence.'; [Cell type]'Source: ''tissue: hESCs; batch: batch1; development stage: Day0; library type: icSHAPE; treatment: DMSO; ', 'tissue: hESCs; batch: batch1; development stage: Day0; library type: icSHAPE; treatment: NAIN3; ', 'tissue: neuronal precursor cells; batch: batch1; development stage: Day7; library type: icSHAPE; treatment: DMSO; ', 'tissue: neuronal precursor cells; batch: batch1; development stage: Day7; library type: icSHAPE; treatment: NAIN3; ', 'tissue: early neurons; batch: batch1; development stage: Day8; library type: icSHAPE; treatment: DMSO; ', 'tissue: early neurons; batch: batch1; development stage: Day8; library type: icSHAPE; treatment: NAIN3; ', 'tissue: neurons; batch: batch1; development stage: Day14; library type: icSHAPE; treatment: DMSO; ', 'tissue: neurons; batch: batch1; development stage: Day14; library type: icSHAPE; treatment: NAIN3; ', 'tissue: hESCs; batch: batch2; development stage: Day0; library type: icSHAPE; treatment: DMSO; ', 'tissue: hESCs; batch: batch2; development stage: Day0; library type: icSHAPE; treatment: NAIN3; ', 'tissue: neuronal precursor cells; batch: batch2; development stage: Day7; library type: icSHAPE; treatment: DMSO; ', 'tissue: neuronal precursor cells; batch: batch2; development stage: Day7; library type: icSHAPE; treatment: NAIN3; ', 'tissue: early neurons; batch: batch2; development stage: Day8; library type: icSHAPE; treatment: DMSO; ', 'tissue: early neurons; batch: batch2; development stage: Day8; library type: icSHAPE; treatment: NAIN3; ', 'tissue: neurons; batch: batch2; development stage: Day14; library type: icSHAPE; treatment: DMSO; ', 'tissue: neurons; batch: batch2; development stage: Day14; library type: icSHAPE; treatment: NAIN3; ', 'tissue: hESCs; batch: batch3; development stage: Day0; library type: RNAseq; treatment: --; ', 'tissue: neuronal precursor cells; batch: batch3; development stage: Day7; library type: RNAseq; treatment: --; ', 'tissue: early neurons; batch: batch3; development stage: Day8; library type: RNAseq; treatment: --; ', 'tissue: neurons; batch: batch3; development stage: Day14; library type: RNAseq; treatment: --; ', 'tissue: hESCs; batch: batch4; development stage: Day0; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: hESCs; batch: batch4; development stage: Day0; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: neuronal precursor cells; batch: batch4; development stage: Day7; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: neuronal precursor cells; batch: batch4; development stage: Day7; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: early neurons; batch: batch4; development stage: Day8; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: early neurons; batch: batch4; development stage: Day8; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: neurons; batch: batch4; development stage: Day14; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: neurons; batch: batch4; development stage: Day14; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: hESCs; batch: batch5; development stage: Day0; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: hESCs; batch: batch5; development stage: Day7; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: neuronal precursor cells; batch: batch5; development stage: Day8; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: neuronal precursor cells; batch: batch5; development stage: Day8; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: early neurons; batch: batch5; development stage: Day0; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: early neurons; batch: batch5; development stage: Day7; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: neurons; batch: batch5; development stage: Day14; library type: Ribosomal Profiling; treatment: mRNA; ', 'tissue: neurons; batch: batch5; development stage: Day14; library type: Ribosomal Profiling; treatment: Footprint; ', 'tissue: hESCs; batch: batch6; development stage: Day0; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: hESCs; batch: batch7; development stage: Day0; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: neuronal precursor cells; batch: batch6; development stage: Day7; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: neuronal precursor cells; batch: batch7; development stage: Day7; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: early neurons; batch: batch6; development stage: Day8; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: early neurons; batch: batch7; development stage: Day8; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: neurons; batch: batch6; development stage: Day14; library type: RNAdecay; treatment: Actinmycin D; ', 'tissue: neurons; batch: batch7; development stage: Day14; library type: RNAdecay; treatment: Actinmycin D; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156671,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE156nnn/GSE156671/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA658654,,,,,,,,
GSE31539,Ribosome footprinting in the cytosol and endoplasmic reticulum,Homo sapiens,4,SRP007963,2011-08-19,"[Overal design]HEK293 cells were fractionated between the cytosol and endoplasmic reticulum. Within each fraction, ribosome footprints were generated and sequenced. In parallel, total mRNA was sequenced.; [Treatment]'Detergent fractionation of cytosol and ER'; [Growth]'Clutured in DMEM + 10% FBS at 37C, 5% CO2'; [Extraction]'Ribosome footprints were generated by nuclease treatment of polyribosomes. The mRNA footprints were purified by centrifugation. In parallel, mRNAs were enriched by treatment of total RNA with RiboMinus, then treated with Rnase III. Each library was generated according to standard SOLiD library preparation. Briefly, primers were ligated onto RNAs and then cDNA was generated by reverse transcription. cDNA was purified by gel electrophoresis, amplified, then emusified to beads and sequenced.'; [Cell type]'Source: ''cell line: HEK293; sample fraction: Purified endoplasmic reticulum; ', 'cell line: HEK293; sample fraction: Purified cytoplasm; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31539,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE31nnn/GSE31539/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA145711,22199352," David W Reid,  Christopher V Nicchitta","In eukaryotic cells, the spatial regulation of protein expression is frequently conferred through the coupling of mRNA localization and the local control of translation. mRNA localization to the endoplasmic reticulum (ER) is a prominent example of such regulation and serves a ubiquitous role in segregating the synthesis of secretory and integral membrane proteins to the ER. Recent genomic and biochemical studies have now expanded this view to suggest a more substantial role for the ER cellular protein synthesis. We have utilized cell fractionation and ribosome profiling to obtain a genomic survey of the subcellular organization of mRNA translation and report that ribosomal loading of mRNAs, a proxy for mRNA translation, is biased to the ER. Notably, ER-associated mRNAs encoding both cytosolic and topogenic signal-encoding proteins display similar ribosome loading densities, suggesting that ER-associated ribosomes serve a global role in mRNA translation. We propose that the partitioning of mRNAs and their translation between the cytosol and ER compartments may represent a novel mechanism for the post-transcriptional regulation of gene expression.",Primary role for endoplasmic reticulum-bound ribosomes in cellular translation identified by ribosome profiling.,10.1074/jbc.M111.312280,2012 Feb 17,PMC3285328,The Journal of biological chemistry
GSE22002,"Analysis of HeLa cells after transfection with miR-1 or miR-155, by microarray profiling",Homo sapiens,6,None,2010-05-26,"[Overal design]Examine mRNA expression levels in HeLa cells transfected with miR-1 or miR-155, versus mock-transfected cells, at two different time points post-transfection.; [Treatment]'All samples were treated with cycloheximide (100 ug/ml) for 8 min just before harvesting.'; [Growth]'None'; [Extraction]""Trizol extraction of total RNA was performed according to the manufacturer's instructions.""; [Cell type]'Source: ''transfection: mock; time: 32hr; ', 'transfection: miR-155 duplex; time: 32hr; ', 'transfection: miR-1 duplex; time: 32hr; ', 'transfection: mock; time: 12hr; ', 'transfection: miR-155 duplex; time: 12hr; ', 'transfection: miR-1 duplex; time: 12hr; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22002,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE22nnn/GSE22002/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA129165,20703300," Huili Guo,  Nicholas T Ingolia,  Jonathan S Weissman,  David P Bartel","MicroRNAs (miRNAs) are endogenous approximately 22-nucleotide RNAs that mediate important gene-regulatory events by pairing to the mRNAs of protein-coding genes to direct their repression. Repression of these regulatory targets leads to decreased translational efficiency and/or decreased mRNA levels, but the relative contributions of these two outcomes have been largely unknown, particularly for endogenous targets expressed at low-to-moderate levels. Here, we use ribosome profiling to measure the overall effects on protein production and compare these to simultaneously measured effects on mRNA levels. For both ectopic and endogenous miRNA regulatory interactions, lowered mRNA levels account for most (>/=84%) of the decreased protein production. These results show that changes in mRNA levels closely reflect the impact of miRNAs on gene expression and indicate that destabilization of target mRNAs is the predominant reason for reduced protein output.",Mammalian microRNAs predominantly act to decrease target mRNA levels.,10.1038/nature09267,2010 Aug 12,PMC2990499,Nature
GSE78959,Modeling the Neuropathology of Tuberous Sclerosis with Human Stem Cells Reveals a Role for Inflammation and Angiogenic Growth Factors [Cell Model],Homo sapiens,24,SRP071232,2016-03-07,"[Overal design]Two TSC+/- cell lines and two TSC-/- cell lines were independently generated from wild-type human embryonic stem cells by genome editting with zinc finger nucleases. Two cell lines were handled in the same way but without any known human gene editted and they are used as negative controls. Two independent biological replicates of each of the six cell lines are profiled with ribosome profiling technique.; [Treatment]'None'; [Growth]'NSCs were cultured according to standard methods. All used tissue culture dishes were coated with poly-L-ornithine (Sigma Aldrich) and laminin (Roche) and undifferentiated cultures were maintained in a basic medium composed of a 1:1 mix of DMEM:F12 Glutamax medium and Neurobasal medium (both Gibco, Invitrogen) that was supplemented with 1x B27, 1x N2 and 0.1 mM beta-mercaptoethanol (all Gibco, Invitrogen). For self-renewing conditions the following growth factors were added: 10 ng/mL FGF2, 20 ng/mL BDNF (both Peprotech) and 10 ng/mL EGF (R&D Systems). Ventralization was induced for a period of seven days by replating the cells at a density of 12000 cells/cm2 and changing the supplementing growth factors to 200 ng/mL Shh, 100 ng/mL FGF8 (both Peprotech) and 100 ?M ascorbic acid phosphate (Sigma Aldrich). Neuronal differentiation was initiated by replating the cells at a density of 40000 cells/cm2 in basic medium supplemented with 20 ng/mL BDNF, 10 ng/mL GDNF (both Peprotech), 0.5 mM cAMP (BIOLOG Life Science) and 100 ?M ascorbic acid phosphate (Sigma Aldrich). Medium was changed twice per week until the day of analysis.'; [Extraction]'Cells for each biological replicate of control, heterozygous and homozygous cells were washed with ice cold PBS and lysed on ice in the presence of 100 ?g/mL cycloheximide (Sigma). The cleared lysate was flash frozen and stored at -80 C until further processing. For ribosomal RNA depletion the RiboZero magnetic Gold kit (Illumina) was used. Quality of amplified libraries was accessed by capillary electrophoresis with a high sensitivity DNA chip on a 2100 Bioanalyzer (Agilent Technologies) and quantified by quantitative PCR with a sequencing library quantification kit (KAPA Biosystems) on a Roche Light Cycler 480. Multiplexed libraries with 1 % spiked in PhiX control were sequenced on a HiSeq2500 instrument for 50 cycles using version 4 chemistry reagents (Illumina).\nRibosome profiling and RNA sequencing libraries were prepared using the TruSeq Ribo Profile kit (Illumina, #RPHMR12126) as detailed in the manufacturers protocol.'; [Cell type]'Embryonic stem cell-derived neurons''cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; parental cell line id: hESC.2; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/-; parental cell line id: hESC.2; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; parental cell line id: hESC.2; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; parental cell line id: hESC.3; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/-; parental cell line id: hESC.3; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; parental cell line id: hESC.3; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; parental cell line id: hESC.2; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/-; parental cell line id: hESC.2; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; parental cell line id: hESC.2; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; parental cell line id: hESC.3; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/-; parental cell line id: hESC.3; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; parental cell line id: hESC.3; assayed molecule: Ribosome protected fragments; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78959,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE78nnn/GSE78959/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA314508,27655340," Nils Grabole,  Jitao David Zhang,  Stefan Aigner,  Nadine Ruderisch,  Veronica Costa,  Felix C Weber,  Michel Theron,  Nikolaos Berntenis,  Olivia Spleiss,  Martin Ebeling,  Gene W Yeo,  Ravi Jagasia,  Anna Kiialainen","BACKGROUND: Tuberous sclerosis complex (TSC) is a genetic disease characterized by benign tumor growths in multiple organs and neurological symptoms induced by mTOR hyperfunction. Because the molecular pathology is highly complex and the etiology poorly understood, we employed a defined human neuronal model with a single mTOR activating mutation to dissect the disease-relevant molecular responses driving the neuropathology and suggest new targets for treatment. METHODS: We investigate the disease phenotype of TSC by neural differentiation of a human stem cell model that had been deleted for TSC2 by genome editing. Comprehensive genomic analysis was performed by RNA sequencing and ribosome profiling to obtain a detailed genome-wide description of alterations on both the transcriptional and translational level. The molecular effect of mTOR inhibitors used in the clinic was monitored and comparison to published data from patient biopsies and mouse models highlights key pathogenic processes. RESULTS: TSC2-deficient neural stem cells showed severely reduced neuronal maturation and characteristics of astrogliosis instead. Transcriptome analysis indicated an active inflammatory response and increased metabolic activity, whereas at the level of translation ribosomal transcripts showed a 5'UTR motif-mediated increase in ribosome occupancy. Further, we observed enhanced protein synthesis rates of angiogenic growth factors. Treatment with mTOR inhibitors corrected translational alterations but transcriptional dysfunction persisted. CONCLUSIONS: Our results extend the understanding of the molecular pathophysiology of TSC brain lesions, and suggest phenotype-tailored pharmacological treatment strategies.",Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model.,10.1186/s13073-016-0347-3,2016 Sep 21,PMC5031259,Genome medicine
GSE103404,Distinct cancer-promoting stromal gene expression depending on lung function,Homo sapiens,64,SRP116952,2017-09-01,"[Overal design]Polysome-profiling of non-cancerous lung stroma tissue samples from patients with or without lung cancer across a range of forced expiratory volume in one second (FEV1); [Treatment]'None'; [Growth]'None'; [Extraction]'Frozen lung tissue samples ranging in weight from 25-60 mg were individually ground to a fine powder using a liquid nitrogen cooled ceramic mortar and pestle. For RNA quality control (QC), approximately 20% of each sample was processed with Tri Reagent (Sigma-Aldrich, St. Louis, MO). Once the initial RNA QC was completed, polyribosome preparations were performed.  For this purpose, the remainder of each frozen powdered sample was solubilized in 100 l of lysis buffer (10 mM Tris-HCl at pH 8.0, 150 mM NaCl, 5 mM MgCl2, 1% Nonidet-P40, 1% sodium deoxycholate, 40 mM dithiothreitol, 500 U/mL RNAsin RNAsin [Promega, Madison, WI], 40 mM VRC [vanadyl ribonucleoside complex], and 150 ?g/ml cycloheximide [Sigma-Aldrich, St. Louis, MO]) and mixed by pipetting.  Nuclei and insoluble material were removed by centrifugation (12,000 x g, 10 minutes, at 4C). Extraction buffer (50 ?L; 0.2 M Tris-HCl at pH 7.5, 0.3 M NaCl, 10 mM PMSF) was added to the supernatant and the sample was mixed by pipetting.  The sample was centrifuged (12,000 x g, 5 minutes, at 4C) and 25% of the supernatant was processed with Tri Reagent to generate a total mRNA sample.  The remaining supernatant was layered onto a 5 mL, linear sucrose gradient (10-50%), 10 mM Tris-HCl pH 7.5, 140 mM NaCl, 3 mM MgCl2, 10 mM DTT (Sigma-Aldrich, St. Louis, MO). Gradients were centrifuged (200,000 x g in a Beckman SW55Ti rotor, Beckman Coulter, Chaska, MN) for 80 min at\xa04?C and the gradients were fractionated into ten, 0.5 mL fractions utilizing an ISCO density gradient fractionator with absorbance monitored at 254 nm. Each fraction was collected into a tube containing 50 ?L 1% SDS and 20 ?L 0.5M EDTA.  The polysome-associated mRNA from fractions 7, 8, 9 and 10 were individually processed with 1 mL of Tri Reagent and 200 ?L chloroform and the resultant RNA pellets from these four fractions were combined to create the polysome-associated mRNA sample corresponding to each tissue sample.\nSmart-Seq2'; [Cell type]'Source: ''patient_id: 4685; cancer status: 1; fev1: 100; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 19062; cancer status: 1; fev1: 56; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 260111; cancer status: 0; fev1: 84; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 81498; cancer status: 1; fev1: 43; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 70021; cancer status: 1; fev1: 49; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 4226; cancer status: 1; fev1: 39; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 57164; cancer status: 0; fev1: 20; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 116903; cancer status: 0; fev1: 67; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 7206; cancer status: 0; fev1: 18; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 196768; cancer status: 1; fev1: 51; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 267445; cancer status: 1; fev1: 98; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 140099; cancer status: 0; fev1: 95; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 257649; cancer status: 0; fev1: 77; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 42988; cancer status: 0; fev1: 16; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 35961; cancer status: 1; fev1: 96; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 284144; cancer status: 0; fev1: 58; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 24201; cancer status: 1; fev1: 127; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 177023; cancer status: 0; fev1: 58; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 15511; cancer status: 1; fev1: 83; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 30586; cancer status: 1; fev1: 106; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 158231; cancer status: 0; fev1: 72; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 227628; cancer status: 0; fev1: 99; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 54921; cancer status: 0; fev1: 17; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 41742; cancer status: 1; fev1: 64; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 4427; cancer status: 1; fev1: 49; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 133110; cancer status: 0; fev1: 116; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 261796; cancer status: 0; fev1: 100; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 15473; cancer status: 1; fev1: 32; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 51242; cancer status: 1; fev1: 19; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 70403; cancer status: 1; fev1: 48; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 276427; cancer status: 1; fev1: 80; tissue: non-cancerous lung stroma tissue; ', 'patient_id: 15837; cancer status: 0; fev1: 16; tissue: non-cancerous lung stroma tissue; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103404,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE103nnn/GSE103404/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA401720,30742544," Brian J Sandri,  Laia Masvidal,  Carl Murie,  Margarita Bartish,  Svetlana Avdulov,  LeeAnn Higgins,  Todd Markowski,  Mark Peterson,  Jonas Bergh,  Ping Yang,  Charlotte Rolny,  Andrew H Limper,  Timothy J Griffin,  Peter B Bitterman,  Chris H Wendt,  Ola Larsson","Rationale: Chronic obstructive pulmonary disease is an independent risk factor for lung cancer, but the underlying molecular mechanisms are unknown. We hypothesized that lung stromal cells activate pathological gene expression programs that support oncogenesis.Objectives: To identify molecular mechanisms operating in the lung stroma that support the development of lung cancer.Methods: The study included subjects with and without lung cancer across a spectrum of lung-function values. We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome, translatome, and proteome.Measurements and Main Results: Cancer-associated gene expression changes predominantly manifested as alterations in the efficiency of mRNA translation modulating protein levels in the absence of corresponding changes in mRNA levels. The molecular mechanisms that drove these cancer-associated translation programs differed based on lung function. In subjects with normal to mildly impaired lung function, the mammalian target of rapamycin (mTOR) pathway served as an upstream driver, whereas in subjects with severe airflow obstruction, pathways downstream of pathological extracellular matrix emerged. Consistent with a role during cancer initiation, both the mTOR and extracellular matrix gene expression programs paralleled the activation of previously identified procancer secretomes. Furthermore, an in situ examination of lung tissue showed that stromal fibroblasts expressed cancer-associated proteins from two procancer secretomes: one that included IL-6 (in cases of mild or no airflow obstruction), and one that included BMP1 (in cases of severe airflow obstruction).Conclusions: Two distinct stromal gene expression programs that promote cancer initiation are activated in patients with lung cancer depending on lung function. Our work has implications both for screening strategies and for personalized approaches to cancer treatment.",Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function.,10.1164/rccm.201801-0080OC,2019 Aug 1,PMC6680296,American journal of respiratory and critical care medicine
GSE41605,Decoding human cytomegalovirus using ribosome profiling,Human betaherpesvirus 5,16,SRP016143,2012-10-15,"[Overal design]Ribosome profiling and mRNA-seq from 3 time points (5hr, 24hr, 72hr) along HCMV infection. The supplementary file 'GSE41605_merlin_final_orfs.bed.gz' includes the 751 ORFs of HCMV that were identified in this study.; [Treatment]'None'; [Growth]'None'; [Extraction]'Cells were lysed with 0.5% Triton, and the lysate was cleared by centrifugation, treated with RNase I for 45min and then loaded on a sucrose cushion. RNA was then isolated from cells using the acid:phenol extraction method.\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circularized and PCR amplified.', 'RNA was extracted by lysing cells with Trizol.\nFragmented mRNA was size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circularized and PCR amplified.'; [Cell type]'HCMV-infected human foreskin fibroblasts''strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: cycloheximide; infection duration: 5hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: cycloheximide; infection duration: 24hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: cycloheximide; infection duration: 72hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: Harringtonine; infection duration: 5hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: Harringtonine; infection duration: 72hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: lactimidomycin (LTM); infection duration: 5hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: lactimidomycin (LTM); infection duration: 72hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: none; infection duration: 5hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; drug pre-treatment: none; infection duration: 72hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; infection duration: 5hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; infection duration: 24hr; ', 'strain: Merlin; cell type: HCMV-infected human foreskin fibroblasts; infection duration: 72hr; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41605,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE41nnn/GSE41605/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA177721,23180859," Noam Stern-Ginossar,  Ben Weisburd,  Annette Michalski,  Vu Thuy Khanh Le,  Marco Y Hein,  Sheng-Xiong Huang,  Ming Ma,  Ben Shen,  Shu-Bing Qian,  Hartmut Hengel,  Matthias Mann,  Nicholas T Ingolia,  Jonathan S Weissman","The human cytomegalovirus (HCMV) genome was sequenced 20 years ago. However, like those of other complex viruses, our understanding of its protein coding potential is far from complete. We used ribosome profiling and transcript analysis to experimentally define the HCMV translation products and follow their temporal expression. We identified hundreds of previously unidentified open reading frames and confirmed a fraction by means of mass spectrometry. We found that regulated use of alternative transcript start sites plays a broad role in enabling tight temporal control of HCMV protein expression and allowing multiple distinct polypeptides to be generated from a single genomic locus. Our results reveal an unanticipated complexity to the HCMV coding capacity and illustrate the role of regulated changes in transcript start sites in generating this complexity.",Decoding human cytomegalovirus.,10.1126/science.1227919,2012 Nov 23,PMC3817102,"Science (New York, N.Y.)"
GSE131111,Translational control of cardiac fibrosis (II),Homo sapiens,30,SRP198270,2019-05-13,"[Overal design]Ribosome profiling of left ventricle tissue of 30 end-stage DCM patients; [Treatment]'None'; [Growth]'None'; [Extraction]'Briefly, snap-frozen cell pellets or 50-100 mg of tissue, previously powdered under liquid nitrogen, were lysed in 1ml cold lysis buffer (formulation as in TruSeq Ribosome Profile, Illumina) supplemented with 0.1mg/ml cycloheximide (CHX) to stabilize ribosomal subunits and prevent post-lysis translocation. Homogenized and cleared lysates were then footprinted with Truseq Nuclease (Illumina) according to manufacturers instructions. Ribosomes were purified using Illustra Sephacryl S400 columns (GE Healthcare) and the protected RNA fragments were extracted with standard phenol:chloroform:isoamylalcohol technique.\nFollowing ribosomal RNA removal (Mammalian RiboZero Magnetic Gold, Illumina), sequencing libraries were prepared out of the footprinted RNA. Ribo-seq libraries were pooled to perform multiplex sequencing on Illumina Hiseq machines.'; [Cell type]'Left ventricle tissue''cell type: Left ventricle tissue; sequencing: Ribo-seq; disease state: end-stage DCM; ', 'cell type: Left ventricle tissue; sequencing: Ribo-seq; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131111,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE131nnn/GSE131111/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA542670,31284728," Sonia Chothani,  Sebastian Schafer,  Eleonora Adami,  Sivakumar Viswanathan,  Anissa A Widjaja,  Sarah R Langley,  Jessie Tan,  Mao Wang,  Nicholas M Quaife,  Chee Jian Pua,  Giuseppe D'Agostino,  Shamini Guna Shekeran,  Benjamin L George,  Stella Lim,  Elaine Yiqun Cao,  Sebastiaan van Heesch,  Franziska Witte,  Leanne E Felkin,  Eleni G Christodoulou,  Jinrui Dong,  Susanne Blachut,  Giannino Patone,  Paul J R Barton,  Norbert Hubner,  Stuart A Cook,  Owen J L Rackham","BACKGROUND: Fibrosis is a common pathology in many cardiac disorders and is driven by the activation of resident fibroblasts. The global posttranscriptional mechanisms underlying fibroblast-to-myofibroblast conversion in the heart have not been explored. METHODS: Genome-wide changes of RNA transcription and translation during human cardiac fibroblast activation were monitored with RNA sequencing and ribosome profiling. We then used RNA-binding protein-based analyses to identify translational regulators of fibrogenic genes. The integration with cardiac ribosome occupancy levels of 30 dilated cardiomyopathy patients demonstrates that these posttranscriptional mechanisms are also active in the diseased fibrotic human heart. RESULTS: We generated nucleotide-resolution translatome data during the transforming growth factor beta1-driven cellular transition of human cardiac fibroblasts to myofibroblasts. This identified dynamic changes of RNA transcription and translation at several time points during the fibrotic response, revealing transient and early-responder genes. Remarkably, about one-third of all changes in gene expression in activated fibroblasts are subject to translational regulation, and dynamic variation in ribosome occupancy affects protein abundance independent of RNA levels. Targets of RNA-binding proteins were strongly enriched in posttranscriptionally regulated genes, suggesting genes such as MBNL2 can act as translational activators or repressors. Ribosome occupancy in the hearts of patients with dilated cardiomyopathy suggested the same posttranscriptional regulatory network was underlying cardiac fibrosis. Key network hubs include RNA-binding proteins such as Pumilio RNA binding family member 2 (PUM2) and Quaking (QKI) that work in concert to regulate the translation of target transcripts in human diseased hearts. Furthermore, silencing of both PUM2 and QKI inhibits the transition of fibroblasts toward profibrotic myofibroblasts in response to transforming growth factor beta1. CONCLUSIONS: We reveal widespread translational effects of transforming growth factor beta1 and define novel posttranscriptional regulatory networks that control the fibroblast-to-myofibroblast transition. These networks are active in human heart disease, and silencing of hub genes limits fibroblast activation. Our findings show the central importance of translational control in fibrosis and highlight novel pathogenic mechanisms in heart failure.",Widespread Translational Control of Fibrosis in the Human Heart by RNA-Binding Proteins.,10.1161/CIRCULATIONAHA.119.039596,2019 Sep 10,PMC6749977,Circulation
GSE85214,MicroRNAs underlie genome-wide transcriptome and translatome regulation in asthma as revealed by Frac-seq (RNA-Seq),Homo sapiens,26,SRP081022,2016-08-04,"[Overal design]We performed cytoplasmic and polyribosome bound RNA-seq of bronchial epithelial cells from healthy controls and severe asthmatic patients. Small RNA-seq was also performed; [Treatment]'None'; [Growth]'Epithelial brushings were collected using disposable, sheathed bronchial brushes (Olympus cytology brushes BC-202D-2010, KeyMed [Medical & Industrial Equipment] Ltd OLYMPUS Group Company), with 4 separate sets of brushings from the central airways. Brushings were placed in a sterile universal tube with 5 ml PBS and washed with 10mL of RPMI medium (PAA, GE Healthcare LifeSciences) supplemented with penicillin/streptomycin (Thermo Fisher Scientific). Brushings were spun at 1200 rpm for 10 minutes, medium was discarded and cells were resuspended in complete BEGM (Lonza). BECs were cultured in collagen (Thermo Fisher Scientific)-coated T25 flasks in BEGM complete medium and passaged onto 15cm2 collagen-coated dishes when 80% confluent. Polyribosome preparation and validations were performed in passage 1 cells'; [Extraction]'Polyribosome profiling was done as described previously (Sterne-Weiler et al. 2013; Martinez-Nunez and Sanford 2016) with the addition of 500\uf06dg/mL cycloheximide (Sigma-Aldrich UK) in the lysis buffer\nTrueSeq Stranded mRNA Library Prep Kit'; [Cell type]'Source: ''seq name: H33388/DS158_Total_L1.D708_505; fraction: Total; disease status: SA; ', 'seq name: H33388/DS191_Total_L1.D702_505; fraction: Total; disease status: HC; ', 'seq name: H33388/DS194_Poly_L1.D705_505; fraction: Polysome; disease status: HC; ', 'seq name: H33388/DS194_Total_L1.D704_505; fraction: Total; disease status: HC; ', 'seq name: H33388/DS198_Poly_L1.D707_506; fraction: Polysome; disease status: SA; ', 'seq name: H33388/DS200_Poly_L1.D709_506; fraction: Polysome; disease status: SA; ', 'seq name: H33388/DS200_Total_L1.D708_506; fraction: Total; disease status: SA; ', 'seq name: H33388/DS203_Poly_L1.D707_505; fraction: Polysome; disease status: HC; ', 'seq name: H33388/DS203_Total_L1.D706_505; fraction: Total; disease status: HC; ', 'seq name: H33388/DS205_Total_L1.D710_506; fraction: Total; disease status: SA; ', 'seq name: H33389/DS159_Poly_L1.D711_505; fraction: Polysome; disease status: SA; ', 'seq name: H33389/DS159_Total_L1.D710_505; fraction: Total; disease status: SA; ', 'seq name: H33389/DS187_Poly_L1.D701_506; fraction: Polysome; disease status: SA; ', 'seq name: H33389/DS187_Total_L1.D712_505; fraction: Total; disease status: SA; ', 'seq name: H33389/DS189_Poly_L1.D703_506; fraction: Polysome; disease status: SA; ', 'seq name: H33389/DS189_Total_L1.D702_506; fraction: Total; disease status: SA; ', 'seq name: H33389/DS197_Poly_L1.D705_506; fraction: Polysome; disease status: SA; ', 'seq name: H33389/DS197_Total_L1.D704_506; fraction: Total; disease status: SA; ', 'seq name: H33389/DS198_Total_L1.D706_506; fraction: Total; disease status: SA; ', 'seq name: V10532/DS158_Poly_L3; fraction: Polysome; disease status: SA; ', 'seq name: V10532/DS171_Poly_L4; fraction: Polysome; disease status: HC; ', 'seq name: V10532/DS171_Total_L5; fraction: Total; disease status: HC; ', 'seq name: V10532/DS190_Poly_L1; fraction: Polysome; disease status: HC; ', 'seq name: V10532/DS190_Total_L6; fraction: Total; disease status: HC; ', 'seq name: V10532/DS191_Poly_L7; fraction: Polysome; disease status: HC; ', 'seq name: V10532/DS205_Poly_L2; fraction: Polysome; disease status: SA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85214,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE85nnn/GSE85214/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA337894,,,,,,,,
GSE157063,Ribosome profiling in DDX3X degron cell lines and covering variants,Homo sapiens,20,SRP279211,2020-08-28,"[Overal design]Ribosome profiling upon auxin-induced degradation of DDX3X, and covered with either wild-type or mutant DDX3X or wild-type DDX3Y was performed from HCT116 cells.; [Treatment]'Cells were treated with either DMSO or 500 micromolar Indole-3-acetic-acid for indicated times and either transfected with indicated plasmids or not transfected'; [Growth]""HCT116 cells expressing Oryza sativa TIR1 protein and miniAID-tagged DDX3X were grown in McCoy's 5A medium with 10% FBS.""; [Extraction]'Cells were treated with 100ug/ml cycloheximide, flash frozen, lysed and treated with 2u/ul RNaseI (Ambion). Illustra MicroSpin Columns S-400 HR (GE Healthcare) were used to enrich for ribosome complexes and ribosome protected RNA fragments were extracted using the DIRECTZol RNA prep kit (Zymo)\nLibrary construction for RPFs was performed as described in McGlincy et al. PMID 28579404', 'Cells were resuspended in TRI reagent (Zymo), and total RNA was extracted using the DIRECTZol RNA Prep kit (Zymo)\nTruSeq Stranded Total RNA kit'; [Cell type]'Source: ''cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: DMSO; rna isolation: ribosome profiling; adapter sequence: TAGACAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; rna isolation: ribosome profiling; adapter sequence: TAGACAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; treatment: DDX3X WT transfected; rna isolation: ribosome profiling; adapter sequence: TAGACAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; treatment: DDX3X R326H transfected; rna isolation: ribosome profiling; adapter sequence: TAGACAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; treatment: DDX3Y transfected; rna isolation: ribosome profiling; adapter sequence: TAGACAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: DMSO; rna isolation: Total RNA; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; rna isolation: Total RNA; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; treatment: DDX3X WT transfected; rna isolation: Total RNA; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; treatment: DDX3X R326H transfected; rna isolation: Total RNA; ', 'cell line background: HCT-116; genotype/variation: HCT-116 pCMV-OsTIR1 DDX3X-mAID; treatment: 500 micromolar IAA; treatment: DDX3Y transfected; rna isolation: Total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157063,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE157nnn/GSE157063/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA660002,,,,,,,,
GSE112891,The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteins,Homo sapiens; Saccharomyces cerevisiae,13,None,2018-04-09,"[Overal design]Ribosome profiling of whole cell or streptavidin-purified ribosomes biotinylated by ER-localized biotin ligase in yeast This series includes re-analyzed samples from GSE61012 and GSE85686.; [Treatment]'Yeast cells were treated with 100 g/ml cycloheximide for 2 minutes prior to biotin induction then induced with 10 nM biotin.  HeLa cells were treated with 100 ug/ml CHX for 2 min.'; [Growth]'Yeast cells were grown in SD media containing 0.125 ng/ml D-biotin to OD600 .4-.6. HeLa Cells were cultured in 15 cm plates with Dulbecco modified eagle medium (DMEM) with 10% fetal bovine serum (Gibco) until ~80% confluency.'; [Extraction]'Yeast cells were harvested by filtration, flash frozen, and cryogenically pulverized in a Retsch mixer-mill.  HeLa cells were lysed using 500 l per polysome lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton x-100, 1 mM DTT, 8% glycerol, 100 g/ml CHX, 24 U/ml Turbo DNase) per plate using a rubber cell scraper to facilitate lysis.\nFootprinting was performed with RNase I (yeast) or MNase (HeLa cells), monosomes were purified on 10-50% sucrose gradients (yeast) or a sucrose cushion (HeLa). For proximity-specific samples, biotinylated ribosomes were purified on streptavidin dynabeads.  RNA was extracted with trizol and protected fragments gel purified.  Ends were repaired with T4 PNK and ligated to a pre-adenylated linker with T4 RNA Ligase 2.  Ligated fragments were gel purified, reverse transcribed and gel purified.  The cDNA was circularized then PCR amplified.'; [Cell type]'Source: ''strain/cell line: S288C; genotype: emc5::EMC5-mVenus-BirA::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; ', 'strain/cell line: HeLa; genotype: n/a; lentivirally transduced transgenes: dCas9-BFP-KRAB; ', 'strain/cell line: HeLa; genotype: n/a; lentivirally transduced transgenes: dCas9-BFP-KRAB; sgEmc2 Puro-T2A-BFP; ', 'strain/cell line: HeLa; genotype: n/a; lentivirally transduced transgenes: dCas9-BFP-KRAB; sgGal4 Puro-T2A-BFP; ', 'strain/cell line: S288C; genotype: ssh1::BirA-mVenus-SSH1::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; ', 'strain/cell line: S288C; genotype: his3::pSEC63-BirA-mVenus-UBC6 TA::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 leu2delta0; lentivirally transduced transgenes: n/a; ', 'strain/cell line: S288C; genotype: sec63::SEC63-mVenus-BirA::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112891,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112891/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA449388,29809151," Matthew J Shurtleff,  Daniel N Itzhak,  Jeffrey A Hussmann,  Nicole T Schirle Oakdale,  Elizabeth A Costa,  Martin Jonikas,  Jimena Weibezahn,  Katerina D Popova,  Calvin H Jan,  Pavel Sinitcyn,  Shruthi S Vembar,  Hilda Hernandez,  Jurgen Cox,  Alma L Burlingame,  Jeffrey L Brodsky,  Adam Frost,  Georg Hh Borner,  Jonathan S Weissman","The endoplasmic reticulum (ER) supports biosynthesis of proteins with diverse transmembrane domain (TMD) lengths and hydrophobicity. Features in transmembrane domains such as charged residues in ion channels are often functionally important, but could pose a challenge during cotranslational membrane insertion and folding. Our systematic proteomic approaches in both yeast and human cells revealed that the ER membrane protein complex (EMC) binds to and promotes the biogenesis of a range of multipass transmembrane proteins, with a particular enrichment for transporters. Proximity-specific ribosome profiling demonstrates that the EMC engages clients cotranslationally and immediately following clusters of TMDs enriched for charged residues. The EMC can remain associated after completion of translation, which both protects clients from premature degradation and allows recruitment of substrate-specific and general chaperones. Thus, the EMC broadly enables the biogenesis of multipass transmembrane proteins containing destabilizing features, thereby mitigating the trade-off between function and stability.",The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteins.,10.7554/eLife.37018,2018 May 29,PMC5995541,eLife
GSE143263,Thousands of novel unannotated proteins expand the MHC I immunopeptidome in cancer,Homo sapiens,10,SRP239882,2020-01-07,"[Overal design]Ribo-seq of B721.221 cells expressing four different HLA alleles, A375 cells, HCT116 cells (cycloheximide pre-treated or not), primary healthy melanocytes (3 replicates). In order to get sufficient reads for analysis, B721.221_A0101, B1501, and B4402 libraries were sequenced twice, Hmel_rep1 and rep2 libraries were sequenced 3 times. The other libraries were sequenced once.; [Treatment]'None'; [Growth]'None'; [Extraction]'Culture media was removed, cells were washed with ice-cold PBS containing cycloheximide (0.1mg/ml) and lysed in Lysis Buffer according to the Illumina protocol (RPHMR12126).\nRibosomes containing ribosome-protected mRNA fragments (RPFs) were enriched using MicroSpin S-400 columns (GE Healthcare, catalog # 27-5140-01). Ribo-zero rRNA Removal Kit (Illumina, MRZH11124, discontinued) was used to deplete rRNA from RPFs. The entire RPF sample was loaded on a 15% urea-polyacrylamide gel. Gel fragments in 28-32 nucleotide range were cut from the gel. Samples were eluted from the gel overnight at 4C. Subsequently, end repair, adapter ligation and reverse transcription were carried out according to the manufacturers protocol. For the cDNA gel purification, the reverse transcription reaction was loaded on a 10% urea-polyacrylamide gel. The samples were eluted from the gel overnight at room temperature. Subsequently, RPFs were circularized and 5 ?l of circDNA was used for library amplification. The number of amplification cycles was determined based on the observed sample quality and expected yield, but usually ranged between 8 and 10 cycles. Following amplification, the library was gel-purified using 4% E-Gel EX Agarose Gel (ThermoFisher G401004) and Zymoclean Gel DNA Recovery Kit (Zymo Research D4007), with 4 volumes of ADB buffer to accommodate 4% agarose gel. The resulting libraries were analyzed for quality using Agilent Bioanalyzer 2100 and sequenced for 51 cycles on the Illumina NextSeq platform, using NextSeq 500 high output kit, V2, 75 cycles.'; [Cell type]'B-lymphoblastoid\xa0cell line', 'malignant melanoma cell line', 'colorectal carcinoma cell line', 'Epidermal Melanocytes, neonatal''cell line: B721.221; cell type: B-lymphoblastoid\xa0cell line; treatment: -; hla allele: A0101; ', 'cell line: B721.221; cell type: B-lymphoblastoid\xa0cell line; treatment: -; hla allele: A3303; ', 'cell line: B721.221; cell type: B-lymphoblastoid\xa0cell line; treatment: -; hla allele: B1501; ', 'cell line: B721.221; cell type: B-lymphoblastoid\xa0cell line; treatment: -; hla allele: B4402; ', 'cell line: A375; cell type: malignant melanoma cell line; treatment: -; ', 'cell line: HCT116; cell type: colorectal carcinoma cell line; treatment: cycloheximide 10 minutes, 0.1mg/ml; ', 'cell line: HCT116; cell type: colorectal carcinoma cell line; treatment: -; ', 'cell line: Hmel; cell type: Epidermal Melanocytes, neonatal; treatment: cycloheximide 5 minutes, 0.1mg/ml; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143263,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143263/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA599422,,,,,,,,
GSE140365,Robust partitioning of microRNA targets from downstream regulatory changes [PRO-seq],Homo sapiens,24,SRP229758,2019-11-13,"[Overal design]Gene expression profiling of HEK293 cells with and without specific miRNAs by high-throughput sequencing, in duplicate or triplicate, using Illumina NextSeq500; [Treatment]'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven days.'; [Growth]'Flp-In T-REx 293 (HEK293) cells were cultured in DMEM containing 10% FBS, 1% Pen/Strap and 0.1% Zeocin.'; [Extraction]""The cells were permeabilized to prepare nuclei. The nascent RNA generated using biotin-run-on reaction of nuclei was used for library preparation.\nThe biotin-labelled RNA was extracted using Trizol, hydrolyzed using NaOH and enriched using streptavidin beads. 3' adapters were ligated and 5' ends were modified, followed by 5' adapter ligation. For batch-2, the 3' adapters containing sample identifiers (allowing to pool libraries after 3' adapter ligation) were used, and both 3' and 5' adapters contained unique molecular index (UMI) at the ligation junction. Purified and adapter ligated biotin-labelled RNAs were reverse transcribed and PCR amplified, followed by size selection and sequencing.""; [Cell type]'Source: ''cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 1; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-1; batch: 1; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-122; batch: 1; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-133a; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-155; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-302a; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-372; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-373; batch: 2; molecule subtype: Nascent RNA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140365,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140365/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA589465,32821933," Ravi K Patel,  Jessica D West,  Ya Jiang,  Elizabeth A Fogarty,  Andrew Grimson","The biological impact of microRNAs (miRNAs) is determined by their targets, and robustly identifying direct miRNA targets remains challenging. Existing methods suffer from high false-positive rates and are unable to effectively differentiate direct miRNA targets from downstream regulatory changes. Here, we present an experimental and computational framework to deconvolute post-transcriptional and transcriptional changes using a combination of RNA-seq and PRO-seq. This novel approach allows us to systematically profile the regulatory impact of a miRNA. We refer to this approach as CARP: Combined Analysis of RNA-seq and PRO-seq. We apply CARP to multiple miRNAs and show that it robustly distinguishes direct targets from downstream changes, while greatly reducing false positives. We validate our approach using Argonaute eCLIP-seq and ribosome profiling, demonstrating that CARP defines a comprehensive repertoire of targets. Using this approach, we identify miRNA-specific activity of target sites within the open reading frame. Additionally, we show that CARP facilitates the dissection of complex changes in gene regulatory networks triggered by miRNAs and identification of transcription factors that mediate downstream regulatory changes. Given the robustness of the approach, CARP would be particularly suitable for dissecting miRNA regulatory networks in vivo.",Robust partitioning of microRNA targets from downstream regulatory changes.,10.1093/nar/gkaa687,2020 Sep 25,PMC7515711,Nucleic acids research
GSE18836,Translation Profiling +/- miR-124,Homo sapiens,10,None,2009-10-30,"[Overal design]Experiments are biological replicates of ribosome occupancy and density 12 hours post mock transfection or miR-124 transfection.; [Treatment]'None'; [Growth]'None'; [Extraction]'not provided'; [Cell type]'Source: ''source1: pooled mRNA unassociated with ribosomes; ', 'source2: pooled mRNA associated with at least one ribosome; ', 'source1: pooled mRNA associated with the light fractions of the polysome; ', 'source2: pooled mRNA associated with the heavy fractions of the polysome; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18836,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE18nnn/GSE18836/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA123847,19901979," David G Hendrickson,  Daniel J Hogan,  Heather L McCullough,  Jason W Myers,  Daniel Herschlag,  James E Ferrell,  Patrick O Brown","MicroRNAs (miRNAs) regulate gene expression posttranscriptionally by interfering with a target mRNA's translation, stability, or both. We sought to dissect the respective contributions of translational inhibition and mRNA decay to microRNA regulation. We identified direct targets of a specific miRNA, miR-124, by virtue of their association with Argonaute proteins, core components of miRNA effector complexes, in response to miR-124 transfection in human tissue culture cells. In parallel, we assessed mRNA levels and obtained translation profiles using a novel global approach to analyze polysomes separated on sucrose gradients. Analysis of translation profiles for approximately 8,000 genes in these proliferative human cells revealed that basic features of translation are similar to those previously observed in rapidly growing Saccharomyces cerevisiae. For approximately 600 mRNAs specifically recruited to Argonaute proteins by miR-124, we found reductions in both the mRNA abundance and inferred translation rate spanning a large dynamic range. The changes in mRNA levels of these miR-124 targets were larger than the changes in translation, with average decreases of 35% and 12%, respectively. Further, there was no identifiable subgroup of mRNA targets for which the translational response was dominant. Both ribosome occupancy (the fraction of a given gene's transcripts associated with ribosomes) and ribosome density (the average number of ribosomes bound per unit length of coding sequence) were selectively reduced for hundreds of miR-124 targets by the presence of miR-124. Changes in protein abundance inferred from the observed changes in mRNA abundance and translation profiles closely matched changes directly determined by Western analysis for 11 of 12 proteins, suggesting that our assays captured most of miR-124-mediated regulation. These results suggest that miRNAs inhibit translation initiation or stimulate ribosome drop-off preferentially near the start site and are not consistent with inhibition of polypeptide elongation, or nascent polypeptide degradation contributing significantly to miRNA-mediated regulation in proliferating HEK293T cells. The observation of concordant changes in mRNA abundance and translational rate for hundreds of miR-124 targets is consistent with a functional link between these two regulatory outcomes of miRNA targeting, and the well-documented interrelationship between translation and mRNA decay.",Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA.,10.1371/journal.pbio.1000238,2009 Nov,PMC2766070,PLoS biology
GSE142897,Robust partitioning of microRNA targets from downstream regulatory changes [AGO-eCLIP-seq],Homo sapiens,6,SRP239342,2020-01-02,"[Overal design]AGO-eCLIP analyses of HEK293 cells with and without specific miRNAs by high-throughput sequencing, in duplicate, using Illumina NextSeq500.; [Treatment]'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven (rep 1) or eight (rep 2) days and UV crosslinked.'; [Growth]'Flp-In T-REx 293 (HEK293) cells were cultured in DMEM containing 10% FBS, 1% Pen/Strap and 0.1% Zeocin.'; [Extraction]'UV-crosslinked cells were lysed and AGO2 was immunoprecipitated, and an RNA adaptor (P-TGGAATTCTCGGGTGCCAAGG/3InvdT) was ligated onto the 3' end of co-immunoprecipitated RNA. AGO2-RNA complexes were run on SDS-PAGE and transferred to nitrocellulose membrane for size selection. Following the proteinase K treatment to digest AGO2 protein, the RNA was extracted using acid phenol:chloroform.\nThe extracted RNA was reverse transcribed, and an ssDNA adaptor with a 10-nucleotide unique molecular identifier (P-NNNNNNNNNNGATCGTCGGACTGTAGAACTCTGAAC/3InvdT) was ligated to the 3' end of the cDNA. Illumina-compatible sequences and sample barcodes were added via PCR.'; [Cell type]'Source: ''cell line: Flp-In T-REx 293 Cell; induced mirna: None; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-122; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142897,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE142nnn/GSE142897/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA598733,32821933," Ravi K Patel,  Jessica D West,  Ya Jiang,  Elizabeth A Fogarty,  Andrew Grimson","The biological impact of microRNAs (miRNAs) is determined by their targets, and robustly identifying direct miRNA targets remains challenging. Existing methods suffer from high false-positive rates and are unable to effectively differentiate direct miRNA targets from downstream regulatory changes. Here, we present an experimental and computational framework to deconvolute post-transcriptional and transcriptional changes using a combination of RNA-seq and PRO-seq. This novel approach allows us to systematically profile the regulatory impact of a miRNA. We refer to this approach as CARP: Combined Analysis of RNA-seq and PRO-seq. We apply CARP to multiple miRNAs and show that it robustly distinguishes direct targets from downstream changes, while greatly reducing false positives. We validate our approach using Argonaute eCLIP-seq and ribosome profiling, demonstrating that CARP defines a comprehensive repertoire of targets. Using this approach, we identify miRNA-specific activity of target sites within the open reading frame. Additionally, we show that CARP facilitates the dissection of complex changes in gene regulatory networks triggered by miRNAs and identification of transcription factors that mediate downstream regulatory changes. Given the robustness of the approach, CARP would be particularly suitable for dissecting miRNA regulatory networks in vivo.",Robust partitioning of microRNA targets from downstream regulatory changes.,10.1093/nar/gkaa687,2020 Sep 25,PMC7515711,Nucleic acids research
GSE114794,Nutrient deprivation elicits a transcriptional and translational inflammatory response coupled to decreased protein synthesis,Homo sapiens,57,SRP148767,2018-05-22,"[Overal design]Ribosome occupancy and mRNAs levels in transformed and non-transformed cells cultured for i) 30 minutes under complete (Ctrl) or glutamine-free (NoQ) DMEM medium, and ii) 4 hours under complete (Ctrl), glucose-free (NoG), glutamine-free (NoQ), cysteine/cystine-free (NoCys) or leucine, isoleucine, valine (NoBCAA)-free DMEM medium. The translation efficiency (TE) was calculated as the log2 ratio of RPKM measured by ribosome profiling over RPKM measured by RNA-seq. Differences in ribosome occupancy (RO) and TE between the metabolic stress condition and the reference sample (either TAM or EtOH cells grown in complete DMEM) were used to examine the transcriptional and translational changes, respectively. The ribosome profiling and RNA sequencing experiments were performed in duplicate with the exception of RNA-seq at 30 minutes (single experiments), ribosome profiling in cysteine/cystine-deprived EtOH cells (triplicate experiments), and the Torin1 ribosome profiling and RNA-seq (single experiment). The complete dataset comprises the raw (.fastq) and processed (RPKM) files of all 57 high-throughput sequenced samples.; [Treatment]'None'; [Growth]'MCF10A-ER-Src cells were grown at 37C with 5% CO2 in phenol red-free DMEM-F12 medium containing 5% charcoal-stripped horse serum, penicillin/streptomycin (1X), EGF (200ng/ml), hydrocortisone (0.5 g/ml final), cholera toxin (100 ng/ml) and insulin (10 g/ml) as described previously (Iliopoulos et al. Cell, 2009). MCF10A-ER-Src cells were treated with 1 M 4-hydroxy-tamoxifen (transformed cells) or with ethanol as vehicle-control (non-transformed cells) for 24 hours, and subjected to nutrient deprivation as indicated.'; [Extraction]'For ribosome profiling, cells were washed with ice-cold PBS containing 100g/ml cycloheximide, and flash-frozen with detergent lysis containing Turbo DNase I and 100g/ml cycloheximide. DNase I-treated lysates were subjected to RNase I digestion, and ribosome-protected fragments purified as previously described (Ingolia et al. Nature Protocols 2012). For RNA sequencing, total RNA was extracted with the Qiazol reagent and on-column isolated with the miRNeasy kit (Qiagen), enriched for poly(A) RNA using Oligo d(T)25 magnetic bead purification (NEB, cat. No. S1419S), and chemically fragmented with ZnCl2.\nBoth ribosome-protected RNA fragments and fragmented poly(A) RNA were PAGE purified on a 15% TBE-Urea gel, 3end ligated to a pre-adenylated universal miRNA linker (5'-rAppCTGTAGGCACCATCAATNH2-3', NEB, cat. no. S1315S), converted into cDNA using Superscript III reverse transcriptase, circularized, depleted for ribosomal RNA using biotinylated probes, and PCR amplified using Illumina indexed primers as previously described (Ingolia et al. Nature Protocols 2012).'; [Cell type]'MCF10A-ER-Src''cell type: MCF10A-ER-Src; passages: 04-10; strain: ER-Src expressing; treatment: Ethanol; ', 'cell type: MCF10A-ER-Src; passages: 04-10; strain: ER-Src expressing; treatment: Tamoxifen; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114794,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE114nnn/GSE114794/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA472636,30089253," Paulo A Gameiro,  Kevin Struhl","Nutrient deprivation inhibits mRNA translation through mTOR and eIF2alpha signaling, but it is unclear how the translational program is controlled to reflect the degree of a metabolic stress. In a model of breast cellular transformation, various forms of nutrient deprivation differentially affect the rate of protein synthesis and its recovery over time. Genome-wide translational profiling of glutamine-deprived cells reveals a rapid upregulation of mRNAs containing uORFs and downregulation of ribosomal protein mRNAs, which are followed by selective translation of cytokine and inflammatory mRNAs. Transcription and translation of inflammatory and cytokine genes are stimulated in response to diverse metabolic stresses and depend on eIF2alpha phosphorylation, with the extent of stimulation correlating with the decrease in global protein synthesis. In accord with the inflammatory stimulus, glutamine deprivation stimulates the migration of transformed cells. Thus, pro-inflammatory gene expression is coupled to metabolic stress, and this can affect cancer cell behavior upon nutrient limitation.",Nutrient Deprivation Elicits a Transcriptional and Translational Inflammatory Response Coupled to Decreased Protein Synthesis.,10.1016/j.celrep.2018.07.021,2018 Aug 7,PMC6419098,Cell reports
GSE142898,Robust partitioning of microRNA targets from downstream regulatory changes [miRNA-seq],Homo sapiens,3,SRP239341,2020-01-02,"[Overal design]MicroRNA profiling of HEK293 cells with and without specific miRNAs by high-throughput sequencing using Illumina NextSeq500.; [Treatment]'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven days.'; [Growth]'Flp-In T-REx 293 (HEK293) cells were cultured in DMEM containing 10% FBS, 1% Pen/Strap and 0.1% Zeocin.'; [Extraction]'Total RNA from HEK293 cells was isolated with Trizol, with an extra chloroform extraction to remove residual phenol and addition of glyco-blue as a carrier to promote RNA precipitation.\nLibraries were prepared from 1000ng total RNA using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs) by the RNA Sequencing Core at Cornell University.'; [Cell type]'Source: ''cell line: Flp-In T-REx 293 Cell; induced mirna: None; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-122; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142898,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE142nnn/GSE142898/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA598737,32821933," Ravi K Patel,  Jessica D West,  Ya Jiang,  Elizabeth A Fogarty,  Andrew Grimson","The biological impact of microRNAs (miRNAs) is determined by their targets, and robustly identifying direct miRNA targets remains challenging. Existing methods suffer from high false-positive rates and are unable to effectively differentiate direct miRNA targets from downstream regulatory changes. Here, we present an experimental and computational framework to deconvolute post-transcriptional and transcriptional changes using a combination of RNA-seq and PRO-seq. This novel approach allows us to systematically profile the regulatory impact of a miRNA. We refer to this approach as CARP: Combined Analysis of RNA-seq and PRO-seq. We apply CARP to multiple miRNAs and show that it robustly distinguishes direct targets from downstream changes, while greatly reducing false positives. We validate our approach using Argonaute eCLIP-seq and ribosome profiling, demonstrating that CARP defines a comprehensive repertoire of targets. Using this approach, we identify miRNA-specific activity of target sites within the open reading frame. Additionally, we show that CARP facilitates the dissection of complex changes in gene regulatory networks triggered by miRNAs and identification of transcription factors that mediate downstream regulatory changes. Given the robustness of the approach, CARP would be particularly suitable for dissecting miRNA regulatory networks in vivo.",Robust partitioning of microRNA targets from downstream regulatory changes.,10.1093/nar/gkaa687,2020 Sep 25,PMC7515711,Nucleic acids research
GSE71808,Post-translational buffering leads to convergent protein expression levels between primates,Homo sapiens; Macaca mulatta; Pan troglodytes,14,SRP062129,2015-08-06,"[Overal design]Using ribosome profiling assays, we measured levels of protein translation transcriptome-wide in lymphoblastoid cell lines derived from 4 HapMap Yoruba individuals, 5 chimpanzee individuals, and 5 rhesus macaque individuals. Note that the data uploaded for the 4 Yoruba individuals were generated by further sequencing the libraries generated as part of the Battle et al QTL mapping study (GSE61742). About 30~50% more data were generated for these individuals and the files uploaded here combined the new sequencing data with the old data from GSE61742 for each respective cell line.; [Treatment]'None'; [Growth]'Cells were cultured at 37 degree Celsius and 5% CO2 in RPMI 1640 (supplemented with 2mM L-glutamine and 15% fetal bovine serum)'; [Extraction]'Ribosome footprint profiling experiments were performed using ARTseqTM Ribosome Profiling kit for mammalian cells (RPHMR12126) following vendors instructions. Cell lysates were prepared from flash frozen pellets of 30 to 50 million live cells by repeat pipetting in 1 ml cold lysis buffer. Sephacryl S400 spin column (GE; 27-5140-01) was used for monosome isolation. For rRNA depletion, Ribo-Zero Magnetic Kit (Epicentre; MRZH11124) was used.\nRibosome footprint cDNA libraries were PCR amplified (12 to 15 thermo-cycles) and barcoded using ScriptMiner Index PCR Primers (Epicentre; SMIP2124). Indexed libraries were pooled to sequence on an Illumina HiSeq 2500.'; [Cell type]'Lymphoblastoid Cell', 'Lymphoblastoid Cell Line''gender: Female; cell type: Lymphoblastoid Cell; cell line: Min18358; enrichment type: ribosome protected fragments; ', 'gender: Female; cell type: Lymphoblastoid Cell; cell line: Min18359; enrichment type: ribosome protected fragments; ', 'gender: Female; cell type: Lymphoblastoid Cell; cell line: NS03659; enrichment type: ribosome protected fragments; ', 'gender: Male; cell type: Lymphoblastoid Cell; cell line: NS04973; enrichment type: ribosome protected fragments; ', 'gender: Male; cell type: Lymphoblastoid Cell; cell line: Pt91; enrichment type: ribosome protected fragments; ', 'gender: Female; cell type: Lymphoblastoid Cell; cell line: 150-99; enrichment type: ribosome protected fragments; ', 'gender: Male; cell type: Lymphoblastoid Cell; cell line: R181-96; enrichment type: ribosome protected fragments; ', 'gender: Male; cell type: Lymphoblastoid Cell; cell line: R249-97; enrichment type: ribosome protected fragments; ', 'gender: Male; cell type: Lymphoblastoid Cell; cell line: 265-95; enrichment type: ribosome protected fragments; ', 'gender: Male; cell type: Lymphoblastoid Cell; cell line: R290-96; enrichment type: ribosome protected fragments; ', 'gender: Female; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; cell line: GM19127; ', 'gender: Female; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; cell line: GM19137; ', 'gender: Male; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; cell line: GM19144; ', 'gender: Female; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; cell line: GM19147; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71808,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71808/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292112,29950183," Sidney H Wang,  Chiaowen Joyce Hsiao,  Zia Khan,  Jonathan K Pritchard","BACKGROUND: Differences in gene regulation between human and closely related species influence phenotypes that are distinctly human. While gene regulation is a multi-step process, the majority of research concerning divergence in gene regulation among primates has focused on transcription. RESULTS: To gain a comprehensive view of gene regulation, we surveyed genome-wide ribosome occupancy, which reflects levels of protein translation, in lymphoblastoid cell lines derived from human, chimpanzee, and rhesus macaque. We further integrated messenger RNA and protein level measurements collected from matching cell lines. We find that, in addition to transcriptional regulation, the major factor determining protein level divergence between human and closely related species is post-translational buffering. Inter-species divergence in transcription is generally propagated to the level of protein translation. In contrast, gene expression divergence is often attenuated post-translationally, potentially mediated through post-translational modifications. CONCLUSIONS: Results from our analysis indicate that post-translational buffering is a conserved mechanism that led to relaxation of selective constraint on transcript levels in humans.",Post-translational buffering leads to convergent protein expression levels between primates.,10.1186/s13059-018-1451-z,2018 Jun 27,PMC6020354,Genome biology
GSE14000,Fine-tuning of human dendritic cells regulation revealed by translational profiling,Homo sapiens,24,None,2008-12-16,"[Overal design]To identify translationally regulated mRNA molecules, gene expression derived from the polysome-bound mRNAs was compared by Affymetrix microarrays analysis to the gene expression derived from unfractionated total mRNAs derived from whole-cell lysates, as recently described on several reports (Johannes 1999, Rajasekhar 2003, Bushell 2006, L 2006, Parent 2008). Polysomal RNA (P) and total RNA (T) were isolated from MoDCs generated from four different blood donors. Since three timepoints (0h, 4h and 16h) were chosen for each blood donor and RNA type, twenty-four RNA samples were totally analyzed by microarrays.; [Treatment]'Oh, NO LPS', '4h LPS', '16h LPS', 'NO LPS'; [Growth]'Fresh human leukapheresis products were obtained from the EFS (Marseille, France). Human peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-PaqueTM PLUS (Amersham Biosciences), washed four times with RPMI 1640 medium and CD14+ cells were immunomagnetically purified with AutoMACS system following the protocol of the manufacturer (Miltenyi Biotech). Purified CD14+ monocytes were analyzed using a FACSCalibur (Becton Dickinson), confirming the purity of CD14+ cells to be 95%. To promote differentiation into immature dendritic cells, the purified CD14+ cells (0.5x106cells/ml) were plated in 6-well plates (2x106 cells/well) and cultured in RPMI 1640 medium supplemented with 10% FCS, non essential amino acids, penicillin/streptomycin 100 ng/mL (>1000U/ml), recombinant human GM-CSF and 20 ng/mL (>100U/ml) IL-4 for 5 days (both from PeproTech). At days 2 and 4, half of the volume of the medium was replaced by fresh medium supplemented with GM-CSF and IL-4. For DC maturation, 100 ng/mL LPS (Escherichia coli type 026:B6; Sigma-Aldrich) was added to the cells at day 5, for 4h or 16h, followed by cell harvesting.'; [Extraction]'Polysomal RNA (Poly) was enriched by sucrose gradient fractionation following the protocol originally developed by Garcia-Sanz and collaborators (Mllner, Immunology Methods Manual, 1997). Total RNA (T) was directly extracted out of DCs without fractionation. Total and Polysomal RNA were purified using the RNeasy kit (Qiagen) including a DNase digestion according to the manufacturers instructions. RNA integrity was always assessed with the an Agilent 2100 Bioanalyzer (Agilent).', 'Polysomal RNA (P = other) was enriched by sucrose gradient fractionation following the protocol originally developed by Garcia-Sanz and collaborators (Mllner, Immunology Methods Manual, 1997). Total RNA (T) was directly extracted out of DCs without fractionation. Total and Polysomal RNA were purified using the RNeasy kit (Qiagen) including a DNase digestion according to the manufacturers instructions. RNA integrity was always assessed with the an Agilent 2100 Bioanalyzer (Agilent).'; [Cell type]'Source: '''",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14000,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE14nnn/GSE14000/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA112501,19943945," Maurizio Ceppi,  Giovanna Clavarino,  Evelina Gatti,  Enrico K Schmidt,  Aude de Gassart,  Derek Blankenship,  Gerald Ogola,  Jacques Banchereau,  Damien Chaussabel,  Philippe Pierre","BACKGROUND: Dendritic cells (DCs) are the sentinels of the mammalian immune system, characterized by a complex maturation process driven by pathogen detection. Although multiple studies have described the analysis of activated DCs by transcriptional profiling, recent findings indicate that mRNAs are also regulated at the translational level. A systematic analysis of the mRNAs being translationally regulated at various stages of DC activation was performed using translational profiling, which combines sucrose gradient fractionation of polysomal-bound mRNAs with DNA microarray analysis. RESULTS: Total and polysomal-bound mRNA populations purified from immature, 4 h and 16 h LPS-stimulated human monocyte-derived DCs were analyzed on Affymetrix microarrays U133 2.0. A group of 375 transcripts was identified as translationally regulated during DC-activation. In addition to several biochemical pathways related to immunity, the most statistically relevant biological function identified among the translationally regulated mRNAs was protein biosynthesis itself. We singled-out a cluster of 11 large ribosome proteins mRNAs, which are disengaged from polysomes at late time of maturation, suggesting the existence of a negative feedback loop regulating translation in DCs and linking ribosomal proteins to immuno-modulatory function. CONCLUSION: Our observations highlight the importance of translation regulation during the immune response, and may favor the identification of novel protein networks relevant for immunity. Our study also provides information on the potential absence of correlation between gene expression and protein production for specific mRNA molecules present in DCs.",Ribosomal protein mRNAs are translationally-regulated during human dendritic cells activation by LPS.,10.1186/1745-7580-5-5,2009 Nov 27,PMC2788525,Immunome research
GSE129702,Super-enhancer redistribution as a mechanism of broad gene dysregulation in repeatedly drug-treated cancer cells,Homo sapiens,48,None,2019-04-12,"[Overal design]Refer to individual Series; [Treatment]'The treatment administrated to A2780cis cells was described in the Sigma-Aldrich website as chronic exposure of the parent A27890 line to increasing concentrations of cisplatin Sigma-Aldrich (_93112517-19). Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.', 'The treatment administrated to A2780cis cells was described in the Sigma-Aldrich website as chronic exposure of the parent A27890 line to increasing concentrations of cisplatin Sigma-Aldrich (#93112517-19). Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.', 'Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.'; [Growth]'Cells  were cultured in RPMI-1640-Glutamax I (#61870-036, Life Technologies) and 10% fetal bovine serum (FBS, _FB-11, Omega Scientific) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.', 'Cells  were cultured in RPMI-1640-Glutamax I (#61870-036, Life Technologies) and 10% fetal bovine serum (FBS, #FB-11, Omega Scientific) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.', 'The human lung adenocarcinoma A549 cell line (RRID:CVCL_0023) were cultured in Dulbeccos modified Eagles-Glutamax I medium (DMEM-Glutamax I, Gibco, Cat#10566-016) supplemented with 10% FBS (FBS, Omega Scientific, Cat#FB-11) and antibiotics penicillin and streptomycin (100 ug/mL, Gemini Bio, Cat#400-109) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.'; [Extraction]'Cells were fixed with 1% formaldehyde for 10mins, and followed by glycine for 5 mins. Chromatin DNA was sheared to 200500 bp average in size by sonication and chromatin was immunoprecipitated with antibodies. Protein G magnetic beads  were added and incubated overnight at 4C. After washing and elution, the proteinDNA complex was reverse-crosslinked by heating at 65C, and immunoprecipitated DNA was purified by using QIAquick Spin column.\nChIP-seq libraries were prepared using the KAPA Library Preparation Kit (KK8201)', 'GRO-seq analysis was perfromed as prevkiously reported (PMID: 21572438, Wang et al., 2011); RNA-seq and ribosome profiling was performed using the ARTseq Ribosome Profiling kit  following the manufactures protocol (Epicentre).\nRNA quality was calculated on TapeStation (Agilent Technologies). PolyA+ RNA-seq libraries were generated using the Illumina TruSeq Stranded RNA LT kit and following manufacturers detailed instructions.', 'GRO-seq analysis was perfromed as previously reported (PMID: 21572438, Wang et al., 2011).\nRNA quality was calculated on TapeStation (Agilent Technologies). PolyA+ RNA-seq libraries were generated using the Illumina TruSeq Stranded RNA LT kit and following manufacturers detailed instructions.'; [Cell type]'Source: ', 'Cells sorted based on ISL1 protein levels''cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me3 (Millipore, 07-473); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me3 (Millipore, 07-473); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me2 (Active Motif, 39141); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K4me2 (Active Motif, 39141); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): p53 (Active Motif, _39334); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): ISL1 (DHSB, _39.4D5-s); ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): EGR1 (Santa Cruz Biotechnology, 588, sc-110); ', 'cell line: A2780-CRISPR/dCas9-KRAB-modified; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780cis-CRISPR/dCas9-VP64-modified; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): H3K27ac (Abcam, ab4729); ', 'cell line: A2780; ', 'cell line: A2780cis; ', 'cell line: A2780-CRISPR/dCas9-KRAB-modified; ', 'cell line: A2780cis-CRISPR/dCas9-VP64-modified; ', 'cell line: A2780; cell type: Cells sorted based on ISL1 protein levels; ', 'cell line: A2780; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): Anti-CCTCF antibody Active Motif (Cat#61932; RRID:AB_2614975); ', 'cell line: A2780cis; chip antibody used for chip or oligonucletides used for chirp (chromatin isolation by rna purification): Anti-CCTCF antibody Active Motif (Cat#61932; RRID:AB_2614975); ', 'cell line: A549; treatment: vehicle; ', 'cell line: A549; treatment: cisplatin; '",Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129702,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129702/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532526,32320655," Qi Ma,  Feng Yang,  Carlos Mackintosh,  Ranveer Singh Jayani,  Soohwan Oh,  Chunyu Jin,  Sreejith Janardhanan Nair,  Daria Merkurjev,  Wubin Ma,  Stephanie Allen,  Dong Wang,  Angels Almenar-Queralt,  Ivan Garcia-Bassets","Cisplatin is an antineoplastic drug administered at suboptimal and intermittent doses to avoid life-threatening effects. Although this regimen shortly improves symptoms in the short term, it also leads to more malignant disease in the long term. We describe a multilayered analysis ranging from chromatin to translation-integrating chromatin immunoprecipitation sequencing (ChIP-seq), global run-on sequencing (GRO-seq), RNA sequencing (RNA-seq), and ribosome profiling-to understand how cisplatin confers (pre)malignant features by using a well-established ovarian cancer model of cisplatin exposure. This approach allows us to segregate the human transcriptome into gene modules representing distinct regulatory principles and to characterize that the most cisplatin-disrupted modules are associated with underlying events of super-enhancer plasticity. These events arise when cancer cells initiate without ultimately ending the program of drug-stimulated death. Using a PageRank-based algorithm, we predict super-enhancer regulator ISL1 as a driver of this plasticity and validate this prediction by using CRISPR/dCas9-KRAB inhibition (CRISPRi) and CRISPR/dCas9-VP64 activation (CRISPRa) tools. Together, we propose that cisplatin reprograms cancer cells when inducing them to undergo near-to-death experiences.",Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells.,10.1016/j.celrep.2020.107532,2020 Apr 21,,Cell reports
GSE116387,mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs,Homo sapiens,24,None,2018-06-28,"[Overal design]Polysome profiling using OVCAR-3 cells treated with INK128, carboplatin, or carboplatin + Ink128 compared to control DMSO treated cells; [Treatment]'Cells (3x150 mm plates per condition) were treated with DMSO as control, 1 ?M carboplatin, 0.25 ?M INK128, 1 ?M carboplatin + 0.25 ?M INK128.  Cells were treated with INK128 for 19 h prior to addition of carboplatin for 5 h.  Plates with only carboplatin were treated at the same time point as the combination plates.  Total combination drug treatment was 24 h'; [Growth]'OVCAR-3 cells were derived from a patient with a platinum resistant recurrence of high-grade serous ovarian cancer with acquired resistance to platinum drugs, Cells were cultured at 37oC, 5% CO2 in RPMI 1640 medium with L-glutamine and supplemented with bovine insulin at 0.01 mg/mL, penicillin/streptomycin at 10 mL/L, plasmocin at 50 ?L/500 mL, and 20% fetal bovine serum (FBS).  Cells were routinely tested and found to be mycoplasma free.'; [Extraction]'RNA was isolated from each fraction by extraction using the QIAGEN RNeasy MinElute Cleanup Kit. Fractions 714, representing high density polysomes, were combined and extracted.  For normalization, an aliquot of total RNA was extracted from the same cell lysates used for polysome sedimentation and purified using the QIAGEN protocol.  RNA quantity and quality for all samples were determined by bioanalysis (Agilent Technologies), and samples stored in nuclease-free water at ?80C. 10 ?g of pooled RNA was used for microarray analysis using GeneChip Human Gene 2.0 ST Array (Affymetrix), according to the manufacturer instructions'; [Cell type]'Ovarian cancer cell line''cell line: OVCAR-3; cell type: Ovarian cancer cell line; rna fraction: polysome RNA; ', 'cell line: OVCAR-3; cell type: Ovarian cancer cell line; rna fraction: total RNA; '",Expression profiling by array; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116387,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE116nnn/GSE116387/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA478373,30237852," Gizelka David-West,  Amanda Ernlund,  Abhilash Gadi,  Robert J Schneider","Platinum resistance is a major cause of treatment failure and mortality in epithelial ovarian cancer. mTORC1/2 inhibitors, which impair mRNA translation, can re-sensitize resistant ovarian cancer cells to platinum chemotherapy but the mechanism remains poorly described. Using platinum-resistant OVCAR-3 cells treated with the selective mTORC1/2 inhibitor INK128/MLN128, we conducted genome-wide transcription and translation studies and analyzed the effect on cell proliferation, AKT-mTOR signaling and cell survival, to determine whether carboplatin resistance involves selective mRNA translational reprogramming, and whether it is sensitive to mTORC1/2 inhibition. Gene ontology and Ingenuity Pathway Analysis (IPA) were used to categorize gene expression changes into experimentally authenticated biochemical and molecular networks. We show that carboplatin resistance involves increased mTORC1/2 signaling, resulting in selective translation of mRNAs involved in DNA damage and repair responses (DDR), cell cycle and anti-apoptosis (survival) pathways. Re-sensitization of ovarian cancer cell killing by carboplatin required only modest mTORC1/2 inhibition, with downregulation of protein synthesis by only 20-30%. Genome-wide transcriptomic and translatomic analyses in OVCAR-3 cells revealed that the modest downregulation of global protein synthesis by dual mTORC1/2 inhibition is associated with greater selective inhibition of DDR, cell cycle and survival mRNA translation, which was confirmed in platinum-resistant SKOV-3 cells. These data suggest a clinical path to re-sensitize platinum resistant ovarian cancer to platinum chemotherapy through partial inhibition of mTORC1/2, resulting in selective translation inhibition of DDR and anti-apoptosis protective mRNAs.",mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs.,10.18632/oncotarget.25869,2018 Sep 4,PMC6145695,Oncotarget
GSE100708,SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis [SLAM-seq],Homo sapiens,104,SRP111133,2017-06-30,"[Overal design]Baseline gene expression profiling of clonal cell lines engineered to express AID-tagged proteins and unedited controls by 3'mRNA sequencing.; [Treatment]'None'; [Growth]'None'; [Extraction]""Total RNA was extracted using a commercial column purification kit and treated with iodoacetamide for alkylation of 4-thiouridine.\n3'UTR sequencing libraries were generated from 500ng of alkylated total RNA using a commercial kit (QuantSeq 3' mRNA-Seq Library Prep Kit FWD for Illumina, Lexogen).""; [Cell type]'Source: ''treatment: DMSO, 60 min; cell line: K562; 4su labeling time before harvest (min): 45; ', 'treatment: 300nM flavopiridol, 60 min; cell line: K562; 4su labeling time before harvest (min): 45; ', 'treatment: DMSO (1:1000), 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM mk2206, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: 10nM trametinib, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: 300nM mk2206 + 10 nM trametinib, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: 100nM nilotinib, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:5000), 90 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 100M indole-3-acetic acid, 90 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM JQ1, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:1000), 90 min; cell line: MV4-11; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM JQ1, 90 min; cell line: MV4-11; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:1000), 90 min; cell line: MOLM-13; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM JQ1, 90 min; cell line: MOLM-13; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:1000), 90 min; cell line: MOLM-13; 4su labeling time before harvest (min): 0; ', 'treatment: 6nM NVP-2, 90 min; cell line: MOLM-13; 4su labeling time before harvest (min): 60; ', 'treatment: 60nM NVP-2, 90 min; cell line: MOLM-13; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM JQ1 + 6nM NVP-2, 90 min; cell line: MOLM-13; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:1000), 90 min; cell line: OCI/AML-3; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM JQ1, 90 min; cell line: OCI/AML-3; 4su labeling time before harvest (min): 60; ', 'treatment: 6nM NVP-2, 90 min; cell line: OCI/AML-3; 4su labeling time before harvest (min): 60; ', 'treatment: 60nM NVP-2, 90 min; cell line: OCI/AML-3; 4su labeling time before harvest (min): 60; ', 'treatment: 200nM JQ1 + 6nM NVP-2, 90 min; cell line: OCI/AML-3; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:5000), 90 min; cell line: K562; genetic modification: MYC-AID / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 100M indole-3-acetic acid, 90 min; cell line: K562; genetic modification: MYC-AID / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:5000), 90 min; cell line: HCT116; genetic modification: MYC-AID / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 100M indole-3-acetic acid, 90 min; cell line: HCT116; genetic modification: MYC-AID / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:5000), 90 min; cell line: K562; genetic modification: SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 100M indole-3-acetic acid, 90 min; cell line: K562; genetic modification: SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 1M JQ1, 90 min; cell line: MV4-11; 4su labeling time before harvest (min): 60; ', 'treatment: 5M JQ1, 90 min; cell line: MV4-11; 4su labeling time before harvest (min): 60; ', 'treatment: 1M JQ1, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; ', 'treatment: 5M JQ1, 90 min; cell line: K562; 4su labeling time before harvest (min): 60; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100708,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE100nnn/GSE100708/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA393189,29622725," Matthias Muhar,  Anja Ebert,  Tobias Neumann,  Christian Umkehrer,  Julian Jude,  Corinna Wieshofer,  Philipp Rescheneder,  Jesse J Lipp,  Veronika A Herzog,  Brian Reichholf,  David A Cisneros,  Thomas Hoffmann,  Moritz F Schlapansky,  Pooja Bhat,  Arndt von Haeseler,  Thomas Kocher,  Anna C Obenauf,  Johannes Popow,  Stefan L Ameres,  Johannes Zuber","Defining direct targets of transcription factors and regulatory pathways is key to understanding their roles in physiology and disease. We combined SLAM-seq [thiol(SH)-linked alkylation for the metabolic sequencing of RNA], a method for direct quantification of newly synthesized messenger RNAs (mRNAs), with pharmacological and chemical-genetic perturbation in order to define regulatory functions of two transcriptional hubs in cancer, BRD4 and MYC, and to interrogate direct responses to BET bromodomain inhibitors (BETis). We found that BRD4 acts as general coactivator of RNA polymerase II-dependent transcription, which is broadly repressed upon high-dose BETi treatment. At doses triggering selective effects in leukemia, BETis deregulate a small set of hypersensitive targets including MYC. In contrast to BRD4, MYC primarily acts as a selective transcriptional activator controlling metabolic processes such as ribosome biogenesis and de novo purine synthesis. Our study establishes a simple and scalable strategy to identify direct transcriptional targets of any gene or pathway.",SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis.,10.1126/science.aao2793,2018 May 18,PMC6409205,"Science (New York, N.Y.)"
GSE138641,Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides [Dataset 4],Homo sapiens,2,SRP224955,2019-10-09,"[Overal design]2 ribosome profiling samples are included from HEK293T cells; [Treatment]'Aminoglycosides were added to cells, and treated for 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 15-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138641,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138641/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576652,31971508," Jamie R Wangen,  Rachel Green",eng,Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.,10.7554/eLife.52611,2020 Jan 23,PMC7089771,eLife
GSE50652,Translatome and transcriptome profiling of SH-SY5Y cells treated with sublytic doses of staphylococcal alpha-hemolysin,Homo sapiens,12,None,2013-09-06,"[Overal design]The comparison between translatome and transcriptome profiling was used to discover mRNA-specific changes of the SH-SY5Y cells transcriptome and translatome in response to sublytic doses of staphylococcal ?-hemolysin (AHL). To identify translationally regulated mRNAs, gene expression signals derived from the polysomal mRNA populations were compared by microarrays analysis to those obtained from total RNAs. Polysomal mRNA and total mRNA were isolated from SH-SY5Y cells treated with sublytic doses (3nM) of AHL for 2 hours. Cells lysates were collected from untreated cells (control) and from treated cells. All experiments were run in biological triplicates.; [Treatment]'SH-SY5Y cells were seeded at a density of 2.5  104 cells/cm2 and maintained for 3 days in the growth medium, until the 80% confluence was reached. All experiments were performed in \xa0the presence of 3nM AHL for 2h in DMEM using medium without phenol red, FBS, and antibiotics \xa0 to avoid any interference with protein.', 'SH-SY5Y cells were seeded at a density of 2.5  104 cells/cm2 and maintained for 3 days in the growth medium, until the 80% confluence was reached. The control experiments were performed in DMEM using medium without phenol red, FBS, and antibiotics to avoid any interference with protein.'; [Growth]'SH-SY5Y cells were maintained in DMEM supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-glutamine, penicillin 100.000 U.I./l and streptomycin 100 mg/l. Cells were cultured at 37 C in humid atmosphere of 5% CO2. All experiments were performed in DMEM using medium without phenol red, FBS, and antibiotics to avoid any interference with protein. If not specified differently, cells were grown to 80% of confluence before each assay.'; [Extraction]""Total RNA was extracted using TRIZOL reagent according to the manufacturer's protocol. Briefly, the aqueous phase was used for RNA precipitation with an equal volume of isopropanol. The RNA pellet was washed once with 75% ethanol, then air-dried and re-dissolved in 20 ?l of RNase-free water. RNA was quantified using a spectrophotometer and its quality was checked by agarose gel electrophoresis and by Agilent 2100 Bioanalyzer platform, following the manifacturers guidelines for sample preparation and analysis of data (Agilent 2100 Bioanalyzer 2100 Expert User's Guide, http://www.agilent.com)."", 'Cells were washed once with phosphate buffer saline (PBS) and treated directly on the plate with 300 l lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/l RNase inhibitor (Fermentas) and 1 mM dithiothreitol] and transferred to an Eppendorf tube. After a few minute incubation on ice with occasional vortexing, the extracts were centrifuged for 10 min at 12000 g at 4C. The supernatant was stored at 80C or loaded directly onto a 1550% linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in an Sorvall rotor for 120 min at 40000 rpm. Polysomal fractions were collected monitoring the absorbance at 254 nm and treated directly with proteinase K. After phenolchloroform extraction and isopropanol precipitation, polysomal RNA was resuspended in 30 l of water. RNA quality was assessed by agarose gel electrophoresis and the Agilent 2100 Bioanalyzer platform.'; [Cell type]'Source: ''cell line: SH-SY5Y; treatment: 3nM AHL, 2 hours; rna fraction: total RNA; ', 'cell line: SH-SY5Y; treatment: control, untreated; rna fraction: total RNA; ', 'cell line: SH-SY5Y; treatment: 3nM AHL, 2 hours; rna fraction: polysomal RNA; ', 'cell line: SH-SY5Y; treatment: control, untreated; rna fraction: polysomal RNA; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50652,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE50nnn/GSE50652/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA218202,26371376," Massimiliano Clamer,  Toma Tebaldi,  Marta Marchioretto,  Paola Bernabo,  Efrem Bertini,  Graziano Guella,  Mauro Dalla Serra,  Alessandro Quattrone,  Gabriella Viero","Genome-wide analyses of translation can provide major contributions in our understanding of the complex interplay between virulent factors and host cells. So far, the activation of host translational control mechanisms by bacterial toxins, owing to specific recruitment of mRNAs, RNA-binding proteins (RBPs) and ncRNAs (non-coding RNAs), are far from being understood. In the present study, we characterize for the first time the changes experienced by the translational control system of host cells in response to the well-known Staphylococcus aureus alpha-haemolysin (AHL) under both sublytic and lytic conditions. By comparing variations occurring in the cellular transcriptome and translatome, we give evidence that global gene expression is primarily rewired at the translational level, with the contribution of the RBP ELAVL1 (HuR) in the sublytic response. These results reveal the importance of translational control during host-pathogen interaction, opening new approaches for AHL-induced diseases.",Global translation variations in host cells upon attack of lytic and sublytic Staphylococcus aureus alpha-haemolysin.,10.1042/BJ20150284,2015 Nov 15,,The Biochemical journal
GSE147324,Nuclease-mediated depletion biases in ribosome footprint profiling libraries,Homo sapiens,26,SRP253534,2020-03-20,"[Overal design]Ribosome profiling libraries were genereated in several cell lines using different rRNA depletion techniques; [Treatment]'None'; [Growth]'HEK Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest, K562 Cells were grown in RPMI with 10% FBS to 500,000 cells/ml for harvest.'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 15-34 nt were gel purified. rRNA depletion was performed with the kit indicated at the step indicated. Upon dephosphorylation of sample RNA, the linker was ligated. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: HEK293T; depletion strategy: none; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: after ligation; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293T; depletion strategy: legacy riboZero gold; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293T; depletion strategy: riboCop; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293T; depletion strategy: NEBNExt; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293T; depletion strategy: none; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: NEBNExt; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: NEBNExt; sizes selected (nt): 20-60; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: qiagen fastselect; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: ribopools; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: ribopools, cold elution; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: ribo-zero plus; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: ribo-zero plus, formaldehyde; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: ribo-zero plus, oligos; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: ribo-zero plus, oligos, formaldehyde; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: K562; depletion strategy: undepleted; sizes selected (nt): 20-34; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293FT; depletion strategy: custom oligos; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293FT; depletion strategy: undepleted; sizes selected (nt): 15-35; adapter: NNNNNNCACTCGGGCACCAAGGAC; depletion step: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147324,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE147nnn/GSE147324/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA613736,32503920," Boris Zinshteyn,  Jamie R Wangen,  Boyang Hua,  Rachel Green","Ribosome footprint profiling is a high-throughput sequencing-based technique that provides detailed and global views of translation in living cells. An essential part of this technology is removal of unwanted, normally very abundant, ribosomal RNA sequences that dominate libraries and increase sequencing costs. The most effective commercial solution (Ribo-Zero) has been discontinued as a standalone product and a number of new, experimentally distinct commercial applications have emerged on the market. Here we evaluated several commercially available alternatives designed for RNA-seq of human samples and find them generally unsuitable for ribosome footprint profiling. We instead recommend the use of custom-designed biotinylated oligos, which were widely used in early ribosome profiling studies. Importantly, we warn that depletion solutions based on targeted nuclease cleavage significantly perturb the high-resolution information that can be derived from the data, and thus do not recommend their use for any applications that require precise determination of the ends of RNA fragments.",Nuclease-mediated depletion biases in ribosome footprint profiling libraries.,10.1261/rna.075523.120,2020 Oct,PMC7491325,"RNA (New York, N.Y.)"
GSE26549,Gene Expression Profiling Predicts the Development of Oral Cancer,Homo sapiens,86,None,2011-01-11,"[Overal design]Gene expression profile was measured in 86 of 162 OPL patients who were enrolled in a clinical chemoprevention trial that used the incidence of oral cancer development as a prespecified endpoint. The median follow-up time was 6.08 years and 35 of the 86 patients developed oral cancer over the course. Gene expression profiles were associated with oral cancer-free survival and used to develope multivariate predictive models for oral cancer prediction.; [Treatment]'Samples were OCT-embedded and frozen before RNA extraction'; [Growth]'Biopsies of oral leukoplakia'; [Extraction]""RNA was extracted and purified from OCT-embedded tissue using the RNeasy Mini Kit (Qiagen) including on-column DNase (Qiagen) digestion as described by the manufacturer's protocol.""; [Cell type]'Source: ''Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 40; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 9.07; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: black; alcohol habits: current; smoking habits: never; age: 66; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 13.63; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 65; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 14.34; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: current; age: 59; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 11.75; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: former; age: 66; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 11.3; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 37; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 11.37; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: current; age: 59; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: NA; podoplanin expression: NA; oral cancer-free survival time (years): 9.16; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: current; age: 56; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 10.67; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: never; age: 66; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 8.3; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: current; age: 60; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 11.59; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 52; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): severe dysplasia; p63 expression: NA; podoplanin expression: NA; oral cancer-free survival time (years): 10.71; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 58; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 7.15; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 40; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 7.83; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 50; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: low expression; oral cancer-free survival time (years): 10.17; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: asian; alcohol habits: never; smoking habits: never; age: 56; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 6.06; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: never; age: 62; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 7.38; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 53; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 6.98; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: former; smoking habits: former; age: 67; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.6; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: current; age: 51; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 5.54; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: former; age: 74; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 5.1; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: never; age: 71; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 4.99; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 58; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 6.63; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: former; age: 48; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.26; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 64; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 6.08; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 68; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 6.5; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 78; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 4.03; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: never; age: 42; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 10.17; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 65; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 4.89; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: former; smoking habits: current; age: 44; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 3.04; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: former; age: 63; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: low expression; oral cancer-free survival time (years): 4.92; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: current; age: 39; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.95; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 72; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 4.3; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 53; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: NA; oral cancer-free survival time (years): 3.45; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: asian; alcohol habits: never; smoking habits: former; age: 23; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 3.07; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: asian; alcohol habits: current; smoking habits: former; age: 24; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 2.64; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 60; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 9.85; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 40; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 8.55; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 54; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 10.28; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: former; age: 51; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 1.71; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: former; smoking habits: never; age: 50; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 4.51; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 40; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 4.53; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 64; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 5.15; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 51; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 3.36; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 65; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 10.7; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 37; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.66; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: former; age: 56; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.18; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 56; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 2.46; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 38; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 2.05; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: former; age: 67; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 1.85; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: current; age: 71; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): severe dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 6.67; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 50; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 1.81; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: former; smoking habits: former; age: 57; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: NA; podoplanin expression: high expression; oral cancer-free survival time (years): 3.32; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: current; age: 68; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 1.58; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: current; age: 71; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 2.24; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 69; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: NA; podoplanin expression: NA; oral cancer-free survival time (years): 2.88; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 32; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 1.24; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 76; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.69; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 79; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 3.36; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: former; age: 50; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.72; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: hawaian; alcohol habits: never; smoking habits: never; age: 74; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 0.56; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: former; age: 75; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 3.52; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: former; smoking habits: former; age: 65; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 2.27; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: former; age: 90; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.56; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: former; smoking habits: former; age: 65; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.57; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: former; age: 71; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 2.3; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: former; smoking habits: current; age: 47; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 1.62; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 31; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: low expression; oral cancer-free survival time (years): 1.12; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 61; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: NA; podoplanin expression: NA; oral cancer-free survival time (years): 0.27; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: hawaian; alcohol habits: current; smoking habits: former; age: 42; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 3.9; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: former; smoking habits: former; age: 78; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 6.21; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: hawaian; alcohol habits: current; smoking habits: former; age: 56; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.06; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: former; age: 54; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 2.05; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: never; age: 71; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 3.76; outcome: oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: never; smoking habits: never; age: 43; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.3; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: former; age: 43; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.77; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: former; age: 66; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): mild dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 6.65; outcome: oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: current; age: 37; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 4.66; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 37; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): NA; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 6.27; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: never; age: 36; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 1.64; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: current; age: 62; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 9.91; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: asian; alcohol habits: never; smoking habits: never; age: 52; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 12.1; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: never; age: 72; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.79; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: female; race: white; alcohol habits: current; smoking habits: current; age: 44; treatment arm: beta-carotene; histology at baseline (hyperplasia versus dysplasia): dysplasia; histology at baseline (breakdown): moderate dysplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 0.92; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: current; age: 36; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 5.28; outcome: no oral cancer development; time of biopsy: biopsy at baseline; ', 'Sex: male; race: white; alcohol habits: current; smoking habits: never; age: 79; treatment arm: 13-cis-retinoic acid; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: low expression; podoplanin expression: low expression; oral cancer-free survival time (years): 7.75; outcome: no oral cancer development; time of biopsy: biopsy at 3 months after inclusion; ', 'Sex: female; race: white; alcohol habits: never; smoking habits: never; age: 80; treatment arm: retinyl palmitate; histology at baseline (hyperplasia versus dysplasia): hyperplasia; histology at baseline (breakdown): hyperplasia; p63 expression: high expression; podoplanin expression: high expression; oral cancer-free survival time (years): 0.69; outcome: oral cancer development; time of biopsy: biopsy at baseline; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26549,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE26nnn/GSE26549/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA136631,21292635," Pierre Saintigny,  Li Zhang,  You-Hong Fan,  Adel K El-Naggar,  Vassiliki A Papadimitrakopoulou,  Lei Feng,  J Jack Lee,  Edward S Kim,  Waun Ki Hong,  Li Mao","Patients with oral premalignant lesion (OPL) have a high risk of developing oral cancer. Although certain risk factors, such as smoking status and histology, are known, our ability to predict oral cancer risk remains poor. The study objective was to determine the value of gene expression profiling in predicting oral cancer development. Gene expression profile was measured in 86 of 162 OPL patients who were enrolled in a clinical chemoprevention trial that used the incidence of oral cancer development as a prespecified endpoint. The median follow-up time was 6.08 years and 35 of the 86 patients developed oral cancer over the course. Gene expression profiles were associated with oral cancer-free survival and used to develop multivariate predictive models for oral cancer prediction. We developed a 29-transcript predictive model which showed marked improvement in terms of prediction accuracy (with 8% predicting error rate) over the models using previously known clinicopathologic risk factors. On the basis of the gene expression profile data, we also identified 2,182 transcripts significantly associated with oral cancer risk-associated genes (P value < 0.01; univariate Cox proportional hazards model). Functional pathway analysis revealed proteasome machinery, MYC, and ribosomal components as the top gene sets associated with oral cancer risk. In multiple independent data sets, the expression profiles of the genes can differentiate head and neck cancer from normal mucosa. Our results show that gene expression profiles may improve the prediction of oral cancer risk in OPL patients and the significant genes identified may serve as potential targets for oral cancer chemoprevention.",Gene expression profiling predicts the development of oral cancer.,10.1158/1940-6207.CAPR-10-0155,2011 Feb,PMC3074595,"Cancer prevention research (Philadelphia, Pa.)"
GSE74511,Ribosome profiling on polysomes extracted via sucrose gradient and IP,Homo sapiens,3,SRP065530,2015-10-30,"[Overal design]1 sucrose gradient sample, 2 immunoprecipitation samples in two concentrations of beads; [Treatment]'None'; [Growth]'MCF7 cells were cultured in DMEM medium supplemented with 10% FBS'; [Extraction]'MCF7 GFP-RPL10a cells were treated with cycloheximide at a final conc of 10ug/m for 5 min. Cells were washed with cold PBS, scraped, and pelleted. Cell pellet was lysed with 1ml of NP40 lysis buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 150mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX) for 15 min, centrifuged for 10 min at 1300 g and 1ml of supernatant recovered. IP samples: (50ul/100ul) GFP-Trap_M beads (Chromotek) were washed for 3 times in 1ml of NP40 lysis buffer, resuspended in 3 ml of NP40 lysis buffer. 1ml of cleared lysate (cell line or tumor) was added to the beads and digested with RNAse I (100U/ul) for 1hr at RT under constant rotation. Beads were washed 3 times with of NP40 Lysis buffer and 3 times with NP40 wash buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 350mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX). Beads were resuspended in 300 ul of lysis buffer with 1% SDS and 15 ul of Proteinase K (Roche) and incubated for 1hr at 45C. Supernatant was recovered and resuspended in TriSure. RNA was isolated and libraries prepared according to the RP protocol.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: '""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: MCF7; protocol: sucrose gradient; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: MCF7; protocol: IP50; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74511,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE74nnn/GSE74511/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA300626,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE144163,Ribosome profiling of ABCE1-knockout cells,Homo sapiens,4,SRP244436,2020-01-23,"[Overal design]Method: Ribosome profiling was performed in HCT116 cells that received, via lentivirus, Cas9 and sgRNAs targeting either ABCE1 or non-targeting control sgRNAs. Two sgRNAs were used for each condition, and thus 4 biological samples were used for these experiments.; [Treatment]'N/A.'; [Growth]'HCT116 cells were infected with lentivirus to deliver Cas9 and sgRNAs targeting ABCE1, or non-target sgRNAs. Successfully transduced cells were selected in puromycin for 4 days, before harvesting for ribosome profiling as described in the manuscript.'; [Extraction]'Ribosome protected fragments were isolated as described in McGlincy and Ingolia, Methods, 2017.\nRibosome profiling libraries were prepared as described in Ingolia et al., Nature Protocols, 2012, and McGlincy and Ingolia, Methods, 2017, and sequenced on a NextSeq500 platform.'; [Cell type]'Source: ''genotype: ABCE1-/-; sgrna received: sgABCE1-1; cell line: NMD reporter; ', 'genotype: ABCE1-/-; sgrna received: sgABCE1-2; cell line: NMD reporter; ', 'genotype: +/+; sgrna received: sgNT1; cell line: NMD reporter; ', 'genotype: +/+; sgrna received: sgNT2; cell line: NMD reporter; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144163,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE144nnn/GSE144163/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA602917,32668236," Xiaoqiang Zhu,  He Zhang,  Joshua T Mendell","Nonsense-mediated decay (NMD) is a pathway that degrades mRNAs containing premature termination codons. Here we describe a genome-wide screen for NMD factors that uncovers an unexpected mechanism that broadly governs 3' untranslated region (UTR)-directed regulation. The screen reveals that NMD requires lysosomal acidification, which allows transferrin-mediated iron uptake, which, in turn, is necessary for iron-sulfur (Fe-S) cluster biogenesis. This pathway maintains the activity of the Fe-S cluster-containing ribosome recycling factor ABCE1, whose impaired function results in movement of ribosomes into 3' UTRs, where they displace exon junction complexes, abrogating NMD. Importantly, these effects extend beyond NMD substrates, with ABCE1 activity required to maintain the accessibility of 3' UTRs to diverse regulators, including microRNAs and RNA binding proteins. Because of the sensitivity of the Fe-S cluster of ABCE1 to iron availability and reactive oxygen species, these findings reveal an unanticipated vulnerability of 3' UTR-directed regulation to lysosomal dysfunction, iron deficiency, and oxidative stress.",Ribosome Recycling by ABCE1 Links Lysosomal Function and Iron Homeostasis to 3' UTR-Directed Regulation and Nonsense-Mediated Decay.,10.1016/j.celrep.2020.107895,2020 Jul 14,PMC7433747,Cell reports
GSE89629,The thrombopoietin/MPL axis is activated in the Gata1 low mouse model of myelofibrosis and is associated with a defective RPS14 signature [spleen],Mus musculus,6,None,2016-11-07,"[Overal design]genetic_modification_design; [Treatment]'The cells were not treated in any way'; [Growth]'These are primary spleen cells from mice matched for sex and age. Cells were obtained by flashing spleen tissue through progressively smaller neddles (19g to 21g)\nwith IMDM supplemented with 100\u2009U\u2009/ml penicillin/streptomycin, 2\u2009mM l-glutamine, 76nM ?-monothioglycerol, 1.5% BSA, 20\u2009?g/ml lipids, insulin transferrin selenium and 10ng/mL of recombinant human thrombopoietin.\nCells were then cryopreserved in DMSO and stored in liquid nitrogen until the time of analysis.'; [Extraction]""Total RNA were extracted using RNeasy Micro Kit (Qiagen) according to manufacturer's instructions. The quantity and quality of the isolated RNAs was determined using ND-1000 Spectrophotometer.""; [Cell type]'Source: ''Sex: male; genotype/variation: wild type; ', 'Sex: female; genotype/variation: wild type; ', 'Sex: male; genotype/variation: gat; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89629,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE89nnn/GSE89629/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA352764,28622305," M Zingariello,  L Sancillo,  F Martelli,  F Ciaffoni,  M Marra,  L Varricchio,  R A Rana,  C Zhao,  J D Crispino,  A R Migliaccio","Myelofibrosis (MF) is characterized by hyperactivation of thrombopoietin (TPO) signaling, which induces a RPS14 deficiency that de-regulates GATA1 in megakaryocytes by hampering its mRNA translation. As mice carrying the hypomorphic Gata1(low) mutation, which reduces the levels of Gata1 mRNA in megakaryocytes, develop MF, we investigated whether the TPO axis is hyperactive in this model. Gata1(low) mice contained two times more Tpo mRNA in liver and TPO in plasma than wild-type littermates. Furthermore, Gata1(low) LSKs expressed levels of Mpl mRNA (five times greater than normal) and protein (two times lower than normal) similar to those expressed by LSKs from TPO-treated wild-type mice. Gata1(low) marrow and spleen contained more JAK2/STAT5 than wild-type tissues, an indication that these organs were reach of TPO-responsive cells. Moreover, treatment of Gata1(low) mice with the JAK inhibitor ruxolitinib reduced their splenomegaly. Also in Gata1(low) mice activation of the TPO/MPL axis was associated with a RSP14 deficiency and a discordant microarray ribosome signature (reduced RPS24, RPS26 and SBDS expression). Finally, electron microscopy revealed that Gata1(low) megakaryocytes contained poorly developed endoplasmic reticulum with rare polysomes. In summary, Gata1(low) mice are a bona fide model of MF, which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed in megakaryocytes from myelofibrotic patients.",The thrombopoietin/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature.,10.1038/bcj.2017.51,2017 Jun 16,PMC5520398,Blood cancer journal
GSE59817,Ribosome profiling and RNA sequencing of MCF10A cells treated with TGFb,Homo sapiens,8,SRP044934,2014-07-28,"[Overal design]Ribosome profiling on 3 biological replicates and matching RNA sequencing on one of the replicates.; [Treatment]'For TGF?1 treatment, MCF10a cells were treated with human recombinant TGF?1 (10ng/ml) for 48 hours (R&D Systems).'; [Growth]'MCF10A cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', ""RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nPoly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the manufacturer's instructions.""; [Cell type]'Source: ''cell line: MCF10A; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59817,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59817/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256319,28274951," Fabricio Loayza-Puch,  Koos Rooijers,  Jelle Zijlstra,  Behzad Moumbeini,  Esther A Zaal,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro P Ugalde,  Celia R Berkers,  Reuven Agami","Cancer cells modulate their metabolic networks to support cell proliferation and a higher demand of building blocks. These changes may restrict the availability of certain amino acids for protein synthesis, which can be utilized for cancer therapy. However, little is known about the amino acid demand changes occurring during aggressive and invasive stages of cancer. Recently, we developed diricore, an approach based on ribosome profiling that can uncover amino acid limitations. Here, we applied diricore to a cellular model in which epithelial breast cells respond rapidly to TGFbeta1, a cytokine essential for cancer progression and metastasis, and uncovered shortage of leucine. Further analyses indicated that TGFbeta1 treatment of human breast epithelial cells reduces the expression of SLC3A2, a subunit of the leucine transporter, which diminishes leucine uptake and inhibits cell proliferation. Thus, we identified a specific amino acid limitation associated with the TGFbeta1 response, a vulnerability that might be associated with aggressiveness in cancer.",TGFbeta1-induced leucine limitation uncovered by differential ribosome codon reading.,10.15252/embr.201744000,2017 Apr,PMC5376977,EMBO reports
GSE59815,Ribosome profiling of harringtonine-treated SUM1315 cells,Homo sapiens,2,SRP044932,2014-07-28,"[Overal design]1 treated and 1 untreated sample; [Treatment]'Cells were treated with of harringtonine (2 ?g/ml) for 5 min.'; [Growth]'SUM1315 cells were culture in DMEM:F12 (1:1) medium supplemented with 5% FCS, EGF (10 ng/ml), and Insulin (5?g/ml)'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: ''cell line: SUM1315; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59815,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59815/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256321,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE138639,Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides [Dataset 2],Homo sapiens,4,SRP224953,2019-10-09,"[Overal design]4 ribosome profiling samples are included from HEK293T cells; [Treatment]'Aminoglycosides were added to cells, and treated for 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 15-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138639,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138639/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576650,31971508," Jamie R Wangen,  Rachel Green",eng,Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.,10.7554/eLife.52611,2020 Jan 23,PMC7089771,eLife
GSE148689,Transcriptomal profiling of early and late response of cells to cell penetrating peptides,Homo sapiens,12,SRP256433,2020-04-15,"[Overal design]RNA seq of HeLa cells treated with different cell penetrating peptides for different time points. 2 replicates for each group; [Treatment]'For peptide treatment, 5x105 cells were seeded in 6-well plates with 2ml of full-DMEM medium 24hrs before the treatment. Next day, medium was exchanged with pre-warmed DMEM medium supplemented with respective peptide and incubated for defined time. As a negative control were used HeLa cells with pre-warmed DMEM medium supplemented with 1xPBS. For the treatment, each peptide stock was mixed with full DMEM media to final concentration of 2 M for each peptide.'; [Growth]'Full DMEM medium with 10%FBS and Pen/Strep'; [Extraction]'RNAzol was used to isolate total RNA\nThe RNA seq libraries were prepared with TruSeq RNA Library Prep kit v2 as per protocol instructions. Resulting libraries concentration, size distribution and quality were assessed on a Qubit fluorometer with a dsDNA high sensitivity kit and on an Agilent 2100 bioanalyzer using a DNA 7500 kit. Then libraries were normalized, pooled and quantified with a KAPA Library quantification kit for Illumina platforms on a ABI StepOnePlus qPCR machine, then loaded on a high output flow cell and single-end sequenced (100 bp) on an Illumina HiSeq 2500 next generation sequencer.'; [Cell type]'Source: ''cell line: HeLa; agent: untreated; time point: untreated; ', 'cell line: HeLa; agent: Penetratin; time point: 1 hour; ', 'cell line: HeLa; agent: Penetratin; time point: 4 hours; ', 'cell line: HeLa; agent: PF14; time point: 4 hours; ', 'cell line: HeLa; agent: mtCPP1; time point: 4 hours; ', 'cell line: HeLa; agent: TP10; time point: 4 hours; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148689,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148689/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA625439,33213097," Tomas Venit,  Moataz Dowaidar,  Maxime Gestin,  Syed Raza Mahmood,  Ulo Langel,  Piergiorgio Percipalle","Cell-penetrating peptides (CPPs) are short peptides that are able to efficiently penetrate cellular lipid bilayers. Although CPPs have been used as carriers in conjugation with certain cargos to target specific genes and pathways, how rationally designed CPPs per se affect global gene expression has not been investigated. Therefore, following time course treatments with 4 CPPs-penetratin, PepFect14, mtCPP1 and TP10, HeLa cells were transcriptionally profiled by RNA sequencing. Results from these analyses showed a time-dependent response to different CPPs, with specific sets of genes related to ribosome biogenesis, microtubule dynamics and long-noncoding RNAs being differentially expressed compared to untreated controls. By using an image-based high content phenotypic profiling platform we confirmed that differential gene expression in CPP-treated HeLa cells strongly correlates with changes in cellular phenotypes such as increased nucleolar size and dispersed microtubules, compatible with altered ribosome biogenesis and cell growth. Altogether these results suggest that cells respond to different cell penetrating peptides by alteration of specific sets of genes, which are possibly part of the common response to such stimulus.","Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to be Part of a Common Response to Cell-Penetrating Peptides.",10.3390/biom10111567,2020 Nov 17,PMC7698553,Biomolecules
GSE129651,Polysome profiling RNAseq of cells transfected with an oligonucleotide targeting the ES6S region of the 40S subunit,Homo sapiens,12,SRP192028,2019-04-11,"[Overal design]Polysome profiling experiments of cuture cells transfected with the oligonucleotide of study and a control oligonucleotide with duplicates. Sequencing of the polysomal and monosomal fraction and the total RNA of each sample. There were 4 biological samples ( duplicates of cells transfected with the targeted oligonucleotide and cells tranfected with the control oligonucleotide), and 12 sequencing samples (monosomal fraction, polysomal fraction and TOTAL RNA of each biological sample); [Treatment]'Transfection with 100mol of problem oligo (4VIC) or control oligo (4) with turbofect, extraction at 16 hours post transfection'; [Growth]'Adherent cells grown in DMEM with 10%FBS  in P100 culture plaques during 24h'; [Extraction]'Lysates were obtained using standard mammalian lysis buffer, clarified and fractionated in a 10%-40% sucrose gradient after ultracentifugation for the monosomes and polysomes samples, or directly from the clarified for the total samples\nRNA libraries were prepared for sequencing using standard Illumina protocols. ERCC RNA spike-in mix (Thermo Fisher) were added to track the dilutions on the mRNA due to the technique\nStranded  libraries'; [Cell type]'Source: ''tissue: Human kidney (embryonic); cell line: HEK293T; transfection: control (4); fraction: Monosomes; ', 'tissue: Human kidney (embryonic); cell line: HEK293T; transfection: control (4); fraction: Polysomes; ', 'tissue: Human kidney (embryonic); cell line: HEK293T; transfection: control (4); fraction: total RNA; ', 'tissue: Human kidney (embryonic); cell line: HEK293T; transfection: oligo (4VIC); fraction: Monosomes; ', 'tissue: Human kidney (embryonic); cell line: HEK293T; transfection: oligo (4VIC); fraction: Polysomes; ', 'tissue: Human kidney (embryonic); cell line: HEK293T; transfection: oligo (4VIC); fraction: total RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129651,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129651/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532392,31789591," Irene Diaz-Lopez,  Rene Toribio,  Juan Jose Berlanga,  Ivan Ventoso","Loading of mRNA onto the ribosomal 43S pre-initiation complex (PIC) and its subsequent scanning require the removal of the secondary structure of the by RNA helicases such as eIF4A. However, the topology and mechanics of the scanning complex bound to mRNA (48S-PIC) and the influence of its solvent-side composition on the scanning process are poorly known. Here, we found that the ES6S region of the 48S-PIC constitutes an extended binding channel for eIF4A-mediated unwinding of mRNA and scanning. Blocking ES6S inhibited the cap-dependent translation of mRNAs that have structured 5\' UTRs (including G-quadruplexes), many of which are involved in signal transduction and growth, but it did not affect IRES-driven translation. Genome-wide analysis of mRNA translation revealed a great diversity in ES6S-mediated scanning dependency. Our data suggest that mRNA threading into the ES6S region makes scanning by 48S PIC slower but more processive. Hence, we propose a topological and functional model of the scanning 48S-PIC.",An mRNA-binding channel in the ES6S region of the translation 48S-PIC promotes RNA unwinding and scanning.,10.7554/eLife.48246,2019 Dec 2,PMC6887119,eLife
GSE132306,N6-methyladenosine (m6A) profiling of EndoC-bH1 cell line and RNA seq of Mettl14 knockout mice beta cell,Homo sapiens; Mus musculus,24,SRP200660,2019-06-06,"[Overal design]Total RNA was extracted from the tissue by TRIzol. mRNA was enriched by polyT beads followed by fragmentation with Bioruptor ultrasonicator. m6A-immunoprecipitation were performed using EpiMark N6-Methyladenosine enrichment kit (NEB cat. E1610S). Kapa RNA hyper kit for Illumina was used to construct library from mRNA for input RNA and eluted RNA from the m6A-IP. The libraries were sequenced by the Hiseq4000 platform at SE50 mode.; [Treatment]'Transient knock-downs were performed using RNAiMAX Reagent following manufacturers instruction.'; [Growth]'The culture flask was coated with DMEM (glucose 4.5 g/L) containing penicillin-streptomycin (1%), fibronectin (2 ?g/mL), and extracellular matrix (1% vol/vol) (Sigma-Aldrich) and incubated for at least 1 h in 5% CO2 at 37C before the cells were seeded. EndoC-bH1 cells were grown on Matrigel/fibronectin coated culture flasks containing DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol) (Roche Diagnostics, Mannheim, Germany), 2-mercaptoethanol (50 ?M), nicotinamide (10 mM), transferrin (5.5 ?g/mL), sodium selenite (6.7 ng/mL), penicillin-streptomycin (1%) (Sigma-Aldrich).'; [Extraction]'Total RNA was extracted using TRIzol (Invitrogen) following manufacture instruction. mRNA was purified using polyT beads (Thermo Fisher). Ribosome depleted RNA was purified using RiboGone kit (Takara).\nm6A-seq (Input and IP) libraries were prepared using SMARTer Stranded total RNA-seq V2 pico input Kit (Takara). RNA-seq libraries were prepared using SMARTer Stranded RNA-seq Kit (Takara).'; [Cell type]'EndoC-bH1 cell line', 'beta cell''genotype/variation: control; cell type: EndoC-bH1 cell line; ', 'genotype/variation: METTL3 knock down; cell type: EndoC-bH1 cell line; ', 'genotype/variation: METTL14 knock down; cell type: EndoC-bH1 cell line; ', 'genotype/variation: wild type; cell type: beta cell; ', 'genotype/variation: Mettl14 beta cell specific knockout; cell type: beta cell; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132306,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132306/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA547579,,,,,,,,
GSE69047,Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics,Homo sapiens,12,SRP058501,2015-05-19,"[Overal design]Timecourse experiment with six points over 48hr after bortezomib exposure in MM.1S myeloma cells. mRNA-seq and ribosome profiling data at each time point.; [Treatment]'Cells were treated with 0.5 nM bortezomib'; [Growth]'None'; [Extraction]'mRNA-seq and ribosome footprint samples were prepared by the method of Ingolia et al. Cell (2011) 147:789.\nmRNA-seq and ribosome footprint sequencing libraries were prepared by the method of Ingolia et al. Cell (2011) 147:789.\nmRNA-seq, ribosome profiling'; [Cell type]'Source: ''drug treatment: untreated; cell lline: MM1.S; ', 'drug treatment: 0.5 nM bortezomib; cell lline: MM1.S; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69047,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69047/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA284399,28578850," Tzu-Yu Liu,  Hector H Huang,  Diamond Wheeler,  Yichen Xu,  James A Wells,  Yun S Song,  Arun P Wiita","Ribosome profiling is a widespread tool for studying translational dynamics in human cells. Its central assumption is that ribosome footprint density on a transcript quantitatively reflects protein synthesis. Here, we test this assumption using pulsed-SILAC (pSILAC) high-accuracy targeted proteomics. We focus on multiple myeloma cells exposed to bortezomib, a first-line chemotherapy and proteasome inhibitor. In the absence of drug effects, we found that direct measurement of protein synthesis by pSILAC correlated well with indirect measurement of synthesis from ribosome footprint density. This correlation, however, broke down under bortezomib-induced stress. By developing a statistical model integrating longitudinal proteomic and mRNA-sequencing measurements, we found that proteomics could directly detect global alterations in translational rate caused by bortezomib; these changes are not detectable by ribosomal profiling alone. Further, by incorporating pSILAC data into a gene expression model, we predict cell-stress specific proteome remodeling events. These results demonstrate that pSILAC provides an important complement to ribosome profiling in measuring proteome dynamics.",Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics.,10.1016/j.cels.2017.05.001,2017 Jun 28,PMC5546878,Cell systems
GSE79306,Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels,Homo sapiens; Mus musculus,175,SRP071876,2016-03-16,"[Overal design]TRAP-seq profiles for E11.5 till E17.5 wild type (WT) brain EC; E14.5 and E17.5 endothelial Ctnnb1 -/- brain EC; E14.5 head, heart, kidney, limb, liver and lung WT EC in triplicate, using Illumina HiSeq 2000. Single cell RNA-sequencing of E14.5 brain EC. RNA-sequenzing of HUVEC infected with either control, Foxf2, Foxq1, ZIC3 or three transcription factors combined in triplicate.; [Treatment]'Lentiviral infection was carried out in gelatin-coated 12-well plates containing 5  10^4 cells per well in 600 l RPMI medium with 200 l viral supernatant for 4 h and cells were cultivated for 7 days in growth medium.'; [Growth]'HUVEC (PromoCell) were cultured in EBM2 bullet kit media (Lonza) on gelatin-coated flasks according to instructions provided by the supplier.'; [Extraction]'TRAP: Translated and transcribed RNA from brain (forebrain and part of the diencephalon), head (without brain), heart, kidney, limb, liver or lung was purified from one to six mCherryTRAP embryos (age-dependent) as described (Hupe et al.: Nucleic Acids Res, 2014).\nHUVEC: RNA was purified using RNeasy Micro Kit (Qiagen) following the manufacturers instructions.\nSingle cell: Forebrains of mCherryTRAP E14.5 embryos were dissected in ice-cold PBS. The tissue was diced with a scalpel and subsequently enzymatically dissociated in PBS containing 1 mg/ml collagenase typ II (Worthington) and 1 l/ml DNase I (Roche) at 37C for 30 min with gentle sequential trituration. The cell suspension was filtered through a 40 m cell strainer and 20 ml of DMEM containing 10 % FBS was added. After centrifugation at 800 x g for 5 min, the cell pellet was resuspended in 2 ml PBS containing 2 % FBS. Cells were sorted on a BD FACSAria III Cell Sorting system (BD Bioscience) based on mCherry fluorescence utilizing the 488-nm laser. mCherryTRAP-negative embryos were used to define background fluorescence. Forward and side scatter analysis were used as gates to avoid cell debris and doublets. Single cells were collected in a 96 well plate contain 4 l of a mild hypotonic lysis buffer [0.1% Triton X-100 (Sigma), 1 U/l recombinant RNase inhibitor (Promega), 2.5 M anchored oligo-dT primer (5'-AAGCAGTGGTATCAACGCAGAGTACT30VN-3', Biomers), and 2.5 mM dNTP mix (Fermentas)] in each well.\nTRAP and HUVEC: RNA libraries were prepared for sequencing using standard Illumina protocols\nSingle cell: Libraries were generated following Smart-seq2 (Picelli et al.: Nat Methods, 2013) and Tn5 transposase tagmentation (Picelli et al.: Genome Res, 2014) protocols.'; [Cell type]'Source: ''mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain EC; age: E11.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain; age: E11.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain EC; age: E12.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain; age: E12.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain EC; age: E13.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain; age: E13.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-;Ctnnb1-/-; tissue: forebrain; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-;Ctnnb1-/-; tissue: forebrain EC; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: head (without brain); age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: heart; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: limb; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: liver; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: lung EC; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: lung; age: E14.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain EC; age: E15.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain; age: E15.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain EC; age: E16.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain; age: E16.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-;Ctnnb1-/-; tissue: forebrain; age: E17.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-;Ctnnb1-/-; tissue: forebrain EC; age: E17.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain EC; age: E17.5; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: brain; age: E17.5; ', 'tissue: umbilical vein; ', 'mouse line: Cdh5CreERT2+/-;R26-mCherry-Rpl10a+/-; tissue: forebrain; age: E14.5; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79306,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE79nnn/GSE79306/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA315441,28698213," Mike Hupe,  Minerva Xueting Li,  Susanne Kneitz,  Daria Davydova,  Chika Yokota,  Julianna Kele,  Belma Hot,  Jan M Stenman,  Manfred Gessler","The blood-brain barrier is a dynamic interface that separates the brain from the circulatory system, and it is formed by highly specialized endothelial cells. To explore the molecular mechanisms defining the unique nature of vascular development and differentiation in the brain, we generated high-resolution gene expression profiles of mouse embryonic brain endothelial cells using translating ribosome affinity purification and single-cell RNA sequencing. We compared the brain vascular translatome with the vascular translatomes of other organs and analyzed the vascular translatomes of the brain at different time points during embryonic development. Because canonical Wnt signaling is implicated in the formation of the blood-brain barrier, we also compared the brain endothelial translatome of wild-type mice with that of mice lacking the transcriptional cofactor beta-catenin (Ctnnb1). Our analysis revealed extensive molecular changes during the embryonic development of the brain endothelium. We identified genes encoding brain endothelium-specific transcription factors (Foxf2, Foxl2, Foxq1, Lef1, Ppard, Zfp551, and Zic3) that are associated with maturation of the blood-brain barrier and act downstream of the Wnt-beta-catenin signaling pathway. Profiling of individual brain endothelial cells revealed substantial heterogeneity in the population. Nevertheless, the high abundance of Foxf2, Foxq1, Ppard, or Zic3 transcripts correlated with the increased expression of genes encoding markers of brain endothelial cell differentiation. Expression of Foxf2 and Zic3 in human umbilical vein endothelial cells induced the production of blood-brain barrier differentiation markers. This comprehensive data set may help to improve the engineering of in vitro blood-brain barrier models.",Gene expression profiles of brain endothelial cells during embryonic development at bulk and single-cell levels.,10.1126/scisignal.aag2476,2017 Jul 11,,Science signaling
GSE148771,3'READS+RIP defines differential Staufen1 binding to alternative 3'UTR isoforms and reveals structures and sequence motifs influencing binding and polysome association,Homo sapiens,12,SRP256562,2020-04-16,"[Overal design]8 3'READS+RIP libraries from STAU1-KO cells (STAU1_IP, GFP_IP, STAU1_Input, GFP_Input in two replicates); 4 3'READS+ libraries from cell frationated samples (KO_C, WT_C, KO_P, WT_P in one replicate); [Treatment]'STAU1-KO (STAU1 C8) human embryonic kidney (HEK)293T-cell lines were established using the CRISP-Cas9n double-nicking strategy with isogenic control (C9). Total-cell lysates from STAU1-KO HEK293T cells (C8) transiently expressing FLAG-GFP or STAU1-FLAG were prepared using Hypotonic Gentle Lysis Buffer (10 mM Tris [pH 7.4], 10 mM NaCl, 10 mM EDTA, 1% [w/w] Triton X-100, 1x Protease and Phosphatase Inhibitor (Pierce)) and two 30-sec rounds of sonication (Branson Sonifier 250, duty cycle 30%, output control = 3).     Separation of HEK293T-cell nuclear and cytoplasmic fractions was performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) following manufacturer instructions. Polysome profiling was performed as described (Esposito et al., 2010) with minor modifications.'; [Growth]'Human HEK293T cells were propagated in Dulbeccos Modified Eagles Medium (Gibco) supplemented with 10% fetal bovine serum.'; [Extraction]""RNA was extracted using phenol/chloroform and precipitated using ethanol.\nThe 3'READS+ procedure has been previously described (Zheng et al., 2016). Briefly, polyA+ RNA in 1 g of total-cell RNA was captured using 10 l of oligo(dT)25 magnetic beads (NEB) in 100 l of 1x Binding Buffer (10 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, and 0.05% TWEEN 20) and fragmented on the beads using 1.5 U of RNase III (NEB) in 30 l of RNase III Buffer (10 mM Tris-Cl pH 8.3, 60 mM NaCl, 10 mM MgCl2, and 1 mM DTT) for 15 min at 37 C. After washing away unbound RNA fragments using Binding Buffer, polyA+ fragments were eluted from the beads using TE Buffer (10 mM Tris-Cl, 1 mM EDTA, pH 7.5) and precipitated using ethanol, followed by ligation to 3 pmol of heat-denatured 5'-adapter (5'-CCUUGGCACCCGAGAAUUCCANNNN-3') in the presence of 1 mM ATP, 0.1 l of SuperaseIn (ThermoFisher Scientific), and 0.25 l of T4 RNA ligase 1 in a 5 l reaction at 22 C for 1 hr. Ligation products were captured using 10 pmol of biotin-T15-(+TT)5 attached to 12 l of Dynabeads MyOne Streptavidin C1 (ThermoFisher Scientific). After washing with Washing Buffer (10 mM Tris-Cl pH 7.5, 1 mM NaCl, 1 mM EDTA, and 0.05% TWEEN 20), RNA fragments on the beads were incubated with 0.01 U/l of RNase H (Epicentre) for 30 min at 37 C in 30 l of RNase H buffer (50 mM Tris-Cl pH 7.5, 5 mM NaCl, 10 mM MgCl2, and 10 mM DTT). After washing with RNase H Buffer, RNA fragments were eluted from the beads in Elution Buffer (1 mM NaCl, 1 mM EDTA pH7.5, and 0.05% TWEEN 20) at 50 C, precipitated using ethanol, and then ligated to 3 pmol of heat-denatured 5'-adenylated 3'-adapter (5'-rApp/NNNGATCGTCGGACTGTAGAACTCTGAAC/3ddC-3') using 0.25 l of T4 RNA ligase 2 (truncated KQ version) for 1 hr at 22 C in a 5 l reaction containing 15% PEG 8000 and 0.2 l of SuperaseIn. Ligation products were precipitated and reverse-transcribed using M-MLV reverse transcriptase, and PCR-amplified using Phusion high-fidelity DNA polymerase (NEB) and bar-coded PCR primers (Sigma-Aldrich) for 15 cycles.""; [Cell type]'Source: '""cell line: HEK293T; sample treatment: STAU1-FLAG IP replicate 1; genotype: STAU1-KO; transfection: STAU1-FLAG; rip antibody: anti-FLAG; protocol: 3'READS+; rna fraction: Poly(A)+ RNA pulled down by anti-FLAG; "", ""cell line: HEK293T; sample treatment: STAU1-FLAG IP replicate 2; genotype: STAU1-KO; transfection: STAU1-FLAG; rip antibody: anti-FLAG; protocol: 3'READS+; rna fraction: Poly(A)+ RNA pulled down by anti-FLAG; "", ""cell line: HEK293T; sample treatment: FLAG-GFP IP replicate 1; genotype: STAU1-KO; transfection: FLAG-GFP; rip antibody: anti-FLAG; protocol: 3'READS+; rna fraction: Poly(A)+ RNA pulled down by anti-FLAG; "", ""cell line: HEK293T; sample treatment: FLAG-GFP IP replicate 2; genotype: STAU1-KO; transfection: FLAG-GFP; rip antibody: anti-FLAG; protocol: 3'READS+; rna fraction: Poly(A)+ RNA pulled down by anti-FLAG; "", ""cell line: HEK293T; sample treatment: STAU1-FLAG input replicate 1; genotype: STAU1-KO; transfection: STAU1-FLAG; rip antibody: none (input); protocol: 3'READS+; rna fraction: Total Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: STAU-FLAG input replicate 2; genotype: STAU1-KO; transfection: STAU1-FLAG; rip antibody: none (input); protocol: 3'READS+; rna fraction: Total Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: FLAG-GFP input replicate 1; genotype: STAU1-KO; transfection: FLAG-GFP; rip antibody: none (input); protocol: 3'READS+; rna fraction: Total Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: FLAG-GFP input replicate 2; genotype: STAU1-KO; transfection: FLAG-GFP; rip antibody: none (input); protocol: 3'READS+; rna fraction: Total Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: STAU1-KO cytoplasm; genotype: STAU1-KO; protocol: 3'READS+; rna fraction: Cytoplasmic Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: WT cytoplasm; genotype: Wild-type; protocol: 3'READS+; rna fraction: Cytoplasmic Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: STAU1-KO polysome; genotype: STAU1-KO; protocol: 3'READS+; rna fraction: Polysome Poly(A)+ RNA; "", ""cell line: HEK293T; sample treatment: WT polysome; genotype: Wild-type; protocol: 3'READS+; rna fraction: Polysome Poly(A)+ RNA; """,Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148771,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148771/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA625690,32796083," Dinghai Zheng,  Hana Cho,  Wei Wang,  Xavier Rambout,  Bin Tian,  Lynne E Maquat","Staufen1 (STAU1) is an RNA-binding protein (RBP) that interacts with double-stranded RNA structures and has been implicated in regulating different aspects of mRNA metabolism. Previous studies have indicated that STAU1 interacts extensively with RNA structures in coding regions (CDSs) and 3'-untranslated regions (3'UTRs). In particular, duplex structures formed within 3'UTRs by inverted-repeat Alu elements (IRAlus) interact with STAU1 through its double-stranded RNA-binding domains (dsRBDs). Using 3' region extraction and deep sequencing coupled to ribonucleoprotein immunoprecipitation (3'READS + RIP), together with reanalyzing previous STAU1 binding and RNA structure data, we delineate STAU1 interactions transcriptome-wide, including binding differences between alternative polyadenylation (APA) isoforms. Consistent with previous reports, RNA structures are dominant features for STAU1 binding to CDSs and 3'UTRs. Overall, relative to short 3'UTR counterparts, longer 3'UTR isoforms of genes have stronger STAU1 binding, most likely due to a higher frequency of RNA structures, including specific IRAlus sequences. Nevertheless, a sizable fraction of genes express transcripts showing the opposite trend, attributable to AU-rich sequences in their alternative 3'UTRs that may recruit antagonistic RBPs and/or destabilize RNA structures. Using STAU1-knockout cells, we show that strong STAU1 binding to mRNA 3'UTRs generally enhances polysome association. However, IRAlus generally have little impact on STAU1-mediated polysome association despite having strong interactions with the protein. Taken together, our work reveals complex interactions of STAU1 with its cognate RNA substrates. Our data also shed light on distinct post-transcriptional fates for the widespread APA isoforms in mammalian cells.",3'READS + RIP defines differential Staufen1 binding to alternative 3'UTR isoforms and reveals structures and sequence motifs influencing binding and polysome association.,10.1261/rna.076133.120,2020 Nov,PMC7566578,"RNA (New York, N.Y.)"
GSE71891,AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [Antibody Arrays (L-493)],Homo sapiens,4,None,2015-08-10,"[Overal design]Secreted protein profiles of MCF7 and HCT116 Akti-1/2 treated cells and MCF7 and HCT116 vehicle (i.e. DMSO) treated cells were generated using antibody arrays.; [Treatment]'MCF7 and HCT116 cells were treated either with DMSO or Akti-1/2 for 6 days and culture supernatant were collected and frozen at -80C until analysis.'; [Growth]'MCF7 was maintained in DMEM, 10% FCS, 40mM glutamine, 100 U/mL penicillin, and 100g/mL streptomycin; HCT116 was maintained in McCoys 5? medium supplemented with 10% FCS, 100U/mL penicillin, and 100g/mL streptomycin. All cells were grown at 37C and 5% CO2.'; [Extraction]'Prepare dialysis buffer (1X PBS) by dissolving 0.6 g KCl, 24 g NaCl, 0.6 g KH2PO4 and 3.45 g Na2HPO4 in 2500 ml de-ionized or distilled water. Adjust to a pH of 8.0 with 1M NaOH and adjust final volume to 3000 ml with de-ionized or distilled water. Load each sample into 2 separate Dialysis Vials, 2.5-3.0 ml of sample per vial, total 5-6 ml per sample) for dialyzing. Carefully place all Dialysis Vials into the Floating Rack. Place the Floating Rack into ?500 ml dialysis buffer in a large beaker. Place beaker on a stir plate and dialyze for at least 3 hours at 4 C, occasionally gently stirring the dialysis buffer. Then exchange the dialysis buffer with fresh buffer and repeat dialysis for at least 3 hours at 4 C. Transfer dialyzed samples into a clean eppendorf tube. Centrifuge dialyzed samples for 5 minutes at 10,000 rpm to remove B24any particulates or precipitates and then transfer and combine each sample into one clean eppendorf tube. Mix well by gently pipetting.'; [Cell type]'breast adenocarcinoma', 'colon carcinoma''cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 Low; ', 'cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 WT; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 Low; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 WT; '",Protein profiling by protein array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71891,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71891/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292425,26637368," Salony,  Xavier Sole,  Cleidson P Alves,  Ipsita Dey-Guha,  Laila Ritsma,  Myriam Boukhali,  Ju H Lee,  Joeeta Chowdhury,  Kenneth N Ross,  Wilhelm Haas,  Shobha Vasudevan,  Sridhar Ramaswamy","Small molecule inhibitors of AKT (v-akt murine thymoma viral oncogene homolog) signaling are being evaluated in patients with various cancer types, but have so far proven therapeutically disappointing for reasons that remain unclear. Here, we treat cancer cells with subtherapeutic doses of Akti-1/2, an allosteric small molecule AKT inhibitor, in order to experimentally model pharmacologic inhibition of AKT signaling in vitro. We then apply a combined RNA, protein, and metabolite profiling approach to develop an integrated, multiscale, molecular snapshot of this ""AKT(low)"" cancer cell state. We find that AKT-inhibited cancer cells suppress thousands of mRNA transcripts, and proteins related to the cell cycle, ribosome, and protein translation. Surprisingly, however, these AKT-inhibited cells simultaneously upregulate a host of other proteins and metabolites posttranscriptionally, reflecting activation of their endo-vesiculo-membrane system, secretion of inflammatory proteins, and elaboration of extracellular microvesicles. Importantly, these microvesicles enable rapidly proliferating cancer cells of various types to better withstand different stress conditions, including serum deprivation, hypoxia, or cytotoxic chemotherapy in vitro and xenografting in vivo. These findings suggest a model whereby cancer cells experiencing a partial inhibition of AKT signaling may actually promote the survival of neighbors through non-cell autonomous communication.",AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.,10.1158/1535-7163.MCT-15-0414,2016 Jan,PMC4707053,Molecular cancer therapeutics
GSE110866,Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (Ribosome profiling),Mus musculus,5,SRP133147,2018-02-20,"[Overal design]Two neural stem cell samples and three brain tumor stem cell samples are used in ribosome profiling experiments.; [Treatment]'None'; [Growth]'None'; [Extraction]'The cells of a 15 cm culture plate were lysed with lysis buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 200 mM KCl, 1 % Triton, 2 mM DTT, 100 g/ml Cyclohexamide, 25 U/ml DNase and EDTA-free protease inhibitors, Roche). The mRNA not protected by ribosomes was digested with RNAseI and the ribosome footprints were collected by centrifugation with a continuous sucrose gradient (10-50 %) with DTT, cyclohexamideand 20 U/ml SUPERaseIN. The fraction with the ribosome footprint RNA was used for acid phenol extraction.\nPrecipitated RNA was resuspended in 10 mM Tris pH7, mixed with 2x sample buffer (TBE-urea, NOVEX, Invitrogen) and loaded on a 15 % TBE-urea gel. The region between 26-34 nt was excised and used for library generation exactly as described previously (Ingolia et al, Nat Protoc 2012). The library was sequenced on the Illumina HiSeq system according to the manufacturers protocol.'; [Cell type]'mouse brain neural stem cells', 'mouse brain tumor stem cells''tissue: brain; cell type: mouse brain neural stem cells; ', 'tissue: brain; cell type: mouse brain tumor stem cells; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110866,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110866/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA434716,,,,,,,,
GSE108821,mRNA length and 3UTR structure govern the translation selectivity in RPS14-haploinsufficient erythroblasts [translatome],Homo sapiens,6,None,2018-01-05,"[Overal design]The purpose of the dataset is to profile analyze the effect of silencing RPS14; [Treatment]'A scramble (SCR) control shRNA and RPS14 shRNA (640 and 641) were cloned in pLKO.1 Tet-On vector. Cells were selected with puromycine (1 mg/mL). shRNA expression was induced by doxycycline (0.2 ?g/mL) for 3 days'; [Growth]'The UT-7/EPO erythro-megakaryocytic cell line was cultured in ?Minimum Essential Medium (?MEM) containing 10% fetal calf serum (FCS), 1mM glutamine, 100UI/mL penicillin-streptomycin and 1 UI/mL EPO'; [Extraction]'RNA was extracted using the Kit QIAamp RNA Blood MiniKit. RNA from ribosomal fractions was purified using Trizol (Invitrogen).'; [Cell type]'Source: ''cell line: UT7/EPO cells; shRNA: lentivirus expressing SCR shRNA; time post induction: 72h; ', 'cell line: UT7/EPO cells; shRNA: lentivirus expressing RPS14 640 shRNA; time post induction: 72h; ', 'cell line: UT7/EPO cells; shRNA: lentivirus expressing RPS14 641 shRNA; time post induction: 72h; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108821,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE108nnn/GSE108821/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA428742,32327500," Ismael Boussaid,  Salome Le Goff,  Celia Floquet,  Emilie-Fleur Gautier,  Anna Raimbault,  Pierre-Julien Viailly,  Dina Al Dulaimi,  Barbara Burroni,  Isabelle Dusanter-Fourt,  Isabelle Hatin,  Patrick Mayeux,  Bertrand Cosson,  Michaela Fontenay",,Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells.,10.3324/haematol.2019.239970,2021 Mar 1,PMC7927886,Haematologica
GSE76393,Profiling of 2'-O-Me in human rRNA reveals a subset of fractionally modified positions and provides evidence for ribosome heterogeneity,Homo sapiens,3,SRP067890,2015-12-29,"[Overal design]HTC116 and HeLa cells were subjected to RiboMeth-seq analysis. 3 barcoded sequencing adapters were used to produce 3 individual libraries from HTC116 RNA sequenced on 1 individual Ion Proton sequencing chip, and 3 x 2 individual libraries from HeLa RNA sequenced on 2 individual Ion Proton sequencing chips. The 3 gzip compressed fastq files from the sequencings, and the 3 final spread-sheets with annotated data are available here.; [Treatment]'None'; [Growth]'None'; [Extraction]'Whole cell total RNA was extracted using QIAZOL (QIAGEN), according to the manufacturers instructions, after which 15g of total RNA per sample was subjected to native agarose gel electrophoresis and the LSU and SSU rRNA subsequently isolated and gel purified, using the NucleoSpin Gel and PCR Clean-up kit (MACHEREY-NAGEL) according to the manufacturers instructions.\nRiboMeth-seq: 5-10 ug of RNA was partially degraded by alkaline at denaturing temperatures. The size fraction 20-40 nt was purified on gels and linkers added using a system relying on a modified Arabidopsis tRNA ligase joining 2,3 cyclic phosphate and 5- phosphate ends. The library fragments were then sequenced on the Ion Proton platform. See Birkedal U, Christensen-Dalsgaard M, Krogh N, Sabarinathan R, Gorodkin J, Nielsen H. Profiling of ribose methylations in RNA by high-throughput sequencing. Angewandte Chemie. 2015;54(2):451-5 for detailed description.', ""Whole cell total RNA was extracted using QIAZOL (QIAGEN), according to the manufacturers instructions, after which 15g of total RNA per sample was subjected to native agarose gel electrophoresis and the LSU and SSU rRNA subsequently isolated and gel purified, using the NucleoSpin Gel and PCR Clean-up kit (MACHEREY-NAGEL) according to the manufacturers instructions.\nRiboMeth-seq: 5-10 ug of RNA was partially degraded by alkaline at denaturing temperatures. The size fraction 20-40 nt was purified on gels and linkers added using a system relying on a modified Arabidopsis tRNA ligase joining 2',3' cyclic phosphate and 5'- phosphate ends. The library fragments were then sequenced on the Ion Proton platform. See Birkedal U, Christensen-Dalsgaard M, Krogh N, Sabarinathan R, Gorodkin J, Nielsen H. Profiling of ribose methylations in RNA by high-throughput sequencing. Angewandte Chemie. 2015;54(2):451-5 for detailed description.""; [Cell type]'Source: ''cell line: HeLa; strain: S3 (ATCC CCL-2.2); ', 'cell line: HTC116; strain: ATCC CCL-247; '",Methylation profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76393,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE76nnn/GSE76393/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA307191,27257078," Nicolai Krogh,  Martin D Jansson,  Sophia J Hafner,  Disa Tehler,  Ulf Birkedal,  Mikkel Christensen-Dalsgaard,  Anders H Lund,  Henrik Nielsen","Ribose methylation is one of the two most abundant modifications in human ribosomal RNA and is believed to be important for ribosome biogenesis, mRNA selectivity and translational fidelity. We have applied RiboMeth-seq to rRNA from HeLa cells for ribosome-wide, quantitative mapping of 2'-O-Me sites and obtained a comprehensive set of 106 sites, including two novel sites, and with plausible box C/D guide RNAs assigned to all but three sites. We find approximately two-thirds of the sites to be fully methylated and the remainder to be fractionally modified in support of ribosome heterogeneity at the level of RNA modifications. A comparison to HCT116 cells reveals similar 2'-O-Me profiles with distinct differences at several sites. This study constitutes the first comprehensive mapping of 2'-O-Me sites in human rRNA using a high throughput sequencing approach. It establishes the existence of a core of constitutively methylated positions and a subset of variable, potentially regulatory positions, and paves the way for experimental analyses of the role of variations in rRNA methylation under different physiological or pathological settings.",Profiling of 2'-O-Me in human rRNA reveals a subset of fractionally modified positions and provides evidence for ribosome heterogeneity.,10.1093/nar/gkw482,2016 Sep 19,PMC5027482,Nucleic acids research
GSE59080,Translational profiling in multiple myeloma to identify novel therapeutic targets,Homo sapiens,16,None,2014-07-03,[Overal design]The overall design is to treat the multiple myeloma cell line MM1.S with 1uM dexamethasone for 0 or 4 hours and collect total RNA and fractionated polysome pooled RNA (in 3 fractions); [Treatment]'MM1.S cells were treated with 1uM dexamethasone for 0 or 4 hours'; [Growth]'MM1.S cells were grown in log phase in 10% FBS/RPMI'; [Extraction]'Total RNA samples were extracted in TriZol per standard protocol. Polysome pooled RNA was precipitated out of sucrose using isoproponal followed by phenol:chloroform purification'; [Cell type]'myeloma''cell line: MM1.S; cell type: myeloma; ',Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59080,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59080/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA254342,28119225," Nicholas Burwick,  Michael Y Zhang,  Pilar de la Puente,  Abdel Kareem Azab,  Teresa S Hyun,  Melisa Ruiz-Gutierrez,  Marilyn Sanchez-Bonilla,  Tomoka Nakamura,  Jeffrey J Delrow,  Vivian L MacKay,  Akiko Shimamura","Dexamethasone (dex) induces apoptosis in multiple myeloma (MM) cells and is a frontline treatment for this disease. However resistance to dex remains a major challenge and novel treatment approaches are needed. We hypothesized that dex utilizes translational pathways to promote apoptosis in MM and that specific targeting of these pathways could overcome dex-resistance. Global unbiased profiling of mRNA translational profiles in MM cells treated with or without dex revealed that dex significantly repressed eIF2 signaling, an important pathway for regulating ternary complex formation and protein synthesis. We demonstrate that dex induces the phosphorylation of eIF2alpha resulting in the translational upregulation of ATF4, a known eIF2 regulated mRNA. Pharmacologic induction of eIF2alpha phosphorylation via activation of the heme-regulated eIF2alpha kinase (HRI) induced apoptosis in MM cell lines and in primary MM cells from patients with dex-resistant disease. In addition, co-culture with marrow stroma failed to protect MM cells from apoptosis induced by targeting the eIF2 pathway. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2alpha kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.",The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.,10.1016/j.leukres.2017.01.007,2017 Apr,PMC5354961,Leukemia research
GSE11517,Radiation-Induced Changes in Gene Expression Involve Recruitment of Existing Messenger RNAs to and from Polysomes,Homo sapiens,32,None,2008-05-20,"[Overal design]There are 32 samples in total in this study. Each sample has a technical duplicate (16samples x2). Comparison of radiation-induced gene expression profiles generated from microarray analysis of total and polysome-bound RNA isolated from three brain tumor cell lines U87, SF126, SF539 and normal astrocytes. Cells were irradiated at the dose of 7gy and collected 6 hours later for isolation of total cellar RNA or polysome-bound RNA. Gene expression was directly compared between irradiated and unirradiated control cells for total and polysome RNA. The array labeling is two-dye method. Labeling two dye samples are labeled using CY3 dye. All the human reference RNA from Stratagene are labeled using CY5 dye.; [Treatment]'Treatment: no treatment, as a control grown in the same condition as treatment group', 'no treatment', 'Treatment:\nno treatment, as a control grown in the same condition as treatment cells', 'Treatment:\nMonolayer cultures were irradiated using a Pantak X-ray source at a dose rate of 1.55 Gy/min.', 'no treatment as control grown in the same condition as irradiated U87 cells', 'No treatment as control grown in the same condition as irradiated U87 cells', 'no treatment as control grown in the same condition as irradiated SF126 cells', 'No treatment as control grown in the same condition as irradiated SF126 cells', 'No treatment as control grown in the same condition as irradiated SF539 cells'; [Growth]'Primary normal human astrocytes were purchased from Cambrex Bioscience and grown in astrocyte Growth Media for no more than three weeks with a change of media every 2 days until cells were 80% confluent. All cultures are maintained at 37 C in an atmosphere of 5% CO2  and 95% room air.', 'reference to the manufacturer', 'Primary normal human astrocytes were purchased from Cambrex Bioscience and grown in astrocyte Growth Media for no more than three weeks with a change of media every 2 days until cells were 80% confluent. All cultures are maintained at 37 C in an atmosphere of 5% CO2 and 95% room air.', 'U87 cells were grown in DMEM containing glutamate (5 mmol/L) and 10% fetal bovine serum(FBS)', 'SF126 cells were grown in RPMI 1640 containing glutamate (5 mmol/L) and 10% fetal bovine serum(FBS)', 'SF539 cells were grown in RPMI 1640 containing glutamate (5 mmol/L) and 10% fetal bovine serum(FBS)'; [Extraction]'Cells were scraped from tissue culture flasks, and total RNA was extracted from each sample using TRIZOL reagent (Invitrogen, Carlsbad, CA) passed through an RNeasy spin column (Qiagen, Valencia, CA) and then amplified using RiboAmp RNA kits (Arcturus, Mountain View, CA) according to manufacturers protocol.', 'PROTOCOL\nUniversal Human Reference RNA is provided in a solution of 70% ethanol and 0.1 M sodium acetate. Prepare the Reference RNA for\nuse as follows:\n1. Centrifuge the tube at 12,000  g for 15 minutes at 4C.\n2. Carefully remove the supernatant.\n3. Wash the pellet in 70% ethanol.\n4. Centrifuge the tube at 12,000  g for 15 minutes at 4C.\n5. Carefully remove the supernatant and air-dry the pellet at room temperature for 30 minutes to remove retained ethanol.\n6. Resuspend the pellet in RNase-free water to the desired concentration.', 'Polysomes were isolated using sucrose-gradient fractionation basically as described by Galban et al. Cells were grown to 80% confluence in 150-mm2 tissue culture dishes and incubated in 100 Ag of cycloheximide/mL for 15 minutes before collection. Cytoplasmic RNA was obtained by lysing cells in 1 mL of polysome buffer [10 mmol/L Tris-HCl (pH 8), 140 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.5% NP40, 10 mmol/L DTT, 100 Ag/mL cycloheximide, 500 Ag/mL heparin, 1 mmol/L phenylmethanesulfonyl fluoride, and 500 units/mL RNasin (Promega, Madison, WI)]. After 10 minutes on ice, lysates were centrifuged (10,000 _ g for 10 minutes), and the resulting cytosolic supernatant was layered onto a 10% to 50% sucrose gradient. Gradients were then centrifuged at 35,000 _ g for 3 hours at 4C and 1-mL fractions collected using an ISCO Density Gradient Fractionation System (ISCO, Lincoln, NE) with continuous monitoring based on A254. The RNA in each fraction was extracted using TRIZOL and used for Northern analysis, or fractions 5 to 11 (corresponding to polysome-bound RNA) were pooled and subjected to microarray analysis.'; [Cell type]'Source: '''",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11517,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE11nnn/GSE11517/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA106351,16424041," Xing Lu,  Lorena de la Pena,  Christopher Barker,  Kevin Camphausen,  Philip J Tofilon","Although ionizing radiation has been shown to influence gene transcription, little is known about the effects of radiation on gene translational efficiency. To obtain a genome-wide perspective of the effects of radiation on gene translation, microarray analysis was done on polysome-bound RNA isolated from irradiated human brain tumor cells; to allow for a comparison with the effects of radiation on transcription, microarray analysis was also done using total RNA. The number of genes whose translational activity was modified by radiation was approximately 10-fold greater than those whose transcription was affected. The radiation-induced change in a gene's translational activity was shown to involve the recruitment of existing mRNAs to and away from polysomes. Moreover, the change in a gene's translational activity after irradiation correlated with changes in the level of its corresponding protein. These data suggest that radiation modifies gene expression primarily at the level of translation. In contrast to transcriptional changes, there was considerable overlap in the genes affected at the translational level among brain tumor cell lines and normal astrocytes. Thus, the radiation-induced translational control of a subset of mRNAs seems to be a fundamental component of cellular radioresponse.",Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes.,10.1158/0008-5472.CAN-05-3459,2006 Jan 15,,Cancer research
GSE89183,Consequences of Ribosomal Protein Haploinsufficiency in Human Hematopoiesis,Homo sapiens,14,SRP092068,2016-10-25,"[Overal design](mRNA-seq) RNA-seq for control (shLuc), RPL5 knockdown (shRPL5), RPS19 knockdown (shRPS19), and TSR2 knockdown (shTSR2) was performed for two biological replicates of primary human erythroid cells at Day 7 of in vitro culture. (RPF-seq) Ribosome profiling was similarly performed for shLuc, shRPL5, and shRPS19 in the matching biological replicates.; [Treatment]'None'; [Growth]'(cell culture) CD34+ cells were obtained from magnetically sorted mononuclear samples of G-CSFmobilized peripheral blood from donors and were frozen after isolation. Cells were obtained from the Fred Hutchinson Cancer Research Center, Seattle, USA or the Department of Hematology/Oncology Flow Cytometry Research Facility at Boston Childrens Hospital. Cells were thawed and washed into PBS with 1% human AB serum (Atlanta Biologicals), pelleted and then seeded in differentiation medium containing IMDM with 2% human AB plasma, 3% human AB serum, 1% P/S, 200 ug/mL holo-transferrin, 10 ng/mL SCF (PeproTech, Inc.), 1 ng/mL IL-3 (PeproTech, Inc.) and 3 U/mL erythropoietin (EPO) (Amgen). Cells were maintained in this differentiation medium at a density between 0.1  106 and 0.5  106 cells per milliliter, with medium changes every other day as necessary. Cells were incubated at 37 C with 5% CO2.'; [Extraction]'RNA was extracted at day 7 of culture using the Direct-zol RNA MiniPrep Kit (Zymo Research)\nApproximately 1 ug of RNA from each sample was used to generate cDNA libraries for sequencing using the TruSeq RNA Sample Prep Kit v2 (Illumina, Inc., San Diego, CA)', 'RNA was extracted at day 7 of culture using phenol chloroform\nrRNA was depleted using Ribo-Zero Gold (Illumina, Inc., San Diego, CA); ribosome profiling libraries were created using approximately 2 ug of RNA from each sample using the TruSeq Ribo Profile kit (Illumina, Inc., San Diego, CA)'; [Cell type]'Erythroid cells''cell type: Erythroid cells; day: 7; modulation: RPL5 knockdown; ', 'cell type: Erythroid cells; day: 7; modulation: RPS19 knockdown; ', 'cell type: Erythroid cells; day: 7; modulation: TSR2 knockdown; ', 'cell type: Erythroid cells; day: 7; modulation: Luc knockdown (control); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89183,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE89nnn/GSE89183/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA350543,29551269," Rajiv K Khajuria,  Mathias Munschauer,  Jacob C Ulirsch,  Claudia Fiorini,  Leif S Ludwig,  Sean K McFarland,  Nour J Abdulhay,  Harrison Specht,  Hasmik Keshishian,  D R Mani,  Marko Jovanovic,  Steven R Ellis,  Charles P Fulco,  Jesse M Engreitz,  Sabina Schutz,  John Lian,  Karen W Gripp,  Olga K Weinberg,  Geraldine S Pinkus,  Lee Gehrke,  Aviv Regev,  Eric S Lander,  Hanna T Gazda,  Winston Y Lee,  Vikram G Panse,  Steven A Carr,  Vijay G Sankaran","Blood cell formation is classically thought to occur through a hierarchical differentiation process, although recent studies have shown that lineage commitment may occur earlier in hematopoietic stem and progenitor cells (HSPCs). The relevance to human blood diseases and the underlying regulation of these refined models remain poorly understood. By studying a genetic blood disorder, Diamond-Blackfan anemia (DBA), where the majority of mutations affect ribosomal proteins and the erythroid lineage is selectively perturbed, we are able to gain mechanistic insight into how lineage commitment is programmed normally and disrupted in disease. We show that in DBA, the pool of available ribosomes is limited, while ribosome composition remains constant. Surprisingly, this global reduction in ribosome levels more profoundly alters translation of a select subset of transcripts. We show how the reduced translation of select transcripts in HSPCs can impair erythroid lineage commitment, illuminating a regulatory role for ribosome levels in cellular differentiation.",Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis.,10.1016/j.cell.2018.02.036,2018 Mar 22,PMC5866246,Cell
GSE73565,Complementary Post Transcriptional Regulatory Information is Detected by PUNCH-P and Ribosome Profiling,Homo sapiens,16,SRP064313,2015-09-29,"[Overal design]Two Ribo-Seq experiments, which included parallel RNA-Seq, one with 3 replicates, and the other with one replicate, totalling 4 technical replicates for the G1 and M phases of the cell cycle, respectively (totalling 16 samples), were performed.; [Treatment]'None'; [Growth]'None'; [Extraction]'Total mRNA and ribosome-protected fragments were analyzed essentially as described in [PMID:22836135]. In brief, 5x106 HeLa S3 cells synchronized to either G1 or M phase were treated with 100 ug/mL cycloheximide for 5 min, harvested on ice and washed twice in ice-cold PBS. Following cell lysis and removal of nuclei by centrifugation, one tenth of the lysate was removed for total mRNA extraction and the rest was digested with 60 units RNase I (Ambion) for 45 min at room temp. Digestion was terminated with SuperaseIN (Ambion) and monosomes were pelleted by ultracentrifugation on a sucrose cushion. Footprint fragments were purified using a 15% polyacrylamide urea gel, and rRNA fragments were removed using Ribo-Zero Magnetic Gold Kit (Epicentre) according to the manufacturers instructions. In parallel, mRNA was purified using Oligo (dT) cellulose (Ambion) according to the manufacturers instructions and fragmented for 25 min at 94C.\nBoth mRNA and ribosome-protected fragments were dephosphorylated with T4 polynucleotide kinase and ligated to Universal miRNA Cloning Linker (NEB). RNA was reverse transcribed using SuperScript III and cDNA was circularized using CircLigase (both Epicentre). Libraries were amplified using indexed Illumina primers, size selected on a 1% agarose gel and extracted using High Pure PCR Purification Kit (Roche).'; [Cell type]'HeLa S3 cells''cell type: HeLa S3 cells; cell cycle phase: M phase; molecule subtype: Total mRNA (RNA-seq); ', 'cell type: HeLa S3 cells; cell cycle phase: M phase; molecule subtype: ribosome-protected fragments  (Ribo-seq); ', 'cell type: HeLa S3 cells; cell cycle phase: G1 phase; molecule subtype: Total mRNA (RNA-seq); ', 'cell type: HeLa S3 cells; cell cycle phase: G1 phase; molecule subtype: ribosome-protected fragments  (Ribo-seq); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73565,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE73nnn/GSE73565/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA297338,,,,,,,,
GSE149697,"eIF3 associates with 80S ribosomes to promote translation elongation, mitochondrial homeostasis, and muscle health",Homo sapiens,3,None,2020-05-01,"[Overal design]Control and eIF3e depleted cells used for tRNA abundance - 5 biological replicates in total; 3- wildtype and 2-eIF3e depleted; [Treatment]'The cells were treated with 20nM si-control or si-eIF3e for 72h.'; [Growth]'MCF-10a cells were cultured in DMEM/F12 medium with 0.5mg/mL hydrocortisone, 10g/mL insulin, 20ng/mL EGF, 5% serum, 1X Pen/Strep, and incubate in 37? with 5% CO2.\nCell were grown independently for each biological experiment and checked frequently for mycoplasma contamination.'; [Extraction]""Total RNA for total tRNA arrays was extracted using TriReagent (Sigma-Aldrich)  according to manufacturer's protocol""; [Cell type]'Source: ''cell line: MCF-10A; treatment: si-control; ', 'treatment: siRNA for eIF3e; cell line: MCF-10A; '",Non-coding RNA profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149697,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE149nnn/GSE149697/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA629777,32589965," Yingying Lin,  Fajin Li,  Linlu Huang,  Christine Polte,  Haoran Duan,  Jianhuo Fang,  Li Sun,  Xudong Xing,  Guiyou Tian,  Yabin Cheng,  Zoya Ignatova,  Xuerui Yang,  Dieter A Wolf","eIF3, a multi-subunit complex with numerous functions in canonical translation initiation, is known to interact with 40S and 60S ribosomal proteins and translation elongation factors, but a direct involvement in translation elongation has never been demonstrated. We found that eIF3 deficiency reduced early ribosomal elongation speed between codons 25 and 75 on a set of approximately 2,700 mRNAs encoding proteins associated with mitochondrial and membrane functions, resulting in defective synthesis of their encoded proteins. To promote elongation, eIF3 interacts with 80S ribosomes translating the first approximately 60 codons and serves to recruit protein quality-control factors, functions required for normal mitochondrial physiology. Accordingly, eIF3e(+/-) mice accumulate defective mitochondria in skeletal muscle and show a progressive decline in muscle strength. Hence, eIF3 interacts with 80S ribosomes to enhance, at the level of early elongation, the synthesis of proteins with membrane-associated functions, an activity that is critical for mitochondrial physiology and muscle health.","eIF3 Associates with 80S Ribosomes to Promote Translation Elongation, Mitochondrial Homeostasis, and Muscle Health.",10.1016/j.molcel.2020.06.003,2020 Aug 20,,Molecular cell
GSE73136,A spectral analysis approach to detects actively translated open reading frames in high resolution ribosome profiling data,Homo sapiens,1,SRP063852,2015-09-17,"[Overal design]Examination of RNA fragments protected by ribosome; [Treatment]'NA'; [Growth]'HEK293 Flip-In T-REx cells containing a FLAG-HA-tagged GFP were cultured in DMEM supplemented with 10% tet-reduced FBS and appropriate selection antibiotics.'; [Extraction]""For cell lysis, the cell medium was aspirated and cells washed with ice-cold PBS containing 100 g/ml cycloheximide. No cycloheximide was added to the culture medium before. After thorough removal of the PBS, the plates were immersed in liquid nitrogen and placed on dried ice. For cell lysis, 400 l mammalian polysome buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, with 1 mM DTT and 100 g/ml cycloheximide added freshly) was supplied with 1% (v/v) Triton X-100 and 25 U/ml Turbo DNase (Life Technologies, AM2238) and dripped on the plate which is subsequently placed tilted on wet ice. The cells were scraped off to the lower portion of the dish so that they thawed in lysis buffer. After dispersal of the cells by pipetting, the lysate was triturated ten times through a 26G needle, cleared by centrifugation at 20000g for 5 minutes, flash-frozen in liquid nitrogen and stored at -80 C until further usage. For isolation of ribosome-protected RNA fragments, 120 l of the lysate were digested with 3 l RNase I (Life Technologies, AM2294) for 45 min. at room temperature with rotation. The digestion was stopped by addition of 4 l Superase-In (Life Technologies, AM2694). Meanwhile, MicroSpin S-400 HR columns (GE Healthcare, 27-5140-01) were equilibrated with 3 ml mammalian polysome buffer by gravity flow and emptied by centrifugation at 600g for four minutes. Of the digested lysate, 100 l were then immediately loaded on the column and eluted by centrifugation at 600g for two minutes. RNA was extracted from the flow-through, approximately 125 l, using Trizol LS (Life Technologies, 10296-010). Ribosomal RNA fragments were then removed using the RiboZero Kit (Illumina, MRZH11124) and separated on a 17% denaturing Urea-PAGE gel (National Diagnostics, EC-829).\nThe size range from 27nt to 30nt as defined by loading 20 pmol each Marker-27nt and Marker-30nt was cut out and the RNA fragments subjected to smallRNA library generation using 3'-Adapter NN-RA3, 5' adapter OR5-NN, RT primer RTP and PCR primers RP1 (forward primer) and RPI6-7 (reverse primer, containing barcodes). Libraries were sequenced on a HiSeq 2000 device (Illumina). After initial quality control, we obtained ~29 Mio raw reads by pooling the RPI6 and RPI7 samples.""; [Cell type]'Source: ''cell line: HEK293; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73136,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE73nnn/GSE73136/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA296059,26657557," Lorenzo Calviello,  Neelanjan Mukherjee,  Emanuel Wyler,  Henrik Zauber,  Antje Hirsekorn,  Matthias Selbach,  Markus Landthaler,  Benedikt Obermayer,  Uwe Ohler","RNA-sequencing protocols can quantify gene expression regulation from transcription to protein synthesis. Ribosome profiling (Ribo-seq) maps the positions of translating ribosomes over the entire transcriptome. We have developed RiboTaper (available at https://ohlerlab.mdc-berlin.de/software/), a rigorous statistical approach that identifies translated regions on the basis of the characteristic three-nucleotide periodicity of Ribo-seq data. We used RiboTaper with deep Ribo-seq data from HEK293 cells to derive an extensive map of translation that covered open reading frame (ORF) annotations for more than 11,000 protein-coding genes. We also found distinct ribosomal signatures for several hundred upstream ORFs and ORFs in annotated noncoding genes (ncORFs). Mass spectrometry data confirmed that RiboTaper achieved excellent coverage of the cellular proteome. Although dozens of novel peptide products were validated in this manner, few of the currently annotated long noncoding RNAs appeared to encode stable polypeptides. RiboTaper is a powerful method for comprehensive de novo identification of actively used ORFs from Ribo-seq data.",Detecting actively translated open reading frames in ribosome profiling data.,10.1038/nmeth.3688,2016 Feb,,Nature methods
GSE139131,Selective Translation Complex Profiling in yeast and human Reveals Staged Initiation and Co-translational  Assembly of Initiation Factor Complexes [Human],Homo sapiens,6,SRP226389,2019-10-20,"[Overal design]2 replicates for 40S and 80S TCP-seq, 1 replicate for eIF3b bound 40S Sel-TCP-seq and mRNA; [Treatment]'incubation of the cell culture with 0.3 % w/v formaldehyde for 5 min in a cold room'; [Growth]'3.5 Mio cell seeded into one  15 cm dish, 48 h growth, around 80 % confluency at harvest; growth at 37C, 5 % CO2, in DMEM + 10% FBS (20 ml per dish)'; [Extraction]'in-plate cell lysis with detergent, RNase I digestion to generate ribosomal footprints, 40S/80S separation (followed by Co-IP if indicated), hot acid phenol RNA extraction\naccording to Ingolia et al., 2010, Methods Enzymol (different RNA fragment size selection, different set of rRNA depletion oligos)', 'in-plate cell lysis with detergent, total RNA extraction with RNeasy Mini Kit, poly(A) selection with poly(A)Purist MAG Kit, fragmentation\naccording to Ingolia et al., 2010, Methods Enzymol (different RNA fragment size selection, different set of rRNA depletion oligos)'; [Cell type]'Source: ''antibody: no; cell line: HEK293T; protocol: RNA 80S footprint; ', 'antibody: no; cell line: HEK293T; protocol: RNA 40S footprint; ', 'antibody: yes (goat polyclonal anit-eIF3b, sc16377); cell line: HEK293T; protocol: RNA 40S footprint; ', 'antibody: no; cell line: HEK293T; protocol: RNA-seq; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139131,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139131/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA578565,32589964," Susan Wagner,  Anna Herrmannova,  Vladislava Hronova,  Stanislava Gunisova,  Neelam D Sen,  Ross D Hannan,  Alan G Hinnebusch,  Nikolay E Shirokikh,  Thomas Preiss,  Leos Shivaya Valasek","Translational control targeting the initiation phase is central to the regulation of gene expression. Understanding all of its aspects requires substantial technological advancements. Here we modified yeast translation complex profile sequencing (TCP-seq), related to ribosome profiling, and adapted it for mammalian cells. Human TCP-seq, capable of capturing footprints of 40S subunits (40Ss) in addition to 80S ribosomes (80Ss), revealed that mammalian and yeast 40Ss distribute similarly across 5'TRs, indicating considerable evolutionary conservation. We further developed yeast and human selective TCP-seq (Sel-TCP-seq), enabling selection of 40Ss and 80Ss associated with immuno-targeted factors. Sel-TCP-seq demonstrated that eIF2 and eIF3 travel along 5' UTRs with scanning 40Ss to successively dissociate upon AUG recognition; notably, a proportion of eIF3 lingers on during the initial elongation cycles. Highlighting Sel-TCP-seq versatility, we also identified four initiating 48S conformational intermediates, provided novel insights into ATF4 and GCN4 mRNA translational control, and demonstrated co-translational assembly of initiation factor complexes.",Selective Translation Complex Profiling Reveals Staged Initiation and Co-translational Assembly of Initiation Factor Complexes.,10.1016/j.molcel.2020.06.004,2020 Aug 20,PMC7447980,Molecular cell
GSE145722,Genome-wide survey of ribosome collision [eif5A siRNA],Homo sapiens,4,SRP250317,2020-02-21,"[Overal design]Ribosome profiling; [Treatment]'None'; [Growth]'None'; [Extraction]'RNase I footprinting, ribosome pelleting, RNA extraction.\nRNA extraction, preadenylated linker ligation, rRNA depletion, reverse transcription, cDNA circularization, PCR amplification for ribosome profiling.'; [Cell type]'Source: ''cell line: HEK293; sirna: control; treatment: Cycloheximide; ', 'cell line: HEK293; sirna: eif5A; treatment: Cycloheximide; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145722,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE145nnn/GSE145722/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA607999,32375038," Peixun Han,  Yuichi Shichino,  Tilman Schneider-Poetsch,  Mari Mito,  Satoshi Hashimoto,  Tsuyoshi Udagawa,  Kenji Kohno,  Minoru Yoshida,  Yuichiro Mishima,  Toshifumi Inada,  Shintaro Iwasaki","Ribosome movement is not always smooth and is rather often impeded. For ribosome pauses, fundamental issues remain to be addressed, including where ribosomes pause on mRNAs, what kind of RNA/amino acid sequence causes this pause, and the physiological significance of this attenuation of protein synthesis. Here, we survey the positions of ribosome collisions caused by ribosome pauses in humans and zebrafish using modified ribosome profiling. Collided ribosomes, i.e., disomes, emerge at various sites: Pro-Pro/Gly/Asp motifs; Arg-X-Lys motifs; stop codons; and 3' untranslated regions. The electrostatic interaction between the charged nascent chain and the ribosome exit tunnel determines the eIF5A-mediated disome rescue at the Pro-Pro sites. In particular, XBP1u, a precursor of endoplasmic reticulum (ER)-stress-responsive transcription factor, shows striking queues of collided ribosomes and thus acts as a degradation substrate by ribosome-associated quality control. Our results provide insight into the causes and consequences of ribosome pause by dissecting collided ribosomes.",Genome-wide Survey of Ribosome Collision.,10.1016/j.celrep.2020.107610,2020 May 5,PMC7746506,Cell reports
GSE143624,Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis [rna-Seq BRx142],Homo sapiens,4,SRP241900,2020-01-14,"[Overal design]We performed mRNA profiling in control and RPL15 overexpressing circulating tumor cell-derived cell lines to determine the translational efficiency for any given transcript (i.e., the ratio of ribosome-bound mRNA to all poly-A mRNA). Two control specimens and two RPL15 overexpressing specimens were profiled.; [Treatment]'Control or a CMV promoter-driven, lentiviral encoded vector to ectopically express RPL15. Lentiviral expression constructs for RPL15 (Accession: BC071672) were obtained from the CCSB-Broad Lentiviral Expression Library.'; [Growth]'CTCs were grown in suspension in ultra-low attachment plates (Corning) in tumor sphere media, consisting of RPMI-1640 with GlutaMAX supplemented with EGF (20ng/mL), FGF (20ng/mL), 1X B27, and 1X antibiotic/antimycotic (Life Technologies), in 4% O2, as previously described (PUBMED IDs  27556950 and 25013076). CTC lines were routinely checked for mycoplasma (MycoAlert, Lonza), and were authenticated by RNA-seq and DNA-seq.'; [Extraction]'RNA was extracted using the RNeasy Mini Kit (Qiagen).\nThe SMART-Seq HT Kit (Takara Bio USA) was used according to the manufacturers instructions.'; [Cell type]'Source: ''tissue: circulating tumor cell - derived cell line; rpl15 overexpressing: control; ', 'tissue: circulating tumor cell - derived cell line; rpl15 overexpressing: RPL15 overexpressing; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143624,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143624/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA601134,32029688," Richard Y Ebright,  Sooncheol Lee,  Ben S Wittner,  Kira L Niederhoffer,  Benjamin T Nicholson,  Aditya Bardia,  Samuel Truesdell,  Devon F Wiley,  Benjamin Wesley,  Selena Li,  Andy Mai,  Nicola Aceto,  Nicole Vincent-Jordan,  Annamaria Szabolcs,  Brian Chirn,  Johannes Kreuzer,  Valentine Comaills,  Mark Kalinich,  Wilhelm Haas,  David T Ting,  Mehmet Toner,  Shobha Vasudevan,  Daniel A Haber,  Shyamala Maheswaran,  Douglas S Micalizzi","Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors, but only a small subset of these cells generates metastases. We conducted an in vivo genome-wide CRISPR activation screen in CTCs from breast cancer patients to identify genes that promote distant metastasis in mice. Genes coding for ribosomal proteins and regulators of translation were enriched in this screen. Overexpression of RPL15, which encodes a component of the large ribosomal subunit, increased metastatic growth in multiple organs and selectively enhanced translation of other ribosomal proteins and cell cycle regulators. RNA sequencing of freshly isolated CTCs from breast cancer patients revealed a subset with strong ribosome and protein synthesis signatures; these CTCs expressed proliferation and epithelial markers and correlated with poor clinical outcome. Therapies targeting this aggressive subset of CTCs may merit exploration as potential suppressors of metastatic progression.",Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis.,10.1126/science.aay0939,2020 Mar 27,PMC7307008,"Science (New York, N.Y.)"
GSE112085,Codon usage optimization in pluripotent embryonic stem cells [RNA-seq],Homo sapiens,16,SRP136094,2018-03-20,"[Overal design]Ribosome profiling and total RNA from self-renewing and differentiating human H9 cells, 4 biological replicates per condition; [Treatment]'Differentiating hESC were cultured in MEF-conditioned KSR media plus 1uM retinoic acid in DMSO, while the control hESC population was maintained in MEF-conditioned KSR media completed with 4 ng/mL FGF2. Self-renewing cells were collected at Day 0, while differentiating cells at day 5 of treatment.'; [Growth]'hESC were maintained in Essential 8 media (Thermo Fisher Scientific) on hESC-Qualified Matrigel (Corning) coated plates at 37C, 5 % CO2. Cultures were dissociated in clumps using 0.5mM EDTA every 4 days and media was renewed daily.'; [Extraction]'mRNA footprints were prepared according to the ribosomal profilig protocol published by Ingolia et al., while total RNA was extracted using Trizol.\xa0\nmRNA footprints were Ribozero treated (Illumina) and libraries were prepared using TruSeq Small RNA Preparation Kit (Illumina) according to manufacturer instructions. For RNA-seq, total RNA was treated with the RiboZero Magnetic Kit (Illumina) to remove ribosomal RNA. Libraries for sequencing were prepared using the NEB next Ultra Directional library prep kit for Illumina.'; [Cell type]'human embryonic stem cells''cell type: human embryonic stem cells; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112085,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112085/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA439265,31174582," Susanne Bornelov,  Tommaso Selmi,  Sophia Flad,  Sabine Dietmann,  Michaela Frye","BACKGROUND: The uneven use of synonymous codons in the transcriptome regulates the efficiency and fidelity of protein translation rates. Yet, the importance of this codon bias in regulating cell state-specific expression programmes is currently debated. Here, we ask whether different codon usage controls gene expression programmes in self-renewing and differentiating embryonic stem cells. RESULTS: Using ribosome and transcriptome profiling, we identify distinct codon signatures during human embryonic stem cell differentiation. We find that cell state-specific codon bias is determined by the guanine-cytosine (GC) content of differentially expressed genes. By measuring the codon frequencies at the ribosome active sites interacting with transfer RNAs (tRNA), we further discover that self-renewing cells optimize translation of codons that depend on the inosine tRNA modification in the anticodon wobble position. Accordingly, inosine levels are highest in human pluripotent embryonic stem cells. This effect is conserved in mice and is independent of the differentiation stimulus. CONCLUSIONS: We show that GC content influences cell state-specific mRNA levels, and we reveal how translational mechanisms based on tRNA modifications change codon usage in embryonic stem cells.",Codon usage optimization in pluripotent embryonic stem cells.,10.1186/s13059-019-1726-z,2019 Jun 7,PMC6555954,Genome biology
GSE109423,A transcriptome-wide divergence in protein translation scales with LIN28B expression,Homo sapiens; Mus musculus,30,SRP131042,2018-01-19,"[Overal design]Examination of LIN28B binding using enhanced CLIP via 2 biological replicates of RNA fragments derived from LIN28B immunoprecipitation and 2 control input replicates for 5 LIN28B expression conditions. X0 is lin28b knockout. X1 through X4 are increasing levels of lin28b expression (X1 < X2 < X3 < X4). X1 through X4 lie within the naturally occurring spectrum of lin28b expression from other cell types such as HepG2, NTera2 and iPSC. Examination of small RNAs expressed in HEK293A and those specifically bound by AGO2, in the presence or absence of LIN28B or transfected let-7a miRNA, single replicate. Examination of changes in transcriptome-wide ribosome occupancy in HEK293A via total RNA (2 replicates) and ribosome-bound RNA (2 replicates) for 5 different LIN28B expression conditions. Experimental design for examining changes in transcriptome-wide ribosome occupancy in NIH3T3 were the same as for HEK293A.; [Treatment]'LIN28B transgenes were induced using 10ng/ml Doxycycline; mature let-7a miRNAs (10nM) were introduced using Lipofectamine RNAiMAX'; [Growth]'standard cell culture in 10% FBS in DMEM'; [Extraction]'Total and polysome derived RNA were extracted using Trizol reagent; small RNA isolation was performed using miRvana kit\nVarious: Illumina polyA Total RNA kit, Illumina Small RNA kit'; [Cell type]'Source: ''cell line: HEK293A; ', 'cell line: NIH3T3; ', 'cell line: HEK293A; antibody: anti-AGO2 Clone 9E8.2, Millipore, Cat# 04-642; '",Other; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109423,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE109nnn/GSE109423/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA430874,30527666," Frederick E Tan,  Shashank Sathe,  Emily C Wheeler,  Julia K Nussbacher,  Samson Peter,  Gene W Yeo","LIN28 RNA binding proteins are dynamically expressed throughout mammalian development and during disease. However, it remains unclear how changes in LIN28 expression define patterns of post-transcriptional gene regulation. Here we show that LIN28 expression level is a key variable that sets the magnitude of protein translation. By systematically varying LIN28B protein levels in human cells, we discovered a dose-dependent divergence in transcriptome-wide ribosome occupancy that enabled the formation of two discrete translational subpopulations composed of nearly all expressed genes. This bifurcation in gene expression was mediated by a redistribution in Argonaute association, from let-7 to non-let-7 microRNA families, resulting in a global shift in cellular miRNA activity. Post-transcriptional effects were scaled across the physiological LIN28 expression range. Together, these data highlight the central importance of RBP expression level and its ability to encode regulation.",A Transcriptome-wide Translational Program Defined by LIN28B Expression Level.,10.1016/j.molcel.2018.10.041,2019 Jan 17,PMC6338497,Molecular cell
GSE103719,"Transcriptome-wide profiling of poly(A)-tail length, translation efficiency and mRNA stability using TED-seq, mRNA-seq, Ribo-seq and PRO-seq in ER stress conditions",Homo sapiens,36,SRP117282,2017-09-11,"[Overal design]1) TED-seq (5 replicates) in cytoplasm and RNA granule fractions (3 replicates) of DMSO- or THAP-treated HEK293 cells 2) RNA-seq (4 replicates), Ribo-seq (4 replicates) and PRO-seq (2 replicates) in whole cells with DMSO- or THAP-treated HEK293 cells; [Treatment]'For ER stress induction, thapsigargin (THAP, Sigma-Aldrich) was treated with 2 M for 2 h in HEK293 cells.'; [Growth]'HEK293 cells were cultured in MEM (Gibco) media with 10% fetal bovine serum in a humidified 5% CO2 atmosphere at 37 degrees Celsius.'; [Extraction]""Cell fractionation was performed by differential centrifugation following by THAP treatment (2 ?M for 2 hr). Briefly, the cells were washed with cold PBS twice and lysed by cold Buffer L (50 mM Tris-HCL (pH7.6), 50 mM NaCl, 5 mM MgCl2, 0.1% NP-40, 1 mM ?-mercaptoethanol, 1x Roche complete protease inhibitor EDTA-free, 10 ?l SUPERaseIN/ml) by scraping and pipetting. Cell lysates were homogenized and centrifuged at 2,000g at 4C for 2 min. Pellet is nucleus fraction and aqua phase includes cytoplasmic fraction. Cytoplasmic fraction was centrifuged at 10,000g at 4C for 10 min and insoluble fraction was obtained from the pellet. The insoluble fraction includes stress granules in TAHP-treated cells.  For TED-seq, total RNA was isolated using TRIzol or TRIzol-LS according to the manufacturers protocol (Invitrogen Life Technologies). Poly(A) RNA was isolated from 5~10 ?g of total RNA using Dynabeads mRNA purification kit (Ambion) according to the manufacturers protocol.   The ribosome footprint strategy was followed as the previous paper (Ingolia et al., 2012) and partially modified for the generation of RNA-seq library. In brief, cultured cells were washed twice with ice-cold 1x PBS and lyzed by adding lysis buffer (20 mM Tris-Cl (pH7.4), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml cycloheximide, 1% (v/v) Triton X-100, 25 U/ml Turbo DNase I) and triturating the cells ten times through a 26-gauge needle. After centrifuging the cell lysate at 20,000g at 4C for 10 min, the supernatant was divided into two groups for ribosome profiling library and mRNA expression profiling library.  For ribosome profiling library, RNase I (100 U/?l) was treated in lysate and incubated at room temperature for 45 min. After nuclease digestion, ribosome footprinted RNAs were purified by sedimenting through a 1 M sucrose cushion and excising the urea gel between 26-34 nucleotides.  For mRNA expression profiling library, TRIzol was added into the supernatant and total RNA was extracted according to the manufacturer's protocol.  For nuclei isolation of PRO-seq, cells were washed twice with 1X cold PBS. Cells were scrapped with 1ml of Buffer D (50mM Tris-Cl, pH 8.0, 25% glycerol, 5mM M MgCl2, 0.1mM EDTA, 5mM DTT). Cells were pelleted at 1000 x g for 5min and then resuspended in 50 l of Buffer D. And then flash frozen in liquid nitrogen.\nIn TED-seq libralies, for 3' RNA adaptor ligation, 40 pmol of RA3 adaptor (5'phosphate-UGGAAUUCUGGGGUGCCAAGG-/3InvdT/-3') was treated into each poly(A) RNA and incubated in 20C for 6 hr. After RNA extraction with TRIzol, RNA fragmentation with 1N NaOH was performed by incubating on ice for 10 min. To remove un-ligated adaptors, poly(A) RNA was isolated from the fragmented RNA using Dynabeads mRNA purification kit (Ambion). 5' end phosphorylation was performed using T4 polynucleotide kinase (PNK, NEB) according to the manufacturers protocol, following by RNA extraction with TRIzol, For 5' RNA adaptor ligation, 30 pmol of RA5 (5'-GUUCAGAGUUCUACAGUCCGACGAUCNNNNNNNN-3') and 50 pmol of RT primer (RTP, 5'-GCCTTGGCACCCGAGAATTCCA-3') were treated into each RNA and incubated in 20C for 6 hr. 5'-ligated RNA was reverse-transcribed using Superscript II Reverse Transcriptase kit (Invitrogen) including 0.1 M DTT, 12.5 mM dNTP mixture, SUPERaseIN (Ambion). For first size selection of the library, first round amplification was performed with 8 cycles. Following by loading the PCR products to big native 6% polyacrylamide gel, gel bands between 350-360 bp (insert 300 bp) from each sample were excised and then DNA was recovered using Ampure XP beads (Beckman Coulter, Inc.) as provided by the manufacturers protocol. To obtain precisely size-selected library, recovered DNA was used for second amplification with optimal cycles and different RPI-X barcode index primer according to TruSeq Library Prep Pooling guide (Illumina). Finally, gel extraction was repeated with bands with 426 bp for each selected insert size. The libraries were pooled and sequenced on Illumina NextSeq500 (75 bp) with PhiX control library and the spike-in mixture.     Ribo-seq libraries, 3' end was dephosphorylated by adding PNK and ligated by adding 40 pmol of RA3 adaptor. 5' end was phosphorylated by adding PNK and ATP and ligated by adding 30 pmol of RA5 adaptor and 50 pmol of RTP primer. After reverse transcription using Superscript II reverse transcriptase (Invitrogen), rRNA products were depleted by hybridization to biotinylated sense-strand oligonucleotides followed by removal of the duplexes through streptavidin bead affinity. Finally, through PCR and gel extraction, the library was generated with 150-160 bp-size.    For mRNA-seq library, poly(A) RNA was isolated using Dynabeads mRNA purification kit (Ambion) according to the manufacturers protocol. After RNA fragmentation with 1 N NaOH at 37C for 3 min, the final library ranging from 150 to 200 bp-size was generated followed by the same process as producing ribosome profiling library from the step of 3' dephosphorylation, except for rRNA depletion.    PRO-seq libraries were prepared as described previously (Kwak et al., 2013)."", ""Cell fractionation was performed by differential centrifugation following by THAP treatment (2 ?M for 2 hr). Briefly, the cells were washed with cold PBS twice and lysed by cold Buffer L (50 mM Tris-HCL (pH7.6), 50 mM NaCl, 5 mM MgCl2, 0.1% NP-40, 1 mM ?-mercaptoethanol, 1x Roche complete protease inhibitor EDTA-free, 10 ?l SUPERaseIN/ml) by scraping and pipetting. Cell lysates were homogenized and centrifuged at 2,000g at 4C for 2 min. Pellet is nucleus fraction and aqua phase includes cytoplasmic fraction. Cytoplasmic fraction was centrifuged at 10,000g at 4C for 10 min and insoluble fraction was obtained from the pellet. The insoluble fraction includes stress granules in TAHP-treated cells.  For TED-seq, total RNA was isolated using TRIzol or TRIzol-LS according to the manufacturers protocol (Invitrogen Life Technologies). Poly(A) RNA was isolated from 5~10 ?g of total RNA using Dynabeads mRNA purification kit (Ambion) according to the manufacturers protocol.   The ribosome footprint strategy was followed as the previous paper (Ingolia et al., 2012) and partially modified for the generation of RNA-seq library. In brief, cultured cells were washed twice with ice-cold 1x PBS and lyzed by adding lysis buffer (20 mM Tris-Cl (pH7.4), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml cycloheximide, 1% (v/v) Triton X-100, 25 U/ml Turbo DNase I) and triturating the cells ten times through a 26-gauge needle. After centrifuging the cell lysate at 20,000g at 4C for 10 min, the supernatant was divided into two groups for ribosome profiling library and mRNA expression profiling library.  For ribosome profiling library, RNase I (100 U/?l) was treated in lysate and incubated at room temperature for 45 min. After nuclease digestion, ribosome footprinted RNAs were purified by sedimenting through a 1 M sucrose cushion and excising the urea gel between 26-34 nucleotides.  For mRNA expression profiling library, TRIzol was added into the supernatant and total RNA was extracted according to the manufacturer's protocol.  For nuclei isolation of PRO-seq, cells were washed twice with 1X cold PBS. Cells were scrapped with 1ml of Buffer D (50mM Tris-Cl, pH 8.0, 25% glycerol, 5mM M MgCl2, 0.1mM EDTA, 5mM DTT). Cells were pelleted at 1000 x g for 5min and then resuspended in 50 l of Buffer D. And then flash frozen in liquid nitrogen.\nIn TED-seq libralies, for 3' RNA adaptor ligation, 40 pmol of RA3 adaptor (5'phosphate-UGGAAUUCUGGGGUGCCAAGG-/3InvdT/-3') was treated into each poly(A) RNA and incubated in 20C for 6 hr. After RNA extraction with TRIzol, RNA fragmentation with 1N NaOH was performed by incubating on ice for 10 min. To remove un-ligated adaptors, poly(A) RNA was isolated from the fragmented RNA using Dynabeads mRNA purification kit (Ambion). 5' end phosphorylation was performed using T4 polynucleotide kinase (PNK, NEB) according to the manufacturers protocol, following by RNA extraction with TRIzol, For 5' RNA adaptor ligation, 30 pmol of RA5 (5'-GUUCAGAGUUCUACAGUCCGACGAUCNNNNNNNN-3') and 50 pmol of RT primer (RTP, 5'-GCCTTGGCACCCGAGAATTCCA-3') were treated into each RNA and incubated in 20C for 6 hr. 5'-ligated RNA was reverse-transcribed using Superscript II Reverse Transcriptase kit (Invitrogen) including 0.1 M DTT, 12.5 mM dNTP mixture, SUPERaseIN (Ambion). For first size selection of the library, first round amplification was performed with 8 cycles. Following by loading the PCR products to big native 6% polyacrylamide gel, gel bands between 350-360 bp (insert 300 bp) from each sample were excised and then DNA was recovered using Ampure XP beads (Beckman Coulter, Inc.) as provided by the manufacturers protocol. To obtain precisely size-selected library, recovered DNA was used for second amplification with optimal cycles and different RPI-X barcode index primer according to TruSeq Library Prep Pooling guide (Illumina). Finally, gel extraction was repeated with bands with 426 bp for each selected insert size. The libraries were pooled and sequenced on Illumina NextSeq500 (75 bp) with PhiX control library and the spike-in mixture.""; [Cell type]'Fetus derived cell line from female human embryonic kidney''cell type: Fetus derived cell line from female human embryonic kidney; passages: 10-20; drug treatment: DMSO for 2h; sirna transfection: none; ', 'cell type: Fetus derived cell line from female human embryonic kidney; passages: 10-20; drug treatment: THAP (2M) for 2h; sirna transfection: none; ', 'cell line: HEK293; cell type: Fetus derived cell line from female human embryonic kidney; passages: 10-20; drug treatment: DMSO for 2h; molecule subtype: total RNA from cytosol fraction; ', 'cell line: HEK293; cell type: Fetus derived cell line from female human embryonic kidney; passages: 10-20; drug treatment: THAP (2M) for 2h; molecule subtype: total RNA from cytosol fraction; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103719,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE103nnn/GSE103719/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA406823,,,,,,,,
GSE52809,Poly(A)-tail profiling reveals an embryonic switch in translational control,Mus musculus; Drosophila melanogaster; Schizosaccharomyces pombe; Danio rerio; Arabidopsis thaliana; Xenopus laevis; Saccharomyces cerevisiae; Homo sapiens,64,SRP033369,2013-11-27,"[Overal design]64 samples from a variety of species; [Treatment]'RNA-seq: Cytoplasmically-enriched RNA was extracted, poly(A)-selected, randomly fragmented by partial alkaline hydrolysis and then size-selected RNA fragments were used for library preparation. Ribosome profiling: Cell extracts were processed as described in Subtelny et al., 2014 (GSE52809).                                 PAL-seq: Polyadenylated ends in total RNA were ligated to a biotinylated adaptor, then partially digested with RNase T1. The resulting fragments were size-selected (104-750 nt), captured on streptavidin beads, and used for library preparation.'; [Growth]'Each sample was grown or maintained in accordance with standard protocols.'; [Extraction]'Libraries were constructed exactly as described in Subtelny et al., 2014 (GSE52809)'; [Cell type]'Source: ''strain: 972; ', 'strain: C57BL/6; developmental stage: 6 week; Sex: Male; ', 'cell line: HEK293T; ', 'cell line: 3T3; ', 'strain: AB; developmental stage: 2 hours post-fertilization; ', 'strain: AB; developmental stage: 4 hours post-fertilization; ', 'strain: AB; developmental stage: 6 hours post-fertilization; ', 'developmental stage: stage 3-4; ', 'developmental stage: stage 9; ', 'strain: BY4741; ', 'ecotype: Columbia; ', 'cell line: S2; ', 'cell line: HeLa; ', 'developmental stage: stage 12-12.5; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52809,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE52nnn/GSE52809/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA230112,24476825," Alexander O Subtelny,  Stephen W Eichhorn,  Grace R Chen,  Hazel Sive,  David P Bartel","Poly(A) tails enhance the stability and translation of most eukaryotic messenger RNAs, but difficulties in globally measuring poly(A)-tail lengths have impeded greater understanding of poly(A)-tail function. Here we describe poly(A)-tail length profiling by sequencing (PAL-seq) and apply it to measure tail lengths of millions of individual RNAs isolated from yeasts, cell lines, Arabidopsis thaliana leaves, mouse liver, and zebrafish and frog embryos. Poly(A)-tail lengths were conserved between orthologous mRNAs, with mRNAs encoding ribosomal proteins and other 'housekeeping' proteins tending to have shorter tails. As expected, tail lengths were coupled to translational efficiencies in early zebrafish and frog embryos. However, this strong coupling diminished at gastrulation and was absent in non-embryonic samples, indicating a rapid developmental switch in the nature of translational control. This switch complements an earlier switch to zygotic transcriptional control and explains why the predominant effect of microRNA-mediated deadenylation concurrently shifts from translational repression to mRNA destabilization.",Poly(A)-tail profiling reveals an embryonic switch in translational control.,10.1038/nature13007,2014 Apr 3,PMC4086860,Nature
GSE111866,Ribosome profiling and transcriptome profiling of MCF-7 cells,Homo sapiens,2,SRP135757,2018-03-15,"[Overal design]We performed ribosome profiling (RIBO-seq) and transcriptome profiling (RNA-seq) on MCF-7 cells; [Treatment]'Cells were maintained in culture at 37C with 5% of CO2 in Dulbeccos Modified Eagles Medium (DMEM) with 4.5 g/l glucose supplemented with 2 mM glutamine, 10% Fetal Bovine Serum, 100 U/ml penicillin e 100 mg/ml streptomycin.'; [Growth]'MCF-7 breast carcinoma cells were uses in the study.'; [Extraction]'Cytoplasmic lysates were digested with 5 Units of ARTseq Nuclease for each A260 of lysate at room temperature for 45 minutes. The RNA was treated with Ribo-Zero rRNA Removal Kit (Illumina) to remove ribosomal RNA contamination and the Ribosome Protected Fragments (RPFs) were then extracted with acid-phenol:chloroform:isoamylalcohol and isopropanol precipitation and size seNGS libraries were prepared starting from RPFs using the ARTseq Ribosome Profiling Kit  Mammalian (Epicentre) following the standard protocol.\nCells (1.5 x 10^6) were seeded in 10 cm cell culture dishes and kept in culture until reaching 80% confluency. Prior to lysis, cycloheximide (10 ?g/mL) was added to the culture that was incubated in this condition at 37C for 4 min. The dishes were then rinsed with ice cold PBS supplemented with 10 ?g/ml cycloheximide and lysated with 150 ?l of polysomes lysis buffer (10 mM NaCl, 10 mM MgCl2, 10 mM, TRIS/HCl-pH 7.5, 1% Triton X-100, 2 U/?l RNAse inhibitor, 1M DTT, 1% Na deoxycholate). The lysates were incubated for 5 in ice, vortexed and centrifuged for 5 at 14.000rpm at 4C to precipitate cellular debris, nuclei and mitochondria. The supernatants have been stored at -80C before the libraries preparation.', ""Total RNA was extracted from cytoplasmic lysates with acid-phenol:chloroform:isoamylalcohol and isopropanol precipitation and ribosomal RNA was removed with Ribo-Zero rRNA Removal Kit (Illumina): Libraries were prepared using the TruSeq RNA Library Prep Kit (Illumina) following the manufacturer's instructions.\nCells (1.5 x 10^6) were seeded in 10 cm cell culture dishes and kept in culture until reaching 80% confluency. Prior to lysis, cycloheximide (10 ?g/mL) was added to the culture that was incubated in this condition at 37C for 4 min. The dishes were then rinsed with ice cold PBS supplemented with 10 ?g/ml cycloheximide and lysated with 150 ?l of polysomes lysis buffer (10 mM NaCl, 10 mM MgCl2, 10 mM, TRIS/HCl-pH 7.5, 1% Triton X-100, 2 U/?l RNAse inhibitor, 1M DTT, 1% Na deoxycholate). The lysates were incubated for 5 in ice, vortexed and centrifuged for 5 at 14.000rpm at 4C to precipitate cellular debris, nuclei and mitochondria. The supernatants have been stored at -80C before the libraries preparation.""; [Cell type]'Source: ''cell line: MCF-7; rna fraction: cytoplasmic RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111866,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111866/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA438445,30102689," Fabio Lauria,  Toma Tebaldi,  Paola Bernabo,  Ewout J N Groen,  Thomas H Gillingwater,  Gabriella Viero","Ribosome profiling is a powerful technique used to study translation at the genome-wide level, generating unique information concerning ribosome positions along RNAs. Optimal localization of ribosomes requires the proper identification of the ribosome P-site in each ribosome protected fragment, a crucial step to determine the trinucleotide periodicity of translating ribosomes, and draw correct conclusions concerning where ribosomes are located. To determine the P-site within ribosome footprints at nucleotide resolution, the precise estimation of its offset with respect to the protected fragment is necessary. Here we present riboWaltz, an R package for calculation of optimal P-site offsets, diagnostic analysis and visual inspection of ribosome profiling data. Compared to existing tools, riboWaltz shows improved accuracies for P-site estimation and neat ribosome positioning in multiple case studies. riboWaltz was implemented in R and is available as an R package at https://github.com/LabTranslationalArchitectomics/RiboWaltz.",riboWaltz: Optimization of ribosome P-site positioning in ribosome profiling data.,10.1371/journal.pcbi.1006169,2018 Aug,PMC6112680,PLoS computational biology
GSE128344,"A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP b-CTFs, not Ab [ribosome profiling]",Homo sapiens,12,SRP188505,2019-03-15,"[Overal design]Ribosome profiling analysis of wildtype and three different mutated human iPS cells differentiated into neurons before; [Treatment]'None'; [Growth]'induction and maturation of cortical neurons from iPS cells (total of 80 days in vitro; detailed protocol in accompanying paper)'; [Extraction]""cell lysis and partial RNAse digestion followed by ribosome immunoprecipitation to extract ribosome associated fragments (detailed protocol in accompanying paper)\npartial RNAse digestion, ribosome associated fragment purification, linker ligation, reverse transcription, cDNA purification, PCR amplification (detailed protocol in accompanying paper)\nligation of 3' linker, addition of 5'linker with barcode and UMI via RT (detailed protocol in accompanying paper)""; [Cell type]'co-isogenic iPS cells''cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: none; ', 'cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: APP Swe/Swe; ', 'cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: PSEN1 M146V/M146V; ', 'cell line background: 7889SA parental cell line; cell line source: 80 day old cortical neurons; cell type: co-isogenic iPS cells; mutation: APP Swe/Swe; PSEN1 M146V/M146V; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128344,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128344/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA527204,31416668," Dylan Kwart,  Andrew Gregg,  Claudia Scheckel,  Elisabeth A Murphy,  Dominik Paquet,  Michael Duffield,  John Fak,  Olav Olsen,  Robert B Darnell,  Marc Tessier-Lavigne","Familial Alzheimer's disease (fAD) results from mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes. Here we leveraged recent advances in induced pluripotent stem cell (iPSC) and CRISPR/Cas9 genome editing technologies to generate a panel of isogenic knockin human iPSC lines carrying APP and/or PSEN1 mutations. Global transcriptomic and translatomic profiling revealed that fAD mutations have overlapping effects on the expression of AD-related and endocytosis-associated genes. Mutant neurons also increased Rab5+ early endosome size. APP and PSEN1 mutations had discordant effects on Abeta production but similar effects on APP beta C-terminal fragments (beta-CTFs), which accumulate in all mutant neurons. Importantly, endosomal dysfunction correlated with accumulation of beta-CTFs, not Abeta, and could be rescued by pharmacological modulation of beta-secretase (BACE). These data display the utility of our mutant iPSCs in studying AD-related phenotypes in a non-overexpression human-based system and support mounting evidence that beta-CTF may be critical in AD pathogenesis.","A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta.",10.1016/j.neuron.2019.07.010,2019 Oct 23,,Neuron
GSE138417,Selective Inhibitors of mTORC1 Activate 4EBP1 and Suppress Tumor Growth,Homo sapiens,50,None,2019-10-03,"[Overal design]4 biological replicates of MCF7 cells under one of the following conditions: Starvation, Full serum + DMSO, Full serum + MLN0128, Full serum + RMC-4627, Full serum + RMC-4745. RMC-4627 and RMC-4745 are selective inhibitors of mTORC1 developed within this study. For one of the biological replicate (replicate 1), we provided 2 technical replicates (1A and 1B); [Treatment]'On day 0, cells were seeded in 15-cm plates. On day 2, cells were washed three times in PBS and starved in RPMI with 0.1% FBS media for 16h. This was followed by a 4h stimulation with complete media in presence of vehicle (DMSO), RMC-4627 (3nM), RMC-4745 (35nM) or MLN0128 (40nM). Cell confluence was at 80% upon harvest. Four biological replicates were generated and polysome-profiling was performed as previously described (Gandin et al. 2014).'; [Growth]'MCF7 scr cells were cultured in RPMI containing 10% FBS and 1% penicillin/streptomycin at 37 C and 5% CO2.'; [Extraction]'Polysome-associated mRNA was extracted from fractions corresponding to mRNA associated with more than 3 ribosomes. RNA extraction was performed in parallel for polysome-associated and cytoplasmic RNA using Tri-reagent followed by purification using the RNeasy MinElute Cleanup Kit (Qiagen).\nSequencing libraries were constructed using the smartSeq2 protocol (Picelli et al., 2014).'; [Cell type]'Source: ''cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4627; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4627; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4745; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4745; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: MLN0128; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: MLN0128; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: DMSO; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: DMSO; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: STARVE; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: STARVE; replicate_identifier: 1A; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4627; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4627; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4745; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4745; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: MLN0128; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: MLN0128; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: DMSO; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: DMSO; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: STARVE; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: STARVE; replicate_identifier: 1B; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4627; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4627; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4745; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4745; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: MLN0128; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: MLN0128; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: DMSO; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: DMSO; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: STARVE; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: STARVE; replicate_identifier: 2; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4627; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4627; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4745; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4745; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: MLN0128; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: MLN0128; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: DMSO; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: DMSO; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: STARVE; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: STARVE; replicate_identifier: 3; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4627; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4627; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: RMC4745; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: RMC4745; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: MLN0128; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: MLN0128; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: DMSO; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: DMSO; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Cytosolic; treatment: STARVE; replicate_identifier: 4; ', 'cell line: MCF7 cells; rna_type: Polysome assoc.; treatment: STARVE; replicate_identifier: 4; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138417,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138417/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA575792,34168367," Bianca J Lee,  Jacob A Boyer,  G Leslie Burnett,  Arun P Thottumkara,  Nidhi Tibrewal,  Stacy L Wilson,  Tientien Hsieh,  Abby Marquez,  Edward G Lorenzana,  James W Evans,  Laura Hulea,  Gert Kiss,  Hui Liu,  Dong Lee,  Ola Larsson,  Shannon McLaughlan,  Ivan Topisirovic,  Zhengping Wang,  Zhican Wang,  Yongyuan Zhao,  David Wildes,  James B Aggen,  Mallika Singh,  Adrian L Gill,  Jacqueline A M Smith,  Neal Rosen","The clinical benefits of pan-mTOR active-site inhibitors are limited by toxicity and relief of feedback inhibition of receptor expression. To address these limitations, we designed a series of compounds that selectively inhibit mTORC1 and not mTORC2. These 'bi-steric inhibitors' comprise a rapamycin-like core moiety covalently linked to an mTOR active-site inhibitor. Structural modification of these components modulated their affinities for their binding sites on mTOR and the selectivity of the bi-steric compound. mTORC1-selective compounds potently inhibited 4EBP1 phosphorylation and caused regressions of breast cancer xenografts. Inhibition of 4EBP1 phosphorylation was sufficient to block cancer cell growth and was necessary for maximal antitumor activity. At mTORC1-selective doses, these compounds do not alter glucose tolerance, nor do they relieve AKT-dependent feedback inhibition of HER3. Thus, in preclinical models, selective inhibitors of mTORC1 potently inhibit tumor growth while causing less toxicity and receptor reactivation as compared to pan-mTOR inhibitors.",Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.,10.1038/s41589-021-00813-7,2021 Oct,,Nature chemical biology
GSE134752,Translational dynamics of recoded neuraminidase of influenza A virus.,Homo sapiens,14,SRP216083,2019-07-23,"[Overal design]Expression plasmids containing recoded IAV neuramindase were transfected into HEK 293T cells and translational dynamics of neuraminidase mRNA was determined by ribosome footprint-profiling experiments; [Treatment]'Expression plasmids containing recoded neuraminidase genes have been transfected into HEK 293T cells for 24h'; [Growth]'HEK293T cells were grown in DMEM + 10%FCS'; [Extraction]'Cells were lysed in mammalian polysome buffer, digested with RNase I, loaded on a MicroSpin S-400 HR colum (GE Healthcare) and RNA was extracted using Trizol LS as described in Calviello et al. 2016 (doi:10.1038/nmeth.3688)\nlibraries were constructed as described in Calviello et al. 2016 (doi:10.1038/nmeth.3688)'; [Cell type]'Source: ''na constructs: 27wt, 72Lmax and 27min; ', 'na constructs: 72Hmax and 46med; ', 'na constructs: 72min; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134752,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE134nnn/GSE134752/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA556267,,,,,,,,
GSE60543,Translatome and transcriptome profiling of SH-SY5Y cells treated with staphylococcal alpha-hemolysin oligomers,Homo sapiens,12,None,2014-08-20,"[Overal design]The comparison between translatome and transcriptome profiling was used to discover mRNA-specific changes of the SH-SY5Y cells transcriptome and translatome in response to staphylococcal ?-hemolysin oligomers (rAHL). To identify translationally regulated mRNAs, gene expression signals derived from the polysomal mRNA populations were compared by microarrays analysis to those obtained from total RNAs. Polysomal mRNA and total mRNA were isolated from SH-SY5Y cells treated with 3nM of extracted oligomers (rAHL) for 2 hours. Cells lysates were collected from untreated cells (control) and from treated cells. All experiments were run in biological triplicates.; [Treatment]'SH-SY5Y cells were seeded at a density of 2.5  104 cells/cm2 and maintained for 3 days in the growth medium, until the 80% confluence was reached. All experiments were performed in \xa0the presence of 3nM rAHL oligomers for 2h in DMEM using medium without phenol red, FBS, and antibiotics \xa0 to avoid any interference with protein.', 'SH-SY5Y cells were seeded at a density of 2.5  104 cells/cm2 and maintained for 3 days in the growth medium, until the 80% confluence was reached. The control experiments were performed in DMEM using medium without phenol red, FBS, and antibiotics to avoid any interference with protein.'; [Growth]'SH-SY5Y cells were maintained in DMEM supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-glutamine, penicillin 100.000 U.I./l and streptomycin 100 mg/l. Cells were cultured at 37 C in humid atmosphere of 5% CO2. All experiments were performed in DMEM using medium without phenol red, FBS, and antibiotics to avoid any interference with protein. If not specified differently, cells were grown to 80% of confluence before each assay.'; [Extraction]""Total RNA was extracted using TRIZOL reagent according to the manufacturer's protocol. Briefly, the aqueous phase was used for RNA precipitation with an equal volume of isopropanol. The RNA pellet was washed once with 75% ethanol, then air-dried and re-dissolved in 20 ?l of RNase-free water. RNA was quantified using a spectrophotometer and its quality was checked by agarose gel electrophoresis and by Agilent 2100 Bioanalyzer platform, following the manifacturers guidelines for sample preparation and analysis of data (Agilent 2100 Bioanalyzer 2100 Expert User's Guide, http://www.agilent.com)."", 'Cells were washed once with phosphate buffer saline (PBS) and treated directly on the plate with 300 l lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/l RNase inhibitor (Fermentas) and 1 mM dithiothreitol] and transferred to an Eppendorf tube. After a few minute incubation on ice with occasional vortexing, the extracts were centrifuged for 10 min at 12000 g at 4C. The supernatant was stored at 80C or loaded directly onto a 1550% linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in an Sorvall rotor for 120 min at 40000 rpm. Polysomal fractions were collected monitoring the absorbance at 254 nm and treated directly with proteinase K. After phenolchloroform extraction and isopropanol precipitation, polysomal RNA was resuspended in 30 l of water. RNA quality was assessed by agarose gel electrophoresis and the Agilent 2100 Bioanalyzer platform.'; [Cell type]'Source: ''cell line: SH-SY5Y; treated with: 3nM rAHLfor 2hrs; rna fraction: total RNA; ', 'cell line: SH-SY5Y; treated with: none (untreated control); rna fraction: total RNA; ', 'cell line: SH-SY5Y; treated with: 3nM rAHLfor 2hrs; rna fraction: cytoplasmic RNA; polysomal RNA; ', 'cell line: SH-SY5Y; treated with: none (untreated control); rna fraction: cytoplasmic RNA; polysomal RNA; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60543,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60543/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA258509,26371376," Massimiliano Clamer,  Toma Tebaldi,  Marta Marchioretto,  Paola Bernabo,  Efrem Bertini,  Graziano Guella,  Mauro Dalla Serra,  Alessandro Quattrone,  Gabriella Viero","Genome-wide analyses of translation can provide major contributions in our understanding of the complex interplay between virulent factors and host cells. So far, the activation of host translational control mechanisms by bacterial toxins, owing to specific recruitment of mRNAs, RNA-binding proteins (RBPs) and ncRNAs (non-coding RNAs), are far from being understood. In the present study, we characterize for the first time the changes experienced by the translational control system of host cells in response to the well-known Staphylococcus aureus alpha-haemolysin (AHL) under both sublytic and lytic conditions. By comparing variations occurring in the cellular transcriptome and translatome, we give evidence that global gene expression is primarily rewired at the translational level, with the contribution of the RBP ELAVL1 (HuR) in the sublytic response. These results reveal the importance of translational control during host-pathogen interaction, opening new approaches for AHL-induced diseases.",Global translation variations in host cells upon attack of lytic and sublytic Staphylococcus aureus alpha-haemolysin.,10.1042/BJ20150284,2015 Nov 15,,The Biochemical journal
GSE61012,Principles of ER Co-Translational Translocation Revealed by Proximity-Specific Ribosome Profiling,Homo sapiens; Saccharomyces cerevisiae,32,SRP046016,2014-09-02,"[Overal design]Ribosome profiling of whole cell or streptavidin-purified ribosomes biotinylated by cytosolic, ER or mitochondrially localized biotin ligase in yeast and mammalian cells; [Treatment]'Where indicated, cells were treated with 100 g/ml cycloheximide for 2 minutes prior to biotin induction for the times shown.  Yeast cells were induced with 10 nM biotin.  Mammalian cells were treated with 50 M biotin'; [Growth]'Yeast cells were grown in SD media containing 0.125 ng/ml D-biotin to OD600 .4-.6.  Mammalian cells were grown in DMEM + 10% charcoal/dextran filtered FBS biotin depleted with streptactin sepharose.'; [Extraction]'Yeast cells were harvested by filtration, flash frozen, and cryogenically pulverized in a Retsch mixer-mill.  Mammalian cells were lysed directly in plates with scraping.\nFootprinting was performed with RNase I (yeast) or MNase (293 cells), monosomes purified on 10-50% sucrose gradients and biotinylated ribosomes purified on streptavidin dynabeads.  RNA was extracted with trizol and protected fragments gel purified.  Ends were repaired with T4 PNK and ligated to a pre-adenylated linker with T4 RNA Ligase 2.  Ligated fragments were gel purified, reverse transcribed and gel purified.  The cDNA was circularized then PCR amplified.'; [Cell type]'Source: ''genotype: rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI leu2::pPGK1-BirA::LEU2 ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: ssh1::BirA-heh2-SSH1::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: ssh1::BirA-mVenus-SSH1::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: his3::pSEC63-BirA-mVenus-UBC6 TA::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 leu2delta0; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: sec66delta::KAN his3::pSEC63-BirA-mVenus-UBC6 TA-HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 leu2delta0; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: sec63::SEC63-mVenus-BirA::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: sec65::sec65-1::KAN sec63::SEC63-mVenus-BirA::HIS5 rpl16a::RPL16a-HA-TEV-AVI rpl16b::RPL16b-HA-TEV-AVI ura3delta0 met15delta0 his3delta1; lentivirally transduced transgenes: n/a; strain: S288C; ', 'genotype: n/a; lentivirally transduced transgenes: pEF1a-ATHmmuRPL10A; pTRE-3xFLAG-BirA-mCherry-Sec61beta; strain: HEK293T; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61012,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE61nnn/GSE61012/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA260073,25378630," Calvin H Jan,  Christopher C Williams,  Jonathan S Weissman","Localized protein synthesis is a fundamental mechanism for creating distinct subcellular environments. Here we developed a generalizable proximity-specific ribosome profiling strategy that enables global analysis of translation in defined subcellular locations. We applied this approach to the endoplasmic reticulum (ER) in yeast and mammals. We observed the large majority of secretory proteins to be cotranslationally translocated, including substrates capable of posttranslational insertion in vitro. Distinct translocon complexes engaged nascent chains at different points during synthesis. Whereas most proteins engaged the ER immediately after or even before signal sequence (SS) emergence, a class of Sec66-dependent proteins entered with a looped SS conformation. Finally, we observed rapid ribosome exchange into the cytosol after translation termination. These data provide insights into how distinct translocation mechanisms act in concert to promote efficient cotranslational recruitment.",Principles of ER cotranslational translocation revealed by proximity-specific ribosome profiling.,10.1126/science.1257521,2014 Nov 7,PMC4285348,"Science (New York, N.Y.)"
GSE49716,A long noncoding RNA protects the heart from pathological hypertrophy,Homo sapiens,2,SRP028720,2013-08-10,"[Overal design]Overexpression of murine non-coding RNAs in human cell line, comparison of RNA-sequencing with Ribosome Profiling; [Treatment]'1 x 10^7 SW13 cells were transfected with 5ug of Add2-Mhrt779 and Add2-Hotair at 80% confluence using Lipofectamine 2000 (Invitrogen #11668) and reduced serum medium Opti-MEM (Gibco #31985). Cells were harvested 48 hours after transfection.'; [Growth]'SW13 cells were grown in DMEM medium supplemented with 10% FBS without antibiotics'; [Extraction]'Total RNA from cultured SW13 cells was extracted by direct lysis using the QIAGEN miRNeasy Mini Kit (Qiagen #217004) according to manufacturers instructions. Ribosome-associated RNA was obtained by using ARTseq Ribosome Profiling Kit (Epicenter, Illumina) and following manufacturers instructions.\nTotal RNA and ribosome-assoctiated RNA fragments were further converted into DNA libraries using ARTseq Ribosome Profiling Kit (Epicenter, Illumina).\nLibraries were sequenced as 50bp paired-end reads on an Illumina MiSeq instrument.'; [Cell type]'human adrenal adenocarcinoma cells''procedure: RNA_sequencing; cell line: SW13; cell type: human adrenal adenocarcinoma cells; genotype/variation: Overexpression of murine non-coding RNAs; ', 'procedure: Ribosome_profiling; cell line: SW13; cell type: human adrenal adenocarcinoma cells; genotype/variation: Overexpression of murine non-coding RNAs; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49716,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE49nnn/GSE49716/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA214890,25119045," Pei Han,  Wei Li,  Chiou-Hong Lin,  Jin Yang,  Ching Shang,  Sylvia T Nuernberg,  Kevin Kai Jin,  Weihong Xu,  Chieh-Yu Lin,  Chien-Jung Lin,  Yiqin Xiong,  Huanchieh Chien,  Bin Zhou,  Euan Ashley,  Daniel Bernstein,  Peng-Sheng Chen,  Huei-Sheng Vincent Chen,  Thomas Quertermous,  Ching-Pin Chang","The role of long noncoding RNA (lncRNA) in adult hearts is unknown; also unclear is how lncRNA modulates nucleosome remodelling. An estimated 70% of mouse genes undergo antisense transcription, including myosin heavy chain 7 (Myh7), which encodes molecular motor proteins for heart contraction. Here we identify a cluster of lncRNA transcripts from Myh7 loci and demonstrate a new lncRNA-chromatin mechanism for heart failure. In mice, these transcripts, which we named myosin heavy-chain-associated RNA transcripts (Myheart, or Mhrt), are cardiac-specific and abundant in adult hearts. Pathological stress activates the Brg1-Hdac-Parp chromatin repressor complex to inhibit Mhrt transcription in the heart. Such stress-induced Mhrt repression is essential for cardiomyopathy to develop: restoring Mhrt to the pre-stress level protects the heart from hypertrophy and failure. Mhrt antagonizes the function of Brg1, a chromatin-remodelling factor that is activated by stress to trigger aberrant gene expression and cardiac myopathy. Mhrt prevents Brg1 from recognizing its genomic DNA targets, thus inhibiting chromatin targeting and gene regulation by Brg1. It does so by binding to the helicase domain of Brg1, a domain that is crucial for tethering Brg1 to chromatinized DNA targets. Brg1 helicase has dual nucleic-acid-binding specificities: it is capable of binding lncRNA (Mhrt) and chromatinized--but not naked--DNA. This dual-binding feature of helicase enables a competitive inhibition mechanism by which Mhrt sequesters Brg1 from its genomic DNA targets to prevent chromatin remodelling. A Mhrt-Brg1 feedback circuit is thus crucial for heart function. Human MHRT also originates from MYH7 loci and is repressed in various types of myopathic hearts, suggesting a conserved lncRNA mechanism in human cardiomyopathy. Our studies identify a cardioprotective lncRNA, define a new targeting mechanism for ATP-dependent chromatin-remodelling factors, and establish a new paradigm for lncRNA-chromatin interaction.",A long noncoding RNA protects the heart from pathological hypertrophy.,10.1038/nature13596,2014 Oct 2,PMC4184960,Nature
GSE164492,Next generation sequencing analysis of control and KSR1 knockdown CRC cell line translatomes.,Homo sapiens,24,SRP301074,2021-01-09,"[Overal design]HCT116 and HCT15 control and KSR1 knockdown cells, total RNA and polysomal RNA was extracted using sucrose gradient fraction from three independent experiments for each condition.; [Treatment]'Cell Treated with 100 g/mL cycloheximide prior to extraction in polysome lysis buffer (10 mM HEPES, 100 mM KCL, 5 mM MgCl2, 100 g/mL cycloheximide, 2 mM DTT, 1% Triton-X100, 2.5 l RNaseOUT).'; [Growth]'DMEM 10% FBS'; [Extraction]'The total RNA and RNA pooled from the polysome fraction (fractions 6-9) was isolated using RNAzol. RNA sequencing libraries were prepared using 500 ng of  RNA using Truseq mRNA protocol kit (Illumina)\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'Source: ''cell line: HCT116; condition: stable expression of non-targeting control shRNA; ', 'cell line: HCT116; condition: stable expression of KSR1 shRNA; ', 'cell line: HCT15; condition: stable expression of non-targeting control shRNA; ', 'cell line: HCT15; condition: stable expression of KSR1 shRNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE164492,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE164nnn/GSE164492/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA690941,,,,,,,,
GSE34966,Chronic colitis in Bacteroides Thetaiotaomicron-Monoassociated HLA-B27 Transgenic rats alters expression of receptor and metabolic genes in luminal bacteria.,Bacteroides thetaiotaomicron,6,None,2012-01-10,"[Overal design]The fully-sequenced human fecal isolate of B.theta (VPI-5482) was grown on Brain-Heart Infusion (BHI) agar and in BHI broth under strict anaerobic conditions using pre-reduced media. Adult germ-free HLA-B27/b2 microglobulin transgenic rats and adult germ-free non-transgenic littermate were monoassociated with B.theta for six weeks in gnotobiotic isolators at the National Gnotobiotic Rodent Resource Center at UNC Chapel Hill. Bacterial RNA was isolated from rat cecal contents and hybridized on Affymetrix human gut microbiota community GeneChip.; [Treatment]'None'; [Growth]'Brain-Heart Infusion (BHI) agar and in BHI broth under strict anaerobic conditions using pre-reduced media'; [Extraction]'Trizol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturers instructions'; [Cell type]'Source: ''strain/isolate: fully-sequenced human fecal isolate of B.theta (VPI-5482); host: germ-free HLA-B27/b2 microglobulin non-transgenic (wild type) rat; ', 'strain/isolate: fully-sequenced human fecal isolate of B.theta (VPI-5482); host: germ-free HLA-B27/b2 microglobulin transgenic rat; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34966,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE34nnn/GSE34966/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA150943,22880065," Jonathan J Hansen,  Yong Huang,  Daniel A Peterson,  Laura Goeser,  Ting-Jia Fan,  Eugene B Chang,  R Balfour Sartor","BACKGROUND: Inflammatory bowel diseases (IBD) may be caused in part by aberrant immune responses to commensal intestinal microbes including the well-characterized anaerobic gut commensal Bacteroides thetaiotaomicron (B. theta). Healthy, germ-free HLA-B27 transgenic (Tg) rats develop chronic colitis when colonized with complex gut commensal bacteria whereas non-transgenic (nTg) rats remain disease-free. However, the role of B. theta in causing disease in Tg rats is unknown nor is much known about how gut microbes respond to host inflammation. METHODS: Tg and nTg rats were monoassociated with a human isolate of B. theta. Colonic inflammation was assessed by histologic scoring and tissue pro-inflammatory cytokine measurement. Whole genome transcriptional profiling of B. theta recovered from ceca was performed using custom GeneChips and data analyzed using dChip, Significance Analysis of Microarrays, and Gene Set Enrichment Analysis (GSEA) software. Western Blots were used to determine adaptive immune responses to a differentially expressed B. theta gene. RESULTS: B. theta monoassociated Tg rats, but not nTg or germ-free controls, developed chronic colitis. Transcriptional profiles of cecal B. theta were significantly different in Tg vs. nTg rats. GSEA revealed that genes in KEGG canonical pathways involved in bacterial growth and metabolism were downregulated in B. theta from Tg rats with colitis though luminal bacterial concentrations were unaffected. Bacterial genes in the Gene Ontology molecular function ""receptor activity"", most of which encode nutrient binding proteins, were significantly upregulated in B. theta from Tg rats and include a SusC homolog that induces adaptive immune responses in Tg rats. CONCLUSIONS: B. theta induces colitis in HLA-B27 Tg rats, which is associated with regulation of bacterial genes in metabolic and nutrient binding pathways that may affect host immune responses. These studies of the host-microbial dialogue may lead to the identification of novel microbial targets for IBD therapies.",The colitis-associated transcriptional profile of commensal Bacteroides thetaiotaomicron enhances adaptive immune responses to a bacterial antigen.,10.1371/journal.pone.0042645,2012,PMC3411805,PloS one
GSE113751,Translational control through differential ribosome pausing during amino acid limitation in mammalian cells,Homo sapiens,34,SRP143452,2018-04-27,"[Overal design]Ribosome profiling was performed in HEK293T, HCT116, or HeLa cells during limitation for leucine or arginine for 3 or 6 hours to determine the effect of limiting single amino acid levels of ribosome elongation kinetics at the cognate codons. The same cell lines grown in nutrient-rich conditions were used as a control. These experiments were repeated in HEK293T cells with 250 nM Torin1, in cells stably expressing a flag-tagged wild-type or Q99L mutant RagB-GTPase or hrGFP, and in a GCN2 knockout cell line to determine the role of the mTORC1 and GCN2 pathways.; [Treatment]'Cells were washed in warm PBS before adding prewarmed treatment medium (see characteristics: treatment medium / treatment length)'; [Growth]'Adherent cells grown in DMEM +10% FBS + P/S at 37 degrees Celsius, 5% CO2. Grown to 75% confluency in two 15 cm. plates before beginning treatment.'; [Extraction]'Cells were flash frozen and lysed at 4 degrees Celsius in polysome lysis buffer containing 100 ug/mL cycloheximide. Monosome-bound mRNA footprints were prepared by MNase digestion, purified by sucrose density gradient fractionation, and recovered by acid phenol chloroform extraction. mRNA footprints were further purified by size selection on a 15% TBE urea polyacrylamide gel before library preparation. See methods section in associated manuscript for more details.\nmRNA footprints were polyA-tailed and then reverse transcribed. RT products were purified on a 10% tbe urea polyacrylamide gel, circularized, subject to rRNA subtraction, and finally amplified by 6-12 cycles of PCR. After purification on a 10% TBE polyacrylamide gel, libraries were quantified by Agilent Tapestation. Multiplexed barcoded subsets of libraries were sequenced on an Illumina HiSeq 2500, using a Rapid Run protocol for 50 bp single end reads. See methods section in associated manuscript for more details.'; [Cell type]'Source: ''cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Arginine; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: October 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Arginine; treatment length: 6 hours; genotype: wild type; date experiment was sequenced: October 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: October 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: October 2017; ', 'cell line: HCT116; tissue lineage: colorectal carcinoma; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: March 2017; ', 'cell line: HCT116; tissue lineage: colorectal carcinoma; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: March 2017; ', 'cell line: HCT116; tissue lineage: colorectal carcinoma; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: March 2017; ', 'cell line: HeLa; tissue lineage: cervical adenocarcinoma; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: August 2013; ', 'cell line: HeLa; tissue lineage: cervical adenocarcinoma; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: August 2013; ', 'cell line: HeLa; tissue lineage: cervical adenocarcinoma; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 3 hours; genotype: wild type; date experiment was sequenced: August 2013; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 3 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine + 250 nM Torin1; treatment length: 3 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 3 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine + 250 nM Torin1; treatment length: 3 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 3 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS + 250 nM Torin1; treatment length: 3 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 3 hours; genotype: AAVS1-iCAG:Flag-RagB-WT; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 3 hours; genotype: AAVS1-iCAG:Flag-RagB-WT; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 3 hours; genotype: AAVS1-iCAG:Flag-RagB-WT; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 3 hours; genotype: AAVS1-iCAG:Flag-RagB-Q99L; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 3 hours; genotype: AAVS1-iCAG:Flag-RagB-Q99L; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 3 hours; genotype: AAVS1-iCAG:Flag-RagB-Q99L; date experiment was sequenced: March 2016; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 6 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 6 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 6 hours; genotype: AAVS1-iCAG:hrGFP; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 6 hours; genotype: AAVS1-iCAG:Flag-RagB-Q99L; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 6 hours; genotype: AAVS1-iCAG:Flag-RagB-Q99L; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 6 hours; genotype: AAVS1-iCAG:Flag-RagB-Q99L; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 6 hours; genotype: complete GCN2 knockout; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 6 hours; genotype: complete GCN2 knockout; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 6 hours; genotype: complete GCN2 knockout; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS  ?Arginine; treatment length: 6 hours; genotype: wild type; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS ?Leucine; treatment length: 6 hours; genotype: wild type; date experiment was sequenced: March 2017; ', 'cell line: HEK293T; tissue lineage: embryonic kidney; treatment medium: DMEM + 10% dialyzed FBS; treatment length: 6 hours; genotype: wild type; date experiment was sequenced: March 2017; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113751,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE113nnn/GSE113751/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA453915,30029003," Alicia M Darnell,  Arvind R Subramaniam,  Erin K O'Shea","Limitation for amino acids is thought to regulate translation in mammalian cells primarily by signaling through the kinases mTORC1 and GCN2. We find that a selective loss of arginine tRNA charging during limitation for arginine regulates translation through ribosome pausing at two of six arginine codons. Surprisingly, limitation for leucine, an essential and abundant amino acid in protein, results in little or no ribosome pausing. Chemical and genetic perturbation of mTORC1 and GCN2 signaling revealed that their robust response to leucine limitation prevents ribosome pausing, while an insufficient response to arginine limitation leads to loss of tRNA charging and ribosome pausing. Ribosome pausing decreases protein production and triggers premature ribosome termination without reducing mRNA levels. Together, our results suggest that amino acids that are not optimally sensed by the mTORC1 and GCN2 pathways still regulate translation through an evolutionarily conserved mechanism based on codon-specific ribosome pausing.",Translational Control through Differential Ribosome Pausing during Amino Acid Limitation in Mammalian Cells.,10.1016/j.molcel.2018.06.041,2018 Jul 19,PMC6516488,Molecular cell
GSE81469,Regulation of highly expressed hCINAP on translatome,Homo sapiens,6,SRP075211,2016-05-16,"[Overal design]For the transcriptional profile, MCF7 cells transfected with control vector or GFP-hCINAP were collected and total RNA was extracted. For the polysoem profile, MCF7 cells with stably expressed GFP or GFP-hCINAP were subjected to surcose gradient fractionation. Ribosome profiles were obtained by measuring the absorbance of the sucrose gradient at a wavelength of 254 nm using a BioComp Gradient Fractionator. The fractions corresponding to subpolysome and polysome were collected and RNA was extracted. The cDNA library was generated and sequenced via Illumina HiSeqTM 2000. The clean reads were mapped to the UCSC hg19 reference genome and FPKM was assigned to calculate expression levels. The recruitment to polysome of each mRNA was calculated according to their FPKM values in the monsome and polysome.; [Treatment]'MCF7 cells were transfected with lentivirus expressing GFP-control or GFP-hCINAP.'; [Growth]'Cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37C with 5% CO2.'; [Extraction]'Total RNA extraction was performed with the Qiagen RNeasy KIT. For the polysome RNA-seq, RNA associated with monosome or polysome was precipitated with 2 volumes of 8M guanidine-HCl and 3 volumes of 99% ethanol at -20C overnight. For extraction of the RNA elutation, using the Qiagen RNeasy KIT.\nThe RNA samples are first treated with DNase I to degrade any possible DNA contamination. Then the mRNA is enriched by using the oligo(dT) magnetic beads. Mixed with the fragmentation buffer, the mRNA is fragmented into short fragments. Then the first strand of cDNA is synthesized by using random hexamer-primer. Buffer, dNTPs, RNase H and DNA polymerase I are added to synthesize the second strand. The double strand cDNA is purified with magnetic beads. End reparation and 3'-end single nucleotide A (adenine) addition is then performed. Finally, sequencing adaptors are ligated to the fragments. The fragments are enriched by PCR amplification. The integrity and concentration of the library were evaluated by Agilent Technologies 2100 Bioanalyzer and ABI StepOnePlusReal-Time PCR System, respectively.'; [Cell type]'human breast adenocarcinoma cell line''cell type: human breast adenocarcinoma cell line; overexpresson: Overexpression of GFP-control vector; ', 'cell type: human breast adenocarcinoma cell line; overexpresson: Overexpression of GFP-hCINAP; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81469,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE81nnn/GSE81469/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA321727,,,,,,,,
GSE160917,Ribosome profiling and mRNA-seq of muscle skeletal muscle and DROSHA KO 293T cells,Homo sapiens; Mus musculus,14,SRP291315,2020-11-05,"[Overal design]Examination of translation status of mouse skeletal muscle and the differences between NTC and DROSHA KO in 293T cells; [Treatment]'None'; [Growth]'DMEM high glucose with 10% FBS, streptomycin, and penicillin'; [Extraction]'Both skeletal muscle and cells were lysed with polysome lysis buffer\nTruSeq Ribo Profile (Mammalian) Kit (illumina) was used with some modifications. For mRNA-Seq, ploA mRNA was purified before library construction.'; [Cell type]'Source: ''strain: C57BL/6; age: 9 week old; genotype/variation: WT; ', 'genotype/variation: WT; ', 'genotype/variation: DROSHA KO; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160917,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE160nnn/GSE160917/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA674837,,,,,,,,
GSE151687,Authentication of Hippuristanol-eIF4A1 Target Engagement Facilitates Identification of eIF4A1 Helicase Dependencies within 5 Leader Regions,Homo sapiens,12,SRP265763,2020-06-03,"[Overal design]Ribosome Profiling and RNA-Sequencing of DMSO and Hippuristanol treated HAP1 cells.; [Treatment]'Cells were treated with 50 nM Hipp for 1h before harvesting'; [Growth]'Hap1 cells were cultured in IMDM supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin/streptomycin and 2 mM L-glutamine at 37C and 5% CO2. NIH/3T3 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin/streptomycin and 2 mM L-glutamine at 37C and 5 % CO2.'; [Extraction]'100 ug/ml Cycloheximide (CHX). Cells were scraped in 250 l of 3x Lysis buffer. Triton X-100 was added to a final concentration of 1 % and vortexed briefly. centrifuged at 4C for 2 min at full speed on a table top centrifuge. Three hundred microgram of sample was brought up to a volume of 500 ul and supplemented with 5.6 mM CaCl2. The sample was digested with 150 U Micrococcal nuclease (MNase) for 45 min at room temperate (RT), rotating end-over-end. Sucrose gradients were centrifuged at 36,000 rpm for 3h.\nRibo-seq library preparation was performed as described by Glincy and Ingolia using 15 ug of RNA sample (64). The RNA-seq library was prepared using the same protocol as Ribo-seq libraries with the following modifications. Ribosomal RNAs were depleted using the NEB Next rRNA depletion kit from 1 ug total RNA. rRNA-depleted RNA was randomly fragmented using the NEBNext Magnesium RNA Fragmentation Module and purified using isopropanol precipitation.\nRibosome profiling, mRNA-Seq'; [Cell type]'HAP1 cells''cell type: HAP1 cells; treatment: DMSO; ', 'cell type: HAP1 cells; treatment: Hippuristanol 50 nM; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151687,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE151nnn/GSE151687/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA636959,32766783," Jutta Steinberger,  Leo Shen,  Stephen J Kiniry,  Sai Kiran Naineni,  Regina Cencic,  Mehdi Amiri,  Sarah A E Aboushawareb,  Jennifer Chu,  Rayelle Itoua Maiga,  Brahm J Yachnin,  Francis Robert,  Nahum Sonenberg,  Pavel V Baranov,  Jerry Pelletier","Hippuristanol (Hipp) is a natural product that selectively inhibits protein synthesis by targeting eukaryotic initiation factor (eIF) 4A, a DEAD-box RNA helicase required for ribosome recruitment to mRNA templates. Hipp binds to the carboxyl-terminal domain of eIF4A, locks it in a closed conformation, and inhibits its RNA binding. The dependencies of mRNAs for eIF4A during initiation is contingent on the degree of secondary structure within their 5' leader region. Interest in targeting eIF4A therapeutically in cancer and viral-infected settings stems from the dependencies that certain cellular (e.g. pro-oncogenic, pro-survival) and viral mRNAs show towards eIF4A. Using a CRISPR/Cas9-based variomics screen, we identify functional EIF4A1 Hipp-resistant alleles, which in turn allowed us to link the translation-inhibitory and cytotoxic properties of Hipp to eIF4A1 target engagement. Genome-wide translational profiling in the absence or presence of Hipp were undertaken and our validation studies provided insight into the structure-activity relationships of eIF4A-dependent mRNAs. We find that mRNA 5' leader length, overall secondary structure and cytosine content are defining features of Hipp-dependent mRNAs.",Identification and characterization of hippuristanol-resistant mutants reveals eIF4A1 dependencies within mRNA 5' leader regions.,10.1093/nar/gkaa662,2020 Sep 25,PMC7515738,Nucleic acids research
GSE35469,The translational landscape of mTOR signaling steers cancer initiation and metastasis,Homo sapiens,12,SRP010679,2012-02-01,"[Overal design]Examination of mRNA translation in human prostate cancer upon differential inhibition of the mTOR signaling pathway.; [Treatment]'None'; [Growth]'None'; [Extraction]'PC3 cells were treated with rapamycin (50 nM - Calbiochem) or PP242 (2.5 M - Intellikine) for 3 hours. Cells were subsequently treated with cycloheximide (100 g/mL - Sigma) and detergent lysis was performed in the dish. The lysate was treated with DNase and clarified, and a sample was taken for RNA-Seq analysis. Lysates were subjected to ribosome footprinting by nuclease treatment. Ribosome-protected fragments were purified, and deep sequencing libraries were generated from these fragments, as well as from poly(A) mRNA purified from non-nuclease treated lysates. These libraries were analyzed by sequencing on the Illumina GAII.'; [Cell type]'Source: ''cell line: PC3; sample type: polyA RNA; treatment: vehicle; ', 'cell line: PC3; sample type: ribosome protected RNA; treatment: vehicle; ', 'cell line: PC3; sample type: polyA RNA; treatment: rapamycin; ', 'cell line: PC3; sample type: ribosome protected RNA; treatment: rapamycin; ', 'cell line: PC3; sample type: polyA RNA; treatment: PP242; ', 'cell line: PC3; sample type: ribosome protected RNA; treatment: PP242; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35469,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE35nnn/GSE35469/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA152347,22367541," Andrew C Hsieh,  Yi Liu,  Merritt P Edlind,  Nicholas T Ingolia,  Matthew R Janes,  Annie Sher,  Evan Y Shi,  Craig R Stumpf,  Carly Christensen,  Michael J Bonham,  Shunyou Wang,  Pingda Ren,  Michael Martin,  Katti Jessen,  Morris E Feldman,  Jonathan S Weissman,  Kevan M Shokat,  Christian Rommel,  Davide Ruggero","The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream translationally regulated nodes of gene expression that may direct cancer development are poorly characterized. Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signalling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism and invasion. We extend these findings by functionally characterizing a class of translationally controlled pro-invasion messenger RNAs that we show direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signalling. Furthermore, we develop a clinically relevant ATP site inhibitor of mTOR, INK128, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure. Together, these findings extend our understanding of how the 'cancerous' translation machinery steers specific cancer cell behaviours, including metastasis, and may be therapeutically targeted.",The translational landscape of mTOR signalling steers cancer initiation and metastasis.,10.1038/nature10912,2012 Feb 22,PMC3663483,Nature
GSE60095,Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes,Homo sapiens; Mus musculus,4,SRP045257,2014-08-05,"[Overal design]Ribosome profiling to verify that true ribosome footprints shift in response to different elongation inhibitors (CHX vs Emetine) and co-purify with an affinity-tagged large ribosomal subunit (bound vs input); [Treatment]'None'; [Growth]'None'; [Extraction]'Rnase I footprinting, ribosome pelleting, RNA extraction\nRNA extraction with Trizol, preadenylated linker ligation, reverse transcription, cDNA circularization, PCR amplification', 'Rnase I footprinting, size exclusion chromatography, RNA extraction\nRNA extraction with Trizol, preadenylated linker ligation, reverse transcription, cDNA circularization, PCR amplification', 'Rnase I footprinting, size exclusion chromatography, streptavidin affinity purification of assembled 80S ribosomes by large subunit affinity tag\nRNA extraction with Trizol, preadenylated linker ligation, reverse transcription, cDNA circularization, PCR amplification'; [Cell type]'Source: ''treatment: ES cell feeder-free, w/ LIF 60 s CYH (100 ug/ml); genetic background: 129/Ola; cell line: E14; growth protocol: Feeder-free, with LIF; ', 'treatment: ES cell feeder-free, w/ LIF 60 s Emetine; genetic background: 129/Ola; cell line: E14; growth protocol: Feeder-free, with LIF; ', 'treatment: DMEM + 10% FBS; cell line: HEK; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60095,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60095/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA257463,25159147," Nicholas T Ingolia,  Gloria A Brar,  Noam Stern-Ginossar,  Michael S Harris,  Gaelle J S Talhouarne,  Sarah E Jackson,  Mark R Wills,  Jonathan S Weissman","Ribosome profiling suggests that ribosomes occupy many regions of the transcriptome thought to be noncoding, including 5' UTRs and long noncoding RNAs (lncRNAs). Apparent ribosome footprints outside of protein-coding regions raise the possibility of artifacts unrelated to translation, particularly when they occupy multiple, overlapping open reading frames (ORFs). Here, we show hallmarks of translation in these footprints: copurification with the large ribosomal subunit, response to drugs targeting elongation, trinucleotide periodicity, and initiation at early AUGs. We develop a metric for distinguishing between 80S footprints and nonribosomal sources using footprint size distributions, which validates the vast majority of footprints outside of coding regions. We present evidence for polypeptide production beyond annotated genes, including the induction of immune responses following human cytomegalovirus (HCMV) infection. Translation is pervasive on cytosolic transcripts outside of conserved reading frames, and direct detection of this expanded universe of translated products enables efforts at understanding how cells manage and exploit its consequences.",Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes.,10.1016/j.celrep.2014.07.045,2014 Sep 11,PMC4216110,Cell reports
GSE83731,mTAIL-seq reveals dynamic poly(A) tail regulation in oocyte-to-embryo development [RNA-seq and mTAIL-seq Human and Drosphila],Homo sapiens; Drosophila melanogaster,25,SRP077234,2016-06-26,"[Overal design]Ten separate sets of TAIL-seq experiments were performed. Two sets of HeLa cells are untransfected normal cells. Eight sets of fly sample include a pair of wild type and mutant.; [Treatment]'No treatment'; [Growth]'HeLa cells were maintained in DMEM (Welgene) supplemented with 10% fetal bovine serum (Welgene).   All the fly strains were obtained from Bloomington stock center. w1118 was used as wild type control. wispKG5287 was previously described as a null allele of wisp (Benoit et al., 2008). Immature oocytes and mature oocytes were collected by hand dissection in Grace's Unsupplemented Insect Media (Gibco, 11595-030) from 3 or 4 day old female flies. Unfertilized activated eggs were produced from w1118 virgin females mated to sterile males (son of tud1 mothers) . Fly eggs and embryos were collected on grape juice plates for the designated time frame at 25C.'; [Extraction]'Total RNAs were extracted from HeLa cells or Drosophila samples by TRIzol reagent (Invitrogen, 15596-018).\nTotal RNA (~15 ug) was ligated to 3' hairpin adaptor using T4 RNA ligase 2 (NEB, M0239) for overnight. 3' ligated RNA was partially digested by RNase T1 (Ambion, AM2283) and subject to streptavidin beads (Invitrogen, 11206D). 5' phosphorylation by PNK reaction (Takara, 2021B) and endonucleolytic cleavage by APE1 reaction (NEB, M0282) were performed on beads. Subsequently, RNA was eluted by 2X RNA loading dye and gel purified by 6% Urea-PAGE gel in the range of 300750 nucleotides. The purified RNAs were ligated to 5' adaptor, subjected to reverse-transcription (Invitrogen, 18080-085) and amplified by PCR using Phusion DNA polymerase (Thermo, F-530L). PCR products were purified by AMPure XP beads (Beckman, A63881).'; [Cell type]'Source: ''cell line: HeLa; ', 'genotype: w1118; developmental stage: oogenesis stage 9-10; ', 'genotype: wispKG5287 (wispy knockout); developmental stage: oogenesis stage 9-10; ', 'genotype: w1118; developmental stage: oogenesis stage 14; ', 'genotype: wispKG5287 (wispy knockout); developmental stage: oogenesis stage 14; ', 'genotype: w1118; developmental stage: activated egg 0-1hr; ', 'genotype: wispKG5287 (wispy knockout); developmental stage: activated egg 0-1hr; ', 'genotype: w1118; developmental stage: activated egg 0-2hr; ', 'cell line: S2; ', 'genotype: w1118; developmental stage: 0-0.5hr after egg laying (AEL); ', 'genotype: w1118; developmental stage: 0.5-1.0hr after egg laying (AEL); ', 'genotype: w1118; developmental stage: 1.0-1.5hr after egg laying (AEL); ', 'genotype: w1118; developmental stage: 1.5-2.0hr after egg laying (AEL); ', 'genotype: w1118; developmental stage: 2.0-3.0hr after egg laying (AEL); ', 'genotype: w1118; developmental stage: 3.0-4.5hr after egg laying (AEL); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83731,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE83nnn/GSE83731/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA326884,27445395," Jaechul Lim,  Mihye Lee,  Ahyeon Son,  Hyeshik Chang,  V Narry Kim","Eukaryotic mRNAs are subject to multiple types of tailing that critically influence mRNA stability and translatability. To investigate RNA tails at the genomic scale, we previously developed TAIL-seq, but its low sensitivity precluded its application to biological materials of minute quantity. In this study, we report a new version of TAIL-seq (mRNA TAIL-seq [mTAIL-seq]) with enhanced sequencing depth for mRNAs (by approximately 1000-fold compared with the previous version). The improved method allows us to investigate the regulation of poly(A) tails in Drosophila oocytes and embryos. We found that maternal mRNAs are polyadenylated mainly during late oogenesis, prior to fertilization, and that further modulation occurs upon egg activation. Wispy, a noncanonical poly(A) polymerase, adenylates the vast majority of maternal mRNAs, with a few intriguing exceptions such as ribosomal protein transcripts. By comparing mTAIL-seq data with ribosome profiling data, we found a strong coupling between poly(A) tail length and translational efficiency during egg activation. Our data suggest that regulation of poly(A) tails in oocytes shapes the translatomic landscape of embryos, thereby directing the onset of animal development. By virtue of the high sensitivity, low cost, technical robustness, and broad accessibility, mTAIL-seq will be a potent tool to improve our understanding of mRNA tailing in diverse biological systems.",mTAIL-seq reveals dynamic poly(A) tail regulation in oocyte-to-embryo development.,10.1101/gad.284802.116,2016 Jul 15,PMC4973296,Genes & development
GSE126736,ribosome profiling of cell line models of human breast cancer,Homo sapiens,30,SRP186252,2019-02-19,"[Overal design]Ribosome profiling of 6 different cell lines in at least 2 biological replicates; [Treatment]'HMECs: Serum deprived media consisted of MEBM supplemented with amphotericin/gentamicin and hydrocortisone (as provided by the manufacturer) admixed with full serum media in a combination ratio of 9:1. Essentially the serum deprived conditions contained 10% of the full concentration of recombinant human EGF, bovine pituitary extract (BPE), and insulin.  MCF10A: Serum deprived conditions consisted of DMEM/F12 media plus full serum media as described previously in a combination ratio of 9:1. The concentration of cholera toxin was kept at 100 ng/mL because it regulates formation of mammary epithelial acini in vitro which is a feature of differentiation.  T47D: Charcoal stripped serum conditions consisted of RPMI-1640 plus 10% charcoal stripped FCS and 10 mM HEPES (no insulin). Fetal calf serum was charcoal stripped according to the following protocol: fetal calf serum was stirred very slowly on a hot plate at 37C with 1% charcoal and 0.1% dextran (Sigma Aldrich, cat#D1662, molecular weight 35,000  45,000) for 4 hours and then collected into 50 mL tubes. The tubes were then spun to precipitate the charcoal, the supernatants were collected and sterile filtered. All experiments were conducted with the same aliquot.  Serum deprived conditions (immunofluorescence microscopy studies) consisted of RPMI-1640 plus FCS 0.5% (no insulin).   ZR75-1: Charcoal stripped serum conditions consisted of RPMI-1640 supplemented with 20% charcoal stripped serum and 10 mM HEPES.  SUM159PT: Serum deprived conditions consisted of Hams F12 media supplemented with 0.5% FCS and 10 mM HEPES (no insulin and hydrocortisone).   MDA-MB-231: Serum deprived conditions consisted of DMEM high glucose (4.5 gr/L) pyruvate L-glutamate supplemented with FCS 1% and penicillin/streptomycin 1%.\nHMECs: Serum deprived media consisted of MEBM supplemented with amphotericin/gentamicin and hydrocortisone (as provided by the manufacturer) admixed with full serum media in a combination ratio of 9:1. Essentially the serum deprived conditions contained 10% of the full concentration of recombinant human EGF, bovine pituitary extract (BPE), and insulin.\nMCF10A: Serum deprived conditions consisted of DMEM/F12 media plus full serum media as described previously in a combination ratio of 9:1. The concentration of cholera toxin was kept at 100 ng/mL because it regulates formation of mammary epithelial acini in vitro which is a feature of differentiation.\nT47D: Charcoal stripped serum conditions consisted of RPMI-1640 plus 10% charcoal stripped FCS and 10 mM HEPES (no insulin). Fetal calf serum was charcoal stripped according to the following protocol: fetal calf serum was stirred very slowly on a hot plate at 37C with 1% charcoal and 0.1% dextran (Sigma Aldrich, cat#D1662, molecular weight 35,000  45,000) for 4 hours and then collected into 50 mL tubes. The tubes were then spun to precipitate the charcoal, the supernatants were collected and sterile filtered. All experiments were conducted with the same aliquot.  Serum deprived conditions (immunofluorescence microscopy studies) consisted of RPMI-1640 plus FCS 0.5% (no insulin).\nZR75-1: Charcoal stripped serum conditions consisted of RPMI-1640 supplemented with 20% charcoal stripped serum and 10 mM HEPES.\nSUM159PT: Serum deprived conditions consisted of Hams F12 media supplemented with 0.5% FCS and 10 mM HEPES (no insulin and hydrocortisone).\nMDA-MB-231: Serum deprived conditions consisted of DMEM high glucose (4.5 gr/L) pyruvate L-glutamate supplemented with FCS 1% and penicillin/streptomycin 1%.'; [Growth]'Human mammary epithelial cells (HMECs): were obtained from Lonza and cultured in the medium recommended by the manufacturer.\nMCF10A cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were propagated using standard techniques in DMEM/F12 media supplemented with 5% horse serum (Invitrogen, cat# 16050-122), recombinant human EGF 20 ng/mL (Peprotech, cat# AF-100-15), hydrocortisone 0.5 mg/mL (Sigma Aldrich, cat# H-0888), cholera toxin 100 ng/mL (Sigma Aldrich, cat# C8052), insulin (ThermoFisher Scientific, cat#12585014), penicillin/streptomycin 1%.\nT47D cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and propagated using standard techniques in RPMI-1640 medium containing 10% fetal calf serum (FCS, HyClone, cat# SH30071.03), 10 ?g/ml insulin, and 10 mM HEPES.\nZR75-1 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and propagated in RPMI-1640 with 20% FCS and 10 mM HEPES.\nSUM159PT cells were obtained from Asterand Bioscience (Detroit, MI, USA) and propagated in Hams F-12 media supplemented with 5% FCS, 10 mM HEPES, 5 ?g/ml insulin, 1 ?g/ml hydrocortisone, and penicillin/streptomycin 1%.'; [Extraction]'Experiments were designed so as cells were ~80% confluent at the time of harvesting and lysis and at least 3 days after plating. Media was changed to fresh media in all flasks 24 hours prior to harvesting and to serum deprived media or media supplemented with charcoal stripped serum (T47D and ZR75-1 cells) 1 hour prior to harvesting as indicated. We used cycloheximide (final concentration 100 g/mL, incubation for 10 minutes prior to collection) to halt the translating ribosomes. Ribosome profiling was conducted following the protocol from Ingolia, et al (Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M. & Weissman, J. S. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc 7, 1534-1550, doi:10.1038/nprot.2012.086 (2012).) with the following modifications: (1) rRNA depletion was performed upfront using the Ribo-zero Gold rRNA removal kit (Illumina, cat# MRZG126) following manufacturers instructions and (2) the linker-ligated ribosome protected fragments were retrieved using the RNA Clean and Concentrator Kit (Zymo Research, cat# R1015) following manufacturers instructions. Total RNA (after digestion with Turbo DNase, Invitrogen cat# AM2238) and digested ribosome protected RNA was isolated using the Qiagen miRNeasy kit (Qiagen, cat# 217004) following manufacturers protocol. Total RNA was rRNA depleted using the Ribo-zero Gold rRNA removal kit (Illumina, cat# MRZG126).\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'Source: ''cell line/type: Human mammary epithelial cells (HMECs); tissue source: breast; developmental stage: adult; tumor stage: no apparent disease; molecule subtype: ribosome protected fragments; ', 'cell line/type: Human mammary epithelial cells (HMECs); tissue source: breast; developmental stage: adult; tumor stage: no apparent disease; ', 'cell line/type: MCF10A; tissue source: breast; developmental stage: adult; tumor stage: fibrocystic disease; molecule subtype: ribosome protected fragments; ', 'cell line/type: MCF10A; tissue source: breast; developmental stage: adult; tumor stage: fibrocystic disease; ', 'cell line/type: T47D; tissue source: breast; developmental stage: adult; tumor stage: metastatic; molecule subtype: ribosome protected fragments; ', 'cell line/type: T47D; tissue source: breast; developmental stage: adult; tumor stage: metastatic; ', 'cell line/type: ZR75-1; tissue source: breast; developmental stage: adult; tumor stage: metastatic; molecule subtype: ribosome protected fragments; ', 'cell line/type: ZR75-1; tissue source: breast; developmental stage: adult; tumor stage: metastatic; ', 'cell line/type: SUM159PT; tissue source: breast; developmental stage: adult; tumor stage: primary tumor; molecule subtype: ribosome protected fragments; ', 'cell line/type: SUM159PT; tissue source: breast; developmental stage: adult; tumor stage: primary tumor; ', 'cell line/type: MDA-MB-231; tissue source: breast; developmental stage: adult; tumor stage: metastatic; molecule subtype: ribosome protected fragments; ', 'cell line/type: MDA-MB-231; tissue source: breast; developmental stage: adult; tumor stage: metastatic; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126736,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126736/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA523167,31911279," Christos Vaklavas,  Scott W Blume,  William E Grizzle","Gene expression is extensively and dynamically modulated at the level of translation. How cancer cells prioritize the translation of certain mRNAs over others from a pool of competing mRNAs remains an open question. Here, we analyze translation in cell line models of breast cancer and normal mammary tissue by ribosome profiling. We identify key recurrent themes of oncogenic translation: higher ribosome occupancy, greater variance of translational efficiencies, and preferential translation of transcriptional regulators and signaling proteins in malignant cells as compared with their nonmalignant counterpart. We survey for candidate RNA interacting proteins that could associate with the 5'untranslated regions of the transcripts preferentially translated in breast tumour cells. We identify SRSF1, a prototypic splicing factor, to have a pervasive direct and indirect impact on translation. In a representative estrogen receptor-positive and estrogen receptor-negative cell line, we find that protein synthesis relies heavily on SRSF1. SRSF1 is predominantly intranuclear. Under certain conditions, SRSF1 translocates from the nucleus to the cytoplasm where it associates with MYC and CDK1 mRNAs and upregulates their internal ribosome entry site-mediated translation. Our results point to a synergy between splicing and translation and unveil how certain RNA-binding proteins modulate the translational landscape in breast cancer.",Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer.,10.1016/j.tranon.2019.12.002,2020 Feb,PMC6948383,Translational oncology
GSE132109,Genome-wide differential gene expression analysis in light or heavy polysomal RNAs of MYCN-amplified neuroblastoma cells after lncNB1 knockdown with siRNAs.,Homo sapiens,20,None,2019-06-03,"[Overal design]We performed Affymetrix Clariom S_array in polysome associated RNA from BE(2)-C cells after transfection with Control siRNA, lncNB1 siRNA-1 or lncNB1 siRNA-2 for 48 hours.; [Treatment]'BE(2)-C neuroblastoma cells were transfected with control siRNA, lncNB1 siRNA-1 or lncNB1-siRNA-2 for 48 hours, followed by polysome profiling.'; [Growth]'BE(2)-C neuroblastoma cells were cultured in Dulbeccos modified Eagles medium (DMEM) supplemented with 10% fetal calf serum.'; [Extraction]""Total RNA was extracted using Rneasy kit (Qiagen, Hamburg, Germany) according to the manufacturer's instructions.""; [Cell type]'MYCN-amplified neuroblastoma cells''cell line: BE(2)-C; cell type: MYCN-amplified neuroblastoma cells; genotype/variation: control siRNA; molecule subtype: light polysomal RNAs; ', 'cell line: BE(2)-C; cell type: MYCN-amplified neuroblastoma cells; genotype/variation: control siRNA; molecule subtype: heavy polysomal RNAs; ', 'cell line: BE(2)-C; cell type: MYCN-amplified neuroblastoma cells; genotype/variation: lncNB siRNA-1; molecule subtype: light polysomal RNAs; ', 'cell line: BE(2)-C; cell type: MYCN-amplified neuroblastoma cells; genotype/variation: lncNB siRNA-1; molecule subtype: heavy polysomal RNAs; ', 'cell line: BE(2)-C; cell type: MYCN-amplified neuroblastoma cells; genotype/variation: lncNB siRNA-2; molecule subtype: light polysomal RNAs; ', 'cell line: BE(2)-C; cell type: MYCN-amplified neuroblastoma cells; genotype/variation: lncNB siRNA-2; molecule subtype: heavy polysomal RNAs; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132109,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132109/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA545962,31690716," Pei Y Liu,  Andrew E Tee,  Giorgio Milazzo,  Katherine M Hannan,  Jesper Maag,  Sujanna Mondal,  Bernard Atmadibrata,  Nenad Bartonicek,  Hui Peng,  Nicholas Ho,  Chelsea Mayoh,  Roberto Ciaccio,  Yuting Sun,  Michelle J Henderson,  Jixuan Gao,  Celine Everaert,  Amy J Hulme,  Matthew Wong,  Qing Lan,  Belamy B Cheung,  Leming Shi,  Jenny Y Wang,  Thorsten Simon,  Matthias Fischer,  Xu D Zhang,  Glenn M Marshall,  Murray D Norris,  Michelle Haber,  Jo Vandesompele,  Jinyan Li,  Pieter Mestdagh,  Ross D Hannan,  Marcel E Dinger,  Giovanni Perini,  Tao Liu","The majority of patients with neuroblastoma due to MYCN oncogene amplification and consequent N-Myc oncoprotein over-expression die of the disease. Here our analyses of RNA sequencing data identify the long noncoding RNA lncNB1 as one of the transcripts most over-expressed in MYCN-amplified, compared with MYCN-non-amplified, human neuroblastoma cells and also the most over-expressed in neuroblastoma compared with all other cancers. lncNB1 binds to the ribosomal protein RPL35 to enhance E2F1 protein synthesis, leading to DEPDC1B gene transcription. The GTPase-activating protein DEPDC1B induces ERK protein phosphorylation and N-Myc protein stabilization. Importantly, lncNB1 knockdown abolishes neuroblastoma cell clonogenic capacity in vitro and leads to neuroblastoma tumor regression in mice, while high levels of lncNB1 and RPL35 in human neuroblastoma tissues predict poor patient prognosis. This study therefore identifies lncNB1 and its binding protein RPL35 as key factors for promoting E2F1 protein synthesis, N-Myc protein stability and N-Myc-driven oncogenesis, and as therapeutic targets.",The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.,10.1038/s41467-019-12971-3,2019 Nov 5,PMC6831662,Nature communications
GSE112186,RPL12/uL11 phosphorylation regulates translation during mitosis [RIP-seq],Homo sapiens,12,SRP136214,2018-03-21,"[Overal design]Gene expression profiling of immunoprecipitated RPL12 protein-RNA complexes; [Treatment]'RPL12 wild-type, S38A or S38D mutant coding sequences were recombined using LR Clonase II (Gateway, Thermo Fischer Scientific) into pFRT/TO/FLAG/HA-DEST (Addgene ID: 26360). The resulting vectors were used to generate stable HEK293 Flp-In T-Rex cells lines overexpressing FLAG/HA-tagged wild-type RPL12, or S38A and S38D RPL12 mutated proteins. Briefly, HEK293 Flp-In T-Rex cells were transfected in a 12-well format by mixing 100 l of Opti-MEM with 1 g of total plasmid DNA (9:1 ratio of pOG44 to destination vector) and 2 l of Lipofectamine 2000 (Thermo Fischer Scientific). After a 5-minute incubation, the transfection mixture was added to the cells. Cells were re-seeded into 10-cm dishes after 48 hr and allowed to attach overnight. Hygromycin (100 g/ml, InvivoGen) was added the next day and the cells were selected for 2-3 weeks by the addition of fresh hygromycin-containing cell culture media every 2-3 days resulting in expansion of monoclonal colonies.'; [Growth]'HEK293 cells (American Type Culture Collection) were cultured in Dulbeccos modified Eagles medium (DMEM) (life technologies) complemented with glutamax (life technologies) and 10% fetal bovine serum (FBS) (PAN-Biotech).'; [Extraction]""Cycloheximide (50 g/ml) was added to each pooled 80S fraction (1 ml) obtained by sucrose gradient fractionation. Aliquots of these input fractions were used for Western blot analysis (20 l) and total RNA extraction with Trizol (50 l). The rest of the sample was subjected to anti-FLAG immunoprecipitation. To prepare anti-FLAG conjugated magnetic beads, 15 l of Dynabeads Protein G (Thermo Fisher Scientific) were used per sample, washed twice in 0.02 % of Tween 20/PBS (PBST) and resuspended in 30 l of PBST containing 0.25 g/l anti-FLAG M2 monoclonal antibody (F3165, Sigma Aldrich). After a 1 hr incubation at room temperature with rotation, the beads were washed twice in PBST, resuspended into the fractionated sample, followed by incubation at 4 C for 90 min. Next, the beads were concentrated and the supernatants removed, followed by 4 washing steps in 1 ml of washing buffer (0.05% (v/v) IGEPAL-CA630, 50 mM Tris pH 7.5, 150 mM KCl, 0.5 mM DTT, 50 g/ml cycloheximide, 1x complete EDTA-free protease inhibitor cocktail (Roche)). Before concentrating the beads during the fourth washing step, 100 l of suspension was removed for Western blot analysis, while the rest of the sample was used for RNA extraction. \xa0After the concentration of beads and removal of the supernatant, the beads were either resuspended in 1 bead volume of 2x Laemmli sample buffer (Western analysis) or 1 ml of Trizol (RNA extraction). After standard Trizol extraction consisting of chloroform addition and centrifugation, the clean-up of the aqueous phase was carried out using miRNAeasy kit (Qiagen) according to manufacturers instruction.\nExtracted RNA (either 1 g of input samples or all of the immunoprecipitated material) was treated with 0.4 U Turbo DNase (Thermo Fisher) for 30 min at 37 C, phenol-chlorotorm extracted, ethanol-precipitated and resuspended in water. For input samples, equal amounts of total RNA (1 g) and 2 l of 1:100 dilution of ERCC Spike-in Control Mix 1 (Thermo Fisher) were mixed and adjusted to 50 l final volume with water. All immunoprecipitated material per sample was mixed with 2 l of 1:100 dilution of ERCC Spike-in Control Mix 1 and adjusted to 50 l final volume with water. These 50-l samples were then input into the Truseq stranded mRNA kit (Illumina) using 2 rounds of oligo-dT enrichment. Manufacturer's instructions were followed in all subsequent steps. cDNA libraries from different samples were multiplexed using Illumina RPI oligonucleotides and sequenced by multiplexing 6 samples per lane on a HiSeq 2000 instrument using 1x101+7 cycles.""; [Cell type]'embryonic kidney cell line; epithelial''cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: WT; antibody: none; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38A1; antibody: none; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38D1; antibody: none; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: WT; antibody: Mouse monoclonal anti-FLAG (M2) [Sigma-Aldrich, Cat# F3165 RRID:AB_259529]; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38A1; antibody: Mouse monoclonal anti-FLAG (M2) [Sigma-Aldrich, Cat# F3165 RRID:AB_259529]; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38D1; antibody: Mouse monoclonal anti-FLAG (M2) [Sigma-Aldrich, Cat# F3165 RRID:AB_259529]; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112186,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112186/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445182,30220558," Koshi Imami,  Miha Milek,  Boris Bogdanow,  Tomoharu Yasuda,  Nicolai Kastelic,  Henrik Zauber,  Yasushi Ishihama,  Markus Landthaler,  Matthias Selbach","Emerging evidence indicates that heterogeneity in ribosome composition can give rise to specialized functions. Until now, research mainly focused on differences in core ribosomal proteins and associated factors. The effect of posttranslational modifications has not been studied systematically. Analyzing ribosome heterogeneity is challenging because individual proteins can be part of different subcomplexes (40S, 60S, 80S, and polysomes). Here we develop polysome proteome profiling to obtain unbiased proteomic maps across ribosomal subcomplexes. Our method combines extensive fractionation by sucrose gradient centrifugation with quantitative mass spectrometry. The high resolution of the profiles allows us to assign proteins to specific subcomplexes. Phosphoproteomics on the fractions reveals that phosphorylation of serine 38 in RPL12/uL11, a known mitotic CDK1 substrate, is strongly depleted in polysomes. Follow-up experiments confirm that RPL12/uL11 phosphorylation regulates the translation of specific subsets of mRNAs during mitosis. Together, our results show that posttranslational modification of ribosomal proteins can regulate translation.",Phosphorylation of the Ribosomal Protein RPL12/uL11 Affects Translation during Mitosis.,10.1016/j.molcel.2018.08.019,2018 Oct 4,,Molecular cell
GSE90469,Ribosome profiling of G2019S LRRK2 human dopamine neurons,Homo sapiens,20,SRP093833,2016-11-23,"[Overal design]hDA neurons: 60 days old samples were used.; [Treatment]'None'; [Growth]'None'; [Extraction]'Mouse samples: samples were dissected and frozen in dry ice, and homogenized and processed. hDA samples: samples were lysed on the culture plates, incubated in refrigerated rotator and processed.\nLibraries were prepared for sequencing using previously published ribosome profiling protocol.', 'hDA samples: samples were lysed on the culture plates, incubated in refrigerated rotator and processed.\nLibraries were prepared for sequencing using previously published ribosome profiling protocol.\nribosome profiling, RNA-seq'; [Cell type]'Source: ''strain: --; tissue: iPSC-differentiated dopamine neurons; age: Differentiation day 60; genotype: wild-type; ', 'strain: --; tissue: iPSC-differentiated dopamine neurons; age: Differentiation day 60; genotype: G2019S LRRK2; ', 'strain: mutation-corrected; tissue: iPSC-differentiated dopamine neurons; age: Differentiation day 60; genotype: wild-type; ', 'strain: patient-derived; tissue: iPSC-differentiated dopamine neurons; age: Differentiation day 60; genotype: G2019S LRRK2; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90469,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE90nnn/GSE90469/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA354729,,,,,,,,
GSE99395,Comparative ribosome profiling uncovers a dominant role for translational control in Toxoplasma gondii,Toxoplasma gondii,8,SRP108243,2017-05-30,"[Overal design]We compared ribosome footprints in intracellular and extracellular parasites.; [Treatment]'Prior to havesting, the parasite cultures were treated for about 10min with cyclohexamide (100ug/ml).'; [Growth]'Type I Toxoplasma gondii was grown on human foreskin fibroblasts and intracellular or extracellular parasites collected after 24 hrs'; [Extraction]""Aftter collection, the parasite samples were divided into two samples: one sample was used for ribosome profling, as previously described (Ingolia et al, 2009) and the other sample was used for high throughput RNA-sequencing.\nLibraries were prepared according to Illumina's instructions. Libraries were sequenced on the Genome Analyzer following the manufacturer's protocols.""; [Cell type]'Source: ''group: Extracellular parasites; replicate: Replicate 1; ', 'group: Extracellular parasites; replicate: Replicate 2; ', 'group: Intracellular parasites; replicate: Replicate 1; ', 'group: Intracellular parasites; replicate: Replicate 2; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99395,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE99nnn/GSE99395/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA388385,29228904," Musa A Hassan,  Juan J Vasquez,  Chew Guo-Liang,  Markus Meissner,  T Nicolai Siegel","BACKGROUND: The lytic cycle of the protozoan parasite Toxoplasma gondii, which involves a brief sojourn in the extracellular space, is characterized by defined transcriptional profiles. For an obligate intracellular parasite that is shielded from the cytosolic host immune factors by a parasitophorous vacuole, the brief entry into the extracellular space is likely to exert enormous stress. Due to its role in cellular stress response, we hypothesize that translational control plays an important role in regulating gene expression in Toxoplasma during the lytic cycle. Unlike transcriptional profiles, insights into genome-wide translational profiles of Toxoplasma gondii are lacking. METHODS: We have performed genome-wide ribosome profiling, coupled with high throughput RNA sequencing, in intracellular and extracellular Toxoplasma gondii parasites to investigate translational control during the lytic cycle. RESULTS: Although differences in transcript abundance were mostly mirrored at the translational level, we observed significant differences in the abundance of ribosome footprints between the two parasite stages. Furthermore, our data suggest that mRNA translation in the parasite is potentially regulated by mRNA secondary structure and upstream open reading frames. CONCLUSION: We show that most of the Toxoplasma genes that are dysregulated during the lytic cycle are translationally regulated.",Comparative ribosome profiling uncovers a dominant role for translational control in Toxoplasma gondii.,10.1186/s12864-017-4362-6,2017 Dec 11,PMC5725899,BMC genomics
GSE101409,Subcellular profiling of macrophage long non-coding RNAs,Homo sapiens,46,SRP111854,2017-07-13,"[Overal design]Expression profiles of poly(A)-RNA from primary human macrophages (+/- LPS treatment) or subcellular macrophage fractions (+/- LPS treatment) were recorded in experimental replicates. RNA profiles of gradient fractionated lysates from LPS-stimulated macrophages were recorded without prior RNA enrichment or depletion steps. For MaIL1 and control RNAi experiments each RNA-Seq dataset (poly(A)-RNA) represents an equimolar pool of RNA from two independent experiments.; [Treatment]'cells were stimulated with Salmonella typhimurium LPS at a concentration of 100 ng / ml for 4 h. Samples 1-8: Cells were pre-incubated with DMSO or inhibitors for 2 h prior to LPS-stimulation', 'cells were stimulated with Escherichia coli LPS at a concentration of 100 ng / ml for 8 h. Samples 1-8: Cells were pre-incubated with DMSO or inhibitors for 2 h prior to LPS-stimulation'; [Growth]'peripheral blood derived CD14+ monocytes (MACS enrichement) were differentiated in cell culture plastic multi-well plates (4*10e5 cell per 12-well, 1 ml of medium per well) using X-Vivo-15 medium supplemented with 5 % FCS and 20 ng / ml of recombinant human GM-CSF for 8 days'; [Extraction]""Cells were washed once with PBS and RNA was extracted with Trizol. For subcellular fractionation cells were lysed with mild detergent buffer and nuclei and cytosol were seperated by centrifugation at low speed. Cytosol was cleared from remaining nuclei by high speed centrifugation and nuclear fraction was carefully washed twice with mild detergent buffer before RNA-Extraction with Trizol.\nLibraries were prepared using the Illumina TruSeq Stranded mRNA kit according to the manufacturer's protocol"", ""Cells were washed once with PBS and RNA was extracted with Trizol. For subcellular fractionation cells were lysed with mild detergent buffer and nuclei and cytosol were seperated by centrifugation at low speed. Cytosol was cleared from remaining nuclei by high speed centrifugation and nuclear fraction was carefully washed twice with mild detergent buffer before RNA-Extraction with Trizol.\nLibraries were prepared using the Illumina TruSeq Stranded mRNA kit according to the manufacturer's protocol or an in-house total RNA strand-specific library protocol from Vertis Biotech AG (Freising, Germany)""; [Cell type]'D8 GM-CSF macrophage''tissue: Peripheral blood leukocytes; cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Mock control; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: LPS; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: control siRNA, mock; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: control siRNA, LPS; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: MaiL1 siRNA1, LPS; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: MaIL1 siRNA2, LPS; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: control MS-RAP; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: MaIL1 MS-RAP; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 1; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 2; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 3; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 4; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 5; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 6; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 7; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 8; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 9; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 10; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 11; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 12; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 13; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 14; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 15; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 16; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 17; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 18; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 19; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 20; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 21; ', 'cell type: D8 GM-CSF macrophage; precursor: CD14+ monocyte; donor: healthy, caucasian; agent: Glycerol gradient, fraction 22; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101409,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE101nnn/GSE101409/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA394134,32241891," Marina Aznaourova,  Harshavardhan Janga,  Stephanie Sefried,  Andreas Kaufmann,  Jens Dorna,  Sarah M Volkers,  Philipp Georg,  Marcus Lechner,  Judith Hoppe,  Simon Dokel,  Nils Schmerer,  Achim D Gruber,  Uwe Linne,  Stefan Bauer,  Leif E Sander,  Bernd Schmeck,  Leon N Schulte","RNA has been proposed as an important scaffolding factor in the nucleus, aiding protein complex assembly in the dense intracellular milieu. Architectural contributions of RNA to cytosolic signaling pathways, however, remain largely unknown. Here, we devised a multidimensional gradient approach, which systematically locates RNA components within cellular protein networks. Among a subset of noncoding RNAs (ncRNAs) cosedimenting with the ubiquitin-proteasome system, our approach unveiled ncRNA MaIL1 as a critical structural component of the Toll-like receptor 4 (TLR4) immune signal transduction pathway. RNA affinity antisense purification-mass spectrometry (RAP-MS) revealed MaIL1 binding to optineurin (OPTN), a ubiquitin-adapter platforming TBK1 kinase. MaIL1 binding stabilized OPTN, and consequently, loss of MaIL1 blunted OPTN aggregation, TBK1-dependent IRF3 phosphorylation, and type I interferon (IFN) gene transcription downstream of TLR4. MaIL1 expression was elevated in patients with active pulmonary infection and was highly correlated with IFN levels in bronchoalveolar lavage fluid. Our study uncovers MaIL1 as an integral RNA component of the TLR4-TRIF pathway and predicts further RNAs to be required for assembly and progression of cytosolic signaling networks in mammalian cells.",Noncoding RNA MaIL1 is an integral component of the TLR4-TRIF pathway.,10.1073/pnas.1920393117,2020 Apr 21,PMC7183186,Proceedings of the National Academy of Sciences of the United States of America
GSE141459,ZAK activation on colliding ribosomes triggers SAPK signaling pathways to regulate cell fate,Homo sapiens,8,SRP234715,2019-12-04,"[Overal design]4 samples for selective ribosome profiling experiments using ZAK OE HeLa cells. 4 samples for ribosome profiling experiments using HeLa cells.; [Treatment]'Expression of ZAK-FLAG was induced by addition of Doxycycline for 24 hr.', 'Monosomes were isolated by sucrose pelleting after RNaseI treatment'; [Growth]'Cells were grown to 75% confluency'; [Extraction]'Monosomes or disomes were isolated by sucrose gradient centrifugation after RNaseI treatment and subjected to immunoprecipitation\nFragments ranging from 24-90 nt  were gel purified for monosome or disome footprints, respectively. rRNA was depleted from this pool through Ribo-Zero Gold treatment. Upon dephosphorylation of sample RNA, linker was ligated and this product was once again gel purified. This was followed by reverse transcription as well as circularization of cDNAs. PCR amplification of this library was then sent for sequencing.', 'Fragments ranging from 15-34 nt  were gel purified for monosome or disome footprints, respectively.\nrRNA was depleted from this pool through Ribo-Zero Gold treatment. Upon dephosphorylation of sample RNA, linker was ligated and this product was once again gel purified. This was followed by reverse transcription (TGIRT) as well as circularization of cDNAs. PCR amplification of this library was then sent for sequencing.'; [Cell type]'Source: ''cell line: HeLa; plasmid(s): ZAK-FLAG; ', 'cell line: HeLa; plasmid(s): ZAK-FLAG; treatment: untreated; sample type: Isolated monosomes; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'cell line: HeLa; plasmid(s): ZAK-FLAG; treatment: UV-irradiated; sample type: Isolated monosomes; molecule subtype: Ribosome Protected mRNA (15-34 nt); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141459,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE141nnn/GSE141459/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA593553,32610081," Colin Chih-Chien Wu,  Amy Peterson,  Boris Zinshteyn,  Sergi Regot,  Rachel Green","Problems arising during translation of mRNAs lead to ribosome stalling and collisions that trigger a series of quality control events. However, the global cellular response to ribosome collisions has not been explored. Here, we uncover a function for ribosome collisions in signal transduction. Using translation elongation inhibitors and general cellular stress conditions, including amino acid starvation and UV irradiation, we show that ribosome collisions activate the stress-activated protein kinase (SAPK) and GCN2-mediated stress response pathways. We show that the MAPKKK ZAK functions as the sentinel for ribosome collisions and is required for immediate early activation of both SAPK (p38/JNK) and GCN2 signaling pathways. Selective ribosome profiling and biochemistry demonstrate that although ZAK generally associates with elongating ribosomes on polysomal mRNAs, it specifically auto-phosphorylates on the minimal unit of colliding ribosomes, the disome. Together, these results provide molecular insights into how perturbation of translational homeostasis regulates cell fate.",Ribosome Collisions Trigger General Stress Responses to Regulate Cell Fate.,10.1016/j.cell.2020.06.006,2020 Jul 23,PMC7384957,Cell
GSE78960,Modeling the Neuropathology of Tuberous Sclerosis with Human Stem Cells Reveals a Role for Inflammation and Angiogenic Growth Factors [Treatment],Homo sapiens,48,SRP071235,2016-03-07,"[Overal design]Rapamycin, AZD-8055, and DMSO were given to two TSC+/+ cell lines and two TSC-/- cell lines after six weeks of differentiation. Cells are harvested after 3 hours treatment and are subject to ribosome profiling and RNA-seq analysis.; [Treatment]'Cells were treated with DMSO, AZD-8055, and Rapamycin for 3 hours, respectively. After 3 hours cells are washed and harvested.'; [Growth]'NSCs were cultured according to standard methods. All used tissue culture dishes were coated with poly-L-ornithine (Sigma Aldrich) and laminin (Roche) and undifferentiated cultures were maintained in a basic medium composed of a 1:1 mix of DMEM:F12 Glutamax medium and Neurobasal medium (both Gibco, Invitrogen) that was supplemented with 1x B27, 1x N2 and 0.1 mM beta-mercaptoethanol (all Gibco, Invitrogen). For self-renewing conditions the following growth factors were added: 10 ng/mL FGF2, 20 ng/mL BDNF (both Peprotech) and 10 ng/mL EGF (R&D Systems). Ventralization was induced for a period of seven days by replating the cells at a density of 12000 cells/cm2 and changing the supplementing growth factors to 200 ng/mL Shh, 100 ng/mL FGF8 (both Peprotech) and 100 ?M ascorbic acid phosphate (Sigma Aldrich). Neuronal differentiation was initiated by replating the cells at a density of 40000 cells/cm2 in basic medium supplemented with 20 ng/mL BDNF, 10 ng/mL GDNF (both Peprotech), 0.5 mM cAMP (BIOLOG Life Science) and 100 ?M ascorbic acid phosphate (Sigma Aldrich). Medium was changed twice per week until the day of analysis.'; [Extraction]'Cells for each biological replicate of heterozygous and homozygous cells with or without drug treatment were washed with ice cold PBS and lysed on ice in the presence of 100 ?g/mL cycloheximide (Sigma). The cleared lysate was flash frozen and stored at -80 C until further processing. For ribosomal RNA depletion the RiboZero magnetic Gold kit (Illumina) was used. Quality of amplified libraries was accessed by capillary electrophoresis with a high sensitivity DNA chip on a 2100 Bioanalyzer (Agilent Technologies) and quantified by quantitative PCR with a sequencing library quantification kit (KAPA Biosystems) on a Roche Light Cycler 480. Multiplexed libraries with 1 % spiked in PhiX control were sequenced on a HiSeq2500 instrument for 50 cycles using version 4 chemistry reagents (Illumina).\nRibosome profiling and RNA sequencing libraries were prepared using the TruSeq Ribo Profile kit (Illumina, #RPHMR12126) as detailed in the manufacturers protocol.'; [Cell type]'Embryonic stem cell-derived neurons''cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: AZD-8055; cell line id: 15; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: AZD-8055; cell line id: 15; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: DMSO; cell line id: 15; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: DMSO; cell line id: 15; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: Rapamycin; cell line id: 15; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: Rapamycin; cell line id: 15; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: AZD-8055; cell line id: 16; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: AZD-8055; cell line id: 16; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: DMSO; cell line id: 16; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: DMSO; cell line id: 16; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: Rapamycin; cell line id: 16; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2+/+; treatment: Rapamycin; cell line id: 16; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: AZD-8055; cell line id: 19; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: AZD-8055; cell line id: 19; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: DMSO; cell line id: 19; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: DMSO; cell line id: 19; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: Rapamycin; cell line id: 19; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: Rapamycin; cell line id: 19; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: AZD-8055; cell line id: 20; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: AZD-8055; cell line id: 20; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: DMSO; cell line id: 20; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: DMSO; cell line id: 20; assayed molecule: mRNA; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: Rapamycin; cell line id: 20; assayed molecule: Ribosome protected fragments; ', 'cell type: Embryonic stem cell-derived neurons; genotype/variation: TSC2-/-; treatment: Rapamycin; cell line id: 20; assayed molecule: mRNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78960,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE78nnn/GSE78960/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA314507,27655340," Nils Grabole,  Jitao David Zhang,  Stefan Aigner,  Nadine Ruderisch,  Veronica Costa,  Felix C Weber,  Michel Theron,  Nikolaos Berntenis,  Olivia Spleiss,  Martin Ebeling,  Gene W Yeo,  Ravi Jagasia,  Anna Kiialainen","BACKGROUND: Tuberous sclerosis complex (TSC) is a genetic disease characterized by benign tumor growths in multiple organs and neurological symptoms induced by mTOR hyperfunction. Because the molecular pathology is highly complex and the etiology poorly understood, we employed a defined human neuronal model with a single mTOR activating mutation to dissect the disease-relevant molecular responses driving the neuropathology and suggest new targets for treatment. METHODS: We investigate the disease phenotype of TSC by neural differentiation of a human stem cell model that had been deleted for TSC2 by genome editing. Comprehensive genomic analysis was performed by RNA sequencing and ribosome profiling to obtain a detailed genome-wide description of alterations on both the transcriptional and translational level. The molecular effect of mTOR inhibitors used in the clinic was monitored and comparison to published data from patient biopsies and mouse models highlights key pathogenic processes. RESULTS: TSC2-deficient neural stem cells showed severely reduced neuronal maturation and characteristics of astrogliosis instead. Transcriptome analysis indicated an active inflammatory response and increased metabolic activity, whereas at the level of translation ribosomal transcripts showed a 5'UTR motif-mediated increase in ribosome occupancy. Further, we observed enhanced protein synthesis rates of angiogenic growth factors. Treatment with mTOR inhibitors corrected translational alterations but transcriptional dysfunction persisted. CONCLUSIONS: Our results extend the understanding of the molecular pathophysiology of TSC brain lesions, and suggest phenotype-tailored pharmacological treatment strategies.",Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model.,10.1186/s13073-016-0347-3,2016 Sep 21,PMC5031259,Genome medicine
GSE148536,Ythdf m6A readers compensate each other in a context dependent manner [Ribo-seq],Mus musculus,12,SRP256256,2020-04-12,"[Overal design]Mouse embryonic stem cells were knocked-out to each of the following proteins: Mettl3, Ythdf1, Ythdf2, Ythdf3, and Ythdf1/2/3 triple-KO. Ribosome footprint (ribo-seq) was generated in each of these KOs, and in WT control.; [Treatment]'For ribosome profiling cells were treated with Cycloheximide as previously described (McGlincy and Ingolia 2017; Ingolia et al. 2009).'; [Growth]'Maintenance of mESCs was conducted in in 500 mL of High-glucose DMEM (ThermoScientific), 15% USDA certified fetal bovine serum (FBS - Biological Industries), 1 mM L-Glutamine (Biological Industries), 1% nonessential amino acids (Biological Industries), 0.1 mM ?-mercaptoethanol (Sigma), 1% penicillin-streptomycin (Biological Industries), 1% Sodium-Pyruvate (Biological Industries), 10?g recombinant human LIF (Peprotech).'; [Extraction]'Cells were lysed in lysis buffer (20mM Tris 7.5, 150mM NaCl, 15mM MgCl2, 1mM dithiothreitol) supplemented with 0.5% triton, 30 U/ml Turbo DNase (Ambion) and 100?g/ml cycloheximide. The lysate was cleared by centrifugation, treated with RNase I for 45min and then loaded on a sucrose cushion. Pellet was resuspended in Trizol and then RNA was isolated from cells using chloroform-based separation.\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circularized and PCR amplified.'; [Cell type]'mouse embryonic stem cells (mESCs)''cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: WT; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf1-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf2-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf3-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Mettl3-/-; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148536,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148536/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA624906,,,,,,,,
GSE158374,Genes with 5' terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 NSP1 protein,Homo sapiens,18,SRP284977,2020-09-22,"[Overal design]Effects of NSP1 and NSP2 expression in translation and transcription in HEK293 cells; [Treatment]'pLVX-EF1alpha-SARS-CoV-2-nsp1-2XStrep-IRES-Puro plasmid (Addgene, 141367), pLVXEF1alpha-SARS-CoV-2-nsp2-2XStrep-IRES-Puro plasmid (Addgene, 141368) and pLVXEF1alpha-SARS-CoV-2-N-2XStrep-IRES-Puro (Addgene, 141391) were obtained from Addgene. The IRES-Puro elements in the above plasmids were replaced with IRES-TagBFP from TRE-KRAB-dCAS9-IRES-BFP (Addgene, 85449) to make them compatible with the MeTAFlow assay. Briefly, IRES-Tag BFP was PCR amplified (Fp 5-TCCGCAGTTTGAAAAGTAAGCCCCTCTCCCTCCCCCCC-3 and Rp 5-CAGAGGTTGATTGTTCCAGATTAATTAAGCTTGTGCCCCAGTTTGCTAGGG-3). The pLVXEF1alpha-SARS-CoV-2-nsp1/nsp2-2XStrep-IRES-Puro plasmids were digested with BamHI (NEB) and MluI (NEB) to remove the IRES-Puromycin fragment followed by gel purification. The purified vector was ligated with the IRES-TagBFP PCR amplified product using Gibson assembly cloning (NEB). For pLVX-EF1alpha-SARS-CoV-2-N-2XStrep-IRES-Puro plasmid, due to presence of internal MluI site in N ORF, a three fragment Gibson cloning was performed. The plasmid was digested with MluI and two PCR amplified products corresponding to a fragment of N ORF and IRES-Tag BFP were PCR amplified using the following oligos. (Fragment 1 Fp 5 5CTCTTGAATAAACACATAGACGCGTATAAGACGTTTCC 3' and RpGGGAGAGGGGCGGGATCCTTACTTTTCAAAC 3' and Fragment 2 5AAGGATCCCGCCCCTCTCCCTCCCCCCC 3' and Rp 5CAGAGGTTGATTGTTCCAGATTAATTAAGCTTGTGCCCCAGTTTGCTAGGG3' The sequences of the resulting plasmid clones were confirmed by Sanger sequencing.'; [Growth]'HEK293T cell line were obtained from ATCC and maintained in Dulbeccos modified Eagles media (DMEM, GIBCO) supplemented with 10% Fetal Bovine Serum (FBS, GIBCO, Life Technologies) and 1% Penicillin and Streptomycin (GIBCO, Life Technologies) at 37C in 5% CO2 atmosphere. Cell lines were tested for mycoplasma contamination every six months and were consistently found negative'; [Extraction]'Ribosome Profiling: Three million HEK293T cells were plated in a 10 cm2 flask followed by transfection to express SARS-CoV-2 NSP1 and NSP2 (see above). Untransfected and transfected cells (~8 million) were washed twice with 10 mL of ice-cold PBS. The plates were immediately placed on ice and 400 ?L of lysis buffer (Tris-Cl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 g/mL Cycloheximide, 1% Triton-X) was added to each plate, cells were scraped and transferred to 1.5 ml tubes. Cells were lysed on ice by pipetting up and down ~5 times every five minutes for a total of 10 min. All experiments were done in triplicate. The lysate was clarified by centrifugation at 160 x g for 10 min at 4C. Ten percent of the clarified lysate by volume was separated, mixed with 700 ?l QIAzol and stored at -20C for RNA-Seq experiments (see below). The rest of the supernatant was immediately processed for ribosome profiling. Briefly, 7 ?L of RNaseI (Invitrogen AM2249) was added to the clarified lysates and digestion was done for 1 h at 4 C. The digestions were stopped with ribonucleoside vanadyl complex (NEB S1402S) at a final concentration of 20 mM. Digested lysates were layered on a 1 M sucrose cushion (Tris, pH 7.4, NaCl 150 mM, MgCl 2 5 mM, DTT 1 mM, 1 M sucrose) and the ribosomes were pelleted by centrifugation in a SW 41 Ti rotor (Beckman Coulter) at 38K rpm and 4C for 2.5 h. RNA was extracted from the ribosome pellets with the addition of 700 ?l QIAzol followed by chloroform and ethanol precipitation. RNA isolated from the pellets were size-selected by running 5 g of each sample in a 15% polyacrylamide TBEUREA gel. The 21-34 nt RNA fragments were excised and extracted by crushing the gel fragment in 400 L of RNA extraction buffer (NaOAc [pH 5.5] 300 mM, EDTA 1 mM, SDS 0.25% v/v) followed by a 30 min incubation on dry ice and an overnight incubation at room temperature. The sample was passed through a Spin X filter (Corning 8160) and the flow through was ethanol precipitated in the presence of MgCl2 5 mM and 1 L of Glycoblue (Invitrogen AM9516). The RNA pellet was resuspended in 10 L of RNase-free water and immediately processed for library preparation.\nRibosome profiling libraries were prepared with the D-Plex Small RNA-Seq Kit (Diagenode). This method incorporates a 3' end dephosphorylation step, 5' unique molecular identifiers (UMI) and a template switching reverse transcriptase that improves the quality of our libraries. Briefly, 25 ng of size-selected ribosome footprints were prepared following the manufacturers instructions with some modifications. The cDNA was amplified for 9 cycles and the resulting DNA libraries were pooled in equimolar amounts (~425 nM each). The library pool was cleaned with the AMPure XP beads (Beckman Coulter A63880) and eluted with 30 L of RNase-free water. To enrich for ~30 bp fragments in the libraries, 3 g of the cleaned libraries were size-selected in a 3% agarose precast-gel (Sage Science) with the BluePippin system (Sage Science) using 171-203 nt range with tight settings. The resulting size-selected libraries were analyzed with the Agilent High Sensitivity DNA Kit (Agilent) and sequenced with the NovaSeq 6000 S1 SE 75 (Illumina).', 'RNA-Seq: Total RNA was extracted with QIAzol and ethanol precipitation from 10% of the lysate volume (see above). Sequencing libraries were generated using the SMARTer Stranded RNA-Seq Kit which uses a template switching reverse transcriptase (Takara Bio 634837). Briefly, 100 ng of total RNA were mixed with 1 L of a 1:10 dilution of ERCC RNA Spike-In Mix controls (Thermo Fisher 4456740). ERCC mix 1 was added to HEK293T and HEK293T-NSP1 and mix 2 was added to HEK293T-NSP2 samples. RNA hydrolysis was done for 4 min and half of the cDNA was amplified for 10 cycles. Samples were sequenced with NovaSeq 6000 S1 PE 100 (Illumina).\nsequencing libraries were generated using the SMARTer Stranded RNA-Seq Kit which uses a template switching reverse transcriptase.'; [Cell type]'Source: ''treatment: NSP1 expressing; cell line: HEK293; rna population: RNA from ribosome footprint; ', 'treatment: NSP2 expressing; cell line: HEK293; rna population: RNA from ribosome footprint; ', 'treatment: no treatment; cell line: HEK293; rna population: RNA from ribosome footprint; ', 'treatment: NSP1 expressing; cell line: HEK293; rna population: Total RNA; ', 'treatment: NSP2 expressing; cell line: HEK293; rna population: Total RNA; ', 'treatment: no treatment; cell line: HEK293; rna population: Total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158374,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE158nnn/GSE158374/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA665035,32995776," Shilpa Rao,  Ian Hoskins,  Tori Tonn,  P Daniela Garcia,  Hakan Ozadam,  Elif Sarinay Cenik,  Can Cenik","Viruses rely on the host translation machinery to synthesize their own proteins. Consequently, they have evolved varied mechanisms to co-opt host translation for their survival. SARS-CoV-2 relies on a non-structural protein, Nsp1, for shutting down host translation. However, it is currently unknown how viral proteins and host factors critical for viral replication can escape a global shutdown of host translation. Here, using a novel FACS-based assay called MeTAFlow, we report a dose-dependent reduction in both nascent protein synthesis and mRNA abundance in cells expressing Nsp1. We perform RNA-Seq and matched ribosome profiling experiments to identify gene-specific changes both at the mRNA expression and translation level. We discover a functionally-coherent subset of human genes are preferentially translated in the context of Nsp1 expression. These genes include the translation machinery components, RNA binding proteins, and others important for viral pathogenicity. Importantly, we uncovered a remarkable enrichment of 5' terminal oligo-pyrimidine (TOP) tracts among preferentially translated genes. Using reporter assays, we validated that 5' UTRs from TOP transcripts can drive preferential expression in the presence of NSP1. Finally, we found that LARP1, a key effector protein in the mTOR pathway may contribute to preferential translation of TOP transcripts in response to Nsp1 expression. Collectively, our study suggests fine tuning of host gene expression and translation by Nsp1 despite its global repressive effect on host protein synthesis.",Genes with 5' terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 Nsp1 protein.,10.1101/2020.09.13.295493,2021 May 25,PMC7523102,bioRxiv : the preprint server for biology
GSE74512,Ribosome profiling on SUM159PT cells grown in vitro or in vivo,Homo sapiens,8,SRP065529,2015-10-30,"[Overal design]Two batches of in vitro grown cells, each having 2 replicates. Two batches of in vivo grown cells from tumors grown in two individual mice, each having tumors on left (first batch) and right side (second batch). Extraction and ribosome profiling was done independently for the two batches of samples.; [Treatment]'None'; [Growth]'SUM159PT cells were cultured in DMEM/F12 1:1 medium supplemented with 5% FBS, insulin (5?g/ml), and hydrocortisone (1?g/ml).'; [Extraction]'SUM-159 GFP-RPL10a cells were treated with cycloheximide at a final conc of 10ug/m for 5 min. Cells were washed with cold PBS, scraped, and pelleted. Cell pellet was lysed with 1ml of NP40 lysis buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 150mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX) for 15 min, centrifuged for 10 min at 1300 g and 1ml of supernatant recovered.     For tumors preparation, each tumor was lysed in 1ml of NP40 lysis buffer in a tissue homogenizer. Tumor lysate was centrifuged at 1300g for 10 min and the supernatant was incubated with the beads.    85 ul per condition of GFP-Trap_M beads (Chromotek) were washed for 3 times in 1ml of NP40 lysis buffer, resuspended in 3 ml of NP40 lysis buffer. 1ml of cleared lysate (cell line or tumor) was added to the beads and digested with  RNAse I (100U/ul) for 1hr at RT under constant rotation. Beads were washed 3 times with of NP40 Lysis buffer and 3 times with NP40 wash buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 350mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX). Beads were resuspended in 300 ul of lysis buffer with 1% SDS and 15 ul of Proteinase K (Roche) and incubated for 1hr at 45C. Supernatant was recovered and resuspended in TriSure. RNA was isolated and libraries prepared according to the RP protocol.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: '""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: SUM159PT; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74512,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE74nnn/GSE74512/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA300625,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE154488,Global Translational Landscape of the Candida albicans Morphological Transition,Candida albicans,12,SRP272074,2020-07-15,"[Overal design]Examination of gene expression by RNA-seq and Ribo-seq in 1 strain of Candida albicans grown under 2 conditions (YEPD + serum at 37C (filament-inducing) and YEPD at 30C (non filament-inducing)). There are three biological replicates for each strain grown under each condition (12 samples total).; [Treatment]'Next, cells were scraped off the filter paper with a cell scraper, placed in ice-cold lysis buffer (1X yeast polysome buffer (Illumina), 10% Triton X-100 (Sigma), 10 mg/mL GMPPNP (Sigma), 10 mg/mL Blasticidin S (InvivoGen) and homogeneously mixed prior to snap freezing in liquid nitrogen.'; [Growth]'Serum inductions were carried out in YEPD (yeast extract peptone dextrose) medium as  described previously using C. albicans wild-type strain DK 318 (Banerjee et al. 2008) with the following exceptions: 1)  the initial starting overnight culture volume was 150 mL and overnight cultures were diluted at OD600 ~ 4.0, 2) cells were diluted into a final culture volume of 450 mL of YEPD at 30C or YEPD + 10% serum at 37C. Cells were harvested at the 1-hour post-induction time point and recovered by rapid filtration.'; [Extraction]'Lysates were prepared as described previously (Spealman et al. 2016) with a few modifications.  Flash frozen cells were thawed on an ice water slurry and cell suspensions were transferred into tubes with 0.5 mm diameter acid-washed glass beads and placed on ice for 5 min. The samples were lysed by vortexing 8 times for 30 sec. each with a 30 sec. rest on ice between each vortex. Samples were further processed according to instructions for the Illumina TrueSeq Ribo Profile (Yeast) Kit. Briefly, lysates were pre-cleared by centrifugation at 3000g for 5 min. at 4C to remove cell debris and further clarified by centrifugation at 20000g for 10 min. at 4C. The lysates were treated for 10 min. on ice with 10U/mL DNase I (Illumina) and quantified by measuring absorbance at 260 nm (A260). Finally, 100 uL aliquots were frozen in liquid nitrogen and stored at -80C until further use.\nRibosome profiling and library preparation were carried out according to the protocol described for the True Seq Ribo Profile (Yeast) Kit (Illumina). Lysates were digested with 15 U RNase I (Ambion) per A260 unit and incubated at room temperature for 45 min. with gentle rotation. The reactions were stopped by the addition of 1000U/mL SUPERase-IN (Ambion). 80S monosome fractions were purified from the cell lysate using MicroSpin S-400 HR columns (GE Healthcare). Ribosome protected fragments (RPFs) were further purified using the RNA Clean & Concentrator-25 Kit (Zymo Research) method. This kit was also used for total RNA purification. rRNA depletion was carried out using a Ribo-Zero Magnetic Gold (Yeast) kit (Illumina). An additional subtraction step was included to remove rRNA sequences from circularized cDNA as described previously (Spealman et al. 2016) with slight modifications.  Subtractions were carried out in a 30 uL reaction volume, with 10 uL sample, 2 uL 20X SSC and 2 uL of a rRNA subtraction pool containing custom-designed biotinylated oligonucleotides (Dataset S8). The circularized DNA was next used as a template for amplification of library PCR products. PCR products of 140-160 bp were recovered from excised gel slices, quantified by Agilent  Bioanalyzer/Fragment analyzer and deep sequencing was performed using an Illumina Hiseq3000 machine at the Greehey Childrens Cancer Research Institute Genome Sequencing Facility (University of Texas Health Science Center at San Antonio). All ribosome profiling experiments were performed in biological triplicate.'; [Cell type]'Source: ''growth_condition: YEPD at 30C; assay: Ribo; tissue: fungal cells; ', 'growth_condition: YEPD + serum at 37C; assay: Ribo; tissue: fungal cells; ', 'growth_condition: YEPD at 30C; assay: RNA; tissue: fungal cells; ', 'growth_condition: YEPD + serum at 37C; assay: RNA; tissue: fungal cells; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154488,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE154nnn/GSE154488/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA646470,33585865," Vasanthakrishna Mundodi,  Saket Choudhary,  Andrew D Smith,  David Kadosh","Candida albicans, a major human fungal pathogen associated with high mortality and/or morbidity rates in a wide variety of immunocompromised individuals, undergoes a reversible morphological transition from yeast to filamentous cells that is required for virulence. While previous studies have identified and characterized global transcriptional mechanisms important for driving this transition, as well as other virulence properties, in C. albicans and other pathogens, considerably little is known about the role of genome-wide translational mechanisms. Using ribosome profiling, we report the first global translational profile associated with C. albicans morphogenesis. Strikingly, many genes involved in pathogenesis, filamentation, and the response to stress show reduced translational efficiency (TE). Several of these genes are known to be strongly induced at the transcriptional level, suggesting that a translational fine-tuning mechanism is in place. We also identify potential upstream open reading frames (uORFs), associated with genes involved in pathogenesis, and novel ORFs, several of which show altered TE during filamentation. Using a novel bioinformatics method for global analysis of ribosome pausing that will be applicable to a wide variety of genetic systems, we demonstrate an enrichment of ribosome pausing sites in C. albicans genes associated with protein synthesis and cell wall functions. Altogether, our results suggest that the C. albicans morphological transition, and most likely additional virulence processes in fungal pathogens, is associated with widespread global alterations in TE that do not simply reflect changes in transcript levels. These alterations affect the expression of many genes associated with processes essential for virulence and pathogenesis.",Global translational landscape of the Candida albicans morphological transition.,10.1093/g3journal/jkaa043,2021 Feb 9,PMC7849906,"G3 (Bethesda, Md.)"
GSE30626,Candidate pathways for promoting differentiation and quiescence of oligodendrocyte progenitor-like cells in glioblastoma,Mus musculus,38,None,2011-07-13,"[Overal design]There are two datasets here. One characterizes the normal translational profiles of neurons, astrocytes, mature and immature oligodendrocytes. Each cell type was profiled in triplicate, from pools of at least two mice, and total RNA controls were collected in parallel. The second dataset includes translational profiles of Olig2 positive cells from tumors form several variations of a murine model of glioma. Each variation was collected at least in triplicate, and total RNA controls were analyzed in parallel. All translational profiles were generated using the Translating Ribosome Affinity Purification protocol.; [Treatment]'Either wildtype or induction of tumor (for tumor samples).'; [Growth]'For first dataset, dissected cortex from adult mice For second dataset, dissected tumors from mice.'; [Extraction]'Trizol followed by Qiagen RNeasy Minelute. Translating Ribosome Affinity Purification protocol (see Pubmed: [19013281])'; [Cell type]'Cortical Neurons', 'Cortical Mature Oligodendrocytes', 'Cortical Astrocytes', 'Cortical Oligodendrocyte Progenitor Cells', 'Cortex', 'Cortical Oligodendroglia', 'Olig2 cells from Pdgf Cre Tumor', 'Total RNA from Pdgf Cre Tumor', 'Olig2 cells from Pdgf Tumor', 'Total RNA from Pdgf Tumor', 'Olig2 cells from Recruited Tumor', 'Total RNA from Recruited Tumor''strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Cortical Neurons; rna subtype: Ribosome bound RNA; dataset: dataset 1; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Cortical Mature Oligodendrocytes; rna subtype: Ribosome bound RNA; dataset: dataset 1; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Cortical Astrocytes; rna subtype: Ribosome bound RNA; dataset: dataset 1; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Cortical Oligodendrocyte Progenitor Cells; rna subtype: Ribosome bound RNA; dataset: dataset 1; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Cortex; rna subtype: Total RNA; dataset: dataset 1; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Cortical Oligodendroglia; rna subtype: Ribosome bound RNA; dataset: dataset 1; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Olig2 cells from Pdgf Cre Tumor; rna subtype: Ribosome bound RNA; dataset: dataset 2; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Total RNA from Pdgf Cre Tumor; rna subtype: Total RNA; dataset: dataset 2; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Olig2 cells from Pdgf Tumor; rna subtype: Ribosome bound RNA; dataset: dataset 2; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Total RNA from Pdgf Tumor; rna subtype: Total RNA; dataset: dataset 2; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Olig2 cells from Recruited Tumor; rna subtype: Ribosome bound RNA; dataset: dataset 2; ', 'strain: mix of c57/bl6j, FVB, and Swiss-Webster; cell type: Total RNA from Recruited Tumor; rna subtype: Total RNA; dataset: dataset 2; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30626,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE30626/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA144543,22865458," Joseph D Dougherty,  Elena I Fomchenko,  Afua A Akuffo,  Eric Schmidt,  Karim Y Helmy,  Elena Bazzoli,  Cameron W Brennan,  Eric C Holland,  Ana Milosevic","Platelet-derived growth factor receptor alpha-positive oligodendrocyte progenitor cells (OPC) located within the mature central nervous system may remain quiescent, proliferate, or differentiate into oligodendrocytes. Human glioblastoma multiforme tumors often contain rapidly proliferating oligodendrocyte lineage transcription factor 2 (Olig2)-positive cells that resemble OPCs. In this study, we sought to identify candidate pathways that promote OPC differentiation or quiescence rather than proliferation. Gene expression profiling conducted in both normal murine OPCs and highly proliferative Olig2-positive glioma cells identified all the transcripts associated with the highly proliferative state of these cells and showed that among the various cell types found within the brain, Olig2-positive tumor cells are most similar to OPCs. We then subtracted OPC transcripts found in tumor samples from those found in normal brain samples and identified 28 OPC transcripts as candidates for promoting differentiation or quiescence. Systematic analysis of human glioma data revealed that these genes have similar expression profiles in human tumors and were significantly enriched in genomic deletions, suggesting an antiproliferative role. Treatment of primary murine glioblastoma cells with agonists of one candidate gene, Gpr17, resulted in a decreased number of neurospheres. Together, our findings show that comparison of the molecular phenotype of progenitor cells in tumors to the equivalent cells in the normal brain represents a novel approach for the identification of targeted therapies.",Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma.,10.1158/0008-5472.CAN-11-2632,2012 Sep 15,PMC3543775,Cancer research
GSE129816,"Next Generation Sequencing Facilitates Quantitative Analysis of Wild Type, genome-edited MTOR(G4448A)-p.C1483Y, and Torin1-treated Wild type Translatomics",Mus musculus,18,SRP192588,2019-04-15,"[Overal design]Examination of transcriptome and translatome in 3 cell types.; [Treatment]'Torin1 200 nM for 3 hr'; [Growth]'Cells were cultured with DMEM with 10% FBS and 1% p/s'; [Extraction]""RNA was extract using Trizol\nLibraries were prepared according to reference (Cho et al., Science 2015, Oct 2;350(6256):82-7. doi: 10.1126/science.aac7368). Libraries were prepared according to Illumina's instructions accompanying the TruSeq small RNA Kit (Cat#RS-200-0012). Briefly, Ribosome protected fragment (RPF) were purifed using a RNase I and Sephacryl S-400 column. mRNAs were heat fragmented. RPF and mRNAs were labeled with 32P using a T4 polynucleotide kinase. RPF and mRNAs were size selected usign Urea-PAGE. RPFs and mRNAs were end-repaired using antarctic phosphatase and T4 polynucleotide kinase. After purification, 3' adaptor and 5' adaptor ligated and purifed by UREA PAGE. After RT-PCR, libraries were sequenced using Hiseq 2000.""; [Cell type]'fibroblast''cell type: fibroblast; cell line: NIH3T3; gneotype: WT; ', 'cell type: fibroblast; cell line: NIH3T3; genotype: WT; ', 'cell type: fibroblast; cell line: NIH3T3; gneotype: C1483Y; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129816,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129816/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532893,31483294," Jang Keun Kim,  Jun Cho,  Se Hoon Kim,  Hoon-Chul Kang,  Dong-Seok Kim,  V Narry Kim,  Jeong Ho Lee","Brain somatic mutations confer genomic diversity in the human brain and cause neurodevelopmental disorders. Recently, brain somatic activating mutations in MTOR have been identified as a major etiology of intractable epilepsy in patients with cortical malformations. However, the molecular genetic mechanism of how brain somatic mutations in MTOR cause intractable epilepsy has remained elusive. In this study, translational profiling of intractable epilepsy mouse models with brain somatic mutations and genome-edited cells revealed a novel translational dysregulation mechanism and mTOR activation-sensitive targets mediated by human MTOR mutations that lead to intractable epilepsy with cortical malformation. These mTOR targets were found to be regulated by novel mTOR-responsive 5'-UTR motifs, distinct from known mTOR inhibition-sensitive targets regulated by 5' terminal oligopyrimidine motifs. Novel mTOR target genes were validated in patient brain tissues, and the mTOR downstream effector eIF4E was identified as a new therapeutic target in intractable epilepsy via pharmacological or genetic inhibition. We show that metformin, an FDA-approved eIF4E inhibitor, suppresses intractable epilepsy. Altogether, the present study describes translational dysregulation resulting from brain somatic mutations in MTOR, as well as the pathogenesis and potential therapeutic targets of intractable epilepsy.",Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy.,10.1172/JCI127032,2019 Oct 1,PMC6763223,The Journal of clinical investigation
GSE120383,Ribosome profiling of MCF10A cells with tRNA-Tyr-GUA depletion by shRNA relative to shControl cells,Homo sapiens,5,SRP162475,2018-09-24,"[Overal design]MCF10A cells with an shRNA against tRNA-Tyr-GUA or a control hairpin were subjected to ribosome profiling; [Treatment]'Experimental cells stably express a hairpin against tRNA-Tyr-GUA and control cells express a control hairpin'; [Growth]'MCF10A cells were grown in MCF10A media'; [Extraction]""RNA was extracted using TRIzol\nThis procedure was conducted as described by (McGlincy and Ingolia, 2017). Briefly, cells were washed and flash frozen with liquid N2 before being lysed with lysis buffer containing cycloheximide (Alfa Aesar). Lysate was digested with RNase I (Lucigen) before ribosomes were isolated through ultracentrifugation through a sucrose cushion. The ribosome pellet was resuspended in a solubilization buffer containing 0.5% SDS and 1mM EDTA and TRIzol before RNA was extracted using the Direct-zol kit (Zymo Research). RNA was separated on a 15% TBE-Urea gel before RNA between 17nt and 34nt were gel extracted. Barcoded pre-adenylated linkers were ligated using T4 RNA ligase 2 truncated K227Q (NEB) and rRNA was depleted using the Ribo-Zero gold kit (Illumina) according to the manufacturer's protocol. RNA was converted to cDNA using SuperScript III (Life Technologies) and the RT product was circularized by CircLigase II (Epicentre). A PCR library was amplified and sequenced using Illumina Nextseq 500.""; [Cell type]'MCF10A''cell type: MCF10A; barcode: GATCA; ', 'cell type: MCF10A; barcode: GCATA; ', 'cell type: MCF10A; barcode: TAGAC; ', 'cell type: MCF10A; barcode: TCTAG; ', 'cell type: MCF10A; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120383,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE120nnn/GSE120383/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA492921,,,,,,,,
GSE21983,The discovery and validation of ten-gene prognostic classifier in gastric cancer by whole genome expression profiling,Homo sapiens,72,None,2010-05-25,"[Overal design]We investigated the transcriptome profiles of gastric cancer patients with different prognosis. Thirty-nine patients from first batch samples were used to discover prognostic markers and another 33 samples from batch two were used for validation.; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA was extracted with Trizol reagent, spectrophotometry (OD UV 260/280 ratio >1.8) and agarose gel electrophoresis.'; [Cell type]'Source: ''patient group: training dataset patient; ', 'patient group: validation dataset patient; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21983,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE21nnn/GSE21983/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA127195,21483631," Yue-Zheng Zhang,  Lian-Hai Zhang,  Yang Gao,  Chao-Hua Li,  Shu-Qin Jia,  Ni Liu,  Feng Cheng,  De-Yun Niu,  William Cs Cho,  Jia-Fu Ji,  Chang-Qing Zeng","AIM: To develop a prognostic gene set that can predict patient overall survival status based on the whole genome expression analysis. METHODS: Using Illumina HumanWG-6 BeadChip followed by semi-supervised analysis, we analyzed the expression of 47,296 transcripts in two batches of gastric cancer patients who underwent surgical resection. Thirty-nine samples in the first batch were used as the training set to discover candidate markers correlated to overall survival, and thirty-three samples in the second batch were used for validation. RESULTS: A panel of ten genes were identified as prognostic marker in the first batch",Discovery and validation of prognostic markers in gastric cancer by genome-wide expression profiling.,10.3748/wjg.v17.i13.1710,2011 Apr 7,PMC3072635,World journal of gastroenterology
GSE153945,Persistent activation of mRNA translation by transient Hsp90 inhibition,Saccharomyces cerevisiae,12,SRP270667,2020-07-07,"[Overal design]Ribosome-profiling data examining heat shock and Hsp90 inhibition in yeast.; [Treatment]'10uM radicicol treatment o/n prior to further diliution to 0.001 OD600 and an additional o/n growth'; [Growth]'Three individual yeast colonies were picked and grown o/n in liquid culture. Each colony culture was dilituded to mediawithand without  10uM radicicol and grown o/n. Cultures were further diluted to 0.001 OD600 in 100ml media and grown for 24 hours and collected for ribosome profiling or RNA-seq'; [Extraction]'Samples were rapidly collected using filtration and ground to a fine powder using a Freezer/Mill (SPEX SamplePrep) and stored at -80 C.\nTo prepare RNA-seq libraries with fragment sizes that matched the ribosome profiling libraries, 25 g of total RNA was poly(A)-selected, digested into 2733 nt fragments, and used to prepare libraries in parallel with the ribosome-protected fragments. For ribosome profiling libraries, aliquots of lysate were digested with 1 U/?L RNase I (Ambion) for 30 min at room temperature and then run on a 1050% sucrose gradient to purify monosomes (Subtelny et al., 2014). RNAs from both RNA-seq and ribosome profiling were then size-selected, ligated to adapters, reverse-transcribed, and amplified (Subtelny et al., 2014).'; [Cell type]'Source: ''treatment: untreated; sequenced molecule: poly(A)-selected, fragmented RNA; ', 'treatment: untreated; sequenced molecule: ribosome-protected RNA fragments; ', 'treatment: 10 M radicicol pre-treatment; sequenced molecule: poly(A)-selected, fragmented RNA; ', 'treatment: 10 M radicicol pre-treatment; sequenced molecule: ribosome-protected RNA fragments; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153945,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE153nnn/GSE153945/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA644594,,,,,,,,
GSE21992,"Analysis of HeLa cells after transfection with miR-1 or miR-155, by ribosome profiling and mRNA-Seq",Homo sapiens,12,SRP002605,2010-05-25,"[Overal design]Examine ribosome footprints and mRNA abundance of HeLa cells transfected with miR-1 or miR-155, versus mock-transfected cells, at two different time points post-transfection. Supplementary processed data files linked below. mir155_summaryTable.txt: log2 fold changes (miR-155-transfected versus mock-transfected HeLa cells, 32hr). mir1_summaryTable.txt: log2 fold changes (miR-1-transfected versus mock-transfected HeLa cells, 32hr).; [Treatment]'All samples were treated with cycloheximide (100 ug/ml) for 8 min just before harvesting.'; [Growth]'None'; [Extraction]""mRNA-Seq: poly(A)-selected RNA was randomly fragmented by partial alkaline hydrolysis. Size-selected RNA fragments (25-45 nt) were used for library preparation.\nRibosome profiling: Cell extracts were digested with RNase I for 30 min at room temperature, and monosomes were purified by sucrose gradient centrifugation. Size-selected RNA fragments (~27-33 nt) were used for library preparation.\nLibrary preparation: Libraries were prepared as in Grimson et al, 2008 (GSE12578) but with the following modifications. Because RNase I-digestion and alkaline-fragmentation products terminate with a 5'-hydroxyl and a 3'-phosphate, they were 3'-dephosphorylated before ligation to the 3' adaptor.  Gel-purified 3'-ligation products were then 5'-phosphorylated before the 5'-ligation step.""; [Cell type]'Source: ''transfection: mock; time: 32hr; ', 'transfection: miR-155 duplex; time: 32hr; ', 'transfection: miR-1 duplex; time: 32hr; ', 'transfection: mock; time: 12hr; ', 'transfection: miR-155 duplex; time: 12hr; ', 'transfection: miR-1 duplex; time: 12hr; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21992,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE21nnn/GSE21992/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA129385,20703300," Huili Guo,  Nicholas T Ingolia,  Jonathan S Weissman,  David P Bartel","MicroRNAs (miRNAs) are endogenous approximately 22-nucleotide RNAs that mediate important gene-regulatory events by pairing to the mRNAs of protein-coding genes to direct their repression. Repression of these regulatory targets leads to decreased translational efficiency and/or decreased mRNA levels, but the relative contributions of these two outcomes have been largely unknown, particularly for endogenous targets expressed at low-to-moderate levels. Here, we use ribosome profiling to measure the overall effects on protein production and compare these to simultaneously measured effects on mRNA levels. For both ectopic and endogenous miRNA regulatory interactions, lowered mRNA levels account for most (>/=84%) of the decreased protein production. These results show that changes in mRNA levels closely reflect the impact of miRNAs on gene expression and indicate that destabilization of target mRNAs is the predominant reason for reduced protein output.",Mammalian microRNAs predominantly act to decrease target mRNA levels.,10.1038/nature09267,2010 Aug 12,PMC2990499,Nature
GSE123611,Codon usage optimization in pluripotent embryonic stem cells,Homo sapiens,24,None,2018-12-11,"[Overal design]Refer to individual Series; [Treatment]'Differentiating hESC were cultured in MEF-conditioned KSR media plus 1uM retinoic acid in DMSO, while the control hESC population was maintained in MEF-conditioned KSR media completed with 4 ng/mL FGF2. Self-renewing cells were collected at Day 0, while differentiating cells at day 5 of treatment.'; [Growth]'hESC were maintained in Essential 8 media (Thermo Fisher Scientific) on hESC-Qualified Matrigel (Corning) coated plates at 37C, 5 % CO2. Cultures were dissociated in clumps using 0.5mM EDTA every 4 days and media was renewed daily.'; [Extraction]'mRNA footprints were prepared according to the ribosomal profilig protocol published by Ingolia et al., while total RNA was extracted using Trizol.\xa0\nmRNA footprints were Ribozero treated (Illumina) and libraries were prepared using TruSeq Small RNA Preparation Kit (Illumina) according to manufacturer instructions. For RNA-seq, total RNA was treated with the RiboZero Magnetic Kit (Illumina) to remove ribosomal RNA. Libraries for sequencing were prepared using the NEB next Ultra Directional library prep kit for Illumina.', 'Total RNA was extracted using Trizol.\xa0After DNAse treatment and de-aminoacylation, tRNAs were size excised from a TBE-UREA polyacrylamide gel. Fragments ends were repaired used T4 PNK.\xa0\nLibraries from the tRNAs were prepared using the TruSeq Small RNA library preparation Kit from Illumina.'; [Cell type]'human embryonic stem cells''cell type: human embryonic stem cells; ', 'cell type: human embryonic stem cells; cell line: H9; condition: self-renewing; ', 'cell type: human embryonic stem cells; cell line: H9; condition: differentiating; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123611,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123611/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA509373,31174582," Susanne Bornelov,  Tommaso Selmi,  Sophia Flad,  Sabine Dietmann,  Michaela Frye","BACKGROUND: The uneven use of synonymous codons in the transcriptome regulates the efficiency and fidelity of protein translation rates. Yet, the importance of this codon bias in regulating cell state-specific expression programmes is currently debated. Here, we ask whether different codon usage controls gene expression programmes in self-renewing and differentiating embryonic stem cells. RESULTS: Using ribosome and transcriptome profiling, we identify distinct codon signatures during human embryonic stem cell differentiation. We find that cell state-specific codon bias is determined by the guanine-cytosine (GC) content of differentially expressed genes. By measuring the codon frequencies at the ribosome active sites interacting with transfer RNAs (tRNA), we further discover that self-renewing cells optimize translation of codons that depend on the inosine tRNA modification in the anticodon wobble position. Accordingly, inosine levels are highest in human pluripotent embryonic stem cells. This effect is conserved in mice and is independent of the differentiation stimulus. CONCLUSIONS: We show that GC content influences cell state-specific mRNA levels, and we reveal how translational mechanisms based on tRNA modifications change codon usage in embryonic stem cells.",Codon usage optimization in pluripotent embryonic stem cells.,10.1186/s13059-019-1726-z,2019 Jun 7,PMC6555954,Genome biology
GSE94454,Selective stalling of human translation through small molecule engagement of the ribosome nascent chain,Homo sapiens,26,SRP098789,2017-02-03,"[Overal design]Study 1: Huh7 cells were treated with 1.5 M PF-06446846, 0.3 M PF-06446846 or vehicle for 10 or 60 minutes, and subjected to ribosome profiling. This study included three biological replicates Study 2: Huh7 cells were treated with 1.5 M PF-06446846 or vehicle for 60 minutes and subjected to both ribosome profiling and mRNA-seq. This study included two biological replicates.; [Treatment]'Huh7 cells were grown in 10 cm plates to a confluence of 50-80%.  The cells were always passaged into fresh media within 24 hours of the experiment. The media was replaced with fresh prewarmed media containing 1.5 M or 0.3 M PF-06446846 or vehicle (0.5% DMSO) and the plates were immediately returned to the incubator for 10 or 60 minutes as indicated.'; [Growth]'Huh7 cells were maintained in RPMI ((Life Technologies 11875-093) supplemented with 10% FBS (Sigma F4135) 1% Penicillin/Streptomycin (Life Technologies 15410-112) and 4 mM Glutamax (Life Technologies 35050-061) at 37 ?C under a 5% CO2 atmosphere.   The cells were tested for mycoplasma and using the Gen-Probe Mycoplasma Tissue Culture NI (MTC-IN) Rapid Detection method.'; [Extraction]'The cells were harvested by aspiration of media and immediate addition of ice-cold PBS containing 100 g/mL cycloheximide.  The PBS plus cycloheximide was aspirated with a vacuum aspirator and 400 L lysis buffer (20 mM Tris-Cl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 100 g/mL cycloheximide, 1% Triton X-100 and 25 U/mL DNase I (Promega)) was added.\nCells were lysed and ribosome footprint or fragmented RNA libraries were generated as described in Ingolia et al. Curr Protoc Mol Biol Chapter 4, Unit 4 18 (2013).'; [Cell type]'Source: ''cell line: Huh7; [pf-06446846]: 1.5 M; treatment time: 10 min; library type: ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 0.3 M; treatment time: 10 min; library type: ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 0.0 M; treatment time: 10 min; library type: ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 1.5 M; treatment time: 60 min; library type: ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 0.3 M; treatment time: 60 min; library type: ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 0.0 M; treatment time: 60 min; library type: ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 0 M; treatment time: 60 min; library type: Ribo-seq; ', 'cell line: Huh7; [pf-06446846]: 1.5 M; treatment time: 60 min; library type: mRNA-seq; ', 'cell line: Huh7; [pf-06446846]: 0.0 M; treatment time: 60 min; library type: polyA-seq; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94454,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE94nnn/GSE94454/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA369742,28323820," Nathanael G Lintner,  Kim F McClure,  Donna Petersen,  Allyn T Londregan,  David W Piotrowski,  Liuqing Wei,  Jun Xiao,  Michael Bolt,  Paula M Loria,  Bruce Maguire,  Kieran F Geoghegan,  Austin Huang,  Tim Rolph,  Spiros Liras,  Jennifer A Doudna,  Robert G Dullea,  Jamie H D Cate,  Nathanael G Lintner,  Kim F McClure,  Donna Petersen,  Allyn T Londregan,  David W Piotrowski,  Liuqing Wei,  Jun Xiao,  Michael Bolt,  Paula M Loria,  Bruce Maguire,  Kieran F Geoghegan,  Austin Huang,  Tim Rolph,  Spiros Liras,  Jennifer A Doudna,  Robert G Dullea,  Jamie H D Cate","Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel. We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing. Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation. The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small molecules to specifically block translation of individual transcripts.",Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain.,10.1371/journal.pbio.2001882,2017 Mar,PMC5360235,PLoS biology
GSE35659,A transcriptional map of the impact of endurance exercise training on skeletal muscle phenotype (resting muscle after endurance training),Homo sapiens,24,None,2012-02-09,"[Overal design]This data is from skeletal muscle post 6 weeks of endurance exercise training matching the samples (pre-training, fasting) provided in GSE18583; [Treatment]'None'; [Growth]'skeletal muscle post 6 weeks of endurance exercise training'; [Extraction]'Muscle was homogenised in Trizol with Polytron motor driven homogeniser and RNA extraction carried out using Trizol protocol (Invitrogen). Hybridization, washing, staining and scanning of the arrays were performed according to manufacturers instructions (Affymetrix)'; [Cell type]'Source: ''protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 151; vo2 (l/min): 2.68; rer: 0.87; ve (l/min): 52.9; duration (mins): 15.995; max work (watts): 360; end borg: 19; end hr (bpm): 186.5; vo2 end (l/min): 4.44; body mass: 104.7; vo2max per kg: 42.4068767908309; rer end: 1.16; ve end (l/min): 157.1; rr end (breaths/min): 54.5; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 123; vo2 (l/min): 1.82; rer: 0.91; ve (l/min): 50.4; duration (mins): 14.98; max work (watts): 310; end borg: 19.5; end hr (bpm): 186.5; vo2 end (l/min): 3.505; body mass: 64.5; vo2max per kg: 54.3410852713178; rer end: 1.19; ve end (l/min): 152.1; rr end (breaths/min): 56.5; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 156; vo2 (l/min): 2.88; rer: 0.99; ve (l/min): 80.4; duration (mins): 16; max work (watts): 340; end borg: 18.5; end hr (bpm): 186; vo2 end (l/min): 4.305; body mass: 83.1; vo2max per kg: 51.8050541516245; rer end: 1.07; ve end (l/min): 148.05; rr end (breaths/min): 51.85; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 137; vo2 (l/min): 2.93; rer: 0.94; ve (l/min): 69.6; duration (mins): 16.33; max work (watts): 370; end borg: 20; end hr (bpm): 188.5; vo2 end (l/min): 4.57; body mass: 78.3; vo2max per kg: 58.3652618135377; rer end: 1.205; ve end (l/min): 179.375; rr end (breaths/min): 50.75; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 135; vo2 (l/min): 2.99; rer: 0.94; ve (l/min): 71.3; duration (mins): 22.5; max work (watts): 450; end borg: 19.5; end hr (bpm): 191; vo2 end (l/min): 5.485; body mass: 78.5; vo2max per kg: 69.8726114649682; rer end: 1.18; ve end (l/min): 211.2; rr end (breaths/min): 58.3; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 155; vo2 (l/min): 2.6; rer: 0.98; ve (l/min): 70.1; duration (mins): 14.75; max work (watts): 320; end borg: 19.5; end hr (bpm): 189; vo2 end (l/min): 3.944; body mass: 70; vo2max per kg: 56.3428571428571; rer end: 1.16; ve end (l/min): 146.75; rr end (breaths/min): 61.5; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 130; vo2 (l/min): 3.17; rer: 0.84; ve (l/min): 58.3; duration (mins): 21.625; max work (watts): 440; end borg: 20; end hr (bpm): 190.5; vo2 end (l/min): 5.115; body mass: 83; vo2max per kg: 61.6265060240964; rer end: 1.115; ve end (l/min): 150.25; rr end (breaths/min): 41.15; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 163; vo2 (l/min): 2.63; rer: 1.01; ve (l/min): 73.2; duration (mins): 17; max work (watts): 340; end borg: 19; end hr (bpm): 189; vo2 end (l/min): 3.995; body mass: 73; vo2max per kg: 54.7260273972603; rer end: 1.26; ve end (l/min): 164.65; rr end (breaths/min): 62.35; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 160; vo2 (l/min): 1.9; rer: 1.01; ve (l/min): 57.1; duration (mins): 13.875; max work (watts): 280; end borg: 18.5; end hr (bpm): 198; vo2 end (l/min): 3.215; body mass: 57.2; vo2max per kg: 56.2062937062937; rer end: 1.265; ve end (l/min): 161.95; rr end (breaths/min): 56.85; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 128; vo2 (l/min): 2.38; rer: 0.89; ve (l/min): 51.3; duration (mins): 19.75; max work (watts): 400; end borg: 19; end hr (bpm): 179.5; vo2 end (l/min): 4.69; body mass: 92; vo2max per kg: 50.9782608695652; rer end: 1.125; ve end (l/min): 159.4; rr end (breaths/min): 46.35; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 131; vo2 (l/min): 2.35; rer: 0.87; ve (l/min): 46.7; duration (mins): 18.875; max work (watts): 380; end borg: 20; end hr (bpm): 186; vo2 end (l/min): 4.665; body mass: 82; vo2max per kg: 56.890243902439; rer end: 1.105; ve end (l/min): 133.15; rr end (breaths/min): 49.75; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 146; vo2 (l/min): 2.88; rer: 0.96; ve (l/min): 72.6; duration (mins): 16.665; max work (watts): 350; end borg: 19.5; end hr (bpm): 186.5; vo2 end (l/min): 4.07; body mass: 74.6; vo2max per kg: 54.5576407506703; rer end: 1.195; ve end (l/min): 155.95; rr end (breaths/min): 45.75; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 163; vo2 (l/min): 2.42; rer: 0.9; ve (l/min): 58.3; duration (mins): 14.415; max work (watts): 320; end borg: 20; end hr (bpm): 191; vo2 end (l/min): 3.51; body mass: 77; vo2max per kg: 45.5844155844156; rer end: 1.15; ve end (l/min): 120.625; rr end (breaths/min): 57.25; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 134; vo2 (l/min): 2.56; rer: 0.95; ve (l/min): 63.3; duration (mins): 17.125; max work (watts): 370; end borg: 18.5; end hr (bpm): 175; vo2 end (l/min): 4.32; body mass: 69.5; vo2max per kg: 62.158273381295; rer end: 1.155; ve end (l/min): 154.25; rr end (breaths/min): 58.6; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 151; vo2 (l/min): 2.96; rer: 0.89; ve (l/min): 65.5; duration (mins): 16; max work (watts): 360; end borg: 19.5; end hr (bpm): 186; vo2 end (l/min): 4.105; body mass: 90; vo2max per kg: 45.6111111111111; rer end: 1.18; ve end (l/min): 139.45; rr end (breaths/min): 44; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 158; vo2 (l/min): 2.21; rer: 0.93; ve (l/min): 55.4; duration (mins): 15.25; max work (watts): 340; end borg: 15.5; end hr (bpm): 196.5; vo2 end (l/min): 4.325; body mass: 69; vo2max per kg: 62.6811594202899; rer end: 1.145; ve end (l/min): 154.25; rr end (breaths/min): 54.5; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 162; vo2 (l/min): 2.407; rer: 0.91; ve (l/min): 53.5; duration (mins): 15; max work (watts): 320; end borg: 19; end hr (bpm): 195; vo2 end (l/min): 3.97; body mass: 65; vo2max per kg: 61.0769230769231; rer end: 1.13; ve end (l/min): 139.7; rr end (breaths/min): 58; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 150; vo2 (l/min): 1.99; rer: 0.89; ve (l/min): 44.2; duration (mins): 16.625; max work (watts): 360; end borg: 19; end hr (bpm): 193.5; vo2 end (l/min): 4.295; body mass: 65; vo2max per kg: 66.0769230769231; rer end: 1.21; ve end (l/min): 151.15; rr end (breaths/min): 45.5; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 165; vo2 (l/min): 2.46; rer: 0.94; ve (l/min): 57.4; duration (mins): 16.125; max work (watts): 350; end borg: 19; end hr (bpm): 184; vo2 end (l/min): 3.835; body mass: 82.5; vo2max per kg: 46.4848484848485; rer end: 1.17; ve end (l/min): 146.15; rr end (breaths/min): 56.25; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 182; vo2 (l/min): 3.2; rer: 0.97; ve (l/min): 72.8; duration (mins): 16.915; max work (watts): 380; end borg: 19.5; end hr (bpm): 199.5; vo2 end (l/min): 4.295; body mass: 79.5; vo2max per kg: 54.0251572327044; rer end: 1.19; ve end (l/min): 146.65; rr end (breaths/min): 51; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 168; vo2 (l/min): 2.2; rer: 1; ve (l/min): 53.9; duration (mins): 12; max work (watts): 260; end borg: 17; end hr (bpm): 197; vo2 end (l/min): 3.27; body mass: 63.5; vo2max per kg: 51.496062992126; rer end: 1.18; ve end (l/min): 123.9; rr end (breaths/min): 37.5; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 151; vo2 (l/min): 3.22; rer: 0.98; ve (l/min): 87.9; duration (mins): 15.415; max work (watts): 350; end borg: 19; end hr (bpm): 186.5; vo2 end (l/min): 4.6; body mass: 79; vo2max per kg: 58.2278481012658; rer end: 1.205; ve end (l/min): 177.4; rr end (breaths/min): 45; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 150; vo2 (l/min): 2.71; rer: 0.92; ve (l/min): 69.1; duration (mins): 17.625; max work (watts): 380; end borg: 19.5; end hr (bpm): 199.5; vo2 end (l/min): 4.895; body mass: 82.5; vo2max per kg: 59.3333333333333; rer end: 1.125; ve end (l/min): 173.75; rr end (breaths/min): 55.25; ', 'protocol: Resting skeletal muscle sample after to endurance training; gender: male; heart rate (bpm): 165; vo2 (l/min): 2.05; rer: 0.95; ve (l/min): 56.3; duration (mins): 15; max work (watts): 320; end borg: 20; end hr (bpm): 196; vo2 end (l/min): 3.21; body mass: 81.5; vo2max per kg: 39.3865030674847; rer end: 1.17; ve end (l/min): 130.8; rr end (breaths/min): 57.5; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35659,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE35nnn/GSE35659/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA155863,20930125," Pernille Keller,  Niels B J Vollaard,  Thomas Gustafsson,  Iain J Gallagher,  Carl Johan Sundberg,  Tuomo Rankinen,  Steven L Britton,  Claude Bouchard,  Lauren G Koch,  James A Timmons","The molecular pathways that are activated and contribute to physiological remodeling of skeletal muscle in response to endurance exercise have not been fully characterized. We previously reported that approximately 800 gene transcripts are regulated following 6 wk of supervised endurance training in young sedentary males, referred to as the training-responsive transcriptome (TRT) (Timmons JA et al. J Appl Physiol 108: 1487-1496, 2010). Here we utilized this database together with data on biological variation in muscle adaptation to aerobic endurance training in both humans and a novel out-bred rodent model to study the potential regulatory molecules that coordinate this complex network of genes. We identified three DNA sequences representing RUNX1, SOX9, and PAX3 transcription factor binding sites as overrepresented in the TRT. In turn, miRNA profiling indicated that several miRNAs targeting RUNX1, SOX9, and PAX3 were downregulated by endurance training. The TRT was then examined by contrasting subjects who demonstrated the least vs. the greatest improvement in aerobic capacity (low vs. high responders), and at least 100 of the 800 TRT genes were differentially regulated, thus suggesting regulation of these genes may be important for improving aerobic capacity. In high responders, proangiogenic and tissue developmental networks emerged as key candidates for coordinating tissue aerobic adaptation. Beyond RNA-level validation there were several DNA variants that associated with maximal aerobic capacity (Vo((2)max)) trainability in the HERITAGE Family Study but these did not pass conservative Bonferroni adjustment. In addition, in a rat model selected across 10 generations for high aerobic training responsiveness, we found that both the TRT and a homologous subset of the human high responder genes were regulated to a greater degree in high responder rodent skeletal muscle. This analysis provides a comprehensive map of the transcriptomic features important for aerobic exercise-induced improvements in maximal oxygen consumption.",A transcriptional map of the impact of endurance exercise training on skeletal muscle phenotype.,10.1152/japplphysiol.00634.2010,2011 Jan,PMC3253010,"Journal of applied physiology (Bethesda, Md. : 1985)"
GSE137553,Translational control of mTOR/4E-BP1 axis in MiaPaca-2 cells,Homo sapiens,16,None,2019-09-17,"[Overal design]Miapaca-2 cells were treated with 2.5?M PP242 for 12 hours. Both cytoplasmic and polysome-associated mRNA was extracted from treatments and a vehicle treated control and probed with microarrays. Experiments were done in 4 replicates for a total of 16 samples.; [Treatment]'Cells were treated or not with PP242 at 2.5uM for 12 hours'; [Growth]""MIAPACA-2 cells were grown in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% defined fetal bovine serum (FBS), 2mM L-glutamine, 100 units/ml penicillin and 100 microgram/ml streptomycin. Cells were seeded in 150mm culture dishes and grown up to 70% confluence (about 20x10^6 cells).""; [Extraction]'Cytosolic and polysome-associated RNA was collected from MIAPACA-2 cells (4 replicates). Briefly, total cytosolic mRNA (Cytosolic RNA) was extracted and sedimented on a 10%-50% sucrose gradient to separate mRNA according to the number of associated ribosomes. Polysome fractions with mRNA associated with >3 ribosomes were pooled (polysome-associated mRNA) and RNA was isolated using Trizol.'; [Cell type]'Pancreatic cancer cells''cell type: Pancreatic cancer cells; cell line: MiaPaca-2; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137553,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE137nnn/GSE137553/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA565914,31672935," David Muller,  Sauyeun Shin,  Theo Goullet de Rugy,  Remi Samain,  Romain Baer,  Manon Strehaiano,  Laia Masvidal-Sanz,  Julie Guillermet-Guibert,  Christine Jean,  Yoshinori Tsukumo,  Nahum Sonenberg,  Frederic Marion,  Nicolas Guilbaud,  Jean-Sebastien Hoffmann,  Ola Larsson,  Corinne Bousquet,  Stephane Pyronnet,  Yvan Martineau","Pancreatic ductal adenocarcinoma (PDAC) relies on hyperactivated protein synthesis. Consistently, human and mouse PDAC lose expression of the translational repressor and mTOR target 4E-BP1. Using genome-wide polysome profiling, we here explore mRNAs whose translational efficiencies depend on the mTOR/4E-BP1 axis in pancreatic cancer cells. We identified a functional enrichment for mRNAs encoding DNA replication and repair proteins, including RRM2 and CDC6. Consequently, 4E-BP1 depletion favors DNA repair and renders DNA replication insensitive to mTOR inhibitors, in correlation with a sustained protein expression of CDC6 and RRM2, which is inversely correlated with 4E-BP1 expression in PDAC patient samples. DNA damage and pancreatic lesions induced by an experimental pancreatitis model uncover that 4E-BP1/2-deleted mice display an increased acinar cell proliferation and a better recovery than WT animals. Targeting translation, independently of 4E-BP1 status, using eIF4A RNA helicase inhibitors (silvestrol derivatives) selectively modulates translation and limits CDC6 expression and DNA replication, leading to reduced PDAC tumor growth. In summary, 4E-BP1 expression loss during PDAC development induces selective changes in translation of mRNA encoding DNA replication and repair protein. Importantly, targeting protein synthesis by eIF4A inhibitors circumvents PDAC resistance to mTOR inhibition.",eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.,10.1172/jci.insight.121951,2019 Nov 1,PMC6948775,JCI insight
GSE43306,Translating transcriptome of cancer cells in situ in mesenchymal-rich tumor microenvironment,Homo sapiens,9,SRP017789,2013-01-06,"[Overal design]EGFP-10a+ MDA-MB-231 cells were orthotopically injected into the mammary fat pad with or without 1:1 ratio of MSCs. The mammary tumors were retrieved for TRAP-RNAseq profiling after 3 weeks.; [Treatment]'None'; [Growth]'EGFP-L10a+ MDA-MB-231 cancer cells were orthotopically injected into the mammary fat pad with or without 1:1 ratio of human bone marrow derived mesenchymal stem cells (MSCs). The mammary tumors were retrieved for TRAP-RNAseq profiling after 3 weeks. Five biological replicates from different mice were included in the ""with MSC"" group (M), and four biological replicates from different mice were included in the ""without MSC"" group (A).'; [Extraction]'Polysome-associated RNA was extracted following the TRAP protocol from Heiman et al, Cell, 2009. Briefly, the whole tumor were harvested and cut into small pieces. Tumor slices were lysed in polysome extraction buffer. Polysomes were pulled down by anti-GFP coated sepharose beads. Polysome-associated RNA was isolated with RNAqeuous micro kit (Life Technologies).\nRNA sequencing libraries were constructed with 500ng polysome-associated RNA using TruSeq RNA Sample Prep Kit v2 (Illumina).'; [Cell type]'Source: ''cell line: EGFP-10a+ MDA-MB-231; protocol: supplemented with 1:1 ratio of MSC; ', 'cell line: EGFP-10a+ MDA-MB-231; protocol: without MSC supplementation; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43306,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE43nnn/GSE43306/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA185392,23993096," Xiang H-F Zhang,  Xin Jin,  Srinivas Malladi,  Yilong Zou,  Yong H Wen,  Edi Brogi,  Marcel Smid,  John A Foekens,  Joan Massague","How organ-specific metastatic traits arise in primary tumors remains unknown. Here, we show a role of the breast tumor stroma in selecting cancer cells that are primed for metastasis in bone. Cancer-associated fibroblasts (CAFs) in triple-negative (TN) breast tumors skew heterogeneous cancer cell populations toward a predominance of clones that thrive on the CAF-derived factors CXCL12 and IGF1. Limiting concentrations of these factors select for cancer cells with high Src activity, a known clinical predictor of bone relapse and an enhancer of PI3K-Akt pathway activation by CXCL12 and IGF1. Carcinoma clones selected in this manner are primed for metastasis in the CXCL12-rich microenvironment of the bone marrow. The evidence suggests that stromal signals resembling those of a distant organ select for cancer cells that are primed for metastasis in that organ, thus illuminating the evolution of metastatic traits in a primary tumor and its distant metastases.",Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.,10.1016/j.cell.2013.07.036,2013 Aug 29,PMC3974915,Cell
GSE67826,Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition [mRNA],Homo sapiens,18,None,2015-04-13,"[Overal design]18 total samples, 9 from control proliferating HL60 cells and 9 from VitD3-treated HL60 cells; [Treatment]'Not applicable'; [Growth]'HL-60 cell line was maintained in RPMI 1640 medium supplemented with 1 x penicillin/streptomycin solution, 1 x L-glutamine and 10% Fetal Bovine Serum.'; [Extraction]'Total RNA for microarray analyses was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) from fractions obtained by sucrose density gradient centrifugation. Genomic DNA contamination was eliminated through a DNase I (Qiagen, Chatsworth, CA) digestion step. RNA was further purified on Qiagen RNeasy columns for gene expression profiling (Qiagen, Chatsworth, CA). The concentration and purity of total RNA were assessed using a Nanodrop TM 1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).'; [Cell type]'HL60 cells, promyeloblasts''cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F3; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F4; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F5; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F6; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F7; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F8; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F9; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F10; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F11; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F3; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F4; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F5; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F6; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F7; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F8; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F9; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F10; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F11; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67826,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE67nnn/GSE67826/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA281006,25970317," Giulia Fontemaggi,  Teresa Bellissimo,  Sara Donzelli,  Ilaria Iosue,  Barbara Benassi,  Giorgio Bellotti,  Giovanni Blandino,  Francesco Fazi","Treatment of leukemia cells with 1,25-dihydroxyvitamin D3 may overcome their differentiation block and lead to the transition from myeloblasts to monocytes. To identify microRNA-mRNA networks relevant for myeloid differentiation, we",Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition.,10.1080/15476286.2015.1044194,2015,PMC4615388,RNA biology
GSE103667,Transcriptome-wide profiling of translation efficiency using mRNA-seq and Ribo-seq in ER stress-induced NIH3T3 cells,Mus musculus,8,SRP117211,2017-09-10,"[Overal design]In this study, we pharmacologically induced ER stress by treatment of thapsigargin (THAP). Ribo-seq and RNA-seq were parallelly conducted in whole cells with DMSO- or THAP-treated NIH3T3 cells in duplicate.; [Treatment]'For ER stress induction, thapsigargin (THAP, Sigma-Aldrich) was treated with 1 M for 1 hr 30 min in NIH3T3 cells.'; [Growth]'NIH3T3 cells were cultured in DMEM (Gibco) media with 10% fetal bovine serum in a humidified 5% CO2 atmosphere at 37 degrees Celsius.'; [Extraction]""For ribosome profiling library, RNase I (100 U/?l) was treated in lysate and incubated at room temperature for 45 min. After nuclease digestion, ribosome footprinted RNAs were purified by sedimenting through a 1 M sucrose cushion and excising the urea gel between 26-34 nucleotides.\nFor mRNA expression profiling library, TRIzol was added into the supernatant and total RNA was extracted according to the manufacturer's protocol.\nRibo-seq libraries, 3' end was dephosphorylated by adding PNK and ligated by adding 40 pmol of RA3 adaptor. 5' end was phosphorylated by adding PNK and ATP and ligated by adding 30 pmol of RA5 adaptor and 50 pmol of RTP primer. After reverse transcription using Superscript II reverse transcriptase (Invitrogen), rRNA products were depleted by hybridization to biotinylated sense-strand oligonucleotides followed by removal of the duplexes through streptavidin bead affinity. Finally, through PCR and gel extraction, the library was generated with 150-160 bp-size.\nFor mRNA-seq library, poly(A) RNA was isolated using Dynabeads mRNA purification kit (Ambion) according to the manufacturers protocol. After RNA fragmentation with 1 N NaOH at 37C for 3 min, the final library ranging from 150 to 200 bp-size was generated followed by the same process as producing ribosome profiling library from the step of 3' dephosphorylation, except for rRNA depletion.""; [Cell type]'Fetus derived cell line from female human embryonic kidney''cell line: NIH3T3; cell type: Fetus derived cell line from female human embryonic kidney; passages: 5-10; treatment: DMSO for 1.5hr; ', 'cell line: NIH3T3; cell type: Fetus derived cell line from female human embryonic kidney; passages: 5-10; treatment: THAP (1M) for 1.5hr; ', 'cell line: NIH3T3; cell type: Fetus derived cell line from female human embryonic kidney; passages: 5-10; treatment: DMSO for 1.5h; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103667,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE103nnn/GSE103667/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA403993,29576526," Sim Namkoong,  Allison Ho,  Yu Mi Woo,  Hojoong Kwak,  Jun Hee Lee","Upon stress, cytoplasmic mRNA is sequestered to insoluble ribonucleoprotein (RNP) granules, such as the stress granule (SG). Partially due to the belief that translationally suppressed mRNAs are recruited to SGs in bulk, stress-induced dynamic redistribution of mRNA has not been thoroughly characterized. Here, we report that endoplasmic reticulum (ER) stress targets only a small subset of translationally suppressed mRNAs into the insoluble RNP granule fraction (RG). This subset, characterized by extended length and adenylate-uridylate (AU)-rich motifs, is highly enriched with genes critical for cell survival and proliferation. This pattern of RG targeting was conserved for two other stress types, heat shock and arsenite toxicity, which induce distinct responses in the total cytoplasmic transcriptome. Nevertheless, stress-specific RG-targeting motifs, such as guanylate-cytidylate (GC)-rich motifs in heat shock, were also identified. Previously underappreciated, transcriptome profiling in the RG may contribute to understanding human diseases associated with RNP dysfunction, such as cancer and neurodegeneration.",Systematic Characterization of Stress-Induced RNA Granulation.,10.1016/j.molcel.2018.02.025,2018 Apr 5,PMC6359928,Molecular cell
GSE105782,N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis[Ribosome Profiling],Homo sapiens,12,SRP120964,2017-10-23,"[Overal design]Contains three replicates of ribosome protected RNA samples and total input RNA from non-targeting control sgRNA HEL cells and WTAP sgRNA KO HEL cells; [Treatment]'Cells were treated with puromycin to kill untransduced cells at the start of the experiement'; [Growth]'Cells were cultured in RPMI+10% FBS at 37C 5% CO2'; [Extraction]'RNA/protein were extracted following the protocol in the TruSeq Ribo Profile kit from Illumina\nRNA libraries were prepared for sequencing following the protocol in the TruSeq Ribo Profile kit from Illumina'; [Cell type]'HEL cells''cell type: HEL cells; fraction: RPF RNA; ', 'cell type: HEL cells; fraction: total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE105782,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE105nnn/GSE105782/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA415390,31601799," Daniel A Kuppers,  Sonali Arora,  Yiting Lim,  Andrea R Lim,  Lucas M Carter,  Philip D Corrin,  Christopher L Plaisier,  Ryan Basom,  Jeffrey J Delrow,  Shiyan Wang,  Housheng Hansen He,  Beverly Torok-Storb,  Andrew C Hsieh,  Patrick J Paddison","Many of the regulatory features governing erythrocyte specification, maturation, and associated disorders remain enigmatic. To identify new regulators of erythropoiesis, we utilize a functional genomic screen for genes affecting expression of the erythroid marker CD235a/GYPA. Among validating hits are genes coding for the N(6)-methyladenosine (m(6)A) mRNA methyltransferase (MTase) complex, including, METTL14, METTL3, and WTAP. We demonstrate that m(6)A MTase activity promotes erythroid gene expression programs through selective translation of ~300 m(6)A marked mRNAs, including those coding for SETD histone methyltransferases, ribosomal components, and polyA RNA binding proteins. Remarkably, loss of m(6)A marks results in dramatic loss of H3K4me3 marks across key erythroid-specific KLF1 transcriptional targets (e.g., Heme biosynthesis genes). Further, each m(6)A MTase subunit and a subset of their mRNAs targets are required for human erythroid specification in primary bone-marrow derived progenitors. Thus, m(6)A mRNA marks promote the translation of a network of genes required for human erythropoiesis.",N(6)-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis.,10.1038/s41467-019-12518-6,2019 Oct 10,PMC6787028,Nature communications
GSE75947,SPECtre: a spectral coherence-based classifier of actively translated transcripts from ribosome profiling sequence data,Homo sapiens,1,SRP067300,2015-12-11,"[Overal design]Classification of actively translated transcripts in ribosome profiling data derived from human neuroblastoma SH-SY5Y cells, and data previously published derived from mouse embryonic stem cells and zebrafish embryos.; [Treatment]'Cells were washed with PBS supplemented with cycloheximide (100ug/ml), then flash frozen and lysed on plate in the presence of cycloheximide in 500uL of ice-cold lysis buffer.'; [Growth]'The neuroblastoma SH-SY5Y cells were plated on 140mm dishes and allowed to propagate to 80% confluency.'; [Extraction]'Lysates from two plates were combined, RNase I treated, and the ribosome fraction of 300uL of lysate was extracted with a 1M sucrose cushion and high speed centrifugation.\nRNA footprints in the range of 26-34nt were gel extracted, rRNA was depleted using the Ribo-Zero rRNA Removal Kit (Illumina), and the remaining RNA served as the template for constructing the amplified cDNA library. Sequencing was performed in a single lane on an Illumina HiSeq2000 with 50 cycles of single-end reads at the University of Michigan DNA Sequencing Core.'; [Cell type]'SH-SY5Y neuroblastoma cells''cell type: SH-SY5Y neuroblastoma cells; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75947,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE75nnn/GSE75947/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA305807,,,,,,,,
GSE79664,Regulation of poly(A) tail and translation during the somatic cell cycle,Homo sapiens,18,SRP072459,2016-03-28,"[Overal design]HeLa cells were synchronized at S or M phase, and subject to RNA-seq, ribosome profiling and TAIL-seq analysis.; [Treatment]'For S phase-arrest, cells were arrested by 2 mM thymidine for 18 hr and then released into fresh medium for 9 hr, which was followed by second thymidine block for 17 hr. For M phase-arrest, cells were treated with 2 mM thymidine for 18 hr, released for 4 hr and then treated with 100 ng/mL nocodazole for 10 hr.'; [Growth]'HeLa cells were maintained in RPMI (Welgene) supplemented with 10% fetal bovine serum (Welgene).'; [Extraction]'Total RNAs were extracted by TRIzol (Invitrogen)\nFor oligo-dT enriched mRNA-seq, total RNA extracted by TRIzol (Life Technologies) was treated with DNaseI (Takara) and purified by RNeasy Minelute Cleanup kit (QIAGEN). mRNAs were enriched by oligo dT capture. 5 ?g of RNAs were fragmented by incubating in the fragmentation buffer provided by NEBNext Magnesium RNA Fragmentation Module at 95 C for 6.5 min. Fragmented RNAs were size-selected for 60-80 nt RNAs, dephosphorylated by Antarctic phosphatase (NEB) and 5' phosphorylated by PNK reaction (Takara). RNAs were then subjected to the library preparation protocol used in ribosome profiling described above. The cDNA libraries were sequenced by Illumina HiSeq (1  51 bp single run).', 'Total RNAs were extracted by TRIzol (Invitrogen)\nFor ribozero treated mRNA-seq, total RNA extracted by TRIzol (Life Technologies) was treated with DNaseI (Takara) and purified by RNeasy Minelute Cleanup kit (QIAGEN). RNAs were depleted of rRNAs using Ribo-Zero kit (Epicentre). 5 ?g of RNAs were fragmented by incubating in the fragmentation buffer provided by NEBNext Magnesium RNA Fragmentation Module at 95 C for 6.5 min. Fragmented RNAs were size-selected for 60-80 nt RNAs, dephosphorylated by Antarctic phosphatase (NEB) and 5' phosphorylated by PNK reaction (Takara). RNAs were then subjected to the library preparation protocol used in ribosome profiling described above. The cDNA libraries were sequenced by Illumina HiSeq (1  51 bp single run).', 'Cells were lysed, treated with RNaseI, purified by spin-column and RNAs were extracted by TRIzol (Invtirgen)\nRibosome profiling libraries were prepared using ARTseq Ribosome Profiling Kit (Epicentre) with some modifications. HeLa cells were grown in two 150 mm dishes, harvested and lysed with lysis buffer. For nuclease digestion, 250 ?l of cell lysates were treated with 3 ?l of ARTseq nuclease at 4 C for 45 min at RT. Monosomes were purified using MicroSpin S-400 column by centrifuging for 2 min at 600 g. RNAs in the flow-through were purified and depleted of rRNAs using Ribo-Zero kit (Epicentre). rRNA depleted RNA fragments were then radiolabeled, and ~30 nt region was purified using 15% Urea-PAGE. Purified RNAs were treated with Antarctic phosphatase (NEB), 5' phosphorylated and gel purified to remove free ATP. Resulting RNAs were subjected to 3' adaptor ligation, and gel purified ligated products were ligated with the 5' adaptor. Adaptor ligated RNAs were reverse transcribed and amplified to yield final ribosome profiling library. The cDNA libraries were sequenced by Illumina HiSeq (1  51 bp single run).', 'Total RNAs were extracted by TRIzol (Invitrogen)\nFor TAIL-seq, 90 ?g of total RNA extracted by TRIzol (Life Technologies) was DNase-treated and purified (>200 nt) by RNeasy MinElute cleanup column (QIAGEN). rRNAs were depleted by using Ribo-Zero kit (Epicentre) and remaining RNAs were ligated to the biotinylated 3' adaptor and partially digested by RNaseT1 (Ambion). Fragmented RNAs were pulled-down by streptavidin beads and eluted RNAs were phosphorylated at the 5' end. RNAs were size fractionated by gel purification (500-1,000 nt), and purified RNAs were ligated to 5' adaptor, reverse-transcribed and amplified by PCR. PCR products were purified using AMPure XP beads (Beckman), and cDNA libraries were sequenced by Illumina HiSeq 2500 (51  251 bp paired end run) with PhiX control library and spike-in mixture with various poly(A) length.'; [Cell type]'human cervical cancer cell line''cell type: human cervical cancer cell line; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79664,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE79nnn/GSE79664/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA316618,27153541," Jong-Eun Park,  Hyerim Yi,  Yoosik Kim,  Hyeshik Chang,  V Narry Kim","Poly(A) tails are critical for mRNA stability and translation. However, recent studies have challenged this view, showing that poly(A) tail length and translation efficiency are decoupled in non-embryonic cells. Using TAIL-seq and ribosome profiling, we investigate poly(A) tail dynamics and translational control in the somatic cell cycle. We find dramatic changes in poly(A) tail lengths of cell-cycle regulatory genes like CDK1, TOP2A, and FBXO5, explaining their translational repression in M phase. We also find that poly(A) tail length is coupled to translation when the poly(A) tail is <20 nucleotides. However, as most genes have >20 nucleotide poly(A) tails, their translation is regulated mainly via poly(A) tail length-independent mechanisms during the cell cycle. Specifically, we find that terminal oligopyrimidine (TOP) tract-containing transcripts escape global translational suppression in M phase and are actively translated. Our quantitative and comprehensive data provide a revised view of translational control in the somatic cell cycle.",Regulation of Poly(A) Tail and Translation during the Somatic Cell Cycle.,10.1016/j.molcel.2016.04.007,2016 May 5,,Molecular cell
GSE74139,A regression-based analysis of ribosome-profiling data reveals a conserved complexity to mammalian translation,Mus musculus,37,SRP064972,2015-10-19,"[Overal design]37 ribosome footprint samples from mouse BMDCs across a time course of LPS stimulation and in the presence or absence of translation inhibitors cycloheximide, harringtonine, or lactimidomycin. A mock (non-LPS stimulated) time course is also included, collected in the presence of cycloheximide. Two replicates are available for the LPS timecourse under CHX treatment. Reads include the 3' linker sequence CTGTAGGCACCATCAAT.; [Treatment]'At day 9, cells were stimulated with LPS (100 ng/mL, rough, ultrapure E. coli K12 strain, Invitrogen) or mock treatment'; [Growth]'At day 0, BMDCs were collected from femora and tibiae and plated on twenty (per mouse), 100 mm non-tissue culture-treated plastic dishes using 10 mL medium per plate. At day 2, cells were fed with another 10 mL medium per dish. At day 5, cells were harvested from 15 mL of the supernatant by spinning at 1,400 rpm for 5 minutes; pellets were resuspended with 5 mL medium and added back to the original dish. Cells were fed with another 5 mL medium at day 7. At day 8, all non-adherent and loosely bound cells were collected and harvested by centrifugation. Cells were then resuspended with medium, plated at a concentration of 10106 cells in 10 mL medium per 100 mm dish.'; [Extraction]'Following treatment with indicated ribosome inhibitors, cells were lysed by triturating 10 times with 400 ?L lysis buffer (20 mM Tris pH 7.56, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100 [Sigma], 1 mM DTT [Sigma], 8% glycerol, 100 ?g/mL CHX, 12 units/mL Turbo DNase [Life Technologies]). Lysates were clarified by centrifuging at 20,000g for 10 min at 4C. Clarified lysate was flash frozen in liquid nitrogen. Clarified cell lysates were treated with RNase I (Life Technologies) to digest RNA not protected by ribosomes. High molecular weight species were isolated by centrifuging lysates through a 34% sucrose cushion at 200,000g for 4 hours at 4C. Pellets were resuspended in Trizol (Life Technologies) and the RNA fraction isolated. Contaminant rRNA was removed using the listed strategies.\nTotal RNase I-treated RNA was size-separated by gel electrophoresis, and RNAs of size 2834 nucleotides were purified. These ribosome protected fragments were cloned and sequenced via a single-end run on an Illumina HiSeq 2500 sequencer.'; [Cell type]'Bone marrow-derived dendritic cells''cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: Mix of 0, 2, 4, 6, and 9 h LPS; ribosome inhibitor treatment: 1 ug/mL harringtonine, 5 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: Mix of 0, 1, 2, 4, 6, 8, 9, and 12 h LPS; ribosome inhibitor treatment: 50 ug/mL lactimidomycin, 30 min; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: None; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 0.5 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 1 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 2 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 4 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 6 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 8 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 9 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 12 h LPS; ribosome inhibitor treatment: None; rrna subtraction strategy: RiboZero; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: None; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 0.5 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 1 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 2 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 4 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 6 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 8 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 9 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 12 h LPS; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 0.5 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 1 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 2 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 4 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 6 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 8 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 9 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; ', 'cell type: Bone marrow-derived dendritic cells; age: 6-8 weeks; stimulation: 12 h mock; ribosome inhibitor treatment: 100 ug/mL cycloheximide, 1 min; rrna subtraction strategy: Subtractive hybridization; strain: C57BL/6J; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74139,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE74nnn/GSE74139/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA299160,26638175," Alexander P Fields,  Edwin H Rodriguez,  Marko Jovanovic,  Noam Stern-Ginossar,  Brian J Haas,  Philipp Mertins,  Raktima Raychowdhury,  Nir Hacohen,  Steven A Carr,  Nicholas T Ingolia,  Aviv Regev,  Jonathan S Weissman","A fundamental goal of genomics is to identify the complete set of expressed proteins. Automated annotation strategies rely on assumptions about protein-coding sequences (CDSs), e.g., they are conserved, do not overlap, and exceed a minimum length. However, an increasing number of newly discovered proteins violate these rules. Here we present an experimental and analytical framework, based on ribosome profiling and linear regression, for systematic identification and quantification of translation. Application of this approach to lipopolysaccharide-stimulated mouse dendritic cells and HCMV-infected human fibroblasts identifies thousands of novel CDSs, including micropeptides and variants of known proteins, that bear the hallmarks of canonical translation and exhibit translation levels and dynamics comparable to that of annotated CDSs. Remarkably, many translation events are identified in both mouse and human cells even when the peptide sequence is not conserved. Our work thus reveals an unexpected complexity to mammalian translation suited to provide both conserved regulatory or protein-based functions.",A Regression-Based Analysis of Ribosome-Profiling Data Reveals a Conserved Complexity to Mammalian Translation.,10.1016/j.molcel.2015.11.013,2015 Dec 3,PMC4720255,Molecular cell
GSE117299,mRNA circularization by METTL3-eIF3h enhances translation,Homo sapiens,56,SRP154311,2018-07-18,"[Overal design]METTL3 expression was depleted in HeLa cells using lentivirus mediated shRNA knockdown. The METTL3 knockdown cells and the control cells were subjected to sucrose gradient ultracentifuge for the polysome profiling. The RNA samples isolated from the polysome fractions and subpolysome fractions were used for high throughput sequencing for the analysis of translation efficiency. For the analysis of mRNA stability, METTL3 knockdown cells and the control cells were treated with ActD for different time points then the RNA samples were isolated for high throughput sequencing and the subsequent calculation of mRNA halflife.; [Treatment]'METTL3 expression were knockdown using shRNA.'; [Growth]'HeLa cells were cultured with DMEM plus 10% FBS and antibiotics. Cells were grown in a 5% CO2 cell culture incubator at 37?.'; [Extraction]""For mRNA half life and translation efficiency, total RNA samples were isolated with Trizol following the manufacturers instructions. For m6A MeRIP-Seq, portions of fresh tumor tissue approximately 0.5 x 0.5 x 0.5cm were snap frozen and preserved at -80C, pulverized in liquid nitrogen and stabilized in Trizol for total RNA isolation. Then the mRNA purification from total RNA was performed using PolyATtract mRNA Isolation Systems (Promega). 2\uf06dg of the purified mRNA was fragmented and immunoprecipitated with ?-m6A antibody (Synaptic Systems, 202003). The purified RNA fragments from m6A MeRIP were used for library construction using the TruSeq Stranded mRNA Sample Prep Kits (Illumina RS-122-2101) and sequenced with Illumina NextSeq 500.\nLibraries were prepared according to Illumina's instructions accompanying the TrueSeq Stranded mRNA library preparation kit.""; [Cell type]'cervical cancer cells', 'lung cancer''cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa parental cells; ', 'cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShGFP control; ', 'cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-2; ', 'cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-3; ', 'actd treatment: 0h; shRNA knockdown: control; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa parental cells; ', 'actd treatment: 0h; shRNA knockdown: ShGFP; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShGFP control; ', 'actd treatment: 0h; shRNA knockdown: ShML3-2; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-2; ', 'actd treatment: 0h; shRNA knockdown: ShML3-3; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-3; ', 'actd treatment: 2h; shRNA knockdown: control; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa parental cells; ', 'actd treatment: 2h; shRNA knockdown: ShGFP; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShGFP control; ', 'actd treatment: 2h; shRNA knockdown: ShML3-2; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-2; ', 'actd treatment: 2h; shRNA knockdown: ShML3-3; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-3; ', 'actd treatment: 4h; shRNA knockdown: control; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa parental cells; ', 'actd treatment: 4h; shRNA knockdown: ShGFP; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShGFP control; ', 'actd treatment: 4h; shRNA knockdown: ShML3-2; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-2; ', 'actd treatment: 4h; shRNA knockdown: ShML3-3; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-3; ', 'actd treatment: 6h; shRNA knockdown: control; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa parental cells; ', 'actd treatment: 6h; shRNA knockdown: ShGFP; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShGFP control; ', 'actd treatment: 6h; shRNA knockdown: ShML3-2; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-2; ', 'actd treatment: 6h; shRNA knockdown: ShML3-3; cell line: HeLa; cell type: cervical cancer cells; experiment: HeLa ShMETTL3 shRNA-3; ', 'cell type: lung cancer; experiment: Tumor sample; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117299,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE117nnn/GSE117299/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA481680,30232453," Junho Choe,  Shuibin Lin,  Wencai Zhang,  Qi Liu,  Longfei Wang,  Julia Ramirez-Moya,  Peng Du,  Wantae Kim,  Shaojun Tang,  Piotr Sliz,  Pilar Santisteban,  Rani E George,  William G Richards,  Kwok-Kin Wong,  Nicolas Locker,  Frank J Slack,  Richard I Gregory","N(6)-methyladenosine (m(6)A) modification of mRNA is emerging as an important regulator of gene expression that affects different developmental and biological processes, and altered m(6)A homeostasis is linked to cancer(1-5). m(6)A modification is catalysed by METTL3 and enriched in the 3' untranslated region of a large subset of mRNAs at sites close to the stop codon(5). METTL3 can promote translation but the mechanism and relevance of this process remain unknown(1). Here we show that METTL3 enhances translation only when tethered to reporter mRNA at sites close to the stop codon, supporting a mechanism of mRNA looping for ribosome recycling and translational control. Electron microscopy reveals the topology of individual polyribosomes with single METTL3 foci in close proximity to 5' cap-binding proteins. We identify a direct physical and functional interaction between METTL3 and the eukaryotic translation initiation factor 3 subunit h (eIF3h). METTL3 promotes translation of a large subset of oncogenic mRNAs-including bromodomain-containing protein 4-that is also m(6)A-modified in human primary lung tumours. The METTL3-eIF3h interaction is required for enhanced translation, formation of densely packed polyribosomes and oncogenic transformation. METTL3 depletion inhibits tumorigenicity and sensitizes lung cancer cells to BRD4 inhibition. These findings uncover a mechanism of translation control that is based on mRNA looping and identify METTL3-eIF3h as a potential therapeutic target for patients with cancer.",mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.,10.1038/s41586-018-0538-8,2018 Sep,PMC6234840,Nature
GSE97461,TRAP sequencing of D1 and D2 spiny projection neurons from young and old mice and ribosome profiling in NIH-3T3 cells,Mus musculus,19,SRP103213,2017-04-06,"[Overal design]sequencing of TRAP isolated cell-type specific mRNA from D1 and D2 spiny projection neurons in aged and young mice. 4 Biological replicates per condition. Additional experiments from ribosome profiling of NIH-3T3 cells treated with paraquat, siRNAs to ABCE1 and a control siRNA; [Treatment]'None'; [Growth]'None'; [Extraction]'translation ribosome affinity purification (TRAP) of cell-type specific ribosome bound mRNA\nNuGEN Ovation V2', 'ribosome footprinting\nSMARTer smRNA Kit - Takara'; [Cell type]'D1 spiny projection neurons', 'D2 spiny projection neurons', 'Source: ''strain: Drd1::EGFP-L10a on C56BL/6J background; cell type: D1 spiny projection neurons; age: 42 days old; Sex: female; ', 'strain: Drd2::EGFP-L10a on C56BL/6J background; cell type: D2 spiny projection neurons; age: 42 days old; Sex: female; ', 'strain: Drd1::EGFP-L10a on C56BL/6J background; cell type: D1 spiny projection neurons; age: 2 years old; Sex: female; ', 'strain: Drd2::EGFP-L10a on C56BL/6J background; cell type: D2 spiny projection neurons; age: 2 years old; Sex: female; ', 'cell line: NIH-3T3; treatment: 100uM paraquat; ', 'cell line: NIH-3T3; treatment: ABCE1 siRNA; ', 'cell line: NIH-3T3; treatment: control siRNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97461,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE97nnn/GSE97461/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA381914,30485811," Peter H Sudmant,  Hyeseung Lee,  Daniel Dominguez,  Myriam Heiman,  Christopher B Burge","Particular brain regions and cell populations exhibit increased susceptibility to aging-related stresses. Here, we describe the age-specific and brain-region-specific accumulation of ribosome-associated 3' UTR RNAs that lack the 5' UTR and open reading frame. Our study reveals that this phenomenon impacts hundreds of genes in aged D1 spiny projection neurons of the mouse striatum and also occurs in the aging human brain. Isolated 3' UTR accumulation is tightly correlated with mitochondrial gene expression and oxidative stress, with full-length mRNA expression that is reduced but not eliminated, and with production of short 3' UTR-encoded peptides. Depletion of the oxidation-sensitive Fe-S cluster ribosome recycling factor ABCE1 induces the accumulation of 3' UTRs, consistent with a model in which ribosome stalling and mRNA cleavage by No-Go decay yields isolated 3' UTR RNAs protected by ribosomes. Isolated 3' UTR accumulation is a hallmark of brain aging, likely reflecting regional differences in metabolism and oxidative stress.",Widespread Accumulation of Ribosome-Associated Isolated 3' UTRs in Neuronal Cell Populations of the Aging Brain.,10.1016/j.celrep.2018.10.094,2018 Nov 27,PMC6354779,Cell reports
GSE59983,Gene expression profiling of primary human retinoblastoma,Homo sapiens,76,None,2014-07-31,"[Overal design]Fresh frozen material from 76 primary human retinoblastoma samples were profiled with Affymetrix human genome u133 plus 2.0 PM microarray; [Treatment]'None'; [Growth]'None'; [Extraction]""Frozen tumour samples were homogenized in Trizol Reagent (Invitrogen, Carlsbad, Canada) with a rotor-stator homogenizer, and RNA was extracted following the manufacturer's instructions. Trizol extracted RNA was treated with rDNase (Macherey-Nagel, Dren, Germany) to digest any contaminating DNA and subsequently purified with the NucleoSpin RNA Clean-up XS kit (Macherey-Nagel)""; [Cell type]'Source: ''tissue: primary Rb tissue; uhc-subgroup: group 3; ', 'tissue: primary Rb tissue; uhc-subgroup: group 1; ', 'tissue: primary Rb tissue; uhc-subgroup: group 2; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59983,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59983/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA257212,26288838," Irsan E Kooi,  Berber M Mol,  Annette C Moll,  Paul van der Valk,  Marcus C de Jong,  Pim de Graaf,  Saskia E van Mil,  Antoinette Y N Schouten-van Meeteren,  Hanne Meijers-Heijboer,  Gertjan L Kaspers,  Hein Te Riele,  Jacqueline Cloos,  Josephine C Dorsman","BACKGROUND: Retinoblastoma is a pediatric eye cancer associated with RB1 loss or MYCN amplification (RB1 (+/+) MYCN(A) ). There are controversies concerning the existence of molecular subtypes within RB1(-/-) retinoblastoma. To test whether these molecular subtypes exist, we performed molecular profiling. METHODS: Genome-wide mRNA expression profiling was performed on 76 primary human retinoblastomas. Expression profiling was complemented by genome-wide DNA profiling and clinical, histopathological, and ex vivo drug sensitivity data. FINDINGS: RNA and DNA profiling identified major variability between retinoblastomas. While gene expression differences between RB1 (+/+) MYCN(A) and RB1(-/-) tumors seemed more dichotomous, differences within the RB1(-/-) tumors were gradual. Tumors with high expression of a photoreceptor gene signature were highly differentiated, smaller in volume and diagnosed at younger age compared with tumors with low photoreceptor signature expression. Tumors with lower photoreceptor expression showed increased expression of genes involved in M-phase and mRNA and ribosome synthesis and increased frequencies of somatic copy number alterations. INTERPRETATION: Molecular, clinical and histopathological differences between RB1(-/-) tumors are best explained by tumor progression, reflected by a gradual loss of differentiation and photoreceptor expression signature. Since copy number alterations were more frequent in tumors with less photoreceptorness, genomic alterations might be drivers of tumor progression. RESEARCH IN CONTEXT: Retinoblastoma is an ocular childhood cancer commonly caused by mutations in the RB1 gene. In order to determine optimal treatment, tumor subtyping is considered critically important. However, except for very rare retinoblastomas without an RB1 mutation, there are controversies as to whether subtypes of retinoblastoma do exist. Our study shows that retinoblastomas are highly diverse but rather than reflecting distinct tumor types with a different etiology, our data suggests that this diversity is a result of tumor progression driven by cumulative genetic alterations. Therefore, retinoblastomas should not be categorized in distinct subtypes, but be described according to their stage of progression.",Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression.,10.1016/j.ebiom.2015.06.022,2015 Jul,PMC4534696,EBioMedicine
GSE37744,The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments,Homo sapiens,3,SRP012648,2012-05-03,"[Overal design]Ribosome profiling in cultured mammalian cells under three different footprinting conditions; [Treatment]'None'; [Growth]'None'; [Extraction]'Cell extract preparation by detergent lysis, RNase I footprinting of ribosomes, ribosome purification by ultracentrifugation through a sucrose cushion, RNA extraction, polyacrylamide gel size selection for footprint fragments, preadenylylated linker ligation, reverse transcription, first-strand cDNA circularization\nlibrary_strategy: Ribosome profiling'; [Cell type]'human embryonic kidney''cell line: HEK293; cell type: human embryonic kidney; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37744,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE37nnn/GSE37744/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA163111,22836135," Nicholas T Ingolia,  Gloria A Brar,  Silvia Rouskin,  Anna M McGeachy,  Jonathan S Weissman","Recent studies highlight the importance of translational control in determining protein abundance, underscoring the value of measuring gene expression at the level of translation. We present a protocol for genome-wide, quantitative analysis of in vivo translation by deep sequencing. This ribosome profiling approach maps the exact positions of ribosomes on transcripts by nuclease footprinting. The nuclease-protected mRNA fragments are converted into a DNA library suitable for deep sequencing using a strategy that minimizes bias. The abundance of different footprint fragments in deep sequencing data reports on the amount of translation of a gene. In addition, footprints reveal the exact regions of the transcriptome that are translated. To better define translated reading frames, we describe an adaptation that reveals the sites of translation initiation by pretreating cells with harringtonine to immobilize initiating ribosomes. The protocol we describe requires 5-7 days to generate a completed ribosome profiling sequencing library. Sequencing and data analysis require a further 4-5 days.",The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments.,10.1038/nprot.2012.086,2012 Jul 26,PMC3535016,Nature protocols
GSE115161,Regulation of Translation Elongation Revealed by Ribosome Profiling [Dataset_4],Homo sapiens; Saccharomyces cerevisiae; Caenorhabditis elegans,28,SRP149446,2018-05-31,"[Overal design]24 biological samples are included for ribosome footprinting samples. These include HeLa, MB-MDA-231 and yeast cells and C. elegans embryos.; [Treatment]'Yeast cells were harvested by vacuum filtration and flash frozen. Samples were homogenized and lysed with lysis buffer using a freezer mill.'; [Growth]'Yeast cells were grown to OD ~0.5; mammalian cells were grown to ~75% confluence; Synchronized L1 worms were plated on HT115 bacteria transformed with pL4440 vector and cultured at 25?C for ~48 hours.', 'Yeast cells were grown to OD ~0.5.'; [Extraction]'Lysates were clarified and monosomes were isolated by sucrose gradient centrifugation after RNaseI treatment. RNA was extracted using SDS/hot phenol/chloroform.\nFragments ranging from 15-34 nt were gel purified and rRNA was depleted from this pool through Ribo-Zero Gold treatment. Upon dephosphorylation of sample RNA, linker was ligated and this product was once again gel purified. This was followed by reverse transcription as well as circularization of cDNAs. PCR amplification of this library was then sent for sequencing.'; [Cell type]'Source: ''cell line: MDA-MB-231; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'tissue: embryos; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'cell line: HeLa; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yCW66; plasmid: None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yCW19; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'genotype/variation: Wild-Type; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'genotype/variation: rck2{delta}; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: yCW66; plasmid(s): pRS416-GalL-gamma toxin; molecule subtype: Ribosome Protected mRNA (15-34 nt); ', 'strain: Wild-Type; plasmid(s): None; molecule subtype: Ribosome Protected mRNA (15-34 nt); '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115161,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE115nnn/GSE115161/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA473989,31858614," Petr Tesina,  Laura N Lessen,  Robert Buschauer,  Jingdong Cheng,  Colin Chih-Chien Wu,  Otto Berninghausen,  Allen R Buskirk,  Thomas Becker,  Roland Beckmann,  Rachel Green","Inhibitory codon pairs and poly(A) tracts within the translated mRNA cause ribosome stalling and reduce protein output. The molecular mechanisms that drive these stalling events, however, are still unknown. Here, we use a combination of in vitro biochemistry, ribosome profiling, and cryo-EM to define molecular mechanisms that lead to these ribosome stalls. First, we use an in vitro reconstituted yeast translation system to demonstrate that inhibitory codon pairs slow elongation rates which are partially rescued by increased tRNA concentration or by an artificial tRNA not dependent on wobble base-pairing. Ribosome profiling data extend these observations by revealing that paused ribosomes with empty A sites are enriched on these sequences. Cryo-EM structures of stalled ribosomes provide a structural explanation for the observed effects by showing",Molecular mechanism of translational stalling by inhibitory codon combinations and poly(A) tracts.,10.15252/embj.2019103365,2020 Feb 3,PMC6996574,The EMBO journal
GSE75290,Thousands of novel translated open reading frames in humans inferred by ribosome footprint profiling.,Homo sapiens,2,SRP066598,2015-11-22,"[Overal design]Ribosome profiling assays were performed on cell lines treated with Harringtonine to generate data for validating translation initiatoin site prediction; [Treatment]'Each culture was treated with 2 ?g/ml harringtonine (final concentration in media) for 2 minutes followed by 100 ?g/ml cycloheximide (final concentration in media).'; [Growth]'Cells were cultured at 37 degree Celsius and 5% CO2 in RPMI 1640 (supplemented with 2mM L-glutamine and 15% fetal bovine serum)'; [Extraction]'Ribosome footprint profiling experiments were performed using ARTseqTM Ribosome Profiling kit for mammalian cells (RPHMR12126) following vendors instructions. Cell lysates were prepared from flash frozen pellets of 30 to 50 million live cells by repeat pipetting in 1 ml cold lysis buffer. Sephacryl S400 spin column (GE; 27-5140-01) was used for monosome isolation. For rRNA depletion, Ribo-Zero Magnetic Kit (Epicentre; MRZH11124) was used.\nRibosome footprint cDNA libraries were PCR amplified (12 to 15 thermo-cycles) and barcoded using ScriptMiner Index PCR Primers (Epicentre; SMIP2124). Indexed libraries were pooled to sequence on an Illumina HiSeq 2500.'; [Cell type]'Source: ''gender: Female; cell line: GM19204; enrichment type: ribosome protected fragments; ', 'gender: Female; cell line: GM19238; enrichment type: ribosome protected fragments; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75290,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE75nnn/GSE75290/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA303958,27232982," Anil Raj,  Sidney H Wang,  Heejung Shim,  Arbel Harpak,  Yang I Li,  Brett Engelmann,  Matthew Stephens,  Yoav Gilad,  Jonathan K Pritchard","Accurate annotation of protein coding regions is essential for understanding how genetic information is translated into function. We describe riboHMM, a new method that uses ribosome footprint data to accurately infer translated sequences. Applying riboHMM to human lymphoblastoid cell lines, we identified 7273 novel coding sequences, including 2442 translated upstream open reading frames. We observed an enrichment of footprints at inferred initiation sites after drug-induced arrest of translation initiation, validating many of the novel coding sequences. The novel proteins exhibit significant selective constraint in the inferred reading frames, suggesting that many are functional. Moreover, ~40% of bicistronic transcripts showed negative correlation in the translation levels of their two coding sequences, suggesting a potential regulatory role for these novel regions. Despite known limitations of mass spectrometry to detect protein expressed at low level, we estimated a 14% validation rate. Our work significantly expands the set of known coding regions in humans.",Thousands of novel translated open reading frames in humans inferred by ribosome footprint profiling.,10.7554/eLife.13328,2016 May 27,PMC4940163,eLife
GSE162730,Reduced Physical Activity Alters the Leucine-Stimulated Translatome in Aged Skeletal Muscle,Homo sapiens,96,SRP296472,2020-12-05,"[Overal design]Design: We performed ribosomal profiling alongside RNA sequencing from skeletal muscle biopsies taken from older adults (n=8; ~72y; 6F/2M) in response to a leucine bolus before (Healthy) and after (Inactive) 2-weeks of reduced physical activity. At both visits, muscle biopsies were taken at baseline, 60min (early response), and 180min (late response) after leucine ingestion.; [Treatment]'None'; [Growth]'None'; [Extraction]'Muscle biopsies were disrupted using a bead beater homogenizer. Total RNA was extracted in qiazol and Ribosomes isolated in a buffer containing 10mM MgCl2.\nNEBNext rRNA removal kit was used to remove rRNA. Heat fragmented total RNA for RNA-Seq and ribosome protected RNA fragments were treated with T4 PNK and libraries constructed using the NEBNext Small RNA Library kit. Libraries were size selected for 25-35 nt fragments by native PAGE.'; [Cell type]'Source: ''tissue: muscle biopsy; time point: Pre reduced activity 0 baseline; ', 'tissue: muscle biopsy; time point: Pre reduced activity 60 min after Leucine; ', 'tissue: muscle biopsy; time point: Pre reduced activity 180 min after Leucine; ', 'tissue: muscle biopsy; time point: Post reduced activity 0 baseline; ', 'tissue: muscle biopsy; time point: Post reduced activity 60 min after Leucine; ', 'tissue: muscle biopsy; time point: Post reduced activity 180 min after Leucine; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162730,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE162nnn/GSE162730/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA682757,,,,,,,,
GSE59816,Ribosome profiling and RNA sequencing of MCF10A cells treated with torin or by serum starvation,Homo sapiens,3,SRP044933,2014-07-28,"[Overal design]1 biological replicate for each condition; [Treatment]'For inhibition of mTOR and nutrient starvation experiments, MCF10A cells were treated either with 250 nM of Torin 1 (Tocris Bioscience, Bristol, UK) or with EBSS medium (Sigma) for 2 hours, respectively.'; [Growth]'MCF10A cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: ''cell line: MCF10A; ', ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: MCF10A; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59816,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59816/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256320,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE79464,Whole translatome profiling of Human Hepatoma culture Huh7.5 and Huh7.5M,Homo sapiens,4,None,2016-03-21,"[Overal design]Agilent-027114 Genotypic Technology designed Custom Human Whole Genome 8x60k Microarray; [Treatment]'70-80% confluent Huh7.5 and Huh7.5M cells were trypsinised with 0.05% Trypsin EDTA. Cells were then washed with 1X PBS containing Cycloheximide (100g/ml). For total RNA preparartion, MN  RNA extraction Kit was used and total RNA was extracted and quantified. For Polysomal RNA preparation, Cells were lysed with Lysis buffer containing 20mM Tris pH-8.0, 140mM KCl, 1.5mM MgCl2, 1% Triton-X-100, 0.5mM DTT, 100 g/ml Cycloheximide, 1X Protease Inhibitor cocktail, 1mg/ml Heparin and 100U of Ribolock and 175 ug of corresponding RNA from crude lysate was loaded onto Sucrose gradient (10%-50%). Samples were then centrifuged at 35000 rpm for 4 hrs at 4C using Beckmann SW41 rotor. Resolved sucrose gradient samples were fractionated using Density gradient fractionator. Polysomal fractions were pooled based on their profilies and RNA was prepared by initial ethanol precipitation followed by Lithium chloride extraction. Enriched polysomal RNA was used for microarray analysis.'; [Growth]'Huh7.5 and Huh7.5M cells were cultured in complete DMEM supplemented with 10% FBS, 1X Non essential Amino acids, 1X Penicillin Streptomycin solution at 37C with 5% CO2'; [Extraction]'For total RNA preparartion, MN RNA extraction Kit was used and total RNA was extracted and quantified. For Polysomal RNA preparation to study translatome, cells were lysed and normalized volumes containing 175 ug of corresponding RNA were separated on Sucrose gradient (10%-50%), samples were then  fractionated into mRNP, monosomal and polysomal fractions. Polysomal fractions were pooled based on their profilies and RNA was prepared by initial ethanol precipitation followed by lithium chloride extraction and subsequent purification by MN RNA kit spin columns. Enriched polysomal RNA was used for microarray analysis.'; [Cell type]'Source: ''cell line: Geneticin sensitive Huh7.5 cells; ', 'cell line: Geneticin resistant Huh 7.5M cells; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79464,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE79nnn/GSE79464/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA315883,,,,,,,,
GSE36200,RAMPAGE dataset for the human K562 cell line,Homo sapiens,1,SRP011185,2012-03-01,"[Overal design]This dataset represents a whole-genome, single-base resolution profiling of transcription start site (TSS) expression in the human K562 cell line. These profiles were established using RAMPAGE, a high-throughput, high-accuracy 5'-complete cDNA sequencing method implemented on the Illumina platform. The data was analyzed using custom scripts and algorithms that are all available upon request.; [Treatment]'None.'; [Growth]'Cells were grown in RPMI medium with 10% FBS in a 37C incubator with 5% CO2. See ATCC website for details.'; [Extraction]""Total RNA was extracted with Trizol (Invitrogen) according to the manufacturer's instructions and treated with DNaseI (Roche). We checked on a Bioanalyzer (Agilent) that the RNA was of very high quality. 5-monophosphate species -- mainly ribosomes -- were depleted by TEX digest (Epicentre). Our 5-complete cDNA synthesis and selection strategy relies on the combination of two orthogonal enrichment methods: reverse-transcriptase template-switching, and cap-trapping. The template-switching approach is based on the ability of reverse-transcriptase to add linker sequences to the ends of 5-complete cDNAs -- preferentially if they are made from capped transcripts. Cap-trapping relies on the biotinylation of capped RNA molecules and specific pulldown of their associated 5-complete cDNAs. The library was run on a DNA HS Bioanalyzer chip for quality control, quantified by quantitative PCR, and sequenced on one lane  on an Illumina GAIIx (2x76bp). Please see Supplemetary Material of the original publication for a detailed protocol.""; [Cell type]'Source: ''cell line: K562; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36200,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE36nnn/GSE36200/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA155757,22936248," Philippe Batut,  Alexander Dobin,  Charles Plessy,  Piero Carninci,  Thomas R Gingeras","Many eukaryotic genes possess multiple alternative promoters with distinct expression specificities. Therefore, comprehensively annotating promoters and deciphering their individual regulatory dynamics is critical for gene expression profiling applications and for our understanding of regulatory complexity. We introduce RAMPAGE, a novel promoter activity profiling approach that combines extremely specific 5'-complete cDNA sequencing with an integrated data analysis workflow, to address the limitations of current techniques. RAMPAGE features a streamlined protocol for fast and easy generation of highly multiplexed sequencing libraries, offers very high transcription start site specificity, generates accurate and reproducible promoter expression measurements, and yields extensive transcript connectivity information through paired-end cDNA sequencing. We used RAMPAGE in a genome-wide study of promoter activity throughout 36 stages of the life cycle of Drosophila melanogaster, and describe here a comprehensive data set that represents the first available developmental time-course of promoter usage. We found that >40% of developmentally expressed genes have at least two promoters and that alternative promoters generally implement distinct regulatory programs. Transposable elements, long proposed to play a central role in the evolution of their host genomes through their ability to regulate gene expression, contribute at least 1300 promoters shaping the developmental transcriptome of D. melanogaster. Hundreds of these promoters drive the expression of annotated genes, and transposons often impart their own expression specificity upon the genes they regulate. These observations provide support for the theory that transposons may drive regulatory innovation through the distribution of stereotyped cis-regulatory modules throughout their host genomes.",High-fidelity promoter profiling reveals widespread alternative promoter usage and transposon-driven developmental gene expression.,10.1101/gr.139618.112,2013 Jan,PMC3530677,Genome research
GSE93052,The human CCHC-type Zinc Finger nucleic acid binding protein binds G-rich elements in target mRNA coding sequences initiation promotes translation (Ribosome profiling).,Homo sapiens,12,SRP095901,2017-01-02,"[Overal design]CNBP protein knockout and Ribosome profiling; [Treatment]'None'; [Growth]'HEK293 cells were grown and routinely passaged in DMEM with 10% FCS and 1% pen/strip.'; [Extraction]'The riboseq library was generated using NEB ultradirectional library preparation kit as per manufacturers protocol.\nRibosome profiling'; [Cell type]'Source: ', 'CRISPR-cas9 mediated CNBP knockout''treatment: Harringtonine-Chyclohexamide treated; cell line: HEK293; ', 'treatment: Cyclohexamide treated; cell line: HEK293; ', 'cell type: CRISPR-cas9 mediated CNBP knockout; treatment: Harringtonine-Chyclohexamide treated; cell line: HEK293; ', 'cell type: CRISPR-cas9 mediated CNBP knockout; treatment: Cyclohexamide treated; cell line: HEK293; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93052,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE93nnn/GSE93052/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA359690,,,,,,,,
GSE52977,Integrative AUF1 PAR-CLIP analysis uncovers AUF1 roles in translation and genome integrity,Homo sapiens,20,None,2013-12-04,"[Overal design]Refer to individual Series; [Treatment]'For AUF1 PAR-CLIP, the four isoforms of AUF1 (p37, p40, p42, and p45) tagged with a Flag epitope were expressed in HEK293 cells. One hundred million cells per culture were incubated in medium supplemented with 100 ?M 4SU for 16 hours, washed with PBS and irradiated with 0.15 mJ/cm2, 365 nm UV light in a Spectrolinker XL-1500 UV cross linker to crosslink RNA to AUF1, and harvested and lysed in the equivalent of 3 cell pellet volumes of NP40 lysis buffer.', 'HEK293 cells were transfected with Control siRNA, AUF1 siRNA, Empty Vector, Flag-AUF1 p37, p40, p42, or p45.', 'WI-38 cells were collected at PDL 15 and 55 and also transfected with Control siRNA, AUF1 siRNA, HuR siRNA', 'HeLa cells were transfected with Control siRNA, AUF1 siRNA, or HuR siRNA.'; [Growth]'Human embryonic kidney 293 (HEK293) cells were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS and antibiotics.', 'Human diploid lung (WI-38) fibroblasts were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS and antibiotics.', 'Human cervical carcinoma (HeLa) cells were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS and antibiotics.'; [Extraction]'For AUF1 PAR-CLIP, the cleared cell lysates were treated with 1 U/?l RNase T1 (Fermentas) and AUF1 proteins immunoprecipitated with monoclonal anti-FLAG antibodies (M2, Sigma) bound to Protein G Dynabeads. The RNA residing in the immunoprecipitate was further trimmed with 100 U/ml RNase T1. The beads were washed in lysis buffer and resuspended in one bead volume of dephosphorylation buffer. RNA was dephosphorylated and radioactively labeled with ?-32P-ATP. The protein-RNA complexes were separated by SDS-PAGE, and RNA-protein complexes visualized by autoradiography. The radioactive bands migrating at approximately ~37, 40, 42, and 45 kDa were recovered and the protein-RNA complex was electroeluted from the gel. The protein was removed by digestion in proteinase K buffer in the presence of 0.2 mg/ml proteinase K (Roche).\nThe RNA was then recovered by acidic phenol/chloroform extraction and ethanol precipitation, converted into a cDNA library as described previously (Hafner et al., 2010)', 'Trizol from Invitrogen was used for total RNA extraction\n100 ng of RNA was used for first-strand and second-strand cDNA synthesis followed by single-primer isothermal amplification (SPIA) using NuGEN Ovation RNA-Seq System V2 kits according to the manufacturers protocol. The kit amplified both polyA-tailed and non-polyA-tailed RNA and removed ribosomal RNA. The amplified cDNA was sheared using Bioruptor (Diagenode) to an average size of 250-450 bases. The sequencing library was prepared using Illumina ChIp-Seq kits according to the manufacturers protocol (Illumina, San Diego, CA). In short, the ends of the fragments were repaired using T4 DNA polymerase, E. coli DNA Pol I large fragment (Klenow polymerase), and T4 polynucleotide kinase (PNK) and adenines were added to the 3 end. Adapters were ligated to the DNA fragments, which were size-selected (250-300 bases) after electrophoresis through a 4% agarose gel. Eighteen cycles of PCR amplification was performed, followed by cluster generation and sequencing with Illumina Genome Analyzer (GA-II).', 'After lysis and Rnase digestion, mono ribosomes were purified by 0.9M sucrose cushion\nSmall RNA libraries were prepared as described previously (Guo et al., 2010)'; [Cell type]'Source: ''rna type: HEK293 with Flag IP; passages: unknown; crosslinking: 4-SU with 365nm; ip protein: Flag - AUF1 p37; cell line: HEK293; ', 'rna type: HEK293 with Flag IP; passages: unknown; crosslinking: 4-SU with 365nm; ip protein: Flag - AUF1 p40; cell line: HEK293; ', 'rna type: HEK293 with Flag IP; passages: unknown; crosslinking: 4-SU with 365nm; ip protein: Flag - AUF1 p42; cell line: HEK293; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: Control siRNA; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: AUF1 siRNA; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: Empty Vector; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: p37 overexpresion; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: p40 overexpresion; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: p42 overexpresion; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: p45 overexpresion; ', 'rna type: HEK293 Total RNA; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HEK293; treatment: p37, p40, p42, p45 overexpresion; ', 'rna type: WI-38 Total RNA; passages: PDL15; crosslinking: not applied; ip protein: not applied; cell line: WI-38; ', 'rna type: WI-38 Total RNA; passages: PDL55; crosslinking: not applied; ip protein: not applied; cell line: WI-38; ', 'rna type: WI-38 Total RNA; passages: PDL15; crosslinking: not applied; ip protein: not applied; cell line: WI-38; treatment: PDL 15 Contro siRNA; ', 'rna type: WI-38 Total RNA; passages: PDL15; crosslinking: not applied; ip protein: not applied; cell line: WI-38; treatment: PDL 15 AUF1 siRNA; ', 'rna type: WI-38 Total RNA; passages: PDL15; crosslinking: not applied; ip protein: not applied; cell line: WI-38; treatment: PDL 15 HuR siRNA; ', 'rna type: HeLa RNA from mono ribosome; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HeLa; treatment: Control siRNA; ', 'rna type: HeLa RNA from mono ribosome; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HeLa; treatment: AUF1 siRNA; ', 'rna type: HeLa RNA from mono ribosome; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HeLa; treatment: HuR siRNA; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52977,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE52nnn/GSE52977/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA230601,25366541," Je-Hyun Yoon,  Supriyo De,  Subramanya Srikantan,  Kotb Abdelmohsen,  Ioannis Grammatikakis,  Jiyoung Kim,  Kyoung Mi Kim,  Ji Heon Noh,  Elizabeth J F White,  Jennifer L Martindale,  Xiaoling Yang,  Min-Ju Kang,  William H 3rd Wood,  Nicole Noren Hooten,  Michele K Evans,  Kevin G Becker,  Vidisha Tripathi,  Kannanganattu V Prasanth,  Gerald M Wilson,  Thomas Tuschl,  Nicholas T Ingolia,  Markus Hafner,  Myriam Gorospe","Post-transcriptional gene regulation is robustly regulated by RNA-binding proteins (RBPs). Here we describe the collection of RNAs regulated by AUF1 (AU-binding factor 1), an RBP linked to cancer, inflammation and aging. Photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) analysis reveals that AUF1 primarily recognizes U-/GU-rich sequences in mRNAs and noncoding RNAs and influences target transcript fate in three main directions. First, AUF1 lowers the steady-state levels of numerous target RNAs, including long noncoding RNA NEAT1, in turn affecting the organization of nuclear paraspeckles. Second, AUF1 does not change the abundance of many target RNAs, but ribosome profiling reveals that AUF1 promotes the translation of numerous mRNAs in this group. Third, AUF1 unexpectedly enhances the steady-state levels of several target mRNAs encoding DNA-maintenance proteins. Through its actions on target RNAs, AUF1 preserves genomic integrity, in agreement with the AUF1-elicited prevention of premature cellular senescence.",PAR-CLIP analysis uncovers AUF1 impact on target RNA fate and genome integrity.,10.1038/ncomms6248,2014 Nov 4,PMC4291169,Nature communications
GSE153597,GIGYF2 and 4EHP Inhibit Translation Initiation of Defective Messenger RNAs to Assist Ribosome-Associated Quality Control,Homo sapiens,14,SRP269441,2020-06-30,"[Overal design]This datasets consists of paired ribosome profiling and RNA-seq datasets collected in replicate after the CRISPRi-mediated knockdown of NEMF, ZNF598, EIF4E2, GIGYF2, and non-targeting negative controls.; [Treatment]'K562-dCas9 cell line stably expressing GFPNon-stop was infected with lentiviral vectors containing a guide RNA against one gene or non-targeting guide RNA (Table 2).  Cells were selected using FACS to recover cells containing sgRNA (labeled with RFP).'; [Growth]'See Methods. K562-dCas9 cell line stably expressing GFPNon-stop were grown in RPMI-1640 with 25mM HEPES, 2.0 g/L NaHCO3, 0.3 g/L L-Glutamine supplemented with 10% FBS, 2 mM glutamine, 100 units/mL penicillin and 100 g/mL streptomycin. Cells were maintained at a density between 250,000 cells per mL and 1,000,000 cells per mL throughout the course of the experiments.'; [Extraction]'Cyclohexamide was added (100mg/ul) to the cells and they were incubated for 5 minutes at 37 C and then pelleted at 400g for 5 minutes. Media was removed and cell pellets were immediately snap frozen. Libraries were prepared according to McGlincy and Ingolia, Methods, 2017.\nLibraries were prepared according to McGlincy and Ingolia, Methods, 2017.'; [Cell type]'Source: ''sgrna: sgEIF4E2; sgrna target: EIF4E2; replicate: r1; ', 'sgrna: sgEIF4E2; sgrna target: EIF4E2; replicate: r2; ', 'sgrna: sgGal4; sgrna target: non-targeting; replicate: r1; ', 'sgrna: sgGal4; sgrna target: non-targeting; replicate: r2; ', 'sgrna: sgGIGYF2; sgrna target: GIGYF2; replicate: r1; ', 'sgrna: sgGIGYF2; sgrna target: GIGYF2; replicate: r2; ', 'sgrna: none; sgrna target: n/a; replicate: r1; ', 'sgrna: none; sgrna target: n/a; replicate: r2; ', 'sgrna: sgNEMF; sgrna target: NEMF; replicate: r1; ', 'sgrna: sgNEMF; sgrna target: NEMF; replicate: r2; ', 'sgrna: sgZNF598; sgrna target: ZNF598; replicate: r1; ', 'sgrna: sgZNF598; sgrna target: ZNF598; replicate: r2; ', 'sgrna: mixed; sgrna target: mixed; replicate: r1; ', 'sgrna: mixed; sgrna target: mixed; replicate: r2; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153597,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE153nnn/GSE153597/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA643292,32726578," Kelsey L Hickey,  Kimberley Dickson,  J Zachery Cogan,  Joseph M Replogle,  Michael Schoof,  Karole N D'Orazio,  Niladri K Sinha,  Jeffrey A Hussmann,  Marco Jost,  Adam Frost,  Rachel Green,  Jonathan S Weissman,  Kamena K Kostova","Ribosome-associated quality control (RQC) pathways protect cells from toxicity caused by incomplete protein products resulting from translation of damaged or problematic mRNAs. Extensive work in yeast has identified highly conserved mechanisms that lead to degradation of faulty mRNA and partially synthesized polypeptides. Here we used CRISPR-Cas9-based screening to search for additional RQC strategies in mammals. We found that failed translation leads to specific inhibition of translation initiation on that message. This negative feedback loop is mediated by two translation inhibitors, GIGYF2 and 4EHP. Model substrates and growth-based assays established that inhibition of additional rounds of translation acts in concert with known RQC pathways to prevent buildup of toxic proteins. Inability to block translation of faulty mRNAs and subsequent accumulation of partially synthesized polypeptides could explain the neurodevelopmental and neuropsychiatric disorders observed in mice and humans with compromised GIGYF2 function.",GIGYF2 and 4EHP Inhibit Translation Initiation of Defective Messenger RNAs to Assist Ribosome-Associated Quality Control.,10.1016/j.molcel.2020.07.007,2020 Sep 17,PMC7891188,Molecular cell
GSE67837,Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition [miRNA],Homo sapiens,18,None,2015-04-14,"[Overal design]18 total samples, 9 from control proliferating HL60 cells and 9 from VitD3-treated HL60 cells; [Treatment]'Not applicable'; [Growth]'HL-60 cell line was maintained in RPMI 1640 medium supplemented with 1 x penicillin/streptomycin solution, 1 x L-glutamine and 10% Fetal Bovine Serum.'; [Extraction]'Total RNA for microarray analyses was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) from fractions obtained by sucrose density gradient centrifugation. Genomic DNA contamination was eliminated through a DNase I (Qiagen, Chatsworth, CA) digestion step. RNA was further purified on Qiagen RNeasy columns for gene expression profiling (Qiagen, Chatsworth, CA). The concentration and purity of total RNA were assessed using a Nanodrop TM 1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).'; [Cell type]'HL60 cells, promyeloblasts''cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F3; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F4; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F5; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F6; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F7; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F8; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F9; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F10; ', 'cell type: HL60 cells, promyeloblasts; treatment: VitD3; sucrose density gradient fraction: F11; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F3; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F4; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F5; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F6; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F7; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F8; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F9; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F10; ', 'cell type: HL60 cells, promyeloblasts; treatment: control; sucrose density gradient fraction: F11; '",Non-coding RNA profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67837,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE67nnn/GSE67837/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA281050,25970317," Giulia Fontemaggi,  Teresa Bellissimo,  Sara Donzelli,  Ilaria Iosue,  Barbara Benassi,  Giorgio Bellotti,  Giovanni Blandino,  Francesco Fazi","Treatment of leukemia cells with 1,25-dihydroxyvitamin D3 may overcome their differentiation block and lead to the transition from myeloblasts to monocytes. To identify microRNA-mRNA networks relevant for myeloid differentiation, we",Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition.,10.1080/15476286.2015.1044194,2015,PMC4615388,RNA biology
GSE42509,"Transcriptome-profiling (RNA-seq) and Ribosome-profiling (Ribo-seq) in proliferation, quiescence, senescence and transformed states.",Homo sapiens,17,SRP017378,2012-11-26,"[Overal design]RNA-seq, using Illumina HiSeq 2000, was applied to BJ cells under 5 conditions: proliferation, quiescence, pre-senescence, full-senescence, and transfomed. Ribosome profiling, using Illumina HiSeq 2000, was applied to BJ cells under 5 conditions: proliferation, quiescence, pre-senescence, full-senescence, and transfomed.; [Treatment]'None'; [Growth]'Immortalized human BJ primary fibroblast cells (by hTERT expression) were cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS) in 5% CO2\xa0at 37\xa0C.'; [Extraction]""Total RNA was isolated using Trizol Reagent (Invitrogen), following the  manufacturer's instructions. Poly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the  manufacturer's instructions."", 'Cells were treated with cycloheximide (100 ?g/ml) for 8-10 minutes, washed with ice-cold PBS (cycloheximide, 100 ?g/ml), pelleted, and lysed in buffer A (20 mM Tris-HCl, pH7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml cycloheximide, 1x complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7%-47%) using the SW-41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in monosomes were polled and treated wih proteinase K (Roche) in 1%SDS. Released RNA fragments were purified using trizol and precipitated in the presence of glycogen.\nRNA from the pooled monosomes was gel-purified on a denaturing 10% polyacrylamide urea (7M) gel. A section corresponding to 30-33 nucleotides, the region where most of the ribosome-protected fragments are comprised, was excised, eluted, and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 PNK (NEB) for 6 h at 37 C in MES buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (NEB) for 2.5h at 37C. Ligation products were 5'-phosphorylated with T4 PNK for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18h at 22C.'; [Cell type]'Source: ''cell line: BJ cells; condition: Proliferation, normal conditions; ', 'cell line: BJ cells; condition: Quiescence induced by serum depletion; ', 'cell line: BJ cells; condition: pre-senescence; 5 dys after RASG12V induction; protocol: BJ cells expressing hTERT and tamoxifen-inducible RASG12V were cultured in the presence of 10-7M 4-OHT-Tamoxifen for 5 days; ', 'cell line: BJ cells; condition: Senescence; 14 dys after RASG12V induction; protocol: BJ cells expressing hTERT and tamoxifen-inducible RASG12V were cultured in the presence of 10-7M 4-OHT-Tamoxifen for 14 days; ', 'cell line: BJ cells; condition: Transformed cells (induced by RASG12V in the background of stable p53 and p16INK4A kds); protocol: BJ cells expressing hTERT, p16INK4A-KD, p53-KD and SV40 small T were retrovirally transduced with pBabe-puro-RASG12V; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42509,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE42nnn/GSE42509/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA182756,23594524," Fabricio Loayza-Puch,  Jarno Drost,  Koos Rooijers,  Rui Lopes,  Ran Elkon,  Reuven Agami","BACKGROUND: Cell growth and proliferation are tightly connected to ensure that appropriately sized daughter cells are generated following mitosis. Energy stress blocks cell growth and proliferation, a critical response for survival under extreme conditions. Excessive oncogenic stress leads to p53 activation and the induction of senescence, an irreversible state of cell-cycle arrest and a critical component in the suppression of tumorigenesis. Nutrient-sensing and mitogenic cues converge on a major signaling node, which regulates the activity of the mTOR kinase. Although transcriptional responses to energy and oncogenic stresses have been examined by many gene-expression experiments, a global exploration of the modulation of mRNA translation in response to these conditions is lacking. RESULTS: We combine RNA sequencing and ribosomal profiling analyses to systematically delineate modes of transcriptional and translational regulation induced in response to conditions of limited energy, oncogenic stress and cellular transformation. We detect a key role for mTOR and p53 in these distinct physiological states, and provide the first genome-wide demonstration that p53 activation results in mTOR inhibition and a consequent global repression of protein translation. We confirm the role of the direct p53 target genes Sestrin1 and Sestrin2 in this response, as part of the broad modulation of gene expression induced by p53 activation. CONCLUSIONS: We delineate a bimodal tumor-suppressive regulatory program activated by p53, in which cell-cycle arrest is imposed mainly at the transcriptional level, whereas cell growth inhibition is enforced by global repression of the translation machinery.",p53 induces transcriptional and translational programs to suppress cell proliferation and growth.,10.1186/gb-2013-14-4-r32,2013 Apr 17,PMC4053767,Genome biology
GSE95024,p53-induced apoptosis is specified by a translation program regulated by PCBP2 and DHX30.,Homo sapiens,24,SRP100158,2017-02-17,"[Overal design]4 biological samples per condition are used. A total of 24 samples were used: 12 polysomal DMSO (scramble, DHX30 silencing and PCBP2 silencing) and 12 polysomal Nutlin (scramble, DHX30 silencing and PCBP2 silencing).; [Treatment]'HCT116 cells were transduced with lentiviral vectors containing a pLK0.1 plasmid expressing shRNA sequences against DHX30 or PCBP2. A scramble sequence SHC206 was also used. Cells were allowed to reach 60-70% confluence before treatment with 10 mM Nutlin-3a (Nutlin) or only  DMSO at 0.1% (v/v).'; [Growth]'HCT116 cells were maintained in RPMI (Gibco) supplemented with 10% FBS, antibiotics (100 units/mL penicillin plus 100 mg/mL streptomycin) and 2mM L-glutamine. Cultures were maintained at 37C in a 5% CO2 incubator.'; [Extraction]'Polysomal separation was performed as follows: samples were loaded in 15-50% linear sucrose gradients, ultra-centrifuged and fractionated with an automated fraction collector. All the fractions containing subpolysomal or polysomal RNA were identified and pooled in two separate tubes. RNA was purified by extraction with 1 volume of phenol-chloroform and, after isopropanol precipitation, a washing step in 70% v/v ethanol was performed in order to remove phenol contaminations.\nRNA libraries were prepared for sequencing using standard Illumina protocols: Illumina TruSeq RNA Sample Prep Kit was used with 1.5 ug of total or polysomal RNA as input.'; [Cell type]'Source: ''cell line: HCT116; genotype: wild type; agent: DMSO; fraction: polysomal RNA; ', 'cell line: HCT116; genotype: wild type; agent: nutlin; fraction: polysomal RNA; ', 'cell line: HCT116; genotype: DHX30 silencing; agent: DMSO; fraction: polysomal RNA; ', 'cell line: HCT116; genotype: DHX30 silencing; agent: nutlin; fraction: polysomal RNA; ', 'cell line: HCT116; genotype: PCBP2 silencing; agent: DMSO; fraction: polysomal RNA; ', 'cell line: HCT116; genotype: PCBP2 silencing; agent: nutlin; fraction: polysomal RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95024,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE95nnn/GSE95024/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA375753,32234473," Dario Rizzotto,  Sara Zaccara,  Annalisa Rossi,  Matthew D Galbraith,  Zdenek Andrysik,  Ahwan Pandey,  Kelly D Sullivan,  Alessandro Quattrone,  Joaquin M Espinosa,  Erik Dassi,  Alberto Inga","Activation of p53 by the small molecule Nutlin can result in a combination of cell cycle arrest and apoptosis. The relative strength of these events is difficult to predict by classical gene expression analysis, leaving uncertainty as to the therapeutic benefits. In this study, we report a translational control mechanism shaping p53-dependent apoptosis. Using polysome profiling, we establish Nutlin-induced apoptosis to associate with the enhanced translation of mRNAs carrying multiple copies of an identified 3' UTR CG-rich motif mediating p53-dependent death (CGPD-motif). We identify PCBP2 and DHX30 as CGPD-motif interactors. We find that in cells undergoing persistent cell cycle arrest in response to Nutlin, CGPD-motif mRNAs are repressed by the PCBP2-dependent binding of DHX30 to the motif. Upon DHX30 depletion in these cells, the translation of CGPD-motif mRNAs increases, and the response to Nutlin shifts toward apoptosis. Instead, DHX30 inducible overexpression in SJSA1 cells leads to decreased translation of CGPD-motif mRNAs.",Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30.,10.1016/j.celrep.2020.03.011,2020 Mar 31,PMC7182397,Cell reports
GSE105082,RNA G-quadruplexes mark repressive upstream open reading frames in human mRNAs,Homo sapiens,24,SRP120157,2017-10-17,"[Overal design]11 Ribo-Seq and RNA-Seq matched samples; 1 iCLIP libraries containing two barcoded replicates; [Treatment]'For siRNA transfection, 5  10^6 HeLa cells per 15 cm dish were cultured overnight and treated with 27 ?L DharmaFECT 1 Transfection Reagent (Dharmacon) and treated with 90 nM indicated siRNA in 1.8 mL OptiMEM media.DHX9 and DHX36 siRNA oligoes were transfected at equimolar concentrations. A pool of four non-targeting siRNAs (ON-TARGETplus Non-targeting Control Pool, Dharmacon) was used as control. The cells were then expended for 48 h. For iCLIP, refer to associated publication.'; [Growth]'HeLa cells were cultured in Dulbeccos modified Eagle Medium (Life Technology) supplemented with 10% FBS (Life Technology).'; [Extraction]'Total RNA and ribosome-protected fragments (RPFs) were isolated using the TruSeq Ribo Profile Mammalian Kit (Illumina) following the manufacturers intructions with some modifications. For RPFs purification, lysates were treated with 5 U TruSeq Ribo Profile Nuclease per A260 of lysate. RPFs were isolated using Illustra MicroSpin S-400 HR Columns (GE Healthcare, 27- 5140-01). rRNAs were removed using the Ribo-zero Magnetic Gold kit (Illumina, MRZG12324). After PAGE purification (15% urea-polyacrylamide gel to select fragments ~28-30 nt in length), end-repair, 3-adapter ligation, reverse transcription (EpiScript reverse transcriptase) and cDNA circularisation (CircLigase, Epicentre), RPFs were amplified using 9 PCR cycles using Phusion polymerase (NEB). For parallel RNA-seq, total RNA was processed similarly, but excluding the nuclease digestion and S-400 columns purification steps. Before the library preparation steps, total RNA samples were heat-fragmented (94C for 25 minutes). PCR amplicons were purified on a 8% native polyacrylamide gel excising bands corresponding to ~70-80 nt and ~80-100 nt for RPF and total RNA samples respectively. Libraries were sequenced on a NextSeq 500 using 75-nt single-read sequencing runs.  For iCLIP, refer to associated publication.\nTruSeq Ribo Profile Mammalian Kit (Illumina)\nRNA-Seq, Ribo-Seq, iCLIP-seq'; [Cell type]'HeLa''cell type: HeLa; treatment: none; ', 'cell type: HeLa; treatment: untreated; ', 'cell type: HeLa; treatment: scramble siRNA; ', 'cell type: HeLa; treatment: DHX36 siRNA; ', 'cell type: HeLa; treatment: DHX9 siRNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE105082,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE105nnn/GSE105082/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA414611,30591072," Pierre Murat,  Giovanni Marsico,  Barbara Herdy,  Avazeh T Ghanbarian,  Guillem Portella,  Shankar Balasubramanian","BACKGROUND: RNA secondary structures in the 5'-untranslated regions (5'-UTR) of mRNAs are key to the post-transcriptional regulation of gene expression. While it is evident that non-canonical Hoogsteen-paired G-quadruplex (rG4) structures somehow contribute to the regulation of translation initiation, the nature and extent of human mRNAs that are regulated by rG4s is not known. Here, we provide new insights into a mechanism by which rG4 formation modulates translation. RESULTS: Using transcriptome-wide ribosome profiling, we identify rG4-driven mRNAs in HeLa cells and reveal that rG4s in the 5'-UTRs of inefficiently translated mRNAs associate with high ribosome density and the translation of repressive upstream open reading frames (uORF). We demonstrate that depletion of the rG4-unwinding helicases DHX36 and DHX9 promotes translation of rG4-associated uORFs while reducing the translation of coding regions for transcripts that comprise proto-oncogenes, transcription factors and epigenetic regulators. Transcriptome-wide identification of DHX9 binding sites shows that reduced translation is mediated through direct physical interaction between the helicase and its rG4 substrate. CONCLUSION: This study identifies human mRNAs whose",,10.1186/s13059-018-1602-2,2018 Dec 27TI - RNA G-quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent translation of human mRNAs.,PMC6307142,Genome biology
GSE13176,The protein kinase Tor1 regulates adhesin expression in Candida albicans,Candida albicans,12,None,2008-10-13,"[Overal design]Study consists of wild type Candida albicans cells grown in Spider liquid medium at 35C and treated either with vehicle or 20 nM rapamycin. Analysis is based off 4 independent biological replicates; [Treatment]'Cell cultures were treated with either 20 nM rapamycin or drug vehicle (90% EtOH 10% Tween-20) and shaken for 90 minutes at 37C.', 'Cell cultures were treated with either 20 nM rapamycin or drug vehicle (90% EtOH 10% Tween-20) and shaken for 60 minutes at 30C.'; [Growth]'Cell cultures were grown in YPD liquid medium at 30C to an O.D600=0.5.  Cells were washed twice and resuspended in Spider liquid medium.  Cultures were treated with either 20 nM rapamycin or drug vehicle (90% EtOH 10% Tween-20) and shaken for 90 minutes at 37C.', 'Cell cultures were grown in YPD liquid medium at 30C to an O.D600=0.5, and treated with either 20 nM rapamycin or drug vehicle (90% EtOH 10% Tween-20) and shaken for 60 minutes at 30C.'; [Extraction]'Total RNA was extracted using a RiboPureTM-Yeast RNA extraction kit (Ambion Inc).'; [Cell type]'Source: ''strain: wild type cells (SC5314); ', 'strain: TOR1-1/TOR1 cells; ', 'strain: TOR1-1/TOR1 cells.; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13176,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE13nnn/GSE13176/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA109719,19197361," Robert J Bastidas,  Joseph Heitman,  Maria E Cardenas","Eukaryotic cell growth is coordinated in response to nutrient availability, growth factors, and environmental stimuli, enabling cell-cell interactions that promote survival. The rapamycin-sensitive Tor1 protein kinase, which is conserved from yeasts to humans, participates in a signaling pathway central to cellular nutrient responses. To gain insight into Tor-mediated processes in human fungal pathogens, we have characterized Tor signaling in Candida albicans. Global transcriptional profiling revealed evolutionarily conserved roles for Tor1 in regulating the expression of genes involved in nitrogen starvation responses and ribosome biogenesis. Interestingly, we found that in C. albicans Tor1 plays a novel role in regulating the expression of several cell wall and hyphal specific genes, including adhesins and their transcriptional repressors Nrg1 and Tup1. In accord with this transcriptional profile, rapamycin induced extensive cellular aggregation in an adhesin-dependent fashion. Moreover, adhesin gene induction and cellular aggregation of rapamycin-treated cells were strongly dependent on the transactivators Bcr1 and Efg1. These findings support models in which Tor1 negatively controls cellular adhesion by governing the activities of Bcr1 and Efg1. Taken together, these results provide evidence that Tor1-mediated cellular adhesion might be broadly conserved among eukaryotic organisms.",The protein kinase Tor1 regulates adhesin gene expression in Candida albicans.,10.1371/journal.ppat.1000294,2009 Feb,PMC2631134,PLoS pathogens
GSE43296,Polysome-associated mRNA profiling of cancer cells in response to CXCL12 and IGF1,Homo sapiens,6,SRP017788,2013-01-04,"[Overal design]MDA-MB-231 cells were engineered to express an EGFP-tagged version of ribosomal protein L10a. This allows the retrieval of polysome-associated mRNA by anti-GFP pull down (TRAP) and profiling the translating transcriptome by RNAseq. EGFP-L10a+ cancer cells were serum starved (0.2% serum) for 24 hours, and then treated with CXCL12 (30ng/mL) + IGF1 (10ng/mL) or CXCL12 (300ng/mL) + IGF1 (100ng/mL) for 6hrs. Two biological replicates were profiled for each condition.; [Treatment]'Cells were starved in 0.2% serum for 24hrs and treated with CXCL12 + IGF1 at two different concentrations for 6 hrs. Two biological replicates were included for each condition.'; [Growth]'None'; [Extraction]'Polysome-associated RNA was extracted following the TRAP protocol from Heiman et al, Cell, 2009. Briefly, cells were harvested in polysome extraction buffer. Polysomes were pulled down by anti-GFP coated sepharose beads. Polysome-associated RNA was isolated with RNAqeuous micro kit (Life Technologies).\nRNA sequencing libraries were constructed with 500ng polysome-associated RNA using TruSeq RNA Sample Prep Kit v2 (Illumina).'; [Cell type]'Source: ''cell line: MDA-MB-231; treatment: CXCL12 (0ng/mL) + IGF1 (0ng/mL); ', 'cell line: MDA-MB-231; treatment: CXCL12 (30ng/mL) + IGF1 (10ng/mL); ', 'cell line: MDA-MB-231; treatment: CXCL12 (300ng/mL) + IGF1 (100ng/mL); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43296,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE43nnn/GSE43296/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA185391,23993096," Xiang H-F Zhang,  Xin Jin,  Srinivas Malladi,  Yilong Zou,  Yong H Wen,  Edi Brogi,  Marcel Smid,  John A Foekens,  Joan Massague","How organ-specific metastatic traits arise in primary tumors remains unknown. Here, we show a role of the breast tumor stroma in selecting cancer cells that are primed for metastasis in bone. Cancer-associated fibroblasts (CAFs) in triple-negative (TN) breast tumors skew heterogeneous cancer cell populations toward a predominance of clones that thrive on the CAF-derived factors CXCL12 and IGF1. Limiting concentrations of these factors select for cancer cells with high Src activity, a known clinical predictor of bone relapse and an enhancer of PI3K-Akt pathway activation by CXCL12 and IGF1. Carcinoma clones selected in this manner are primed for metastasis in the CXCL12-rich microenvironment of the bone marrow. The evidence suggests that stromal signals resembling those of a distant organ select for cancer cells that are primed for metastasis in that organ, thus illuminating the evolution of metastatic traits in a primary tumor and its distant metastases.",Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.,10.1016/j.cell.2013.07.036,2013 Aug 29,PMC3974915,Cell
GSE119168,N6-methyladenosine (m6A) profiling of ovarian cancer tissues,Homo sapiens,26,SRP159033,2018-08-28,"[Overal design]Six omental tumor tissues were collected from newly diagnosed patients with advanced, metastatic high-grade serous ovarian cancer. Seven normal fallopian tube tissues were collected from patients with benign gynecological conditions. Total RNA was extracted from the tissue by TRIzol followed by fragmentation with Bioruptor ultrasonicator. m6A-immunoprecipitation were performed using EpiMark N6-Methyladenosine enrichment kit (NEB cat. E1610S). Takara Pico-Input Strand-Specific Total RNA-seq for Illumina was used to construct library from total RNA where ribosome-derived cDNA was removed before final library amplification. The libraries were sequenced by the NextSeq 500 platform at PE37 mode.; [Treatment]'None'; [Growth]'None'; [Extraction]'TRIzol (Invitrogen)\nTakara Pico-Input Strand-Specific Total RNA-seq for Illumina\nMeRIP-seq'; [Cell type]'Source: ''group: omental tumor; age: 62; ', 'group: omental tumor; age: 68; ', 'group: omental tumor; age: 70; ', 'group: omental tumor; age: 64; ', 'group: omental tumor; age: 73; ', 'group: normal Fallopian tube; age: 36; ', 'group: normal Fallopian tube; age: 59; ', 'group: normal Fallopian tube; age: 35; ', 'group: normal Fallopian tube; age: 45; ', 'group: normal Fallopian tube; age: 54; ', 'group: normal Fallopian tube; age: 51; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119168,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE119nnn/GSE119168/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA488293,31870409," Zijie Zhang,  Qi Zhan,  Mark Eckert,  Allen Zhu,  Agnieszka Chryplewicz,  Dario F De Jesus,  Decheng Ren,  Rohit N Kulkarni,  Ernst Lengyel,  Chuan He,  Mengjie Chen","Epitranscriptome profiling using MeRIP-seq is a powerful technique for in vivo functional studies of reversible RNA modifications. We develop RADAR, a comprehensive analytical tool for detecting differentially methylated loci in MeRIP-seq data. RADAR enables accurate identification of altered methylation sites by accommodating variability of pre-immunoprecipitation expression level and post-immunoprecipitation count using different strategies. In addition, it is compatible with complex study design when covariates need to be incorporated in the analysis. Through simulation and real dataset analyses, we show that RADAR leads to more accurate and reproducible differential methylation analysis results than alternatives, which is available at https://github.com/scottzijiezhang/RADAR.",RADAR: differential analysis of MeRIP-seq data with a random effect model.,10.1186/s13059-019-1915-9,2019 Dec 23,PMC6927177,Genome biology
GSE112705,Landscapes of gene translation in hepatocellular carcinoma tumors revealed by ribosome profiling,Homo sapiens,40,SRP137150,2018-04-04,"[Overal design]We profiled the paired tumor and adjacent normal tissue samples from 10 patients of HCC by the procedure of ribosome profiling, which was adapted and optimized for processing of clinical solid tissue samples. Total RNA sequencing was performed in parallel for the same samples.; [Treatment]'None'; [Growth]'None'; [Extraction]'Tumors and adjacent normal tissues from HCC patients were flash-frozen and stored in liquid nitrogen. Prior to the experiments, the tissue samples were crushed into powder in an automatic cryogenic grinder (HORIBA, Freezer/Mill 6770) filled with liquid nitrogen. About 50 mg of each of the powdered samples was lysed in 400 ul of lysis buffer containing 20 mM Tris-HCl (PH 7.4) (Invitrogen, AM9850G), 150mM NaCl (Invitrogen, AM9760G), 5mM MgCl2 (Invitrogen, AM9530G), 1% Triton X-100 (Sigma Aldrich, T8787), 0.1% NP40 (Amresco, E109), 1 mM DTT (Sigma Aldrich, 43816), 25 U/ml DNase I (Invitrogen, AM2239) and 0.1 mg/ml cycloheximide (Inalco, 1758-9310). The mixture was clarified for 10 minutes at 20,000 g at 4C. 200ul of the clarified lysate was used for purification of the RPF, which will be profiled by ribosome profiling, and 100ul of the lysate was for the total RNA sequencing in parallel.\nFor RPF, 90 Units of RNase I (Life Technologies, AM2294) for each A260 of the lysate was added to 200 ul of the supernatant and incubated at room temperature for 45 min with gentle mixing. Nuclease digestion was stopped with 15 ul of SUPERase InTM RNase Inhibitor (Life Technologies, AM2696) and chilled on ice. Ribosome-RNA complexes were purified by Sephacryl S400 spin column chromatography (GE Healthcare, 27514001). The ribosome-protected RNA was extracted with Trizol (Invitrogen, 15596018), following the manufacturers protocol. Then the ribosomal RNA was depleted using the RiboZero kit (Illumina; MRZH11124), following the manufacturers protocol, omitting the 50C incubation step. Next, the samples were resolved in a 15% Urea gel by electrophoresis, and the fragment at 25-35 nucleotides was excised from the gel. The RNA fragments were then eluted at least 2h in 400ul Nuclease-Free Water, 40 ul of 5 M Ammonium Acetate (Invitrogen, AM9070G) and 2 ul of 10% SDS (Invitrogen, AM9823), followed by Isopropanol (Sigma Aldrich, I9030) precipitation.\nTotal RNA from the tissue samples was isolated from 100 ul of the clarified tissue lysate with Trizol (Invitrogen, 15596018), and the ribosomal RNA was then depleted using the RiboZero kit (Illumina; MRZH11124). Next, the rRNA-depleted total RNA was fragmented with PNK buffer (NEB, M0201L) at 95?C for 20min.\nBoth RPF and fragmented total RNA were cloned and amplified for next-generation sequencing with a tagging-based workflow. In brief, the RNA fragments were end repaired with T4 PNK (NEB, M0201L) and ligated with 3 adaptor, followed by cDNA synthesis, cDNA gel purification, circularization and PCR amplification20. The sequencing libraries were assessed with a BioAnalyzer and quantified using KAPA SYBR FAST Universal qPCR Kit (Kapa Biosystems, KK4601) prior to and after pooling for sequencing. Library insert sizes were typically about 30bp. The pooled libraries were sequenced on the Illumina HiSeq 2500 platform with a single-end sequencing strategy for 50 cycles.'; [Cell type]'Source: ''subject status: HCC patient; subject id: LC001; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC001; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC001; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC001; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC033; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC033; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC033; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC033; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC034; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC034; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC034; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC034; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC501; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC501; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC501; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC501; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC502; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC502; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC502; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC502; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC505; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC505; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC505; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC505; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC506; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC506; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC506; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC506; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC507; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC507; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC507; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC507; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC508; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC508; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC508; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC508; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC509; tissue type: adjacent normal liver tissue; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC509; tissue type: adjacent normal liver tissue; molecule subtype: rRNA-depleted, fragmented total RNA; ', 'subject status: HCC patient; subject id: LC509; tissue type: liver tumor; molecule subtype: ribosome-protected mRNA fragment (RPF); ', 'subject status: HCC patient; subject id: LC509; tissue type: liver tumor; molecule subtype: rRNA-depleted, fragmented total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112705,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112705/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA448763,31281537," Qin Zou,  Zhengtao Xiao,  Rongyao Huang,  Xin Wang,  Xun Wang,  Haitao Zhao,  Xuerui Yang","Despite the critical position of translation in the multilevel gene expression regulation program, high-resolution and genome-wide view of the landscape of RNA translation in solid tumors is still limited. Methods: With a ribosome profiling procedure optimized for solid tissue samples, we profiled the translatomes of liver tumors and their adjacent noncancerous normal liver tissues from 10 patients with hepatocellular carcinoma (HCC). A set of bioinformatics tools was then applied to these data for the mining of novel insights into the translation shifts in HCC. Results: This is the first translatome data resource for dissecting dysregulated translation in HCC at the sub-codon resolution. Based on our data, quantitative comparisons of mRNA translation rates yielded the genes and processes that were subjected to patient specific or universal dysregulations of translation efficiencies in tumors. For example, multiple proteins involved in extracellular matrix organization exhibited significant translational upregulation in tumors. We then experimentally validated the tumor-promoting functions of two such genes as examples: AGRN and VWA1. In addition, the data was also used for de novo annotation of the translatomes in tumors and normal tissues, including multiple types of novel non-canonical small ORFs, which would be a resource for further functional studies. Conclusions: The present study generates the first survey of the HCC translatome with ribosome profiling, which is an insightful data resource for dissecting the translatome shift in liver cancer, at sub-codon resolution.",Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling.,10.7150/thno.35033,2019,PMC6592166,Theranostics
GSE121391,Genome-wide analysis of eIF4G-RNA interaction in CDK12-depleted cells (Ribo-Seq),Homo sapiens,8,SRP165989,2018-10-17,"[Overal design]Ribosome footprinting followed by sequencing (Ribo-Seq) in 2 different treatments in U2OS cells.; [Treatment]'siRNA transfection for 48 hr'; [Growth]'DMEM supplemeted with 10% (v/v) Fetal Bovine Serum, Glutamine, 5% CO2'; [Extraction]'100 g/mL cycloheximide treatment\nRibo-Zero Mammalian Kit (Illumina)\nsingle-end RIP-Seq'; [Cell type]'Source: ''knockdown: CDK12; library: ribosome footprinting; replicate: A; ', 'knockdown: CDK12; library: total RNA control; replicate: A; ', 'knockdown: CDK12; library: ribosome footprinting; replicate: B; ', 'knockdown: CDK12; library: total RNA control; replicate: B; ', 'knockdown: control; library: ribosome footprinting; replicate: A; ', 'knockdown: control; library: total RNA control; replicate: A; ', 'knockdown: control; library: ribosome footprinting; replicate: B; ', 'knockdown: control; library: total RNA control; replicate: B; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121391,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE121nnn/GSE121391/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA497255,,,,,,,,
GSE129869,Ribo-seq of Toxoplasma-infected host cells,Homo sapiens,24,SRP192707,2019-04-16,"[Overal design]Ribosome profiling and RNA-seq of Toxoplasma-infected confluent and subconfluent human foreskin fibroblasts in triplicate; [Treatment]'HFFs were split, allowed to grow for 24 hours then infected with RH strain T. gondii for 24 hours in DMEM supplemented with 10% heat-inactivated FBS w/o antibiotic'; [Growth]'parasites routinely subcultured in HFFs in DMEM supplemented with 1% heat-inactivated FBS w/o antibiotic; HFFs routinely subcultured in DMEM supplemented with 10% heat-inactivated FBS w/o antibiotics'; [Extraction]""cytoplasmic lysate was collected and an aliquot was immediately stored in Trizol for RNA-seq samples.  The rest was digested with RNaseI and monosomes were collecte by ultracentrifugation on a sucrose gradient. Ribosome-protected fragments (RFP) were purified after gel electrophoresis\nRNA-seq and Ribo-seq samples of confluent samples were processed with the TruSeq Ribo Profile kit (Illumina) as per manufacturer. Subconfluent samples: total RNA was fragmented by alkaline hydrolysis. Fragments were purfied by gel electrophoresis. fragments were dephosphorylated, ligated at 5' end with barcoded adapter, rRNA removal with RiboZero mammalian kit (Illumina), phosphorylated, ligated at 3' end with SR-adapter, reverse transcribed & PCR with NEBnext barcoded adapters""; [Cell type]'Source: ''host cell type: human foreskin fibroblasts; parasite: Toxoplasma gondii RH; host growth: confluent; ', 'host cell type: human foreskin fibroblasts; parasite: Toxoplasma gondii RH; host growth: subconfluent; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129869,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129869/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA533074,31167946," Michael J Holmes,  Premal Shah,  Ronald C Wek,  William J Jr Sullivan","Toxoplasma gondii is a ubiquitous obligate intracellular parasite that infects the nucleated cells of warm-blooded animals. From within the parasitophorous vacuole in which they reside, Toxoplasma tachyzoites secrete an arsenal of effector proteins that can reprogram host gene expression to facilitate parasite survival and replication. Gaining a better understanding of how host gene expression is altered upon infection is central for understanding parasite strategies for host invasion and for developing new parasite therapies. Here, we applied ribosome profiling coupled with mRNA measurements to concurrently study gene expression in the parasite and in host human foreskin fibroblasts. By examining the parasite transcriptome and translatome, we identified potential upstream open reading frames that may permit the stress-induced preferential translation of parasite mRNAs. We also determined that tachyzoites reduce host death-associated pathways and increase survival, proliferation, and motility in both quiescent and proliferative host cell models of infection. Additionally, proliferative cells alter their gene expression in ways that are consistent with massive transcriptional rewiring, while quiescent cells were best characterized by reentry into the cell cycle. We also identified a translational control regimen consistent with mechanistic target of rapamycin (mTOR) activation in quiescent cells and, to a lesser degree, in proliferative cells. This study illustrates the utility of the method for dissection of gene expression programs simultaneously in the parasite and host.IMPORTANCE Toxoplasma gondii is a single-celled parasite that has infected up to one-third of the world's population. Significant overhauls in gene expression in both the parasite and the host cell accompany parasite invasion, and a better understanding of these changes may lead to the development of new therapeutic agents. In this study, we employed ribosome profiling to determine the changes that occur at the levels of transcription and translation in both the parasite and the infected host cell at the same time. We discovered features of Toxoplasma mRNAs that suggest a means for controlling parasite gene expression under stressful conditions. We also show that differences in host gene expression occur depending on whether they are confluent or not. Our findings demonstrate the feasibility of using ribosomal profiling to interrogate the host-parasite dynamic under a variety of conditions.",Simultaneous Ribosome Profiling of Human Host Cells Infected with Toxoplasma gondii.,10.1128/mSphere.00292-19,2019 Jun 5,PMC6553554,mSphere
GSE85215,MicroRNAs underlie genome-wide transcriptome and translatome regulation in asthma as revealed by Frac-seq (miRNA-Seq),Homo sapiens,13,SRP080955,2016-08-04,"[Overal design]We performed cytoplasmic and polyribosome bound RNA-seq of bronchial epithelial cells from healthy controls and severe asthmatic patients. Small RNA-seq was also performed; [Treatment]'None'; [Growth]'Epithelial brushings were collected using disposable, sheathed bronchial brushes (Olympus cytology brushes BC-202D-2010, KeyMed [Medical & Industrial Equipment] Ltd OLYMPUS Group Company), with 4 separate sets of brushings from the central airways. Brushings were placed in a sterile universal tube with 5 ml PBS and washed with 10mL of RPMI medium (PAA, GE Healthcare LifeSciences) supplemented with penicillin/streptomycin (Thermo Fisher Scientific). Brushings were spun at 1200 rpm for 10 minutes, medium was discarded and cells were resuspended in complete BEGM (Lonza). BECs were cultured in collagen (Thermo Fisher Scientific)-coated T25 flasks in BEGM complete medium and passaged onto 15cm2 collagen-coated dishes when 80% confluent. Cells were harvested at passage 1.'; [Extraction]'Cytoplasmic extracts were prepared as described previously (Sterne-Weiler et al. 2013; Martinez-Nunez and Sanford 2016) with the addition of 500\uf06dg/mL cycloheximide (Sigma-Aldrich UK) in the lysis buffer.\nNEBNext Small RNA-Seq Library Preparation Kit (New England Biolabs- Ipswich, USA). The purified libraries were electrophoresed through a freshly cast 8% native polyacrylamide gel. The library fragments of appropriate size (~134-152 nt) were excised and recovered by agitation of the fragments overnight at 37C at 200 rpm in elution buffer, passage of the eluate through a 0.45?m filter, and ethanol precipitation.\nmiRNA-seq. Run across two lanes (L001 and L002).'; [Cell type]'Source: ''seq name: CM3919803; disease status: SA; ', 'seq name: CM3919805; disease status: SA; ', 'seq name: CM3919811; disease status: SA; ', 'seq name: CM3919817; disease status: HC; ', 'seq name: CM3919819; disease status: HC; ', 'seq name: CM3919821; disease status: HC; ', 'seq name: CM4005801; disease status: SA; ', 'seq name: CM4005807; disease status: SA; ', 'seq name: CM4005809; disease status: SA; ', 'seq name: CM4005813; disease status: SA; ', 'seq name: CM4005815; disease status: SA; ', 'seq name: CM4005823; disease status: HC; ', 'seq name: CM4005825; disease status: HC; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85215,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE85nnn/GSE85215/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA336574,29769273," Rocio T Martinez-Nunez,  Hitasha Rupani,  Manuela Plate,  Mahesan Niranjan,  Rachel C Chambers,  Peter H Howarth,  Tilman Sanchez-Elsner","MicroRNAs are small noncoding RNAs that inhibit gene expression posttranscriptionally, implicated in virtually all biological processes. Although the effect of individual microRNAs is generally studied, the genome-wide role of multiple microRNAs is less investigated. We assessed paired genome-wide expression of microRNAs with total (cytoplasmic) and translational (polyribosome-bound) mRNA levels employing subcellular fractionation and RNA sequencing (Frac-seq) in human primary bronchoepithelium from healthy controls and severe asthmatics. Severe asthma is a chronic inflammatory disease of the airways characterized by poor response to therapy. We found genes (i.e., isoforms of a gene) and mRNA isoforms differentially expressed in asthma, with novel inflammatory and structural pathophysiological mechanisms related to bronchoepithelium disclosed solely by polyribosome-bound mRNAs (e.g., IL1A and LTB genes or ITGA6 and ITGA2 alternatively spliced isoforms). Gene expression (i.e., isoforms of a gene) and mRNA expression analysis revealed different molecular candidates and biological pathways, with differentially expressed polyribosome-bound and total mRNAs also showing little overlap. We reveal a hub of six dysregulated microRNAs accounting for approximately 90% of all microRNA targeting, displaying preference for polyribosome-bound mRNAs. Transfection of this hub in bronchial epithelial cells from healthy donors mimicked asthma characteristics. Our work demonstrates extensive posttranscriptional gene dysregulation in human asthma, in which microRNAs play a central role, illustrating the feasibility and importance of assessing posttranscriptional gene expression when investigating human disease.",Genome-Wide Posttranscriptional Dysregulation by MicroRNAs in Human Asthma as Revealed by Frac-seq.,10.4049/jimmunol.1701798,2018 Jul 1,PMC6013048,"Journal of immunology (Baltimore, Md. : 1950)"
GSE104028,Analysis of the translational landscape of Arabidopsis mitochondria,Arabidopsis thaliana,8,SRP118154,2017-09-19,"[Overal design]In this study, 2 Arabidopsis mutants are compared to the wild type using duplicates for the Ribosome Profiling experiment. RNASEQ: was conducted to observe the editing rates of Col0 transcripts. RIBOSEQ: was conducted to observe the ribosome occupancy on each transcript of wild type and mutants.; [Treatment]'None'; [Growth]'Plants were grown in a greenhouse in long day conditions for 10 to 12 weeks. Flowers were harvested simultaneously for all genotypes, snap-frozen in liquid nitrogen and stored at -80C until use.'; [Extraction]'Total RNA extraction in Trizol from flowers. Total RNA were treated with DNase and rRNA were removed using Ribozero Plant Leaf.\nStandard RNA-seq sequencing at Genewiz company (TruSeq RNA sample preparation v2).', 'About 2.5 g of flowers were ground in liquid nitrogen and resuspended in 15 mL of ribosome extraction buffer.\nIllumina TruSeq Small RNA RS-200-0012.'; [Cell type]'Source: ''ecotype/background: Col-0; genotype/variation: wild type; tissue: flower; ', 'ecotype/background: Col-0; genotype/variation: wild type; tissue: flower; organelle: mitochondria; ', 'ecotype/background: Col-0; genotype/variation: ppr mutant (nad7 mRNA translation); tissue: flower; organelle: mitochondria; ', 'ecotype/background: Col-0; genotype/variation: ppr mutant (nad4 mRNA stability); tissue: flower; organelle: mitochondria; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104028,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE104nnn/GSE104028/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA407986,29873797," Noelya Planchard,  Pierre Bertin,  Martine Quadrado,  Celine Dargel-Graffin,  Isabelle Hatin,  Olivier Namy,  Hakim Mireau","Messenger RNA translation is a complex process that is still poorly understood in eukaryotic organelles like mitochondria. Growing evidence indicates though that mitochondrial translation differs from its bacterial counterpart in many key aspects. In this analysis, we have used ribosome profiling technology to generate a genome-wide snapshot view of mitochondrial translation in Arabidopsis. We show that, unlike in humans, most Arabidopsis mitochondrial ribosome footprints measure 27 and 28 bases. We also reveal that respiratory subunits encoding mRNAs show much higher ribosome association than other mitochondrial mRNAs, implying that they are translated at higher levels. Homogenous ribosome densities were generally detected within each respiratory complex except for complex V, where higher ribosome coverage corroborated with higher requirements for specific subunits. In complex I respiratory mutants, a reorganization of mitochondrial mRNAs ribosome association was detected involving increased ribosome densities for certain ribosomal protein encoding transcripts and a reduction in translation of a few complex V mRNAs. Taken together, our observations reveal that plant mitochondrial translation is a dynamic process and that translational control is important for gene expression in plant mitochondria. This study paves the way for future advances in the understanding translation in higher plant mitochondria.",The translational landscape of Arabidopsis mitochondria.,10.1093/nar/gky489,2018 Jul 6,PMC6159524,Nucleic acids research
GSE86214,YTHDF3 facilitates translation and decay of the N6-methyladenosine-modified RNA,Homo sapiens,25,SRP083699,2016-08-30,"[Overal design]We utilized PAR-CLIP triplicates and RIP replicates to identify binding sites and target transcripts of YTHDF3, and performed ribosome profling replicates to assess the consequences of YTHDF3 siRNA knock-down in HeLa cells.; [Treatment]'None'; [Growth]'Human HeLa cell line used in this study was purchased from ATCC (CCL-2) and grown in DMEM (Gibco, 11995) media supplemented with 10% FBS and 1% 100  Pen/Strep (Gibco).'; [Extraction]'Fed with 200 uM 4SU, 365 nm UV crosslinked, partial digested with Rnase T1, anti-Flag beads IP, SDS-PAGE gel size selection\nNEBNext Multiplex Small RNA Library Prep Set for Illumina', 'Anti-Flag beads IP\nIllumina TruSeq Stranded mRNA Library Prep Kit', 'Extracted with Trizol, and poly-dT beads selection\nIllumina TruSeq Stranded mRNA Library Prep Kit', 'Extracted with Trizol, and rRNA removal with ribominus kit\nIllumina TruSeq Stranded mRNA Library Prep Kit', 'Isolated according to illumina Truseq Ribo Profile kit: Nuclease digestion, Microspin S-400 column separation, RNA extration, TBE gel size selection\nNEBNext Multiplex Small RNA Library Prep Set for Illumina', 'Isolated according to illumina Truseq Ribo Profile kit: total RNA (>200 nt) extraction, rRNA removal, and fragmentation\nNEBNext Multiplex Small RNA Library Prep Set for Illumina', 'Anti-Flag beads IP, and then rRNA removal with ribominus kit\nIllumina TruSeq Stranded mRNA Library Prep Kit'; [Cell type]'Source: ''cell line: HeLa cells; cell treatment: N terminal Flag-HA tagged YTHDF3 HeLa stable expression cell line; ', 'cell line: HeLa cells; cell treatment: overexpress N terminal Flag tagged YTHDF3 for 24 hr (0.75 ug plasmid/ml media); ', 'cell line: HeLa cells; cell treatment: 40 nM siRNA knockdown for 48 hr, then 100 ug/ml Cycloheximide (CHX) incubation; ', 'cell line: HeLa cells; cell treatment: 40 nM siRNA knockdown for 48 hr in Flag-HA-YTHDF1 stable expression HeLa cell line; ', 'cell line: HeLa cells; cell treatment: 40 nM siRNA knockdown for 48 hr in Flag-HA-YTHDF2 stable expression HeLa cell line; '",Genome binding/occupancy profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86214,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE86nnn/GSE86214/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA340948,28106072," Hailing Shi,  Xiao Wang,  Zhike Lu,  Boxuan S Zhao,  Honghui Ma,  Phillip J Hsu,  Chang Liu,  Chuan He","N(6)-methyladenosine (m(6)A) is the most abundant internal modification in eukaryotic messenger RNAs (mRNAs), and plays important roles in cell differentiation and tissue development. It regulates multiple steps throughout the RNA life cycle including RNA processing, translation, and decay, via the recognition by selective binding proteins. In the cytoplasm, m(6)A binding protein YTHDF1 facilitates translation of m(6)A-modified mRNAs, and YTHDF2 accelerates the decay of m(6)A-modified transcripts. The biological function of YTHDF3, another cytoplasmic m(6)A binder of the YTH (YT521-B homology) domain family, remains unknown. Here, we report that YTHDF3 promotes protein synthesis in synergy with YTHDF1, and affects methylated mRNA decay mediated through YTHDF2. Cells deficient in all three YTHDF proteins experience the most dramatic accumulation of m(6)A-modified transcripts. These results indicate that together with YTHDF1 and YTHDF2, YTHDF3 plays critical roles to accelerate metabolism of m(6)A-modified mRNAs in the cytoplasm. All three YTHDF proteins may act in an integrated and cooperative manner to impact fundamental biological processes related to m(6)A RNA methylation.",YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA.,10.1038/cr.2017.15,2017 Mar,PMC5339834,Cell research
GSE148245,HUMAN-VIRUS CHIMERIC PROTEINS GENERATED DURING INFECTION,Homo sapiens,4,SRP255621,2020-04-07,"[Overal design]Ribosome profiling of influenza A infected cells; [Treatment]'Cells were infected with A/Puerto Rico/8/1934 (H1N1) at an MOI of 3'; [Growth]'A549 human lung epithelial cells  were cultured in Dulbeccos Modified Eagles Medium supplemented with 10% foetal bovine serum, and maintained at 37C and 5% CO2'; [Extraction]'RNaseI footprinting, pelleting of ribosomes, RNA-extraction with TRIzol reagent, linker ligation onto footprints, reverse-transcription,cDNA circularization, rRNA depletion, PCR amplification'; [Cell type]'Source: ''innoculum: A/Puerto Rico/8/1934 (H1N1); treatment: harringtonine; ', 'innoculum: A/Puerto Rico/8/1934 (H1N1); treatment: dmso; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148245,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148245/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA623585,32559462," Jessica Sook Yuin Ho,  Matthew Angel,  Yixuan Ma,  Elizabeth Sloan,  Guojun Wang,  Carles Martinez-Romero,  Marta Alenquer,  Vladimir Roudko,  Liliane Chung,  Simin Zheng,  Max Chang,  Yesai Fstkchyan,  Sara Clohisey,  Adam M Dinan,  James Gibbs,  Robert Gifford,  Rong Shen,  Quan Gu,  Nerea Irigoyen,  Laura Campisi,  Cheng Huang,  Nan Zhao,  Joshua D Jones,  Ingeborg van Knippenberg,  Zeyu Zhu,  Natasha Moshkina,  Lea Meyer,  Justine Noel,  Zuleyma Peralta,  Veronica Rezelj,  Robyn Kaake,  Brad Rosenberg,  Bo Wang,  Jiajie Wei,  Slobodan Paessler,  Helen M Wise,  Jeffrey Johnson,  Alessandro Vannini,  Maria Joao Amorim,  J Kenneth Baillie,  Emily R Miraldi,  Christopher Benner,  Ian Brierley,  Paul Digard,  Marta Luksza,  Andrew E Firth,  Nevan Krogan,  Benjamin D Greenbaum,  Megan K MacLeod,  Harm van Bakel,  Adolfo Garcia-Sastre,  Jonathan W Yewdell,  Edward Hutchinson,  Ivan Marazzi","RNA viruses are a major human health threat. The life cycles of many highly pathogenic RNA viruses like influenza A virus (IAV) and Lassa virus depends on host mRNA, because viral polymerases cleave 5\'-m7G-capped host transcripts to prime viral mRNA synthesis (""cap-snatching""). We hypothesized that start codons within cap-snatched host transcripts could generate chimeric human-viral mRNAs with coding potential. We report the existence of this mechanism of gene origination, which we named ""start-snatching."" Depending on the reading frame, start-snatching allows the translation of host and viral ""untranslated regions"" (UTRs) to create N-terminally extended viral proteins or entirely novel polypeptides by genetic overprinting. We show that both types of chimeric proteins are made in IAV-infected cells, generate T cell responses, and contribute to virulence. Our results indicate that during infection with IAV, and likely a multitude of other human, animal and plant viruses, a host-dependent mechanism allows the genesis of hybrid genes.",Hybrid Gene Origination Creates Human-Virus Chimeric Proteins during Infection.,10.1016/j.cell.2020.05.035,2020 Jun 25,PMC7323901,Cell
GSE46273,Polysome profiling of Huh7.5 cells expressing HCV NS5A,Homo sapiens,8,None,2013-04-22,"[Overal design]Agilent-027114 Genotypic Technology designed Custom Human Whole Genome 8x60k Microarray; [Treatment]'80% confluent pcDNA3.1 c_myc/His carrying and HCV NS5A (Full Length) expressing cells were trypsinised with 0.05% Trypsin EDTA. Cell were then washed with 1X PBS containing Cycloheximide (100g/ml). For total RNA preparartion, Qiagen Rneasy Kit was used and total RNA was extracted and quantified. For Polysomal RNA preparation, Cells were lysed with Lysis buffer containing 20mM Tris pH-8.0, 140mM KCl, 1.5mM MgCl2, 1% Triton-X-100, 0.5mM DTT, 100 g/ml Cycloheximide, 1X Protease Inhibitor cocktail, 1mg/ml Heparin and 100U of Ribolock and 175 ug of corresponding RNA from crude lysate was loaded onto Sucrose gradient (10%-50%). Samples were then centrifuged at 35000 rpm for 4 hrs at 4C using Beckmann SW41 rotor. Resolved sucrose gradient samples were fractionated using Density gradient fractionator. Polysomal fractions were pooled based on their profilies and RNA was prepared by initial ethanol precipitation followed by Lithium chloride extraction. Enriched polysomal RNA was used for microarray analysis.'; [Growth]'HCV NS5A (Full Length) expressing and control Huh7.5 cells were cultured in complete DMEM supplemented with 10% FBS, 1X Non essential Amino acids, 1X Penicillin Streptomycin solution at 37C with 5% CO2'; [Extraction]'For total RNA preparartion, Qiagen Rneasy Kit was used and total RNA was extracted and quantified. For Polysomal RNA preparation, cells were lysed and normalized volumes containing 175 ug of corresponding RNA were separated on Sucrose gradient (10%-50%), samples were then  fractionated into mRNP, monosomal and polysomal fractions. Polysomal fractions   were pooled based on their profilies and RNA was prepared by initial ethanol precipitation followed by lithium chloride extraction and subsequent purification by RNeasy columns. Enriched polysomal RNA was used for microarray analysis.'; [Cell type]'Source: ''cell line: pcDNA3.1 c_myc His carrying Huh7.5; rna fraction: total RNA; ', 'cell line: HCV NS5A (Full length) expressing huh7.5; rna fraction: total RNA; ', 'cell line: pcDNA3.1 c_myc His carrying Huh7.5; rna fraction: polysome fraction; ', 'cell line: HCV NS5A (Full length) expressing huh7.5; rna fraction: polysome fraction; '",Expression profiling by array; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46273,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE46nnn/GSE46273/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA198502,,,,,,,,
GSE64962,Improved transcription and translation with L-leucine stimulation of mTORC1,Homo sapiens,42,SRP052229,2015-01-14,"[Overal design]42 samples of human fibroblast cell lines with various genotypes (wt, corrected, and esco2 mutants) are treated with l-leucine or d-leucine (control) for 3 or 24 hours. Biological replicates are present.; [Treatment]'The cells were supplemented with 10 mM D-Leucine or L-Leucine and incubated for either 3 hrs or 24 hrs.'; [Growth]'human wild-type fibroblasts, ESCO2-mutant RBS fibroblasts, and ESCO2-corrected RBS fibroblasts were grown on 15-cm plates in DMEM medium supplemented with 10% Fetal Bovine Serum (FBS). At 80% confluence, the cells were washed two times with PBS, and grown for another 24 hrs in DMEM/10% FBS.'; [Extraction]'Prior to lysis, the cells were incubated for 1 minute in DMEM containing 0.1 mg/mL cycloheximide (USBiological, cat. no. C8500-10). After a rinse with ice cold PBS containing 0.1 mg/mL cycloheximide, the cells from up to three plates were collected by scraping into 800 l chilled Mammalian Lysis Buffer (ART-Seq 1X Mammalian Polysome Buffer, 1% Triton X-100, 0.1% NP-40, 1 mM DTT, 10 U/ml DNase I, 0.1 mg/ml cycloheximide). The cell lysate was triturated 10 times through a 26G needle to insure complete lysis, incubated for 10 minutes on ice with periodic agitation, and clarified by a 10 minute centrifugation at 20,000 x g at 4C.  The RNA concentration of the supernatant was determined using the Quant-iT RiboGreen RNA Assay Kit (Invitrogen) and a SpectraMax M2 reader (Molecular Devices) according to manufacturers instructions.  Aliquots were flash-frozen in liquid nitrogen and stored at -80C.  Ribosome-protected mRNA fragments (RPFs) and fragmented total RNA depleted for ribosomal RNA were sequenced for each sample.  Footprinting was performed at room temperature for 45 min using ART-Seq Nuclease (Epicentre), then stopped with SUPERaseIn RNase Inhibitor (Life Technologies).  For the 24 hr timepoint samples, 2.8 units of nuclease was added per g of RNA.  For the 3 hr timepoint samples, the amount of nuclease was reduced to 0.5 units/g.  RPFs were isolated from the nuclease/SUPERaseIn treated lysate using Sephacryl S400 columns (GE Healthcare: MicroSpin S-400 HR, cat. no. 27-5140-01), followed by acid phenol:chloroform extraction and isopropanol precipitation. Total RNA was isolated from untreated lysate by acid phenol:chloroform extraction and isopropanol precipitation.\nRibosomal RNA was removed from 1-5 g of RPFs and total RNA using either the Ribo-Zero Magnetic or the Ribo-Zero Magnetic Gold Kit (Human/Mouse/Rat) (Epicentre). To purify the Ribo-Zero treated samples, the RNA Clean & Concentrator-5 Kit (Zymo Research) was used as described in the ART-Seq protocol.  26-34 nt RPFs were further size selected by PAGE purification and the total RNA heat fragmented.  Libraries were constructed as described in the Mammalian ARTseq Ribosome Profiling Kit (Epicentre, cat. no. RPHMR12126, protocol version 2012).'; [Cell type]'Source: ''experiment type: RNA-seq; genotype: wt; timepoint after treatment: 24 hours; treatment: d-leucine; ', 'experiment type: RNA-seq; genotype: wt; timepoint after treatment: 24 hours; treatment: l-leucine; ', 'experiment type: RNA-seq; genotype: corrected; timepoint after treatment: 24 hours; treatment: d-leucine; ', 'experiment type: RNA-seq; genotype: corrected; timepoint after treatment: 24 hours; treatment: l-leucine; ', 'experiment type: RNA-seq; genotype: esco2 mutant; timepoint after treatment: 24 hours; treatment: d-leucine; ', 'experiment type: RNA-seq; genotype: esco2 mutant; timepoint after treatment: 24 hours; treatment: l-leucine; ', 'experiment type: Ribosomal profiling; genotype: wt; timepoint after treatment: 24 hours; treatment: d-leucine; ', 'experiment type: Ribosomal profiling; genotype: wt; timepoint after treatment: 24 hours; treatment: l-leucine; ', 'experiment type: Ribosomal profiling; genotype: corrected; timepoint after treatment: 24 hours; treatment: d-leucine; ', 'experiment type: Ribosomal profiling; genotype: corrected; timepoint after treatment: 24 hours; treatment: l-leucine; ', 'experiment type: Ribosomal profiling; genotype: esco2 mutant; timepoint after treatment: 24 hours; treatment: d-leucine; ', 'experiment type: Ribosomal profiling; genotype: esco2 mutant; timepoint after treatment: 24 hours; treatment: l-leucine; ', 'experiment type: RNA-seq; genotype: corrected; timepoint after treatment: 3 hours; treatment: d-leucine; ', 'experiment type: RNA-seq; genotype: corrected; timepoint after treatment: 3 hours; treatment: l-leucine; ', 'experiment type: RNA-seq; genotype: esco2 mutant; timepoint after treatment: 3 hours; treatment: d-leucine; ', 'experiment type: RNA-seq; genotype: esco2 mutant; timepoint after treatment: 3 hours; treatment: l-leucine; ', 'experiment type: Ribosomal profiling; genotype: corrected; timepoint after treatment: 3 hours; treatment: d-leucine; ', 'experiment type: Ribosomal profiling; genotype: corrected; timepoint after treatment: 3 hours; treatment: l-leucine; ', 'experiment type: Ribosomal profiling; genotype: esco2 mutant; timepoint after treatment: 3 hours; treatment: d-leucine; ', 'experiment type: Ribosomal profiling; genotype: esco2 mutant; timepoint after treatment: 3 hours; treatment: l-leucine; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64962,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE64nnn/GSE64962/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA272597,26729373," Baoshan Xu,  Madelaine Gogol,  Karin Gaudenz,  Jennifer L Gerton","BACKGROUND: Roberts syndrome (RBS) is a human developmental disorder caused by mutations in the cohesin acetyltransferase ESCO2. We previously reported that mTORC1 signaling was depressed and overall translation was reduced in RBS cells and zebrafish models for RBS. Treatment of RBS cells and zebrafish RBS models with L-leucine partially rescued mTOR function and protein synthesis, correlating with increased cell division and improved development. RESULTS: In this study, we use RBS cells to model mTORC1 repression and analyze transcription and translation with ribosome profiling to determine gene-level effects of L-leucine. L-leucine treatment partially rescued translational efficiency of ribosomal subunits, translation initiation factors, snoRNA production, and mitochondrial function in RBS cells, consistent with these processes being mTORC1 controlled. In contrast, other genes are differentially expressed independent of L-leucine treatment, including imprinted genes such as H19 and GTL2, miRNAs regulated by GTL2, HOX genes, and genes in nucleolar associated domains. CONCLUSIONS: Our study distinguishes between gene expression changes in RBS cells that are TOR dependent and those that are independent. Some of the TOR independent gene expression changes likely reflect the architectural role of cohesin in chromatin looping and gene expression. This study reveals the dramatic rescue effects of L-leucine stimulation of mTORC1 in RBS cells and supports that normal gene expression and translation requires ESCO2 function.",Improved transcription and translation with L-leucine stimulation of mTORC1 in Roberts syndrome.,10.1186/s12864-015-2354-y,2016 Jan 5,PMC4700579,BMC genomics
GSE118049,Protein Syndesmos is a novel RNA binding protein that regulates primary cilia formation [iCLIP-seq],Homo sapiens,6,SRP156196,2018-08-02,"[Overal design]iCLIP combined with high-throughput sequencing was used to generate a transcriptome-wide binding map of SDOS.; [Treatment]'Cells were treated with doxycycline (1 ug/mL) for 16 hrs to induce the expression of GFP-fusion proteins. HeLa SDOS-eGFP cells were treated with 100 ?M 4-thiouridine for 16 hrs before the lysis.'; [Growth]'HeLa cells were grown on 15-cm dishes until were approximately 85% confluent'; [Extraction]'SDOS-eGFP cells were photoactivable ribonucleoside-cross-linked on ice at and 0.30 J cm?2 with UV light at 365 nM. eGFP cells were cross-linked on ice at 0.15 J cm?2 with UV light at 254 nM. Immediately after irradiation, cells were lysed in 1 mL of lysis buffer (NaCl 100mM, MgCl2 5mM, Tris pH 7.5 10mM, NP40 0.5%, SDS 0.1%, Na deoxycholate 0.5%, DTT 1mM (fresh), 1x AEBSF (fresh). The cell lysate was passed 3 times through 27 1/2G needle and sonicated using a bioruptor (Digenode) for 3 cycles of 10 seconds (pause 15 seconds), level M at 4C, then it was cleared by centrifugation at 17900g for 10 min at 4C.\nRNA was then partially digested by adding 10 ?l of 1:100 dilution of RNase I (Ambion, AM2295), as well as 2 ?l of Turbo DNase (Ambion, AM 2238). After 3 min of incubation at 37C under shaking at 1100 rpm 11 ?l of Ribolock (Invitrogen) were added to each lysate. The lysates were precleared by incubation with 50 L of equilibrated control agarose beads (Thermo Scientific) for 30 min at 4C under gentle rotation. eGFP-fusion proteins were then captured from precleared lysates by incubation with 40 L of GFP-Trap agarose beads (GFP-Trap_A, Chromotek) per mL of lysate for 2 h, 4C, gentle rotation. Beads were collected by centrifugation and washed twice with High salt buffer (NaCl 500mM, Tris HCL pH7.5 20mM, MgCl2 1mM, NP40 0.05%, SDS 0.10%, 1x AEBSF (fresh)); twice with Medium salt buffer (NaCl 250mM, Tris HCl pH7.5 20mM, MgCl2 1mM, NP40 0.05%, 1x AEBSF (fresh)) and twice with Low salt buffer (NaCl 150mM, Tris HCl pH7.5 20mM, MgCl2 1mM, NP40 0.01%, 1x AEBSF (fresh)). The RNA was then dephosphorylated, and 3-linker ligated as described in [16]. The protein/RNA complexes were isolated as described in [17]. Samples were processed for subsequent steps as described in Huppertz et al 2014. cDNA libraries obtained after PCR amplification with universal Solexa primers (25 cycles) were multiplexed and sequenced using an Illumina Next-generation sequencing platform.'; [Cell type]'T-REx-HeLa Cell Line''cell type: T-REx-HeLa Cell Line; genotype: eGFP under Tet repressor; ', 'cell type: T-REx-HeLa Cell Line; genotype: SDOS-eGFP under Tet repressor; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118049,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE118nnn/GSE118049/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA484188,30260431," Rosario Avolio,  Aino I Jarvelin,  Shabaz Mohammed,  Ilenia Agliarulo,  Valentina Condelli,  Pietro Zoppoli,  Giovanni Calice,  Daniela Sarnataro,  Elias Bechara,  Gian G Tartaglia,  Matteo Landriscina,  Alfredo Castello,  Franca Esposito,  Danilo S Matassa","Syndesmos (SDOS) is a functionally poorly characterized protein that directly interacts with p53 binding protein 1 (53BP1) and regulates its recruitment to chromatin. We show here that SDOS interacts with another important cancer-linked protein, the chaperone TRAP1, associates with actively translating polyribosomes and represses translation. Moreover, we demonstrate that SDOS directly binds RNA in living cells. Combining individual gene expression profiling, nucleotide crosslinking and immunoprecipitation (iCLIP), and ribosome profiling, we discover several crucial pathways regulated post-transcriptionally by SDOS. Among them, we identify a small subset of mRNAs responsible for the biogenesis of primary cilium that have been linked to developmental and degenerative diseases, known as ciliopathies, and cancer. We discover that SDOS binds and regulates the translation of several of these mRNAs, controlling cilia development.",Protein Syndesmos is a novel RNA-binding protein that regulates primary cilia formation.,10.1093/nar/gky873,2018 Dec 14,PMC6294507,Nucleic acids research
GSE71900,AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [RNA-Seq],Homo sapiens,8,SRP062230,2015-08-10,"[Overal design]Profiles of MCF7 and HCT116 Akti-1/2 treated cells and MCF7 and HCT116 vehicle (i.e. DMSO) treated cells were generated, each in duplicate, using RNA-Seq.; [Treatment]'Cells were treated for 72h with vehicle (DMSO), Akti-1/2 inhibitor (HCT116: 20M; MCF7: 2M) (Sigma)'; [Growth]'MCF7 was maintained in DMEM, 10% FCS, 40mM glutamine, 100 U/mL penicillin, and 100g/mL streptomycin; HCT116 was maintained in McCoys 5? medium supplemented with 10% FCS, 100U/mL penicillin, and 100g/mL streptomycin. All cells were grown at 37C and 5% CO2.'; [Extraction]'Total RNA was purified using RNAeasy miniprep kit (Qiagen) and the RNA integrity was checked using RNA 6000 Nano assay on Agilent 2100 Bioanalyzer. 4g of total RNA were used for library construction.\nPurification, fragmentation and first strand synthesis were performed as described in the Illumina Tru-Seq RNA Sample kit v2. The second strand cDNA synthesis was modified using the dUTP second strand method. End repair, 3 adenylation and adapter ligation steps were done using Tru-Seq protocol.'; [Cell type]'breast adenocarcinoma', 'colon carcinoma''cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 Low; ', 'cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 WT; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 Low; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 WT; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71900,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71900/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292420,26637368," Salony,  Xavier Sole,  Cleidson P Alves,  Ipsita Dey-Guha,  Laila Ritsma,  Myriam Boukhali,  Ju H Lee,  Joeeta Chowdhury,  Kenneth N Ross,  Wilhelm Haas,  Shobha Vasudevan,  Sridhar Ramaswamy","Small molecule inhibitors of AKT (v-akt murine thymoma viral oncogene homolog) signaling are being evaluated in patients with various cancer types, but have so far proven therapeutically disappointing for reasons that remain unclear. Here, we treat cancer cells with subtherapeutic doses of Akti-1/2, an allosteric small molecule AKT inhibitor, in order to experimentally model pharmacologic inhibition of AKT signaling in vitro. We then apply a combined RNA, protein, and metabolite profiling approach to develop an integrated, multiscale, molecular snapshot of this ""AKT(low)"" cancer cell state. We find that AKT-inhibited cancer cells suppress thousands of mRNA transcripts, and proteins related to the cell cycle, ribosome, and protein translation. Surprisingly, however, these AKT-inhibited cells simultaneously upregulate a host of other proteins and metabolites posttranscriptionally, reflecting activation of their endo-vesiculo-membrane system, secretion of inflammatory proteins, and elaboration of extracellular microvesicles. Importantly, these microvesicles enable rapidly proliferating cancer cells of various types to better withstand different stress conditions, including serum deprivation, hypoxia, or cytotoxic chemotherapy in vitro and xenografting in vivo. These findings suggest a model whereby cancer cells experiencing a partial inhibition of AKT signaling may actually promote the survival of neighbors through non-cell autonomous communication.",AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.,10.1158/1535-7163.MCT-15-0414,2016 Jan,PMC4707053,Molecular cancer therapeutics
GSE105147,Translation control of the immune checkpoint in cancer and its therapeutic targeting,Mus musculus,14,SRP120478,2017-10-19,"[Overal design]To identify the transcripts specifically translated in primary liver tumors in MYC; KRAS(G12D) and KRAS(G12D) mice, we first carefully micro-dissected primary liver tumor nodules in MYC; KRAS(G12D) and KRAS(G12D) mice as well as wildtype (WT) controls. We sequenced total mRNAs (2 replicates each) and ribosome-protected mRNA fragments (RPFs) using ribosome profiling (2 replicates each) to generate genome-wide transcriptional and translational landscapes, respectively.; [Treatment]'None'; [Growth]'None'; [Extraction]'Mouse liver tumours were micro-dissected immediately after animal euthanization. Liver perfusion (with ice cold PBS containing 10 mg/ml cycloheximide (CHX)) and placed in ice cold PBS containing 10 mg/ml CHX for 5 min. Tumours were minced into small pieces with a scalpel and incubated for 20 min in 0.5% collagenase supplemented with 10 mg/ml CHX. After spun down, tumour was resuspended in 4 ml trypsin containing 5 mg/ml CHX for 10 to 15 min at 37 C, followed by filtering through a 40 \uf06dm cell strainer and resuspension in the lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 15 mM MgCl2, 100 ?g/ml cycloheximide, 1 mM DTT, 0.5% Triton X-100, 0.1 mg/ml heparin, 8% glycerol, 20 U/ml TURBO DNase, 1x Combined Protease and Phosphatase Inhibitor)\nAll Ribo-Seq libraries were prepared as described in Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M. & Weissman, J. S. After removing the nuclei and mitochondria, lysate was treated with RNase A/T1 mix (0.5 mg RNase A (Ambion, AM2272) and 1,000 U RNase T1 (Life Technologies, 2280)) to digest mRNAs that are not protected by the ribosome. The digestion was stopped by adding SUPERase-In RNase Inhibitor (20 U/?l, Ambion, AM2696), followed by centrifuging to pellet ribosomes. Ribosome-protected fragments were purified by TRIzol, and two biological replicates were performed for each type of Ribo-Seq and all Ribo-Seq libraries (three biological replicates for WT liver).'; [Cell type]'Source: ''genotype: Wild type; strain: C57BL/6; sample type: polyA RNA; ', 'genotype: Wild type; strain: C57BL/6; sample type: ribosome protected RNA; ', 'genotype: Alb Cre specific expression of LSL-KRAS(G12D); strain: C57BL/6; sample type: polyA RNA; ', 'genotype: Alb Cre specific expression of LSL-KRAS(G12D); strain: C57BL/6; sample type: ribosome protected RNA; ', 'genotype: Alb Cre specific expression of HA-epitope tagged c-MYC (human) and LSL-KRAS(G12D); strain: C57BL/6; sample type: polyA RNA; ', 'genotype: Alb Cre specific expression of HA-epitope tagged c-MYC (human) and LSL-KRAS(G12D); strain: C57BL/6; sample type: ribosome protected RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE105147,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE105nnn/GSE105147/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA414959,30643286," Yichen Xu,  Mauro Poggio,  Hyun Yong Jin,  Zhen Shi,  Craig M Forester,  Ying Wang,  Craig R Stumpf,  Lingru Xue,  Emily Devericks,  Lomon So,  Hao G Nguyen,  Alice Griselin,  John D Gordan,  Sarah E Umetsu,  Siegfried H Reich,  Stephen T Worland,  Saurabh Asthana,  Maria Barna,  Kevin R Webster,  John T Cunningham,  Davide Ruggero","Cancer cells develop mechanisms to escape immunosurveillance, among which modulating the expression of immune suppressive messenger RNAs is most well-documented. However, how this is molecularly achieved remains largely unresolved. Here, we develop an in vivo mouse model of liver cancer to study oncogene cooperation in immunosurveillance. We show that MYC overexpression (MYC(Tg)) synergizes with KRAS(G12D) to induce an aggressive liver tumor leading to metastasis formation and reduced mouse survival compared with KRAS(G12D) alone. Genome-wide ribosomal footprinting of MYC(Tg);KRAS(G12) tumors compared with KRAS(G12D) revealed potential alterations in translation of mRNAs, including programmed-death-ligand 1 (PD-L1). Further analysis revealed that PD-L1 translation is repressed in KRAS(G12D) tumors by functional, non-canonical upstream open reading frames in its 5' untranslated region, which is bypassed in MYC(Tg);KRAS(G12D) tumors to evade immune attack. We show that this mechanism of PD-L1 translational upregulation was effectively targeted by a potent, clinical compound that inhibits eIF4E phosphorylation, eFT508, which reverses the aggressive and metastatic characteristics of MYC(Tg);KRAS(G12D) tumors. Together, these studies reveal how immune-checkpoint proteins are manipulated by distinct oncogenes at the level of mRNA translation, which can be exploited for new immunotherapies.",Translation control of the immune checkpoint in cancer and its therapeutic targeting.,10.1038/s41591-018-0321-2,2019 Feb,PMC6613562,Nature medicine
GSE20277,Translatome and transcriptome profiling of EGF response in HeLa cells,Homo sapiens,18,None,2010-02-11,"[Overal design]The comparison between transcriptional and polysomal profiling was used for the discovery of general and mRNA-specific changes in the translation state of the serum starved HeLa cells transcriptome in response to EGF stimulus. To identify translationally regulated mRNA molecules, gene expression signals derived from the polysomal and subpolysomal RNA populations were compared by microarrays analysis to those obtained from unfractionated total RNAs. Polysomal RNA, subpolysomal RNA and total RNA were isolated from HeLa cells serum starved and treated with EGF. Cells lysates were collected before (t = 0 min) and after (t = 40 min) EGF treatment. All experiments were run in triplicates.; [Treatment]'HeLa cells were seeded on adherent plates and serum starved for 12h with DMEM, 0.5% FBS, 2mM glutamine. Cells were treated for 40 minutes with recombinant human epidermal growth factor (hEGF) at final concentration of 1 ?g/ml.', 'HeLa cells were seeded on adherent plates and serum starved for 12h with DMEM, 0.5% FBS, 2mM glutamine.'; [Growth]'HeLa cells were  cultured in Dulbecco Modified Eagle Medium (DMEM)  supplemented with 10% fetal bovine serum (FBS), 2mM glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin at 37 C in a humidified atmosphere of 5% CO2.'; [Extraction]""Total RNA was extracted using TRIZOL reagent according to the manufacturer's protocol. Briefly, the aqueous phase was used for RNA precipitation with an equal volume of isopropanol. The RNA pellet was washed once with 75% ethanol, then air-dried and re-dissolved in 20 ?l of RNase-free water. RNA was quantified using a spectrophotometer and its quality was checked by agarose gel electrophoresis and by Agilent 2100 Bioanalyzer platform, following the manifacturers guidelines for sample preparation and analysis of data (Agilent 2100 Bioanalyzer 2100 Expert User's Guide, http://www.agilent.com)."", 'Cells were washed once with phosphate buffer saline (PBS) and treated directly on the plate with 300 l lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/l RNase inhibitor (Fermentas) and 1 mM dithiothreitol] and transferred to an Eppendorf tube. After a few minute incubation on ice with occasional vortexing, the extracts were centrifuged for 10 min at 12000 g at 4C. The supernatant was stored at 80C or loaded directly onto a 1550% linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in an Sorvall rotor for 120 min at 40000 rpm. Polysomal fractions were collected monitoring the absorbance at 254 nm and treated directly with proteinase K. After phenolchloroform extraction and isopropanol precipitation, polysomal RNA was resuspended in 30 l of water and then repurified with RNeasy kit (Qiagen, Hilden, Germany). RNA quality was assessed by agarose gel electrophoresis and the Agilent 2100 Bioanalyzer platform.', 'Cells were washed once with phosphate buffer saline (PBS) and treated directly on the plate with 300 l lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/l RNase inhibitor (Fermentas) and 1 mM dithiothreitol] and transferred to an Eppendorf tube. After a few minute incubation on ice with occasional vortexing, the extracts were centrifuged for 10 min at 12000 g at 4C. The supernatant was stored at 80C or loaded directly onto a 1550% linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in an Sorvall rotor for 120 min at 40000 rpm. Subpolysomal fractions were collected monitoring the absorbance at 254 nm and treated directly with proteinase K. After phenolchloroform extraction and isopropanol precipitation, subpolysomal RNA was resuspended in 30 l of water and then repurified with RNeasy kit (Qiagen, Hilden, Germany). RNA quality was assessed by agarose gel electrophoresis and the Agilent 2100 Bioanalyzer platform.'; [Cell type]'Source: ''cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: total RNA; biological replicate: #1; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: total RNA; biological replicate: #2; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: total RNA; biological replicate: #3; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: polysomal RNA; biological replicate: #1; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: polysomal RNA; biological replicate: #2; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: polysomal RNA; biological replicate: #3; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: subpolysomal RNA; biological replicate: #1; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: subpolysomal RNA; biological replicate: #2; ', 'cell line: Hela cells, CCL-2; agent: EGF; time point: 40 min; population: subpolysomal RNA; biological replicate: #3; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: subpolysomal RNA; biological replicate: #1; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: subpolysomal RNA; biological replicate: #2; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: subpolysomal RNA; biological replicate: #3; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #1; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #2; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #3; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: total RNA; biological replicate: #1; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: total RNA; biological replicate: #2; ', 'cell line: Hela cells, CCL-2; agent: none; time point: 0 min; population: total RNA; biological replicate: #3; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20277,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE20nnn/GSE20277/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA125367,22672192," Toma Tebaldi,  Angela Re,  Gabriella Viero,  Ilaria Pegoretti,  Andrea Passerini,  Enrico Blanzieri,  Alessandro Quattrone","BACKGROUND: The classical view on eukaryotic gene expression proposes the scheme of a forward flow for which fluctuations in mRNA levels upon a stimulus contribute to determine variations in mRNA availability for translation. Here we address this issue by simultaneously profiling with microarrays the total mRNAs (the transcriptome) and the polysome-associated mRNAs (the translatome) after EGF treatment of human cells, and extending the analysis to other 19 different transcriptome/translatome comparisons in mammalian cells following different stimuli or undergoing cell programs. RESULTS: Triggering of the EGF pathway results in an early induction of transcriptome and translatome changes, but 90% of the significant variation is limited to the translatome and the degree of concordant changes is less than 5%. The survey of other 19 different transcriptome/translatome comparisons shows that extensive uncoupling is a general rule, in terms of both RNA movements and inferred cell activities, with a strong tendency of translation-related genes to be controlled purely at the translational level. By different statistical approaches, we finally provide evidence of the lack of dependence between changes at the transcriptome and translatome levels. CONCLUSIONS: We propose a model of diffused independency between variation in transcript abundances and variation in their engagement on polysomes, which implies the existence of specific mechanisms to couple these two ways of regulating gene expression.",Widespread uncoupling between transcriptome and translatome variations after a stimulus in mammalian cells.,10.1186/1471-2164-13-220,2012 Jun 6,PMC3441405,BMC genomics
GSE59095,DDX3X regulation of global translation is impaired by medulloblastoma-associated mutations [RiboSeq],Homo sapiens,3,SRP044064,2014-07-03,"[Overal design]Examination of translation at whole genome scale under conditions of overexpression of WT DDX3X or cancer-associated DDX3X mutant G325E; [Treatment]'HEK293T cells were transfected with either empty vector or FLAG-tagged DDX3X constructs for 24 h. After transfection, cells were pre-treated with harringtonine (2 ?g/ml for 90 seconds, LKT Laboratories, cat. no. H0169) followed by addition of cycloheximide (100 ?g/ml, Sigma/Aldrich).'; [Growth]'HEK293T cellswere grown in Dulbeccos Modified Eagles Serum,  DMEM,  supplemented with 10% fetal bovine serum, FBS and 1% Pen-Strep (100 U/ml penicillin, 100 g/ml streptomycin. Cells were incubated at 37 C and with a 5% CO2 concentration.'; [Extraction]'RNA was extracted from sedimented polysomal fraction using miRNeasy kit (Qiagen)\nRNA library was performed as done by: Ingolia, N.T., Brar, G.A., Rouskin, S., McGeachy, A.M., and Weissman, J.S. (2012).  Nat Protoc 7, 1534-1550. Sequencing was performed on an Illumina HiSeq 2000 using TruSeq SBS v3 reagents according to the manufacturers instructions.'; [Cell type]'Neuronal''cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with empty pCDNA3.1 vector; over-expression product: none (control); ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with WT DDX3X expressing vector; over-expression product: FLAG-tagged WT DDX3X; ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with DDX3X-G325E expressing vector; over-expression product: FLAG-tagged DDX3X G325E; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59095,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59095/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA254361,27180681," Yasmine A Valentin-Vega,  Yong-Dong Wang,  Matthew Parker,  Deanna M Patmore,  Anderson Kanagaraj,  Jennifer Moore,  Michael Rusch,  David Finkelstein,  David W Ellison,  Richard J Gilbertson,  Jinghui Zhang,  Hong Joo Kim,  J Paul Taylor","DDX3X is a DEAD-box RNA helicase that has been implicated in multiple aspects of RNA metabolism including translation initiation and the assembly of stress granules (SGs). Recent genomic studies have reported recurrent DDX3X mutations in numerous tumors including medulloblastoma (MB), but the physiological impact of these mutations is poorly understood. Here we show that a consistent feature of MB-associated mutations is SG hyper-assembly and concomitant translation impairment. We used CLIP-seq to obtain a comprehensive assessment of DDX3X binding targets and ribosome profiling for high-resolution assessment of global translation. Surprisingly, mutant DDX3X expression caused broad inhibition of translation that impacted DDX3X targeted and non-targeted mRNAs alike. Assessment of translation efficiency with single-cell resolution revealed that SG hyper-assembly correlated precisely with impaired global translation. SG hyper-assembly and translation impairment driven by mutant DDX3X were rescued by a genetic approach that limited SG assembly and by deletion of the N-terminal low complexity domain within DDX3X. Thus, in addition to a primary defect at the level of translation initiation caused by DDX3X mutation, SG assembly itself contributes to global translation inhibition. This work provides mechanistic insights into the consequences of cancer-related DDX3X mutations, suggesting that globally reduced translation may provide a context-dependent survival advantage that must be considered as a possible contributor to tumorigenesis.",Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation.,10.1038/srep25996,2016 May 16,PMC4867597,Scientific reports
GSE82232,A systematic view on Influenza induced host shut-off,Homo sapiens,17,SRP076102,2016-06-03,"[Overal design]Ribosome profiling and mRNA-seq along IAV infection; [Treatment]'None'; [Growth]'None'; [Extraction]'Cells were lysed with 0.5% Triton, and the lysate was cleared by centrifugation, treated with RNase I for 45min and then loaded on a sucrose cushion. RNA was then isolated from cells using the acid:phenol extraction method.\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circularized and PCR amplified.'; [Cell type]'human lung adenocarcinoma epithelial cells''cell line: A549; cell type: human lung adenocarcinoma epithelial cells; pathogen: none; ', 'cell line: A549; cell type: human lung adenocarcinoma epithelial cells; pathogen: Influenza A; virus strain: A/Puerto Rico/8/1934 H1N1 (PR8); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82232,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE82nnn/GSE82232/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA324409,27525483," Adi Bercovich-Kinori,  Julie Tai,  Idit Anna Gelbart,  Alina Shitrit,  Shani Ben-Moshe,  Yaron Drori,  Shalev Itzkovitz,  Michal Mandelboim,  Noam Stern-Ginossar","Host shutoff is a common strategy used by viruses to repress cellular mRNA translation and concomitantly allow the efficient translation of viral mRNAs. Here we use RNA-sequencing and ribosome profiling to explore the mechanisms that are being utilized by the Influenza A virus (IAV) to induce host shutoff. We show that viral transcripts are not preferentially translated and instead the decline in cellular protein synthesis is mediated by viral takeover on the mRNA pool. Our measurements also uncover strong variability in the levels of cellular transcripts reduction, revealing that short transcripts are less affected by IAV. Interestingly, these mRNAs that are refractory to IAV infection are enriched in cell maintenance processes such as oxidative phosphorylation. Furthermore, we show that the continuous oxidative phosphorylation activity is important for viral propagation. Our results advance our understanding of IAV-induced shutoff, and suggest a mechanism that facilitates the translation of genes with important housekeeping functions.",A systematic view on influenza induced host shutoff.,10.7554/eLife.18311,2016 Aug 15,PMC5028189,eLife
GSE103308,Simultaneous and systematic analysis of cellular and viral gene expression during Enterovirus 71-induced host shutoff,Homo sapiens,20,SRP131318,2017-08-30,"[Overal design]Ribosome profiling and RNA-Seq of RD cell infected with EV71 or mock, 3 time points, two triplicate in the last two time points, using Illumina Hiseq 2000.; [Treatment]'100 ?g/mL cycloheximaide for 9 minutes'; [Growth]'High glucose DMEM with 10% FBS and 4mM L-Gln'; [Extraction]'Cell were harvest and RNA was extracted as TruSeq Ribo Profile (Mammalian) Kit (Illumina) manual.\nRNA libraries were prepared for sequencing using TruSeq Ribo Profile (Mammalian) Kit (Illumina)'; [Cell type]'RD''cell type: RD; infection: mock; virus strain: not applicable; time: 1.75 h; ', 'cell type: RD; infection: Enterovirus 71; virus strain: SK-EV006/Malaysia/97; time: 1.75 h; ', 'cell type: RD; infection: mock; virus strain: not applicable; time: 3.5 h; ', 'cell type: RD; infection: Enterovirus 71; virus strain: SK-EV006/Malaysia/97; time: 3.5 h; ', 'cell type: RD; infection: mock; virus strain: not applicable; time: 6.25 h; ', 'cell type: RD; infection: Enterovirus 71; virus strain: SK-EV006/Malaysia/97; time: 6.25 h; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103308,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE103nnn/GSE103308/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA401882,29696588," Yongquan Lin,  Yan Wang,  Hui Li,  Yuhang Chen,  Wentao Qiao,  Zhi Xie,  Juan Tan,  Zhilong Yang",,Simultaneous and systematic analysis of cellular and viral gene expression during Enterovirus 71-induced host shutoff.,10.1007/s13238-018-0535-6,2019 Jan,PMC6321815,Protein & cell
GSE135363,Comprehensive Annotations of Human Herpesvirus 6A and 6B Genomes Reveals Novel and Conserved Genomic Features,Homo sapiens,14,SRP217339,2019-08-04,"[Overal design]Ribosme profiling and RNA-seq along HHV-6A and HHV-6B infection; [Treatment]'None'; [Growth]'None'; [Extraction]'cells were treated with 100g/mL cycloheximide for 1 minute.  Subsequenct isolation of ribosome protected fragments was performed as previously described (Ignolia et al. 2011)\nRibo-seq library generation was performed as previously described (Ingolia et al., 2011)', 'cells were treated with 50M LTM for 30 minutes and subsequently treated with 100g/mL cycloheximide for 1 minute.  Subsequenct isolation of ribosome protected fragments was performed as previously described (Ignolia et al. 2011)\nRibo-seq library generation was performed as previously described (Ingolia et al., 2011)', 'cells were treated with 2g/mL Harringtonine for 5 minutes abd subsequently treated with 100g/mL cycloheximide for 1 minute.  Subsequenct isolation of ribosome protected fragments was performed as previously described (Ignolia et al. 2011)\nRibo-seq library generation was performed as previously described (Ingolia et al., 2011)', 'cells were harvested with Tri-Reagent (Sigma) and total RNA was extracted following manufacturer protocol\nRNA-seq library generation was performed as previously described (Ingolia et al., 2011)'; [Cell type]'Source: ''cell line: HSB2; strain: HHV-6A GS; hours post infection: 72; ', 'cell line: Molt-3; strain: HHV-6B Z29; hours post infection: 72; ', 'cell line: Molt-3; strain: HHV-6B Z29; hours post infection: 5; ', 'cell line: Molt-3; strain: HHV-6B Z29; hours post infection: 24; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135363,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE135nnn/GSE135363/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA558563,31944176," Yaara Finkel,  Dominik Schmiedel,  Julie Tai-Schmiedel,  Aharon Nachshon,  Roni Winkler,  Martina Dobesova,  Michal Schwartz,  Ofer Mandelboim,  Noam Stern-Ginossar","Human herpesvirus-6 (HHV-6) A and B are ubiquitous betaherpesviruses, infecting the majority of the human population. They encompass large genomes and our understanding of their protein coding potential is far from complete. Here, we employ ribosome-profiling and systematic transcript-analysis to experimentally define HHV-6 translation products. We identify hundreds of new open reading frames (ORFs), including upstream ORFs (uORFs) and internal ORFs (iORFs), generating a complete unbiased atlas of HHV-6 proteome. By integrating systematic data from the prototypic betaherpesvirus, human cytomegalovirus, we uncover numerous uORFs and iORFs conserved across betaherpesviruses and we show uORFs are enriched in late viral genes. We identified three highly abundant HHV-6 encoded long non-coding RNAs, one of which generates a non-polyadenylated stable intron appearing to be a conserved feature of betaherpesviruses. Overall, our work reveals the complexity of HHV-6 genomes and highlights novel features conserved between betaherpesviruses, providing a rich resource for future functional studies.",Comprehensive annotations of human herpesvirus 6A and 6B genomes reveal novel and conserved genomic features.,10.7554/eLife.50960,2020 Jan 16,PMC6964970,eLife
GSE71763,Ribosomal profiling of CRISPR edited and parental CHL-1 cell line,Homo sapiens,6,SRP062074,2015-08-05,"[Overal design]We have used CRISPR genome editing tool to KD snoRNAs SNORD50A/B from CHL-1 genome and assessed ribosomal binding genome-wide using ribosome profiling; [Treatment]'To induce ribosomal stress were treated with a combination of the amino acid analog L-azetidine-2-carboxylic-acid (AZC, 10mM) and proteasome inhibitor MG132 (20uM) for 20 minutes'; [Growth]'CHL-1 cells were cultured in DMEM, 10%FBS,'; [Extraction]'Cells were washed with ice-cold PBS, lysed on ice with cyclohexamide-containing buffer\nSequencing library was prepared as described in Ingolia NT, Brar GA, Rouskin S, McGeachy AM, Weissman JS. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc. 2012, 7(8):1534-50'; [Cell type]'melanoma cell line''cell line: CHL-1; cell type: melanoma cell line; treatment: CRISPR SNORD50A/B; ', 'cell line: CHL-1; cell type: melanoma cell line; treatment: CRISPR SNORD50A/B - rRNA removed; ', 'cell line: CHL-1; cell type: melanoma cell line; treatment: CHL-1; ', 'cell line: CHL-1; cell type: melanoma cell line; treatment: CHL-1 rRNA removed; ', 'cell line: CHL-1; cell type: melanoma cell line; treatment: 10mM AZC + MG132; ', 'cell line: CHL-1; cell type: melanoma cell line; treatment: 10mM AZC + MG132 - rRNA removed; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71763,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71763/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292020,,,,,,,,
GSE125832,Ribosome profiling analysis of lncRNA TINCR silenced primary melanoma cell line WM902B,Homo sapiens,8,SRP182817,2019-01-29,"[Overal design]Analysis of differential translation in shScrambled and shTINCR expressing WM902B cells; [Treatment]'The cells were treated with 100ug/ml cycloheximide for 5 min'; [Growth]'None'; [Extraction]'Ribosome prtotected fragments were prepared by sucrose gradient centrifugation and RNAseI digestion using to Riboprofile Trueseq Illumina Kit\nRibo Profile (Mammalian) Trueseq Library Prep Kit (Illumina). The libraries were prepared in two biological replicates for each condition'; [Cell type]'primary melanoma cell line''cell line: WM902B; cell type: primary melanoma cell line; passage: 18; melanoma mutation: BRAFV600E; infected shrna: shSCR; molecule subtype: ribosome protected RNA fragments (RPF); ', 'cell line: WM902B; cell type: primary melanoma cell line; passage: 18; melanoma mutation: BRAFV600E; infected shrna: shTINCR; molecule subtype: ribosome protected RNA fragments (RPF); ', 'cell line: WM902B; cell type: primary melanoma cell line; passage: 18; melanoma mutation: BRAFV600E; infected shrna: shSCR; molecule subtype: polyA RNA; ', 'cell line: WM902B; cell type: primary melanoma cell line; passage: 18; melanoma mutation: BRAFV600E; infected shrna: shTINCR; molecule subtype: polyA RNA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125832,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE125nnn/GSE125832/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA517673,33586907," Marine Melixetian,  Daniela Bossi,  Marija Mihailovich,  Simona Punzi,  Iros Barozzi,  Federica Marocchi,  Alessandro Cuomo,  Tiziana Bonaldi,  Giuseppe Testa,  Jean-Christophe Marine,  Eleonora Leucci,  Saverio Minucci,  Pier Giuseppe Pelicci,  Luisa Lanfrancone","Transition from proliferative-to-invasive phenotypes promotes metastasis and therapy resistance in melanoma. Reversion of the invasive phenotype, however, is challenged by the poor understanding of mechanisms underlying its maintenance. Here, we report that the lncRNA TINCR is down-regulated in metastatic melanoma and its silencing increases the expression levels of invasive markers, in vitro migration, in vivo tumor growth, and resistance to BRAF and MEK inhibitors. The critical mediator is ATF4, a central player of the integrated stress response (ISR), which is activated in TINCR-depleted cells in the absence of starvation and eIF2alpha phosphorylation. TINCR depletion increases global protein synthesis and induces translational reprogramming, leading to increased translation of mRNAs encoding ATF4 and other ISR proteins. Strikingly, re-expression of TINCR in metastatic melanoma suppresses the invasive phenotype, reduces numbers of tumor-initiating cells and metastasis formation, and increases drug sensitivity. Mechanistically, TINCR interacts with mRNAs associated with the invasive phenotype, including ATF4, preventing their binding to ribosomes. Thus, TINCR is a suppressor of the melanoma invasive phenotype, which functions in nutrient-rich conditions by repressing translation of selected ISR RNAs.",Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation.,10.15252/embr.202050852,2021 Mar 3,PMC7926219,EMBO reports
GSE125114,DDX3 depletion selectively represses translation of structured mRNAs,Homo sapiens,12,SRP179636,2019-01-15,"[Overal design]Ribosome profiling upon DDX3 knockdown and DDX3 PAR-CLIP was performed from HEK 293 cells.; [Treatment]'Cells were subjected to RNA interference as indicated.'; [Growth]'HEK 293 FlpIn TRex cells (Invitrogen R78007) were cultured in DMEM supplemented with 10% Fetal Bovine Serum (FBS). Stable cell lines expressing inducible flag-HA-DDX3 were generated as described (Spitzer et al., PMID: 24011039)'; [Extraction]'TruSeq Stranded mRNA Library Prep Kit\nFor  RNA-sequencing, Cells were resuspended in Trizol (Invitrogen) and, following Chloroform-mediate phase separation, RNA extracted from the aqueous phase using the RNeasy kit (Qiagen). Ribosome profiling (Calviello et al., PMID: 26657557) and PAR-CLIP (Maatz et al., PMID: 28369676) were performed as described.\nSee column ""library construction protocol"" in the SAMPLES section.', 'smallRNA sequencing library\nFor  RNA-sequencing, Cells were resuspended in Trizol (Invitrogen) and, following Chloroform-mediate phase separation, RNA extracted from the aqueous phase using the RNeasy kit (Qiagen). Ribosome profiling (Calviello et al., PMID: 26657557) and PAR-CLIP (Maatz et al., PMID: 28369676) were performed as described.\nSee column ""library construction protocol"" in the SAMPLES section.'; [Cell type]'Source: ''RNAi treatment: ctrl siRNA pool; rna isolation: total RNA; adapter sequence: GATCGGAAGAGCACACGT; ', 'RNAi treatment: DDX3 siRNA pool; rna isolation: total RNA; adapter sequence: GATCGGAAGAGCACACGT; ', 'RNAi treatment: ctrl siRNA pool; rna isolation: Ribosome Profiling; adapter sequence: TGGAATTCTCGGGTGCCA; ', 'RNAi treatment: DDX3 siRNA pool; rna isolation: Ribosome Profiling; adapter sequence: TGGAATTCTCGGGTGCCA; ', 'RNAi treatment: Untreated; rna isolation: PAR-CLIP; adapter sequence: TGGAATTCTCGGGTGCCA; '",Expression profiling by high throughput sequencing; Other; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125114,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE125nnn/GSE125114/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA515289,,,,,,,,
GSE115165,Whole transcriptome profiling by RNA-sequencing of RNA from N2 and F01D4.5(baf20) C. elegans,Caenorhabditis elegans,10,SRP149465,2018-05-31,"[Overal design]mRNA profiles of N2 and F01D4.5(baf20) C. elegans 48 hours post-L1 arrest generated by deep sequencing, five biological replicates per strain, using the Illumina HiSeq 3000 platform; [Treatment]'None'; [Growth]'L1 arrested C. elegans were grown on standard NGA media plates spotted with OP50 for 48 hours at 20 degrees Celsius'; [Extraction]""1000-2000 worms per sample were collected for RNA extraction. Extraction was performed by adding 1 mL QIAzol Lysis Reagent to the worm pellet and freezing. After two freeze/thaw cycles, total RNA was extracted and purified utilizing the QIAGEN miRNeasy Mini Kit according to manufacturer's protocol. Total RNA quality was checked with an Advanced Analytical Fragment Analyzer, and RQNs greater than 7 wer accepted.\nApproximately 500 ng total RNA was used for library preparation by folloiwng the Illumina TruSeq Stranded mRNA Sample Preparation Guide.""; [Cell type]'Source: ''strain: N2; ', 'strain: F01D4.5(baf20); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115165,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE115nnn/GSE115165/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA474005,31043480," Brett R Ipson,  Rebecca A Green,  John T Wilson,  Jacob N Watson,  Kym F Faull,  Alfred L Fisher","Under oxidative stress conditions, hydroxyl radicals can oxidize the phenyl ring of phenylalanine, producing the abnormal tyrosine isomer meta-tyrosine (m-tyrosine). m-Tyrosine levels are commonly used as a biomarker of oxidative stress, and its accumulation has recently been reported to adversely affect cells, suggesting a direct role for m-tyrosine in oxidative stress effects. We found that the Caenorhabditis elegans ortholog of tyrosine aminotransferase (TATN-1)-the first enzyme involved in the metabolic degradation of tyrosine-is up-regulated in response to oxidative stress and directly activated by the oxidative stress-responsive transcription factor SKN-1. Worms deficient in tyrosine aminotransferase activity displayed increased sensitivity to multiple sources of oxidative stress. Biochemical assays revealed that m-tyrosine is a substrate for TATN-1-mediated deamination, suggesting that TATN-1 also metabolizes m-tyrosine. Consistent with a toxic effect of m-tyrosine and a protective function of TATN-1, tatn-1 mutant worms exhibited delayed development, marked reduction in fertility, and shortened lifespan when exposed to m-tyrosine. A forward genetic screen identified a mutation in the previously uncharacterized gene F01D4.5-homologous with human transcription factor 20 (TCF20) and retinoic acid-induced 1 (RAI1)-that suppresses the adverse phenotypes observed in m-tyrosine-treated tatn-1 mutant worms. RNA-Seq analysis of F01D4.5 mutant worms disclosed a significant reduction in the expression of specific isoforms of genes encoding ribosomal proteins, suggesting that alterations in protein synthesis or ribosome structure could diminish the adverse effects of m-tyrosine. Our findings uncover a critical role for tyrosine aminotransferase in the oxidative stress response via m-tyrosine metabolism.",Tyrosine aminotransferase is involved in the oxidative stress response by metabolizing meta-tyrosine in Caenorhabditis elegans.,10.1074/jbc.RA118.004426,2019 Jun 14,PMC6579467,The Journal of biological chemistry
GSE71895,AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [Microvesicles small RNA-Seq],Homo sapiens,8,SRP062228,2015-08-10,"[Overal design]Microvesicle content profiles of MCF7 and HCT116 Akti-1/2 treated cells and MCF7 and HCT116 vehicle (i.e. DMSO) treated cells were generated, using technical replicates, using small RNA-Seq.; [Treatment]'Cells were treated for 72h with vehicle (DMSO), Akti-1/2 inhibitor (HCT116: 20M; MCF7: 2M) (Sigma)'; [Growth]'MCF7 was maintained in DMEM, 10% FCS, 40mM glutamine, 100 U/mL penicillin, and 100g/mL streptomycin; HCT116 was maintained in McCoys 5? medium supplemented with 10% FCS, 100U/mL penicillin, and 100g/mL streptomycin. All cells were grown at 37C and 5% CO2.'; [Extraction]'Exosomal RNA was isolated as per manufacturers instructions using the Total Exosome RNA and Protein isolation kit (Invitrogen). RNA recovered was characterized using RNA Pico Kit on Agilent 2100 Bioanalyzer. We used 1g of total RNA for library construction\nThe library of microvesicle small RNA was made using Illuminas Tru-Seq Small RNA kit. The 3 and 5 adaptors were ligated and an RT reaction is used to create single stranded cDNA, then PCR amplified using a common primer and one index sequences before size selection on 6% native polyacrylamide gel. Fragment range of 105-150bp corresponding to the small RNA population were excised, eluted, precipitated and resuspended in 20?l of nuclease free water. The size, quality and quantity of the DNA in each final small RNA library were verified using the High Sensitivity kit (Agilent).'; [Cell type]'breast adenocarcinoma', 'colon carcinoma''cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 Low; ', 'cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 WT; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 Low; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 WT; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71895,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71895/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292422,26637368," Salony,  Xavier Sole,  Cleidson P Alves,  Ipsita Dey-Guha,  Laila Ritsma,  Myriam Boukhali,  Ju H Lee,  Joeeta Chowdhury,  Kenneth N Ross,  Wilhelm Haas,  Shobha Vasudevan,  Sridhar Ramaswamy","Small molecule inhibitors of AKT (v-akt murine thymoma viral oncogene homolog) signaling are being evaluated in patients with various cancer types, but have so far proven therapeutically disappointing for reasons that remain unclear. Here, we treat cancer cells with subtherapeutic doses of Akti-1/2, an allosteric small molecule AKT inhibitor, in order to experimentally model pharmacologic inhibition of AKT signaling in vitro. We then apply a combined RNA, protein, and metabolite profiling approach to develop an integrated, multiscale, molecular snapshot of this ""AKT(low)"" cancer cell state. We find that AKT-inhibited cancer cells suppress thousands of mRNA transcripts, and proteins related to the cell cycle, ribosome, and protein translation. Surprisingly, however, these AKT-inhibited cells simultaneously upregulate a host of other proteins and metabolites posttranscriptionally, reflecting activation of their endo-vesiculo-membrane system, secretion of inflammatory proteins, and elaboration of extracellular microvesicles. Importantly, these microvesicles enable rapidly proliferating cancer cells of various types to better withstand different stress conditions, including serum deprivation, hypoxia, or cytotoxic chemotherapy in vitro and xenografting in vivo. These findings suggest a model whereby cancer cells experiencing a partial inhibition of AKT signaling may actually promote the survival of neighbors through non-cell autonomous communication.",AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.,10.1158/1535-7163.MCT-15-0414,2016 Jan,PMC4707053,Molecular cancer therapeutics
GSE128538,Ribosome profiling in RPEI cells upon CDK1-inhibition,Homo sapiens,12,SRP188848,2019-03-19,"[Overal design]RO-3306 or DMSO treated RPEI cells were subjected to ribosome profiling in three biological replicates. As a spike-in to detect global changes in translation efficiency, S. cerevisiae lysate was added to the RPEI lysates. To determine ribosome densities, both ribosome protected fragments and alkaline-fragmented input material were analyzed, amounting to 12 samples in total.; [Treatment]'RPE1 cells were cultured in in HAMs F-12 medium (HAMs F-12 (1:1), Millipore) containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 ?g/ml streptomycin. For the experiment RPE1 cells were seeded and kept in the absence of FBS for 48 h. Afterwards cells were incubated  in fresh medium without FBS supplemented with either DMSO or Ro3306 (Sigma, 10 M) for 4 h.'; [Growth]'None'; [Extraction]'Cells were washed once in ice-cold PBS supplemented with 100 g/ml CHX and harvested by scraping in polysome lysis buffer (20 mM Tris HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 mg/ml CHX, 1% Triton X-100, 40 U/ml RNasin, EDTA-free complete protease inhibitors (Roche)). Lysates were incubated end over end for 10 min at 4C and cleared by centrifugation at 10,000 rpm for 10 min at 4C. The DMSO and Ro3306 treated sample was adjusted to the same OD260 and afterwards combined to one sample. Yeast polysome lysate (2% of the RPE1 lysate) was spiked in. 10% of the lysate was saved as input sample. The lysate was subsequently digested with RNase I (60 units/ per OD260) for 5 min at 4C. The reaction was stopped by the addition of Superase Inhibitor (6 units/per sample). Samples were loaded onto linear 17 to 50% sucrose gradients (dissolved in 20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 150 mM NaCl). Sucrose density gradient centrifugation was carried out at 35,000 rpm at 4C using a SW60 rotor (Beckman) for 2.5 h. Sucrose gradients were fractionated by time (14 s/ fraction) using a Teledyne ISCO Foxy Jr. system.  RNA was purified from the cytoplasmic lysate (input) or from the monosomal fractions (ribosome protected fragments)  with Phenol:Chloroform:Isamylalcohol (25:24:1) by phase separation.  Both input and ribosome protected fragements were depleted of rRNA with the Ribo-Zero Gold Kit (Illumina).  Input RNA was randomly fragmented at pH ~10 for 12 min at 95C.  Fragmented RNA and ribosome protected fragments were size-selected (25 - 35 nt) on a 15% polyacrylamide TBE-urea gel.  After end-repair with T4 PNK, 3 ng per sample were used for library preparation.\nSmall RNA libraries were prepared with the NEXTflex Small RNA-Seq Kit v3 according to the manufacturers manual.'; [Cell type]'Source: ''fraction: cytoplasmic lysate (input); agent: DMSO; spike-in: Saccharomyces cerevisiae; ', 'fraction: cytoplasmic lysate (input); agent: RO-3306; spike-in: Saccharomyces cerevisiae; ', 'fraction: cytoplasmic lysate (input); agent: RO-3305; spike-in: Saccharomyces cerevisiae; ', 'fraction: cytoplasmic lysate (input); agent: RO-3304; spike-in: Saccharomyces cerevisiae; ', 'fraction: Ribosome protected fragments; agent: DMSO; spike-in: Saccharomyces cerevisiae; ', 'fraction: Ribosome protected fragments; agent: RO-3303; spike-in: Saccharomyces cerevisiae; ', 'fraction: Ribosome protected fragments; agent: RO-3302; spike-in: Saccharomyces cerevisiae; ', 'fraction: Ribosome protected fragments; agent: RO-3301; spike-in: Saccharomyces cerevisiae; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128538,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128538/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA528026,32040547," Katharina Haneke,  Johanna Schott,  Doris Lindner,  Anne Kruse Hollensen,  Christian Kroun Damgaard,  Cyril Mongis,  Michael Knop,  Wilhelm Palm,  Alessia Ruggieri,  Georg Stoecklin","Cell proliferation exerts a high demand on protein synthesis, yet the mechanisms coupling the two processes are not fully understood. A kinase and phosphatase screen for activators of translation, based on the formation of stress granules in human cells, revealed cell cycle-associated kinases as major candidates. CDK1 was identified as a positive regulator of global translation, and cell synchronization experiments showed that this is an extramitotic function of CDK1. Different pathways including eIF2alpha, 4EBP, and S6K1 signaling contribute to controlling global translation downstream of CDK1. Moreover, Ribo-Seq analysis uncovered that CDK1 exerts a particularly strong effect on the translation of 5'TOP mRNAs, which includes mRNAs encoding ribosomal proteins and several translation factors. This effect requires the 5'TOP mRNA-binding protein LARP1, concurrent to our finding that LARP1 phosphorylation is strongly dependent on CDK1. Thus, CDK1 provides a direct means to couple cell proliferation with biosynthesis of the translation machinery and the rate of protein synthesis.",CDK1 couples proliferation with protein synthesis.,10.1083/jcb.201906147,2020 Mar 2,PMC7054999,The Journal of cell biology
GSE100026,Transcriptome characterization of chronic myeloid leukemia by RNA sequencing,Homo sapiens,15,SRP109177,2017-06-14,"[Overal design]mRNA profiles of peripheral blood mononuclear cells from five patients in chronic phase(CP), five in blast crisis(BC) of chronic myeloid leukemia and five healthy volunteers were generated by deep sequencing using Illumina NextSeq 500.; [Treatment]'None'; [Growth]'None'; [Extraction]'Peripheral blood  mononuclear cells were harvested, flash frozen on dry ice, and RNA was harvested using Trizol reagent. RNA-Seq Library Preparation Kit forWhole Transcriptome DiscoveryIllumina Compatible (K02421) was used with 5 ug of total RNA for the construction of sequencing libraries.\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'mononuclear''disease state: Healthy; tissue: Peripheral blood; cell type: mononuclear; bcr/abl fusion gene: Negative; ', 'disease state: Chronic phase of chronic myeloid leukemia; tissue: Peripheral blood; cell type: mononuclear; bcr/abl fusion gene: Positive; ', 'disease state: Blast crisis of chronic myeloid leukemia; tissue: Peripheral blood; cell type: mononuclear; bcr/abl fusion gene: Positive; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100026,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE100nnn/GSE100026/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA390519,32405436," Shu-Qi Li,  Jing Liu,  Jing Zhang,  Xue-Lian Wang,  Dong Chen,  Yan Wang,  Yan-Mei Xu,  Bo Huang,  Jin Lin,  Jing Li,  Xiao-Zhong Wang","Chronic myeloid leukemia (CML) is a malignancy that evolves through a multi-step process. Alternative splicing of several genes has been linked to the progression of the disease, but involvement of alternations in splicing profiles has not been reported. RNA-seq of peripheral blood mononuclear cell (PBMC) samples characterized the differentially expressed and spliced transcripts in five CML chronic phase (CP) and five blast phase (BP) patients, and five healthy controls. Global splicing alteration analysis detected 6474 altered splicing events altered between CML and healthy samples, including many of the previously reported splicing variants and showing a more profound altered splicing deregulation in BP samples. Functional clustering of differentially spliced genes in CP revealed a preferred enrichment relating to cell signaling, while the spliceosome pathway was most overrepresented in BP samples. One differentially spliced spliceosome gene hnRNPA1 showed two splice isoforms; the longer isoform contained exon 8 was preferentially expressed in the BP patients, and the short one excluding exon 8 was specific to healthy controls. Our findings suggested that alternative splicing deregulation played a central role during the progression of CML from CP to BP, and the longer isoform of hnRNPA1 might represent a diagnostic marker and therapeutic target for CML.",Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia.,10.1016/j.jare.2020.04.016,2020 Jul,PMC7210475,Journal of advanced research
GSE52461,Profiling transcriptional and translational response to anoxia or hypoxia of genes in DNA damage response and repair pathways in human fibroblast and prostate cancer cells using NanoString nCounter.,Homo sapiens,16,None,2013-11-18,"[Overal design]Comparison of mRNA abundance and translation efficiency of genes in DNA damage response and repair pathways in selected anoxia/hypoxia-treated cells with those in normoxia-treated controls.; [Treatment]'GM05757 cells were exposed to anoxia (0% oxygen) and normoxia for 24 hours. DU145 cells were exposed to hypoxia (0.2% oxygen) and normoxia for 72 hours.'; [Growth]'Both cell lines, GM05757 and DU145, were cultured in alpha-modified Eagles Medium. DU145 was supplemented with 10% fetal calf serum and 1% L-Glutamine. GM05757 was supplemented with 15% of calf serum.'; [Extraction]""Total RNA was extracted from GM05757 and DU145 with TRIZOL, according to the manufacturer's protocol. Polysome mRNAs from GM05757 and DU145 cytoplasmic lysates were isolated by sedimentation through a sucrose gradient and subsequent fractionation. Fractions containing the different numbers of polysomes were collected in 0.55 M final concentration of guanidiniumHCl, phenol-chloroform extracted and subjected to precipitation with ethanol. Spike-in control RNAs were added at this stage.  Glycogen was used as carrier.""; [Cell type]'normal human fibroblast', 'human prostate cancer cells''cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of anoxia; pooled polysome fraction: 0 to 3 ribosomes; molecule subtype: mRNA with 0 to 3 attached ribosomes; ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of anoxia; pooled polysome fraction: 4 to 7 ribosomes; molecule subtype: mRNA with 4 to 7 attached ribosomes; ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of anoxia; pooled polysome fraction: 8 or more ribosomes; molecule subtype: mRNA with 8 or more attached ribosomes; ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of anoxia; pooled polysome fraction: total RNA (nuclear + cytoplasmic); molecule subtype: total RNA (nuclear + cytoplasmic); ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of normoxia; pooled polysome fraction: 0 to 3 ribosomes; molecule subtype: mRNA with 0 to 3 attached ribosomes; ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of normoxia; pooled polysome fraction: 4 to 7 ribosomes; molecule subtype: mRNA with 4 to 7 attached ribosomes; ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of normoxia; pooled polysome fraction: 8 or more ribosomes; molecule subtype: mRNA with 8 or more attached ribosomes; ', 'cell line: GM05757; cell type: normal human fibroblast; treatment: 24 hours of normoxia; pooled polysome fraction: total RNA (nuclear + cytoplasmic); molecule subtype: total RNA (nuclear + cytoplasmic); ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of hypoxia; pooled polysome fraction: 0 to 3 ribosomes; molecule subtype: mRNA with 0 to 3 attached ribosomes; ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of hypoxia; pooled polysome fraction: 4 to 7 ribosomes; molecule subtype: mRNA with 4 to 7 attached ribosomes; ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of hypoxia; pooled polysome fraction: 8 or more ribosomes; molecule subtype: mRNA with 8 or more attached ribosomes; ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of hypoxia; pooled polysome fraction: total RNA (nuclear + cytoplasmic); molecule subtype: total RNA (nuclear + cytoplasmic); ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of normoxia; pooled polysome fraction: 0 to 3 ribosomes; molecule subtype: mRNA with 0 to 3 attached ribosomes; ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of normoxia; pooled polysome fraction: 4 to 7 ribosomes; molecule subtype: mRNA with 4 to 7 attached ribosomes; ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of normoxia; pooled polysome fraction: 8 or more ribosomes; molecule subtype: mRNA with 8 or more attached ribosomes; ', 'cell line: DU145; cell type: human prostate cancer cells; treatment: 72 hours of normoxia; pooled polysome fraction: total RNA (nuclear + cytoplasmic); molecule subtype: total RNA (nuclear + cytoplasmic); '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52461,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE52nnn/GSE52461/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA229050,,,,,,,,
GSE133925,CircMYBL2 Regulates FLT3-ITD FLT3AML Translation in AML,Homo sapiens,8,SRP213599,2019-07-08,[Overal design]Sh-NC and sh-circMYBL2 MOLM-13 cells used; [Treatment]'None'; [Growth]'None'; [Extraction]'QIAseq FastSelectTM RNA Removal Kit\nPrecision small RNA library prep for Illumina NGS systems'; [Cell type]'acute myeloid leukemia cells''cell line: MOLM-13; cell type: acute myeloid leukemia cells; ',Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133925,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE133nnn/GSE133925/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA553142,31387917," Yu-Meng Sun,  Wen-Tao Wang,  Zhan-Cheng Zeng,  Tian-Qi Chen,  Cai Han,  Qi Pan,  Wei Huang,  Ke Fang,  Lin-Yu Sun,  Yan-Fei Zhou,  Xue-Qun Luo,  Chengwei Luo,  Xin Du,  Yue-Qin Chen","Internal tandem duplication (ITD) mutations within FMS-like tyrosine kinase-3 (FLT3) occur in up to 30% of acute myeloid leukemia (AML) patients and confer a very poor prognosis. The oncogenic form of FLT3 is an important therapeutic target, and inhibitors specifically targeting FLT3 kinase can induce complete remission; however, relapse after remission has been observed due to acquired resistance with secondary mutations in FLT3, highlighting the need for new strategies to target FLT3-ITD mutations. Recent studies have reported that the aberrant formations of circular RNAs (circRNAs) are biological tumorigenesis-relevant mechanisms and potential therapeutic targets. Herein, we discovered a circRNA, circMYBL2, derived from the cell-cycle checkpoint gene MYBL2. circMYBL2 is more highly expressed in AML patients with FLT3-ITD mutations than in those without the FLT3-ITD mutation. We found that circMYBL2 knockdown specifically inhibits proliferation and promotes the differentiation of FLT3-ITD AML cells in vitro and in vivo. Interestingly, we found that circMYBL2 significantly influences the protein level of mutant FLT3 kinase, which contributes to the activation of FLT3-ITD-dependent signaling pathways. Mechanistically, circMYBL2 enhanced the translational efficiency of FLT3 kinase by increasing the binding of polypyrimidine tract-binding protein 1 (PTBP1) to FLT3 messenger RNA. Moreover, circMYBL2 knockdown impaired the cytoactivity of inhibitor-resistant FLT3-ITD+ cells, with a significant decrease in FLT3 kinase expression, followed by the inactivation of its downstream pathways. In summary, we are the first to reveal a circRNA that specifically influences FLT3-ITD AML and regulates FLT3 kinase levels through translational regulation, suggesting that circMYBL2 may be a potential therapeutic target for FLT3-ITD AML.","circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.",10.1182/blood.2019000802,2019 Oct 31,PMC6839953,Blood
GSE123627,Bias-minimized quantification of microRNA reveals widespread alternative processing and 3' end modification,Homo sapiens,11,SRP173274,2018-12-11,"[Overal design]Total RNA was isolated from HEK293T and HeLa cells, mixed with thirty synthetic miRNA-like spike-in oligos, and subjected to small RNA-seq library preparation using TruSeq (Illumina) or the AQ-seq method.; [Treatment]'None'; [Growth]'HEK293T and HeLa cells were grown in DMEM media (Welgene) supplemented with 10% FBS (Welgene).'; [Extraction]""Total RNA was isolated using TRIzol (Invitrogen).\nTotal RNA was mixed with thirty synthetic miRNA-like spike-in oligos. The RNA mixture was size-fractionated by 15% urea-polyacrylamide gel electrophoresis to enrich miRNA species. Small RNA libraries were constructed using either TruSeq small RNA library preparation kit (Illumina) according to manufacturer's instructions or AQ-seq as follows: miRNA-enriched RNA was ligated to 3' randomized adapter with 20% PEG 8000, then ligated to 5' randomized adapter with 20% PEG 8000, reverse-transcribed, and amplified. The cDNA was sequenced using a HiSeq 2500 platform.""; [Cell type]'Source: ''cell line: HEK293T; ', 'cell line: HeLa; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123627,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123627/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA509424,30605524," Haedong Kim,  Jimi Kim,  Kijun Kim,  Hyeshik Chang,  Kwontae You,  V Narry Kim","MicroRNAs (miRNAs) modulate diverse biological and pathological processes via post-transcriptional gene silencing. High-throughput small RNA sequencing (sRNA-seq) has been widely adopted to investigate the functions and regulatory mechanisms of miRNAs. However, accurate quantification of miRNAs has been limited owing to the severe ligation bias in conventional sRNA-seq methods. Here, we quantify miRNAs and their variants (known as isomiRs) by an improved sRNA-seq protocol, termed AQ-seq (accurate quantification by sequencing), that utilizes adapters with terminal degenerate sequences and a high concentration of polyethylene glycol (PEG), which minimize the ligation bias during library preparation. Measurement using AQ-seq allows us to correct the previously misannotated 5' end usage and strand preference in public databases. Importantly, the analysis of 5' terminal heterogeneity reveals widespread alternative processing events which have been underestimated. We also identify highly uridylated miRNAs originating from the 3p strands, indicating regulations mediated by terminal uridylyl transferases at the pre-miRNA stage. Taken together, our study reveals the complexity of the miRNA isoform landscape, allowing us to refine miRNA annotation and to advance our understanding of miRNA regulation. Furthermore, AQ-seq can be adopted to improve other ligation-based sequencing methods including crosslinking-immunoprecipitation-sequencing (CLIP-seq) and ribosome profiling (Ribo-seq).",Bias-minimized quantification of microRNA reveals widespread alternative processing and 3' end modification.,10.1093/nar/gky1293,2019 Mar 18,PMC6411932,Nucleic acids research
GSE126383,Modeling ribosome dwell times and relationship with tRNA loading and codon usage in mammals (Ribosome Profiling),Mus musculus,11,SRP185485,2019-02-11,"[Overal design]Ribosome profiling of liver harvested from mice fed Ad libitum or fasted; [Treatment]'Immediately after the organ collection, livers were homogenized in lysis buffer containing 20 mM HEPES (pH 7.6), 250 mM NaCl, 10 mM MgCl2, 10 mM DTT, 20 g/ml cycloheximide (CHX conditions) or no cycloheximide (NOCHX conditions), 10 U/l RNase inhibitor (New England Biolabs), and a protease inhibitor cocktail containing 0.5 mM PMSF, 10 g/ml Aprotinin, 0.7 g/ml Pepstatin A, and 0.7 g/ml Leupeptin.'; [Growth]'None'; [Extraction]""Ribosome unprotected-mRNAs were digested with RNAse I (350 U/mg of protein, Invitrogen) and resulting footprints were isolated (sucrose gradients, monosome peaks) and extracted with classical methods using guanidium  thiocyanate lysis buffer.\nEluted RNA was heat denatured 3 min at 65C. The 3-terminal cyclophosphate resulting from the RNAse I digestion was removed in a 50 L reaction with 10 U of T4 PNK (New England Biolabs) in the absence of ATP. After 60 min incubation at 37C, ATP is supplemented to a final concentration of 1 mM together with an addition of 10 U T4 PNK and reaction is further incubated 60 min at 37C. Libraries were generated using NEXTflex Small RNA Sequencing Kit 3. For both methods, manufacturer's recommendations were stricly followed.""; [Cell type]'Source: ''strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Ad Libitum; lysis buffer drugs: CHX-; ', 'strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Fasted; lysis buffer drugs: CHX+; ', 'strain: C57BL/6; tissue: Liver; time: ZT04; feeding: Fasted; lysis buffer drugs: CHX-; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Ad Libitum; lysis buffer drugs: CHX+; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Ad Libitum; lysis buffer drugs: CHX-; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Fasted; lysis buffer drugs: CHX+; ', 'strain: C57BL/6; tissue: Liver; time: ZT12; feeding: Fasted; lysis buffer drugs: CHX-; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Ad Libitum; lysis buffer drugs: CHX+; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Ad Libitum; lysis buffer drugs: CHX-; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Fasted; lysis buffer drugs: CHX+; ', 'strain: C57BL/6; tissue: Liver; time: ZT18; feeding: Fasted; lysis buffer drugs: CHX-; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126383,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126383/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA521742,32295881," Cedric Gobet,  Benjamin Dieter Weger,  Julien Marquis,  Eva Martin,  Nagammal Neelagandan,  Frederic Gachon,  Felix Naef","Translation depends on messenger RNA (mRNA)-specific initiation, elongation, and termination rates. While translation elongation is well studied in bacteria and yeast, less is known in higher eukaryotes. Here we combined ribosome and transfer RNA (tRNA) profiling to investigate the relations between translation elongation rates, (aminoacyl-) tRNA levels, and codon usage in mammals. We modeled codon-specific ribosome dwell times from ribosome profiling, considering codon pair interactions between ribosome sites. In mouse liver, the model revealed",Robust landscapes of ribosome dwell times and aminoacyl-tRNAs in response to nutrient stress in liver.,10.1073/pnas.1918145117,2020 Apr 28,PMC7196831,Proceedings of the National Academy of Sciences of the United States of America
GSE49197,Ribosome profiling reveals pervasive and regulated stop codon readthrough  in Drosophila melanogaster,Drosophila melanogaster,12,SRP028243,2013-07-25,"[Overal design]12 samples of Drosophila ribosome profiling and poly(A)+ mRNA-seq, including technical replicates in S2 cells, and biological replicates of 0-2 hour embryos; [Treatment]'None'; [Growth]'None'; [Extraction]'Samples were lysed using the indicated strategies in the indicated buffers. For ribosome profiling samples, monosomes were resolved by digestion with micrococcal nuclease,  isolated by sucrose cushions or gradients as indicated and  RNA was isolated from monosome fractions using acid:Phenol and chloroform extractions. For RNA-seq samples, RNA was extracted with Trizol\nFor RNA-seq, poly(A)+ RNA was selected on oligo dT(25) dynabeads, randomly fragmented to approximately 50 nt in length, and size-selected to 40-60mers via gel purification. For ribosome profiling, 28-34mers were size-selected via gel purification. All fragments were then dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circulizarized, PCR amplified, and subjected to 50-57 cycles of sequencing on an Illumina HiSeq, as indicated'; [Cell type]'Source: ''strain: y w; tissue: whole 0-2 hour embryo; monosome enrichment strategy: sucrose cushion; lysis buffer ion concentrations: 150 mM Na+, 5 mM Mg++; lysis strategy: Cryolysis; ', 'strain: y w; tissue: whole 0-2 hour embryo; monosome enrichment strategy: na; lysis buffer ion concentrations: 150 mM Na+, 5 mM Mg++; lysis strategy: Cryolysis; ', 'strain: y w; tissue: whole 0-2 hour embryo; monosome enrichment strategy: sucrose gradient; lysis buffer ion concentrations: 150 mM Na+, 5 mM Mg++; lysis strategy: Cryolysis; ', 'strain: Oregon R; cell line: S2; monosome enrichment strategy: sucrose cushion; lysis buffer ion concentrations: 150 mM Na+, 5 mM Mg++; lysis strategy: Dounce homogenizeation; ', 'strain: Oregon R; cell line: S2; monosome enrichment strategy: sucrose cushion; lysis buffer ion concentrations: 250 mM Na+, 15 mM Mg++; lysis strategy: Dounce homogenizeation; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49197,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE49nnn/GSE49197/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA213294,24302569," Joshua G Dunn,  Catherine K Foo,  Nicolette G Belletier,  Elizabeth R Gavis,  Jonathan S Weissman","Ribosomes can read through stop codons in a regulated manner, elongating rather than terminating the nascent peptide. Stop codon readthrough is essential to diverse viruses, and phylogenetically predicted to occur in a few hundred genes in Drosophila melanogaster, but the importance of regulated readthrough in eukaryotes remains largely unexplored. Here, we present a ribosome profiling assay (deep sequencing of ribosome-protected mRNA fragments) for Drosophila melanogaster, and provide the first genome-wide experimental analysis of readthrough. Readthrough is far more pervasive than expected: the vast majority of readthrough events evolved within D. melanogaster and were not predicted phylogenetically. The resulting C-terminal protein extensions show evidence of selection, contain functional subcellular localization signals, and their readthrough is regulated, arguing for their importance. We further demonstrate that readthrough occurs in yeast and humans. Readthrough thus provides general mechanisms both to regulate gene expression and function, and to add plasticity to the proteome during evolution. DOI: http://dx.doi.org/10.7554/eLife.01179.001.",Ribosome profiling reveals pervasive and regulated stop codon readthrough in Drosophila melanogaster.,10.7554/eLife.01179,2013 Dec 3,PMC3840789,eLife
GSE129701,Super-enhancer redistribution as a mechanism of broad gene dysregulation in repeatedly drug-treated cancer cells [dataset 2],Homo sapiens,22,SRP192310,2019-04-12,"[Overal design]All ChIP-Seq, GRO-seq, RNA-seq, and ribosome-profiling experiments were designed to understand the effects of cisplatin on 6 different layers of gene-expression regulation in cancer cells.; [Treatment]'The treatment administrated to A2780cis cells was described in the Sigma-Aldrich website as chronic exposure of the parent A27890 line to increasing concentrations of cisplatin Sigma-Aldrich (#93112517-19). Acute treatments (IC50) were administrated for 3 days, adding fresh media with drug at day 0 and after 2 days again.'; [Growth]'Cells  were cultured in RPMI-1640-Glutamax I (#61870-036, Life Technologies) and 10% fetal bovine serum (FBS, #FB-11, Omega Scientific) at 5% CO2 37C, and sub-cultured at 1:5 to 1:6 dilutions after dissociation with 0.25% trypsin. Media was changed every other day, or daily when cells reached >50-60% confluency.'; [Extraction]'GRO-seq analysis was perfromed as prevkiously reported (PMID: 21572438, Wang et al., 2011); RNA-seq and ribosome profiling was performed using the ARTseq Ribosome Profiling kit  following the manufactures protocol (Epicentre).\nRNA quality was calculated on TapeStation (Agilent Technologies). PolyA+ RNA-seq libraries were generated using the Illumina TruSeq Stranded RNA LT kit and following manufacturers detailed instructions.'; [Cell type]'Source: ', 'Cells sorted based on ISL1 protein levels''cell line: A2780; ', 'cell line: A2780cis; ', 'cell line: A2780-CRISPR/dCas9-KRAB-modified; ', 'cell line: A2780cis-CRISPR/dCas9-VP64-modified; ', 'cell line: A2780; cell type: Cells sorted based on ISL1 protein levels; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129701,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129701/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532532,32320655," Qi Ma,  Feng Yang,  Carlos Mackintosh,  Ranveer Singh Jayani,  Soohwan Oh,  Chunyu Jin,  Sreejith Janardhanan Nair,  Daria Merkurjev,  Wubin Ma,  Stephanie Allen,  Dong Wang,  Angels Almenar-Queralt,  Ivan Garcia-Bassets","Cisplatin is an antineoplastic drug administered at suboptimal and intermittent doses to avoid life-threatening effects. Although this regimen shortly improves symptoms in the short term, it also leads to more malignant disease in the long term. We describe a multilayered analysis ranging from chromatin to translation-integrating chromatin immunoprecipitation sequencing (ChIP-seq), global run-on sequencing (GRO-seq), RNA sequencing (RNA-seq), and ribosome profiling-to understand how cisplatin confers (pre)malignant features by using a well-established ovarian cancer model of cisplatin exposure. This approach allows us to segregate the human transcriptome into gene modules representing distinct regulatory principles and to characterize that the most cisplatin-disrupted modules are associated with underlying events of super-enhancer plasticity. These events arise when cancer cells initiate without ultimately ending the program of drug-stimulated death. Using a PageRank-based algorithm, we predict super-enhancer regulator ISL1 as a driver of this plasticity and validate this prediction by using CRISPR/dCas9-KRAB inhibition (CRISPRi) and CRISPR/dCas9-VP64 activation (CRISPRa) tools. Together, we propose that cisplatin reprograms cancer cells when inducing them to undergo near-to-death experiences.",Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells.,10.1016/j.celrep.2020.107532,2020 Apr 21,,Cell reports
GSE115142,A widespread alternate form of cap-dependent mRNA translation initiation,Homo sapiens,14,SRP149421,2018-05-31,"[Overal design]Examination of transcriptomics and translatomics in breast cancer cells.; [Treatment]'Cells were treated to with 1ug/mL of doxycycline for 6 days before polysome profiling was performed.'; [Growth]'MDA-MB-231 cells containing either stable doxycycline inducible non-silencing (NS) construct or sh Dap5 were grown to 70-80 % confluency.'; [Extraction]""Cells were lysed in buffer intended for isolation of cytoplasmic fractions and enrichment of ribosomes.\nLibraries were prepared according to Illumina's instructions""; [Cell type]'Source: ''cell line: MDA-MB-231; shRNA: non-silencing (NS) construct; ', 'cell line: MDA-MB-231; shRNA: sh Dap5; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115142,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE115nnn/GSE115142/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA473917,30076308," Columba de la Parra,  Amanda Ernlund,  Amandine Alard,  Kelly Ruggles,  Beatrix Ueberheide,  Robert J Schneider","Translation initiation of most mammalian mRNAs is mediated by a 5' cap structure that binds eukaryotic initiation factor 4E (eIF4E). However, inactivation of eIF4E does not impair translation of many capped mRNAs, suggesting an unknown alternate mechanism may exist for cap-dependent but eIF4E-independent translation. We show that DAP5, an eIF4GI homolog that lacks eIF4E binding, utilizes eIF3d to facilitate cap-dependent translation of approximately 20% of mRNAs. Genome-wide transcriptomic and translatomic analyses indicate that DAP5 is required for translation of many transcription factors and receptor capped mRNAs and their mRNA targets involved in cell survival, motility, DNA repair and translation initiation, among other mRNAs. Mass spectrometry and crosslinking studies demonstrate that eIF3d is a direct binding partner of DAP5. In vitro translation and ribosome complex studies demonstrate that DAP5 and eIF3d are both essential for eIF4E-independent capped-mRNA translation. These studies disclose a widespread and previously unknown mechanism for cap-dependent mRNA translation by DAP5-eIF3d complexes.",A widespread alternate form of cap-dependent mRNA translation initiation.,10.1038/s41467-018-05539-0,2018 Aug 3,PMC6076257,Nature communications
GSE144140,Use of NanoLuc-Based Reporters that Monitor Nonsense Suppression and Inhibition of Nonsense-Mediated mRNA Decay to Identify Potent New Agents That Partially Reverse the Effects of Nonsense Mutations,Homo sapiens,9,SRP244347,2020-01-23,"[Overal design]9 ribosome profiling samples are included from HEK293T cells; [Treatment]'Drugs were added to cells and treated for 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation.\nFor ribosome profiling, fragments ranging from 15-34 nt were gel purified. Upon dephosphorylation of sample RNA, the linker was ligated and this product and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: HEK293T; treatment: DMSO; concentration: 0.10%; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293T; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); ', 'cell line: HEK293T; treatment: SRI37240; concentration: 10 uM; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; molecule subtype: Ribosome Protected mRNA (15-35 nt); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144140,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE144nnn/GSE144140/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA602876,,,,,,,,
GSE94827,Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma,Homo sapiens,10,SRP099436,2017-02-13,"[Overal design]RNA sequencing of 5 cell lines (NCI-H929, NAMALWA, U266, MM1S and OPM2) treated with CMLD010509 or vehicle control (DMSO); [Treatment]'Cells were treated by either CMLD010509-treated 50nM 6 hours or vehicle control (DMSO)'; [Growth]'Cells were grown in RPMI 10% FBS'; [Extraction]'Total RNA was extracted using RNeasy Mini kit (QIAGEN).\nNEBNext RNA library prep kit'; [Cell type]'Multiple Myeloma cell line', 'Burkitt Lymphoma cell line''cell line: NCI-H929; cell type: Multiple Myeloma cell line; condition: DMSO-treated; ', 'cell line: NCI-H929; cell type: Multiple Myeloma cell line; condition: CMLD010509-treated 50nM 6 hours; ', 'cell line: NAMALWA; cell type: Burkitt Lymphoma cell line; condition: DMSO-treated; ', 'cell line: NAMALWA; cell type: Burkitt Lymphoma cell line; condition: CMLD010509-treated 50nM 6 hours; ', 'cell line: MM1S; cell type: Multiple Myeloma cell line; condition: DMSO-treated; ', 'cell line: MM1S; cell type: Multiple Myeloma cell line; condition: CMLD010509-treated 50nM 6 hours; ', 'cell line: OPM2; cell type: Multiple Myeloma cell line; condition: DMSO-treated; ', 'cell line: OPM2; cell type: Multiple Myeloma cell line; condition: CMLD010509-treated 50nM 6 hours; ', 'cell line: U266; cell type: Multiple Myeloma cell line; condition: DMSO-treated; ', 'cell line: U266; cell type: Multiple Myeloma cell line; condition: CMLD010509-treated 50nM 6 hours; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94827,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE94nnn/GSE94827/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA374537,28490664," Salomon Manier,  Daisy Huynh,  Yu J Shen,  Jia Zhou,  Timur Yusufzai,  Karma Z Salem,  Richard Y Ebright,  Jiantao Shi,  Jihye Park,  Siobhan V Glavey,  William G Devine,  Chia-Jen Liu,  Xavier Leleu,  Bruno Quesnel,  Catherine Roche-Lestienne,  John K Snyder,  Lauren E Brown,  Nathanael Gray,  James Bradner,  Luke Whitesell,  John A Jr Porco,  Irene M Ghobrial","Multiple myeloma (MM) is a frequently incurable hematological cancer in which overactivity of MYC plays a central role, notably through up-regulation of ribosome biogenesis and translation. To better understand the oncogenic program driven by MYC and investigate its potential as a therapeutic target, we screened a chemically diverse small-molecule library for anti-MM activity. The most potent hits identified were rocaglate scaffold inhibitors of translation initiation. Expression profiling of MM cells revealed reversion of the oncogenic MYC-driven transcriptional program by CMLD010509, the most promising rocaglate. Proteome-wide reversion correlated with selective depletion of short-lived proteins that are key to MM growth and survival, most notably MYC, MDM2, CCND1, MAF, and MCL-1. The efficacy of CMLD010509 in mouse models of MM confirmed the therapeutic relevance of these findings in vivo and supports the feasibility of targeting the oncogenic MYC-driven translation program in MM with rocaglates.",Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.,10.1126/scitranslmed.aal2668,2017 May 10,PMC5718051,Science translational medicine
GSE126385,Divergent effects of eRF3 and Upf1 on the expression of uORF carrying mRNAs and ribosome protein genes,Homo sapiens,12,SRP185496,2019-02-11,"[Overal design]Examination of the translational consequences of the inactivation of the eRF3 and Upf1 in HCT-116; [Treatment]'None'; [Growth]'Maintained in McCoy medium (Invitrogen) supplemented with 10% fetal calf serum, 100 mg/ml streptomycin and 100 U/ml penicillin at 37C under 5% CO2 atmosphere'; [Extraction]'Ribosome Profiling was performed as described in Baudin-Baillieu et al, 2016 and total RNA was purified by hot acid phenol extraction\ncDNA library from 100 ng RNA was prepared by the Imagif plateform (Institut de Biologie Intgrative de la Cellule, Gif sur Yvette, France), using the TruSeq Small RNA Sample Prep Kit with 3 sRNA Adapter (Illumina) according to the manufacturers protocol. RNA integrity and quality was verified using Bioanalyzer Small RNA Analysis kit (Agilent). Sequencing was performed at the genomic plateform of the Institut de Biologie de lcole Normale Suprieure (Paris, France) on an Illumina Nextseq 500 and with a single-read 75 cycle runs. Four sequencing libraries were prepared from purified RPFs and total RNA, for each biological replicate of eRF3-depleted, Upf1-depleted and control cells. A minimum of 7 108 reads were achieved for bioinformatics analysis.'; [Cell type]'HCT116 (ATCC CCL-247)''tissue: human colon cancer cell line; cell type: HCT116 (ATCC CCL-247); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126385,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126385/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA521751,31619139," Affaf Aliouat,  Isabelle Hatin,  Pierre Bertin,  Pauline Francois,  Verene Stierle,  Olivier Namy,  Samia Salhi,  Olivier Jean-Jean","In addition to its role in translation termination, eRF3A has been implicated in the nonsense-mediated mRNA decay (NMD) pathway through its interaction with UPF1. NMD is a RNA quality control mechanism, which detects and degrades aberrant mRNAs as well as some normal transcripts including those that harbour upstream open reading frames in their 5' leader sequence. In this study, we used RNA-sequencing and ribosome profiling to perform a genome wide analysis of the effect of either eRF3A or UPF1 depletion in human cells. Our bioinformatics analyses allow to delineate the features of the transcripts controlled by eRF3A and UPF1 and to compare the effect of each of these factors on gene expression. We find that eRF3A and UPF1 have very different impacts on the human transcriptome, less than 250 transcripts being targeted by both factors. We show that eRF3A depletion globally derepresses the expression of mRNAs containing translated uORFs while UPF1 knockdown derepresses only the mRNAs harbouring uORFs with an AUG codon in an optimal context for translation initiation. Finally, we also find that eRF3A and UPF1 have opposite effects on ribosome protein gene expression. Together, our results provide important elements for understanding the impact of translation termination and NMD on the human transcriptome and reveal novel determinants of ribosome biogenesis regulation.",Divergent effects of translation termination factor eRF3A and nonsense-mediated mRNA decay factor UPF1 on the expression of uORF carrying mRNAs and ribosome protein genes.,10.1080/15476286.2019.1674595,2020 Feb,PMC6973328,RNA biology
GSE111460,SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis [ChIP-Seq],Homo sapiens,14,SRP134016,2018-03-06,"[Overal design]Baseline gene expression profiling of clonal cell lines engineered to express AID-tagged proteins and unedited controls by 3'mRNA sequencing.; [Treatment]'None'; [Growth]'None'; [Extraction]'Cells were cross-linked with 1% formaldehyde (10, RT). Nuclei were isolated, lysed, and chromatin was sheared by sonication. Mouse chromatin (ratio 10:1, human:mouse) was added for internal normalization. Antibodies against total Pol2, Pol2-S2p or Pol2-S5p (active motif) were added overnight at 4 and captured with magnetic sepharose beads for 2h at 4C. Beads were washed, immune complexes eluted, and cross-links reversed for 6h at 65C. Genomic DNA was recovered by phenol-chloroform extraction and ethanol precipitation.\nDeep sequencing libraries were prepared using the NEBNext Ultra II DNA Library Prep Kit for Illumina.'; [Cell type]'Source: ''treatment: DMSO (1:5000), 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: 100M indole-3-acetic acid, 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; ', 'treatment: DMSO (1:5000), 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; antibody: Pol2; ', 'treatment: 100M indole-3-acetic acid, 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; antibody: Pol2; ', 'treatment: DMSO (1:5000), 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; antibody: S5-phosphorylated Pol2; ', 'treatment: 100M indole-3-acetic acid, 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; antibody: S5-phosphorylated Pol2; ', 'treatment: DMSO (1:5000), 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; antibody: S2-phosphorylated Pol2; ', 'treatment: 100M indole-3-acetic acid, 60 min; cell line: K562; genetic modification: AID-BRD4 / SFFV-OsTir1-T2A-BlastR; 4su labeling time before harvest (min): 60; antibody: S2-phosphorylated Pol2; '",Genome binding/occupancy profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111460,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111460/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA437112,,,,,,,,
GSE104033,The dual methyltransferase METTL13 targets N-terminus and Lys55 of eEF1A and regulates codon-specific translation rates,Homo sapiens,11,SRP118278,2017-09-20,"[Overal design]ribosome profiling and poly(A) RNA sequencing of wildtype and MELL13-KO cells. Libraries were prepared as triplicates, except for wt ribosome profiling libraries that are duplicates only.; [Treatment]'Cells were treated with 100 g/ml cycloheximide (CHX) for 1 min, washed with ice cold PBS containing 100 g/ml CHX and subsequently lysed in lysis buffer (10 mM Tris pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 % Triton X-100, 0.5 mM DTT, 100 g/ml CHX).'; [Growth]'Wild type and EEF1AKMT4-deficient HAP-1 cells were cultured in IMDM GlutaMAX, 10 % FBS and 100 U/ml penicillin-streptomycin.'; [Extraction]'For ribosome profiling, lysates were treated with 250 U RNase I (Ambion) for 10 min at 22 C and shaking at 1400 rpm. The digestion was stopped by addition of 100 U SUPERase In RNase inhibitor (Ambion). Ribosomes were separated on a 10-50 % (w/v) sucrose density gradient in 50 mM Tris pH 7.5, 50 mM NH4Cl, 12 mM MgCl2, 0.5 mM DTT, 100 g/ml CHX for 3 h at 35 000 rpm and 4 C in a TH-641 rotor (Thermo Scientific). Gradients were fractionated at 0.75 ml/min with continuous monitoring of OD254 on a density gradient fractionator (Isco) coupled to a SYR-101 syringe pump (Brandel). SDS was added immediately to 1 % and 400 l fractions were flash-frozen in liquid nitrogen and stored at -80 C until further processing. Monosome fractions were pooled, RNA isolated and separated on 15 % polyacrylamide gels (8 M urea, 1 x TBE). Ribosome footprints were excised between 28 nucleotide (nt) and 32 nt RNA size markers.\nSequencing libraries from ribosome footprints were generated essentially as described by Ingolia and colleagues (Ingolia et al. Nat Prot 2012 , except for ligation to a preadenylated 3-adapter (5 rAppNNNNCTGTAGGCACCATCAAT/3ddC/ 3) in a reaction containing 200 000 U T4 RNA ligase 2 (truncated, NEB), 25 % PEG 8000 and 10 U SUPERase In RNase inhibitor for 4 h at 22 C. RNAseq libraries were prepared using the TruSeq Stranded mRNA Library Prep Kit (Illumina).'; [Cell type]'Source: ''genotype: METTL13-KO; tissue: HAP-1 cells; ', 'genotype: wild type; tissue: HAP-1 cells; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104033,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE104nnn/GSE104033/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA408071,30143613," Magnus E Jakobsson,  Jedrzej M Malecki,  Levon Halabelian,  Benedikt S Nilges,  Rita Pinto,  Srikanth Kudithipudi,  Stephanie Munk,  Erna Davydova,  Fawzi R Zuhairi,  Cheryl H Arrowsmith,  Albert Jeltsch,  Sebastian A Leidel,  Jesper V Olsen,  Pal O Falnes","Eukaryotic elongation factor 1 alpha (eEF1A) delivers aminoacyl-tRNA to the ribosome and thereby plays a key role in protein synthesis. Human eEF1A is subject to extensive post-translational methylation, but several of the responsible enzymes remain unknown. Using a wide range of experimental approaches, we here show that human methyltransferase (MTase)-like protein 13 (METTL13) contains two distinct MTase domains targeting the N terminus and Lys55 of eEF1A, respectively. Our biochemical and structural analyses provide detailed mechanistic insights into recognition of the eEF1A N terminus by METTL13. Moreover, through ribosome profiling, we demonstrate that loss of METTL13 function alters translation dynamics and results in changed translation rates of specific codons. In summary, we here unravel the function of a human MTase, showing that it methylates eEF1A and modulates mRNA translation in a codon-specific manner.",The dual methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates codon-specific translation rates.,10.1038/s41467-018-05646-y,2018 Aug 24,PMC6109062,Nature communications
GSE130898,The RNA hairpin binder TRIM71 modulates alternative splicing by repressing Mbnl1 [RNA-seq & Ribo-seq],Homo sapiens; Mus musculus,60,SRP197096,2019-05-08,"[Overal design]RNA-seq of WT (10 replicates), TRIM71 KO (10 replicates), TRIM71 RING_mut (TRIM71RING; 5 replicates), and TRIM71 NHL_mut(TRIM71NHL, 5 replicates) mESC cells. RNA-seq of WT (8 replicates) and TRIM71 KO (8 replicates) Ne4C cells. RNA-seq of WT (3 replicates) and TRIM71 KO (3 replicates) Huh-7 cells. Ribosome profiling of WT (4 replicates), and TRIM71 KO (4 replicates) mES cells.; [Treatment]'mES (129xC57BL/6) Rosa26Cre-ERT2/BirA-V5', 'mES (129xC57BL/6)  Rosa26Cre-ERT2/BirA-V5 TRIM71-/-', 'mES (129xC57BL/6) Rosa26Cre-ERT2/BirA-V5 TRIM71-/-', 'mES (129xC57BL/6) Rosa26Cre-ERT2/BirA-V5 TRIM71C12AC15A/C12AC15A', 'mES (129xC57BL/6) Rosa26Cre-ERT2/BirA-V5 TRIM71R738A/R738A', 'Ne4C CRL-2925', 'Ne4C CRL-2925 TRIM71-/-', 'Huh-7 AAVS1EGFP::unc-54unc-54::mab-10condensed/EGFP::unc-54unc-54::mab-10condensed', 'Huh-7 AAVS1EGFP::unc-54unc-54::mab-10condensed/EGFP::unc-54unc-54::mab-10condensed TRIM71 -/-'; [Growth]'Mouse embryonic stem cells (129xC57BL/6 Rosa26Cre-ERT2/BirA-V5 [cMB063 (Ostapcuk et al., 2018)]) were cultured on gelatin-coated dishes in mES medium (DMEM [Gibco; 11995065]) supplemented with 15% fetal bovine serum [Gibco], 1 x non-essential amino acids [Gibco], 1mM sodium pyruvate [Gibco], 2mM L-glutamine [Gibco], 0.1 mM -mercaptoethanol [Sigma], 50 g/ml penicillin, 80 g/ml streptomycin, 1x MycoZap Prophylactic [Lonza; VZA-2032], 1x ESGRO LIF [MerckMillipore; ESG1107]) at 37 C in 5% CO2.   Ne4C cells (ATCC CRL-2925 (Schlett and Madarasz, 1997)) were cultured on poly-l-lysine coated dishes in Ne4C medium (DMEM [Gibco; 11885084] supplemented with 10% fetal bovine serum [Sigma], 2mM L-glutamine [Gibco; 25030081], 50 g/ml penicillin, 80 g/ml streptomycin, 1x MycoZap Prophylactic [Lonza; VZA-2032]) at 37 C in 5% CO2.   Huh-7 cells (JCRB0403 (Nakabayashi et al., 1982)) were cultured in Huh-7 medium (DMEM [Gibco; 31966021] supplemented with 10% fetal bovine serum [Sigma] 50 g/ml penicillin, 80 g/ml streptomycin, 1x MycoZap Prophylactic [Lonza; VZA-2032]) at 37 C in 5% CO2.'; [Extraction]'TriZol, RNEasy Mini kit [Quiagen: 74104] with on-column DNAse digestion\nScriptSeq Illumina Total RNA-seq (stranded - high input)', 'Norgen Single Cell RNA Purification Kit [Norgen; 51800] with on-column DNAse digestion [Norgen; 25710]\nScriptSeq Illumina Total RNA-seq (stranded - high input)', 'Norgen Single Cell RNA Purification Kit [Norgen; 51800] with on-column DNAse digestion [Norgen; 25710]\nTruSeq Illumina Total RNA-seq (stranded - high input)', 'TriZol\nTruSeq small RNA kit [Illumina; RS-200] adjusted as described in (Aeschimann et al., 2015)'; [Cell type]'mESC', 'Ne4C', 'Huh-7''cell type: mESC; strain: (129xC57BL/6); genotype: Rosa26Cre-ERT2/BirA-V5; ', 'cell type: mESC; strain: (129xC57BL/6); genotype: Rosa26Cre-ERT2/BirA-V5 TRIM71-/-; ', 'cell type: mESC; strain: (129xC57BL/6); genotype: Rosa26Cre-ERT2/BirA-V5 TRIM71C12AC15A/C12AC15A; ', 'cell type: mESC; strain: (129xC57BL/6); genotype: Rosa26Cre-ERT2/BirA-V5 TRIM71R738A/R738A; ', 'cell type: Ne4C; strain: CRL-2925; genotype: -; ', 'cell type: Ne4C; strain: CRL-2925; genotype: TRIM71-/-; ', 'cell type: Huh-7; strain: JCRB0403; genotype: -; ', 'cell type: Huh-7; strain: JCRB0403; genotype: TRIM71 -/-; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130898,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE130nnn/GSE130898/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA541924,31371437," Thomas Welte,  Alex C Tuck,  Panagiotis Papasaikas,  Sarah H Carl,  Matyas Flemr,  Philip Knuckles,  Aneliya Rankova,  Marc Buhler,  Helge Grosshans","TRIM71/LIN-41, a phylogenetically conserved regulator of development, controls stem cell fates. Mammalian TRIM71 exhibits both RNA-binding and protein ubiquitylation activities, but the functional contribution of either activity and relevant primary targets remain poorly understood. Here, we demonstrate that TRIM71 shapes the transcriptome of mouse embryonic stem cells (mESCs) predominantly through its RNA-binding activity. We reveal that TRIM71 binds targets through 3' untranslated region (UTR) hairpin motifs and that it acts predominantly by target degradation. TRIM71 mutations implicated in etiogenesis of human congenital hydrocephalus impair target silencing. We identify a set of primary targets consistently regulated in various human and mouse cell lines, including MBNL1 (Muscleblind-like protein 1). MBNL1 promotes cell differentiation through regulation of alternative splicing, and we demonstrate that TRIM71 promotes embryonic splicing patterns through MBNL1 repression. Hence, repression of MBNL1-dependent alternative splicing may contribute to TRIM71's function in regulating stem cell fates.",The RNA hairpin binder TRIM71 modulates alternative splicing by repressing MBNL1.,10.1101/gad.328492.119,2019 Sep 1,PMC6719626,Genes & development
GSE92598,mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells,Homo sapiens,35,None,2016-12-19,"[Overal design]35 samples were analyzed. We examined the following comparisons using Limma with a p-value < 0.05, log fold-change > 1.5: PP242 vs. DMSO, PP242+IR vs. DMSO, RAD001 vs DMSO, RAD001 + IR vs DMSO, IR vs DMSO in polysome samples, total sampes, and using translational efficiency.; [Treatment]'not applicable'; [Growth]'Mouse forelimbs dissected from day 11.5 mouse embryos'; [Extraction]'Shh mutant phenotypes were manually identified as wild-type or mutants. All other samples were snap frozen in liquid N2 and genotyped. Either single or dual samples of equivalent genotyped samples (2-4 forelimbs) were used for all other samples. All samples contained 5g of carrier glycogen and were prepared using Trizol. Samples were then treated with the RiobMinus rRNA reduction kit (Invitrogen), cDNA synthesis and amplification was performed using the WT cDNA synthesis and amplification kit (Affymetrix).'; [Cell type]'Source: ''cell line: SUM149; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92598,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE92nnn/GSE92598/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA358095,27956700," Deborah Silvera,  Amanda Ernlund,  Rezina Arju,  Eileen Connolly,  Viviana Volta,  Jinhua Wang,  Robert J Schneider","mTOR coordinates growth signals with metabolic pathways and protein synthesis and is hyperactivated in many human cancers. mTOR exists in two complexes: mTORC1, which stimulates protein, lipid, and ribosome biosynthesis, and mTORC2, which regulates cytoskeleton functions. While mTOR is known to be involved in the DNA damage response, little is actually known regarding the functions of mTORC1 compared to mTORC2 in this regard or the respective impacts on transcriptional versus translational regulation. We show that mTORC1 and mTORC2 are both required to enact DNA damage repair and cell survival, resulting in increased cancer cell survival during DNA damage. Together mTORC1 and -2 enact coordinated transcription and translation of protective cell cycle and DNA replication, recombination, and repair genes. This coordinated transcriptional-translational response to DNA damage was not impaired by rapalog inhibition of mTORC1 or independent inhibition of mTORC1 or mTORC2 but was blocked by inhibition of mTORC1/2. Only mTORC1/2 inhibition reversed cancer cell resistance to DNA damage and replicative stress and increased tumor cell killing and tumor control by DNA damage therapies in animal models. When combined with DNA damage, inhibition of mTORC1/2 blocked transcriptional induction more strongly than translation of DNA replication, survival, and DNA damage response mRNAs.",mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.,10.1128/MCB.00577-16,2017 Mar 1,PMC5311240,Molecular and cellular biology
GSE106899,Multi-Omic Molecular Profiling of Lung Cancer Risk in Chronic Obstructive Pulmonary Disease,Homo sapiens,66,SRP125001,2017-11-15,"[Overal design]Polysome-profiling of lung tumor, adjacent non-cancerous lung stroma tissue samples from the same patient compared to patients without lung cancer across a range of forced expiratory volume in one second (FEV1); [Treatment]'None'; [Growth]'None'; [Extraction]'Frozen lung tissue samples ranging in weight from 25-60 mg were individually ground to a fine powder using a liquid nitrogen cooled ceramic mortar and pestle. For RNA quality control (QC), approximately 20% of each sample was processed with TRI Reagent (Sigma Aldrich, St Louis, MO). Once the initial RNA QC was completed, polyribosome preparations were performed in random sample pairs. For this purpose, the remainder of each frozen powdered sample was solubilized in 100 L of lysis buffer (10 mM Tris-HCl at pH 8.0, 150 mM NaCl, 5 mM MgCl2, 1% Nonidet-P40, 1% sodium deoxycholate, 40 mM dithiothreitol, 500 U/mL RNAsin (Promega, Madison, WI), 40 mM VRC (vanadyl ribonucleoside complex), and 150 g/ml cycloheximide) and mixed by pipetting. Nuclei and insoluble material were removed by centrifugation (12,000 x g, 10 seconds, at 4C). Extraction buffer (50 L; 0.2 M Tris-HCl at pH 7.5, 0.3 M NaCl, 10 mM PMSF) was added to the supernatant and the sample was mixed by pipetting. The sample was centrifuged (12,000 x g, 5 min, at 4 C) and 25% of the supernatant was processed with TRI Reagent to generate a cytosolic total RNA sample. The remaining supernatant was layered onto a 5 mL, linear sucrose gradient (0.51.5 M), 10 mM Tris-HCl pH 7.5, 140 mM NaCl, 3 mM MgCl2, 10 mM DTT. Gradients were centrifuged (200,000 x g in a Beckman SW55Ti rotor for 80 minutes at\xa04o C) and the gradients were fractionated into ten, 0.5 mL fractions utilizing an ISCO density gradient fractionator with absorbance monitored at 254 nm. Each fraction was collected into a tube containing 50 L 1%SDS and 20 L 0.5 M EDTA. The polyribosomal mRNA from fractions 7, 8, 9 and 10 were individually processed with 1 mL of TRI Reagent and 200 L chloroform and the resultant RNA pellets from these four fractions were combined to create the polyribosomal mRNA sample corresponding to each tissue sample. Polyribosomal mRNA and cytosolic RNA were sent to the University of Minnesota Genomics Core for quality assessment by Caliper High Sensitivity Lab Chip. Those samples passing the Caliper QC were processed into indexed library samples for analysis by RNA sequencing. This was accomplished using the SMART-Seq protocol.\nLibraries were quantified using a fluorimetric PicoGreen assay. Library size was assessed using capillary electrophoresis on an Agilent BioAnalyzer 2100 and only libraries quantifying higher than 10 nM were analyzed. Libraries were pooled and assessed using Kapa qPCR to ensure adapters were ligated to DNA fragments and functional. Nextera libraries were hybridized to a single read flow cell and individual fragments were clonally amplified by bridge amplification on the Illumina cBot. Once clustering was complete, the flow cell was loaded on a HiSeq 2000 and sequenced using Illumina SBS chemistry. Upon completion of read 1, an 8-base pair index read for Index 1 was performed. The Index 1 product was removed and the template was reannealed to the flow cell surface. The run proceeded with 8 chemistry-only cycles, followed by an 8-base pair index read to read Index 2.'; [Cell type]'Source: ''tissue: Lung tissue; fraction: Total RNA; group: Lung_tumor; ', 'tissue: Lung tissue; fraction: Heavy, Polyribosomal-bound RNA; group: Lung_tumor; ', 'tissue: Lung tissue; fraction: Total RNA; group: Lung_tumor_adjacent; ', 'tissue: Lung tissue; fraction: Heavy, Polyribosomal-bound RNA; group: Lung_tumor_adjacent; ', 'tissue: Lung tissue; fraction: Total RNA; group: Control; ', 'tissue: Lung tissue; fraction: Heavy, Polyribosomal-bound RNA; group: Control; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106899,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE106nnn/GSE106899/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA418402,29794131," Brian J Sandri,  Adam Kaplan,  Shane W Hodgson,  Mark Peterson,  Svetlana Avdulov,  LeeAnn Higgins,  Todd Markowski,  Ping Yang,  Andrew H Limper,  Timothy J Griffin,  Peter Bitterman,  Eric F Lock,  Chris H Wendt","Chronic obstructive pulmonary disease (COPD) is a known risk factor for developing lung cancer but the underlying mechanisms remain unknown. We hypothesise that the COPD stroma contains molecular mechanisms supporting tumourigenesis.We conducted an unbiased multi-omic analysis to identify gene expression patterns that distinguish COPD stroma in patients with or without lung cancer. We obtained lung tissue from patients with COPD and lung cancer (tumour and adjacent non-malignant tissue) and those with COPD without lung cancer for profiling of proteomic and mRNA (both cytoplasmic and polyribosomal). We used the Joint and Individual Variation Explained (JIVE) method to integrate and analyse across the three datasets.JIVE identified eight latent patterns that robustly distinguished and separated the three groups of tissue samples (tumour, adjacent and control). Predictive variables that associated with the tumour, compared to adjacent stroma, were mainly represented in the transcriptomic data, whereas predictive variables associated with adjacent tissue, compared to controls, were represented at the translatomic level. Pathway analysis revealed extracellular matrix and phosphatidylinositol-4,5-bisphosphate 3-kinase-protein kinase B signalling pathways as important signals in the tumour adjacent stroma.The multi-omic approach distinguishes tumour adjacent stroma in lung cancer and reveals two stromal expression patterns associated with cancer.",Multi-omic molecular profiling of lung cancer in COPD.,10.1183/13993003.02665-2017,2018 Jul,PMC6618293,The European respiratory journal
GSE112230,LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade,Homo sapiens; Mus musculus,29,SRP136272,2018-03-22,"[Overal design]Gene expression profiling of in vitro control and LSD1 KD MCF-7 cells (in biological replicates), as well as ex vivo scramble, LSD1 KO and LSD1/MDA5 DKO B16 tumor cells (in biological triplicates) was analyzed by RNA-seq. Genomic occupancy of LSD1, H3K4me1 and H3K4me2 in in vitro control and LSD1 KD MCF-7 cells, as well as ex vivo scramble and LSD1 KO B16 tumor cells was analyzed by ChIP-seq.; [Treatment]'MCF-7 cells were infected with lentiviral shRNA targeting scramble or LSD1, and selected for 6-8 days before sample collections. B16 tumors grew in mice for 14 days before being excised and digested with collagenase for single cell suspension. GFP+ B16 cells were sorted.'; [Growth]'MCF-7 cells were cultured in normal DMEM supplemented with 10% FBS and 1% penicillin/streptomycin in 5% CO2 incubator at 37 C. GFP-labeled B16 cells were transplanted into WT C56BL/6 mice subcutaneously and tumor grew for 14 days.'; [Extraction]""For MCF-7 cells, cell nuclei were obtained by lysing whole cells in hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% v/v glycerol, 1 mM DTT, and 0.1% v/v Triton X-100) supplemented with protease inhibitor. For GFP-labeled B16 cells isolated from tumor-bearing immunocompetent mice, intact cells were used for the following steps. After washing with PBS, nuclei/cells were fixed in 1% formaldehyde for 10 min at room temperature, followed by quenching in 125 mM glycine. Nuclei/cells were then washed twice with ice-cold PBS, lysed in ChIP sonication buffer (50 mM HEPES pH7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.2% SDS) supplemented with protease inhibitor, and were subjected to sonication to obtain DNA fragments of 300-800 bp. Subsequent procedures were carried out by following the Epigenesys protocol (https://www.epigenesys.eu/en/). The following antibodies were used to ChIP: anti-LSD1 (Abcam, cat# ab17721), anti-H3K4me1 (Abcam, cat#ab8895), anti-H3K4me2 (EMDMillipore, cat#07-030), and mouse IgG (Santa Cruz Biotechnology, cat# sc-2025). || For RNA extraction, cells weredirectly lyzed in TRIzol and total RNA was extracted according to manufacture's instructions.\nChIP-seq libraries were prepared using NEBNext Ultra DNA Library Prep Kit for Illumina (New England Biolabs, cat#E7370L) and NEBNext Multiplex Oligos for Illumina (New England Biolabs, cat# E7335L) according to the manufactures instructions. Library concentrations were quantified by Qubit (Invitrogen) and mixed equally for sequencing at HiSeq 2500 (Illumina) to generate 50 bp reads from single-end. || Purified total RNA from MCF-7 cells or GFP-labeled B16 cells isolated from tumor-bearing immunocompetent mice was quantified by Qubit (Invitrogen) and analyzed by Agilent Bioanalyzer to assess RNA integrity. 1 ?g RNA (RIN>9) was used to generate rRNA-depleted RNA with NEBNext rRNA Depletion Kit (New England Biolabs, cat# E6310S) or poly(A)+ RNA with Magnetic mRNA Isolation Kit (New England Biolabs, cat# S1550S) according to the manufacturers instructions. The rRNA-depleted or poly(A)+ RNA was subjected to Agilent Bioanalyzer to ensure the complete removal of rRNA, and then used to generate directional RNA library with NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs, cat# E7760L) and NEBNext Multiplex Oligos for Illumina (New England Biolabs, cat# E7335L) according to the manufacturers instructions. Library concentrations were quantified by Qubit (Invitrogen) and mixed equally for sequencing at HiSeq 2500 or Nextseq 500 (Illumina) to generate 50 bp reads (MCF-7) or 75 bp (B16) from paired-ends.""; [Cell type]'Source: ''tissue: MCF-7 breast cancer cell line; molecule: genomic DNA; antibody: n/a; ', 'tissue: MCF-7 breast cancer cell line; molecule: genomic DNA; antibody: LSD1 (Abcam, cat#17721); ', 'tissue: MCF-7 breast cancer cell line; molecule: genomic DNA; antibody: H3K4me1 (Abcam, cat#ab8895); ', 'tissue: MCF-7 breast cancer cell line; molecule: genomic DNA; antibody: H3K4me2 (EMDMIpplipore, cat#07-030); ', 'tissue: MCF-7 breast cancer cell line; molecule: Ribosome depleted RNA; ', 'tissue: B16 tumor transplanted in C56BL/6 mice; molecule: genomic DNA; antibody: n/a; ', 'tissue: B16 tumor transplanted in C56BL/6 mice; molecule: genomic DNA; antibody: LSD1 (Abcam, cat#17721); ', 'tissue: B16 tumor transplanted in C56BL/6 mice; molecule: genomic DNA; antibody: H3K4me1 (Abcam, cat#ab8895); ', 'tissue: B16 tumor transplanted in C56BL/6 mice; molecule: genomic DNA; antibody: H3K4me2 (EMDMIpplipore, cat#07-030); ', 'tissue: B16 tumor transplanted in C56BL/6 mice; molecule: Ribosome depleted RNA; ', 'tissue: B16 tumor transplanted in C56BL/6 mice; molecule: Poly-A enriched RNA; '",Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112230,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112230/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445303,29937226," Jesse Milzman,  Wanqiang Sheng,  Doron Levy,  Wanqiang Sheng,  Martin W LaFleur,  Thao H Nguyen,  Sujun Chen,  Ankur Chakravarthy,  Jake Ryan Conway,  Ying Li,  Hao Chen,  Henry Yang,  Pang-Hung Hsu,  Eliezer M Van Allen,  Gordon J Freeman,  Daniel D De Carvalho,  Housheng Hansen He,  Arlene H Sharpe,  Yang Shi","Chromatin regulators play a broad role in regulating gene expression and, when gone awry, can lead to cancer. Here, we demonstrate that ablation of the histone demethylase LSD1 in cancer cells increases repetitive element expression, including endogenous retroviral elements (ERVs), and decreases expression of RNA-induced silencing complex (RISC) components. Significantly, this leads to double-stranded RNA (dsRNA) stress and activation of type 1 interferon, which stimulates anti-tumor T cell immunity and restrains tumor growth. Furthermore, LSD1 depletion enhances tumor immunogenicity and T cell infiltration in poorly immunogenic tumors and elicits significant responses of checkpoint blockade-refractory mouse melanoma to anti-PD-1 therapy. Consistently, TCGA data analysis shows an inverse correlation between LSD1 expression and CD8(+) T cell infiltration in various human cancers. Our study identifies LSD1 as a potent inhibitor of anti-tumor immunity and responsiveness to immunotherapy and suggests LSD1 inhibition combined with PD-(L)1 blockade as a novel cancer treatment strategy.",LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.,10.1016/j.cell.2018.05.052,2018 Jul 26,PMC6063761,Cell
GSE111457,SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis [Quant-Seq],Homo sapiens,19,SRP134014,2018-03-06,"[Overal design]Baseline gene expression profiling of clonal cell lines engineered to express AID-tagged proteins and unedited controls by 3'mRNA sequencing.; [Treatment]'None'; [Growth]'None'; [Extraction]""Total RNA was extracted using a commercial column purification kit.\n3'UTR sequencing libraries were generated from 500ng total RNA using a commercial kit (QuantSeq 3' mRNA-Seq Library Prep Kit FWD for Illumina, Lexogen).""; [Cell type]'Source: ''cell line: K562; ', 'cell line: K562; genetic modification: AID-BRD4; ', 'cell line: K562; genetic modification: MYC-AID; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111457,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111457/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA437106,,,,,,,,
GSE66927,Ribo_seq (aka ribosome profiling) analysis of control and Myc-induced U2OS cells,Homo sapiens,10,SRP056200,2015-03-16,"[Overal design]We measure ribosome occupancy profiles in U2OS cells containing an inducible Myc expression vector that were induced or mock-treated in duplicates for 36 hours. In addition, we repeated the experiments in the presence of Torin-1, an inhibitor of mTOR.; [Treatment]'U2OS cells containing inducible Myc expression vector were induced or mock-treated in duplicates for 36 hours'; [Growth]""Myc-inducible U2OS cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum in 5% CO2\xa0at 37C.""; [Extraction]'Cells were treated with cycloheximide (100\xa0?g/ml) for 5 minutes, washed with ice-cold phosphate-buffered saline (cycloheximide, 100\xa0?g/ml), pelleted, and lysed in buffer A (20\xa0mM Tris-HCl, pH\xa07.8, 100\xa0mM KCl, 10\xa0mM MgCl2, 1% Triton X-100, 2\xa0mM DTT, 100\xa0?g/ml cycloheximide, 1X complete protease inhibitor). Lysates were centrifuged at 5,000\xa0rpm and the supernatant was treated with 2\xa0U/?l of RNase I (Ambion) for 40 min at room temperature. Lysates were fractionated on a linear sucrose gradient (7% to 47%) using the SW-41Ti rotor at 36,000\xa0rpm for 2\xa0h. Fractions enriched in monosomes were pooled and treated with proteinase K (Roche) in a 1% SDS solution. Released RNA fragments were purified using TRIsure reagent and precipitated in the presence of glycogen. For libraries preparation, RNA was gel-purified on a denaturing 10% polyacrylamide urea (7\xa0M) gel. A section corresponding to 30 to 33 nucleotides, the region where most of the ribosome-protected fragments are comprised, was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England BioLabs, Inc.) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England BioLabs, Inc.) for 2.5\xa0h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18\xa0h at 22C.\n3' adaptor was added with T4 RNA ligase 1 (New England BioLabs, Inc.) for 2.5\xa0h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18\xa0h at 22C.'; [Cell type]'U2OS''cell type: U2OS; treatment: control; ', 'cell type: U2OS; treatment: Myc activation (36 hr); ', 'cell type: U2OS; treatment: Torin-1; ', 'cell type: U2OS; treatment: Myc activation + Torin-1; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66927,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE66nnn/GSE66927/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA278390,26538417," Ran Elkon,  Fabricio Loayza-Puch,  Gozde Korkmaz,  Rui Lopes,  Pieter C van Breugel,  Onno B Bleijerveld,  A F Maarten Altelaar,  Elmar Wolf,  Francesca Lorenzin,  Martin Eilers,  Reuven Agami","c-Myc is one of the major human proto-oncogenes and is often associated with tumor aggression and poor clinical outcome. Paradoxically, Myc was also reported as a suppressor of cell motility, invasiveness, and metastasis. Among the direct targets of Myc are many components of the protein synthesis machinery whose induction results in an overall increase in protein synthesis that empowers tumor cell growth. At present, it is largely unknown whether beyond the global enhancement of protein synthesis, Myc activation results in translation modulation of specific genes. Here, we measured Myc-induced global changes in gene expression at the transcription, translation, and protein levels and uncovered extensive transcript-specific regulation of protein translation. Particularly, we detected a broad coordination between regulation of transcription and translation upon modulation of Myc activity and showed the connection of these responses to mTOR signaling to enhance oncogenic transformation and to the TGFbeta pathway to modulate cell migration and invasiveness. Our results elucidate novel facets of Myc-induced cellular responses and provide a more comprehensive view of the consequences of its activation in cancer cells.",Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.,10.15252/embr.201540717,2015 Dec,PMC4687422,EMBO reports
GSE138638,Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides [Dataset 1],Homo sapiens,26,SRP224952,2019-10-09,"[Overal design]18 ribosome profiling and 8 paired-end RNA-seq samples are included from HEK293T cells; [Treatment]'Aminoglycosides were added to cells, and treated for either 10 minutes or 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation. For RNAseq, total RNA was extracted using Trizol, and sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Library Prep Gold (20020598) kit.\nFor ribosome profiling, fragments ranging from 15-34 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing. RNA-seq samples were prepared from 1 ug of total RNA following the Truseq protocol.'; [Cell type]'Source: ''cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Gentamicin; concentration: 500 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Paromomycin; concentration: 3000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Neomycin; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Tobramycin; concentration: 1000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Amikacin; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Amikcain; concentration: 2000 ug/mL; duration: 24 hours; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 10 minutes; adapter: NNNNNNCACTCGGGCACCAAGGAC; ', 'cell line: HEK293T cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: G418; concentration: 2000 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: HEK293T cells; treatment: G418; concentration: 500 ug/mL; duration: 10 minutes; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138638,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138638/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576649,31971508," Jamie R Wangen,  Rachel Green",eng,Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.,10.7554/eLife.52611,2020 Jan 23,PMC7089771,eLife
GSE68705,Genome-wide reprogramming of transcript architecture by temperature specifies the developmental states of the human pathogen Histoplasma [ribosome profiling],Histoplasma capsulatum,8,SRP058148,2015-05-08,"[Overal design]mRNA libraries were prepared with or without ribosome footprinting for two biological replicates each from cells grown in the yeast or hyphal phase (8 samples total).; [Treatment]'None'; [Growth]'Biological duplicates of G217B yeast cells were grown at 37C in HMM liquid medium to mid-log phase. Biological duplicates of G217B hyphal cells were grown for 4  6 weeks with passaging three times (1:5 dilution) into fresh HMM medium at RT before reaching a sufficient density of cells for harvesting.'; [Extraction]'Hyphal and yeast cells were treated with 100 ?g/mL cycloheximide for 2 minutes (MP Biomedicals, Santa Ana, CA) before harvesting of cells by filtration. Total RNA for mRNA library preparation was isolated from a small fraction of the total yeast or hyphal cells collected for ribosome profiling using a guanidine thiocyanate lysis protocol as previously described (Hwang et al, Molecular Biology of the Cell 14:2314).\nRibosome profiling and matched mRNA-seq sample preparation and library building were performed as described (Ingolia et al Science 324:218), except that the 3' linker ligation strategy was used instead of poly(A) tailing for marking and capturing the 3 RNA end (Dunn et al eLife 2:e01179). Libraries were multiplexed and subjected to 50 bp single-end sequencing with an Illumina HiSeq2000 sequencer (Illumina).'; [Cell type]'Source: ''strain: G217B; growth phase: hyphae; ', 'strain: G217B; growth phase: yeast; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68705,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68705/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA283425,26177267," Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil,  Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil","Eukaryotic cells integrate layers of gene regulation to coordinate complex cellular processes; however, mechanisms of post-transcriptional gene regulation remain poorly studied. The human fungal pathogen Histoplasma capsulatum (Hc) responds to environmental or host temperature by initiating unique transcriptional programs to specify multicellular (hyphae) or unicellular (yeast) developmental states that function in infectivity or pathogenesis, respectively. Here we used recent advances in next-generation sequencing to uncover a novel re-programming of transcript length between Hc developmental cell types. We found that ~2% percent of Hc transcripts exhibit 5' leader sequences that differ markedly in length between morphogenetic states. Ribosome density and mRNA abundance measurements of differential leader transcripts revealed nuanced transcriptional and translational regulation. One such class of regulated longer leader transcripts exhibited tight transcriptional and translational repression. Further examination of these dually repressed genes revealed that some control Hc morphology and that their strict regulation is necessary for the pathogen to make appropriate developmental decisions in response to temperature.",Genome-Wide Reprogramming of Transcript Architecture by Temperature Specifies the Developmental States of the Human Pathogen Histoplasma.,10.1371/journal.pgen.1005395,2015 Jul,PMC4503680,PLoS genetics
GSE45366,Loss of a Conserved tRNA Anticodon Modification Perturbs Cellular Signaling,Saccharomyces cerevisiae,24,SRP019833,2013-03-20,"[Overal design]WT yeast and mutants lacking anticodon tRNA modifications were grown in YPD, and subjected to ribosome footprint profiling (ribo-seq) and RNA-seq of poly-A selected RNA. Dataset contains biological replicates for WT, ?ncs6 and ?uba4. Technical replicates were also performed for all RNA-seq datasets (using a different poly-A selection method).; [Treatment]'Cells were treated with 100ug/ml cycloheximide, then harvested by centrifugation. Cell pellet was frozen in liquid nitrogen.'; [Growth]'Yeast were grown to mid-exponential phase (OD~0.7) at 30C in YPD'; [Extraction]""Small RNA sequencing by polyadenylation and circularization. RNA fragments were dephosphorylated, purified by filtration then gel to isolate ~28nt fragments. After subtractive hybridization to remove rRNA, fragments were poly(A) tailed and reverse transcribed with an anchored oligo-dT primer, followed by cDNA circularization and PCR. Frozen cell pellets were thawed in lysis buffer and lysis was performed with glass beads as described in the text. Extracts were clarified by a 20' spin at 11,500 rpm in an SS-34 rotor.\nFootprints: 50 OD units of extract were treated with 150U of RNAse1 and subsequently purified from the monosome region of a sucrose gradient. RNA was extracted by hot acid phenol. Total RNA: RNA was extracted from 50 OD of extract by SDS and hot acid phenol, and poly(A) RNA was purified on oligo-dT cellulose or DynaBeads. RNA was fragmented at 95C with zinc chloride""; [Cell type]'Source: ''triton addition: Before lysis; strain: BY4741; ', 'triton addition: After lysis; strain: BY4741; ', 'poly-a selection: oligo-dT DynaBeads; triton addition: Before lysis; strain: BY4741; ', 'poly-a selection: oligo-dT DynaBeads; triton addition: After lysis; strain: BY4741; ', 'poly-a selection: oligo-dT cellulose; triton addition: Before lysis; strain: BY4741; ', 'poly-a selection: oligo-dT cellulose; triton addition: After lysis; strain: BY4741; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45366,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE45nnn/GSE45366/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA193543,23935536," Boris Zinshteyn,  Wendy V Gilbert","Transfer RNA (tRNA) modifications enhance the efficiency, specificity and fidelity of translation in all organisms. The anticodon modification mcm(5)s(2)U(34) is required for normal growth and stress resistance in yeast; mutants lacking this modification have numerous phenotypes. Mutations in the homologous human genes are linked to neurological disease. The yeast phenotypes can be ameliorated by overexpression of specific tRNAs, suggesting that the modifications are necessary for efficient translation of specific codons. We determined the in vivo ribosome distributions at single codon resolution in yeast strains lacking mcm(5)s(2)U. We found accumulations at AAA, CAA, and GAA codons, suggesting that translation is slow when these codons are in the ribosomal A site, but these changes appeared too small to affect protein output. Instead, we observed activation of the GCN4-mediated stress response by a non-canonical pathway. Thus, loss of mcm(5)s(2)U causes global effects on gene expression due to perturbation of cellular signaling.",Loss of a conserved tRNA anticodon modification perturbs cellular signaling.,10.1371/journal.pgen.1003675,2013,PMC3731203,PLoS genetics
GSE119681,Ribosome profiling of selenoproteins in vivo reveals consequences of pathogenic Secisbp2 missense mutations,Mus musculus,8,SRP160398,2018-09-07,"[Overal design]Ribosome profiling and RNA-sequencing of cortex samples from 2 Secisbp2 R543Q/fl; Camk-Cre pos mice and 2 control mice.; [Treatment]'None'; [Growth]'None'; [Extraction]""Tissue powder was lysed in lysis buffer (10 mM Tris-Cl (pH 7.5), 300 mM KCl, 10 mM MgCl2, 25 mg/ml cycloheximide, 100 mM DTT and 1% Triton X-100), ribosome pellets were resuspended in Qiazol (Qiagen) after centrifugation of RNaseI digested monosomes in 50% sucrose buffer, ribosome protected fragments were isolated using miRNeasy kit (Qiagen) according to manufacturer protocol with modification to retain small RNAs.\nRPFs were electrophoresed on a 15% Tris-Borate-EDTA (TBE) Urea gel and RNA fragments between 20 and 40 nts in size were purified prior to the construction of libraries for deep-sequencing. Small RNA sequencing libraries were constructed using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs), according to the manufacturer's instructions."", ""Qiazol (Qiagen) according to manufacturer protocol, Poly(A) Purist Mag kit (Ambion) was used to isolate polyA mRNA.\nRandomly fragmented PolyA enriched total RNA was electrophoresed on a 15% Tris-Borate-EDTA (TBE) Urea gel and RNA fragments between 20 and 40 nts in size were purified prior to the construction of libraries for deep-sequencing. Small RNA sequencing libraries were constructed using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs), according to the manufacturer's instructions.""; [Cell type]'Source: ''strain/background: C57BL/6; genotype/variation: Sbp2 wt/wt; Camk-Cre neg; gender: male; tissue: brain cortex; age: postnatal day 34; ', 'strain/background: C57BL/6; genotype/variation: Sbp2 fl/R543Q; Camk-Cre pos; gender: male; tissue: brain cortex; age: postnatal day 34; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119681,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE119nnn/GSE119681/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA489895,31350336," Wenchao Zhao,  Simon Bohleber,  Henrik Schmidt,  Sandra Seeher,  Michael T Howard,  Doreen Braun,  Simone Arndt,  Uschi Reuter,  Hagen Wende,  Carmen Birchmeier,  Noelia Fradejas-Villar,  Ulrich Schweizer","Recoding of UGA codons as selenocysteine (Sec) codons in selenoproteins depends on a selenocysteine insertion sequence (SECIS) in the 3'-UTR of mRNAs of eukaryotic selenoproteins. SECIS-binding protein 2 (SECISBP2) increases the efficiency of this process. Pathogenic mutations in SECISBP2 reduce selenoprotein expression and lead to phenotypes associated with the reduction of deiodinase activities and selenoprotein N expression in humans. Two functions have been ascribed to SECISBP2: binding of SECIS elements in selenoprotein mRNAs and facilitation of co-translational Sec insertion. To separately probe both functions, we established here two mouse models carrying two pathogenic missense mutations in Secisbp2 previously identified in patients. We found that the C696R substitution in the RNA-binding domain abrogates SECIS binding and does not support selenoprotein translation above the level of a complete Secisbp2 null mutation. The R543Q missense substitution located in the selenocysteine insertion domain resulted in residual activity and caused reduced selenoprotein translation, as demonstrated by ribosomal profiling to determine the impact on UGA recoding in individual selenoproteins. We found, however, that the R543Q variant is thermally unstable in vitro and completely degraded in the mouse liver in vivo, while being partially functional in the brain. The moderate impairment of selenoprotein expression in neurons led to astrogliosis and transcriptional induction of genes associated with immune responses. We conclude that differential SECISBP2 protein stability in individual cell types may dictate clinical phenotypes to a much greater extent than molecular interactions involving a mutated amino acid in SECISBP2.",Ribosome profiling of selenoproteins in vivo reveals consequences of pathogenic Secisbp2 missense mutations.,10.1074/jbc.RA119.009369,2019 Sep 27,PMC6768643,The Journal of biological chemistry
GSE61742,Impact of regulatory variation from RNA to protein,Homo sapiens,72,SRP047476,2014-09-25,"[Overal design]We measured level of translation transcriptome-wide in lymphoblastoid cell lines derived from 72 HapMap Yoruba individuals using ribosome profiling assay, for which we have transcript level, protein level (62 out of 72) and genotype information collected.; [Treatment]'None'; [Growth]'Cells were cultured at 37 degree Celsius and 5% CO2 in RPMI 1640 (supplemented with 2mM L-glutamine and 15% fetal bovine serum)'; [Extraction]'Ribosome footprint profiling experiments were performed using ARTseqTM Ribosome Profiling kit for mammalian cells (RPHMR12126) following vendors instructions. Cell lysates were prepared from flash frozen pellets of 30 to 50 million live cells by repeat pipetting in 1 ml cold lysis buffer. Sephacryl S400 spin column (GE; 27-5140-01) was used for monosome isolation. For rRNA depletion, Ribo-Zero Magnetic Kit (Epicentre; MRZH11124) was used.\nRibosome footprint cDNA libraries were PCR amplified (12 to 15 thermo-cycles) and barcoded using ScriptMiner Index PCR Primers (Epicentre; SMIP2124). Indexed libraries were pooled to sequence on an Illumina HiSeq 2500.'; [Cell type]'Lymphoblastoid Cell Line''gender: Male; cell line: GM18486; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18498; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18499; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18501; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18502; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18504; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18505; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18507; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18508; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18510; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18511; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18516; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18517; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18519; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18520; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18522; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18523; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18852; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18853; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18855; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18856; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18858; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18861; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18862; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18870; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18907; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18909; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18912; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM18913; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM18916; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19092; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19093; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19098; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19099; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19101; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19102; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19108; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19114; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19116; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19119; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19127; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19128; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19130; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19131; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19137; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19138; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19140; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19141; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19143; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19144; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19147; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19152; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19153; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19159; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19160; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19171; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19172; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19190; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19192; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19193; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19200; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19201; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19204; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19207; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19209; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19210; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19222; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19223; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19225; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19238; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Male; cell line: GM19239; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; ', 'gender: Female; cell line: GM19257; cell type: Lymphoblastoid Cell Line; enrichment type: ribosome protected fragments; molecule subtype: cytoplasmic RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61742,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE61nnn/GSE61742/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA262009,25657249," Alexis Battle,  Zia Khan,  Sidney H Wang,  Amy Mitrano,  Michael J Ford,  Jonathan K Pritchard,  Yoav Gilad","The phenotypic consequences of expression quantitative trait loci (eQTLs) are presumably due to their effects on protein expression levels. Yet the impact of genetic variation, including eQTLs, on protein levels remains poorly understood. To address this, we mapped genetic variants that are associated with eQTLs, ribosome occupancy (rQTLs), or protein abundance (pQTLs). We found that most QTLs are associated with transcript expression levels, with consequent effects on ribosome and protein levels. However, eQTLs tend to have significantly reduced effect sizes on protein levels, which suggests that their potential impact on downstream phenotypes is often attenuated or buffered. Additionally, we identified a class of cis QTLs that affect protein abundance with little or no effect on messenger RNA or ribosome levels, which suggests that they may arise from differences in posttranslational regulation.",Genomic variation. Impact of regulatory variation from RNA to protein.,10.1126/science.1260793,2015 Feb 6,PMC4507520,"Science (New York, N.Y.)"
GSE45785,"Transcriptome-profiling (RNA-seq) and Ribosome-profiling (Ribo-seq) of BJ cells treated with Nutlin-3a, an MDM2 inhibitor, which induces p53.",Homo sapiens,10,SRP020544,2013-04-04,"[Overal design]RNA-seq, using Illumina HiSeq 2000, was applied to BJ cells treated with Nutlin-3a, at 5 timepoints: 0, 2, 4, 6, 19 hrs Ribosome profiling was applied to BJ cells treated with Nutlin-3a, at 5 timepoints: 0, 2, 4, 6, 19 hrs; [Treatment]'None'; [Growth]'Immortalized human BJ primary fibroblast cells (by hTERT expression) were cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS) in 5% CO2\xa0at 37\xa0C.'; [Extraction]""Total RNA was isolated using Trizol Reagent (Invitrogen), following the  manufacturer's instructions. Poly(A) was isolated using the Oligotex mRNA mini kit (Qiagen)\nLibraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the  manufacturer's instructions."", 'Cells were treated with cycloheximide (100 ?g/ml) for 8-10 minutes, washed with ice-cold PBS (cycloheximide, 100 ?g/ml), pelleted, and lysed in buffer A (20 mM Tris-HCl, pH7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml cycloheximide, 1x complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7%-47%) using the SW-41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in monosomes were polled and treated wih proteinase K (Roche) in 1%SDS. Released RNA fragments were purified using trizol and precipitated in the presence of glycogen.\nRNA from the pooled monosomes was gel-purified on a denaturing 10% polyacrylamide urea (7M) gel. A section corresponding to 30-33 nucleotides, the region where most of the ribosome-protected fragments are comprised, was excised, eluted, and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 PNK (NEB) for 6 h at 37 C in MES buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (NEB) for 2.5h at 37C. Ligation products were 5'-phosphorylated with T4 PNK for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18h at 22C.'; [Cell type]'Source: ''cell line: BJ cells; condition: Control sample; ', 'cell line: BJ cells; condition: Nutlin-3a, 2h; ', 'cell line: BJ cells; condition: Nutlin-3a, 4h; ', 'cell line: BJ cells; condition: Nutlin-3a, 6h; ', 'cell line: BJ cells; condition: Nutlin-3a, 19h; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45785,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE45nnn/GSE45785/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA196335,23594524," Fabricio Loayza-Puch,  Jarno Drost,  Koos Rooijers,  Rui Lopes,  Ran Elkon,  Reuven Agami","BACKGROUND: Cell growth and proliferation are tightly connected to ensure that appropriately sized daughter cells are generated following mitosis. Energy stress blocks cell growth and proliferation, a critical response for survival under extreme conditions. Excessive oncogenic stress leads to p53 activation and the induction of senescence, an irreversible state of cell-cycle arrest and a critical component in the suppression of tumorigenesis. Nutrient-sensing and mitogenic cues converge on a major signaling node, which regulates the activity of the mTOR kinase. Although transcriptional responses to energy and oncogenic stresses have been examined by many gene-expression experiments, a global exploration of the modulation of mRNA translation in response to these conditions is lacking. RESULTS: We combine RNA sequencing and ribosomal profiling analyses to systematically delineate modes of transcriptional and translational regulation induced in response to conditions of limited energy, oncogenic stress and cellular transformation. We detect a key role for mTOR and p53 in these distinct physiological states, and provide the first genome-wide demonstration that p53 activation results in mTOR inhibition and a consequent global repression of protein translation. We confirm the role of the direct p53 target genes Sestrin1 and Sestrin2 in this response, as part of the broad modulation of gene expression induced by p53 activation. CONCLUSIONS: We delineate a bimodal tumor-suppressive regulatory program activated by p53, in which cell-cycle arrest is imposed mainly at the transcriptional level, whereas cell growth inhibition is enforced by global repression of the translation machinery.",p53 induces transcriptional and translational programs to suppress cell proliferation and growth.,10.1186/gb-2013-14-4-r32,2013 Apr 17,PMC4053767,Genome biology
GSE132010,Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection,Homo sapiens,28,None,2019-05-31,"[Overal design]Refer to individual Series; [Treatment]'N/A.', 'N/A'; [Growth]'HCT116 cells were infected with lentivirus to deliver Cas9 and sgRNAs targeting either EIF5A or DOHH, or non-target sgRNAs. Successfully transduced cells were selected in puromycin for 6 days, before harvesting for both ribosome profiling and RNA-sequencing as described in McGlincy and Ingolia, Methods, 2017.', ""Fluorescent-reporter coupled CRISPR/Cas9-mediated loss of function screening was carried out as described in Golden et al., Nature, 2017, in both MYC 5' UTR and control EGFP reporter cell lines. Reporter cell line generation is described in the manuscript.""; [Extraction]'Ribosome protected fragments were isolated as described in McGlincy and Ingolia, Methods, 2017.\nRibosome profiling libraries were prepared as described in Ingolia et al., Nature Protocols, 2012, and McGlincy and Ingolia, Methods, 2017, and sequenced on a NextSeq500 platform.', 'Cells were harvested in lysis buffer and RNA was extracted using the Direct-zol RNA miniprep kit (Zymoresearch) as described in McGlincy and Ingolia, Methods, 2017.\nRNA-seq libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina) and sequenced using the 75 bp single-read protocol on a NextSeq 500 platform (Illumina).', 'Genomic DNA was extracted from cell pellets using either a gDNA isolation method that has been previously described Golden et al., Nature, 2017 for the sorted cells or the DNeasy Blood and Tissue Kit (Qiagen) for the unsorted cells.\nPCR amplicon libraries were generated as described in Golden et al., Nature, 2017.'; [Cell type]'Source: ''genotype: EIF5A-/-; sgrna received: EIF5A sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: EIF5A-/-; sgrna received: EIF5A sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'genotype: DOHH-/-; sgrna received: DOHH sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: DOHH-/-; sgrna received: DOHH sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'genotype: +/+; sgrna received: NT sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: +/+; sgrna received: NT sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'reporter cell line: control EGFP reporter; lentiviral library received: GeCKO v2_Library A; tissue: HCT116 colon cancer cell line; ', 'reporter cell line: control EGFP reporter; lentiviral library received: GeCKO v2_Library B; tissue: HCT116 colon cancer cell line; ', ""reporter cell line: MYC 5' UTR reporter; lentiviral library received: GeCKO v2_Library A; tissue: HCT116 colon cancer cell line; "", ""reporter cell line: MYC 5' UTR reporter; lentiviral library received: GeCKO v2_Library B; tissue: HCT116 colon cancer cell line; """,Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132010,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132010/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA545619,31801078," Hema Manjunath,  He Zhang,  Frederick Rehfeld,  Jaeil Han,  Tsung-Cheng Chang,  Joshua T Mendell","Sequences within 5' UTRs dictate the site and efficiency of translation initiation. In this study, an unbiased screen designed to interrogate the 5' UTR-mediated regulation of the growth-promoting gene MYC unexpectedly revealed the ribosomal pause relief factor eIF5A as a regulator of translation initiation codon selection. Depletion of eIF5A enhances upstream translation within 5' UTRs across yeast and human transcriptomes, including on the MYC transcript, where this results in increased production of an N-terminally extended protein. Furthermore, ribosome profiling experiments established that the function of eIF5A as a suppressor of ribosomal pausing at sites of suboptimal peptide bond formation is conserved in human cells. We present evidence that proximal ribosomal pausing on a transcript triggers enhanced use of upstream suboptimal or non-canonical initiation codons. Thus, we propose that eIF5A functions not only to maintain efficient translation elongation in eukaryotic cells but also to maintain the fidelity of translation initiation.",Suppression of Ribosomal Pausing by eIF5A Is Necessary to Maintain the Fidelity of Start Codon Selection.,10.1016/j.celrep.2019.10.129,2019 Dec 3,PMC6917043,Cell reports
GSE124800,Rules governing translation selectivity under limiting ribosome availability,Homo sapiens,6,None,2019-01-08,"[Overal design]The purpose of the dataset is to profile analyze the effect of silencing RPS14; [Treatment]'A scramble (SCR) control shRNA and RPS14 shRNA (640 and 641) were cloned in pLKO.1 Tet-On vector. Cells were selected with puromycine (1 mg/mL). shRNA expression was induced by doxycycline (0.2 ?g/mL) for 3 days'; [Growth]'The K562 cell line was cultured in ?Minimum Essential Medium (?MEM) containing 10% fetal calf serum (FCS), 1mM glutamine, 100UI/mL penicillin-streptomycin'; [Extraction]'RNA was extracted using the Kit QIAamp RNA Blood MiniKit. RNA from ribosomal fractions was purified using Trizol (Invitrogen).'; [Cell type]'Source: ''cell line: K562; genotype/variation: lentivirus expressing scramble (SCR) control shRNA; time post induction: 5 days after induction; molecule subtype: RNA extracted from heavy polysomes; ', 'cell line: K562; genotype/variation: lentivirus expressing RPS14 shRNA; time post induction: 5 days after induction; molecule subtype: RNA extracted from heavy polysomes; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124800,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE124nnn/GSE124800/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA513511,32327500," Ismael Boussaid,  Salome Le Goff,  Celia Floquet,  Emilie-Fleur Gautier,  Anna Raimbault,  Pierre-Julien Viailly,  Dina Al Dulaimi,  Barbara Burroni,  Isabelle Dusanter-Fourt,  Isabelle Hatin,  Patrick Mayeux,  Bertrand Cosson,  Michaela Fontenay",,Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells.,10.3324/haematol.2019.239970,2021 Mar 1,PMC7927886,Haematologica
GSE56924,Ribosome profiling reveals an important role for translational control in circadian gene expression,Homo sapiens,96,SRP041298,2014-04-18,"[Overal design]U2-OS cell time course over one day of 12 wildtype total RNA-seq samples, 12 wildtype ribosome profiling samples, 12 Bmal1 knockdown total RNA-seq samples and 12 Bmal1 knockdown ribosome profiling samples. All samples have duplicates.; [Treatment]'To synchronize cells grown overnight, their media was replaced with phenol red free DMEM containing 0.1 mM luciferin and 0.1 ?M dexamethasone. Plates were then sealed with sterile vacuum grease (Corning) and incubated in a 36?C, non-humidified incubator at 5% CO2'; [Growth]'A U2OS human osteosarcoma cell line expressing luciferase under the control of the Per2 promoter was used. Cells were maintained in a humidified 37?C incubator at 5% CO2 in DMEM (Life Technologies), supplemented with 10% FBS, 4 mM L-glutamine, 50 units/mL penicillin, and 50 ?g/mL streptomycin. 2.25x10^6 cells were seeded per 15 cm plate. These cells were grown overnight.'; [Extraction]'Cells in 15 cm plates were treated with 100 ?g/mL cycloheximide for 3 minutes at 36?C, 24.5 hours post-synchronization when luciferase levels were at their nadir. Cells were 80% confluent at the time of collection. All subsequent steps were done on ice. Spent media was aspirated from the plates and the cells were washed with 10 mL of cold PBS before treatment with 790 ?L of cold lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 100 ?g/mL cycloheximide, 1% Triton X-100, and 0.02 units/?L Turbo DNase]. Cells were recovered from the plate using a cell scraper, triturated with a 1.0 mL pipette, and incubated on ice for 10 minutes with occasional mixing. The lysate was then triturated 10 times through a 26 gauge needle and centrifuged at 20,000 g for 10 minutes at 4?C. 150 ?L of the cleared lysate was added to 700 ?L of QIAzol lysis reagent and stored at -80?C. Collection of cells was repeated every 2 hours for an entire 24 hour time course. Cleared lysate frozen with QIAzol lysis reagent was processed according to the Qiagen miRNeasy Quick-Start Protocol.\nRNA integrity was verified by Bioanalyzer (Agilent Technologies) before library preparation as described according to the TruSeq Stranded Total RNA Sample Prep Kit (Illumina).', 'Cells in 15 cm plates were treated with 100 ?g/mL cycloheximide for 3 minutes at 36?C, 24.5 hours post-synchronization when luciferase levels were at their nadir. Cells were 80% confluent at the time of collection. All subsequent steps were done on ice. Spent media was aspirated from the plates and the cells were washed with 10 mL of cold PBS before treatment with 790 ?L of cold lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 100 ?g/mL cycloheximide, 1% Triton X-100, and 0.02 units/?L Turbo DNase]. Cells were recovered from the plate using a cell scraper, triturated with a 1.0 mL pipette, and incubated on ice for 10 minutes with occasional mixing. The lysate was then triturated 10 times through a 26 gauge needle and centrifuged at 20,000 g for 10 minutes at 4?C. Cleared lysate was flash frozen in a dry ice/ethanol bath before storage at -80?C. Collection of cells was repeated every 2 hours for an entire 24 hour time course.\nFrozen cleared lysate was thawed on ice, and RNase I (Life Technologies) was added to 400 ?L of cleared lysate to a final activity of 0.75 units/?L. This mixture was incubated for 45 minutes at room temperature with gentle mixing on a tube rotator, and the nuclease was subsequently inactivated by the addition of 20 ?L of SUPERaseIn (Life Technologies). The digestion was carefully layered onto a 0.9 mL sucrose cushion [20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 100 ?g/mL cycloheximide, 20 units/mL SUPERaseIn, 34% sucrose, w/v] in an 11 \uf0b4 34 mm polycarbonate ultracentrifuge tube (Beckman Coulter), and centrifuged for 4 hours at 78,000 rpm in a prechilled TLA-100.2 rotor. The ribosome pellet was resuspended in 700 ?L of QIAzol lysis reagent and processed according to the Qiagen miRNeasy Quick-Start Protocol. RNA was then isopropanol precipitated from the elution, and resuspended in 5 ?L of 10 mM Tris, pH 8.0. RNA samples were run on a 15% TBE-Urea gel (Life Technologies), stained with SYBR Gold, and visualized with a Dark Reader blue light transilluminator (Clare Chemical Research). The 26-34 nt region demarcated by the size selection RNA oligos NI-NI-19 and NI-NI-20 was excised from the gel, and the RPFs were extracted and isopropanol precipitated from the gel fragment. Library generation was performed as described previously, with some modifications. Briefly, RPFs were resuspended in 10 ?L of 10 mM Tris, pH 8.0, and dephosphorylated with T4 polynucleotide kinase (New England Biolabs) in the presence of 20 units of SUPERaseIn in a final volume of 40 ?L. The reaction was incubated for 1 hour at 37?C, and inactivated for 10 minutes at 70?C. RNAs were isopropanol precipitated, and ligated to the preadenylated and 3' blocked cloning Linker-1 (IDT) by incubation with truncated T4 RNA ligase 2 (New England Biolabs) for 2.5 hours at room temperature. Ligated RPFs were isopropanol precipitated and gel purified from a 15% TBE-Urea gel before being reverse transcribed with SuperScript III (Life Technologies), using primer NI-NI-9. The RNA template was then removed by alkaline hydrolysis, and the reverse transcription products were isopropanol precipitated and gel purified. DNA fragments were circularized with CircLigase (Epicentre) in a final volume of 20 ?L and reverse transcription products corresponding to rRNAs were removed by subtractive hybridization using MyOne Streptavidin C1 Dynabeads (Life Technologies) and the three biotinylated DNA oligos NI-NI-21, NI-NI-23, and NI-NI-24, which are complementary to the rRNAs with accession numbers NR_003285.2:124-155, NR_003287.1:182-213, and NR_003287.1:1435-1461, respectively. The resulting DNA was precipitated and used as a template for PCR amplification with Phusion polymerase (New England Biolabs) using NI-NI-2 and one of the index amplification primers CJ-NI-4, CJ-NI-6, CJ-NI-12, or CJ-NI-23.'; [Cell type]'osteosarcoma''cell type: osteosarcoma; cell line: U2-OS; replicate: 1; sirna treatment: None; ', 'cell type: osteosarcoma; cell line: U2-OS; replicate: 2; sirna treatment: None; ', 'cell type: osteosarcoma; cell line: U2-OS; replicate: 1; sirna treatment: Bmal1 siRNA; ', 'cell type: osteosarcoma; cell line: U2-OS; replicate: 2; sirna treatment: Bmal1 siRNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56924,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE56nnn/GSE56924/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA244941,26338483," Christopher Jang,  Nicholas F Lahens,  John B Hogenesch,  Amita Sehgal","Physiological and behavioral circadian rhythms are driven by a conserved transcriptional/translational negative feedback loop in mammals. Although most core clock factors are transcription factors, post-transcriptional control introduces delays that are critical for circadian oscillations. Little work has been done on circadian regulation of translation, so to address this deficit we conducted ribosome profiling experiments in a human cell model for an autonomous clock. We found that most rhythmic gene expression occurs with little delay between transcription and translation, suggesting that the lag in the accumulation of some clock proteins relative to their mRNAs does not arise from regulated translation. Nevertheless, we found that translation occurs in a circadian fashion for many genes, sometimes imposing an additional level of control on rhythmically expressed mRNAs and, in other cases, conferring rhythms on noncycling mRNAs. Most cyclically transcribed RNAs are translated at one of two major times in a 24-h day, while rhythmic translation of most noncyclic RNAs is phased to a single time of day. Unexpectedly, we found that the clock also regulates the formation of cytoplasmic processing (P) bodies, which control the fate of mRNAs, suggesting circadian coordination of mRNA metabolism and translation.",Ribosome profiling reveals an important role for translational control in circadian gene expression.,10.1101/gr.191296.115,2015 Dec,PMC4665005,Genome research
GSE65778,The Small Molecule ISRIB Reverses the Effects of eIF2? Phosphorylation on Translation and Stress Granule Assembly,Homo sapiens,16,SRP053402,2015-02-09,"[Overal design]Ribosome profiling with paired RNA-seq; [Treatment]'None'; [Growth]'maintained at 37o C, 5% CO2 in DMEM media supplemented with 10% FBS, L-glutamine and antibiotics (penicillin and streptomycin)'; [Extraction]'library construction: IlluminaTruSeqstranded prep\nRNA extraction, preadenylated linker ligation, reverse transcription, cDNA circularization, PCR amplification', 'library construction: Rnase I footprinting, ribosome pelleting, RNA extraction\nRNA extraction, preadenylated linker ligation, reverse transcription, cDNA circularization, PCR amplification'; [Cell type]'Source: ''cell line: HEK293T; treatment: untreated; ', 'cell line: HEK293T; treatment: ISRIB (200 nM) for 1 hour; ', 'cell line: HEK293T; treatment: 1?g/ml of tunicamycin for 1 hour; ', 'cell line: HEK293T; treatment: 1?g/ml of tunicamycin and ISRIB (200 nM) for 1 hour; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65778,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE65nnn/GSE65778/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA274997,25719440," Carmela Sidrauski,  Anna M McGeachy,  Nicholas T Ingolia,  Peter Walter","Previously, we identified ISRIB as a potent inhibitor of the integrated stress response (ISR) and showed that ISRIB makes cells resistant to the effects of eIF2alpha phosphorylation and enhances long-term memory in rodents (Sidrauski et al., 2013). Here, we show by genome-wide in vivo ribosome profiling that translation of a restricted subset of mRNAs is induced upon ISR activation. ISRIB substantially reversed the translational effects elicited by phosphorylation of eIF2alpha and induced no major changes in translation or mRNA levels in unstressed cells. eIF2alpha phosphorylation-induced stress granule (SG) formation was blocked by ISRIB. Strikingly, ISRIB addition to stressed cells with pre-formed SGs induced their rapid disassembly, liberating mRNAs into the actively translating pool. Restoration of mRNA translation and modulation of SG dynamics may be an effective treatment of neurodegenerative diseases characterized by eIF2alpha phosphorylation, SG formation, and cognitive loss.",The small molecule ISRIB reverses the effects of eIF2alpha phosphorylation on translation and stress granule assembly.,10.7554/eLife.05033,2015 Feb 26,PMC4341466,eLife
GSE60675,Transcriptome and translatome profiling of CPX 90m effects in neuroblastoma cells CHP134,Homo sapiens,12,None,2014-08-22,"[Overal design]Microarray analysis was performed to enable a comprehensive view of the changes in the transcriptional and translational status of the cells in response to the treatment with an iron chelator CPX. Polysomal RNA and total RNA were isolated from vehicle-treated CHP134 cells and CHP134 cells treated with 5 M CPX for 90 minutes. Each condition is represented by three biological replicates, i.e. the experiment was repeated starting each time from cells seeding yielding an independent RNA sample. In total, 12 samples corresponding to 4 conditions were subjected to microarray analysis.; [Treatment]'CHP134 cells growing in 10 cm cell culture dishes were treated with vehicle for 90 minutes.', 'CHP134 cells growing in 10 cm cell culture dishes were treated with 5 M CPX for 90 minutes.'; [Growth]'CHP134 cells were purchased from ECACC (Cat. No. 06122002). The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 1640 medium supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine at 37 C in a humidified atmosphere of 5 % CO2.'; [Extraction]'To extract polysomal RNA, the following procedure was applied. CHP134 cells were incubated with 100 ?g/ml cycloheximide for 4 minutes, rinsed with phosphate buffer saline and lysed directly in cell-culture vessels [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1 % Triton X-100, 1 % sodium deoxycholate, 100 ?g/ml cycloheximide, 0.2 U/?l RNase inhibitor, 1 mM DTT]. The lysate was collected with a cell scraper, pipetted into a microcentrifuge tube and after 5 minutes incubation on ice centrifuged for 10 min at 12000 g at 4 C. The supernatant was transferred into a new microcentrifuge tube and stored at 80 C. The lysates were fractionated by ultracentrifugation (Sorvall rotor, 100 min at 180000 g) through 1550 % linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2.  Polysomal fractions were collected monitoring the absorbance at 254 nm. Polysomal RNA was isolated after proteinase K treatment, phenolchloroform extraction and isopropanol precipitation and finally resuspended in 50 ?l of water. RNA quality was assessed using the Agilent 2100 Bioanalyzer platform.', 'Total RNA was extracted using RNeasy Plus Mini kit (Qiagen) following the instructions of the supplier and eluted in 50 ?l of water.'; [Cell type]'Source: ''disease: neuroblastoma; cell line: CHP134; compound: vehicle; rna fraction: polysomal RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; compound: CPX; rna fraction: polysomal RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; compound: vehicle; rna fraction: total RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; compound: CPX; rna fraction: total RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; compound: vehicle; rna fraction: polysomal RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; compound: CPX; rna fraction: polysomal RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; compound: vehicle; rna fraction: total RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; compound: CPX; rna fraction: total RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; compound: vehicle; rna fraction: polysomal RNA; biological replicate: #3; ', 'disease: neuroblastoma; cell line: CHP134; compound: CPX; rna fraction: polysomal RNA; biological replicate: #3; ', 'disease: neuroblastoma; cell line: CHP134; compound: vehicle; rna fraction: total RNA; biological replicate: #3; ', 'disease: neuroblastoma; cell line: CHP134; compound: CPX; rna fraction: total RNA; biological replicate: #3; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60675,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60675/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA259226,25564462," Viktoryia Sidarovich,  Valentina Adami,  Pamela Gatto,  Valentina Greco,  Toma Tebaldi,  Gian Paolo Tonini,  Alessandro Quattrone","Iron is an essential cellular nutrient, being a critical cofactor of several proteins involved in cell growth and replication. Compared with normal cells, neoplastic cells have been shown to require a greater amount of iron, thus laying the basis for the promising anticancer activity of iron chelators. In this work, we evaluated the effects of molecules with iron chelation activity on neuroblastoma (NB) cell lines. Of the 17 iron chelators tested, six reduced cell viability of two NB cell lines with an inhibition of growth of 50% below 10 microM; four of the six molecules-ciclopirox olamine (CPX), piroctone, 8-hydroxyquinoline, and deferasirox-were also shown to efficiently chelate intracellular iron within minutes after addition. Effects on cell viability of one of the compounds, CPX, were indeed dependent on chelation of intracellular iron and mediated by both G0/G1 cell cycle block and induction of apoptosis. By combined transcriptome and translatome profiling we identified early translational downregulation of several members of the heat shock protein group as a specific effect of CPX treatment. We functionally confirmed iron-dependent depletion of HSP90 and its client proteins at pharmacologically achievable concentrations of CPX, and we extended this effect to piroctone, 8-hydroxyquinoline, and deferasirox. Given the documented sensitivity of NB cells to HSP90 inhibition, we propose CPX and other iron chelators as investigational antitumor agents in NB therapy.",Translational downregulation of HSP90 expression by iron chelators in neuroblastoma cells.,10.1124/mol.114.095729,2015,,Molecular pharmacology
GSE107169,Circular RNA profiling reveals the different distribution/characteristic and possible transport mechanism among the subcellular fractions,Homo sapiens,14,SRP125321,2017-11-20,"[Overal design]Examined seven fractions of HepG2 (cell, nucleus, cytoplasm, ribsome, cytosol, exosome, mitochodria) and each has two repeats; [Treatment]'None'; [Growth]'None'; [Extraction]'Total RNAs from HepG2 cells and its subcellular fractions were extracted using RNAiso Plus reagent (9108, TaKaRa, Dalian, China), and those except for exosomal RNAs were treated with Ribo-Zero Gold rRNA Removal Kit (MRZG12324, Illumina) to remove ribosomal RNA before constructing RNA-seq libraries.\nStrand-specific RNA-seq libraries were prepared using Next Ultra Directional RNA Library Prep Kit for Illumina (E7420, NEB, MA, USA) following the manufacturers instructions. Library quality was determined on Bioanalyzer 2100 (Agilent Technologies, CA, USA).'; [Cell type]'Source: ''cell line: HepG2; fractions: cell; ', 'cell line: HepG2; fractions: nucleus; ', 'cell line: HepG2; fractions: cytoplasm; ', 'cell line: HepG2; fractions: ribosome; ', 'cell line: HepG2; fractions: cytosol; ', 'cell line: HepG2; fractions: exosome; ', 'cell line: HepG2; fractions: mitochondria; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107169,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE107nnn/GSE107169/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA419198,30614753," Ju Zhang,  Xiuli Zhang,  Cuidan Li,  Liya Yue,  Nan Ding,  Tim Riordan,  Li Yang,  Yang Li,  Charles Jen,  Sen Lin,  Dongsheng Zhou,  Fei Chen","Circular RNA (circRNA) is a novel RNA molecule that has become a research focus recently. Although some research indicated that the circRNAs in different subcellular compartments could execute different regulatory functions, a panoramic analysis of the subcellular distribution and the transport mechanism of circRNA is still required. In this study, we comprehensively analyzed the subcellular distribution/characteristics and the transport mechanism, through systemically investigating the circRNA profiles among the subcellular fractions of HepG2 cell (nucleus, cytoplasm, mitochondria, ribosome, cytosol and exosome). CircRNAs were widely distributed among the subcellular fractions except in the mitochondria, with differences in the subcellular distribution/characteristics in terms of classification, length, GC content, alternative circularization and parental gene function. Further analysis indicated this might be due to the selective transportation mediated by the transport-related RNA binding proteins (RBPs). The circRNAs may follow the same transportation mechanism of linear RNAs, in which the RBPs specially recognize/transport the RNAs with the corresponding binding motifs. Interestingly, we found that the exosome could selectively package the circRNAs containing the purine-rich 5'-GMWGVWGRAG-3' motif, with the characteristic of 'garbage dumping' and 'intercellular signaling' functions. Besides, although we observed numerous circRNAs enriched in the ribosome, we did not reliably identify any unique-peptides from circRNAs using 3D-LC-MS/MS strategy. This suggests that circRNAs rarely function as translation templates in vivo like lincRNA. Our findings not only indicates the differential distributions/characteristics among the subcellular fractions, but also reveals the possible transportation mechanism. This provides an improved understanding of the life history and molecular behavior of circRNA in cells.",Circular RNA profiling provides insights into their subcellular distribution and molecular characteristics in HepG2 cells.,10.1080/15476286.2019.1565284,2019 Feb,PMC6380345,RNA biology
GSE160803,Genome wide analysis of mRNA expression and polysome profiling in DDX3 knockdown SAS cells,Homo sapiens,4,SRP291111,2020-11-04,"[Overal design]Examination of RNAseq and RIBOseq in control or DDX3-depleted SAS cells; [Treatment]'Transfection of siRNA was performed using Lipofectamine 3000 (ThermoFisher) according to manufacturers instructions.'; [Growth]'SAS cells were cultured in Dulbeccos modified Eagles medium (DMEM) supplemented with 10% (v/v) fetal bovine serum at 37C with a humidified atmosphere of 5% CO2, 100 U/ml penicillin, 100 ?g/ml streptomycin, and 2 mM L-glutamine.'; [Extraction]'For RNAseq, total RNA was extracted using Trizol Reagent (ThermoFisher) according to the manufacturers instructions. Ribosomal RNA (rRNA) was depleted using the Ribo-off rRNA Depletion Kit (Vazyme). For Riboseq, cells were lysed with the polysome buffer containing 20 mM Tris-HCl pH7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 200 g/ml cycloheximide, 1% (v/v) Triton X-100 and 25 U/ml Turbo DNase I (Ambion). The lysates were subsequnetly digested with RNase I (Ambion). After purification, rRNA was depleted using the Ribo-off rRNA Depetion Kit (Vazyme). Ribosome-protected fragments (RPF) were purified with PAGE and dephosphorylated with T4 Polynucleotide Kinase (New England BioLabs).\nFor RNAseq, library preparation was performed using the NETNext Ultra Directional RNA Library Prep Kit for Illumina (New England BioLabs) according to the manufacturers instructions. For RIBOseq, linkers were ligated to RPFs using T4 RNA ligase 2, truncated K227Q (New England BioLabs) and the cDNA was synthesized using SuperScript III reverse transcriptase (ThermoFisher). The cDNA samples were circularized by CircLigase ssDNA Ligase (Lucigen), amplified by Phusion High-Fidelity DNA Polymerase (New England BioLabs) and purified using AMPure XP for PCR Purification (Beckman Coulter). The quality and quantity of the libraries were respectively analyzed by Fragment Analyzer Automated CE System (Advanced Analytical Technologies) and Qubit Fluorometer (ThermoFisher).'; [Cell type]'Patient-derived oral squamous cell carcinoma (OSCC)''cell type: Patient-derived oral squamous cell carcinoma (OSCC); gender: Female; treatment: Transfection of siC; ', 'cell type: Patient-derived oral squamous cell carcinoma (OSCC); gender: Female; treatment: Transfection of siD; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160803,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE160nnn/GSE160803/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA674567,,,,,,,,
GSE112295,Active translatome profiling with RiboLace in MCF7 cells,Homo sapiens,24,SRP136387,2018-03-24,"[Overal design]We performed RiboLace sequencing, polysomal RNA sequencing (POL-seq), total RNA sequencing (RNA-seq) and sequencing of the pull-down with mP-beads. Experiments were performed in duplicate on MCF7 cells in three conditions: control, serum starved (12h), serum starved and EGF treated (12h+4h).; [Treatment]'For EGF treatment, after seeding, MCF7 cells were maintained in culture until 80% of confluence before replacing the media with DMEM-red phenol supplemented with 0.5% FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100 mg/mL of streptomycin (starvation condition). Cells were kept in starvation for 12 hours at 37 C, 5% CO2 before adding EGF (1 g/L) for 4 hours. For the starvation condition, cells were kept in starvation for 12 hours at 37 C, 5% CO2 before lysis.'; [Growth]'MCF7 cells were seeded at 1.5  10^6 cells/dish and left until they reached 80% of confluence. After treatments, cells were then treated with 10 g/mL of cycloheximide (CHX) for 5 min at 37C before lysis in order to inhibit translation elongation. Cells were washed at 4C with PBS complemented with cycloheximide 10 ?g/mL and scraped on the plate with 300 ?L of lysis buffer (10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 5 U/mL DNAseI, 200 U/mL RNase inhibitor, 1 mM dithiothreitol and 10 ?g/mL cycloheximide) for each dish. Nuclei and cellular debris were removed by two centrifugations at 18000g, 4C, 5 min. RNA absorbance was measured (260 nm) by Nanodrop ND-1000 UV-VIS Spectrophotometer before use or storage. The lysate was aliquoted and stored at -80C for not more than a month, avoiding more than one freeze/thaw cycle.'; [Extraction]'RNA was extracted by acidic-phenol chloroform separation. The quality of the RNA samples was assessed using Agilent Bioanalyzer 2100 and Nanodrop ND-1000 Spectrophotometer (Thermo Scientific).\nWhole transcriptome library preparation was performed starting from 1 g of total RNA with RIN ? 8. Following enrichment of poly-A containing mRNA molecules using poly-dT oligo-attached magnetic beads, all recovered RNA was processed using the Illumina TruSeq RNA Sample Preparation Kit (Illumina #FC-122-1001 #FC-122-1002) and the protocol v2 Rev. C. Completed libraries were evaluated by DNA quantification and Bioanalyzer analysis (mean fragment length = 274 bp), and then submitted for sequencing. RNA-seq was constructed with barcodes to allow multiplexing of 12 samples per lane. Sequencing was carried out by the NGS UniTrento Facility on Illumina HiSeq 2000 using the protocol HCS 1.5.15.1 in single reads.'; [Cell type]'Source: ''cell line: MCF7; treatment: control; rna fraction: mP beads; replicate: #1; ', 'cell line: MCF7; treatment: control; rna fraction: mP beads; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: mP beads; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: mP beads; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: mP beads; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: mP beads; replicate: #2; ', 'cell line: MCF7; treatment: control; rna fraction: polysomal RNA; replicate: #1; ', 'cell line: MCF7; treatment: control; rna fraction: polysomal RNA; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: polysomal RNA; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: polysomal RNA; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: polysomal RNA; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: polysomal RNA; replicate: #2; ', 'cell line: MCF7; treatment: control; rna fraction: riboLace; replicate: #1; ', 'cell line: MCF7; treatment: control; rna fraction: riboLace; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: riboLace; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: riboLace; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: riboLace; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: riboLace; replicate: #2; ', 'cell line: MCF7; treatment: control; rna fraction: total RNA; replicate: #1; ', 'cell line: MCF7; treatment: control; rna fraction: total RNA; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: total RNA; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation + EGF treatment; rna fraction: total RNA; replicate: #2; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: total RNA; replicate: #1; ', 'cell line: MCF7; treatment: serum starvation; rna fraction: total RNA; replicate: #2; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112295,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112295/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445552,30355487," Massimiliano Clamer,  Toma Tebaldi,  Fabio Lauria,  Paola Bernabo,  Rodolfo F Gomez-Biagi,  Marta Marchioretto,  Divya T Kandala,  Luca Minati,  Elena Perenthaler,  Daniele Gubert,  Laura Pasquardini,  Graziano Guella,  Ewout J N Groen,  Thomas H Gillingwater,  Alessandro Quattrone,  Gabriella Viero","Ribosome profiling, or Ribo-seq, is based on large-scale sequencing of RNA fragments protected from nuclease digestion by ribosomes. Thanks to its unique ability to provide positional information about ribosomes flowing along transcripts, this method can be used to shed light on mechanistic aspects of translation. However, current Ribo-seq approaches lack the ability to distinguish between fragments protected by either ribosomes in active translation or inactive ribosomes. To overcome this possible limitation, we developed RiboLace, a method based on an original puromycin-containing molecule capable of isolating active ribosomes by means of an antibody-free and tag-free pull-down approach. RiboLace is fast, works reliably with low amounts of input material, and can be easily and rapidly applied both in vitro and in vivo, thereby generating a global snapshot of active ribosome footprints at single nucleotide resolution.",Active Ribosome Profiling with RiboLace.,10.1016/j.celrep.2018.09.084,2018 Oct 23,,Cell reports
GSE68219,MYC is a major determinant of mitotic cell fate,Homo sapiens,21,SRP057613,2015-04-23,"[Overal design]Total RNA was extracted from at least four replicates of siRNA-transfected cells and libraries for sequencing was prepared for each replicate.; [Treatment]'siRNA-transfected or mock-transfected'; [Growth]'Standard culture conditions'; [Extraction]'TRIzol-extracted RNA\nRNA libraries were prepared for sequencing using Illumina TruSeq Stranded mRNA Sample Preparation Kit'; [Cell type]'colon carcinoma cell line''cell line: RKO; cell type: colon carcinoma cell line; tansfected with: non-targeting siRNAs; ', 'cell line: RKO; cell type: colon carcinoma cell line; tansfected with: none (mock-transfected); ', 'cell line: RKO; cell type: colon carcinoma cell line; tansfected with: Myc siRNA; ', 'cell line: RKO; cell type: colon carcinoma cell line; tansfected with: SNTA1 siRNA; ', 'cell line: RKO; cell type: colon carcinoma cell line; tansfected with: KCNK1 siRNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68219,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68219/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA282044,26175417," Caroline Topham,  Anthony Tighe,  Peter Ly,  Ailsa Bennett,  Olivia Sloss,  Louisa Nelson,  Rachel A Ridgway,  David Huels,  Samantha Littler,  Claudia Schandl,  Ying Sun,  Beatrice Bechi,  David J Procter,  Owen J Sansom,  Don W Cleveland,  Stephen S Taylor","Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible for patient benefit remain unclear. Following a genome-wide siRNA screen, we identified the oncogenic transcription factor Myc as a taxol sensitizer. Using time-lapse imaging to correlate mitotic behavior with cell fate, we show that Myc sensitizes cells to mitotic blockers and agents that accelerate mitotic progression. Myc achieves this by upregulating a cluster of redundant pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL. Gene expression analysis of breast cancers indicates that taxane responses correlate positively with Myc and negatively with Bcl-xL. Accordingly, pharmacological inhibition of Bcl-xL restores apoptosis in Myc-deficient cells. These results open up opportunities for biomarkers and combination therapies that could enhance traditional and second-generation antimitotic agents.",MYC Is a Major Determinant of Mitotic Cell Fate.,10.1016/j.ccell.2015.06.001,2015 Jul 13,PMC4518499,Cancer cell
GSE53693,Identification of small ORFs in vertebrates using ribosome footprinting and evolutionary conservation,Danio rerio,30,SRP034750,2013-12-27,"[Overal design]Ribosome profiling experiments at five timepoints across zebrafish development in WT embryos; [Treatment]'None'; [Growth]'Embryos are incubated at 28C'; [Extraction]'For ribosome profiling, 50 wild type embryos for each condition were collected at a given stage. Embryos were lysed using 800ul of a mammalian cell lysis buffer containing 100ug/ml Cycloheximide as per the manufacturers instruction (ARTseq Ribosome Profiling Kit, RPHMR12126, Epicentre). For nuclease treatment, 3ul of ARTseq Nuclease was used. Ribosome protected fragments were run and 28-29nt fragments were gel purified as previously described in (Bazzini et al., 2012) and cloned according to the manufacturers protocol (ARTseq Ribosome Profiling Kit, RPHMR12126, Epicentre). For RNA input, total RNA was isolated from 400 ul of the 800 ul of clarified extract before ART- seq Nuclease treatment. Poly-A selection was done according to manufacturer guide- lines (Dynabeads mRNA Purification Kit, Cat no.610.06), and RNA fragmented using the Artseq Ribosome Profiling Kit Mammalian protocol.\nBoth RPF and RNA input fragments were cloned according to the Artseq Ribosome Profiling Kit, Mammalian. The final PCR was carried out with an initial 15 second denaturation at 98 C, followed by 9-12 cycles of 15 seconds at 98 C, 5 seconds at 55 C and extension at 72 C for 10 s. Reactions were separated on a non-denaturing 8% polyacrylamide TBE gel and DNA fragments of the correct size were extracted and sequenced.'; [Cell type]'Source: ''strain: TUAB; Stage: 5hpf; separation: column; ', 'strain: TUAB; Stage: 5hpf; separation: sucrose cushion; ', 'strain: TUAB; Stage: 2hpf; separation: column; ', 'strain: TUAB; Stage: 12hpf; separation: column; ', 'strain: TUAB; Stage: 24hpf; separation: column; ', 'strain: TUAB; Stage: 48hpf; separation: column; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53693,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE53nnn/GSE53693/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232649,24705786," Ariel A Bazzini,  Timothy G Johnstone,  Romain Christiano,  Sebastian D Mackowiak,  Benedikt Obermayer,  Elizabeth S Fleming,  Charles E Vejnar,  Miler T Lee,  Nikolaus Rajewsky,  Tobias C Walther,  Antonio J Giraldez","Identification of the coding elements in the genome is a fundamental step to understanding the building blocks of living systems. Short peptides (< 100 aa) have emerged as important regulators of development and physiology, but their identification has been limited by their size. We have leveraged the periodicity of ribosome movement on the mRNA to define actively translated ORFs by ribosome footprinting. This approach identifies several hundred translated small ORFs in zebrafish and human. Computational prediction of small ORFs from codon conservation patterns corroborates and extends these findings and identifies conserved sequences in zebrafish and human, suggesting functional peptide products (micropeptides). These results identify micropeptide-encoding genes in vertebrates, providing an entry point to define their function in vivo.",Identification of small ORFs in vertebrates using ribosome footprinting and evolutionary conservation.,10.1002/embj.201488411,2014 May 2,PMC4193932,The EMBO journal
GSE51424,Cell type-specific ribosome profiling in vivo.,Homo sapiens; Mus musculus,25,SRP031501,2013-10-18,"[Overal design]We report a strategy for cell-type specific ribosome profiling in vivo. Our strategy was applied to the characterization of a mouse glioma model.; [Treatment]'None'; [Growth]'Tumors were induced by PDGF/Cre retroviral infection.'; [Extraction]""Tumor and normal tissues were homogenized using a glass dounce homogenizer. Lysates were clarified and one half used for poly(A)+ RNA extraction and the other to generate and isolate ribosome-protected RNA fragments.\nFor RNA-Seq libraries: Standard RNA-Seq library preparation. For ribosome profiling libraries: Ribosome footpring libraries were prepared by ligating a 3' adapter, reverse transcribing, and circularizing. The circles were then used for PCR amplification of the footprints."", ""Ribosome footpring libraries were prepared by ligating a 3' adapter, reverse transcribing, and circularizing. The circles were then used for PCR amplification of the footprints.\nTumor and normal tissues were homogenized using a glass dounce homogenizer. Lysates were clarified and one half used for poly(A)+ RNA extraction and the other to generate and isolate ribosome-protected RNA fragments."", 'Standard RNA-Seq library preparation (TruSeq V2 RNA-Seq preparation).\nTumor and normal tissues were homogenized using a glass dounce homogenizer. Lysates were clarified and one half used for poly(A)+ RNA extraction and the other to generate and isolate ribosome-protected RNA fragments.'; [Cell type]'Source: ''tissue: normal brain; Stage: n/a; ', 'tissue: PDGF/Cre tumor; Stage: end-stage; ', 'tissue origin: normal brain; ', 'tissue origin: Tumor; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51424,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE51nnn/GSE51424/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA223060,25122893," Christian Gonzalez,  Jennifer S Sims,  Nicholas Hornstein,  Angeliki Mela,  Franklin Garcia,  Liang Lei,  David A Gass,  Benjamin Amendolara,  Jeffrey N Bruce,  Peter Canoll,  Peter A Sims","Glioma growth is driven by signaling that ultimately regulates protein synthesis. Gliomas are also complex at the cellular level and involve multiple cell types, including transformed and reactive cells in the brain tumor microenvironment. The distinct functions of the various cell types likely lead to different requirements and regulatory paradigms for protein synthesis. Proneural gliomas can arise from transformation of glial progenitors that are driven to proliferate via mitogenic signaling that affects translation. To investigate translational regulation in this system, we developed a RiboTag glioma mouse model that enables cell-type-specific, genome-wide ribosome profiling of tumor tissue. Infecting glial progenitors with Cre-recombinant retrovirus simultaneously activates expression of tagged ribosomes and delivers a tumor-initiating mutation. Remarkably, we find that although genes specific to transformed cells are highly translated, their translation efficiencies are low compared with normal brain. Ribosome positioning reveals sequence-dependent regulation of ribosomal activity in 5'-leaders upstream of annotated start codons, leading to differential translation in glioma compared with normal brain. Additionally, although transformed cells express a proneural signature, untransformed tumor-associated cells, including reactive astrocytes and microglia, express a mesenchymal signature. Finally, we observe the same phenomena in human disease by combining ribosome profiling of human proneural tumor and non-neoplastic brain tissue with computational deconvolution to assess cell-type-specific translational regulation.",Ribosome profiling reveals a cell-type-specific translational landscape in brain tumors.,10.1523/JNEUROSCI.0084-14.2014,2014 Aug 13,PMC4131009,The Journal of neuroscience : the official journal of the Society for Neuroscience
GSE135338,Receptor-specific interactome as a hub for rapid cue-induced selective translation in axons,Homo sapiens,9,None,2019-08-03,"[Overal design]The profiling of mRNAs binding with DCC or Nrp1 in SH-SY5Y cells; [Treatment]'None'; [Growth]'The cells were cultured at 37C and 5% CO2 in DMEM high glucose medium supplemented with 10% FBS'; [Extraction]'The lysate of SH-SY5Y cells was incubated with magnetic Dynabeads pre-coupled with antibodies (mouse-anti-DCC (BD Biosciences, 554223); rabbit-anti-Nrp1 (Abcam, ab81321)) for 1.5 hours at 4C. Beads were then washed 3 times and processed for RNA isolation.\nImmunopurified RNAs are reverse-transcribed, and then amplified by a PCR-based method (Tang et al., Nat Methods 6, 2009).'; [Cell type]'neuroblastoma cells''cell line: SH-SY5Y; cell type: neuroblastoma cells; rip antibody: mouse-anti-DCC (BD Biosciences, 554223); ', 'cell line: SH-SY5Y; cell type: neuroblastoma cells; rip antibody: rabbit-anti-Nrp1 (Abcam, ab81321); ', 'cell line: SH-SY5Y; cell type: neuroblastoma cells; rip antibody: Input; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135338,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE135nnn/GSE135338/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA558460,31746735," Max Koppers,  Roberta Cagnetta,  Toshiaki Shigeoka,  Lucia Cs Wunderlich,  Pedro Vallejo-Ramirez,  Julie Qiaojin Lin,  Sixian Zhao,  Maximilian Ah Jakobs,  Asha Dwivedy,  Michael S Minett,  Anais Bellon,  Clemens F Kaminski,  William A Harris,  John G Flanagan,  Christine E Holt","Extrinsic cues trigger the local translation of specific mRNAs in growing axons via cell surface receptors. The coupling of ribosomes to receptors has been proposed as a mechanism linking signals to local translation but it is not known how broadly this mechanism operates, nor whether it can selectively regulate mRNA translation. We report that receptor-ribosome coupling is employed by multiple guidance cue receptors and this interaction is mRNA-dependent. We find that different receptors associate with distinct sets of mRNAs and RNA-binding proteins. Cue stimulation of growing Xenopus retinal ganglion cell axons induces rapid dissociation of ribosomes from receptors and the selective translation of receptor-specific mRNAs. Further, we show that receptor-ribosome dissociation and cue-induced selective translation are inhibited by co-exposure to translation-repressive cues, suggesting a novel mode of signal integration. Our findings reveal receptor-specific interactomes and suggest a generalizable model for cue-selective control of the local proteome.",Receptor-specific interactome as a hub for rapid cue-induced selective translation in axons.,10.7554/eLife.48718,2019 Nov 20,PMC6894925,eLife
GSE14784,GATA3 overexpression in utricle sensory epithelia,Gallus gallus,8,None,2009-02-10,"[Overal design]Dissociated sensory epithelia were plated in 96 well cultures, 5 wells per sample. 4 days post plating, ~ 30% confluency, cells were transfected with a pMES vector containing an internal ribosome entry site regulating expression of GATA3 and eGFP under control of a chick beta-actin promoter. Controls were transfected with a vector containing EGFP only. There are 2 biological samples and experiments include technical replicates as well as dye-switches for a total of 8 microarrays.; [Treatment]'None'; [Growth]'None'; [Extraction]'Isolation of RNA, cDNA synthesis and amplification were carried out as described in Hawkins et al, 2003 (PMID: 12761041). Following the second round of amplification, cDNA was added to an in vitro transcription kit (Ambion) as per the manufacturers instructions'; [Cell type]'Source: ''tissue: Utricle sensory epithelia; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14784,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE14nnn/GSE14784/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA114447,19924793," David M Alvarado,  Rose Veile,  Judith Speck,  Mark Warchol,  Michael Lovett","Haploinsufficiency for the transcription factor GATA3 leads to hearing loss in humans. It is expressed throughout the auditory sensory epithelium (SE). In the vestibular organs, GATA3 is limited to the striola reversal zone of the utricle. Stereocilia orientation shifts 180 degrees at this region, which contains morphologically distinct type-I hair cells. The striola is conserved in all amniotes, its function is unknown, and GATA3 is the only known marker of the reversal zone. To identify downstream targets of GATA3 that might point to striolar function, we measured gene expression differences between striolar and extra-striolar SE. These were compared with profiles after GATA3 RNAi and GATA3 over-expression. We identified four genes (BMP2, FKHL18, LMO4, and MBNL2) that consistently varied with GATA3. Two of these (LMO4 and MBNL2) were shown to be direct targets of GATA3 by ChIP. Our results suggest that GATA3 impacts WNT signaling in this region of the sensory macula.",Downstream targets of GATA3 in the vestibular sensory organs of the inner ear.,10.1002/dvdy.22149,2009 Dec,PMC3086404,Developmental dynamics : an official publication of the American Association of Anatomists
GSE148636,Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A,Homo sapiens,16,SRP256332,2020-04-14,"[Overal design]Ribosome profiling; [Treatment]'DMSO or RocA for 30min'; [Growth]'None'; [Extraction]'RNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification (for ribosome profiling)'; [Cell type]'Source: ''treatment: DMSO; genetic background: WT; cell line: NCI-H1650; ', 'treatment: DMSO; genetic background: WT; cell line: NCI-H520; ', 'treatment: DMSO; genetic background: WT; cell line: NCI-H521; ', 'treatment: DMSO; genetic background: WT; cell line: Hs 936.T; ', 'treatment: DMSO; genetic background: WT; cell line: A375; ', 'treatment: RocA 0.3 microM; genetic background: WT; cell line: NCI-H1650; ', 'treatment: RocA 3 microM; genetic background: WT; cell line: NCI-H1650; ', 'treatment: RocA 0.3 microM; genetic background: WT; cell line: NCI-H520; ', 'treatment: RocA 3 microM; genetic background: WT; cell line: NCI-H521; ', 'treatment: RocA 0.3 microM; genetic background: WT; cell line: Hs 936.T; ', 'treatment: RocA 3 microM; genetic background: WT; cell line: Hs 936.T; ', 'treatment: RocA 0.3 microM; genetic background: WT; cell line: A375; ', 'treatment: RocA 3 microM; genetic background: WT; cell line: A375; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148636,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148636/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA625261,33296667," Mingming Chen,  Miwako Asanuma,  Mari Takahashi,  Yuichi Shichino,  Mari Mito,  Koichi Fujiwara,  Hironori Saito,  Stephen N Floor,  Nicholas T Ingolia,  Mikiko Sodeoka,  Kosuke Dodo,  Takuhiro Ito,  Shintaro Iwasaki","The translation inhibitor rocaglamide A (RocA) has shown promising antitumor activity because it uniquely clamps eukaryotic initiation factor (eIF) 4A onto polypurine RNA for selective translational repression. As eIF4A has been speculated to be a unique target of RocA, alternative targets have not been investigated. Here, we reveal that DDX3 is another molecular target of RocA. Proximity-specific fluorescence labeling of an O-nitrobenzoxadiazole-conjugated derivative revealed that RocA binds to DDX3. RocA clamps the DDX3 protein onto polypurine RNA in an ATP-independent manner. Analysis of a de novo-assembled transcriptome from the plant Aglaia, a natural source of RocA, uncovered the amino acid critical for RocA binding. Moreover, ribosome profiling showed that because of the dominant-negative effect of RocA, high expression of eIF4A and DDX3 strengthens translational repression in cancer cells. This study indicates that sequence-selective clamping of DDX3 and eIF4A, and subsequent dominant-negative translational repression by RocA determine its tumor toxicity.",Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.,10.1016/j.chembiol.2020.11.008,2021 Apr 15,2022/04/15 00:00,Cell chemical biology
GSE175554,Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression dissects recognition of multiple PPAR-? associated gene regulation (TRAP-Seq).,Drosophila melanogaster,10,SRP321450,2021-05-25,"[Overal design]TRAP control (3X), PARIS wild type (3X), PARIS mutant (C571A) (3X), and whole brain (1X) samples, adding up to a total of 10 replicate samples representing 4 different groups. Whole brain serves as a control for TRAP enrichment. TRAP control serves as a control for PARIS transgenic constructs.; [Treatment]'For trap experiments, both male and female flies were used. In each experiment, the dTH-Gal4 heterozygous flies were used as control. For the TRAP analysis of fly DA neurons, translated mRNAs in DA neurons were purified from dTH-GAL4/UAS-GFP::RpL10A with and without hPARIS wt or mutant (C571A)'; [Growth]'Human PARIS and C571A constructs cloned and expressed in pUAST plasmid (DGRC) were microinjected into w1118 embryos (The BestGene, Inc). Transgenic dTH-Gal4 lines were obtained from the Bloomington Drosophila Stock Center (BDSC). All experimental maintenance and crosses between transgenic lines were made at 25 C. Drosophila melanogaster fly stocks were handled using standard protocols, maintained in a 12 h light/dark cycle and fed Drosophila standard diet consisting of cornmeal, agar, yeast, sucrose, and dextrose.'; [Extraction]'The libraries were prepared from three independent biological samples from 500 (control and hPARIS mutant lines) - 1,500 (hPARIS wt line) of a mixture of male and female heads, whereas a sequencing library using the total mRNA from whole head was prepared for one biological sample to provide quality-assurance of DA neuron-specific translatome.\nLibraries for RNA sequencing were prepared with the TruSeq RNA Sample preparation v2 kit (Illumina) and sequenced on an Illumina HiSeq 2000 sequencer.'; [Cell type]'Source: ''strain: w1118; tissue: brain; age: post natal day 30; genotype: wild type; ', 'strain: w1118XdTH-Gal4; tissue: brain; age: post natal day 30; genotype: dTH+TRAP(GFP-RpL10a); ', 'strain: w1118XdTH-Gal4; tissue: brain; age: post natal day 30; genotype: dTH+TRAP(hPARIS wild type); ', 'strain: w1118XdTH-Gal4; tissue: brain; age: post natal day 30; genotype: dTH+TRAP(hPARIS C571A); '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE175554,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE175nnn/GSE175554/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA732783,,,,,,,,
GSE101485,Pseudouridylation of tRNA-derived fragments steers translation control in stem cells [Polysome-Seq],Homo sapiens,12,SRP112341,2017-07-16,"[Overal design]Polysome Profiling of samples; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA was extracted from cell cultures every two weeks during the exponential growth phase; RNA was isolated from 0.5-1.010^6 cells. Total RNA was prepared using RNeasy Mini Kit with DNase I (Qiagen). RNA concentration and quality (A260/A280) was measured using a NanoDrop 1000 Spectrophotometer (Thermo Scientific)\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'stem cell cultures''cell type: stem cell cultures; genotype/variation: WT; sample type: polysome sample; ', 'cell type: stem cell cultures; genotype/variation: PUS7 KO; sample type: polysome sample; ', 'cell type: stem cell cultures; genotype/variation: WT; sample type: total sample; ', 'cell type: stem cell cultures; genotype/variation: PUS7 KO; sample type: total sample; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101485,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE101nnn/GSE101485/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA394611,29628141," Nicola Guzzi,  Maciej Ciesla,  Phuong Cao Thi Ngoc,  Stefan Lang,  Sonali Arora,  Marios Dimitriou,  Kristyna Pimkova,  Mikael N E Sommarin,  Roberto Munita,  Michal Lubas,  Yiting Lim,  Kazuki Okuyama,  Shamit Soneji,  Goran Karlsson,  Jenny Hansson,  Goran Jonsson,  Anders H Lund,  Mikael Sigvardsson,  Eva Hellstrom-Lindberg,  Andrew C Hsieh,  Cristian Bellodi","Pseudouridylation (Psi) is the most abundant and widespread type of RNA epigenetic modification in living organisms; however, the biological role of Psi remains poorly understood. Here, we show that a Psi-driven posttranscriptional program steers translation control to impact stem cell commitment during early embryogenesis. Mechanistically, the Psi ""writer"" PUS7 modifies and activates a novel network of tRNA-derived small fragments (tRFs) targeting the translation initiation complex. PUS7 inactivation in embryonic stem cells impairs tRF-mediated translation regulation, leading to increased protein biosynthesis and defective germ layer specification. Remarkably, dysregulation of this posttranscriptional regulatory circuitry impairs hematopoietic stem cell commitment and is common to aggressive subtypes of human myelodysplastic syndromes. Our findings unveil a critical function of Psi in directing translation control in stem cells with important implications for development and disease.",Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells.,10.1016/j.cell.2018.03.008,2018 May 17,,Cell
GSE133315,C6orf203 is an RNA-binding protein involved in mitochondrial protein synthesis,Homo sapiens,2,SRP212089,2019-06-25,"[Overal design]Mitochondrial Ribosome profiling RNASeq data of Mitochondrial ribosomal profling from C6orf203 knock-out HEK cells versus wildtype; [Treatment]'Generation of HEK293T knockout cell line for C6orf203 was performed using CRISPR/Cas9 system. Briefly, guide RNAs (gRNAs) designed to generate an out-of-frame deletion in exon 1 were cloned into pSpCas9(BB)-2A-Puro (pX459) V2.0 vector. C6orf203 targeting pX459 vectors were transfected to cells using Lipofectamine 3000 according to the manufacturers instructions. After 48 h of puromycin (1.5 ?g/ml) selection, cells were serially diluted to plate single cells in each well of a 96-well plate. Resultant clones were screened by PCR and Western blotting. Loss of C6orf203 in selected clones was confirmed by Sanger sequencing'; [Growth]'Flp-In T-Rex human embryonic kidney 293T (HEK293T, Invitrogen) cells (wildtype and C6orf203 KO) were cultured in DMEM (Dulbeccos modified eagle medium) supplemented with 10% (v/v) tetracycline-free fetal bovine serum (FBS), 2 mM GlutaMax (Gibco), 1x Penicillin/Streptomycin (Gibco), 50 ?g/ml uridine, 100 ?g/ml Zeocin (Invitrogen) and 10 ?g/ml blasticidin (Gibco) at 37C under 5% CO2 humidified atmosphere'; [Extraction]'200 ?l aliquots of cell lysates were treated with 7.5 ?l RNase 1 (100 units/?l) at 28C. The reaction was layered onto a 1030% sucrose gradient as described above for Analysis of mitochondrial ribosome integrity. Subsequently, all fractions containing mitochondrial monosomes, ascertained by western blotting, were pooled and digested with proteinase K (200 ?g/ml) for 30 min at 42C. RPFs were recovered by extracting twice with pre-warmed (65C) acidic phenol:chloroform and once with chloroform (1:1, v/v, buffered with 10 mM Tris pH 7.5, 0.1 mM EDTA) followed by ethanol precipitation\nRPFs (1 ?g) were separated on 15% denaturing polyacrylamide gels and RNA species migrating between 10 and 50 nt were harvested. RNA was eluted from the gel slices and ethanol precipitated. The RNA samples from above were heated at 80C for 2 min, cooled and the 3 phosphate group removed using T4 polynucleotide kinase (New England Biolabs) for 2 hr at 37C in a 20 ?l reaction. The RNA was concentrated by ethanol precipitation, resuspended in 10 mM Tris-HCl (pH 7.5) and ligated in a 20 ?l reaction overnight at 14C to a preadenylated 3-adaptor using T4 RNA Ligase 2 (New England Biolabs). RNA was precipitated, loaded into a 15% denaturing polyacrylamide gel and ligated RNA fragments migrating between 10 and 50 nt were excised. The RNA was eluted, precipitated, resuspended as above, and 5 phosphorylated using T4 PNK in the presence of 1 mM ATP for 2 hr at 37C. RNA was concentrated by ethanol precipitation, resuspended in 10 mM Tris-HCl (pH 7.5) and ligated to a 5 RNA adaptor overnight at 14C using T4 RNA Ligase (New England Biolabs). The fully adapted RNAs were recovered by ethanol precipitation, dissolved in 6 ?l 10 mM Tris-HCl (pH 7.5), and ligated product annealed to an RT primer for 5 min at 65C. The RNA was subsequently reverse transcribed for 50 min at 55C in using SuperScript III according to manufacturers instructions, followed by heat inactivation for 5 min at 85C. Standard PCR reactions were used to prepare amplicons using forward primer RP1 and RPIX as reverse primer, where X is primer number (1-24). PCR reactions were loaded onto 10% non-denaturing polyacrylamide-TBE gels and products of\xa0~150 bp were excised from the gel and eluted. These amplicon libraries were ethanol precipitated and resuspended in 15 ?l 10 mM Tris-HCl (pH 7.5)\nRibosomal RNA was depleted from MitoRibo-Seq samples at the library amplicon stage; 12 L of the relevant MitoRibo-Seq library was mixed with 4 L of 4\xa0\xa0hybridization buffer (200 mM HEPES pH 7.5 and 2 M NaCl) and denatured at 98C for 2 min. DNA was re-annealed for 5 hr at 68C prior to addition of 2 L of 10\xa0\xa0DSN master buffer and 2 L of DSN (four units, Evrogen). Digestion was allowed to proceed for 25 min at 68C, before addition of 20 L 10 mM EDTA and incubation for a further 5 min at 68C. DNA was recovered by a single extraction with phenolchloroform (1:1, vol/vol) followed by ethanol precipitation and resuspended in 4 L 10 mM TrisHCl pH 7.5. The treated amplicon library was subjected to another round of PCR (as above) and the resulting library subjected to a second round of DSN treatment.'; [Cell type]'Source: ''genotype: Wildtype; ', 'genotype: C6orf203 -/-; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133315,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE133nnn/GSE133315/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA551033,31396629," Shreekara Gopalakrishna,  Sarah F Pearce,  Adam M Dinan,  Florian A Schober,  Miriam Cipullo,  Henrik Spahr,  Anas Khawaja,  Camilla Maffezzini,  Christoph Freyer,  Anna Wredenberg,  Ilian Atanassov,  Andrew E Firth,  Joanna Rorbach","In all biological systems, RNAs are associated with RNA-binding proteins (RBPs), forming complexes that control gene regulatory mechanisms, from RNA synthesis to decay. In mammalian mitochondria, post-transcriptional regulation of gene expression is conducted by mitochondrial RBPs (mt-RBPs) at various stages of mt-RNA metabolism, including polycistronic transcript production, its processing into individual transcripts, mt-RNA modifications, stability, translation and degradation. To date, only a handful of mt-RBPs have been characterized. Here, we describe a putative human mitochondrial protein, C6orf203, that contains an S4-like domain-an evolutionarily conserved RNA-binding domain previously identified in proteins involved in translation. Our data show C6orf203 to bind highly structured RNA in vitro and associate with the mitoribosomal large subunit in HEK293T cells. Knockout of C6orf203 leads to a decrease in mitochondrial translation and consequent OXPHOS deficiency, without affecting mitochondrial RNA levels. Although mitoribosome stability is not affected in C6orf203-depleted cells, mitoribosome profiling analysis revealed a global disruption of the association of mt-mRNAs with the mitoribosome, suggesting that C6orf203 may be required for the proper maturation and functioning of the mitoribosome. We therefore propose C6orf203 to be a novel RNA-binding protein involved in mitochondrial translation, expanding the repertoire of factors engaged in this process.",C6orf203 is an RNA-binding protein involved in mitochondrial protein synthesis.,10.1093/nar/gkz684,2019 Sep 26,PMC6755124,Nucleic acids research
GSE60426,mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues (sequencing),Homo sapiens; Mus musculus,85,SRP045501,2014-08-14,"[Overal design]85 samples from a variety of cell types and species; [Treatment]'RNA-seq: For most samples, cytoplasmically-enriched RNA was extracted, poly(A)-selected, randomly fragmented by partial alkaline hydrolysis and then size-selected RNA fragments were used for library preparation In the case of B cells total RNA was extracted and then poly(A)-selected. In the case of U2OS cells, three different isolation methods were performed, two of them are the aforementioned isolation methods, the third total RNA was depleted of tRNA and rRNA. Ribosome profiling: In most cases, cell extracts were processed as described in Subtelny et al., 2014 (GSE52809). For U2OS and B cell samples, cell extracts were processed as described in Guo et al., 2010 (GSE22004). SmallRNA-seq: Total RNA was extracted as described in Chiang et al., 2010 (GSE20384)'; [Growth]'Each sample was grown or maintained according to standard protocols'; [Extraction]'RNA-seq and RPF libraries were constructed exactly as described in Subtelny et al., 2014 (GSE52809) except for B cell and U2OS samples, which were constructed as described in Guo et al., 2010 (GSE22004). SmallRNA-seq libraries were constructed as described in Chiang et al., 2010 (GSE20384).\nRNA-seq or SmallRNA-seq'; [Cell type]'primary B cell', 'Source: ', 'primary Macrophage', 'primary Neutrophil''time: 2 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 4 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 8 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 48 h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 2h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 4h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 8h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'time: 48h; cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; treatment: LPS, IL-4, and anti-CD-40 antibody; ', 'cell line: U2OS cell line; treatment: mock transfection; ', 'cell line: U2OS cell line; treatment: miR-1 transfection; ', 'cell line: U2OS cell line; treatment: miR-155 transfection; ', 'cell line: HEK293T cell line; treatment: mock transfection; ', 'cell line: HEK293T cell line; treatment: miR-1 transfection; ', 'tissue: primary liver tissue; strain: C57BL/6; age: 6 weeks; Sex: male; ', 'time: 0 h; cell line: 3T3 cell line; growth condition: contact inhibited; ', 'time: 4 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 8 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 12 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 48 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 6 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 10 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline; ', 'time: 0 h; cell line: 3T3 cell line; growth condition: actively dividing; ', 'time: 12 h; cell line: 3T3 cell line; growth condition: actively dividing; treatment: doxycycline; ', 'time: 0 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: Torin1; ', 'time: 12 h; cell line: 3T3 cell line; growth condition: contact inhibited; treatment: doxycycline, Torin1; ', 'cell type: primary B cell; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary Macrophage; strain: C57BL/6; age: 3 months; Sex: male; ', 'cell type: primary Neutrophil; strain: C57BL/6; age: 3 months; Sex: male; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing; Third-party reanalysis,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60426,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60426/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA258219,25263593," Stephen W Eichhorn,  Huili Guo,  Sean E McGeary,  Ricard A Rodriguez-Mias,  Chanseok Shin,  Daehyun Baek,  Shu-Hao Hsu,  Kalpana Ghoshal,  Judit Villen,  David P Bartel","MicroRNAs (miRNAs) regulate target mRNAs through a combination of translational repression and mRNA destabilization, with mRNA destabilization dominating at steady state in the few contexts examined globally. Here, we extend the global steady-state measurements to additional mammalian contexts and find that regardless of the miRNA, cell type, growth condition, or translational state, mRNA destabilization explains most (66%->90%) miRNA-mediated repression. We also determine the relative dynamics of translational repression and mRNA destabilization for endogenous mRNAs as a miRNA is induced. Although translational repression occurs rapidly, its effect is relatively weak, such that by the time consequential repression ensues, the effect of mRNA destabilization dominates. These results imply that consequential miRNA-mediated repression is largely irreversible and provide other insights into the nature of miRNA-mediated regulation. They also simplify future studies, dramatically extending the known contexts and time points for which monitoring mRNA changes captures most of the direct miRNA effects.",mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues.,10.1016/j.molcel.2014.08.028,2014 Oct 2,PMC4292926,Molecular cell
GSE124279,The RNA-binding protein HuR is a negative regulator in adipogenesis [Ribo-seq_RNA-seq_matched],Mus musculus,8,SRP174218,2018-12-21,"[Overal design]8 samples were included. Duplicate of epididymal white fat from control and huR knockout animals were harvested for matched RNA-seq and RIBO-seq.; [Treatment]'male mice were sacrificed at 6-weeks old to harvest epididymal white adipose tissue (WAT). Tissues from 3 mice were pooled together as one replicate. Tissues were minced into small pieces and separated into 2 shares for RNA-seq and ribosome profiling. For RNA-seq, total RNAs were extracted with miRNeasy\nFor ribosome profiling, adipose tissue were homogenized with pestle and mortar in the presence of liquid nitrogen. The homogenized powder was transferred into 1.5 ml tubes and lysed with 1 ml lysis buffer (1% NP-40, 200 mM KOAc, 25 mM K-HEPES pH 7.2, 14 mM MgCl, 4 mM CaCl2). Samples were incubated on ice for 5 minutes and centrifuged at 9,000 g in a benchtop centrifuge at 4 C for 10 minutes. The fat layer on top was removed and the 300 ul supernatant was collected. Following steps were conducted according to a published protocol from Reid, D. W., Shenolikar, S. & Nicchitta, C. V. Methods 91, 6974, doi:10.1016/j.ymeth.2015.07.003 (2015).'; [Growth]'HuRflox/flox mice were originally purchased from the Jackson Laboratory and subsequently bred in house. HuRflox/floxmice were backcrossed with C57BL/6 mice for 2 generations and then used to cross adiponectin-Cre mice to generate AdipoQ-Cre;HuRf/+ mice. Heterozygous AdipoQ-Cre;HuRf/+ were then crossed with HuRf/f  to produce homozygous AdipoQ-Cre;HuRf/f. AdipoQ-Cre;HuRf/f were further bred with HuRf/f mice to generate AdipoQ-Cre;HuRf/f (HuR-FKO) and littermate HuRf/f controls (Ctrl) for experiments. All mice were kept under specific pathogenfree conditions in the animal vivarium at DUKE-NUS Medical School. All animal experimental protocols were approved by the Singapore SingHealth Research Facilities Institutional Animal Care and Use Committee.'; [Extraction]'Qiagen miRNeasy Mini Kit\nNEBNext Ultra RNA Library Prep Kit, NEBNext Small RNA Library Prep Set for Illumina'; [Cell type]'Source: ''genotype: huR knockout; tissue: epididymal white fat; ', 'genotype: control; tissue: epididymal white fat; ', 'genotype: control; tissue: epididymal white fat; rip antibody: HuR antibody (Santa Cruz); ', 'genotype: huR knockout; tissue: epididymal white fat; rip antibody: HuR antibody (Santa Cruz); '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124279,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE124nnn/GSE124279/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA511455,31924774," Diana Teh Chee Siang,  Yen Ching Lim,  Aung Maung Maung Kyaw,  Khaing Nwe Win,  Sook Yoong Chia,  Ufuk Degirmenci,  Xiang Hu,  Bryan C Tan,  Arcinas Camille Esther Walet,  Lei Sun,  Dan Xu","Human antigen R (HuR) is an essential regulator of RNA metabolism, but its function in metabolism remains unclear. This study identifies HuR as a major repressor during adipogenesis. Knockdown and overexpression of HuR in primary adipocyte culture enhances and inhibits adipogenesis in vitro, respectively. Fat-specific knockout of HuR significantly enhances adipogenic gene program in adipose tissues, accompanied by a systemic glucose intolerance and insulin resistance. HuR knockout also results in depot-specific phenotypes: it can repress myogenesis program in brown fat, enhance inflammation program in epidydimal white fat and induce browning program in inguinal white fat. Mechanistically, HuR may inhibit adipogenesis by recognizing and modulating the stability of hundreds of adipocyte transcripts including Insig1, a negative regulator during adipogenesis. Taken together, our work establishes HuR as an important posttranscriptional regulator of adipogenesis and provides insights into how RNA processing contributes to adipocyte development.",The RNA-binding protein HuR is a negative regulator in adipogenesis.,10.1038/s41467-019-14001-8,2020 Jan 10,PMC6954112,Nature communications
GSE116082,The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [ribosome profiling],Mus musculus,10,SRP151006,2018-06-20,"[Overal design]Androgen receptor low prostate cancer has been on the rise with the advent of potent androgen receptor and androgen biosynthesis inhibitors and is uniformly fatal. The mechanisms underlying disease progression remains unresolved. We have identified a previously unknown direct interaction between the androgen receptor and the translation initiation complex inhibitor 4EBP1 which plays a critical role in protein synthesis rates, mRNA specific translation, and disease progression in vivo. This is mediated through the hyperactivation of the downstream eIF4F translation initiation complex which usurps a network of pro-proliferation mRNAs. Importantly, using both genetic and pharmacologic methods, we demonstrate that dissociation of the eIF4F complex reverses the proliferation program leading to tumor regression. As such, we have identified a new therapeutic paradigm for targeting lethal androgen receptor low prostate cancer. Ribosome profiling of prostate tissue from castrated or intact PB-Cre4;PTENLoxP/LoxP mice.; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA was extracted from cell cultures every two weeks during the exponential growth phase; RNA was isolated from 0.5-1.010^6 cells. Total RNA was prepared using RNeasy Mini Kit with DNase I (Qiagen). RNA concentration and quality (A260/A280) was measured using a NanoDrop 1000 Spectrophotometer (Thermo Scientific)\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'Source: ''tissue: prostate; genotype: PB-Cre4;PTENLoxP/LoxP; castration status: Castrate; rna fraction: Total RNA; ', 'tissue: prostate; genotype: PB-Cre4;PTENLoxP/LoxP; castration status: Castrate; rna fraction: RP RNA; ', 'tissue: prostate; genotype: PB-Cre4;PTENLoxP/LoxP; castration status: Intact; rna fraction: Total RNA; ', 'tissue: prostate; genotype: PB-Cre4;PTENLoxP/LoxP; castration status: Intact; rna fraction: RP RNA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116082,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE116nnn/GSE116082/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA476979,31366581," Yuzhen Liu,  Jessie L Horn,  Kalyan Banda,  Asha Z Goodman,  Yiting Lim,  Sujata Jana,  Sonali Arora,  Alexandre A Germanos,  Lexiaochuan Wen,  William R Hardin,  Yu C Yang,  Ilsa M Coleman,  Robin G Tharakan,  Elise Y Cai,  Takuma Uo,  Smitha P S Pillai,  Eva Corey,  Colm Morrissey,  Yu Chen,  Brett S Carver,  Stephen R Plymate,  Slobodan Beronja,  Peter S Nelson,  Andrew C Hsieh","The androgen receptor (AR) is a driver of cellular differentiation and prostate cancer development. An extensive body of work has linked these normal and aberrant cellular processes to mRNA transcription; however, the extent to which AR regulates posttranscriptional gene regulation remains unknown. Here, we demonstrate that AR uses the translation machinery to shape the cellular proteome. We show that AR is a negative regulator of protein synthesis and identify an unexpected relationship between AR and the process of translation initiation in vivo. This is mediated through direct transcriptional control of the translation inhibitor 4EBP1. We demonstrate that lowering AR abundance increases the assembly of the eIF4F translation initiation complex, which drives enhanced tumor cell proliferation. Furthermore, we uncover a network of pro-proliferation mRNAs characterized by a guanine-rich cis-regulatory element that is particularly sensitive to eIF4F hyperactivity. Using both genetic and pharmacologic methods, we demonstrate that dissociation of the eIF4F complex reverses the proliferation program, resulting in decreased tumor growth and improved survival in preclinical models. Our findings reveal a druggable nexus that functionally links the processes of mRNA transcription and translation initiation in an emerging class of lethal AR-deficient prostate cancer.",The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.,10.1126/scitranslmed.aaw4993,2019 Jul 31,PMC6746573,Science translational medicine
GSE130220,Polysome profiling of a human glioblastoma reveals intratumoral heterogeneity,Homo sapiens,24,None,2019-04-23,"[Overal design]Six histologically distinct fragments from a secondary glioblastoma, which were classified as high- or low-grade, by an experienced pathologist according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System. Total mRNA and polysome-associated (poly) mRNA were purified using Trizol (Life Technologies). RNA integrity was verified by Agilent 2100 Bioanalyzer with an RNA Pico 6000 microfluidics kit (Agilent Technologies). Gene expression in total and poly mRNA was determined using a two-color microarray-based gene expression (Whole Human Genome 4x44K microarray platform) and the Quick Amp Labeling Kit (Agilent Technologies, CA, USA) according to the manufacturers recommendations. Microarrays for total and poly mRNA from each of the six fragments were run in duplicates. RNA from the GBM cell line LN-229 (ATCC CRL-2611) was used as reference in all reactions (Cy5 channel).; [Treatment]'None'; [Growth]'None'; [Extraction]'The tissues were lysed in a Polytron with 400 ml of lysis buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 1 mM DTT, 100 ?g/mL cycloheximide, 100 units of RNAse inhibitor (Promega) and 1X protease inhibitor cocktail (EDTA-free)). The lysates were incubated on ice for 10 minutes, then centrifuged at 10.000 xg for 10 minutes at 4 C. The supernatants were collected, 60 ml were reserved for total RNA extraction and 300 L were loaded into 747% sucrose gradients (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT). Each gradient was formed by mixing 5.5 mL of the indicated concentration of sucrose in a Beckman Centrifuge tube (1489 mm; Beckman Instruments #3311372, CA, USA) using a Labconco pump (Kansas City, MO, USA). Gradients were placed in a Beckman SW41Ti rotor and centrifuged at 39,000 rpm for 2.5 hours at 4 C. The absorbance at 254 nm was measured in a continuous flow and fractions were collected (1 mL each). Translational rates were measured by the ratio between the area under the curve of the polysome and 80S peaks, using Image J software (U. S. National Institutes of Health, Bethesda, MD, USA).'; [Cell type]'Source: ''tissue: Glioblastoma; histological grade: low; rna type: total; ', 'tissue: glioblastoma cell line LN-229; ', 'tissue: Glioblastoma; histological grade: low; rna type: polysome associated; ', 'tissue: Glioblastoma; histological grade: high; rna type: total; ', 'tissue: Glioblastoma; histological grade: high; rna type: polysome associated; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130220,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE130nnn/GSE130220/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA534298,,,,,,,,
GSE121981,Cellular response to small molecules that selectively stall protein synthesis by the ribosome,Homo sapiens,9,SRP167245,2018-10-30,"[Overal design]Huh7 cells were treated with 1.5 M PF-06446846, 1.5M PF-06378503 or vehicle for 60 minutes, and subjected to ribosome profiling. This study included three biological replicates; [Treatment]'Treated with 1.5 M PF-06744846, 1.5 M PF-06378503, or 0.5% DMSO control for 1 hr, in biological triplicate'; [Growth]'Overnight cultures of 7x10^5 Huh7 cells in 10 cm dishes'; [Extraction]'Rinsed with phosphate-buffered saline (PBS) containing cycloheximide (100 g/mL) and triturated in lysis buffer (20 mM Tris-Cl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 g/mL cycloheximide, 1% Triton X-100 and 25 U/mL DNAse I, Promega). The lysates were aliquoted, flash frozen and stored at -80 C until used for ribosome footprint library preparation.\nRibosomes and libraries were prepared as described in Ingolia NT, Brar GA, Rouskin S, McGeachy AM, Weissman JS. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc. 2012;7: 15341550.'; [Cell type]'Source: ''cell line: Huh7; treatment: 1.5 M PF-067446846for 1 hr; molecule subtype: mRNA, ribosome protected fragments; ', 'cell line: Huh7; treatment: 1.5 M PF-06378503for 1 hr; molecule subtype: mRNA, ribosome protected fragments; ', 'cell line: Huh7; treatment: 0.5% DMSOfor 1 hr; molecule subtype: mRNA, ribosome protected fragments; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121981,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE121nnn/GSE121981/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA501880,30875366," Nadege Liaud,  Max A Horlbeck,  Luke A Gilbert,  Ketrin Gjoni,  Jonathan S Weissman,  Jamie H D Cate","Identifying small molecules that inhibit protein synthesis by selectively stalling the ribosome constitutes a new strategy for therapeutic development. Compounds that inhibit the translation of PCSK9, a major regulator of low-density lipoprotein cholesterol, have been identified that reduce LDL cholesterol in preclinical models and that affect the translation of only a few off-target proteins. Although some of these compounds hold potential for future therapeutic development, it is not known how they impact the physiology of cells or ribosome quality control pathways. Here we used a genome-wide CRISPRi screen to identify proteins and pathways that modulate cell growth in the presence of high doses of a selective PCSK9 translational inhibitor, PF-06378503 (PF8503). The two most potent genetic modifiers of cell fitness in the presence of PF8503, the ubiquitin binding protein ASCC2 and helicase ASCC3, bind to the ribosome and protect cells from toxic effects of high concentrations of the compound. Surprisingly, translation quality control proteins Pelota (PELO) and HBS1L sensitize cells to PF8503 treatment. In genetic interaction experiments, ASCC3 acts together with ASCC2, and functions downstream of HBS1L. Taken together, these results identify new connections between ribosome quality control pathways, and provide new insights into the selectivity of compounds that stall human translation that will aid the development of next-generation selective translation stalling compounds to treat disease.",Cellular response to small molecules that selectively stall protein synthesis by the ribosome.,10.1371/journal.pgen.1008057,2019 Mar,PMC6436758,PLoS genetics
GSE107590,Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming,Homo sapiens,18,SRP125951,2017-12-01,"[Overal design]Polysome profiling examining eIF4E knock-down in tamoxifen resistant breast cancer cells (MCF7); [Treatment]'None'; [Growth]'MCF7 cells were maintained in Improved MEM with L-glutamine without phenol red (Cellgro), 5% fetal bovine serum (FBS, Gibco), 0.4% gentamicin sulfate (Lonza), 0.5 g/mL Fungizone (Gibco), and 5 g/mL plasmocin at 37?C in a 5% CO2 tissue culture incubator. 1 M of 4-hydroxytamoxifen was added to TamR cells every 72 h'; [Extraction]'Lysates were either purified (total mRNA) or subjected to polysome profiling.  Polysome profiling samples pertaining to 2-3 ribsomes (light mRNA) were purified or >4 ribosomes were purified (heavy mRNA).  All samples were purified using the RNeasy Mini Kit (Qiagen) as per manufacture instructions.\nRNA libraries were prepared for sequencing using poly A enrichment standard Illumina protocols'; [Cell type]'Source: ''tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: heavy polysome mRNA; genotype: non-silencing; replicate: replicate 1; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: light polysome mRNA; genotype: non-silencing; replicate: replicate 1; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: total mRNA; genotype: non-silencing; replicate: replicate 1; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: heavy polysome mRNA; genotype: eIF4E-silenced; replicate: replicate 1; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: light polysome mRNA; genotype: eIF4E-silenced; replicate: replicate 1; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: total mRNA; genotype: eIF4E-silenced; replicate: replicate 1; ', 'tissue: tamoxifen sensitive MCF7 breast cancer cells; extraction: heavy polysome mRNA; genotype: non-silencing; replicate: replicate 1; ', 'tissue: tamoxifen sensitive MCF7 breast cancer cells; extraction: light polysome mRNA; genotype: non-silencing; replicate: replicate 1; ', 'tissue: tamoxifen sensitive MCF7 breast cancer cells; extraction: total mRNA; genotype: non-silencing; replicate: replicate 1; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: heavy polysome mRNA; genotype: non-silencing; replicate: replicate 2; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: light polysome mRNA; genotype: non-silencing; replicate: replicate 2; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: total mRNA; genotype: non-silencing; replicate: replicate 2; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: heavy polysome mRNA; genotype: eIF4E-silenced; replicate: replicate 2; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: light polysome mRNA; genotype: eIF4E-silenced; replicate: replicate 2; ', 'tissue: selected tamoxifen resistant MCF7 breast cancer cells; extraction: total mRNA; genotype: eIF4E-silenced; replicate: replicate 2; ', 'tissue: tamoxifen sensitive MCF7 breast cancer cells; extraction: heavy polysome mRNA; genotype: non-silencing; replicate: replicate 2; ', 'tissue: tamoxifen sensitive MCF7 breast cancer cells; extraction: light polysome mRNA; genotype: non-silencing; replicate: replicate 2; ', 'tissue: tamoxifen sensitive MCF7 breast cancer cells; extraction: total mRNA; genotype: non-silencing; replicate: replicate 2; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107590,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE107nnn/GSE107590/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA420692,,,,,,,,
GSE132009,Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection (CRISPR screen),Homo sapiens,16,SRP199982,2019-05-31,"[Overal design]A genome-scale CRISPR/Cas9-mediated loss of function screen was performed in HCT116 cells expressing either a MYC 5' UTR EGFP reporter or a control EGFP reporter.; [Treatment]'N/A'; [Growth]""Fluorescent-reporter coupled CRISPR/Cas9-mediated loss of function screening was carried out as described in Golden et al., Nature, 2017, in both MYC 5' UTR and control EGFP reporter cell lines. Reporter cell line generation is described in the manuscript.""; [Extraction]'Genomic DNA was extracted from cell pellets using either a gDNA isolation method that has been previously described Golden et al., Nature, 2017 for the sorted cells or the DNeasy Blood and Tissue Kit (Qiagen) for the unsorted cells.\nPCR amplicon libraries were generated as described in Golden et al., Nature, 2017.'; [Cell type]'Source: ''reporter cell line: control EGFP reporter; lentiviral library received: GeCKO v2_Library A; tissue: HCT116 colon cancer cell line; ', 'reporter cell line: control EGFP reporter; lentiviral library received: GeCKO v2_Library B; tissue: HCT116 colon cancer cell line; ', ""reporter cell line: MYC 5' UTR reporter; lentiviral library received: GeCKO v2_Library A; tissue: HCT116 colon cancer cell line; "", ""reporter cell line: MYC 5' UTR reporter; lentiviral library received: GeCKO v2_Library B; tissue: HCT116 colon cancer cell line; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132009,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132009/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA545621,31801078," Hema Manjunath,  He Zhang,  Frederick Rehfeld,  Jaeil Han,  Tsung-Cheng Chang,  Joshua T Mendell","Sequences within 5' UTRs dictate the site and efficiency of translation initiation. In this study, an unbiased screen designed to interrogate the 5' UTR-mediated regulation of the growth-promoting gene MYC unexpectedly revealed the ribosomal pause relief factor eIF5A as a regulator of translation initiation codon selection. Depletion of eIF5A enhances upstream translation within 5' UTRs across yeast and human transcriptomes, including on the MYC transcript, where this results in increased production of an N-terminally extended protein. Furthermore, ribosome profiling experiments established that the function of eIF5A as a suppressor of ribosomal pausing at sites of suboptimal peptide bond formation is conserved in human cells. We present evidence that proximal ribosomal pausing on a transcript triggers enhanced use of upstream suboptimal or non-canonical initiation codons. Thus, we propose that eIF5A functions not only to maintain efficient translation elongation in eukaryotic cells but also to maintain the fidelity of translation initiation.",Suppression of Ribosomal Pausing by eIF5A Is Necessary to Maintain the Fidelity of Start Codon Selection.,10.1016/j.celrep.2019.10.129,2019 Dec 3,PMC6917043,Cell reports
GSE107588,Ribosome profiling in transgenic and HEK293T cells,Homo sapiens,2,SRP125941,2017-12-01,[Overal design]Examine the physical locations of ribosomes along 15662 TAG terminated transcripts in both transgenic and HEK293T cells; [Treatment]'In the present of NAEK.'; [Growth]'HEK293T and transgenic cells were maintained in DMEM medium (Macgene) supplemented with 10% FBS (PAA) at 37 C in a 5% CO2 incubator.'; [Extraction]'The ribosome footprint libraries of transgenic cells and HEK-293T cells were constructed using Illuminas TrueSeq Ribo Profiling (Mammalian) Kit.\nThe ribosome footprint libraries of transgenic cells and HEK-293T cells were constructed using Illuminas TrueSeq Ribo Profiling (Mammalian) Kit'; [Cell type]'Embryonic kidney cells''cell type: Embryonic kidney cells; passages: 10; ',Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107588,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE107nnn/GSE107588/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA420695,,,,,,,,
GSE69923,Ribosome profiling on glutamine-starved panel of luminal and basal breast cancer cell lines,Homo sapiens,8,SRP059548,2015-06-16,"[Overal design]1 replicate per condition; [Treatment]'For starvation experiments, cells were culture for 48hrs in glutamine-free DMEM (Life Technologies) supplemented with 10% dialyzed FBS in 5% CO2 at 37C.'; [Growth]'All breast cancer cell lines were grown in DMEM supplemented with 10% FBS in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: ''cell line: MCF7; ', 'cell line: T47D; ', 'cell line: MDA-MB-231; ', 'cell line: Hs578t; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69923,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69923/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA287137,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE22012,Translatome and transcriptome profiling of estradiol response in MCF7 cells,Homo sapiens,16,None,2010-05-26,"[Overal design]The comparison between transcriptional and polysomal profiling was used for the discovery of general and mRNA-specific changes in the translation state of the serum starved MCF7 cells transcriptome in response to E2 stimulus. To identify translationally regulated mRNA molecules, gene expression signals derived from the polysomal populations were compared by microarrays analysis to those obtained from unfractionated total RNAs. Polysomal RNA and total RNA were isolated from MCF7 cells serum starved and treated with E2. Cells lysates were collected before (t = 0 min) and after (t = 60 min) E2 treatment. All experiments were run in quadruplicates.; [Treatment]'MCF7 cells were seeded on adherent plates and starved with 0.5% charcoal treated serum for 48h in white DMEM, 2mM glutamine. Cells were treated for 60 minutes with estradiol (E2) at final concentration of 10 nM.', 'MCF7 cells were seeded on adherent plates and starved with 0.5% charcoal treated serum for 48h in white DMEM, 2mM glutamine.'; [Growth]'MCF7 cells were cultured in Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2mM glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin at 37 C in a humidified atmosphere of 5% CO2.'; [Extraction]""Total RNA was extracted using RNeasy Mini Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany). RNA was quantified using a spectrophotometer and its quality was checked by agarose gel electrophoresis and by Agilent 2100 Bioanalyzer platform, following the manifacturers guidelines for sample preparation and analysis of data (Agilent 2100 Bioanalyzer 2100 Expert User's Guide, http://www.agilent.com)."", 'Cells were washed once with phosphate buffer saline (PBS) and treated directly on the plate with 300 l lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/l RNase inhibitor (Fermentas) and 1 mM dithiothreitol] and transferred to an Eppendorf tube. After a few minute incubation on ice with occasional vortexing, the extracts were centrifuged for 10 min at 12000 g at 4C. The supernatant was stored at 80C or loaded directly onto a 1550% linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged in an Sorvall rotor for 120 min at 40000 rpm. Polysomal fractions were collected monitoring the absorbance at 254 nm and treated directly with proteinase K. After phenolchloroform extraction and isopropanol precipitation, polysomal RNA was resuspended in 30 l of water and then repurified with RNeasy kit (Qiagen, Hilden, Germany). RNA quality was assessed by agarose gel electrophoresis and the Agilent 2100 Bioanalyzer platform.'; [Cell type]'Source: ''cell line: MCF7 cells; agent: E2; time point: 60 min; population: total RNA; biological replicate: #1; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: total RNA; biological replicate: #2; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: total RNA; biological replicate: #3; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: total RNA; biological replicate: #4; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: polysomal RNA; biological replicate: #1; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: polysomal RNA; biological replicate: #2; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: polysomal RNA; biological replicate: #3; ', 'cell line: MCF7 cells; agent: E2; time point: 60 min; population: polysomal RNA; biological replicate: #4; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: total RNA; biological replicate: #1; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: total RNA; biological replicate: #2; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: total RNA; biological replicate: #3; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: total RNA; biological replicate: #4; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #1; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #2; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #3; ', 'cell line: MCF7 cells; agent: none; time point: 0 min; population: polysomal RNA; biological replicate: #4; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22012,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE22nnn/GSE22012/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA127465,,,,,,,,
GSE139238,High-Throughput Translational Profiling with riboPLATE-seq,Homo sapiens,14,SRP226588,2019-10-22,"[Overal design]96 paired riboPLATE- and PLATE-seq libraries, corresponding to independent TS543 glioma neurosphere samples seeded on a 96-well plate, plus six each of ribosome profiling and RNA sequencing libraries. 6 replicates per drug treatment (PP242, MNK-i1, BKM120, PP242+BKM120, PP242+MNK-i1, BKM120+MNK-i1, AZD8055, 4EGi-1), and 48 DMSO-treated controls.; [Treatment]'Drugs were dissolved in DMSO to create stock solutions, which were then diluted with NS-A basal medium lacking growth factors and heparin. Drug treatments and concentrations consisted of 50nM AZD8055, 625nM PP242, 100nM BKM120, 1uM MNK-i1, and 50uM 4EGi-1, including in pairwise combination-treated samples. Drug treatment proceeded for 6 hours in the tissue culture incubator prior to lysis.'; [Growth]'TS-543 glioma neurospheres were seeded in a 96-well tissue culture plate at passage #11, to a starting density of 50K cells/mL, in 150 uL NeuroCult NS-A complete medium per well. Separately, passage #11 TS543 were seeded in a 6-well tissue culture plate (2mL medium/well), using the same media and to the same density. Cultures were allowed to expand for 36 hours.'; [Extraction]'PLATE-seq: Following lysis in a polysome-preserving buffer containing RNase inhibitors, cycloheximide, and magnesium, all polyadenylated RNA was isolated by pulldown on a poly(T) capture plate. riboPLATE-seq: Following lysis in polysome-preserving buffer containing RNase inhibitors, cycloheximide, and magnesium, ribosome-associated RNA was isolated by indirect IP, in which lysates were combined with streptavidin-coated magnetic beads following a pre-incubation with biotinylated y10b anti-rRNA antibody. Next, the polyadenylated subset of this ribosome-associated RNA was isolated with use of a poly(T) capture plate. Ribosome Profiling: Monosomes were isolated from RNase I-digested TS543 lysates on a sucrose gradient fractionator. RNA-Seq: Total RNA was isolated from TS543 lysates using a Qiagen RNeasy kit (cat no. 74104) and ribosomal RNA was depleted using the Ribo-Zero rRNA removal kit from Illumina (Cat no. MRZH11124) according to the manufacturers instructions.\nPLATE-seq/riboPLATE-seq: Polyadenylated RNA (for PLATE-seq) or ribosome-associated RNA (for riboPLATE-seq) was barcoded through reverse transcription primed with barcoded, adapter-linked oligo(dT), after which single-strand cDNA were pooled. Second-strand synthesis with adapter-linked random hexamers, cDNA purification, and PCR enrichment were all performed on these 96-way multiplexed pools with the Hamilton Microlab STAR liquid handling robot according to the PLATE-seq protocol (Bush et al, 2017). Ligation-free ribosome profiling : Ligation-free ribosome profiling libraries were prepared from dephosphorylated foot-prints (~ 28-34 nucleotides in length) using a commercially available kit (SMARTer small RNA-Seq Library Preparation Kit, Clontech, Cat no. 635029) following manufacturers instructions.   RNA-Seq library construction : rRNA depleted total RNA samples were converted to a strand-specific sequencing library using the NEBNext Ultra Directional RNA Library Prep Kit from Illumina (Cat no.E7420S).'; [Cell type]'TS543 glioblastoma''cell type: TS543 glioblastoma; passages: 11; drug treatment: DMSO; ', 'cell type: TS543 glioblastoma; passages: 11; drug treatment: MNK-i1; ', 'cell type: TS543 glioblastoma; passages: 11; drug treatment: PP242; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139238,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139238/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA578863,,,,,,,,
GSE108334,eIF1A residues implicated in cancer stabilize translation preinitiation complexes and favor suboptimal initiation sites in yeast,Saccharomyces cerevisiae,48,SRP127274,2017-12-20,"[Overal design]We examined the effect of tif11-R13P on global translational efficiencies (TEs) by ribosome footprint profiling of isogenic WT and tif11-R13P strains. The study includes 8 samples, comprised of 4 mRNA-Seq samples and 4 ribosome footprint profiling samples, derived from 2 biological replicates of tif11? mutant strains harboring plasmid-borne tif11-R13P or the WT TIF11 allele. Additional Ribosome profiling data were used for yeast uORF identification.; [Treatment]'No additional treatment', 'Cultures were treated with cycloheximide (100 ug / ml) for 2 min prior to harvesting', 'Cultures were treated with cycloheximide (100 g/ml) for 2 min prior to harvesting'; [Growth]'Yeast cells were generally grown to an OD600 of ~ 0.7  in synthetic complete medium at 30C,without treatment with cycloheximide before harvesting.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in YPD medium at 23?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in synthetic complete medium at 33?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in synthetic complete medium at 20?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in synthetic complete medium at 25?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in synthetic completemedium at 25?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in synthetic complete medium at 30?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7 in synthetic complete medium at 37?.', 'Yeast cells were generally grown to an OD600 of ~ 0.7  in synthetic complete medium at 20C,without treatment with cycloheximide before harvesting.', 'Yeast cells were generally grown to an OD600 of ~ 0.7  in synthetic complete medium at 25C,without treatment with cycloheximide before harvesting.', 'Yeast cells were generally grown to an OD600 of ~ 0.7  in synthetic complete medium at 37C,without treatment with cycloheximide before harvesting.'; [Extraction]'Cells were rapidly vacuum filtered and flash frozen. Whole cell extracts were prepared by breaking cells in freezer mill in cell lysis buffer containing 500 g/ml cycloheximide. Total mRNA isolated from whole cell extract using miRNeasy minikt (Qiagen). Total RNA fragmentation, Size selection,  linker ligation, reverse transcription, cDNA circularization, PCR amplification) was done as described Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. 2009. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324(5924):218-223. Ribo-Zero Gold rRNA Removal Kit (Illumina) was used to to remove ribosome contamination after linker ligation step.', 'Cells were rapidly vacuum filtered and flash frozen. Whole cell extracts were prepared by breaking cells in freezer mill in cell lysis buffer containing 500 g/ml cycloheximide. Whole cell extracts were RNase treated, and run over sucrose gradients to extract the monosome peak. RNA was then extracted using SDS/hot phenol/chloroform and footprints of the specified size were retained by gel purification. Briefly, RNAs were ligated to a universal DNA linker followed by reverse transcription. cDNAs were then circularized and PCR amplified. Ribosome profiling circularized cDNA was subject to ribosomal RNA subtraction using custom biotinylated oligos.', 'Cells were rapidly vacuum filtered and flash frozen. Whole cell extracts were prepared by breaking cells in freezer mill in cell lysis buffer containing 100 g/ml cycloheximide. Ribosome profiling (Rnase I footprinting, size selection,RNA extraction,  linker ligation, reverse transcription, cDNA circularization, subtractive hybridization, PCR amplification) was done as described Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. 2009. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324(5924):218-223', 'Cells were rapidly vacuum filtered and flash frozen. Whole cell extracts were prepared by breaking cells in freezer mill in cell lysis buffer containing 100 ug/ml cycloheximide. Ribosome profiling (Rnase I footprinting, size selection,RNA extraction,  linker ligation, reverse transcription, cDNA circularization, subtractive hybridization, PCR amplification) was done as described Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. 2009. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324(5924):218-223'; [Cell type]'Source: ''strain: FZY010; ', 'strain: FJZ011; ', 'strain: PMY337; ', 'strain: PMY338; ', 'strain: PMY335; ', 'strain: PMY336; ', 'strain: PMY316; ', 'strain: FJZ012; ', 'strain: FJZ013; ', 'strain: FJZ014; ', 'strain: FJZ015; ', 'strain: PMY71; ', 'strain: PMY72; ', 'strain: FJZ052; ', 'strain: FJZ046; ', 'strain: PMY33; ', 'strain: PMY30; ', 'strain: BY4741; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108334,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE108nnn/GSE108334/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA423281,29206102," Pilar Martin-Marcos,  Fujun Zhou,  Charm Karunasiri,  Fan Zhang,  Jinsheng Dong,  Jagpreet Nanda,  Shardul D Kulkarni,  Neelam Dabas Sen,  Mercedes Tamame,  Michael Zeschnigk,  Jon R Lorsch,  Alan G Hinnebusch","The translation pre-initiation complex (PIC) scans the mRNA for an AUG codon in favorable context, and AUG recognition stabilizes a closed PIC conformation. The unstructured N-terminal tail (NTT) of yeast eIF1A deploys five basic residues to contact tRNAi, mRNA, or 18S rRNA exclusively in the closed state. Interestingly, EIF1AX mutations altering the human eIF1A NTT are associated with uveal melanoma (UM). We found that substituting all five basic residues, and seven UM-associated substitutions, in yeast eIF1A suppresses initiation at near-cognate UUG codons and AUGs in poor context. Ribosome profiling of NTT substitution R13P reveals heightened discrimination against unfavorable AUG context genome-wide. Both R13P and K16D substitutions destabilize the closed complex at UUG codons in reconstituted PICs. Thus, electrostatic interactions involving the eIF1A NTT stabilize the closed conformation and promote utilization of suboptimal start codons. We predict UM-associated mutations alter human gene expression by increasing discrimination against poor initiation sites.",eIF1A residues implicated in cancer stabilize translation preinitiation complexes and favor suboptimal initiation sites in yeast.,10.7554/eLife.31250,2017 Dec 5,PMC5756025,eLife
GSE139135,Molecular characterization of BRSK2 and BRSK1 kinases as negative regulators of the NRF2 transcription factor,Homo sapiens,10,SRP226409,2019-10-21,"[Overal design]Evaluation of BRSK2/1 induced changes in RNA via overexpression in HEK293Ts.; [Treatment]'hcRED, BRSK2, and BRSK1 were overexpressed for 24 hours before collection'; [Growth]'HEK293T cells were cultured in DMEM with 10% FBS in standard incubator.'; [Extraction]'RNA was collected using PureLink RNA Mini Kit (Invitrogen, 12183018A) per manufacturer instruction, and 3ug of RNA was sent for highthorughput sequencing to Novogene Corp.\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'Source: ''cell line: HEK293T; genotype/variation: BRSK1; ', 'cell line: HEK293T; genotype/variation: BRSK2; ', 'cell line: HEK293T; genotype/variation: Mock; ', 'cell line: HEK293T; genotype/variation: hcRED; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139135,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139135/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA578614,,,,,,,,
GSE33674,Preservation of cone photoreceptors after a rapid yet transient degeneration and remodeling in cone-only Nrl-/- mouse retina,Mus musculus,20,None,2011-11-14,"[Overal design]Targets were generated from a pair of retinas (one Nrl-/- mouse) per biological replicate. Four biological replicates were generated for each of the five aging timepoints (1, 2, 4, 6, and 10 months post natal).; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA was extracted using RNeasy with on-column DNase treatment (Qiagen).  Ribosomal RNA was reduced from one microgram of total RNA using RiboMinus Transcriptome Isolation Kit (Human/Mouse) (Invitrogen).'; [Cell type]'Source: ''tissue: Retina; strain: C57Bl/6J; genotype: Nrl-/-; age: 1 month; ', 'tissue: Retina; strain: C57Bl/6J; genotype: Nrl-/-; age: 2 month; ', 'tissue: Retina; strain: C57Bl/6J; genotype: Nrl-/-; age: 4 month; ', 'tissue: Retina; strain: C57Bl/6J; genotype: Nrl-/-; age: 6 month; ', 'tissue: Retina; strain: C57Bl/6J; genotype: Nrl-/-; age: 10 month; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33674,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE33nnn/GSE33674/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA148293,22238088," Jerome E Roger,  Keerthi Ranganath,  Lian Zhao,  Radu I Cojocaru,  Matthew Brooks,  Norimoto Gotoh,  Shobi Veleri,  Avinash Hiriyanna,  Rivka A Rachel,  Maria Mercedes Campos,  Robert N Fariss,  Wai T Wong,  Anand Swaroop","Cone photoreceptors are the primary initiator of visual transduction in the human retina. Dysfunction or death of rod photoreceptors precedes cone loss in many retinal and macular degenerative diseases, suggesting a rod-dependent trophic support for cone survival. Rod differentiation and homeostasis are dependent on the basic motif leucine zipper transcription factor neural retina leucine zipper (NRL). The loss of Nrl (Nrl(-/-)) in mice results in a retina with predominantly S-opsin-containing cones that exhibit molecular and functional characteristics of wild-type cones. Here, we report that Nrl(-/-) retina undergoes a rapid but transient period of degeneration in early adulthood, with cone apoptosis, retinal detachment, alterations in retinal vessel structure, and activation and translocation of retinal microglia. However, cone degeneration stabilizes by 4 months of age, resulting in a thinner but intact outer nuclear layer with",Preservation of cone photoreceptors after a rapid yet transient degeneration and,10.1523/JNEUROSCI.3591-11.2012,2012 Jan 11,PMC3567450,The Journal of neuroscience : the official journal of the Society for Neuroscience
GSE124737,Ribosome profiling in transgenic and HEK293T cells treated with NAEK,Homo sapiens,8,SRP176433,2019-01-07,"[Overal design]Examine the physical locations of ribosomes in both transgenic and HEK293T cells; [Treatment]'None'; [Growth]'None'; [Extraction]'using TruSeq Ribo Profile kits (illumina)'; [Cell type]'Source: ''cell line: HEK293T cells stably transfected with Mb pyltRNA; treatment: with the addition of 1mM NAEK; ', 'cell line: HEK293T cells stably transfected with Mb pyltRNA; treatment: NA; ', 'cell line: HEK293T; treatment: with the addition of 1mM NAEK; ', 'cell line: HEK293T; treatment: NA; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124737,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE124nnn/GSE124737/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA513305,,,,,,,,
GSE71893,AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [Cellular small RNA-Seq],Homo sapiens,8,SRP062227,2015-08-10,"[Overal design]Profiles of MCF7 and HCT116 Akti-1/2 treated cells and MCF7 and HCT116 vehicle (i.e. DMSO) treated cells were generated, each in duplicate, using small RNA-Seq.; [Treatment]'Cells were treated for 72h with vehicle (DMSO), Akti-1/2 inhibitor (HCT116: 20M; MCF7: 2M) (Sigma)'; [Growth]'MCF7 was maintained in DMEM, 10% FCS, 40mM glutamine, 100 U/mL penicillin, and 100g/mL streptomycin; HCT116 was maintained in McCoys 5? medium supplemented with 10% FCS, 100U/mL penicillin, and 100g/mL streptomycin. All cells were grown at 37C and 5% CO2.'; [Extraction]'Total RNA was purified using RNAeasy miniprep kit (Qiagen) and the RNA integrity was checked using RNA 6000 Nano assay on Agilent 2100 Bioanalyzer. 1g of total RNA were used for library construction.\nThe library of cellular small RNA was made using Illuminas Tru-Seq Small RNA kit. The 3 and 5 adaptors were ligated and an RT reaction is used to create single stranded cDNA, then PCR amplified using a common primer and one index sequences before size selection on 6% native polyacrylamide gel. Fragment range of 105-150bp corresponding to the small RNA population were excised, eluted, precipitated and resuspended in 20?l of nuclease free water. The size, quality and quantity of the DNA in each final small RNA library were verified using the High Sensitivity kit (Agilent).'; [Cell type]'breast adenocarcinoma', 'colon carcinoma''cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 Low; ', 'cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 WT; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 Low; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 WT; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71893,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71893/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292423,26637368," Salony,  Xavier Sole,  Cleidson P Alves,  Ipsita Dey-Guha,  Laila Ritsma,  Myriam Boukhali,  Ju H Lee,  Joeeta Chowdhury,  Kenneth N Ross,  Wilhelm Haas,  Shobha Vasudevan,  Sridhar Ramaswamy","Small molecule inhibitors of AKT (v-akt murine thymoma viral oncogene homolog) signaling are being evaluated in patients with various cancer types, but have so far proven therapeutically disappointing for reasons that remain unclear. Here, we treat cancer cells with subtherapeutic doses of Akti-1/2, an allosteric small molecule AKT inhibitor, in order to experimentally model pharmacologic inhibition of AKT signaling in vitro. We then apply a combined RNA, protein, and metabolite profiling approach to develop an integrated, multiscale, molecular snapshot of this ""AKT(low)"" cancer cell state. We find that AKT-inhibited cancer cells suppress thousands of mRNA transcripts, and proteins related to the cell cycle, ribosome, and protein translation. Surprisingly, however, these AKT-inhibited cells simultaneously upregulate a host of other proteins and metabolites posttranscriptionally, reflecting activation of their endo-vesiculo-membrane system, secretion of inflammatory proteins, and elaboration of extracellular microvesicles. Importantly, these microvesicles enable rapidly proliferating cancer cells of various types to better withstand different stress conditions, including serum deprivation, hypoxia, or cytotoxic chemotherapy in vitro and xenografting in vivo. These findings suggest a model whereby cancer cells experiencing a partial inhibition of AKT signaling may actually promote the survival of neighbors through non-cell autonomous communication.",AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.,10.1158/1535-7163.MCT-15-0414,2016 Jan,PMC4707053,Molecular cancer therapeutics
GSE48680,Glucocorticoid effect on mRNA translation in childhood acute lymphoblastic leukemia,Homo sapiens,36,None,2013-07-10,"[Overal design]Translational efficiency of genes was estimated by comparing the amount of a gene's mRNA in pool 3 with the total amount of mRNA of the gene (in all 3 pools). Translational regulation by GC was estimated by contrasting gene regulations in pool 3 with gene regulation between GC-treated and control samples in all 3 pools (depicted as transcriptional regulation). Moderated t-tests were used to assess significance for translational regulation.; [Treatment]'Cells were treated in 3 independent experiments for 6 hours either with 100nM dexamethasone (a synthetic glucocorticoid) or 0.1% ethanol as empty carrier control.'; [Growth]'T-ALL CCRF-CEM-C7H2 and PreB-ALL NALM6 cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum and 2mM L-glutamine at 37C, 5% carbon-dioxide and saturated humidity.'; [Extraction]""Total RNA was extracted using the TRIZOL protocol according to the manufacturer's protocol, depleted of ribosomal RNA and transcribed into cDNA using T7-promoter-tagged hexamer primers. Antisense RNA was produced by T7-polymerase and transcribed into cDNA using random priming in the presence of dUTP which was used to enzymatically fragment the cDNA. The protocol for sample processed with Ambion reagents was identical to the one before (using Affymetrix reagents) with the exception that the ribosomal RNA depletion step was omitted, because specifically designed hexamere primer were used in the Ambion protocol, that preferentially do not bind to, and thus amplify, ribosomal RNA.""; [Cell type]'Source: ''cell line: CCRF-CEM-C7H2 T-ALL; treatment: ethanol; pool: 1; ', 'cell line: CCRF-CEM-C7H2 T-ALL; treatment: ethanol; pool: 3; ', 'cell line: CCRF-CEM-C7H2 T-ALL; treatment: dexamethasone; pool: 1; ', 'cell line: CCRF-CEM-C7H2 T-ALL; treatment: dexamethasone; pool: 3; ', 'cell line: CCRF-CEM-C7H2 T-ALL; treatment: ethanol; pool: 2; ', 'cell line: CCRF-CEM-C7H2 T-ALL; treatment: dexamethasone; pool: 2; ', 'cell line: NALM6 precursor B-ALL; treatment: ethanol; pool: 1; ', 'cell line: NALM6 precursor B-ALL; treatment: dexamethasone; pool: 1; ', 'cell line: NALM6 precursor B-ALL; treatment: ethanol; pool: 2; ', 'cell line: NALM6 precursor B-ALL; treatment: dexamethasone; pool: 2; ', 'cell line: NALM6 precursor B-ALL; treatment: ethanol; pool: 3; ', 'cell line: NALM6 precursor B-ALL; treatment: dexamethasone; pool: 3; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48680,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE48nnn/GSE48680/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA211180,24289529," Tatsiana Aneichyk,  Daniel Bindreither,  Christine Mantinger,  Daniela Grazio,  Katrin Goetsch,  Reinhard Kofler,  Johannes Rainer","BACKGROUND: Glucocorticoids (GCs) are natural stress induced steroid hormones causing cell cycle arrest and cell death in lymphoid tissues. Therefore they are the central component in the treatment of lymphoid malignancies, in particular childhood acute lymphoblastic leukemia (chALL). GCs act mainly via regulating gene transcription, which has been intensively studied by us and others. GC control of mRNA translation has also been reported but has never been assessed systematically. In this study we investigate the effect of GCs on mRNA",Translational profiling in childhood acute lymphoblastic leukemia: no evidence for glucocorticoid regulation of mRNA translation.,10.1186/1471-2164-14-844,2013 Dec 1,PMC4046653,BMC genomics
GSE59094,DDX3X regulation of global translation is impaired by medulloblastoma-associated mutations [CLIP-Seq],Homo sapiens,5,SRP044063,2014-07-03,"[Overal design]Examination of RNA targets od endogenous DDX3X; [Treatment]'Cells were seeded in 10 cm dish and harvested 24 hr later to obtain protein extracts. No additional treatments were done'; [Growth]'HEK293T cellswere grown in Dulbeccos Modified Eagles Serum,  DMEM,  supplemented with 10% fetal bovine serum, FBS and 1% Pen-Strep (100 U/ml penicillin, 100 g/ml streptomycin. Cells were incubated at 37 C and with a 5% CO2 concentration.'; [Extraction]'Ptotein lysis was performed in cold Nonidet P-40 buffer for 10 min on ice followed by addition of a 1:100 volume of RQ1 DNase (Promega). After DNAse treatment, RNAse I was added (0.02 U) and samples were incubated for 4 min at 37 C.\nAfter RNA extraction, library was prepared using Nextflex Small RNA Sequencing Kit and Sequencing was performed on an Illumina HiSeq 2000 using TruSeq SBS v3 reagents according to the manufacturers instructions'; [Cell type]'neuronal''cell line: HEK293T; cell type: neuronal; clip antibody: anti-DDX3X monoclonal (clone 2253C5a); antibody manufacturer: Santa Cruz Biotechnologies; antibody catalog number: sc-81247; protein immunoprecipitated: DDX3X; ', 'cell line: HEK293T; cell type: neuronal; clip antibody: mouse IgG; antibody manufacturer: Santa Cruz Biotechnologies; antibody catalog number: sc-2025; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59094,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59094/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA254362,27180681," Yasmine A Valentin-Vega,  Yong-Dong Wang,  Matthew Parker,  Deanna M Patmore,  Anderson Kanagaraj,  Jennifer Moore,  Michael Rusch,  David Finkelstein,  David W Ellison,  Richard J Gilbertson,  Jinghui Zhang,  Hong Joo Kim,  J Paul Taylor","DDX3X is a DEAD-box RNA helicase that has been implicated in multiple aspects of RNA metabolism including translation initiation and the assembly of stress granules (SGs). Recent genomic studies have reported recurrent DDX3X mutations in numerous tumors including medulloblastoma (MB), but the physiological impact of these mutations is poorly understood. Here we show that a consistent feature of MB-associated mutations is SG hyper-assembly and concomitant translation impairment. We used CLIP-seq to obtain a comprehensive assessment of DDX3X binding targets and ribosome profiling for high-resolution assessment of global translation. Surprisingly, mutant DDX3X expression caused broad inhibition of translation that impacted DDX3X targeted and non-targeted mRNAs alike. Assessment of translation efficiency with single-cell resolution revealed that SG hyper-assembly correlated precisely with impaired global translation. SG hyper-assembly and translation impairment driven by mutant DDX3X were rescued by a genetic approach that limited SG assembly and by deletion of the N-terminal low complexity domain within DDX3X. Thus, in addition to a primary defect at the level of translation initiation caused by DDX3X mutation, SG assembly itself contributes to global translation inhibition. This work provides mechanistic insights into the consequences of cancer-related DDX3X mutations, suggesting that globally reduced translation may provide a context-dependent survival advantage that must be considered as a possible contributor to tumorigenesis.",Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation.,10.1038/srep25996,2016 May 16,PMC4867597,Scientific reports
GSE94613,Promoter-bound METTL3 maintains myeloid leukemia by m6A-dependent regulation of protein translation,Homo sapiens,42,SRP099081,2017-02-07,"[Overal design]This experiment contains data for 3 high-throughput sequencing experiments; ChIP seq, m6A RNA IP seq and Riboprofiling. ChIP seq of METTL3 and METTL14 was conducted with 5 biological replicates each, with IgG and Input controls in triplicate and H3K4me3 in duplicate. All biological replicates were run across 2 lanes on an Illumina HiSeq 1500 providing technical replicates and increased coverage. m6A RNA IP was run in duplicate for two METTL3 shRNA inducible knockdown cell lines (KD1 and KD2) and a scramble shRNA control at day 8 following doxycyclin induction. In addition, matching non-immuno-precipitated Input controls were also sequenced. All biological replicates were run across 2 lanes on an Illumina HiSeq 4000 providing technical replicates and increased coverage. Riboprofiling was performed on two METTL3 shRNA inducible knockdown (KD) cell lines and a scramble shRNA control at day 5 and day 8 following doxycyclin induction. Matching Input controls were sequenced for each condition for direct comparison. All samples were run across 6 lanes on an Illumina HiSeq 1500 as technical replicates and to provide increased coverage. Files are named with the following structure: [Experiment Type]_[Sample Name]_[Biological Replicate Num]_[Technical Replicate Num].[File Extension].; [Treatment]'shRNA was induced by 200 ng/ml doxycycline treatment for the indicated times (5 days or 8 days).'; [Growth]'MOLM13 cells  were cultured in RPMI1640 (Invitrogen) supplemented with 10% FBS (PAA) and 1% penicillin/streptomycin/glutamine. 5*10^5 MOLM13 cells were infected using PLKO-TETon-Puro lentiviral vectors expressing shRNAs against the coding sequence of human METTL3 or a scramble control.'; [Extraction]""5*10^7 MOLM13 CTRL or METTL3 KD cells at day 5 or day 8 after doxycycline induction were treated with 0.1 mg/ml of cycloheximide for 1 minute and the ribosome protected fragment (RPF) fraction of mRNA or total input control mRNA was isolated using the RNeasy Mini Kit (Quiagen) following the manufacturer instruction. Ribosomal RNA was removed using the Illumina Ribozero Kit.\nSingle end 50 bp stranded libraries were prepared using the Illumina TRUseq Ribo Profile kit following manufacturer's recommendations. Reads were sequenced using HiSeq 1500 and multiplexed reads were split based on their barcodes using Illumina Basespace."", ""Total RNA was isolated from MOLM13 Ctrl cells or METTL3 KD cells 8 days after doxycycline administration using the RNeasy midi Kit (Quiagen). Successively polyA+ RNA was purified from 300 ug of total RNA using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). 500 ng of polyA+ purified RNA were used for each immunoprecipitation reaction. The m6A RNA immunoprecipitation was performed using the Magna MeRIP m6A kit (Millipore) according with the manufacturer instructions.\nSingle end 50 bp stranded libraries were prepared using the Bioo Scientific NEXTflex Rapid Directional RNA kit following manufacturer's recommendations. Reads were sequenced using HiSeq 4000 and multiplexed reads were split based on their barcodes using Illumina Basespace."", ""Chromatin immunoprecipitation was performed as previously described (Dawson et al., 2009). Firstly MOLM13 cells were cross-linked with 1% formaldehyde for 10 minutes.  20*10^6 cells were used for each immunoprecipitation with 3ug of specific antibodies or IgG. Immunoprecipitated DNA was purified using the ChIP DNA purification kit (Zymo).\nSingle end 50 bp libraries were prepared using the Bioo Scientific NEXTflex ChIP seq kit following manufacturer's recommendations. Reads were sequenced using HiSeq 1500 and multiplexed reads were split based on their barcodes using Illumina Basespace.""; [Cell type]'Source: ''cell line: leukemia cell line MOLM13; truseq barcode: TGACCA; genotype/variation: Scramble shRNA; time: Day 5; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TAGCTT; genotype/variation: Scramble shRNA; time: Day 8; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ACAGTG; genotype/variation: METTL3 KD1 shRNA; time: Day 5; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GGCTAC; genotype/variation: METTL3 KD1 shRNA; time: Day 8; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GCCAAT; genotype/variation: METTL3 KD2 shRNA; time: Day 5; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CTTGTA; genotype/variation: METTL3 KD2 shRNA; time: Day 8; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ATCACG; genotype/variation: Scramble shRNA; time: Day 5; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CAGATC; genotype/variation: Scramble shRNA; time: Day 8; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CGATGT; genotype/variation: METTL3 KD1 shRNA; time: Day 5; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ACTTGA; genotype/variation: METTL3 KD1 shRNA; time: Day 8; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TTAGGC; genotype/variation: METTL3 KD2 shRNA; time: Day 5; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GATCAG; genotype/variation: METTL3 KD2 shRNA; time: Day 8; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GTGAAA; genotype/variation: Scramble shRNA; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GTGGCC; genotype/variation: Scramble shRNA; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GTTTCG; genotype/variation: METTL3 KD1 shRNA; time: Day8; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CGTACG; genotype/variation: METTL3 KD1 shRNA; time: Day8; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GAGTGG; genotype/variation: METTL3 KD2 shRNA; time: Day8; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TAGCTT; genotype/variation: METTL3 KD2 shRNA; time: Day8; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: AGTCAA; genotype/variation: Scramble shRNA; ip antibody: Magna MeRIP m6A kit; antibody vendor: Millipore; antibody catalog num: MABE1006; antibody lot num: 2749196; ', 'cell line: leukemia cell line MOLM13; truseq barcode: AGTTCC; genotype/variation: Scramble shRNA; ip antibody: Magna MeRIP m6A kit; antibody vendor: Millipore; antibody catalog num: MABE1006; antibody lot num: 2749196; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ATGTCA; genotype/variation: METTL3 KD1 shRNA; time: Day8; ip antibody: Magna MeRIP m6A kit; antibody vendor: Millipore; antibody catalog num: MABE1006; antibody lot num: 2749196; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CCGTCC; genotype/variation: METTL3 KD1 shRNA; time: Day8; ip antibody: Magna MeRIP m6A kit; antibody vendor: Millipore; antibody catalog num: MABE1006; antibody lot num: 2749196; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GATCAG; genotype/variation: METTL3 KD2 shRNA; time: Day8; ip antibody: Magna MeRIP m6A kit; antibody vendor: Millipore; antibody catalog num: MABE1006; antibody lot num: 2749196; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GTCCGC; genotype/variation: METTL3 KD2 shRNA; time: Day8; ip antibody: Magna MeRIP m6A kit; antibody vendor: Millipore; antibody catalog num: MABE1006; antibody lot num: 2749196; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CGATGT; genotype/variation: WT; ip antibody: METTL3; antibody vendor: Bethyl Laboratories; antibody catalog num: A301-568A; antibody lot num: 1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CTTGTA; genotype/variation: WT; ip antibody: METTL3; antibody vendor: Bethyl Laboratories; antibody catalog num: A301-568A; antibody lot num: 1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TGACCA; genotype/variation: WT; ip antibody: METTL3; antibody vendor: Bethyl Laboratories; antibody catalog num: A301-568A; antibody lot num: 1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ACAGTG; genotype/variation: WT; ip antibody: METTL3; antibody vendor: Bethyl Laboratories; antibody catalog num: A301-568A; antibody lot num: 1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TGACCA; genotype/variation: WT; ip antibody: METTL14; antibody vendor: Abcam; antibody catalog num: ab98166; antibody lot num: GR277753-1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ATCACG; genotype/variation: WT; ip antibody: METTL14; antibody vendor: Abcam; antibody catalog num: ab98166; antibody lot num: GR277753-1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GCCAAT; genotype/variation: WT; ip antibody: METTL14; antibody vendor: Abcam; antibody catalog num: ab98166; antibody lot num: GR277753-1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CAGATC; genotype/variation: WT; ip antibody: METTL14; antibody vendor: Abcam; antibody catalog num: ab98166; antibody lot num: GR277753-1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CTTGTA; genotype/variation: WT; ip antibody: METTL14; antibody vendor: Abcam; antibody catalog num: ab98166; antibody lot num: GR277753-1; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ACAGTG; genotype/variation: WT; ip antibody: H3K4me3; antibody vendor: Abcam; antibody catalog num: ab8580; antibody lot num: GR240214-4; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TTAGGC; genotype/variation: WT; ip antibody: H3K4me3; antibody vendor: Abcam; antibody catalog num: ab8580; antibody lot num: GR240214-4; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GCCAAT; genotype/variation: WT; ip antibody: IgG; antibody vendor: Abcam; antibody catalog num: ab171870; antibody lot num: GR260971; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ACTTGA; genotype/variation: WT; ip antibody: IgG; antibody vendor: Abcam; antibody catalog num: ab171870; antibody lot num: GR260971; ', 'cell line: leukemia cell line MOLM13; truseq barcode: ATCACG; genotype/variation: WT; ip antibody: IgG; antibody vendor: Abcam; antibody catalog num: ab171870; antibody lot num: GR260971; ', 'cell line: leukemia cell line MOLM13; truseq barcode: CAGATC; genotype/variation: WT; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: GATCAG; genotype/variation: WT; ip antibody: none; ', 'cell line: leukemia cell line MOLM13; truseq barcode: TTAGGC; genotype/variation: WT; ip antibody: none; '",Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94613,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE94nnn/GSE94613/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA371833,29186125," Isaia Barbieri,  Konstantinos Tzelepis,  Luca Pandolfini,  Junwei Shi,  Gonzalo Millan-Zambrano,  Samuel C Robson,  Demetrios Aspris,  Valentina Migliori,  Andrew J Bannister,  Namshik Han,  Etienne De Braekeleer,  Hannes Ponstingl,  Alan Hendrick,  Christopher R Vakoc,  George S Vassiliou,  Tony Kouzarides","N(6)-methyladenosine (m(6)A) is an abundant internal RNA modification in both coding and non-coding RNAs that is catalysed by the METTL3-METTL14 methyltransferase complex. However, the specific role of these enzymes in cancer is still largely unknown. Here we define a pathway that is specific for METTL3 and is implicated in the maintenance of a leukaemic state. We identify METTL3 as an essential gene for growth of acute myeloid leukaemia cells in two distinct genetic screens. Downregulation of METTL3 results in cell cycle arrest, differentiation of leukaemic cells and failure to establish leukaemia in immunodeficient mice. We show that METTL3, independently of METTL14, associates with chromatin and localizes to the transcriptional start sites of active genes. The vast majority of these genes have the CAATT-box binding protein CEBPZ present at the transcriptional start site, and this is required for recruitment of METTL3 to chromatin. Promoter-bound METTL3 induces m(6)A modification within the coding region of the associated mRNA transcript, and enhances its translation by relieving ribosome stalling. We show that genes regulated by METTL3 in this way are necessary for acute myeloid leukaemia. Together, these data define METTL3 as a regulator of a chromatin-based pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.",Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control.,10.1038/nature24678,2017 Dec 7,PMC6217924,Nature
GSE53187,Transcriptome and translatome profiling of CPX 24h effects in neuroblastoma cells CHP134,Homo sapiens,12,None,2013-12-10,"[Overal design]Microarray analysis was performed to enable a comprehensive view of the changes in the transcriptional and translational status of the cells in response to the treatment with an iron chelator CPX. Polysomal RNA and total RNA were isolated from vehicle-treated CHP134 cells and CHP134 cells treated with 5 M CPX for 24 hours. Each condition is represented by three biological replicates, i.e. the experiment was repeated starting each time from cells seeding yielding an independent RNA sample. In total, 12 samples corresponding to 4 conditions were subjected to microarray analysis.; [Treatment]'CHP134 cells growing in 10 cm cell culture dishes were treated with vehicle for 24 hours.', 'CHP134 cells growing in 10 cm cell culture dishes were treated with 5 M CPX for 24 hours.'; [Growth]'CHP134 cells were purchased from ECACC (Cat. No. 06122002). The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 1640 medium supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine at 37 C in a humidified atmosphere of 5 % CO2.'; [Extraction]'To extract polysomal RNA, the following procedure was applied. CHP134 cells were incubated with 100 ?g/ml cycloheximide for 4 minutes, rinsed with phosphate buffer saline and lysed directly in cell-culture vessels [10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1 % Triton X-100, 1 % sodium deoxycholate, 100 ?g/ml cycloheximide, 0.2 U/?l RNase inhibitor, 1 mM DTT]. The lysate was collected with a cell scraper, pipetted into a microcentrifuge tube and after 5 minutes incubation on ice centrifuged for 10 min at 12000 g at 4 C. The supernatant was transferred into a new microcentrifuge tube and stored at 80 C. The lysates were fractionated by ultracentrifugation (Sorvall rotor, 100 min at 180000 g) through 1550 % linear sucrose gradient containing 30 mM TrisHCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2.  Polysomal fractions were collected monitoring the absorbance at 254 nm. Polysomal RNA was isolated after proteinase K treatment, phenolchloroform extraction and isopropanol precipitation and finally resuspended in 50 ?l of water. RNA quality was assessed using the Agilent 2100 Bioanalyzer platform.', 'Total RNA was extracted using RNeasy Plus Mini kit (Qiagen) following the instructions of the supplier and eluted in 50 ?l of water.'; [Cell type]'Source: ''disease: neuroblastoma; cell line: CHP134; agent (compound): vehicle; rna fraction: polysomal RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): CPX; rna fraction: polysomal RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): vehicle; rna fraction: total RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): CPX; rna fraction: total RNA; biological replicate: #1; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): vehicle; rna fraction: total RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): CPX; rna fraction: total RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): vehicle; rna fraction: polysomal RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): CPX; rna fraction: polysomal RNA; biological replicate: #2; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): vehicle; rna fraction: polysomal RNA; biological replicate: #3; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): CPX; rna fraction: polysomal RNA; biological replicate: #3; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): vehicle; rna fraction: total RNA; biological replicate: #3; ', 'disease: neuroblastoma; cell line: CHP134; agent (compound): CPX; rna fraction: total RNA; biological replicate: #3; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53187,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE53nnn/GSE53187/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA231066,,,,,,,,
GSE118239,Cancer associated mRNAs regulated by the Helix Loop Helix motif of human EIF3A,Homo sapiens,4,SRP156569,2018-08-07,"[Overal design]Ribosome profiling and RNA-seq analysis of control and EIF3A triple mutant HEK293T cells in biological triplicates.; [Treatment]'None'; [Growth]'Lentiviral engineered HEK293T cells were grown in DMEM media with 10% FBS. Each biological replicate was thawed separately into a 10cm plate and passaged twice before collection.'; [Extraction]""Extract was prepared according to protocol published in (Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., and Weissman, J. S. 2013. Genome-wide annotation and quantitation of translation by ribosome pro?ling. Curr. Protoc. Mol. Biol.103:4.18.1-4.18.18.doi: 10.1002/0471142727.mb0418s103).\nRibosome profiling libraries were prepared according to protocol published in (Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., and Weissman, J. S. 2013. Genome-wide annotation and quantitation of translation by ribosome pro?ling. Curr. Protoc. Mol. Biol.103:4.18.1-4.18.18.doi: 10.1002/0471142727.mb0418s103). RNA-seq libraries were prepared according to Illumina TruSeq RNA Library Prep kit manufacturer's instructions.""; [Cell type]'Source: ''cell line: HEK293T; passages: 15-18; lentivirus 1: anti-EIF3A shRNA; lentivirus 2: Control (CT) EIF3A; ', 'cell line: HEK293T; passages: 15-18; lentivirus 1: anti-EIF3A shRNA; lentivirus 2: HLH mutant EIF3A; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118239,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE118nnn/GSE118239/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA484941,,,,,,,,
GSE122071,Cap-specific terminal N6-methylation of RNA by an RNA polymerase II-associated methyltransferase.,Homo sapiens,11,SRP167457,2018-11-01,"[Overal design]Ribosome profiling and RNA-seq; [Treatment]'None'; [Growth]'None'; [Extraction]'Rnase I footprinting, ribosome pelleting, RNA extraction\nRNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification (for ribosome profiling) or TruSeq (illumina) (for mRNA-seq)\nRibosome profiling&mRNA-seq', 'Truseq stranded mRNA library prep\nRNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification (for ribosome profiling) or TruSeq (illumina) (for mRNA-seq)\nRibosome profiling&mRNA-seq'; [Cell type]'Source: ''genetic background: WT; cell line: HEK293T; extracted molecule: total RNA; ', 'genetic background: CSAM-KO#1; cell line: HEK293T; extracted molecule: total RNA; ', 'genetic background: CSAM-KO#2; cell line: HEK293T; extracted molecule: total RNA; ', 'genetic background: WT#1; cell line: HEK293T; extracted molecule: total RNA; ', 'genetic background: WT#2; cell line: HEK293T; extracted molecule: total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122071,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE122nnn/GSE122071/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA503400,30467178," Shinichiro Akichika,  Seiichi Hirano,  Yuichi Shichino,  Takeo Suzuki,  Hiroshi Nishimasu,  Ryuichiro Ishitani,  Ai Sugita,  Yutaka Hirose,  Shintaro Iwasaki,  Osamu Nureki,  Tsutomu Suzuki","N (6)-methyladenosine (m(6)A), a major modification of messenger RNAs (mRNAs), plays critical roles in RNA metabolism and function. In addition to the internal m(6)A, N (6), 2'-O-dimethyladenosine (m(6)Am) is present at the transcription start nucleotide of capped mRNAs in vertebrates. However, its biogenesis and functional role remain elusive. Using a reverse genetics approach, we identified PCIF1, a factor that interacts with the serine-5-phosphorylated carboxyl-terminal domain of RNA polymerase II, as a cap-specific adenosine methyltransferase (CAPAM) responsible for N (6)-methylation of m(6)Am. The crystal structure of CAPAM in complex with substrates revealed the molecular basis of cap-specific m(6)A formation. A transcriptome-wide analysis revealed that N (6)-methylation of m(6)Am promotes the translation of capped mRNAs. Thus, a cap-specific m(6)A writer promotes translation of mRNAs starting from m(6)Am.",Cap-specific terminal N (6)-methylation of RNA by an RNA polymerase II-associated methyltransferase.,10.1126/science.aav0080,2019 Jan 11,,"Science (New York, N.Y.)"
GSE128322,Ribosome profiling of HSV-1 infected cells,Homo sapiens,10,SRP188457,2019-03-14,"[Overal design]Ribosome profiling was performed a 0, 1, 2, 4, 6 and 8 h post infection. Translation start site profiling was performed using Harringtonin (2/ml for for 30 min) or Lactimidomycin (50M for 30 min) prior to cell lysis. Two biological replicates were analysed.; [Treatment]'Cells were infected for 10 min with HSV-1 strain 17 at an MOI of 10 followed by PBS wash and media replacement. 500M 4-thiouridine was added to the cell culture at the indicated time points.'; [Growth]'Human foreskin fibroblasts were cultured in DMEM supplements with 10% FBS and P/S. Cells at passage 13 were infected at 60% confluency 24h after the last split.'; [Extraction]'Cells were snap frozen followed by cell lysis in presence of cycloheximide. Following removal of cell nuclei by centrifugation and stringent RNAse digest, ribosomes were pelleted through a sucrose cushion. Translated RNA fragments were recovered by size selection.\nTranslated RNA fragments were cloned following the protocol described by Stern-Ginossar N et al. Science 2012. rRNA depletion involved additional biotinylated oligos to improve depletion. To efficiently remove all biotinylated oligos complementary to specific rRNA sequences, two rounds of streptavidin depletion were performed. cDNA libraries were amplified by PCR and sequenced (HiSeq 50nt reads).'; [Cell type]'human foreskin fibroblasts''cell type: human foreskin fibroblasts; time post infection: 2 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNAATANN; ', 'cell type: human foreskin fibroblasts; time post infection: 8 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNTTAANN; ', 'cell type: human foreskin fibroblasts; time post infection: mock; infection with: mock; barcode: NNNTTGTNN; ', 'cell type: human foreskin fibroblasts; time post infection: 4 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCAATNN; ', 'cell type: human foreskin fibroblasts; time post infection: 8 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCCGGNN; ', 'cell type: human foreskin fibroblasts; time post infection: mock; infection with: mock; barcode: NNNCGGANN; ', 'cell type: human foreskin fibroblasts; time post infection: 4 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNAATAANN; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128322,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128322/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA527127,32341360," Adam W Whisnant,  Christopher S Jurges,  Thomas Hennig,  Emanuel Wyler,  Bhupesh Prusty,  Andrzej J Rutkowski,  Anne L'hernault,  Lara Djakovic,  Margarete Gobel,  Kristina Doring,  Jennifer Menegatti,  Robin Antrobus,  Nicholas J Matheson,  Florian W H Kunzig,  Guido Mastrobuoni,  Chris Bielow,  Stefan Kempa,  Chunguang Liang,  Thomas Dandekar,  Ralf Zimmer,  Markus Landthaler,  Friedrich Grasser,  Paul J Lehner,  Caroline C Friedel,  Florian Erhard,  Lars Dolken","The predicted 80 open reading frames (ORFs) of herpes simplex virus 1 (HSV-1) have been intensively studied for decades. Here, we unravel the complete viral transcriptome and translatome during lytic infection with base-pair resolution by computational integration of multi-omics data. We identify a total of 201 transcripts and 284 ORFs including all known and 46 novel large ORFs. This includes a so far unknown ORF in the locus deleted in the FDA-approved oncolytic virus Imlygic. Multiple transcript isoforms expressed from individual gene loci explain translation of the vast majority of ORFs as well as N-terminal extensions (NTEs) and truncations. We show that NTEs with non-canonical start codons govern the subcellular protein localization and packaging of key viral regulators and structural proteins. We extend the current nomenclature to include all viral gene products and provide a genome browser that visualizes all the obtained data from whole genome to single-nucleotide resolution.",Integrative functional genomics decodes herpes simplex virus 1.,10.1038/s41467-020-15992-5,2020 Apr 27,PMC7184758,Nature communications
GSE104329,Ribosomal coverage with codon resulation in response to RPL12 siRNA treatment vs. no treatment,Homo sapiens,5,SRP118987,2017-09-27,"[Overal design]Ribosome Profiling of cells 96h after siRNA transfection; [Treatment]'None'; [Growth]""Cystic Fibrosis Bronchial Epithelial cells were grown at 37C to 80% confluency in Eagle's MEM, transfected with siRNA and recovered for 96 h.""; [Extraction]'Total RNA was extracted using TRIzol reagent (Invitrogen) and the sample was enriched in mRNA using the Ribo-Zero Gold rRNA Removal Kit (Illumina) and spiked with ERCC RNA Spike-In Mix(Thermo Fisher).\nRNA-size selection and generation of the cDNA libraries was performed as described {Ingolia, 2009}'; [Cell type]'CFBE cells''cell type: CFBE cells; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104329,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE104nnn/GSE104329/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA412370,31657788," Kathryn E Oliver,  Robert Rauscher,  Marjolein Mijnders,  Wei Wang,  Matthew J Wolpert,  Jessica Maya,  Carleen M Sabusap,  Robert A Kesterson,  Kevin L Kirk,  Andras Rab,  Ineke Braakman,  Jeong S Hong,  John L 4th Hartman,  Zoya Ignatova,  Eric J Sorscher","Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR), with approximately 90% of patients harboring at least one copy of the disease-associated variant F508del. We utilized a yeast phenomic system to identify genetic modifiers of F508del-CFTR biogenesis, from which ribosomal protein L12 (RPL12/uL11) emerged as a molecular target. In the present study, we investigated mechanism(s) by which suppression of RPL12 rescues F508del protein synthesis and activity. Using ribosome profiling, we found that rates of translation initiation and elongation were markedly slowed by RPL12 silencing. However, proteolytic stability and patch-clamp assays revealed RPL12 depletion significantly increased F508del-CFTR steady-state expression, interdomain assembly, and baseline open-channel probability. We next evaluated whether Rpl12-corrected F508del-CFTR could be further enhanced with concomitant pharmacologic repair (e.g., using clinically approved modulators lumacaftor and tezacaftor) and demonstrated additivity of these treatments. Rpl12 knockdown also partially restored maturation of specific CFTR variants in addition to F508del, and WT Cftr biogenesis was enhanced in the pancreas, colon, and ileum of Rpl12 haplosufficient mice. Modulation of ribosome velocity therefore represents a robust method for understanding both CF pathogenesis and therapeutic response.",Slowing ribosome velocity restores folding and function of mutant CFTR.,10.1172/JCI124282,2019 Dec 2,PMC6877332,The Journal of clinical investigation
GSE112353,Active ribosome profiling  with RiboLace and standard ribosome profiling in HEK-293 cells,Homo sapiens,4,SRP136497,2018-03-26,"[Overal design]We performed active ribosome profiling with RiboLace and standard ribosome profiling in HEK-293 cells. Experiments were performed in biological duplicate.; [Treatment]'Cells were then treated with 10 g/mL of cycloheximide (CHX) for 5 min at 37C before lysis in order to inhibit translation elongation.'; [Growth]'HEK-293 were seeded at 1.5  106 cells/dish  on adherent plates and maintained at 37 C, 5% CO2 in DMEM with red phenol supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 mg/mL of streptomycin. Cells were grown until 80% of confluence before lysis.'; [Extraction]'Cells were washed at 4C with PBS complemented with cycloheximide 10 ?g/mL and scraped on the plate with 300 ?L of lysis buffer (10 mM NaCl, 10 mM MgCl2, 10 mM TrisHCl, pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 5 U/mL DNAseI, 200 U/mL RNase inhibitor and 10 ?g/mL cycloheximide) for each dish. Nuclei and cellular debris were removed by two centrifugations at 18000g, 4C, 5 min. The lysate was aliquoted and stored at -80C for not more than a month, avoiding more than one freeze/thaw cycle.\nFor RiboLace Ribo-Seq, the RNA absorbance of the lysate (at 260 nm) was measured by Nanodrop ND-1000 UV-VIS Spectrophotometer and the lysate diluted to 1.7 a.u. A260/L with W-buffer (10 mM NaCl, 10 mM MgCl2, 20 g/mL cycloheximide, 10 mM Hepes, pH 7 in DEPC water). RNase I nuclease (catalog no AM2295, diluted 1:100, L used for each sample = 1.7 x 0,75) was used to footprint ribosomes for 45 min at 20C. The reaction was then quenced  with SUPERase?In RNase Inhibitor on ice for 15 min. Then, the reaction was added directly to the RiboLace beads and the suspension incubated on a wheel for at least 1 hour in orbital rotation, 3 rpm at 4C. After incubation, the tubes were kept on ice on a magnetic stand for 5 min to capture the beadsbounded-ribosomes. The supernatant was discarded (unbound fraction) and beads washed two times with 500 L of W-buffer. Beads were resuspended in 200 L of W-buffer containing 20 U SUPERase?In, 1% SDS and treated with 0.1 mg of proteinase K (Euroclone, catalog no. EMR022001) at 37C for 75 min. Ribosome Protected Fragments (RPFs) were extracted with acid-phenol:chloroform:isoamylalcohol and isopropanol precipitation and size selected (25-35 nt) by urea-page. RPFs were treated to remove 3 phosphate, ligated to the 3 adaptor and purified by UREA page. Ligated RPFs were retrotranscribed and the cDNA circularized. Libraries were finally amplified by PCR using Illumina PCR Primer Index.   Standard ribosome Ribosome profiling was performed as RboLace Ribo-Seq buth without incubation with RiboLace beads. Briefly, CHX-treated cells were lysed with 300 ?L of lysis buffer and the cell lysate diluted to 1.7 a.u. A260/L with W-buffer (10 mM NaCl, 10 mM MgCl2, 20 g/mL cycloheximide, 10 mM Hepes, pH 7 in DEPC water) to a final volume of 150 L. RNase I nuclease (catalog no AM2295, diluted 1:100, L used for each sample = 1.7 x 0,75) was used to footprint ribosomes for 45 min at 20C. The reaction was then quenced with  SUPERase?In RNase Inhibitor on ice for 15 min. Samples were then incubated with 1% SDS and treated with 0.1 mg of proteinase K (Euroclone, catalog no. EMR022001) at 37C for 75 min. Ribosome Protected Fragments (RPFs) were extracted with acid-phenol:chloroform:isoamylalcohol and isopropanol precipitation and size selected (25-35 nt) by urea-page. RPFs were treated to remove 3 phosphate, ligated to the 3 adaptor and purified by UREA page. Ligated RPFs were retrotranscribed and the cDNA circularized. Libraries were finally amplified by PCR using Illumina PCR Primer Index.'; [Cell type]'Source: ''cells: HEK-293; rna fraction: RiboLace-RIBOseq; replicate: #1; ', 'cells: HEK-293; rna fraction: RiboLace-RIBOseq; replicate: #2; ', 'cells: HEK-293; rna fraction: standard-RIBOseq; replicate: #1; ', 'cells: HEK-293; rna fraction: standard-RIBOseq; replicate: #2; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112353,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112353/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445733,30355487," Massimiliano Clamer,  Toma Tebaldi,  Fabio Lauria,  Paola Bernabo,  Rodolfo F Gomez-Biagi,  Marta Marchioretto,  Divya T Kandala,  Luca Minati,  Elena Perenthaler,  Daniele Gubert,  Laura Pasquardini,  Graziano Guella,  Ewout J N Groen,  Thomas H Gillingwater,  Alessandro Quattrone,  Gabriella Viero","Ribosome profiling, or Ribo-seq, is based on large-scale sequencing of RNA fragments protected from nuclease digestion by ribosomes. Thanks to its unique ability to provide positional information about ribosomes flowing along transcripts, this method can be used to shed light on mechanistic aspects of translation. However, current Ribo-seq approaches lack the ability to distinguish between fragments protected by either ribosomes in active translation or inactive ribosomes. To overcome this possible limitation, we developed RiboLace, a method based on an original puromycin-containing molecule capable of isolating active ribosomes by means of an antibody-free and tag-free pull-down approach. RiboLace is fast, works reliably with low amounts of input material, and can be easily and rapidly applied both in vitro and in vivo, thereby generating a global snapshot of active ribosome footprints at single nucleotide resolution.",Active Ribosome Profiling with RiboLace.,10.1016/j.celrep.2018.09.084,2018 Oct 23,,Cell reports
GSE131809,"Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation (Ribo-seq, RNA-seq)",Homo sapiens,16,SRP199612,2019-05-28,"[Overal design]Four replicates of ribosome profiling in adult and newborn erythroid cells with matching RNA-seq per sample.; [Treatment]'CD34+ HSPCs from adult and newborn were differentiated until day 7 (proerythroblast stage) for examining ribosome profiles.'; [Growth]'None'; [Extraction]""Cells were incubated with 100\xa0?g/ml of cycloheximide (Sigma Aldrich) for 5 minutes at 37C, washed twice with ice-cold PBS containing 100\xa0?g/ml of cycloheximide and lysed in 10 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 100 mM KCl, 1% Triton X-100, 3 mM DTT, 100\xa0?g/ml cycloheximide, 500 U/ml RNasin (Promega) and 1x\xa0Complete Protease Inhibitor, EDTA-free (Roche). Lysates for ribosome profiling were prepared and ribosome protected RNA fragments (RPFs) were isolated as described previouslywith the following modifications: rRNA was depleted using the RiboMinus Eukaryote Kit v2 (Thermo Fisher Scientific) by following the manufacturers instructions. rRNA depleted RPFs were purified with the Zymo RNA Clean & Concentrator-5 kit by following the manufacturers instructions for small RNAs. PAGE purification of RPFs was performed as described previously and resulting RPFs were dephosphorylated in FastAP mix (19.5 l H2O, 2.5 l 10x FastAP buffer (Thermo Fisher Scientific), 2.5 U FastAP enzyme (1 U/l; Thermo Fisher Scientific), 0.5 l Murine RNase Inhibitor (New England Biolabs)) and incubating for 20 minutes at 37C. In the meantime, polynucleotide kinase mix was prepared (57 l H2O, 10 l 10x PNK buffer (New England Biolabs), 0.5 l Murine RNase Inhibitor, 6.5 l T4 PNK (10 U/l; New England Biolabs), 1 l TURBO DNase) and added 75 l to each 25 l sample and incubated 20 minutes at 37C. RPFs were purified with the Zymo RNA Clean & Concentrator-5 kit following the manufacturers instructions for small RNAs.\nRNA was eluted in 7 l H2O, 1.5 l DMSO and 10 pM 3 adapter (/Phos/AGATCGGAAGAGCACACGTCTG/ddC) were added before denaturation at 65C for 2 minutes and transferring samples to ice. Subsequently, 11 l ligation mix was added (2 l 10x T4 RNA ligation buffer (New England Biolabs), 0.3 l DMSO, 0.2 l ATP, 0.3 l RNAse inhibitor, 7 l 50% PEG 8000, 1.2 l T4 RNA Ligase 1 High Concentration (New England Biolabs)) using low retention pipette tips and incubated 1 hour at 23C with agitation. Ligation reactions were purified to remove free 3 adapter using Silane bead purifications. For each reaction, 15 l Silane beads (Thermo Fisher Scientific) were washed twice in 1 ml RLT buffer (Qiagen), beads were resuspended in 60 l RLT, and 60 l beads in RLT was combined with 20 l ligation reaction. 0.7 volumes 100% ethanol were added and incubated for 10 minutes at room temperature. Supernatant was removed and beads were washed twice with 70 % ethanol before eluting air-dried beads in 10 l H2O. Next, 10 pM reverse transcription primer (/5biotin/GACGTGTGCTCTTCCGA) was added and samples were denatured at 72C for 3 minutes before transferring to ice. To each reaction 7 l reverse transcription mix (0.25 l H2O, 2 l 5x Smartscribe first strand buffer (Takara), 0.25 l RNase inhibitor, 2 l Smartscribe RT (Takara), 2 l dNTP, 0.5 l 20 mM DTT) were added and samples were incubated at 42C for 15 minutes. Next, 2 l template-switching oligo (5'biotin/TACACGACGCTCTTCCGATCTrGrG+G) were added and samples were incubated 90 minutes at 42C, followed by 10 minutes at 70C. Samples were purified with Silane beads and subjected to PCR amplification using 2x NEBNext Q5 Hot Start HiFi PCR Master Mix (New England Biolabs) as described previously. Amplicons migrating at a size of ~157 bp were subjected to two consecutive rounds of gel purification. For preparation of mRNA sequencing libraries, total RNA was extracted with the Direct-zol RNA MiniPrep Plus Kit (Zymo Research) according to the manufacturers instructions. Total RNA was poly-A selected using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs) according to the manufacturers instructions. mRNA was eluted in 27 l H2O, 3 l 10x FastAP buffer were added and RNA was heat fragmented for 3 minutes at 91C. Fragmented RNA was end-repaired, adapter ligated, reverse transcribed and PCR amplified.""; [Cell type]'hematopoetic cells''cell type: hematopoetic cells; cell type: adult erythroid cells; ', 'cell type: hematopoetic cells; cell type: newborn erythroid cells; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131809,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE131nnn/GSE131809/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA545050,31959994," Anindita Basak,  Mathias Munschauer,  Caleb A Lareau,  Kara E Montbleau,  Jacob C Ulirsch,  Christina R Hartigan,  Monica Schenone,  John Lian,  Yaomei Wang,  Yumin Huang,  Xianfang Wu,  Lee Gehrke,  Charles M Rice,  Xiuli An,  Helen A Christou,  Narla Mohandas,  Steven A Carr,  Jane-Jane Chen,  Stuart H Orkin,  Eric S Lander,  Vijay G Sankaran","Increased production of fetal hemoglobin (HbF) can ameliorate the severity of sickle cell disease and beta-thalassemia(1). BCL11A represses the genes encoding HbF and regulates human hemoglobin switching through variation in its expression during development(2-7). However, the mechanisms underlying the developmental expression of BCL11A remain mysterious. Here we show that BCL11A is regulated at the level of messenger RNA (mRNA) translation during human hematopoietic development. Despite decreased BCL11A protein synthesis earlier in development, BCL11A mRNA continues to be associated with ribosomes. Through unbiased genomic and proteomic analyses, we demonstrate that the RNA-binding protein LIN28B, which is developmentally expressed in a pattern reciprocal to that of BCL11A, directly interacts with ribosomes and BCL11A mRNA. Furthermore, we show that BCL11A mRNA translation is suppressed by LIN28B through direct interactions, independently of its role in regulating let-7 microRNAs, and that BCL11A is the major target of LIN28B-mediated HbF induction. Our results reveal a previously unappreciated mechanism underlying human hemoglobin switching that illuminates new therapeutic opportunities.",Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation.,10.1038/s41588-019-0568-7,2020 Feb,PMC7031047,Nature genetics
GSE129757,Whole transcriptome profiles and ribosome profiling of thapsigargin- and tunicamycin-treated LN308 cells,Homo sapiens,22,SRP192442,2019-04-12,"[Overal design]Whole transcriptome profiles and ribosome profiling libraries were generated for thapsigargin- and tunicamycin-treated LN308 cell lines by next generation sequencing (Illumina Next Seq 500). Samples were taken after 0, 2 and 6 hours of pharmacological treatment.; [Treatment]'To induce ER stress the medium was supplemented with 200nM Thapsigargin or 2.5g/ml Tunicamycin (dissolved in DMSO); DMSO only served as a control.'; [Growth]'LN308 cells were cultured in DMEM supplemented with 10% FBS, 100 units/ml penicillin and 100g/ml streptomycin at 37C and at 5% CO2.'; [Extraction]'Ribo-Seq  TH- or TM-stimulated cells were treated with 0.1mg/ml cycloheximide for 5min.  After washing with ice-cold PBS (supplemented with cycloheximide), cells were harvested and lysed for 15min on ice in a buffer containing 5mM Tris pH7.4, 1.5mM KCl, 5mM MgCl2, 0.5% Triton-X, 0.5% sodium deoxycholate, 0.1mg/ml cycloheximide, RNasin and 1x cOmplete protease inhibitor cocktail (Roche).  The cell lysate was cleared by centrifugation and digested with 0.2U RNaseI (Ambion) per 1g RNA for 15min.  To stop the reaction, 1U SUPERaseIn RNase Inhibitor (Invitrogen) was added per unit of RNaseI.  Ribosomal complexes were separated on 12ml 10-50% sucrose gradients (in a buffer containing 20mM Tris pH7.4, 75 mM NaCl, 5mM MgCl2, 0.1mg/ml cycloheximide, and 1mM DTT) by centrifugation at 4C and 35,000rpm for 3h in a SW41 rotor.  Fractions were collected at 0.5ml/min with continuous monitoring of conductivity and UV absorption at 254nm.  Fractions containing 80S monosomes were diluted with an equal amount of RNase-free water followed by organic extraction with Phenol:Chloroform:Isoamylalkohol 25:24:1 (Roth) and ethanol precipitation.  RNAs were then separated by denaturing Urea-PAGE and visualized by SYBR Gold staining.  RNAs with a length of 27-33nt were excised from the gel and eluted overnight in a buffer containing 300mM NaOAc pH 5.5, 1mM EDTA, and 0.25% SDS followed by ethanol precipitation.\nRNA-Seq  Total cellular RNA was extracted using TRIzol reagent according to the manufacturers instructions.\nRibo-Seq  After dephosphorylation for 1h at 37C with 20U of T4 Polynucleotide Kinase (NEB), RNAs were ligated to a universal miRNA cloning linker (NEB) using truncated T4 RNA ligase 2.  After gelpurification reverse transcription was performed using SuperscriptIII reverse transcriptase and a primer complementary to the ligated adapter, followed by alkaline hydrolysis of the RNA strand.  The resulting cDNAs were gelpurified and contaminating sequences originating from rRNA were depleted by substractive hybridization to a mixture of biotinylated DNA oligonucleotides and Streptavidin magnetic beads (New England Biolabs).  The recovered RNAs were then circularized with CircLigase II ssDNA Ligase (Epicentre) according to the manufacturers instructions and subjected to PCR amplification to generate amplicons suitable for Illumina sequencing.  After gelpurification, DNA concentration was determined using a Qubit Fluorometer (Qubit 2.0, Thermo Fisher Scientific).  Bioanalyzer or TapeStation (Agilent) analyses were performed to assess the quality of the samples followed by deep sequencing on the Illumina platform.\nRNA-Seq  RNA integrity was checked using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA), and concentration was measured with Qubit RNA Assay Kit in Qubit 2.0 Flurometer (Life Technologies).  Starting with ~300ng of total RNA as input, ribosomal RNA was removed by NEBNext rRNA Depletion Kit (Human/Mouse/Rat) (New England Biolabs).  Subsequently, stranded total RNA-seq libraries were prepared from rRNA free RNA sample using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs) according to the protocol.  RNA-seq barcoded libraries that passed the QC step, which was assessed on the Agilent Bioanalyzer system, were then pooled in equimolar amounts;  1.8 pM solution of this pool was loaded on the Illumina sequencer NextSeq 500 and sequenced bi-directionally.'; [Cell type]'Astrocytoma-derived p53-deficient glial cells''cell line: LN308; cell type: Astrocytoma-derived p53-deficient glial cells; time: 0 h; treatment: untreated; ', 'cell line: LN308; cell type: Astrocytoma-derived p53-deficient glial cells; time: 2 h; treatment: tunicamycin; ', 'cell line: LN308; cell type: Astrocytoma-derived p53-deficient glial cells; time: 6 h; treatment: tunicamycin; ', 'cell line: LN308; cell type: Astrocytoma-derived p53-deficient glial cells; time: 2 h; treatment: thapsigargin; ', 'cell line: LN308; cell type: Astrocytoma-derived p53-deficient glial cells; time: 6 h; treatment: thapsigargin; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129757,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129757/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA532643,,,,,,,,
GSE143415,Co-existence of compulsory and plastic rRNA 2'-O-Methylation sites in human breast tumours,Homo sapiens,200,SRP241165,2020-01-10,"[Overal design]rRNA 2'OMe profiling in a series of 195 primary breast tumours; [Treatment]'None'; [Growth]'None'; [Extraction]'RNAeasy kit (Qiagen)\nTotal RNA was first subjected to partial alkaline hydrolysis to generate RNA fragments ranging from 50 to 100 bp. Libraries were then prepared using NEBNext Multiplex Small RNA Library Prep Set'; [Cell type]'Source: ''tissue: primary breast tumour; subtype: LumiNAl; p53 status: WT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: TNBC; p53 status: MT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: LumiNAl; p53 status: WT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: LumiNAl; p53 status: MT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: LumiNAl; p53 status: WT; Stage: Stage 1; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: WT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: TNBC; p53 status: NA; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: LumiNAl; p53 status: MT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: TNBC; p53 status: WT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: NA; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: WT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: MT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: WT; Stage: Stage 1; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: TNBC; p53 status: WT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: NA; p53 status: MT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: WT; Stage: NA; molecule subtype: ribosomal RNA; ', 'tissue: pool of different origins; subtype: NA; p53 status: NA; Stage: NA; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: NA; p53 status: WT; Stage: Stage 1; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: NA; p53 status: WT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: NA; p53 status: WT; Stage: NA; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: LumiNAl; p53 status: NA; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: NA; p53 status: MT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: LumiNAl; p53 status: NA; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: ER+ HER2-; p53 status: WT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: ER+ HER2-; p53 status: WT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: NA; p53 status: WT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: ER+ HER2-; p53 status: WT; Stage: Stage 1; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: ER+ HER2-; p53 status: MT; Stage: Stage 2; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: ER+ HER2-; p53 status: MT; Stage: Stage 3; molecule subtype: ribosomal RNA; ', 'tissue: primary breast tumour; subtype: HER2; p53 status: MT; Stage: NA; molecule subtype: ribosomal RNA; '",Other; Methylation profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143415,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE143nnn/GSE143415/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA600412,,,,,,,,
GSE70211,Rocaglamide A converts RNA helicase eIF4A into a sequence-specific translational repressor,Homo sapiens; synthetic construct,23,SRP059825,2015-06-24,"[Overal design]Ribosome profiling, mRNA-Seq, RIP-Seq, and Bind-n-Seq Ribosome profiling for sample 1-5, and 11-15. Sample1 and 2 are replicates of control of DMSO treatment for sample 3-5, and 11, with RocA and PP242 treatments. Sample 12 and 13 are replicates of control of DMSO treatment for sample 14 and 15 with Hipp treatments. mRNA-Seq for sample 6-10. Sample 6 and 7 are replicates of control of DMSO treatment for sample 8-10 with RocA treatments. RIP-Seq for 16-19. Sample 16 and 17 are replicates of control of DMSO treatment for sample 18-19 with RocA treatments. Bind-n-Seq for 20-23. Sample 21 is control of DMSO treatment for sample 22-23 with RocA treatments. Sample 20 is a input contol for protein-bound fraction of sample 21. We stably expressed SBP (streptavidin binding peptide)-tagged eIF4A in HEK 293T-REx cells and purified it via M270 streptavidin beads (life techonologies).; [Treatment]'None'; [Growth]'None'; [Extraction]'Rnase I footprinting, ribosome pelleting, RNA extraction\nTRI-reagent (sigma) and following Direct-zol RNA-MiniPrep (zymo research).', 'Standard mRNA-seq\nTRI-reagent (sigma) and following Direct-zol RNA-MiniPrep (zymo research).', 'randomized synthetic RNAs\nTRI-reagent (sigma) and following Direct-zol RNA-MiniPrep (zymo research).'; [Cell type]'Source: ''cell line: HEK 293 T-REx cell; treatment: DMSO; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; treatment: RocA 0.03 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; treatment: RocA 0.3 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; treatment: RocA 3 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; treatment: PP242 2.5 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; treatment: Hipp 0.01 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; treatment: Hipp 1 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; genotype/variation: stabley expressing SBP-tagged eIF4A; treatment: DMSO; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; genotype/variation: stabley expressing SBP-tagged eIF4A; treatment: RocA 0.03 uM; molecule: total RNA; ', 'cell line: HEK 293 T-REx cell; genotype/variation: stabley expressing SBP-tagged eIF4A; treatment: RocA 0.3 uM; molecule: total RNA; ', 'treatment: None; molecule subtype: randomized synthetic RNAs; molecule: total RNA; ', 'treatment: DMSO; molecule subtype: randomized synthetic RNAs; molecule: total RNA; ', 'treatment: RocA 0.03 uM; molecule subtype: randomized synthetic RNAs; molecule: total RNA; ', 'treatment: RocA 0.3 uM; molecule subtype: randomized synthetic RNAs; molecule: total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70211,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE70nnn/GSE70211/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA287879,27309803," Shintaro Iwasaki,  Stephen N Floor,  Nicholas T Ingolia","Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumour cells and repress translation of specific messenger RNAs. RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its messenger RNA selectivity is proposed to reflect highly structured 5' untranslated regions that depend strongly on eIF4A-mediated unwinding. However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these drugs actually increase the affinity between eIF4A and RNA. Here we show that secondary structure in 5' untranslated regions is only a minor determinant for RocA selectivity and that RocA does not repress translation by reducing eIF4A availability. Rather, in vitro and in cells, RocA specifically clamps eIF4A onto polypurine sequences in an ATP-independent manner. This artificially clamped eIF4A blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein expression from transcripts bearing the RocA-eIF4A target sequence. In elucidating the mechanism of selective translation repression by this lead anti-cancer compound, we provide an example of a drug stabilizing sequence-selective RNA-protein interactions.",Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.,10.1038/nature17978,2016 Jun 23,PMC4946961,Nature
GSE133393,Genome-wide survey of ribosome collision [monosome/disome],Homo sapiens,4,SRP212162,2019-06-27,"[Overal design]Ribosome profiling; [Treatment]'None'; [Growth]'None'; [Extraction]'Rnase I footprinting, ribosome pelleting, RNA extraction\nRNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification for ribosome profiling'; [Cell type]'Source: ''genotype: WT; cell line: HEK293; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133393,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE133nnn/GSE133393/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA551384,32375038," Peixun Han,  Yuichi Shichino,  Tilman Schneider-Poetsch,  Mari Mito,  Satoshi Hashimoto,  Tsuyoshi Udagawa,  Kenji Kohno,  Minoru Yoshida,  Yuichiro Mishima,  Toshifumi Inada,  Shintaro Iwasaki","Ribosome movement is not always smooth and is rather often impeded. For ribosome pauses, fundamental issues remain to be addressed, including where ribosomes pause on mRNAs, what kind of RNA/amino acid sequence causes this pause, and the physiological significance of this attenuation of protein synthesis. Here, we survey the positions of ribosome collisions caused by ribosome pauses in humans and zebrafish using modified ribosome profiling. Collided ribosomes, i.e., disomes, emerge at various sites: Pro-Pro/Gly/Asp motifs; Arg-X-Lys motifs; stop codons; and 3' untranslated regions. The electrostatic interaction between the charged nascent chain and the ribosome exit tunnel determines the eIF5A-mediated disome rescue at the Pro-Pro sites. In particular, XBP1u, a precursor of endoplasmic reticulum (ER)-stress-responsive transcription factor, shows striking queues of collided ribosomes and thus acts as a degradation substrate by ribosome-associated quality control. Our results provide insight into the causes and consequences of ribosome pause by dissecting collided ribosomes.",Genome-wide Survey of Ribosome Collision.,10.1016/j.celrep.2020.107610,2020 May 5,PMC7746506,Cell reports
GSE140367,Robust partitioning of microRNA targets from downstream regulatory changes,Homo sapiens,69,None,2019-11-13,"[Overal design]Refer to individual Series; [Treatment]'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven days.', 'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven days. To stall ribosomes, cells were treated with 100 ug/ml cycloheximide for two minutes at 37C.', 'The cells were transduced with lentiviral vectors with or without miRNA expression cassette. After 6 days of selection in 1 mg/mL Geneticin, the stably integrated cells, both control and experimental, were treated with 1 ug/mL Doxycycline to induce the expression of miRNAs for seven (rep 1) or eight (rep 2) days and UV crosslinked.'; [Growth]'Flp-In T-REx 293 (HEK293) cells were cultured in DMEM containing 10% FBS, 1% Pen/Strap and 0.1% Zeocin.'; [Extraction]""The cells were permeabilized to prepare nuclei. The nascent RNA generated using biotin-run-on reaction of nuclei was used for library preparation.\nThe biotin-labelled RNA was extracted using Trizol, hydrolyzed using NaOH and enriched using streptavidin beads. 3' adapters were ligated and 5' ends were modified, followed by 5' adapter ligation. For batch-2, the 3' adapters containing sample identifiers (allowing to pool libraries after 3' adapter ligation) were used, and both 3' and 5' adapters contained unique molecular index (UMI) at the ligation junction. Purified and adapter ligated biotin-labelled RNAs were reverse transcribed and PCR amplified, followed by size selection and sequencing."", 'Cycloheximide-treated cells were lysed and digested with nuclease to generate ribosome footprints (RBFs). Ribosomes and ribosome footprints were isolated by size exclusion with a MicroSpin S-400 column. The cycloheximide-treated cells from the same pool were also used to extract total RNA for RNA-seq libraries.\nRibosome profiling libraries and RNA-seq libraries (used for normalizing ribosome footprint (RBF) data) were generated using the TruSeq Ribo Profile (Mammalian) Kit (illumina). The rRNA was depleted from the ribosome footprints and the total RNA using Ribo-Zero rRNA Removal Kit (illumina). The ribosome footprints were size selected using Urea-PAGE before library preparation. The total RNA was fragmented with heat. The size selected RBFs and fragmented total RNA were ligated to a 3' adaptor, and reverse transcribed. cDNA was purified by Urea-PAGE and circularized. The cDNA library was amplified and barcoded with Illumina-compatible primers.', 'Total RNA from HEK293 cells was isolated with Trizol, with an extra chloroform extraction to remove residual phenol and addition of glyco-blue as a carrier to promote RNA precipitation.\nDirectional RNA-seq libraries were prepared from 1000ng total RNA per sample using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs), with initial polyA+ isolation, by the RNA Sequencing Core and the Transcriptional Regulation and Expression Facility at Cornell University.', 'UV-crosslinked cells were lysed and AGO2 was immunoprecipitated, and an RNA adaptor (P-TGGAATTCTCGGGTGCCAAGG/3InvdT) was ligated onto the 3' end of co-immunoprecipitated RNA. AGO2-RNA complexes were run on SDS-PAGE and transferred to nitrocellulose membrane for size selection. Following the proteinase K treatment to digest AGO2 protein, the RNA was extracted using acid phenol:chloroform.\nThe extracted RNA was reverse transcribed, and an ssDNA adaptor with a 10-nucleotide unique molecular identifier (P-NNNNNNNNNNGATCGTCGGACTGTAGAACTCTGAAC/3InvdT) was ligated to the 3' end of the cDNA. Illumina-compatible sequences and sample barcodes were added via PCR.', 'Total RNA from HEK293 cells was isolated with Trizol, with an extra chloroform extraction to remove residual phenol and addition of glyco-blue as a carrier to promote RNA precipitation.\nLibraries were prepared from 1000ng total RNA using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs) by the RNA Sequencing Core at Cornell University.'; [Cell type]'Source: ''cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 1; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-1; batch: 1; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-122; batch: 1; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-133a; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-155; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-302a; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-372; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-373; batch: 2; molecule subtype: Nascent RNA; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: None; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: has-miR-122; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-1; batch: 1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-122; batch: 1; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: None; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-133a; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-155; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-302a; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-372; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-373; batch: 2; ', 'cell line: Flp-In T-REx 293 Cell; induced mirna: hsa-miR-122; '",Other; Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140367,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140367/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA589374,32821933," Ravi K Patel,  Jessica D West,  Ya Jiang,  Elizabeth A Fogarty,  Andrew Grimson","The biological impact of microRNAs (miRNAs) is determined by their targets, and robustly identifying direct miRNA targets remains challenging. Existing methods suffer from high false-positive rates and are unable to effectively differentiate direct miRNA targets from downstream regulatory changes. Here, we present an experimental and computational framework to deconvolute post-transcriptional and transcriptional changes using a combination of RNA-seq and PRO-seq. This novel approach allows us to systematically profile the regulatory impact of a miRNA. We refer to this approach as CARP: Combined Analysis of RNA-seq and PRO-seq. We apply CARP to multiple miRNAs and show that it robustly distinguishes direct targets from downstream changes, while greatly reducing false positives. We validate our approach using Argonaute eCLIP-seq and ribosome profiling, demonstrating that CARP defines a comprehensive repertoire of targets. Using this approach, we identify miRNA-specific activity of target sites within the open reading frame. Additionally, we show that CARP facilitates the dissection of complex changes in gene regulatory networks triggered by miRNAs and identification of transcription factors that mediate downstream regulatory changes. Given the robustness of the approach, CARP would be particularly suitable for dissecting miRNA regulatory networks in vivo.",Robust partitioning of microRNA targets from downstream regulatory changes.,10.1093/nar/gkaa687,2020 Sep 25,PMC7515711,Nucleic acids research
GSE135826,Dynamic RNA acetylation revealed by quantitative cross-evolutionary mapping,Pyrococcus furiosus; Saccharolobus solfataricus; Thermococcus sp. AM4; Methanocaldococcus jannaschii; Saccharomyces cerevisiae; Thermococcus kodakarensis; Homo sapiens,96,SRP218339,2019-08-14,"[Overal design]polyA-enriched RNA from HEK-293T WT (single sample) or Nat10+Thumpd1 overexpressing (2 replicates) cells under NaCNBH3, deacetylation or mock treatment. Total RNA from HeLa WT or Nat10 depleted cells (3 replicates each) under NaCNBH3, deacetylation or mock treatment. polyA-enriched RNA from HeLa WT (3 replicates) or Nat10 depleted (2 replicates) cells under NaCNBH3 or mock treatment. Total RNA from M. jannaschiae under NaCNBH3, deacetylation or mock treatment. Total RNA from S. solfataricus under NaCNBH3, deacetylation or mock treatment. Total RNA from T. sp. AM4 under NaCNBH3 or mock treatment, grown in 65, 75 and 85 degrees celsius. Total RNA from P. furiosus under NaCNBH3 or mock treatment, grown in 75, 85 and 95 degrees celsius. Total RNA from T. kodakarensis (T.kod) under NaCNBH3 or mock treatment, grown in 55 (1 sample), 65 (2 samples), 75 (2 samples), 85 (4 samples) and 95 (1 sample) degrees celsius. One of the replicates of 85 degree of T.kod underwent also deacetylation. Total RNA from T. kod strains deleted for TK0754 or TK2097 grown at 85 degrees and treated with NaCMBH3 or mock (in duplicates). T.kod purified ribosomes treated with NaCNBH3. rRNA-depleted RNA from WT T.kod grown at 85 and 95 degrees were treatedd with NaCNBH3 or NaCNBH3 and mock, respectively.; [Treatment]'HEK-293T cells transfected with 3xFLAG-tagged NAT10 and myc-tagged THUMPD1 using FuGENE 6 transfection reagent (Promega, #E2691) 24 hours prior to harvesting.', 'growth at various temperatures'; [Growth]'T. kodakarensis and T. sp AM4 strains  TS559 can derivatives thereof  were grown as previously described (Santangelo et al. 2007; Hileman and Santangelo 2012; Gehring et al. 2017) in artificial sea water (ASW) medium supplemented with vitamins and trace minerals. Pyrococcus furiosus strain COM1 was cultured at 75-95?C in an artificial sea water based medium supplemented with cellobiose, maltose, yeast extract, S?, trace minerals, cysteine and sodium tungstate as previously described (Lipscomb et al, APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Apr. 2011, p. 22322238).\nHEK-293T and HeLa (WT and Nat10 depleted) cells were grown in DMEM media.\nSaccharomyces cerevisiae\xa0strains were grown at 30C in standard YEP medium (1% yeast extract, 2% Bacto Peptone) supplemented with 2% galactose (YPG), or 2% dextrose (YPD).', 'T. kodakarensis and T. sp AM4 strains  TS559 can derivatives thereof  were grown as previously described (Santangelo et al. 2007; Hileman and Santangelo 2012; Gehring et al. 2017) in artificial sea water (ASW) medium supplemented with vitamins and trace minerals. Pyrococcus furiosus strain COM1 was cultured at 75-95?C in an artificial sea water based medium supplemented with cellobiose, maltose, yeast extract, S?, trace minerals, cysteine and sodium tungstate as previously described (Lipscomb et al, APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Apr. 2011, p. 22322238).'; [Extraction]""Total RNA was isolated from T. kodakarensis using TRIZOL according to manufacturers protocol.\xa0For the indicated samples of T. kodakarensis ,rRNAs were depleted according to  Morlan et al.(Morlan et al. 2012) using reagents provided in the NEBNext rRNA Depletion Kit (NEB #E6310). For indicated samples purifications of T. kodakarensis ribosomes of the wild-type and TkNat10 knockout were conducted similar to previously documented procedures (Matzov et al. 2017).\nTotal RNA from Human Cells was extracted using TRIZOL according to manufacturer's protocol. For the indicated samples Poly(A) RNA from yeast and human total RNA was isolated by two rounds of purification using the  GenElute mRNA miniprep kit (Sigma) according to manufacturer's protocol.  500ug total RNA was used per purification column.  Typical yield after two rounds of isolation was 1.2%.\nTotal RNA was isolated from Yeast using hot acidic phenol.\xa0 Briefly, frozen yeast (S. cerevisiae) pellet suspended in 1.0 mL AES buffer (50mM NaOAc, 10mM EDTA ph 8.0, 1% SDS) per 0.5mL pellet volume.\xa0 To suspended pellet, 1.0 mL Acid buffered Phenol per mL of AES buffer used was added. Sample was mixed by vortexing and incubated in a 65?C water bath for 30 min, vortexing every 2 minutes to mix.\xa0 Samples were put on ice for 10 minutes and 1.0 mL Chloroform:isoamyl alcohol (24:1) was added for each 1.0 mL phenol used. Sample was vortexed to mix and centrifuged 5000 rcf for 15 minutes. Aqueous layer (top) was transferred to a clean tube and extracted 3X with an equal volume of acid buffered phenol:chlorofom:isoamyl alcohol (24:23:1).\xa0 After each extraction sample was centrifuged at 5000 rcf for 10 minutes and aqueous layer transferred to a new tube. A final extraction with chloroform:isoamyl alcohol was carried out to remove residual phenol. Aqueous layer was transferred to a clean tube and RNA was precipitated by the addition of an equal volume of 100% isopropanol and 1/9th volume of 3M Sodium Acetate.\xa0 Samples were incubated -20?C for 30 minutes and centrifuged 12000 rcf at 4?C for 15 minutes. Supernatant was decanted and the pellet washed with 4 mL ice fold 70% ethanol. RNA pellet was resuspended by briefly heating at 50 ?C in 1.0 mL 1X TE buffer pH 8.0. Samples were quantified by UV absorbance and stored at -80?C. Typical extractions were carried out with 1.0 mL volume cell pellets and yielded 20mg of total RNA\nFragmentation, 3' adapter ligation, cDNA synthesis, second adapter ligation and enrichment"", ""Total RNA was isolated from T. kodakarensis using TRIZOL according to manufacturers protocol.\xa0For the indicated samples of T. kodakarensis ,rRNAs were depleted according to  Morlan et al.(Morlan et al. 2012) using reagents provided in the NEBNext rRNA Depletion Kit (NEB #E6310). For indicated samples purifications of T. kodakarensis ribosomes of the wild-type and TkNat10 knockout were conducted similar to previously documented procedures (Matzov et al. 2017).\nFragmentation, 3' adapter ligation, cDNA synthesis, second adapter ligation and enrichment""; [Cell type]'Source: ''cell line: Hela; genetic background: WT; treatment: deacetylation; growth condition: 37 degrees; ', 'cell line: Hela; genetic background: WT; treatment: NaCNBH3; growth condition: 37 degrees; ', 'cell line: Hela; genetic background: Nat10 KD; treatment: NaCNBH3; growth condition: 37 degrees; ', 'cell line: Hela; genetic background: WT; treatment: mock; growth condition: 37 degrees; ', 'cell line: HEK-293T; genetic background: Nat10/Thumpd1 overexpression; treatment: deacetylation; growth condition: 37 degrees; ', 'cell line: HEK-293T; genetic background: Nat10/Thumpd1 overexpression; treatment: NaCNBH3; growth condition: 37 degrees; ', 'cell line: HEK-293T; genetic background: Nat10/Thumpd1 overexpression; treatment: mock; growth condition: 37 degrees; ', 'cell line: HEK-293T; genetic background: WT; treatment: deacetylation; growth condition: 37 degrees; ', 'cell line: HEK-293T; genetic background: WT; treatment: NaCNBH3; growth condition: 37 degrees; ', 'cell line: HEK-293T; genetic background: WT; treatment: mock; growth condition: 37 degrees; ', 'genetic background: WT; treatment: NaCNBH3; growth condition: 30 degrees; ', 'genetic background: Kre33/Tan1 overexpression; treatment: NaCNBH3; growth condition: 30 degrees; ', 'genetic background: Kre33/Tan1 overexpression; treatment: mock; growth condition: 30 degrees; ', 'genetic background: WT; treatment: mock; growth condition: 30 degrees; ', 'genetic background: Kre33 catalytic mutant; treatment: NaCNBH3; growth condition: 30 degrees; ', 'genetic background: TK2097 deletion; treatment: NaCNBH3; growth condition: 85 degrees; ', 'genetic background: WT; treatment: deacetylation; growth condition: 85 degrees; ', 'genetic background: WT; treatment: NaCNBH3; growth condition: 85 degrees; ', 'genetic background: WT; treatment: mock; growth condition: 85 degrees; ', 'genetic background: WT; treatment: NaCNBH3; growth condition: 55 degrees; ', 'genetic background: WT; treatment: mock; growth condition: 55 degrees; ', 'genetic background: WT; treatment: NaCNBH3; growth condition: 65 degrees; ', 'genetic background: WT; treatment: mock; growth condition: 65 degrees; ', 'genetic background: WT; treatment: NaCNBH3; growth condition: 75 degrees; ', 'genetic background: WT; treatment: mock; growth condition: 75 degrees; ', 'genetic background: TK0754 deletion; treatment: NaCNBH3; growth condition: 85 degrees; ', 'genetic background: WT; treatment: NaCNBH3; growth condition: 95 degrees; ', 'genetic background: WT; treatment: mock; growth condition: 95 degrees; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135826,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE135nnn/GSE135826/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA560218,32555463," Aldema Sas-Chen,  Justin M Thomas,  Donna Matzov,  Masato Taoka,  Kellie D Nance,  Ronit Nir,  Keri M Bryson,  Ran Shachar,  Geraldy L S Liman,  Brett W Burkhart,  Supuni Thalalla Gamage,  Yuko Nobe,  Chloe A Briney,  Michaella J Levy,  Ryan T Fuchs,  G Brett Robb,  Jesse Hartmann,  Sunny Sharma,  Qishan Lin,  Laurence Florens,  Michael P Washburn,  Toshiaki Isobe,  Thomas J Santangelo,  Moran Shalev-Benami,  Jordan L Meier,  Schraga Schwartz","N(4)-acetylcytidine (ac(4)C) is an ancient and highly conserved RNA modification that is present on tRNA and rRNA and has recently been investigated in eukaryotic mRNA(1-3). However, the distribution, dynamics and functions of cytidine acetylation have yet to be fully elucidated. Here we report ac(4)C-seq, a chemical genomic method for the transcriptome-wide quantitative mapping of ac(4)C at single-nucleotide resolution. In human and yeast mRNAs, ac(4)C sites are not detected but can be induced-at a conserved sequence motif-via the ectopic overexpression of eukaryotic acetyltransferase complexes. By contrast, cross-evolutionary profiling revealed unprecedented levels of ac(4)C across hundreds of residues in rRNA, tRNA, non-coding RNA and mRNA from hyperthermophilic archaea. Ac(4)C is markedly induced in response to increases in temperature, and acetyltransferase-deficient archaeal strains exhibit temperature-dependent growth defects. Visualization of wild-type and acetyltransferase-deficient archaeal ribosomes by cryo-electron microscopy provided structural insights into the temperature-dependent distribution of ac(4)C and its potential thermoadaptive role. Our studies quantitatively define the ac(4)C landscape, providing a technical and conceptual foundation for elucidating the role of this modification in biology and disease(4-6).",Dynamic RNA acetylation revealed by quantitative cross-evolutionary mapping.,10.1038/s41586-020-2418-2,2020 Jul,PMC8130014,Nature
GSE145046,Decoding mRNA translatability and stability from 5 UTR,Homo sapiens,30,SRP247978,2020-02-10,"[Overal design]To accelerate our understanding of cis-regulatory code embedded in 5UTR of mRNA, we devised a high-throughput uORF reporter assay from a synthetic mRNA library composed of over one million 5UTR variants. This reporter assay is compatible with fluorescence-activated cell sorting and polysome profiling.; [Treatment]'None'; [Growth]'HEK293 cells and HEK293-Kb cells are cultured in Dulbeccos Modification of Eagles Medium (Corning 10-013-CV) supplemented with 10% fetal bovine serum (Sigma 12306C).'; [Extraction]'Total RNAs from sorted cells are extracted using Trizol reagent (Invitrogen).\nPurified total RNAs are suspended in nuclease-free water for reverse transcription.In brief, RNA samples are mixed with 1 ?l 10 mM dNTP and 2 pmol reverse primer overlap with 3end of GFP (oligo 2) and incubated at 65 C for 5 min, followed by incubation on ice for 5 min. The reverse transcription is carried out by incubating the reaction mixture with 1  First-Strand Buffer, 10 mM DTT, 40 U RNaseOUT and 200 U SuperScript III at 50 C for 60 min followed by heating at 70C for 15minutes. First-strand cDNA is then used as the template for PCR amplification catalyzed by the Phusion High-Fidelity enzyme (NEB). The PCR is performed in a 20 ?L reaction (1 HF buffer, 0.2 mM dNTP, 0.5 ?M forward and reverse primers and 0.5 U Phusion polymerase) with barcoded primers (Table S1). PCR is set up based on the following condit 110 ion: 16 cycles of 98 C, 10 s; 60 C, 20 s; 72 C, 10 s followed by 72 C, 10 min. The PCR products with the expected size 163 base pairs are excised from a 8% polyacrylamide TBE gel (Invitrogen). The DNA products are recovered from DNA gel elution buffer (300 mM NaCl, 1 mM EDTA) followed by quantification using Agilent BioAnalyzer DNA 1000 assay. Equal amounts of barcoded samples were pooled together followed by deep sequencing (Illumina HiSeq).'; [Cell type]'Source: ''cell line: HEK293, stably expressing H-2Kb; treatment: Originally synthesized oligo pool; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation. Sucrose gradient: Monosome fraction; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation. Sucrose gradient: Polysome fraction; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation. Sucrose gradient: Ribosome free fraction; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: Non-funtional cap, in vivo translation. Sucrose gradient: Ribosome free fraction; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: Non-funtional cap, in vivo translation. Sucrose gradient: Ribosome bound fraction; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation,  FACS 25D negative cells; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation,  FACS 25D positive cells; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation,  FACS GFP negative cells; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo translation,  FACS GFP positive cells; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo half life. RNA levels at 2h time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vivo half life. RNA levels at 5h time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vitro half life. RNA levels at 0 min time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vitro half life. RNA levels at 10 min time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vitro half life. RNA levels at 30 min time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: In vitro half life. RNA levels at 60 min time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: Non-functional cap, in vivo half life. RNA levels at 2h time point; ', 'cell line: HEK293, stably expressing H-2Kb; treatment: Non-functional cap, in vivo half life. RNA levels at 5h time point; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145046,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE145nnn/GSE145046/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA605796,32719458," Longfei Jia,  Yuanhui Mao,  Quanquan Ji,  Devin Dersh,  Jonathan W Yewdell,  Shu-Bing Qian","Precise control of protein synthesis by engineering sequence elements in 5' untranslated regions (5' UTRs) remains a fundamental challenge. To accelerate our understanding of the cis-regulatory code embedded in 5' UTRs, we devised massively parallel reporter assays from a synthetic messenger RNA library composed of over one million 5' UTR variants. A completely randomized 10-nucleotide sequence preceding an upstream open reading frame (uORF) and downstream GFP drives a broad range of translational outputs and mRNA stability in mammalian cells. While efficient translation protects mRNA from degradation, uORF translation triggers mRNA decay in a UPF1-dependent manner. We also identified translational inhibitory elements with G-quadruplexes as marks for mRNA decay in P-bodies. Unexpectedly, an unstructured A-rich element in 5' UTRs destabilizes mRNAs in the absence of translation, although it enables cap-independent translation. Our results not only identify diverse sequence features of 5' UTRs that control mRNA translatability, but they also reveal ribosome-dependent and ribosome-independent mRNA-surveillance pathways.",Decoding mRNA translatability and stability from the 5' UTR.,10.1038/s41594-020-0465-x,2020 Sep,,Nature structural & molecular biology
GSE110867,Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: NSC vs BTSC),Mus musculus,4,SRP133176,2018-02-20,"[Overal design]Two neural stem cells and two brain tumor stem cells are used in RNA-seq experiments; [Treatment]'None'; [Growth]'None'; [Extraction]'For RNA isolation from cultured NSCs, BTSCs and cells were harvested in TRI Reagent (Sigma) following the protocol.\nAfter chloroform phase separation the transparent upper phase was added to an equal volume of 70 % ethanol and transferred to an RNeasy Mini spin column (Qiagen). The RNA was purified according to the protocol and send for library preparation and Illumina HiSeq sequencing to our in house facility.'; [Cell type]'neural stem cells', 'brain tumor stem cell''tissue: brain; cell type: neural stem cells; ', 'tissue: brain; cell type: brain tumor stem cell; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110867,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110867/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA434717,,,,,,,,
GSE85864,"Ribosome profiling of human platelets, reticulocytes, and in vitro cell lines",Homo sapiens,32,SRP082436,2016-08-19,"[Overal design]Analysis of ribosome profiling and RNA sequencing data from primary human platelets, primary human reticulocytes, in vitro derived platelet-like particles, and hemin-induced differentiation of K562 cells; manipulation by knockdown and overexpression of Pelota (PELO) and HBS1L in K562 cells and Meg01/platelet-like particles.; [Treatment]'None'; [Growth]'None'; [Extraction]'Samples were extracted as described previously in Ingolia et al., 2014\nRibosome profiling libraries were prepared as described previously in Ingolia et al., 2014'; [Cell type]'primary cell type', 'cell line''cell type: primary cell type; drug treatment: vehicle; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: primary cell type; drug treatment: 0.01U/ml thrombin for 60 min at 37C - replicate 1; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: primary cell type; drug treatment: 0.01U/ml thrombin for 60 min at 37C - replicate 2; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: primary cell type; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: primary cell type; rrna depletion: Globin RNA depletion; ', 'cell type: cell line; drug treatment: untreated - 0 days - replicate 1; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: untreated - 0 days - replicate 2; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: 50 micromolar hemin - replicate 1; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: 50 micromolar hemin - replicate 2; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: untreated - 0 days; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: 50 micromolar hemin - 2 days; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: 50 micromolar hemin - 4 days; rrna depletion: RiboZero-Gold rRNA depletion; ', 'cell type: cell line; drug treatment: 50 micromolar hemin - 6 days; rrna depletion: RiboZero-Gold rRNA depletion; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85864,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE85nnn/GSE85864/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA339577,27681415," Eric W Mills,  Jamie Wangen,  Rachel Green,  Nicholas T Ingolia","Protein synthesis continues in platelets and maturing reticulocytes, although these blood cells lack nuclei and do not make new mRNA or ribosomes. Here, we analyze translation in primary human cells from anucleate lineages by ribosome profiling and uncover a dramatic accumulation of post-termination unrecycled ribosomes in the 3\' UTRs of mRNAs. We demonstrate that these ribosomes accumulate as a result of the natural loss of the ribosome recycling factor ABCE1 during terminal differentiation. Induction of the ribosome rescue factors PELO and HBS1L is required to support protein synthesis when ABCE1 levels fall and for hemoglobin production during blood cell development. Our observations suggest that this distinctive loss of ABCE1 in anucleate blood lineages could sensitize them to defects in ribosome homeostasis, perhaps explaining in part why genetic defects in the fundamental process of ribosome production (""ribosomopathies"") often affect hematopoiesis specifically.",Dynamic Regulation of a Ribosome Rescue Pathway in Erythroid Cells and Platelets.,10.1016/j.celrep.2016.08.088,2016 Sep 27,PMC5111367,Cell reports
GSE58207,PROTEOFORMER: deep proteome coverage through ribosome profiling and MS integration,Homo sapiens,2,SRP042937,2014-06-04,"[Overal design]Ribosome profiling of lactimidomycin and cycloheximide treated HCT116 cells; [Treatment]'Cultures at 80-90% confluence were treated with 50 M LTM or 100 g/ml CHX (Sigma, USA) for 30 min at 37C. Subsequently, cells were washed with PBS, harvested by trypsin-EDTA, suspended and washed again with PBS and recovered by 5 min of centrifugation at 1,500  g, all in the presence of CHX to maintain the polysomal state. Cell pellets were resuspended in ice-cold lysis buffer, formulated according to Guo et al. (2010)3 (10 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 100 mM KCl, 1% Triton X-100, 2 mM dithiothreitol (DTT), 100 mg/ml CHX, 1  complete and EDTA-free protease inhibitor cocktail (Roche)), at a concentration of 40  106 cells/ml. After 10 min of incubation on ice with periodic agitation, lysed samples were passed through QIAshredder spin columns (Qiagen) to shear the DNA. Subsequently, the flow-throughs were centrifuged for 10 min at 16,000  g and 4C. The recovered supernatant was aliquoted, snap-frozen in liquid nitrogen and stored at -80C for subsequent ribosome footprint recovery and cDNA library generation.'; [Growth]""HCT116 cells were cultivated in McCoy's 5A (Modified) Medium (Gibco) supplemented with 10% fetal bovine serum, 2 mM alanyl-L-glutamine dipeptide (GlutaMAX, Gibco), 50 units/ml penicillin and 50 g/ml steptamycin at 37C and 5% CO2.""; [Extraction]'100 l of the clarified HCT116 cell lysate (equivalent to 4  106 cells) was used as input for ribosome footprinting. The A260 absorbance of the lysate was measured with Nanodrop (Thermo Scientific) and for each A260, 5 units of ARTseq Nuclease (Epd icentre) were added to the samples. The nuclease digestion proceeded for 45 min at room temperature and was stopped by adding SUPERase.In Rnase Inhibitor (Life Technologies). Next, the ribosome protected fragments (RPFs) were isolated using Sephacryl S400 spin columns (GE Healthcare) according to the procedure described in ARTseq Ribosome Profiling Kit, Mammalian (Epicentre). The RNA was extracted from the samples using acid 125 phenol:24 chloroform:1 isoamyl alcohol and precipitated overnight at -20C by adding 2 ?l glycogen, 1/10th volume of 5 M ammonium acetate and 1.5 volumes of 100% isopropyl alcohol. After centrifugation at 18,840  g and 4C for 20 min, the purified RNA pellet was resuspended in 10 ?l nuclease free water.\nThe HCT116 libraries were created according to the guidelines described in the ARTseq Ribosome profiling Kit, Mammalian protocol (Epicentre). The RPFs were initially rRNA depleted using the Ribo-Zero Magnetic Kit (Human/Mouse/Rat, Epicentre), omitting the 50C incubation step. Cleanup of the rRNA depletion reactions was performed through Zymo RNA Clean & Concentrator-5 kit (Zymo Research) using 200 ?l binding buffer and 450 ?l absolute ethanol. The samples were separated on a 15% urea-polyacrylamide gel and footprints of 26 to 34 nucleotides long were excised. RNA was extracted from the gel and precipitated. The pellet was resuspended in 20 ?l nuclease-free water. Next, RPFs were end polished, 3 adaptor ligated, reverse transcribed and PAGE purified. 5 ?l of circularized template DNA was used in the PCR reaction and amplification proceeded for 11 cycles. The libraries were purified with AMPure XP beads (Beckman Coulter) and their quality was assessed on a High Sensitivity DNA assay chip (Agilent technologies). The concentration of the libraries was measured with qPCR and they were single end sequenced on a Hiseq (Illumina) for 50 cycles.'; [Cell type]'HCT116''cell type: HCT116; cell type: Colorectal carcinoma derived cell line; treated with: 100 g/ml cycloheximide for 30 min at 37C; molecule subtype: Ribosome protected fragments; ', 'cell type: HCT116; cell type: Colorectal carcinoma derived cell line; treated with: 50 M lactimidomycin for 30 min at 37C; molecule subtype: Ribosome protected fragments; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58207,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE58nnn/GSE58207/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA251587,25510491," Jeroen Crappe,  Elvis Ndah,  Alexander Koch,  Sandra Steyaert,  Daria Gawron,  Sarah De Keulenaer,  Ellen De Meester,  Tim De Meyer,  Wim Van Criekinge,  Petra Van Damme,  Gerben Menschaert","An increasing amount of studies integrate mRNA sequencing data into MS-based proteomics to complement the translation product search space. However, several factors, including extensive regulation of mRNA translation and the need for",PROTEOFORMER: deep proteome coverage through ribosome profiling and MS integration.,10.1093/nar/gku1283,2015 Mar 11,PMC4357689,Nucleic acids research
GSE48933,Ribosome profiling reveals features of normal and disease-associated mitochondrial translation,Homo sapiens,10,SRP027514,2013-07-16,"[Overal design]51-base length single read ribosome profiling data on human fibroblasts and cybrid cells using an adapted ribosome profiling protocol; and 51-base length single read RNAseq on polyA enriched RNA; [Treatment]'None'; [Growth]'Cells were cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS) in 5% CO2 at 37 deg. Celcius.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 25-36 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', 'RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nRNA libraries were prepared for sequencing using standard Illumina protocols.'; [Cell type]'Foreskin fibroblast', 'Cybrid''cell type: Foreskin fibroblast; cell line: BJ; sample type: other; ', 'cell type: Foreskin fibroblast; cell line: BJ; sample type: polyA RNA; ', 'cell type: Cybrid; mtdna genotype: control; sample type: other; ', 'cell type: Cybrid; mtdna genotype: 5556GA; sample type: other; ', 'cell type: Cybrid; mtdna genotype: control; sample type: polyA RNA; ', 'cell type: Cybrid; mtdna genotype: 5556GA; sample type: polyA RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48933,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE48nnn/GSE48933/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA212323,24301020," Koos Rooijers,  Fabricio Loayza-Puch,  Leo G Nijtmans,  Reuven Agami","Mitochondria are essential cellular organelles for generation of energy and their dysfunction may cause diabetes, Parkinson's disease and multi-systemic failure marked by failure to thrive, gastrointestinal problems, lactic acidosis and early lethality. Disease-associated mitochondrial mutations often affect components of the mitochondrial translation machinery. Here we perform ribosome profiling to measure mitochondrial translation at nucleotide resolution. Using a protocol optimized for the retrieval of mitochondrial ribosome protected fragments (RPFs) we show that the size distribution of wild-type mitochondrial RPFs follows a bimodal distribution peaking at 27 and 33 nucleotides, which is distinct from the 30-nucleotide peak of nuclear RPFs. Their cross-correlation suggests generation of mitochondrial RPFs during ribosome progression. In contrast, RPFs from patient-derived mitochondria mutated in tRNA-Tryptophan are centered on tryptophan codons and reduced downstream, indicating ribosome stalling. Intriguingly, long RPFs are enriched in mutated mitochondria, suggesting they characterize stalled ribosomes. Our findings provide the first model for translation in wild-type and disease-triggering mitochondria.",Ribosome profiling reveals features of normal and disease-associated mitochondrial translation.,10.1038/ncomms3886,2013,PMC3863897,Nature communications
GSE112643,Effects of single amino acid deficiency on mRNA translation are markedly different for methionine versus leucine,Homo sapiens,8,SRP137018,2018-04-03,"[Overal design]Ribosome profiling of single Amino acid starvation; [Treatment]'Experimental control medium was the same as normal growth medium with the following changes: medium was prepared using DMEM that lacked sulfur amino acids, histidine, leucine and arginine (custom prepared by Gibco/Invitrogen) and was supplemented with 10% dialyzed FBS and L-cysteine, L-methionine, L-histidine, L-leucine and L-arginine to levels found in normal DMEM. Methionine-deficient (Met-), leucine-deficient (Leu-) and arginine deficient (Arg-) media were prepared similarly except the respective amino acids were not added back to the deficient DMEM.'; [Growth]'Wild-type human embryonic kidney (HEK) 293T cells immortalized with SV40 Large T antigen were plated at a concentration of 4.0 x 104 cells/cm2 and allowed to grow overnight before growth medium was replaced with experimental control or amino acid-deficient medium.'; [Extraction]'Equal aliquots of the ribosome fractions separated by sucrose gradient were pooled and treated with E. coli RNase I (Ambion) to digest regions of mRNAs not protected by ribosomes. RNAs were extracted using TRIzol LS.\ncDNA libraries were constructed from the ribosome-protected mRNA fragments by poly(A)tailing and reverse transcription using barcode containing oligonucleotides (one for each treatment condition). For deep sequencing, the cDNA library was amplified by PCR using the Phusion High-Fidelity polymerase and primers containing Illumina cluster generation sequences. Equal amounts of barcoded samples for the three conditions were mixed together, and approximately 35 pM of the pooled DNA sample was used for cluster generation followed by deep sequencing.'; [Cell type]'Source: ''cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Control, AA sufficient, CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Control, AA sufficient, no CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Arg starvation over night, CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Arg starvation over night, no CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Leu starvation over night, CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Leu starvation over night, no CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Met starvation over night, CHX pre-treated; ', 'cell line: HEK293T cells immortalized with SV40 Large T antigen; molecule: ribosomes protected RNA; condition: Met starvation over night, no CHX pre-treated; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112643,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112643/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA448601,29795412," Kevin M Mazor,  Leiming Dong,  Yuanhui Mao,  Robert V Swanda,  Shu-Bing Qian,  Martha H Stipanuk","Although amino acids are known regulators of translation, the unique contributions of specific amino acids are not well understood. We compared effects of culturing HEK293T cells in medium lacking either leucine, methionine, histidine, or arginine on eIF2 and 4EBP1 phosphorylation and measures of mRNA translation. Methionine starvation caused the most drastic decrease in translation as assessed by polysome formation, ribosome profiling, and a measure of protein synthesis (puromycin-labeled polypeptides) but had no significant effect on eIF2 phosphorylation, 4EBP1 hyperphosphorylation or 4EBP1 binding to eIF4E. Leucine starvation suppressed polysome formation and was the only tested condition that caused a significant decrease in 4EBP1 phosphorylation or increase in 4EBP1 binding to eIF4E, but effects of leucine starvation were not replicated by overexpressing nonphosphorylatable 4EBP1. This suggests the binding of 4EBP1 to eIF4E may not by itself explain the suppression of mRNA translation under conditions of leucine starvation. Ribosome profiling suggested that leucine deprivation may primarily inhibit ribosome loading, whereas methionine deprivation may primarily impair start site recognition. These data underscore our lack of a full understanding of how mRNA translation is regulated and point to a unique regulatory role of methionine status on translation initiation that is not dependent upon eIF2 phosphorylation.",Effects of single amino acid deficiency on mRNA translation are markedly different for methionine versus leucine.,10.1038/s41598-018-26254-2,2018 May 24,PMC5967319,Scientific reports
GSE122869,The RNA-binding ubiquitin ligase MKRN1 functions in ribosome-associated quality control of poly(A)-translation,Homo sapiens,3,SRP170545,2018-11-23,"[Overal design]iCLIP experiments for GFP-MKRN1 with crosslinking at 254 nm and with 4SU and crosslinking at 365 nm; [Treatment]'None'; [Growth]'GFP-MKRN1 was transiently overexpressed in HEK293T cells for 48h.'; [Extraction]'HEK293T cells overexpressing GFP-MKRN1 were lysed in 1ml lysis buffer followed by immunoprecipitation as described on previously published protocol (Huppertz et al., 2014; Sutandy et al., 2016)\nin vivo iCLIP libraries were prepared from HEK293Tcells overexpressing GFP-MKRN1 according to the previously published protocol (Huppertz et al., 2014; Sutandy et al., 2016). For immunoprecipitation, we used 20 l slurry of GFPtrap magnetic agarose bease (Chromotek, GFP-Trap_MA) per sample. The libraries were sequenced as single-end reads on an Illumina MiSeq sequencing system.'; [Cell type]'Source: ''cell line: HEK239T; barcode: CGCC; cross-linking: 4SU + 365 nm; iped-protein: GFP-MKRN1; ', 'cell line: HEK239T; barcode: TATT; cross-linking: 4SU + 365 nm; iped-protein: GFP-MKRN1; ', 'cell line: HEK239T; barcode: TACG; cross-linking: 4SU + 365 nm; iped-protein: GFP-MKRN1; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122869,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE122nnn/GSE122869/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA506725,31640799," Andrea Hildebrandt,  Mirko Bruggemann,  Cornelia Ruckle,  Susan Boerner,  Jan B Heidelberger,  Anke Busch,  Heike Hanel,  Andrea Voigt,  Martin M Mockel,  Stefanie Ebersberger,  Anica Scholz,  Annabelle Dold,  Tobias Schmid,  Ingo Ebersberger,  Jean-Yves Roignant,  Kathi Zarnack,  Julian Konig,  Petra Beli","BACKGROUND: Cells have evolved quality control mechanisms to ensure protein homeostasis by detecting and degrading aberrant mRNAs and proteins. A common source of aberrant mRNAs is premature polyadenylation, which can result in non-functional protein products. Translating ribosomes that encounter poly(A) sequences are terminally stalled, followed by ribosome recycling and decay of the truncated nascent polypeptide via ribosome-associated quality control. RESULTS: Here, we demonstrate that the conserved RNA-binding E3 ubiquitin ligase Makorin Ring Finger Protein 1 (MKRN1) promotes ribosome stalling at poly(A) sequences during ribosome-associated quality control. We show that MKRN1 directly binds to the cytoplasmic poly(A)-binding protein (PABPC1) and associates with polysomes. MKRN1 is positioned upstream of poly(A) tails in mRNAs in a PABPC1-dependent manner. Ubiquitin remnant profiling and in vitro ubiquitylation assays uncover PABPC1 and ribosomal protein RPS10 as direct ubiquitylation substrates of MKRN1. CONCLUSIONS: We propose that MKRN1 mediates the recognition of poly(A) tails to prevent the production of erroneous proteins from prematurely polyadenylated transcripts, thereby maintaining proteome integrity.",The RNA-binding ubiquitin ligase MKRN1 functions in ribosome-associated quality control of poly(A) translation.,10.1186/s13059-019-1814-0,2019 Oct 22,PMC6805484,Genome biology
GSE22871,Expression data from wild-type and PPARalpha-null mice exposed to perfluorooctane sulfonate (PFOS),Mus musculus,30,None,2010-07-09,"[Overal design]PPARalpha-null and wild-type male mice at 6-9 months of age were dosed by gavage for 7 consecutive days with either 0, 3, or 10 mg/kg PFOS (potassium salt) in 0.5% Tween 20. Five biological replicates consisting of individual animals were included in each dosage group. Data were compared to results previously published by our group for PFOA and Wy-14,643, a commonly used agonist of PPARalpha (Rosen et al., Toxicol Pathol. 36:592-607, 2008; GSE9796); [Treatment]'PPAR?-null and wild-type male mice at 6-9 months of age were dosed by gavage for 7 consecutive days with either 0, 3, or 10 mg/kg  PFOS (potassium salt) in 0.5% Tween 20.'; [Growth]'Animals were housed 5 per cage and allowed to acclimate for a period of one week prior to the conduct of the study.  Food and municipal tap water were provided ad libitum.  Animal facilities were controlled for temperature (20-24C), relative humidity (40-60%), and kept under a 12 hr light-dark cycle.'; [Extraction]'Collected tissue (? 50 mg) was immediately placed in 1 ml RNAlater and stored at -20?C.  RNA preparations were then completed by homogenizing the tissue in 1 ml TRI reagent followed by processing according to the manufacturers instructions.'; [Cell type]'Source: ''strain: 129S4/SvJae-Pparatm1Gonz/J; genotype: PPARalpha-null; tissue: liver; gender: male; age: 6-9 months; treatment: untreated; treatment dosage: 0mg/kg; treatment time: 7 days; ', 'strain: 129S4/SvJae-Pparatm1Gonz/J; genotype: PPARalpha-null; tissue: liver; gender: male; age: 6-9 months; treatment: perfluorooctane sulfonate (PFOS); treatment dosage: 3mg/kg; treatment time: 7 days; ', 'strain: 129S4/SvJae-Pparatm1Gonz/J; genotype: PPARalpha-null; tissue: liver; gender: male; age: 6-9 months; treatment: perfluorooctane sulfonate (PFOS); treatment dosage: 10mg/kg; treatment time: 7 days; ', 'strain: 129S1/SvlmJ; genotype: wildtype; tissue: liver; gender: male; age: 6-9 months; treatment: untreated; treatment dosage: 0mg/kg; treatment time: 7 days; ', 'strain: 129S1/SvlmJ; genotype: wildtype; tissue: liver; gender: male; age: 6-9 months; treatment: perfluorooctane sulfonate (PFOS); treatment dosage: 3mg/kg; treatment time: 7 days; ', 'strain: 129S1/SvlmJ; genotype: wildtype; tissue: liver; gender: male; age: 6-9 months; treatment: perfluorooctane sulfonate (PFOS); treatment dosage: 10mg/kg; treatment time: 7 days; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22871,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE22nnn/GSE22871/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA128117,20936131," Mitchell B Rosen,  Judith R Schmid,  J Christopher Corton,  Robert D Zehr,  Kaberi P Das,  Barbara D Abbott,  Christopher Lau","Perfluorooctane sulfonate (PFOS) is a perfluoroalkyl acid (PFAA) and a persistent environmental contaminant found in the tissues of humans and wildlife. Although blood levels of PFOS have begun to decline, health concerns remain because of the long half-life of PFOS in humans. Like other PFAAs, such as, perfluorooctanoic acid (PFOA), PFOS is an activator of peroxisome proliferator-activated receptor-alpha (PPARalpha) and exhibits hepatocarcinogenic potential in rodents. PFOS is also a developmental toxicant in rodents where, unlike PFOA, its mode of action is independent of PPARalpha. Wild-type (WT) and PPARalpha-null (Null) mice were dosed with 0, 3, or 10 mg/kg/day PFOS for 7 days. Animals were euthanized, livers weighed, and liver samples collected for histology and preparation of total RNA. Gene profiling was conducted using Affymetrix 430_2 microarrays. In WT mice, PFOS induced changes that were characteristic of PPARalpha transactivation including regulation of genes associated with lipid metabolism, peroxisome biogenesis, proteasome activation, and inflammation. PPARalpha-independent changes were indicated in both WT and Null mice by altered expression of genes related to lipid metabolism, inflammation, and xenobiotic metabolism. Such results are similar to studies done with PFOA and are consistent with modest activation of the constitutive androstane receptor (CAR), and possibly PPARgamma and/or PPARbeta/delta. Unique treatment-related effects were also found in Null mice including altered expression of genes associated with ribosome biogenesis, oxidative phosphorylation, and cholesterol biosynthesis. Of interest was up-regulation of Cyp7a1, a gene which is under the control of various transcription regulators. Hence, in addition to its ability to modestly activate PPARalpha, PFOS induces a variety of PPARalpha-independent effects as well.",Gene Expression Profiling in Wild-Type and PPARalpha-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARalpha-Independent Effects.,10.1155/2010/794739,2010,PMC2948942,PPAR research
GSE99745,RNA-Seq of polysome profiling fractions and whole cell lysates of UVB-irradiated N-TERT keratinocytes,Homo sapiens,18,SRP108720,2017-06-06,"[Overal design]Untreated and irradiated N-TERT keratinocytes are split into 3 groups: monosome fraction, polysome fraction, and whole cell lysate. N=3.; [Treatment]'UVB irradiation of N-TERT keratinocytes was carried out using Philips FS20T12 UVB broadband light sources as described previously (Lewis et al., 2010). A IL1700 radiometer and a SED240 UVB detector (International Light, Newburyport, MA) were used to measure UVB intensity prior to each experiment using a distance of 8cm from the light source to the culture dish. Cells were always irradiated in EpiLife media, which eliminates any UVC wavelengths, followed by normal incubation settings (37C and 5% CO2).'; [Growth]'N-TERT keratinocytes (Dickson et al., 2000) were cultured in EpiLife media (Invitrogen, Carlsbad, CA) supplemented with human keratinocyte growth supplement (HKGS, Invitrogen) and 1000U Penicillin-Streptomycin (Roche, Indianapolis, IN).'; [Extraction]'RNA was isolated using Trizol followed by phenol/chloroform extraction. The concentration and quality of total RNA samples were first assessed using Agilent 2100 Bioanalyzer. A RIN (RNA Integrity Number) of five or higher was required to\xa0pass the quality control.\nThe samples are first spiked-in with ERCC Mix 1 to no treatment and Mix 2 to all treated.\xa0Then\xa0five hundred\xa0nanograms of RNA per sample were used to prepared\xa0dual-indexed\xa0strand-specific cDNA library using\xa0TruSeq\xa0Stranded mRNA Library PrepKit (Illumina). The resulting libraries were assessed for its quantity and size distribution using Qubit and Agilent 2100 Bioanalyzer.\xa0One and a half\xa0pico molar pooled libraries\xa0were sequenced with\xa02x75bp paired-end configuration on\xa0NextSeq500\xa0(Illumina) using\xa0NextSeq 500/550 High Output Kit. A Phred quality score (Qscore) was used to measure the quality of sequencing. More than 90% of the sequencing reads reached Q30 (99.9% base call accuracy).'; [Cell type]'keratinocytes''cell line: N-TERT; cell type: keratinocytes; treatment: 0 J/m2 UVB + 8hr incubation; fraction: Whole Cell Lysate; ', 'cell line: N-TERT; cell type: keratinocytes; treatment: 0 J/m2 UVB + 8hr incubation; fraction: Monosome; ', 'cell line: N-TERT; cell type: keratinocytes; treatment: 0 J/m2 UVB + 8hr incubation; fraction: Polysome; ', 'cell line: N-TERT; cell type: keratinocytes; treatment: 100 J/m2 UVB + 8hr incubation; fraction: Whole Cell Lysate; ', 'cell line: N-TERT; cell type: keratinocytes; treatment: 100 J/m2 UVB + 8hr incubation; fraction: Monosome; ', 'cell line: N-TERT; cell type: keratinocytes; treatment: 100 J/m2 UVB + 8hr incubation; fraction: Polysome; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99745,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE99nnn/GSE99745/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA389466,29118075," Ann E Collier,  Dan F Spandau,  Ronald C Wek","In response to sublethal ultraviolet B (UVB) irradiation, human keratinocytes transiently block progression of the cell cycle to allow ample time for DNA repair and cell fate determination. These cellular activities are important for avoiding the initiation of carcinogenesis in skin. Central to these processes is the repression of initiation of mRNA translation through GCN2 phosphorylation of eIF2alpha (eIF2alpha-P). Concurrent with reduced global protein synthesis, eIF2alpha-P and the accompanying integrated stress response (ISR) selectively enhance translation of mRNAs involved in stress adaptation. In this study, we elucidated a mechanism for eIF2alpha-P cytoprotection in response to UVB in human keratinocytes. Loss of eIF2alpha-P induced by UVB diminished G1 arrest, DNA repair, and cellular senescence coincident with enhanced cell death in human keratinocytes. Genome-wide analysis of translation revealed that the mechanism for these critical adaptive responses by eIF2alpha-P involved induced expression of CDKN1A encoding the p21 (CIP1/WAF1) protein. We further show that human CDKN1A mRNA splice variant 4 is preferentially translated following stress-induced eIF2alpha-P by a mechanism mediated in part by upstream ORFs situated in the 5'-leader of CDKN1A mRNA. We conclude that eIF2alpha-P is cytoprotective in response to UVB by a mechanism featuring translation of a specific splice variant of CDKN1A that facilitates G1 arrest and subsequent DNA repair.",Translational control of a human CDKN1A mRNA splice variant regulates the fate of UVB-irradiated human keratinocytes.,10.1091/mbc.E17-06-0362,2018 Jan 1,PMC5746064,Molecular biology of the cell
GSE53772,Translatome and transcriptome profiling of FK866 response in Jurkat cells,Homo sapiens,24,None,2014-01-02,"[Overal design]Gene expression signals derived from the polysomal and subpolysomal RNA populations were compared by microarrays analysis to those obtained from total RNAs (derived from the sum of all the fractions in the polysomal gradient). Polysomal RNA, subpolysomal RNA and total RNA were isolated from Jurkat cells treated with FK866 5 nM or DMSO (mock, control treatment) for 48 hr. Cells lysates were collected from control cells (mock) and from treated cells (FK866). All experiments were run in biological quadruplicates.; [Treatment]'Jurkat cells were treated with 5nM FK866 for 48 hr (5*10^5 cells/ ml)', 'Jurkat cells were treated with DMSO for 48 hr (5*10^5 cells/ ml)'; [Growth]'Jurkat cells were grown in RPMI supplemented with 10% FBS, antibiotics (100 units/ml penicillin-streptomycin) and 2mM L-Glutamine at 37 C under 5% CO2.'; [Extraction]'Cells were treated with 100 ?g/ml Cycloheximide for 5 min at 37C in order to stabilize the polysomal complexes. After washing cells twice with cold PBS containing 10 ?g/ml Cycloheximide, 1 ml of lysis buffer was added [10 mM NaCl, 10 mM MgCl2, 10 mM TrisCl pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/?l RNase inhibitor (Fermentas), 10 ?g/ml Cycloheximide and 1 mM dithiothreitol]. Lysates were transferred to microcentrifuge tubes, incubated on ice for 2 min and centrifuged for 5 min at 12000 g at 4C. The supernatant was loaded directly onto a 1550% linear sucrose gradient prepared in a buffer containing 30 mM TrisCl pH 7.5, 100 mM NaCl, 10 mM MgCl2, and centrifuged at 4C in a SW41 rotor (Sorvall) for 110 min at 180000 g. Sub-polysomal and polysomal fractions were collected using a Density Gradient System (Teledyne ISCO) with automated fraction collector (Foxy R1, Teledine ISCO) monitoring the absorbance at 254 nm. For RNA extraction, fractions were treated with proteinase K (100 ?g/ml) in 1% SDS for 3 hr at 37C. After phenolchloroform separation and isopropanol precipitation, recovered RNA pellets were resuspended with 30 ?l of RNase-free water. RNAs extracted from fractions were pooled (sub-polysomal RNA: fraction 2-7; polysomal RNA: fraction 8-11; total: fraction 2-11) for microarray analysis.'; [Cell type]'Source: ''cell line: Jurkat; treatment: FK866; rna fraction: polysomal RNA; biological replicate: #1; ', 'cell line: Jurkat; treatment: FK866; rna fraction: polysomal RNA; biological replicate: #2; ', 'cell line: Jurkat; treatment: FK866; rna fraction: polysomal RNA; biological replicate: #3; ', 'cell line: Jurkat; treatment: FK866; rna fraction: polysomal RNA; biological replicate: #4; ', 'cell line: Jurkat; treatment: mock; rna fraction: polysomal RNA; biological replicate: #1; ', 'cell line: Jurkat; treatment: mock; rna fraction: polysomal RNA; biological replicate: #2; ', 'cell line: Jurkat; treatment: mock; rna fraction: polysomal RNA; biological replicate: #3; ', 'cell line: Jurkat; treatment: mock; rna fraction: polysomal RNA; biological replicate: #4; ', 'cell line: Jurkat; treatment: FK866; rna fraction: subpolysomal RNA; biological replicate: #1; ', 'cell line: Jurkat; treatment: FK866; rna fraction: subpolysomal RNA; biological replicate: #2; ', 'cell line: Jurkat; treatment: FK866; rna fraction: subpolysomal RNA; biological replicate: #3; ', 'cell line: Jurkat; treatment: FK866; rna fraction: subpolysomal RNA; biological replicate: #4; ', 'cell line: Jurkat; treatment: mock; rna fraction: subpolysomal RNA; biological replicate: #1; ', 'cell line: Jurkat; treatment: mock; rna fraction: subpolysomal RNA; biological replicate: #2; ', 'cell line: Jurkat; treatment: mock; rna fraction: subpolysomal RNA; biological replicate: #3; ', 'cell line: Jurkat; treatment: mock; rna fraction: subpolysomal RNA; biological replicate: #4; ', 'cell line: Jurkat; treatment: FK866; rna fraction: total RNA; biological replicate: #1; ', 'cell line: Jurkat; treatment: FK866; rna fraction: total RNA; biological replicate: #2; ', 'cell line: Jurkat; treatment: FK866; rna fraction: total RNA; biological replicate: #3; ', 'cell line: Jurkat; treatment: FK866; rna fraction: total RNA; biological replicate: #4; ', 'cell line: Jurkat; treatment: mock; rna fraction: total RNA; biological replicate: #1; ', 'cell line: Jurkat; treatment: mock; rna fraction: total RNA; biological replicate: #2; ', 'cell line: Jurkat; treatment: mock; rna fraction: total RNA; biological replicate: #3; ', 'cell line: Jurkat; treatment: mock; rna fraction: total RNA; biological replicate: #4; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53772,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE53nnn/GSE53772/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232849,,,,,,,,
GSE131650,Pervasive functional translation of noncanonical open reading frames,Homo sapiens,14,SRP199285,2019-05-22,"[Overal design]Paired RNA-seq and ribosome profiling sequencing data for human induced pluripotent stem cells (iPSCs) and iPSC-derived cardiomyocytes, either with or without the translational inhibitor harringtonine. Three replicates are availble for the no drug treatment samples.; [Treatment]'None'; [Growth]'WTC iPSCs (Coriell Biorepository #GM25256) were maintained under feeder-free conditions on growth factor-reduced Matrigel (Corning) in mTeSR medium (STEMCELL Technologies). Accutase (STEMCELL Technologies) was used to enzymatically dissociate iPSCs into single cells to passage. To promote cell survival during enzymatic passaging, cells were passaged with 10 uM p160-Rho-associated coiled-coil kinase (ROCK) inhibitor Y-27632 (Selleckchem). iPSCs were differentiated into iPS-derived cardiomyocytes using the WNT modulation-differentiation method following previously published protocols (Mandegar M.A., et al, 2016, Cell Stem Cell and Lian X., et al, 2012, PNAS)'; [Extraction]'Cells were lysed and lysates were clarified by centrifugation at 20,000g for 10 min.  The lysate is used to prepare RNA-seq libraries, as well as treated with RNase I to  digest RNA not protected by ribosomes for ribosome profiling. For ribosome profiling, high molecular weight species were then isolated by centrifuging lysates through a 34% sucrose cushion at 200,000g for 4 hours at 4C. Pellets were resuspended in Trizol (Life Technologies) and the RNA fraction isolated.\nRibosome profiling and RNA-seq libraries were generated essentially as described in MGlincy, N.J. and Ingolia, N.T., 2017, Methods.'; [Cell type]'iPSC', 'iPSC-derived cardiomyocytes''cell type: iPSC; cell line: WTC-11; drug treatment: harringtonine; ', 'cell type: iPSC-derived cardiomyocytes; cell line: WTC-11; drug treatment: harringtonine; ', 'cell type: iPSC; cell line: WTC-11; drug treatment: no drug; ', 'cell type: iPSC-derived cardiomyocytes; cell line: WTC-11; drug treatment: no drug; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131650,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE131nnn/GSE131650/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA544411,32139545," Jin Chen,  Andreas-David Brunner,  J Zachery Cogan,  James K Nunez,  Alexander P Fields,  Britt Adamson,  Daniel N Itzhak,  Jason Y Li,  Matthias Mann,  Manuel D Leonetti,  Jonathan S Weissman","Ribosome profiling has revealed pervasive but largely uncharacterized translation outside of canonical coding sequences (CDSs). In this work, we exploit a systematic CRISPR-based screening strategy to identify hundreds of noncanonical CDSs that are essential for cellular growth and whose disruption elicits specific, robust transcriptomic and phenotypic changes in human cells. Functional characterization of the encoded microproteins reveals distinct cellular localizations, specific protein binding partners, and hundreds of microproteins that are presented by the human leukocyte antigen system. We find multiple microproteins encoded in upstream open reading frames, which form stable complexes with the main, canonical protein encoded on the same messenger RNA, thereby revealing the use of functional bicistronic operons in mammals. Together, our results point to a family of functional human microproteins that play critical and diverse cellular roles.",Pervasive functional translation of noncanonical human open reading frames.,10.1126/science.aay0262,2020 Mar 6,PMC7289059,"Science (New York, N.Y.)"
GSE59819,Ribosome profiling and RNA sequencing of U2OS cells overexpressing myc,Homo sapiens,8,SRP044936,2014-07-28,"[Overal design]2 biological replicates of each condition.; [Treatment]'For induction of Myc gene, U2OS WII-I cells were treated with doxycycline for 36 hours.'; [Growth]""U2OS WII-I cells containing the doxycycline-inducible Myc (a gift from Martin Ellers) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.""; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', ""RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nPoly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the manufacturer's instructions.""; [Cell type]'Source: ''cell line: U2OS; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59819,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59819/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256317,,,,,,,,
GSE139130,Selective Translation Complex Profiling in yeast and human Reveals Staged Initiation and Co-translational  Assembly of Initiation Factor Complexes [Yeast],Saccharomyces cerevisiae,16,SRP226388,2019-10-20,"[Overal design]3 sets; set1: 3 replicates for 40S and 80S TCP-seq, 1 replicate for each eIF3a, eIF3c and eIF2beta bound 40S Sel-TCP-seq and 1 replicate each for eIF3a and eIF3c bound 80S Sel-TCP-seq (1-1, 1-2, 1-3); set2+3: 2 more replicates (in addition to set1) of 80S TCP-seq and eIF3a bound 80S Sel-TCP-seq (2-1, 3-1); [Treatment]'incubation of the cell culture with 0.8 % w/v formaldehyde on ice for 1 h'; [Growth]'in 1 litre YPD at 30C up to OD600 of ~0.7-0.8'; [Extraction]'cell lysis with bead beater, RNase I digestion to generate ribosomal footprints, 40S/80S separation (followed by Co-IP if indicated), hot acid phenol RNA extraction\nlibrary construction according to Ingolia et al., 2010, Methods Enzymol (different RNA fragment size selection, different set of rRNA depletion oligos)', 'cell lysis with bead beater, total RNA extraction with RNeasy Mini Kit, poly(A) selection with poly(A)Purist MAG Kit, fragmentation\nlibrary construction according to Ingolia et al., 2010, Methods Enzymol (different RNA fragment size selection, different set of rRNA depletion oligos)'; [Cell type]'Source: ''strain: SY182 (eIF3a/TIF32-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA 40S footprint; ', 'strain: H25 (eIF3c/NIP1-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA 40S footprint; ', 'strain: SY194 (eIF2beta/SUI3-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA 40S footprint; ', 'strain: SY182 (eIF3a/TIF32-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: yes (anti-FLAG, Sigma A2220); protocol: RNA 40S footprint; ', 'strain: H25 (eIF3c/NIP1-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: yes (anti-FLAG, Sigma A2220); protocol: RNA 40S footprint; ', 'strain: SY194 (eIF2beta/SUI3-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: yes (anti-FLAG, Sigma A2220); protocol: RNA 40S footprint; ', 'strain: SY182 (eIF3a/TIF32-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA 80S footprint; ', 'strain: H25 (eIF3c/NIP1-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA 80S footprint; ', 'strain: SY194 (eIF2beta/SUI3-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA 80S footprint; ', 'strain: SY182 (eIF3a/TIF32-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: yes (anti-FLAG, Sigma A2220); protocol: RNA 80S footprint; ', 'strain: H25 (eIF3c/NIP1-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: yes (anti-FLAG, Sigma A2220); protocol: RNA 80S footprint; ', 'strain: SY182 (eIF3a/TIF32-FLAG); rna fragment size selection: approximately 18 to 85; co-ip: no; protocol: RNA-seq; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139130,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139130/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA578566,32589964," Susan Wagner,  Anna Herrmannova,  Vladislava Hronova,  Stanislava Gunisova,  Neelam D Sen,  Ross D Hannan,  Alan G Hinnebusch,  Nikolay E Shirokikh,  Thomas Preiss,  Leos Shivaya Valasek","Translational control targeting the initiation phase is central to the regulation of gene expression. Understanding all of its aspects requires substantial technological advancements. Here we modified yeast translation complex profile sequencing (TCP-seq), related to ribosome profiling, and adapted it for mammalian cells. Human TCP-seq, capable of capturing footprints of 40S subunits (40Ss) in addition to 80S ribosomes (80Ss), revealed that mammalian and yeast 40Ss distribute similarly across 5'TRs, indicating considerable evolutionary conservation. We further developed yeast and human selective TCP-seq (Sel-TCP-seq), enabling selection of 40Ss and 80Ss associated with immuno-targeted factors. Sel-TCP-seq demonstrated that eIF2 and eIF3 travel along 5' UTRs with scanning 40Ss to successively dissociate upon AUG recognition; notably, a proportion of eIF3 lingers on during the initial elongation cycles. Highlighting Sel-TCP-seq versatility, we also identified four initiating 48S conformational intermediates, provided novel insights into ATF4 and GCN4 mRNA translational control, and demonstrated co-translational assembly of initiation factor complexes.",Selective Translation Complex Profiling Reveals Staged Initiation and Co-translational Assembly of Initiation Factor Complexes.,10.1016/j.molcel.2020.06.004,2020 Aug 20,PMC7447980,Molecular cell
GSE153502,Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets,Homo sapiens,81,SRP269234,2020-06-29,"[Overal design]Cell cultures were analyzed in biological triplicates, tissue and tumor samples in technical triplicates.; [Treatment]'None'; [Growth]'None'; [Extraction]""Tissue and tumor samples were homogenized prior to RNA extraction, otherwise was whole cell RNA extracted using Trizol according to the manufacturer.\nRiboMeth-seq: 5-10 ug of RNA was partially degraded by alkaline at denaturing temperatures. The size fraction 20-40 nt was purified on gels and linkers added using a system relying on a modified Arabidopsis tRNA ligase joining 2',3' cyclic phosphate and 5' phosphate ends. The library fragments were then sequenced on the Ion Proton platform. See Birkedal U, Christensen-Dalsgaard M, Krogh N, Sabarinathan R, Gorodkin J, Nielsen H. Profiling of ribose methylations in RNA by high-throughput sequencing. Angewandte Chemie. 2015;54(2):451-5 for detailed description""; [Cell type]'Source: ''sample type: Adult; ', 'sample type: Tumor; ', 'sample type: DLBCL derived cell line; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153502,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE153nnn/GSE153502/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA642861,,,,,,,,
GSE93210,Interactome (iCLIP) and Translatome ( Polysome profiling) of Musashi 2 (MSI2) targets in K562,Homo sapiens,18,SRP096137,2017-01-05,"[Overal design]iCLIP and Polysome profiling; [Treatment]'none'; [Growth]'K562 cells were grown in RPMI-1640 media supplemented with 10% fetal bovin serum.'; [Extraction]'iCLIP per Huppert I et. al. Methods. 2014 Feb;65(3):274-287, PMID: 24184352  Methods. 2014 Feb;65(3):274-87.PMID:24184352  24184352\nPolysome profiling: Polysome RNA extracted by Trizol extraction from control and MSI2-KD cells\nRNA-Seq library prepared by Illumina Truseq v2 kit. iCLIP library prepared per custom protocol as referenced above.\nRNA-Seq (SE)'; [Cell type]'Source: ''shRNA: Control shRNA; ', 'shRNA: MSI2-KD shRNA; ', 'transgene: FLAG-MSI2; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93210,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE93nnn/GSE93210/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA360304,,,,,,,,
GSE128648,Transcriptome of mature erythrocytes,Homo sapiens,4,SRP189031,2019-03-21,"[Overal design]RNA transcriptome profiling was done for total mature erythrocyte lysates and polysome fractions using Illumina Seq; [Treatment]'None'; [Growth]'None'; [Extraction]'Red blood cells were isolated from whole blood. CD71 negative mature erythrocytes were isolated using CD71 magnetic beads based depletion. The cells were lysed using lysis buffer. RNA from this lysate was isolated using GeneJet RNA purification kit (Thermo Fisher Scientific) and corresponds to ""Total RNA"". For Polysome RNA, Toal erythrocytes were lysed using polysome buffer containing 2mM Dithiothreitol, 100?g/mL Cycloheximide, and 1% Triton X-100. The lysate was loaded on a sucrose gradient (10%-50%) and ultracentrifuged at 29000 RPM for 4 hours. The RNA from heavier fractions were isolated using the same kit as mentioned above and this RNA corresponds to ""Polysome RNA"".\nThe RNA library was prepared according to the protocol for Illumina sequencing'; [Cell type]'Erythrocytes''tissue: Whole Blood; cell type: Erythrocytes; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128648,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE128nnn/GSE128648/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA528391,,,,,,,,
GSE70804,Profiles of ribosome-associated mRNAs regulated by expression of wild-type (WT) or R534H variant of DDX3 with or without Sodium Arsenite treatment,Homo sapiens,32,None,2015-07-11,"[Overal design]Refer to individual Series; [Treatment]'Cells were UV crosslinked at 254nm for 0.3J/cm^2 to in vivo fix RNA-RBP interactions', 'Cells were treated with or without 0.5 mM sodium arsenite for 45 minutes.'; [Growth]'HEK293 cells were grown under standard serum conditions and FLAG-tagged DDX3 variant expression (FLAG-DDX3 WT or R534H) was induced with doxycycline', 'HEK293 cells were grown under standard serum conditions and FLAG-tagged Renilla luciferease (Rluc) control, DDX3 WT, or DDX3 R534H expression was induced by doxycycline addition.'; [Extraction]'Lysates were clarified from sonicated HEK293 and DDX3-RNA complexes were isolated first with anti-FLAG (Sigma, A2220) then anti-DDX3 (Abcam, ab37160) antibody.\nLibraries were prepared according to the FAST-iCLIP protocol (PMID: 25411354)', 'Lysates were treated with RNase I, ribosomes were collected, ribosomal RNAs were depleted with Ribo-Zero kit (EpiCentre), and ribosome-protected mRNA fragments were enriched.\nLibraries were prepared according to the ribosome profiling protocol (PMID: 19213877) and ARTseqTM Ribosome Profiling Kit protocol (EpiCentre).', 'Total RNAs were extracted using Zymo RNA Clean & Concentrator after depleting ribosomal RNAs with Ribo-Zero kit (EpiCentre).\nLibraries were prepared according to the ribosome profiling protocol (PMID: 19213877) and ARTseqTM Ribosome Profiling Kit protocol (EpiCentre).'; [Cell type]'Embryonic kidney''cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; flag-tagged protein: DDX3 R534H; rip antibody: anti-FLAG (Sigma, catalog# F1804, lot# SLBF6631) then anti-DDX3 (Abcam, catalog# ab37160, lot# GR57731-4 ) antibody; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; flag-tagged protein: DDX3 R534H; rip antibody: anti-FLAG (Sigma, catalog# F1804, lot# SLBF6631) then anti-DDX3 (Abcam, catalog# ab37160, lot# GR57731-4 ) antibody; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; flag-tagged protein: DDX3 WT; rip antibody: anti-FLAG (Sigma, catalog# F1804, lot# SLBF6631) then anti-DDX3 (Abcam, catalog# ab37160, lot# GR57731-4 ) antibody; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; flag-tagged protein: DDX3 WT; rip antibody: anti-FLAG (Sigma, catalog# F1804, lot# SLBF6631) then anti-DDX3 (Abcam, catalog# ab37160, lot# GR57731-4 ) antibody; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; expressed protein: Rluc control; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; expressed protein: DDX3 WT; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: control; expressed protein: DDX3 R534H; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; expressed protein: Rluc control; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; expressed protein: DDX3 WT; ', 'cell type: Embryonic kidney; cell line: HEK293-Flp-In-T-Rex; gender: female; treatment: sodium arsenite; expressed protein: DDX3 R534H; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70804,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE70nnn/GSE70804/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA289567,27058758," Sekyung Oh,  Ryan A Flynn,  Stephen N Floor,  James Purzner,  Lance Martin,  Brian T Do,  Simone Schubert,  Dedeepya Vaka,  Sorana Morrissy,  Yisu Li,  Marcel Kool,  Volker Hovestadt,  David T W Jones,  Paul A Northcott,  Thomas Risch,  Hans-Jorg Warnatz,  Marie-Laure Yaspo,  Christopher M Adams,  Ryan D Leib,  Marcus Breese,  Marco A Marra,  David Malkin,  Peter Lichter,  Jennifer A Doudna,  Stefan M Pfister,  Michael D Taylor,  Howard Y Chang,  Yoon-Jae Cho","DDX3X encodes a DEAD-box family RNA helicase (DDX3) commonly mutated in medulloblastoma, a highly aggressive cerebellar tumor affecting both children and adults. Despite being implicated in several facets of RNA metabolism, the nature and scope of DDX3's interactions with RNA remain unclear. Here, we show DDX3 collaborates extensively with the translation initiation machinery through direct binding to 5'UTRs of nearly all coding RNAs, specific sites on the 18S rRNA, and multiple components of the translation initiation complex. Impairment of translation initiation is also evident in primary medulloblastomas harboring mutations in DDX3X, further highlighting DDX3's role in this process. Arsenite-induced stress shifts DDX3 binding from the 5'UTR into the coding region of mRNAs concomitant with a general reduction of translation, and both the shift of DDX3 on mRNA and decreased translation are blunted by expression of a catalytically-impaired, medulloblastoma-associated DDX3R534H variant. Furthermore, despite the global repression of translation induced by arsenite, translation is preserved on select genes involved in chromatin organization in DDX3R534H-expressing cells. Thus, DDX3 interacts extensively with RNA and ribosomal machinery to help remodel the translation landscape in response to stress, while cancer-related DDX3 variants adapt this response to selectively preserve translation.",Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress.,10.18632/oncotarget.8612,2016 May 10,PMC5053718,Oncotarget
GSE65885,Ribosome profiling and RNA sequencing of MCF10A-ER-Src and fibroblast cell transformation,Homo sapiens,36,SRP054971,2015-02-12,"[Overal design]Ribosome profiling and RNA sequencing in two cancer cell models; [Treatment]'None'; [Growth]'All cultures were performed at 37C under 5% CO2. BJ fibroblast cell lines (EH, EL and ELR) were cultured on Knockout DMEM (Invitrogen) with 10% FBS, medium 199, glutamine and penicillin-streptomycin(Hahn et al., 1999).  The breast epithelial cell line (MCF-10A-ER-Src) was grown in DMEM/F12 with 5% charcoal-stripped fetal bovine serum (Invitrogen) and supplements(Iliopoulos et al., 2009). Cells were seeded at 1\u2009\u2009106 cells per 10-cm culture dish and cultured overnight. MCF-10A-ER-Src cells were treated by 1 M 4-hydroxy-tamoxifen for various time points (1, 4, and 24 hr) to induce transformation.'; [Extraction]'For RNA-seq, total RNA was purified from DNase-treated lysates, and ribosomal RNA was depleted with RiboMinus Eukaryote Kit (Invitrogen).\nRNA-seq libraries were prepared with a tagging-based workflow(Pease and Kinross, 2013). In brief, rRNA-depleted RNA was fragmented at 85C for 5 min, followed by cDNA synthesis, terminal tagging and PCR amplification with ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre).', 'For ribosome profiling, cells were pretreated with cycloheximide (100 g/ml; Sigma-Aldrich) for 90 seconds or harringtonine (2 g/ml; Santa Cruz) for 5 minutes, and detergent lysis was then performed with flash-freezing in liquid nitrogen. DNase I-treated lysates were then treated with RNase I, and ribosome-protected fragments were purified as previously described (Ingolia et al., 2012).\nFor ribosome profiling, ribosome-protected fragments were subjected to Illumina TruSeq library construction as previously described (Ingolia et al., 2012).'; [Cell type]'breast epithelial', 'Fibroblast''cell line: MCF10A-ER-Src; cell type: breast epithelial; rna type: Total RNA; ', 'cell line: MCF10A-ER-Src; cell type: breast epithelial; rna type: Ribosome protected fragments; ', 'cell line: BJ; cell type: Fibroblast; rna type: Total RNA; ', 'cell line: BJ; cell type: Fibroblast; rna type: Ribosome protected fragments; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65885,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE65nnn/GSE65885/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA275305,26900662," Zhe Ji,  Ruisheng Song,  Hailiang Huang,  Aviv Regev,  Kevin Struhl","Ribosome profiling is widely used to study translation in vivo, but not all sequence reads correspond to ribosome-protected RNA. Here we describe Rfoot, a computational pipeline that analyzes ribosomal profiling data and identifies native, nonribosomal RNA-protein complexes. We use Rfoot to precisely map RNase-protected regions within small nucleolar RNAs, spliceosomal RNAs, microRNAs, tRNAs, long noncoding (lnc)RNAs and 3' untranslated regions of mRNAs in human cells. We show that RNAs of the same class can show differential complex association. Although only a subset of lncRNAs show RNase footprints, many of these have multiple footprints, and the protected regions are evolutionarily conserved, suggestive of biological functions.",Transcriptome-scale RNase-footprinting of RNA-protein complexes.,10.1038/nbt.3441,2016 Apr,PMC4824641,Nature biotechnology
GSE48785,Global response to chemotherapy-induced apoptosis,Homo sapiens,12,SRP027015,2013-07-11,"[Overal design]We examined MM1.S myeloma cells exposed to 20 nM bortezomib across a time course with independent samples of poly(A) mRNA and ribosome footprints isolated at each of six time points (0h (untreated), 1.5h, 3h, 6h, 9h, 12h). Sequencing was performed on a Illumina HiSeq 2000 with single-end.; [Treatment]'0h samples untreated, all others 20 nM bortezomib treated. Ribosome footprint samples treated with 0.1 mg/mL cycloheximide for 1 min immediately prior to harvesting.'; [Growth]'None'; [Extraction]'Ribosome footprints were isolated from 80S ribosomes by ultracentrifugation followed by gel-based size selection, as previously described (Ingolia et al, Cell 2011). Poly(A) mRNA was isolated using poly-d(T) coated magnetic beads, then size-selected by PAGE after alkaline fragmentation.\nLibraries were constructed as previously described (Ingolia et al, 2011). Briefly, size-selected ribosome footprint and poly(A) mRNA fragments were ligated to Linker-1 oligonucleotide (IDT) by T4 RNA ligase following PNK dephosphorylation. Ligated RNA was purified after gel-based separation.  Reverse transcription to cDNA was carried out using SuperScript III enzyme. cDNA fragments were purified after gel-based separation. Ribosomal RNA subtraction was performed on ribosome footprint samples using biotinylated oligonucleotides (listed in Stern-Ginossar et al, Science 2012) and streptavidin-coated magnetic beads.  Samples were circularized using Circ Ligase (Epicentre) and PCR amplified using primers containing Illumina barcodes for final libraries. Up to four samples were multiplexed in a single lane for sequencing.'; [Cell type]'Source: ''cycloheximide: none; time point: 0h (untreated); sample type: poly(A) mRNA; ', 'cycloheximide: 0.1 mg/mL cycloheximide; time point: 0h (untreated); sample type: ribosome footprint; ', 'cycloheximide: none; time point: 1.5h; sample type: poly(A) mRNA; ', 'cycloheximide: 0.1 mg/mL cycloheximide; time point: 1.5h; sample type: ribosome footprint; ', 'cycloheximide: none; time point: 3h; sample type: poly(A) mRNA; ', 'cycloheximide: 0.1 mg/mL cycloheximide; time point: 3h; sample type: ribosome footprint; ', 'cycloheximide: none; time point: 6h; sample type: poly(A) mRNA; ', 'cycloheximide: 0.1 mg/mL cycloheximide; time point: 6h; sample type: ribosome footprint; ', 'cycloheximide: none; time point: 9h; sample type: poly(A) mRNA; ', 'cycloheximide: 0.1 mg/mL cycloheximide; time point: 9h; sample type: ribosome footprint; ', 'cycloheximide: none; time point: 12h; sample type: poly(A) mRNA; ', 'cycloheximide: 0.1 mg/mL cycloheximide; time point: 12h; sample type: ribosome footprint; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48785,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE48nnn/GSE48785/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA211752,24171104," Arun P Wiita,  Etay Ziv,  Paul J Wiita,  Anatoly Urisman,  Olivier Julien,  Alma L Burlingame,  Jonathan S Weissman,  James A Wells","How cancer cells globally struggle with a chemotherapeutic insult before succumbing to apoptosis is largely unknown. Here we use an integrated systems-level examination of transcription, translation, and proteolysis to understand these events central to cancer treatment. As a model we study myeloma cells exposed to the proteasome inhibitor bortezomib, a first-line therapy. Despite robust transcriptional changes, unbiased quantitative proteomics detects production of only a few critical anti-apoptotic proteins against a background of general translation inhibition. Simultaneous ribosome profiling further reveals potential translational regulation of stress response genes. Once the apoptotic machinery is engaged, degradation by caspases is largely independent of upstream bortezomib effects. Moreover, previously uncharacterized non-caspase proteolytic events also participate in cellular deconstruction. Our systems-level data also support co-targeting the anti-apoptotic regulator HSF1 to promote cell death by bortezomib. This integrated approach offers unique, in-depth insight into apoptotic dynamics that may prove important to preclinical evaluation of any anti-cancer compound. DOI:http://dx.doi.org/10.7554/eLife.01236.001.",Global cellular response to chemotherapy-induced apoptosis.,10.7554/eLife.01236,2013 Oct 29,PMC3808542,eLife
GSE59093,DDX3X regulation of global translation is impaired by medulloblastoma-associated mutations [RNA-Seq],Homo sapiens,6,SRP044062,2014-07-03,"[Overal design]Examination of the whole tarnscriptome under conditions of DDX3X knockdown or overexpression of WT DDX3X or cancer-associated DDX3X mutants; [Treatment]'For knockdown experiments, HEK293T cells were treated with control or DDX3X siRNA oligos for 48 h. For overexpression experiments, cells were transfected with 5 g of GFP alone, or GFP-DDX3X variants for 32 h followed by collection of GFP-positive cell population by flow-cytometry (FACS LSR II D, BD Biosciences)cells were transfected with plasmids from 30 h'; [Growth]'HEK293T cells were grown in Dulbeccos Modified Eagles Serum,  DMEM,  supplemented with 10% fetal bovine serum, FBS and 1% Pen-Strep (100 U/ml penicillin, 100 g/ml streptomycin. Cells were incubated at 37 C and with a 5% CO2 concentration.'; [Extraction]'RNA was extracted using RNAeasy kit (Qiagen)\nRNA sequencing libraries were prepared using approximately 1 g total RNA using TruSeq RNA Sample Prep v2 kits according to the manufacturers instructions (Illumina, San Diego, CA.). Sequencing was performed on an Illumina HiSeq 2000 using TruSeq SBS v3 reagents according to the manufacturers instructions.'; [Cell type]'Neuronal''cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with GFP expressing plasmid; sorting parameter: sorted by flow cytometry for GFP+ population; over-expression product: GFP; ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with GFP WT DDX3X expressing plasmid; sorting parameter: sorted by flow cytometry for GFP+ population; over-expression product: GFP-WT DDX3X; ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with GFP DDX3X T275M expressing plasmid; sorting parameter: sorted by flow cytometry for GFP+ population; over-expression product: GFP-DDX3X T275M; ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transiently transfected with GFP DDX3X G302V expressing plasmid; sorting parameter: sorted by flow cytometry for GFP+ population; over-expression product: GFP-DDX3X G302V; ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transfected with control siRNA for 48 hr; ', 'cell line: HEK293T; cell type: Neuronal; transfection construct: cells transfected with DDX3X siRNA for 48 hr; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59093,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59093/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA254363,27180681," Yasmine A Valentin-Vega,  Yong-Dong Wang,  Matthew Parker,  Deanna M Patmore,  Anderson Kanagaraj,  Jennifer Moore,  Michael Rusch,  David Finkelstein,  David W Ellison,  Richard J Gilbertson,  Jinghui Zhang,  Hong Joo Kim,  J Paul Taylor","DDX3X is a DEAD-box RNA helicase that has been implicated in multiple aspects of RNA metabolism including translation initiation and the assembly of stress granules (SGs). Recent genomic studies have reported recurrent DDX3X mutations in numerous tumors including medulloblastoma (MB), but the physiological impact of these mutations is poorly understood. Here we show that a consistent feature of MB-associated mutations is SG hyper-assembly and concomitant translation impairment. We used CLIP-seq to obtain a comprehensive assessment of DDX3X binding targets and ribosome profiling for high-resolution assessment of global translation. Surprisingly, mutant DDX3X expression caused broad inhibition of translation that impacted DDX3X targeted and non-targeted mRNAs alike. Assessment of translation efficiency with single-cell resolution revealed that SG hyper-assembly correlated precisely with impaired global translation. SG hyper-assembly and translation impairment driven by mutant DDX3X were rescued by a genetic approach that limited SG assembly and by deletion of the N-terminal low complexity domain within DDX3X. Thus, in addition to a primary defect at the level of translation initiation caused by DDX3X mutation, SG assembly itself contributes to global translation inhibition. This work provides mechanistic insights into the consequences of cancer-related DDX3X mutations, suggesting that globally reduced translation may provide a context-dependent survival advantage that must be considered as a possible contributor to tumorigenesis.",Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation.,10.1038/srep25996,2016 May 16,PMC4867597,Scientific reports
GSE69602,Ribosome profiling analysis of Dengue Virus,Homo sapiens,116,SRP059187,2015-06-05,"[Overal design]Translational and transcriptional analysis of the cellular response to Dengue virus infection; [Treatment]'Infection with DENV or treatment with interferon'; [Growth]'Cultured in DMEM + 10% FBS, 37C, 5% CO2'; [Extraction]'Pre-treatment with 180 uM cycloheximide for 30s. PBS wash. For fractionated cells, release cytosol with digitonin. Extract remaining sample with dodecyl maltoside.\nNEB Directional Small RNA kit\nPNK end polishing, linker ligation, reverse transcription, PCR amplification'; [Cell type]'Source: ''cell line: Huh7 cells; protocol: 6 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: ER; analysis: ribosome profiling; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 1; strain: none; ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: ER; analysis: ribosome profiling; replicate: Rep 1; strain: none; ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: ER; analysis: ribosome profiling; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 2; strain: none; ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: ER; analysis: ribosome profiling; replicate: Rep 2; strain: none; ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: ER; analysis: ribosome profiling; replicate: Rep 3; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 3; strain: none; ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: ER; analysis: ribosome profiling; replicate: Rep 3; strain: none; ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: ER; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: ER; analysis: ribosome profiling; replicate: Rep 4; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: cytosol; analysis: ribosome profiling; replicate: Rep 4; strain: none; ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: ER; analysis: ribosome profiling; replicate: Rep 4; strain: none; ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: ER; analysis: mRNA-seq; replicate: Rep 1; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 1; strain: none; ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: ER; analysis: mRNA-seq; replicate: Rep 1; strain: none; ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 6 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 12 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 24 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: 40 h infection; compartment: ER; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Interferon treatment; compartment: ER; analysis: mRNA-seq; replicate: Rep 2; strain: DENV2 (M29095.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: cytosol; analysis: mRNA-seq; replicate: Rep 2; strain: none; ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: ER; analysis: mRNA-seq; replicate: Rep 2; strain: none; ', 'cell line: Huh7 cells; protocol: 12 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: none; ', 'cell line: Huh7 cells; protocol: 12 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV1 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: none; ', 'cell line: Huh7 cells; protocol: 12 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 12 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV2 infection; compartment: Total cell lysate; analysis: ribosome profiling; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 12 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: none; ', 'cell line: Huh7 cells; protocol: 12 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV1 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV1 (EU081230.1); ', 'cell line: Huh7 cells; protocol: Uninfected; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: none; ', 'cell line: Huh7 cells; protocol: 12 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 1; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 12 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 24 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 48 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 6 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV2 (EU081177.1); ', 'cell line: Huh7 cells; protocol: 72 h DENV2 infection; compartment: Total cell lysate; analysis: mRNA-seq; replicate: rep 2; strain: DENV2 (EU081177.1); '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69602,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE69nnn/GSE69602/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA285961,29321322," David W Reid,  Rafael K Campos,  Jessica R Child,  Tianli Zheng,  Kitti Wing Ki Chan,  Shelton S Bradrick,  Subhash G Vasudevan,  Mariano A Garcia-Blanco,  Christopher V Nicchitta","A primary question in dengue virus (DENV) biology is the molecular strategy for recruitment of host cell protein synthesis machinery. Here, we combined cell fractionation, ribosome profiling, and transcriptome sequencing (RNA-seq) to investigate the subcellular organization of viral genome translation and replication as well as host cell translation and its response to DENV infection.",Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis.,10.1128/JVI.01766-17,2018 Apr 1,PMC5972907,Journal of virology
GSE151877,"Parallel spatial transcriptomics, single-cell and bulk RNA-Seq analysis of the human embryonic HSC niche, the dorsal aorta",Homo sapiens,44,None,2020-06-05,"[Overal design]Two LCM-Seq transcriptome analyses of spatially defined regions around the dorsal aorta (Carnegie Stages (CS) 16-17, N=6); RNA-Seq analysis of hematoendothelial populations from the dorsal and ventral portions of the dorsal aorta (AoV, AoD respectively) (CS15-16, N=2); single cell RNA-Seq analysis of the AoV (N=1) and central portion of the dorsal aorta (N=1).; [Treatment]'None'; [Growth]'None'; [Extraction]'The dorsal aortae were dissected from human embryos CS15-16 (N=2) then further bisected into ventral and dorsal portions (AoV and AoD respectively). Tissues were dissociated into single cells in 1mg/ml Collagenase-Dispase (Roche) and 0.12 mg/ml of DNase I (Roche) for 35 min in a 37 oC rotating water bath and stained with conjugated antibodies anti-human VE-Cadherin-PE (Beckman Coulter, 5g/ml), anti-human CD45 v450 (Clone: HI30, BioLegend, 6g/ml) and anti-human CD235A  APC (BD Bioscience, 0.2g/ml) for 1 hour at 4 oC. Dead cells and erythroid cells were excluded by 7AAD and CD235A staining respectively. VC+CD45-, VC+CD45+ and VC-CD45+ populations were sorted using a FACS Aria-II (BD Bioscience) into Eppendorf tubes containing RLT buffer from the RNeasy Micro kit ready for RNA purification. RNA was purified using the RNeasy Micro kit.\nSMARTer Stranded Total RNA-Seq Kit v2 -Pico Input Mammalian kit (Takara) for samples 1-12', 'Human embryos embedded in OCT were sectioned in a caudal-to-rostral direction using a cryotome FSE cryostat (Thermo Scientific).  Sections were stained using a rapid Haematoxylin and Eosin staining protocol - 3 minutes (min) in 70% ethanol, 1 min H2O, 4 min Mayers Haematoxylin Solution (Sigma-Aldrich), 2 min tap H2O, 15 seconds Eosin Y (Sigma-Aldrich), 1 min 70% ethanol, 1 min 90% ethanol, 3 mins 100% ethanol. All H2O was treated with diethyl pyrocarbonate (DEPC) and all reagents were pre-cooled in ice except 100% ethanol which was room temperature. The laser capture microscope used was the PALM microbeam (Zeiss). The microscope and surrounding area were sprayed down with RNaseAWAY  (Sigma-Aldrich). Sections were viewed and microdissected in brightfield using a 10X objective. The microdissected regions were collected into the caps of AdhesiveCap 500 opaque (Zeiss) 500l PCR tubes. 15l lysis buffer (0.2% Triton X-100 (Sigma-Aldrich), 2U/l RNase inhibitor (Takara), Phosphate Buffer Solution (PBS, (Nichterwitz et al., 2016)) was added directly on top of the dissected tissue in the tube caps and the tubes closes in an inverted position. PicoPure RNA Isolation Kit was used to extract RNA for samples 1-12. Samples 13-30 were directly amplified from lysed material\nSMARTer Stranded Total RNA-Seq Kit v2 -Pico Input Mammalian kit (Takara) for samples 1-12, LCM-Seq (Picelli et al., 2014) for samples 13-30.', ""The dorsal aortae (Ao) were dissected from human embryos CS16 - sample 1 was further bisected into ventral (AoV) and dorsal (AoD) portions with only AoV taken for analysis, sample 2 was trimmed to the mid portion of the Ao. Tissues were dissociated into single cells in 1mg/ml Collagenase-Dispase. For sample 1 CD34+ cells were enriched using the human CD34 MicroBead Kit and LS MACS Columns (both Miltenyi Biotec). For sample 2, live cells were sorted using a FACS Aria-II (BD Bioscience) using 7AAD as a marker of dead cells.\nLibraries were prepared using the Single Cell 3 Reagent Kit v2 (10x Genomics) according to manufacturer's protocol.""; [Cell type]'Source: ''embryo: 1; developmental stage: CS15-16; tissue: Dorsal aorta; population: Ventral endothelial (VC+CD45-); ', 'embryo: 1; developmental stage: CS15-16; tissue: Dorsal aorta; population: Ventral hematopoietic stem/progenitor cells (VC+CD45+); ', 'embryo: 1; developmental stage: CS15-16; tissue: Dorsal aorta; population: Ventral hematopoietic (VC-CD45+); ', 'embryo: 1; developmental stage: CS15-16; tissue: Dorsal aorta; population: Dorsal endothelial (VC+CD45-); ', 'embryo: 1; developmental stage: CS15-16; tissue: Dorsal aorta; population: Dorsal hematopoietic stem/progenitor cells (VC+CD45+); ', 'embryo: 1; developmental stage: CS15-16; tissue: Dorsal aorta; population: Dorsal hematopoietic (VC-CD45+); ', 'embryo: 2; developmental stage: CS15-16; tissue: Dorsal aorta; population: Ventral endothelial (VC+CD45-); ', 'embryo: 2; developmental stage: CS15-16; tissue: Dorsal aorta; population: Ventral hematopoietic stem/progenitor cells (VC+CD45+); ', 'embryo: 2; developmental stage: CS15-16; tissue: Dorsal aorta; population: Ventral hematopoietic (VC-CD45+); ', 'embryo: 2; developmental stage: CS15-16; tissue: Dorsal aorta; population: Dorsal endothelial (VC+CD45-); ', 'embryo: 2; developmental stage: CS15-16; tissue: Dorsal aorta; population: Dorsal hematopoietic stem/progenitor cells (VC+CD45+); ', 'embryo: 2; developmental stage: CS15-16; tissue: Dorsal aorta; population: Dorsal hematopoietic (VC-CD45+); ', 'embryo: 1; developmental stage: CS17; tissue: dorsal aorta; subdomain: Ventral ([V]); ', 'embryo: 1; developmental stage: CS17; tissue: dorsal aorta; subdomain: Ventro-lateral ([VL]); ', 'embryo: 1; developmental stage: CS17; tissue: dorsal aorta; subdomain: Dorsal-lateral ([DL]); ', 'embryo: 1; developmental stage: CS17; tissue: dorsal aorta; subdomain: Dorsal ([D]); ', 'embryo: 2; developmental stage: CS17; tissue: dorsal aorta; subdomain: Ventral ([V]); ', 'embryo: 2; developmental stage: CS17; tissue: dorsal aorta; subdomain: Ventro-lateral ([VL]); ', 'embryo: 2; developmental stage: CS17; tissue: dorsal aorta; subdomain: Dorsal-lateral ([DL]); ', 'embryo: 2; developmental stage: CS17; tissue: dorsal aorta; subdomain: Dorsal ([D]); ', 'embryo: 3; developmental stage: CS17; tissue: dorsal aorta; subdomain: Ventral ([V]); ', 'embryo: 3; developmental stage: CS17; tissue: dorsal aorta; subdomain: Ventro-lateral ([VL]); ', 'embryo: 3; developmental stage: CS17; tissue: dorsal aorta; subdomain: Dorsal-lateral ([DL]); ', 'embryo: 3; developmental stage: CS17; tissue: dorsal aorta; subdomain: Dorsal ([D]); ', 'embryo: 4; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Inner (V_Inner); ', 'embryo: 4; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Inner (D_Inner); ', 'embryo: 4; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Mid (V_Mid); ', 'embryo: 4; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Mid (D_Mid); ', 'embryo: 4; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Outer (V_Outer); ', 'embryo: 4; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Outer (D_Outer); ', 'embryo: 5; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Inner (V_Inner); ', 'embryo: 5; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Inner (D_Inner); ', 'embryo: 5; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Mid (V_Mid); ', 'embryo: 5; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Mid (D_Mid); ', 'embryo: 5; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Outer (V_Outer); ', 'embryo: 5; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Outer (D_Outer); ', 'embryo: 6; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Inner (V_Inner); ', 'embryo: 6; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Inner (D_Inner); ', 'embryo: 6; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Mid (V_Mid); ', 'embryo: 6; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Mid (D_Mid); ', 'embryo: 6; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Ventral Outer (V_Outer); ', 'embryo: 6; developmental stage: CS16; tissue: dorsal aorta and surrounding mesenchyme; subdomain: Dorsal Outer (D_Outer); ', 'embryo: 1; developmental stage: CS16; tissue: Ventral dorsal aorta (AoV); cell population: CD34-enriched; ', 'embryo: 2; developmental stage: CS16; tissue: Dorsal aorta - mid (around vitelline artery); cell population: Total; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151877,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE151nnn/GSE151877/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA637571,32946788," Edie I Crosse,  Sabrina Gordon-Keylock,  Stanislav Rybtsov,  Anahi Binagui-Casas,  Hannah Felchle,  Nneka C Nnadi,  Kristina Kirschner,  Tamir Chandra,  Sara Tamagno,  David J Webb,  Fiona Rossi,  Richard A Anderson,  Alexander Medvinsky","Hematopoietic stem cells (HSCs) first emerge in the embryonic aorta-gonad-mesonephros (AGM) region. Studies of model organisms defined intersecting signaling pathways that converge to promote HSC emergence predominantly in the ventral domain of the dorsal aorta. Much less is known about mechanisms driving HSC development in humans. Here, to identify secreted signals underlying human HSC development, we combined spatial transcriptomics analysis of dorsoventral polarized signaling in the aorta with gene expression profiling of sorted cell populations and single cells. Our analysis revealed a subset of aortic endothelial cells with a downregulated arterial signature and a predicted lineage relationship with the emerging HSC/progenitor population. Analysis of the ventrally polarized molecular landscape identified endothelin 1 as an important secreted regulator of human HSC development. The obtained gene expression datasets will inform future studies on mechanisms of HSC development in vivo and on generation of clinically relevant HSCs in vitro.",Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development.,10.1016/j.stem.2020.08.004,2020 Nov 5,PMC7671940,Cell stem cell
GSE60040,Wide-spread disruption of transcription termination in HSV-1 infection: Next-generation sequencing of translational activityd by ribosome profiling,Homo sapiens,12,SRP045214,2014-08-04,"[Overal design]Ribosome profiling was performed a 0, 1, 2, 4, 6 and 8 h post infection. Two biological replicates were analysed.; [Treatment]'Cells were infected for 10 min with HSV-1 strain 17 at an MOI of 10 followed by PBS wash and media replacement. 500M 4-thiouridine was added to the cell culture at the indicated time points.'; [Growth]'Human foreskin fibroblasts were cultured in DMEM supplements with 10% FBS and P/S. Cells at passage 13 were infected at 60% confluency 24h after the last split.'; [Extraction]'Cells were snap frozen followed by cell lysis in presence of cycloheximide. Following removal of cell nuclei by centrifugation and stringent RNAse digest, ribosomes were pelleted through a sucrose cushion. Translated RNA fragments were recovered by size selection.\nTranslated RNA fragments were cloned following the protocol described by Stern-Ginossar N et al. Science 2012. rRNA depletion involved additional biotinylated oligos to improve depletion. To efficiently remove all biotinylated oligos complementary to specific rRNA sequences, two rounds of streptavidin depletion were performed. cDNA libraries were amplified by PCR and sequenced (HiSeq 50nt reads).\n50 nt single end reads:    Solexa P5, 9 nt barcode, ribosome protected mRNA fragment, Solexa P3 adaptor'; [Cell type]'human foreskin fibroblasts''cell type: human foreskin fibroblasts; time post infection: mock; infection with: mock; barcode: NNNTTGTNN; ', 'cell type: human foreskin fibroblasts; time post infection: 1 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCAATNN; ', 'cell type: human foreskin fibroblasts; time post infection: 2 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNGGCGNN; ', 'cell type: human foreskin fibroblasts; time post infection: 4 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCCGGNN; ', 'cell type: human foreskin fibroblasts; time post infection: 6 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNTGGCNN; ', 'cell type: human foreskin fibroblasts; time post infection: 8 h p.i.; infection with: Herpes simplex virus 1, strain 17; barcode: NNNCCACNN; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60040,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60040/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA257365,25989971," Andrzej J Rutkowski,  Florian Erhard,  Anne L'Hernault,  Thomas Bonfert,  Markus Schilhabel,  Colin Crump,  Philip Rosenstiel,  Stacey Efstathiou,  Ralf Zimmer,  Caroline C Friedel,  Lars Dolken","Herpes simplex virus 1 (HSV-1) is an important human pathogen and a paradigm for virus-induced host shut-off. Here we show that global changes in transcription and RNA processing and their impact on translation can be analysed in a single experimental setting by applying 4sU-tagging of newly transcribed RNA and ribosome profiling to lytic HSV-1 infection. Unexpectedly, we find that HSV-1 triggers the disruption of transcription termination of cellular, but not viral, genes. This results in extensive transcription for tens of thousands of nucleotides beyond poly(A) sites and into downstream genes, leading to novel intergenic splicing between exons of neighbouring cellular genes. As a consequence, hundreds of cellular genes seem to be transcriptionally induced but are not translated. In contrast to previous reports, we show that HSV-1 does not inhibit co-transcriptional splicing. Our approach thus substantially advances our understanding of HSV-1 biology and establishes HSV-1 as a model system for studying transcription termination.",Widespread disruption of host transcription termination in HSV-1 infection.,10.1038/ncomms8126,2015 May 20,PMC4441252,Nature communications
GSE102720,Ternary proteindrugRNA interface explains RocA sequence selectivity and Aglaia resistance,Homo sapiens,6,SRP115648,2017-08-16,"[Overal design]Ribosome,profiling; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification\nRibosome profiling'; [Cell type]'Source: ''treatment: control DMSO treatment; cell line: HEK293T-REx; extracted molecule: total RNA; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; ', 'treatment: RocA treatment; cell line: HEK293T-REx; extracted molecule: total RNA; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102720,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102720/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA398585,30595437," Shintaro Iwasaki,  Wakana Iwasaki,  Mari Takahashi,  Ayako Sakamoto,  Chiduru Watanabe,  Yuichi Shichino,  Stephen N Floor,  Koichi Fujiwara,  Mari Mito,  Kosuke Dodo,  Mikiko Sodeoka,  Hiroaki Imataka,  Teruki Honma,  Kaori Fukuzawa,  Takuhiro Ito,  Nicholas T Ingolia","A class of translation inhibitors, exemplified by the natural product rocaglamide A (RocA), isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic translation initiation factor 4A (eIF4A) onto polypurine sequences in mRNAs. This unusual inhibitory mechanism raises the question of how the drug imposes sequence selectivity onto a general translation factor. Here, we determined the crystal structure of the human eIF4A1ATP analogRocApolypurine RNA complex. RocA targets the ""bi-molecular cavity"" formed characteristically by eIF4A1 and a sharply bent pair of consecutive purines in the RNA. Natural amino acid substitutions found in Aglaia eIF4As changed the cavity shape, leading to RocA resistance. This study provides an example of an RNA-sequence-selective interfacial inhibitor fitting into the space shaped cooperatively by protein and RNA with specific sequences.",The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.,10.1016/j.molcel.2018.11.026,2019 Feb 21,PMC6386617,Molecular cell
GSE71892,AKT Inhibition Promotes Non-autonomous Cancer Cell Survival [Antibody Arrays (L-507)],Homo sapiens,4,None,2015-08-10,"[Overal design]Secreted protein profiles of MCF7 and HCT116 Akti-1/2 treated cells and MCF7 and HCT116 vehicle (i.e. DMSO) treated cells were generated using antibody arrays.; [Treatment]'MCF7 and HCT116 cells were treated either with DMSO or Akti-1/2 for 6 days and culture supernatant were collected and frozen at -80C until analysis.'; [Growth]'MCF7 was maintained in DMEM, 10% FCS, 40mM glutamine, 100 U/mL penicillin, and 100g/mL streptomycin; HCT116 was maintained in McCoys 5? medium supplemented with 10% FCS, 100U/mL penicillin, and 100g/mL streptomycin. All cells were grown at 37C and 5% CO2.'; [Extraction]'Prepare dialysis buffer (1X PBS) by dissolving 0.6 g KCl, 24 g NaCl, 0.6 g KH2PO4 and 3.45 g Na2HPO4 in 2500 ml de-ionized or distilled water. Adjust to a pH of 8.0 with 1M NaOH and adjust final volume to 3000 ml with de-ionized or distilled water. Load each sample into 2 separate Dialysis Vials, 2.5-3.0 ml of sample per vial, total 5-6 ml per sample) for dialyzing. Carefully place all Dialysis Vials into the Floating Rack. Place the Floating Rack into ?500 ml dialysis buffer in a large beaker. Place beaker on a stir plate and dialyze for at least 3 hours at 4 C, occasionally gently stirring the dialysis buffer. Then exchange the dialysis buffer with fresh buffer and repeat dialysis for at least 3 hours at 4 C. Transfer dialyzed samples into a clean eppendorf tube. Centrifuge dialyzed samples for 5 minutes at 10,000 rpm to remove B24any particulates or precipitates and then transfer and combine each sample into one clean eppendorf tube. Mix well by gently pipetting.'; [Cell type]'breast adenocarcinoma', 'colon carcinoma''cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 Low; ', 'cell line: MCF7; cell type: breast adenocarcinoma; cell state: AKT1 WT; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 Low; ', 'cell line: HCT116; cell type: colon carcinoma; cell state: AKT1 WT; '",Protein profiling by protein array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71892,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE71nnn/GSE71892/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA292424,26637368," Salony,  Xavier Sole,  Cleidson P Alves,  Ipsita Dey-Guha,  Laila Ritsma,  Myriam Boukhali,  Ju H Lee,  Joeeta Chowdhury,  Kenneth N Ross,  Wilhelm Haas,  Shobha Vasudevan,  Sridhar Ramaswamy","Small molecule inhibitors of AKT (v-akt murine thymoma viral oncogene homolog) signaling are being evaluated in patients with various cancer types, but have so far proven therapeutically disappointing for reasons that remain unclear. Here, we treat cancer cells with subtherapeutic doses of Akti-1/2, an allosteric small molecule AKT inhibitor, in order to experimentally model pharmacologic inhibition of AKT signaling in vitro. We then apply a combined RNA, protein, and metabolite profiling approach to develop an integrated, multiscale, molecular snapshot of this ""AKT(low)"" cancer cell state. We find that AKT-inhibited cancer cells suppress thousands of mRNA transcripts, and proteins related to the cell cycle, ribosome, and protein translation. Surprisingly, however, these AKT-inhibited cells simultaneously upregulate a host of other proteins and metabolites posttranscriptionally, reflecting activation of their endo-vesiculo-membrane system, secretion of inflammatory proteins, and elaboration of extracellular microvesicles. Importantly, these microvesicles enable rapidly proliferating cancer cells of various types to better withstand different stress conditions, including serum deprivation, hypoxia, or cytotoxic chemotherapy in vitro and xenografting in vivo. These findings suggest a model whereby cancer cells experiencing a partial inhibition of AKT signaling may actually promote the survival of neighbors through non-cell autonomous communication.",AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.,10.1158/1535-7163.MCT-15-0414,2016 Jan,PMC4707053,Molecular cancer therapeutics
GSE125086,Ribosome queuing enables non-AUG translation to be resistant to multiple protein synthesis inhibitors,Homo sapiens,12,SRP179458,2019-01-15,"[Overal design]Measuring translational efficiency genome-wide in response to prolonged cyclohexamide treatment; [Treatment]'HeLa cells were seeded in duplicate for each time point in 10 cm plates with 10 mL media. After 24 hr, cells (~50% confluency) were transfected with 5 ?g of GUG-nLuc plasmid DNA using Viafect (Promega) at a 2:1 (reagent:DNA) ratio following the manufacturers protocol. 24 hr later, media was replaced with fresh media containing 100 ?g/mL CHX and cells were grown for 15 min or 24 hr.'; [Growth]'HeLa cells grown in DMEM with high glucose, 10% FBS, 1% non-essential amino acids, 1% penicillin-streptomycin'; [Extraction]'At each time point, cells were placed on ice, washed with 10 mL ice-cold PBS with 100 ?g/mL CHX, and lysed in plate in 400 uL of cold lysis buffer (20 mM Tris, pH.4; 150 mM NaCl; 5 mM MgCl2; 1 mM DTT; 1% Triton X-100; 50 ?g/mL emetine; 25 U/mLTurbo DNase [Thermo Fisher Scientific]). Cells were then scraped off the plate, transferred to a 1.5 mL tube, and incubated on ice for 5 min. Cell debris was pelleted at 16,000 x g for 10 min at 4C. The resulting supernatant was then snap frozen in liquid nitrogen before storing at -80C.\nRibosome profiling was performed as previously described (Ingolia et al. 2012) with minor modifications. Briefly, cell lysates were thawed, treated with RNase I, and then pelleted over a 1 M sucrose cushion containing 100 ?g/mL emetine. RNA was then size-selected by excising between the 15 and 34 nt marker oligonucleotides, and ligated to the Universal miRNA Cloning Linker (NEB). rRNA depletion was then performed using the RiboZero rRNA Removal Kit (Human version, Illumina), followed by reverse transcription, circularization, and PCR amplification. For RNA-seq, total RNA was extracted from thawed cell lysates. Libraries were then made from 0.3 ?g of total RNA using the TruSeq Stranded Total RNA kit (Illumina) according to the manufacturers instructions, and amplified by PCR for 10 cycles. All libraries were sequenced on a HiSeq 2500 system at the Genetic Resource Core Facility of the Johns Hopkins University School of Medicine'; [Cell type]'Source: ''cell line: HeLa; treatment: control; ', 'cell line: HeLa; treatment: CHX; time: 15 min; ', 'cell line: HeLa; treatment: CHX; time: 24 h; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125086,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE125nnn/GSE125086/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA515197,,,,,,,,
GSE66809,"IFN-g Regulates mTORC1, Cellular Metabolism and mRNA Translation to Potentiate Inflammatory Macrophage Activation [RNA-Seq]",Homo sapiens,8,SRP056098,2015-03-12,"[Overal design]RPF and RNAseq libraries were generated from mock or IFN-g-primed human macrophages. Cells were stimulated with Pam3Cys and harvested at 4 hours. Libraries were generated using protocol modified from Illumina Truseq technology.; [Treatment]'Cells cultured for 24h were stimulated with Pam3Cys (10ng/ml) for 4h'; [Growth]'Cells were maintained in RPMI1640 supplemented with 10% FBS, P/S, 2mM L-Gln and 20ng/ml MCSF, under 5% CO2 at 37C.'; [Extraction]'For RNAseq total RNA was isolated via Trizol extraction; for RPF cell lysates were treated with micrococccal nuclease, and momosomes were purified by sucrose gradient followed by sucrose cushion; RPFs were extracted by Trizol\nRPF and RNA libraries were prepared for sequencing using modified Illumina protocols with polyA selection (see online methods).'; [Cell type]'Source: ''tlr stimulation: TLR2 stimulated; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66809,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE66nnn/GSE66809/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA278009,26147685," Xiaodi Su,  Yingpu Yu,  Yi Zhong,  Eugenia G Giannopoulou,  Xiaoyu Hu,  Hui Liu,  Justin R Cross,  Gunnar Ratsch,  Charles M Rice,  Lionel B Ivashkiv","Interferon-gamma (IFN-gamma) primes macrophages for enhanced microbial killing and inflammatory activation by Toll-like receptors (TLRs), but little is known about the regulation of cell metabolism or mRNA translation during this priming. We found that IFN-gamma regulated the metabolism and mRNA translation of human macrophages by targeting the kinases mTORC1 and MNK, both of which converge on the selective regulator of translation initiation eIF4E. Physiological downregulation of mTORC1 by IFN-gamma was associated with autophagy and translational suppression of repressors of inflammation such as HES1. Genome-wide ribosome profiling in TLR2-stimulated macrophages showed that IFN-gamma selectively modulated the macrophage translatome to promote inflammation, further reprogram metabolic pathways and modulate protein synthesis. These results show that IFN-gamma-mediated metabolic reprogramming and translational regulation are key components of classical inflammatory macrophage activation.",Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation.,10.1038/ni.3205,2015 Aug,PMC4509841,Nature immunology
GSE22004,Mammalian microRNAs predominantly act to decrease target mRNA levels,Homo sapiens; Mus musculus,24,None,2010-05-26,"[Overal design]Refer to individual Series.; [Treatment]'All samples were treated with cycloheximide (100 ug/ml) for 8 min just before harvesting.'; [Growth]'None', 'Haematopoietic progenitors were isolated from wild-type and mir-223 knockout male mice and cultured in media containing granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) for six days before harvesting.'; [Extraction]""mRNA-Seq: poly(A)-selected RNA was randomly fragmented by partial alkaline hydrolysis. Size-selected RNA fragments (25-45 nt) were used for library preparation.\nRibosome profiling: Cell extracts were digested with RNase I for 30 min at room temperature, and monosomes were purified by sucrose gradient centrifugation. Size-selected RNA fragments (~27-33 nt) were used for library preparation.\nLibrary preparation: Libraries were prepared as in Grimson et al, 2008 (GSE12578) but with the following modifications. Because RNase I-digestion and alkaline-fragmentation products terminate with a 5'-hydroxyl and a 3'-phosphate, they were 3'-dephosphorylated before ligation to the 3' adaptor.  Gel-purified 3'-ligation products were then 5'-phosphorylated before the 5'-ligation step."", ""Trizol extraction of total RNA was performed according to the manufacturer's instructions.""; [Cell type]'Source: ''transfection: mock; time: 32hr; ', 'transfection: miR-155 duplex; time: 32hr; ', 'transfection: miR-1 duplex; time: 32hr; ', 'transfection: mock; time: 12hr; ', 'transfection: miR-155 duplex; time: 12hr; ', 'transfection: miR-1 duplex; time: 12hr; ', 'strain: C57BL/6; genotype: wild-type; ', 'strain: C57BL/6; genotype: mir-223 knockout; '",Expression profiling by high throughput sequencing; Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22004,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE22nnn/GSE22004/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA127467,20703300," Huili Guo,  Nicholas T Ingolia,  Jonathan S Weissman,  David P Bartel","MicroRNAs (miRNAs) are endogenous approximately 22-nucleotide RNAs that mediate important gene-regulatory events by pairing to the mRNAs of protein-coding genes to direct their repression. Repression of these regulatory targets leads to decreased translational efficiency and/or decreased mRNA levels, but the relative contributions of these two outcomes have been largely unknown, particularly for endogenous targets expressed at low-to-moderate levels. Here, we use ribosome profiling to measure the overall effects on protein production and compare these to simultaneously measured effects on mRNA levels. For both ectopic and endogenous miRNA regulatory interactions, lowered mRNA levels account for most (>/=84%) of the decreased protein production. These results show that changes in mRNA levels closely reflect the impact of miRNAs on gene expression and indicate that destabilization of target mRNAs is the predominant reason for reduced protein output.",Mammalian microRNAs predominantly act to decrease target mRNA levels.,10.1038/nature09267,2010 Aug 12,PMC2990499,Nature
GSE132703,mTORC1 controls a dynamic program of TOP mRNA translation via LARP1,Homo sapiens,28,SRP201361,2019-06-13,"[Overal design]Ribosome profiling and RNA-seq datasets from wild-type HEK-293T, sgLARP1, and sgLARP1/1B cells treated for 2 h with 250 nM of the mTOR inhibitor Torin 1. Please note that the 'larp1dko_*_RPF_rep*' processed data (e.g. DKO_DMSOa_RPF_unique.htseqcounts.txt) was generated together with the corresponding *reseq sample (e.g. GSM3889093 and GSM4146393) and is linked to the LP* sample records (e.g. GSM3889093 LP: larp1dko_dmso_RPF_rep1).; [Treatment]'Cells were treatred with 250 nM Torin 1 or an equivalent volume of vehicle (DMSO) for 2 h.'; [Growth]'Cells were grown in DMEM + 10%FBS.'; [Extraction]'Cells were lysed on plate in 15 mM Hepes pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1% Triton-X100. Clarified lysates were split in two to make libraries for ribosome profiling and RNA-seq.\nFor ribosome profiling lysates were RNase I treated and centrifuged through a sucrose cushion. RNA was extracted from the resulting ribosome pellet by proteinase K treatment and acid phenol extraction. rRNA was removed with the Ribo-Zero Gold kit. 28-34 nt footprints were then isolated on polyacrylamide gel, dephosphorylated followed by 5\' adapter ligation (in case of the double knock out samples, this adapter contained a unique molecular identifier and an additional barcode) and reverse transcription. The resulting cDNA was circularized and PCR amplified, incorporating Illumina sequences. For RNA-seq on WT cells RNA was extracted from the lysate by proteinase K digestion followed by phenol acid extraction and fragmented by alkaline hydrolysis. 40-80 nt fragments were purified and libraries were further prepared similar to the RPF libraries. For sgLARP1 and sgLARP1/1B cells, RNA-seq libraries were prepared using the NEB Next Ultra II Directional RNA Library Prep kit along with the NEBNext rRNA Depletion kit. RPF libraries for LARP1/1B DKO cells were sequenced twice to improve coverage. These samples are identified with ""reseq"" in the sample name.'; [Cell type]'Source: ''cell line: HEK-293T; genotype/variation: wild-type; treatment: DMSO; ', 'cell line: HEK-293T; genotype/variation: wild-type; treatment: Torin 1; ', 'cell line: HEK-293T; genotype/variation: sgLARP1; treatment: DMSO; ', 'cell line: HEK-293T; genotype/variation: sgLARP1; treatment: Torin 1; ', 'cell line: HEK-293T; genotype/variation: sgLARP1/1B; treatment: DMSO; ', 'cell line: HEK-293T; genotype/variation: sgLARP1/1B; treatment: Torin 1; ', 'cell line: HEK-293T; genotype/variation: sgLARP1+sgLARP1B; treatment: DMSO for 2h; molecule subtype: RNA  (RPFs); ', 'cell line: HEK-293T; genotype/variation: sgLARP1+sgLARP1B; treatment: 250 nM Torin 1 for 2h; molecule subtype: RNA  (RPFs); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132703,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132703/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA548784,32094190," Lucas Philippe,  Antonia M G van den Elzen,  Maegan J Watson,  Carson C Thoreen","Terminal oligopyrimidine (TOP) motifs are sequences at the 5\' ends of mRNAs that link their translation to the mTOR Complex 1 (mTORC1) nutrient-sensing signaling pathway. They are commonly regarded as discrete elements that reside on approximately 100 mRNAs that mostly encode translation factors. However, the full spectrum of TOP sequences and their prevalence throughout the transcriptome remain unclear, primarily because of uncertainty over the mechanism that detects them. Here, we globally analyzed translation targets of La-related protein 1 (LARP1), an RNA-binding protein and mTORC1 effector that has been shown to repress TOP mRNA translation in a few specific cases. We establish that LARP1 is the primary translation regulator of mRNAs with classical TOP motifs genome-wide, and also that these motifs are extreme instances of a broader continuum of regulatory sequences. We identify the features of TOP sequences that determine their potency and quantify these as a metric that accurately predicts mTORC1/LARP1 regulation called a TOPscore. Analysis of TOPscores across the transcriptomes of 16 mammalian tissues defines a constitutive ""core"" set of TOP mRNAs, but also identifies tissue-specific TOP mRNAs produced via alternative transcription initiation sites. These results establish the central role of LARP1 in TOP mRNA regulation on a transcriptome scale and show how it connects mTORC1 to a tunable and dynamic program of gene expression that is tailored to specific biological contexts.",Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5\' TOP motifs.,10.1073/pnas.1912864117,2020 Mar 10,PMC7071917,Proceedings of the National Academy of Sciences of the United States of America
GSE68706,Genome-wide reprogramming of transcript architecture by temperature specifies the developmental states of the human pathogen Histoplasma [transcriptional profiling],Histoplasma capsulatum,16,SRP058149,2015-05-08,"[Overal design]Expression profiling by paired-end RNA sequencing was performed for two biological replicates for each of four strains of Histoplasma capsulatum (G217B, G186AR, H88, and H143) from cells grown in the yeast or hyphal phase (16 samples total).; [Treatment]'None'; [Growth]'G217B, G186AR, H88, and H143 yeast cells were inoculated from HMM agarose plates into HMM liquid medium for yeast-phase growth. Yeast cells were passaged at a 1:25 dilution three times and 2-day cultures of each strain were harvested for RNA collection after the third passage. For hyphal cells, G217B, G186AR, H88, and H143 hyphae were inoculated from Sabouraud dextrose agar plates grown at RT into HMM liquid medium. Hyphal cells were grown for 4  6 weeks with passaging 3 times (1:5 dilution) into fresh HMM medium at RT before reaching a sufficient density of cells for harvesting.'; [Extraction]'Hyphal and yeast cells were collected by centrifugation or filtration and total RNA was isolated using a guanidine thiocyanate lysis protocol as previously described (Hwang et al, Molecular Biology of the Cell 14:2314).\nPaired-end RNA-seq libraries were made from biological duplicate cultures of G217B, G186AR, H88, and H143 for both yeast and hyphae. DNA was depleted from 10  20 ?g of total RNA by 1 hour of DNaseI digestion at 37C (Ambion by Life Technologies, Carlsbad, CA). Poly(A)+ RNA was selected from DNA-depleted RNA on oligo- dT25 DynaBeads (Invitrogen by Life Technologies) using 2 rounds of selection per the manufacturers instructions. Approximately 50 ng of poly(A)+ RNA was used as input for generating sequencing libraries with the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre, Madison, WI) per the manufacturers instructions with the following modifications.  After 11 cycles of the ScriptSeq v2 PCR cDNA amplification step, cDNA libraries were resolved on an 8% TBE gel (Invitrogen by Life Technologies) and a 350  500 bp range of cDNA library was excised, eluted, and precipitated from the gel. Seven additional PCR cycles were resumed following the ScriptSeq v2 Kit protocol. cDNA libraries were purified with AMPure XP beads (Beckman Coulter, Brea, CA) to deplete primers. Libraries were multiplexed and subjected to 100 bp paired-end sequencing using the Illumina HiSeq2000 sequencer (Illumina, San Diego, CA).'; [Cell type]'Source: ''strain: G217B; growth phase: hyphae; ', 'strain: G217B; growth phase: yeast; ', 'strain: G186AR; growth phase: hyphae; ', 'strain: G186AR; growth phase: yeast; ', 'strain: H88; growth phase: hyphae; ', 'strain: H88; growth phase: yeast; ', 'strain: H143; growth phase: hyphae; ', 'strain: H143; growth phase: yeast; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68706,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68706/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA283426,26177267," Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil,  Sarah A Gilmore,  Mark Voorhies,  Dana Gebhart,  Anita Sil","Eukaryotic cells integrate layers of gene regulation to coordinate complex cellular processes; however, mechanisms of post-transcriptional gene regulation remain poorly studied. The human fungal pathogen Histoplasma capsulatum (Hc) responds to environmental or host temperature by initiating unique transcriptional programs to specify multicellular (hyphae) or unicellular (yeast) developmental states that function in infectivity or pathogenesis, respectively. Here we used recent advances in next-generation sequencing to uncover a novel re-programming of transcript length between Hc developmental cell types. We found that ~2% percent of Hc transcripts exhibit 5' leader sequences that differ markedly in length between morphogenetic states. Ribosome density and mRNA abundance measurements of differential leader transcripts revealed nuanced transcriptional and translational regulation. One such class of regulated longer leader transcripts exhibited tight transcriptional and translational repression. Further examination of these dually repressed genes revealed that some control Hc morphology and that their strict regulation is necessary for the pathogen to make appropriate developmental decisions in response to temperature.",Genome-Wide Reprogramming of Transcript Architecture by Temperature Specifies the Developmental States of the Human Pathogen Histoplasma.,10.1371/journal.pgen.1005395,2015 Jul,PMC4503680,PLoS genetics
GSE30783,Prenatal Arsenic Exposure Alters Gene Expression in the Adult Liver to a Proinflammatory State Contributing to Accelerated Atherosclerosis,Mus musculus,15,None,2011-07-19,"[Overal design]Samples from three frozen livers from each group (newborn exposed and unexposed, 10 week old exposed and unexposed), and from separate litters, were homogenized and total RNA purified using mirVANA RNA pufification kits (Ambion, Carlsbad, CA). RNA was quantitated and intergrity determined on a Nanochip using a Bioanalyzer (Agilent, Santa Clara, CA). Microarray analyses for miRNAs abundance in total liver RNAs was performed by Exiqon (Woburn, MA) using two-color design against mouse standard total RNA (Ambion, now part of Applied Biosystems) and Exiqon LNA 1500 microarrays. Microarray analyses for mRNA abundance was performed using 2 color design against mouse standard total RNA (Stratgene, LaJolla, CA) and 44k arrays produced at the NIA . The processed data on Exiqon LNA-1500 are attached as a Series supplementary file. The data are based on the same samples as described in Agilent data submitted here. The supplementary data includes only the murine miRNA data on the array because these are the only data supplied by Exiqon. The relationship between GEO's sample names here (Agilent data) and column heads of spreadsheets (Exiqon data) are described in the first sheet of supplemental file: Project_Summary_Report_Heather_Miller_01042009_MTE.xls; [Treatment]'Pregnant dams were provided drinking water containing 49 ppm arsenic (85 mg/L sodium arsenite) from gestational day 8 (GD) 8 to day of parturition. The dams were then provided arsenic-free tap water as were the pups. The pups from these litters are designated As/Tap. On day of birth, 3 pups, each from a separate litter, were sacrificed and the livers dissected and snap frozen. These are designated newborn As/Tap or PND1 As/Tap. Other pups were allowed to wean and then maintained on arsenic free tap water until sacrifice at age 10 weeks (10w As/Tap or PND70 As/Tap).Alternatively, pregnant dams were provided only arsenic-free tap water. On the day of birth, 3 pups were taken from separate litters and the livers dissected and snap frozen. These are designated newborn tap/tap or PND1 Tap/Tap. Other pups were maintained on arsenic-free tap water until weaning at PND21. Three mice from separate litters were continued on arsenic-free tap water until age 10 weeks when they were sacrificed and livers were dissected and snap frozen. These mice are designated 10w tap/tap or PND70 tap/tap. An additional 3 mice, each from separate litters, were provided  drinking water containing 49 ppm arsenic (85 mg/L sodium arsenite) from PND21 to age 10 weeks when were sacrificed and livers were dissected and snap frozen. These mice are designated 10w tap/as or PND70 tap/as.'; [Growth]'None'; [Extraction]'Total RNA was purified from samples of frozen livers using the miRVana kit from Ambion (now Life Technologies).', 'Total RNA was extracted from cultured cells using a Stratagene Absolutely RNA kit. DNase-treated total RNA samples from 11 cultured cell lines derived from embryo, embryo fibroblast, kidney, liver/hepatocyte, lung/alveolar macrophage, B-lymphocyte, T-lymphocyte (thymus), mammary gland, muscle myoblast, skin, and testis were pooled in equal parts'; [Cell type]'Source: ', 'Universale Mouse Reference''strain: C57/BL6J; age: 10 week; individual identifier: 251411710143; 10w, tap/tap #1 (C1); ', 'cell type: Universale Mouse Reference; ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710144; 10w, tap/tap #2 (404; ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710145; 10w, tap/tap #3 (406; ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710146; 10w, as/tap #1 (389); ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710147; 10w, as/tap #2 (433); ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710148; 10w, as/tap #3 (439); ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710151; 10w, tap/as #1 (394); ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710152; 10w, tap/as #2 (402); ', 'strain: C57/BL6J; age: 10 week; individual identifier: 251411710153; 10w, tap/as #3 (403); ', 'strain: C57/BL6J; age: newborn; individual identifier: 251411710154; newborn, as #1 (Mm2); ', 'strain: C57/BL6J; age: newborn; individual identifier: 251411710155; newborn, as #2 (Rm2); ', 'strain: C57/BL6J; age: newborn; individual identifier: 251411710156; newborn, as #3 (Rm4); ', 'strain: C57/BL6J; age: newborn; individual identifier: 251411710159; newborn, tap #1 (Km2; ', 'strain: C57/BL6J; age: newborn; individual identifier: 251411710160; newborn, tap #2 (441; ', 'strain: C57/BL6J; age: newborn; individual identifier: 251411710161; newborn, tap #3 (441; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30783,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE30783/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA144303,22719926," J Christopher States,  Amar V Singh,  Thomas B Knudsen,  Eric C Rouchka,  Ntube O Ngalame,  Gavin E Arteel,  Yulan Piao,  Minoru S H Ko","The mechanisms by which environmental toxicants alter developmental processes predisposing individuals to adult onset chronic disease are not well-understood. Transplacental arsenic exposure promotes atherogenesis in apolipoprotein E-knockout (ApoE(-/-)) mice. Because the liver plays a central role in atherosclerosis, diabetes and metabolic syndrome, we hypothesized that accelerated atherosclerosis may be linked to altered hepatic development. This hypothesis was tested in ApoE(-/-) mice exposed to 49 ppm arsenic in utero from gestational day (GD) 8 to term. GD18 hepatic arsenic was 1.2 microg/g in dams and 350 ng/g in fetuses. The hepatic transcriptome was evaluated by microarray analysis to assess mRNA and microRNA abundance in control and exposed pups at postnatal day (PND) 1 and PND70. Arsenic exposure altered postnatal developmental trajectory of mRNA and microRNA profiles. We identified an arsenic exposure related 51-gene signature at PND1 and PND70 with several hubs of interaction (Hspa8, IgM and Hnf4a). Gene ontology (GO) annotation analyses indicated that pathways for gluconeogenesis and glycolysis were suppressed in exposed pups at PND1, and pathways for protein export, ribosome, antigen processing and presentation, and complement and coagulation cascades were induced by PND70. Promoter analysis of differentially-expressed transcripts identified enriched transcription factor binding sites and clustering to common regulatory sites. SREBP1 binding sites were identified in about 16% of PND70 differentially-expressed genes. Western blot analysis confirmed changes in the liver at PND70 that included increases of heat shock protein 70 (Hspa8) and active SREBP1. Plasma AST and ALT levels were increased at PND70. These results suggest that transplacental arsenic exposure alters developmental programming in fetal liver, leading to an enduring stress and proinflammatory response postnatally that may contribute to early onset of atherosclerosis. Genes containing SREBP1 binding sites also suggest pathways for diabetes mellitus and rheumatoid arthritis, both diseases that contribute to increased cardiovascular disease in humans.",Prenatal arsenic exposure alters gene expression in the adult liver to a proinflammatory state contributing to accelerated atherosclerosis.,10.1371/journal.pone.0038713,2012,PMC3376138,PloS one
GSE112187,RPL12/uL11 phosphorylation regulates translation during mitosis,Homo sapiens; Mus musculus,36,None,2018-03-21,"[Overal design]Refer to individual Series; [Treatment]'The mouse B cells were cultured in three 15 cm plates per condition until 60-70 % confluent and incubated with 100 ng/mL nocodazole (Sigma-Aldrich) for 8 hr to synchronize the cells in mitosis. Cellular DNA content before and after the nocodazole treatment was measured by flow cytometry. Nocodazole was then released by washing the cells twice in pre-warmed PBS and cells were incubated in fresh medium for 10 min. Cells were harvested by centrifugation in the presence of cycloheximide (100 g/ml).', 'RPL12 wild-type, S38A or S38D mutant coding sequences were recombined using LR Clonase II (Gateway, Thermo Fischer Scientific) into pFRT/TO/FLAG/HA-DEST (Addgene ID: 26360). The resulting vectors were used to generate stable HEK293 Flp-In T-Rex cells lines overexpressing FLAG/HA-tagged wild-type RPL12, or S38A and S38D RPL12 mutated proteins. Briefly, HEK293 Flp-In T-Rex cells were transfected in a 12-well format by mixing 100 l of Opti-MEM with 1 g of total plasmid DNA (9:1 ratio of pOG44 to destination vector) and 2 l of Lipofectamine 2000 (Thermo Fischer Scientific). After a 5-minute incubation, the transfection mixture was added to the cells. Cells were re-seeded into 10-cm dishes after 48 hr and allowed to attach overnight. Hygromycin (100 g/ml, InvivoGen) was added the next day and the cells were selected for 2-3 weeks by the addition of fresh hygromycin-containing cell culture media every 2-3 days resulting in expansion of monoclonal colonies.'; [Growth]'Murine B cell lymphoma line, 19PP, was established from Rag2-/-?C-/- mouse reconstituted with C?1-Cre; Myc/P110*flSTOP mouse BM cells (Sander et al., 2012). 19PP cells were transfected with Flp-expressing plasmid to delete GFP and hCD2 reporter genes. Reporter negative subline, 19DN, was established by FACS sorting of reporter double-negative 19PP cells. 19DN cells were maintained in DMEM medium (Gibco) containing 10% heat inactivated FBS, glutamax, sodium pyruvate, HEPES, non-essential amino acids, penicillin streptomycin (all 1%) and 52 ?M ?-mercaptoethanol.', 'HEK293 cells (American Type Culture Collection) were cultured in Dulbeccos modified Eagles medium (DMEM) (life technologies) complemented with glutamax (life technologies) and 10% fetal bovine serum (FBS) (PAN-Biotech).'; [Extraction]'Cell pellets were flash-frozen in liquid nitrogen, transferred to ice and lysed in mammalian polysome buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml CHX), supplemented with 1% (v/v) Triton X-100 and 25 U/ml TurboDNase (Thermo Fischer Scientific). Afterwards, lysates were triturated ten times through a 26-gauge needle, cleared by centrifugation (20.000 xg, 5 min, 4 C), flesh frozen in liquid nitrogen and stored at -80 C. To obtain 3 mRNA-seq datasets for mRNA quantification, we isolated total RNA from mammalian polysome buffer lysates (120-l aliquots) using Trizol LS.\nNext, 1 g of total RNA was mixed with 1 l of 1:50 dilution of ERCC Spike-in Control Mix 1 (Thermo Fisher Scientific), TurboDNase-treated and input into QuantSeq 3 mRNA-Seq Library Prep Kit FWD (Lexogen, Inc.). Subsequent steps were performed according to manufacturers instruction. All cDNA libraries were multiplexed at 12 samples per lane and sequenced on a HiSeq 2500 instrument using 1x51+7 cycles.', 'Cell pellets were flash-frozen in liquid nitrogen, transferred to ice and lysed in mammalian polysome buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml CHX), supplemented with 1% (v/v) Triton X-100 and 25 U/ml TurboDNase (Thermo Fischer Scientific). Afterwards, lysates were triturated ten times through a 26-gauge needle, cleared by centrifugation (20.000 xg, 5 min, 4 C), flesh frozen in liquid nitrogen and stored at -80 C. To obtain ribosome-protected fragments, lysates (120-l aliquots) were treated with 3 l of RNase I (Ambion, AM2294, 100 U/l) for 45 min at room temperature with slow agitation. RNase activity was inhibited by the addition of 4 l of SUPERaseIn (Thermo Fischer Scientific, AM2696, 20 U/l). Meanwhile, MicroSpin S-400 HR columns (GE Healthcare, 27-5140-01) were equilibrated with 3 ml of mammalian polysome buffer without DTT and CHX by gravity flow and emptied by centrifugation at 600 xg for 4 min. We then immediately loaded 100 ?l of the digested lysate on the column and eluted the column by centrifugation at 600 xg for 2 min. We extracted RNA from the flow-through (approximately 125 ?l) using Trizol LS (Life Technologies, 10296-010) in combination with the RNA Clean & Concentrator kit (Zymo Research).\nWe then depleted ribosomal RNA fragments using the RiboZero Kit (Illumina, MRZH11124) and separated the remaining RNA on a 17% denaturing urea-PAGE gel (National Diagnostics, EC-829). The size range from 27 nt to 30 nt, defined by loading with 20 pmol each of Marker-27 nt and Marker-30 nt, was cut out, and the RNA fragments were subjected to small RNA cloning and library generation (Hafner et al.,2012) using 3' adaptor 4N-RA3, 5' adaptor OR5-4N, RT primer RTP and PCR primers RP1 (forward primer) and RPI1-12 (reverse primer, containing barcodes, for sequences see Illumina Truseq small RNA oligonucleotides). All cDNA libraries were multiplexed at 12 samples per lane and sequenced on a HiSeq 2500 instrument using 1x51+7 cycles.', ""Cycloheximide (50 g/ml) was added to each pooled 80S fraction (1 ml) obtained by sucrose gradient fractionation. Aliquots of these input fractions were used for Western blot analysis (20 l) and total RNA extraction with Trizol (50 l). The rest of the sample was subjected to anti-FLAG immunoprecipitation. To prepare anti-FLAG conjugated magnetic beads, 15 l of Dynabeads Protein G (Thermo Fisher Scientific) were used per sample, washed twice in 0.02 % of Tween 20/PBS (PBST) and resuspended in 30 l of PBST containing 0.25 g/l anti-FLAG M2 monoclonal antibody (F3165, Sigma Aldrich). After a 1 hr incubation at room temperature with rotation, the beads were washed twice in PBST, resuspended into the fractionated sample, followed by incubation at 4 C for 90 min. Next, the beads were concentrated and the supernatants removed, followed by 4 washing steps in 1 ml of washing buffer (0.05% (v/v) IGEPAL-CA630, 50 mM Tris pH 7.5, 150 mM KCl, 0.5 mM DTT, 50 g/ml cycloheximide, 1x complete EDTA-free protease inhibitor cocktail (Roche)). Before concentrating the beads during the fourth washing step, 100 l of suspension was removed for Western blot analysis, while the rest of the sample was used for RNA extraction. \xa0After the concentration of beads and removal of the supernatant, the beads were either resuspended in 1 bead volume of 2x Laemmli sample buffer (Western analysis) or 1 ml of Trizol (RNA extraction). After standard Trizol extraction consisting of chloroform addition and centrifugation, the clean-up of the aqueous phase was carried out using miRNAeasy kit (Qiagen) according to manufacturers instruction.\nExtracted RNA (either 1 g of input samples or all of the immunoprecipitated material) was treated with 0.4 U Turbo DNase (Thermo Fisher) for 30 min at 37 C, phenol-chlorotorm extracted, ethanol-precipitated and resuspended in water. For input samples, equal amounts of total RNA (1 g) and 2 l of 1:100 dilution of ERCC Spike-in Control Mix 1 (Thermo Fisher) were mixed and adjusted to 50 l final volume with water. All immunoprecipitated material per sample was mixed with 2 l of 1:100 dilution of ERCC Spike-in Control Mix 1 and adjusted to 50 l final volume with water. These 50-l samples were then input into the Truseq stranded mRNA kit (Illumina) using 2 rounds of oligo-dT enrichment. Manufacturer's instructions were followed in all subsequent steps. cDNA libraries from different samples were multiplexed using Illumina RPI oligonucleotides and sequenced by multiplexing 6 samples per lane on a HiSeq 2000 instrument using 1x101+7 cycles.""; [Cell type]'cell line; lymphoma', 'embryonic kidney cell line; epithelial''cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; ', 'cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; genotype/variation: WT; cell cycle phase: asynchronous; ', 'cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; genotype/variation: RPL12 S38A; cell cycle phase: asynchronous; ', 'cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; genotype/variation: RPL12 S38D; cell cycle phase: asynchronous; ', 'cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; genotype/variation: WT; cell cycle phase: mitotic cells nocodazole; ', 'cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; genotype/variation: RPL12 S38A; cell cycle phase: mitotic cells nocodazole; ', 'cell line: 19PP; cell type: cell line; lymphoma; culture medium: DMEM; genotype/variation: RPL12 S38D; cell cycle phase: mitotic cells nocodazole; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: WT; antibody: none; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38A1; antibody: none; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38D1; antibody: none; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: WT; antibody: Mouse monoclonal anti-FLAG (M2) [Sigma-Aldrich, Cat# F3165 RRID:AB_259529]; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38A1; antibody: Mouse monoclonal anti-FLAG (M2) [Sigma-Aldrich, Cat# F3165 RRID:AB_259529]; ', 'cell line: HEK293; cell type: embryonic kidney cell line; epithelial; culture medium: DMEM; genotype/variation: RPL12_S38D1; antibody: Mouse monoclonal anti-FLAG (M2) [Sigma-Aldrich, Cat# F3165 RRID:AB_259529]; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112187,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE112nnn/GSE112187/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA445179,30220558," Koshi Imami,  Miha Milek,  Boris Bogdanow,  Tomoharu Yasuda,  Nicolai Kastelic,  Henrik Zauber,  Yasushi Ishihama,  Markus Landthaler,  Matthias Selbach","Emerging evidence indicates that heterogeneity in ribosome composition can give rise to specialized functions. Until now, research mainly focused on differences in core ribosomal proteins and associated factors. The effect of posttranslational modifications has not been studied systematically. Analyzing ribosome heterogeneity is challenging because individual proteins can be part of different subcomplexes (40S, 60S, 80S, and polysomes). Here we develop polysome proteome profiling to obtain unbiased proteomic maps across ribosomal subcomplexes. Our method combines extensive fractionation by sucrose gradient centrifugation with quantitative mass spectrometry. The high resolution of the profiles allows us to assign proteins to specific subcomplexes. Phosphoproteomics on the fractions reveals that phosphorylation of serine 38 in RPL12/uL11, a known mitotic CDK1 substrate, is strongly depleted in polysomes. Follow-up experiments confirm that RPL12/uL11 phosphorylation regulates the translation of specific subsets of mRNAs during mitosis. Together, our results show that posttranslational modification of ribosomal proteins can regulate translation.",Phosphorylation of the Ribosomal Protein RPL12/uL11 Affects Translation during Mitosis.,10.1016/j.molcel.2018.08.019,2018 Oct 4,,Molecular cell
GSE145723,Genome-wide survey of ribosome collision,Homo sapiens,10,None,2020-02-21,"[Overal design]Refer to individual Series; [Treatment]'None'; [Growth]'None'; [Extraction]'Rnase I footprinting, ribosome pelleting, RNA extraction\nRNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification for ribosome profiling', 'RNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification for ribosome profiling', 'RNase I footprinting, ribosome pelleting, RNA extraction.\nRNA extraction, preadenylated linker ligation, rRNA depletion, reverse transcription, cDNA circularization, PCR amplification for ribosome profiling.'; [Cell type]'Source: ''genotype: WT; cell line: HEK293; ', 'treatment: anisomycin; genetic background: WT; cell line: HEK293; extracted molecule: total RNA; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; ', 'cell line: HEK293; sirna: control; treatment: Cycloheximide; ', 'cell line: HEK293; sirna: eif5A; treatment: Cycloheximide; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145723,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE145nnn/GSE145723/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA607993,32375038," Peixun Han,  Yuichi Shichino,  Tilman Schneider-Poetsch,  Mari Mito,  Satoshi Hashimoto,  Tsuyoshi Udagawa,  Kenji Kohno,  Minoru Yoshida,  Yuichiro Mishima,  Toshifumi Inada,  Shintaro Iwasaki","Ribosome movement is not always smooth and is rather often impeded. For ribosome pauses, fundamental issues remain to be addressed, including where ribosomes pause on mRNAs, what kind of RNA/amino acid sequence causes this pause, and the physiological significance of this attenuation of protein synthesis. Here, we survey the positions of ribosome collisions caused by ribosome pauses in humans and zebrafish using modified ribosome profiling. Collided ribosomes, i.e., disomes, emerge at various sites: Pro-Pro/Gly/Asp motifs; Arg-X-Lys motifs; stop codons; and 3' untranslated regions. The electrostatic interaction between the charged nascent chain and the ribosome exit tunnel determines the eIF5A-mediated disome rescue at the Pro-Pro sites. In particular, XBP1u, a precursor of endoplasmic reticulum (ER)-stress-responsive transcription factor, shows striking queues of collided ribosomes and thus acts as a degradation substrate by ribosome-associated quality control. Our results provide insight into the causes and consequences of ribosome pause by dissecting collided ribosomes.",Genome-wide Survey of Ribosome Collision.,10.1016/j.celrep.2020.107610,2020 May 5,PMC7746506,Cell reports
GSE56148,"A novel IRES identified in DMD results in a functional N-truncated dystrophin, providing a potential route to therapy for patients with 5 mutations.",Homo sapiens,4,SRP040550,2014-03-24,"[Overal design]Skeletal muscle ribosome-protected fragment and RNA-Seq profiles from a patient with an NM_004006:c.40_41delGA dystrophin mutation and a normal control were generated by deep sequencing using the Illumina HiSeq 2000.; [Treatment]'None'; [Growth]'Tissue homogenates were prepared from 40 frozen ten-micron sections of muscle biopsy obtained from a patient with an NM_004006:c.40_41delGA mutation and a normal control.'; [Extraction]'Sections were lysed by 20 passages through a 26 gauge needle after addition of 500 ?l of ice-cold 20 mM Tris*Cl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1% Triton X-100 and 100 ?g / ml cycloheximide (Sigma).  For RNA-Seq, 100 ?l of lysate was added to 300 ?l of TriZOL LS reagent (Life Technologies) and total RNA was extracted according to the manufacturers specifications. For RPF-Seq, 6 ?l of RNase I (100 U/ ?l, Ambion) and 3 ?l of Turbo DNase (2 U/ ?l, Ambion) was added to 250 ?l of lysate and incubated at room temperature with gentle agitation.  After 90 min., 750 ?l of TriZOL LS reagent was added and ribonuclease-resistant RNA fragments were isolated by extraction.  RNA fragments were electrophoresed on a denaturing 15% polyacrylamide TBE-urea gel (Life Technologies, EC68852BOX). The gel region containing 26-38 nucleotide size RNA fragments was excised and RNA isolated by passive elution. Gel-purified RNA fragments were treated with 5 units of Antarctic Phosphatase (5 U/ ?l NEB) in the presence of 40 units of RNase Inhibitor (40 U/ ?l, Ambion) for 30 min. at 37oC, followed by 5 min. at 65oC to deactivate the enzyme.  Fragments were then treated with 20 units of T4 polynucleotide kinase (10 U/ ?l NEB) for 60 min. at 37oC and purified using RNeasy MinElute columns (Qiagen) according to the manufacturers recommendations for small RNA.\nRPF-Seq libraries were built using the TruSeq Small RNA Sample Preparation Kit (Illumina) according to the manufacturers specifications, using Superscript II (Invitrogen).  After PCR to enrich for ligated fragments, the final gel purification was eliminated and instead the amplified library samples were cleaned using 50 ?l of AMPure XP magnetic beads (Agencourt) according to the manufacturers specifications.   For RNA-Seq libraries, 4 ?g of TRIzol-extracted total RNA from each sample was depleted for rRNA using Ribo-Zero rRNA Removal Kit Human/Mouse/Rat (Epicentre).  The rRNA-depleted total RNA was then processed using the TruSeq RNA Sample Preparation v2 Kit (Illumina) according to the manufacturers specifications using Superscript II (Invitrogen).'; [Cell type]'Source: ''tissue: skeletal muscle; genotype/variation: c.40_41delGA dystrophin mutation; ', 'tissue: skeletal muscle; genotype/variation: normal control; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56148,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE56nnn/GSE56148/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA242628,25108525," Nicolas Wein,  Adeline Vulin,  Maria S Falzarano,  Christina Al-Khalili Szigyarto,  Baijayanta Maiti,  Andrew Findlay,  Kristin N Heller,  Mathias Uhlen,  Baskar Bakthavachalu,  Sonia Messina,  Giuseppe Vita,  Chiara Passarelli,  Simona Brioschi,  Matteo Bovolenta,  Marcella Neri,  Francesca Gualandi,  Steve D Wilton,  Louise R Rodino-Klapac,  Lin Yang,  Diane M Dunn,  Daniel R Schoenberg,  Robert B Weiss,  Michael T Howard,  Alessandra Ferlini,  Kevin M Flanigan","Most mutations that truncate the reading frame of the DMD gene cause loss of dystrophin expression and lead to Duchenne muscular dystrophy. However, amelioration of disease severity has been shown to result from alternative translation initiation beginning in DMD exon 6 that leads to expression of a highly functional N-truncated dystrophin. Here we demonstrate that this isoform results from usage of an internal ribosome entry site (IRES) within exon 5 that is glucocorticoid inducible. We confirmed IRES activity by both peptide sequencing and ribosome profiling in muscle from individuals with minimal symptoms despite the presence of truncating mutations. We generated a truncated reading frame upstream of the IRES by exon skipping, which led to synthesis of a functional N-truncated isoform in both human subject-derived cell lines and in a new DMD mouse model, where expression of the truncated isoform protected muscle from contraction-induced injury and corrected muscle force to the same level as that observed in control mice. These results support a potential therapeutic approach for patients with mutations within the 5' exons of DMD.",Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice.,10.1038/nm.3628,2014 Sep,PMC4165597,Nature medicine
GSE49339,m6A-dependent regulation of messenger RNA stability,Homo sapiens,29,SRP028325,2013-07-30,"[Overal design]PAR-CLIP and RIP was used to identify YTHDF2 binding sites followed by ribosome profling and RNA seq to assess the consequences of YTHDF2 siRNA knock-down; [Treatment]'None'; [Growth]'None'; [Extraction]'fed with 4SU, UV crosslink, partial digested by RNase T1, anti-flag-beads IP, recovered by trizol\nTruseq small RNA sample prepration kit (illumina)', 'anti-flag-beads IP, recovered by trizol\nTruseq stranded mRNA sample prepration kit (illumina)', 'Extract by trizol, then poly-dT beads pull-down\nTruseq stranded mRNA sample prepration kit (illumina)', 'Extract by trizol, then rRNA removal\nTruseq stranded mRNA sample prepration kit (illumina)', 'Isolate from surcrose gradient, recovered by trizol\nTruseq small RNA sample prepration kit (illumina)', 'Extract by trizol, poly-dT beads pull-down\nTruseq small RNA sample prepration kit (illumina)', 'Extracy by trizol, then rRNA removal\nTruseq small RNA sample prepration kit (illumina)', 'Extract total RNA by Rneasy kit (QIAGEN), Dnase I treated, then add ERCC RNA spike-in control\nTruseq small RNA sample prepration kit (illumina)', 'Extract total RNA by Rneasy kit (QIAGEN), Dnase I treated, then add ERCC RNA spike-in control\nTruseq RNA sample prepration kit (illumina)', 'Extract total RNA by Rneasy kit (QIAGEN), Dnase I treated, then add ERCC RNA spike-in control\nTruseq stranded mRNA sample prepration kit (illumina)'; [Cell type]'Source: ''cell line: HeLa; treatment: over-express N-terminal flag-tagged YTHDF2 for 24h (0.75ug plasmid/mL); ', 'cell line: HeLa; treatment: over-express N-terminal flag-tagged YTHDF2 for 24h(0.75ug plasmid/mL); ', 'cell line: HeLa; treatment: 40nM siRNA knock-down for 48h; ', 'cell line: HeLa; treatment: 40nM siRNA knock-down for 48h, then add actinomycin for 0h; ', 'cell line: HeLa; treatment: 40nM siRNA knock-down for 48h, then add actinomycin for 3h; ', 'cell line: HeLa; treatment: 40nM siRNA knock-down for 48h, then add actinomycin for 6h; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49339,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE49nnn/GSE49339/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA213675,24284625," Xiao Wang,  Zhike Lu,  Adrian Gomez,  Gary C Hon,  Yanan Yue,  Dali Han,  Ye Fu,  Marc Parisien,  Qing Dai,  Guifang Jia,  Bing Ren,  Tao Pan,  Chuan He","N(6)-methyladenosine (m(6)A) is the most prevalent internal (non-cap) modification present in the messenger RNA of all higher eukaryotes. Although essential to cell viability and development, the exact role of m(6)A modification remains to be determined. The recent discovery of two m(6)A demethylases in mammalian cells highlighted the importance of m(6)A in basic biological functions and disease. Here we show that m(6)A is selectively recognized by the human YTH domain family 2 (YTHDF2) 'reader' protein to regulate mRNA degradation. We identified over 3,000 cellular RNA targets of YTHDF2, most of which are mRNAs, but which also include non-coding RNAs, with a conserved core motif of G(m(6)A)C. We further establish the role of YTHDF2 in RNA metabolism, showing that binding of YTHDF2 results in the localization of bound mRNA from the translatable pool to mRNA decay sites, such as processing bodies. The carboxy-terminal domain of YTHDF2 selectively binds to m(6)A-containing mRNA, whereas the amino-terminal domain is responsible for the localization of the YTHDF2-mRNA complex to cellular RNA decay sites. Our results indicate that the dynamic m(6)A modification is recognized by selectively binding proteins to affect the translation status and lifetime of mRNA.",N6-methyladenosine-dependent regulation of messenger RNA stability.,10.1038/nature12730,2014 Jan 2,PMC3877715,Nature
GSE151460,"bacTRAP profiling of seven different types of neurons , vulnerable and resistant to Alzheimer's disease (AD) across the lifetime of the mouse",Mus musculus,122,SRP265281,2020-05-29,"[Overal design]We constructed bacTRAP mice overexpressing eGFP-L10a in a cell-type specific manner. Cell-type specific expression was achieved using bacterial artificial chromosomes (BAC) that contain the regulatory regions of cell-type specific genes. For ECII neurons, we used four different lines: two Rasgrp2-bacTRAP lines (using BACs RP23-199D5 and RP24-344N1), two different founder lines for Sh3bgrl2 (using BAC RP23-307B16); for CA1 neurons, two different lines: one SSTR4-bacTRAP (BAC RP23-126C5), and one Cck-bacTRAP line generated previously by the Heintz lab; for CA2 neurons: one Cacng5-bacTRAP line (BAC RP23- 329L1); for CA3 neurons: one Gprin3-bacTRAP line generated previously by the Heintz lab; for dentate gyrus granule neurons: one SSTR4-bacTRAP line (using BAC RP23-126C5, another founder from the one used for CA1, with ectopic expression in DG granule neurons); for V1: one Calca-bacTRAP line (BAC RP23-181A2); for S1: one Cartpt-bacTRAP line (BAC RP24-68J22). We used these mice to immunoprecipitate polysomes from these neurons at 4-5, 12 and 24 months of age, and profiled the isolated mRNA using RNAseq. Additionally, we profiled APP/PS1 mice crossed to ECII-bacTRAP mice (one of the Sh3bgrl2-bacTRAP lines) at 6 months of age to study the effects of Amyloid accumulation on ECII gene expression. In the end we had 3 to 12 replicates for each neuron type at each age. Each replicate consisted in the pooling of 2 different mice. Male mice were used for the profiling in wild-type mice. For the APP/PS1 profiling we used male and female mice.; [Treatment]'no treatment'; [Growth]'None'; [Extraction]'see bacTRAP protocol in Roussarie et al., Neuron, 2020\n5 ng of immunoprecipitated RNA was reverse transcribed and amplified using the Ovation RNAseq v2 kit. cDNA were then ultrasonicated and used to generate sequencing library using the Truseq RNA sample prep kit'; [Cell type]'ECII', 'CA1', 'DG', 'CA3', 'CA2', 'S1', 'V1''cell type: ECII; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA1; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: DG; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA3; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA2; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: S1; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: ECII; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA2; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA1; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA3; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: DG; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: V1; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: S1; mouse age: 12 month; Sex: M; appps1 positive/negative: neg; ', 'cell type: ECII; mouse age: 24 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA1; mouse age: 24 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: DG; mouse age: 24 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: CA3; mouse age: 24 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: V1; mouse age: 24 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: S1; mouse age: 24 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: V1; mouse age: 4-5 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: ECII; mouse age: 6 months; Sex: F; appps1 positive/negative: pos; ', 'cell type: ECII; mouse age: 6 months; Sex: M; appps1 positive/negative: pos; ', 'cell type: ECII; mouse age: 6 months; Sex: M; appps1 positive/negative: neg; ', 'cell type: ECII; mouse age: 6 months; Sex: F; appps1 positive/negative: neg; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151460,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE151nnn/GSE151460/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA635898,32603655," Jean-Pierre Roussarie,  Vicky Yao,  Patricia Rodriguez-Rodriguez,  Rose Oughtred,  Jennifer Rust,  Zakary Plautz,  Shirin Kasturia,  Christian Albornoz,  Wei Wang,  Eric F Schmidt,  Ruth Dannenfelser,  Alicja Tadych,  Lars Brichta,  Alona Barnea-Cramer,  Nathaniel Heintz,  Patrick R Hof,  Myriam Heiman,  Kara Dolinski,  Marc Flajolet,  Olga G Troyanskaya,  Paul Greengard","A major obstacle to treating Alzheimer's disease (AD) is our lack of understanding of the molecular mechanisms underlying selective neuronal vulnerability, a key characteristic of the disease. Here, we present a framework integrating high-quality neuron-type-specific molecular profiles across the lifetime of the healthy mouse, which we generated using bacTRAP, with postmortem human functional genomics and quantitative genetics data. We demonstrate human-mouse conservation of cellular taxonomy at the molecular level for neurons vulnerable and resistant in AD, identify specific genes and pathways associated with AD neuropathology, and pinpoint a specific functional gene module underlying selective vulnerability, enriched in processes associated with axonal remodeling, and affected by amyloid accumulation and aging. We have made all cell-type-specific profiles and functional networks available at http://alz.princeton.edu. Overall, our study provides a molecular framework for understanding the complex interplay between Abeta, aging, and neurodegeneration within the most vulnerable neurons in AD.",Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis.,10.1016/j.neuron.2020.06.010,2020 Sep 9,PMC7580783,Neuron
GSE111222,A Multi-Parameter Analysis of Cellular Coordination of Major Transcriptome Regulation Mechanisms,Homo sapiens,7,SRP133625,2018-02-27,"[Overal design]Simultaneous measurement of transcription rate with GRO-seq, mRNA abundance with RNA-seq and mRNA translation activity with polysome profiling; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'Source: ''cell line: HCT116; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111222,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111222/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA436186,29636505," Wen Jiang,  Zhanyong Guo,  Nuno Lages,  W Jim Zheng,  Denis Feliers,  Fangyuan Zhang,  Degeng Wang","To understand cellular coordination of multiple transcriptome regulation mechanisms, we simultaneously measured transcription rate (TR), mRNA abundance (RA) and translation activity (TA). This revealed multiple insights. First, the three parameters displayed systematic statistical differences. Sequentially more genes exhibited extreme (low or high) expression values from TR to RA, and then to TA; that is, cellular coordination of multiple transcriptome regulatory mechanisms leads to sequentially enhanced gene expression selectivity as the genetic information flow from the genome to the proteome. Second, contribution of the stabilization-by-translation regulatory mechanism to the cellular coordination process was assessed. The data enabled an estimation of mRNA stability, revealing a moderate but significant positive correlation between mRNA stability and translation activity. Third, the proportion of mRNA occupied by un-translated regions (UTR) exhibited a negative relationship with the level of this correlation, and was thus a major determinant of the mode of regulation of the mRNA. High-UTR-proportion mRNAs tend to defy the stabilization-by-translation regulatory mechanism, staying out of the polysome but remaining stable; mRNAs with little UTRs largely followed this regulation. In summary, we quantitatively delineated the relationship among multiple transcriptome regulation parameters, i.e., cellular coordination of corresponding regulatory mechanisms.",A Multi-Parameter Analysis of Cellular Coordination of Major Transcriptome Regulation Mechanisms.,10.1038/s41598-018-24039-1,2018 Apr 10,PMC5893539,Scientific reports
GSE134888,Transcriptome wide analysis of translation efficiency in MCF7 cells using polysome profiling with and without eIF4A inhibition by hippuristanol treatment,Homo sapiens,18,SRP216411,2019-07-25,"[Overal design]Polysomal, sub-polysomal and total RNA samples were sequenced from both control and hippuristanol treated cells in triplicate; [Treatment]'Cells were treated for 1h with 150nM hippuristanol or an equal volume of DMSO (0.07%) by replenishment of the growth media. Following 1h incubation, cells were treated for 5 mins with 100  g/ml cycloheximide at 37C before being washed with ice cold PBS containing 100 g/ml cycloheximide.'; [Growth]'MCF7 cells grown in DMEM, high glucose, GlutaMAX Supplement, pyruvate (ThermoFisher 31966-021), supplemented with 10% FCS'; [Extraction]""Cells were collected by gentle scraping and then lysed in 500 l lysis buffer (15mM Tris-HCl pH 7.5, 300mM NaCl, 15mM MgCl2, 2mM DTT and 100 g/ml cycloheximide, 1% Triton X, 1000U/ml SuperaseIn (AM2694)) for 1 min on ice. Lysate was centrifuged at 12,000g for 1 min at 4C and the supernatant collected. 400 l was loaded onto a 10-50% sucrose density gradient (15mM Tris-HCl pH 7.5, 300mM NaCl, 15mM MgCl2, 2mM DTT and 100 g/ml cycloheximide) and centrifuged in a pre-cooled ultra-centrifuge with the SW40 Ti rotor at 38,000 rpm for 2h at 4C. For total RNA samples, 50 l lysate was added to 1ml TRIzol (ThermoFisher 15596026) and RNA was extracted as per manufacturer's instructions followed by isopropanol precipitation. Gradients were fractionated and 11 x 1ml fractions were collected and the RNA precipitated overnight at -20C following the addition of 3ml guanidine HCl (7.7M) and 4ml 100% ethanol. Precipitated RNA was dissolved in 350 l TE buffer and ethanol precipitated with 500mM ammonium acetate and 1 l GlycoBlue. RNA was then dissolved in 30 l Tris-HCl pH 7.5. Equal volumes of RNA from fractions 1-5 and 6-11 were each pooled to form the sub-polysomal and polysomal RNA respectively.\nIllumina TrueSeq Stranded mRNA library preparation""; [Cell type]'Source: ''strain: MCF7; molecule type: polysomal; treatment: control; ', 'strain: MCF7; molecule type: polysomal; treatment: 150nM hippuristanol; ', 'strain: MCF7; molecule type: sub-polysomal; treatment: control; ', 'strain: MCF7; molecule type: sub-polysomal; treatment: 150nM hippuristanol; ', 'strain: MCF7; molecule type: total RNA; treatment: control; ', 'strain: MCF7; molecule type: total RNA; treatment: 150nM hippuristanol; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134888,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE134nnn/GSE134888/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA556699,31888698," Joseph A Waldron,  David C Tack,  Laura E Ritchey,  Sarah L Gillen,  Ania Wilczynska,  Ernest Turro,  Philip C Bevilacqua,  Sarah M Assmann,  Martin Bushell,  John Le Quesne","BACKGROUND: The RNA helicase eIF4A1 is a key component of the translation initiation machinery and is required for the translation of many pro-oncogenic mRNAs. There is increasing interest in targeting eIF4A1 therapeutically in cancer, thus understanding how this protein leads to the selective re-programming of the translational landscape is critical. While it is known that eIF4A1-dependent mRNAs frequently have long GC-rich 5'UTRs, the details of how 5'UTR structure is resculptured by eIF4A1 to enhance the translation of specific mRNAs are unknown. RESULTS: Using Structure-seq2 and polysome profiling, we assess global mRNA structure and translational efficiency in MCF7 cells, with and without eIF4A inhibition with hippuristanol. We find that eIF4A inhibition does not lead to global increases in 5'UTR structure, but rather it leads to 5'UTR remodeling, with localized gains and losses of structure. The degree of these localized structural changes is associated with 5'UTR length, meaning that eIF4A-dependent mRNAs have greater localized gains of structure due to their increased 5'UTR length. However, it is not solely increased localized structure that causes eIF4A-dependency but the position of the structured regions, as these structured elements are located predominantly at the 3' end of the 5'UTR. CONCLUSIONS: By measuring changes in RNA structure following eIF4A inhibition, we show that eIF4A remodels local 5'UTR structures. The location of these structural elements ultimately determines the dependency on eIF4A, with increased structure just upstream of the CDS being the major limiting factor in translation, which is overcome by eIF4A activity.",mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity.,10.1186/s13059-019-1901-2,2019 Dec 30,PMC6936103,Genome biology
GSE106483,Genome organization of dengue and Zika viruses,Dengue virus 2; Dengue virus 4; Dengue virus 1; Zika virus; Homo sapiens; Dengue virus 3,87,SRP123568,2017-11-03,"[Overal design]Local RNA structure probing and long-range RNA interactome mapping in 4 dengue serotypes and 4 Zika strains; [Treatment]'Fresh virus particles are treated with NAI for secondary structure mapping, and with biotinylated psoralen for interactome mapping, at 37C for 10 min. Virions treated with biotinylated psoralen were then crosslinked using UV.'; [Growth]'Dengue 1-4 are amplified from african green monkey kidney (Vero) cells.  Zika strains are amplified by mosquito C6/36 cells. Huh7 cells were grown in DMEM, supplemented with 10% FBS and 1% Pen-Strep.'; [Extraction]'NAI or biotinylated treated RNA was extracted from virus particles using Trizol extraction.  RNA from Dengue1 infected Huh7 cells were extracted using Trizol.\nLocal secondary structure mapping was performed using SHAPE-map strategy, and long-range interactome mapping was performed using SPLASH.  Ribsome profiling was performed using the Artseq ribosome profiling kit (Epicenter).'; [Cell type]'Source: ', 'Huh7 cells''assembly: EU081230.1; tissue: Virus particle; ', 'assembly: EU081177.1; tissue: Virus particle; ', 'assembly: EU081190.1; tissue: Virus particle; ', 'assembly: GQ398256.1; tissue: Virus particle; ', 'assembly: AY632535.1; strain: MR 766; tissue: Virus particle; ', 'assembly: KU365780.1; strain: BeH815744; tissue: Virus particle; ', 'assembly: KJ776791.2; strain: H/PF/2013; tissue: Virus particle; ', 'assembly: KY241702.1; strain: ZIKV-SG-032; tissue: Virus particle; ', 'assembly: AY632535.1; strain: MR766; tissue: Virus particle; ', 'assembly: EU081230.1; cell type: Huh7 cells; agent: Dengue 1; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106483,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE106nnn/GSE106483/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA417011,30926818," Roland G Huber,  Xin Ni Lim,  Wy Ching Ng,  Adelene Y L Sim,  Hui Xian Poh,  Yang Shen,  Su Ying Lim,  Karin B Sundstrom,  Xuyang Sun,  Jong Ghut Aw,  Horng Khit Too,  Peng Hee Boey,  Andreas Wilm,  Tanu Chawla,  Milly M Choy,  Lu Jiang,  Paola Florez de Sessions,  Xian Jun Loh,  Sylvie Alonso,  Martin Hibberd,  Niranjan Nagarajan,  Eng Eong Ooi,  Peter J Bond,  October M Sessions,  Yue Wan","Dengue (DENV) and Zika (ZIKV) viruses are clinically important members of the Flaviviridae family with an 11 kb positive strand RNA genome that folds to enable virus function. Here, we perform structure and interaction mapping on four DENV and ZIKV strains inside virions and in infected cells. Comparative analysis of SHAPE reactivities across serotypes nominates potentially functional regions that are highly structured, conserved, and contain low synonymous mutation rates. Interaction mapping by SPLASH identifies many pair-wise interactions, 40% of which form alternative structures, suggesting extensive structural heterogeneity. Analysis of shared interactions between serotypes reveals a conserved macro-organization whereby interactions can be preserved at physical locations beyond sequence identities. We further observe that longer-range interactions are preferentially disrupted inside cells, and show the importance of new interactions in virus fitness. These findings deepen our understanding of Flavivirus genome organization and serve as a resource for designing therapeutics in targeting RNA viruses.",Structure mapping of dengue and Zika viruses reveals functional long-range interactions.,10.1038/s41467-019-09391-8,2019 Mar 29,PMC6441010,Nature communications
GSE138642,Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides [Dataset 5],Homo sapiens,6,SRP224956,2019-10-09,"[Overal design]2 ribosome profiling and 4 RNA-seq samples are included from Calu-6 cells; [Treatment]'Aminoglycosides were added to cells, and treated for 24 hours'; [Growth]'Cells were grown in DMEM with 10% FBS to ~75% confluency before harvest'; [Extraction]'Cells were lysed on ice in the presence of cycloheximide. Lysates were clarified by centrifugation. For ribosome profiling, monosomes were generated by RNaseI digest followed by ultracentrifugation. For RNAseq, total RNA was extracted using Trizol, and sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Library Prep Gold (20020598) kit.\nFor ribosome profiling, fragments ranging from 26-35 nt were gel purified. Upon dephosphorylation of sample RNA, linker was ligated and this product and and rRNA was depleted using Ribo-Zero Gold from Illumina. This was followed by reverse transcription and gel purification. Libraries were then circularized, PCR-amplified, and gel-purified cDNA was submitted for sequencing.'; [Cell type]'Source: ''cell line: Calu-6 cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: Calu-6 cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: CTGTAGGCACCATCAAT; ', 'cell line: Calu-6 cells; treatment: Untreated; concentration: 0 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; ', 'cell line: Calu-6 cells; treatment: G418; concentration: 500 ug/mL; duration: 24 hours; adapter: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC, AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138642,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138642/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576653,31971508," Jamie R Wangen,  Rachel Green",eng,Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.,10.7554/eLife.52611,2020 Jan 23,PMC7089771,eLife
GSE139910,Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer,Homo sapiens,18,SRP228560,2019-11-04,"[Overal design]Ribosome profiling was performed in PATU-8902 cells grown with or without serine and glycine for 24hours.; [Treatment]'Cells were washed once with PBS  and media was changed to DMEM (2.78mM glucose, 4mM glutamine, 1mM pyruvate) + 10% dialyzed FBS with or without 400uM serine and 400uM glycine for 24 hours.'; [Growth]'PATU-8902 cells were passaged in DMEM (no pyruvate) + 10% FBS + 1% Pen/Strep. 25,000,000 cells were seeded into a 15cm plate and allowed to adhere overnight.'; [Extraction]'Total and ribosome protected fragments (RPFs) were purified as described by Ingolia N.T., et al. Nature protocols. 2012.', 'tRNAs were purified as described by Evans, M.E., et al. Nucleic Acid. 2017.'; [Cell type]'Pancreactic Ductal Adenocarcinoma Cell Line', 'Pancreatic Ductal Adenocarcinoma Cell Line''cell line: PATU-8902; cell type: Pancreactic Ductal Adenocarcinoma Cell Line; treatment: +Ser/Gly; ', 'cell line: PATU-8902; cell type: Pancreactic Ductal Adenocarcinoma Cell Line; treatment: -Ser/Gly; ', 'cell type: Pancreatic Ductal Adenocarcinoma Cell Line; treatment: +Ser/Gly; ', 'cell type: Pancreatic Ductal Adenocarcinoma Cell Line; treatment: -Ser/Gly; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139910,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE139nnn/GSE139910/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA587516,33142117," Robert S Banh,  Douglas E Biancur,  Keisuke Yamamoto,  Albert S W Sohn,  Beth Walters,  Miljan Kuljanin,  Ajami Gikandi,  Huamin Wang,  Joseph D Mancias,  Robert J Schneider,  Michael E Pacold,  Alec C Kimmelman","Pancreatic ductal adenocarcinoma (PDAC) tumors have a nutrient-poor, desmoplastic, and highly innervated tumor microenvironment. Although neurons can release stimulatory factors to accelerate PDAC tumorigenesis, the metabolic contribution of peripheral axons has not been explored. We found that peripheral axons release serine (Ser) to support the growth of exogenous Ser (exSer)-dependent PDAC cells during Ser/Gly (glycine) deprivation. Ser deprivation resulted in ribosomal stalling on two of the six Ser codons, TCC and TCT, and allowed the selective translation and secretion of nerve growth factor (NGF) by PDAC cells to promote tumor innervation. Consistent with this, exSer-dependent PDAC tumors grew slower and displayed enhanced innervation in mice on a Ser/Gly-free diet. Blockade of compensatory neuronal innervation using LOXO-101, a Trk-NGF inhibitor, further decreased PDAC tumor growth. Our data indicate that axonal-cancer metabolic crosstalk is a critical adaptation to support PDAC growth in nutrient poor environments.",Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer.,10.1016/j.cell.2020.10.016,2020 Nov 25,PMC8100789,Cell
GSE130595,Effect of ILF3 depletion in HeLa cells on RNA steady state levels,Homo sapiens,12,SRP194425,2019-05-01,"[Overal design]HeLa cells were depleted of ILF3 using a pool of siRNAs that target ILF3 (siILF3) and a pool of non targeting siRNAs as a control (Mock) for 72 hours. the cells were then transfected with or without poly(I:C) for 4 hours and harvested using Trizol. For each experimental condition we used 3 biological replicates. The RNA was the sequenced using the Illumina Platform; [Treatment]'HeLa cells were transfected with siRNAs targetting ILF3 (siILF3) or with non-targetting siRNAs(Mock) for 72h. The cells were then transfected with or without poly(I:C) for 4 hours'; [Growth]'HeLa cells were grown in DMEM supplemented with 10% FBS'; [Extraction]'RNA was extracted using Trizol\nThe libraries were depleted of Ribosomes using the Ribo-zero rRNA depletion kit (Illumina) and strand-specific libraries were prepared using the Illumina Truseq protocol (Illumina)'; [Cell type]'HeLa, cervix adenocarcinoma cells''cell type: HeLa, cervix adenocarcinoma cells; treatment: Mock transfected, poly(IC) -; ', 'cell type: HeLa, cervix adenocarcinoma cells; treatment: Mock transfected, poly(IC) +; ', 'cell type: HeLa, cervix adenocarcinoma cells; treatment: siILF3 transfected, poly(IC) -; ', 'cell type: HeLa, cervix adenocarcinoma cells; treatment: siILF3 transfected, poly(IC) +; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130595,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE130nnn/GSE130595/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA540710,31701124," Samir F Watson,  Nicolas Bellora,  Sara Macias","Upon detection of viral infections, cells activate the expression of type I interferons (IFNs) and pro-inflammatory cytokines to control viral dissemination. As part of their antiviral response, cells also trigger the translational shutoff response which prevents translation of viral mRNAs and cellular mRNAs in a non-selective manner. Intriguingly, mRNAs encoding for antiviral factors bypass this translational shutoff, suggesting the presence of additional regulatory mechanisms enabling expression of the self-defence genes. Here, we identified the dsRNA binding protein ILF3 as an essential host factor required for efficient translation of the central antiviral cytokine, IFNB1, and a subset of interferon-stimulated genes. By combining polysome profiling and next-generation sequencing, ILF3 was also found to be necessary to establish the dsRNA-induced transcriptional and translational programs. We propose a central role for the host factor ILF3 in enhancing expression of the antiviral defence mRNAs in cellular conditions where cap-dependent translation is compromised.",ILF3 contributes to the establishment of the antiviral type I interferon program.,10.1093/nar/gkz1060,2020 Jan 10,PMC7145544,Nucleic acids research
GSE117998,Protein Syndesmos is a novel RNA binding protein that regulates primary cilia formation [Ribo-seq],Homo sapiens,6,SRP156197,2018-08-01,"[Overal design]Evaluation of differentially translated transcripts in SDOS-eGFP over eGFP expressing cells; [Treatment]'Cells were treated with doxycycline (1 ug/mL) for 24 hrs to induce the expression of GFP-fusion proteins'; [Growth]'HeLa cells were grown on 15-cm dishes until were approximately 85% confluent'; [Extraction]'Following 15 min incubation with 100 ?g/ml cycloheximide (Sigma-Aldrich; C4859) at 37C, cells were washed with ice cold PBS and 1 mL of lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml cycloheximide, 1% Triton-X100) was added. Cells were then collected and incubated on ice; glass beads (Sigma-Aldrich; G8772) were added to the lysate and cells were broken by vortexing at medium speed for 3 pulses of 10 s. After 10 min of incubation on ice, lysates were centrifuged for 10 min at 10000 rpm at 4C, and the supernatant was recovered.\nRNA was partially digested with 3.5 ?l of RNase I (100 U/?l, Invitrogen AM2294) per 800 ?l of lysate. After 15 min of incubation at 24C, lysates were placed on ice and supplemented with 10 ?l of SUPERaseIn (20 U/?l, Invitrogen AM2694). Lysates were then loaded on a 34% sucrose cushion (34% sucrose in 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT and 100 ?g/ml cycloheximide) and monosomes were pelleted by centrifugation for 1 hr at 70000 rpm using a Beckman TLA 100.3 rotor. RNA was extracted from the pellet and ribosome protected footprints (RPFs) of 30 nucleotides were purified on a 15% TBE-Urea polyacrylamide gel (Invitrogen). RPFs were depleted of ribosomal RNA with the Ribo-Zero rRNA removal kit (Epicentre MRZH116) according to manufacturers indications. cDNA libraries were generated as described in Ingolia, NT et al Nat Protoc 7, 15341550 (2012), and sequenced by Solexa using a HiSeq 2000, Single Read, 50 nt.'; [Cell type]'T-REx-HeLa Cell Line''cell type: T-REx-HeLa Cell Line; genotype: eGFP under Tet repressor; rna type: Ribosome protected fragments; ', 'cell type: T-REx-HeLa Cell Line; genotype: SDOS-eGFP under Tet repressor; rna type: Ribosome protected fragments; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117998,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE117nnn/GSE117998/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA484185,30260431," Rosario Avolio,  Aino I Jarvelin,  Shabaz Mohammed,  Ilenia Agliarulo,  Valentina Condelli,  Pietro Zoppoli,  Giovanni Calice,  Daniela Sarnataro,  Elias Bechara,  Gian G Tartaglia,  Matteo Landriscina,  Alfredo Castello,  Franca Esposito,  Danilo S Matassa","Syndesmos (SDOS) is a functionally poorly characterized protein that directly interacts with p53 binding protein 1 (53BP1) and regulates its recruitment to chromatin. We show here that SDOS interacts with another important cancer-linked protein, the chaperone TRAP1, associates with actively translating polyribosomes and represses translation. Moreover, we demonstrate that SDOS directly binds RNA in living cells. Combining individual gene expression profiling, nucleotide crosslinking and immunoprecipitation (iCLIP), and ribosome profiling, we discover several crucial pathways regulated post-transcriptionally by SDOS. Among them, we identify a small subset of mRNAs responsible for the biogenesis of primary cilium that have been linked to developmental and degenerative diseases, known as ciliopathies, and cancer. We discover that SDOS binds and regulates the translation of several of these mRNAs, controlling cilia development.",Protein Syndesmos is a novel RNA-binding protein that regulates primary cilia formation.,10.1093/nar/gky873,2018 Dec 14,PMC6294507,Nucleic acids research
GSE114636,Comprehensive profiling of translation initiation in influenza-virus infected cells,Homo sapiens,12,SRP148422,2018-05-18,"[Overal design]We use genome-wide methods (Ribo-Seq and RNA-Seq) to examine how translation initiation is altered in influenza virus infected lung-epithelial cells; [Treatment]'At the start of treatment, samples treated with IFN-b were given media containing IFN-b at 20 U/ml, treatment with IFN was for 10 hrs total. 5 hrs after IFN-b treatment was started, samples were infected with influenza virus, viral infection proceeded for 5 hrs. For Ribo-Seq + LTM samples, the last 30 min of treatment occured in the presence of 5 ?M'; [Growth]'Cells were seeded 16 hrs prior to start of assay to be 70 % confluent at treatment, using two 15 cm plates per sample'; [Extraction]'Samples were flash frozen in liquid nitrogen and lysed.\nA portion of the lysate was used to generate RNA-Seq libraries using NEBNext 893 Ultra Directional RNA Library Prep Kit  after depleting ribosome RNA using the Ribozero Gold kit. For ribosome profiling, we performed nuclease footprinting treatment by adding RNase I . We collected ribosome protected mRNA fragments using MicroSpin S-400 HR Columns, and purified RNA from the flow through for size selection. We gel-purified ribosome protected fragments with length between 26 and 34 nt using RNA oligo size markers. We used polyA tailing instead of linker ligation, performed reverse transcription, circularization of cDNA, and PCR amplification of cDNA. Libraries were sequenced on Illumina HiSeq 2500 in 50bp single end mode.'; [Cell type]'human lung adenocarcinoma epithelial cells''cell line: A549; cell type: human lung adenocarcinoma epithelial cells; ', 'cell line: A549; cell type: human lung adenocarcinoma epithelial cells; treatment: IFN-b (20 U/ml); ', 'cell line: A549; cell type: human lung adenocarcinoma epithelial cells; pathogen: influenza virus mixture of low and high CTG NP (reassortant A/PeurtoRico/1934 (PA, PB1, PB2) and A/WSN/1933 (M, NS, HA, NA) and either low or high CTG PR8 NP); ', 'cell line: A549; cell type: human lung adenocarcinoma epithelial cells; pathogen: influenza virus mixture of low and high CTG NP (reassortant A/PeurtoRico/1934 (PA, PB1, PB2) and A/WSN/1933 (M, NS, HA, NA) and either low or high CTG PR8 NP); treatment: IFN-b (20 U/ml); ', 'cell line: A549; cell type: human lung adenocarcinoma epithelial cells; pathogen: influenza virus (reassortant A/PeurtoRico/1934 and A/WSN/1933); ', 'cell line: A549; cell type: human lung adenocarcinoma epithelial cells; pathogen: influenza virus (reassortant A/PeurtoRico/1934 and A/WSN/1933); treatment: IFN-b (20 U/ml); '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114636,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE114nnn/GSE114636/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA472015,30673779," Heather M Machkovech,  Jesse D Bloom,  Arvind R Subramaniam","Translation can initiate at alternate, non-canonical start codons in response to stressful stimuli in mammalian cells. Recent studies suggest that viral infection and anti-viral responses alter sites of translation initiation, and in some cases, lead to production of novel immune epitopes. Here we systematically investigate the extent and impact of alternate translation initiation in cells infected with influenza virus. We perform evolutionary analyses that suggest selection against non-canonical initiation at CUG codons in influenza virus lineages that have adapted to mammalian hosts. We then use ribosome profiling with the initiation inhibitor lactimidomycin to experimentally delineate translation initiation sites in a human lung epithelial cell line infected with influenza virus. We identify several candidate sites of alternate initiation in influenza mRNAs, all of which occur at AUG codons that are downstream of canonical initiation codons. One of these candidate downstream start sites truncates 14 amino acids from the N-terminus of the N1 neuraminidase protein, resulting in loss of its cytoplasmic tail and a portion of the transmembrane domain. This truncated neuraminidase protein is expressed on the cell surface during influenza virus infection, is enzymatically active, and is conserved in most N1 viral lineages. We do not detect globally higher levels of alternate translation initiation on host transcripts upon influenza infection or during the anti-viral response, but the subset of host transcripts induced by the anti-viral response is enriched for alternate initiation sites. Together, our results systematically map the landscape of translation initiation during influenza virus infection, and shed light on the evolutionary forces shaping this landscape.",Comprehensive profiling of translation initiation in influenza virus infected cells.,10.1371/journal.ppat.1007518,2019 Jan,PMC6361465,PLoS pathogens
GSE97384,mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4,Homo sapiens,18,SRP103009,2017-04-04,"[Overal design]RNA-seq analysis of wild-type and ATF4-null HEK293T cells treated with Torin 1 or tunicamycin for 6 h, and ribosome profiling analysis of HEK293T cells treated with Torin 1 for 24 h.; [Treatment]'Cells were treated with vehicle (DMSO), 250 nM Torin 1, or 1 M tunicamycin, as indicated.'; [Growth]'Cells were grown in DMEM + 10% heat-inactivated FBS.'; [Extraction]'Trizol, SDS/Proteinase K\nClontech SMARTer RNA-seq or adapter ligation. Duplicate RNA-seq libraries for wild-type or ATF4-null HEK-293T cells treated with Torin 1 or tunicamycin for 6 h were prepared using the Clontech SMARTer Stranded Total RNA kit according to the manufacturers instructions. For ribosome profiling experiments, including both ribosome footprint (RPF) and total (RNA) libraries, HEK-293T cells were seeded in 15 cm dishes at 10 million cells/plate, incubated overnight, and then treated with vehicle (DMSO) or 250 nM Torin1 for 24 h. Cells were washed 3x in 5 ml cold PBS- and then lysed in polysome lysis buffer (15 mM Hepes pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1% Triton-X100). For RNA libraries, lysates were adjusted to 0.5% SDS, digested with proteinase K, and then extracted with acid-phenol. RNA was then fragmented by alkaline hydrolysis. RNA fragments of 40-80 nt were gel purified and used to prepare libraries as described below. For RPF libraries, lysates were digested with RNAse If for 45 min at RT, and centrifuged through 5-50% sucrose gradients to isolate monosomes. RNA was extracted from fractions containing the monosome peak by proteinase K digest, followed by acid-phenol extraction. Ribosome footprints were then isolated by excising and extracting 28-32 nt fragments from 15% polyacrylamide gels. Samples were depleted of abundant rRNA contaminants by hybridization with rRNA-specific biotinylated oligonucleotides. From this step, RNA and RPF libraries were treated identically. Samples were dephosphorylated using PNK, followed by 3 ligation using T4 RNA ligase 1 to the 3 linker, and ligation products were size selected by PAGE. Fragments were next 5 phosphorylated using PNK, immediately followed by ligation to the 5 linker using T4 RNA ligase 1. RNA was precipitated and subjected to reverse transcription using Superscript III with RT primer, after which RNA was destroyed by alkaline hydrolysis. RT products were purified by PAGE, and then amplified using the Phusion DNA polymerase. All samples were sequenced on an Illumina Hiseq system. Two biological replicates were prepared for each library.'; [Cell type]'Source: ''source: cell culture; library protocol: adapter ligation; ', 'source: cell culture; library protocol: Clontech SMARTer RNA-seq kit; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97384,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE97nnn/GSE97384/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA381596,28494858," Yeonwoo Park,  Andrea Reyna-Neyra,  Lucas Philippe,  Carson C Thoreen","The mammalian target of rapamycin complex 1 (mTORC1) is a master regulator of cell growth that is commonly deregulated in human diseases. Here we find that mTORC1 controls a transcriptional program encoding amino acid transporters and metabolic enzymes through a mechanism also used to regulate protein synthesis. Bioinformatic analysis of mTORC1-responsive mRNAs identified a promoter element recognized by activating transcription factor 4 (ATF4), a key effector of the integrated stress response. ATF4 translation is normally induced by the phosphorylation of eukaryotic initiation factor 2 alpha (eIF2alpha) through a mechanism that requires upstream open reading frames (uORFs) in the ATF4 5' UTR. mTORC1 also controls ATF4 translation through uORFs, but independently of changes in eIF2alpha phosphorylation. mTORC1 instead employs the 4E-binding protein (4E-BP) family of translation repressors. These results link mTORC1-regulated demand for protein synthesis with an ATF4-regulated transcriptional program that controls the supply of amino acids to the translation machinery.",mTORC1 Balances Cellular Amino Acid Supply with Demand for Protein Synthesis through Post-transcriptional Control of ATF4.,10.1016/j.celrep.2017.04.042,2017 May 9,PMC5811220,Cell reports
GSE67902,Regulation of protein translation during mitosis,Homo sapiens,12,SRP057253,2015-04-15,"[Overal design]Ribosome profiling and mRNA-seq from 3 time points in the cell cycle; [Treatment]'None'; [Growth]'None'; [Extraction]'Cells were lysed with 0.5% triton, the lysate was cleard by centirifugation, treated with RNaseI for 45min and then loaded on a sucrose cushion. RNA was then isolated from cells using acid:Phenol extraction method\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circulizarized and PCR amplified.', 'RNA was extracted by lysing cells with Trizol\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circulizarized and PCR amplified.'; [Cell type]'RPE-1 cells immortalized with hTERT''cell type: RPE-1 cells immortalized with hTERT; cell synchronization: Cells were treated with 6 micromolar RO-3306 for 18 hr. RO-3306 was then removed and mitotic cells were collected 45 min later through mitotic shake-off and replated to allow normal mitotic exit. 3hr later G1 cells were harvested.; cell cycle timepoint: G1; drug pre-treatment: cells were pretreated with cycloheximide; ', 'cell type: RPE-1 cells immortalized with hTERT; cell synchronization: Cells were treated with 6 micromolar RO-3306 for 18 hr and harvested; cell cycle timepoint: G2; drug pre-treatment: cells were pretreated with cycloheximide; ', 'cell type: RPE-1 cells immortalized with hTERT; cell synchronization: Cells were treated with 6 micromolar RO-3306 for 18 hr. RO-3306 was then removed and mitotic cells were harvested 45 min later through mitotic shake-off; cell cycle timepoint: M; drug pre-treatment: cells were pretreated with cycloheximide; '",Other; Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67902,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE67nnn/GSE67902/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA281177,26305499," Marvin E Tanenbaum,  Noam Stern-Ginossar,  Jonathan S Weissman,  Ronald D Vale","Passage through mitosis is driven by precisely-timed changes in transcriptional regulation and protein degradation. However, the importance of translational regulation during mitosis remains poorly understood. Here, using ribosome profiling, we find both a global translational repression and identified ~200 mRNAs that undergo specific translational regulation at mitotic entry. In contrast, few changes in mRNA abundance are observed, indicating that regulation of translation is the primary mechanism of modulating protein expression during mitosis. Interestingly, 91% of the mRNAs that undergo gene-specific regulation in mitosis are translationally repressed, rather than activated. One of the most pronounced translationally-repressed genes is Emi1, an inhibitor of the anaphase promoting complex (APC) which is degraded during mitosis. We show that full APC activation requires translational repression of Emi1 in addition to its degradation. These results identify gene-specific translational repression as a means of controlling the mitotic proteome, which may complement post-translational mechanisms for inactivating protein function.",Regulation of mRNA translation during mitosis.,10.7554/eLife.07957,2015 Aug 25,PMC4548207,eLife
GSE159210,Relaxed initiation pausing of ribosomes drives oncogenic translation,Homo sapiens,38,SRP286677,2020-10-07,"[Overal design]We took advantage of a human TtH cell line stably expressing a 4-hydroxytamoxifen (4-OHT)-inducible ER:HRASG12V fusion protein. QTI-seq, Ribo-seq, RNA-seq, m6A-seq and corresponding experiments were performed on the ER:HRASG12V cells with or without 4-OHT treatment and METTL3 or FTO knockdown.; [Treatment]'HEK-TtH-ER:HRASG12V cells were treated with or without 4-OHT for 48 hours and METTL3 or FTO knockdown using sh-RNA'; [Growth]'HEK-TtH-ER:HRASG12V cells were grown in high glucose Dulbeccos modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum, 1X Penicillin-Streptomycin-Glutamine at 37C and 5% CO2.'; [Extraction]'For cell lysates, at least four 10 cm dishes of cells were harvested in 400 l ice-cold polysome buffer (10 mM HEPES, pH 7.4, 100 mM KCl, 5 mM MgCl2) containing CHX (100 g ml-1, for Ribo-seq) or LTM (5 M, for QTI-seq), cells were then disrupted by vortexing six times for 20s using lysing matrix D (Fisher), followed by a 40 s interval each time on ice, then centrifuged at 12,000g, 4 C for 10 min. For QTI-seq, to dissociate non-initiating ribosomes, cell lysates were incubated in a solution containing 16 mM HEPES buffer, pH 7.4, 10 mM creatine phosphate, 0.1 mM spermidine, 40 g ml-1 creatine phosphokinase, 0.8 mM ATP, and 25 M puromycin at 35 C for 15 min. Samples were then subjected to sucrose gradient sedimentation.  Sucrose solutions were prepared in polysome buffer (10 mM HEPES, pH 7.4, 100 mM KCl, 5 mM MgCl2 and 2% Triton X-100). A 15%-45% (w/v) sucrose density gradients were freshly prepared in SW41 ultracentrifuge tubes (Backman) using a Gradient Master (BioComp Instruments). 500 l of supernatant from cell lysates prepared as described above was loaded onto sucrose gradients followed by centrifugation for 2.5 hr at 32,000 rpm, 4 C in a SW41 rotor. Separated samples were fractionated at 1.5 ml min-1 through an automated fractionation system (Isco) that continually monitors OD254 values.   For RNA-seq, total RNA was first isolated using Trizol reagent followed by fragmentation using freshly prepared RNA fragmentation buffer (10 mM Tris-HCl, pH 7.0, 10 mM ZnCl2). 5 g fragmented RNA was saved as input control. For m6A immunoprecipitation, 1 mg fragmented RNA was incubated with 15\u2009?g anti-m6A antibody (Millipore ABE572) in 1 IP buffer (10\u2009mM Tris-HCl, pH 7.4, 150\u2009mM NaCl, and 0.1% Igepal CA-630) for 2\u2009hr at 4C. The m6A-IP mixture was then incubated with Protein A beads for additional 2\u2009hr at 4 C on a rotating wheel. After washing 3 times with IP buffer, bound RNA was eluted using 100\u2009?l elution buffer (6.7 mM N6-Methyladenosine 5-monophosphate sodium salt in 1  IP buffer), followed by ethanol precipitation. Precipitated RNA was used for cDNA library construction and high-throughput sequencing.\nFor Ribo-seq and QTI-seq, to convert the polysome into monosome, E. coli RNase I (750 U per 100 A260 units) was added into the pooled fractions from ribosome profiling and incubated at 4 C for 1 hr, then total RNAs were extracted using Trizol reagent. RNA extracts (Ribo-seq and QTI-seq), fragmented RNAs (RNA-seq) and m6A-IP elutes (m6A-seq) were dephosphorylated for 2 hr at 37 C in a 15 l reaction (1 T4 polynucleotide kinase buffer, 10 U SUPERase_In and 20 U T4 polynucleotide kinase). The products were separated on a 15% polyacrylamide TBE-urea gel and visualized using SYBR Gold. Selected regions in the gel corresponding to 40-60 nt (for RNA-seq and m6A-seq) or 25-35 nt (for Ribo-seq and QTI-seq) were excised. The gel slices were disrupted by using centrifugation through the holes at the bottom of the tube. RNA fragments were dissolved by soaking overnight in 400 ?l RNA elution buffer (300 mM NaOAc, pH 5.2 1 mM EDTA, 0.1 U ml-1 SUPERase_In). The gel debris was removed using a Spin-X column (Corning), followed by ethanol precipitation. Purified RNA fragments were re-suspended in nuclease-free water. Poly-(A) tailing reaction was carried out for 45 min at 37 C (1  poly-(A) polymerase buffer, 1 mM ATP, 0.75 U ?l-1 SUPERase_In and 3 U E. coli polyA polymerase). For reverse transcription, the following oligos containing barcodes were used:   MCA:5-pCAGATCGTCGGACTGTAGAACTCTCAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3;   LGT:5-pGTGATCGTCGGACTGTAGAACTCTCAACAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3;   YAG:5-pAGGATCGTCGGACTGTAGAACTCTCAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3;   HTC:5-pTCGATCGTCGGACTGTAGAACTCTCAAGCAGAAGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-3,  where  represents abasic residue.  In brief, the tailed-RNA sample was mixed with 0.5 mM dNTP and 2.5 mM synthesized primer and incubated at 65 C for 5 min, followed by incubation on ice for 5 min. The reaction mix was then added with 20 mM Tris (pH 8.4), 50 mM KCl, 5 mM MgCl2, 10 mM DTT, 40 U RNaseOUT and 200 U SuperScript III. Reverse transcription reaction was performed according to the manufacturers instruction. Reverse transcription products were separated on a 10% polyacrylamide TBE-urea gel as described earlier. The extended first-strand product band was expected to be approximately 100 nt, and the corresponding region was excised. The cDNA was recovered by using DNA gel elution buffer (300 mM NaCl, 1 mM EDTA). First-strand cDNA was circularized in 20 ?l of reaction containing 1 CircLigase buffer, 2.5 mM MnCl2, 1M Betaine and 100 U CircLigase II (Epicentre). Circularization was performed at 60 C for 1 hr, and the reaction was heat inactivated at 80 C for 10 min, then was precipitated by ethanol. Circular template was amplified by PCR by using the Phusion high-fidelity (HF) enzyme (NEB) according to the manufacturers instructions. The oligonucleotide primers qNTI200 (5-CAAGCAGAAGACGGCATA-3) and qNTI201 (5-AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACG-3) were used to create DNA suitable for sequencing. The PCR contains 1 HF buffer, 0.2 mM dNTP, 0.5 M oligonucleotide primers, and 0.5 U Phusion polymerase. PCR was carried out with an initial 30 s denaturation at 98 C, followed by 12 cycles of 10 s denaturation at 98 C, 20 s annealing at 60 C, and 10 s extension at 72 C. PCR products were separated on a nondenaturing 8% polyacrylamide TBE gel as described earlier. Expected DNA at 120 bp was excised and recovered as described earlier. After quantification by Agilent BioAnalyzer DNA 1000 assay, equal amounts of barcoded samples were pooled into one sample. Approximately 5 pM mixed DNA samples were used for cluster generation followed by sequencing by using sequencing primer5-CGACAGGTTCAGAGTTCTACAGTCCGACGATC-3 (Illumina HiSeq).'; [Cell type]'HEK-TtH cells stably expressing fused ER:HRasG12V', 'HEK293''cell type: HEK-TtH cells stably expressing fused ER:HRasG12V; ', 'cell type: HEK293; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159210,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE159nnn/GSE159210/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA667952,33597240," Leiming Dong,  Yuanhui Mao,  Aidong Zhou,  Xiao-Min Liu,  Jun Zhou,  Ji Wan,  Shu-Bing Qian","Translation is a crucial process in cancer development and progression. Many oncogenic signaling pathways target the translation initiation stage to satisfy the increased anabolic demands of cancer cells. Using quantitative profiling of initiating ribosomes, we found that ribosomal pausing at the start codon serves as a ""brake"" to restrain the translational output. In response to oncogenic RAS signaling, the initiation pausing relaxes and contributes to the increased translational flux. Intriguingly, messenger RNA (mRNA) m(6)A modification in the vicinity of start codons influences the behavior of initiating ribosomes. Under oncogenic RAS signaling, the reduced mRNA methylation leads to relaxed initiation pausing, thereby promoting malignant transformation and tumor growth. Restored initiation pausing by inhibiting m(6)A demethylases suppresses RAS-mediated oncogenic translation and subsequent tumorigenesis. Our findings unveil a paradigm of translational control that is co-opted by RAS mutant cancer cells to drive malignant phenotypes.",Relaxed initiation pausing of ribosomes drives oncogenic translation.,10.1126/sciadv.abd6927,2021 Feb,PMC7888950,Science advances
GSE132725,Transcriptome and ribosome profiling of XRN1-null HEK293T human cell line generated by CRISPR/Cas9 gene editing,Homo sapiens,8,SRP201395,2019-06-13,"[Overal design]Two cell types with two biological replicates analysed using two methods.; [Treatment]'None'; [Growth]'6.4x10^6 cells of HEK293T WT or XRN1-null cells were plated on 15 cm dishes 24 hrs before harvesting.'; [Extraction]'Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and a library prepared using the TruSeq RNA Sample Prep Kit (Illumina). For Ribo-Seq, the original procedure of Ingolia et al (2012) Nature Protocols was followed with modifications from Calviello et al (2016) Nature Methods.\nRNA libraries were prepared for sequencing using standard Illumina protocols'; [Cell type]'Source: ''cell line: HEK293T; genotype: Wild-type; ', 'cell line: HEK293T; genotype: XRN1-null; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132725,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132725/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA548813,31340047," Chung-Te Chang,  Sowndarya Muthukumar,  Ramona Weber,  Yevgen Levdansky,  Ying Chen,  Dipankar Bhandari,  Catia Igreja,  Lara Wohlbold,  Eugene Valkov,  Elisa Izaurralde","XRN1 is the major cytoplasmic exoribonuclease in eukaryotes, which degrades deadenylated and decapped mRNAs in the last step of the 5'-3' mRNA decay pathway. Metazoan XRN1 interacts with decapping factors coupling the final stages of decay. Here, we reveal a direct interaction between XRN1 and the CCR4-NOT deadenylase complex mediated by a low-complexity region in XRN1, which we term the 'C-terminal interacting region' or CIR. The CIR represses reporter mRNA deadenylation in human cells when overexpressed and inhibits CCR4-NOT and isolated CAF1 deadenylase activity in vitro. Through complementation studies in an XRN1-null cell line, we dissect the specific contributions of XRN1 domains and regions toward decay of an mRNA reporter. We observe that XRN1 binding to the decapping activator EDC4 counteracts the dominant negative effect of CIR overexpression on decay. Another decapping activator PatL1 directly interacts with CIR and alleviates the CIR-mediated inhibition of CCR4-NOT activity in vitro. Ribosome profiling revealed that XRN1 loss impacts not only on mRNA levels but also on the translational efficiency of many cellular transcripts likely as a consequence of incomplete decay. Our findings reveal an additional layer of direct interactions in a tightly integrated network of factors mediating deadenylation, decapping and 5'-3' exonucleolytic decay.",A low-complexity region in human XRN1 directly recruits deadenylation and decapping factors in 5'-3' messenger RNA decay.,10.1093/nar/gkz633,2019 Sep 26,PMC6753473,Nucleic acids research
GSE84746,Dual randomization of oligonucleotides to reduce the bias in ribosome-profiling libraries,Saccharomyces cerevisiae,19,SRP079402,2016-07-22,"[Overal design]Ribosome profiling and mRNA-seq libraries from wt yeast comparing different library preparation approaches using different combinations of randomized and non-randomized linkers and RT primers.; [Treatment]'YPD medium; cycloheximide (1 min)'; [Growth]'Cells were grown from OD600 of 0.02 to OD600=0.4, collected by rapid vacuum filtration, and immediately frozen in liquid nitrogen.'; [Extraction]""Frozen yeast cells for ribosome profiling were pulverized under cryogenic conditions in 50 mM Tris-HCl pH=7.5, 50 mM NH4Cl, 12 mM MgCl2, 0.5 mM DTT and 100 ?g/ml CHX. Extracts were treated with RNAse I and resolved on sucrose gradients. RNA from monosome fractions was extracted by hot phenol and ribosome footprints of 28-32 nt were purified by size selection and gel extraction.\nFootprints were dephosphorylated and ligated to one of three preadenylated 3' linkers. Footprints were reverse transcribed using the specified RT primer and cDNA was circularized and PCR-amplified.""; [Cell type]'Source: ''strain background: BY4741; genotype/variation: wild-type; replicate: 1; ', 'strain background: BY4741; genotype/variation: wild-type; replicate: 2; ', 'strain background: BY4741; genotype/variation: wild-type; replicate: 3; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84746,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE84nnn/GSE84746/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA330982,27450428," Aaron Lecanda,  Benedikt S Nilges,  Puneet Sharma,  Danny D Nedialkova,  Juliane Schwarz,  Juan M Vaquerizas,  Sebastian A Leidel","Protein translation is at the heart of cellular metabolism and its in-depth characterization is key for many lines of research. Recently, ribosome profiling became the state-of-the-art method to quantitatively characterize translation dynamics at a transcriptome-wide level. However, the strategy of library generation affects its outcomes. Here, we present a modified ribosome-profiling protocol starting from yeast, human cells and vertebrate brain tissue. We use a DNA linker carrying four randomized positions at its 5' end and a reverse-transcription (RT) primer with three randomized positions to reduce artifacts during library preparation. The use of seven randomized nucleotides allows to efficiently detect library-generation artifacts. We find that the effect of polymerase chain reaction (PCR) artifacts is relatively small for global analyses when sufficient input material is used. However, when input material is limiting, our strategy improves the sensitivity of gene-specific analyses. Furthermore, randomized nucleotides alleviate the skewed frequency of specific sequences at the 3' end of ribosome-protected fragments (RPFs) likely resulting from ligase specificity. Finally, strategies that rely on dual ligation show a high degree of gene-coverage variation. Taken together, our approach helps to remedy two of the main problems associated with ribosome-profiling data. This will facilitate the analysis of translational dynamics and increase our understanding of the influence of RNA modifications on translation.",Dual randomization of oligonucleotides to reduce the bias in ribosome-profiling libraries.,10.1016/j.ymeth.2016.07.011,2016 Sep 1,PMC5024760,"Methods (San Diego, Calif.)"
GSE150439,Effect of QTRT2 KO  on mitochondrial translation,Homo sapiens,4,SRP261344,2020-05-12,"[Overal design]Ribosome profiling and RNA-seq; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA extraction, RNaseI footprinting, ribosome pelletting, 17-34 nt gel excision, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification'; [Cell type]'Source: ''genetic background: WT; cell line: HEK293T; ', 'genetic background: QTRT2 KO; cell line: HEK293T; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150439,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE150nnn/GSE150439/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA632042,32859890," Takeo Suzuki,  Yuka Yashiro,  Ittoku Kikuchi,  Yuma Ishigami,  Hironori Saito,  Ikuya Matsuzawa,  Shunpei Okada,  Mari Mito,  Shintaro Iwasaki,  Ding Ma,  Xuewei Zhao,  Kana Asano,  Huan Lin,  Yohei Kirino,  Yuriko Sakaguchi,  Tsutomu Suzuki","Mitochondria generate most cellular energy via oxidative phosphorylation. Twenty-two species of mitochondrial (mt-)tRNAs encoded in mtDNA translate essential subunits of the respiratory chain complexes. mt-tRNAs contain post-transcriptional modifications introduced by nuclear-encoded tRNA-modifying enzymes. They are required for deciphering genetic code accurately, as well as stabilizing tRNA. Loss of tRNA modifications frequently results in severe pathological consequences. Here, we perform a comprehensive analysis of post-transcriptional modifications of all human mt-tRNAs, including 14 previously-uncharacterized species. In total, we find 18 kinds of RNA modifications at 137 positions (8.7% in 1575 nucleobases) in 22 species of human mt-tRNAs. An up-to-date list of 34 genes responsible for mt-tRNA modifications are provided. We identify two genes required for queuosine (Q) formation in mt-tRNAs. Our results provide insight into the molecular mechanisms underlying the decoding system and could help to elucidate the molecular pathogenesis of human mitochondrial diseases caused by aberrant tRNA modifications.",Complete chemical structures of human mitochondrial tRNAs.,10.1038/s41467-020-18068-6,2020 Aug 28,PMC7455718,Nature communications
GSE133111,Ribosome profiling of A549 cells depleted of RPLP1 and RPLP2 and infected with DENV.,Homo sapiens,12,SRP202033,2019-06-20,"[Overal design]A549 cells were plated at 1.5 x 106 cells per 10 cm dish. Three 10cm dishes were transfected with NSC siRNA whereas three other dishes were transfected with either siP1_1, siP2_1 or siP2_4 siRNAs as described in the transfections section. 48 h later cells were infected as described previously with DENV-2 (NGC strain) at MOI of 10 in a total volume of 10 ml, rocked every 15 minutes for 1 h and the infection was allowed to proceed for more 1.5 h (2.5 h total time). Cells were then flash frozen in liquid nitrogen without cycloheximide pretreatment and cold lysis buffer containing CHX was used to lyse the cells on ice. The RIBOseq strategy was adapted from Ingolia and colleagues with a few modifications described next. After nuclease digestion, samples were run in a polysome gradient and the ribosome fractions were collected. As described by Reid and colleagues, fractions were extracted using Trizol LS (Thermo Fisher Scientific), and rRNAs were removed using the Ribo-Zero gold rRNA removal kit (Illumina, San Diego CA) according to the manufacturer's protocol. For adapter ligation and library building we used NEBNext Small RNA Library Prep Set (Illumina).; [Treatment]'None'; [Growth]'Cells were grown in DMEM supplemented with 10% fetal bovine serum, non-essential amino acids, 100 U/ml penicillin and 100 ?g/ml streptomycin in a humidified incubator with 5% CO2 at 37C.'; [Extraction]""A549 cells were plated at 1.5 x 106 cells per 10 cm dish. Three 10cm dishes were transfected with NSC siRNA whereas three other dishes were transfected with either siP1_1, siP2_1 or siP2_4 siRNAs as described in the transfections section. 48 h later cells were infected as described previously with DENV-2 (NGC strain) at MOI of 10 in a total volume of 10 ml, rocked every 15 minutes for 1 h and the infection was allowed to proceed for more 1.5 h (2.5 h total time). Cells were then flash frozen in liquid nitrogen without cycloheximide pretreatment and cold lysis buffer containing CHX was used to lyse the cells on ice. The RIBOseq strategy was adapted from Ingolia and colleagues with a few modifications described next. After nuclease digestion, samples were run in a polysome gradient and the ribosome fractions were collected. As described by Reid and colleagues, fractions were extracted using Trizol LS (Thermo Fisher Scientific), and rRNAs were removed using the Ribo-Zero gold rRNA removal kit (Illumina, San Diego CA) according to the manufacturer's protocol.\nFor adapter ligation and library building we used NEBNext Small RNA Library Prep Set (Illumina).""; [Cell type]'A549''cell type: A549; sirna: Control; viral strain: Dengue 2, strain New Guinea C; sample treatment: Ribo seq; ', 'cell type: A549; sirna: siP1_1; viral strain: Dengue 2, strain New Guinea C; sample treatment: Ribo seq; ', 'cell type: A549; sirna: siP2_1; viral strain: Dengue 2, strain New Guinea C; sample treatment: Ribo seq; ', 'cell type: A549; sirna: siP2_4; viral strain: Dengue 2, strain New Guinea C; sample treatment: Ribo seq; ', 'cell type: A549; sirna: Control; viral strain: Dengue 2, strain New Guinea C; sample treatment: RNA seq; ', 'cell type: A549; sirna: siP1_1; viral strain: Dengue 2, strain New Guinea C; sample treatment: RNA seq; ', 'cell type: A549; sirna: siP2_1; viral strain: Dengue 2, strain New Guinea C; sample treatment: RNA seq; ', 'cell type: A549; sirna: siP2_4; viral strain: Dengue 2, strain New Guinea C; sample treatment: RNA seq; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133111,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE133nnn/GSE133111/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA549955,,,,,,,,
GSE140639,Genome-wide survey of ribosome collision [anisomycin],Homo sapiens,2,SRP230602,2019-11-19,"[Overal design]Ribosome profiling; [Treatment]'None'; [Growth]'None'; [Extraction]'RNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification for ribosome profiling'; [Cell type]'Source: ''treatment: anisomycin; genetic background: WT; cell line: HEK293; extracted molecule: total RNA; extract_protocol: Rnase I footprinting, ribosome pelleting, RNA extraction; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140639,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140639/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA590355,32375038," Peixun Han,  Yuichi Shichino,  Tilman Schneider-Poetsch,  Mari Mito,  Satoshi Hashimoto,  Tsuyoshi Udagawa,  Kenji Kohno,  Minoru Yoshida,  Yuichiro Mishima,  Toshifumi Inada,  Shintaro Iwasaki","Ribosome movement is not always smooth and is rather often impeded. For ribosome pauses, fundamental issues remain to be addressed, including where ribosomes pause on mRNAs, what kind of RNA/amino acid sequence causes this pause, and the physiological significance of this attenuation of protein synthesis. Here, we survey the positions of ribosome collisions caused by ribosome pauses in humans and zebrafish using modified ribosome profiling. Collided ribosomes, i.e., disomes, emerge at various sites: Pro-Pro/Gly/Asp motifs; Arg-X-Lys motifs; stop codons; and 3' untranslated regions. The electrostatic interaction between the charged nascent chain and the ribosome exit tunnel determines the eIF5A-mediated disome rescue at the Pro-Pro sites. In particular, XBP1u, a precursor of endoplasmic reticulum (ER)-stress-responsive transcription factor, shows striking queues of collided ribosomes and thus acts as a degradation substrate by ribosome-associated quality control. Our results provide insight into the causes and consequences of ribosome pause by dissecting collided ribosomes.",Genome-wide Survey of Ribosome Collision.,10.1016/j.celrep.2020.107610,2020 May 5,PMC7746506,Cell reports
GSE49310,The Transcriptional Stress Response of Candida albicans to Weak Organic Acids,Candida albicans,96,SRP028297,2013-07-29,"[Overal design]Transcriptional profiling of wild-type Candida albicans strain SC5314 under 6 differents condition (2 controls, 4 weak acids) at 4 time points by cDNA deep-sequencing, with 4 biological replicates, on the Illumina HiSeq 2000 platform. 96 total samples were sequenced (6 x 4 x 4).; [Treatment]'Overnight cultures of C. albicans were relaunched in fresh MRS medium, supplemented with hydrocholoric acid, lactic acid, acetic acid, propionic acid or butyric acid.'; [Growth]'Cells were grown in De Man, Rogosa and Sharpe (MRS) media (Sigma), supplemented with one of the indicated acids, at 37 C in a shaking incubator at 150-200 rpm. On a daily basis, overnight cultures were relaunched into fresh media.'; [Extraction]'Yeast were centrifuged, flash frozen in liquid nitrogen, and total RNA was extraced using the hot phenol protocol.\nRNA samples were subjected to cDNA synthesis using Illumina TruSeq RNA sample preparation kit version 2 (Low-Throughput protocol) according to manufacturers protocol.'; [Cell type]'Source: ''strain: SC5314; treatment: None; ph: 5.8; time point: T1 (4h); replicate: B; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T4 (76h); replicate: B; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: B; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T1 (4h); replicate: B; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: B; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T1 (4h); replicate: B; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T4 (76h); replicate: B; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: B; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: B; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T1 (4h); replicate: B; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T4 (76h); replicate: B; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T4 (76h); replicate: C; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: C; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: C; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: C; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T1 (4h); replicate: C; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: C; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T4 (76h); replicate: C; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T1 (4h); replicate: C; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T4 (76h); replicate: C; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T4 (76h); replicate: C; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T1 (4h); replicate: C; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T1 (4h); replicate: C; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T4 (76h); replicate: D; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T4 (76h); replicate: D; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T1 (4h); replicate: D; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T1 (4h); replicate: D; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T4 (76h); replicate: D; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: D; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T4 (76h); replicate: D; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: D; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: D; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T1 (4h); replicate: D; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T1 (4h); replicate: D; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: D; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T4 (76h); replicate: F; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T1 (4h); replicate: F; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: F; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T1 (4h); replicate: F; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T4 (76h); replicate: F; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T1 (4h); replicate: F; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: F; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T4 (76h); replicate: F; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T1 (4h); replicate: F; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T1 (4h); replicate: F; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T4 (76h); replicate: F; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T3 (52h); replicate: B; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T2 (28h); replicate: B; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: B; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T2 (28h); replicate: B; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T3 (52h); replicate: B; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T2 (28h); replicate: B; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T3 (52h); replicate: B; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T2 (28h); replicate: B; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: B; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T4 (76h); replicate: B; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: B; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: B; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T3 (52h); replicate: B; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T2 (28h); replicate: C; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T3 (52h); replicate: C; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: C; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T3 (52h); replicate: C; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T2 (28h); replicate: C; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T3 (52h); replicate: C; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: C; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T2 (28h); replicate: C; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: C; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T3 (52h); replicate: C; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T2 (28h); replicate: C; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: C; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T3 (52h); replicate: D; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: D; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T3 (52h); replicate: D; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: D; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: D; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T3 (52h); replicate: D; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T2 (28h); replicate: D; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T2 (28h); replicate: D; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T3 (52h); replicate: D; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T2 (28h); replicate: D; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T2 (28h); replicate: D; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: D; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T2 (28h); replicate: F; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: F; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T3 (52h); replicate: F; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: F; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T3 (52h); replicate: F; ', 'strain: SC5314; treatment: Propionic acid (IC50); ph: 5.5; time point: T2 (28h); replicate: F; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T2 (28h); replicate: F; ', 'strain: SC5314; treatment: Acetic acid (IC15); ph: 5.5; time point: T3 (52h); replicate: F; ', 'strain: SC5314; treatment: None; ph: 5.8; time point: T2 (28h); replicate: F; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T2 (28h); replicate: F; ', 'strain: SC5314; treatment: Butyric acid (IC50); ph: 5.5; time point: T3 (52h); replicate: F; ', 'strain: SC5314; treatment: Lactic acid (IC50); ph: 5.5; time point: T4 (76h); replicate: F; ', 'strain: SC5314; treatment: HCl; ph: 5.5; time point: T3 (52h); replicate: F; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49310,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE49nnn/GSE49310/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA213618,25636313," Fabien Cottier,  Alrina Shin Min Tan,  Jinmiao Chen,  Josephine Lum,  Francesca Zolezzi,  Michael Poidinger,  Norman Pavelka","Candida albicans is the most important fungal pathogen of humans, causing severe infections, especially in nosocomial and immunocompromised settings. However, it is also the most prevalent fungus of the normal human microbiome, where it shares its habitat with hundreds of trillions of other microbial cells. Despite weak organic acids (WOAs) being among the most abundant metabolites produced by bacterial microbiota, little is known about their effect on C. albicans. Here we used a sequencing-based profiling strategy to systematically investigate the transcriptional stress response of C. albicans to lactic, acetic, propionic, and butyric acid at several time points after treatment. Our data reveal a complex transcriptional response, with individual WOAs triggering unique gene expression profiles and with important differences between acute and chronic exposure. Despite these dissimilarities, we found significant overlaps between the gene expression changes induced by each WOA, which led us to uncover a core transcriptional response that was largely unrelated to other previously published C. albicans transcriptional stress responses. Genes commonly up-regulated by WOAs were enriched in several iron transporters, which was associated with an overall decrease in intracellular iron concentrations. Moreover, chronic exposure to any WOA lead to down-regulation of RNA synthesis and ribosome biogenesis genes, which resulted in significant reduction of total RNA levels and of ribosomal RNA in particular. In conclusion, this study suggests that gastrointestinal microbiota might directly influence C. albicans physiology via production of WOAs, with possible implications of how this fungus interacts with its host in both health and disease.",The transcriptional stress response of Candida albicans to weak organic acids.,10.1534/g3.114.015941,2015 Jan 29,PMC4390566,"G3 (Bethesda, Md.)"
GSE153346,TRIBE editing reveals specific mRNA targets of eIF4E-BP in Drosophila and in mammals,Homo sapiens; Drosophila melanogaster,35,SRP269009,2020-06-26,"[Overal design]We used hyperTRIBE (Targets of RNA-binding proteins identified by editing) to identify in vivo 4E-BP mRNA targets in both Drosophila S2 cells and human prostate cancer cell PC3 under conditions known to activate 4E-BP. We also carried out ribosome profiling after mTOR inhibition.; [Treatment]'None'; [Growth]'S2 cells were grown in Hyclone SFX-insect media with 10% of FBS. PC3 cells were grown in F-12K Medium (ATCC) with 10% of FBS.'; [Extraction]'GFP-positive cells were sorted and collected with a BD FACSAria II machine. Total RNA was extracted with TRIzol LS reagent.\nTRIBE: Standard Illumina TruSeq RNA Library Kit.'; [Cell type]'Source: ''cell line: S2; transfected plasmids: pAC5.1-eGFP; expression of gene in pmta: Uninduced; treatment: DMSO for 5 hrs; ', 'cell line: S2; transfected plasmids: pAC5.1-eGFP and pMTA-hyperADARcd; expression of gene in pmta: Induced the expression overnight; treatment: DMSO for 5 hrs; ', 'cell line: S2; transfected plasmids: pAC5.1-eGFP and pMTA-thor-hyperADARcd; expression of gene in pmta: Induced the expression overnight; treatment: DMSO for 5 hrs; ', 'cell line: S2; transfected plasmids: pAC5.1-eGFP and pMTA-thor-hyperADARcd; expression of gene in pmta: Induced the expression overnight; treatment: Serum depletion and 50nM of Rapamycin for 5 hrs; ', 'cell line: S2; transfected plasmids: pAC5.1-eGFP and pMTA-thor-hyperADARcd; expression of gene in pmta: Induced the expression overnight; treatment: 50nM of Rapamycin for 5 hrs; ', 'cell line: S2; transfected plasmids: pAC5.1-eGFP and pMTA-thor-hyperADARcd; expression of gene in pmta: Induced the expression overnight; treatment: 50nM of Torin-1 for 5 hrs; ', 'cell line: S2; transfected plasmids: pAC5.1-eGFP and pMTA-thor-hyperADARcd; expression of gene in pmta: Uninduced; treatment: DMSO for 5 hrs; ', 'cell line: S2; transfected plasmids: None; treatment: DMSO for 2 hrs; ', 'cell line: S2; transfected plasmids: None; treatment: 100nM of Rapamycin for 2 hrs; ', 'cell line: S2; transfected plasmids: None; treatment: 100nM of Torin-1 for 2 hrs; ', 'cell line: PC3; transfected plasmids: pAAV-CMV-eGFP3 and pCMV-hADAR2cd-E488Q; treatment: DMSO for 5 hrs; ', 'cell line: PC3; transfected plasmids: pAAV-CMV-eGFP3 and pCMV-3HA-h4E-BP1-hADAR2cd-E488Q; treatment: DMSO for 5 hrs; ', 'cell line: PC3; transfected plasmids: pAAV-CMV-eGFP3 and pCMV-3HA-h4E-BP1-hADAR2cd-E488Q; treatment: 200 nM of INK-128 for 5 hrs; ', 'cell line: PC3; transfected plasmids: pAAV-CMV-eGFP3 and pCMV-3HA-h4E-BP1-hADAR2cd-E488Q; treatment: 2.5 ?M of PP242 for 5 hrs; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153346,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE153nnn/GSE153346/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA642123,32851185," Hua Jin,  Weijin Xu,  Reazur Rahman,  Daxiang Na,  Allegra Fieldsend,  Wei Song,  Shaobo Liu,  Chong Li,  Michael Rosbash","4E-BP (eIF4E-BP) represses translation initiation by binding to the 5' cap-binding protein eIF4E and inhibiting its activity. Although 4E-BP has been shown to be important in growth control, stress response, cancer, neuronal activity, and mammalian circadian rhythms, it is not understood how it preferentially represses a subset of mRNAs. We successfully used HyperTRIBE (targets of RNA binding proteins identified by editing) to identify in vivo 4E-BP mRNA targets in both Drosophila and mammals under conditions known to activate 4E-BP. The protein associates with specific mRNAs, and ribosome profiling data show that mTOR inhibition changes the translational efficiency of 4E-BP TRIBE targets more substantially compared to nontargets. In both systems, these targets have specific motifs and are enriched in translation-related pathways, which correlate well with the known activity of 4E-BP and suggest that it modulates the binding specificity of eIF4E and contributes to mTOR translational specificity.",TRIBE editing reveals specific mRNA targets of eIF4E-BP in Drosophila and in mammals.,10.1126/sciadv.abb8771,2020 Aug,PMC7423359,Science advances
GSE59385,The zinc finger protein ZNF658 regulates the transcription of genes involved in zinc homeostasis and affects ribosome biogenesis through the zinc transcriptional regulatory element (ZTRE),Homo sapiens,12,None,2014-07-14,"[Overal design]Gene expression profiling by Illumina BeadArray of the effects of ZNF658 gene knockdown by siRNA. 2 different siRNAs were used, with appropriate non-targetting controls. All experiments were carried out in triplicate.; [Treatment]'Cells were transfected with oligonucleotides using lipofectamine RNAiMAX'; [Growth]'Human epithelial colonic adenocarcinoma, Caco-2, cells were grown in Dulbecos Modified Eagle medium, containing 10% (v/v) fetal calf serum; 60 ?g/ml gentamycin and 1% (v/v) non essential amino acids (Sigma).'; [Extraction]'Total RNA isolated using Pure Link RNAmini kit [Ambion] following manufacturers protocol, RNA integrity checked using Agilent Bioanalyzer.'; [Cell type]'Source: ''sirna: siRNA1 (Ambion); cell line: Human epithelial colonic adenocarcinoma, Caco-2; ', 'sirna: Sense Control siRNA (Ambion); cell line: Human epithelial colonic adenocarcinoma, Caco-2; ', 'sirna: siRNA2 (Dhamacon); cell line: Human epithelial colonic adenocarcinoma, Caco-2; ', 'sirna: Dhamracon negative siGENOME Non-Targeting siRNA; cell line: Human epithelial colonic adenocarcinoma, Caco-2; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59385,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59385/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA255227,25582195," Ogo A Ogo,  John Tyson,  Simon J Cockell,  Alison Howard,  Ruth A Valentine,  Dianne Ford","We previously identified the ZTRE (zinc transcriptional regulatory element) in genes involved in zinc homeostasis and showed that it mediates transcriptional repression in response to zinc. We now report that ZNF658 acts at the ZTRE. ZNF658 was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry of a band excised after electrophoretic mobility shift assay using a ZTRE probe. The protein contains a KRAB domain and 21 zinc fingers. It has similarity with ZAP1 from Saccharomyces cerevisiae, which regulates the response to zinc restriction, including a conserved DNA binding region we show to be functional also in ZNF658. Small interfering RNA (siRNA) targeted to ZNF658 abrogated the zinc-induced, ZTRE-dependent reduction in SLC30A5 (ZnT5 gene), SLC30A10 (ZnT10 gene), and CBWD transcripts in human Caco-2 cells and the ability of zinc to repress reporter gene expression from corresponding promoter-reporter constructs. Microarray analysis of the effect of reducing ZNF658 expression by siRNA uncovered a large decrease in rRNA. We find that ZTREs are clustered within the 45S rRNA precursor. We also saw effects on expression of multiple ribosomal proteins. ZNF658 thus links zinc homeostasis with ribosome biogenesis, the most active transcriptional, and hence zinc-demanding, process in the cell. ZNF658 is thus a novel transcriptional regulator that plays a fundamental role in the orchestrated cellular response to zinc availability.",The zinc finger protein ZNF658 regulates the transcription of genes involved in zinc homeostasis and affects ribosome biogenesis through the zinc transcriptional regulatory element.,10.1128/MCB.01298-14,2015 Mar,PMC4333095,Molecular and cellular biology
GSE123539,Ribosomal protein RPL26 is the principal target of UFMylation,Homo sapiens,18,SRP173217,2018-12-10,"[Overal design]ribosome profiling of membrane and cytosolic fractions of UFM1-KO, UFSP2-KO, and wild-type HEK cells in duplicate (12 samples); mRNA-seq of whole cell lysates of UFM1-KO, UFSP2-KO, and wild-type HEK cells in duplicate (6 samples); [Treatment]'Cas9 knockout with sgUFM1', 'Cas9 knockout with sgUFSP2', 'None'; [Growth]""Cells cultured in DMEM, 10% FBS at 37'C and 5% CO2""; [Extraction]'Triton-X lysis of leftover pellet from cytosolic fractionation followed by centrifugation to remove cell debris\nRNase I footprinting, ultracentrifugation, denaturing RNA extraction, dephosphorylation, preadenylated inker ligation, reverse transcription, cDNA circularization, PCR amplification', 'Detergent lysis with digitonin, centrifugation to remove cell debris and organelles\nRNase I footprinting, ultracentrifugation, denaturing RNA extraction, dephosphorylation, preadenylated inker ligation, reverse transcription, cDNA circularization, PCR amplification', 'Detergent lysis with Triton-X followed by centrifugation to remove cell debris\nDenaturing RNA extraction, TruSeq stranded RNA-Seq library generation with Ribo-Zero Gold (Illumina)'; [Cell type]'Source: ''cell line: Clonal UFM1-KO HEK293 cells generated with Cas9; fraction: membrane; ', 'cell line: Clonal UFM1-KO HEK293 cells generated with Cas9; fraction: cytosolic; ', 'cell line: Clonal UFSP2-KO HEK293 cells generated with Cas9; fraction: membrane; ', 'cell line: Clonal UFSP2-KO HEK293 cells generated with Cas9; fraction: cytosolic; ', 'cell line: HEK 293; fraction: membrane; ', 'cell line: HEK 293; fraction: cytosolic; ', 'cell line: Clonal UFM1-KO HEK293 cells generated with Cas9; fraction: whole cell lysate; ', 'cell line: Clonal UFSP2-KO HEK293 cells generated with Cas9; fraction: whole cell lysate; ', 'cell line: HEK 293; fraction: whole cell lysate; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123539,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE123nnn/GSE123539/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA509149,30626644," Christopher P Walczak,  Dara E Leto,  Lichao Zhang,  Celeste Riepe,  Ryan Y Muller,  Paul A DaRosa,  Nicholas T Ingolia,  Joshua E Elias,  Ron R Kopito","Ubiquitin fold modifier 1 (UFM1) is a small, metazoan-specific, ubiquitin-like protein modifier that is essential for embryonic development. Although loss-of-function mutations in UFM1 conjugation are linked to endoplasmic reticulum (ER) stress, neither the biological function nor the relevant cellular targets of this protein modifier are known. Here, we show that a largely uncharacterized ribosomal protein, RPL26, is the principal target of UFM1 conjugation. RPL26 UFMylation and de-UFMylation is catalyzed by enzyme complexes tethered to the cytoplasmic surface of the ER and UFMylated RPL26 is highly enriched on ER membrane-bound ribosomes and polysomes. Biochemical analysis and structural modeling establish that UFMylated RPL26 and the UFMylation machinery are in close proximity to the SEC61 translocon, suggesting that this modification plays a direct role in cotranslational protein translocation into the ER. These data suggest that UFMylation is a ribosomal modification specialized to facilitate metazoan-specific protein biogenesis at the ER.",Ribosomal protein RPL26 is the principal target of UFMylation.,10.1073/pnas.1816202116,2019 Jan 22,PMC6347690,Proceedings of the National Academy of Sciences of the United States of America
GSE94384,RNA sequencing of primary human platelets and in vitro cell lines,Homo sapiens,14,SRP098699,2017-02-01,"[Overal design]Analysis of RNA sequencing data from primary human platelets and in vitro derived platelet-like particles; manipulation by overexpression of Pelota (PELO) in Meg01/platelet-like particles.; [Treatment]'None'; [Growth]'Cells were grown as described in Mills EW et al., 2017'; [Extraction]'Samples were extracted as described previously in Ingolia et al., 2014\nRNA-Seq libraries were prepared as described previously in Ingolia et al., 2014 using the TruSeq stranded RNA-Seq protocol'; [Cell type]'Source: ''tissue: primary cell type; rrna depletion: RiboZero-Gold rRNA depletion; ', 'tissue: cell line; drug treatment: 0.05ng Promega Firefly luciferase per 100ng Total RNA; rrna depletion: RiboZero-Gold rRNA depletion; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94384,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE94nnn/GSE94384/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA369543,28213379," Eric W Mills,  Rachel Green,  Nicholas T Ingolia","Platelets are anucleate cytoplasmic fragments that lack genomic DNA, but continue to synthesize protein using a pool of messenger RNAs (mRNAs), ribosomes, and regulatory small RNAs inherited from the precursor megakaryocyte (MK). The regulatory processes that shape the platelet transcriptome and the full scope of platelet translation have remained elusive. Using RNA sequencing (RNA-Seq) and ribosome profiling of primary human platelets, we show the platelet transcriptome encompasses a subset of transcripts detected by RNA-Seq analysis of in vitro-derived MK cells and that these platelet-enriched transcripts are broadly occupied by ribosomes. We use RNA-Seq of synchronized populations of in vitro-derived platelet-like particles to show that mRNA decay strongly shapes the nascent platelet transcriptome. Our data suggest that the decay of platelet mRNAs is slowed by the natural loss of the mRNA surveillance and ribosome rescue factor Pelota.",Slowed decay of mRNAs enhances platelet specific translation.,10.1182/blood-2016-08-736108,2017 Apr 27,PMC5409447,Blood
GSE70270,Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes,Homo sapiens,32,None,2015-06-25,"[Overal design]WISH cells were induced with interferon in the presence of vehicle, torin-1 or rapamycin. Both polysome-associated and total RNA was analyzed.; [Treatment]'WISH cells were trypsinized and plated in 10cm tissue culture dishes at 4 X 10^6 cells/dish. After 30 hrs, cells were re-fed with fresh medium with or without IFN \uf062 (100pM) and/or mTOR inhibitors at saturating concentrations (rapamycin 100nM or Torin1 1\uf06dM) for 12h.'; [Growth]'WISH cells were cultured as previously described [Francois-Newton V, Livingstone M, Payelle-Brogard B, Uze G, Pellegrini S (2012) USP18 establishes the transcriptional and anti-proliferative interferon alpha/beta differential. Biochem J 446: 509-516 and Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S (2007) Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J 407: 141-151]. WISH cells were obtained from G. Uz (CNRS, Montpellier) and originate from ATCC (CCL-25). Their identity was compared to HeLa S3 cells by short tandem repeat (STR) loci profiling. This analysis, performed by IdentiCell (Department of Molecular Medicine, Aarhus University Hospital), showed that the two cell lines have identical STR profiles.'; [Extraction]'RNAeasy (Qiagen)'; [Cell type]'Source: ''cell line: WISH; rna type: Polysome-associated; treatment: dmso; replicate: 1; ', 'cell line: WISH; rna type: Polysome-associated; treatment: dmso; replicate: 2; ', 'cell line: WISH; rna type: Polysome-associated; treatment: dmso; replicate: 3; ', 'cell line: WISH; rna type: Polysome-associated; treatment: dmso; replicate: 4; ', 'cell line: WISH; rna type: total; treatment: dmso; replicate: 1; ', 'cell line: WISH; rna type: total; treatment: dmso; replicate: 2; ', 'cell line: WISH; rna type: total; treatment: dmso; replicate: 3; ', 'cell line: WISH; rna type: total; treatment: dmso; replicate: 4; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn; replicate: 1; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn; replicate: 2; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn; replicate: 3; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn; replicate: 4; ', 'cell line: WISH; rna type: total; treatment: ifn; replicate: 1; ', 'cell line: WISH; rna type: total; treatment: ifn; replicate: 2; ', 'cell line: WISH; rna type: total; treatment: ifn; replicate: 3; ', 'cell line: WISH; rna type: total; treatment: ifn; replicate: 4; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_rapamycin; replicate: 1; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_rapamycin; replicate: 2; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_rapamycin; replicate: 3; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_rapamycin; replicate: 4; ', 'cell line: WISH; rna type: total; treatment: ifn_rapamycin; replicate: 1; ', 'cell line: WISH; rna type: total; treatment: ifn_rapamycin; replicate: 2; ', 'cell line: WISH; rna type: total; treatment: ifn_rapamycin; replicate: 3; ', 'cell line: WISH; rna type: total; treatment: ifn_rapamycin; replicate: 4; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_torin1; replicate: 1; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_torin1; replicate: 2; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_torin1; replicate: 3; ', 'cell line: WISH; rna type: Polysome-associated; treatment: ifn_torin1; replicate: 4; ', 'cell line: WISH; rna type: total; treatment: ifn_torin1; replicate: 1; ', 'cell line: WISH; rna type: total; treatment: ifn_torin1; replicate: 2; ', 'cell line: WISH; rna type: total; treatment: ifn_torin1; replicate: 3; ', 'cell line: WISH; rna type: total; treatment: ifn_torin1; replicate: 4; '",Expression profiling by array; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70270,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE70nnn/GSE70270/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA288136,26207988," Mark Livingstone,  Kristina Sikstrom,  Philippe A Robert,  Gilles Uze,  Ola Larsson,  Sandra Pellegrini","Type-I interferon (IFN)-induced activation of the mammalian target of rapamycin (mTOR) signaling pathway has been implicated in translational control of mRNAs encoding interferon-stimulated genes (ISGs). However, mTOR-sensitive translatomes commonly include mRNAs with a 5' terminal oligopyrimidine tract (TOP), such as those encoding ribosomal proteins, but not ISGs. Because these translatomes were obtained under conditions when ISG expression is not induced, we examined the mTOR-sensitive translatome in human WISH cells stimulated with IFN beta. The mTOR inhibitor Torin1 resulted in a repression of global protein synthesis, including that of ISG products, and translation of all but 3 ISG mRNAs (TLR3, NT5C3A, and RNF19B) was not selectively more sensitive to mTOR inhibition. Detailed studies of NT5C3A revealed an IFN-induced change in transcription start site resulting in a switch from a non-TOP to a TOP-like transcript variant and mTOR sensitive translation. Thus, we show that, in the cell model used, translation of the vast majority of ISG mRNAs is not selectively sensitive to mTOR activity and describe an uncharacterized mechanism wherein the 5'-UTR of an mRNA is altered in response to a cytokine, resulting in a shift from mTOR-insensitive to mTOR-sensitive translation.",Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes.,10.1371/journal.pone.0133482,2015,PMC4514843,PloS one
GSE129061,Ribo-seq on K562 and HepG2 cells,Homo sapiens,4,SRP189887,2019-03-29,"[Overal design]After RNase I footprinting in CHX-containing lysis buffer, RNA fragments around 29nt were isolated and subjected to rRNA depletion using RiboZero.; [Treatment]'None'; [Growth]'None'; [Extraction]'Cell lysis was performed in lysis buffer supplemented with 100?g/ml CHX. RNA fragments around 29nt were isolated and subjected to rRNA depletion using RiboZero.'; [Cell type]'Source: ''cell line: K562; ', 'cell line: HepG2; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129061,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE129nnn/GSE129061/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA529885,32601440," Lorenzo Calviello,  Antje Hirsekorn,  Uwe Ohler","Translation has a fundamental function in defining the fate of the transcribed genome. RNA-sequencing (RNA-seq) data enable the quantification of complex transcript mixtures, often detecting several transcript isoforms of unknown functions for one gene. Here, we describe ORFquant, a method to annotate and quantify translation at the level of single open reading frames (ORFs), using information from Ribo-seq data. By developing an approach for transcript filtering, we quantify translation transcriptome-wide, revealing translated ORFs on multiple isoforms per gene. For most genes, one ORF represents the dominant translation product, but we also detect genes with translated ORFs on multiple transcript isoforms, including targets of RNA surveillance mechanisms. Measuring translation across human cell lines reveals the extent of gene-specific differences in protein production, supported by steady-state protein abundance estimates. Computational analysis of Ribo-seq data with ORFquant (https://github.com/lcalviell/ORFquant) provides insights into the heterogeneous functions of complex transcriptomes.",Quantification of translation uncovers the functions of the alternative transcriptome.,10.1038/s41594-020-0450-4,2020 Aug,,Nature structural & molecular biology
GSE149973,Decoding SARS-CoV-2 coding capacity,Homo sapiens; Chlorocebus aethiops aethiops; Severe acute respiratory syndrome coronavirus 2,26,SRP260279,2020-05-06,"[Overal design]To capture the SARS-CoV-2 coding capacity, we applied a suits of ribosome profiling approaches to two types of infected cells, Vero 6 and Calu 3. The Vero 6 cells were infected for 5 and 24 hours with BavPat1/2020 EPI_ISL_406862, and the Calu 3 cells were infected for 7 hours with BavPat1/2020 Ref-SKU: 026V-03883. For each time point we mapped genome-wide translation events by preparing three different ribosome-profiling libraries. Two libraries facilitate mapping of translation initiation sites, by treating cells with lactimidomycin (LTM) or harringtonine (Harr), drugs that inhibit translation initiation, and the third library was prepared from cells treated with the translation elongation inhibitor cycloheximide (CHX). In parallel, we used a tailored RNA-seq protocol which on top of quantification of RNA levels allows identification of transcription start sites (TSSs).; [Treatment]'Cells were infected for 5 or 24 hours before treatment. For Ribo-seq libraries, cells were treated with either 50?M lactimidomycin(LTM) for 30 minutes or 2?g/mL Harringtonine (Harr) for 5 minutes, for translation initiation libraries (LTM and Harr libraries correspondingly), or left untreated for the translation elongation libraries (cycloheximide [CHX] library). All three samples were subsequently treated with 100?g/mL CHX for 1 minute. Cells were placed on ice immediately after treatment, washed twice with PBS containing 100?g/mL CHX.'; [Growth]'None'; [Extraction]'For RNA-seq, cells were harvested with Tri-Reagent (Sigma-Aldrich), total RNA was extracted, and poly-A selection was performed using Dynabeads mRNA DIRECT Purification Kit (Invitrogen). For ribosome profiling, medium was aspirated from dishes, which were immediately placed on ice and rinsed with 10 ml ice-cold PBS supplemented with drugs used in pretreatment of the cells. PBS was aspirated and 800 ?l ice-cold lysis buffer (20 mM Tris, pH 7.4, 250 mM NaCl, 15 mM MgCl2, 1 mM dithiothreito, 0.5% Triton X-100 and 24 U / ml Turbo DNase (Ambion, AM2239), along with any drugs used for sample treatment) was dripped onto dishes. Cells were scraped and the lysate was removed and incubated 10 min on ice. The lysate was then clarified by centrifugation for 10 min at 20,000  g, 4C and ?1.1 ml supernatant was recovered.\nRNA-seq: mRNA samplewas subjected to DNAseI treatment and 3 dephpsphorylation using FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific) and T4 PNK (NEB) followed by 3 adaptor ligation using T4 ligase (NEB). The ligated products used for reverse transcription with SSIII (Invitrogen) for first strand cDNA synthesis. The cDNA products were 3 ligated with a second adaptor using T4 ligase and amplified for 8 cycles in a PCR for final library products of 200-300bp. Ribo-seq:\nRNAseq and ribosome profiling'; [Cell type]'Source: ''virus strain: BetaCoV/Germany/BavPat1/2020 EPI_ISL_406862; cell line: Vero cells, ATCC, CCL-81; hours post infection: 5; ', 'virus strain: BetaCoV/Germany/BavPat1/2020 EPI_ISL_406862; cell line: Vero cells, ATCC, CCL-81; hours post infection: 24; ', 'virus strain: BavPat1/2020 EPI_ISL_406862; ', 'virus strain: BavPat1/2020 Ref-SKU: 026V-03883; ', 'virus strain: BavPat1/2020 Ref-SKU: 026V-03883; cell line: Calu 3 cells, ATCC HTB-55; hours post infection: 7; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149973,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE149nnn/GSE149973/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA630716,32906143," Yaara Finkel,  Orel Mizrahi,  Aharon Nachshon,  Shira Weingarten-Gabbay,  David Morgenstern,  Yfat Yahalom-Ronen,  Hadas Tamir,  Hagit Achdout,  Dana Stein,  Ofir Israeli,  Adi Beth-Din,  Sharon Melamed,  Shay Weiss,  Tomer Israely,  Nir Paran,  Michal Schwartz,  Noam Stern-Ginossar","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic(1). To understand the pathogenicity and antigenic potential of SARS-CoV-2 and to develop therapeutic tools, it is essential to profile the full repertoire of its expressed proteins. The current map of SARS-CoV-2 coding capacity is based on computational predictions and relies on homology with other coronaviruses. As the protein complement varies among coronaviruses, especially in regard to the variety of accessory proteins, it is crucial to characterize the specific range of SARS-CoV-2 proteins in an unbiased and open-ended manner. Here, using a suite of ribosome-profiling techniques(2-4), we present a high-resolution map of coding regions in the SARS-CoV-2 genome, which enables us to accurately quantify the expression of canonical viral open reading frames (ORFs) and to identify 23 unannotated viral ORFs. These ORFs include upstream ORFs that are likely to have a regulatory role, several in-frame internal ORFs within existing ORFs, resulting in N-terminally truncated products, as well as internal out-of-frame ORFs, which generate novel polypeptides. We further show that viral mRNAs are not translated more efficiently than host mRNAs; instead, virus translation dominates host translation because of the high levels of viral transcripts. Our work provides a resource that will form the basis of future functional studies.",The coding capacity of SARS-CoV-2.,10.1038/s41586-020-2739-1,2021 Jan,,Nature
GSE14335,Whole genome profiling of fibroblasts from Diamond-Blackfan Anemia patients,Homo sapiens,10,None,2009-01-08,"[Overal design]Analyzed samples include fibroblasts from 4 DBA patients and 6 healthy controls.; [Treatment]'Total RNA was extracted from 1 million cells upon reaching 80% confluence, within passages 2-5 of tissue culture.'; [Growth]""Fibroblasts were cultured in IMDM (Iscove's Modified Dulbecco's Medium) supplemented with 4 mM L-glutamine, 10% foetal calf serum, 0.1 mg/ml streptomycin, 100U/ml penicylline (Sigma-Aldrich, St. Louis, MO, USA) at 37C and 5% CO2.""; [Extraction]""Trizol extraction of total RNA was performed according to the manufacturer's instructions.""; [Cell type]'Source: ''disease state: Healthy Control; gender: Female; ', 'disease state: Healthy Control; gender: Male; ', 'disease state: Diamond-Blackfan anaemia; gender: Male; ', 'disease state: Diamond-Blackfan anaemia; gender: Female; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14335,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE14nnn/GSE14335/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA111515,19765279," Federica Avondo,  Paola Roncaglia,  Nicoletta Crescenzio,  Helena Krmac,  Emanuela Garelli,  Marta Armiraglio,  Carlotta Castagnoli,  Maria Francesca Campagnoli,  Ugo Ramenghi,  Stefano Gustincich,  Claudio Santoro,  Irma Dianzani","BACKGROUND: Diamond-Blackfan anaemia (DBA) is a rare inherited red cell hypoplasia characterised by a defect in the maturation of erythroid progenitors and in some cases associated with malformations. Patients have an increased risk of solid tumors. Mutations have been found in several ribosomal protein (RP) genes, i.e RPS19, RPS24, RPS17, RPL5, RPL11, RPL35A. Studies in haematopoietic progenitors from patients show that haplo-insufficiency of an RP impairs rRNA processing and ribosome biogenesis. DBA lymphocytes show reduced protein synthesis and fibroblasts display abnormal rRNA processing and impaired proliferation. RESULTS: To evaluate the involvement of non-haematopoietic tissues in DBA, we have analysed global gene expression in fibroblasts from DBA patients compared to healthy controls. Microarray expression profiling using Affymetrix GeneChip Human Genome U133A 2.0 Arrays revealed that 421 genes are differentially expressed in DBA patient fibroblasts. These genes include a large cluster of ribosomal proteins and factors involved in protein synthesis and amino acid metabolism, as well as genes associated to cell death, cancer and tissue development. CONCLUSION: This analysis reports for the first time an abnormal gene expression profile in a non-haematopoietic cell type in DBA. These data support the hypothesis that DBA may be due to a defect in general or specific protein synthesis.","Fibroblasts from patients with Diamond-Blackfan anaemia show abnormal expression of genes involved in protein synthesis, amino acid metabolism and cancer.",10.1186/1471-2164-10-442,2009 Sep 18,PMC2760583,BMC genomics
GSE101760,Viral infection identifies micropeptides differentially regulated in smORF-containing lncRNA,Homo sapiens,16,SRP113333,2017-07-21,"[Overal design]RNA-seq and ribosome profiling in A549 cells infected with H1N1 PR8 influenza, PR8dNS1 deletion strain, mock infection, or uninfected, in duplicates; [Treatment]""Cells were infected with PR8 or PR8?NS1 as described (Talon et al. ASM 74:7989, 2000). Control cells were not subject to any media changes, while mock infected cells were washed with PBS, rocked in 4mL's of DMEM without any supplements for 1 hour, then washed with PBS, followed by the addition of culture medium""; [Growth]'A549 cells were grown in a 15cm dish in culture medium'; [Extraction]""12 hours post infection, cells were harvested.\nLibrary preparation proceeded according to manufacturer's protocol using the TruSeq Ribo Profile for Mammalian kit. Depletion of ribosomal RNA was performed using the Ribo-Zero rRNA Removal Kit (H/M/R).""; [Cell type]'A549 cells''infection: control; cell type: A549 cells; molecule: RPF; ', 'infection: H1N1 PR8[delta]NS1; cell type: A549 cells; molecule: RPF; ', 'infection: mock; cell type: A549 cells; molecule: RPF; ', 'infection: H1N1 PR8; cell type: A549 cells; molecule: RPF; ', 'infection: control; cell type: A549 cells; molecule: total RNA; ', 'infection: H1N1 PR8[delta]NS1; cell type: A549 cells; molecule: total RNA; ', 'infection: mock; cell type: A549 cells; molecule: total RNA; ', 'infection: H1N1 PR8; cell type: A549 cells; molecule: total RNA; ', 'infection: none; cell type: A549 cells; molecule: total RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101760,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE101nnn/GSE101760/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA395384,28825667," Brandon S Razooky,  Benedikt Obermayer,  Joshua Biggs O'May,  Alexander Tarakhovsky","Viral infection leads to a robust cellular response whereby the infected cell produces hundreds of molecular regulators to combat infection. Currently, non-canonical components, e.g., long noncoding RNAs (lncRNAs) have been added to the repertoire of immune regulators involved in the antiviral program. Interestingly, studies utilizing next-generation sequencing technologies show that a subset of the >10,000 lncRNAs in the mammalian genome contain small open reading frames (smORFs) associated with active translation, i.e., many lncRNAs are not noncoding. Here, we use genome-wide high-throughput methods to identify potential micropeptides in smORF-containing lncRNAs involved in the immune response. Using influenza as a viral infection model, we performed RNA-seq and ribosome profiling to track expression and translation of putative lncRNAs that may encode for peptides and identify tens of potential candidates. Interestingly, many of these peptides are highly conserved at the protein level, strongly suggesting biological relevance and activity. By perusing publicly available data sets, four potential peptides of interest seem common to stress induction and/or are highly conserved; potential peptides from the MMP24-AS1, ZFAS1, RP11-622K12.1, and MIR22HG genes. Interestingly, using an antibody against the potential peptide encoded by MIR22HG RNA, we show that the peptide is stably expressed in the absence of infection, and upregulated in response to infection, corroborating the prediction of the ribosome profiling results. These data show the utility of perturbation approaches in identifying potentially relevant novel molecules encoded in the genome.",Viral Infection Identifies Micropeptides Differentially Regulated in smORF-Containing lncRNAs.,10.3390/genes8080206,2017 Aug 21,PMC5575669,Genes
GSE68435,"Yeast m6A methylated mRNAs are enriched on translating ribosomes during meiosis, and under Rapamycin treatment",Schizosaccharomyces pombe,12,None,2015-04-30,"[Overal design]GeneChip analyses were performed to investigate the distribution of early meiotic transcripts (3hours) on different polysome and monosome fractions; [Treatment]'Polysome profiles The ribosomal complexes in the yeast cultures were stabilized by adding cycloheximide to a 100g/ml final concentration prior to harvest. The cell were spun down immediately, and frozen in liquid N2. They were either stored at -70oC or processed immediately by grinding in pestle and mortar, under liquid N2 to fine powder. The cells were lysed in 0.5ml lysis buffer (0.3M NaCl, 15mM MgCl2, 15mM Tris-HCl pH7.5, cycloheximide 100ug/ml, Heparin (sodium salt) 1mg/ml, 1% Triton X-100). The lysates were loaded on a sucrose gradient column and spun for two hours at 38 000 rpm at 4oC. After the gradient centrifugation 12x 1ml fractions were collected and precipitated in equal volume isopropanol. After several washes with 80% ethanol the samples were resuspended in water and processed.'; [Growth]'All analysis was carried out using the SK1 (can1), diploid strain (ATCC).  Cultures were routinely grown in YPD (1% Bacto-yeast extract, 2% Bacto-peptone, 2% glucose) to the required cell density. For sporulation experiments, one single colony was inoculated in YPD and grown to 2x107cell/ml. After centrifugation and washing with sterile water, the pellet was resuspended to a 5x106cell/ml density in PSP2 medium (31). The culture was grown for five generations at 28-30oC with vigorous shaking, and then harvested and washed with water, followed by resuspending in SPM (0.3% potassium acetate, 0.02% raffinose) (31) to a 107cell/ml density to induce sporulation. Following 3 hours vigorous shaking at 28-30oC, the culture was spun down and the pellet was used for RNA extraction, or polysome profiling.'; [Extraction]'For total RNA extraction we used a hot phenol extraction method ,and the quality of the mRNA was checked on an RNA 6000 LabChip, with Agilent Bioanalyzer (Ambion).'; [Cell type]'Source: ''line: SK1; developmental stage: 3 hours sporulating; fraction: polysome fractions 4-6; ', 'line: SK1; developmental stage: 3 hours sporulating; fraction: polysome fractions 7-8; ', 'line: SK1; developmental stage: 3 hours sporulating; fraction: polysome fractions 9-10; ', 'line: SK1; developmental stage: 3 hours sporulating; fraction: input RNA (non-fractionated); '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68435,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE68nnn/GSE68435/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA282733,26186436," Zsuzsanna Bodi,  Andrew Bottley,  Nathan Archer,  Sean T May,  Rupert G Fray","Interest in mRNA methylation has exploded in recent years. The sudden interest in a 40 year old discovery was due in part to the finding of FTO's (Fat Mass Obesity) N6-methyl-adenosine (m6A) deaminase activity, thus suggesting a link between obesity-associated diseases and the presence of m6A in mRNA. Another catalyst of the sudden rise in mRNA methylation research was the release of mRNA methylomes for human, mouse and Saccharomyces cerevisiae. However, the molecular function, or functions of this mRNA 'epimark' remain to be discovered. There is supportive evidence that m6A could be a mark for mRNA degradation due to its binding to YTH domain proteins, and consequently being chaperoned to P bodies. Nonetheless, only a subpopulation of the methylome was found binding to YTHDF2 in HeLa cells.The model organism Saccharomyces cerevisiae, has only one YTH domain protein (Pho92, Mrb1), which targets PHO4 transcripts for degradation under phosphate starvation. However, mRNA methylation is only found under meiosis inducing conditions, and PHO4 transcripts are apparently non-methylated. In this paper we set out to investigate if m6A could function alternatively to being a degradation mark in S. cerevisiae; we also sought to test whether it can be induced under non-standard sporulation conditions. We find a positive association between the presence of m6A and message translatability. We also find m6A induction following prolonged rapamycin treatment.","Yeast m6A Methylated mRNAs Are Enriched on Translating Ribosomes during Meiosis, and under Rapamycin Treatment.",10.1371/journal.pone.0132090,2015,PMC4505848,PloS one
GSE102336,A new N6-methyladenosine methyltransferase ZCCHC4 mediates rRNA methylation and mRNA interaction,Homo sapiens,22,SRP114978,2017-08-07,"[Overal design]We used PAR-CLIP to identify the binding targets of ZCCHC4 in HeLa cells. We used polysome sequencing to identify targets of ZCCHC4 wild type and knock out HepG2 cell for translation. We used m6A-seq to identify changes in m6A and RNA expression ZCCHC4 KO HepG2 cells.; [Treatment]'For PARCLIP treat the cell with 4SU at 100uM 24 hour'; [Growth]'None'; [Extraction]'NEBNext Multiplex Small RNA Library Prep Set for Illumina', 'Illumina TruSeq Stranded mRNA Library Prep Kit'; [Cell type]'Source: ''cell line: HeLa cells; genotype: N terminal Flag-HA tagged ZCCHC4 HeLa stable expression cell line; ', 'cell line: HepG2 wild-type; genotype: wild type; ', 'cell line: HepG2 ZCCHC4 knockout; genotype: ZCCHC4 knockout; '",Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102336,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE102nnn/GSE102336/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA397443,30531910," Honghui Ma,  Xiaoyun Wang,  Jiabin Cai,  Qing Dai,  S Kundhavai Natchiar,  Ruitu Lv,  Kai Chen,  Zhike Lu,  Hao Chen,  Yujiang Geno Shi,  Fei Lan,  Jia Fan,  Bruno P Klaholz,  Tao Pan,  Yang Shi,  Chuan He","N(6)-Methyladenosine (m(6)A) RNA modification is present in messenger RNAs (mRNA), ribosomal RNAs (rRNA), and spliceosomal RNAs (snRNA) in humans. Although mRNA m(6)A modifications have been extensively studied and shown to play critical roles in many cellular processes, the identity of m(6)A methyltransferases for rRNAs and the function of rRNA m(6)A modifications are unknown. Here we report a new m(6)A methyltransferase, ZCCHC4, which primarily methylates human 28S rRNA and also interacts with a subset of mRNAs. ZCCHC4 knockout eliminates m(6)A4220 modification in 28S rRNA, reduces global translation, and inhibits cell proliferation. We also find that ZCCHC4 protein is overexpressed in hepatocellular carcinoma tumors, and ZCCHC4 knockout significantly reduces tumor size in a xenograft mouse model. Our results highlight the functional significance of an rRNA m(6)A modification in translation and in tumor biology.",N(6-)Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation.,10.1038/s41589-018-0184-3,2019 Jan,PMC6463480,Nature chemical biology
GSE50648,Whole Adult Organism Transcriptional Profiling of Metal Exposures in Zebrafish,Danio rerio,48,None,2013-09-06,"[Overal design]Metal induced changes in gene expression in zebrafish were measured after 24 h exposures to each of three metals (nickel, chromium or cobalt). A total of 48 arrays were processed - 16 arrays per metal with 4 replicates for each exposure condition (control, low, mid, and high).; [Treatment]'Exposures were conducted for 24 h using control (no toxicant) plus the high, mid, and low concentrations of each metal in the flow-through aquaria with metal concentrations maintained for the duration of the exposure.'; [Growth]'Exposures were conducted in 5-gallon glass aquaria adapted for flow-through use (60 mL/min; 5.4 turnovers/day) and maintained at 25C with a 12h:12h (light:dark) photoperiod.'; [Extraction]'Whole frozen fish were pulverized under liquid nitrogen using a SPEX 6750 freezer mill (SPEX Sample Prep, Metuchen, NJ). Total RNA was isolated from the pulverized material using Trizol (Invitrogen, Carlsbad, CA) with an extra clarification centrifugation step to remove bone, scales, lipid and other debris, followed by column purification with RNeasy Mini kits (Qiagen, GmbH, Germany) to remove residual salt and organic solvents. Total RNA quality and quantity were evaluated using an Agilent Bioanalyzer 2100 (Agilent, Santa Clara, CA) and verified using the NanoDrop ND-1000 Spectrophotometer (NanoDrop, Wilmington, DE).'; [Cell type]'Source: ''age: adult (6 - 9 months); chemical group: Cr; dose: low; chemical concentration (measured): 56.5 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Cr; dose: mid; chemical concentration (measured): 69.9 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Cr; dose: high; chemical concentration (measured): 80.6 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Ni; dose: control; chemical concentration (measured): 0 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Cr; dose: control; chemical concentration (measured): 0 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Ni; dose: low; chemical concentration (measured): 42.4 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Ni; dose: mid; chemical concentration (measured): 51.0 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Ni; dose: high; chemical concentration (measured): 64.0 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Co; dose: control; chemical concentration (measured): 0 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Co; dose: low; chemical concentration (measured): 39.7 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Co; dose: mid; chemical concentration (measured): 46.3 mg/L; tissue: whole organism; ', 'age: adult (6 - 9 months); chemical group: Co; dose: high; chemical concentration (measured): 59.5 mg/L; tissue: whole organism; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50648,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE50nnn/GSE50648/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA218201,24612858," Naissan Hussainzada,  John A Lewis,  Christine E Baer,  Danielle L Ippolito,  David A Jackson,  Jonathan D Stallings","BACKGROUND: A convergence of technological breakthroughs in the past decade has facilitated the development of rapid screening tools for biomarkers of toxicant exposure and effect. Platforms using the whole adult organism to evaluate the genome-wide response to toxicants are especially attractive. Recent work demonstrates the feasibility of this approach in vertebrates using the experimentally robust zebrafish model. In the present study, we evaluated gene expression changes in whole adult male zebrafish following an acute 24 hr high dose exposure to three metals with known human health risks. Male adult zebrafish were exposed to nickel chloride, cobalt chloride or sodium dichromate concentrations corresponding to their respective 96 hr LC20, LC40 and LC60. Histopathology was performed on a subset of metal-exposed zebrafish to phenotypically anchor transcriptional changes associated with each metal. RESULTS: Comparative analysis identified subsets of differentially expressed transcripts both overlapping and unique to each metal. Application of gene ontology (GO) and transcription factor (TF) enrichment algorithms revealed a number of key biological processes perturbed by metal poisonings and the master transcriptional regulators mediating gene expression changes. Metal poisoning differentially activated biological processes associated with ribosome biogenesis, proteosomal degradation, and p53 signaling cascades, while repressing oxygen-generating pathways associated with amino acid and lipid metabolism. Despite appreciable effects on gene regulation, nickel poisoning did not induce any morphological alterations in male zebrafish organs and tissues. Histopathological effects of cobalt remained confined to the olfactory system, while chromium targeted the gills, pharynx, and intestinal mucosa. A number of enriched transcription factors mediated the observed gene response to metal poisoning, including known targets such as p53, HIF1alpha, and the myc oncogene, and novel regulatory factors such as XBP1, GATA6 and HNF3beta. CONCLUSIONS: This work uses an experimentally innovative approach to capture global responses to metal poisoning and provides mechanistic insights into metal toxicity.",Whole adult organism transcriptional profiling of acute metal exposures in male zebrafish.,10.1186/2050-6511-15-15,2014 Mar 10,PMC4007779,BMC pharmacology & toxicology
GSE155727,Transcriptome-wide analysis of mRNA translation and associated post-transcriptional regulatory mechanisms following neuronal membrane depolarisation,Homo sapiens,36,SRP276055,2020-08-05,"[Overal design]Examination of changes in mRNA translation, expression and small RNA expression in neuronally differentiated SH-SY5Y cells.; [Treatment]""Depolarised cells were incubated in Hank's Balanced Salt Solution (35mM NaCl, 0.6mM MgSO4.7H2O, 2.5 mM CaCl2.2H2O, 10mM HEPES, 6mM Glucose) supplemented with stimulating concentrations of KCl (100mM). Cells were incubated for 3 min at room temp, then rested at standard culturing conditions for 10 min. A total of 4 consecutive stimulus-rest cycles were conducted, after which cells were harvested either immediately or 2 hours after the final stimulus-rest cycle.""; [Growth]'SH-SY5Y cultures were neuronally differentiated using all-trans retinoic acid (ATRA; Sigma-Aldrich) (Encinas et al. 2000). One day prior to differentiation (day -1), cells were seeded at a density of 25,000 cells/cm2 in complete culture medium. The next day (day 0), standard culture medium was replaced with ATRA-supplemented medium (10M final) and cells were wrapped in foil to protect from light exposure. ATRA-medium was subsequently replaced on days 2, 4 and 6, after which the methods were continued as described on day 7.'; [Extraction]'Cells were exposed to cycloheximide (0.1mg/mL) prior to detergent lysis and scraping as per the Illumina TruSeq Ribo Profile kit manual.\nProduction of ribosome protected mRNA fragments (RPFs) and library preparation were then performed using the Illumina TruSeq Ribo Profile kit (H/M/R), with minor amendments to the manufacturers protocol. Briefly, 300L clarified lysate was treated with 9L RNase I (45 min) to digest unprotected RNAs, after which reactions were stopped with 15L SUPERase inhibitor (Invitrogen). Small RNA fragments were then enriched using MicroSpin S-400 columns (GE Life Sciences), prior to ribosomal RNA depletion, RPF size selection, end repair, adapter ligation, reverse transcription and PAGE purification, conducted according to the manufacturers instructions. RPF cDNA amplicons were subsequently produced with 12x PCR cycles, adapter dimers were removed via 8% native polyacrylamide gel and samples were quantified via Agilent high sensitivity DNA chip. For sequencing, samples were pooled in equal volumes and concentrations, denatured with NaOH (0.2mM) and diluted to a final concentration of 1.8pM in Tris-HCl (200mM, pH 7) and HT1 buffer. RPF libraries were then subjected to 76 single-end sequencing cycles using the Illumina NextSeq 500 benchtop sequencer.'; [Cell type]'Neuronally differentiated SH-SY5Y''cell type: Neuronally differentiated SH-SY5Y; passages: 7; depolarised: No; molecule subtype: Poly(A) mRNA; ', 'cell type: Neuronally differentiated SH-SY5Y; passages: 7; depolarised: No; molecule subtype: ribosome-protected mRNA; ', 'cell type: Neuronally differentiated SH-SY5Y; passages: 7; depolarised: No; molecule subtype: small RNA; ', 'cell type: Neuronally differentiated SH-SY5Y; passages: 7; depolarised: Yes; molecule subtype: Poly(A) mRNA; ', 'cell type: Neuronally differentiated SH-SY5Y; passages: 7; depolarised: Yes; molecule subtype: ribosome-protected mRNA; ', 'cell type: Neuronally differentiated SH-SY5Y; passages: 7; depolarised: Yes; molecule subtype: small RNA; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155727,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE155nnn/GSE155727/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA655417,32992958," Dylan J Kiltschewskij,  Murray J Cairns","Experience-dependent changes to neural circuitry are shaped by spatially-restricted activity-dependent mRNA translation. Although the complexity of mRNA translation in neuronal cells is widely appreciated, translational profiles associated with neuronal excitation remain largely uncharacterized, and the associated regulatory mechanisms are poorly understood. Here, we employed ribosome profiling, mRNA sequencing and small RNA sequencing to profile transcriptome-wide changes in mRNA translation after whole cell depolarization of differentiated neuroblast cultures, and investigate the contribution of sequence-specific regulatory mechanisms. Immediately after depolarization, a functional partition between transcriptional and translational responses was uncovered, in which many mRNAs were subjected to significant changes in abundance or ribosomal occupancy, but not both. After an extended (2 h) post-stimulus rest phase, however, these changes became synchronized, suggesting that there are different layers of post-transcriptional regulation which are temporally separated but become coordinated over time. Globally, changes in mRNA abundance and translation were found to be associated with a number of intrinsic mRNA features, including mRNA length, GC% and secondary structures; however, the effect of these factors differed between both post-depolarization time-points. Furthermore, small RNA sequencing revealed that miRNAs and tRNA-derived small RNA fragments were subjected to peak changes in expression immediately after stimulation, during which these molecules were predominantly associated with fluctuations in mRNA abundance, consistent with known regulatory mechanisms. These data suggest that excitation-associated neuronal translation is subjected to extensive temporal coordination, with substantial contributions from a number of sequence-dependent regulatory mechanisms.","Transcriptome-Wide Analysis of Interplay between mRNA Stability, Translation and Small RNAs in Response to Neuronal Membrane Depolarization.",10.3390/ijms21197086,2020 Sep 25,PMC7582590,International journal of molecular sciences
GSE94460,Ribosome profiling of HEK293 cells.,Homo sapiens,3,SRP098797,2017-02-03,"[Overal design]Ribosome protected fragments were extracted from HEK293 cells treated with cycloheximide or harringtonine plus cycloheximide.; [Treatment]'None'; [Growth]'HKE293 cells were grown in high-glucose DMEM supplemented with 10% fetal bovine serum, penicillin and streptomycin at 37? under an atmosphere of 5% CO2.'; [Extraction]'For CHX treatment, HEK293 cells were treated with CHX (Sigma-Aldrich, final concentration 0.1mg/ml) for 1 minutes. For Harr treatment, the cells were firstly treated with Harr (LKT Laboratories, final concentation 2 ?g/ml) for 2 minutes at 37? in the incubator and then proceed CHX treatment. In-dish cell lysis were performed using Mammalian Lysis Buffer (including CHX at a concentration of 0.1mg/ml). Then 600 ?l of lysate were taken and 15 ul of RNase I (100 U/?l, Thermo Fisher Scientific) were added and the mixtures were incubated for 45min at room temperature followed by adding 15 ?l SUPERaseIn RNase inhibitor (Thermo Fisher Scientific) to stop the reaction. Ribosome recovery were done by illustra MicroSpin S-400 HR Columns (GE Healthcare) and the Ribosomal Protected Fragments (PFFs) were purified by RNA Clean & Concentrator (Zymo Research). Ribosomal RNA was subtracted using Ribo-Zero Magnetic Gold Kit (Human/Mouse/Rat, Illumina). RPFs without ribosomal RNA were ran on a 15% Urea denaturing-PAGE gel, and the gel slides from 28nt~30nt were excised.'; [Cell type]'Source: ''cell line: HEK293; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94460,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE94nnn/GSE94460/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA369756,29170441," Peng Zhang,  Dandan He,  Yi Xu,  Jiakai Hou,  Bih-Fang Pan,  Yunfei Wang,  Tao Liu,  Christel M Davis,  Erik A Ehli,  Lin Tan,  Feng Zhou,  Jian Hu,  Yonghao Yu,  Xi Chen,  Tuan M Nguyen,  Jeffrey M Rosen,  David H Hawke,  Zhe Ji,  Yiwen Chen","Translation is principally regulated at the initiation stage. The development of the translation initiation (TI) sequencing (TI-seq) technique has enabled the global mapping of TIs and revealed unanticipated complex translational landscapes in metazoans. Despite the wide adoption of TI-seq, there is no computational tool currently available for analyzing TI-seq data. To fill this gap, we develop a comprehensive toolkit named Ribo-TISH, which allows for detecting and quantitatively comparing TIs across conditions from TI-seq data. Ribo-TISH can also predict novel open reading frames (ORFs) from regular ribosome profiling (rRibo-seq) data and outperform several established methods in both computational efficiency and prediction accuracy. Applied to published TI-seq/rRibo-seq data sets, Ribo-TISH uncovers a novel signature of elevated mitochondrial translation during amino-acid deprivation and predicts novel ORFs in 5'UTRs, long noncoding RNAs, and introns. These successful applications demonstrate the power of Ribo-TISH in extracting biological insights from TI-seq/rRibo-seq data.",Genome-wide identification and differential analysis of translational initiation.,10.1038/s41467-017-01981-8,2017 Nov 23,PMC5701008,Nature communications
GSE140997,Sequence- and structure-specific cytosine-5 methylation in mRNAs by NSUN6,Homo sapiens,61,SRP233222,2019-11-25,"[Overal design]Ribosome profiling and total RNA-seq from human H9 and HEK293 cells. Control or NSUN6-knockout samples. Identification of NSUN6 methylation targets by miCLIP in human HEK293 cells.; [Treatment]'None'; [Growth]'The human embryonic stem cell (hESC) line Hues9 (H9) was obtained from the Wicell Research Institute (Madison, WI) and maintained in Essential 8 media (Thermo Fisher Scientific) on hESC-Qualified Matrigel (Corning) coated plates. Media was refreshed daily and the cultures were dissociated in clumps every 4 days using 0.5mM EDTA in PBS. HEK293 (HEK) cells were obtained from ATCC and grown in DMEM Media (Thermo Fisher Scientific) supplemented with 1mM Glutamax (Thermo Fisher Scientific), 10% heat inactivated FBS (Thermo Fisher Scientific). All cells were grown at 37C, 5 % CO2.'; [Extraction]'Total RNA extraction by non ionic detergent-based cell lysis was performed for both H9 and HEK293 cells.\nLibraries for H9 WT and NSun6 KO cells (at least 4 replicates each) were performed as described before (Bornelov et al, 2019, Blanco et al. 2016). For the RNA seq samples, we used the NEB ultra-directional library prep kit (NEB). Ribosomal profiling samples were made into libraries using the Illumina Truseq small RNA kit (Illumina). HEK293 WT and NSun6 KO libraries (4 replicates each) were prepared using the Illumina TruSeq Ribo Profile kit; the Total RNA libraries were depleted of ribosomal RNAs using the Illumina Ribo-Zero rRNA removal kit.', 'For miCLIP, myc-tagged NSun6 constructs were transfected into HEK293 cells which were harvested 24 hours post-transfection. Cells were then lysed in lysis buffer and treated with high concentration of DNase and low concentration of RNaseI to partially fragment RNAs. Lysates were incubated with proteinG dynabeads in the presence of anti-myc antibody to isolate NSUN-RNA complexes. Libraries were then prepared following isolation of RNAs from the protein-RNA complexes.\nLibraries were prepared using Illumina TruSeq RNA prep kits'; [Cell type]'Source: ''cell line: HEK293; genotype: Nsun6 knockout (Clone 1 nucleotide indel); batch: 4; ', 'cell line: HEK293; genotype: Nsun6 knockout (Clone 2 nucleotide indel); batch: 4; ', 'cell line: HEK293; genotype: Control (Wild-type); batch: 4; ', 'cell line: H9; genotype: Nsun6 knockout (Clone 1 nucleotide indel exon2); batch: 1; ', 'cell line: H9; genotype: Nsun6 knockout (Clone 2 nucleotide indel exon2); batch: 2; ', 'cell line: H9; genotype: Nsun6 knockout (Clone 3 nucleotide indel exon9); batch: 3; ', 'cell line: H9; genotype: Nsun6 knockout (Clone 4 nucleotide indel exon2); batch: 2; ', 'cell line: H9; genotype: Control (Wild-type); batch: 1; ', 'cell line: H9; genotype: Control (Wild-type); batch: 2; ', 'cell line: H9; genotype: Control (Wild-type Crispr control (random)); batch: 3; ', 'genotype: Control (Wild-type); cell line: HEK293; rip antibody: anti c-myc 9E10; rip antibody manufacturer: Sigma; catalog number M4439; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140997,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE140nnn/GSE140997/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA591625,33330931," Tommaso Selmi,  Shobbir Hussain,  Sabine Dietmann,  Matthias Heiss,  Kayla Borland,  Sophia Flad,  Jean-Michel Carter,  Rebecca Dennison,  Ya-Lin Huang,  Stefanie Kellner,  Susanne Bornelov,  Michaela Frye","The highly abundant N6-methyladenosine (m6A) RNA modification affects most aspects of mRNA function, yet the precise function of the rarer 5-methylcytidine (m5C) remains largely unknown. Here, we map m5C in the human transcriptome using methylation-dependent individual-nucleotide resolution cross-linking and immunoprecipitation (miCLIP) combined with RNA bisulfite sequencing. We identify NSUN6 as a methyltransferase with strong substrate specificity towards mRNA. NSUN6 primarily targeted three prime untranslated regions (3'UTR) at the consensus sequence motif CTCCA, located in loops of hairpin structures. Knockout and rescue experiments revealed enhanced mRNA and translation levels when NSUN6-targeted mRNAs were methylated. Ribosome profiling further demonstrated that NSUN6-specific methylation correlated with translation termination. While NSUN6 was dispensable for mouse embryonic development, it was down-regulated in human tumours and high expression of NSUN6 indicated better patient outcome of certain cancer types. In summary, our study identifies NSUN6 as a methyltransferase targeting mRNA, potentially as part of a quality control mechanism involved in translation termination fidelity.",,10.1093/nar/gkaa1193,2021 Jan 25TI - Sequence- and structure-specific cytosine-5 mRNA methylation by NSUN6.,PMC7826283,Nucleic acids research
GSE76766,mTORC1 and CK2 coordinate ternary and eIF4F complex assembly,Homo sapiens,24,None,2016-01-12,"[Overal design]Comparisons of polysome-associated and cytoplasmic mRNA from starved cells or cells stimulated with insulin in the presence or absence of Torin-1.; [Treatment]'MCF7 cells were seeded in a 15 cm Petri dish, serum starved for 16 hours  (control) and then treated with 4.2 nM of recombinant human insulin (Sigma-Aldrich) for 4 hours alone (insulin) or in combination with 250 nM torin1 (insulin+torin1).  Cells were harvested at 80% confluency and lysed in hypotonic lysis buffer [5 mM Tris HCl pH (7.5), 2.5 mM MgCl2, 1.5 mM KCl, 100 ?g/ml cycloheximide, 2 mM DTT, 0.5% Triton, 0.5% Sodium Deoxycholate). 10% of the lysates was saved to isolate cytoplasmic mRNA. The amount of RNA in each lysate was measured at 254 nm and 12 ODs were loaded on 5%-50% sucrose gradients generated using Gradient Master (Biocomp) and subjected to ultracentrifugation (SW41 rotor; Beckman 36,000, 2h and 4oC). Sucrose gradients were fractionated by displacement by 60% sucrose/0.01% bromphenol blue using ISCO Foxy fraction collector (35 seconds for each fraction=750 ?l/fraction) equipped with a UV-lamp for continuous absorbance monitoring. Fractions were flash frozen immediately after fractionation and stored at -80oC. RNA was isolated with Trizol according to manufacturers instruction. For microarray analysis fractions corresponding to polysome-associated RNA (more than 3 ribsomes) were pooled.'; [Growth]'MCF7 cells were obtained from ATCC and maintained inRPMI-1640, supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% L-Glutamine (all from Wisent Bio Products).'; [Extraction]'Total RNA was extracted using Trizol.'; [Cell type]'Source: ''cell line: MCF7; condition: Control; rna source: Cytoplasmic; replicate: rep1; ', 'cell line: MCF7; condition: Control; rna source: Cytoplasmic; replicate: rep2; ', 'cell line: MCF7; condition: Control; rna source: Cytoplasmic; replicate: rep3; ', 'cell line: MCF7; condition: Control; rna source: Cytoplasmic; replicate: rep4; ', 'cell line: MCF7; condition: Control; rna source: Polysome-associated; replicate: rep1; ', 'cell line: MCF7; condition: Control; rna source: Polysome-associated; replicate: rep2; ', 'cell line: MCF7; condition: Control; rna source: Polysome-associated; replicate: rep3; ', 'cell line: MCF7; condition: Control; rna source: Polysome-associated; replicate: rep4; ', 'cell line: MCF7; condition: Ins; rna source: Cytoplasmic; replicate: rep1; ', 'cell line: MCF7; condition: Ins; rna source: Cytoplasmic; replicate: rep2; ', 'cell line: MCF7; condition: Ins; rna source: Cytoplasmic; replicate: rep3; ', 'cell line: MCF7; condition: Ins; rna source: Cytoplasmic; replicate: rep4; ', 'cell line: MCF7; condition: Ins; rna source: Polysome-associated; replicate: rep1; ', 'cell line: MCF7; condition: Ins; rna source: Polysome-associated; replicate: rep2; ', 'cell line: MCF7; condition: Ins; rna source: Polysome-associated; replicate: rep3; ', 'cell line: MCF7; condition: Ins; rna source: Polysome-associated; replicate: rep4; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Cytoplasmic; replicate: rep1; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Cytoplasmic; replicate: rep2; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Cytoplasmic; replicate: rep3; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Cytoplasmic; replicate: rep4; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Polysome-associated; replicate: rep1; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Polysome-associated; replicate: rep2; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Polysome-associated; replicate: rep3; ', 'cell line: MCF7; condition: Ins+Torin1; rna source: Polysome-associated; replicate: rep4; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76766,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE76nnn/GSE76766/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA308553,27040916," Valentina Gandin,  Laia Masvidal,  Marie Cargnello,  Laszlo Gyenis,  Shannon McLaughlan,  Yutian Cai,  Clara Tenkerian,  Masahiro Morita,  Preetika Balanathan,  Olivier Jean-Jean,  Vuk Stambolic,  Matthias Trost,  Luc Furic,  Louise Larose,  Antonis E Koromilas,  Katsura Asano,  David Litchfield,  Ola Larsson,  Ivan Topisirovic","Ternary complex (TC) and eIF4F complex assembly are the two major rate-limiting steps in translation initiation regulated by eIF2alpha phosphorylation and the mTOR/4E-BP pathway, respectively. How TC and eIF4F assembly are coordinated, however, remains largely unknown. We show that mTOR suppresses translation of mRNAs activated under short-term stress wherein TC recycling is attenuated by eIF2alpha phosphorylation. During acute nutrient or growth factor stimulation, mTORC1 induces eIF2beta phosphorylation and recruitment of NCK1 to eIF2, decreases eIF2alpha phosphorylation and bolsters TC recycling. Accordingly, eIF2beta mediates the effect of mTORC1 on protein synthesis and proliferation. In addition, we demonstrate a formerly undocumented role for CK2 in regulation of translation initiation, whereby CK2 stimulates phosphorylation of eIF2beta and simultaneously bolsters eIF4F complex assembly via the mTORC1/4E-BP pathway. These findings imply a previously unrecognized mode of translation regulation, whereby mTORC1 and CK2 coordinate TC and eIF4F complex assembly to stimulate cell proliferation.",mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.,10.1038/ncomms11127,2016 Apr 4,PMC4822005,Nature communications
GSE65912,"Integrative analysis of RNA, translation and protein levels reveals distinct regulatory variation across humans",Homo sapiens,68,SRP055009,2015-02-13,"[Overal design]Ribosome profiling and RNA sequencing experiments from human lymphoblastoid cells; [Treatment]'For ribosome profiling experiments, the cell pellets were frozen in liquid nitrogen prior to cell lysis. Cells were lysed in 150ul of lysis buffer (20 mM Tris-HCl pH 7.5; 150 mM NaCl; 5mM MgCl2; 1mM DTT; 100 ?g.ml-1 Cycloheximide; 1% Triton X-100; 25U.ml-1 Turbo DNase I). Lysate was homogenized using a P1000 pipettor and gently pipetting up and down. Lysate was then incubated at 4C for 10 minutes before centrifugation at 1300g for 10 minutes at 4C. The supernatant was recovered and absorbance at 260nm measured.'; [Growth]'Human lymphoblastoid cell lines (LCLs) were obtained from Coriell Cell Repository and grown in 15% fetal bovine serum and 1% Pen-Strep. For replicate experiments, cells were grown separately to a density of 0.8-1.0 x 10^6 cells/mL. Approximately 20 million cells were pelleted at 250g at 4C and washed with PBS.'; [Extraction]'For ribosome profiling experiments, a 34% (Weight/Volume) sucrose cushion was used. 7 A260 Units of the cleared cell lysate were incubated with 300 Units of RNase T1 (Fermentas) and 500ng of RNaseA (Ambion) for 30 minutes at room temperature. RNase digestion was stopped with 20 mM Ribonucleoside Vanadyl Complex (NEB: S1402S). No RNase control included 20 mM Ribonucleoside Vanadyl Complex in cell lysis buffer to inhibit any endogenous RNase activity. The sample was ultracentrifuged in a TLA120.3 rotor at 4C for 4 h at 70,000 rpm.\nFor ribosome profiling experiments, the pellet was resuspended in 700ul of Qiazol reagent from miRNeasy kit. The RNA was purified using manufacturers instructions. Purified RNA was 3end dephosphorylated using 10U of T4 PNK (NEB) at 37C for 3 hours. Dephosphorylated RNA was heated to 80C for 90 seconds before loading onto 15% (Weight/Volume) polyacrylamide TBE-Urea gel that was prerun at 180V for 15min. Electrophoresis was carried out for ~1.5hr at 180V. Custom RNA oligos were used to determine the 26-34nt size range on the gel and was excised on a DarkReader Transilluminator (Clare Chemical Research). Excised gel pieces were placed in GeBAflex electroelution tubes with 8 kDA molecular weight cutoff (Gerard Biotech). Electroelution was carried out at 120V for 90min, and the eluate was filtered through Spin-X 0.22um Cellulose Acetate centrifuge filter tubes (Sigma). 300 mM sodium acetate pH 5.5, 10 mM MgCl2, and 22.5 ?g of GlycoBlue (Life Technologies) was added to filtrate. Equal volume of 100% isopropanol was used for precipitation at -20C overnight. RNA was pelleted by centrifugation at 21000g at 4C. RNA pellet was washed once with cold 75% ethanol and resuspended in 6ul of nuclease free water. NEBNext Small RNA Library preparation kit was used to convert the isolated RNA fragments into Illumina sequencing library using manufacturers instructions except for the choice of 30C for 3hrs for all ligation reactions.', 'For RNA sequencing experiments, Total RNA was extracted using Trizol reagent according to the manufacturers instructions (Lifetechnologies), then purified using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and treated with RNAse-free DNase (Qiagen, Valencia, CA). RNA integrity was checked with a Bioanalyzer (Agilent, Santa Clara CA) and only samples with an RNA integrity number (RIN) of > 9.5 were subsequently subjected to poly-A-selection. For poly-A selection, 10 ?g of purified total RNA were enriched by performing two cycles of selection using the Dynabeads mRNA Purification Kit (Life Technologies).\nFor RNA sequencing experiments, stranded libraries were prepared following the dUTP protocol (Parkhomchuk et al., 2009). In brief: ~100 ng of poly-A-selected RNA were fragmented with 10 x fragmentation buffer (Life Technologies, #AM8740) for 2 min at 70 C. First-strand cDNA synthesis was primed with random hexamers. Actinomycin D was added to reduce anti-sense artifacts. For the second-strand synthesis dTTP was replaced with dUTP. The cDNA was end-repaired and phosphorylated with the End-It kit from Epicentre (ER0720). After treatment with Klenow fragment (NEB, Cat# M0212s) and dATP, Illumina TruSeq adapters were ligated to the protruding 3_-A base (LigaFast, Promega Cat#M8221). After size-selection on an agarose gel the second strand was eliminated by digestion with AmpErase Uracil N-glycosylase (UNG) (Life Technologies, N8080096).'; [Cell type]'EBV-transformed lymphoblastoid''cell line: GM10847; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM12878; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM12890; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM12891; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM12892; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18489; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18499; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18501; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18502; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18504; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18505; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18511; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18519; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18522; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18523; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18526; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18870; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18951; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19098; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19099; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19137; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19138; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19139; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19193; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19200; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19201; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19238; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19239; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM19240; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM18507; cell type: EBV-transformed lymphoblastoid; adapter: AGATCGGAAGAGCACACGTCT; rna type: ribosome protected fragment; ', 'cell line: GM12878; cell type: EBV-transformed lymphoblastoid; rna type: polyA RNA; ', 'cell line: GM12891; cell type: EBV-transformed lymphoblastoid; rna type: polyA RNA; ', 'cell line: GM12892; cell type: EBV-transformed lymphoblastoid; rna type: polyA RNA; ', 'cell line: GM19238; cell type: EBV-transformed lymphoblastoid; rna type: polyA RNA; ', 'cell line: GM19239; cell type: EBV-transformed lymphoblastoid; rna type: polyA RNA; ', 'cell line: GM19240; cell type: EBV-transformed lymphoblastoid; rna type: polyA RNA; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65912,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE65nnn/GSE65912/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA275386,26297486," Can Cenik,  Elif Sarinay Cenik,  Gun W Byeon,  Fabian Grubert,  Sophie I Candille,  Damek Spacek,  Bilal Alsallakh,  Hagen Tilgner,  Carlos L Araya,  Hua Tang,  Emiliano Ricci,  Michael P Snyder","Elucidating the consequences of genetic differences between humans is essential for understanding phenotypic diversity and personalized medicine. Although variation in RNA levels, transcription factor binding, and chromatin have been explored, little is known about global variation in translation and its genetic determinants. We used ribosome profiling, RNA sequencing, and mass spectrometry to perform an integrated analysis in lymphoblastoid cell lines from a diverse group of individuals. We find significant differences in RNA, translation, and protein levels suggesting diverse mechanisms of personalized gene expression control. Combined analysis of RNA expression and ribosome occupancy improves the identification of individual protein level differences. Finally, we identify genetic differences that specifically modulate ribosome occupancy--many of these differences lie close to start codons and upstream ORFs. Our results reveal a new level of gene expression variation among humans and indicate that genetic variants can cause changes in protein levels through effects on translation.","Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans.",10.1101/gr.193342.115,2015 Nov,PMC4617958,Genome research
GSE121952,Active ribosome profiling in SETD2 or METTL14 knockdown HepG2 cells,Homo sapiens,12,SRP167238,2018-10-29,"[Overal design]We performed active ribosome profiling in HepG2 cells with stably expressed SETD2, METTL14 or control shRNA.; [Treatment]'Lentivirus were produced in HEK293T cells by co-transfecting individual shRNA construct with packing vectors (pMD2.G, pMDLg/pRRE and pRSV-Rev) into HEK293T cells in 60 mm cell culture dish using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics, Grenzach-Wyhlen, Germany). The lentivirus particles were harvested at 48 and 72 hours after transfection and directly added into HepG2 cells with 4 ?g/mL polybrene. After two rounds of infection, cells were selected for at least two passages by adding 1 ?g/mL puromycin into growth medium. Cells were grown at around 70% confluence and treated with 100 ug/mL cycloheximide (Sigma) at 37 ?C for 7 min before collection.'; [Growth]'The human hepatocellular carcinoma cell line HepG2 (ATCC HB-8065) was maintained in EMEM medium (ATCC) supplemented with 10% FBS (Invitrogen, Carlsbad, CA), 2 mM L-Glutamine and 1% penicillin-streptomycin.'; [Extraction]'For each replicate, 1x107 cells were used and 1 mL lysis buffer (20\u2009mM HEPES pH 7.6, 100\u2009mM KCl, 5\u2009mM MgCl2, 100\u2009?g/ml cycloheximide, 1% Triton X-100) was added supplemented with 1:100 protease inhibitor (Roche), 40\u2009U/mL SUPERNase inhibitor (Ambion). Cells were resuspended and the mixture was rotated at 4 ?C for 15 min. After centrifuge at 14,000 rpm for 15 min, the supernatant was collected and 8 ?L Turbo DNase (Invitrogen) was added. 20% of the lysate was saved as input, from which total RNA and mRNA were isolated. 40 L 10 MNase buffer and 3 L MNase (NEB) were added to the rest 80% of the lysate and the mixture was incubated at room temperature for 15 min before 8 L SUPERNase inhibitor was added. The mixture was then loaded onto a 10/50% (w/v) sucrose gradient prepared in a lysis buffer without Triton X-100 and centrifuged at 4 ?C for 3 h at 27,500 rpm. The sample was then fractioned and analyzed by Gradient Station (BioCamp) equipped with ECONO UV monitor (BioRad) and fraction collector (Gilson, FC203B). The fractions corresponding to 80S monosome were collected. RNA were isolated from the collected fractions and rRNAs were removed by using RiboMinus Eukaryote kit (Invitrogen). rRNA-depleted RNA was separated on a 15% TBE-Urea gel and the gel band between 20-30 nt was cut. RNA was recovered from the gel by elution buffer (300 mM NaOAc pH 5.5, 1 mM EDTA, 0.1 U/mL SUPERNase inhibitor) by rotating at 4 ?C overnight and the RNA was purified from the eluent by EtOH precipitation. For input, mRNA was fragmented by using 1 PNK buffer (NEB) by heating at 94 ?C for 25 min. RNA were then subjected to end repair using T4 PNK (NEB) according to manufacturers protocol and then purified by the RNA Clean and Concentrator kit (Zymo).\nLibraries were constructed using the NEBNext small RNA library prep kit (E7330S) and sequenced on illumina Hiseq4000.'; [Cell type]'Source: ''cell line: HepG2; shRNA: Non specific control; fraction: input; ', 'cell line: HepG2; shRNA: shMETTL14; fraction: input; ', 'cell line: HepG2; shRNA: shSETD2; fraction: input; ', 'cell line: HepG2; shRNA: Non specific control; fraction: 80S monosome; ', 'cell line: HepG2; shRNA: shMETTL14; fraction: 80S monosome; ', 'cell line: HepG2; shRNA: shSETD2; fraction: 80S monosome; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121952,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE121nnn/GSE121952/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA501872,30867593," Huilin Huang,  Hengyou Weng,  Keren Zhou,  Tong Wu,  Boxuan Simen Zhao,  Mingli Sun,  Zhenhua Chen,  Xiaolan Deng,  Gang Xiao,  Franziska Auer,  Lars Klemm,  Huizhe Wu,  Zhixiang Zuo,  Xi Qin,  Yunzhu Dong,  Yile Zhou,  Hanjun Qin,  Shu Tao,  Juan Du,  Jun Liu,  Zhike Lu,  Hang Yin,  Ana Mesquita,  Celvie L Yuan,  Yueh-Chiang Hu,  Wenju Sun,  Rui Su,  Lei Dong,  Chao Shen,  Chenying Li,  Ying Qing,  Xi Jiang,  Xiwei Wu,  Miao Sun,  Jun-Lin Guan,  Lianghu Qu,  Minjie Wei,  Markus Muschen,  Gang Huang,  Chuan He,  Jianhua Yang,  Jianjun Chen","DNA and histone modifications have notable effects on gene expression(1). Being the most prevalent internal modification in mRNA, the N(6)-methyladenosine (m(6)A) mRNA modification is as an important post-transcriptional mechanism of gene regulation(2-4) and has crucial roles in various normal and pathological processes(5-12). However, it is unclear how m(6)A is specifically and dynamically deposited in the transcriptome. Here we report that histone H3 trimethylation at Lys36 (H3K36me3), a marker for transcription elongation, guides m(6)A deposition globally. We show that m(6)A modifications are enriched in the vicinity of H3K36me3 peaks, and are reduced globally when cellular H3K36me3 is depleted. Mechanistically, H3K36me3 is recognized and bound directly by METTL14, a crucial component of the m(6)A methyltransferase complex (MTC), which in turn facilitates the binding of the m(6)A MTC to adjacent RNA polymerase II, thereby delivering the m(6)A MTC to actively transcribed nascent RNAs to deposit m(6)A co-transcriptionally. In mouse embryonic stem cells, phenocopying METTL14 knockdown, H3K36me3 depletion also markedly reduces m(6)A abundance transcriptome-wide and in pluripotency transcripts, resulting in increased cell stemness. Collectively, our studies reveal the important roles of H3K36me3 and METTL14 in determining specific and dynamic deposition of m(6)A in mRNA, and uncover another layer of gene expression regulation that involves crosstalk between histone modification and RNA methylation.",Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally.,10.1038/s41586-019-1016-7,2019 Mar,PMC6438714,Nature
GSE60374,Polysome purified mRNA in control and RACK1 silenced in human hepatocarcinoma cells,Homo sapiens,8,None,2014-08-13,"[Overal design]4 Controls 4 RACK1 silenced cells; [Treatment]'Cycloheximide treatment   Ribosome profiling begins with the preparation of cell lysates where ribosome-mRNA complexes accurately reflect in vivo translation. Polysomes have been stabilized by treating the cells with the translation elongation inhibitor cycloheximide. This molecule inhibits ribosomal translocation yet does not lead to the disassembly of ribosomes from the mRNA. As an A37 ribosomes remain associated with the mRNA throughout the procedure. Since the effect of cycloheximide on ribosome translocation is instantaneous, it is assumed that the ribosomal association obtained truly represents the intracellular association.   Huh7.5.1 cells cultured in 10 cm dish are treated with cycloheximide (C-7698, Sigma) to a final concentration of 100 \uf06dg/ml for 10 sec.   The cells are washed twice in 5 ml ice-cold PBS. The PBS is aspirated thoroughly and the cells are flash-frozen by immersing the plate in a reservoir of liquid nitrogen.'; [Growth]'Gene silencing was performed in Huh 7.5.1 cells by reverse transfection with 10 nM of siRNA (SilenceSelect siRNA, Ambion) specific for RACK1 (siRACK1-1 : 5-CAGGCUAUCUGAACACGGU-3 or a nonspecific control siRNA (siCTRL)'; [Extraction]'Cell lysis   The cells are dissolved in 400 ?l ice-cold lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml cycloheximide, 1% Triton X-100 and Turbo DNase I 25 U/ml) and transferred to a microfuge tube on ice. Cell clumps are dispersed by piptting several times and incubated for 10 min on ice. To achieve efficient cell lysis, we triturate the cells ten times through a 26 gauge needle. Finally, we clarify the lysate by centrifugation for 10 min at 20,000  g, 4C and recover the soluble supernatant.  The sample is carefully loaded on the sucrose gradient. Polysomal complexes are resolved by ultracentrifugation at 36,000 rpm for 150 min at 4 C in a SW41 rotor. These settings are optimal for separation between polysomal and non-polysomal complexes.  Polysomes-associated mRNAs isolation  Following centrifugation, the gradient is divided into two fractions that are collected based on the ribosomal complexes they contain. The polysome-containing fraction (\uf07e 5 ml) is collected into a 50 ml falcon tube, mixed with one volume of 5M guanidine thiocyanate and two volumes of 100% ethanol, and stored at -20 C over night.   The RNA from the collected fractions is precipitated by centrifugation at 2000 x g for 2 h at 4 C, washed with 5 ml ice-cold 70% ethanol and dissolved in 400 \uf06dl of RNase-free water. Finally, the RNA is precipitated with 0.1 volume 3 M sodium acetate pH 5.2 and 2 volumes of 100% ethanol, washed with 70% ethanol and air dried. The RNA pellet is dissolved in RNasefree water and stored at -80 C.'; [Cell type]'Source: ''tissue: Liver; cell line: Huh7.5.1; genotype/variation: control; ', 'tissue: Liver; cell line: Huh7.5.1; genotype/variation: RACK1 silenced; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60374,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE60nnn/GSE60374/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA258133,25416947," Karim Majzoub,  Mohamed Lamine Hafirassou,  Carine Meignin,  Akira Goto,  Stefano Marzi,  Antonina Fedorova,  Yann Verdier,  Joelle Vinh,  Jules A Hoffmann,  Franck Martin,  Thomas F Baumert,  Catherine Schuster,  Jean-Luc Imler","Fighting viral infections is hampered by the scarcity of viral targets and their variability, resulting in development of resistance. Viruses depend on cellular molecules-which are attractive alternative targets-for their life cycle, provided that they are dispensable for normal cell functions. Using the model organism Drosophila melanogaster, we identify the ribosomal protein RACK1 as a cellular factor required for infection by internal ribosome entry site (IRES)-containing viruses. We further show that RACK1 is an essential determinant for hepatitis C virus translation and infection, indicating that its function is conserved for distantly related human and fly viruses. Inhibition of RACK1 does not affect Drosophila or human cell viability and proliferation, and RACK1-silenced adult flies are viable, indicating that this protein is not essential for general translation. Our findings demonstrate a specific function for RACK1 in selective mRNA translation and uncover a target for the development of broad antiviral intervention.",RACK1 controls IRES-mediated translation of viruses.,10.1016/j.cell.2014.10.041,2014 Nov 20,PMC4243054,Cell
GSE116233,Optimization of Ribosome Profiling Using Brain Tissue from Fragile X Mice,Homo sapiens; Mus musculus,56,SRP151279,2018-06-25,"[Overal design]Ribosome profiling libraries of wild type mouse hippocampus were generated with different concentrations of ribonucleases and sequenced with Illumina Nextseq500. 5 experimental and 51 QC samples.; [Treatment]'None', 'iPSCs and iPSC-neurons were treated with 100ug/ul cycloheximide at 37C for 1min and then washed with ice-cold PBS with 100ug/ul cycloheximide. Cells were scraped off the plates in  ice-cold PBS with 100ug/ul cycloheximide, pelleted at 15,000g for 3min at C, and snap-frozen in liquid nitrogen. Hippocampal tissues were collected and snap-frozen in liquid nitrogen.'; [Growth]'None', 'Human iPSC colonies were maintained in mTeSR1 medium (STEMCELL Technologies). Neural progenitor cells (NPCs) were derived from iPSCs using STEMdiff Neuron Differentiation Kit (STEMCELL Technologies) and mantained in STEMdiff Neural Progenitor Medium (STEMCELL Technologies). For the neural differentiation, NPCs were plated at 2X10^4 cells /cm2 onto Poly-L-Ornithine/laminin coated 15-cm dishes in neural differentiation medium (Neurobasal Medium, 1X N2, 1X B27, 1X GlutaMAX, 0.2uM L-Ascorbic acid, 1uM cAMP,10ng/ml BDNF, 10ng/ml GDNF) supplemented with 0.1uM Compound E  and 5uM ROCK inhibitor. Neural cultures were maintained in neural differentiation medium for 1 month before collection.'; [Extraction]'Hippocampal tissues were collected and snap-frozen in liquid nitrogen. Frozen tissues were thawed in ice-cold polysome lysis buffer [20mM Tris-HCl pH7.4, 5mM MgCl2, 100mM KCl, 1mM DTT, 100g/ml cycloheximide, 25U/ml Turbo DNaseI (Ambion, #AM2238), 1% NP-40 in nuclease-free water] and lysed by trituration through a 25-G need for 10 times. After 10-min incubation on ice, lysates were clarified by centrifugation at 2000g 4 C for 10min. The supernatants were collected and clarified again by centrifugation at 20,000g 4 C for 10min. The supernatants were collected and the amounts of nucleic acids were measured with Nanodrop (Thermo Fisher Scientific) and Qubit HS assays (Invitrogen). Lysate containing 2g RNA in 0.3ml was digested with 5-fold serial diluted RNase A (Ambion, #AM2270) and RNase T1 (Thermo Fisher Scientific, #EN0542) at 25C for 30min, including RNase1 (4.8ng RNase A + 0.6U RNase T1/g RNA), RNase2 (24ng RNase A + 3U RNase T1/g RNA), RNase3 (120ng RNase A + 15U RNase T1/g RNA), RNase4 (600ng RNase A + 75U RNase T1/g RNA), and RNase5 (3000ng RNase A + 375U RNase T1/g RNA). The digestion was stopped by adding 50U SUPERase In RNase inhibitor (Ambion, #AM2694) and chilling on ice. Digested lysates were loaded on 10%-50% sucrose gradients prepared in 1X polysome buffer (20mM Tris-HCl pH7.4, 5mM MgCl2, 100mM KCl, 1mM DTT, 100g/ml cycloheximide in nuclease-free water). After the ultracentrifugation in a SW41Ti rotor (Beckman Coulter) at 35,000 rpm 4C for 2.5 hours, gradients were fractionated at 1.5 ml/min and 12 sec collection interval through a fractionation system (Brandel) that continually monitored A260 values. Monosome fractions were identified, pooled, and extracted with TRIzol LS.\nLibraries were prepared following the published protocols (Heyer et al., 2015; Ingolia et al., 2012). Briefly, rRNA was depleted from the purified monosomal RNA samples with RiboZero (Illumina, #MRZG12324). Remaining RNA samples were separated on a 15% TBU gel (National Diagnostics, #EC-833) and the ribosome footprints were size-selected based on the 26 and 34nt markers. RNA was eluted from the crushed gel pieces in RNA elution buffer (300mM NaOAc pH5.5, 1mM EDTA, 0.25% SDS) at RT overnight, filtered with Spin-X Centrifuge Tube Filters (Corning, #8162) and precipitated with equal volume of isopropanol. Recovered RNA was dephosphorylated with T4 Polynucleotide Kinase (NEB, #M0201S) and ligated with preadenylated adaptor in miRCat-33 Conversion Oligos Pack (IDT) using T4RNL2Tr.K227Q ligase (NEB, #M0351L). Reverse transcription was performed with RT primers with 5nt-barcode and 5nt or 8nt unique molecular identifier (UMI) and SuperScript III (Invitrogen, #18080-044) in 1X first-strand buffer without MgCl2 (50 mM Tris-HCl, pH 8.3, 75 mM KCl). RT products were separated on a 10% TBU gel and the 130-140nt region was selected. cDNA was eluted in DNA elution buffer (10mM Tris pH 8.0, 300mM NaCl, 1mM EDTA) at RT overnight, filtered, and precipitated with isopropanol. Purified cDNA was circularized with CircLigase (Epicentre, #CL4115K). Optimal PCR cycle was determined empirically by test PCR reactions with titrated cycle numbers. Final PCR amplification was performed with KAPA Library Amplification Kit (Kapa Biosystems, #KK2611) and 180-190bp products were size-selected on an 8% TBE gel. DNA was eluted in DNA elution buffer and precipitated with isopropanol. The final library DNA was purified with AMPure XP beads (Beckman Coulter, #A63880).', 'For the RNase titration experiments, frozen tissues were thawed in ice-cold polysome lysis buffer [20mM Tris-HCl pH7.4, 5mM MgCl2, 100mM KCl, 1mM DTT, 100g/ml cycloheximide, 25U/ml Turbo DNaseI (Ambion, #AM2238), 1% NP-40 in nuclease-free water] and lysed by trituration through a 25-G need for 10 times. After 10-min incubation on ice, lysates were clarified by centrifugation at 2000g 4 C for 10min. The supernatants were collected and clarified again by centrifugation at 20,000g 4 C for 10min. The supernatants were collected and the amounts of nucleic acids were measured with Nanodrop (Thermo Fisher Scientific) and Qubit HS assays (Invitrogen). Lysate containing 2g RNA in 0.3ml was digested with 5-fold serial diluted RNase A (Ambion, #AM2270) and RNAse T1 (Thermo Fisher Scientific, #EN0542) at 25C for 30min, including RNase1 (4.8ng RNase A + 0.6U RNase T1/g RNA), RNase2 (24ng RNase A + 3U RNase T1/g RNA), RNase3 (120ng RNase A + 15U RNase T1/g RNA), RNase4(600ng RNase A + 75U RNase T1/g RNA), and RNase5 (3000ng RNase A + 375U RNase T1/g RNA). The digestion was stopped by adding 50U SUPERase In RNase inhibitor (Ambion, #AM2694) and chilling on ice. Digested lysates were loaded on 10%-50% sucrose gradients prepared in 1Xpolysome buffer (20mM Tris-HCl pH7.4, 5mM MgCl2, 100mM KCl, 1mM DTT, 100g/ml cycloheximide in nuclease-free water). After the ultracentrifugation in a SW41Ti rotor (Beckman Coulter) at 35,000 rpm 4C for 2.5 hours, gradients were fractionated at 1.5 ml/min and 12 sec collection interval through a fractionation system (Brandel) that continually monitored A260 values. Monosome fractions were identified, pooled, and extracted with TRIzol LS. For other samples, RNase A+T1 or RNase I were added as indicated based on the A260 units in the lysates.\nLibraries were prepared following the published protocols (Heyer et al., 2015; Ingolia et al., 2012). Briefly, rRNA was depleted from the purified monosomal RNA or cytoplasmic RNA samples with RiboZero (Illumina, #MRZG12324). For cyptoplamic RNA, RNA samples were fragmented in 1Xalkaline fragmentation solution at 95 C for 15min. RNA samples were separated on a 15% TBU gel (National Diagnostics, #EC-833). Ribosome footprints were size-selected between 26-34nt, while cytoplamic RNAs were size-selected between 100-150nt.. RNA was eluted from the crushed gel pieces in RNA elution buffer (300mM NaOAc pH5.5, 1mM EDTA, 0.25% SDS) at RT overnight, filtered with Spin-X Centrifuge Tube Filters (Corning, #8162) and precipitated with equal volume of isopropanol. Recovered RNA was dephosphorylated with T4 Polynucleotide Kinase (NEB, #M0201S) and ligated with preadenylated adaptor in miRCat-33 Conversion Oligos Pack (IDT) using T4RNL2Tr.K227Q ligase (NEB, #M0351L). Reverse transcription was performed with RT primers with 5nt-barcode and 5nt or 8nt unique molecular identifier (UMI) and SuperScript III (Invitrogen, #18080-044) in 1X first-strand buffer without MgCl2 (50 mM Tris-HCl, pH 8.3, 75 mM KCl). RT products were separated on a 10% TBU gel and the 130-140nt region was selected. cDNA was eluted in DNA elution buffer (10mM Tris pH 8.0, 300mM NaCl, 1mM EDTA) at RT overnight, filtered, and precipitated with isopropanol. Purified cDNA was circularized with CircLigase (Epicentre, #CL4115K). Optimal PCR cycle was determined empirically by test PCR reactions with titrated cycle numbers. Final PCR amplification was performed with KAPA Library Amplification Kit (Kapa Biosystems, #KK2611) and 180-190bp products were size-selected on an 8% TBE gel. DNA was eluted in DNA elution buffer and precipitated with isopropanol. The final library DNA was purified with AMPure XP beads (Beckman Coulter, #A63880).\nRibosome profiling'; [Cell type]'Source: ''strain/background: C57BL/6; genotype/variation: wild-type; tissue: Hippocampus; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 2.43; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 3.11; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.33; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.43; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.7; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.95; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 5.82; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: Ribosome profiling; monosome rna yield (ug): 5.72; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 5.72; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.69; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 3.14; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.93; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 6.74; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 5.75; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 3.25; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: wild-type; extract_protocol: RNA-seq; monosome rna yield (ug): N/A; rnase concentration: N/A; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: RNA-seq; monosome rna yield (ug): N/A; rnase concentration: N/A; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 8.8; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: C57BL/6; genotype: Fmr1 -/y; extract_protocol: Ribosome profiling; monosome rna yield (ug): 6.9; rnase concentration: 5U RNase I/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 6.6742; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 4.5942; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 5.1298; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 5.1246; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 15.2542; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 12.4956; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 14.625; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 11.3672; rnase concentration: 20ng RNase A + 12U RNase T1/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 1.4768; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 8.151; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 1; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 9.4198; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 0.9854; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 2.5584; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 1; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 2.3062; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 2; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 0.4992; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 2; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 22.126; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 2; genotype: Fragile X Syndrome; extract_protocol: Ribosome profiling; monosome rna yield (ug): 27.585; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 2; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 0.3172; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 2; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 1.0712; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; ', 'strain: Patient 2; genotype: CRISPR-rescued; extract_protocol: Ribosome profiling; monosome rna yield (ug): 8.7334; rnase concentration: 100ng RNaseA + 60U RNase T1/A260; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116233,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE116nnn/GSE116233/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA477831,30590705," Botao Liu,  Gemma Molinaro,  Huan Shu,  Emily E Stackpole,  Kimberly M Huber,  Joel D Richter","Dysregulated protein synthesis is a major underlying cause of many neurodevelopmental diseases including fragile X syndrome. In order to capture subtle but biologically significant differences in translation in these disorders, a robust technique is required. One powerful tool to study translational control is ribosome profiling, which is based on deep sequencing of mRNA fragments protected from ribonuclease (RNase) digestion by ribosomes. However, this approach has been mainly applied to rapidly dividing cells where translation is active and large amounts of starting material are readily available. The application of ribosome profiling to low-input brain tissue where translation is modest and gene expression changes between genotypes are expected to be small has not been carefully evaluated. Using hippocampal tissue from wide type and fragile X mental retardation 1 (Fmr1) knockout mice, we show that variable RNase digestion can lead to significant sample batch effects. We also establish GC content and ribosome footprint length as quality control metrics for RNase digestion. We performed RNase titration experiments for low-input samples to identify optimal conditions for this critical step that is often improperly conducted. Our data reveal that optimal RNase digestion is essential to ensure high quality and reproducibility of ribosome profiling for low-input brain tissue.",Optimization of ribosome profiling using low-input brain tissue from fragile X syndrome model mice.,10.1093/nar/gky1292,2019 Mar 18,PMC6411937,Nucleic acids research
GSE52976,Integrative AUF1 PAR-CLIP analysis uncovers AUF1 roles in translation and genome integrity (Ribosome),Homo sapiens,3,SRP033503,2013-12-04,"[Overal design]Please see individual series. In short, For AUF1 PAR-CLIP, the four isoforms of AUF1 (p37, p40, p42, and p45) tagged with a Flag epitope were expressed in HEK293 cells. For total RNA-Seq HEK293 cells were transfected with Control siRNA, AUF1 siRNA, Empty Vector, Flag-AUF1 p37, p40, p42, or p45 as well as WI-38 cells were collected at PDL 15 and 55 and also transfected with Control siRNA, AUF1 siRNA, HuR siRNA. For Ribo-Seq HeLa cells were transfected with Control siRNA, AUF1 siRNA, or HuR siRNA.; [Treatment]'HeLa cells were transfected with Control siRNA, AUF1 siRNA, or HuR siRNA.'; [Growth]'Human cervical carcinoma (HeLa) cells were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) FBS and antibiotics.'; [Extraction]'After lysis and Rnase digestion, mono ribosomes were purified by 0.9M sucrose cushion\nSmall RNA libraries were prepared as described previously (Guo et al., 2010)'; [Cell type]'Source: ''rna type: HeLa RNA from mono ribosome; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HeLa; treatment: Control siRNA; ', 'rna type: HeLa RNA from mono ribosome; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HeLa; treatment: AUF1 siRNA; ', 'rna type: HeLa RNA from mono ribosome; passages: unknown; crosslinking: not applied; ip protein: not applied; cell line: HeLa; treatment: HuR siRNA; '",Non-coding RNA profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52976,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE52nnn/GSE52976/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA230610,25366541," Je-Hyun Yoon,  Supriyo De,  Subramanya Srikantan,  Kotb Abdelmohsen,  Ioannis Grammatikakis,  Jiyoung Kim,  Kyoung Mi Kim,  Ji Heon Noh,  Elizabeth J F White,  Jennifer L Martindale,  Xiaoling Yang,  Min-Ju Kang,  William H 3rd Wood,  Nicole Noren Hooten,  Michele K Evans,  Kevin G Becker,  Vidisha Tripathi,  Kannanganattu V Prasanth,  Gerald M Wilson,  Thomas Tuschl,  Nicholas T Ingolia,  Markus Hafner,  Myriam Gorospe","Post-transcriptional gene regulation is robustly regulated by RNA-binding proteins (RBPs). Here we describe the collection of RNAs regulated by AUF1 (AU-binding factor 1), an RBP linked to cancer, inflammation and aging. Photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) analysis reveals that AUF1 primarily recognizes U-/GU-rich sequences in mRNAs and noncoding RNAs and influences target transcript fate in three main directions. First, AUF1 lowers the steady-state levels of numerous target RNAs, including long noncoding RNA NEAT1, in turn affecting the organization of nuclear paraspeckles. Second, AUF1 does not change the abundance of many target RNAs, but ribosome profiling reveals that AUF1 promotes the translation of numerous mRNAs in this group. Third, AUF1 unexpectedly enhances the steady-state levels of several target mRNAs encoding DNA-maintenance proteins. Through its actions on target RNAs, AUF1 preserves genomic integrity, in agreement with the AUF1-elicited prevention of premature cellular senescence.",PAR-CLIP analysis uncovers AUF1 impact on target RNA fate and genome integrity.,10.1038/ncomms6248,2014 Nov 4,PMC4291169,Nature communications
GSE55195,Ribosome profiling data obtained from HEK293T cells 30 minutes after treatment with arsenite to a final concentration of 40 M,Homo sapiens,8,SRP038695,2014-02-20,"[Overal design]Ribosome profiling of sodium arsenite treated cells for examination of translational response to induction of eIF2 phosphoylation; [Treatment]'40 M sodium arsenite or vehicle were added and 30 mins later cells were harvested: dishes were immediately chilled on ice and washed with PBS+cycloheximide (100 ug/ml)'; [Growth]'Hek293T cells were grown in DMEM'; [Extraction]'Detergent lysis was performed in the dish, and after DNAse treatment sample was taken for mRNA isolation. Lysates were subjected to ribosome footprinting by RNAse I treatment. After sucrose density gradient fractionation ribosome-protected fragments were purified from 80S peak fractions. In parallel, mRNA isolated with Oligotex kit (Quiagen) was subjected to alkaline hydrolysis and fragments of the same size as ribosome protected fragments were isolated.\nLibrary preparation was carried out as described in Ingolia et al (2012),Nature Protocols'; [Cell type]'Source: ''treatment: vehicle; rna type: ribosome protected fragment; cell line: Hek293T; ', 'treatment: vehicle; rna type: naked mRNAseq; cell line: Hek293T; ', 'treatment: 0.5 hour arsenite; rna type: ribosome protected fragment; cell line: Hek293T; ', 'treatment: 0.5 hour arsenite; rna type: naked mRNAseq; cell line: Hek293T; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55195,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE55nnn/GSE55195/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA238879,25621764," Dmitry E Andreev,  Patrick B F O'Connor,  Ciara Fahey,  Elaine M Kenny,  Ilya M Terenin,  Sergey E Dmitriev,  Paul Cormican,  Derek W Morris,  Ivan N Shatsky,  Pavel V Baranov","Eukaryotic cells rapidly reduce protein synthesis in response to various stress conditions. This can be achieved by the phosphorylation-mediated inactivation of a key translation initiation factor, eukaryotic initiation factor 2 (eIF2). However, the persistent translation of certain mRNAs is required for deployment of an adequate stress response. We carried out ribosome profiling of cultured human cells under conditions of severe stress induced with sodium arsenite. Although this led to a 5.4-fold general translational repression, the protein coding open reading frames (ORFs) of certain individual mRNAs exhibited resistance to the inhibition. Nearly all resistant transcripts possess at least one efficiently translated upstream open reading frame (uORF) that represses translation of the main coding ORF under normal conditions. Site-specific mutagenesis of two identified stress resistant mRNAs (PPP1R15B and IFRD1) demonstrated that a single uORF is sufficient for eIF2-mediated translation control in both cases. Phylogenetic analysis suggests that at least two regulatory uORFs (namely, in SLC35A4 and MIEF1) encode functional protein products.",Translation of 5' leaders is pervasive in genes resistant to eIF2 repression.,10.7554/eLife.03971,2015 Jan 26,PMC4383229,eLife
GSE50938,Global reprogramming of the cellular translational landscape facilitates cytomegalovirus replication,Homo sapiens,16,None,2013-09-17,"[Overal design]Two biological replicate experiments were performed profiling total and polysomal mRNAs from i) HCMV-infected vs mock-infected cells and ii) uninfected cells transduced with a lentivirus expressing doxycyclin (dox)-inducible HCMV UL38 +/- dox. Analysis of translationally-controlled host genes in HCMV-infected cell and cells expressing the HCMV UL38 gene product; [Treatment]'NHDFs were mock-infected or infected with HCMV. NHDFs containing a dox-inducible UL38 were treated +/- dox'; [Growth]'Normal human dermal fibroblasts (NHDFs) and NHDFs ransduced with a lentivirus expressing doxycyclin (dox)-inducible HCMV UL38 were grown in DMEM + fetal bovine serum.'; [Extraction]'Total RNA was isolated and used unfractionated or cell free extracts were first fractionated on 15-50% linear sucrose gradients and RNA isolated from pooled polysomal fractions'; [Cell type]'Normal fibroblasts''sample type: extracted total RNA; cell type: Normal fibroblasts; treatment: Mock infected; ', 'sample type: extracted total RNA; cell type: Normal fibroblasts; treatment: HCMV infected; ', 'sample type: polysomal RNA; cell type: Normal fibroblasts; treatment: Mock infected; ', 'sample type: polysomal RNA; cell type: Normal fibroblasts; treatment: HCMV infected; ', 'sample type: extracted total RNA; cell type: Normal fibroblasts; treatment: uninduced; ', 'sample type: extracted total RNA; cell type: Normal fibroblasts; treatment: UL38 induced; ', 'sample type: polysomal RNA; cell type: Normal fibroblasts; treatment: uninduced; ', 'sample type: polysomal RNA; cell type: Normal fibroblasts; treatment: UL38 induced; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50938,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE50nnn/GSE50938/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA219395,24373965," Caleb McKinney,  Jiri Zavadil,  Christopher Bianco,  Lora Shiflett,  Stuart Brown,  Ian Mohr","Unlike many viruses that suppress cellular protein synthesis, host mRNA translation and polyribosome formation are stimulated by human cytomegalovirus (HCMV). How HCMV impacts the translationally regulated cellular mRNA repertoire and its contribution to virus biology remains unknown. Using polysome profiling, we show that HCMV presides over the cellular translational landscape, selectively accessing the host genome to extend its own coding capacity and regulate virus replication. Expression of the HCMV UL38 mTORC1-activator partially recapitulates these translational alterations in uninfected cells. The signature of cellular mRNAs translationally stimulated by HCMV resembles pathophysiological states (such as cancer) where translation initiation factor levels or activity increase. In contrast, cellular mRNAs repressed by HCMV include those involved in differentiation and the immune response. Surprisingly, interfering with the virus-induced activation of cellular mRNA translation can either limit or enhance HCMV growth. The unanticipated extent to which HCMV specifically manipulates host mRNA translation may aid in understanding its association with complex inflammatory disorders and cancer.",Global reprogramming of the cellular translational landscape facilitates cytomegalovirus replication.,10.1016/j.celrep.2013.11.045,2014 Jan 16,PMC3975909,Cell reports
GSE80156,A coding sequence-embedded principle governs translational reading frame fidelity,Homo sapiens; Mus musculus,7,SRP073116,2016-04-11,"[Overal design]Investigating the role of 18S rRNA in controlling translational reading frame fidelity; [Treatment]'cycloheximide for 3 mins (100 ug/ml)'; [Growth]'None'; [Extraction]'Rnase I Digestion, RNA dephosphorylation, Size Selection\nPoly-A Tailing, cDNA synthesis, Size selection, circularization, DNA precipitation, Linearization, PCR amplification'; [Cell type]'Source: ''cell line: HEK293; tissue: Embryonic Kidney; ', 'cell line: MEF; tissue: Embryonc Fibroblasts; '",Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80156,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE80nnn/GSE80156/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA318051,31549036," Ji Wan,  Xiangwei Gao,  Yuanhui Mao,  Xingqian Zhang,  Shu-Bing Qian","Upon initiation at a start codon, the ribosome must maintain the correct reading frame for hundreds of codons in order to produce functional proteins. While some sequence elements are able to trigger programmed ribosomal frameshifting (PRF), very little is known about how the ribosome normally prevents spontaneous frameshift errors that can have dire consequences if uncorrected. Using high resolution ribosome profiling data sets, we discovered that the translating ribosome uses the 3\' end of 18S rRNA to scan the AUG-like codons after the decoding process. The postdecoding mRNA:rRNA interaction not only contributes to predominant translational pausing, but also provides a retrospective mechanism to safeguard the ribosome in the correct reading frame. Partially eliminating the AUG-like ""sticky"" codons in the reporter message leads to increased +1 frameshift errors. Remarkably, mutating the highly conserved CAU triplet of 18S rRNA globally changes the codon ""stickiness"". Further supporting the role of ""sticky"" sequences in reading frame maintenance, the codon composition of open reading frames is highly optimized across eukaryotic genomes. These results suggest an important layer of information embedded within the protein-coding sequences that instructs the ribosome to ensure reading frame fidelity during translation.",A Coding Sequence-Embedded Principle Governs Translational Reading Frame Fidelity.,10.1155/2018/7089174,2018,PMC6750092,"Research (Washington, D.C.)"
GSE126298,Selective translation mechanism through two paralogs of eukaryotic initiation factor 4A,Homo sapiens,8,SRP184677,2019-02-08,"[Overal design]Ribosome profiling and RNA-seq; [Treatment]'None'; [Growth]'None'; [Extraction]'Rnase I footprinting, ribosome pelleting, RNA extraction\nRNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification (for ribosome profiling) or TruSeq (illumina) (for mRNA-seq)', 'Truseq stranded mRNA library prep\nRNA extraction, preadenylated linker ligation, rRNA depeletion, reverse transcription, cDNA circularization, PCR amplification (for ribosome profiling) or TruSeq (illumina) (for mRNA-seq)'; [Cell type]'Source: ''genetic background: WT; cell line: HEK293T; ', 'genetic background: EIF4A2KO; cell line: HEK293T; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126298,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE126nnn/GSE126298/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA521496,,,,,,,,
GSE87328,eIF1 modulates the recognition of sub-optimal translation start sites and steers gene expression control mediated by uORFs,Homo sapiens,6,SRP090415,2016-09-24,"[Overal design]Ribosome profiling and mRNA sequening of human HCT116 cells upon eIF1 knockdown and in control conditions.; [Treatment]'For knockdown experiments, HCT116 cells were transferred to serum-free McCoys medium and seeded at a density of 2.4*10E6 cells per 10 cm2 plate. Cells were transfected with either 10nM control si-RNA (si-Ctrl, ON-TARGETplus Non-targeting Control siRNAs: D-001810-01-05, Dharmacon, GE Healthcare Life Sciences) or 10nM si-RNAs targeting eIF1 (si-eIF1, SMARTpool: M-015804-01-0005, Dharmacon, GE Healthcare Life Sciences) using 63ul of HiPerFect (QIAGEN) per 10 cm2 plate. 5 hours post-transfection, cells were supplemented with FBS at a final concentration (f.c.) of 10%. Overall, 4 x 10 cm2 plates of si-Ctrl and 4 x 10 cm2 plates of si-eIF1 treated HCT116 cells were obtained. Subsequently, 2 plates per condition were incubated with either 50 M lactimidomycin (LTM) or 100 g/ml cycloheximide (CHX) (Sigma, USA) in a total volume of 5 ml per plate for 30 min at 37C.'; [Growth]'The human colon cancer HCT116 cells were cultivated in McCoys medium (Gibco, Thermo Fisher Scientific Inc.)supplemented with 10% fetal bovine serum (FBS, HyClone, Thermo Fisher Scientific Inc.), 2 mM alanyl-L-glutamine dipeptide (GlutaMAX, Gibco, Thermo Fisher Scientific Inc.), 50 units/ml penicillin (Gibco, Thermo Fisher Scientific Inc.) and 50 g/ml streptomycin (Gibco, Thermo Fisher Scientific Inc.) in a humidified incubator at 37C and 5% CO2.'; [Extraction]'Cells were harvested by trypsinitation (Trypsin/EDTA solution, Thermo Fisher Scientific Inc.), collected by centrifugation (5 min at 300g), washed with ice-cold PBS with 100 g/ml CHX added and recovered again by centrifugation. Cells were re-suspended in 1 ml ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 100 mM KCl, 1% Triton X-100, 2 mM dithiothreitol (DTT), 100 g/ml CHX, 1  complete and EDTA-free protease inhibitor cocktail (Roche)), lysed by incubation on ice for 10 min and subsequently passed through QIAshredder spin columns (Qiagen). The flow-through was clarified by centrifugation for 10 min at 16,000  g and 4C. The supernatant was recovered and protein concentration was measured. For ribosome profiling (ribo-seq), 600 l of each lysate was subjected to RNase I (Thermo Fisher Scientific Inc.) digestion using 3000 U of enzyme for every 7 mg protein. Digestion of polysomes proceeded for 45 min at room temperature  and was stopped with SUPERase.In RNase Inhibitor (Life Technologies). Next, monosomes were recovered by ultracentrifugation at 75,000 RPM in a cooled TLA-120.2 rotor over a 1 M sucrose cushion in 20 mM HEPES-KOH pH 7.4, 5 mM MgCl2, 100 mM KCl, 2 mM DTT, 100 g/ml CHX and 100 U/ml Superase.In. RNA was extracted from the samples using a heated acid phenol; chloroform; isoamyl alcohol (125:24:1) procedure.\nFor ribo-seq, ribosome protected fragments (RPFs) of 26-34 nucleotides were extracted from 22 g of RNA subjected to electrophoresis under denaturing conditions in 15% TBE-Urea polyacrylamide gel (Life Technologies). Extraction from gel was performed in RNase-free water for 10 min at 70C and precipitated with 1/10 volume of 3 M sodium acetate pH 5.2, 1.5 l GlycoBlue (Life Technologies) and 1 volume of isopropanol overnight at ? 80 C. Following a dephosphorylation reaction (end-repair) with 10 U of T4 polynucleotide kinase (New England Biolabs), the RPFs were ligated to a 1.5 g of Universal cloning linker using 200 U of T4 RNA ligase II (both New England Biolabs). The ligated product was size-selected using denaturing gel electrophoresis and purified from gel as described above. Subsequently, reverse transcription (RT) was performed with 200 U of SuperScript III (Life Technologies) according to (Ingolia et al, 2011), followed by a size-selection of the RT product (described above). Ribosomal RNA derived contaminants were depleted from reverse transcribed samples using a custom set of 20 biotynylated deoxyoligonucleotides. 100 pmol of mixed probes with 60ul MyOne Streptavidin C1 DynaBeads (Thermo Fisher Scientific Inc.) were used each time. Next, samples were subjected to circular ligation using 100 U of CircLigase (Illumina), diluted and amplified by PCR using Phusion polymerase (New England Biolabs) for 12 cycles of denaturation (10 s at 98C), annealing (10 s of 65C) and elongation (5 s at 72C) using primer pairs compatible with the Illumina sequencing platform. The resulting ribosome-profiling libraries were duplexed (samples treated with the same inhibitor, LTM or CHX, were joined).', 'For mRNA-sequencing (RNA-seq), total RNA was isolated from 400ul cell lysate with TRIzol reagent (Invitrogen, Thermo Fisher Scientific Inc.) according to manufacturers instructions. RNA quality was assessed by Agilent Bioanalyzer RNA 600 Nano Kit and RIN values above 9 were accepted.\nFor mRNA-seq, rRNA depletion with Ribo-Zero probes, random fragmentation, cDNA synthesis and library generation were performed according to TruSeq Stranded Total RNA Sample Preparation protocol (Illumina). mRNA-seq and ribo-seq libraries were subjected to sequencing on a NextSeq 500 instrument (Illumina) to yield 75 bp single-end reads.'; [Cell type]'Source: ''tissue: colon; cell line: HCT116; phenotype: colorectal carcinoma; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87328,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE87nnn/GSE87328/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA344393,28541577," Daria Fijalkowska,  Steven Verbruggen,  Elvis Ndah,  Veronique Jonckheere,  Gerben Menschaert,  Petra Van Damme","Alternative translation initiation mechanisms such as leaky scanning and reinitiation potentiate the polycistronic nature of human transcripts. By allowing for reprogrammed translation, these mechanisms can mediate biological responses to stimuli. We combined proteomics with ribosome profiling and mRNA sequencing to identify the biological targets of translation control triggered by the eukaryotic translation initiation factor 1 (eIF1), a protein implicated in the stringency of start codon selection. We quantified expression changes of over 4000 proteins and 10 000 actively translated transcripts, leading to the identification of 245 transcripts undergoing translational control mediated by upstream open reading frames (uORFs) upon eIF1 deprivation. Here, the stringency of start codon selection and preference for an optimal nucleotide context were largely diminished leading to translational upregulation of uORFs with suboptimal start. Interestingly, genes affected by eIF1 deprivation were implicated in energy production and sensing of metabolic stress.",eIF1 modulates the recognition of suboptimal translation initiation sites and steers gene expression via uORFs.,10.1093/nar/gkx469,2017 Jul 27,PMC5570006,Nucleic acids research
GSE74510,ASNase treatment in PC3 cells,Homo sapiens,5,SRP065528,2015-10-30,"[Overal design]2 individual batches: (i) 1 control and 1 treated sample, (ii) 1 control and 2 treated samples; [Treatment]'For samples which were ASNase treated: PC3 cells were treated with L-Asparaginase (Sigma) at 1U/ml for 48hrs in RPMI supplemented with 10% dialyzed FBS'; [Growth]'PC3 cells were cultured in RPMI medium supplemented with 10% FBS'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: '""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: PC3; agent: none; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: PC3; agent: L-Asparaginase; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74510,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE74nnn/GSE74510/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA300627,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE117291,Large-scale tethered function assays identify factors that regulate mRNA stability and translation (polysome profiling),Homo sapiens,12,SRP154579,2018-07-18,[Overal design]RNAseq; [Treatment]'None'; [Growth]'HEK293T cells were grown in standard cell culture in 10% FBS in DMEM'; [Extraction]'Total and polysome derived RNA were extracted using Trizol reagent\nStrand-specific RNA sequencing libraries were prepared from 0.5-3 g total RNA using the TruSeq Stranded mRNA Sample Preparation kit (Illumina).'; [Cell type]'Source: ''tissue: HEK293T cells; ',Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117291,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE117nnn/GSE117291/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA482134,,,,,,,,
GSE132008,Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection (RNA-sequencing),Homo sapiens,6,SRP199981,2019-05-31,"[Overal design]Ribosome profiling (and complementary RNA-sequencing) was performed in HCT116 cells that received, via lentivirus, Cas9 and sgRNAs targeting either EIF5A, DOHH or non-targeting control sgRNAs. Two sgRNAs were used for each condition, and thus 6 biological samples were used for these experiments.; [Treatment]'N/A.'; [Growth]'HCT116 cells were infected with lentivirus to deliver Cas9 and sgRNAs targeting either EIF5A or DOHH, or non-target sgRNAs. Successfully transduced cells were selected in puromycin for 6 days, before harvesting for both ribosome profiling and RNA-sequencing as described in McGlincy and Ingolia, Methods, 2017.'; [Extraction]'Cells were harvested in lysis buffer and RNA was extracted using the Direct-zol RNA miniprep kit (Zymoresearch) as described in McGlincy and Ingolia, Methods, 2017.\nRNA-seq libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina) and sequenced using the 75 bp single-read protocol on a NextSeq 500 platform (Illumina).'; [Cell type]'Source: ''genotype: EIF5A-/-; sgrna received: EIF5A sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: EIF5A-/-; sgrna received: EIF5A sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'genotype: DOHH-/-; sgrna received: DOHH sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: DOHH-/-; sgrna received: DOHH sgRNA #2; tissue: HCT116 colon cancer cell line; ', 'genotype: +/+; sgrna received: NT sgRNA #1; tissue: HCT116 colon cancer cell line; ', 'genotype: +/+; sgrna received: NT sgRNA #2; tissue: HCT116 colon cancer cell line; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132008,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE132nnn/GSE132008/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA545624,31801078," Hema Manjunath,  He Zhang,  Frederick Rehfeld,  Jaeil Han,  Tsung-Cheng Chang,  Joshua T Mendell","Sequences within 5' UTRs dictate the site and efficiency of translation initiation. In this study, an unbiased screen designed to interrogate the 5' UTR-mediated regulation of the growth-promoting gene MYC unexpectedly revealed the ribosomal pause relief factor eIF5A as a regulator of translation initiation codon selection. Depletion of eIF5A enhances upstream translation within 5' UTRs across yeast and human transcriptomes, including on the MYC transcript, where this results in increased production of an N-terminally extended protein. Furthermore, ribosome profiling experiments established that the function of eIF5A as a suppressor of ribosomal pausing at sites of suboptimal peptide bond formation is conserved in human cells. We present evidence that proximal ribosomal pausing on a transcript triggers enhanced use of upstream suboptimal or non-canonical initiation codons. Thus, we propose that eIF5A functions not only to maintain efficient translation elongation in eukaryotic cells but also to maintain the fidelity of translation initiation.",Suppression of Ribosomal Pausing by eIF5A Is Necessary to Maintain the Fidelity of Start Codon Selection.,10.1016/j.celrep.2019.10.129,2019 Dec 3,PMC6917043,Cell reports
GSE74509,Ribosome profiling of TGFb-treated cells indicates reduced leucine availability,Homo sapiens,23,None,2015-10-30,"[Overal design]Refer to individual Series; [Treatment]'For TGF?1 treatment, MCF10a cells were treated with human recombinant TGF?1 (10ng/ml) for 48 hours (R&D Systems).', ""MCF10A cells were transfected using Dharmafect I reagent (Dharmacon) following the manufacturer's instructions. For TGF?1 treatment, MCF10a cells were treated with human recombinant TGF?1 (10ng/ml) for 48 hours (R&D Systems)."", 'SLC3A2 expression vector were kindly provided by Roy Zent. Stable expression clones were selected with blasticidin. For TGF?1 treatment, MCF10a cells were treated with human recombinant TGF?1 (10ng/ml) for 48 hours (R&D Systems).', 'Cells were treated with TGF-beta (10ng/ml) for 48 hrs. For rescue experiments, cells were treated with esterified Leucine (2.5 mM) for 18 hrs'; [Growth]'MCF10A cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.', 'MCF10A-inducible RASV12 cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', ""RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nPoly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the manufacturer's instructions.""; [Cell type]'Source: ''cell line: MCF10A; '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74509,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE74nnn/GSE74509/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA300628,28274951," Fabricio Loayza-Puch,  Koos Rooijers,  Jelle Zijlstra,  Behzad Moumbeini,  Esther A Zaal,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro P Ugalde,  Celia R Berkers,  Reuven Agami","Cancer cells modulate their metabolic networks to support cell proliferation and a higher demand of building blocks. These changes may restrict the availability of certain amino acids for protein synthesis, which can be utilized for cancer therapy. However, little is known about the amino acid demand changes occurring during aggressive and invasive stages of cancer. Recently, we developed diricore, an approach based on ribosome profiling that can uncover amino acid limitations. Here, we applied diricore to a cellular model in which epithelial breast cells respond rapidly to TGFbeta1, a cytokine essential for cancer progression and metastasis, and uncovered shortage of leucine. Further analyses indicated that TGFbeta1 treatment of human breast epithelial cells reduces the expression of SLC3A2, a subunit of the leucine transporter, which diminishes leucine uptake and inhibits cell proliferation. Thus, we identified a specific amino acid limitation associated with the TGFbeta1 response, a vulnerability that might be associated with aggressiveness in cancer.",TGFbeta1-induced leucine limitation uncovered by differential ribosome codon reading.,10.15252/embr.201744000,2017 Apr,PMC5376977,EMBO reports
GSE138533,Analysis of PDCD4 knockdown effects by high throughput sequencing of a human epithelial cell line,Homo sapiens,12,SRP224660,2019-10-07,"[Overal design]Knockdown induction: hTERT-RPE-1 cells were transfected either with PDCD4-siRNA or control-siRNA (100 nM) and incubated for 24 h. Induced effects were analyzed by ribosome profiling and RNA-seq in triplicate (IlluminaSequencing).; [Treatment]'hTERT-RPE-1 cells were reversely transfected with siRNA via Lipofectamine RNAiMAX reagent and cultured for 24 h (PDCD4-siRNA: GCUUCUUUCUGACCUUUGU; control-siRNA (targeting renilla luciferase): AAACAUGCAGAAAAUGCUG)'; [Growth]""hTERT-RPE-1 adherent cells were cultured at coated plastic (T75 flask, Greiner Bio-One or cell culture plates, 10 cm, Corning (Falcon)) in DMEM/Ham's F12 medium (Biochrom).""; [Extraction]'RNA-seq: Total RNA samples were extracted with TRIzol\nRNA libraries for RNA-seq were prepared for sequencing using the TruSeq Standard mRNA LT Kit from Illumina', 'For ribosome proliferation RPE cells were incubated for 24 h after transfection with siRNA (Pdcd4 siRNA-2 or control siRNA (100 nM), reverse transfection with Lipofectamine RNAiMAX) and media was changed two hours before harvesting. To stabilize elongating ribosomes, cells were treated with 100 g/mL cycloheximide (CHX) for 5 min at 37 C, following a washing step with ice cold PBS (+ 100 g/mL CHX). Cells were lysed in lysis buffer (10 mM Tris-HCl (pH=7.4), 10 mM MgCl2, 100 mM NaCl, 1% Triton, 1 mM DTT, 100 g/mL CHX) per sample (sample = 8 dishes  10 cm), and cell debris pelleted at 4 C, 10 000 g for 3 min.  10 OD260 units of extract were treated with 900 U RNase I (Ambion)(+ 0.5 % deoxycholate) for 20 min at 22 C, 800 rpm in a Thermomixer. The reaction was stopped by addition of 240 U SUPERase In (Ambion)(+ 0.5 % deoxycholate) and extracts were resolved by centrifugation at 4 C, 35 000 rpm for 3 h in a SW-41 Ti swinging-bucket rotor (Beckman Coulter) on 10-50% sucrose density gradients (20 mM Tris-HCl (pH=7.5), 10 mM MgCl2, 100 mM NH4Cl, 2 mM DTT, 100 g/mL CHX). Gradients were fractionated at 0.75 mL/min with continuous monitoring of OD254 values using a Biocomp Instruments Gradient Station (Teledyne Isco.). Monosome fractions were collected and, following addition of SDS 1%, flash-frozen and stored at -80 C. RNA was isolated from gradient fractions by the hot acid phenol method (1-bromo-3-chloropropane used instead of chloroform), and ribosome footprints were purified from monosome RNA by size selection of 28-30 nt fragments (excluding major band around 31 nt) on 15 % polyacrylamide, 8 M urea, 1xTBE gels. rRNA depletion with RiboZero Kit was skipped, since contaminating reads were removed by aligning against a reference containing all the rRNA of the organism of interest\nRNA libraries for ribosome profiling were prepared accoding to the protocol from Lecanda2016 (Lecanda A, Nilges BS, Sharma P, Nedialkova DD, Schwarz J, Vaquerizas JM, Leidel SA (2016). Dual randomization of oligonucleotides to reduce the bias in  ribosomeprofiling libraries. Methods 107:8997)'; [Cell type]'hTERT-immortalized retinal pigment epithelial cell line''cell type: hTERT-immortalized retinal pigment epithelial cell line; treatment: PDCD4-siRNA2 (100 nM); passages: 12-14; ', 'cell type: hTERT-immortalized retinal pigment epithelial cell line; treatment: control-siRNA (100 nM); passages: 12-14; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138533,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138533/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576260,32066800," Astrid Haas,  Benedikt S Nilges,  Sebastian A Leidel,  Karl-Heinz Klempnauer","PDCD4, the protein encoded by the tumor suppressor gene PDCD4 (programmed cell death 4) has been implicated in the control of cellular transcription and translation by modulating the activity of specific transcription factors and suppressing the translation of mRNAs with structured 5'-UTRs. Most studies of human PDCD4 have employed tumor cell lines, possibly resulting in a biased picture of its role in normal cells. Here, we have studied the function of PDCD4 in a telomerase-immortalized human epithelial cell line. We show for the first time that PDCD4 is required for the G1/S-transition, demonstrating its crucial role in the cell cycle. Inhibition of p53-dependent activation of p21(WAF1/CIP1) overrides the requirement for PDCD4 for the G1/S-transition, suggesting that PDCD4 counteracts basal p53 activity to prevent activation of the G1/S checkpoint by p53. Transcriptome and ribosome profiling data show that silencing of PDCD4 changes the expression levels and translation of many mRNAs, providing an unbiased view of the cellular processes that are affected by PDCD4 in an epithelial cell line. Our data identify PDCD4 as a key regulator of cell cycle- and DNA-related functions that are inhibited when it is silenced, suggesting that decreased expression of PDCD4 might contribute to tumor development by compromising genomic integrity.",PDCD4 controls the G1/S-phase transition in a telomerase-immortalized epithelial cell line and affects the expression level and translation of multiple mRNAs.,10.1038/s41598-020-59678-w,2020 Feb 17,PMC7026441,Scientific reports
GSE148039,Ythdf m6A readers compensate each other in a context dependent manner,Mus musculus,93,None,2020-04-03,"[Overal design]Refer to individual Series; [Treatment]'None', 'For RNA stability assay 5x105 cells of each cell type were plated on a gelatin-coated 6 cm plate. 48 hours later, the media was replaced with fresh media containing 5 ?M Actinomycin-D for the inhibition of mRNA transcription. Cell samples were harvested at the indicated time points (0, 4 and 8 hours).', 'For ribosome profiling cells were treated with Cycloheximide as previously described (McGlincy and Ingolia 2017; Ingolia et al. 2009).'; [Growth]'Maintenance of mESCs was conducted in in 500 mL of High-glucose DMEM (ThermoScientific), 15% USDA certified fetal bovine serum (FBS - Biological Industries), 1 mM L-Glutamine (Biological Industries), 1% nonessential amino acids (Biological Industries), 0.1 mM ?-mercaptoethanol (Sigma), 1% penicillin-streptomycin (Biological Industries), 1% Sodium-Pyruvate (Biological Industries), 10?g recombinant human LIF (Peprotech).'; [Extraction]'Total RNA was extracted using Trizol, followed by ethanol precipitation.\nPolyadenylated RNA was purified using Dynabeads mRNA purification kit (Invitrogen, Cat #61006), followed by library preparation using ScriptSeq v2 RNA-seq Library Preparation Kit (Illumina) according to manufacturers instruction.', 'Oocytes were lysed using Smart-seq2 lysis buffer.\nLibrary was prepared according to SMART-seq2 protocol as previously described (Simone Picelli et al, 2014), with few changes: oocytes from each mouse were collected in 3 ul M2 and added to 7.9ul lysis buffer. Additional 1.1 ul of DDW was added prior to the library preparation.', 'Male germ cell populations were isolated using FACS. Total RNA was extracted using Trizol, followed by ethanol precipitation.\nTotal RNA was purified using rRNA depletion (Ribo-Zero rRna removal Kit, Illumina), followed by library preparation using ScriptSeq V2 RNA-seq Library Preparation Kit (Illumina) according to manufacturers instruction.', 'Total RNA was extracted using Trizol, followed by ethanol precipitation.\n3 Poly A-RNA-seq library preparation was done as previously described (Geula, 2015).', 'Cells were lysed in lysis buffer (20mM Tris 7.5, 150mM NaCl, 15mM MgCl2, 1mM dithiothreitol) supplemented with 0.5% triton, 30 U/ml Turbo DNase (Ambion) and 100?g/ml cycloheximide. The lysate was cleared by centrifugation, treated with RNase I for 45min and then loaded on a sucrose cushion. Pellet was resuspended in Trizol and then RNA was isolated from cells using chloroform-based separation.\nSmall RNA fragments were size selected via gel purification, dephosphorylated, ligated, and reverse transcribed. The resulting cDNA was circularized and PCR amplified.', 'Cells were lysed in iCLIP lysis buffer, followed by limited digestion with RNase I (Ambion), immunoprecipitation of RBP-RNA complexes with a specific antibody of interest (Protein G sheep anti-rabbit Dynabeads), and stringent washes. After dephosphorylation with FastAP (Thermo Fisher) and T4 PNK (NEB), a barcoded RNA adapter is ligated to the 3 end (T4 RNA Ligase, NEB) (at this step, multiple replicates of the same RBP, or potentially RBPs of similar size and bound RNA amount, can be uniquely barcoded and pooled after ligation to simplify downstream steps - see Supplementary Fig. 2A). Ligations are performed on-bead (to allow washing away unincorporated adapter) in high concentration of PEG8000, which improves ligation efficiency to > 90%. Samples are then run on standard protein gels and transferred to nitrocellulose membranes, and a region 75 kDa (~150 nt of RNA) above the protein size is isolated and proteinase K (NEB) treated to isolate RNA. RNA is reverse transcribed with AffinityScript (Agilent), and treated with ExoSAP-IT (Affymetrix) to remove excess oligonucleotides. A second DNA adapter (containing a random-mer of 5 (N5) or 10 (N10) random bases at the 5 end) is then ligated to the cDNA fragment 3 end (T4 RNA Ligase, NEB), performed with high concentration of PEG8000 (to improve ligation efficiency) and DMSO (to decrease inhibition of ligation due to secondary structure). After cleanup (Dynabeads MyOne Silane, ThermoFisher), an aliquot of each sample is first subjected to qPCR (to identify the proper number of PCR cycles), and then the remainder is PCR amplified (Q5, NEB) and size selected via agarose gel electrophoresis.'; [Cell type]'mouse embryonic stem cells', 'germinal vesicle (GV) stage mouse oocytes', 'post-germinal vesicle (GV) stage mouse oocytes', 'mouse round spermatids', 'mouse Embryonic Stem Cells (mESCs)', 'mouse embryonic stem cells (mESCs)', 'mouse emrbyonic stem cells''strain background: KH2 (C57BL/6 x 129/Sv); genotype: WT; cell type: mouse embryonic stem cells; library strategy: PolyA RNA-seq; ', 'strain background: KH2 (C57BL/6 x 129/Sv); genotype: Ythdf1-/-; cell type: mouse embryonic stem cells; library strategy: PolyA RNA-seq; ', 'strain background: KH2 (C57BL/6 x 129/Sv); genotype: Ythdf2-/-; cell type: mouse embryonic stem cells; library strategy: PolyA RNA-seq; ', 'strain background: KH2 (C57BL/6 x 129/Sv); genotype: Ythdf3-/-; cell type: mouse embryonic stem cells; library strategy: PolyA RNA-seq; ', 'strain background: KH2 (C57BL/6 x 129/Sv); genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; cell type: mouse embryonic stem cells; library strategy: PolyA RNA-seq; ', 'strain background: KH2 (C57BL/6 x 129/Sv); genotype: Mettl3-/-; cell type: mouse embryonic stem cells; library strategy: PolyA RNA-seq; ', 'strain background: BDF1 X C57BL/6 X Jax#003651; genotype: Mettl3f/f Zp3-Cre+; cell type: germinal vesicle (GV) stage mouse oocytes; library strategy: SMART-seq2; ', 'strain background: BDF1 X C57BL/6 X Jax#003651; genotype: Mettl3f/f Zp3-Cre-; cell type: germinal vesicle (GV) stage mouse oocytes; library strategy: SMART-seq2; ', 'strain background: CB6F1 X C57BL/6; genotype: Ythdf2-/-; cell type: post-germinal vesicle (GV) stage mouse oocytes; library strategy: SMART-seq2; ', 'strain background: CB6F1 X C57BL/6; genotype: Ythdf2+/-; cell type: post-germinal vesicle (GV) stage mouse oocytes; library strategy: SMART-seq2; ', 'strain background: CB6F1 X C57BL/6; genotype: Ythdf2-/-; cell type: mouse round spermatids; library strategy: Ribo-Zero RNA-seq; ', 'strain background: CB6F1 X C57BL/6; genotype: Ythdf2+/+; cell type: mouse round spermatids; library strategy: Ribo-Zero RNA-seq; ', ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: WT; treatment/time point: 0h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: WT; treatment/time point: 4h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: WT; treatment/time point: 8h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: WT; treatment/time point: 8h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: WT; treatment/time point: 0h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: WT; treatment/time point: 4h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1--/-; treatment/time point: 8h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1--/-; treatment/time point: 0h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1--/-; treatment/time point: 4h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1--/-; treatment/time point: 8h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1--/-; treatment/time point: 0h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1--/-; treatment/time point: 4h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf2--/-; treatment/time point: 0h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf2--/-; treatment/time point: 4h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf2--/-; treatment/time point: 8h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf2--/-; treatment/time point: 0h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf2--/-; treatment/time point: 4h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf2--/-; treatment/time point: 8h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf3--/-; treatment/time point: 0h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf3--/-; treatment/time point: 4h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf3--/-; treatment/time point: 8h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf3--/-; treatment/time point: 0h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf3--/-; treatment/time point: 4h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf3--/-; treatment/time point: 8h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; treatment/time point: 0h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; treatment/time point: 4h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; treatment/time point: 8h after actinomycin D treatment; replicate: A; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; treatment/time point: 0h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; treatment/time point: 4h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", ""cell line: KH2; cell type: mouse Embryonic Stem Cells (mESCs); strain background: C57BL/6 x 129/Sv; genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; treatment/time point: 8h after actinomycin D treatment; replicate: B; library strategy: 3'UTR RNA-seq; "", 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: WT; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf1-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf2-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf3-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Ythdf1-/-Ythdf2-/-Ythdf3-/-; ', 'cell line: KH2; cell type: mouse embryonic stem cells (mESCs); strain background: (C57BL/6 x 129/Sv); genotype: Mettl3-/-; ', 'mouse strain: V6.5; genotype: V6.5 X2FLAG-mYthdf1-ires-puro polyclonal mouse ESC; cell type: mouse emrbyonic stem cells; ', 'mouse strain: V6.5; genotype: V6.5 X2FLAG-mYthdf2-ires-puro polyclonal mouse ESC; cell type: mouse emrbyonic stem cells; ', 'mouse strain: V6.5; genotype: V6.5 X2FLAG-mYthdf3-ires-puro polyclonal mouse ESC; cell type: mouse emrbyonic stem cells; ', 'mouse strain: V6.5; genotype: V6.5; cell type: mouse emrbyonic stem cells; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148039,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE148nnn/GSE148039/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA622932,32943573," Lior Lasman,  Vladislav Krupalnik,  Sergey Viukov,  Nofar Mor,  Alejandro Aguilera-Castrejon,  Dan Schneir,  Jonathan Bayerl,  Orel Mizrahi,  Shani Peles,  Shadi Tawil,  Shashank Sathe,  Aharon Nachshon,  Tom Shani,  Mirie Zerbib,  Itay Kilimnik,  Stefan Aigner,  Archana Shankar,  Jasmine R Mueller,  Schraga Schwartz,  Noam Stern-Ginossar,  Gene W Yeo,  Shay Geula,  Noa Novershtern,  Jacob H Hanna","The N6-methyladenosine (m(6)A) modification is the most prevalent post-transcriptional mRNA modification, regulating mRNA decay and splicing. It plays a major role during normal development, differentiation, and disease progression. The modification is regulated by a set of writer, eraser, and reader proteins. The YTH domain family of proteins consists of three homologous m(6)A-binding proteins, Ythdf1, Ythdf2, and Ythdf3, which were suggested to have different cellular functions. However, their sequence similarity and their tendency to bind the same targets suggest that they may have overlapping roles. We systematically knocked out (KO) the Mettl3 writer, each of the Ythdf readers, and the three readers together (triple-KO). We then estimated the effect in vivo in mouse gametogenesis, postnatal viability, and in vitro in mouse embryonic stem cells (mESCs). In gametogenesis, Mettl3-KO severity is increased as the deletion occurs earlier in the process, and Ythdf2 has a dominant role that cannot be compensated by Ythdf1 or Ythdf3, due to differences in readers' expression pattern across different cell types, both in quantity and in spatial location. Knocking out the three readers together and systematically testing viable offspring genotypes revealed a redundancy in the readers' role during early development that is Ythdf1/2/3 gene dosage-dependent. Finally, in mESCs there is compensation between the three Ythdf reader proteins, since the resistance to differentiate and the significant effect on mRNA decay occur only in the triple-KO cells and not in the single KOs. Thus, we suggest a new model for the Ythdf readers function, in which there is profound dosage-dependent redundancy when all three readers are equivalently coexpressed in the same cell types.",Context-dependent functional compensation between Ythdf m(6)A reader proteins.,10.1101/gad.340695.120,2020 Oct 1,PMC7528697,Genes & development
GSE109343,Lso2 is a conserved ribosome-bound protein required for translational recovery in yeast,Saccharomyces cerevisiae,25,SRP131127,2018-01-18,"[Overal design]Enhanced crosslinking and immunoprecipitation (IP) followed by deep sequencing: 5 IP samples of Lso2 and CCDC124, 6 controls of size-matched input and untagged IP. Ribosome footprint profiling: 7 samples of wild-type and 7 samples of lso2 null mutants.; [Treatment]'For UV crosslinking, cultures were poured over ice and pelleted, then resuspended in cold water and transferred to a Petri dish situated on ice. Resuspended cells were crosslinked in a Stratalinker at 365 nm, approximately 5 cm from the UV bulb, for a total of 7.2 J/cm2 (680 s). UV-treated culture was pelleted.', 'Cells were collected by rapid filtration and freezing in the absence of translation inhibitors.', 'Cycloheximide-treated cells were poured over ice, spun down, and washed twice with polysome lysis buffer (20 mM HEPES-KOH pH 7.4, 2 mM MgAc, 0.1 M KAc, 0.1 mg/mL cycloheximide, 1% TritonX-100).'; [Growth]'Cells were grown in synthetic complete medium with 120 ?M uracil to OD600 1.0. 4-thiouracil was added to each culture to a final concentration of 500 ?M. Cultures were grown with shaking at 30C for an additional 3 hours.', 'Cells were grown for 96 hours to stationary phase, then shifted to rich medium for 30 minutes.', 'Cells were grown in YPAD to OD600 0.6-0.7 (early log phase). Cycloheximide was added to culture to a final concentration of 0.1 mg/mL and shaken for 2 minutes.', 'Cells were grown in YPAD to OD600 1.0, then spun down and transferred to YPA (lacking glucose) for 3 hours. Cycloheximide was added to culture to a final concentration of 0.1 mg/mL and shaken for 2 minutes.'; [Extraction]'Cells were lysed by vortexing with glass beads in lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1:200 Protease Inhibitor Cocktail III, 0.44U/mL murine RNase inhibitor). Extracts were clarified at 10,000 x g for 5 minutes.\nLysate was digested with 1:20,000,000 RNase I and immunoprecipitated with anti-c-Myc-conjugated beads. A 3' adapter was ligated and the RNPs separated on a denaturing gel. 55-130 kDa species were size-selected and treated with proteinase K. RNAs were reverse transcribed. A second adapter was ligated to the 3' end of first-strand cDNA. cDNAs were then amplified by PCR.', 'Cells were lysed by vortexing with glass beads in lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1:200 Protease Inhibitor Cocktail III, 0.44U/mL murine RNase inhibitor). Extracts were clarified at 10,000 x g for 5 minutes.\nLysate was digested with 1:2,000,000 RNase I and immunoprecipitated with anti-c-Myc-conjugated beads. A 3' adapter was ligated and the RNPs separated on a denaturing gel. 35-100 kDa species were size-selected and treated with proteinase K. RNAs were reverse transcribed. A second adapter was ligated to the 3' end of first-strand cDNA. cDNAs were then amplified by PCR.', 'Cells were lysed by vortexing with glass beads in lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1:200 Protease Inhibitor Cocktail III, 0.44U/mL murine RNase inhibitor). Extracts were clarified at 10,000 x g for 5 minutes.\nLysate was digested with 1:2,000,000 RNase I and immunoprecipitated with anti-c-Myc-conjugated beads. A 3' adapter was ligated and the RNPs separated on a denaturing gel. 55-130 kDa species were size-selected and treated with proteinase K. RNAs were reverse transcribed. A second adapter was ligated to the 3' end of first-strand cDNA. cDNAs were then amplified by PCR.', 'Cells were lysed by vortexing with glass beads in lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1:200 Protease Inhibitor Cocktail III, 0.44U/mL murine RNase inhibitor). Extracts were clarified at 10,000 x g for 5 minutes.\nLysate was digested with 1:2,000,000 RNase I and immunoprecipitated with anti-c-Myc-conjugated beads. A 3' adapter was ligated and the RNPs separated on a denaturing gel. 35-130 kDa species were size-selected and treated with proteinase K. RNAs were reverse transcribed. A second adapter was ligated to the 3' end of first-strand cDNA. cDNAs were then amplified by PCR.', 'Cells were ground in lysis buffer (20 mM Tris-HCl pH 8.0, 140 mM KCl, 1.5 mM MgCl2, 1% Triton X-100, 0.1 mg/mL cycloheximide) using a cryogenic ball mill.\nLysate was digested with 15U/A260 RNase I. Footprinted HeLa lysate was doped in at a fixed fraction to ribosomal RNA per volume of yeast lysate. 80S footprints were isolated from a sucrose gradient, enriched for small RNAs, and size-selected from 15-34 nucleotides. A 3' adapter was ligated and samples treated with RiboZero. The RNA was reverse transcribed, circularized, and PCR amplified.', 'Cells were lysed by vortexing with glass beads in polysome lysis buffer (20 mM HEPES-KOH pH 7.4, 2 mM MgAc, 0.1 M KAc, 0.1 mg/mL cycloheximide, 1% TritonX-100). Extracts were clarified at 21,000  g for 20 minutes.\nLysate was digested with 15U/A260 RNase I. 80S footprints were isolated from a sucrose gradient, enriched for small RNAs, and size-selected from 26-31 nucleotides. A 3' adapter was ligated and samples treated with subtractive hybridization oligos to deplete ribosomal RNA. The RNA was reverse transcribed, circularized, and PCR amplified.'; [Cell type]'Source: ''background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1 lso2{delta}::LSO2-9XHis-2XPrescission-9XMyc-HIS3; antibody: anti-c-Myc; fraction: Crosslinked pulldown RNA; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1 lso2{delta}::LSO2-9XHis-2XPrescission-9XMyc-HIS3; antibody: none; fraction: Crosslinked input RNA; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1; antibody: anti-c-Myc; fraction: Crosslinked pulldown RNA; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1 lso2{delta}::CCDC124-9XHis-2XPrescission-9XMyc-HIS3; antibody: anti-c-Myc; fraction: Crosslinked pulldown RNA; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1; antibody: N/A; fraction: Ribosome-protected mRNA; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1 lso2{delta}::kan; antibody: N/A; fraction: Ribosome-protected mRNA; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1; ', 'background: Sigma1278b Strain F1950; genotype: MATa ura3 his3 leu2 trp1 lso2{delta}::kan; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109343,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE109nnn/GSE109343/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA430526,30208026," Yinuo J Wang,  Pavanapuresan P Vaidyanathan,  Maria F Rojas-Duran,  Namrata D Udeshi,  Kristen M Bartoli,  Steven A Carr,  Wendy V Gilbert","Ribosome-binding proteins function broadly in protein synthesis, gene regulation, and cellular homeostasis, but the complete complement of functional ribosome-bound proteins remains unknown. Using quantitative mass spectrometry, we identified late-annotated short open reading frame 2 (Lso2) as a ribosome-associated protein that is broadly conserved in eukaryotes. Genome-wide crosslinking and immunoprecipitation of Lso2 and its human ortholog coiled-coil domain containing 124 (CCDC124) recovered 25S ribosomal RNA in a region near the A site that overlaps the GTPase activation center. Consistent with this location, Lso2 also crosslinked to most tRNAs. Ribosome profiling of yeast lacking LSO2 (lso2Delta) revealed global translation defects during recovery from stationary phase with translation of most genes reduced more than 4-fold. Ribosomes accumulated at start codons, were depleted from stop codons, and showed codon-specific changes in occupancy in lso2Delta. These defects, and the conservation of the specific ribosome-binding activity of Lso2/CCDC124, indicate broadly important functions in translation and physiology.",Lso2 is a conserved ribosome-bound protein required for translational recovery in yeast.,10.1371/journal.pbio.2005903,2018 Sep,PMC6135351,PLoS biology
GSE97140,Methylation of human eukaryotic elongation factor alpha (eEF1A) by a member of a novel protein lysine methyltransferase family modulates mRNA translation,Homo sapiens,11,SRP102616,2017-03-28,"[Overal design]Ribosome profiling and RNAseq data for wt and EEF1AKMT4 knockout cells. This study includes the re-use of samples GSM2445294 and GSM2445295 from GSE93133. These two samples have been re-accessioned here so that the complete study is available from the SRP ID.; [Treatment]'Cells were treated with 100 g/ml cycloheximide (CHX) for 1 min, washed with ice cold PBS containing 100 g/ml CHX and subsequently lysed in lysis buffer (10 mM Tris pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 % Triton X-100, 0.5 mM DTT, 100 g/ml CHX).'; [Growth]'Wild type and EEF1AKMT4-deficient HAP-1 cells were cultured  in IMDM GlutaMAX, 10 % FBS and 100 U/ml penicillin-streptomycin.'; [Extraction]'For ribosome profiling, lysates were subsequently treated with 250 U RNase I (Ambion) for 10 min at 22 C and shaking at 1400 rpm. The digestion was stopped by addition of 100 U SUPERase In RNase inhibitor (Ambion). Ribosomes were separated on a 10-50 % (w/v) sucrose density gradient in 50 mM Tris pH 7.5, 50 mM NH4Cl, 12 mM MgCl2, 0.5 mM DTT, 100 g/ml CHX for 3 h at 35 000 rpm and 4 C in a TH-641 rotor (Thermo Scientific). Gradients were fractionated at 0.75 ml/min with continuous monitoring of OD254 on a density gradient fractionator (Isco) coupled to a SYR-101 syringe pump (Brandel). SDS was added immediately to 1\xa0% and 400 l fractions were flash-frozen in liquid nitrogen and stored at -80 C until further processing. Monosome fractions were pooled, RNA isolated and separated on 15\xa0% polyacrylamide gels (8 M urea, 1 x TBE). Ribosome footprints were excised between 28 nucleotide (nt) and 32 nt RNA size markers.\nSequencing libraries from ribosome footprints were generated essentially as described (27), except for ligation to a preadenylated 3-adapter (5 rAppNNNNCTGTAGGCACCATCAAT/3ddC/ 3) in a reaction containing 200 000 U T4 RNA ligase 2 (truncated, NEB), 25 % PEG 8000 and 10 U SUPERase In RNase inhibitor for 4 h at 22 C. The first four bases of the 3-adapter were randomized to minimize ligation bias (28).', 'For ribosome profiling, lysates were subsequently treated with 250 U RNase I (Ambion) for 10 min at 22 C and shaking at 1400 rpm. The digestion was stopped by addition of 100 U SUPERase In RNase inhibitor (Ambion). Ribosomes were separated on a 10-50 % (w/v) sucrose density gradient in 50 mM Tris pH 7.5, 50 mM NH4Cl, 12 mM MgCl2, 0.5 mM DTT, 100 g/ml CHX for 3 h at 35 000 rpm and 4 C in a TH-641 rotor (Thermo Scientific). Gradients were fractionated at 0.75 ml/min with continuous monitoring of OD254 on a density gradient fractionator (Isco) coupled to a SYR-101 syringe pump (Brandel). SDS was added immediately to 1\xa0% and 400 l fractions were flash-frozen in liquid nitrogen and stored at -80 C until further processing. Monosome fractions were pooled, RNA isolated and separated on 15\xa0% polyacrylamide gels (8 M urea, 1 x TBE). Ribosome footprints were excised between 28 nucleotide (nt) and 32 nt RNA size markers. Sequencing libraries from ribosome footprints were generated essentially as described (27), except for ligation to a preadenylated 3-adapter (5 rAppNNNNCTGTAGGCACCATCAAT/3ddC/ 3) in a reaction containing 200 000 U T4 RNA ligase 2 (truncated, NEB), 25 % PEG 8000 and 10 U SUPERase In RNase inhibitor for 4 h at 22 C. The first four bases of the 3-adapter were randomized to minimize ligation bias (28).\nSequencing libraries from ribosome footprints were generated essentially as described (27), except for ligation to a preadenylated 3-adapter (5 rAppNNNNCTGTAGGCACCATCAAT/3ddC/ 3) in a reaction containing 200 000 U T4 RNA ligase 2 (truncated, NEB), 25 % PEG 8000 and 10 U SUPERase In RNase inhibitor for 4 h at 22 C. The first four bases of the 3-adapter were randomized to minimize ligation bias (28).', ""Cell lysates were incubated with RNAseI and subjected to sucrose gradient centrifugation. Monosomes were isolated and used for library preparation.\nLibraries were prepared by isolating ribosome prorotected fragments, 3' linker ligation, reverse transcription with an RT primer complementary to the linker, cicularization of the resulting ssDNA and a final PCR to attach illumina index primers and amplify the library."", ""RNASeq libraries were prepared from cells lysed similar to ribosome profiling samples. RNA was isolated from cleared lysates by addition of 1 % SDS (w/v) and 5 min incubation at 65 C with intermittent vortexing followed by three rounds of extraction using 10:1 acid-phenol pH 4.3 and bromochloropropane.\nTotal RNA was precipitated and 5 g used for library generation with the TruSeq Stranded mRNA Library Prep Kit (Illumina) according to the manufacturer's instructions. Libraries were sequenced on an Illumina HiScanSQ generating 50 nt single-end reads.""; [Cell type]'Source: ''commercial name: Horizon Genomics, HZGHC000530c010; cell line: HAP-1; genotype: EEF1AKMT4 KO; ', 'commercial name: Horizon Genomics, HZGHC000530c011; cell line: HAP-1; genotype: EEF1AKMT4 KO; ', 'commercial name: Horizon Genomics, HZGHC000530c012; cell line: HAP-1; genotype: EEF1AKMT4 KO; ', 'cell line: Flp-In T-REx-293; genotype: wildtype; ', 'commercial name: Horizon Genomics, HZGHC000530c013; cell line: HAP-1; genotype: EEF1AKMT4 KO; ', 'commercial name: Horizon Genomics, HZGHC000530c014; cell line: HAP-1; genotype: EEF1AKMT4 KO; ', 'commercial name: Horizon Genomics, HZGHC000530c015; cell line: HAP-1; genotype: EEF1AKMT4 KO; ', 'commercial name: Horizon Genomics, HAP1; cell line: HAP-1; genotype: wildtype; '",Expression profiling by high throughput sequencing; Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97140,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE97nnn/GSE97140/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA380795,28520920," Magnus E Jakobsson,  Jedrzej Malecki,  Benedikt S Nilges,  Anders Moen,  Sebastian A Leidel,  Pal O Falnes","Many cellular proteins are methylated on lysine residues and this has been most intensively studied for histone proteins. Lysine methylations on non-histone proteins are also frequent, but in most cases the functional significance of the methylation event, as well as the identity of the responsible lysine (K) specific methyltransferase (KMT), remain unknown. Several recently discovered KMTs belong to the so-called seven-beta-strand (7BS) class of MTases and we have here investigated an uncharacterized human 7BS MTase currently annotated as part of the endothelin converting enzyme 2, but which should be considered a separate enzyme. Combining in vitro enzymology and analyzes of knockout cells, we demonstrate that this MTase efficiently methylates K36 in eukaryotic translation elongation factor 1 alpha (eEF1A) in vitro and in vivo. We suggest that this novel KMT is named eEF1A-KMT4 (gene name EEF1AKMT4), in agreement with the recently established nomenclature. Furthermore, by ribosome profiling we show that the absence of K36 methylation affects translation dynamics and changes translation speed of distinct codons. Finally, we show that eEF1A-KMT4 is part of a novel family of human KMTs, defined by a shared sequence motif in the active site and we demonstrate the importance of this motif for catalytic activity.",Methylation of human eukaryotic elongation factor alpha (eEF1A) by a member of a novel protein lysine methyltransferase family modulates mRNA translation.,10.1093/nar/gkx432,2017 Aug 21,PMC5737405,Nucleic acids research
GSE158044,Activation of the antiviral factor RNase L triggers translation of non-coding mRNA sequences,Homo sapiens,30,SRP282584,2020-09-16,"[Overal design]30 Ribsome profiling datasets on 2-5A or poly I:C treated or untreated A549 lung carcinoma cells.; [Treatment]'2-5A and poly I:C were transfected by Lipofectamine 3000. Transfection controls were only treated with Lipofectamine 3000. Cells were washed with ice cold DPBS and flash frozen in liquid nitrogen. Then cells were lysed in lysis buffer.'; [Growth]'cell line appropriate media + 10% FBS, 37?C, 5% CO2'; [Extraction]'Ribosome profiling lysates were clarified, Rnase I treated, and separated over sucrose cushion. RNA was then extracted using trizol and footprints of the specified size were retained by gel purification.\nSamples starting with ""GJ"" were prepared accoring to Ingolia et al, 2009. Samples starting with ""AK"" were prepared using the protocol published in McGlincy and Ingolia, 2017. Briefly, RNAs were ligated to a universal DNA linker followed by reverse transcription. rRNA was subtracted using Ribo-Zero Illumina kit after ligation. cDNAs were then circularized and PCR amplified.'; [Cell type]'Source: ''cell line: Hap1; treatment: untreated; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: Hap1; treatment: 10 M 2-5A treated, 3 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: HeLa; treatment: untreated; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: HeLa; treatment: 1 M trimer 2-5A, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: HeLa; treatment: 1 M tetramer 2-5A. 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: HeLa; treatment: 10 M trimer 2-5A, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: HeLa; treatment: 10 M tetramer 2-5A, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: untreated; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: untreated; genotype: RNASEL KO; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 1 M trimer 2-5A, 4.5 h; genotype: RNASEL KO; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 0.1 M trimer 2-5A, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 1 M trimer 2-5A, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 10 M trimer 2-5A, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 0.25 g/ml poly I:C, 4.5 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 1 M trimer 2-5A, 2.25 h; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 1 M dimer 2-5A; genotype: wild type; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 0.25 g/ml poly I:C, 4.5 h; genotype: RNASEL KO; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: untreated; genotype: RNASEL KO, wild type RNAse L transently transfected; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: untreated; genotype: RNASEL KO, H672N RNAse L transently transfected; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 1 M trimer 2-5A, 4.5 h; genotype: RNASEL KO,H672N RNAse L transently transfected; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 0.25 g/ml poly I:C, 4.5 h; genotype: RNASEL KO,H672N RNAse L transently transfected; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 1 M trimer 2-5A, 4.5 h; genotype: RNASEL KO,wild type RNAse L transently transfected; molecule subtype: 80S ribosome protected RNA (25-34 nt); ', 'cell line: A549; treatment: 0.25 g/ml poly I:C, 4.5 h; genotype: RNASEL KO,wild type RNAse L transently transfected; molecule subtype: 80S ribosome protected RNA (25-34 nt); '",Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158044,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE158nnn/GSE158044/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA663848,33556964," Agnes Karasik,  Grant D Jones,  Andrew V DePass,  Nicholas R Guydosh","Ribonuclease L (RNase L) is activated as part of the innate immune response and plays an important role in the clearance of viral infections. When activated, it endonucleolytically cleaves both viral and host RNAs, leading to a global reduction in protein synthesis. However, it remains unknown how widespread RNA decay, and consequent changes in the translatome, promote the elimination of viruses. To study how this altered transcriptome is translated, we assayed the global distribution of ribosomes in RNase L activated human cells with ribosome profiling. We found that RNase L activation leads to a substantial increase in the fraction of translating ribosomes in ORFs internal to coding sequences (iORFs) and ORFs within 5' and 3' UTRs (uORFs and dORFs). Translation of these alternative ORFs was dependent on RNase L's cleavage activity, suggesting that mRNA decay fragments are translated to produce short peptides that may be important for antiviral activity.",Activation of the antiviral factor RNase L triggers translation of non-coding mRNA sequences.,10.1093/nar/gkab036,2021 Jun 21,PMC8216459,Nucleic acids research
GSE66808,"IFN-g Regulates mTORC1, Cellular Metabolism and mRNA Translation to Potentiate Inflammatory Macrophage Activation [miRNA-Seq]",Homo sapiens,8,SRP056097,2015-03-12,"[Overal design]microRNA-seq libraries were generated from mock or IFN-g-primed human macrophages. Cells were stimulated with or without Pam3Cys and harvested at 4 hours Libraries were generated using Illumina Truseq small RNA technology.; [Treatment]'Cells cultured for 24h were stimulated with or without Pam3Cys (10ng/ml) for 4h'; [Growth]'Cells were maintained in RPMI1640 supplemented with 10% FBS and 20ng/ml MCSF, under 5% CO2 at 37C.'; [Extraction]'Total RNA was extracted by using mirVana miRNA isolation kit\nmiRNA libraries were prepared by using TruSeq small RNA library prep kit (Illumina)'; [Cell type]'Source: ''tlr stimulation: unstimulated; ', 'tlr stimulation: TLR2 stimulated; '",Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66808,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE66nnn/GSE66808/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA278007,26147685," Xiaodi Su,  Yingpu Yu,  Yi Zhong,  Eugenia G Giannopoulou,  Xiaoyu Hu,  Hui Liu,  Justin R Cross,  Gunnar Ratsch,  Charles M Rice,  Lionel B Ivashkiv","Interferon-gamma (IFN-gamma) primes macrophages for enhanced microbial killing and inflammatory activation by Toll-like receptors (TLRs), but little is known about the regulation of cell metabolism or mRNA translation during this priming. We found that IFN-gamma regulated the metabolism and mRNA translation of human macrophages by targeting the kinases mTORC1 and MNK, both of which converge on the selective regulator of translation initiation eIF4E. Physiological downregulation of mTORC1 by IFN-gamma was associated with autophagy and translational suppression of repressors of inflammation such as HES1. Genome-wide ribosome profiling in TLR2-stimulated macrophages showed that IFN-gamma selectively modulated the macrophage translatome to promote inflammation, further reprogram metabolic pathways and modulate protein synthesis. These results show that IFN-gamma-mediated metabolic reprogramming and translational regulation are key components of classical inflammatory macrophage activation.",Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation.,10.1038/ni.3205,2015 Aug,PMC4509841,Nature immunology
GSE78807,Genome-wide profiling of mTOR-dependent translation in Oikopleura dioica,Oikopleura dioica,12,SRP071049,2016-03-01,"[Overal design]Ribosome-protected RNA fragments and total RNA extracted from animals treated with mTOR inhibitor Torin 1 and control animals (DMSO) in three biological replicates (12 samples in total) sequenced on two lanes on each of two Illumina flow cells; [Treatment]'Animals were placed into beakers of seawater containing normal algal food dose for day 6 and either 1 ?M Torin 1 (treatment) or 1 ?M DMSO (vehicle control). Animals were exposed to treatment and control for 1.5 hrs before being collected, washed, spun down and frozen in liquid nitrogen.'; [Growth]'None'; [Extraction]'Total RNA was extracted using RNeasy. Ribosome protected fragments (RPFs) were extracted using the ARTSeq kit from epicentre using the using MicroSpin S-400 column option.  rRNA was depleted from all samples using RiboZero.\nLibraries were prepared for sequencing using the ARTSeq kit from epicentre and the included indices were added for multiplex sequencing creating barcodes as follows: Sample 1 CTTGTA; Sample 2 GCCAAT; Sample 3 ATCACG; Sample 4 CGATGT; Sample 5 TTAGGC; Sample 6 ACAGTG; Sample 7 CAGATC; Sample 8 ACTTGA; Sample 9 TGACCA; Sample 10 GATCAG; Sample 11 TAGCTT; Sample 12 GGCTAC'; [Cell type]'Source: ''drug treatment: DMSO; tissue: Whole animal; developmental stage: Day 6; ', 'drug treatment: Torin 1; tissue: Whole animal; developmental stage: Day 6; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78807,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE78nnn/GSE78807/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA314019,31783727," Gemma B Danks,  Heloisa Galbiati,  Martina Raasholm,  Yamila N Torres Cleuren,  Eivind Valen,  Pavla Navratilova,  Eric M Thompson","BACKGROUND: In phylogenetically diverse organisms, the 5' ends of a subset of mRNAs are trans-spliced with a spliced leader (SL) RNA. The functions of SL trans-splicing, however, remain largely enigmatic. RESULTS: We quantified translation genome-wide in the marine chordate, Oikopleura dioica, under inhibition of mTOR, a central growth regulator. Translation of trans-spliced TOP mRNAs was suppressed, consistent with a role of the SL sequence in nutrient-dependent translational control of growth-related mRNAs. Under crowded, nutrient-limiting conditions, O. dioica continued to filter-feed, but arrested growth until favorable conditions returned. Upon release from unfavorable conditions, initial recovery was independent of nutrient-responsive, trans-spliced genes, suggesting animal density sensing as a first trigger for resumption of development. CONCLUSION: Our results are consistent with a proposed role of trans-splicing in the coordinated translational down-regulation of nutrient-responsive genes under growth-limiting conditions.",Trans-splicing of mRNAs links gene transcription to translational control regulated by mTOR.,10.1186/s12864-019-6277-x,2019 Nov 29,PMC6883708,BMC genomics
GSE111477,Inflammatory versus non-inflammatory breast cancers,Homo sapiens,122,None,2018-03-06,"[Overal design]Training set of 33 IBC and 28 non IBC; [Treatment]'NA'; [Growth]'NA'; [Extraction]'Rneasy (Qiagen)'; [Cell type]'Source: ''condition: Non-Inflammatory; ', 'condition: Inflammatory; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111477,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE111nnn/GSE111477/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA437146,33364047," F Lerebours,  S Vacher,  J M Guinebretiere,  S Rondeau,  M Caly,  D Gentien,  S Van Laere,  F Bertucci,  P de la Grange,  L Bieche,  X Liang,  C Callens","Introduction: Inflammatory Breast Cancer (IBC) is the most aggressive form of breast carcinoma characterized by rapid onset of inflammatory signs and its molecular fingerprint has not yet been elucidated. Objectives: The objective of this study was to detect both gene expression levels and alternate RNA splice variants specific for IBC. Methods: W e performed splice-sensitive array profiling using Affymetrix Exon Array and quantitative RT-PCR analyses in 177 IBC compared to 183 non-IBC. We also assessed the prognostic value of the identified candidate genes and splice variants. Results: A 5-splice signature (HSPA8, RPL10, RPL4, DIDO1 and EVL) was able to distinguish IBC from non-IBC tumors (p<10(-7)). This splice signature was associated with poor metastasis-free survival in hormone receptor-negative non-IBC (p=0.02), but had no prognostic value in IBC. PAM analysis of dysregulated genes in IBC compared to non-IBC identified a 10-gene signature highly predictive of IBC phenotype and conferring a poor prognosis in non-IBC. The genes most commonly upregulated in IBC were 3 hemoglobin genes able to reliably discriminate IBC from non-IBC (p<10(-4)). Hb protein expression in epithelial breast tumor cells was confirmed by immunohistochemistry. Conclusion: IBC has a specific spliced transcript profile and is characterized by hemoglobin gene overexpression that should be investigated in further functional studies.",Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?,10.1016/j.jare.2020.08.009,2021 Feb,PMC7753232,Journal of advanced research
GSE138729,Induction of extracellular adenosine salvage and metabolic quiescence regulate the transitional to follicular B cell checkpoint in humans.,Homo sapiens; Mus musculus,22,SRP225109,2019-10-10,"[Overal design]RNAseq analysis of transitional and follicular B cells from healthy human donors and C57BL/6 (wild-type) mice; [Treatment]'None'; [Growth]'None'; [Extraction]'Qiagen RNAeasy kit\nSmartseq2'; [Cell type]'Transitional (T1)  B cells', 'Transitional (T2)  B cells', 'Transitional (T3)  B cells', 'Follicular B cells', 'T1/T2 B cells', 'T3 B cells''strain: C57BL/6J; mouse id: Mouse 1; genotype: wild-type; cell type: Transitional (T1)  B cells; ', 'strain: C57BL/6J; mouse id: Mouse 2; genotype: wild-type; cell type: Transitional (T2)  B cells; ', 'strain: C57BL/6J; mouse id: Mouse 3; genotype: wild-type; cell type: Transitional (T3)  B cells; ', 'strain: C57BL/6J; mouse id: Mouse 1; genotype: wild-type; cell type: Follicular B cells; ', 'strain: C57BL/6J; mouse id: Mouse 2; genotype: wild-type; cell type: Follicular B cells; ', 'strain: C57BL/6J; mouse id: Mouse 3; genotype: wild-type; cell type: Follicular B cells; ', 'strain: C57BL/6J; mouse id: Mouse 4; genotype: wild-type; cell type: Follicular B cells; ', 'disease: Healhty donor 1; cell type: Follicular B cells; ', 'disease: Healhty donor 1; cell type: T1/T2 B cells; ', 'disease: Healhty donor 1; cell type: T3 B cells; ', 'disease: Healhty donor 2; cell type: Follicular B cells; ', 'disease: Healhty donor 2; cell type: T1/T2 B cells; ', 'disease: Healhty donor 2; cell type: T3 B cells; ', 'disease: Healhty donor 3; cell type: Follicular B cells; ', 'disease: Healhty donor 3; cell type: T1/T2 B cells; ', 'disease: Healhty donor 3; cell type: T3 B cells; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138729,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE138nnn/GSE138729/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576910,,,,,,,,
GSE63591,N6-methyladenosine Modulates Messenger RNA Translation Efficiency,Homo sapiens,18,SRP050213,2014-11-24,"[Overal design]PAR-CLIP and RIP was used to identify YTHDF1 binding sites followed by ribosome profling and RNA seq to assess the consequences of YTHDF1 siRNA knock-down; [Treatment]'None'; [Growth]'None'; [Extraction]'Truseq small RNA sample prepration kit (illumina)', 'Truseq stranded mRNA sample prepration kit (illumina)', 'NEBNext small RNA library prep set for Illumina (NEB)', 'Isolate from surcrose gradient, recovered by trizol\nTruSeq Small RNA Library Preparation Kits (Illumina)', 'Extract by trizol, then poly(A) selection\nTruSeq Small RNA Library Preparation Kits (Illumina)'; [Cell type]'Source: ''cell line: HeLa; cell treatment: over-express N-terminal flag-tagged YTHDF1 for 24h (0.75ug plasmid/mL); sample treatment and extract: fed with 4SU, UV crosslink, partial digested by RNase T1, anti-flag-beads IP; ', 'cell line: HeLa; cell treatment: over-express N-terminal flag-tagged YTHDF1 for 24h (0.75ug plasmid/mL); sample treatment and extract: anti-flag-beads IP; ', 'cell line: HeLa; cell treatment: over-express N-terminal flag-tagged YTHDF1 for 24h (0.75ug plasmid/mL); sample treatment and extract: Extract by trizol, then poly-dT beads pull-down; ', 'cell line: HeLa; cell treatment: over-express N-terminal flag-tagged YTHDF1 for 24h(0.75ug plasmid/mL); sample treatment and extract: Extract by trizol, then rRNA removal; ', 'cell line: HeLa; cell treatment: 40nM siRNA knock-down for 48h; sample treatment and extract: Isolate from surcrose gradient, recovered by trizol; ', 'cell line: HeLa; cell treatment: 40nM siRNA knock-down for 48h; sample treatment and extract: Extract by trizol, then rRNA removal; ', 'cell line: HeLa; cell treatment: 40nM siRNA knock-down for 48h; sample treatment and extract: Extracy by trizol, then rRNA removal; ', 'cell line: HeLa; transfection: siControl-RPF; cell treatment: 40nM siRNA knock-down for 48h; ', 'cell line: HeLa; transfection: siControl; cell treatment: 40nM siRNA knock-down for 48h; ', 'cell line: HeLa; transfection: SiMETTL3-RPF; cell treatment: 40nM siRNA knock-down for 48h; ', 'cell line: HeLa; transfection: SiMETTL3; cell treatment: 40nM siRNA knock-down for 48h; '",Expression profiling by high throughput sequencing; Other; Non-coding RNA profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63591,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE63nnn/GSE63591/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA268354,26046440," Xiao Wang,  Boxuan Simen Zhao,  Ian A Roundtree,  Zhike Lu,  Dali Han,  Honghui Ma,  Xiaocheng Weng,  Kai Chen,  Hailing Shi,  Chuan He","N(6)-methyladenosine (m(6)A) is the most abundant internal modification in mammalian mRNA. This modification is reversible and non-stoichiometric and adds another layer to the dynamic control of mRNA metabolism. The stability of m(6)A-modified mRNA is regulated by an m(6)A reader protein, human YTHDF2, which recognizes m(6)A and reduces the stability of target transcripts. Looking at additional functional roles for the modification, we find that another m(6)A reader protein, human YTHDF1, actively promotes protein synthesis by interacting with translation machinery. In a unified mechanism of m(6)A-based regulation in the cytoplasm, YTHDF2-mediated degradation controls the lifetime of target transcripts, whereas YTHDF1-mediated translation promotion increases translation efficiency, ensuring effective protein production from dynamic transcripts that are marked by m(6)A. Therefore, the m(6)A modification in mRNA endows gene expression with fast responses and controllable protein production through these mechanisms.",N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.,10.1016/j.cell.2015.05.014,2015 Jun 4,PMC4825696,Cell
GSE120159,Targeting the eIF4A dependent translation of KRAS and other oncoproteins in pancreatic cancer,Homo sapiens,12,SRP162072,2018-09-18,"[Overal design]We performed ribosome footprinting and RNA sequencing on six samples of PANC1 cells including three untreated samples (DMSO) and three samples that were collected 45 minutes after treatment with CR31B (25 nM). DMSO treated samples are indicated as CT and CR31B treated samples are indicate as S.; [Treatment]'Cells wre treated with DMSO (CT) or CR31B (CR) (25 nM for 45 minutues).'; [Growth]'Pancreatic cancer cell lines were cultured in DMEM media supplemented with 10% fetal bovine serum and Penicillin/Streptomycin and 10mM Glutamine or as per the ATCC recommended medium.'; [Extraction]'Human pancreatic cancer cell line PANC1 cells were treated with CR31B (25 nM; 45 minutes) followed by cycloheximide treatment for 10 minutes. Total RNA and ribosome-protected fragments were isolated following published protocol (Ingolia et al 2012). Deep sequencing libraries were generated from these fragments and sequenced on the HiSeq 2000 platform. Genome annotation was from the Ensembl database release 75 (http:// www.ensembl.org).'; [Cell type]'Source: ''sample type: control; molecule: Ribosome protected RNA; ', 'sample type: CR31B treated; molecule: Ribosome protected RNA; ', 'sample type: control; molecule: RNA; ', 'sample type: CR31B treated; molecule: RNA; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120159,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE120nnn/GSE120159/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA491747,,,,,,,,
GSE104587,tsRibo-Seq: An Approach to Zoom In into Translation of Single Transcripts,Homo sapiens,1,SRP119397,2017-10-04,"[Overal design]Ribosome Profiling of CFBE cells 48h after transfection with wild-type CFTR; [Treatment]'None'; [Growth]""Cystic Fibrosis Bronchial Epithelial cells were grown at 37C to 70% confluency in Eagle's MEM, transfected with wild-type CFTR vector and incubated for 48h prior to harvesting""; [Extraction]'Cells were harvested in ice-cold polysome lysis buffer and CFTR transcripts were enriched using specific biotin-labeled oligos. CFTR enriched, dephosphorylated RPFs were then subjected to denaturating PAGE for size exclusion\nRNA-size selection and generation of the cDNA libraries was performed as described {Ingolia, 2009}'; [Cell type]'Cystic Fibrosis Bronchial Epithelial (CFBE) cells''cell type: Cystic Fibrosis Bronchial Epithelial (CFBE) cells; transfected with: wild-type CFTR; time point: 48h after transfection; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104587,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE104nnn/GSE104587/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA413138,,,,,,,,
GSE110868,Identification and validation of GPD1 as an essential cancer stem cell specific target in glioblastoma (RNA-seq: Gpd1 KO),Mus musculus,9,SRP133177,2018-02-20,"[Overal design]Two sgRNAs guided Gpd1 knock out in mouse brain tumor stem cells; [Treatment]'From the colonies of interest DNA was purified and sequenced to prove the GPD1 KO. All five gRNAs could knock-out GPD1. We chose the two gRNAs closest to the start ATG of the GPD1 gene and used the colonies established with them. gRNA1: AAAGTCTGCATTGTCGGCTC, gRNA2: TGCATTGCTACCCACGATCT.'; [Growth]'For the GPD1 KO with CRISPR /Cas9 the vector lentiCRISPv2 was used following the protocol published by the Zhang lab on the GeCKO (genome-scale CRISPR knock-out)40. We used the CRISPR Design tool provided in GeCKO, which is based on the specificity analysis performed in Hsu et al., Nature Biotechnology, 2013. Five gRNAS were used to transfect mouse BTSCs with lipofectamine LTX&PLUS reagent (Invitrogen) according to the manufacturers protocol. After two days puromycin was added to the media for one week to select transfected cells. These cells were seeded as 1000/10 cm coated dish to grow colonies deriving from one single cell. Once the colonies were visible they were gently picked with a pipette tip and resuspended in a coated 24 well plate to expand. Western blots were performed to confirm the GPD1 KO in the expanded colonies.'; [Extraction]'For RNA isolation from cultured NSCs, BTSCs and cells were harvested in TRI Reagent (Sigma) following the protocol.\nAfter chloroform phase separation the transparent upper phase was added to an equal volume of 70 % ethanol and transferred to an RNeasy Mini spin column (Qiagen). The RNA was purified according to the protocol and send for library preparation and Illumina HiSeq sequencing to our in house facility.'; [Cell type]'brain tumor stem cells', 'brain tumor stem cells Gpd1 knock-out by Crispr-cas9''tissue: brain; cell type: brain tumor stem cells; ', 'tissue: brain; cell type: brain tumor stem cells Gpd1 knock-out by Crispr-cas9; '",Expression profiling by high throughput sequencing,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110868,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE110nnn/GSE110868/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA434718,,,,,,,,
GSE59821,Restrictions in amino acid availability revealed by differential ribosome codon reading,Homo sapiens,51,None,2014-07-28,"[Overal design]Refer to individual Series; [Treatment]'Cells were treated with of harringtonine (2 ?g/ml) for 5 min.', 'For inhibition of mTOR and nutrient starvation experiments, MCF10A cells were treated either with 250 nM of Torin 1 (Tocris Bioscience, Bristol, UK) or with EBSS medium (Sigma) for 2 hours, respectively.', 'For starvation experiments, cells were culture for 48hrs in glutamine-free DMEM (Life Technologies) supplemented with 10% dialyzed FBS in 5% CO2 at 37C.', 'For samples which were ASNase treated: PC3 cells were treated with L-Asparaginase (Sigma) at 1U/ml for 48hrs in RPMI supplemented with 10% dialyzed FBS'; [Growth]'SUM1315 cells were culture in DMEM:F12 (1:1) medium supplemented with 5% FCS, EGF (10 ng/ml), and Insulin (5?g/ml)', 'MCF10A cells were cultured in DMEM/F12 1:1 medium supplemented with 5% horse serum, EGF (10 ng/ml), insulin (10 ?g/ml), cholera toxin (100 ng/ml), and hydrocortisone (500 ng/ml) in 5% CO2 at 37C.', 'All breast cancer cell lines were grown in DMEM supplemented with 10% FBS in 5% CO2 at 37C.', 'PC3 cells were cultured in RPMI medium supplemented with 10% FBS', 'MCF7 cells were cultured in DMEM medium supplemented with 10% FBS', 'SUM159PT cells were cultured in DMEM/F12 1:1 medium supplemented with 5% FBS, insulin (5?g/ml), and hydrocortisone (1?g/ml).'; [Extraction]'Approximately 30e6 cells were treated with chloramphenicol (100?g/ml) for 15 minutes and cycloheximide (100?g/ml) for 5 minutes. Cells were lysed in buffer B (20 mM Tris-HCl, pH 7.8, 100mM KCl, 10mM MgCl2, 1% Triton X-100, 2mM DTT, 100 ?g/ml chloramphenicol, 100 ?g/ml cycloheximide, 1x Complete protease inhibitor). Lysates were centrifuged at 5000 rpm and the supernatant was treated with 2U/?l of RNase I (Ambion) for 40 minutes at room temperature. Lysates were fractionated on a linear sucrose gradient (7% - 47%) using the SW- 41Ti rotor at 36,000 rpm for 2hrs. Fractions enriched in mito-monosomes and cytosolic monosomes were identified by western blotting, pooled and treated with proteinase K (Roche) in 1% SDS. Released RPFs were purified using Trizol reagent (Invitrogen) following the manufacturers instructions.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', ""RNA was harvested using Trizol reagent. Illumina TruSeq RNA Sample Prep Kit was used with 1 ug of total RNA for the construction of sequencing libraries.\nPoly(A) was isolated using the Oligotex mRNA mini kit (Qiagen). Libraries were prepared using the TruSeq RNA sample preparation kit (Illumina) following the manufacturer's instructions."", 'MCF7 GFP-RPL10a cells were treated with cycloheximide at a final conc of 10ug/m for 5 min. Cells were washed with cold PBS, scraped, and pelleted. Cell pellet was lysed with 1ml of NP40 lysis buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 150mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX) for 15 min, centrifuged for 10 min at 1300 g and 1ml of supernatant recovered. IP samples: (50ul/100ul) GFP-Trap_M beads (Chromotek) were washed for 3 times in 1ml of NP40 lysis buffer, resuspended in 3 ml of NP40 lysis buffer. 1ml of cleared lysate (cell line or tumor) was added to the beads and digested with RNAse I (100U/ul) for 1hr at RT under constant rotation. Beads were washed 3 times with of NP40 Lysis buffer and 3 times with NP40 wash buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 350mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX). Beads were resuspended in 300 ul of lysis buffer with 1% SDS and 15 ul of Proteinase K (Roche) and incubated for 1hr at 45C. Supernatant was recovered and resuspended in TriSure. RNA was isolated and libraries prepared according to the RP protocol.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.', 'SUM-159 GFP-RPL10a cells were treated with cycloheximide at a final conc of 10ug/m for 5 min. Cells were washed with cold PBS, scraped, and pelleted. Cell pellet was lysed with 1ml of NP40 lysis buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 150mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX) for 15 min, centrifuged for 10 min at 1300 g and 1ml of supernatant recovered.     For tumors preparation, each tumor was lysed in 1ml of NP40 lysis buffer in a tissue homogenizer. Tumor lysate was centrifuged at 1300g for 10 min and the supernatant was incubated with the beads.    85 ul per condition of GFP-Trap_M beads (Chromotek) were washed for 3 times in 1ml of NP40 lysis buffer, resuspended in 3 ml of NP40 lysis buffer. 1ml of cleared lysate (cell line or tumor) was added to the beads and digested with  RNAse I (100U/ul) for 1hr at RT under constant rotation. Beads were washed 3 times with of NP40 Lysis buffer and 3 times with NP40 wash buffer (20mM Tris-HCl pH 7.8, 10mM MgCl2, 350mM KCl, 1% NP40, 2 mM DTT, 1X Complete protease Inhibitors, 100 ug/ml CHX). Beads were resuspended in 300 ul of lysis buffer with 1% SDS and 15 ul of Proteinase K (Roche) and incubated for 1hr at 45C. Supernatant was recovered and resuspended in TriSure. RNA was isolated and libraries prepared according to the RP protocol.\nRNA was gel-purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding to 30-33 nucleotides was excised, eluted and ethanol precipitated. The resulting fragments were 3'-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. Beverly, MA, USA) for 6 h at 37C in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM ?-mercaptoethanol, 300 mM NaCl). 3' adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. Beverly, MA, USA) for 2.5 h at 37C. Ligation products were 5'-phosphorylated with T4 polynucleotide kinase for 30 min at 37C. 5' adaptor was added with T4 RNA ligase 1 for 18 h at 22C.'; [Cell type]'Source: ''cell line: SUM1315; ', 'cell line: MCF10A; ', 'tissue: Kidney; ', 'tissue: kidney; ', 'cell line: MCF7; ', 'cell line: T47D; ', 'cell line: MDA-MB-231; ', 'cell line: Hs578t; ', ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: PC3; agent: none; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: PC3; agent: L-Asparaginase; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: MCF7; protocol: sucrose gradient; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: MCF7; protocol: IP50; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: SUM159PT; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; cell line: MCF10A; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; tissue: normal; "", ""adapter sequence (3'): TGGAATTCTCGGGTGCCAAGGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG; tissue: tumor; """,Other,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59821,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE59nnn/GSE59821/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA256314,26878238," Fabricio Loayza-Puch,  Koos Rooijers,  Levi C M Buil,  Jelle Zijlstra,  Joachim F Oude Vrielink,  Rui Lopes,  Alejandro Pineiro Ugalde,  Pieter van Breugel,  Ingrid Hofland,  Jelle Wesseling,  Olaf van Tellingen,  Axel Bex,  Reuven Agami","Tumour growth and metabolic adaptation may restrict the availability of certain amino acids for protein synthesis. It has recently been shown that certain types of cancer cells depend on glycine, glutamine, leucine and serine metabolism to proliferate and survive. In addition, successful therapies using L-asparaginase-induced asparagine deprivation have been developed for acute lymphoblastic leukaemia. However, a tailored detection system for measuring restrictive amino acids in each tumour is currently not available. Here we harness ribosome profiling for sensing restrictive amino acids, and develop diricore, a procedure for differential ribosome measurements of codon reading. We first demonstrate the functionality and constraints of diricore using metabolic inhibitors and nutrient deprivation assays. Notably, treatment with L-asparaginase elicited both specific diricore signals at asparagine codons and high levels of asparagine synthetase (ASNS). We then applied diricore to kidney cancer and discover signals indicating restrictive proline. As for asparagine, this observation was linked to high levels of PYCR1, a key enzyme in proline production, suggesting a compensatory mechanism allowing tumour expansion. Indeed, PYCR1 is induced by shortage of proline precursors, and its suppression attenuated kidney cancer cell proliferation when proline was limiting. High PYCR1 is frequently observed in invasive breast carcinoma. In an in vivo model system of this tumour, we also uncover signals indicating restrictive proline. We further show that CRISPR-mediated knockout of PYCR1 impedes tumorigenic growth in this system. Thus, diricore has the potential to reveal unknown amino acid deficiencies, vulnerabilities that can be used to target key metabolic pathways for cancer treatment.",Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.,10.1038/nature16982,2016 Feb 25,,Nature
GSE118035,Protein Syndesmos is a novel RNA binding protein that regulates primary cilia formation [Illumina array],Homo sapiens,18,None,2018-08-02,"[Overal design]Evaluation of differentially expressed transcripts in inducible SDOS-eGFP over eGFP expressing HeLa cells; [Treatment]'Cells were treated with doxycycline (1 ug/mL) for 24 hrs to induce the expression of GFP-fusion proteins'; [Growth]'HeLa cells were grown on 10-cm dishes until were approximately 85% confluent'; [Extraction]'Total RNA from HeLa cells was extracted using a standard acid guanidinium thiocyanate-phenol-chloroform extraction protocol'; [Cell type]'Source: ''protocol: shGFP; cell line: T-REx-HeLa Cell Line; ', 'protocol: iperTRAP; cell line: T-REx-HeLa Cell Line; ', 'protocol: shTRAP; cell line: T-REx-HeLa Cell Line; ', 'protocol: iperSDOS; cell line: T-REx-HeLa Cell Line; ', 'protocol: iperGFP; cell line: T-REx-HeLa Cell Line; ', 'protocol: shSDOS; cell line: T-REx-HeLa Cell Line; '",Expression profiling by array,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118035,ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE118nnn/GSE118035/suppl,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA484186,30260431," Rosario Avolio,  Aino I Jarvelin,  Shabaz Mohammed,  Ilenia Agliarulo,  Valentina Condelli,  Pietro Zoppoli,  Giovanni Calice,  Daniela Sarnataro,  Elias Bechara,  Gian G Tartaglia,  Matteo Landriscina,  Alfredo Castello,  Franca Esposito,  Danilo S Matassa","Syndesmos (SDOS) is a functionally poorly characterized protein that directly interacts with p53 binding protein 1 (53BP1) and regulates its recruitment to chromatin. We show here that SDOS interacts with another important cancer-linked protein, the chaperone TRAP1, associates with actively translating polyribosomes and represses translation. Moreover, we demonstrate that SDOS directly binds RNA in living cells. Combining individual gene expression profiling, nucleotide crosslinking and immunoprecipitation (iCLIP), and ribosome profiling, we discover several crucial pathways regulated post-transcriptionally by SDOS. Among them, we identify a small subset of mRNAs responsible for the biogenesis of primary cilium that have been linked to developmental and degenerative diseases, known as ciliopathies, and cancer. We discover that SDOS binds and regulates the translation of several of these mRNAs, controlling cilia development.",Protein Syndesmos is a novel RNA-binding protein that regulates primary cilia formation.,10.1093/nar/gky873,2018 Dec 14,PMC6294507,Nucleic acids research
E-MTAB-5519,Analysis of mitochondrial gene expression with Ribosome Profiling,Homo sapiens,3,None,2017-07-25,"[1228782] nucleic acid sequencing protocol: Amplicon libraries were deep sequenced using an Illumina NextSeq500 platform.""; ""[1228785] nucleic acid extraction protocol: Cells were rinsed with 5 ml of ice-cold PBS, the dishes were submerged in a reservoir of liquid nitrogen for 10 s and transferred to dry ice. Cells were lysed in 400 l of lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1 % Triton X-100, 100 g/ml chloramphenicol and cycloheximide). Cells were scraped and lysates clarified by centrifugation for 20 min at 13,000 g at 4C. 200 l aliquots of cell lysates were treated with 7.5 l RNase 1 (100 units/l) at 28C. The reaction was layered onto a 10-30 % sucrose gradient [2ml 10-30% (v/v)] in 50mM Tris-HCl (pH7.2), 20mM Mg(OAc)2, 80mM NH4Cl, 0.1M KCl, 1mM PMSF and centrifuged for 2h 15min at 100,000 gmax at 4C (39,000 rpm, Beckman Coulter TLS-55 rotor) and fractions collected. Subsequently, all fractions containing mitochondrial monosomes, ascertained by western blotting, were pooled and digested with proteinase K (200 g/ml) for 30 min at 42C. RPFs were recovered by extracting twice with pre-warmed (65C) acidic phenol:chloroform and once with chloroform (1:1, v/v, buffered with 10 mM Tris pH 7.5, 0.1 mM EDTA) followed by ethanol precipitation.""; ""[1228783] treatment protocol: For Ribo-Seq, parental HEK293 and PDE12-/- cells were treated with 100 g/ml chloramphenicol and 100 g/mL cycloheximide for 5 min.""; ""[1228784] nucleic acid library construction protocol: RPFs (1 g) were separated on 15 % denaturing polyacrylamide gels and RNA species migrating between 25 and 35 nt were harvested. RNA was eluted from the gel slices and ethanol precipitated. The RNA samples from above were heated at 80C for 2 min, cooled and the 3 phosphate group removed using T4 polynucleotide kinase (New England Biolabs) for 2 h at 37C in a 20 l reaction. The RNA was concentrated by ethanol precipitation, resuspended in 10 mM Tris-HCl (pH 7.5) and ligated in a 20 l reaction overnight at 14C to a preadenylated 3-adaptor using T4 RNA Ligase 2 (New England Biolabs). RNA was precipitated, loaded into a 15 % denaturing polyacrylamide gel and ligated RNA fragments migrating between 48 and 54 nt were excised. The RNA was eluted, precipitated, resuspended as above, and 5 phosphorylated using T4 PNK in the presence of 1 mM ATP for 2 h at 37C. RNA was concentrated by ethanol precipitation, resuspended in 10 mM Tris-HCl (pH 7.5) and ligated to a 5 RNA adaptor overnight at 14C using T4 RNA Ligase (New England Biolabs). The fully adapted RNAs were recovered by ethanol precipitation, dissolved in 6 l 10 mM Tris-HCl (pH 7.5), and ligated product annealed to an RT primer for 5 min at 65C. The RNA was subsequently reverse transcribed for 50 min at 55C in using SuperScript III according to manufacturers instructions, followed by heat inactivation for 5 min at 85C. Standard PCR reactions were used to prepare amplicons using forward primer RP1 and RPIX as reverse primer, where X is primer number (1-24). PCR reactions were loaded onto 10 % non-denaturing polyacrylamide-TBE gels and products of ~150 bp were excised from the gel and eluted. These amplicon libraries were ethanol precipitated and resuspended in 15 l 10 mM Tris-HCl (pH 7.5). Ribosomal RNA was depleted from Ribo-seq samples at the library amplicon stage; 12 L of the relevant Ribo-seq library was mixed with 4 L of 4 hybridization buffer (200 mM HEPES pH 7.5 and 2 M NaCl) and denatured at 98C for 2 min. DNA was re-annealed for 5 h at 68C prior to addition of 2 L of 10 DSN master buffer and 2 L of DSN (4 units, Evrogen). Digestion was allowed to proceed for 25 min at 68C, before addition of 20 L 10 mM EDTA and incubation for a further 5 min at 68C. DNA was recovered by a single extraction with phenolchloroform (1:1, vol/vol) followed by ethanol precipitation and resuspended in 4 L 10 mM TrisHCl pH 7.5. The treated amplicon library was subjected to another round of PCR (as above) and the resulting library subjected to a second round of DSN treatment.""; E-MTAB-2941Homo sapiens3translation profilingNoneAnalysis of ribosomal occupancy with ribosome profiling2015-03-01Ribosome profiling was prepared in parallel with RNA-seq, using the same protocol for cDNA library preparation.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2941hiCLIP reveals the in vivo atlas of mRNA secondary structures recognized by Staufen 1.Nature43.070https://doi.org/10.1038/nature14280{Nature (43.070) doi:10.1038/nature14280}; {Nature (43.070) doi:10.1038/nature14280}; NoneNoneNoneNone[Growth] compound treatment design; ""[1076795] treatment protocol: Cells were not treated with siRNA (untreated), treated with anti-STAU1 siRNA (knockdown), or treated with anti-STAU1 siRNA and the STAU1 level was rescued by the expression of siRNA-resistant STAU1 (rescue). Cells were subjected to Cycloheximide treatment before collection.""; ""[1076793] nucleic acid sequencing protocol: Single-end Illumina sequencing. Sequencing was performed at CRI, CRUK using HiSeq.""; ""[1076794] nucleic acid library construction protocol: Ribosome profiling protocol was followed to isolate protected RNA from the Cycloheximide teated cells and amplify cDNA library as described in the manuscript. Specific barcodes were used for each RT reaction as described in the manuscript. Random barcodes were also incoperated into cDNAs to distinguish between PCR duplication of cDNA products. The final products were obtained by PCR with Illumina paired-end sequencing primers: 5-CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-3; 5-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3""; E-MTAB-3815Homo sapiens6translation profilingNoneRibosome profiling of UNR (CSDE1) shRNA knockdown in SK-MEL-103 melanocytes2016-11-07Investigation of the effects of UNR (CSDE1) knock-down on translation in Melanoma Cells using Ribosome Profilinghttps://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3815NoneNoneNoneNone{Nature (43.070) doi:10.1038/nature14280}; {Nature (43.070) doi:10.1038/nature14280}; NoneNoneNoneNone[Growth] compound treatment design; ""[1145816] nucleic acid extraction protocol: Cells were collected in one tube and incubated on ice. Glass beads (Sigma-Aldrich; G8772) were added to the lysate and cells were broken by vortexing at medium speed, 3x 10 seconds. After 10 min of incubation on ice, lysates were centrifuged 5 min at 5000 rpm at 4C, and the supernatant was recovered. RNA was partially digested with 3.5 l of RNase I (100U/l, Invitrogen AM2294) per 800 l of lysate. After 15 min of incubation at 24C, lysates were placed on ice and supplemented with 10 l of SUPERase In (20U/l, Invitrogen AM2694). Lysates were then loaded on a 34% sucrose cushion (34% sucrose in 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT and 100 ?g/ml cycloheximide) and monosomes were pelleted by centrifugation for 4 h at 70000 rpm using a Beckman TLA 100.3 rotor. RNA was extracted from the pellet and ribosome protected fragments (RPF) of 30 nucleotides were purified as described (Ingolia et. al 2012). RPFs were depleted of ribosomal RNA with the Ribo-Zero rRNA removal kit (Epicentre MRZH116) according to manufacturers indications.""; ""[1145817] nucleic acid library construction protocol: cDNA libraries were generated according to (Ingolia et. al 2012)""; ""[1145814] nucleic acid sequencing protocol: cDNA libraries were sequenced at the EMBL Gencore Facility with an illumina HiSeq2000 sequencer.""; ""[1145815] treatment protocol: Ribosome profiling was done according to the protocol described in (Ingolia et. al 2012). Briefly, shControl and shUNR melanoma cells were cultured in 10 cm plates and induced with doxycycline for 5 days. New medium supplemented with 100 g/ml cycloheximide (Sigma-Aldrich; C4859) was added to 3 plates. After 3 min incubation, cells were washed with ice cold PBS and 250 l of lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 ?g/ml cycloheximide, 1% Triton-X100) were added.""; ""[1145812] high throughput sequence alignment protocol: After adapter clipping only reads of length 21-38nts were kept. Reads mapping to a custom genome composed of hg19 ribosomal and tRNA sequences were filtered out. Remaining reads were aligned with Tophat 2 on the hg19 human genome with parameters: --no-novel-juncs -g 1 --b2-very-sensitive""; ""[1145813] normalization data transformation protocol: No normalization""; E-MTAB-5961Homo sapiens4RIP-seqNoneRibosome profiling and RNA-seq of in vitro differentiated human CD4+ Th1 cells2020-04-08We investigated the translatome of in vitro differentiated human CD4+ Th1 cells.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5961NoneNoneNoneNone{Nature (43.070) doi:10.1038/nature14280}; {Nature (43.070) doi:10.1038/nature14280}; NoneNoneNoneNone[Growth] development or differentiation design; ""[1236779] nucleic acid extraction protocol: For RNAseq samples, RNA was extracted using the mirVana isolation kit according to manufacturer's instructions (mirVana ThermoFisher #AM 1560)""; ""[1236774] nucleic acid sequencing protocol: Sequencing was performed using the Rapid Run SR100 mode on Illumina HiSeq2000. Samples were sequenced  by the NGS Facility (LABSSAH) at the Centre for Integrative Biology (CIBIO), University of Trento, Via Sommarive, 18, Povo  (TN) - Italy""; ""[1236776] growth protocol: Naive CD4+ T cells purified from the blood of healthy donors were polarized in vitro to TH1 in RPMI media with 10% FBS, 0.1% Penicillin/Streptomycin 0.1 % nonessential amino acids and  0,1% Sodium Pyruvate  at 37C and 5% CO2.""; ""[1236778] nucleic acid library construction protocol: Libraries for Riboseq were prepared according to Ingolia et al., 2012 DOI :10.1038/nprot.2012.086.""; ""[1236777] nucleic acid extraction protocol: For Riboseq samples, RNA footprints were extracted according to Ingolia et al., 2012  DOI : 10.1038/nprot.2012.086.""; ""[1236775] nucleic acid library construction protocol: Libraries for RNAseq were prepared using Illumina TruSeq Stranded Total RNA Library Prep Kit""; E-MTAB-2278Homo sapiens5RNA-seq of coding RNANoneRibosome profiling upon overexpression of the RNA-binding protein Unkempt2015-03-09Ribosome profiling to assess changes in ribosome occpancy upon overexpression of the RNA-binding protein Unkempt (most likely acts as a translational regulator) in human HeLa cell lines.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2278Control of a neuronal morphology program by an RNA-binding zinc finger protein, Unkempt.Genes & development8.990https://doi.org/10.1101/gad.258483.115{Genes & development (8.990): 10.1101/gad.258483.115}NoneNoneNoneNone[Growth] co-expression; ""[942831] treatment protocol: To create Dox-inducible cell lines, we first transduced HeLa cells with MSCV-rtTA3-IRES-EcoR-PGK-Neo (pRIEN), a retrovirus we constructed in the MSCV backbone (Clontech) to co-express an improved reverse transactivator (rtTA3), the ecotropic receptor, and a neomycin resistance marker. Following G418 selection, stably rtTA3-expressing cells were subsequently infected ecotropically with a second retrovirus expressing a puromycin resistance gene and a TREtight-driven transcript encoding GFP alone (pTt-IGPP) or GFP and either full-length mouse or zebrafish Unkempt protein, or any of the mouse Unkempt-deletion mutants (pTtight-X-IGPP, where X is an ortholog or mutant of Unkempt), which we constructed in a self-inactivating retroviral backbone (pQCXIX, Clontech). To induce transgene expression, double-selected cells were treated with doxycycline (Sigma-Aldrich) at 1 micro-g/ml.""; ""[942829] nucleic acid extraction protocol: To determine the effect of Unkempt on the rate of protein synthesis, we performed ribosome profiling experiment on inducible HeLa cells essentially as described (Ingolia et al., Nature Protocols, 2012), but using the linker and the primers as for the iCLIP experiments (Konig et al., JoVE, 2011). GFP-only or GFP and Unkempt-inducible Hela cells were grown in 15 cm dishes and harvested at 70% confluency. Prior to harvest, cells were treated with Dox for 18 hour to induce the expression of transgenes. Cells were then washed in ice-cold PBS, lysed for 10 minutes on ice in lysis buffer, triturated by passing twice through a syringe fitted with a 26-gauge needle, and spun at 20,000 xg for 10 minutes at 4  degrees C. Cell lysate was digested with RNase I for 45 mintues at room temperature followed by the addition of SUPERase IN to stop nuclease digestion. The lysate was underlayed with 1 M sucrose and spun in a TLA 100.3 rotor at 70,000 rpm for 4 hours at 4  degrees C. Ribosomal pellet was resuspended in Trizol reagent (Life Technologies) and RNA extracted according to the manufacturer's instructions.""; ""[942828] growth protocol: HeLa cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 micro-g/mL streptomycin at 37  degrees C and 5% CO2.""; ""[942830] nucleic acid library construction protocol: The extracted RNA was size-selected by denaturing PAGE, retaining only fragments between 26 and 34 nts, and 3' end-dephosphorylated with T4 PNK for 20 minutes at 37  degrees C. Dephosphorylated RNA was precipitated, resuspended, and ligated to a pre-adenylated linker (L3-App) as described for the iCLIP procedure (Konig et al., JoVE, 2011). The ligation mix was precipitated, resuspended, and the ligation products (between 47 and 55 nts) were purified by denaturing PAGE. Reverse transcription (RT) was carried out using barcoded Rclip primers used for the iCLIP experiments (Konig et al., JoVE, 2011) by resuspending the ligation products in 8.5 micro-l water, 0.5 ul Rclip primer (100 micro-M; Rclip primer with a different barcode was used for each sample), and 1 micro-l dNTP (10 mM), with SuperScript III Reverse Transcriptase (Life Technologies) according to the manufacturer's instructions, including the treatment with RNase H. The reaction mix was precipitated and the produced cDNA (between 79 and 87 nts) was purified by denaturing PAGE. RT products were circularized, cut, and precipitated as described for the iCLIP procedure (Konig et al., JoVE, 2011). PCR amplification (12-15 cycles) was carried out using P5/P3 Solexa primers and Accuprime Supermix 1 enzyme (Life Technologies). The prepared cDNA libraries were purified using the Agencourt AMPure XP system (Beckman Coulter).""; ""[942827] nucleic acid sequencing protocol: Ribosome profiling cDNA libraries were analyzed by non-denaturing PAGE and the 2100 Bioanalyzer (Agilent Technologies), quantified with the Qubit 2.0 Fluorometer (Life Technologies), pooled by library and cell type (up to six libraries per pool), and sequenced using the HiSeq 2000 system (Illumina). All libraries were processed by single-end sequencing with read lengths of 50 bases.""; E-MTAB-7247Gallus gallus132RNA-seq of coding RNANoneUsing ribosome profiling and matched RNA sequencing to study the co-evolution of transcriptome and translatome in mammalian organs2020-07-23Ribosome profiling (Ribo-seq) and matched RNA sequencing (RNA-seq) data for three major mammalian organs (brain (cerebrum), liver, and testis) from five representatives of the three main mammalian lineages: human, rhesus macaque, mouse (placental mammals); grey short-tailed opossum (marsupials); and platypus (egg-laying monotremes). Corresponding data were generated for a bird (red junglefowl, the progenitor of domestic chicken; henceforth referred to as chicken), to be used as an evolutionary outgroup.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7247NoneNoneNoneNone{Genes & development (8.990): 10.1101/gad.258483.115}NoneNoneNoneNone[Growth] organism part comparison design; ""[1391150] normalization data transformation protocol: Uniquely aligned reads with up to a single mismatch between the query sequence and the reference sequence were accepted. For each gene, only reads that map inside the coding region of its dominant splice isoform were quantified and used. RNA abundance and ribosome occupancy (translation rate) for each gene were measured in fragments per kilobase of CDS per million uniquely CDS-aligning reads (FPKM), a unit which corrects for both feature length and sequencing depth. We calculated FPKM based only on the coding region of each locus (i.e., the dominant splice isoform) for both Ribo-seq and RNA-seq libraries, to exclude biased measurements due to heterogeneous quality of annotations for UTRs across species/tissues and the fact that Ribo-seq reads, contrary to RNA-seq reads, predominantly map to the main coding region.""; ""[1391152] normalization data transformation protocol: To render the expression values (FPKMs) comparable across species and tissues, translational and transcriptional FPKMs were separately normalized based on our published approach. Specifically, among the genes with expression values in the interquartile range, we identified the 1,000 genes that have the most conserved ranks among samples and calculated their median expression levels in each sample. We then derived scaling factors that adjusted these medians to a common value (i.e., dividing each individual median value by the mean of all median values). Finally, these factors were used to scale expression values of all genes in the corresponding samples.""; ""[1391151] high throughput sequence alignment protocol: Initial quality assessment of the sequencing reads (e.g., average GC, base composition, and variability between clusters) was conducted based on the preliminary quality values produced by the Illumina Casava 1.82 software. Raw reads with known 3 adaptor and low quality bases (Phred score < 20) were trimmed with cutadapt v1.8.3 (parameters: --adapter=AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC --minimum-length=6 --maximum-length=60 -q 20), and then the clipped reads were sequentially mapped to the index libraries of species-specific rRNAs, human/mouse/rat rRNAs, species-specific tRNAs and species-specific snoRNAs using Bowtie2 v2.3.1 (parameters: --phred33 -L 20 -N 1 -t --no-unal). We discarded the alignments in each step and kept the unaligned reads. Only reads with specific lengths (26-34 and 20-50 nt for Ribo-seq and RNA-seq reads, respectively) were used in downstream analyses.   Overall, the RNA-seq reads (median at ~37 nt) are slightly longer than the Ribo-seq reads (median at ?29 nt). To avoid differences in the mappability of reads spanning the exon-exon junction due to read length differences between Ribo-seq and RNA-seq data, RNA-seq reads longer than 29 nt were clipped down to 29 nt to match Ribo-seq reads. Subsequently, the reads were first aligned against organ transcriptomes and then mapped to their respective reference genome with Tophat2 v2.1.1 (parameters: --no-novel-juncs --library-type fr-firststrand --read-realign-edit-dist 0 --segment-length 20 --min-anchor-length 5 --min-intron-length 50).""; ""[1391153] nucleic acid sequencing protocol: Libraries were sequenced on Illumina HiSeq 2500 or (for tests) Illumina MiSeq machines (read lengths: 50 or 100 nucleotides, nt).""; ""[1391156] nucleic acid library construction protocol: Prior to library preparation, a total of 5 ?g RNA from each sample was subjected to ribosomal RNA depletion (Ribo-Zero rRNA Removal kit, Illumina) and subsequently purified using the RNA Clean & Concentrator-5 kit (Zymo Research) according to the manufacturers protocol. The rRNA-depleted RNA was separated on a denaturing 15% urea polyacrylamide gel (Thermo Fisher Scientific) and stained with SYBR-Gold (Thermo Fisher Scientific). Gel slices between 26-34 nt were excised and the RNA was extracted using a 450 ?l gel extraction buffer (0.5 M Ammonium acetate and 0.05% SDS) for 2 hours at room temperature and with gentle agitation. Gel pieces were removed by centrifugation over Spin-X filter tubes (Corning) for 2 min at 15,000 x g. RNA was precipitated over night at -20C in the presence of 1 ml 100% ethanol and 3 ?l glycogen. RNA was pelleted for 25 min and washed with 80% ethanol in a tabletop centrifuge at maximum speed and 4C. Sequencing libraries were generated using the TruSeq Ribo Profile (Mammalian) Library Prep Kit (Illumina). End-repair, 3 adapter, reverse transcription, cDNA purification, and circularization were done according to the manufacturers instructions.   For opossum, platypus, and chicken samples, an additional rRNA depletion step was implemented, given that the standard depletion step is based on human, mouse and rat sequence information and was determined to be inefficient for these non-model species (which are evolutionarily highly diverged from human/mouse) in test experiments. Specifically, to reduce rRNA contamination for these species (and thus reduce the number of sequencing reads needed for in-depth analyses), first strand cDNAs derived from species specific rRNA contaminants were further depleted after circularization by hybridization to 5-biotinylated sense strand oligonucleotides followed by removal of the duplexes through streptavidin affinity as previously described. PCR amplification of the circularized cDNA product was done using the TruSeq Ribo Profile (Mammalian) Library Prep Kit (Illumina) according to the manufacturers instructions. The final library of 150-200 bp was gel-purified on a 10% polyacrylamide non-denaturing gel (Thermo Fisher Scientific), excised and recovered with 330 ?l gel extraction buffer for 1 hour at 37C and gentle agitation. Gel pieces were removed by centrifugation over Spin-X filter tubes (Corning) for 2 min at 15,000 x g. Libraries were precipitated at -20C for 1 hour in the presence of 525 ?l 100% isopropanol and 2 ?l glycogen, pelleted for 25 min at 4C and 15,000 x g, washed with 80% ethanol and resuspended in water.   In parallel to Ribo-seq library preparation, matched RNA-seq libraries were prepared from the same lysates using TruSeq Ribo Profile (Mammalian) Library Prep Kit (Illumina). There was no extra rRNA depletion step during the preparation of RNA-seq libraries. The concentration and the quality of both the Ribo-seq and RNA-seq libraries were determined using Qubit (Thermo Fisher Scientific) and Fragment Analyzer (Advanced Analyticals) platforms.""; ""[1391154] nucleic acid extraction protocol: The Ingolia 2012 protocol has been implemented in the TruSeq Ribo Profile (Mammalian) Library Prep Kit (Illumina) (formerly ARTseq), which was used in our study. Specifically, frozen tissues were treated in 3 volumes of ice-cold lysis buffer (150 mM NaCl, 20 mM Tris-HCl pH7.4, 5 mM MgCl2, 5 mM DTT, 100 ?g/ml cycloheximide, 1% Triton X-100, 0.5% Sodium deoxycholate, complete EDTA-free protease inhibitors (Roche) and 40 U/ml RNasin plus (Promega)) using a Teflon homogenizer. Lysates were incubated for 10 min on ice and cleared by centrifugation at 3,000 x g, 4C for 3 min. Supernatants were flash-frozen and stored in liquid nitrogen. For absorbance measurements, lysates were gently thawed on ice and the OD260 was determined using a Nanodrop spectrophotometer (Thermo Fisher Scientific). From the lysate pool, 15 OD260 were incubated with 650 U RNase I (Ambion) and 5 U Turbo DNase (Ambion) for 45 min at room temperature and gentle agitation. Nuclease digestion was stopped through addition of 8.7 ?l SUPERase In RNase Inhibitor (Ambion). Subsequently, lysates were applied to Sephacryl MicroSpin S-400 HR columns (GE Healthcare Life Sciences), pre-washed 3 times with 700 ?l polysome buffer (150 mM NaCl, 20 mM Tris-HCl pH7.4, 5 mM MgCl2, 5 mM DTT, 100 ?g/ml cycloheximide, complete EDTA-free protease inhibitors (Roche)) for 1 min at 600 x g, and centrifuged for 2 min at 600 x g and 4C. The flowthrough was immediately mixed with 1 ml Qiazol (Qiagen) and ribosome-protected mRNA fragments were purified using the miRNeasy Micro kit (Qiagen) according to the manufacturers instructions, and the concentration of the RNA was determined using a NanoDrop spectrophotometer.""; ""[1391155] sample collection protocol: We generated Ribo-seq and matched RNA-seq data for the following samples: brain (cerebrum), liver, and testis samples from human (Homo sapiens), rhesus macaque (Macaca mulatta), mouse (Mus musculus, strain: CD-1, RjOrl:SWISS), grey short-tailed opossum (Monodelphis domestica), platypus (Ornithorhynchus anatinus), and chicken (red junglefowl, Gallus gallus). Our study complies with all relevant ethical regulations with respect to both human samples and samples for the other mammals. Human samples were obtained from official scientific tissue banks or dedicated companies; informed consent was obtained by these sources from donors prior to death or from next-of-kin. The use of all human samples for the type of work described in this study was approved by an Ethics Screening panel from the European Research Council (ERC) (associated with H.K.'s ERC Consolidator Grant 615253, OntoTransEvol) and local ethics committees; that is, from the Cantonal Ethics Commission Lausanne (authorization 504/12) and Ethics Commission from the Medical Faculty of Heidelberg University (authorization S-220/2017). The use of all other mammalian samples for the type of work in this study was approved by ERC Ethics Screening panels (ERC Starting Grant 242597, SexGenTransEvolution, and ERC Consolidator Grant 615253, OntoTransEvol).""; E-MTAB-6196Homo sapiens14RNA-seq of coding RNANoneRibosome profiling of CLL patient samples2018-08-07The functional consequences of many of the genetic changes, or combinations of genetic changes, in chronic lymphocytic leukaemia (CLL) are not known, but it is essential to discover these in order to understand the biology of the disease and the causes of individual variation in response to novel and conventional treatments.   In this proof-of-principle study the translational landscape of CLL was determined for the first time by ribosome profiling.   Individual variation in response to stimuli from the tumour microenvironment has not been systematically explored previously, but is likely to influence response to treatment and survival.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6196CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.Blood advancesNonehttps://doi.org/10.1182/bloodadvances.2017015560{Blood advances (None): 10.1182/bloodadvances.2017015560}NoneNoneNoneNone[Growth] disease state design; ""[1240201] nucleic acid library construction protocol: This total RNA sample was used to prepare the whole transcriptome (WT) library using the TruSeq Stranded mRNA library prep kit (Illumina).""; ""[1240199] nucleic acid sequencing protocol: The libraries were sequenced using the Illumina HiSeq 2500 platform (single end, 100 bp).""; ""[1240202] sample collection protocol: Cycloheximide (100 g/ml) was added to the wells for 5 min at 37deg to stop translation and, working at 4deg C, CLL cells were removed from the plates by pipetting and transferred to 15 ml Falcon tubes on ice prior to centrifugation at 300g, 4deg C for 3 minutes.   The pellet was resuspended in 5 ml of ice cold PBS with cycloheximide (100 g/ml) and centrifuged again at 300g, 4deg C for 3 minutes.   Following the addition of 0.5 ml lysis buffer (3M NaCl, 150mM MgCl2, 150mM Tris-HCl (pH7.5), 20mM DTT, cycloheximide (1mg/ml), 1% Triton X-100 and RNasin (12.4l/ml), lysates were centrifuged at 3000 rpm, 4deg C for 5 minutes before being snap frozen in liquid nitrogen and stored at -80deg C.""; ""[1240205] nucleic acid extraction protocol: Trizol LS (1.4 ml) was added to the fractions, mixed, and allowed to stand for 5 minutes at room temperature to dissociate the nucleoprotein complexes.   Bromochloropropane (BCP) (200 l) was added and samples were shaken for 15 seconds to mix and allowed to settle for 5 to 10 minutes prior to centrifugation in a refrigerated centrifuge for 15 minutes at 4deg C.   The aqueous layer was carefully removed and isopropanol (1 ml) and GlycoBlue (1 l) were added.   Following incubation at room temperature for 10 minutes the lysates were centrifuged at 13000 rpm in a refrigerated microfuge at 4deg C.   The supernatant was removed and the pellet washed with 75% ethanol followed by a further centrifugation for 10 minutes at 13000 rpm in a refrigerated microfuge at 4deg C.   The pellet was washed, air dried for 5 to 10 minutes and resuspended in 10 l ultrapure water and stored at -80deg C.   Total RNA samples were submitted to two rounds of poly-A selection using the Invitrogen RiboMinus Transcriptome Isolation kit, and RiboMinus Concentration Module.   Briefly, total RNA was hybridised to the RiboMinus probe, and the resulting rRNA/probe complex removed using RiboMinus beads.   The remaining sample was mixed with binding buffer and ethanol, and purified using the RiboMinus Concentration Module spin columns.   Columns were washed twice with wash buffer and RNA was eluted in RNase-free water.   This was done twice.""; ""[1240204] nucleic acid library construction protocol: This RPF sample was end-repaired using PNK enzyme, and then the library was prepared using the TruSeq Small RNA library prep kit (Illumina).""; ""[1240200] growth protocol: Fibroblasts expressing CD40L were irradiated (35 Gy for 15 minutes) and placed on a 6-well plate so as to produce an ~80% confluent culture.   1 day following irradiation CLL cells at 3x106 cell/ml were added to this feeder layer with IL-4 (10 ng/ml).   CLL cells were cultured for 72 hours before harvesting.""; ""[1240203] nucleic acid extraction protocol: RNase I (0.5 U/l) was added to lysates for 30 minutes at room temperature with gentle rotation.   Lysates were then layered on sucrose gradients and centrifuged at 38000 rpm, 4deg C for 2 hours in a Sorvall centrifuge with settings acceleration 9 and deceleration 6 with a SW-41 Ti rotor.   Samples were fractionated using FoxyR1 Fractionation System and RPF UV traces were compared (plus/minus RNAse I) to determine those fractions (typically 9 to 11) that contained ribosome protected fragments (RPF).   Trizol LS (1.4 ml) was added to the fractions, mixed, and allowed to stand for 5 minutes at room temperature to dissociate the nucleoprotein complexes.   Bromochloropropane (BCP) (200 l) was added and samples were shaken for 15 seconds to mix and allowed to settle for 5 to 10 minutes prior to centrifugation in a refrigerated centrifuge for 15 minutes at 4deg C.   The aqueous layer was carefully removed and isopropanol (1 ml) and GlycoBlue (1 l) were added.   Following incubation at room temperature for 10 minutes the lysates were centrifuged at 13000 rpm in a refrigerated microfuge at 4deg C.   The supernatant was removed and the pellet washed with 75% ethanol followed by a further centrifugation for 10 minutes at 13000 rpm in a refrigerated microfuge at 4deg C.   The pellet was washed, air dried for 5 to 10 minutes and resuspended in 10 l ultrapure water and stored at -80deg C.   RPFs were size selected on a PRE-cast 15% TBE-urea gel.   RNA (10 l) was mixed with 2x sample buffer (7M Urea, 12% Ficoll, 1xTBE, 0.03% bromophenol blue, 0.03% xylene cyanol) (10 l).   28-mer and 34-mer size marker controls (500 nM) were similarly mixed with 2x sample buffer and both samples and controls were heated at 80deg C for 2 minutes and then snap cooled on ice prior to loading and running at 180 V for about 75 minutes.   RNA was visualised and the RPFs, defined by the 28-mer and 34-mers, were excised prior to elution by shredding, addition of 300l pure water and rotation overnight at 4deg C;  followed by precipitation with ethanol and sodium acetate.   The pellet obtained by centrifugation in a refrigerated microfuge at 13000 rpm for 30 minutes at 4deg C was washed with 75% ethanol, and centrifuged again for 10 minutes at 4deg C.   The supernatant was removed and the pellet allowed to air dry following which it was resuspended in ultrapure water (10 l) and stored at -80deg C.""; E-MTAB-10805Homo sapiens2Ribo-seqNoneRibo-seq of human colorectal cancer cell line HCT116/L-OHP against HCT1162021-11-12Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. Dysregulation of lncRNA is involved in cancer and recent translatomics has found some alleged lncRNA actually contained small open reading frames and could encode short peptides. This ribosome footprint profiling (Ribo-seq) was a paired-end sequencing and aimed to investigate whether lncRNA could regulate oxaliplatin resistance in colorectal cancer by encoding short peptides.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-10805NoneNoneNoneNone{Blood advances (None): 10.1182/bloodadvances.2017015560}NoneNoneNoneNone[Growth] cell type comparison design; ""[1419214] nucleic acid extraction protocol: It was performed by Genedenovo Biotechnology Co., Ltd. (Guangzhou, China)""; ""[1419213] sample collection protocol: Cells were pre-treated with 2 ?g/mL harringtonine and 100 ?g/mL cycloheximide, washed with pre-chilled 1x PBS and scraped for subsequent Ribo-seq.""; ""[1419211] nucleic acid sequencing protocol: It was performed by Genedenovo Biotechnology Co., Ltd. (Guangzhou, China)""; ""[1419212] nucleic acid library construction protocol: It was performed by Genedenovo Biotechnology Co., Ltd. (Guangzhou, China)""; E-MTAB-6180Homo sapiens12RNA-seq of coding RNANoneRibo-Seq transcriptomic analysis of human RD cells infected with enterovirus strains EV7, EV71, and PV12018-10-19Ribosome profiling (Ribo-Seq) (maps positions of translating ribosomes on the transcriptome) analysis of human (RD) cells infected with enterovirus strains EV7, EV71, and PV1.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6180NoneNoneNoneNone{Blood advances (None): 10.1182/bloodadvances.2017015560}NoneNoneNoneNone""[1239257] sample collection protocol: RD cells were grown on 150-mm dishes to reach 90% confluency and infected at MOI 20 with EV7, PV1 or EV71 virus stocks. At indicated times postinfection, cells were treated with 3 mM cycloheximide for 3 min, flash frozen in a dry ice/ethanol bath, and lysed in the presence of 100 g/ml cycloheximide. Cell lysates were subjected to Ribo-Seq based on the previously described protocols (Irigoyen et al. 2016; Ingolia et al. 2012).""; ""[1239258] nucleic acid extraction protocol: Cells were rinsed with 10 ml of ice-cold PBS, the dishes were freezed for 45 s in dry ice / ethanol bath, transferred to ice and 600 l of lysis buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1% Triton X-100, 100 g/ml cycloheximide and 25 U/ml TURBO DNase (Life Technologies)] dripped on. Cells were scraped extensively to ensure lysis, collected and triturated with a 27-G needle ten times. Lysates were clarified by centrifugation for 20 min at 13,000 g at 4 C, the supernatants recovered and stored at -80 C.""; ""[1239259] nucleic acid library construction protocol: Cell lysates were subjected to RiboSeq. The methodologies employed were based on the protocols described before. Briefly, cells are lysed under conditions optimised to minimise further ribosome movement (addition of translation inhibitors, rapid freezing), the lysate is treated with ribonuclease (often RNase 1) to degrade regions of mRNAs that are not physically protected, and the ribosomes harvested on sucrose gradients or through a sucrose cushion. The ribosome pellet is de-proteinized, the ribosome-protected fragments (RPFs) harvested by elution from a polyacrylamide gel, ligated to adapters, subjected to RT-PCR, deep sequenced and mapped back to the genome. This analysis reveals the location and abundance of ribosomes on mRNAs with up to single-nucleotide precision. The corresponding transcriptome is also determined from the same lysate: total RNA is harvested, fragmented, cloned and sequenced to generate a parallel RNA sequencing (RNASeq) library. (Irigoyen et al., 2016 doi: 10.1371/journal.ppat.1005473, Ingolia et al., 2012 doi:  10.1038/nprot.2012.086).""; ""[1239256] nucleic acid sequencing protocol: Amplicon libraries were deep sequenced using an Illumina NextSeq platform with 75 cycles (University of Cambridge Biochemistry Department).""; E-MTAB-3135Drosophila melanogaster11RNA-seq of coding RNANoneAnalysis of conditions leading to 3'UTR ribosome protected footprints2015-01-08Ribosome profiling data from U2OS, HeLa and Kc167 cells under various lysis conditions and using immunoprecipitation to purifiy ribosome associated footprints. Two human cell lines (U2OS and HeLa cells) and a Drosophila melanogaster cell line (Kc167) are used to see if the 3'UTR reads are identified in each cell type. Immunoprecipitation of ribosomes is used to analyse if 3'UTR reads derive from ribosomes (are found with ribosome immunoprecipitates) and to which extent the lysis conditions contribute to the identification of the 3'UTR reads.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3135Modified ribosome profiling reveals high abundance of ribosome protected mRNA fragments derived from 3' untranslated regions.Nucleic acids research11.147https://doi.org/10.1093/nar/gku1310{Nucleic acids research (11.147) doi:10.1093/nar/gku1310}; {Nucleic acids research (11.147) doi:10.1093/nar/gku1310}; NoneNoneNoneNone[Growth] optimization design; ""[1098145] nucleic acid library construction protocol: 5-15 picomoles of each RNA sample was used for phosphatase and poly-A tailing reaction by mixing 3.25ul of RNA with the following: 0.5ul 10x poly-A buffer (0.5 M Tris-HCl, pH 7.0, 2.5 M NaCl, 100 mM MgCl2, 50 mM DTT, 1 mg/ml BSA), 0.25ul Yeast poly-A polymerase (600 U/ul, Affymetrix), 0.5ul 10 mM ATP, 0.3ul (3 U) T4 polynucleotide kinase (ThermoFisher), 0.2ul SUPERase-In. Samples were incubated at 37 degrees C for 3 h. Note that RNase I digestion results in cyclic 2'3'-phosphate, which will be resolved by the inherent phosphatase activity of the T4 polynucleotide kinase. 4ul of each sample was mixed with 1ul 10uM abasic-oligo dT primers containing random 8 nt sequence used for absolute molecular counting (Casbon et al., 2011; Kivioja et al., 2012), incubated at 72 degrees C for 3 min and put on ice. Reverse transcription was started by adding the following to the samples: 5.25ul H20, 3ul 5x RT-buffer (ThermoFisher), 0.75ul 10 mM dNTP, 0.25ul SUPERase-In and 0.4ul Maxima Reverse transcriptase (75 U, ThermoFisher). Samples were incubated at 50 degrees C for 1 h, heat inactivated at 85 degrees C for 6 min after which 0.5ul RNAse H (ThermoFisher) was added and samples were incubated at 37 degrees C for 30 min. Reverse transcription products were purified on 10% TBE-urea gel and cDNA was eluted into 700ul of DNA gel elution buffer (1x TE + 300 mM NaCl) by incubating o/n at 4 degrees C with mixing on Eppendorf Thermomixer. cDNA was precipitated as before, samples were centrifuged for 10 min at 16000 g,  pellets were washed and cDNA was suspended into 5ul of circularization mix (0.5ul CircLigase buffer (10x), 0.25ul 50 mM MnCl2, 0.25ul CircLigase II (Epicentre), 1ul 5 M betaine, 3ul sterile water). Samples were incubated o/n at 60 degrees C and heat-inactivate for 10 min at 80  degrees C. cDNA was linearized by adding 3ul of relinearization supplement (50 mM KCl, 1 mM DTT) followed by 0.7ul (7 U) APE1 (New England Biolabs). Samples were incubated for 1 hour at 37 degrees C. Libraries were then amplified using 18 cycles of PCR with Solexa-primer-F and R and Phusion DNA polymerase (ThermoFisher). PCR products were separated on agarose gel, eluated using Qiagen MinElute Gel extraction kit and quantified with Quant-it PicoGreen DNA dye (LifeTechnologies) using Qubit fluorometer (LifeTechnologies). ""; ""[1098144] nucleic acid sequencing protocol: Samples were sequenced using Illumina HiSeq using single end sequencing with 50 bp read length at the GenePool sequencing facility (University of Edinburgh).""; ""[1098146] growth protocol: Cells were  cultured in the presence of 10% FBS in DMEM (U2OS/Hela cells) or in Schneider's medium (Kc167 cells). ""; ""[1098147] treatment protocol: Both cell types were stimulated with 10 % extra FBS for 1h followed by 250 uM cycloheximide for 10 min.""; ""[1098148] nucleic acid extraction protocol: Cells were rinsed twice with cold PBS and lysed in 1 ml polysome extraction buffer (1 % deoxycholate, 1 % NP40, 10 mM HEPES (pH 7.4), 350 mM KCl, 5 mM MgCl2, 5 mM CaCl2, 250uM cycloheximide, 1x protease inhibitors (Sigma, P8340) and 2ul RiboLock RNase inhibitor (ThermoFisher). Lysates were centrifuged for 10 min at 16000 xg and supernatant (leaving lowest ~25% behind) was used for ribosome profiling.The lysate samples were split in to two different digestion samples and digested with either 200 U of E. coli MBP-RNAse I (New England BioLabs) or 100 U of MN (ThermoFisher) by incubating for 40 min (U2OS) or 60 min (Kc167) at RT with slow mixing. 2 U of DNase I (ThermoFisher) was also added to each U2OS sample at the start of digestion. MN reaction was stopped with 10 mM EGTA. The samples were centrifuged at 6000 xg for 5 min to pellet insoluble material. The ribosomes were separated by sucrose step centrifugation using 0.5 M sucrose in polysome extraction buffer supplied with SUPERase-In (1/500) (Ambion). 0.35 ml lysate was layered on top of 0.2 ml sucrose cushion and centrifuged at 100000 xg for 45 min (55000 rpm using TLA 120.1 rotor). Supernatant was removed and pellet was suspended in 600ul Qiazol reagent (Qiagen). Samples were incubated for 15 min at 70 C with mixing to dissolve the pellet after which 200ul of chloroform was added, the samples were vortexed and centrifuged for 10 min at 12000 xg at 4C. RNA was precipitated in the presence of Pink Co-precipitant (Bioline) at -80C o/n. RNA was washed and suspended in 20ul of sterile water and mixed with 80ul 2x TBE-urea sample buffer (without Xylene Cyanol FF). Samples were run on a 15 % TBE-urea gel, the gel was stained using 1x SYBR Gold (Invitrogen) and 28-35 nt sized RNA was cut out of the gel with the help of oligoribonucleotide size markers (28 and 35 nt RNA oligos). The gel pieces were disrupted and RNA was eluted with 300 mM NaAcetate (pH 5.0), 1 mM EDTA and SUPERase-In for 30 min at 65 C. RNA was precipitated, centrifuged and washed with 80% ethanol and then suspended in 5ul of sterile water. RNA yields were quantified with SYBR Gold using Qubit fluorometer (Invitrogen). All samples had over 1 pmol/ul RNA. For comparisons of digestion conditions U2OS and HeLa cells were treated with FBS and cycloheximide as before and lysed with 0.7 ml polysome extraction buffer. The lysis buffer was modified for each sample: Control samples (buffer as before), low NaCl sample (100 mM NaCl, no KCl), low KCl sample (100 mM KCl), TritonX-100 sample (0.5 % TritonX-100, no deoxycholate or NP40), high MN sample (6x more MN, with 2.5h incubation instead of 40 min, buffer as before). In addition a sample without FBS pre-treatment was made using control polysome extraction buffer. After lysis samples were processed as before, with the exception of high MN samples, which was digested with 600 U of MN for 2.5 h followed by 20 mM EGTA treatment.""; ""[1098149] nucleic acid extraction protocol: For ribosome profiling of Drosophila RpS8, RpL13 and RpL22 ORFs tagged with O6-alkylguanine-DNA-alkyltransferase (AGT)-2xprotein G tag to the C terminus of the ORF., 30 ml of each culture were lysed and digested as before with MN (200 U). Digestion was stopped with EGTA and 350ul goat anti-rabbit IgG magnetic bead suspension (New England BioLabs) together with SUPERase-In (1/500) were added to the lysates and incubated o/n at 4 degrees C with gentle mixing. The beads were collected and washed three times with the lysis buffer. RNA was extracted from the beads using 500ul Qiazol reagent and the ribosome profiling was continued as before. ""; E-MTAB-2421Drosophila melanogaster4translation profilingNoneRibosome profiling with MN and RNaseI2015-01-08The aim of this experiment is to compare nucleases used in ribosome profiling using Drosophila melanogaster Kc167 cells and human U2OS osteosarcoma cells. Ribosome profiling was performed from nuclease digested samples using sucrose cushion centrifugation separated ribosomes.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2421Modified ribosome profiling reveals high abundance of ribosome protected mRNA fragments derived from 3' untranslated regions.Nucleic acids research11.147https://doi.org/10.1093/nar/gku1310{Nucleic acids research (11.147): 10.1093/nar/gku1310}NoneNoneNoneNone[Growth] co-expression; ""[972776] growth protocol: Cells were  cultured in the presence of 10% FBS in DMEM (U2OS cells) or in Schneider's medium (Kc167 cells). ""; ""[972778] treatment protocol: Both cell types were stimulated with 10 % extra FBS for 1h followed by 250 uM cycloheximide for 10 min.""; ""[972777] nucleic acid extraction protocol: Cells were rinsed twice with cold PBS and lysed in 1 ml polysome extraction buffer (1 % deoxycholate, 1 % NP40, 10 mM HEPES (pH 7.4), 350 mM KCl, 5 mM MgCl2, 5 mM CaCl2, 250 uM cycloheximide, 1x protease inhibitors (Sigma, P8340) and 2 ul RiboLock RNase inhibitor (ThermoFisher). Lysates were centrifuged for 10 min at 16000 xg and supernatant (leaving lowest ~25% behind) was used for ribosome profiling.The lysate samples were split in to two different digestion samples and digested with either 200 U of E. coli MBP-RNAse I (New England BioLabs) or 100 U of MN (ThermoFisher) by incubating for 40 min (U2OS) or 60 min (Kc167) at RT with slow mixing. 2 U of DNase I (ThermoFisher) was also added to each U2OS sample at the start of digestion. MN reaction was stopped with 10 mM EGTA. The samples were centrifuged at 6000 xg for 5 min to pellet insoluble material. The ribosomes were separated by sucrose step centrifugation using 0.5 M sucrose in polysome extraction buffer supplied with SUPERase-In (1/500) (Ambion). 0.35 ml lysate was layered on top of 0.2 ml sucrose cushion and centrifuged at 100000 xg for 45 min (55000 rpm using TLA 120.1 rotor). Supernatant was removed and pellet was suspended in 600 ul Qiazol reagent (Qiagen). Samples were incubated for 15 min at 70C with mixing to dissolve the pellet after which 200 ul of chloroform was added, the samples were vortexed and centrifuged for 10 min at 12000 xg at 4C. RNA was precipitated in the presence of Pink Co-precipitant (Bioline) at -80C o/n. RNA was washed and suspended in 20 ul of sterile water and mixed with 80 ul 2x TBE-urea sample buffer (without Xylene Cyanol FF). Samples were run on a 15 % TBE-urea gel, the gel was stained using 1x SYBR Gold (Invitrogen) and 28-35 nt sized RNA was cut out of the gel with the help of oligoribonucleotide size markers (28 and 35 nt RNA oligos). The gel pieces were disrupted and RNA was eluted with 300 mM NaAcetate (pH 5.0), 1 mM EDTA and SUPERase-In for 30 min at 65C. RNA was precipitated, centrifuged and washed with 80% ethanol and then suspended in 5 ul of sterile water. RNA yields were quantified with SYBR Gold using Qubit fluorometer (Invitrogen). All samples had over 1 pmol/ul RNA.""; ""[972775] nucleic acid library construction protocol: 5-15 picomoles of each RNA sample was used for phosphatase and poly-A tailing reaction by mixing 3.25 ul of RNA with the following: 0.5 ul 10x poly-A buffer (0.5 M Tris-HCl, pH 7.0, 2.5 M NaCl, 100 mM MgCl2, 50 mM DTT, 1 mg/ml BSA), 0.25 ul Yeast poly-A polymerase (600 U/ul, Affymetrix), 0.5 ul 10 mM ATP, 0.3 ul (3 U) T4 polynucleotide kinase (ThermoFisher), 0.2 ul SUPERase-In. Samples were incubated at 37C for 3 h. Note that RNase I digestion results in cyclic 2'3'-phosphate, which will be resolved by the inherent phosphatase activity of the T4 polynucleotide kinase. 4 ul of each sample was mixed with 1 ul 10 uM abasic-oligo dT primers containing random 8 nt sequence used for absolute molecular counting (Casbon et al., 2011; Kivioja et al., 2012), incubated at 72C for 3 min and put on ice. Reverse transcription was started by adding the following to the samples: 5.25 ul H20, 3 ul 5x RT-buffer (ThermoFisher), 0.75 ul 10 mM dNTP, 0.25 ul SUPERase-In and 0.4 ul Maxima Reverse transcriptase (75 U, ThermoFisher). Samples were incubated at 50C for 1 h, heat inactivated at 85C for 6 min after which 0.5 ul RNAse H (ThermoFisher) was added and samples were incubated at 37C for 30 min. Reverse transcription products were purified on 10% TBE-urea gel and cDNA was eluted into 700 ul of DNA gel elution buffer (1x TE + 300 mM NaCl) by incubating o/n at 4C with mixing on Eppendorf Thermomixer. cDNA was precipitated as before, samples were centrifuged for 10 min at 16000 g,  pellets were washed and cDNA was suspended into 5 ul of circularization mix (0.5 ul CircLigase buffer (10x), 0.25 ul 50 mM MnCl2, 0.25 ul CircLigase II (Epicentre), 1 ul 5 M betaine, 3 ul sterile water). Samples were incubated o/n at 60C and heat-inactivate for 10 min at 80C. cDNA was linearized by adding 3 ul of relinearization supplement (50 mM KCl, 1 mM DTT) followed by 0.7 ul (7 U) APE1 (New England Biolabs). Samples were incubated for 1 hour at 37C. Libraries were then amplified using 18 cycles of PCR with Solexa-primer-F and R and Phusion DNA polymerase (ThermoFisher). PCR products were separated on agarose gel, eluated using Qiagen MinElute Gel extraction kit and quantified with Quant-it PicoGreen DNA dye (LifeTechnologies) using Qubit fluorometer (LifeTechnologies). ""; ""[972774] nucleic acid sequencing protocol: Samples were sequenced using Illumina GAiix using single end sequencing with 50 bp read length at the GenePool sequencing facility (University of Edinburgh).""; E-MTAB-8045Homo sapiens4Ribo-seqNoneRibosome profiling of astrovirus-infected cells2020-07-04Ribosome profiling (RiboSeq) is a high-throughput sequencing technique for globally mapping the positions of translating ribosomes on the transcriptome. We infected Caco2 cells with human astrovirus 1 (HAstV1). Cells were harvested at 12 hpi and either flash frozen with no pre-treatment (NT), or pre-treated with lactimidomycin for 30 minutes followed by flash freezing (LTM). These samples where then used for ribosome profiling.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8045NoneNoneNoneNone{Nucleic acids research (11.147): 10.1093/nar/gku1310}NoneNoneNoneNone""[1279220] sample collection protocol: At 12 h post infection, cells were either not treated (NT) or treated with 50 M LTM for 30 minutes, flash frozen in a dry ice/ethanol bath, and lysed in the presence of 100 g/ml cycloheximide.""; ""[1279219] growth protocol: Caco2 cells were grown on 150-mm dishes to reach 80-90% confluency, then infected at a multiplicity of infection (MOI) of 5 with HAstV1 virus stock (passage 2, derived from pAVIC1 T7 RNA; Geigenmller et al., 1997, PMID 8995706).""; ""[1279218] nucleic acid sequencing protocol: Amplicon libraries were deep sequenced using an Illumina NextSeq platform (single-end; 76 cycles).""; ""[1279222] nucleic acid library construction protocol: Cell lysates were subjected to ribosome profiling based on previously described protocols (Chung et al., 2015, PMID 26286745; Irigoyen et al., 2016, PMID 26919232), except Ribo-Zero Gold rRNA removal kit (Illumina), not DSN, was used to deplete ribosomal RNA, and a 7-nt randomized sequence was appended to the 5' end of every read during library preparation.""; ""[1279221] nucleic acid extraction protocol: After flash freezing, cells were transferred to dry ice and 400 l of lysis buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1% Triton X-100, 100 g/ml cycloheximide and 25 U/ml TURBO DNase (Life Technologies)] dripped on. Cells were scraped extensively to ensure lysis, collected and triturated with a 26-G needle ten times. Lysates were clarified by centrifugation for 20 min at 13,000 g at 4 C, the supernatants recovered and stored in liquid nitrogen.""; E-MTAB-2940Homo sapiens3RNA-seq of coding RNANoneExpression profiling by high throughput sequencing2015-03-01RNAseq was prepared in parallel with ribosome profiling, using the same protocol for cDNA library preparation.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2940hiCLIP reveals the in vivo atlas of mRNA secondary structures recognized by Staufen 1.Nature43.070https://doi.org/10.1038/nature14280{Nature (43.070) doi:10.1038/nature14280}; {Nature (43.070) doi:10.1038/nature14280}; NoneNoneNoneNone[Growth] compound treatment design; ""[1076833] treatment protocol: Cells were not treated with siRNA (untreated), treated with anti-STAU1 siRNA (knockdown), or treated with anti-STAU1 siRNA and the STAU1 level was rescued by the rescue expression of siRNA-resistant STAU1 (rescue). Cells were subjected to Cycloheximide treatment before collection.""; ""[1076832] nucleic acid sequencing protocol: Single-end Illumina sequencing. Sequencing was performed at CRI, CRUK using HiSeq.""; ""[1076834] nucleic acid library construction protocol: RNA-Seq was performed in parallel with ribosome profiling. The protocol was followed to isolate RNA from the Cycloheximide teated cells and amplify cDNA library as described in the manuscript. Specific barcodes were used for each RT reaction as described in the manuscript. Random barcodes were also incoperated into cDNAs to distinguish between PCR duplication of cDNA products. The final products were obtained by PCR with Illumina paired-end sequencing primers: 5-CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-3; 5-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3""; E-MTAB-8100Homo sapiens18Ribo-seqNoneUsing ribosome profiling to investigate the effect of p53 on translation in cancer cells2021-02-22p53 is deleted or dysfunctional, or develops these features during the course of disease, with a frequency of about 50% in human cancers. This is clinically important because this group of patients respond very poorly to treatment. Our approach to discovering novel biomarkers or targets for therapy for p53 deleted/dysfunctional disease is to find genes that are translationally regulated by p53. The aim of this experiment is to compare translational efficiencies in cancer cells that are p53 WT, p53-/-, or p53 R175H, in response to doxorubicin.https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8100NoneNoneNoneNone{Nature (43.070) doi:10.1038/nature14280}; {Nature (43.070) doi:10.1038/nature14280}; NoneNoneNoneNone[Growth] case control design; ""[1282280] nucleic acid extraction protocol: Cells were lysed and RNA was purified by TRI Reagent (Sigma) and PureLink RNA Micro Kit (Invitrogen). Samples were treated with Ribo-Zero Gold rRNA removal Kit (Illumina) for rRNA depletion.""; ""[1282281] sample collection protocol: Prior to collection cells were treated with 1 microgram/ml doxycycline (for Tetracycline-controlled transcriptional activation) and 1 microM doxorubicin (to activate p53) for 19 hours, and with 100 microgram/ml cycloheximide for the last 10 minutes. The cells were lysed on plate, scraped, centrifuged, and the supernatant was used for RNA extraction.""; ""[1282279] growth protocol: Three cell lines were established using H1299 cells with a Tet-on expression system with an empty response vector (control), with a response vector expressing p53 WT (WT), and with a response vector expressing mutated (R175H) p53 (mutant).""; ""[1282276] nucleic acid sequencing protocol: Libraries were sequenced on the Illumina HiSeq 2500 platform using SE 50bp read length.   Each library was sequenced twice.""; ""[1282278] nucleic acid library construction protocol: Libraries were generated using the TruSeq Ribo Profile (Mammalian) Kit from Illumina.   Heat fragmented total RNA and size-selected RPF RNA samples were end-repaired, 3' adapter ligated and reverse transcribed. Resulting cDNA samples were PAGE-purified, circularised, and PCR-amplified with Index primers.""; ""[1282277] nucleic acid extraction protocol: Lysate was digested with RNaseI (Ambion), the reaction was stopped by SUPERase-In RNase Inhibitor (ThermoFisher) and the RPFs were purified by MicroSpin S-400 columns (GE Healthcare). Samples were treated with Ribo-Zero Gold rRNA removal Kit (Illumina) for rRNA depletion. RNA was size selected between 26 and 32 nt by PAGE purification.""; ",RNA-seq of coding RNA,,,,,,,,,,,
